assays_ASSI,assays_BFOR,assays_Descri,assays_TISI,assays_RELAT,assays_SI,assays_ASSCET,assays_CHI,assays_ASTET,assays_T,assays_DI,assays_ASSUBCEFR,assays_ASTIS,assays_ASSTY,assays_ASSST,assays_ASSCAT,assays_CURAB,assays_SASI,assays_CI,assays_VARI
1,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,H,1,,CHEMBL615117,,12052,11087,,,B,,,Autocuration,,,
2,BAO_0000219,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,U,1,,CHEMBL615118,,22226,684,,,F,,,Autocuration,,,
3,BAO_0000019,,,U,1,,CHEMBL615119,,22226,15453,,,B,,,Autocuration,,,
4,BAO_0000249,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,H,1,,CHEMBL615120,,104729,17841,,,B,,,Autocuration,,,
5,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,N,1,143B,CHEMBL615121,,80001,17430,,,F,,,Intermediate,,163.0,
6,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,N,1,143B,CHEMBL615122,,80001,17430,,,F,,,Intermediate,,163.0,
7,BAO_0000219,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,N,1,143B,CHEMBL615123,,80001,13799,,,F,,,Intermediate,,163.0,
8,BAO_0000219,In vitro cell cytotoxicity was determined against 143B cell line,,N,1,143B,CHEMBL615124,,80001,17774,,,F,,,Expert,,163.0,
9,BAO_0000219,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,N,1,143B,CHEMBL615125,,80001,3801,,,F,,,Intermediate,,163.0,
10,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,N,1,143B,CHEMBL615126,,80001,17430,,,F,,,Intermediate,,163.0,
11,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,N,1,143B,CHEMBL615127,,80001,17430,,,F,,,Intermediate,,163.0,
12,BAO_0000219,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,N,1,143B,CHEMBL615128,,80001,17774,,,F,,,Expert,,163.0,
13,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,1,,CHEMBL857900,,50185,11324,,,F,,,Intermediate,,,
14,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,1,,CHEMBL615129,,50185,11324,,,F,,,Intermediate,,,
15,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,1,,CHEMBL615130,,50185,11324,,,F,,,Intermediate,,,
16,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,1,,CHEMBL615131,,50185,11324,,,F,,,Intermediate,,,
17,BAO_0000357,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,D,1,,CHEMBL884521,,100122,11347,,,A,,,Expert,,,
18,BAO_0000357,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,H,1,,CHEMBL615132,,12054,16474,,,B,,,Autocuration,,,
19,BAO_0000019,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,H,1,,CHEMBL615133,,12054,10091,,,B,,,Autocuration,,,
20,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,H,1,,CHEMBL615134,,12054,16474,,,B,,,Autocuration,,,
21,BAO_0000357,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,H,1,,CHEMBL615135,,12054,16474,,,B,,,Autocuration,,,
22,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,H,1,,CHEMBL615136,,12054,16474,,,B,,,Autocuration,,,
23,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,H,1,,CHEMBL615137,,12054,16474,,,B,,,Autocuration,,,
24,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,H,1,,CHEMBL615138,,12054,16474,,,B,,,Autocuration,,,
25,BAO_0000219,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,U,1,,CHEMBL836324,,22226,14352,,,B,,,Autocuration,,,
26,BAO_0000357,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,H,1,,CHEMBL615139,,12054,5646,,,B,,,Autocuration,,,
27,BAO_0000357,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,H,1,,CHEMBL615140,,12054,5646,,,B,,,Autocuration,,,
28,BAO_0000219,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,H,1,,CHEMBL615141,,12426,10997,,,B,,,Autocuration,,,
29,BAO_0000357,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,H,1,,CHEMBL615142,,12054,6309,,,B,,,Autocuration,,,
30,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,H,1,,CHEMBL615143,,12054,167,,,B,,,Autocuration,,,
31,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,H,1,,CHEMBL615144,,12054,167,,,B,,,Autocuration,,,
32,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,H,1,,CHEMBL872867,,12054,11087,,,B,,,Autocuration,,,
33,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,H,1,,CHEMBL615145,,12054,11087,,,B,,,Autocuration,,,
34,BAO_0000357,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,H,1,,CHEMBL615146,,12054,13622,,,B,,,Autocuration,,,
35,BAO_0000357,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,H,1,,CHEMBL615147,,12054,13622,,,B,,,Autocuration,,,
36,BAO_0000019,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,U,1,,CHEMBL615148,,22226,11347,,,A,,,Autocuration,,,
37,BAO_0000019,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,U,1,,CHEMBL615149,,22226,5926,,,B,,,Autocuration,,,
38,BAO_0000019,Dissociation constant with dimeric 16S rRNA RNA construct B,,U,1,,CHEMBL615150,,22226,4567,,,B,,,Autocuration,,,
39,BAO_0000225,Dissociation constant towards 16S rRNA construct A,,M,1,,CHEMBL615151,,22222,3782,,,B,,,Intermediate,,,
40,BAO_0000225,Dissociation constant towards 16S rRNA construct B,,M,1,,CHEMBL615152,,22222,3782,,,B,,,Intermediate,,,
41,BAO_0000225,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,M,1,,CHEMBL615153,,100263,4466,,,B,,,Expert,,,
42,BAO_0000225,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,M,1,,CHEMBL615154,,100263,6592,,,B,,,Expert,,,
43,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,H,1,,CHEMBL615155,,13053,898,,,B,,,Autocuration,,,
44,BAO_0000019,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,H,1,,CHEMBL615156,,13053,898,,,B,,,Autocuration,,,
45,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,H,1,,CHEMBL615157,,20001,13163,,,B,,,Autocuration,,,
46,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,H,1,,CHEMBL615158,,20001,13163,,,B,,,Autocuration,,,
47,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,D,1,,CHEMBL615159,,12971,10691,,,B,,,Expert,,,
48,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,D,1,,CHEMBL615172,,12971,10691,,,B,,,Expert,,,
49,BAO_0000019,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,D,1,,CHEMBL615173,,12971,10691,,,B,,,Expert,,,
50,BAO_0000019,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,D,1,,CHEMBL615174,,12971,10691,,,B,,,Expert,,,
51,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,H,1,,CHEMBL884518,,13053,898,,,B,,,Autocuration,,,
52,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,H,1,,CHEMBL615175,,11512,912,,,B,,,Autocuration,,,
53,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,H,1,,CHEMBL615176,,11512,912,,,B,,,Autocuration,,,
54,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,H,1,,CHEMBL615177,,11512,912,,,B,,,Autocuration,,,
55,BAO_0000249,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,D,1,,CHEMBL615178,,104740,15103,Membranes,,B,,,Autocuration,,,
56,BAO_0000219,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,N,1,1A9,CHEMBL615179,,80002,5116,,,F,,,Intermediate,,506.0,
57,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,D,1,Oocytes,CHEMBL615180,,104835,14578,,,F,,,Autocuration,,,
58,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,D,1,Oocytes,CHEMBL615181,,104821,14578,,,F,,,Autocuration,,,
59,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,D,1,Oocytes,CHEMBL615182,,104848,14578,,,F,,,Autocuration,,,
60,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,N,1,1A9,CHEMBL615183,,80002,4787,,,F,,,Expert,,506.0,
61,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,N,1,1A9,CHEMBL615184,,80002,4787,,,F,,,Intermediate,,506.0,
62,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line,,N,1,1A9,CHEMBL615185,,80002,3547,,,F,,,Intermediate,,506.0,
63,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,N,1,1A9,CHEMBL615186,,80002,3547,,,F,,,Intermediate,,506.0,
64,BAO_0000219,Effective dose of compound against replication of 1A9 cell line was evaluated,,N,1,1A9,CHEMBL615187,,80002,6726,,,F,,,Intermediate,,506.0,
65,BAO_0000219,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,N,1,1A9,CHEMBL885343,,80002,3455,,,F,,,Expert,,506.0,
66,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,N,1,1A9,CHEMBL615188,,80002,5726,,,F,,,Intermediate,,506.0,
67,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,N,1,1A9,CHEMBL615189,,80002,5726,,,F,,,Intermediate,,506.0,
68,BAO_0000219,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,N,1,1A9,CHEMBL615190,,80002,5726,,,F,,,Intermediate,,506.0,
69,BAO_0000219,Inhibitory activity against Taxol resistant 1A9 cell lines,,N,1,1A9,CHEMBL615191,,80002,3395,,,F,,,Intermediate,,506.0,
70,BAO_0000219,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,N,1,1A9,CHEMBL615192,,80002,3415,,,F,,,Expert,,506.0,
71,BAO_0000219,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,N,1,1A9,CHEMBL827083,,80002,3415,,,F,,,Expert,,506.0,
72,BAO_0000219,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,N,1,1A9,CHEMBL615193,,80002,17099,,,F,,,Expert,,506.0,
73,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,N,1,1A9,CHEMBL615194,,80002,17099,,,F,,,Intermediate,,506.0,
74,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,N,1,1A9,CHEMBL615195,,80002,17099,,,F,,,Intermediate,,506.0,
75,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,N,1,1A9,CHEMBL615196,,80002,17099,,,F,,,Intermediate,,506.0,
76,BAO_0000219,Inhibitory concentration against Jurkat cells,,N,1,Jurkat,CHEMBL615197,,81072,17721,,,F,,,Intermediate,,503.0,
77,BAO_0000019,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,U,1,,CHEMBL615198,,22226,1229,,,F,,,Intermediate,,,
78,BAO_0000357,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,D,1,,CHEMBL615199,,100121,11347,,,A,,,Expert,,,
79,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,H,1,,CHEMBL615200,,11231,17117,,,B,,,Expert,,,
80,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,H,1,,CHEMBL615201,,11231,17117,,,B,,,Expert,,,
81,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,H,1,,CHEMBL615202,,11231,17117,,,B,,,Expert,,,
82,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,H,1,,CHEMBL615203,,11231,11375,Microsomes,,B,,,Autocuration,,,
83,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,H,1,,CHEMBL615204,,11231,11375,Microsomes,,B,,,Autocuration,,,
84,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,H,1,,CHEMBL615205,,11231,11375,Microsomes,,B,,,Autocuration,,,
85,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,H,1,,CHEMBL615206,,11231,11375,Microsomes,,B,,,Autocuration,,,
86,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",2107.0,H,1,,CHEMBL615207,,12083,11375,Microsomes,Liver,B,,,Autocuration,,,
87,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,H,1,,CHEMBL827084,,11231,791,,,B,,,Autocuration,,,
88,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,H,1,,CHEMBL615208,,11231,791,,,B,,,Autocuration,,,
89,BAO_0000019,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,H,1,,CHEMBL615209,,11231,791,,,B,,,Autocuration,,,
90,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",2107.0,D,1,,CHEMBL615210,,12083,11375,Microsomes,Liver,B,,,Autocuration,,,
91,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",2107.0,D,1,,CHEMBL615211,,12083,11375,Microsomes,Liver,B,,,Autocuration,,,
92,BAO_0000251,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",2107.0,D,1,,CHEMBL615212,,12083,153,Microsomes,Liver,B,,,Autocuration,,,
93,BAO_0000357,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,H,1,,CHEMBL615213,,11377,8269,,,B,,,Expert,,,
94,BAO_0000357,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,H,1,,CHEMBL615273,,11377,8269,,,B,,,Expert,,,
95,BAO_0000219,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,N,1,HepG2,CHEMBL615274,,81020,17653,,,F,,,Expert,,726.0,
96,BAO_0000219,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,N,1,HepG2,CHEMBL615275,,81020,14277,,,F,,,Intermediate,,726.0,
97,BAO_0000219,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,N,1,HepG2,CHEMBL615276,,81020,1717,,,F,,,Intermediate,,726.0,
98,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,N,1,HepG2,CHEMBL615277,,81020,14091,,,F,,,Intermediate,,726.0,
99,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,N,1,HepG2,CHEMBL615326,,81020,14091,,,F,,,Intermediate,,726.0,
100,BAO_0000218,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,N,1,,CHEMBL883130,,50606,17653,,,F,,,Expert,,,
101,BAO_0000219,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,N,1,HepG2,CHEMBL884519,,81020,13105,,,F,,,Intermediate,,726.0,
102,BAO_0000219,Concentration required to inhibit 50% of 2.2.15 cell line,,N,1,HepG2,CHEMBL615327,,81020,1717,,,F,,,Intermediate,,726.0,
103,BAO_0000219,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,N,1,HepG2,CHEMBL615328,,81020,13105,,,A,,,Intermediate,,726.0,
104,BAO_0000218,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,N,1,2.2.15,CHEMBL615329,,50587,13600,,,F,,,Intermediate,,,
105,BAO_0000218,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,N,1,2.2.15,CHEMBL615330,,50587,13467,,,F,,,Intermediate,,,
106,BAO_0000218,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,N,1,2.2.15,CHEMBL615331,,50606,17477,,,F,,,Expert,,,
107,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells,,N,1,2.2.15,CHEMBL615332,,50587,1593,,,F,,,Intermediate,,,
108,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,N,1,2.2.15,CHEMBL615333,,50587,1593,,,F,,,Intermediate,,,
109,BAO_0000218,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,N,1,2.2.15,CHEMBL615334,,50587,15089,,,F,,,Intermediate,,,
110,BAO_0000218,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,N,1,2.2.15,CHEMBL615335,,50587,15089,,,F,,,Intermediate,,,
111,BAO_0000218,Cytotoxicity in 2.2.15 cells,,N,1,2.2.15,CHEMBL615336,,50587,1593,,,F,,,Intermediate,,,
112,BAO_0000218,Cytotoxicity in 2.2.15 cells; Not determined,,N,1,2.2.15,CHEMBL615337,,50587,1593,,,F,,,Intermediate,,,
113,BAO_0000218,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,N,1,2.2.15,CHEMBL615338,,50587,13600,,,F,,,Intermediate,,,
114,BAO_0000218,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,N,1,2.2.15,CHEMBL615339,,50587,13467,,,F,,,Intermediate,,,
115,BAO_0000218,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,N,1,2.2.15,CHEMBL615340,,50587,13467,,,F,,,Intermediate,,,
116,BAO_0000219,Antiviral activity against HBV was determined in 2.215 cell line,,N,1,HepG2,CHEMBL615341,,81020,14764,,,F,,,Intermediate,,726.0,
117,BAO_0000251,Inhibition of 20-HETE synthesis in human renal microsomes,,U,1,,CHEMBL615342,,22226,6531,Microsomes,,B,,,Autocuration,,,
118,BAO_0000019,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,U,1,,CHEMBL615343,,22226,17322,,,B,,,Autocuration,,,
119,BAO_0000219,Inhibitory concentration against 2008 (ovarian) cells,,N,1,2008,CHEMBL615344,,80612,17072,,,F,,,Intermediate,,388.0,
120,BAO_0000219,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,N,1,2008,CHEMBL615345,,80612,16936,,,F,,,Intermediate,,388.0,
121,BAO_0000219,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,N,1,2008,CHEMBL615346,,80612,16936,,,F,,,Intermediate,,388.0,
122,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,N,1,2008,CHEMBL615347,,80612,17146,,,F,,,Intermediate,,388.0,
123,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,N,1,2008,CHEMBL615348,,80612,17146,,,F,,,Intermediate,,388.0,
124,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line,,N,1,2008/R,CHEMBL827085,,80613,10797,,,F,,,Intermediate,,561.0,
125,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,N,1,2008/R,CHEMBL615349,,80613,10797,,,F,,,Intermediate,,561.0,
126,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line,,N,1,2008/S,CHEMBL615350,,80614,10797,,,F,,,Intermediate,,389.0,
127,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,N,1,2008/S,CHEMBL615351,,80614,10797,,,F,,,Intermediate,,389.0,
128,BAO_0000220,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,S,1,,CHEMBL615352,,100256,4823,,,B,,,Expert,,,
129,BAO_0000220,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,S,1,,CHEMBL615353,,100256,12912,,,B,,,Intermediate,,,
130,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome,,S,1,,CHEMBL615354,,100256,2957,,,B,,,Expert,,,
131,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,S,1,,CHEMBL615355,,100256,2957,,,B,,,Expert,,,
132,BAO_0000220,Inhibitory activity against 20S proteosome,,S,1,,CHEMBL615356,,100256,3260,,,B,,,Intermediate,,,
133,BAO_0000019,Compound was tested for inhibitory activity against tryptase,,U,1,,CHEMBL615357,,22226,3451,,,B,,,Autocuration,,,
134,BAO_0000219,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,N,1,HepG2,CHEMBL615358,,81020,13885,,,F,,,Intermediate,,726.0,
135,BAO_0000219,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,N,1,HepG2,CHEMBL827086,,81020,13885,,,F,,,Intermediate,,726.0,
136,BAO_0000019,Compound was tested for the inhibition of Alpha-glucosidase,,U,1,,CHEMBL615359,,22226,3676,,,B,,,Autocuration,,,
137,BAO_0000357,Inhibitory concentration against human neutrophil elastase (HNE),,H,1,,CHEMBL615360,,235,6043,,,B,,,Autocuration,,,
138,BAO_0000218,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,948.0,U,1,,CHEMBL615361,,22226,11140,,Heart,F,,,Autocuration,,,
139,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,H,1,,CHEMBL615362,,19640,10543,,,F,,,Autocuration,,,
140,BAO_0000019,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,H,1,,CHEMBL615363,,19640,10543,,,F,,,Expert,,,
141,BAO_0000357,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,H,1,,CHEMBL615364,,19640,10543,,,B,,,Autocuration,,,
142,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,H,1,,CHEMBL615365,,19640,10543,,,F,,,Expert,,,
143,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,N,1,P338,CHEMBL615366,,80360,11365,,,F,,,Intermediate,,524.0,
144,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,N,1,P338,CHEMBL615367,,80360,11365,,,F,,,Intermediate,,524.0,
145,BAO_0000219,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,N,1,PBL,CHEMBL615368,,80384,11803,,,F,,,Intermediate,,554.0,
146,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,U,1,,CHEMBL615369,,22226,11803,,,F,,,Autocuration,,,
147,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,U,1,,CHEMBL615370,,22226,11803,,,F,,,Autocuration,,,
148,BAO_0000357,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,H,1,,CHEMBL615673,,191,12278,,,B,,,Autocuration,,,
149,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,U,1,,CHEMBL615674,,22226,8249,,,F,,,Autocuration,,,
150,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,U,1,,CHEMBL615675,,22226,8249,,,F,,,Autocuration,,,
151,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,U,1,CCRF-CEM,CHEMBL615676,,22226,8249,,,F,,,Autocuration,,635.0,
152,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,U,1,CCRF-CEM,CHEMBL615677,,22226,8249,,,F,,,Autocuration,,635.0,
153,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,U,1,CCRF-CEM,CHEMBL615678,,22226,8249,,,F,,,Autocuration,,635.0,
154,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,U,1,CCRF-CEM,CHEMBL615679,,22226,8249,,,F,,,Autocuration,,635.0,
155,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,U,1,,CHEMBL615680,,22226,8249,,,F,,,Autocuration,,,
156,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,U,1,,CHEMBL615681,,22226,8249,,,F,,,Autocuration,,,
157,BAO_0000249,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,H,1,,CHEMBL857972,,104290,16992,,,B,,,Autocuration,,,
158,BAO_0000218,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,N,1,,CHEMBL857899,,50264,10543,,,F,,,Intermediate,,,
159,BAO_0000218,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,N,1,,CHEMBL615371,,50527,17833,,,F,,,Intermediate,,,
160,BAO_0000218,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,N,1,HEL,CHEMBL615372,,50527,17290,,,F,,,Expert,,468.0,
161,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND: No data,,N,1,,CHEMBL615373,,50527,17290,,,F,,,Intermediate,,,
162,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND=No data,,N,1,,CHEMBL615374,,50527,17290,,,F,,,Intermediate,,,
163,BAO_0000218,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,N,1,,CHEMBL615375,,50145,10932,,,F,,,Intermediate,,,
164,BAO_0000019,Ratio of Ki at A2 to Ki at A1 receptors,,U,1,,CHEMBL615376,,22226,9707,,,B,,,Autocuration,,,
165,BAO_0000249,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,H,1,,CHEMBL615377,,11143,2346,,,B,,,Expert,,,
166,BAO_0000357,"Inhibition of 1,3-beta-glucan synthase",,H,1,,CHEMBL615378,,18077,2205,,,B,,,Expert,,,
167,BAO_0000219,Inhibition of growth of 1-87 human tumor cell line,,N,1,1-87 tumor cell line,CHEMBL615379,,80609,11900,,,F,,,Intermediate,,832.0,
168,BAO_0000219,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,D,1,,CHEMBL615380,,12166,14864,,,B,,,Expert,,,
169,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO),,D,1,,CHEMBL615381,,100171,16474,,,B,,,Autocuration,,,
170,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,D,1,,CHEMBL615382,,100171,16474,,,B,,,Autocuration,,,
171,BAO_0000357,% inhibition against soybean 1-lipoxygenase (SLO),,D,1,,CHEMBL615383,,100171,16474,,,B,,,Autocuration,,,
172,BAO_0000357,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,D,1,,CHEMBL615384,,100171,16474,,,B,,,Autocuration,,,
173,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,D,1,,CHEMBL615385,,100171,3094,,,B,,,Autocuration,,,
174,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,D,1,,CHEMBL615386,,100171,3094,,,B,,,Autocuration,,,
175,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,D,1,,CHEMBL615387,,100171,3094,,,B,,,Autocuration,,,
176,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,D,1,,CHEMBL615388,,100171,3094,,,B,,,Autocuration,,,
177,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,D,1,,CHEMBL615214,,100171,3094,,,B,,,Autocuration,,,
178,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,D,1,,CHEMBL827087,,100171,3094,,,B,,,Autocuration,,,
179,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,D,1,,CHEMBL615215,,100171,3094,,,B,,,Autocuration,,,
180,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,D,1,,CHEMBL615216,,100171,3094,,,B,,,Autocuration,,,
181,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,D,1,,CHEMBL615217,,100171,3094,,,B,,,Autocuration,,,
182,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,D,1,,CHEMBL615218,,100171,3094,,,B,,,Autocuration,,,
183,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,D,1,,CHEMBL615219,,100171,3094,,,B,,,Autocuration,,,
184,BAO_0000019,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,U,1,,CHEMBL615220,,22226,10413,,,B,,,Autocuration,,,
185,BAO_0000219,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,N,1,C3H 10T1/2,CHEMBL615221,,80049,16929,,,F,,,Intermediate,,294.0,
186,BAO_0000019,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,U,1,,CHEMBL615222,,22226,1229,,,F,,,Intermediate,,,
187,BAO_0000357,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,H,1,,CHEMBL615223,,11489,16587,,,B,,,Autocuration,,,
188,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,H,1,,CHEMBL615224,,11862,16587,,,B,,,Autocuration,,,
189,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,H,1,,CHEMBL615225,,11862,16587,,,B,,,Autocuration,,,
190,BAO_0000357,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,H,1,,CHEMBL615226,,11489,16587,,,B,,,Autocuration,,,
191,BAO_0000357,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,H,1,,CHEMBL615227,,11862,16587,,,B,,,Autocuration,,,
192,BAO_0000019,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,D,1,,CHEMBL615228,,12347,8058,,,F,,,Expert,,,
193,BAO_0000357,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,D,1,,CHEMBL615229,,100120,9065,,,B,,,Expert,,,
194,BAO_0000357,Inhibition of 11 beta-hydroxylase from rat adrenal gland,2369.0,D,1,,CHEMBL615230,,100120,8865,,Adrenal gland,B,,,Expert,,,
195,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,,D,1,,CHEMBL615231,,100120,9066,,,B,,,Expert,,,
196,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,,D,1,,CHEMBL884520,,100120,8394,,,B,,,Expert,,,
197,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,D,1,,CHEMBL615232,,100120,8394,,,B,,,Expert,,,
198,BAO_0000019,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,H,1,,CHEMBL615233,,10328,6431,,,B,,,Autocuration,,,
199,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,H,1,,CHEMBL827088,,11490,6431,,,B,,,Autocuration,,,
200,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,H,1,,CHEMBL615234,,11490,6431,,,B,,,Autocuration,,,
201,BAO_0000019,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,H,1,,CHEMBL615235,,11134,9295,,,F,,,Autocuration,,,
202,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,H,1,,CHEMBL615236,,12052,10193,,,B,,,Autocuration,,,
203,BAO_0000019,Compound was tested in vitro for inhibition of 12-LO human platelet,,H,1,,CHEMBL615237,,11134,13622,,,B,,,Autocuration,,,
204,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,,H,1,,CHEMBL615238,,11134,12079,,,F,,,Autocuration,,,
205,BAO_0000019,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,H,1,,CHEMBL615239,,11134,13622,,,B,,,Autocuration,,,
206,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,,D,1,,CHEMBL615240,,11134,12079,,,F,,,Autocuration,,,
207,BAO_0000019,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,H,1,,CHEMBL615241,,11835,13500,,,B,,,Expert,,,
208,BAO_0000357,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,H,1,,CHEMBL615242,,11601,13723,,,B,,,Expert,,,
209,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,H,1,,CHEMBL615243,,11134,16474,,,B,,,Autocuration,,,
210,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase,,H,1,,CHEMBL615244,,11134,1630,,,B,,,Autocuration,,,
211,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,H,1,,CHEMBL615245,,11134,167,,,B,,,Autocuration,,,
212,BAO_0000019,% inhibition against human platelet 12-lipoxygenase (12-HLO),,H,1,,CHEMBL615246,,11134,16474,,,B,,,Autocuration,,,
213,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,H,1,,CHEMBL615247,,11134,167,,,B,,,Autocuration,,,
214,BAO_0000019,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,H,1,,CHEMBL615248,,11134,16474,,,B,,,Autocuration,,,
215,BAO_0000357,Inhibitory activity towards porcine 12-lipoxygenase,,H,1,,CHEMBL615249,,11601,10091,,,B,,,Autocuration,,,
216,BAO_0000357,Tested for inhibition against porcine 12-LO,,H,1,,CHEMBL615250,,11601,11966,,,B,,,Autocuration,,,
217,BAO_0000019,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,H,1,,CHEMBL615251,,12052,951,,,B,,,Autocuration,,,
218,BAO_0000019,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,H,1,,CHEMBL615252,,12052,10997,,,B,,,Autocuration,,,
219,BAO_0000019,In vitro inhibition of rat platelet 12-lipoxygenase,,H,1,,CHEMBL828340,,12052,10193,,,B,,,Expert,,,
220,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,H,1,,CHEMBL615253,,12052,10193,,,B,,,Autocuration,,,
221,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,H,1,,CHEMBL615254,,12052,10193,,,B,,,Autocuration,,,
222,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,H,1,,CHEMBL615255,,12052,10193,,,B,,,Autocuration,,,
223,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,H,1,,CHEMBL615256,,12052,10193,,,B,,,Autocuration,,,
224,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,H,1,,CHEMBL615257,,12052,10193,,,B,,,Autocuration,,,
225,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,H,1,,CHEMBL615258,,12052,11087,,,B,,,Autocuration,,,
226,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,N,1,41M,CHEMBL615259,,80007,15569,,,F,,,Intermediate,,621.0,
227,BAO_0000219,In vitro antitumor activity against 41M cell line.,,N,1,41M,CHEMBL615260,,80007,12989,,,F,,,Expert,,621.0,
228,BAO_0000219,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,N,1,41M,CHEMBL615261,,80007,16745,,,F,,,Intermediate,,621.0,
229,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,N,1,41M,CHEMBL615262,,80007,15569,,,F,,,Intermediate,,621.0,
230,BAO_0000219,In vitro antitumor activity against 41McisR cell line.,,N,1,41M,CHEMBL615263,,80007,12989,,,F,,,Expert,,621.0,
231,BAO_0000219,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,N,1,41M,CHEMBL838393,,80007,12989,,,F,,,Expert,,621.0,
232,BAO_0000219,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,N,1,41M,CHEMBL615264,,80007,16745,,,F,,,Intermediate,,621.0,
233,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,D,1,,CHEMBL615265,,84,6210,,,B,,,Expert,,,
234,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,D,1,,CHEMBL615266,,68,6210,,,B,,,Expert,,,
235,BAO_0000357,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,H,1,,CHEMBL615267,,68,6226,,,B,,,Expert,,,
236,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,H,1,,CHEMBL615268,,10201,17855,,,B,,,Expert,,,
237,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,H,1,,CHEMBL615269,,10201,17855,,,B,,,Expert,,,
238,BAO_0000357,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,H,1,,CHEMBL615270,,10201,17855,,,B,,,Expert,,,
239,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,H,1,,CHEMBL615271,,12220,10413,,,B,,,Autocuration,,,
240,BAO_0000357,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,H,1,,CHEMBL615272,,11303,10413,,,B,,,Autocuration,,,
241,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,H,1,,CHEMBL615103,,11303,10413,,,B,,,Autocuration,,,
242,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,H,1,,CHEMBL615104,,11303,10413,,,B,,,Autocuration,,,
243,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,H,1,,CHEMBL615105,,12220,10413,,,B,,,Autocuration,,,
244,BAO_0000357,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,H,1,,CHEMBL872866,,12220,10413,,,B,,,Autocuration,,,
245,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,H,1,,CHEMBL615106,,11303,7587,,,B,,,Autocuration,,,
246,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,H,1,,CHEMBL615107,,11303,7587,,,B,,,Autocuration,,,
247,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,H,1,,CHEMBL615108,,11303,7587,,,B,,,Autocuration,,,
248,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,H,1,,CHEMBL615109,,11303,7587,,,B,,,Autocuration,,,
249,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,H,1,,CHEMBL615110,,11303,7587,,,B,,,Autocuration,,,
250,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,H,1,,CHEMBL840105,,11303,7587,,,B,,,Autocuration,,,
251,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,H,1,,CHEMBL615111,,11303,7587,,,B,,,Autocuration,,,
252,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,H,1,,CHEMBL615112,,11303,7587,,,B,,,Autocuration,,,
253,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,H,1,,CHEMBL615113,,11303,7587,,,B,,,Autocuration,,,
254,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,H,1,,CHEMBL615114,,11303,7587,,,B,,,Autocuration,,,
255,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,H,1,,CHEMBL615115,,11303,7587,,,B,,,Autocuration,,,
256,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,H,1,,CHEMBL615116,,11303,7587,,,B,,,Autocuration,,,
257,BAO_0000357,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,H,1,,CHEMBL615698,,11303,7323,,,B,,,Autocuration,,,
258,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,U,1,,CHEMBL615699,,22226,7587,,,B,,,Autocuration,,,
259,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,U,1,,CHEMBL615700,,22226,7587,,,B,,,Autocuration,,,
260,BAO_0000357,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,H,1,,CHEMBL615701,,100249,13750,,,B,,,Expert,,,
261,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,U,1,,CHEMBL615702,,22226,7662,,,B,,,Autocuration,,,
262,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,U,1,,CHEMBL615703,,22226,7662,,,B,,,Autocuration,,,
263,BAO_0000019,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,U,1,,CHEMBL615704,,22226,7662,,,B,,,Autocuration,,,
264,BAO_0000019,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,H,1,,CHEMBL615705,,104698,12211,,,F,,,Autocuration,,,
265,BAO_0000019,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,H,1,,CHEMBL615706,,104698,12211,,,F,,,Autocuration,,,
266,BAO_0000221,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,2116.0,D,1,,CHEMBL615707,,20033,12211,,Ileum,F,,,Intermediate,,,
267,BAO_0000019,Stimulatory activity of intragastric pressure was tested in the rat,,H,1,,CHEMBL615708,,10623,12211,,,F,,,Expert,,,
268,BAO_0000357,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,H,1,,CHEMBL615709,,121,15453,,,B,,,Autocuration,,,
269,BAO_0000218,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,U,1,,CHEMBL615710,,22226,11884,,,F,,,Autocuration,,,
270,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,H,1,,CHEMBL615711,,12688,7185,,,F,,,Autocuration,,,
271,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,D,1,,CHEMBL615712,,121,6876,,,B,,,Expert,,,
272,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,D,1,,CHEMBL836325,,121,6876,,,B,,,Expert,,,
273,BAO_0000019,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,H,1,,CHEMBL615713,,12198,11863,,,F,,,Autocuration,,,
274,BAO_0000357,Inhibition constant of high-affinity 5-HT uptake,,H,1,,CHEMBL615714,,12198,11863,,,B,,,Autocuration,,,
275,BAO_0000019,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,H,1,,CHEMBL615715,,12198,11863,,,F,,,Autocuration,,,
276,BAO_0000019,Maximum rate was determined for high affinity transport of 5-HT,,H,1,,CHEMBL615716,,12198,11863,,,F,,,Autocuration,,,
277,BAO_0000019,Compound was tested for agonistic activity against 5-HT uptake,,H,1,,CHEMBL615717,,104714,4639,,,F,,,Autocuration,,,
278,BAO_0000019,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,H,1,,CHEMBL881818,,10577,15796,,,B,,,Expert,,,
279,BAO_0000357,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,H,1,,CHEMBL884540,,105,15796,,,B,,,Expert,,,
280,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,D,1,,CHEMBL615718,,104744,12801,,,B,,,Autocuration,,,
281,BAO_0000224,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,H,1,,CHEMBL615719,,104744,12801,,,B,,,Autocuration,,,
282,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,H,1,,CHEMBL615720,,104744,12120,Membranes,,B,,,Autocuration,,,
283,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,H,1,,CHEMBL615721,,104744,12120,Membranes,,B,,,Autocuration,,,
284,BAO_0000019,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,1,,CHEMBL615722,,104744,11963,,,B,,,Autocuration,,,
285,BAO_0000019,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,H,1,,CHEMBL615723,,51,11701,,,F,,,Autocuration,,,
286,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615724,,51,9995,,Hippocampus,B,,,Autocuration,,,
287,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615725,,51,9995,,Hippocampus,B,,,Autocuration,,,
288,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615726,,51,9995,,Hippocampus,B,,,Autocuration,,,
289,BAO_0000218,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,H,1,,CHEMBL615727,In vivo,10576,16394,,,F,,,Autocuration,,,
290,BAO_0000019,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,D,1,,CHEMBL615728,,105570,11574,,,F,,,Intermediate,,,
291,BAO_0000219,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,1,CHO,CHEMBL857971,,279,15779,,,B,,,Autocuration,,449.0,
292,BAO_0000357,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL615729,,107,15363,,,B,,,Autocuration,,,
293,BAO_0000019,Efficacy against 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL615730,,12687,15363,,,F,,,Expert,,,
294,BAO_0000019,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,H,1,,CHEMBL615731,,12687,15329,,,F,,,Expert,,,
295,BAO_0000019,Relative potency towards 5-HT2A receptor of rat tail artery,,H,1,,CHEMBL615732,,12687,15329,,,F,,,Expert,,,
296,BAO_0000019,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,H,1,,CHEMBL615733,,12687,15329,,,F,,,Expert,,,
297,BAO_0000019,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,H,1,,CHEMBL615734,,12687,15329,,,F,,,Expert,,,
298,BAO_0000019,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,H,1,,CHEMBL615735,,12687,15329,,,F,,,Autocuration,,,
299,BAO_0000019,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,H,1,,CHEMBL615736,,12687,15329,,,F,,,Expert,,,
300,BAO_0000221,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,D,1,,CHEMBL615737,,20033,273,,Ileum,F,,,Intermediate,,,
301,BAO_0000221,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),2116.0,D,1,,CHEMBL615738,,20033,273,,Ileum,F,,,Intermediate,,,
302,BAO_0000221,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,D,1,,CHEMBL615739,,20033,273,,Ileum,F,,,Intermediate,,,
303,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,H,1,,CHEMBL615278,,10623,12092,,,B,,,Autocuration,,,
304,BAO_0000019,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,D,1,,CHEMBL615279,,10623,1317,,,F,,,Expert,,,
305,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL615280,,168,12409,,,B,,,Expert,,,
306,BAO_0000019,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,U,1,,CHEMBL615281,,22226,11126,,,B,,,Autocuration,,,
307,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,U,1,,CHEMBL615282,,22226,11126,,,F,,,Autocuration,,,
308,BAO_0000019,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,U,1,,CHEMBL615283,,22226,11126,,,F,,,Autocuration,,,
309,BAO_0000219,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,N,1,HL-60,CHEMBL615284,,80156,11126,,,B,,,Autocuration,,649.0,
310,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,U,1,,CHEMBL615285,,22226,11126,,,B,,,Autocuration,,,
311,BAO_0000019,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,U,1,,CHEMBL615286,,22226,11126,,,B,,,Autocuration,,,
312,BAO_0000219,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,D,1,Oocytes,CHEMBL615287,,104703,17807,,,B,,,Autocuration,,,
313,BAO_0000220,Chymotryptic inhibitory activity against 26S proteasome,,S,1,,CHEMBL615288,,100256,16575,,,F,,,Intermediate,,,
314,BAO_0000220,Inhibitory activity against 26S proteasome degradation of IkB,,S,1,,CHEMBL615289,,100256,15407,,,B,,,Intermediate,,,
315,BAO_0000219,In vitro inhibition of 2780/DOX ovarian cancer cell line,,N,1,A2780,CHEMBL615290,,81034,10797,,,F,,,Intermediate,,478.0,
316,BAO_0000219,In vitro inhibition of 2780/S ovarian cancer cell line,,N,1,A2780,CHEMBL884522,,81034,10797,,,F,,,Intermediate,,478.0,
317,BAO_0000019,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,U,1,,CHEMBL615291,,22226,3469,,,F,,,Autocuration,,,
318,BAO_0000225,Association constant for binding to AATT 28-mer AATT hairpin,,M,1,,CHEMBL615292,,22222,16037,,,B,,,Intermediate,,,
319,BAO_0000225,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,M,1,,CHEMBL615293,,22222,16037,,,B,,,Intermediate,,,
320,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,,M,1,,CHEMBL615294,,22222,16037,,,B,,,Intermediate,,,
321,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,,M,1,,CHEMBL615295,,22222,16037,,,B,,,Intermediate,,,
322,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,U,1,,CHEMBL825021,,22226,16524,,,F,,,Autocuration,,,
323,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,U,1,,CHEMBL615296,,22226,16524,,,F,,,Autocuration,,,
324,BAO_0000019,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,U,1,,CHEMBL615297,,22226,16524,,,F,,,Autocuration,,,
325,BAO_0000019,Cytotoxicity against cell line 2SC/20 determined by MTT test,,U,1,,CHEMBL615298,,22226,16758,,,F,,,Autocuration,,,
326,BAO_0000019,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,U,1,,CHEMBL615299,,22226,16758,,,F,,,Autocuration,,,
327,BAO_0000019,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,U,1,,CHEMBL615300,,22226,16758,,,F,,,Autocuration,,,
328,BAO_0000357,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,H,1,,CHEMBL615301,,241,14360,,,B,,,Autocuration,,,
329,BAO_0000357,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,D,1,,CHEMBL615302,,241,14360,,,B,,,Expert,,,
330,BAO_0000019,Selectivity ratio of ID50 in liver and heart,,U,1,,CHEMBL615303,,22226,9964,,,B,,,Autocuration,,,
331,BAO_0000019,"Selectivity, ratio of relative ID50 in liver and heart",,H,1,,CHEMBL615304,,12132,9964,,,B,,,Autocuration,,,
332,BAO_0000019,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,H,1,,CHEMBL615305,,12132,9964,,,B,,,Autocuration,,,
333,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615306,,12132,9964,,,B,,,Autocuration,,,
334,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615307,,12132,9964,,,B,,,Autocuration,,,
335,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615308,In vivo,12132,9964,,,B,,,Autocuration,,,
336,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615309,In vivo,12132,9964,,,F,,,Autocuration,,,
337,BAO_0000019,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,U,1,,CHEMBL615310,,22226,9964,,,B,,,Autocuration,,,
338,BAO_0000019,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,H,1,,CHEMBL615311,,12132,9964,,,B,,,Autocuration,,,
339,BAO_0000019,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,U,1,,CHEMBL615312,,22226,9964,,,B,,,Autocuration,,,
340,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,H,1,,CHEMBL615313,,12132,9964,,,B,,,Autocuration,,,
341,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,H,1,,CHEMBL615314,,12132,9964,,,F,,,Autocuration,,,
342,BAO_0000019,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615315,,12132,9964,,,B,,,Autocuration,,,
343,BAO_0000218,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,U,1,,CHEMBL615316,,22226,9964,,,B,,,Autocuration,,,
344,BAO_0000218,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,H,1,,CHEMBL615317,In vivo,12132,9964,,,B,,,Autocuration,,,
345,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615318,,12132,9964,,,B,,,Autocuration,,,
346,BAO_0000218,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,U,1,,CHEMBL615319,,22226,9964,,,B,,,Autocuration,,,
347,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615320,,12132,9964,,,B,,,Autocuration,,,
348,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,H,1,,CHEMBL615321,,12132,9964,,,F,,,Autocuration,,,
349,BAO_0000019,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,U,1,,CHEMBL615322,,22226,3796,,,B,,,Autocuration,,,
350,BAO_0000357,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,H,1,,CHEMBL615323,,19690,4251,,,B,,,Autocuration,,,
351,BAO_0000357,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,H,1,,CHEMBL615407,,19690,4251,,,B,,,Autocuration,,,
352,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,H,1,,CHEMBL857267,,19690,4251,,,B,,,Autocuration,,,
353,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,H,1,,CHEMBL615408,,19690,4251,,,B,,,Autocuration,,,
354,BAO_0000357,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,H,1,,CHEMBL615409,,19690,166,,,B,,,Autocuration,,,
355,BAO_0000357,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,H,1,,CHEMBL615410,,19690,17861,,,B,,,Autocuration,,,
356,BAO_0000357,Inhibition constant against 3-dehydroquinate synthase,,H,1,,CHEMBL615411,,19690,166,,,B,,,Autocuration,,,
357,BAO_0000357,Association rate constant against 3-dehydroquinate synthase,,H,1,,CHEMBL615412,,19690,166,,,B,,,Autocuration,,,
358,BAO_0000357,Rate constant against 3-dehydroquinate synthase,,H,1,,CHEMBL615413,,19690,166,,,B,,,Autocuration,,,
359,BAO_0000019,Inhibitory activity against fuc-TVII,,U,1,,CHEMBL615414,,22226,3548,,,B,,,Autocuration,,,
360,BAO_0000251,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,D,1,,CHEMBL615415,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
361,BAO_0000251,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,D,1,,CHEMBL615416,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
362,BAO_0000251,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,D,1,,CHEMBL615417,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
363,BAO_0000251,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,D,1,,CHEMBL615418,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
364,BAO_0000251,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,D,1,,CHEMBL615419,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
365,BAO_0000251,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,2107.0,D,1,,CHEMBL615420,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
366,BAO_0000251,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,2107.0,D,1,,CHEMBL615421,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
367,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,2107.0,D,1,,CHEMBL615422,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
368,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,2107.0,D,1,,CHEMBL615423,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
369,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,2107.0,D,1,,CHEMBL872868,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
370,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,2107.0,D,1,,CHEMBL615424,,12236,9877,Microsomes,Liver,B,,,Autocuration,,,
371,BAO_0000224,Inhibitory activity against 3-phosphoglycerate kinase.,,H,1,,CHEMBL825022,,104832,3003,,,B,,,Autocuration,,,
372,BAO_0000224,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,H,1,,CHEMBL615425,,104832,3003,,,B,,,Autocuration,,,
373,BAO_0000224,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,H,1,,CHEMBL615426,,104832,3003,,,B,,,Autocuration,,,
374,BAO_0000357,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,D,1,,CHEMBL615427,,10612,17185,,,B,,,Expert,,,
375,BAO_0000219,Cytotoxicity on 3677 melanoma cells,,N,1,3677 melanoma cell line,CHEMBL615428,,80616,6072,,,F,,,Intermediate,,844.0,
376,BAO_0000219,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,N,1,3677 melanoma cell line,CHEMBL615429,,80616,6072,,,F,,,Intermediate,,844.0,
377,BAO_0000219,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,N,1,MC-38,CHEMBL615430,,80617,5018,,,F,,,Intermediate,,700.0,
378,BAO_0000019,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,U,1,,CHEMBL615431,,22226,2852,,,F,,,Intermediate,,,
379,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,U,1,B16,CHEMBL615432,,22226,8663,,,F,,,Autocuration,,798.0,
380,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,U,1,B16,CHEMBL615433,,22226,8663,,,F,,,Autocuration,,798.0,
381,BAO_0000019,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,D,1,,CHEMBL615434,,12464,3245,,,F,,,Expert,,,
382,BAO_0000218,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,N,1,,CHEMBL615435,,50085,3245,,,F,,,Intermediate,,,
383,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,N,1,,CHEMBL615436,,50679,3877,,,F,,,Intermediate,,,
384,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,N,1,,CHEMBL615437,,50679,3877,,,F,,,Intermediate,,,
385,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,D,1,,CHEMBL615438,,12464,5861,,,F,,,Expert,,,
386,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,D,1,,CHEMBL615439,,12464,5861,,,F,,,Expert,,,
387,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,D,1,,CHEMBL615440,,12464,5861,,,F,,,Expert,,,
388,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,D,1,,CHEMBL615441,,12464,5861,,,F,,,Expert,,,
389,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,N,1,,CHEMBL615641,,50665,13748,,,F,,,Intermediate,,,
390,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,N,1,,CHEMBL872065,,50665,13748,,,F,,,Intermediate,,,
391,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,N,1,,CHEMBL825023,,50665,13748,,,F,,,Intermediate,,,
392,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,N,1,,CHEMBL615642,,50665,13748,,,F,,,Intermediate,,,
393,BAO_0000357,Inhibition of human rhinovirus 3C protease,,H,1,,CHEMBL615643,,12464,13748,,,B,,,Expert,,,
394,BAO_0000019,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,U,1,,CHEMBL615644,,22226,17699,,,B,,,Autocuration,,,
395,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,N,1,3EM 37,CHEMBL615645,,80619,7145,,,F,,,Intermediate,,833.0,
396,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,N,1,3EM 37,CHEMBL615646,,80619,7145,,,F,,,Intermediate,,833.0,
397,BAO_0000218,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,N,1,3EM 37,CHEMBL615647,,80619,7145,,,F,,,Intermediate,,833.0,
398,BAO_0000218,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,N,1,3EM 37,CHEMBL615648,,80619,7145,,,F,,,Intermediate,,833.0,
399,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,N,1,3EM 37,CHEMBL615649,,80619,7145,,,F,,,Intermediate,,833.0,
400,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,N,1,3EM 37,CHEMBL615650,,80619,7145,,,F,,,Intermediate,,833.0,
401,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,N,1,3LL cell line,CHEMBL615651,,80620,5325,,,F,,,Intermediate,,847.0,
402,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,N,1,3LL cell line,CHEMBL615652,,80620,5325,,,F,,,Intermediate,,847.0,
403,BAO_0000218,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,N,1,3LL cell line,CHEMBL615653,,80620,5325,,,F,,,Expert,,847.0,
404,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,N,1,3LL cell line,CHEMBL615654,,80620,16169,,,F,,,Intermediate,,847.0,
405,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,N,1,3LL cell line,CHEMBL615655,,80620,16169,,,F,,,Intermediate,,847.0,
406,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,N,1,3LL cell line,CHEMBL825024,,80620,16169,,,F,,,Intermediate,,847.0,
407,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,N,1,3LL cell line,CHEMBL615656,,80620,16169,,,F,,,Intermediate,,847.0,
408,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,N,1,3LL cell line,CHEMBL615657,,80620,16169,,,F,,,Intermediate,,847.0,
409,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,N,1,3LL cell line,CHEMBL615658,,80620,16169,,,F,,,Intermediate,,847.0,
410,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,N,1,3LL cell line,CHEMBL615659,,80620,16169,,,F,,,Intermediate,,847.0,
411,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,N,1,3LL cell line,CHEMBL615660,,80620,16169,,,F,,,Intermediate,,847.0,
412,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,N,1,3LL cell line,CHEMBL615661,,80620,16169,,,F,,,Intermediate,,847.0,
413,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,N,1,3LL cell line,CHEMBL615662,,80620,16169,,,F,,,Intermediate,,847.0,
414,BAO_0000219,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,N,1,3LL cell line,CHEMBL615663,,80620,16169,,,F,,,Intermediate,,847.0,
415,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,N,1,3LL cell line,CHEMBL615664,,80620,16169,,,F,,,Intermediate,,847.0,
416,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,N,1,3LL cell line,CHEMBL615665,,80620,16169,,,F,,,Intermediate,,847.0,
417,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,N,1,3LL cell line,CHEMBL615666,,80620,16169,,,F,,,Intermediate,,847.0,
418,BAO_0000219,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,N,1,3LL cell line,CHEMBL615667,,80620,16169,,,F,,,Intermediate,,847.0,
419,BAO_0000219,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,N,1,3LL cell line,CHEMBL615668,,80620,16169,,,F,,,Intermediate,,847.0,
420,BAO_0000219,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,N,1,3LL cell line,CHEMBL615669,,80620,16169,,,F,,,Intermediate,,847.0,
421,BAO_0000219,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,N,1,3LL cell line,CHEMBL615670,,80620,16169,,,F,,,Intermediate,,847.0,
422,BAO_0000219,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,N,1,3LL cell line,CHEMBL836739,,80620,16169,,,F,,,Intermediate,,847.0,
423,BAO_0000219,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,N,1,3LL cell line,CHEMBL615671,,80620,16169,,,F,,,Intermediate,,847.0,
424,BAO_0000219,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,N,1,3LL cell line,CHEMBL615672,,80620,16169,,,F,,,Intermediate,,847.0,
425,BAO_0000219,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,N,1,3LL cell line,CHEMBL615791,,80620,16169,,,F,,,Intermediate,,847.0,
426,BAO_0000219,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,N,1,3LL cell line,CHEMBL615792,,80620,16169,,,F,,,Intermediate,,847.0,
427,BAO_0000219,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,N,1,3LL cell line,CHEMBL615793,,80620,16169,,,F,,,Intermediate,,847.0,
428,BAO_0000219,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,N,1,3LL cell line,CHEMBL615794,,80620,16169,,,F,,,Intermediate,,847.0,
429,BAO_0000219,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,N,1,3LL cell line,CHEMBL615795,,80620,16169,,,F,,,Intermediate,,847.0,
430,BAO_0000219,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,N,1,3LLD122,CHEMBL615590,,80621,15547,,,F,,,Intermediate,,971.0,
431,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,U,1,,CHEMBL615591,,22226,8663,,,F,,,Autocuration,,,
432,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,U,1,,CHEMBL615592,,22226,8663,,,F,,,Autocuration,,,
433,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,U,1,,CHEMBL615593,,22226,8663,,,F,,,Autocuration,,,
434,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,U,1,,CHEMBL615594,,22226,8663,,,F,,,Autocuration,,,
435,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,N,1,NIH3T3,CHEMBL615595,,80951,4504,,,F,,,Intermediate,,723.0,
436,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,N,1,NIH3T3,CHEMBL615596,,80951,4504,,,F,,,Intermediate,,723.0,
437,BAO_0000219,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,H,1,NIH3T3,CHEMBL615597,,11169,12695,,,F,,,Expert,,723.0,
438,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,N,1,NIH3T3,CHEMBL615598,,80951,12695,,,F,,,Intermediate,,723.0,
439,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,N,1,NIH3T3,CHEMBL615599,,80951,12695,,,F,,,Intermediate,,723.0,
440,BAO_0000219,Effective dose against murine 3T3 fibroblasts cells,,N,1,NIH3T3,CHEMBL615600,,80951,17642,,,F,,,Expert,,723.0,
441,BAO_0000219,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,N,1,NIH3T3,CHEMBL615601,,80951,17642,,,F,,,Expert,,723.0,
442,BAO_0000219,Cytotoxic effect on 3T3 cells,,N,1,NIH3T3,CHEMBL615602,,80951,12340,,,F,,,Expert,,723.0,
443,BAO_0000219,Cytotoxic effect on 3T3 cells,,N,1,NIH3T3,CHEMBL615603,,80951,12340,,,F,,,Expert,,723.0,
444,BAO_0000219,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,N,1,NIH3T3,CHEMBL615604,,80951,12716,,,F,,,Intermediate,,723.0,
445,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,N,1,NIH3T3,CHEMBL615605,,80951,6277,,,F,,,Intermediate,,723.0,
446,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,N,1,NIH3T3,CHEMBL615606,,80951,6277,,,F,,,Intermediate,,723.0,
447,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,N,1,NIH3T3,CHEMBL884526,,80951,6277,,,F,,,Expert,,723.0,
448,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,N,1,NIH3T3,CHEMBL615607,,80951,6277,,,F,,,Expert,,723.0,
449,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,N,1,NIH3T3,CHEMBL615608,,80951,6277,,,F,,,Intermediate,,723.0,
450,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,N,1,NIH3T3,CHEMBL615609,,80951,6277,,,F,,,Expert,,723.0,
451,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,N,1,NIH3T3,CHEMBL615682,,80951,6277,,,F,,,Expert,,723.0,
452,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,N,1,NIH3T3,CHEMBL615683,,80951,6277,,,F,,,Intermediate,,723.0,
453,BAO_0000218,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,N,1,NIH3T3,CHEMBL615684,,80951,17780,,,F,,,Expert,,723.0,
454,BAO_0000219,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,D,1,,CHEMBL615685,,104860,12751,,,F,,,Autocuration,,,
455,BAO_0000219,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,N,1,NIH3T3,CHEMBL615686,,80951,12380,,,F,,,Expert,,723.0,
456,BAO_0000219,Inhibitory activity against 3T3 cell line,,N,1,NIH3T3,CHEMBL615687,,80951,14892,,,F,,,Intermediate,,723.0,
457,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,N,1,NIH3T3,CHEMBL884523,,80951,12695,,,F,,,Intermediate,,723.0,
458,BAO_0000019,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,H,1,,CHEMBL615688,,11169,12695,,,F,,,Expert,,,
459,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,N,1,NIH3T3,CHEMBL615689,,80951,12695,,,F,,,Intermediate,,723.0,
460,BAO_0000219,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,N,1,NIH3T3,CHEMBL615690,,80951,12695,,,F,,,Intermediate,,723.0,
461,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,H,1,,CHEMBL615691,,11169,12695,,,F,,,Expert,,,
462,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,H,1,,CHEMBL615692,,11169,12695,,,F,,,Expert,,,
463,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,N,1,NIH3T3,CHEMBL615693,,80951,6277,,,F,,,Intermediate,,723.0,
464,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,N,1,NIH3T3,CHEMBL615324,,80951,6277,,,F,,,Expert,,723.0,
465,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,D,1,NIH3T3,CHEMBL615325,,9,4959,,,F,,,Expert,,723.0,
466,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,D,1,NIH3T3,CHEMBL615490,,9,4959,,,F,,,Expert,,723.0,
467,BAO_0000219,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,D,1,NIH3T3,CHEMBL615491,,188,4959,,,F,,,Expert,,723.0,
468,BAO_0000219,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,D,1,NIH3T3,CHEMBL615492,,188,4959,,,F,,,Expert,,723.0,
469,BAO_0000219,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,N,1,NIH3T3,CHEMBL615493,,80951,12082,,,F,,,Intermediate,,723.0,
470,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,N,1,NIH3T3,CHEMBL615494,,80951,12082,,,F,,,Intermediate,,723.0,
471,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,N,1,NIH3T3,CHEMBL615495,,80951,12082,,,F,,,Intermediate,,723.0,
472,BAO_0000219,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,N,1,NIH3T3,CHEMBL615496,,80951,12082,,,F,,,Intermediate,,723.0,
473,BAO_0000219,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,N,1,NIH3T3,CHEMBL615497,,80951,2643,,,F,,,Intermediate,,723.0,
474,BAO_0000219,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,N,1,NIH3T3,CHEMBL615498,,80951,11926,,,F,,,Expert,,723.0,
475,BAO_0000219,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,N,1,NIH3T3,CHEMBL615499,,80951,15204,,,A,,,Intermediate,,723.0,
476,BAO_0000219,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,N,1,NIH3T3,CHEMBL835522,,80951,15992,,,F,,,Expert,,723.0,
477,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,N,1,NIH3T3,CHEMBL615500,,80951,16279,,,F,,,Intermediate,,723.0,
478,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,1,NIH3T3,CHEMBL615501,,80951,16279,,,F,,,Intermediate,,723.0,
479,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,1,NIH3T3,CHEMBL615502,,80951,16279,,,F,,,Intermediate,,723.0,
480,BAO_0000219,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,1,NIH3T3,CHEMBL615503,,80951,16279,,,F,,,Intermediate,,723.0,
481,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,1,NIH3T3,CHEMBL615504,,80951,16279,,,F,,,Intermediate,,723.0,
482,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,1,NIH3T3,CHEMBL615505,,80951,16279,,,F,,,Intermediate,,723.0,
483,BAO_0000219,Inhibition of swiss 3T3 mouse fibroblast proliferation,,N,1,NIH3T3,CHEMBL615506,,80951,12831,,,F,,,Expert,,723.0,
484,BAO_0000219,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,N,1,NIH3T3,CHEMBL615507,,80951,13497,,,F,,,Intermediate,,723.0,
485,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,N,1,3T3-L1,CHEMBL615508,,80006,13715,,,F,,,Intermediate,,620.0,
486,BAO_0000219,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,N,1,3T3-L1,CHEMBL615509,,80006,13618,,,F,,,Intermediate,,620.0,
487,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,N,1,3T3-L1,CHEMBL615510,,80006,11902,,,F,,,Intermediate,,620.0,
488,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,N,1,3T3-L1,CHEMBL615511,,80006,11902,,,F,,,Intermediate,,620.0,
489,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,N,1,3T3-L1,CHEMBL615512,,80006,11902,,,F,,,Intermediate,,620.0,
490,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,N,1,3T3-L1,CHEMBL615513,,80006,14840,,,F,,,Intermediate,,620.0,
491,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,N,1,3T3-L1,CHEMBL615514,,80006,14840,,,F,,,Intermediate,,620.0,
492,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,N,1,3T3-L1,CHEMBL615515,,80006,13715,,,F,,,Intermediate,,620.0,
493,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,N,1,3T3-L1,CHEMBL615516,,80006,13715,,,F,,,Intermediate,,620.0,
494,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,N,1,3T3-L1,CHEMBL615517,,80006,13715,,,F,,,Intermediate,,620.0,
495,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,N,1,3T3-L1,CHEMBL615518,,80006,13715,,,F,,,Intermediate,,620.0,
496,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,N,1,3T3-L1,CHEMBL615519,,80006,13715,,,F,,,Intermediate,,620.0,
497,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,N,1,3T3-L1,CHEMBL615520,,80006,13715,,,F,,,Intermediate,,620.0,
498,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,N,1,3T3-L1,CHEMBL615521,,80006,13715,,,F,,,Intermediate,,620.0,
499,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,N,1,3T3-L1,CHEMBL615522,,80006,13715,,,F,,,Intermediate,,620.0,
500,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,N,1,3T3-L1,CHEMBL615523,,80006,13715,,,F,,,Intermediate,,620.0,
501,BAO_0000218,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,N,1,3T3-L1,CHEMBL615524,,80006,13715,,,F,,,Expert,,620.0,
502,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,N,1,3T3-L1,CHEMBL615525,,80006,13715,,,F,,,Expert,,620.0,
503,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,N,1,3T3-L1,CHEMBL615526,,80006,13715,,,F,,,Intermediate,,620.0,
504,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,N,1,3T3-L1,CHEMBL615527,,80006,13715,,,F,,,Intermediate,,620.0,
505,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,N,1,3T3-L1,CHEMBL615528,,80006,13715,,,F,,,Intermediate,,620.0,
506,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,N,1,3T3-L1,CHEMBL615529,,80006,13715,,,F,,,Expert,,620.0,
507,BAO_0000218,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,N,1,3T3-L1,CHEMBL615530,,80006,13715,,,F,,,Expert,,620.0,
508,BAO_0000218,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,N,1,3T3-L1,CHEMBL615531,,80006,13715,,,F,,,Expert,,620.0,
509,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,N,1,3T3-L1,CHEMBL615532,,80006,13715,,,F,,,Intermediate,,620.0,
510,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,N,1,3T3-L1,CHEMBL615533,,80006,13715,,,F,,,Intermediate,,620.0,
511,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,N,1,3T3-L1,CHEMBL615534,,80006,13715,,,F,,,Intermediate,,620.0,
512,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,N,1,3T3-L1,CHEMBL615535,,80006,13715,,,F,,,Intermediate,,620.0,
513,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,N,1,3T3-L1,CHEMBL615536,,80006,13715,,,F,,,Intermediate,,620.0,
514,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,N,1,3T3-L1,CHEMBL615537,,80006,13715,,,F,,,Intermediate,,620.0,
515,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,N,1,3T3-L1,CHEMBL615538,,80006,13715,,,F,,,Intermediate,,620.0,
516,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,N,1,3T3-L1,CHEMBL836166,,80006,13715,,,F,,,Intermediate,,620.0,
517,BAO_0000219,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,H,1,3T3-L1,CHEMBL615539,,11214,6411,,,F,,,Expert,,620.0,
518,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,N,1,3T3-L1,CHEMBL615540,,80006,6411,,,F,,,Intermediate,,620.0,
519,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,H,1,3T3-L1,CHEMBL615541,,11214,6411,,,F,,,Expert,,620.0,
520,BAO_0000219,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,N,1,3T3-L1,CHEMBL615542,,80006,3966,,,F,,,Expert,,620.0,
521,BAO_0000219,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,N,1,3T3-L1,CHEMBL615543,,80006,3966,,,F,,,Intermediate,,620.0,
522,BAO_0000219,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,N,1,3T3-L1,CHEMBL615544,,80006,15556,,,F,,,Expert,,620.0,
523,BAO_0000219,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,N,1,3T3-L1,CHEMBL615545,,80006,5845,,,F,,,Expert,,620.0,
524,BAO_0000219,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,N,1,3T3-L1,CHEMBL615546,,80006,14422,,,F,,,Expert,,620.0,
525,BAO_0000219,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,N,1,3T3-L1,CHEMBL615547,,80006,5845,,,F,,,Expert,,620.0,
526,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,N,1,3T3-L1,CHEMBL615548,,80006,14508,,,F,,,Expert,,620.0,
527,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,N,1,3T3-L1,CHEMBL615549,,80006,14508,,,F,,,Expert,,620.0,
528,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,N,1,3T3-L1,CHEMBL615550,,80006,14508,,,F,,,Expert,,620.0,
529,BAO_0000219,Inhibitory activity against rat fibroblast (3Y1) cell line,,N,1,3Y1 cell line,CHEMBL615551,,80622,6349,,,F,,,Intermediate,,1118.0,
530,BAO_0000219,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,N,1,3Y1 cell line,CHEMBL615552,,80622,15899,,,F,,,Expert,,1118.0,
531,BAO_0000219,Cytotoxicity in 3Y1 cells.,,N,1,3Y1 cell line,CHEMBL615553,,80622,15899,,,F,,,Expert,,1118.0,
532,BAO_0000219,Cytostatic effect in 3Y1 cells.,,N,1,3Y1 cell line,CHEMBL615554,,80622,15899,,,F,,,Expert,,1118.0,
533,BAO_0000219,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,N,1,3Y1 cell line,CHEMBL615555,,80622,15899,,,F,,,Intermediate,,1118.0,
534,BAO_0000219,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,N,1,3Y1 cell line,CHEMBL615556,,80622,17038,,,F,,,Expert,,1118.0,
535,BAO_0000019,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,U,1,,CHEMBL615557,,22226,12421,,,B,,,Autocuration,,,
536,BAO_0000019,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,U,1,,CHEMBL615558,,22226,12947,,,B,,,Autocuration,,,
537,BAO_0000019,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,U,1,,CHEMBL872066,,22226,12947,,,B,,,Autocuration,,,
538,BAO_0000019,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,D,1,,CHEMBL615559,,11607,4896,,,B,,,Expert,,,
539,BAO_0000019,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,H,1,,CHEMBL615560,,11607,6148,,,B,,,Autocuration,,,
540,BAO_0000019,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,H,1,,CHEMBL615561,,11607,16432,,,B,,,Autocuration,,,
541,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,H,1,,CHEMBL857062,,11607,4978,,,B,,,Expert,,,
542,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,H,1,,CHEMBL615562,,11607,4978,,,B,,,Expert,,,
543,BAO_0000019,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,H,1,,CHEMBL615563,,11607,3723,,,B,,,Autocuration,,,
544,BAO_0000357,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,H,1,,CHEMBL615564,,11607,3518,,,B,,,Autocuration,,,
545,BAO_0000019,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,H,1,,CHEMBL615565,,11607,4164,,,B,,,Autocuration,,,
546,BAO_0000019,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,H,1,,CHEMBL615566,,11607,3518,,,B,,,Autocuration,,,
547,BAO_0000019,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,D,1,,CHEMBL615567,,11607,4164,,,B,,,Expert,,,
548,BAO_0000019,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,H,1,,CHEMBL615568,,11607,3518,,,B,,,Autocuration,,,
549,BAO_0000357,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,H,1,,CHEMBL615569,,11607,3518,,,B,,,Autocuration,,,
550,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,H,1,,CHEMBL615570,,11607,4978,,,B,,,Autocuration,,,
551,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,H,1,,CHEMBL615571,,11607,4978,,,B,,,Autocuration,,,
552,BAO_0000224,Binding affinity against melatonin (MT1) receptor (pC1),,H,1,,CHEMBL615572,,104733,6455,,,B,,,Autocuration,,,
553,BAO_0000019,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,U,1,,CHEMBL615573,,22226,2222,,,B,,,Autocuration,,,
554,BAO_0000019,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,U,1,,CHEMBL615574,,22226,13020,,,B,,,Autocuration,,,
555,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,U,1,,CHEMBL615575,,22226,13021,,,B,,,Autocuration,,,
556,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,H,1,,CHEMBL615576,,10619,14532,,,B,,,Autocuration,,,
557,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL615577,,10619,14118,,,B,,,Autocuration,,,
558,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,10000000.0,H,1,,CHEMBL615578,,51,11884,,Hippocampus,B,,,Autocuration,,,
559,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615579,,51,13969,,,B,,,Expert,,,
560,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615580,,51,13392,,,B,,,Expert,,,
561,BAO_0000019,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,H,1,,CHEMBL615581,,51,14430,,,B,,,Expert,,,
562,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,H,1,,CHEMBL615582,,51,12248,,Hippocampus,B,,,Autocuration,,,
563,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,H,1,,CHEMBL615583,,51,12249,,Hippocampus,B,,,Autocuration,,,
564,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615584,,51,9995,,Hippocampus,B,,,Autocuration,,,
565,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL833691,,51,9995,,Hippocampus,B,,,Autocuration,,,
566,BAO_0000221,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615585,,51,9995,,Hippocampus,B,,,Autocuration,,,
567,BAO_0000221,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615586,,51,9995,,Hippocampus,B,,,Autocuration,,,
568,BAO_0000221,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL884524,,51,9995,,Hippocampus,B,,,Autocuration,,,
569,BAO_0000221,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,H,1,,CHEMBL615587,,51,12249,,Hippocampus,B,,,Autocuration,,,
570,BAO_0000221,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",10000000.0,H,1,,CHEMBL615588,,51,11799,,Hippocampus,B,,,Autocuration,,,
571,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,D,1,,CHEMBL615589,,10576,14331,Membranes,,B,,,Expert,,,
572,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,10000000.0,H,1,,CHEMBL615442,,51,11884,,Hippocampus,B,,,Expert,,,
573,BAO_0000221,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,10000000.0,H,1,,CHEMBL615443,,51,14331,,Hippocampus,B,,,Autocuration,,,
574,BAO_0000221,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,10000000.0,H,1,,CHEMBL615444,,51,11701,,Hippocampus,B,,,Autocuration,,,
575,BAO_0000221,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,10000000.0,H,1,,CHEMBL615445,,51,11701,,Hippocampus,B,,,Expert,,,
576,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,10000000.0,H,1,,CHEMBL615446,,51,12248,,Hippocampus,B,,,Autocuration,,,
577,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,H,1,CHO,CHEMBL615447,,51,12248,,,B,,,Autocuration,,449.0,
578,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,H,1,,CHEMBL615448,,51,12248,,Hippocampus,B,,,Expert,,,
579,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,H,1,,CHEMBL615449,,51,12249,,Hippocampus,B,,,Expert,,,
580,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,1,CHO,CHEMBL615450,,51,12248,,,B,,,Autocuration,,449.0,
581,BAO_0000221,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",10000000.0,H,1,,CHEMBL615451,,51,11799,,Hippocampus,B,,,Expert,,,
582,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,H,1,,CHEMBL615452,,51,634,,,B,,,Autocuration,,,
583,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615453,,51,9995,,Hippocampus,B,,,Autocuration,,,
584,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615454,,51,9995,,Hippocampus,B,,,Autocuration,,,
585,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615455,,51,9995,,Hippocampus,B,,,Autocuration,,,
586,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615456,,51,9995,,Hippocampus,B,,,Autocuration,,,
587,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615457,,51,9995,,Hippocampus,B,,,Autocuration,,,
588,BAO_0000218,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,10000000.0,H,1,,CHEMBL615458,,51,12210,,Hippocampus,B,,,Expert,,,
589,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL615459,,51,13311,,Hippocampus,B,,,Expert,,,
590,BAO_0000219,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,D,1,CHO,CHEMBL615460,,51,2331,,,B,,,Expert,,449.0,
591,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,H,1,,CHEMBL615461,,51,1375,,,F,,,Autocuration,,,
592,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,H,1,,CHEMBL615462,,51,1375,,,F,,,Autocuration,,,
593,BAO_0000221,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,10000000.0,H,1,,CHEMBL615463,,51,11574,,Hippocampus,F,,,Autocuration,,,
594,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,2116.0,H,1,,CHEMBL615464,,51,12867,,Ileum,B,,,Autocuration,,,
595,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,H,1,,CHEMBL615465,,51,12867,,Ileum,B,,,Autocuration,,,
596,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,2116.0,H,1,,CHEMBL615466,,51,12867,,Ileum,B,,,Autocuration,,,
597,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,H,1,,CHEMBL615467,,51,12867,,Ileum,B,,,Autocuration,,,
598,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,H,1,,CHEMBL615468,,51,12867,,Ileum,B,,,Autocuration,,,
599,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,2116.0,H,1,,CHEMBL615469,,51,12867,,Ileum,B,,,Autocuration,,,
600,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615470,,51,11574,,,B,,,Autocuration,,,
601,BAO_0000357,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615471,,51,13114,,,B,,,Autocuration,,,
602,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615472,,51,13181,,,B,,,Autocuration,,,
603,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10000000.0,H,1,,CHEMBL883242,,106,10639,,Hippocampus,B,,,Autocuration,,,
604,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10000000.0,H,1,,CHEMBL615473,,106,10639,,Hippocampus,F,,,Autocuration,,,
605,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,H,1,CHO,CHEMBL615474,,11863,11883,,,B,,,Autocuration,,449.0,
606,BAO_0000357,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615475,,51,17785,,,B,,,Autocuration,,,
607,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,H,1,HeLa,CHEMBL615476,,51,1558,,,F,,,Autocuration,,308.0,
608,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,H,1,HeLa,CHEMBL615477,,51,1558,,,F,,,Autocuration,,308.0,
609,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615478,,51,15740,,,F,,,Autocuration,,,
610,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,H,1,CHO,CHEMBL615160,,51,17624,,,F,,,Autocuration,,449.0,
611,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,H,1,CHO,CHEMBL615161,,51,17624,,,F,,,Expert,,449.0,
612,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,H,1,CHO,CHEMBL615162,,51,17624,,,F,,,Autocuration,,449.0,
613,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,H,1,CHO,CHEMBL615163,,51,17624,,,F,,,Autocuration,,449.0,
614,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,1,CHO,CHEMBL615164,,51,17624,,,B,,,Expert,,449.0,
615,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,1,CHO,CHEMBL615165,,51,17624,,,B,,,Expert,,449.0,
616,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,H,1,CHO,CHEMBL615166,,51,17624,,,B,,,Autocuration,,449.0,
617,BAO_0000219,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,H,1,,CHEMBL615167,,51,14256,,,F,,,Autocuration,,,
618,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,D,1,HeLa,CHEMBL615168,,51,3445,,,B,,,Expert,,308.0,
619,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,D,1,HeLa,CHEMBL615169,,51,3445,,,B,,,Expert,,308.0,
620,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,D,1,CHO,CHEMBL615170,,51,17200,,,B,,,Expert,,449.0,
621,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,D,1,CHO,CHEMBL615171,,51,17200,,,B,,,Expert,,449.0,
622,BAO_0000019,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615694,,51,15180,,,F,,,Autocuration,,,
623,BAO_0000019,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615695,,51,15180,,,F,,,Autocuration,,,
624,BAO_0000019,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL615696,,51,16026,,,F,,,Autocuration,,,
625,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,H,1,CHO,CHEMBL615697,,51,2759,,,F,,,Autocuration,,449.0,
626,BAO_0000219,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,D,1,CHO,CHEMBL859410,,51,2759,,,F,,,Expert,,449.0,
627,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,H,1,CHO,CHEMBL615841,,51,2759,,,F,,,Autocuration,,449.0,
628,BAO_0000219,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,D,1,CHO,CHEMBL615842,,51,2759,,,F,,,Expert,,449.0,
629,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,H,1,CHO,CHEMBL835003,,51,2759,,,F,,,Autocuration,,449.0,
630,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,H,1,CHO,CHEMBL615843,,51,2759,,,F,,,Autocuration,,449.0,
631,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,D,1,CHO,CHEMBL615979,,51,2759,,,F,,,Expert,,449.0,
632,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,H,1,CHO,CHEMBL615980,,51,2759,,,F,,,Autocuration,,449.0,
633,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,D,1,CHO,CHEMBL615981,,51,2759,,,F,,,Expert,,449.0,
634,BAO_0000019,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,D,1,,CHEMBL615982,,51,3445,,,F,,,Expert,,,
635,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,D,1,,CHEMBL615983,,51,5272,,,F,,,Expert,,,
636,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,D,1,,CHEMBL615984,,51,5272,,,F,,,Expert,,,
637,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,D,1,,CHEMBL615985,,51,5272,,,F,,,Expert,,,
638,BAO_0000219,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,H,1,CHO,CHEMBL615986,,51,17624,,,F,,,Autocuration,,449.0,
639,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,H,1,CHO,CHEMBL615987,,51,17624,,,F,,,Autocuration,,449.0,
640,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,H,1,CHO,CHEMBL615988,,51,17624,,,F,,,Autocuration,,449.0,
641,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,H,1,CHO,CHEMBL615989,,51,17624,,,F,,,Expert,,449.0,
642,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,H,1,CHO,CHEMBL615990,,51,17624,,,F,,,Autocuration,,449.0,
643,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,H,1,CHO,CHEMBL615991,,51,17624,,,F,,,Autocuration,,449.0,
644,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,H,1,CHO,CHEMBL615992,,51,17624,,,F,,,Autocuration,,449.0,
645,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,H,1,CHO,CHEMBL615993,,51,17624,,,F,,,Autocuration,,449.0,
646,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,H,1,CHO,CHEMBL615994,,51,17624,,,F,,,Expert,,449.0,
647,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,H,1,CHO,CHEMBL615995,,51,17624,,,F,,,Autocuration,,449.0,
648,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,H,1,CHO,CHEMBL615996,,51,17624,,,F,,,Autocuration,,449.0,
649,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,H,1,CHO,CHEMBL615997,,51,17624,,,F,,,Autocuration,,449.0,
650,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,1,,CHEMBL615998,,51,6563,,,F,,,Autocuration,,,
651,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,1,,CHEMBL615999,,51,6563,,,F,,,Autocuration,,,
652,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,H,1,,CHEMBL616000,,51,6563,,,F,,,Autocuration,,,
653,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,1,HEK293,CHEMBL616001,,51,17296,,,F,,,Autocuration,,722.0,
654,BAO_0000019,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,D,1,,CHEMBL616002,,51,6876,,,F,,,Expert,,,
655,BAO_0000019,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,H,1,,CHEMBL616003,,51,6876,,,F,,,Expert,,,
656,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616004,,51,5272,,,F,,,Expert,,,
657,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,D,1,,CHEMBL616005,,51,5272,,,F,,,Expert,,,
658,BAO_0000019,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,H,1,,CHEMBL616006,,51,5548,,,F,,,Autocuration,,,
659,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,H,1,,CHEMBL616007,,51,5548,,,F,,,Expert,,,
660,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,H,1,,CHEMBL616008,,51,5548,,,F,,,Autocuration,,,
661,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,H,1,,CHEMBL616009,,51,5548,,,F,,,Autocuration,,,
662,BAO_0000019,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,H,1,,CHEMBL616010,,51,5929,,,F,,,Expert,,,
663,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,D,1,,CHEMBL616011,,51,5929,,,F,,,Expert,,,
664,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,D,1,,CHEMBL615740,,51,5929,,,F,,,Expert,,,
665,BAO_0000019,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL615741,,51,16245,,,F,,,Autocuration,,,
666,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,H,1,,CHEMBL615742,,51,5640,,,F,,,Expert,,,
667,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,H,1,,CHEMBL615743,,51,5640,,,F,,,Autocuration,,,
668,BAO_0000219,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,H,1,CHO,CHEMBL615744,,51,14509,,,F,,,Autocuration,,449.0,
669,BAO_0000219,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,H,1,CHO,CHEMBL615745,,51,14509,,,F,,,Expert,,449.0,
670,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,H,1,,CHEMBL615746,,51,15331,,,B,,,Autocuration,,,
671,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,H,1,,CHEMBL615747,,51,15331,,,B,,,Autocuration,,,
672,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,1,,CHEMBL615748,,51,6563,,,F,,,Autocuration,,,
673,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,H,1,,CHEMBL615749,,51,6563,,,F,,,Autocuration,,,
674,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,H,1,,CHEMBL615750,,51,6563,,,F,,,Autocuration,,,
675,BAO_0000019,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616259,,51,6563,,,F,,,Expert,,,
676,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,1,,CHEMBL616260,,51,6563,,,F,,,Autocuration,,,
677,BAO_0000019,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,D,1,,CHEMBL616261,,51,5272,,,F,,,Expert,,,
678,BAO_0000019,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,D,1,,CHEMBL616262,,51,5272,,,F,,,Expert,,,
679,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,D,1,,CHEMBL616263,,51,5272,,,F,,,Expert,,,
680,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,D,1,,CHEMBL616264,,51,5272,,,F,,,Expert,,,
681,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,D,1,,CHEMBL616265,,51,5272,,,F,,,Expert,,,
682,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,D,1,,CHEMBL616266,,51,5272,,,F,,,Expert,,,
683,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,D,1,,CHEMBL616267,,51,5272,,,F,,,Expert,,,
684,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,D,1,,CHEMBL616268,,51,5272,,,F,,,Expert,,,
685,BAO_0000357,Inhibition of human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616269,,51,16146,,,B,,,Expert,,,
686,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,1,CHO,CHEMBL884528,,51,17624,,,B,,,Autocuration,,449.0,
687,BAO_0000219,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,D,1,HEK293,CHEMBL616270,,105,13706,,,B,,,Expert,,722.0,
688,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616271,,51,15250,,,B,,,Autocuration,,449.0,
689,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,H,1,CHO,CHEMBL616272,,51,17624,,,F,,,Autocuration,,449.0,
690,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,H,1,,CHEMBL616273,,51,6861,,,B,,,Expert,,,
691,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616274,,51,17200,,,B,,,Expert,,,
692,BAO_0000219,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,H,1,CHO,CHEMBL616275,,51,17624,,,B,,,Autocuration,,449.0,
693,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,1,CHO,CHEMBL616276,,51,17624,,,B,,,Autocuration,,449.0,
694,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,U,1,,CHEMBL616277,In vivo,22226,12058,,,F,,,Autocuration,,,
695,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,U,1,,CHEMBL616278,In vivo,22226,12058,,,F,,,Autocuration,,,
696,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,U,1,,CHEMBL616279,In vivo,22226,12058,,,F,,,Autocuration,,,
697,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,U,1,,CHEMBL616280,In vivo,22226,12058,,,F,,,Autocuration,,,
698,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,U,1,,CHEMBL616281,In vivo,22226,12058,,,F,,,Autocuration,,,
699,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,U,1,,CHEMBL616282,In vivo,22226,12058,,,F,,,Autocuration,,,
700,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,U,1,,CHEMBL616283,In vivo,22226,12058,,,F,,,Autocuration,,,
701,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,U,1,,CHEMBL616284,In vivo,22226,12058,,,F,,,Autocuration,,,
702,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,U,1,,CHEMBL616285,In vivo,22226,12058,,,F,,,Autocuration,,,
703,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,U,1,,CHEMBL616286,In vivo,22226,12058,,,F,,,Autocuration,,,
704,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,U,1,,CHEMBL616287,In vivo,22226,12058,,,F,,,Autocuration,,,
705,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,U,1,,CHEMBL616288,In vivo,22226,12058,,,F,,,Autocuration,,,
706,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,U,1,,CHEMBL616289,In vivo,22226,12058,,,F,,,Autocuration,,,
707,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,U,1,,CHEMBL615610,In vivo,22226,12058,,,F,,,Autocuration,,,
708,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,U,1,,CHEMBL615611,In vivo,22226,12058,,,F,,,Autocuration,,,
709,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,U,1,,CHEMBL615612,In vivo,22226,12058,,,F,,,Autocuration,,,
710,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,U,1,,CHEMBL615613,In vivo,22226,12058,,,F,,,Autocuration,,,
711,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,U,1,,CHEMBL615614,In vivo,22226,12058,,,F,,,Autocuration,,,
712,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,U,1,,CHEMBL615615,In vivo,22226,12058,,,F,,,Autocuration,,,
713,BAO_0000019,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,H,1,,CHEMBL615616,,105093,11440,,,B,,,Autocuration,,,
714,BAO_0000249,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1898.0,H,1,,CHEMBL615617,,11923,6238,,Hypothalamus,B,,,Autocuration,,,
715,BAO_0000019,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,H,1,,CHEMBL615618,,10577,10046,,,B,,,Autocuration,,,
716,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,H,1,,CHEMBL615619,,10577,10046,,,B,,,Autocuration,,,
717,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,H,1,,CHEMBL615620,,10577,10046,,,B,,,Expert,,,
718,BAO_0000357,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,H,1,,CHEMBL615621,,55,167,,,B,,,Autocuration,,,
719,BAO_0000357,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,H,1,,CHEMBL615622,,55,167,,,B,,,Autocuration,,,
720,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,H,1,,CHEMBL615623,,12166,11520,,,F,,,Autocuration,,,
721,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,H,1,,CHEMBL615624,,12166,11520,,,F,,,Autocuration,,,
722,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,H,1,,CHEMBL615625,,12166,11520,,,F,,,Autocuration,,,
723,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,H,1,,CHEMBL767045,,12166,11520,,,F,,,Autocuration,,,
724,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,H,1,,CHEMBL615626,,55,135,,,F,,,Autocuration,,,
725,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,H,1,,CHEMBL615627,,55,135,,,F,,,Autocuration,,,
726,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,H,1,,CHEMBL615628,,55,11311,,,B,,,Autocuration,,,
727,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,H,1,,CHEMBL615629,,55,10193,,,B,,,Autocuration,,,
728,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from human whole blood,,D,1,,CHEMBL615630,,55,12281,,,B,,,Expert,,,
729,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL615631,,55,11311,,,B,,,Autocuration,,,
730,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,H,1,,CHEMBL615632,,17087,12576,,,F,,,Autocuration,,,
731,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,H,1,,CHEMBL615633,,17087,12281,,,B,,,Autocuration,,,
732,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,H,1,,CHEMBL615634,,17087,12576,,,F,,,Autocuration,,,
733,BAO_0000019,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,H,1,,CHEMBL615635,,55,11089,,,B,,,Expert,,,
734,BAO_0000357,In vitro inhibition of rat 5-Lipoxygenase,,H,1,,CHEMBL615636,,12166,11006,,,B,,,Expert,,,
735,BAO_0000357,Inhibitory activity against 5-Lipoxygenase,,D,1,,CHEMBL615637,,12166,11481,,,B,,,Expert,,,
736,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,H,1,RBL-1,CHEMBL615638,,12166,10864,,,B,,,Expert,,702.0,
737,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,H,1,RBL-1,CHEMBL615639,,12166,3595,,,B,,,Autocuration,,702.0,
738,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,H,1,RBL-1,CHEMBL615640,,12166,11311,,,B,,,Autocuration,,702.0,
739,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,H,1,,CHEMBL615796,,12166,11311,,,B,,,Autocuration,,,
740,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL615845,,12166,11311,,,B,,,Autocuration,,,
741,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,H,1,,CHEMBL615846,,12166,11006,,,B,,,Autocuration,,,
742,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,H,1,RBL-1,CHEMBL615847,,12166,3595,,,B,,,Autocuration,,702.0,
743,BAO_0000357,The compound was tested for inhibition of isolated 5-Lipoxygenase,,H,1,,CHEMBL615848,,12166,11311,,,B,,,Autocuration,,,
744,BAO_0000019,Ratio of IC50 against 5-LO and COX,,U,1,,CHEMBL615849,,22226,11481,,,B,,,Autocuration,,,
745,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,H,1,,CHEMBL615850,,12166,11006,,,B,,,Autocuration,,,
746,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,H,1,,CHEMBL615851,,12166,11006,,,B,,,Autocuration,,,
747,BAO_0000219,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,H,1,,CHEMBL615852,,12166,11311,,,B,,,Autocuration,,,
748,BAO_0000019,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,H,1,,CHEMBL615853,,12166,11006,,,F,,,Autocuration,,,
749,BAO_0000357,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,2367.0,H,1,,CHEMBL884527,,120,4288,,Prostate gland,B,,,Autocuration,,,
750,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,U,1,,CHEMBL872871,,22226,7587,,,B,,,Autocuration,,,
751,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,U,1,,CHEMBL615854,,22226,7587,,,B,,,Autocuration,,,
752,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,U,1,,CHEMBL767046,,22226,7587,,,B,,,Autocuration,,,
753,BAO_0000357,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,H,1,,CHEMBL615855,,10732,11249,,,B,,,Autocuration,,,
754,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,D,1,,CHEMBL615856,,12198,8003,,,F,,,Expert,,,
755,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,D,1,,CHEMBL615857,,12198,8003,,,F,,,Expert,,,
756,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,D,1,,CHEMBL615858,,12198,8003,,,F,,,Expert,,,
757,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10000000.0,H,1,,CHEMBL615859,,10576,12416,,Hippocampus,B,,,Expert,,,
758,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,H,1,,CHEMBL615860,,51,16293,,,B,,,Autocuration,,,
759,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,U,1,,CHEMBL615861,,22226,13047,,,B,,,Autocuration,,,
760,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,U,1,,CHEMBL615862,,22226,13047,,,B,,,Autocuration,,,
761,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,U,1,,CHEMBL615863,,22226,13047,,,B,,,Autocuration,,,
762,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,U,1,,CHEMBL615864,,22226,13047,,,B,,,Autocuration,,,
763,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,H,1,,CHEMBL615865,,104744,10085,,Hippocampus,B,,,Autocuration,,,
764,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,H,1,,CHEMBL615866,,104744,10085,,Hippocampus,B,,,Autocuration,,,
765,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,H,1,,CHEMBL615867,,104744,10085,,Hippocampus,B,,,Autocuration,,,
766,BAO_0000249,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,H,1,,CHEMBL615868,,104744,9841,Membranes,,B,,,Autocuration,,,
767,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,D,1,,CHEMBL615869,,104744,8822,,,B,,,Autocuration,,,
768,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,D,1,,CHEMBL615870,,104744,9806,,,B,,,Autocuration,,,
769,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,D,1,,CHEMBL615871,,104744,9806,,,B,,,Autocuration,,,
770,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,H,1,,CHEMBL615872,,104744,8868,,,B,,,Autocuration,,,
771,BAO_0000221,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,10000000.0,H,1,,CHEMBL833492,,104744,9036,,Hippocampus,B,,,Autocuration,,,
772,BAO_0000221,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,10000000.0,H,1,,CHEMBL615873,,104744,11374,,Hippocampus,B,,,Autocuration,,,
773,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,H,1,,CHEMBL615479,,104744,10881,,,B,,,Autocuration,,,
774,BAO_0000019,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,H,1,,CHEMBL615480,,104744,8822,,,B,,,Autocuration,,,
775,BAO_0000249,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,D,1,,CHEMBL615481,,104744,9806,,,B,,,Autocuration,,,
776,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,1,,CHEMBL872869,,104744,15463,,,B,,,Autocuration,,,
777,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,1,,CHEMBL615482,,104744,15463,,,B,,,Autocuration,,,
778,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,H,1,,CHEMBL615483,,104744,14542,,Brain,B,,,Autocuration,,,
779,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,H,1,,CHEMBL615484,,104744,14542,,Brain,B,,,Autocuration,,,
780,BAO_0000019,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,H,1,,CHEMBL615485,,104744,8569,,,B,,,Autocuration,,,
781,BAO_0000224,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,D,1,,CHEMBL615486,,104744,10062,,,B,,,Autocuration,,,
782,BAO_0000224,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,H,1,,CHEMBL615487,,104744,4771,,,B,,,Autocuration,,,
783,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,H,1,,CHEMBL615488,,104744,10062,,,B,,,Autocuration,,,
784,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,H,1,,CHEMBL615489,,104744,10062,,,B,,,Autocuration,,,
785,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,H,1,,CHEMBL615389,,104744,10062,,,B,,,Autocuration,,,
786,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,H,1,,CHEMBL615390,,104744,15463,,,B,,,Autocuration,,,
787,BAO_0000019,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,H,1,,CHEMBL615391,,104744,15463,,,B,,,Autocuration,,,
788,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,H,1,,CHEMBL615392,,104744,9098,,,B,,,Autocuration,,,
789,BAO_0000019,Affinity for 5-hydroxytryptamine 1 receptor,,U,1,,CHEMBL615393,,22226,3070,,,B,,,Autocuration,,,
790,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,955.0,H,1,,CHEMBL615394,,104744,14542,,Brain,B,,,Autocuration,,,
791,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,H,1,,CHEMBL615395,,104744,14542,,Brain,B,,,Autocuration,,,
792,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,H,1,,CHEMBL615396,,104744,6398,,,B,,,Autocuration,,,
793,BAO_0000221,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,955.0,H,1,,CHEMBL615397,,104744,1344,,Brain,B,,,Autocuration,,,
794,BAO_0000019,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,1,,CHEMBL615398,,104744,11963,,,B,,,Autocuration,,,
795,BAO_0000019,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,U,1,,CHEMBL615399,,22226,8908,,,B,,,Autocuration,,,
796,BAO_0000019,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,H,1,,CHEMBL615400,,104744,9098,,,B,,,Autocuration,,,
797,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,D,1,,CHEMBL615401,,104744,8841,,,B,,,Autocuration,,,
798,BAO_0000019,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,U,1,,CHEMBL615402,,22226,8814,,,B,,,Autocuration,,,
799,BAO_0000019,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,H,1,,CHEMBL615403,,104744,11752,,,B,,,Autocuration,,,
800,BAO_0000221,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,955.0,H,1,,CHEMBL615404,,104744,11642,,Brain,B,,,Autocuration,,,
801,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,H,1,,CHEMBL615781,,104744,11642,,,B,,,Autocuration,,,
802,BAO_0000220,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,955.0,H,1,,CHEMBL615782,,104744,9231,,Brain,B,,,Autocuration,,,
803,BAO_0000221,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,955.0,H,1,,CHEMBL615783,,104744,11351,,Brain,B,,,Autocuration,,,
804,BAO_0000019,Compound was tested for binding affinity against 5-HT1 receptor,,U,1,,CHEMBL873481,,22226,4639,,,B,,,Autocuration,,,
805,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,U,1,,CHEMBL615784,,22226,1205,,,B,,,Autocuration,,,
806,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,H,1,,CHEMBL615785,,10576,10025,,,B,,,Expert,,,
807,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL615786,,10576,13241,,,F,,,Autocuration,,,
808,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,H,1,,CHEMBL615787,In vivo,10576,16245,,,F,,,Autocuration,,,
809,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,H,1,,CHEMBL615788,In vivo,10576,16245,,,F,,,Autocuration,,,
810,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL767044,,10576,12438,,,F,,,Autocuration,,,
811,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,H,1,,CHEMBL615789,In vivo,10576,16245,,,F,,,Autocuration,,,
812,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,H,1,,CHEMBL615790,In vivo,10576,16245,,,F,,,Autocuration,,,
813,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,H,1,,CHEMBL615813,,10576,15740,,,F,,,Autocuration,,,
814,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,H,1,,CHEMBL615814,,10576,15535,,,F,,,Autocuration,,,
815,BAO_0000219,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,H,1,,CHEMBL615815,,51,15535,,,F,,,Expert,,,
816,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,H,1,,CHEMBL615816,,10576,15535,,,F,,,Autocuration,,,
817,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,H,1,,CHEMBL615817,,10576,9888,,,B,,,Expert,,,
818,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10000000.0,H,1,,CHEMBL615818,,10576,10085,,Hippocampus,B,,,Autocuration,,,
819,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10000000.0,H,1,,CHEMBL615819,,10576,10085,,Hippocampus,B,,,Autocuration,,,
820,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,H,1,,CHEMBL615820,,10576,17331,Membranes,,B,,,Expert,,,
821,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10000000.0,D,1,,CHEMBL615821,,10576,10845,,Hippocampus,B,,,Expert,,,
822,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10000000.0,D,1,,CHEMBL615822,,10576,10845,,Hippocampus,B,,,Expert,,,
823,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL615823,,10576,10845,,Hippocampus,B,,,Expert,,,
824,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10000000.0,D,1,,CHEMBL615824,,10576,10845,,Hippocampus,B,,,Expert,,,
825,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10000000.0,D,1,,CHEMBL615825,,10576,10845,,Hippocampus,B,,,Expert,,,
826,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615826,,10576,13730,,,B,,,Expert,,,
827,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615827,,10576,13508,,,B,,,Expert,,,
828,BAO_0000249,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL615828,,10576,13508,,Hippocampus,B,,,Expert,,,
829,BAO_0000221,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL615829,,10576,12073,,Hippocampus,B,,,Expert,,,
830,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL615830,,10576,4671,,Hippocampus,B,,,Autocuration,,,
831,BAO_0000221,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10000000.0,H,1,,CHEMBL615831,,10576,13631,,Hippocampus,B,,,Expert,,,
832,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615832,,10576,12438,,,B,,,Autocuration,,,
833,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,H,1,,CHEMBL615833,,10576,10483,,,B,,,Autocuration,,,
834,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10000000.0,H,1,,CHEMBL615834,,10576,10483,,Hippocampus,B,,,Autocuration,,,
835,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,H,1,,CHEMBL615835,,10576,12352,,,B,,,Intermediate,,,
836,BAO_0000249,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10000000.0,H,1,,CHEMBL615836,,10576,14732,,Hippocampus,B,,,Autocuration,,,
837,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,D,1,,CHEMBL615837,,10576,11049,,,B,,,Expert,,,
838,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,D,1,,CHEMBL615838,,10576,11049,,,B,,,Expert,,,
839,BAO_0000249,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,H,1,,CHEMBL615839,,10576,13657,,,B,,,Expert,,,
840,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,H,1,,CHEMBL884525,,10576,11473,,,B,,,Autocuration,,,
841,BAO_0000249,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,H,1,,CHEMBL615840,,10576,2014,,,B,,,Autocuration,,,
842,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL615405,,10576,3086,,Hippocampus,B,,,Expert,,,
843,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,H,1,,CHEMBL615406,,10576,15854,,,B,,,Expert,,,
844,BAO_0000221,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10000000.0,H,1,,CHEMBL615900,,10576,10922,,Hippocampus,B,,,Expert,,,
845,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10000000.0,H,1,,CHEMBL615901,,10576,13346,,Hippocampus,B,,,Expert,,,
846,BAO_0000357,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,H,1,,CHEMBL615902,,10576,15311,,,B,,,Expert,,,
847,BAO_0000221,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10000000.0,H,1,,CHEMBL615903,,10576,10922,,Hippocampus,B,,,Autocuration,,,
848,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,H,1,,CHEMBL615904,,10576,10025,,,B,,,Autocuration,,,
849,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,H,1,,CHEMBL615905,,10576,10025,,,B,,,Expert,,,
850,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,H,1,,CHEMBL615906,,10576,9742,,,B,,,Autocuration,,,
851,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,H,1,,CHEMBL615907,,10576,9742,,,F,,,Autocuration,,,
852,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,H,1,,CHEMBL615908,,10576,12304,,,B,,,Expert,,,
853,BAO_0000221,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10000000.0,H,1,,CHEMBL615909,,10576,15789,,Hippocampus,B,,,Autocuration,,,
854,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,H,1,,CHEMBL615910,,10576,9912,,,B,,,Autocuration,,,
855,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,H,1,,CHEMBL615911,,10576,9912,,,B,,,Autocuration,,,
856,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,H,1,,CHEMBL615912,,10576,9912,,,B,,,Autocuration,,,
857,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615913,,10576,16693,,,B,,,Expert,,,
858,BAO_0000357,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,H,1,,CHEMBL615914,,10576,13276,,,B,,,Expert,,,
859,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10000000.0,H,1,,CHEMBL615915,,10576,12678,,Hippocampus,B,,,Autocuration,,,
860,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,H,1,,CHEMBL615916,,10576,11825,,,B,,,Autocuration,,,
861,BAO_0000357,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,H,1,,CHEMBL615917,,10576,12443,,,B,,,Expert,,,
862,BAO_0000357,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615918,,10576,13830,,,B,,,Expert,,,
863,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10000000.0,H,1,,CHEMBL615919,,10576,14286,,Hippocampus,B,,,Expert,,,
864,BAO_0000221,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,D,1,,CHEMBL615920,,10576,14356,,Hippocampus,B,,,Expert,,,
865,BAO_0000357,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615921,,10576,15306,,,B,,,Autocuration,,,
866,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,H,1,,CHEMBL615922,,10576,15306,,,B,,,Expert,,,
867,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,D,1,,CHEMBL881290,,10576,16616,,,F,,,Expert,,,
868,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10000000.0,H,1,,CHEMBL615923,,10576,3651,,Hippocampus,B,,,Autocuration,,,
869,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL615924,,10576,14331,,Hippocampus,F,,,Autocuration,,,
870,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL615925,,10576,14331,,Hippocampus,F,,,Autocuration,,,
871,BAO_0000357,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL615926,,10576,14178,,,B,,,Expert,,,
872,BAO_0000019,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL615927,,10576,10639,,,B,,,Expert,,,
873,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,H,1,,CHEMBL615928,,10576,12306,,Hippocampus,B,,,Autocuration,,,
874,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,D,1,,CHEMBL615929,,10576,1348,,,B,,,Expert,,,
875,BAO_0000221,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL615930,,10576,13605,,Hippocampus,B,,,Autocuration,,,
876,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,1,CHO,CHEMBL615931,,51,17624,,,B,,,Autocuration,,449.0,
877,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,H,1,CHO,CHEMBL615932,,51,17624,,,F,,,Autocuration,,449.0,
878,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,H,1,CHO,CHEMBL615933,,51,17624,,,F,,,Autocuration,,449.0,
879,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615934,,51,15267,,,B,,,Autocuration,,,
880,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,H,1,,CHEMBL615935,,51,16532,,,B,,,Autocuration,,,
881,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,1,,CHEMBL615936,,51,6563,,,F,,,Autocuration,,,
882,BAO_0000219,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,H,1,CHO,CHEMBL615937,,51,4751,,,B,,,Autocuration,,449.0,
883,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615938,,51,15463,,,B,,,Autocuration,,,
884,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,H,1,,CHEMBL615797,,51,3805,,,B,,,Autocuration,,,
885,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615798,,51,5640,,,B,,,Autocuration,,,
886,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,H,1,,CHEMBL872870,,51,6563,,,B,,,Autocuration,,,
887,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,H,1,,CHEMBL615799,,51,5548,,,B,,,Autocuration,,,
888,BAO_0000357,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615800,,51,6347,,,B,,,Autocuration,,,
889,BAO_0000219,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,1,HEK293,CHEMBL615801,,51,17296,,,F,,,Autocuration,,722.0,
890,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,H,1,,CHEMBL615802,,51,13047,,,B,,,Autocuration,,,
891,BAO_0000357,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,H,1,,CHEMBL615803,,51,15740,,,B,,,Autocuration,,,
892,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,H,1,,CHEMBL835002,,51,5640,,,F,,,Expert,,,
893,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,H,1,,CHEMBL615804,,51,5640,,,F,,,Autocuration,,,
894,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,H,1,HeLa,CHEMBL615805,,51,17211,,,B,,,Expert,,308.0,
895,BAO_0000219,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,H,1,CHO,CHEMBL615806,,51,4751,,,B,,,Autocuration,,449.0,
896,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,D,1,,CHEMBL615807,,51,6491,,,B,,,Expert,,,
897,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,H,1,,CHEMBL615808,,51,4707,,,B,,,Autocuration,,,
898,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL615809,,51,13910,,,B,,,Expert,,,
899,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,H,1,HeLa,CHEMBL615810,,51,16190,,,B,,,Autocuration,,308.0,
900,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615811,,51,16633,,,B,,,Autocuration,,,
901,BAO_0000219,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,H,1,CHO,CHEMBL615812,,51,11898,,,B,,,Autocuration,,449.0,
902,BAO_0000219,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,1,CHO,CHEMBL615751,,51,11898,,,B,,,Autocuration,,449.0,
903,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615752,,51,14331,,,B,,,Autocuration,,,
904,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,H,1,CHO,CHEMBL615753,,51,17624,,,B,,,Expert,,449.0,
905,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,H,1,CHO,CHEMBL615754,,51,17624,,,B,,,Autocuration,,449.0,
906,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615755,,51,3307,,,B,,,Autocuration,,,
907,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,D,1,CHO,CHEMBL615756,,51,6563,,,B,,,Expert,,449.0,
908,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615757,,51,14165,,,B,,,Autocuration,,,
909,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL615758,,51,5732,,,B,,,Autocuration,,,
910,BAO_0000357,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,H,1,,CHEMBL615759,,51,13366,,,B,,,Expert,,,
911,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615760,,51,17626,,,B,,,Autocuration,,,
912,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,H,1,HeLa,CHEMBL615761,,51,6588,,,B,,,Expert,,308.0,
913,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,H,1,,CHEMBL872104,,51,16209,,,B,,,Autocuration,,,
914,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615762,,51,15463,,,B,,,Autocuration,,,
915,BAO_0000357,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615763,,51,15463,,,B,,,Autocuration,,,
916,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL615764,,51,14770,,,B,,,Autocuration,,,
917,BAO_0000219,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,H,1,Cell line,CHEMBL615765,,51,16245,,,B,,,Autocuration,,1167.0,
918,BAO_0000019,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,H,1,,CHEMBL615766,,51,16245,,,B,,,Autocuration,,,
919,BAO_0000357,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615767,,51,5548,,,B,,,Autocuration,,,
920,BAO_0000357,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615768,,51,5548,,,B,,,Expert,,,
921,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615769,,51,5548,,,B,,,Autocuration,,,
922,BAO_0000357,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,H,1,,CHEMBL615770,,51,6876,,,B,,,Expert,,,
923,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615771,,51,2598,,,B,,,Autocuration,,,
924,BAO_0000357,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,H,1,,CHEMBL615772,,51,17785,,,B,,,Expert,,,
925,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL615773,,51,6013,,,B,,,Autocuration,,,
926,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615774,,51,5929,,,B,,,Expert,,,
927,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615775,,51,16633,,,B,,,Autocuration,,,
928,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL615776,,51,1558,,,B,,,Autocuration,,,
929,BAO_0000357,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615777,,51,16026,,,B,,,Expert,,,
930,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,H,1,,CHEMBL615778,,51,12469,,,B,,,Autocuration,,,
931,BAO_0000357,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,D,1,,CHEMBL615779,,51,15874,,,B,,,Expert,,,
932,BAO_0000357,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,H,1,,CHEMBL615780,,51,15874,,,B,,,Autocuration,,,
933,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616298,,51,3935,,,B,,,Autocuration,,,
934,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616299,,51,15818,,,B,,,Autocuration,,,
935,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL616300,,51,13706,,,B,,,Autocuration,,485.0,
936,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,H,1,CHO-K1,CHEMBL616301,,51,13729,,,F,,,Expert,,485.0,
937,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616302,,51,15413,,,B,,,Autocuration,,,
938,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,H,1,,CHEMBL616117,,51,15413,,,B,,,Autocuration,,,
939,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,H,1,,CHEMBL616118,,51,15413,,,B,,,Autocuration,,,
940,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,H,1,,CHEMBL616119,,51,15413,,,B,,,Autocuration,,,
941,BAO_0000219,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,D,1,HeLa,CHEMBL616120,,51,3445,,,B,,,Expert,,308.0,
942,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616121,,51,15740,,,B,,,Autocuration,,,
943,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,H,1,,CHEMBL616122,,51,15740,,,B,,,Autocuration,,,
944,BAO_0000357,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616123,,51,17626,,,B,,,Autocuration,,,
945,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616124,,51,4234,,,B,,,Expert,,,
946,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,H,1,,CHEMBL616125,,51,5640,,,B,,,Expert,,,
947,BAO_0000357,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,H,1,,CHEMBL616126,,51,5272,,,B,,,Expert,,,
948,BAO_0000219,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,H,1,CHO,CHEMBL616127,,51,4622,,,B,,,Autocuration,,449.0,
949,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616128,,51,17085,,,B,,,Expert,,,
950,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,H,1,,CHEMBL616129,,51,3025,,,B,,,Autocuration,,,
951,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616130,,51,15315,,,B,,,Expert,,,
952,BAO_0000357,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,H,1,,CHEMBL616131,,51,15267,,,B,,,Autocuration,,,
953,BAO_0000219,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,H,1,HeLa,CHEMBL616132,,51,17158,,,B,,,Autocuration,,308.0,
954,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,D,1,HeLa,CHEMBL616133,,51,14214,,,B,,,Expert,,308.0,
955,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616134,,51,17133,,,B,,,Autocuration,,,
956,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,H,1,,CHEMBL616135,,51,16532,,,B,,,Autocuration,,,
957,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor subtype,,D,1,,CHEMBL616136,,51,2391,,,B,,,Expert,,,
958,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,H,1,,CHEMBL616137,,51,14447,,,B,,,Autocuration,,,
959,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,H,1,,CHEMBL872105,,51,14447,,,B,,,Autocuration,,,
960,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,H,1,,CHEMBL616138,,51,15086,,,B,,,Autocuration,,,
961,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616139,,51,13051,,,B,,,Expert,,,
962,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,H,1,,CHEMBL616140,,51,16026,,,F,,,Autocuration,,,
963,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,H,1,,CHEMBL616141,,51,17085,,,B,,,Expert,,,
964,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616142,,51,17133,,,B,,,Autocuration,,,
965,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,H,1,,CHEMBL616143,,51,17133,,,B,,,Autocuration,,,
966,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,H,1,HeLa,CHEMBL616144,,51,17211,,,B,,,Autocuration,,308.0,
967,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,H,1,HeLa,CHEMBL616145,,51,17211,,,B,,,Autocuration,,308.0,
968,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,H,1,HeLa,CHEMBL616012,,51,17211,,,B,,,Autocuration,,308.0,
969,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,H,1,HeLa,CHEMBL616013,,51,17211,,,B,,,Autocuration,,308.0,
970,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,H,1,,CHEMBL616014,,51,16394,,,F,,,Autocuration,,,
971,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,H,1,,CHEMBL616015,,51,16394,,,F,,,Autocuration,,,
972,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,H,1,,CHEMBL616016,,51,16394,,,F,,,Autocuration,,,
973,BAO_0000218,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,H,1,,CHEMBL616017,In vivo,51,16394,,,F,,,Autocuration,,,
974,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,H,1,,CHEMBL616018,,51,16394,,,B,,,Autocuration,,,
975,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,H,1,,CHEMBL616019,,51,15740,,,F,,,Autocuration,,,
976,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,H,1,,CHEMBL616020,,51,15740,,,F,,,Autocuration,,,
977,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL858018,,51,15740,,,B,,,Autocuration,,,
978,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,1,HEK293,CHEMBL616021,,51,17296,,,F,,,Autocuration,,722.0,
979,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,H,1,,CHEMBL616022,,51,5640,,,F,,,Expert,,,
980,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,H,1,,CHEMBL616023,,51,5640,,,F,,,Autocuration,,,
981,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,H,1,,CHEMBL616024,,51,5640,,,F,,,Autocuration,,,
982,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,H,1,,CHEMBL616025,,51,5640,,,F,,,Autocuration,,,
983,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,H,1,CHO,CHEMBL616026,,51,2759,,,F,,,Autocuration,,449.0,
984,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,H,1,,CHEMBL616027,,51,16394,,,F,,,Autocuration,,,
985,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,D,1,,CHEMBL616028,,51,16394,,,F,,,Expert,,,
986,BAO_0000019,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,D,1,,CHEMBL616029,,51,3445,,,F,,,Expert,,,
987,BAO_0000219,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,H,1,CHO,CHEMBL616030,,51,4316,,,B,,,Expert,,449.0,
988,BAO_0000019,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,H,1,,CHEMBL616031,,51,4316,,,B,,,Expert,,,
989,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,D,1,,CHEMBL616032,,51,15180,,,F,,,Expert,,,
990,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,D,1,,CHEMBL616033,,51,15180,,,F,,,Expert,,,
991,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,1,,CHEMBL616034,,51,15042,,,F,,,Autocuration,,,
992,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,1,,CHEMBL616035,,51,15042,,,F,,,Autocuration,,,
993,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616036,,51,15042,,,F,,,Autocuration,,,
994,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,1,,CHEMBL616037,,51,15042,,,F,,,Autocuration,,,
995,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,1,,CHEMBL616038,,51,15042,,,F,,,Autocuration,,,
996,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,1,,CHEMBL616039,,51,15042,,,F,,,Autocuration,,,
997,BAO_0000019,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616040,,51,15042,,,F,,,Autocuration,,,
998,BAO_0000219,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,D,1,HeLa,CHEMBL616041,,51,15180,,,F,,,Expert,,308.0,
999,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,D,1,HeLa,CHEMBL616042,,51,15180,,,F,,,Expert,,308.0,
1000,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,D,1,HeLa,CHEMBL616043,,51,15180,,,F,,,Expert,,308.0,
1001,BAO_0000019,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL616044,,51,16245,,,F,,,Autocuration,,,
1002,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL616045,,51,16026,,,F,,,Autocuration,,,
1003,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,1,HEK293,CHEMBL616046,,51,17296,,,F,,,Autocuration,,722.0,
1004,BAO_0000219,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,H,1,CHO,CHEMBL616047,,51,2759,,,F,,,Autocuration,,449.0,
1005,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,H,1,CHO,CHEMBL616048,,51,2759,,,F,,,Autocuration,,449.0,
1006,BAO_0000219,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,D,1,CHO,CHEMBL616049,,51,2759,,,F,,,Expert,,449.0,
1007,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,H,1,CHO,CHEMBL616050,,51,2759,,,F,,,Autocuration,,449.0,
1008,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,H,1,,CHEMBL616051,,51,15419,,,F,,,Expert,,,
1009,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,H,1,,CHEMBL616212,,51,15419,,,F,,,Autocuration,,,
1010,BAO_0000019,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL616213,,51,16026,,,F,,,Autocuration,,,
1011,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,H,1,,CHEMBL616214,In vitro,51,1414,,,B,,,Expert,,,
1012,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,H,1,,CHEMBL616215,In vitro,51,1414,,,B,,,Expert,,,
1013,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL616216,,51,12861,,,B,,,Autocuration,,,
1014,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,1,,CHEMBL616217,,51,12861,,,B,,,Autocuration,,,
1015,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616218,,51,5104,,,B,,,Autocuration,,,
1016,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616219,,51,5105,,,B,,,Autocuration,,,
1017,BAO_0000357,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616220,,51,16312,,,B,,,Autocuration,,,
1018,BAO_0000357,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL833493,,51,15180,,,B,,,Expert,,,
1019,BAO_0000357,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616221,,51,5033,,,B,,,Autocuration,,,
1020,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,D,1,CHO,CHEMBL616222,,51,16909,,,B,,,Expert,,449.0,
1021,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616223,,51,2590,,,F,,,Autocuration,,,
1022,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,H,1,,CHEMBL616224,,51,2590,,,F,,,Autocuration,,,
1023,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,H,1,,CHEMBL616225,,51,16394,,,B,,,Expert,,,
1024,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,D,1,HEK293,CHEMBL616226,,51,4540,,,B,,,Expert,,722.0,
1025,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,H,1,HEK293,CHEMBL616227,,51,17296,,,B,,,Autocuration,,722.0,
1026,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,H,1,HEK293,CHEMBL616228,,51,17296,,,B,,,Autocuration,,722.0,
1027,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,H,1,HEK293,CHEMBL616229,,51,15779,,,B,,,Autocuration,,722.0,
1028,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,H,1,HEK293,CHEMBL616230,,51,15779,,,B,,,Autocuration,,722.0,
1029,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,H,1,HEK293,CHEMBL616231,,51,15779,,,B,,,Autocuration,,722.0,
1030,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616232,,51,6166,,,B,,,Autocuration,,,
1031,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,H,1,HEK293,CHEMBL616233,,51,15779,,,B,,,Autocuration,,722.0,
1032,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,H,1,HEK293,CHEMBL857973,,51,4199,,,B,,,Autocuration,,722.0,
1033,BAO_0000219,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,H,1,,CHEMBL616234,,51,15316,,,B,,,Autocuration,,,
1034,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616235,,51,14875,,,B,,,Autocuration,,,
1035,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,H,1,HeLa,CHEMBL616236,,51,14727,,,B,,,Expert,,308.0,
1036,BAO_0000019,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,H,1,,CHEMBL616237,,51,14727,,,B,,,Expert,,,
1037,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,H,1,HEK293,CHEMBL616238,,51,15146,,,B,,,Autocuration,,722.0,
1038,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,H,1,HEK293,CHEMBL616239,,51,5213,,,B,,,Autocuration,,722.0,
1039,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,H,1,,CHEMBL616240,,51,16429,,,B,,,Autocuration,,,
1040,BAO_0000219,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,D,1,HeLa,CHEMBL616241,,51,15042,,,B,,,Expert,,308.0,
1041,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,H,1,HEK293,CHEMBL616242,,51,14818,,,B,,,Autocuration,,722.0,
1042,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,H,1,HEK293,CHEMBL616243,,51,4829,,,B,,,Autocuration,,722.0,
1043,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616244,,51,17200,,,B,,,Expert,,,
1044,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616245,,51,13051,,,B,,,Autocuration,,,
1045,BAO_0000357,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,H,1,,CHEMBL616246,,106,5486,,,B,,,Autocuration,,,
1046,BAO_0000357,Binding affinity against 5-HT1D receptor,,H,1,,CHEMBL616247,,105,5254,,,B,,,Autocuration,,,
1047,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616248,,105,5254,,,B,,,Autocuration,,,
1048,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,H,1,,CHEMBL616249,,107,15331,,,B,,,Autocuration,,,
1049,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,H,1,,CHEMBL616250,,10576,13506,,,B,,,Autocuration,,,
1050,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616251,,51,15267,,,B,,,Autocuration,,,
1051,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,H,1,,CHEMBL616252,In vivo,11863,16616,,,F,,,Autocuration,,,
1052,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,H,1,,CHEMBL616253,In vivo,11863,16616,,,F,,,Autocuration,,,
1053,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,H,1,,CHEMBL616254,In vivo,11863,16616,,,F,,,Autocuration,,,
1054,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,D,1,,CHEMBL616255,,11863,16616,,,F,,,Expert,,,
1055,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,D,1,,CHEMBL832872,,11863,16616,,,F,,,Expert,,,
1056,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,D,1,,CHEMBL616256,,11863,16616,,,F,,,Expert,,,
1057,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,D,1,,CHEMBL616257,,11863,16616,,,F,,,Expert,,,
1058,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,D,1,,CHEMBL616258,,11863,16616,,,F,,,Expert,,,
1059,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,D,1,,CHEMBL616384,,11863,16616,,,F,,,Expert,,,
1060,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10000000.0,H,1,,CHEMBL616385,,11863,10297,,Hippocampus,B,,,Autocuration,,,
1061,BAO_0000357,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,H,1,,CHEMBL616386,,11863,13704,,,B,,,Expert,,,
1062,BAO_0000221,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10000000.0,D,1,,CHEMBL616387,,11863,10297,,Hippocampus,B,,,Expert,,,
1063,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10000000.0,H,1,,CHEMBL616388,,11863,10297,,Hippocampus,B,,,Autocuration,,,
1064,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10000000.0,D,1,,CHEMBL616389,,11863,10297,,Hippocampus,B,,,Expert,,,
1065,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10000000.0,H,1,,CHEMBL616390,,11863,10297,,Hippocampus,B,,,Autocuration,,,
1066,BAO_0000357,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,H,1,,CHEMBL616391,,11863,217,,,B,,,Autocuration,,,
1067,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10000000.0,D,1,,CHEMBL616392,,11863,10297,,Hippocampus,B,,,Expert,,,
1068,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616393,,51,4921,,,B,,,Autocuration,,,
1069,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,H,1,,CHEMBL616394,,51,4921,,,B,,,Autocuration,,,
1070,BAO_0000019,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,H,1,,CHEMBL616395,,51,4996,,,B,,,Autocuration,,,
1071,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT1A receptor,,H,1,,CHEMBL616396,,51,12918,,,B,,,Autocuration,,,
1072,BAO_0000019,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,H,1,,CHEMBL872907,,51,5333,,,B,,,Autocuration,,,
1073,BAO_0000019,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,H,1,,CHEMBL616397,,51,4437,,,B,,,Autocuration,,,
1074,BAO_0000019,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,H,1,,CHEMBL616398,,51,1742,,,B,,,Autocuration,,,
1075,BAO_0000357,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616399,,51,16688,,,B,,,Expert,,,
1076,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL857065,,51,12861,,,B,,,Autocuration,,,
1077,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,H,1,,CHEMBL616400,,51,12861,,,B,,,Expert,,,
1078,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,H,1,,CHEMBL616401,,51,12861,,,B,,,Autocuration,,,
1079,BAO_0000019,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,H,1,,CHEMBL616402,,10624,12490,,,B,,,Expert,,,
1080,BAO_0000019,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616403,,51,11828,,,B,,,Expert,,,
1081,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,10000000.0,H,1,,CHEMBL616404,,51,11866,,Hippocampus,B,,,Autocuration,,,
1082,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,H,1,,CHEMBL616405,,51,12827,,,B,,,Autocuration,,,
1083,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,H,1,,CHEMBL616406,,51,12918,,,B,,,Autocuration,,,
1084,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,H,1,,CHEMBL616407,,51,12919,,,F,,,Expert,,,
1085,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,H,1,,CHEMBL616408,,51,13047,,,B,,,Autocuration,,,
1086,BAO_0000249,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,D,1,,CHEMBL616409,,10576,15796,,,B,,,Expert,,,
1087,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10000000.0,D,1,,CHEMBL616410,,10576,3651,,Hippocampus,B,,,Expert,,,
1088,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,H,1,,CHEMBL616411,,10576,188,,,B,,,Autocuration,,,
1089,BAO_0000249,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,D,1,,CHEMBL616412,,10576,16616,Membranes,,F,,,Expert,,,
1090,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10000000.0,D,1,,CHEMBL616413,,10576,16616,Membranes,Hippocampus,F,,,Expert,,,
1091,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,H,1,,CHEMBL616414,,10576,12306,,Hippocampus,B,,,Autocuration,,,
1092,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10000000.0,D,1,,CHEMBL616415,,10576,17167,,Hippocampus,B,,,Expert,,,
1093,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,H,1,,CHEMBL616416,,10576,14776,,,B,,,Autocuration,,,
1094,BAO_0000357,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,H,1,,CHEMBL616417,,10576,12158,,,B,,,Expert,,,
1095,BAO_0000357,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,H,1,,CHEMBL616418,,10576,13481,,,B,,,Autocuration,,,
1096,BAO_0000219,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,H,1,,CHEMBL616419,In vitro,10576,13427,,,B,,,Autocuration,,,
1097,BAO_0000357,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,H,1,,CHEMBL616420,,10576,10210,,,B,,,Autocuration,,,
1098,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,H,1,,CHEMBL616421,,10576,10205,Membranes,,B,,,Autocuration,,,
1099,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,H,1,,CHEMBL616422,,10576,10205,Membranes,,B,,,Autocuration,,,
1100,BAO_0000249,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,H,1,,CHEMBL616423,,10576,10205,Membranes,,B,,,Expert,,,
1101,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,D,1,,CHEMBL616424,,10576,12280,,,B,,,Expert,,,
1102,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616425,,10576,17386,,,B,,,Expert,,,
1103,BAO_0000357,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,H,1,,CHEMBL616426,,10576,13654,,,B,,,Expert,,,
1104,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10000000.0,H,1,,CHEMBL616427,,10576,14423,,Hippocampus,B,,,Autocuration,,,
1105,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10000000.0,H,1,,CHEMBL616428,,10576,15412,,Hippocampus,B,,,Autocuration,,,
1106,BAO_0000221,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616290,,10576,12073,,Hippocampus,B,,,Autocuration,,,
1107,BAO_0000357,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616052,,10576,4101,,,B,,,Expert,,,
1108,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616053,,10576,10062,,,B,,,Autocuration,,,
1109,BAO_0000249,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616054,,10576,6238,,,B,,,Autocuration,,,
1110,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616055,,10576,16273,,,B,,,Autocuration,,,
1111,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,H,1,,CHEMBL616056,,10576,11139,,,B,,,Autocuration,,,
1112,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,H,1,,CHEMBL616057,,10576,16796,,,B,,,Expert,,,
1113,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,D,1,,CHEMBL616058,,10576,9548,,Brain,B,,,Expert,,,
1114,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,H,1,,CHEMBL616059,,10576,10381,,Brain,B,,,Autocuration,,,
1115,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616060,,10576,13408,,,B,,,Autocuration,,,
1116,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10000000.0,D,1,,CHEMBL616061,,10576,13825,,Hippocampus,B,,,Expert,,,
1117,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10000000.0,H,1,,CHEMBL616062,,10576,11147,,Hippocampus,B,,,Expert,,,
1118,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616063,,10576,10552,,,B,,,Autocuration,,,
1119,BAO_0000249,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",2435.0,H,1,,CHEMBL616064,,10576,10552,,Striatum,B,,,Autocuration,,,
1120,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,D,1,,CHEMBL616065,,10576,17136,Membranes,,B,,,Expert,,,
1121,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,D,1,,CHEMBL616066,,10576,5778,Membranes,,B,,,Expert,,,
1122,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616067,,10576,13481,,Hippocampus,B,,,Autocuration,,,
1123,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10000000.0,H,1,,CHEMBL616068,,10576,13481,,Hippocampus,B,,,Autocuration,,,
1124,BAO_0000221,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616069,,10576,13630,,Hippocampus,B,,,Intermediate,,,
1125,BAO_0000249,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,H,1,,CHEMBL616070,,10576,16245,,,B,,,Expert,,,
1126,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616071,,10576,14509,,Hippocampus,B,,,Autocuration,,,
1127,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10000000.0,H,1,,CHEMBL616072,,10576,14509,,Hippocampus,B,,,Expert,,,
1128,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10000000.0,H,1,,CHEMBL616073,,10576,14509,,Hippocampus,B,,,Autocuration,,,
1129,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10000000.0,H,1,,CHEMBL616074,,10576,14509,,Hippocampus,B,,,Autocuration,,,
1130,BAO_0000019,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,H,1,,CHEMBL616075,,10576,14256,,,B,,,Expert,,,
1131,BAO_0000357,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616076,,10576,11139,,,B,,,Autocuration,,,
1132,BAO_0000019,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,D,1,,CHEMBL616077,,10576,11047,,,B,,,Expert,,,
1133,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,D,1,,CHEMBL616078,,10576,11047,,,B,,,Expert,,,
1134,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,D,1,,CHEMBL616079,,10576,11047,,,B,,,Expert,,,
1135,BAO_0000219,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,D,1,CHO-K1,CHEMBL616080,,10576,2395,,,B,,,Expert,,485.0,
1136,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616081,,10576,9699,,,B,,,Autocuration,,,
1137,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10000000.0,D,1,,CHEMBL616082,,10576,12028,,Hippocampus,B,,,Expert,,,
1138,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10000000.0,H,1,,CHEMBL616083,,10576,12028,,Hippocampus,B,,,Autocuration,,,
1139,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,H,1,,CHEMBL616084,,10576,5815,,,B,,,Autocuration,,,
1140,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,H,1,,CHEMBL616085,,10576,16616,,,B,,,Expert,,,
1141,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,H,1,,CHEMBL616086,,10576,5815,,,B,,,Autocuration,,,
1142,BAO_0000221,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10000000.0,H,1,,CHEMBL616087,,10576,2761,,Hippocampus,B,,,Autocuration,,,
1143,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,H,1,,CHEMBL616088,,10576,13133,,,B,,,Expert,,,
1144,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,H,1,,CHEMBL616089,,10576,10444,,,B,,,Autocuration,,,
1145,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,D,1,,CHEMBL616090,,10576,13278,,,B,,,Expert,,,
1146,BAO_0000357,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,H,1,,CHEMBL616091,,10576,15874,,,B,,,Autocuration,,,
1147,BAO_0000249,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",2435.0,H,1,,CHEMBL616092,,10576,10552,Membranes,Striatum,B,,,Autocuration,,,
1148,BAO_0000357,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,H,1,,CHEMBL616093,,10576,11130,,,B,,,Autocuration,,,
1149,BAO_0000218,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,H,1,,CHEMBL616094,In vivo,10576,11130,,,B,,,Autocuration,,,
1150,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,955.0,H,1,,CHEMBL616095,,10576,14542,,Brain,B,,,Autocuration,,,
1151,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616096,,10576,13670,,,B,,,Expert,,,
1152,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,H,1,,CHEMBL616097,,10576,9888,,,B,,,Expert,,,
1153,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,D,1,,CHEMBL616098,,10576,3678,Membranes,,B,,,Expert,,,
1154,BAO_0000221,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616099,,10576,11332,,Hippocampus,B,,,Autocuration,,,
1155,BAO_0000221,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616100,,10576,11332,,Hippocampus,B,,,Autocuration,,,
1156,BAO_0000357,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616101,,10576,1185,,,B,,,Expert,,,
1157,BAO_0000249,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,H,1,,CHEMBL616102,,10576,2014,,,B,,,Expert,,,
1158,BAO_0000357,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616103,,10576,1185,,,B,,,Autocuration,,,
1159,BAO_0000019,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,H,1,,CHEMBL616104,,10576,14429,,,B,,,Expert,,,
1160,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,H,1,,CHEMBL616105,,10576,16288,,,B,,,Expert,,,
1161,BAO_0000019,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616106,,10576,5432,,,B,,,Expert,,,
1162,BAO_0000019,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,H,1,,CHEMBL616107,,10576,14429,,,B,,,Autocuration,,,
1163,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,H,1,,CHEMBL616108,,10576,13672,,,B,,,Expert,,,
1164,BAO_0000221,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,H,1,,CHEMBL616109,,10576,11296,,Hippocampus,B,,,Expert,,,
1165,BAO_0000357,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,H,1,,CHEMBL616110,,10576,11296,,,B,,,Autocuration,,,
1166,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,H,1,CHO,CHEMBL616111,,10576,14749,,,B,,,Expert,,449.0,
1167,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,H,1,,CHEMBL616112,,10576,15086,,,B,,,Expert,,,
1168,BAO_0000221,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10000000.0,H,1,,CHEMBL616113,,10576,13462,,Hippocampus,B,,,Autocuration,,,
1169,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616114,,10576,15363,,,B,,,Autocuration,,,
1170,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616115,,10576,15363,,,B,,,Autocuration,,,
1171,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616116,,10576,10796,,,B,,,Autocuration,,,
1172,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,955.0,H,1,,CHEMBL615844,,10576,12816,,Brain,B,,,Expert,,,
1173,BAO_0000221,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,H,1,,CHEMBL615939,,10576,13542,,Hippocampus,B,,,Expert,,,
1174,BAO_0000019,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,H,1,,CHEMBL615940,,10576,13308,,,B,,,Expert,,,
1175,BAO_0000221,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10000000.0,H,1,,CHEMBL615941,,10576,13541,,Hippocampus,B,,,Expert,,,
1176,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10000000.0,H,1,,CHEMBL615942,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1177,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,H,1,,CHEMBL615943,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1178,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10000000.0,H,1,,CHEMBL615944,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1179,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10000000.0,H,1,,CHEMBL615945,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1180,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10000000.0,H,1,,CHEMBL615946,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1181,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10000000.0,H,1,,CHEMBL615947,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1182,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10000000.0,H,1,,CHEMBL615948,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1183,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10000000.0,H,1,,CHEMBL615949,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1184,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10000000.0,H,1,,CHEMBL615950,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1185,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10000000.0,H,1,,CHEMBL615951,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1186,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10000000.0,H,1,,CHEMBL615952,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1187,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10000000.0,H,1,,CHEMBL615953,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1188,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10000000.0,H,1,,CHEMBL615954,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1189,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,D,1,,CHEMBL615955,,10576,10058,,Hippocampus,B,,,Expert,,,
1190,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10000000.0,H,1,,CHEMBL615956,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1191,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10000000.0,H,1,,CHEMBL615957,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1192,BAO_0000019,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,H,1,,CHEMBL615958,,10576,12879,,,B,,,Expert,,,
1193,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,H,1,,CHEMBL615959,,10576,11964,,,B,,,Expert,,,
1194,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,H,1,,CHEMBL615960,,10576,11964,,,B,,,Autocuration,,,
1195,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,H,1,,CHEMBL615961,,10576,11964,,,B,,,Autocuration,,,
1196,BAO_0000221,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,H,1,,CHEMBL615962,,10576,9548,,Brain,B,,,Expert,,,
1197,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,H,1,,CHEMBL615963,,10576,9098,,,B,,,Expert,,,
1198,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,H,1,,CHEMBL615964,,10576,9098,,,B,,,Autocuration,,,
1199,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,H,1,,CHEMBL615965,,10576,9098,,,B,,,Autocuration,,,
1200,BAO_0000219,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,H,1,CHO,CHEMBL615966,,10576,13248,,,B,,,Expert,,449.0,
1201,BAO_0000249,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,H,1,,CHEMBL615967,,10576,3147,,,B,,,Expert,,,
1202,BAO_0000019,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,H,1,,CHEMBL615968,,10576,13949,,,B,,,Expert,,,
1203,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,H,1,CHO,CHEMBL615969,,10576,11883,,,B,,,Autocuration,,449.0,
1204,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,H,1,,CHEMBL615970,,10576,11883,,,B,,,Autocuration,,,
1205,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,D,1,,CHEMBL615971,,10576,11883,,,B,,,Expert,,,
1206,BAO_0000249,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,H,1,,CHEMBL615972,,10576,15535,Membranes,,B,,,Expert,,,
1207,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,H,1,,CHEMBL615973,,10576,15535,,,B,,,Autocuration,,,
1208,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,H,1,,CHEMBL615974,,10576,15535,,,B,,,Autocuration,,,
1209,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,D,1,CHO,CHEMBL615975,,51,16372,,,B,,,Expert,,449.0,
1210,BAO_0000249,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,H,1,,CHEMBL615976,,10576,14608,,,B,,,Expert,,,
1211,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,D,1,,CHEMBL872106,,10576,4795,,Hippocampus,B,,,Expert,,,
1212,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL615977,,10576,13863,,,B,,,Autocuration,,,
1213,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,H,1,,CHEMBL615978,,10576,13863,,,B,,,Autocuration,,,
1214,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,H,1,,CHEMBL616166,,10576,13863,,,B,,,Autocuration,,,
1215,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,H,1,,CHEMBL616167,,10576,13863,,,B,,,Autocuration,,,
1216,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,H,1,,CHEMBL616168,,10576,13863,,,B,,,Autocuration,,,
1217,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,H,1,,CHEMBL616169,,10576,13863,,,B,,,Autocuration,,,
1218,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,H,1,,CHEMBL616170,,10576,13863,,,B,,,Autocuration,,,
1219,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,H,1,,CHEMBL616171,,10576,13863,,,B,,,Autocuration,,,
1220,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,H,1,,CHEMBL616172,,10576,13863,,,B,,,Autocuration,,,
1221,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,H,1,,CHEMBL616173,,10576,13863,,,B,,,Autocuration,,,
1222,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,H,1,,CHEMBL616174,,10576,13863,,,B,,,Autocuration,,,
1223,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,H,1,,CHEMBL616175,,10576,13863,,,B,,,Autocuration,,,
1224,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,H,1,,CHEMBL616176,,10576,13863,,,B,,,Autocuration,,,
1225,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,H,1,,CHEMBL616177,,10576,13863,,,B,,,Autocuration,,,
1226,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,H,1,,CHEMBL616178,,10576,13863,,,B,,,Autocuration,,,
1227,BAO_0000019,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,H,1,,CHEMBL616179,,10576,9742,,,B,,,Autocuration,,,
1228,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616180,,10576,12073,,,B,,,Autocuration,,,
1229,BAO_0000357,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,H,1,,CHEMBL616181,,10576,4101,,,B,,,Autocuration,,,
1230,BAO_0000019,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,H,1,,CHEMBL616182,,10576,15360,,,B,,,Autocuration,,,
1231,BAO_0000221,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,H,1,,CHEMBL616183,,10576,11576,,Hippocampus,B,,,Autocuration,,,
1232,BAO_0000019,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,H,1,,CHEMBL615874,,10576,5834,,,B,,,Expert,,,
1233,BAO_0000219,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,D,1,CHO-K1,CHEMBL615875,,10576,2395,,,B,,,Expert,,485.0,
1234,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,H,1,,CHEMBL615876,,10576,1375,,,B,,,Autocuration,,,
1235,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,H,1,,CHEMBL615877,,10576,1375,,,B,,,Autocuration,,,
1236,BAO_0000357,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,H,1,,CHEMBL615878,,10576,3967,,,B,,,Autocuration,,,
1237,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,H,1,,CHEMBL615879,,10576,12884,,,B,,,Expert,,,
1238,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,H,1,,CHEMBL615880,,10576,2343,,,B,,,Expert,,,
1239,BAO_0000019,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,H,1,,CHEMBL615881,,10576,11511,,,B,,,Autocuration,,,
1240,BAO_0000019,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,D,1,,CHEMBL615882,,10576,11511,,,B,,,Expert,,,
1241,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,H,1,,CHEMBL615883,In vivo,10576,16394,,,F,,,Autocuration,,,
1242,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,H,1,,CHEMBL615884,In vivo,10576,16394,,,F,,,Autocuration,,,
1243,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,H,1,,CHEMBL615885,In vivo,10576,16394,,,F,,,Autocuration,,,
1244,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,H,1,,CHEMBL615886,In vivo,10576,16394,,,F,,,Autocuration,,,
1245,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,H,1,,CHEMBL615887,In vivo,10576,16394,,,F,,,Autocuration,,,
1246,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,H,1,,CHEMBL615888,In vivo,10576,16394,,,F,,,Autocuration,,,
1247,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,H,1,,CHEMBL615889,In vivo,10576,16394,,,F,,,Autocuration,,,
1248,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,H,1,,CHEMBL615890,In vivo,10576,16394,,,F,,,Autocuration,,,
1249,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,H,1,,CHEMBL615891,In vivo,10576,16394,,,F,,,Autocuration,,,
1250,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,H,1,,CHEMBL615892,In vivo,10576,16394,,,F,,,Autocuration,,,
1251,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,H,1,,CHEMBL615893,In vivo,10576,16394,,,F,,,Autocuration,,,
1252,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,H,1,,CHEMBL615894,In vivo,10576,16394,,,F,,,Autocuration,,,
1253,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,H,1,,CHEMBL615895,In vivo,10576,16394,,,F,,,Autocuration,,,
1254,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,H,1,,CHEMBL615896,In vivo,10576,16394,,,F,,,Autocuration,,,
1255,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,H,1,,CHEMBL615897,In vivo,10576,16394,,,F,,,Autocuration,,,
1256,BAO_0000249,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,D,1,,CHEMBL615898,,10576,16616,Membranes,,F,,,Expert,,,
1257,BAO_0000019,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,H,1,,CHEMBL615899,,10576,16796,,,B,,,Autocuration,,,
1258,BAO_0000019,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,H,1,,CHEMBL616291,,10576,16796,,,B,,,Autocuration,,,
1259,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,H,1,,CHEMBL616292,,10576,15629,,,B,,,Autocuration,,,
1260,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,H,1,,CHEMBL616293,,10576,13241,,,F,,,Autocuration,,,
1261,BAO_0000221,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616294,,10576,12073,,Hippocampus,B,,,Expert,,,
1262,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10000000.0,H,1,,CHEMBL616295,,10576,14286,,Hippocampus,B,,,Autocuration,,,
1263,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,955.0,H,1,,CHEMBL616296,,10576,14542,,Brain,B,,,Autocuration,,,
1264,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,H,1,,CHEMBL616297,,10576,13630,,,F,,,Autocuration,,,
1265,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,H,1,,CHEMBL616605,,10576,13630,,,F,,,Autocuration,,,
1266,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,H,1,,CHEMBL616606,,10576,13630,,,F,,,Autocuration,,,
1267,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,H,1,,CHEMBL616607,,10576,13630,,,F,,,Autocuration,,,
1268,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,H,1,,CHEMBL616608,,10576,13630,,,F,,,Expert,,,
1269,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,H,1,,CHEMBL616609,,10576,13630,,,F,,,Autocuration,,,
1270,BAO_0000019,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,D,1,,CHEMBL616610,,10576,13630,,,F,,,Expert,,,
1271,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,H,1,,CHEMBL616611,,10576,13630,,,F,,,Autocuration,,,
1272,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,H,1,,CHEMBL616612,,10576,13630,,,F,,,Expert,,,
1273,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,H,1,,CHEMBL616613,,10576,13630,,,F,,,Autocuration,,,
1274,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,H,1,,CHEMBL616614,,10576,13630,,,F,,,Expert,,,
1275,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,H,1,,CHEMBL616615,,10576,13630,,,F,,,Autocuration,,,
1276,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,H,1,,CHEMBL616616,,10576,13630,,,F,,,Expert,,,
1277,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,H,1,,CHEMBL616617,,10576,13630,,,F,,,Autocuration,,,
1278,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,H,1,,CHEMBL616618,,10576,13630,,,F,,,Autocuration,,,
1279,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,H,1,,CHEMBL616619,,10576,13630,,,F,,,Autocuration,,,
1280,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,H,1,,CHEMBL616620,,10576,13630,,,F,,,Expert,,,
1281,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,H,1,,CHEMBL616621,,10576,13630,,,F,,,Expert,,,
1282,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,H,1,,CHEMBL616622,,10576,13630,,,F,,,Autocuration,,,
1283,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,H,1,,CHEMBL616146,,10576,13630,,,F,,,Expert,,,
1284,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,H,1,,CHEMBL832873,,10576,13630,,,F,,,Autocuration,,,
1285,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,H,1,,CHEMBL616147,,10576,13630,,,F,,,Autocuration,,,
1286,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,H,1,,CHEMBL872872,,10576,13630,,,F,,,Autocuration,,,
1287,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,H,1,,CHEMBL616148,,10576,13630,,,F,,,Autocuration,,,
1288,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10000000.0,H,1,,CHEMBL616149,,10576,9783,,Hippocampus,B,,,Autocuration,,,
1289,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10000000.0,H,1,,CHEMBL616150,,10576,9783,,Hippocampus,B,,,Expert,,,
1290,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,D,1,,CHEMBL616151,,10576,14331,Membranes,,B,,,Expert,,,
1291,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10000000.0,H,1,,CHEMBL872873,,10576,15260,,Hippocampus,B,,,Expert,,,
1292,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10000000.0,H,1,,CHEMBL616670,,10576,15260,,Hippocampus,B,,,Autocuration,,,
1293,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10000000.0,H,1,,CHEMBL616671,,10576,15260,,Hippocampus,B,,,Autocuration,,,
1294,BAO_0000249,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,D,1,,CHEMBL884861,,10576,16616,,,F,,,Expert,,,
1295,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,H,1,,CHEMBL616672,,10576,15629,,,B,,,Autocuration,,,
1296,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,H,1,,CHEMBL616673,,10576,15086,,,B,,,Autocuration,,,
1297,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,H,1,,CHEMBL616674,,10576,5717,,,F,,,Expert,,,
1298,BAO_0000357,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,H,1,,CHEMBL616675,,10576,12652,,,B,,,Autocuration,,,
1299,BAO_0000221,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10000000.0,H,1,,CHEMBL616676,,10576,14608,,Hippocampus,B,,,Autocuration,,,
1300,BAO_0000221,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,H,1,,CHEMBL616677,,10576,12306,,Hippocampus,B,,,Autocuration,,,
1301,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,H,1,,CHEMBL616678,,10576,12306,,Hippocampus,B,,,Autocuration,,,
1302,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616679,,10576,15247,,,B,,,Expert,,,
1303,BAO_0000221,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10000000.0,H,1,,CHEMBL616680,,10576,17529,,Hippocampus,B,,,Expert,,,
1304,BAO_0000221,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616681,,10576,14826,,Hippocampus,B,,,Autocuration,,,
1305,BAO_0000221,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616682,,10576,14826,,Hippocampus,B,,,Autocuration,,,
1306,BAO_0000221,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,H,1,,CHEMBL616683,,10576,13241,,Hippocampus,B,,,Autocuration,,,
1307,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10000000.0,H,1,,CHEMBL616684,,10576,14093,,Hippocampus,B,,,Autocuration,,,
1308,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10000000.0,H,1,,CHEMBL616685,,10576,14093,,Hippocampus,B,,,Autocuration,,,
1309,BAO_0000221,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,955.0,H,1,,CHEMBL616686,,10576,14442,,Brain,B,,,Autocuration,,,
1310,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,,H,1,,CHEMBL616687,,10576,9919,,,B,,,Autocuration,,,
1311,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,,H,1,,CHEMBL616688,,10576,9919,,,B,,,Autocuration,,,
1312,BAO_0000221,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10000000.0,H,1,,CHEMBL616689,,10576,11440,,Hippocampus,B,,,Autocuration,,,
1313,BAO_0000357,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,H,1,,CHEMBL616690,,10576,11257,,,B,,,Autocuration,,,
1314,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,H,1,,CHEMBL616691,,10576,10330,,,B,,,Expert,,,
1315,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10000000.0,D,1,,CHEMBL616692,,10576,17331,,Hippocampus,B,,,Expert,,,
1316,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,H,1,,CHEMBL616693,,10576,16567,,,B,,,Expert,,,
1317,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,D,1,,CHEMBL616694,,10576,12058,,,B,,,Expert,,,
1318,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10000000.0,H,1,,CHEMBL616695,,10576,9699,,Hippocampus,B,,,Autocuration,,,
1319,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,H,1,,CHEMBL616696,,10576,9547,,,B,,,Autocuration,,,
1320,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,H,1,,CHEMBL616697,,10576,10330,,,B,,,Autocuration,,,
1321,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616698,,10576,14331,,,B,,,Autocuration,,,
1322,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616949,,10576,14060,,,B,,,Expert,,,
1323,BAO_0000221,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10000000.0,H,1,,CHEMBL616950,,10576,14744,,Hippocampus,B,,,Autocuration,,,
1324,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,H,1,,CHEMBL832875,,10576,13506,,,B,,,Autocuration,,,
1325,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,H,1,,CHEMBL616951,,10576,10862,,Brain,B,,,Expert,,,
1326,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,H,1,,CHEMBL616952,,10576,10862,,Brain,B,,,Expert,,,
1327,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,H,1,,CHEMBL616953,,10576,10062,,,B,,,Expert,,,
1328,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,H,1,,CHEMBL616954,,10576,12073,,,B,,,Autocuration,,,
1329,BAO_0000357,GTPgammaS radioligand binding assay,,H,1,,CHEMBL616955,,106,14875,,,B,,,Autocuration,,,
1330,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,H,1,,CHEMBL616956,,106,2391,,,B,,,Autocuration,,,
1331,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,H,1,,CHEMBL616957,,106,2391,,,F,,,Autocuration,,,
1332,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,H,1,,CHEMBL616958,,106,2391,,,F,,,Autocuration,,,
1333,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616959,,106,2391,,,B,,,Autocuration,,,
1334,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,H,1,,CHEMBL616960,,106,2391,,,B,,,Autocuration,,,
1335,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,H,1,,CHEMBL616961,,106,2391,,,F,,,Autocuration,,,
1336,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,H,1,HeLa,CHEMBL616962,,106,17211,,,B,,,Expert,,308.0,
1337,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,H,1,HeLa,CHEMBL616963,,106,17211,,,B,,,Autocuration,,308.0,
1338,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,D,1,,CHEMBL616524,,106,6491,,,B,,,Expert,,,
1339,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,H,1,CHO,CHEMBL616525,,106,16190,,,B,,,Autocuration,,449.0,
1340,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,H,1,,CHEMBL872908,,106,14165,,,B,,,Autocuration,,,
1341,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,H,1,,CHEMBL616526,,106,14165,,,B,,,Autocuration,,,
1342,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616527,,106,4234,,,B,,,Expert,,,
1343,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,H,1,,CHEMBL616528,,106,6328,,,B,,,Expert,,,
1344,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL616529,,106,14770,,,B,,,Autocuration,,,
1345,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,H,1,,CHEMBL616530,,106,2598,,,B,,,Autocuration,,,
1346,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616531,,106,6897,,,B,,,Expert,,,
1347,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616532,,106,6897,,,B,,,Autocuration,,,
1348,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616533,,106,6013,,,B,,,Autocuration,,,
1349,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616534,,106,5843,,,B,,,Expert,,,
1350,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,H,1,,CHEMBL616535,,106,14454,,,B,,,Expert,,,
1351,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,H,1,,CHEMBL616536,,106,16209,,,B,,,Autocuration,,,
1352,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616537,,106,3935,,,B,,,Autocuration,,,
1353,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,H,1,CHO-K1,CHEMBL616538,,106,13729,,,F,,,Expert,,485.0,
1354,BAO_0000019,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616539,,106,14251,,,F,,,Expert,,,
1355,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616540,,106,17085,,,B,,,Expert,,,
1356,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,H,1,,CHEMBL616429,,106,3025,,,B,,,Autocuration,,,
1357,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616430,,106,15315,,,B,,,Expert,,,
1358,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,D,1,,CHEMBL616431,,106,14214,,,B,,,Expert,,,
1359,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616432,,106,3804,,,B,,,Expert,,,
1360,BAO_0000357,Affinity for 5-hydroxytryptamine 1B receptor subtype,,D,1,,CHEMBL616433,,106,2391,,,B,,,Expert,,,
1361,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616434,,106,4175,,,B,,,Expert,,,
1362,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,H,1,CHO,CHEMBL616435,,106,17296,,,B,,,Autocuration,,449.0,
1363,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,H,1,,CHEMBL616436,,106,17085,,,B,,,Expert,,,
1364,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,H,1,HeLa,CHEMBL616437,,106,17211,,,B,,,Autocuration,,308.0,
1365,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,H,1,HeLa,CHEMBL616438,,106,17211,,,B,,,Autocuration,,308.0,
1366,BAO_0000219,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,H,1,HeLa,CHEMBL616439,,106,17211,,,B,,,Autocuration,,308.0,
1367,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,D,1,,CHEMBL616440,,106,15926,,,B,,,Expert,,,
1368,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,H,1,CHO-K1,CHEMBL616441,,106,16312,,,B,,,Autocuration,,485.0,
1369,BAO_0000357,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,H,1,,CHEMBL616442,,106,5843,,,B,,,Expert,,,
1370,BAO_0000357,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616443,,106,5843,,,B,,,Autocuration,,,
1371,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,H,1,CHO-K1,CHEMBL616444,,106,16312,,,B,,,Expert,,485.0,
1372,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616445,,106,15926,,,B,,,Expert,,,
1373,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616446,,106,15926,,,B,,,Expert,,,
1374,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,D,1,CHO,CHEMBL616447,,106,4540,,,B,,,Expert,,449.0,
1375,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,H,1,,CHEMBL616448,,106,6166,,,B,,,Autocuration,,,
1376,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,H,1,CHO,CHEMBL616449,,106,17296,,,B,,,Autocuration,,449.0,
1377,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,H,1,CHO,CHEMBL616450,,106,17296,,,B,,,Autocuration,,449.0,
1378,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,H,1,CHO,CHEMBL857974,,106,17296,,,B,,,Autocuration,,449.0,
1379,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,H,1,CHO,CHEMBL616451,,106,15779,,,B,,,Autocuration,,449.0,
1380,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,H,1,CHO,CHEMBL616452,,106,15779,,,B,,,Autocuration,,449.0,
1381,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,H,1,CHO,CHEMBL616453,,106,15779,,,B,,,Autocuration,,449.0,
1382,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,H,1,CHO,CHEMBL616454,,106,4199,,,B,,,Autocuration,,449.0,
1383,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616455,,106,14875,,,B,,,Expert,,,
1384,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,H,1,CHO,CHEMBL616456,,106,15146,,,B,,,Autocuration,,449.0,
1385,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,H,1,,CHEMBL616457,,106,5213,,,B,,,Autocuration,,,
1386,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,H,1,CHO,CHEMBL616458,,106,14818,,,B,,,Autocuration,,449.0,
1387,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL616459,,106,4829,,,B,,,Autocuration,,449.0,
1388,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,H,1,,CHEMBL616460,,106,14454,,,F,,,Expert,,,
1389,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,H,1,,CHEMBL616461,,106,14454,,,F,,,Expert,,,
1390,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,H,1,CHO,CHEMBL616462,,106,14875,,,F,,,Autocuration,,449.0,
1391,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,H,1,CHO,CHEMBL616463,,106,14875,,,F,,,Autocuration,,449.0,
1392,BAO_0000019,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,H,1,,CHEMBL616464,,105,15250,,,F,,,Autocuration,,,
1393,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,H,1,CHO,CHEMBL616465,,105,15250,,,B,,,Autocuration,,449.0,
1394,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL832874,,17105,15086,,,B,,,Autocuration,,,
1395,BAO_0000019,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,H,1,,CHEMBL616184,,106,3025,,,F,,,Autocuration,,,
1396,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,H,1,,CHEMBL616185,,106,14998,,,B,,,Autocuration,,,
1397,BAO_0000019,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,H,1,,CHEMBL616186,,106,14998,,,B,,,Intermediate,,,
1398,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,H,1,,CHEMBL616187,,106,14998,,,B,,,Autocuration,,,
1399,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,H,1,,CHEMBL616188,,10577,13969,,,B,,,Expert,,,
1400,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL873475,,10577,13392,,,B,,,Intermediate,,,
1401,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,2435.0,D,1,,CHEMBL616189,,10577,3651,,Striatum,B,,,Expert,,,
1402,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,H,1,,CHEMBL616190,,10577,10025,,,B,,,Expert,,,
1403,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,H,1,,CHEMBL616191,,10576,13863,,,B,,,Autocuration,,,
1404,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,H,1,,CHEMBL616192,,10576,13863,,,B,,,Autocuration,,,
1405,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,H,1,,CHEMBL616193,,10576,13863,,,B,,,Autocuration,,,
1406,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,H,1,,CHEMBL616194,,10576,13863,,,B,,,Autocuration,,,
1407,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,H,1,,CHEMBL616195,,10576,13863,,,B,,,Autocuration,,,
1408,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,H,1,,CHEMBL616196,,10576,13863,,,B,,,Autocuration,,,
1409,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10000000.0,H,1,,CHEMBL616197,,10576,4622,,Hippocampus,B,,,Autocuration,,,
1410,BAO_0000019,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616198,,10576,14911,,,B,,,Intermediate,,,
1411,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10000000.0,H,1,,CHEMBL616199,,10576,12678,,Hippocampus,B,,,Autocuration,,,
1412,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10000000.0,H,1,,CHEMBL616200,,10576,12678,,Hippocampus,B,,,Expert,,,
1413,BAO_0000221,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616201,,10576,14235,,Hippocampus,B,,,Expert,,,
1414,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10000000.0,H,1,,CHEMBL616202,,10576,14949,,Hippocampus,B,,,Expert,,,
1415,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10000000.0,H,1,,CHEMBL616203,,10576,14949,,Hippocampus,B,,,Expert,,,
1416,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10000000.0,H,1,,CHEMBL616204,,10576,14949,,Hippocampus,B,,,Expert,,,
1417,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10000000.0,H,1,,CHEMBL616205,,10576,14949,,Hippocampus,B,,,Expert,,,
1418,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10000000.0,H,1,,CHEMBL616206,,10576,14949,,Hippocampus,B,,,Expert,,,
1419,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,H,1,,CHEMBL616207,,10576,16118,,,B,,,Expert,,,
1420,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,H,1,,CHEMBL616208,,10576,3268,,,B,,,Autocuration,,,
1421,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,H,1,,CHEMBL616209,,10576,3268,,,B,,,Autocuration,,,
1422,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,H,1,,CHEMBL616210,,10576,16117,,,B,,,Expert,,,
1423,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10000000.0,H,1,,CHEMBL616211,,10576,9783,,Hippocampus,B,,,Expert,,,
1424,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10000000.0,H,1,,CHEMBL616504,,10576,9783,,Hippocampus,B,,,Autocuration,,,
1425,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,D,1,,CHEMBL616505,,10576,14356,,Hippocampus,B,,,Expert,,,
1426,BAO_0000019,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616506,,10576,15740,,,F,,,Autocuration,,,
1427,BAO_0000221,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,H,1,,CHEMBL872107,,10576,12306,,Hippocampus,B,,,Autocuration,,,
1428,BAO_0000221,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10000000.0,D,1,,CHEMBL616507,,10576,13348,,Hippocampus,B,,,Expert,,,
1429,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,H,1,,CHEMBL616303,,10576,10394,,,B,,,Autocuration,,,
1430,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10000000.0,H,1,,CHEMBL616304,,10576,15260,,Hippocampus,B,,,Autocuration,,,
1431,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,H,1,,CHEMBL616305,,10576,10046,,Hippocampus,B,,,Expert,,,
1432,BAO_0000221,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10000000.0,H,1,,CHEMBL616306,,10576,15260,,Hippocampus,F,,,Intermediate,,,
1433,BAO_0000357,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616307,,10576,12851,,,B,,,Autocuration,,,
1434,BAO_0000221,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10000000.0,D,1,,CHEMBL881829,,10576,2148,,Hippocampus,B,,,Expert,,,
1435,BAO_0000357,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,H,1,,CHEMBL616308,,10576,13134,,,B,,,Expert,,,
1436,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,H,1,,CHEMBL616309,,10576,12462,,,B,,,Autocuration,,,
1437,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,H,1,,CHEMBL616310,,10576,12462,,,B,,,Expert,,,
1438,BAO_0000219,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,H,1,CHO,CHEMBL616311,,10576,12462,,,B,,,Autocuration,,449.0,
1439,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616312,,10576,11933,,,B,,,Expert,,,
1440,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,H,1,,CHEMBL616313,,10576,11933,,,B,,,Autocuration,,,
1441,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,D,1,,CHEMBL616314,,10576,403,,Hippocampus,B,,,Expert,,,
1442,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616315,,10576,15538,,Hippocampus,B,,,Autocuration,,,
1443,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10000000.0,H,1,,CHEMBL616567,,10576,15538,,Hippocampus,B,,,Autocuration,,,
1444,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10000000.0,H,1,,CHEMBL616568,,10576,15538,,Hippocampus,B,,,Autocuration,,,
1445,BAO_0000019,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,H,1,,CHEMBL616569,,10576,12464,,,B,,,Intermediate,,,
1446,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,H,1,,CHEMBL616570,,10576,1455,,,B,,,Expert,,,
1447,BAO_0000357,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,H,1,,CHEMBL616571,,10576,12652,,,B,,,Autocuration,,,
1448,BAO_0000221,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10000000.0,H,1,,CHEMBL616572,,10576,12639,,Hippocampus,B,,,Autocuration,,,
1449,BAO_0000249,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,H,1,,CHEMBL616573,,10576,13949,,,B,,,Expert,,,
1450,BAO_0000357,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,D,1,,CHEMBL616574,,10576,12463,,,B,,,Expert,,,
1451,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10000000.0,H,1,,CHEMBL616575,,10576,14829,,Hippocampus,B,,,Expert,,,
1452,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10000000.0,H,1,,CHEMBL872108,,10576,14829,,Hippocampus,B,,,Autocuration,,,
1453,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,H,1,,CHEMBL616576,,10576,12092,,,B,,,Autocuration,,,
1454,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,H,1,,CHEMBL616577,,10576,403,,,B,,,Autocuration,,,
1455,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,H,1,,CHEMBL616578,,10576,403,,,B,,,Autocuration,,,
1456,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,H,1,,CHEMBL616579,,10576,3967,,,B,,,Expert,,,
1457,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,D,1,,CHEMBL616580,,10576,12771,,,B,,,Expert,,,
1458,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,H,1,,CHEMBL616581,,10576,15086,,,B,,,Autocuration,,,
1459,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616582,,10576,14909,,Hippocampus,B,,,Autocuration,,,
1460,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,H,1,,CHEMBL616583,,10576,14949,,Hippocampus,B,,,Expert,,,
1461,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10000000.0,D,1,,CHEMBL616584,,10576,2309,,Hippocampus,B,,,Expert,,,
1462,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616585,,10576,4170,,,B,,,Expert,,,
1463,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10000000.0,D,1,,CHEMBL616586,,10576,11642,,Hippocampus,B,,,Expert,,,
1464,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10000000.0,H,1,,CHEMBL616587,,10576,11642,,Hippocampus,B,,,Autocuration,,,
1465,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616588,,10576,12953,,Hippocampus,B,,,Autocuration,,,
1466,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10000000.0,H,1,,CHEMBL616589,,10576,12953,,Hippocampus,B,,,Autocuration,,,
1467,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,H,1,,CHEMBL616590,,10576,12953,,Hippocampus,B,,,Expert,,,
1468,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,H,1,CHO,CHEMBL616591,,10576,12903,,,B,,,Expert,,449.0,
1469,BAO_0000357,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616592,,10576,12536,,,B,,,Expert,,,
1470,BAO_0000357,The inhibition activity of 5-HT1A at 1 uM,,H,1,,CHEMBL616593,,10576,10058,,,B,,,Autocuration,,,
1471,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,H,1,CHO-K1,CHEMBL616594,,10576,12902,,,B,,,Expert,,485.0,
1472,BAO_0000249,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,H,1,,CHEMBL616595,,10576,14057,,,B,,,Expert,,,
1473,BAO_0000357,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,H,1,,CHEMBL616596,,10576,11296,,,B,,,Autocuration,,,
1474,BAO_0000221,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,H,1,,CHEMBL616597,,10576,11296,,Hippocampus,B,,,Autocuration,,,
1475,BAO_0000221,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,H,1,,CHEMBL616598,,10576,11296,,Hippocampus,B,,,Expert,,,
1476,BAO_0000249,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,D,1,,CHEMBL616599,,10576,16616,Membranes,,F,,,Expert,,,
1477,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10000000.0,D,1,,CHEMBL616600,,10576,16616,Membranes,Hippocampus,F,,,Expert,,,
1478,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,H,1,,CHEMBL616601,,10576,16567,,,B,,,Autocuration,,,
1479,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,H,1,,CHEMBL616602,,10576,16567,,,B,,,Autocuration,,,
1480,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,H,1,,CHEMBL616603,,10576,16567,,,B,,,Autocuration,,,
1481,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,H,1,,CHEMBL616604,,10576,16567,,,B,,,Autocuration,,,
1482,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,H,1,,CHEMBL616316,,10576,17136,,,B,,,Autocuration,,,
1483,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,H,1,,CHEMBL616317,,10576,17136,,,B,,,Autocuration,,,
1484,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,D,1,,CHEMBL616318,,10576,16616,,,B,,,Expert,,,
1485,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10000000.0,H,1,,CHEMBL616319,,10576,17331,,Hippocampus,B,,,Autocuration,,,
1486,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10000000.0,H,1,,CHEMBL616320,,10576,17331,,Hippocampus,B,,,Autocuration,,,
1487,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10000000.0,D,1,,CHEMBL616321,,10576,17167,,Hippocampus,B,,,Expert,,,
1488,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,H,1,,CHEMBL616322,,10576,15740,,,F,,,Autocuration,,,
1489,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,H,1,,CHEMBL616323,,10576,15740,,,F,,,Autocuration,,,
1490,BAO_0000357,Ratio of binding affinity to 5-HT 1A and D2 receptor,,H,1,,CHEMBL616324,,10576,4671,,,B,,,Autocuration,,,
1491,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10000000.0,H,1,,CHEMBL616325,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1492,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10000000.0,H,1,,CHEMBL616326,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1493,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10000000.0,H,1,,CHEMBL616327,,10576,10058,,Hippocampus,B,,,Autocuration,,,
1494,BAO_0000357,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616328,,10576,12073,,,B,,,Autocuration,,,
1495,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,H,1,,CHEMBL858110,,10576,2759,,,B,,,Autocuration,,,
1496,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,H,1,,CHEMBL616329,,10576,2759,,,F,,,Autocuration,,,
1497,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,H,1,,CHEMBL616330,,10576,2759,,,B,,,Autocuration,,,
1498,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,H,1,,CHEMBL616331,,10576,2759,,,F,,,Autocuration,,,
1499,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,H,1,,CHEMBL616332,,10576,2759,,,F,,,Autocuration,,,
1500,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,H,1,,CHEMBL857063,,10576,9737,,Brain,B,,,Autocuration,,,
1501,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,H,1,,CHEMBL616333,,10576,9737,,,B,,,Autocuration,,,
1502,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,H,1,,CHEMBL616334,,10576,5717,,,F,,,Expert,,,
1503,BAO_0000221,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,H,1,,CHEMBL616335,,10576,12253,,Hippocampus,B,,,Autocuration,,,
1504,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,H,1,,CHEMBL616336,,10576,14025,,,B,,,Autocuration,,,
1505,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,H,1,,CHEMBL616337,,10576,10425,,,B,,,Expert,,,
1506,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,H,1,,CHEMBL616338,,10576,14998,,,B,,,Autocuration,,,
1507,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10000000.0,H,1,,CHEMBL616339,,10576,13694,,Hippocampus,B,,,Autocuration,,,
1508,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10000000.0,H,1,,CHEMBL616340,,10576,13694,,Hippocampus,B,,,Autocuration,,,
1509,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL616341,,10576,4342,,,B,,,Autocuration,,,
1510,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616342,,10576,12936,,,B,,,Expert,,,
1511,BAO_0000019,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,D,1,,CHEMBL616343,,10576,13144,,,B,,,Expert,,,
1512,BAO_0000019,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,H,1,,CHEMBL616344,,10576,13343,,,B,,,Expert,,,
1513,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,H,1,,CHEMBL616345,,10576,12132,,,B,,,Expert,,,
1514,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,H,1,,CHEMBL616346,,10576,15419,,,B,,,Expert,,,
1515,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,H,1,,CHEMBL616347,,10576,1479,,Hippocampus,B,,,Autocuration,,,
1516,BAO_0000019,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,H,1,,CHEMBL616348,,10576,14287,,,B,,,Expert,,,
1517,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616349,,10576,13116,,,B,,,Expert,,,
1518,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,D,1,,CHEMBL616152,,10576,2759,Membranes,,B,,,Expert,,,
1519,BAO_0000249,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,H,1,,CHEMBL616153,,10576,2759,,,B,,,Autocuration,,,
1520,BAO_0000019,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,H,1,,CHEMBL616154,,10576,14748,,,B,,,Expert,,,
1521,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,H,1,,CHEMBL616155,,10576,12304,,,B,,,Autocuration,,,
1522,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10000000.0,D,1,,CHEMBL616156,,10576,12409,,Hippocampus,B,,,Expert,,,
1523,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10000000.0,D,1,,CHEMBL616157,,10576,12409,,Hippocampus,B,,,Expert,,,
1524,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10000000.0,H,1,,CHEMBL616158,,10576,13267,,Hippocampus,B,,,Autocuration,,,
1525,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,H,1,,CHEMBL616159,,10576,15194,,,B,,,Autocuration,,,
1526,BAO_0000357,pKi value against rat 5-hydroxytryptamine 1A receptor.,,H,1,,CHEMBL616160,,10576,14256,,,B,,,Expert,,,
1527,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,H,1,,CHEMBL616161,,10576,16567,,,B,,,Autocuration,,,
1528,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,H,1,,CHEMBL616162,,10576,15740,,,F,,,Autocuration,,,
1529,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,D,1,,CHEMBL616163,,12687,13278,,,B,,,Expert,,,
1530,BAO_0000249,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,H,1,,CHEMBL616164,,10626,1970,Membranes,,B,,,Expert,,,
1531,BAO_0000221,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,955.0,H,1,,CHEMBL616165,,10576,10034,,Brain,B,,,Autocuration,,,
1532,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,H,1,,CHEMBL616355,,51,13348,,,B,,,Autocuration,,,
1533,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,H,1,,CHEMBL616356,,10576,13630,,,F,,,Autocuration,,,
1534,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,H,1,,CHEMBL616357,,10576,10862,,Brain,B,,,Autocuration,,,
1535,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,H,1,,CHEMBL616358,,10576,12058,,,B,,,Autocuration,,,
1536,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616359,,51,4639,,,B,,,Autocuration,,,
1537,BAO_0000357,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,H,1,,CHEMBL616360,,51,15453,,,B,,,Expert,,,
1538,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616361,,51,4820,,,B,,,Expert,,,
1539,BAO_0000357,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616362,,51,1089,,,B,,,Autocuration,,,
1540,BAO_0000249,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,H,1,,CHEMBL616363,,51,386,Brain membranes,,B,,,Autocuration,,,
1541,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,H,1,,CHEMBL616364,,51,6011,,,B,,,Autocuration,,,
1542,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616365,,51,5014,,,B,,,Autocuration,,,
1543,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616366,,51,4402,,,B,,,Expert,,,
1544,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL872906,,51,17066,,,B,,,Expert,,,
1545,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,H,1,,CHEMBL616367,,51,17515,,,B,,,Autocuration,,,
1546,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616368,,51,2474,,,B,,,Autocuration,,,
1547,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL616369,,51,4775,,,B,,,Autocuration,,,
1548,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,D,1,,CHEMBL616370,,51,14294,,,B,,,Expert,,,
1549,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,D,1,,CHEMBL616371,,51,14294,,,B,,,Expert,,,
1550,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,1,CHO,CHEMBL616372,,51,12249,,,B,,,Autocuration,,449.0,
1551,BAO_0000219,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,H,1,,CHEMBL616373,,51,11376,,,B,,,Expert,,,
1552,BAO_0000218,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616374,In vivo,51,2474,,,B,,,Autocuration,,,
1553,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,H,1,,CHEMBL616375,,51,13311,,Hippocampus,B,,,Autocuration,,,
1554,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL616376,,51,4373,,,B,,,Autocuration,,,
1555,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,H,1,,CHEMBL857064,,51,1633,,,B,,,Expert,,,
1556,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL616377,,51,11866,,,B,,,Autocuration,,,
1557,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,H,1,,CHEMBL616378,,51,4373,,,B,,,Autocuration,,,
1558,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616379,,51,4687,,,B,,,Autocuration,,,
1559,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616380,,11863,16946,,,B,,,Autocuration,,,
1560,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,H,1,,CHEMBL616381,,11863,13291,,,B,,,Autocuration,,,
1561,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616382,,11863,14159,,,B,,,Autocuration,,,
1562,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,H,1,,CHEMBL616383,,11863,10812,,,B,,,Autocuration,,,
1563,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,D,1,CHO,CHEMBL616350,,11863,3032,,,B,,,Expert,,449.0,
1564,BAO_0000357,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616351,,11863,16655,,,B,,,Autocuration,,,
1565,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,H,1,,CHEMBL616352,,11863,14532,,,B,,,Autocuration,,,
1566,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616353,,11863,13944,,,B,,,Autocuration,,,
1567,BAO_0000357,Binding affinity against serotonergic 5-HT1a receptor,,H,1,,CHEMBL616354,,11863,13033,,,B,,,Autocuration,,,
1568,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616508,,11863,10321,,,B,,,Autocuration,,,
1569,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616559,,11863,2968,,,B,,,Expert,,,
1570,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616560,,11863,13964,,,B,,,Autocuration,,,
1571,BAO_0000357,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,H,1,,CHEMBL616561,,11863,15527,,,B,,,Autocuration,,,
1572,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,1,CHO,CHEMBL616562,,11863,12248,,,B,,,Autocuration,,449.0,
1573,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,1,CHO,CHEMBL616563,,11863,12249,,,B,,,Autocuration,,449.0,
1574,BAO_0000357,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616564,,11863,15120,,,B,,,Autocuration,,,
1575,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,H,1,,CHEMBL616565,,11863,13313,,,B,,,Autocuration,,,
1576,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616566,,11863,2613,,,B,,,Autocuration,,,
1577,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,H,1,,CHEMBL616989,,11863,16700,,,B,,,Autocuration,,,
1578,BAO_0000357,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL857975,,11863,2201,,,B,,,Autocuration,,,
1579,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,D,1,,CHEMBL616990,,11863,1274,,,B,,,Expert,,,
1580,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,H,1,,CHEMBL616991,,11863,1317,,,B,,,Autocuration,,,
1581,BAO_0000357,Tested against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616992,,11863,12146,,,B,,,Autocuration,,,
1582,BAO_0000357,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL616993,,11863,14059,,,B,,,Autocuration,,,
1583,BAO_0000019,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,H,1,,CHEMBL616994,,106,14025,,,B,,,Expert,,,
1584,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,H,1,,CHEMBL616995,,106,14025,,,B,,,Autocuration,,,
1585,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,D,1,HEK293,CHEMBL616996,,105571,14447,,,B,,,Intermediate,,722.0,
1586,BAO_0000218,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,H,1,,CHEMBL616997,In vivo,106,3025,,,F,,,Autocuration,,,
1587,BAO_0000218,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,H,1,,CHEMBL616998,In vivo,106,3025,,,F,,,Autocuration,,,
1588,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,H,1,,CHEMBL616999,,106,15329,,,F,,,Autocuration,,,
1589,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,H,1,,CHEMBL617000,,106,15329,,,F,,,Autocuration,,,
1590,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,H,1,,CHEMBL617001,,106,15847,,,F,,,Autocuration,,,
1591,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,H,1,,CHEMBL858111,,106,15847,,,F,,,Autocuration,,,
1592,BAO_0000019,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,H,1,,CHEMBL617002,,106,14165,,,F,,,Autocuration,,,
1593,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,H,1,,CHEMBL617003,,106,14214,,,F,,,Autocuration,,,
1594,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,H,1,,CHEMBL617004,,106,14214,,,F,,,Autocuration,,,
1595,BAO_0000019,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,D,1,,CHEMBL617005,,106,14214,,,F,,,Expert,,,
1596,BAO_0000219,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,D,1,CHO-K1,CHEMBL616623,,106,13729,,,F,,,Expert,,485.0,
1597,BAO_0000219,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,H,1,CHO,CHEMBL616624,,106,3025,,,F,,,Autocuration,,449.0,
1598,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL883243,,106,2391,,,B,,,Autocuration,,,
1599,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,H,1,,CHEMBL616625,,106,2391,,,F,,,Autocuration,,,
1600,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,H,1,CHO,CHEMBL616626,,106,14956,,,F,,,Expert,,449.0,
1601,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,H,1,CHO,CHEMBL616627,,106,2598,,,F,,,Autocuration,,449.0,
1602,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,H,1,CHO,CHEMBL616628,,106,2598,,,F,,,Autocuration,,449.0,
1603,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,H,1,CHO,CHEMBL616629,,106,2598,,,F,,,Autocuration,,449.0,
1604,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,H,1,CHO,CHEMBL616630,,106,2598,,,F,,,Autocuration,,449.0,
1605,BAO_0000019,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,H,1,,CHEMBL616631,,106,14956,,,F,,,Expert,,,
1606,BAO_0000019,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,H,1,,CHEMBL616632,,106,14956,,,F,,,Autocuration,,,
1607,BAO_0000357,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616633,,106,14214,,,B,,,Expert,,,
1608,BAO_0000219,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,H,1,CHO,CHEMBL616634,,106,3463,,,B,,,Expert,,449.0,
1609,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,H,1,,CHEMBL616635,,106,15331,,,B,,,Autocuration,,,
1610,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL885358,,106,16146,,,B,,,Expert,,,
1611,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,D,1,CHO,CHEMBL616636,,106,14159,,,B,,,Expert,,449.0,
1612,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,H,1,CHO,CHEMBL616637,,106,14158,,,B,,,Expert,,449.0,
1613,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616638,,106,14159,,,B,,,Autocuration,,,
1614,BAO_0000219,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616639,,106,15250,,,B,,,Expert,,449.0,
1615,BAO_0000219,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,H,1,CHO,CHEMBL616640,,106,15250,,,B,,,Expert,,449.0,
1616,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616641,,106,15331,,,B,,,Expert,,449.0,
1617,BAO_0000219,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,H,1,CHO,CHEMBL616642,,106,15332,,,B,,,Expert,,449.0,
1618,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,H,1,CHO,CHEMBL616643,,106,14956,,,B,,,Expert,,449.0,
1619,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,H,1,,CHEMBL616644,,106,3805,,,B,,,Autocuration,,,
1620,BAO_0000357,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,H,1,,CHEMBL616645,,106,14875,,,B,,,Autocuration,,,
1621,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,H,1,,CHEMBL616646,,105,14454,,,F,,,Autocuration,,,
1622,BAO_0000019,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,H,1,,CHEMBL616647,,105,14454,,,F,,,Expert,,,
1623,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,H,1,,CHEMBL616509,,105,16288,,,B,,,Autocuration,,,
1624,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,H,1,,CHEMBL616510,,105,16288,,,B,,,Autocuration,,,
1625,BAO_0000357,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616511,,105,16312,,,B,,,Autocuration,,,
1626,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,H,1,,CHEMBL616512,,105,1348,,,B,,,Expert,,,
1627,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,H,1,,CHEMBL616513,,105,5834,,,B,,,Autocuration,,,
1628,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,2435.0,H,1,,CHEMBL616514,,105,13366,,Striatum,B,,,Autocuration,,,
1629,BAO_0000357,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,H,1,,CHEMBL616515,,105,1414,,,B,,,Expert,,,
1630,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,H,1,,CHEMBL616516,,105,14998,,,B,,,Autocuration,,,
1631,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,H,1,,CHEMBL616517,,105,11473,,,B,,,Autocuration,,,
1632,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,H,1,,CHEMBL616518,,105,11473,,,B,,,Autocuration,,,
1633,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,H,1,,CHEMBL616519,,105,10639,,,B,,,Autocuration,,,
1634,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,H,1,,CHEMBL616520,,105,10639,,,B,,,Autocuration,,,
1635,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,H,1,,CHEMBL616521,,105,1375,,,B,,,Autocuration,,,
1636,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,H,1,,CHEMBL616522,,105,1375,,,B,,,Autocuration,,,
1637,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,H,1,,CHEMBL884531,,105,16532,,,B,,,Autocuration,,,
1638,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL616523,,105,11147,,,B,,,Autocuration,,,
1639,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,2435.0,H,1,,CHEMBL616731,,105,13366,,Striatum,B,,,Autocuration,,,
1640,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,H,1,,CHEMBL616732,,105,10444,,,B,,,Autocuration,,,
1641,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,H,1,,CHEMBL616733,,105,16532,,,B,,,Autocuration,,,
1642,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,H,1,,CHEMBL616734,,105,16532,,,B,,,Autocuration,,,
1643,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,H,1,,CHEMBL616735,,105,12827,,,B,,,Autocuration,,,
1644,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,H,1,,CHEMBL616736,,105,12827,,,B,,,Autocuration,,,
1645,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,1,,CHEMBL616737,,105,12919,,,F,,,Expert,,,
1646,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,H,1,,CHEMBL616738,,105,14025,,,B,,,Autocuration,,,
1647,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,1,,CHEMBL616739,,105,12919,,,F,,,Expert,,,
1648,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,1,,CHEMBL616740,,105,12919,,,F,,,Expert,,,
1649,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,1,,CHEMBL616741,,105,12919,,,F,,,Expert,,,
1650,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,H,1,HEK293,CHEMBL616742,,105,14447,,,B,,,Autocuration,,722.0,
1651,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,D,1,,CHEMBL616743,,105570,1375,,,B,,,Intermediate,,,
1652,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,D,1,,CHEMBL616744,,105570,1375,,,B,,,Intermediate,,,
1653,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,D,1,,CHEMBL616745,,105570,12409,,,F,,,Intermediate,,,
1654,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,1,,CHEMBL616746,,105570,12409,,,F,,,Intermediate,,,
1655,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,D,1,,CHEMBL616747,,105570,12409,,,F,,,Intermediate,,,
1656,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,D,1,,CHEMBL616748,,105570,12409,,,F,,,Intermediate,,,
1657,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,D,1,,CHEMBL616648,,105570,12409,,,F,,,Intermediate,,,
1658,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616649,,105570,11574,,,B,,,Intermediate,,,
1659,BAO_0000357,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,D,1,,CHEMBL616650,,105570,1558,,,B,,,Intermediate,,,
1660,BAO_0000218,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,1,,CHEMBL616651,,105570,12409,,,F,,,Intermediate,,,
1661,BAO_0000218,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,1,,CHEMBL616652,,105570,12409,,,F,,,Intermediate,,,
1662,BAO_0000218,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,1,,CHEMBL616653,,105570,12409,,,F,,,Intermediate,,,
1663,BAO_0000218,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,D,1,,CHEMBL616654,,105570,12409,,,F,,,Intermediate,,,
1664,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,D,1,,CHEMBL616655,,105570,12253,,,B,,,Intermediate,,,
1665,BAO_0000357,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616656,,105570,12936,,,B,,,Intermediate,,,
1666,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,H,1,,CHEMBL616657,,105,13181,,,B,,,Autocuration,,,
1667,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,2435.0,D,1,,CHEMBL616658,,105570,12409,,Striatum,B,,,Intermediate,,,
1668,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,D,1,,CHEMBL616659,,105570,10639,,,B,,,Intermediate,,,
1669,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616660,,51,5254,,,B,,,Autocuration,,,
1670,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,H,1,,CHEMBL616661,,106,13051,,,B,,,Autocuration,,,
1671,BAO_0000019,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616662,,105,3463,,,F,,,Expert,,,
1672,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616663,,105,15315,,,F,,,Autocuration,,,
1673,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616664,,105,6011,,,F,,,Autocuration,,,
1674,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,D,1,CHO,CHEMBL881820,,105,14159,,,F,,,Expert,,449.0,
1675,BAO_0000219,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,H,1,CHO,CHEMBL616665,,105,14159,,,F,,,Autocuration,,449.0,
1676,BAO_0000219,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,H,1,CHO,CHEMBL616666,,105,15250,,,B,,,Expert,,449.0,
1677,BAO_0000219,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,H,1,CHO,CHEMBL616667,,105,15250,,,B,,,Autocuration,,449.0,
1678,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,H,1,CHO,CHEMBL616668,,105,15331,,,F,,,Expert,,449.0,
1679,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,D,1,CHO,CHEMBL616669,,105,15332,,,F,,,Expert,,449.0,
1680,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,H,1,CHO,CHEMBL617040,,105,15332,,,F,,,Expert,,449.0,
1681,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,H,1,CHO,CHEMBL617041,,105,3294,,,F,,,Autocuration,,449.0,
1682,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,H,1,CHO,CHEMBL617042,,105,14158,,,F,,,Expert,,449.0,
1683,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,H,1,CHO,CHEMBL617043,,105,14956,,,F,,,Expert,,449.0,
1684,BAO_0000019,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617044,,105,12469,,,F,,,Autocuration,,,
1685,BAO_0000219,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,H,1,CHO,CHEMBL617045,,105,3463,,,F,,,Expert,,449.0,
1686,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,D,1,CHO,CHEMBL617046,,105,15250,,,F,,,Expert,,449.0,
1687,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,D,1,CHO,CHEMBL617047,,105,15250,,,F,,,Expert,,449.0,
1688,BAO_0000019,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,H,1,,CHEMBL617048,,105,14956,,,F,,,Expert,,,
1689,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,H,1,,CHEMBL616897,,105,14159,,,F,,,Autocuration,,,
1690,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,D,1,,CHEMBL616898,,105,14159,,,F,,,Expert,,,
1691,BAO_0000219,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,D,1,CHO,CHEMBL858201,,105,14499,,,F,,,Expert,,449.0,
1692,BAO_0000019,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616899,,105,15315,,,F,,,Autocuration,,,
1693,BAO_0000219,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,H,1,,CHEMBL616900,In vitro,105,3294,,,B,,,Autocuration,,,
1694,BAO_0000219,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,H,1,CHO,CHEMBL616901,,105,3463,,,B,,,Expert,,449.0,
1695,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,H,1,,CHEMBL616902,,105,15331,,,B,,,Autocuration,,,
1696,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,D,1,CHO,CHEMBL616903,,105,14159,,,B,,,Expert,,449.0,
1697,BAO_0000219,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,H,1,CHO,CHEMBL616904,,105,14158,,,B,,,Expert,,449.0,
1698,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616905,,105,14159,,,B,,,Autocuration,,,
1699,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,H,1,CHO,CHEMBL616906,,105,15250,,,B,,,Expert,,449.0,
1700,BAO_0000219,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616907,,105,15250,,,B,,,Expert,,449.0,
1701,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616908,,105,15331,,,B,,,Expert,,449.0,
1702,BAO_0000219,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,D,1,CHO,CHEMBL616909,,105,15332,,,B,,,Expert,,449.0,
1703,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,D,1,CHO,CHEMBL616910,,105,14499,,,B,,,Expert,,449.0,
1704,BAO_0000219,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616911,,105,15332,,,B,,,Expert,,449.0,
1705,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,H,1,CHO,CHEMBL616912,,105,14956,,,B,,,Expert,,449.0,
1706,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,H,1,,CHEMBL616913,,105,3805,,,B,,,Autocuration,,,
1707,BAO_0000219,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,D,1,CHO,CHEMBL616914,,105,6011,,,B,,,Expert,,449.0,
1708,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,H,1,CHO,CHEMBL616915,,105,16190,,,B,,,Autocuration,,449.0,
1709,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,H,1,,CHEMBL616916,,105,14165,,,B,,,Autocuration,,,
1710,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616917,,105,4234,,,B,,,Expert,,,
1711,BAO_0000357,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,H,1,,CHEMBL616918,,105,15527,,,B,,,Autocuration,,,
1712,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,H,1,,CHEMBL616919,,105,6328,,,B,,,Expert,,,
1713,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,H,1,,CHEMBL616920,,105,16209,,,B,,,Autocuration,,,
1714,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL872914,,105,14770,,,B,,,Autocuration,,,
1715,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,H,1,,CHEMBL616921,,105,2598,,,B,,,Autocuration,,,
1716,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616922,,105,6897,,,B,,,Expert,,,
1717,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616923,,105,6013,,,B,,,Autocuration,,,
1718,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616924,,105,5843,,,B,,,Expert,,,
1719,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,H,1,,CHEMBL875909,,105,14454,,,B,,,Expert,,,
1720,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,H,1,,CHEMBL616925,,105,14454,,,B,,,Autocuration,,,
1721,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,H,1,,CHEMBL616926,,105,14454,,,B,,,Autocuration,,,
1722,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616927,,105,15818,,,B,,,Autocuration,,,
1723,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,H,1,CHO-K1,CHEMBL616928,,105,13729,,,F,,,Expert,,485.0,
1724,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,D,1,,CHEMBL616929,In vitro,105,6011,,,B,,,Expert,,,
1725,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616930,,105,4234,,,B,,,Expert,,,
1726,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616931,,105,17085,,,B,,,Expert,,,
1727,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,H,1,,CHEMBL616932,,105,3025,,,B,,,Autocuration,,,
1728,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616933,,105,15315,,,B,,,Expert,,,
1729,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,D,1,,CHEMBL616934,,105,14214,,,B,,,Expert,,,
1730,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616935,,105,3804,,,B,,,Expert,,,
1731,BAO_0000357,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,H,1,,CHEMBL616936,,105,16700,,,B,,,Autocuration,,,
1732,BAO_0000357,Affinity for 5-hydroxytryptamine 1D receptor subtype,,D,1,,CHEMBL616937,,105,2391,,,B,,,Expert,,,
1733,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616938,,105,4175,,,B,,,Expert,,,
1734,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616939,,105,17085,,,B,,,Autocuration,,,
1735,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,H,1,,CHEMBL616940,,105,17085,,,B,,,Expert,,,
1736,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,D,1,,CHEMBL616941,,105,15926,,,B,,,Expert,,,
1737,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,H,1,CHO-K1,CHEMBL616942,,105,16312,,,B,,,Autocuration,,485.0,
1738,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,H,1,CHO-K1,CHEMBL616943,,105,16312,,,B,,,Autocuration,,485.0,
1739,BAO_0000219,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,H,1,CHO,CHEMBL616944,,104802,14956,,,B,,,Autocuration,,449.0,
1740,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,H,1,,CHEMBL616945,,105,3294,,,F,,,Autocuration,,,
1741,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL616946,,105,12861,,,B,,,Autocuration,,,
1742,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,1,,CHEMBL616947,,105,12861,,,B,,,Autocuration,,,
1743,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,H,1,CHO-K1,CHEMBL616948,,105,16312,,,B,,,Expert,,485.0,
1744,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616851,,105,5104,,,B,,,Autocuration,,,
1745,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616852,,105,5105,,,B,,,Autocuration,,,
1746,BAO_0000357,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616853,,105,14499,,,B,,,Autocuration,,,
1747,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616854,,105,15926,,,B,,,Expert,,,
1748,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,D,1,CHO,CHEMBL616855,,105,4540,,,B,,,Expert,,449.0,
1749,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,H,1,CHO,CHEMBL616856,,105,15779,,,B,,,Autocuration,,449.0,
1750,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,1,CHO,CHEMBL616857,,105,15779,,,B,,,Autocuration,,449.0,
1751,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616858,,105,6166,,,B,,,Autocuration,,,
1752,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,H,1,CHO,CHEMBL616859,,105,15779,,,B,,,Autocuration,,449.0,
1753,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,H,1,CHO,CHEMBL616860,,105,15779,,,B,,,Autocuration,,449.0,
1754,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,H,1,HEK293,CHEMBL616861,,105,17451,,,B,,,Autocuration,,722.0,
1755,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,H,1,HEK293,CHEMBL616541,,105,17451,,,B,,,Autocuration,,722.0,
1756,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,H,1,HEK293,CHEMBL616542,,105,17451,,,B,,,Autocuration,,722.0,
1757,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,H,1,CHO,CHEMBL616543,,105,4199,,,B,,,Autocuration,,449.0,
1758,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL616544,,105,14875,,,B,,,Expert,,,
1759,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,H,1,CHO,CHEMBL616545,,105,15146,,,B,,,Autocuration,,449.0,
1760,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,H,1,,CHEMBL616546,,105,5213,,,B,,,Autocuration,,,
1761,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,H,1,CHO,CHEMBL616547,,105,14818,,,B,,,Autocuration,,449.0,
1762,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL616548,,105,4829,,,B,,,Autocuration,,449.0,
1763,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,H,1,,CHEMBL616549,,105,14454,,,F,,,Expert,,,
1764,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,H,1,,CHEMBL616550,,105,14454,,,F,,,Expert,,,
1765,BAO_0000357,Binding affinity against 5-HT2C receptor,,H,1,,CHEMBL857066,,108,5254,,,B,,,Autocuration,,,
1766,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616551,,108,5254,,,B,,,Autocuration,,,
1767,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,H,1,,CHEMBL616552,,10577,10639,,,B,,,Autocuration,,,
1768,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,H,1,,CHEMBL832876,,10577,10639,,,F,,,Autocuration,,,
1769,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,H,1,,CHEMBL616553,,10577,12352,,,B,,,Expert,,,
1770,BAO_0000357,Binding affinity towards 5-HT1B was determined,,H,1,,CHEMBL616554,,10577,9098,,,B,,,Autocuration,,,
1771,BAO_0000019,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,H,1,,CHEMBL616555,,10577,14430,,,B,,,Expert,,,
1772,BAO_0000019,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,H,1,,CHEMBL616556,,10577,13657,,,B,,,Expert,,,
1773,BAO_0000019,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,H,1,,CHEMBL616557,,10577,13657,,,B,,,Autocuration,,,
1774,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,H,1,,CHEMBL616558,,10577,15854,,,B,,,Expert,,,
1775,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,D,1,,CHEMBL616749,,10577,10639,,,B,,,Expert,,,
1776,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,H,1,,CHEMBL616750,,10577,10025,,,B,,,Autocuration,,,
1777,BAO_0000357,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,H,1,,CHEMBL616751,,10577,10025,,,B,,,Autocuration,,,
1778,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,H,1,,CHEMBL616752,,10577,14286,,,B,,,Autocuration,,,
1779,BAO_0000019,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,2435.0,H,1,,CHEMBL616753,,10577,3651,,Striatum,B,,,Autocuration,,,
1780,BAO_0000357,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616754,,10577,14178,,,B,,,Expert,,,
1781,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,H,1,,CHEMBL616755,,10577,10639,,,B,,,Autocuration,,,
1782,BAO_0000019,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,2435.0,H,1,,CHEMBL616756,,10577,13605,,Striatum,B,,,Autocuration,,,
1783,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,2435.0,H,1,,CHEMBL616757,,10577,5834,,Striatum,B,,,Autocuration,,,
1784,BAO_0000357,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,2435.0,H,1,,CHEMBL616758,,10577,10922,,Striatum,B,,,Autocuration,,,
1785,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,H,1,,CHEMBL616759,,10577,14286,,,B,,,Autocuration,,,
1786,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,H,1,,CHEMBL616760,,10577,11825,,,B,,,Autocuration,,,
1787,BAO_0000019,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,2435.0,H,1,,CHEMBL616761,,10577,14826,,Striatum,B,,,Autocuration,,,
1788,BAO_0000019,Binding affinity against 5-HT1B serotonin receptor in rat striatum,2435.0,H,1,,CHEMBL616762,,10577,9699,,Striatum,B,,,Autocuration,,,
1789,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,H,1,,CHEMBL616763,,10577,14423,,,B,,,Autocuration,,,
1790,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,H,1,,CHEMBL872909,,10577,10062,,,B,,,Expert,,,
1791,BAO_0000357,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616764,,10577,10062,,,B,,,Autocuration,,,
1792,BAO_0000357,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616765,,10577,12280,,,B,,,Expert,,,
1793,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,2435.0,H,1,,CHEMBL616766,,10577,15412,,Striatum,B,,,Autocuration,,,
1794,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,2435.0,H,1,,CHEMBL616767,,10577,15412,,Striatum,B,,,Autocuration,,,
1795,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616768,,10577,10062,,,B,,,Autocuration,,,
1796,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL616769,,10577,11147,,,B,,,Autocuration,,,
1797,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,H,1,,CHEMBL616770,,10577,9547,,,B,,,Autocuration,,,
1798,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,H,1,,CHEMBL616771,,10577,10444,,,B,,,Autocuration,,,
1799,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,2435.0,H,1,,CHEMBL616772,,10577,12469,,Striatum,B,,,Autocuration,,,
1800,BAO_0000019,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,H,1,,CHEMBL616773,,10577,9098,,,B,,,Expert,,,
1801,BAO_0000019,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,H,1,,CHEMBL616774,,10577,9098,,,B,,,Autocuration,,,
1802,BAO_0000357,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616775,,10577,9699,,,B,,,Autocuration,,,
1803,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,H,1,,CHEMBL616776,,10577,10394,,,B,,,Autocuration,,,
1804,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,H,1,,CHEMBL616777,,10577,12092,,,B,,,Autocuration,,,
1805,BAO_0000357,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,H,1,,CHEMBL616778,,10577,16700,,,B,,,Autocuration,,,
1806,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,D,1,,CHEMBL616779,,10577,403,,,B,,,Expert,,,
1807,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,,D,1,,CHEMBL616780,,10577,12771,,,B,,,Expert,,,
1808,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,H,1,,CHEMBL616781,,10577,11642,,,B,,,Autocuration,,,
1809,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,H,1,,CHEMBL616782,,10577,12953,,,B,,,Autocuration,,,
1810,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,H,1,,CHEMBL616783,,10577,12953,,,B,,,Autocuration,,,
1811,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,2435.0,H,1,,CHEMBL616784,,10577,12953,,Striatum,B,,,Expert,,,
1812,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,H,1,,CHEMBL616785,,10577,12953,,,B,,,Autocuration,,,
1813,BAO_0000249,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,H,1,,CHEMBL857067,,10577,9737,,Brain,B,,,Autocuration,,,
1814,BAO_0000019,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,H,1,,CHEMBL616786,,10577,9737,,,B,,,Autocuration,,,
1815,BAO_0000249,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,H,1,,CHEMBL616787,,10577,9737,,Brain,B,,,Autocuration,,,
1816,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,H,1,,CHEMBL616788,,10577,12827,,,B,,,Autocuration,,,
1817,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616789,,10577,5033,,,B,,,Autocuration,,,
1818,BAO_0000019,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,D,1,,CHEMBL616790,,10577,9786,,,B,,,Expert,,,
1819,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616791,,10577,13116,,,B,,,Expert,,,
1820,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,H,1,,CHEMBL616792,,10577,16429,,,B,,,Autocuration,,,
1821,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,D,1,,CHEMBL616793,,10577,12409,,,B,,,Expert,,,
1822,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL616794,,10577,15194,,,B,,,Autocuration,,,
1823,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL616795,,10577,15194,,,B,,,Autocuration,,,
1824,BAO_0000019,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,H,1,,CHEMBL616796,,104686,5486,,,B,,,Autocuration,,,
1825,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616797,,106,4639,,,B,,,Autocuration,,,
1826,BAO_0000249,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,H,1,,CHEMBL616798,,106,386,Brain membranes,,B,,,Autocuration,,,
1827,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,H,1,,CHEMBL616799,,106,2474,,,B,,,Autocuration,,,
1828,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,H,1,,CHEMBL616800,,106,6011,,,B,,,Autocuration,,,
1829,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616801,,106,5014,,,B,,,Autocuration,,,
1830,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,H,1,,CHEMBL616802,,106,17515,,,B,,,Autocuration,,,
1831,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,H,1,,CHEMBL616803,,106,4373,,,B,,,Autocuration,,,
1832,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,H,1,,CHEMBL857068,,106,1633,,,B,,,Expert,,,
1833,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,H,1,,CHEMBL616804,,106,1633,,,B,,,Autocuration,,,
1834,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,H,1,,CHEMBL616805,,106,4373,,,B,,,Autocuration,,,
1835,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616806,,106,4687,,,B,,,Autocuration,,,
1836,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,,H,1,,CHEMBL616807,,106,11574,,,B,,,Autocuration,,,
1837,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,H,1,,CHEMBL616808,,106,10321,,,B,,,Autocuration,,,
1838,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL616809,,106,15527,,,B,,,Autocuration,,,
1839,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,H,1,,CHEMBL616810,,106,17200,,,B,,,Autocuration,,,
1840,BAO_0000224,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,H,1,,CHEMBL616811,,104802,14423,,,B,,,Autocuration,,,
1841,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,H,1,,CHEMBL616812,,108,5834,,,B,,,Autocuration,,,
1842,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,H,1,,CHEMBL616813,,108,11473,,,B,,,Autocuration,,,
1843,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,H,1,,CHEMBL616814,,108,11473,,,B,,,Autocuration,,,
1844,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,H,1,,CHEMBL616815,,108,10639,,,B,,,Autocuration,,,
1845,BAO_0000357,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,H,1,,CHEMBL616816,,108,10639,,,B,,,Autocuration,,,
1846,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,H,1,,CHEMBL616817,,108,14331,,,B,,,Autocuration,,,
1847,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,H,1,,CHEMBL616818,,108,10796,,,B,,,Autocuration,,,
1848,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,H,1,,CHEMBL616819,,108,9098,,,B,,,Expert,,,
1849,BAO_0000357,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,H,1,,CHEMBL616820,,108,14331,,,B,,,Expert,,,
1850,BAO_0000019,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,H,1,,CHEMBL616821,,108,11828,,,B,,,Expert,,,
1851,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,H,1,,CHEMBL616822,,108,11866,,,B,,,Autocuration,,,
1852,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,H,1,,CHEMBL616823,,108,13047,,,B,,,Autocuration,,,
1853,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,D,1,,CHEMBL616824,,12689,188,,,B,,,Autocuration,,,
1854,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,D,1,,CHEMBL616825,,12689,11825,,,B,,,Autocuration,,,
1855,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,D,1,,CHEMBL616826,,12689,11825,,,B,,,Autocuration,,,
1856,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,D,1,,CHEMBL616827,,12689,11624,,,B,,,Expert,,,
1857,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,D,1,,CHEMBL616828,,12689,11139,,,B,,,Autocuration,,,
1858,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,D,1,,CHEMBL616829,,12689,11147,,,B,,,Autocuration,,,
1859,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,D,1,,CHEMBL616830,,12689,10444,,,B,,,Autocuration,,,
1860,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,D,1,,CHEMBL616831,,12689,11624,,,B,,,Expert,,,
1861,BAO_0000019,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,1,,CHEMBL616832,,12689,11662,,,B,,,Autocuration,,,
1862,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,1,,CHEMBL616833,,12689,11662,,,B,,,Autocuration,,,
1863,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,1,,CHEMBL616834,,12689,11662,,,B,,,Expert,,,
1864,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,1,,CHEMBL829595,,12689,11662,,,B,,,Autocuration,,,
1865,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,D,1,,CHEMBL616835,,12689,9098,,,B,,,Autocuration,,,
1866,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,D,1,,CHEMBL872910,,12689,10394,,,B,,,Autocuration,,,
1867,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,H,1,,CHEMBL616836,,12689,11933,,,B,,,Expert,,,
1868,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,D,1,,CHEMBL616837,,12689,12092,,,B,,,Autocuration,,,
1869,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,D,1,,CHEMBL616466,,12689,12253,,,B,,,Autocuration,,,
1870,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,D,1,HEK293,CHEMBL616467,,12689,12253,,,B,,,Autocuration,,722.0,
1871,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,H,1,,CHEMBL616468,,108,1558,,,B,,,Autocuration,,,
1872,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,H,1,,CHEMBL616469,,108,2474,,,B,,,Autocuration,,,
1873,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,H,1,,CHEMBL616470,,108,2474,,,B,,,Autocuration,,,
1874,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,H,1,,CHEMBL616471,,12689,11574,,,B,,,Autocuration,,,
1875,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,H,1,,CHEMBL616472,,12689,1558,,,B,,,Autocuration,,,
1876,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,H,1,,CHEMBL616473,,12689,13944,,,B,,,Autocuration,,,
1877,BAO_0000357,Binding affinity against serotonergic 5-HT1c receptor,,H,1,,CHEMBL616474,,12689,13033,,,B,,,Autocuration,,,
1878,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,H,1,,CHEMBL616475,,12689,10321,,,B,,,Autocuration,,,
1879,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,H,1,,CHEMBL616476,,12689,11866,,,B,,,Autocuration,,,
1880,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,H,1,,CHEMBL616477,,105,14454,,,B,,,Autocuration,,,
1881,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,H,1,,CHEMBL616478,,104686,11574,,,B,,,Autocuration,,,
1882,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,H,1,,CHEMBL616479,,104686,11574,,,B,,,Autocuration,,,
1883,BAO_0000019,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,H,1,,CHEMBL616480,,104686,13631,,,B,,,Autocuration,,,
1884,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,D,1,,CHEMBL616481,,104686,9630,,,B,,,Autocuration,,,
1885,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,D,1,,CHEMBL616482,,104686,8822,,,B,,,Autocuration,,,
1886,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,955.0,D,1,,CHEMBL884713,,104686,9064,,Brain,B,,,Autocuration,,,
1887,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,H,1,,CHEMBL616483,,104686,8868,,,B,,,Autocuration,,,
1888,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,H,1,,CHEMBL616484,,104686,9064,,,B,,,Autocuration,,,
1889,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,H,1,,CHEMBL616485,,104686,9806,,,B,,,Autocuration,,,
1890,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,H,1,,CHEMBL616486,,104686,9098,,,B,,,Autocuration,,,
1891,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,H,1,,CHEMBL616487,,104686,8868,,,B,,,Autocuration,,,
1892,BAO_0000224,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,H,1,,CHEMBL616488,,104686,12765,,,B,,,Autocuration,,,
1893,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,1,,CHEMBL616489,,104686,11049,,,B,,,Autocuration,,,
1894,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,1,,CHEMBL616490,,104686,11049,,,B,,,Autocuration,,,
1895,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,H,1,,CHEMBL616491,,104686,11049,,,B,,,Autocuration,,,
1896,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,H,1,,CHEMBL616492,,104686,11049,,,B,,,Autocuration,,,
1897,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,1,,CHEMBL616493,,104686,11049,,,B,,,Autocuration,,,
1898,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,H,1,,CHEMBL616494,,104686,11473,,,B,,,Autocuration,,,
1899,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,H,1,,CHEMBL616495,,104686,11473,,,B,,,Autocuration,,,
1900,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,H,1,,CHEMBL616496,,104686,3086,,,B,,,Autocuration,,,
1901,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,1,,CHEMBL616497,,104686,11049,,,B,,,Autocuration,,,
1902,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,1,,CHEMBL616498,,104686,11049,,,B,,,Autocuration,,,
1903,BAO_0000019,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,H,1,,CHEMBL616499,,104686,10639,,,B,,,Autocuration,,,
1904,BAO_0000019,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,H,1,,CHEMBL616500,,104686,10922,,,B,,,Autocuration,,,
1905,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,955.0,D,1,,CHEMBL616501,,104686,9064,,Brain,B,,,Autocuration,,,
1906,BAO_0000221,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,955.0,H,1,,CHEMBL616502,,104686,10748,,Brain,B,,,Autocuration,,,
1907,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,H,1,,CHEMBL884529,,104686,11614,Membranes,,B,,,Autocuration,,,
1908,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,H,1,,CHEMBL616503,,104686,11615,Membranes,,B,,,Autocuration,,,
1909,BAO_0000224,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL616964,,104686,11615,,,B,,,Autocuration,,,
1910,BAO_0000249,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,H,1,,CHEMBL616965,,104686,11614,Membranes,,B,,,Autocuration,,,
1911,BAO_0000224,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,H,1,,CHEMBL616966,,104686,11702,,,B,,,Autocuration,,,
1912,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,H,1,,CHEMBL616967,,104686,11702,,,B,,,Autocuration,,,
1913,BAO_0000224,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL616968,,104686,11702,,,B,,,Autocuration,,,
1914,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,H,1,,CHEMBL616969,,104686,11702,,,B,,,Autocuration,,,
1915,BAO_0000019,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,H,1,,CHEMBL884530,,104686,13346,,,B,,,Autocuration,,,
1916,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL616970,,104686,10025,,,B,,,Autocuration,,,
1917,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,H,1,,CHEMBL616971,,104686,10025,,,B,,,Autocuration,,,
1918,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,H,1,,CHEMBL616972,,104686,10025,,,B,,,Autocuration,,,
1919,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,H,1,,CHEMBL616973,,104686,9036,,,B,,,Autocuration,,,
1920,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,H,1,,CHEMBL616974,,104686,9036,,,B,,,Autocuration,,,
1921,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,H,1,,CHEMBL616975,,104686,9161,,,B,,,Autocuration,,,
1922,BAO_0000019,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,H,1,,CHEMBL616976,,104686,12304,,,B,,,Autocuration,,,
1923,BAO_0000224,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,H,1,,CHEMBL616977,,104686,13276,,,B,,,Autocuration,,,
1924,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,H,1,,CHEMBL616978,,104686,11825,,,B,,,Autocuration,,,
1925,BAO_0000224,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,H,1,,CHEMBL616979,,104686,12443,,,B,,,Autocuration,,,
1926,BAO_0000224,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL616980,,104686,13830,,,B,,,Autocuration,,,
1927,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,H,1,,CHEMBL616981,,104686,9592,Membranes,,B,,,Autocuration,,,
1928,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,H,1,,CHEMBL616982,,104686,9592,Membranes,,B,,,Autocuration,,,
1929,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,H,1,,CHEMBL616983,,104686,10881,,,B,,,Autocuration,,,
1930,BAO_0000019,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,H,1,,CHEMBL616984,,104686,13605,,,B,,,Autocuration,,,
1931,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL616985,,104686,11624,,,B,,,Autocuration,,,
1932,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,H,1,,CHEMBL616986,,104686,4101,,,B,,,Autocuration,,,
1933,BAO_0000224,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,H,1,,CHEMBL616987,,104686,4101,,,B,,,Autocuration,,,
1934,BAO_0000019,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,H,1,,CHEMBL616988,,104686,15360,,,B,,,Autocuration,,,
1935,BAO_0000019,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,H,1,,CHEMBL617243,,104686,11576,,,B,,,Autocuration,,,
1936,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,H,1,,CHEMBL617244,,104686,5834,,,B,,,Autocuration,,,
1937,BAO_0000219,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,D,1,CHO-K1,CHEMBL617245,,104686,2395,,,B,,,Autocuration,,485.0,
1938,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,H,1,,CHEMBL617246,,104686,11965,Membranes,,B,,,Autocuration,,,
1939,BAO_0000224,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,H,1,,CHEMBL617546,,104686,3967,,,B,,,Autocuration,,,
1940,BAO_0000249,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,H,1,,CHEMBL617547,,104686,11130,Brain membranes,,B,,,Autocuration,,,
1941,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,H,1,,CHEMBL617548,In vitro,104686,13427,,,B,,,Autocuration,,,
1942,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617549,,104686,9443,,,B,,,Autocuration,,,
1943,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,H,1,,CHEMBL617550,,104686,9443,,,B,,,Autocuration,,,
1944,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,H,1,,CHEMBL617551,,104686,11825,,,B,,,Autocuration,,,
1945,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,H,1,,CHEMBL617552,,104686,12120,Membranes,,B,,,Autocuration,,,
1946,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,H,1,,CHEMBL617553,,104686,12120,Membranes,,B,,,Autocuration,,,
1947,BAO_0000019,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1515.0,H,1,,CHEMBL617554,,104686,11963,,Thoracic aorta,F,,,Autocuration,,,
1948,BAO_0000019,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617555,,104686,9069,,,B,,,Autocuration,,,
1949,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,H,1,,CHEMBL617556,,104686,8868,,,B,,,Autocuration,,,
1950,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,H,1,,CHEMBL617557,,10624,17200,,,B,,,Autocuration,,,
1951,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,H,1,,CHEMBL617558,,10624,17200,,,B,,,Autocuration,,,
1952,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,H,1,,CHEMBL617559,,17106,13969,,,B,,,Expert,,,
1953,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor,,D,1,,CHEMBL617560,,17106,13392,,,B,,,Expert,,,
1954,BAO_0000249,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,H,1,,CHEMBL617561,,17106,1742,,,B,,,Autocuration,,,
1955,BAO_0000249,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,H,1,,CHEMBL617562,,17106,1742,,,B,,,Autocuration,,,
1956,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,2435.0,H,1,,CHEMBL617563,,17106,14331,,Striatum,B,,,Autocuration,,,
1957,BAO_0000019,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617564,,17106,12861,,,F,,,Autocuration,,,
1958,BAO_0000019,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,H,1,,CHEMBL617565,,17106,12861,,,B,,,Expert,,,
1959,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL856076,,17106,12861,,,B,,,Autocuration,,,
1960,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,H,1,,CHEMBL617566,,17106,12861,,,B,,,Autocuration,,,
1961,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,1,,CHEMBL875911,,17106,12861,,,B,,,Expert,,,
1962,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,H,1,,CHEMBL617567,,17106,12861,,,B,,,Autocuration,,,
1963,BAO_0000249,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,H,1,,CHEMBL617568,,17106,675,,,B,,,Autocuration,,,
1964,BAO_0000019,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,H,1,,CHEMBL617569,,17106,12490,,,B,,,Expert,,,
1965,BAO_0000249,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,H,1,,CHEMBL617570,,17106,11828,,,B,,,Expert,,,
1966,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,H,1,,CHEMBL617571,,17106,11866,,,B,,,Autocuration,,,
1967,BAO_0000357,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,H,1,,CHEMBL617572,,105,773,,,B,,,Autocuration,,,
1968,BAO_0000357,The compound was tested for intrinsic activity against 5-HT1D receptor,,H,1,,CHEMBL617573,,105,13047,,,B,,,Expert,,,
1969,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,H,1,,CHEMBL617574,,105,13047,,,B,,,Autocuration,,,
1970,BAO_0000357,The compound was tested for binding affinity against 5-HT1D receptor,,H,1,,CHEMBL617575,,105,13047,,,B,,,Expert,,,
1971,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,H,1,,CHEMBL617576,,10578,188,,,B,,,Autocuration,,,
1972,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,H,1,,CHEMBL617577,,10578,10639,,,F,,,Autocuration,,,
1973,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617578,,10578,12438,,,F,,,Autocuration,,,
1974,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617579,,10578,12438,,,B,,,Autocuration,,,
1975,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,H,1,,CHEMBL617580,,10578,15854,,,B,,,Expert,,,
1976,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,H,1,,CHEMBL617581,,10578,10394,,,B,,,Autocuration,,,
1977,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,H,1,,CHEMBL617582,,10578,12092,,,B,,,Autocuration,,,
1978,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,H,1,,CHEMBL617583,,10578,3389,,,B,,,Expert,,,
1979,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,H,1,,CHEMBL617584,,105,6011,,,B,,,Autocuration,,,
1980,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617585,,105,4639,,,B,,,Autocuration,,,
1981,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,H,1,,CHEMBL875912,,105,2474,,,B,,,Autocuration,,,
1982,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617586,,105,5014,,,B,,,Autocuration,,,
1983,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,H,1,,CHEMBL617587,,105,17515,,,B,,,Autocuration,,,
1984,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,H,1,,CHEMBL617588,,105,11866,,,B,,,Autocuration,,,
1985,BAO_0000357,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL857980,,105,4687,,,B,,,Autocuration,,,
1986,BAO_0000357,Tested against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL617589,,105,12146,,,B,,,Autocuration,,,
1987,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,H,1,,CHEMBL617590,,105,10321,,,B,,,Autocuration,,,
1988,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL617591,,105,13267,,,B,,,Autocuration,,722.0,
1989,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 1D receptor,,D,1,,CHEMBL617592,,105,1274,,,B,,,Expert,,,
1990,BAO_0000357,,,H,1,,CHEMBL617593,,105,15250,,,B,,,Autocuration,,,
1991,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL617594,,106,13706,,,B,,,Autocuration,,485.0,
1992,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL617595,,105,13706,,,B,,,Autocuration,,485.0,
1993,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,H,1,HEK293,CHEMBL617596,,105,13706,,,B,,,Autocuration,,722.0,
1994,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,H,1,HEK293,CHEMBL617597,,105,13706,,,B,,,Autocuration,,722.0,
1995,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,H,1,,CHEMBL617598,,105,13047,,,B,,,Autocuration,,,
1996,BAO_0000357,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,H,1,,CHEMBL872916,,105,13366,,,B,,,Autocuration,,,
1997,BAO_0000357,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,H,1,,CHEMBL617599,,105,13366,,,B,,,Expert,,,
1998,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,H,1,,CHEMBL617091,,105,1558,,,B,,,Autocuration,,,
1999,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,H,1,CHO-K1,CHEMBL617092,,105,12902,,,B,,,Expert,,485.0,
2000,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL617093,,105,13706,,,B,,,Autocuration,,485.0,
2001,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,H,1,,CHEMBL617094,,105,13706,,,F,,,Autocuration,,,
2002,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,H,1,,CHEMBL617095,,105,13706,,,F,,,Autocuration,,,
2003,BAO_0000019,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,H,1,,CHEMBL617096,,105,14251,,,F,,,Autocuration,,,
2004,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,H,1,,CHEMBL617097,,105,14251,,,F,,,Autocuration,,,
2005,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,H,1,,CHEMBL617098,,105,14251,,,F,,,Autocuration,,,
2006,BAO_0000357,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,H,1,,CHEMBL617301,,105,13313,,,B,,,Autocuration,,,
2007,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,H,1,,CHEMBL617302,,105,13313,,,B,,,Autocuration,,,
2008,BAO_0000357,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617303,,105,13366,,,B,,,Autocuration,,,
2009,BAO_0000357,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617304,,105,13051,,,B,,,Expert,,,
2010,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL617305,,105,12903,,,B,,,Expert,,449.0,
2011,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,D,1,,CHEMBL617306,,105,12469,,,B,,,Autocuration,,,
2012,BAO_0000357,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,H,1,,CHEMBL617307,,17106,5619,,,B,,,Autocuration,,,
2013,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,H,1,,CHEMBL617308,,105,13047,,,B,,,Autocuration,,,
2014,BAO_0000357,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617309,,105,16633,,,B,,,Autocuration,,,
2015,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617310,,105,16633,,,B,,,Autocuration,,,
2016,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617311,,105,16633,,,B,,,Autocuration,,,
2017,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL617312,,105,16633,,,B,,,Autocuration,,,
2018,BAO_0000357,Affinity against 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617313,,105,3269,,,B,,,Autocuration,,,
2019,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,H,1,,CHEMBL617314,,105,12409,,,B,,,Expert,,,
2020,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,H,1,,CHEMBL617315,,106,13706,,,F,,,Autocuration,,,
2021,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,H,1,HEK293,CHEMBL617316,,106,13706,,,B,,,Autocuration,,722.0,
2022,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,H,1,HEK293,CHEMBL617317,,106,13706,,,B,,,Autocuration,,722.0,
2023,BAO_0000219,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL617318,,106,12903,,,B,,,Autocuration,,449.0,
2024,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,H,1,,CHEMBL617319,,106,13047,,,B,,,Autocuration,,,
2025,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,D,1,,CHEMBL617320,,106,13366,,,B,,,Expert,,,
2026,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,D,1,,CHEMBL617321,,106,13366,,,B,,,Expert,,,
2027,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,D,1,,CHEMBL617322,,106,13366,,,B,,,Expert,,,
2028,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616862,,106,13366,,,B,,,Autocuration,,,
2029,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL616863,,106,13366,,,B,,,Autocuration,,,
2030,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,H,1,CHO,CHEMBL616864,,106,12469,,,B,,,Autocuration,,449.0,
2031,BAO_0000219,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL616865,,106,13706,,,B,,,Autocuration,,485.0,
2032,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL616866,,106,13706,,,B,,,Autocuration,,485.0,
2033,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,H,1,,CHEMBL616867,,106,13706,,,F,,,Autocuration,,,
2034,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,H,1,CHO-K1,CHEMBL616868,,106,12902,,,B,,,Expert,,485.0,
2035,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,H,1,,CHEMBL616869,,105,13051,,,B,,,Expert,,,
2036,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL616870,,106,12903,,,B,,,Expert,,449.0,
2037,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,H,1,CHO-K1,CHEMBL616871,,105,1558,,,F,,,Autocuration,,485.0,
2038,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,H,1,CHO-K1,CHEMBL616872,,105,1558,,,F,,,Autocuration,,485.0,
2039,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,H,1,CHO-K1,CHEMBL616873,,105,1558,,,F,,,Autocuration,,485.0,
2040,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,H,1,CHO-K1,CHEMBL616838,,105,1558,,,F,,,Autocuration,,485.0,
2041,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,H,1,,CHEMBL616839,,105,1558,,,B,,,Autocuration,,,
2042,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,H,1,,CHEMBL616840,,106,13047,,,B,,,Autocuration,,,
2043,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,H,1,,CHEMBL616841,,105,13313,,,B,,,Autocuration,,,
2044,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,H,1,,CHEMBL616842,,105,13313,,,B,,,Autocuration,,,
2045,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,H,1,,CHEMBL857976,,105,12409,,,B,,,Expert,,,
2046,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616843,,10618,15250,,,B,,,Autocuration,,449.0,
2047,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,D,1,,CHEMBL616844,,10618,1348,,,B,,,Expert,,,
2048,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,H,1,,CHEMBL616845,,10618,1348,,,B,,,Autocuration,,,
2049,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,D,1,,CHEMBL616846,,10618,4234,,,B,,,Expert,,,
2050,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,H,1,,CHEMBL616847,,10618,16209,,,B,,,Autocuration,,,
2051,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,H,1,,CHEMBL616848,,10618,10444,,,B,,,Autocuration,,,
2052,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,H,1,,CHEMBL616849,,10618,3935,,,B,,,Autocuration,,,
2053,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,H,1,,CHEMBL872911,,10618,15818,,,B,,,Autocuration,,,
2054,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,H,1,,CHEMBL616850,,10618,17085,,,B,,,Autocuration,,,
2055,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,D,1,CHO,CHEMBL616699,,10618,12936,,,B,,,Expert,,449.0,
2056,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,H,1,,CHEMBL616700,,10618,6166,,,B,,,Autocuration,,,
2057,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,1,CHO,CHEMBL616701,,10618,15779,,,B,,,Autocuration,,449.0,
2058,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,H,1,CHO,CHEMBL616702,,10618,15779,,,B,,,Autocuration,,449.0,
2059,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,H,1,CHO,CHEMBL616703,,10618,15779,,,B,,,Autocuration,,449.0,
2060,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,H,1,,CHEMBL616704,,10618,13181,,,B,,,Autocuration,,,
2061,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,H,1,CHO,CHEMBL616705,,10618,4199,,,B,,,Autocuration,,449.0,
2062,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,H,1,,CHEMBL616706,,10618,14875,,,B,,,Autocuration,,,
2063,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,H,1,CHO,CHEMBL616707,,10618,15146,,,B,,,Autocuration,,449.0,
2064,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,H,1,,CHEMBL616708,,10618,5213,,,B,,,Autocuration,,,
2065,BAO_0000357,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL616709,,10618,12146,,,B,,,Autocuration,,,
2066,BAO_0000219,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,H,1,CHO,CHEMBL616710,,10618,13267,,,B,,,Autocuration,,449.0,
2067,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,H,1,CHO,CHEMBL616711,,10618,14818,,,B,,,Autocuration,,449.0,
2068,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL616712,,10618,4829,,,B,,,Autocuration,,449.0,
2069,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,H,1,,CHEMBL616713,,10618,4373,,,B,,,Autocuration,,,
2070,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,H,1,,CHEMBL616714,,10618,4373,,,B,,,Autocuration,,,
2071,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,H,1,,CHEMBL616715,,10618,14159,,,B,,,Autocuration,,,
2072,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1E receptor,,H,1,,CHEMBL616716,,10618,16633,,,B,,,Autocuration,,,
2073,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,H,1,,CHEMBL616717,,279,17085,,,F,,,Autocuration,,,
2074,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,H,1,,CHEMBL616718,,279,17085,,,F,,,Expert,,,
2075,BAO_0000019,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL875905,,279,16209,,,F,,,Autocuration,,,
2076,BAO_0000019,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL616719,,279,16209,,,F,,,Autocuration,,,
2077,BAO_0000019,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,H,1,,CHEMBL616720,,279,17085,,,F,,,Expert,,,
2078,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL616721,,279,14159,,,B,,,Autocuration,,,
2079,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL616722,,279,15250,,,B,,,Autocuration,,449.0,
2080,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,H,1,,CHEMBL616723,,279,3805,,,B,,,Autocuration,,,
2081,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,H,1,CHO,CHEMBL616724,,279,16190,,,B,,,Autocuration,,449.0,
2082,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,H,1,,CHEMBL616725,,279,16190,,,B,,,Autocuration,,,
2083,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL616726,,279,16209,,,B,,,Autocuration,,,
2084,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,H,1,,CHEMBL616727,,279,16209,,,B,,,Autocuration,,,
2085,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,H,1,,CHEMBL616728,,279,16209,,,B,,,Autocuration,,,
2086,BAO_0000357,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL616729,,279,6866,,,B,,,Autocuration,,,
2087,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL616730,,279,17085,,,B,,,Expert,,,
2088,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL617125,,279,16312,,,B,,,Autocuration,,,
2089,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,H,1,,CHEMBL857977,,279,6166,,,B,,,Autocuration,,,
2090,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,1,CHO,CHEMBL617126,,279,15779,,,B,,,Autocuration,,449.0,
2091,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,H,1,CHO,CHEMBL617127,,279,4199,,,B,,,Autocuration,,449.0,
2092,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL617128,,279,14875,,,B,,,Autocuration,,,
2093,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,H,1,CHO,CHEMBL617129,,279,15146,,,B,,,Autocuration,,449.0,
2094,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,H,1,,CHEMBL617130,,279,5213,,,B,,,Autocuration,,,
2095,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,H,1,CHO,CHEMBL617131,,279,14818,,,B,,,Autocuration,,449.0,
2096,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL617132,,279,4829,,,B,,,Autocuration,,449.0,
2097,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,H,1,CHO,CHEMBL617133,,279,4829,,,B,,,Autocuration,,449.0,
2098,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,H,1,,CHEMBL617134,,279,4373,,,B,,,Autocuration,,,
2099,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,H,1,,CHEMBL617135,,279,4373,,,B,,,Autocuration,,,
2100,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,H,1,,CHEMBL617136,,279,5014,,,B,,,Autocuration,,,
2101,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,H,1,,CHEMBL617137,,104686,11662,,,B,,,Autocuration,,,
2102,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,H,1,,CHEMBL617138,,104686,11662,,,B,,,Autocuration,,,
2103,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,H,1,,CHEMBL617139,,104686,11662,,,B,,,Autocuration,,,
2104,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617140,,12687,14093,,,B,,,Autocuration,,,
2105,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,H,1,,CHEMBL617141,In vivo,104686,11200,,,F,,,Autocuration,,,
2106,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,1,,CHEMBL858112,,104686,11200,,,F,,,Autocuration,,,
2107,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,H,1,,CHEMBL617142,,17005,12352,,,B,,,Intermediate,,,
2108,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,U,1,,CHEMBL617143,,22226,13657,,,B,,,Autocuration,,,
2109,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,U,1,,CHEMBL617144,,22226,14331,,,B,,,Autocuration,,,
2110,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,U,1,,CHEMBL617145,,22226,14331,,,B,,,Autocuration,,,
2111,BAO_0000019,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,U,1,,CHEMBL617146,,22226,14331,,,B,,,Autocuration,,,
2112,BAO_0000019,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,H,1,,CHEMBL617147,,104784,12685,,,B,,,Autocuration,,,
2113,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,H,1,,CHEMBL617148,,104784,14389,,,B,,,Autocuration,,,
2114,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,H,1,,CHEMBL617149,,104784,14386,,,B,,,Autocuration,,,
2115,BAO_0000224,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,H,1,,CHEMBL617150,,104784,5732,,,B,,,Autocuration,,,
2116,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,H,1,,CHEMBL617151,,104784,16293,,,B,,,Autocuration,,,
2117,BAO_0000224,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617201,,104784,2078,,,B,,,Autocuration,,,
2118,BAO_0000357,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,H,1,,CHEMBL617202,,10209,5486,,,B,,,Autocuration,,,
2119,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,H,1,,CHEMBL617203,In vivo,104826,11820,,,B,,,Autocuration,,,
2120,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,H,1,,CHEMBL617204,,104826,10297,,,B,,,Autocuration,,,
2121,BAO_0000224,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,H,1,,CHEMBL617205,,104826,13704,,,B,,,Autocuration,,,
2122,BAO_0000019,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,D,1,,CHEMBL617206,,104826,10297,,,B,,,Autocuration,,,
2123,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,H,1,,CHEMBL617207,In vivo,104826,11820,,,B,,,Autocuration,,,
2124,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,D,1,,CHEMBL617208,,104826,10297,,,B,,,Autocuration,,,
2125,BAO_0000224,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617209,,104826,11555,,,B,,,Autocuration,,,
2126,BAO_0000224,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,H,1,,CHEMBL617210,,104826,11555,,,B,,,Autocuration,,,
2127,BAO_0000224,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,H,1,,CHEMBL617211,,104826,11555,,,B,,,Autocuration,,,
2128,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,D,1,,CHEMBL617212,,104826,10297,,,B,,,Autocuration,,,
2129,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,H,1,,CHEMBL617213,,104784,16688,,,B,,,Autocuration,,,
2130,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,H,1,,CHEMBL617214,,104784,16688,,,B,,,Autocuration,,,
2131,BAO_0000221,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,U,1,,CHEMBL617215,,22226,5333,,,B,,,Autocuration,,,
2132,BAO_0000221,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,U,1,,CHEMBL617216,,22226,4437,,,B,,,Autocuration,,,
2133,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617217,,17005,5033,,,B,,,Autocuration,,,
2134,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617218,,104686,15267,,,B,,,Autocuration,,,
2135,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL872913,,104686,15267,,,B,,,Autocuration,,,
2136,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,H,1,,CHEMBL617219,,104826,11820,,,B,,,Autocuration,,,
2137,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL873482,,104686,9069,,,B,,,Autocuration,,,
2138,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,D,1,,CHEMBL617220,,104686,9162,,,B,,,Autocuration,,,
2139,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,H,1,,CHEMBL617221,,104686,9162,,,B,,,Autocuration,,,
2140,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,H,1,,CHEMBL617222,,104686,9162,,,B,,,Autocuration,,,
2141,BAO_0000019,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,H,1,,CHEMBL875906,,104686,10428,,,F,,,Autocuration,,,
2142,BAO_0000019,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,H,1,,CHEMBL617223,,104686,9628,,,B,,,Autocuration,,,
2143,BAO_0000224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617224,,104686,12704,,,B,,,Autocuration,,,
2144,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,D,1,,CHEMBL617225,,104686,15453,,,B,,,Autocuration,,,
2145,BAO_0000224,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,H,1,,CHEMBL617226,,104686,188,,,B,,,Autocuration,,,
2146,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,H,1,,CHEMBL617227,,104686,10349,,,B,,,Autocuration,,,
2147,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,H,1,,CHEMBL617228,,104686,10349,,,B,,,Autocuration,,,
2148,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,H,1,,CHEMBL617229,,104686,8868,,,B,,,Autocuration,,,
2149,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,H,1,,CHEMBL617230,,104686,10025,,,B,,,Autocuration,,,
2150,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,H,1,,CHEMBL617231,,104686,10025,,,B,,,Autocuration,,,
2151,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,H,1,,CHEMBL617232,,104686,11702,,,B,,,Autocuration,,,
2152,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617233,,104686,11702,,,B,,,Autocuration,,,
2153,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,H,1,,CHEMBL617234,,104686,11702,,,B,,,Autocuration,,,
2154,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats,,H,1,,CHEMBL617235,,104686,11702,,,F,,,Autocuration,,,
2155,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,H,1,,CHEMBL617236,,104686,11702,,,F,,,Autocuration,,,
2156,BAO_0000221,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,10000000.0,H,1,,CHEMBL617237,,104686,10085,,Hippocampus,B,,,Autocuration,,,
2157,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,10000000.0,H,1,,CHEMBL617238,,104686,10085,,Hippocampus,B,,,Autocuration,,,
2158,BAO_0000221,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,955.0,D,1,,CHEMBL617239,,104686,9630,,Brain,B,,,Autocuration,,,
2159,BAO_0000019,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,H,1,,CHEMBL617240,,104686,11070,,,B,,,Autocuration,,,
2160,BAO_0000249,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,H,1,,CHEMBL617241,,104686,9841,Membranes,,B,,,Autocuration,,,
2161,BAO_0000249,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,H,1,,CHEMBL875907,,104686,9841,Membranes,,B,,,Autocuration,,,
2162,BAO_0000019,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,H,1,,CHEMBL617242,,104686,13291,,,B,,,Autocuration,,,
2163,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,H,1,,CHEMBL617152,,104686,10590,,,F,,,Autocuration,,,
2164,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,955.0,D,1,,CHEMBL617153,,104686,9064,,Brain,B,,,Autocuration,,,
2165,BAO_0000249,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,D,1,,CHEMBL617154,,104686,12268,Membranes,,B,,,Autocuration,,,
2166,BAO_0000221,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,955.0,H,1,,CHEMBL617155,,104686,13508,,Brain,B,,,Autocuration,,,
2167,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,H,1,,CHEMBL617156,,104686,11279,,,F,,,Autocuration,,,
2168,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,H,1,,CHEMBL617157,,104686,11200,,,F,,,Autocuration,,,
2169,BAO_0000019,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,1,,CHEMBL617158,,104686,11200,,,F,,,Autocuration,,,
2170,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,H,1,,CHEMBL617159,,104686,11200,,,F,,,Autocuration,,,
2171,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,H,1,,CHEMBL617160,,104686,11200,,,F,,,Autocuration,,,
2172,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,1,,CHEMBL858113,,104686,11200,,,F,,,Autocuration,,,
2173,BAO_0000220,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,955.0,H,1,,CHEMBL617247,,104686,9231,,Brain,B,,,Autocuration,,,
2174,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,H,1,,CHEMBL617248,,104686,9737,,,B,,,Autocuration,,,
2175,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,H,1,,CHEMBL617249,,104686,9737,,Brain,B,,,Autocuration,,,
2176,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,H,1,,CHEMBL617250,,104686,9737,,,B,,,Autocuration,,,
2177,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,H,1,,CHEMBL617251,,104686,9737,,,B,,,Autocuration,,,
2178,BAO_0000019,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617252,,104686,11828,,,B,,,Autocuration,,,
2179,BAO_0000019,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,H,1,,CHEMBL617006,,104686,12253,,,B,,,Autocuration,,,
2180,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,H,1,,CHEMBL617007,,104686,12253,,,B,,,Autocuration,,,
2181,BAO_0000019,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,H,1,,CHEMBL617008,,104686,11279,,,F,,,Autocuration,,,
2182,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,H,1,,CHEMBL617009,,104686,11866,,,B,,,Autocuration,,,
2183,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,D,1,,CHEMBL617010,,104686,14424,,,B,,,Autocuration,,,
2184,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL857978,,104686,15180,,,B,,,Autocuration,,,
2185,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617011,,104686,15180,,,B,,,Autocuration,,,
2186,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,D,1,,CHEMBL617012,,104686,9786,,,B,,,Autocuration,,,
2187,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,H,1,,CHEMBL617013,,104686,12132,,,B,,,Autocuration,,,
2188,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,H,1,,CHEMBL617014,,104686,5486,,,B,,,Autocuration,,,
2189,BAO_0000019,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617015,,104686,15316,,,B,,,Autocuration,,,
2190,BAO_0000019,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,H,1,,CHEMBL617016,,104686,16429,,,B,,,Autocuration,,,
2191,BAO_0000224,pKi value for 5-hydroxytryptamine 2 receptor binding site,,H,1,,CHEMBL617017,,104686,14617,,,B,,,Autocuration,,,
2192,BAO_0000221,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,955.0,H,1,,CHEMBL617018,,104686,11351,,Brain,B,,,Autocuration,,,
2193,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,H,1,,CHEMBL617019,,104686,11279,,,F,,,Autocuration,,,
2194,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,H,1,,CHEMBL617020,,105075,9523,,,B,,,Autocuration,,,
2195,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,H,1,,CHEMBL617021,,105075,9523,,,B,,,Autocuration,,,
2196,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,H,1,,CHEMBL617022,,105075,9523,,,B,,,Autocuration,,,
2197,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,H,1,,CHEMBL617023,,105075,9523,,,B,,,Autocuration,,,
2198,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,H,1,,CHEMBL617024,,105075,9523,,,B,,,Autocuration,,,
2199,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,H,1,,CHEMBL617025,,105075,9523,,,B,,,Autocuration,,,
2200,BAO_0000224,Hill coefficient of compound was determined,,H,1,,CHEMBL617026,,105075,9523,,,B,,,Autocuration,,,
2201,BAO_0000019,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,U,1,,CHEMBL617027,,22226,4771,,,B,,,Autocuration,,,
2202,BAO_0000019,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,D,1,,CHEMBL617028,,104686,5033,,,B,,,Autocuration,,,
2203,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,H,1,,CHEMBL617029,,12687,10845,,,B,,,Expert,,,
2204,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,H,1,,CHEMBL875908,,12687,10845,,,B,,,Expert,,,
2205,BAO_0000357,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,H,1,,CHEMBL617030,,12687,16288,,,B,,,Autocuration,,,
2206,BAO_0000019,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,H,1,,CHEMBL617031,,12687,16288,,,B,,,Autocuration,,,
2207,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,H,1,,CHEMBL617032,,12687,16190,,,B,,,Autocuration,,,
2208,BAO_0000224,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,D,1,,CHEMBL617033,,104686,12463,,,B,,,Autocuration,,,
2209,BAO_0000224,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,H,1,,CHEMBL617034,,104686,9699,,,B,,,Autocuration,,,
2210,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,H,1,,CHEMBL617035,,104686,9699,,,B,,,Autocuration,,,
2211,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,H,1,,CHEMBL617036,,104686,11662,,,B,,,Autocuration,,,
2212,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617037,,104784,1205,,,B,,,Autocuration,,,
2213,BAO_0000219,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,U,1,,CHEMBL617038,,22226,11376,,,B,,,Autocuration,,,
2214,BAO_0000219,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,H,1,,CHEMBL617039,,104784,11376,,,B,,,Autocuration,,,
2215,BAO_0000224,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617161,,104784,4639,,,B,,,Autocuration,,,
2216,BAO_0000224,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617162,,104784,2222,,,B,,,Autocuration,,,
2217,BAO_0000224,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617163,,104784,1558,,,B,,,Autocuration,,,
2218,BAO_0000224,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617164,,104784,1089,,,B,,,Autocuration,,,
2219,BAO_0000249,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,H,1,,CHEMBL617165,,104784,386,Brain membranes,,B,,,Autocuration,,,
2220,BAO_0000224,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,H,1,,CHEMBL617166,,104784,2474,,,B,,,Autocuration,,,
2221,BAO_0000224,Binding affinity towards 5-HT2 receptor,,H,1,,CHEMBL617167,,104784,17066,,,B,,,Autocuration,,,
2222,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL872912,,104784,959,,,B,,,Autocuration,,,
2223,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,H,1,,CHEMBL617168,,104784,6398,,,B,,,Autocuration,,,
2224,BAO_0000224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,H,1,,CHEMBL617169,,104686,11889,,,B,,,Autocuration,,,
2225,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617170,,104784,4221,,,B,,,Autocuration,,,
2226,BAO_0000224,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,H,1,,CHEMBL617171,,104784,11026,,,B,,,Autocuration,,,
2227,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,H,1,,CHEMBL617172,,104784,11866,,,B,,,Autocuration,,,
2228,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617173,,104784,4221,,,B,,,Autocuration,,,
2229,BAO_0000019,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,U,1,,CHEMBL617174,,22226,13950,,,B,,,Autocuration,,,
2230,BAO_0000224,5-hydroxytryptamine 2 receptor binding affinity,,H,1,,CHEMBL617175,,104784,1263,,,B,,,Autocuration,,,
2231,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,H,1,,CHEMBL617176,,17005,13291,,,B,,,Autocuration,,,
2232,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,H,1,,CHEMBL617177,,17005,10812,,,B,,,Autocuration,,,
2233,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,H,1,,CHEMBL617178,,104784,13020,,,B,,,Autocuration,,,
2234,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,H,1,,CHEMBL617179,,104784,13021,,,B,,,Autocuration,,,
2235,BAO_0000224,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,H,1,,CHEMBL617180,,104784,13020,,,B,,,Autocuration,,,
2236,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,H,1,,CHEMBL617181,,17005,14532,,,B,,,Autocuration,,,
2237,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617182,,17005,13944,,,B,,,Autocuration,,,
2238,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617183,,17005,14331,,,B,,,Autocuration,,,
2239,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL617184,,17005,14118,,,B,,,Autocuration,,,
2240,BAO_0000357,Binding affinity against serotonergic 5-HT2 receptor,,H,1,,CHEMBL617185,,17005,13033,,,B,,,Autocuration,,,
2241,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,H,1,,CHEMBL617186,,17005,10321,,,B,,,Autocuration,,,
2242,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT2 receptor,,H,1,,CHEMBL617187,,17005,12918,,,B,,,Autocuration,,,
2243,BAO_0000357,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617188,,17005,15120,,,B,,,Autocuration,,,
2244,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617189,,17005,2613,,,B,,,Autocuration,,,
2245,BAO_0000224,Inhibitory activity against cloned human 5-HT2 receptor,,D,1,,CHEMBL617190,,104784,13378,,,B,,,Autocuration,,,
2246,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,D,1,CHO,CHEMBL617191,,104784,2331,,,B,,,Autocuration,,449.0,
2247,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,D,1,CHO,CHEMBL617192,,104784,2331,,,B,,,Autocuration,,449.0,
2248,BAO_0000219,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,D,1,CHO,CHEMBL617193,,104784,2331,,,B,,,Autocuration,,449.0,
2249,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,D,1,CHO,CHEMBL617194,,104784,2331,,,B,,,Autocuration,,449.0,
2250,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617195,,104784,4170,,,B,,,Autocuration,,,
2251,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,H,1,,CHEMBL881830,,104784,15453,,,B,,,Autocuration,,,
2252,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617196,,17005,1479,,,B,,,Autocuration,,,
2253,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,H,1,,CHEMBL617197,,104686,11139,,,B,,,Autocuration,,,
2254,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,H,1,,CHEMBL617198,,17005,13969,,,B,,,Expert,,,
2255,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL873476,,17005,13392,,,B,,,Expert,,,
2256,BAO_0000019,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,H,1,,CHEMBL617199,,17005,14430,,,B,,,Expert,,,
2257,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617200,,107,13181,,,B,,,Autocuration,,,
2258,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,1,,CHEMBL617484,,51,17200,,,B,,,Autocuration,,,
2259,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,1,,CHEMBL617485,,107,17200,,,B,,,Autocuration,,,
2260,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,1,,CHEMBL617486,,51,17200,,,B,,,Autocuration,,,
2261,BAO_0000357,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,H,1,,CHEMBL858022,,107,13463,,,B,,,Autocuration,,,
2262,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,H,1,CHO,CHEMBL617049,,107,6347,,,B,,,Autocuration,,449.0,
2263,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,D,1,CHO,CHEMBL617050,,107,6857,,,F,,,Expert,,449.0,
2264,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,H,1,,CHEMBL617051,,107,4176,,,F,,,Autocuration,,,
2265,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,H,1,,CHEMBL617052,,107,4176,,,F,,,Autocuration,,,
2266,BAO_0000219,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,H,1,,CHEMBL617053,,107,4176,,,F,,,Autocuration,,,
2267,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,H,1,CHO,CHEMBL617054,,107,6347,,,B,,,Autocuration,,449.0,
2268,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,H,1,CHO,CHEMBL617055,,107,6347,,,B,,,Autocuration,,449.0,
2269,BAO_0000357,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,H,1,,CHEMBL882924,,107,15331,,,B,,,Autocuration,,,
2270,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617056,,107,16146,,,B,,,Expert,,,
2271,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL617057,,107,15250,,,B,,,Autocuration,,449.0,
2272,BAO_0000219,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,H,1,,CHEMBL617058,,107,13631,,,B,,,Expert,,,
2273,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,H,1,,CHEMBL617059,,107,3805,,,B,,,Autocuration,,,
2274,BAO_0000219,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,H,1,CHO,CHEMBL617060,,107,4011,,,B,,,Autocuration,,449.0,
2275,BAO_0000219,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,H,1,CHO,CHEMBL617061,,107,4012,,,B,,,Expert,,449.0,
2276,BAO_0000219,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,H,1,L929,CHEMBL617062,,107,6366,,,B,,,Expert,,307.0,
2277,BAO_0000219,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL617063,,107,15949,,,B,,,Expert,,449.0,
2278,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,H,1,,CHEMBL617064,,107,14093,,,F,,,Autocuration,,,
2279,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,1,,CHEMBL617065,,107,13481,,,F,,,Autocuration,,,
2280,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,H,1,CHO,CHEMBL617066,,107,6347,,,B,,,Autocuration,,449.0,
2281,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,H,1,CHO,CHEMBL617067,,107,6347,,,B,,,Autocuration,,449.0,
2282,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,H,1,,CHEMBL617068,,107,14093,,,F,,,Autocuration,,,
2283,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,H,1,,CHEMBL617069,,107,14093,,,F,,,Autocuration,,,
2284,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL617070,,107,13481,,,F,,,Autocuration,,,
2285,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,H,1,,CHEMBL617071,,107,14442,,,B,,,Autocuration,,,
2286,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL872915,,107,14442,,,B,,,Autocuration,,,
2287,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,H,1,,CHEMBL617072,,107,14755,,,B,,,Autocuration,,,
2288,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,H,1,,CHEMBL617073,,107,16441,,,B,,,Autocuration,,,
2289,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,H,1,,CHEMBL617074,,107,14744,,,B,,,Autocuration,,,
2290,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL617075,,107,16659,,,B,,,Expert,,449.0,
2291,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617076,,107,3307,,,B,,,Autocuration,,,
2292,BAO_0000019,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,D,1,,CHEMBL617077,,107,6857,,,B,,,Expert,,,
2293,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,H,1,,CHEMBL617078,,107,5635,,,B,,,Expert,,,
2294,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617079,,107,4234,,,B,,,Expert,,,
2295,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL617080,,107,15527,,,B,,,Autocuration,,,
2296,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,H,1,CHO,CHEMBL617081,,107,6588,,,B,,,Expert,,449.0,
2297,BAO_0000219,Binding affinity towards human 5-HT2A receptor in BEK cells,,H,1,,CHEMBL617082,,107,13631,,,B,,,Expert,,,
2298,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617083,,107,17723,,,B,,,Autocuration,,,
2299,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,H,1,,CHEMBL617084,,107,14770,,,B,,,Autocuration,,,
2300,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617085,,107,16293,,,B,,,Expert,,,
2301,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,1,,CHEMBL617086,,107,16209,,,B,,,Autocuration,,,
2302,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,H,1,,CHEMBL617087,,107,12469,,,B,,,Autocuration,,,
2303,BAO_0000357,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617088,,107,15363,,,B,,,Autocuration,,,
2304,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617089,,107,15363,,,B,,,Autocuration,,,
2305,BAO_0000019,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,H,1,,CHEMBL617090,,107,16441,,,B,,,Expert,,,
2306,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,H,1,,CHEMBL617513,,107,8,,,B,,,Autocuration,,,
2307,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL617514,,107,4176,,,B,,,Autocuration,,722.0,
2308,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617515,,107,17085,,,B,,,Autocuration,,,
2309,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,1,,CHEMBL617516,,107,17200,,,B,,,Autocuration,,,
2310,BAO_0000357,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,D,1,,CHEMBL617517,,107,17200,,,B,,,Expert,,,
2311,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,D,1,CHO,CHEMBL617518,,107,4013,,,B,,,Expert,,449.0,
2312,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617519,,107,5088,,,B,,,Autocuration,,,
2313,BAO_0000357,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617520,,107,5088,,,B,,,Expert,,,
2314,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,H,1,,CHEMBL617521,,107,5088,,,B,,,Autocuration,,,
2315,BAO_0000357,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617522,,107,5088,,,B,,,Expert,,,
2316,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL617523,,107,5088,,,B,,,Autocuration,,,
2317,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,1,,CHEMBL617524,,107,5088,,,B,,,Autocuration,,,
2318,BAO_0000019,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,H,1,,CHEMBL617525,,104686,9786,,,B,,,Autocuration,,,
2319,BAO_0000019,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,D,1,,CHEMBL617526,,104686,9205,,,B,,,Autocuration,,,
2320,BAO_0000224,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,H,1,,CHEMBL617527,,104686,11257,,,B,,,Autocuration,,,
2321,BAO_0000019,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,H,1,,CHEMBL617528,,104686,9362,,,B,,,Autocuration,,,
2322,BAO_0000019,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,H,1,,CHEMBL617529,,104686,9362,,,B,,,Autocuration,,,
2323,BAO_0000224,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,H,1,,CHEMBL617530,,104686,10590,,,B,,,Autocuration,,,
2324,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,H,1,,CHEMBL617531,,104686,10468,,,B,,,Autocuration,,,
2325,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,H,1,,CHEMBL617532,,104686,13050,,,B,,,Autocuration,,,
2326,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,H,1,,CHEMBL617533,,104686,11624,,,B,,,Autocuration,,,
2327,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,H,1,,CHEMBL617534,,104686,10468,,,B,,,Autocuration,,,
2328,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL617535,,104686,10330,,,B,,,Autocuration,,,
2329,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,H,1,,CHEMBL617536,,104686,10062,,,B,,,Autocuration,,,
2330,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617537,,104686,11642,,,B,,,Autocuration,,,
2331,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617538,,104686,10062,,,B,,,Autocuration,,,
2332,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,H,1,,CHEMBL617539,In vitro,104686,13427,,,B,,,Autocuration,,,
2333,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617540,,104686,12280,,,B,,,Autocuration,,,
2334,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,D,1,,CHEMBL617541,,104686,4101,,,B,,,Autocuration,,,
2335,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617542,,104686,10062,,,B,,,Autocuration,,,
2336,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,H,1,,CHEMBL617543,,104686,11147,,,B,,,Autocuration,,,
2337,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,D,1,CHO-K1,CHEMBL617544,,104686,2395,,,B,,,Autocuration,,485.0,
2338,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,D,1,CHO-K1,CHEMBL617545,,104686,2395,,,B,,,Autocuration,,485.0,
2339,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,D,1,,CHEMBL617413,,104686,9098,,,B,,,Autocuration,,,
2340,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,H,1,,CHEMBL617414,,104686,9098,,,B,,,Autocuration,,,
2341,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,D,1,,CHEMBL617415,,104686,9098,,,B,,,Autocuration,,,
2342,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617416,,104686,9443,,,B,,,Autocuration,,,
2343,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,H,1,,CHEMBL617417,,104686,9443,,,B,,,Autocuration,,,
2344,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,H,1,,CHEMBL617418,,104686,9699,,,B,,,Autocuration,,,
2345,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,H,1,,CHEMBL617419,,104686,9699,,,B,,,Autocuration,,,
2346,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,H,1,,CHEMBL617420,,104686,9098,,,B,,,Autocuration,,,
2347,BAO_0000224,Affinity for 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617421,,104686,3070,,,B,,,Autocuration,,,
2348,BAO_0000224,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,H,1,,CHEMBL617422,,104686,9547,,,B,,,Autocuration,,,
2349,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,H,1,,CHEMBL617423,,104686,10444,,,B,,,Autocuration,,,
2350,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,H,1,,CHEMBL617424,,104686,14617,,,B,,,Autocuration,,,
2351,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,H,1,,CHEMBL617425,,104686,14617,,,B,,,Autocuration,,,
2352,BAO_0000224,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,H,1,,CHEMBL617426,,104686,11130,,,B,,,Autocuration,,,
2353,BAO_0000218,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,H,1,,CHEMBL617427,In vivo,104686,11130,,,B,,,Autocuration,,,
2354,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,955.0,H,1,,CHEMBL617428,,104686,14542,,Brain,B,,,Autocuration,,,
2355,BAO_0000224,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,H,1,,CHEMBL617429,,104686,2797,,,B,,,Autocuration,,,
2356,BAO_0000019,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,H,1,,CHEMBL617430,,104686,11332,,,B,,,Autocuration,,,
2357,BAO_0000019,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,H,1,,CHEMBL617431,,104686,11332,,,B,,,Autocuration,,,
2358,BAO_0000019,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1870.0,H,1,,CHEMBL617432,,104686,10752,,Frontal cortex,B,,,Autocuration,,,
2359,BAO_0000224,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617433,,104686,1185,,,B,,,Autocuration,,,
2360,BAO_0000224,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617434,,104686,1185,,,B,,,Autocuration,,,
2361,BAO_0000224,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,D,1,,CHEMBL617435,,104686,11624,,,B,,,Autocuration,,,
2362,BAO_0000019,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,H,1,,CHEMBL617436,,104686,1344,,,B,,,Autocuration,,,
2363,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,2435.0,D,1,,CHEMBL617437,,104686,15453,,Striatum,B,,,Autocuration,,,
2364,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,H,1,,CHEMBL617438,,104686,11662,,,B,,,Autocuration,,,
2365,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,H,1,,CHEMBL617439,,104686,11662,,,B,,,Autocuration,,,
2366,BAO_0000224,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617440,,104686,10796,,,B,,,Autocuration,,,
2367,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617441,,104686,9069,,,B,,,Autocuration,,,
2368,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,D,1,,CHEMBL872918,,104686,8814,,,B,,,Autocuration,,,
2369,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,D,1,,CHEMBL617442,,104686,8908,,,B,,,Autocuration,,,
2370,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,H,1,,CHEMBL617443,,104686,9098,,,B,,,Autocuration,,,
2371,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,H,1,,CHEMBL617444,,104686,9098,,,B,,,Autocuration,,,
2372,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,H,1,,CHEMBL617445,,104686,9098,,,B,,,Autocuration,,,
2373,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,H,1,,CHEMBL617446,,104686,9098,,,B,,,Autocuration,,,
2374,BAO_0000249,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,H,1,,CHEMBL617447,,104686,9098,,,B,,,Autocuration,,,
2375,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,H,1,,CHEMBL617448,,104686,9098,,,B,,,Autocuration,,,
2376,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,H,1,,CHEMBL617449,,104686,9098,,,B,,,Autocuration,,,
2377,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,H,1,,CHEMBL617450,,104686,9161,,,B,,,Autocuration,,,
2378,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,H,1,,CHEMBL617451,,104686,9161,,,B,,,Autocuration,,,
2379,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,H,1,,CHEMBL617452,,104686,9161,,,B,,,Autocuration,,,
2380,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,H,1,,CHEMBL617453,,104686,9161,,,B,,,Autocuration,,,
2381,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,H,1,,CHEMBL617660,,104686,9161,,,B,,,Autocuration,,,
2382,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,H,1,,CHEMBL617661,,104686,9161,,,B,,,Autocuration,,,
2383,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,H,1,,CHEMBL617662,,104686,9161,,,B,,,Autocuration,,,
2384,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,H,1,,CHEMBL872919,,104686,9161,,,B,,,Autocuration,,,
2385,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,H,1,,CHEMBL617663,,104686,9161,,,B,,,Autocuration,,,
2386,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,H,1,,CHEMBL617664,,104686,9161,,,B,,,Autocuration,,,
2387,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,H,1,,CHEMBL617665,,104686,9161,,,B,,,Autocuration,,,
2388,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,H,1,,CHEMBL617666,,104686,9161,,,B,,,Autocuration,,,
2389,BAO_0000019,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,H,1,,CHEMBL617667,,104686,12094,,,B,,,Autocuration,,,
2390,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,H,1,,CHEMBL617668,,104686,12018,,,B,,,Autocuration,,,
2391,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,H,1,,CHEMBL617669,,104686,10394,,,B,,,Autocuration,,,
2392,BAO_0000224,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617670,,104686,15260,,,B,,,Autocuration,,,
2393,BAO_0000224,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617671,,104686,11624,,,B,,,Autocuration,,,
2394,BAO_0000224,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617672,,104686,13654,,,B,,,Autocuration,,,
2395,BAO_0000019,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,H,1,,CHEMBL617673,,104686,9541,,,B,,,Autocuration,,,
2396,BAO_0000224,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,H,1,,CHEMBL617674,,104686,11933,,,B,,,Autocuration,,,
2397,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,H,1,,CHEMBL617675,,104686,15538,,,B,,,Autocuration,,,
2398,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,H,1,,CHEMBL617676,,104686,15538,,,B,,,Autocuration,,,
2399,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,H,1,,CHEMBL617677,,104686,15538,,,B,,,Autocuration,,,
2400,BAO_0000019,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617678,,104686,8841,,,B,,,Autocuration,,,
2401,BAO_0000224,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,H,1,,CHEMBL617679,,104686,1455,,,B,,,Autocuration,,,
2402,BAO_0000224,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,H,1,,CHEMBL617680,,104686,1455,,,B,,,Autocuration,,,
2403,BAO_0000019,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,H,1,,CHEMBL617681,,104686,11752,,,B,,,Autocuration,,,
2404,BAO_0000221,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,955.0,H,1,,CHEMBL617682,,104686,11642,,Brain,B,,,Autocuration,,,
2405,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,H,1,,CHEMBL617683,,104686,12092,,,B,,,Autocuration,,,
2406,BAO_0000224,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,H,1,,CHEMBL617684,,104686,3967,,,B,,,Autocuration,,,
2407,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,D,1,,CHEMBL617685,,104686,12771,,,B,,,Autocuration,,,
2408,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,H,1,,CHEMBL617686,,104686,11642,,,B,,,Autocuration,,,
2409,BAO_0000224,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,H,1,,CHEMBL617687,,104686,11628,,,B,,,Autocuration,,,
2410,BAO_0000224,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,H,1,,CHEMBL617688,,104686,13654,,,B,,,Autocuration,,,
2411,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,1,,CHEMBL617689,,104686,11200,,,F,,,Autocuration,,,
2412,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,1,,CHEMBL617690,,104686,11200,,,F,,,Autocuration,,,
2413,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,H,1,,CHEMBL617691,In vivo,104686,11200,,,F,,,Autocuration,,,
2414,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,H,1,,CHEMBL617692,In vivo,104686,11200,,,F,,,Autocuration,,,
2415,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,H,1,,CHEMBL617693,In vivo,104686,11200,,,F,,,Autocuration,,,
2416,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,H,1,,CHEMBL617694,In vivo,104686,11200,,,F,,,Autocuration,,,
2417,BAO_0000221,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,955.0,H,1,,CHEMBL857985,,12687,15436,,Brain,B,,,Expert,,,
2418,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,D,1,,CHEMBL617695,,12687,15436,,,B,,,Expert,,,
2419,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,H,1,,CHEMBL617696,,12687,14025,,,B,,,Autocuration,,,
2420,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,H,1,,CHEMBL617697,,12687,4342,,,B,,,Autocuration,,,
2421,BAO_0000019,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,D,1,,CHEMBL617257,,12687,13735,,,B,,,Expert,,,
2422,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,D,1,,CHEMBL617258,,12687,5816,,,B,,,Expert,,,
2423,BAO_0000019,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,H,1,,CHEMBL617259,,12687,14287,,,B,,,Expert,,,
2424,BAO_0000357,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,H,1,,CHEMBL617260,,12687,15738,,,B,,,Autocuration,,,
2425,BAO_0000357,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617261,,12687,15738,,,B,,,Expert,,,
2426,BAO_0000019,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,H,1,,CHEMBL617262,,12687,15026,,,B,,,Autocuration,,,
2427,BAO_0000019,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,H,1,,CHEMBL617263,,12687,16647,,,B,,,Expert,,,
2428,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,H,1,,CHEMBL617264,,12687,16647,,,B,,,Autocuration,,,
2429,BAO_0000019,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617265,,12687,13345,,,B,,,Expert,,,
2430,BAO_0000249,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617266,,12687,1543,Membranes,,B,,,Autocuration,,,
2431,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,H,1,,CHEMBL617267,,12687,12444,,,B,,,Autocuration,,,
2432,BAO_0000019,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,H,1,,CHEMBL617268,,12687,16404,,,B,,,Expert,,,
2433,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,H,1,CHO,CHEMBL617269,,12687,16404,,,B,,,Autocuration,,449.0,
2434,BAO_0000357,Kinetic inhibition constant evaluated by measuring serotonergic activity,,H,1,,CHEMBL617323,,12687,15577,,,B,,,Expert,,,
2435,BAO_0000357,Serotonergic activity of the compound.,,H,1,,CHEMBL617324,,12687,15577,,,B,,,Autocuration,,,
2436,BAO_0000249,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,H,1,,CHEMBL617325,,12687,2495,,,B,,,Autocuration,,,
2437,BAO_0000019,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,D,1,,CHEMBL617326,,12687,15042,,,B,,,Expert,,,
2438,BAO_0000249,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,H,1,,CHEMBL617327,,12687,15026,,,B,,,Expert,,,
2439,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,1,,CHEMBL617328,,12687,12919,,,F,,,Expert,,,
2440,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,1,,CHEMBL617329,,12687,12919,,,F,,,Expert,,,
2441,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,1,,CHEMBL617330,,12687,12919,,,F,,,Expert,,,
2442,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL617331,,12687,15194,,,B,,,Autocuration,,,
2443,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,H,1,,CHEMBL617332,,12687,15194,,,B,,,Autocuration,,,
2444,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617333,,107,4820,,,B,,,Expert,,,
2445,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,H,1,,CHEMBL617334,,107,6736,,,B,,,Autocuration,,,
2446,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,H,1,,CHEMBL617335,,107,5163,,,B,,,Autocuration,,,
2447,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,H,1,,CHEMBL617336,,107,5163,,,B,,,Autocuration,,,
2448,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,H,1,,CHEMBL617337,,107,6011,,,B,,,Autocuration,,,
2449,BAO_0000357,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,D,1,,CHEMBL617338,,107,14294,,,B,,,Expert,,,
2450,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617339,,107,5014,,,B,,,Autocuration,,,
2451,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617340,,107,17066,,,B,,,Expert,,,
2452,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,H,1,,CHEMBL617341,,107,17515,,,B,,,Autocuration,,,
2453,BAO_0000357,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617342,,107,6736,,,B,,,Expert,,,
2454,BAO_0000357,Affinity for 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617343,,107,5163,,,B,,,Expert,,,
2455,BAO_0000219,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,H,1,NIH3T3,CHEMBL617344,,107,16911,,,B,,,Expert,,723.0,
2456,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,H,1,,CHEMBL617345,,107,6841,,,B,,,Expert,,,
2457,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,H,1,,CHEMBL617346,,107,6119,,,B,,,Expert,,,
2458,BAO_0000357,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617347,,107,3962,,,B,,,Autocuration,,,
2459,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,H,1,,CHEMBL617348,,107,4373,,,B,,,Autocuration,,,
2460,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,H,1,,CHEMBL617349,,107,4373,,,B,,,Autocuration,,,
2461,BAO_0000019,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617350,,107,3962,,,F,,,Autocuration,,,
2462,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,H,1,,CHEMBL872339,,107,1633,,,B,,,Expert,,,
2463,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,H,1,,CHEMBL617351,,107,4373,,,B,,,Autocuration,,,
2464,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617352,,107,6576,,,B,,,Expert,,,
2465,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617353,,107,4687,,,B,,,Autocuration,,,
2466,BAO_0000357,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617354,,107,16946,,,B,,,Autocuration,,,
2467,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617355,,107,14159,,,B,,,Autocuration,,,
2468,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,H,1,CHO,CHEMBL617356,,107,3032,,,B,,,Expert,,449.0,
2469,BAO_0000357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617357,,107,16655,,,B,,,Autocuration,,,
2470,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617358,,107,13964,,,B,,,Autocuration,,,
2471,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617359,,107,16989,,,B,,,Expert,,,
2472,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,H,1,,CHEMBL617360,,107,16117,,,B,,,Autocuration,,,
2473,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,H,1,,CHEMBL875913,,107,16700,,,B,,,Autocuration,,,
2474,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617361,,107,3269,,,B,,,Autocuration,,,
2475,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2A receptor,,D,1,,CHEMBL617362,,107,1274,,,B,,,Expert,,,
2476,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,H,1,,CHEMBL617363,,107,1317,,,B,,,Autocuration,,,
2477,BAO_0000357,Tested against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617364,,107,12146,,,B,,,Autocuration,,,
2478,BAO_0000224,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,H,1,,CHEMBL617365,,105075,12652,,,B,,,Autocuration,,,
2479,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,H,1,,CHEMBL617366,,105075,12652,,,B,,,Autocuration,,,
2480,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,H,1,,CHEMBL617367,,105075,12652,,,B,,,Autocuration,,,
2481,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,H,1,,CHEMBL617368,,105075,12652,,,B,,,Autocuration,,,
2482,BAO_0000357,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,H,1,,CHEMBL617369,,107,16647,,,B,,,Autocuration,,,
2483,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,D,1,HEK293,CHEMBL617370,,227,15851,,,B,,,Expert,,722.0,
2484,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,D,1,CHO,CHEMBL617371,,227,6857,,,F,,,Expert,,449.0,
2485,BAO_0000357,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,H,1,,CHEMBL617372,,227,3805,,,B,,,Autocuration,,,
2486,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,D,1,,CHEMBL617373,,227,6491,,,B,,,Expert,,,
2487,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,H,1,,CHEMBL617374,,227,14093,,,F,,,Autocuration,,,
2488,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,H,1,,CHEMBL617375,,227,13481,,,F,,,Autocuration,,,
2489,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,H,1,,CHEMBL617376,,227,14093,,,F,,,Autocuration,,,
2490,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,H,1,,CHEMBL617377,,227,14093,,,F,,,Autocuration,,,
2491,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,H,1,,CHEMBL617378,,227,14093,,,F,,,Autocuration,,,
2492,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,H,1,,CHEMBL617379,,227,13481,,,F,,,Autocuration,,,
2493,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,H,1,,CHEMBL617380,,227,14442,,,B,,,Autocuration,,,
2494,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,H,1,,CHEMBL617381,,227,14442,,,B,,,Autocuration,,,
2495,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,H,1,,CHEMBL617382,,227,14442,,,B,,,Autocuration,,,
2496,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617383,,107,12369,,,B,,,Autocuration,,,
2497,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,H,1,,CHEMBL617384,,107,12369,,,B,,,Expert,,,
2498,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,H,1,,CHEMBL617385,,107,12369,,,B,,,Expert,,,
2499,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,H,1,,CHEMBL617386,,107,14447,,,B,,,Autocuration,,,
2500,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,H,1,,CHEMBL617387,,107,14447,,,B,,,Autocuration,,,
2501,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,1,NIH3T3,CHEMBL617388,,107,17451,,,B,,,Autocuration,,723.0,
2502,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,H,1,CHO,CHEMBL617389,,107,6857,,,F,,,Autocuration,,449.0,
2503,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,1,CHO,CHEMBL617390,,107,6857,,,F,,,Expert,,449.0,
2504,BAO_0000224,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,H,1,,CHEMBL617391,,104817,5635,,,B,,,Autocuration,,,
2505,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL617392,,107,12861,,,B,,,Autocuration,,,
2506,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,H,1,,CHEMBL617393,,107,12861,,,B,,,Autocuration,,,
2507,BAO_0000219,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,H,1,L929,CHEMBL617394,,107,5105,,,B,,,Autocuration,,307.0,
2508,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,H,1,L929,CHEMBL617395,,107,5104,,,B,,,Expert,,307.0,
2509,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,H,1,L929,CHEMBL617396,,107,5105,,,B,,,Expert,,307.0,
2510,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,H,1,L929,CHEMBL617397,,107,5105,,,B,,,Autocuration,,307.0,
2511,BAO_0000357,Binding affinity against 5-HT2A receptor,,H,1,,CHEMBL617398,,107,5254,,,B,,,Autocuration,,,
2512,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617399,,107,5254,,,B,,,Autocuration,,,
2513,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL617400,,107,13267,,,B,,,Autocuration,,722.0,
2514,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,H,1,HEK293,CHEMBL617401,,107,13267,,,B,,,Autocuration,,722.0,
2515,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,D,1,HEK293,CHEMBL617402,,107,14157,,,B,,,Expert,,722.0,
2516,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,1,HEK293,CHEMBL617403,,107,12936,,,B,,,Expert,,722.0,
2517,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,H,1,,CHEMBL617404,,107,14068,,,B,,,Expert,,,
2518,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,1,HEK293,CHEMBL857981,,107,12936,,,B,,,Expert,,722.0,
2519,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,1,HEK293,CHEMBL617405,,107,12936,,,B,,,Expert,,722.0,
2520,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,D,1,HEK293,CHEMBL617253,,107,4540,,,B,,,Expert,,722.0,
2521,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,H,1,,CHEMBL617254,,107,6166,,,B,,,Expert,,,
2522,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL617255,,107,17296,,,B,,,Autocuration,,722.0,
2523,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL617256,,107,17296,,,B,,,Autocuration,,722.0,
2524,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL616874,,107,17296,,,B,,,Autocuration,,722.0,
2525,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,D,1,HEK293,CHEMBL616875,,107,15779,,,B,,,Expert,,722.0,
2526,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,H,1,HEK293,CHEMBL616876,,107,14391,,,B,,,Expert,,722.0,
2527,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,H,1,HEK293,CHEMBL616877,,107,15851,,,B,,,Expert,,722.0,
2528,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,D,1,HEK293,CHEMBL616878,,107,15851,,,B,,,Expert,,722.0,
2529,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,H,1,HEK293,CHEMBL616879,,107,3832,,,B,,,Expert,,722.0,
2530,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,H,1,HEK293,CHEMBL616880,,107,3833,,,B,,,Expert,,722.0,
2531,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,1,HEK293,CHEMBL616881,,107,12936,,,B,,,Expert,,722.0,
2532,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,H,1,NIH3T3,CHEMBL616882,,107,17451,,,B,,,Autocuration,,723.0,
2533,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,1,NIH3T3,CHEMBL616883,,107,17451,,,B,,,Autocuration,,723.0,
2534,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,1,NIH3T3,CHEMBL616884,,107,17451,,,B,,,Autocuration,,723.0,
2535,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,H,1,HEK293,CHEMBL616885,,107,4199,,,B,,,Autocuration,,722.0,
2536,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,H,1,CHO-K1,CHEMBL616886,,107,1883,,,B,,,Autocuration,,485.0,
2537,BAO_0000219,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,H,1,CHO-K1,CHEMBL616887,,107,1883,,,B,,,Expert,,485.0,
2538,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL616888,,107,14875,,,B,,,Expert,,,
2539,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,H,1,HEK293,CHEMBL616889,,107,15146,,,B,,,Autocuration,,722.0,
2540,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,H,1,HEK293,CHEMBL616890,,107,5213,,,B,,,Autocuration,,722.0,
2541,BAO_0000219,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,D,1,CHO,CHEMBL616891,,107,16404,,,B,,,Expert,,449.0,
2542,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,H,1,HEK293,CHEMBL616892,,107,14818,,,B,,,Autocuration,,722.0,
2543,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,H,1,HEK293,CHEMBL616893,,107,4829,,,B,,,Autocuration,,722.0,
2544,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,H,1,NIH3T3,CHEMBL616894,,10620,12652,,,F,,,Autocuration,,723.0,
2545,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,H,1,NIH3T3,CHEMBL616895,,107,4682,,,B,,,Expert,,723.0,
2546,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL616896,,10620,12652,,,F,,,Autocuration,,,
2547,BAO_0000357,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617099,,10621,4921,,,B,,,Autocuration,,,
2548,BAO_0000357,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,H,1,,CHEMBL617100,,10621,4921,,,B,,,Autocuration,,,
2549,BAO_0000357,Binding affinity against rabbit aorta 5-HT2A receptor,,H,1,,CHEMBL884532,,107,16312,,,B,,,Autocuration,,,
2550,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,H,1,,CHEMBL617101,,107,14998,,,B,,,Expert,,,
2551,BAO_0000357,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,H,1,,CHEMBL617102,,107,14025,,,B,,,Expert,,,
2552,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,H,1,,CHEMBL617103,,107,13047,,,B,,,Autocuration,,,
2553,BAO_0000357,The compound was tested for binding affinity against 5-HT2A receptor,,H,1,,CHEMBL617104,,107,13047,,,B,,,Expert,,,
2554,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,H,1,CHO-K1,CHEMBL857979,,10576,1883,,,B,,,Autocuration,,485.0,
2555,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,H,1,,CHEMBL857502,,12687,13463,,,B,,,Autocuration,,,
2556,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,H,1,,CHEMBL617105,,12687,13463,,,B,,,Autocuration,,,
2557,BAO_0000019,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,945.0,H,1,,CHEMBL858021,,12687,13463,,Stomach,B,,,Autocuration,,,
2558,BAO_0000019,Binding affinity for 5-HT 2A in rat stomach fundus,945.0,D,1,,CHEMBL875910,,12687,13463,,Stomach,B,,,Expert,,,
2559,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,H,1,,CHEMBL617106,,12687,13463,,,B,,,Autocuration,,,
2560,BAO_0000219,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,H,1,NIH3T3,CHEMBL617107,,12687,16326,,,B,,,Expert,,723.0,
2561,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617108,,12687,14093,,,F,,,Autocuration,,,
2562,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617109,,12687,14093,,,F,,,Autocuration,,,
2563,BAO_0000357,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617110,,12687,15740,,,B,,,Autocuration,,,
2564,BAO_0000357,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,H,1,,CHEMBL617111,,12687,16633,,,B,,,Autocuration,,,
2565,BAO_0000019,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,D,1,,CHEMBL617112,,12687,17200,,,F,,,Expert,,,
2566,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617113,,12687,17133,,,B,,,Autocuration,,,
2567,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617114,,12687,17133,,,B,,,Autocuration,,,
2568,BAO_0000357,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617115,,12687,17133,,,B,,,Autocuration,,,
2569,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,H,1,,CHEMBL617116,,12687,17200,,,F,,,Autocuration,,,
2570,BAO_0000019,Efficacy at 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617117,,12687,15363,,,F,,,Autocuration,,,
2571,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,H,1,,CHEMBL617118,,12687,17200,,,B,,,Autocuration,,,
2572,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,D,1,,CHEMBL617119,,12687,17200,,,B,,,Expert,,,
2573,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,D,1,,CHEMBL617120,,12687,17200,,,B,,,Expert,,,
2574,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,D,1,,CHEMBL617121,,12687,17200,,,F,,,Expert,,,
2575,BAO_0000219,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,H,1,,CHEMBL617122,,12687,17200,,,F,,,Autocuration,,,
2576,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617123,,12687,17211,,,B,,,Autocuration,,,
2577,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,H,1,,CHEMBL617124,,12687,17331,,,B,,,Expert,,,
2578,BAO_0000249,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,H,1,,CHEMBL617600,,12687,13565,,,B,,,Expert,,,
2579,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,H,1,,CHEMBL617601,,12687,13730,,,B,,,Expert,,,
2580,BAO_0000019,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,H,1,,CHEMBL882923,,12687,12416,,,B,,,Expert,,,
2581,BAO_0000357,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617602,,12687,15295,,,B,,,Autocuration,,,
2582,BAO_0000019,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,H,1,,CHEMBL617603,,12687,1742,,,B,,,Autocuration,,,
2583,BAO_0000357,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617604,,12687,15295,,,B,,,Autocuration,,,
2584,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,H,1,,CHEMBL617605,,12687,14970,,,B,,,Expert,,,
2585,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,H,1,,CHEMBL617606,,12687,16693,,,B,,,Expert,,,
2586,BAO_0000019,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617607,,12687,14776,,,B,,,Expert,,,
2587,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,1,,CHEMBL617455,,12687,14286,,,B,,,Autocuration,,,
2588,BAO_0000019,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,D,1,,CHEMBL617456,,12687,17200,,,B,,,Expert,,,
2589,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,H,1,,CHEMBL617457,,12687,15306,,,B,,,Expert,,,
2590,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617458,,12687,14178,,,B,,,Expert,,,
2591,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,D,1,,CHEMBL617459,,12687,14229,,,B,,,Expert,,,
2592,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,H,1,,CHEMBL617460,,12687,12884,,,B,,,Expert,,,
2593,BAO_0000357,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,H,1,,CHEMBL617461,,12687,13149,,,B,,,Expert,,,
2594,BAO_0000019,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,D,1,,CHEMBL617462,,12687,15295,,,B,,,Expert,,,
2595,BAO_0000357,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,H,1,,CHEMBL617463,,12687,15740,,,B,,,Autocuration,,,
2596,BAO_0000019,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,H,1,,CHEMBL617464,,12687,15185,,,B,,,Autocuration,,,
2597,BAO_0000019,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,H,1,,CHEMBL617465,,12687,15185,,,B,,,Autocuration,,,
2598,BAO_0000019,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,H,1,,CHEMBL617466,,12687,17529,,,B,,,Expert,,,
2599,BAO_0000019,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,H,1,,CHEMBL617467,,12687,14826,,,B,,,Autocuration,,,
2600,BAO_0000019,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,H,1,,CHEMBL617468,,12687,17211,,,B,,,Expert,,,
2601,BAO_0000019,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,H,1,,CHEMBL617469,,12687,14826,,,B,,,Autocuration,,,
2602,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617470,,12687,14093,,,B,,,Autocuration,,,
2603,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,H,1,,CHEMBL617471,,12687,14093,,,B,,,Autocuration,,,
2604,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,H,1,NIH3T3,CHEMBL617472,,12687,13246,,,B,,,Expert,,723.0,
2605,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,H,1,,CHEMBL617473,,12687,13246,,,B,,,Expert,,,
2606,BAO_0000019,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,D,1,,CHEMBL617474,,12687,15436,,,B,,,Expert,,,
2607,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,D,1,,CHEMBL617475,,12687,15436,,,B,,,Expert,,,
2608,BAO_0000221,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,955.0,H,1,,CHEMBL617476,,12687,14442,,Brain,B,,,Autocuration,,,
2609,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617477,,12687,12457,,,B,,,Expert,,,
2610,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,H,1,NIH3T3,CHEMBL617478,,12687,12457,,,B,,,Expert,,723.0,
2611,BAO_0000221,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,H,1,,CHEMBL617479,,12687,14755,,,F,,,Autocuration,,,
2612,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,H,1,,CHEMBL617480,,12687,4707,,,B,,,Autocuration,,,
2613,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617481,,12687,13297,,,B,,,Expert,,,
2614,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,H,1,,CHEMBL617482,,12687,17331,,,B,,,Expert,,,
2615,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,H,1,,CHEMBL617483,,12687,4664,,,B,,,Autocuration,,,
2616,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,1,,CHEMBL621528,,12687,16633,,,B,,,Autocuration,,,
2617,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,D,1,NIH3T3,CHEMBL621529,,12687,4664,,,B,,,Expert,,723.0,
2618,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,1,,CHEMBL621530,,12687,16133,,,B,,,Expert,,,
2619,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL621531,,12687,16133,,,B,,,Expert,,,
2620,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL621532,,12687,14060,,,B,,,Expert,,,
2621,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,1,,CHEMBL621533,,12687,16326,,,B,,,Expert,,,
2622,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL621534,,12687,16659,,,B,,,Expert,,449.0,
2623,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,H,1,,CHEMBL621535,,12687,14776,,,B,,,Autocuration,,,
2624,BAO_0000357,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,H,1,,CHEMBL621536,,12687,13481,,,B,,,Autocuration,,,
2625,BAO_0000357,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL621537,,12687,17386,,,B,,,Autocuration,,,
2626,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL621538,,12687,6611,,,B,,,Expert,,,
2627,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,H,1,,CHEMBL621539,,12687,14423,,,B,,,Autocuration,,,
2628,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,H,1,,CHEMBL621540,,12687,15412,,,B,,,Autocuration,,,
2629,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,H,1,,CHEMBL621541,,12687,15412,,,B,,,Autocuration,,,
2630,BAO_0000019,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,H,1,,CHEMBL621542,,12687,6238,,,B,,,Autocuration,,,
2631,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,H,1,,CHEMBL621543,,12687,6648,,,B,,,Expert,,,
2632,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,H,1,,CHEMBL621544,,12687,5667,,,B,,,Expert,,,
2633,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,D,1,,CHEMBL621545,,12687,6611,,,B,,,Expert,,,
2634,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL621546,,12687,13481,,,B,,,Autocuration,,,
2635,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,H,1,,CHEMBL621547,,12687,13481,,,B,,,Autocuration,,,
2636,BAO_0000219,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,H,1,NIH3T3,CHEMBL618692,,12687,15558,,,B,,,Expert,,723.0,
2637,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL618693,,12687,6013,,,B,,,Autocuration,,,
2638,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,1,,CHEMBL872922,,12687,16633,,,B,,,Autocuration,,,
2639,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,H,1,,CHEMBL618694,,12687,6013,,,B,,,Autocuration,,,
2640,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,D,1,,CHEMBL618695,,12687,6013,,,B,,,Expert,,,
2641,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,H,1,,CHEMBL618696,,12687,6013,,,B,,,Autocuration,,,
2642,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,H,1,,CHEMBL618697,,12687,6013,,,B,,,Expert,,,
2643,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,H,1,,CHEMBL618892,,12687,6013,,,B,,,Autocuration,,,
2644,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,H,1,,CHEMBL618893,,12687,6013,,,B,,,Autocuration,,,
2645,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL618894,,12687,16293,,,B,,,Autocuration,,,
2646,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,H,1,NIH3T3,CHEMBL618895,,12687,17175,,,B,,,Expert,,723.0,
2647,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,D,1,,CHEMBL618896,,12687,13278,,,B,,,Expert,,,
2648,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,5383.0,H,1,,CHEMBL618897,,12687,3682,,Caudate-putamen,B,,,Autocuration,,,
2649,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,H,1,,CHEMBL618898,,12687,2014,,,B,,,Autocuration,,,
2650,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,H,1,,CHEMBL618899,,12687,2014,,,B,,,Autocuration,,,
2651,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,H,1,,CHEMBL618900,,12687,4932,,,B,,,Autocuration,,,
2652,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,H,1,,CHEMBL618901,,12687,4932,,,B,,,Autocuration,,,
2653,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL618902,,12687,3935,,,B,,,Autocuration,,,
2654,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,10000000.0,D,1,,CHEMBL618903,,12687,5432,,Hippocampus,B,,,Expert,,,
2655,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL618904,,12687,15818,,,B,,,Autocuration,,,
2656,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,H,1,,CHEMBL618905,,12687,13672,,,B,,,Autocuration,,,
2657,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,H,1,,CHEMBL618906,,12687,13672,,,B,,,Autocuration,,,
2658,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,H,1,NIH3T3,CHEMBL618907,,12687,14749,,,B,,,Expert,,723.0,
2659,BAO_0000019,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,H,1,,CHEMBL618908,,12687,13462,,,B,,,Autocuration,,,
2660,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617909,,12687,15740,,,B,,,Autocuration,,,
2661,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,H,1,,CHEMBL617910,,12687,16647,,,B,,,Expert,,,
2662,BAO_0000221,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,955.0,H,1,,CHEMBL617911,,12687,13345,,Brain,B,,,Autocuration,,,
2663,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,1,,CHEMBL872923,,12687,16740,,,B,,,Autocuration,,,
2664,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,1,,CHEMBL617912,,12687,16740,,,B,,,Autocuration,,,
2665,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,D,1,,CHEMBL617913,,12687,15535,,,B,,,Expert,,,
2666,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,1,,CHEMBL617914,,12687,16740,,,B,,,Expert,,,
2667,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,1,,CHEMBL617915,,12687,16740,,,B,,,Autocuration,,,
2668,BAO_0000249,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,1,,CHEMBL617916,,12687,16740,,,B,,,Autocuration,,,
2669,BAO_0000019,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,D,1,,CHEMBL617917,,12687,4795,,,B,,,Expert,,,
2670,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,H,1,,CHEMBL617918,,12687,8,,,B,,,Expert,,,
2671,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,H,1,,CHEMBL617919,,12687,8,,,B,,,Autocuration,,,
2672,BAO_0000019,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,D,1,,CHEMBL617920,,12687,17200,,,B,,,Expert,,,
2673,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,D,1,,CHEMBL617921,,12687,2148,,,B,,,Expert,,,
2674,BAO_0000224,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,D,1,,CHEMBL617922,,105102,13345,,,B,,,Expert,,,
2675,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,1,,CHEMBL617923,,12687,5088,,,B,,,Autocuration,,,
2676,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,1,,CHEMBL617924,,12687,5088,,,B,,,Autocuration,,,
2677,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,H,1,,CHEMBL617925,,12687,17133,,,B,,,Autocuration,,,
2678,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,D,1,,CHEMBL617926,,12687,17133,,,B,,,Expert,,,
2679,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,H,1,,CHEMBL617927,,12687,16532,,,B,,,Autocuration,,,
2680,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,H,1,,CHEMBL617928,,12687,15086,,,B,,,Autocuration,,,
2681,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,1,,CHEMBL617929,,12687,2309,,,B,,,Expert,,,
2682,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,H,1,,CHEMBL617930,,12687,12953,,,B,,,Expert,,,
2683,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,H,1,,CHEMBL617931,,12687,12953,,,B,,,Autocuration,,,
2684,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,H,1,,CHEMBL617932,,12687,12953,,,B,,,Autocuration,,,
2685,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,H,1,CHO,CHEMBL617933,,12687,16659,,,B,,,Autocuration,,449.0,
2686,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,H,1,,CHEMBL617934,,12687,16740,,,B,,,Autocuration,,,
2687,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,H,1,,CHEMBL617935,,12687,16740,,,B,,,Autocuration,,,
2688,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,H,1,,CHEMBL617936,,12687,17133,,,B,,,Autocuration,,,
2689,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,H,1,,CHEMBL617937,,12687,17211,,,B,,,Autocuration,,,
2690,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,H,1,,CHEMBL617938,,12687,17331,,,B,,,Autocuration,,,
2691,BAO_0000218,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,H,1,,CHEMBL617939,,12687,16633,,,B,,,Autocuration,,,
2692,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,H,1,,CHEMBL617940,,12687,16633,,,B,,,Autocuration,,,
2693,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,H,1,,CHEMBL617941,,12687,16633,,,B,,,Autocuration,,,
2694,BAO_0000357,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,H,1,,CHEMBL617942,,12687,15026,,,B,,,Expert,,,
2695,BAO_0000357,Ratio of pKi of 5-HT2A to that of D2 receptor,,H,1,,CHEMBL617943,,12687,15026,,,B,,,Expert,,,
2696,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617944,,105093,16404,,,B,,,Expert,,,
2697,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617945,,105093,16404,,,B,,,Expert,,,
2698,BAO_0000224,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617946,,105075,16404,,,B,,,Expert,,,
2699,BAO_0000357,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,H,1,,CHEMBL617947,,12687,16404,,,B,,,Autocuration,,,
2700,BAO_0000357,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,H,1,,CHEMBL617948,,12687,16326,,,B,,,Expert,,,
2701,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,H,1,,CHEMBL858116,,12687,15847,,,F,,,Autocuration,,,
2702,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,H,1,,CHEMBL617949,,12687,15847,,,F,,,Autocuration,,,
2703,BAO_0000019,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,H,1,,CHEMBL617950,,12687,15329,,,F,,,Autocuration,,,
2704,BAO_0000019,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1515.0,H,1,,CHEMBL617951,,12687,16404,,Thoracic aorta,F,,,Expert,,,
2705,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1515.0,H,1,,CHEMBL617952,,12687,16404,,Thoracic aorta,F,,,Expert,,,
2706,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1515.0,H,1,,CHEMBL617953,,12687,16404,,Thoracic aorta,F,,,Autocuration,,,
2707,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL617954,,12687,12861,,,B,,,Autocuration,,,
2708,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,H,1,,CHEMBL617955,,12687,12861,,,B,,,Expert,,,
2709,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,H,1,,CHEMBL857071,,12687,12861,,,B,,,Autocuration,,,
2710,BAO_0000019,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,H,1,,CHEMBL617270,,12687,12490,,,B,,,Expert,,,
2711,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,H,1,N1E-115,CHEMBL617271,,12687,12827,,,B,,,Autocuration,,339.0,
2712,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,H,1,N1E-115,CHEMBL617272,,12687,12827,,,B,,,Autocuration,,339.0,
2713,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,H,1,,CHEMBL617273,,12687,12918,,,B,,,Autocuration,,,
2714,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,D,1,,CHEMBL617274,,12687,12919,,,F,,,Expert,,,
2715,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617275,,108,17723,,,B,,,Autocuration,,,
2716,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617276,,108,6013,,,B,,,Autocuration,,,
2717,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617277,,108,16293,,,B,,,Autocuration,,,
2718,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617278,,108,3857,,,B,,,Expert,,,
2719,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,H,1,,CHEMBL617279,,108,3857,,,B,,,Expert,,,
2720,BAO_0000019,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617280,,108,3857,,,B,,,Expert,,,
2721,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617281,,108,15363,,,B,,,Autocuration,,,
2722,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617282,,108,15363,,,B,,,Autocuration,,,
2723,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,H,1,,CHEMBL617283,,108,16441,,,B,,,Expert,,,
2724,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,H,1,,CHEMBL617284,,108,16441,,,B,,,Expert,,,
2725,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,H,1,HEK293,CHEMBL617285,,108,4176,,,B,,,Autocuration,,722.0,
2726,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617286,,108,17085,,,B,,,Autocuration,,,
2727,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,D,1,,CHEMBL617287,,108,17200,,,B,,,Expert,,,
2728,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,H,1,,CHEMBL617288,,108,5088,,,B,,,Expert,,,
2729,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,H,1,,CHEMBL617289,,108,5088,,,B,,,Autocuration,,,
2730,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,1,,CHEMBL872917,,108,5088,,,B,,,Autocuration,,,
2731,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL617290,,108,5088,,,B,,,Autocuration,,,
2732,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL617291,,108,16659,,,B,,,Autocuration,,449.0,
2733,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,H,1,CHO,CHEMBL617292,,108,16659,,,B,,,Autocuration,,449.0,
2734,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,1,NIH3T3,CHEMBL617293,,108,17451,,,B,,,Autocuration,,723.0,
2735,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,1,CHO,CHEMBL617294,,108,6857,,,F,,,Expert,,449.0,
2736,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,H,1,,CHEMBL617295,,108,3857,,,B,,,Expert,,,
2737,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL617296,,108,12861,,,B,,,Autocuration,,,
2738,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,H,1,,CHEMBL617297,,108,12861,,,B,,,Autocuration,,,
2739,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,H,1,CHO,CHEMBL617298,,108,5104,,,B,,,Expert,,449.0,
2740,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,H,1,CHO,CHEMBL617299,,108,5105,,,B,,,Expert,,449.0,
2741,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,H,1,CHO,CHEMBL617300,,108,5105,,,B,,,Autocuration,,449.0,
2742,BAO_0000357,Binding affinity against 5-HT2C receptor,,H,1,,CHEMBL617454,,108,5254,,,B,,,Autocuration,,,
2743,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,H,1,HEK293,CHEMBL617505,,108,13267,,,B,,,Autocuration,,722.0,
2744,BAO_0000219,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,D,1,HEK293,CHEMBL617506,,108,14157,,,B,,,Expert,,722.0,
2745,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,D,1,HEK293,CHEMBL617507,,108,12936,,,B,,,Expert,,722.0,
2746,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,H,1,,CHEMBL617508,,108,14068,,,B,,,Expert,,,
2747,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,D,1,HEK293,CHEMBL857982,,108,12936,,,B,,,Expert,,722.0,
2748,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,D,1,HEK293,CHEMBL617509,,108,4540,,,B,,,Expert,,722.0,
2749,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,D,1,HEK293,CHEMBL617510,,108,4540,,,B,,,Expert,,722.0,
2750,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,H,1,,CHEMBL617511,,108,6166,,,B,,,Autocuration,,,
2751,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,H,1,HEK293,CHEMBL617512,,108,17296,,,B,,,Autocuration,,722.0,
2752,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,H,1,HEK293,CHEMBL617749,,108,17296,,,B,,,Autocuration,,722.0,
2753,BAO_0000219,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,1,HEK293,CHEMBL617750,,108,15779,,,B,,,Autocuration,,722.0,
2754,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,1,HEK293,CHEMBL617751,,108,15779,,,B,,,Autocuration,,722.0,
2755,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,H,1,HEK293,CHEMBL617752,,108,14391,,,B,,,Expert,,722.0,
2756,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,H,1,HEK293,CHEMBL617753,,108,15779,,,B,,,Autocuration,,722.0,
2757,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,H,1,HEK293,CHEMBL617754,,108,15851,,,B,,,Expert,,722.0,
2758,BAO_0000219,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,D,1,HEK293,CHEMBL617755,,108,15851,,,B,,,Expert,,722.0,
2759,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,H,1,HEK293,CHEMBL617756,,108,15779,,,B,,,Autocuration,,722.0,
2760,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,H,1,HEK293,CHEMBL617757,,108,3832,,,B,,,Expert,,722.0,
2761,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,H,1,HEK293,CHEMBL617758,,108,3833,,,B,,,Expert,,722.0,
2762,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,H,1,NIH3T3,CHEMBL617759,,108,17451,,,B,,,Autocuration,,723.0,
2763,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,H,1,HEK293,CHEMBL617760,,108,4199,,,B,,,Autocuration,,722.0,
2764,BAO_0000219,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,H,1,CHO-K1,CHEMBL617761,,108,1883,,,B,,,Expert,,485.0,
2765,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,D,1,,CHEMBL617762,,108,4321,,,B,,,Expert,,,
2766,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617763,,108,14875,,,B,,,Autocuration,,,
2767,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,H,1,HEK293,CHEMBL857983,,108,15146,,,B,,,Autocuration,,722.0,
2768,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,H,1,HEK293,CHEMBL617764,,108,5213,,,B,,,Autocuration,,722.0,
2769,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,H,1,HeLa,CHEMBL617765,,108,16404,,,B,,,Autocuration,,308.0,
2770,BAO_0000019,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617766,,108,13267,,,F,,,Autocuration,,,
2771,BAO_0000221,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,10000000.0,H,1,,CHEMBL617767,,108,13267,,Hippocampus,F,,,Autocuration,,,
2772,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,H,1,HEK293,CHEMBL617768,,108,14818,,,B,,,Autocuration,,722.0,
2773,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,H,1,HEK293,CHEMBL617769,,108,4829,,,B,,,Autocuration,,722.0,
2774,BAO_0000357,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,H,1,,CHEMBL858023,,11864,13463,,,B,,,Autocuration,,,
2775,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus,945.0,H,1,,CHEMBL617770,,11864,13463,,Stomach,B,,,Autocuration,,,
2776,BAO_0000019,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,945.0,H,1,,CHEMBL617771,,11864,13463,,Stomach,B,,,Autocuration,,,
2777,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,H,1,A9,CHEMBL617772,,11864,12652,,,F,,,Autocuration,,625.0,
2778,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,H,1,NIH3T3,CHEMBL617773,,11864,4682,,,B,,,Autocuration,,723.0,
2779,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,H,1,NIH3T3,CHEMBL617850,,11864,4682,,,B,,,Autocuration,,723.0,
2780,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,H,1,NIH3T3,CHEMBL617851,,11864,4682,,,B,,,Autocuration,,723.0,
2781,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617852,,11864,12652,,,F,,,Autocuration,,,
2782,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,945.0,H,1,,CHEMBL858024,,12689,13463,,Stomach,B,,,Autocuration,,,
2783,BAO_0000019,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,945.0,D,1,,CHEMBL617853,,12689,13463,,Stomach,B,,,Expert,,,
2784,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,H,1,,CHEMBL617854,,108,13969,,,B,,,Expert,,,
2785,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL873477,,108,13392,,,B,,,Expert,,,
2786,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617855,,108,13392,,,B,,,Expert,,,
2787,BAO_0000019,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,H,1,,CHEMBL617856,,108,14430,,,B,,,Expert,,,
2788,BAO_0000019,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,H,1,,CHEMBL617857,,108,1742,,,B,,,Autocuration,,,
2789,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,H,1,,CHEMBL617858,,108,14286,,,B,,,Autocuration,,,
2790,BAO_0000357,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617859,,108,5619,,,B,,,Autocuration,,,
2791,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617860,,108,15086,,,B,,,Autocuration,,,
2792,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL617861,,108,12861,,,B,,,Autocuration,,,
2793,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,H,1,,CHEMBL617862,,108,12861,,,B,,,Expert,,,
2794,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,H,1,,CHEMBL617863,,108,12861,,,B,,,Autocuration,,,
2795,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,H,1,,CHEMBL617864,,108,12827,,,B,,,Autocuration,,,
2796,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,H,1,,CHEMBL617649,,108,12827,,,B,,,Autocuration,,,
2797,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,H,1,,CHEMBL617650,,108,12919,,,F,,,Expert,,,
2798,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,H,1,,CHEMBL617651,,108,12919,,,F,,,Expert,,,
2799,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,H,1,,CHEMBL617652,,108,16429,,,B,,,Autocuration,,,
2800,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,H,1,,CHEMBL857072,,108,773,,,B,,,Autocuration,,,
2801,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617653,,108,5033,,,B,,,Autocuration,,,
2802,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,H,1,,CHEMBL617654,,12687,12861,,,B,,,Autocuration,,,
2803,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617655,,12689,14093,,,F,,,Autocuration,,,
2804,BAO_0000357,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,H,1,,CHEMBL617656,,12689,14970,,,B,,,Expert,,,
2805,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,H,1,,CHEMBL617657,,12689,14970,,,B,,,Autocuration,,,
2806,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,H,1,,CHEMBL617658,,12689,14970,,,B,,,Autocuration,,,
2807,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,D,1,,CHEMBL617659,,12689,14178,,,B,,,Expert,,,
2808,BAO_0000357,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,D,1,,CHEMBL617838,,12689,14178,,,B,,,Expert,,,
2809,BAO_0000249,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,D,1,,CHEMBL617839,,12689,14229,Brain membranes,,B,,,Expert,,,
2810,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,H,1,,CHEMBL617840,,12689,16532,,,B,,,Autocuration,,,
2811,BAO_0000019,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,H,1,,CHEMBL617841,,12689,14826,,,B,,,Autocuration,,,
2812,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,H,1,,CHEMBL875915,,12689,17211,,,B,,,Autocuration,,,
2813,BAO_0000219,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,H,1,,CHEMBL617842,In vitro,12689,17211,,,B,,,Expert,,,
2814,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,H,1,NIH3T3,CHEMBL617843,,12689,13246,,,B,,,Expert,,723.0,
2815,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,H,1,,CHEMBL617844,,12689,13246,,,B,,,Expert,,,
2816,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617845,,12689,12457,,,B,,,Expert,,,
2817,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,H,1,NIH3T3,CHEMBL617846,,12689,12457,,,B,,,Expert,,723.0,
2818,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,H,1,,CHEMBL617847,,12689,4707,,,B,,,Autocuration,,,
2819,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617848,,12689,13297,,,B,,,Expert,,,
2820,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,H,1,,CHEMBL617849,,12689,16633,,,B,,,Autocuration,,,
2821,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,1,,CHEMBL621507,,12689,16133,,,B,,,Expert,,,
2822,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,H,1,,CHEMBL621508,,12689,16326,,,B,,,Expert,,,
2823,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,H,1,,CHEMBL621509,,12689,14423,,,B,,,Autocuration,,,
2824,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,H,1,,CHEMBL621510,,12689,15412,,,B,,,Autocuration,,,
2825,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,H,1,,CHEMBL621511,,12689,15412,,,B,,,Autocuration,,,
2826,BAO_0000219,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,H,1,A9,CHEMBL621512,,12689,15558,,,B,,,Expert,,625.0,
2827,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,H,1,,CHEMBL621513,,12689,16633,,,B,,,Autocuration,,,
2828,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,H,1,,CHEMBL621514,,12689,6013,,,B,,,Expert,,,
2829,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,H,1,,CHEMBL621515,In vitro,12689,17175,,,B,,,Expert,,,
2830,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,H,1,,CHEMBL621516,,12689,12469,,,B,,,Autocuration,,,
2831,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,5383.0,H,1,,CHEMBL621517,,12689,3682,,Caudate-putamen,B,,,Autocuration,,,
2832,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,H,1,,CHEMBL621518,,12689,4932,,,B,,,Autocuration,,,
2833,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,H,1,,CHEMBL621519,,12689,4932,,,B,,,Autocuration,,,
2834,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL621520,,12689,3935,,,B,,,Autocuration,,,
2835,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL621521,,12689,15818,,,B,,,Autocuration,,,
2836,BAO_0000357,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL621522,,12689,15818,,,B,,,Autocuration,,,
2837,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,H,1,,CHEMBL621523,,12689,14749,,,B,,,Expert,,,
2838,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL621524,,12689,15740,,,B,,,Autocuration,,,
2839,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,D,1,,CHEMBL621525,,12689,17133,,,B,,,Expert,,,
2840,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,H,1,,CHEMBL872921,,12689,16532,,,B,,,Autocuration,,,
2841,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL621526,,12689,12369,,,B,,,Autocuration,,,
2842,BAO_0000219,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,H,1,,CHEMBL621527,,12689,12369,,,B,,,Expert,,,
2843,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,D,1,,CHEMBL617865,,12689,2309,,,B,,,Expert,,,
2844,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617866,,12689,12953,,,B,,,Autocuration,,,
2845,BAO_0000019,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,H,1,,CHEMBL617867,,12689,12953,,,B,,,Autocuration,,,
2846,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,H,1,,CHEMBL617487,,12689,12953,,,B,,,Autocuration,,,
2847,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617488,,12689,12953,,,B,,,Expert,,,
2848,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,H,1,,CHEMBL617489,,12689,17133,,,B,,,Autocuration,,,
2849,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,H,1,,CHEMBL617490,,12689,17211,,,B,,,Autocuration,,,
2850,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,H,1,,CHEMBL617491,,12689,17211,,,B,,,Autocuration,,,
2851,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,H,1,,CHEMBL617492,,12689,14025,,,B,,,Autocuration,,,
2852,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,H,1,,CHEMBL617493,,12689,14998,,,B,,,Autocuration,,,
2853,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,H,1,,CHEMBL617494,,12689,4342,,,B,,,Autocuration,,,
2854,BAO_0000019,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,D,1,,CHEMBL617495,,12689,13735,,,B,,,Expert,,,
2855,BAO_0000357,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL617496,,12689,13181,,,B,,,Autocuration,,,
2856,BAO_0000219,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,H,1,CHO-K1,CHEMBL617497,,12689,1883,,,B,,,Autocuration,,485.0,
2857,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,1,,CHEMBL617498,,12689,15194,,,B,,,Autocuration,,,
2858,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,H,1,,CHEMBL617499,,12689,15194,,,B,,,Autocuration,,,
2859,BAO_0000019,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617500,,12689,14579,,,F,,,Autocuration,,,
2860,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617501,,108,4639,,,B,,,Autocuration,,,
2861,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617502,,108,4820,,,B,,,Expert,,,
2862,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,H,1,,CHEMBL617503,,227,14442,,,B,,,Autocuration,,,
2863,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,H,1,,CHEMBL617504,,227,14755,,,B,,,Autocuration,,,
2864,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,H,1,,CHEMBL617406,,227,14744,,,B,,,Autocuration,,,
2865,BAO_0000019,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,D,1,,CHEMBL617407,,227,6857,,,B,,,Expert,,,
2866,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL617408,,227,16209,,,B,,,Autocuration,,,
2867,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617409,,227,15363,,,B,,,Autocuration,,,
2868,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617410,,227,15363,,,B,,,Autocuration,,,
2869,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617411,,227,15363,,,B,,,Autocuration,,,
2870,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617412,,227,17085,,,B,,,Autocuration,,,
2871,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,D,1,,CHEMBL617774,,227,17200,,,B,,,Expert,,,
2872,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,D,1,HEK293,CHEMBL617775,,227,15851,,,B,,,Expert,,722.0,
2873,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,D,1,HEK293,CHEMBL617776,,227,15851,,,B,,,Expert,,722.0,
2874,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,1,CHO,CHEMBL617777,,227,6857,,,F,,,Expert,,449.0,
2875,BAO_0000219,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,1,CHO,CHEMBL617778,,227,6857,,,F,,,Expert,,449.0,
2876,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,H,1,HEK293,CHEMBL617779,,227,15779,,,B,,,Autocuration,,722.0,
2877,BAO_0000219,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,H,1,HEK293,CHEMBL617780,,227,15851,,,B,,,Expert,,722.0,
2878,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,H,1,HEK293,CHEMBL617781,,227,15779,,,B,,,Autocuration,,722.0,
2879,BAO_0000219,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,D,1,HEK293,CHEMBL617782,,227,14157,,,B,,,Expert,,722.0,
2880,BAO_0000219,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,D,1,HEK293,CHEMBL617783,,227,4540,,,B,,,Expert,,722.0,
2881,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,H,1,,CHEMBL617784,,227,6166,,,B,,,Autocuration,,,
2882,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,H,1,HEK293,CHEMBL617785,,227,15779,,,B,,,Autocuration,,722.0,
2883,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,H,1,HEK293,CHEMBL857984,,227,14391,,,B,,,Expert,,722.0,
2884,BAO_0000219,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,H,1,HEK293,CHEMBL617786,,227,3832,,,B,,,Expert,,722.0,
2885,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,H,1,HEK293,CHEMBL617787,,227,3833,,,B,,,Expert,,722.0,
2886,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,D,1,HEK293,CHEMBL617788,,227,15851,,,B,,,Expert,,722.0,
2887,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,D,1,HEK293,CHEMBL617789,,227,15851,,,B,,,Expert,,722.0,
2888,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,H,1,HEK293,CHEMBL617790,,227,4199,,,B,,,Autocuration,,722.0,
2889,BAO_0000219,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,H,1,CHO-K1,CHEMBL617791,,227,1883,,,B,,,Expert,,485.0,
2890,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617608,,227,4321,,,B,,,Expert,,,
2891,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,H,1,HEK293,CHEMBL617609,,227,15146,,,B,,,Autocuration,,722.0,
2892,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,H,1,HEK293,CHEMBL617610,,227,5213,,,B,,,Autocuration,,722.0,
2893,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,H,1,HEK293,CHEMBL617611,,227,14818,,,B,,,Autocuration,,722.0,
2894,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,H,1,HEK293,CHEMBL617612,,227,4829,,,B,,,Autocuration,,722.0,
2895,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,H,1,HEK293,CHEMBL617613,,227,4829,,,B,,,Autocuration,,722.0,
2896,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,H,1,,CHEMBL617614,,227,14025,,,B,,,Autocuration,,,
2897,BAO_0000019,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,945.0,H,1,,CHEMBL617615,,12688,13463,,Stomach,B,,,Expert,,,
2898,BAO_0000357,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,945.0,H,1,,CHEMBL858114,,12688,7259,,Stomach,B,,,Expert,,,
2899,BAO_0000357,Affinity against serotonergic receptor in the isolated rat stomach fundus,945.0,H,1,,CHEMBL617616,,12688,7259,,Stomach,B,,,Autocuration,,,
2900,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,945.0,D,1,,CHEMBL617617,,12688,7185,,Stomach,F,,,Expert,,,
2901,BAO_0000019,Antagonistic against 5-hydroxytryptamine 2B receptor,,D,1,,CHEMBL875914,,12688,7185,,,F,,,Expert,,,
2902,BAO_0000019,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,945.0,H,1,,CHEMBL617618,,12688,13267,,Stomach,F,,,Autocuration,,,
2903,BAO_0000357,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,945.0,D,1,,CHEMBL617619,,12688,13735,,Stomach,B,,,Expert,,,
2904,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,H,1,,CHEMBL617620,,12688,15738,,,F,,,Autocuration,,,
2905,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,H,1,,CHEMBL617621,,12688,15738,,,F,,,Autocuration,,,
2906,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,H,1,,CHEMBL617622,,12688,15738,,,F,,,Autocuration,,,
2907,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,D,1,,CHEMBL617623,,12688,12936,,Stomach,B,,,Expert,,,
2908,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,D,1,,CHEMBL617624,,12688,12936,,Stomach,B,,,Expert,,,
2909,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,D,1,,CHEMBL617625,,12688,12936,,Stomach,B,,,Expert,,,
2910,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,D,1,,CHEMBL617626,,12688,12936,,Stomach,B,,,Expert,,,
2911,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,H,1,,CHEMBL617627,,12688,16404,,Stomach,F,,,Autocuration,,,
2912,BAO_0000019,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,H,1,,CHEMBL617628,,12688,16404,,Stomach,F,,,Expert,,,
2913,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,945.0,H,1,,CHEMBL617629,,12688,16404,,Stomach,F,,,Autocuration,,,
2914,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,945.0,H,1,,CHEMBL858115,,12688,16404,,Stomach,F,,,Autocuration,,,
2915,BAO_0000019,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,945.0,D,1,,CHEMBL617630,,12688,16404,,Stomach,F,,,Expert,,,
2916,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1515.0,H,1,,CHEMBL617631,,12688,16404,,Thoracic aorta,F,,,Autocuration,,,
2917,BAO_0000357,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,H,1,,CHEMBL617632,,12688,7483,,,B,,,Autocuration,,,
2918,BAO_0000357,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,H,1,,CHEMBL617633,,12688,7483,,,B,,,Expert,,,
2919,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,H,1,,CHEMBL617634,,12688,7483,,,B,,,Autocuration,,,
2920,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,H,1,,CHEMBL617635,,12688,7483,,,B,,,Autocuration,,,
2922,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,D,1,,CHEMBL617637,,12688,16404,,Stomach,F,,,Autocuration,,,
2923,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,1,,CHEMBL617638,,227,6347,,,B,,,Autocuration,,,
2924,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,H,1,,CHEMBL617639,,227,4373,,,B,,,Autocuration,,,
2925,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,H,1,,CHEMBL617640,,227,4373,,,B,,,Autocuration,,,
2926,BAO_0000357,Evaluated for the binding affinity to 5-HT 2B receptor,,H,1,,CHEMBL617641,,227,4687,,,B,,,Autocuration,,,
2927,BAO_0000357,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617642,,227,16946,,,B,,,Autocuration,,,
2928,BAO_0000357,Binding affinities against 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617643,,227,16633,,,B,,,Autocuration,,,
2929,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 2B receptor,,H,1,,CHEMBL617644,,227,16633,,,B,,,Autocuration,,,
2930,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,H,1,,CHEMBL617645,,227,16633,,,B,,,Autocuration,,,
2931,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,H,1,,CHEMBL617646,,108,15026,,,B,,,Expert,,,
2932,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,H,1,,CHEMBL617647,,108,15738,,,B,,,Autocuration,,,
2933,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,H,1,,CHEMBL617648,,108,15738,,,B,,,Autocuration,,,
2934,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,H,1,,CHEMBL617875,,108,15738,,,B,,,Autocuration,,,
2935,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,H,1,,CHEMBL617876,,108,15738,,,B,,,Autocuration,,,
2936,BAO_0000357,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,H,1,,CHEMBL617877,,108,16404,,,B,,,Expert,,,
2937,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,H,1,,CHEMBL617878,,108,15026,,,B,,,Expert,,,
2938,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,H,1,,CHEMBL617879,,108,15738,,,B,,,Autocuration,,,
2939,BAO_0000019,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,H,1,,CHEMBL617880,,108,16312,,,B,,,Autocuration,,,
2940,BAO_0000357,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,2435.0,D,1,,CHEMBL617881,,20033,5486,,Striatum,B,,,Intermediate,,,
2941,BAO_0000357,Binding affinity against 5-HT1A receptor,,H,1,,CHEMBL857073,,51,5254,,,B,,,Autocuration,,,
2942,BAO_0000219,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,H,1,CHO,CHEMBL617882,,108,3857,,,F,,,Expert,,449.0,
2943,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,D,1,CHO,CHEMBL617883,,108,6857,,,F,,,Expert,,449.0,
2944,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,H,1,,CHEMBL617884,,108,4176,,,F,,,Autocuration,,,
2945,BAO_0000219,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,H,1,CHO,CHEMBL617885,,108,6347,,,B,,,Autocuration,,449.0,
2946,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,H,1,CHO,CHEMBL617886,,108,6347,,,B,,,Autocuration,,449.0,
2947,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2C receptor,,D,1,,CHEMBL617887,,108,16146,,,B,,,Expert,,,
2948,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,H,1,,CHEMBL617888,,108,3805,,,B,,,Autocuration,,,
2949,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,H,1,,CHEMBL617889,,108,3857,,,B,,,Autocuration,,,
2950,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL617890,,108,5635,,,B,,,Autocuration,,,
2951,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,H,1,,CHEMBL617891,,108,5635,,,B,,,Autocuration,,,
2952,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,H,1,,CHEMBL617892,,108,5635,,,B,,,Autocuration,,,
2953,BAO_0000219,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,H,1,CHO,CHEMBL617893,,108,4012,,,B,,,Expert,,449.0,
2954,BAO_0000219,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,H,1,CHO,CHEMBL617894,,108,6366,,,B,,,Expert,,449.0,
2955,BAO_0000219,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL617895,,108,15949,,,B,,,Expert,,449.0,
2956,BAO_0000219,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,H,1,CHO,CHEMBL617896,,108,17211,,,B,,,Autocuration,,449.0,
2957,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,D,1,,CHEMBL617897,,108,6491,,,B,,,Expert,,,
2958,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,H,1,,CHEMBL617898,,108,14093,,,F,,,Autocuration,,,
2959,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,H,1,,CHEMBL617899,,108,13481,,,F,,,Autocuration,,,
2960,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,H,1,CHO,CHEMBL617900,,108,6347,,,B,,,Expert,,449.0,
2961,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,H,1,,CHEMBL617901,,108,14093,,,F,,,Autocuration,,,
2962,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,H,1,,CHEMBL617902,,108,14093,,,F,,,Autocuration,,,
2963,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,1,,CHEMBL617903,,108,13481,,,F,,,Autocuration,,,
2964,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,H,1,,CHEMBL617904,,108,14442,,,B,,,Autocuration,,,
2965,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,H,1,,CHEMBL617905,,108,14442,,,B,,,Autocuration,,,
2966,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,H,1,,CHEMBL617906,,108,14442,,,B,,,Autocuration,,,
2967,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,H,1,,CHEMBL617907,,108,14755,,,B,,,Autocuration,,,
2968,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,H,1,,CHEMBL617908,,108,14744,,,B,,,Autocuration,,,
2969,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL620617,,108,16659,,,B,,,Expert,,449.0,
2970,BAO_0000019,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,D,1,,CHEMBL620618,,108,6857,,,B,,,Expert,,,
2971,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,H,1,,CHEMBL620619,,108,5635,,,B,,,Expert,,,
2972,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,D,1,,CHEMBL620620,,108,4234,,,B,,,Expert,,,
2973,BAO_0000357,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,H,1,,CHEMBL620621,,108,16209,,,B,,,Autocuration,,,
2974,BAO_0000249,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,D,1,,CHEMBL872920,,104698,5778,Membranes,,B,,,Autocuration,,,
2975,BAO_0000223,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,H,1,,CHEMBL620622,,104698,5094,,,B,,,Autocuration,,,
2976,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,D,1,,CHEMBL620623,,104698,809,,,B,,,Autocuration,,,
2977,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,H,1,,CHEMBL620624,,104698,1578,,,B,,,Autocuration,,,
2978,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,H,1,,CHEMBL620625,,104698,809,,,B,,,Autocuration,,,
2979,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,H,1,,CHEMBL620626,,104698,12469,,,B,,,Autocuration,,,
2980,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,H,1,,CHEMBL621307,,104698,14290,,,B,,,Autocuration,,,
2981,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,H,1,,CHEMBL621308,,104698,14290,,,B,,,Autocuration,,,
2982,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,H,1,,CHEMBL621309,,104698,10609,,,B,,,Autocuration,,,
2983,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,H,1,,CHEMBL621310,,104698,10609,,,B,,,Autocuration,,,
2984,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,H,1,,CHEMBL621311,,104698,10609,,,B,,,Autocuration,,,
2985,BAO_0000249,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,H,1,,CHEMBL621502,,104698,15253,,,B,,,Autocuration,,,
2986,BAO_0000249,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,H,1,,CHEMBL621503,,104698,15253,,,B,,,Autocuration,,,
2987,BAO_0000249,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,H,1,,CHEMBL621504,,104698,11683,Membranes,,B,,,Autocuration,,,
2988,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL621505,,104698,12092,,,B,,,Autocuration,,,
2989,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,H,1,,CHEMBL621506,,104698,1946,,,B,,,Autocuration,,,
2990,BAO_0000223,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,H,1,,CHEMBL619781,,104698,11623,,,B,,,Autocuration,,,
2991,BAO_0000223,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,H,1,,CHEMBL619782,,104698,11623,,,B,,,Autocuration,,,
2992,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,H,1,,CHEMBL619783,,104698,14788,,,B,,,Autocuration,,,
2993,BAO_0000019,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,D,1,,CHEMBL619784,,104698,5432,,,B,,,Autocuration,,,
2994,BAO_0000249,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,H,1,,CHEMBL619785,,104698,14826,,,B,,,Autocuration,,,
2995,BAO_0000223,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL619786,,104698,2222,,,B,,,Autocuration,,,
2996,BAO_0000019,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,H,1,,CHEMBL619787,,104698,11963,,,B,,,Autocuration,,,
2997,BAO_0000019,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,H,1,,CHEMBL872925,,104698,14145,,,B,,,Autocuration,,,
2998,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,H,1,,CHEMBL619788,,104698,17819,,,B,,,Autocuration,,,
2999,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,H,1,,CHEMBL619789,,104698,10394,,,B,,,Autocuration,,,
3000,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,H,1,,CHEMBL619790,,104698,10394,,,B,,,Autocuration,,,
3001,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,H,1,,CHEMBL619791,,104698,15034,,,B,,,Autocuration,,,
3002,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,H,1,,CHEMBL619792,,104698,691,,,B,,,Autocuration,,,
3003,BAO_0000249,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,H,1,,CHEMBL619793,,104698,12092,Membranes,,B,,,Autocuration,,,
3004,BAO_0000223,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL619794,,104698,11752,,,B,,,Autocuration,,,
3005,BAO_0000221,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,955.0,H,1,,CHEMBL619795,,104698,11752,,Brain,B,,,Autocuration,,,
3006,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,H,1,,CHEMBL619796,,104698,301,,,B,,,Autocuration,,,
3007,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,H,1,,CHEMBL620448,,104698,16532,,,B,,,Autocuration,,,
3008,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,H,1,,CHEMBL620449,,104698,16532,,,B,,,Autocuration,,,
3009,BAO_0000223,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,H,1,,CHEMBL620450,,104698,12092,,,B,,,Autocuration,,,
3010,BAO_0000223,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,H,1,,CHEMBL620451,,104698,11684,,,B,,,Autocuration,,,
3011,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,H,1,,CHEMBL620631,,104698,11684,,,B,,,Autocuration,,,
3012,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,H,1,,CHEMBL620632,,104698,12953,,,B,,,Autocuration,,,
3013,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,H,1,,CHEMBL620633,,104698,12953,,,B,,,Autocuration,,,
3014,BAO_0000223,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,H,1,,CHEMBL620634,,104698,12953,,,B,,,Autocuration,,,
3015,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,H,1,,CHEMBL620635,,104698,12861,,,B,,,Autocuration,,,
3016,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,1,,CHEMBL620636,In vivo,104698,11454,,,F,,,Autocuration,,,
3017,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,H,1,,CHEMBL620637,In vivo,104698,11454,,,F,,,Autocuration,,,
3018,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,H,1,,CHEMBL620638,In vivo,104698,11454,,,F,,,Autocuration,,,
3019,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,H,1,,CHEMBL620639,In vivo,104698,11454,,,F,,,Autocuration,,,
3020,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,1,,CHEMBL620640,In vivo,104698,11454,,,F,,,Autocuration,,,
3021,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,H,1,,CHEMBL620641,In vivo,104698,11454,,,F,,,Autocuration,,,
3022,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,H,1,,CHEMBL620642,In vivo,104698,11454,,,F,,,Autocuration,,,
3023,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,H,1,,CHEMBL620643,In vivo,104698,11454,,,F,,,Autocuration,,,
3024,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,H,1,,CHEMBL620644,In vivo,104698,11454,,,F,,,Autocuration,,,
3025,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,1,,CHEMBL620645,In vivo,104698,11454,,,F,,,Autocuration,,,
3026,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,H,1,,CHEMBL620646,In vivo,104698,11454,,,F,,,Autocuration,,,
3027,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,H,1,,CHEMBL620647,In vivo,104698,11454,,,F,,,Autocuration,,,
3028,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,H,1,,CHEMBL620648,In vivo,104698,11454,,,F,,,Autocuration,,,
3029,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,1,,CHEMBL620649,In vivo,104698,11454,,,F,,,Autocuration,,,
3030,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,H,1,,CHEMBL620650,In vivo,104698,11454,,,F,,,Autocuration,,,
3031,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,H,1,,CHEMBL620651,In vivo,104698,11454,,,F,,,Autocuration,,,
3032,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,H,1,,CHEMBL872875,In vivo,104698,11454,,,F,,,Autocuration,,,
3033,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,H,1,,CHEMBL620652,In vivo,104698,11454,,,F,,,Autocuration,,,
3034,BAO_0000019,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,H,1,,CHEMBL620653,,104698,10609,,,F,,,Autocuration,,,
3035,BAO_0000019,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,H,1,,CHEMBL857076,,104698,12861,,,B,,,Autocuration,,,
3036,BAO_0000019,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL620654,,104698,12861,,,B,,,Autocuration,,,
3037,BAO_0000223,Binding activity radioligand.,,H,1,,CHEMBL620655,,104698,12861,,,B,,,Autocuration,,,
3038,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,H,1,,CHEMBL620656,,104698,10728,Brain membranes,,B,,,Autocuration,,,
3039,BAO_0000249,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,H,1,,CHEMBL620657,,104698,10728,Brain membranes,,B,,,Autocuration,,,
3040,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,H,1,,CHEMBL620658,,108,5163,,,B,,,Autocuration,,,
3041,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,H,1,,CHEMBL620659,,108,5163,,,B,,,Autocuration,,,
3042,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,H,1,,CHEMBL620660,,108,6011,,,B,,,Autocuration,,,
3043,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620661,,108,5014,,,B,,,Autocuration,,,
3044,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620662,,108,5635,,,B,,,Autocuration,,,
3045,BAO_0000357,Affinity for 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620663,,108,5163,,,B,,,Expert,,,
3046,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,1,,CHEMBL620664,,108,6841,,,B,,,Autocuration,,,
3047,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,H,1,,CHEMBL620665,,108,6119,,,B,,,Expert,,,
3048,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,H,1,,CHEMBL620666,,108,4373,,,B,,,Autocuration,,,
3049,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,H,1,,CHEMBL620667,,108,1633,,,B,,,Autocuration,,,
3050,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,H,1,,CHEMBL620668,,108,1633,,,B,,,Expert,,,
3051,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,H,1,,CHEMBL620669,,108,4373,,,B,,,Autocuration,,,
3052,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620670,,108,6576,,,B,,,Expert,,,
3053,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620671,,108,4687,,,B,,,Autocuration,,,
3054,BAO_0000357,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,H,1,,CHEMBL620672,,108,12146,,,B,,,Autocuration,,,
3055,BAO_0000357,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,H,1,,CHEMBL620673,,108,12146,,,B,,,Autocuration,,,
3056,BAO_0000357,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620674,,108,16946,,,B,,,Autocuration,,,
3057,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL620675,,108,14159,,,B,,,Autocuration,,,
3058,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,H,1,,CHEMBL620676,,108,16700,,,B,,,Autocuration,,,
3059,BAO_0000357,Affinity against 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL621382,,108,3269,,,B,,,Autocuration,,,
3060,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,D,1,,CHEMBL621383,,108,1274,,,B,,,Expert,,,
3061,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,H,1,,CHEMBL621384,,108,1317,,,B,,,Autocuration,,,
3062,BAO_0000357,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,H,1,,CHEMBL621385,,144,5834,,,B,,,Autocuration,,,
3063,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,H,1,,CHEMBL617989,,144,11147,,,B,,,Autocuration,,,
3064,BAO_0000019,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,H,1,,CHEMBL617990,,104714,14145,,,F,,,Expert,,,
3065,BAO_0000221,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,2116.0,H,1,,CHEMBL875085,,104714,10561,,Ileum,B,,,Autocuration,,,
3066,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,H,1,,CHEMBL617991,,104714,15847,,,F,,,Autocuration,,,
3067,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,H,1,,CHEMBL617992,,104714,15847,,,F,,,Autocuration,,,
3068,BAO_0000221,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,2116.0,H,1,,CHEMBL617993,,104714,10561,,Ileum,B,,,Autocuration,,,
3069,BAO_0000221,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,2116.0,H,1,,CHEMBL617994,,104714,11454,,Ileum,B,,,Autocuration,,,
3070,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,H,1,,CHEMBL617995,,104714,4639,,,F,,,Autocuration,,,
3071,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,H,1,,CHEMBL617996,,104714,4639,,,F,,,Autocuration,,,
3072,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,H,1,,CHEMBL617997,,104714,4639,,,F,,,Autocuration,,,
3073,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,H,1,,CHEMBL617998,,104714,4639,,,F,,,Autocuration,,,
3074,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,H,1,,CHEMBL617999,,104714,4639,,,F,,,Autocuration,,,
3075,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,H,1,,CHEMBL618000,,104714,4639,,,F,,,Autocuration,,,
3076,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",2116.0,H,1,,CHEMBL617815,,104714,15253,,Ileum,F,,,Autocuration,,,
3077,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",2116.0,H,1,,CHEMBL617816,,104714,15253,,Ileum,F,,,Autocuration,,,
3078,BAO_0000221,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,2116.0,H,1,,CHEMBL617817,,104714,11963,,Ileum,F,,,Autocuration,,,
3079,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,2116.0,H,1,,CHEMBL617818,,104714,1946,,Ileum,B,,,Autocuration,,,
3080,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,2116.0,H,1,,CHEMBL617819,,104714,1946,,Ileum,B,,,Autocuration,,,
3081,BAO_0000223,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,H,1,,CHEMBL617820,,104714,12045,,,B,,,Autocuration,,,
3082,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,H,1,,CHEMBL617821,,104714,1559,,Ileum,B,,,Autocuration,,,
3083,BAO_0000221,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,H,1,,CHEMBL617822,,104714,273,,Ileum,F,,,Autocuration,,,
3084,BAO_0000221,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),2116.0,H,1,,CHEMBL617823,,104714,273,,Ileum,F,,,Autocuration,,,
3085,BAO_0000221,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,2116.0,H,1,,CHEMBL617824,,104714,188,,Ileum,F,,,Autocuration,,,
3086,BAO_0000221,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,2116.0,H,1,,CHEMBL617825,,104714,12919,,Ileum,F,,,Autocuration,,,
3087,BAO_0000221,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,2116.0,H,1,,CHEMBL617826,,104714,12918,,Ileum,F,,,Autocuration,,,
3088,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,H,1,,CHEMBL617827,,104714,1559,,Ileum,B,,,Autocuration,,,
3089,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,H,1,,CHEMBL617828,,104714,273,,Ileum,F,,,Autocuration,,,
3090,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,H,1,,CHEMBL617829,,104714,1559,,Ileum,B,,,Autocuration,,,
3091,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,2116.0,H,1,,CHEMBL617830,,104714,1559,,Ileum,B,,,Autocuration,,,
3092,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,2116.0,H,1,,CHEMBL617831,,104714,1559,,Ileum,B,,,Autocuration,,,
3093,BAO_0000221,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,2116.0,H,1,,CHEMBL617832,,104714,14424,,Ileum,B,,,Autocuration,,,
3094,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,U,1,,CHEMBL617833,,22226,13181,,,B,,,Autocuration,,,
3095,BAO_0000357,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,H,1,,CHEMBL617834,,51,5486,,,B,,,Autocuration,,,
3096,BAO_0000223,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,D,1,,CHEMBL617835,,104714,6491,,,B,,,Expert,,,
3097,BAO_0000223,Binding affinity towards 5-HT3 receptor,,H,1,,CHEMBL617836,,104714,6013,,,B,,,Autocuration,,,
3098,BAO_0000223,Binding activity radioligand.,,H,1,,CHEMBL617837,,104714,12861,,,B,,,Autocuration,,,
3099,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,H,1,,CHEMBL620392,,104714,12861,,,B,,,Autocuration,,,
3100,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620393,,104714,5104,,,B,,,Autocuration,,,
3101,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620394,,104714,5105,,,B,,,Autocuration,,,
3102,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,H,1,,CHEMBL620395,,104714,5104,,,B,,,Autocuration,,,
3103,BAO_0000019,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,U,1,,CHEMBL620396,,22226,3935,,,B,,,Autocuration,,,
3104,BAO_0000219,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,H,1,NG108-15,CHEMBL620582,,105030,13657,,,B,,,Expert,,433.0,
3105,BAO_0000218,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,H,1,,CHEMBL620583,In vivo,105030,10369,,,B,,,Autocuration,,,
3106,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,H,1,,CHEMBL620584,,105030,10369,,,B,,,Autocuration,,,
3107,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,H,1,,CHEMBL620585,,105030,12918,,,B,,,Autocuration,,,
3108,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor,,H,1,,CHEMBL620586,,105030,12918,,,B,,,Autocuration,,,
3109,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,H,1,,CHEMBL620587,,105030,10369,,,B,,,Autocuration,,,
3110,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,H,1,,CHEMBL620588,,105030,773,,,B,,,Autocuration,,,
3111,BAO_0000218,5-hydroxytryptamine 3 receptor agonism in mouse,,H,1,,CHEMBL620589,,105030,12918,,,F,,,Autocuration,,,
3112,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,H,1,,CHEMBL620590,,105030,10561,,,B,,,Autocuration,,,
3113,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,H,1,,CHEMBL617956,,105030,12827,,,B,,,Autocuration,,,
3114,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,H,1,,CHEMBL617957,,105030,12827,,,B,,,Autocuration,,,
3115,BAO_0000224,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,H,1,,CHEMBL617958,,105030,12918,,,B,,,Autocuration,,,
3116,BAO_0000219,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,H,1,,CHEMBL617959,,105030,273,,,B,,,Autocuration,,,
3117,BAO_0000219,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,H,1,,CHEMBL617960,,105030,273,,,B,,,Autocuration,,,
3118,BAO_0000224,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,H,1,,CHEMBL617961,,105030,10561,,,B,,,Autocuration,,,
3119,BAO_0000219,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,H,1,,CHEMBL617962,In vitro,105030,5033,,,B,,,Autocuration,,,
3120,BAO_0000219,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,H,1,N1E-115,CHEMBL617963,,105030,16429,,,B,,,Autocuration,,339.0,
3121,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,H,1,,CHEMBL617964,,11765,10322,,,B,,,Autocuration,,,
3122,BAO_0000219,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,H,1,,CHEMBL617965,,11765,14331,,,B,,,Autocuration,,,
3123,BAO_0000357,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,D,1,,CHEMBL617966,,10630,13462,,,B,,,Autocuration,,,
3124,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,1,,CHEMBL857074,,17106,12861,,,B,,,Autocuration,,,
3125,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL617967,,144,15086,,,B,,,Autocuration,,,
3126,BAO_0000357,Binding activity radioligand.,,H,1,,CHEMBL617968,,144,12861,,,B,,,Autocuration,,,
3127,BAO_0000223,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,H,1,,CHEMBL617969,,104714,10561,,,B,,,Autocuration,,,
3128,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,H,1,,CHEMBL617970,,104714,10561,,,B,,,Autocuration,,,
3129,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,H,1,,CHEMBL617971,,104714,10561,,,B,,,Autocuration,,,
3130,BAO_0000019,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,H,1,,CHEMBL617972,,104714,10561,,,B,,,Autocuration,,,
3131,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,H,1,,CHEMBL617973,,104714,273,,,F,,,Autocuration,,,
3132,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,H,1,,CHEMBL617974,,104714,273,,,F,,,Autocuration,,,
3133,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,H,1,,CHEMBL617975,,104714,273,,Ileum,F,,,Autocuration,,,
3134,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,H,1,,CHEMBL617976,,104714,273,,,F,,,Autocuration,,,
3135,BAO_0000019,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,H,1,,CHEMBL617977,,104714,273,,,F,,,Autocuration,,,
3136,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,H,1,,CHEMBL617978,,104714,273,,,F,,,Autocuration,,,
3137,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,H,1,,CHEMBL617979,,104714,273,,,F,,,Autocuration,,,
3138,BAO_0000219,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,H,1,CHO,CHEMBL617980,,104714,13047,,,B,,,Autocuration,,449.0,
3139,BAO_0000019,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL617981,,104698,1650,,,B,,,Autocuration,,,
3140,BAO_0000019,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,H,1,,CHEMBL617982,,12020,16288,,,B,,,Autocuration,,,
3141,BAO_0000357,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,H,1,,CHEMBL617983,,12020,16288,,,B,,,Autocuration,,,
3142,BAO_0000019,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,D,1,,CHEMBL617984,,104698,10254,,,B,,,Autocuration,,,
3143,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,H,1,,CHEMBL617985,,104698,14532,,,B,,,Autocuration,,,
3144,BAO_0000218,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",948.0,H,1,,CHEMBL617986,In vivo,104698,13392,,Heart,F,,,Autocuration,,,
3145,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",948.0,H,1,,CHEMBL617987,,104698,13392,,Heart,F,,,Autocuration,,,
3146,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",948.0,H,1,,CHEMBL617988,,104698,13392,,Heart,F,,,Autocuration,,,
3147,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",948.0,H,1,,CHEMBL617792,,104698,13392,,Heart,F,,,Autocuration,,,
3148,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",948.0,H,1,,CHEMBL617793,,104698,13392,,Heart,F,,,Autocuration,,,
3149,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,H,1,,CHEMBL617794,,104698,13392,,,F,,,Autocuration,,,
3150,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,H,1,,CHEMBL617795,,104698,13392,,,F,,,Autocuration,,,
3151,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,H,1,,CHEMBL617796,,104698,13392,,,F,,,Autocuration,,,
3152,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,H,1,,CHEMBL617797,,104698,13392,,,F,,,Autocuration,,,
3153,BAO_0000218,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,D,1,,CHEMBL617798,In vivo,104698,1089,,,F,,,Autocuration,,,
3154,BAO_0000218,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,H,1,,CHEMBL617799,In vivo,104698,1089,,,F,,,Autocuration,,,
3155,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,D,1,,CHEMBL617800,In vivo,104698,11454,,,F,,,Autocuration,,,
3156,BAO_0000019,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,D,1,,CHEMBL617801,,104698,11454,,,F,,,Autocuration,,,
3157,BAO_0000218,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,D,1,,CHEMBL617802,In vivo,104698,12205,,,F,,,Autocuration,,,
3158,BAO_0000019,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,D,1,,CHEMBL617803,,104698,1089,,,F,,,Autocuration,,,
3159,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,,H,1,,CHEMBL617804,,104698,5094,,,B,,,Autocuration,,,
3160,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL617805,,104698,2622,,,B,,,Autocuration,,,
3161,BAO_0000223,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL617806,,104698,245,,,B,,,Autocuration,,,
3162,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,H,1,,CHEMBL617807,,104698,14788,,,B,,,Autocuration,,,
3163,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,H,1,,CHEMBL617808,,104698,14788,,,B,,,Autocuration,,,
3164,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,H,1,,CHEMBL617809,,104698,3020,,,B,,,Autocuration,,,
3165,BAO_0000019,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,H,1,,CHEMBL617810,,104698,1742,,,B,,,Autocuration,,,
3166,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,955.0,H,1,,CHEMBL617811,,104698,17394,,Brain,B,,,Autocuration,,,
3167,BAO_0000221,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,955.0,H,1,,CHEMBL617812,,104698,17394,,Brain,B,,,Autocuration,,,
3168,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,H,1,,CHEMBL617813,,104698,17394,,,B,,,Autocuration,,,
3169,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,H,1,,CHEMBL617814,,104698,14286,,,B,,,Autocuration,,,
3170,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,H,1,,CHEMBL617698,,104698,14178,,,B,,,Autocuration,,,
3171,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,D,1,,CHEMBL617699,,104698,14178,,,B,,,Autocuration,,,
3172,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,D,1,,CHEMBL617700,,104698,14178,,,B,,,Autocuration,,,
3173,BAO_0000223,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL617701,,104698,14178,,,B,,,Autocuration,,,
3174,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,H,1,,CHEMBL617702,,104698,15034,,,B,,,Autocuration,,,
3175,BAO_0000249,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,H,1,,CHEMBL617703,,104698,1089,Membranes,,B,,,Autocuration,,,
3176,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,D,1,,CHEMBL617704,,104698,1089,,,B,,,Autocuration,,,
3177,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,H,1,,CHEMBL617705,,104698,16532,,,B,,,Autocuration,,,
3178,BAO_0000223,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL617706,,104698,12801,,,B,,,Autocuration,,,
3179,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,H,1,NG108-15,CHEMBL617707,,104698,15194,,,B,,,Autocuration,,433.0,
3180,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,H,1,NG108-15,CHEMBL617708,,104698,15194,,,B,,,Autocuration,,433.0,
3181,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,H,1,,CHEMBL617709,,104698,15194,,,B,,,Autocuration,,,
3182,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,H,1,,CHEMBL617710,,104698,15194,,,B,,,Autocuration,,,
3183,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,H,1,,CHEMBL882925,,104698,15194,,,B,,,Autocuration,,,
3184,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,H,1,,CHEMBL617711,,104698,15194,,,B,,,Autocuration,,,
3185,BAO_0000019,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,H,1,,CHEMBL617712,,104698,10610,,,F,,,Autocuration,,,
3186,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,D,1,,CHEMBL617713,,104698,10355,,,F,,,Autocuration,,,
3187,BAO_0000019,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,H,1,,CHEMBL617714,,104698,691,,,F,,,Autocuration,,,
3188,BAO_0000218,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,H,1,,CHEMBL617715,,104698,10611,,,F,,,Autocuration,,,
3189,BAO_0000218,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,H,1,,CHEMBL617716,In vivo,104698,12801,,,F,,,Autocuration,,,
3190,BAO_0000218,Inhibition of 5-HT evoked reflex bradycardia in rat.,,H,1,,CHEMBL617717,,104698,10609,,,F,,,Autocuration,,,
3191,BAO_0000218,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617718,In vivo,104698,11454,,,F,,,Autocuration,,,
3192,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617719,In vivo,104698,11454,,,F,,,Autocuration,,,
3193,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,H,1,,CHEMBL617720,In vivo,104698,11454,,,F,,,Autocuration,,,
3194,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,D,1,,CHEMBL617721,In vivo,104698,11454,,,F,,,Autocuration,,,
3195,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617722,In vivo,104698,11454,,,F,,,Autocuration,,,
3196,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,H,1,,CHEMBL617723,In vivo,104698,11454,,,F,,,Autocuration,,,
3197,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617724,In vivo,104698,11454,,,F,,,Autocuration,,,
3198,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617725,In vivo,104698,11454,,,F,,,Autocuration,,,
3199,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617726,In vivo,104698,11454,,,F,,,Autocuration,,,
3200,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617727,In vivo,104698,11454,,,F,,,Autocuration,,,
3201,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617728,In vivo,104698,11454,,,F,,,Autocuration,,,
3202,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617729,In vivo,104698,11454,,,F,,,Autocuration,,,
3203,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617730,In vivo,104698,11454,,,F,,,Autocuration,,,
3204,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617731,In vivo,104698,11454,,,F,,,Autocuration,,,
3205,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617732,In vivo,104698,11454,,,F,,,Autocuration,,,
3206,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617733,In vivo,104698,11454,,,F,,,Autocuration,,,
3207,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617734,In vivo,104698,11454,,,F,,,Autocuration,,,
3208,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,H,1,,CHEMBL872874,In vivo,104698,11454,,,F,,,Autocuration,,,
3209,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,H,1,,CHEMBL617735,In vivo,104698,11454,,,F,,,Autocuration,,,
3210,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,H,1,,CHEMBL617736,In vivo,104698,11454,,,F,,,Autocuration,,,
3211,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,H,1,,CHEMBL617737,In vivo,104698,11454,,,F,,,Autocuration,,,
3212,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,H,1,,CHEMBL617738,In vivo,104698,11454,,,F,,,Autocuration,,,
3213,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617739,In vivo,104698,11454,,,F,,,Autocuration,,,
3214,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617740,In vivo,104698,11454,,,F,,,Autocuration,,,
3215,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617741,In vivo,104698,11454,,,F,,,Autocuration,,,
3216,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617742,In vivo,104698,11454,,,F,,,Autocuration,,,
3217,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617743,In vivo,104698,11454,,,F,,,Autocuration,,,
3218,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617744,In vivo,104698,11454,,,F,,,Autocuration,,,
3219,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,H,1,,CHEMBL617745,In vivo,104698,11454,,,F,,,Autocuration,,,
3220,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,H,1,,CHEMBL617746,,104698,670,,,F,,,Autocuration,,,
3221,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,H,1,,CHEMBL617747,,104698,670,,,F,,,Autocuration,,,
3222,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,H,1,,CHEMBL617748,In vivo,104698,10321,,,F,,,Autocuration,,,
3223,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,H,1,,CHEMBL618909,In vivo,104698,10321,,,F,,,Autocuration,,,
3224,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,H,1,,CHEMBL618910,In vivo,104698,10321,,,F,,,Autocuration,,,
3225,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,H,1,,CHEMBL618911,In vivo,104698,10321,,,F,,,Autocuration,,,
3226,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,H,1,,CHEMBL618912,In vivo,104698,10321,,,F,,,Autocuration,,,
3227,BAO_0000218,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,H,1,,CHEMBL618913,In vivo,104698,10322,,,F,,,Autocuration,,,
3228,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,H,1,,CHEMBL618914,,104698,15412,,,F,,,Autocuration,,,
3229,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,H,1,,CHEMBL618915,,104698,15412,,,F,,,Autocuration,,,
3230,BAO_0000223,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL618916,,104698,15412,,,B,,,Autocuration,,,
3231,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,H,1,,CHEMBL618917,,104698,15412,,,F,,,Autocuration,,,
3232,BAO_0000221,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,10000000.0,D,1,,CHEMBL618918,,104698,15412,,Hippocampus,B,,,Intermediate,,,
3233,BAO_0000019,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,D,1,,CHEMBL618919,,104698,15412,,,B,,,Autocuration,,,
3234,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL618920,,104698,17394,,,B,,,Autocuration,,,
3235,BAO_0000223,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618921,,104698,12457,,,B,,,Autocuration,,,
3236,BAO_0000019,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618922,,104698,12457,,,B,,,Autocuration,,,
3237,BAO_0000019,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,H,1,,CHEMBL618923,,104698,12205,,,B,,,Autocuration,,,
3238,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,H,1,,CHEMBL618924,,104698,14532,,,B,,,Autocuration,,,
3239,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,H,1,,CHEMBL618925,,104698,1122,,,B,,,Autocuration,,,
3240,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,,H,1,,CHEMBL618926,,104698,5094,,,B,,,Autocuration,,,
3241,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,2116.0,D,1,,CHEMBL618927,,20033,809,,Ileum,F,,,Intermediate,,,
3242,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,2116.0,D,1,,CHEMBL618928,,20033,809,,Ileum,F,,,Intermediate,,,
3243,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",2116.0,D,1,,CHEMBL618929,,20033,14290,,Ileum,F,,,Intermediate,,,
3244,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",2116.0,D,1,,CHEMBL618930,,20033,14290,,Ileum,F,,,Intermediate,,,
3245,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",2116.0,D,1,,CHEMBL618931,,20033,14290,,Ileum,F,,,Intermediate,,,
3246,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",2116.0,D,1,,CHEMBL619594,,20033,14290,,Ileum,F,,,Intermediate,,,
3247,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",2116.0,D,1,,CHEMBL619595,,20033,14290,,Ileum,F,,,Intermediate,,,
3248,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,2116.0,D,1,,CHEMBL619596,,20033,13961,,Ileum,F,,,Intermediate,,,
3249,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,2116.0,D,1,,CHEMBL619755,,20033,13961,,Ileum,F,,,Intermediate,,,
3250,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,2116.0,D,1,,CHEMBL619756,,20033,809,,Ileum,F,,,Intermediate,,,
3251,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,2116.0,D,1,,CHEMBL619757,,20033,809,,Ileum,F,,,Intermediate,,,
3252,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,2116.0,D,1,,CHEMBL619758,,20033,809,,Ileum,F,,,Intermediate,,,
3253,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",2116.0,D,1,,CHEMBL619759,,20033,14290,,Ileum,F,,,Intermediate,,,
3254,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",2116.0,D,1,,CHEMBL619760,,20033,14290,,Ileum,F,,,Intermediate,,,
3255,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",2116.0,D,1,,CHEMBL619761,,20033,14290,,Ileum,F,,,Intermediate,,,
3256,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,2116.0,D,1,,CHEMBL619762,,20033,14290,,Ileum,F,,,Intermediate,,,
3257,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",2116.0,D,1,,CHEMBL619763,,20033,14290,,Ileum,F,,,Intermediate,,,
3258,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",2116.0,D,1,,CHEMBL617868,,20033,14290,,Ileum,F,,,Intermediate,,,
3259,BAO_0000357,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,D,1,,CHEMBL617869,,20033,15034,,,B,,,Intermediate,,,
3260,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,D,1,,CHEMBL882926,,20033,5094,,Striatum,B,,,Intermediate,,,
3261,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,D,1,,CHEMBL617870,,20033,5094,,Striatum,B,,,Intermediate,,,
3262,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,2435.0,D,1,,CHEMBL617871,,20033,5399,,Striatum,B,,,Intermediate,,,
3263,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,2435.0,D,1,,CHEMBL617872,,20033,17394,,Striatum,B,,,Intermediate,,,
3264,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,2435.0,D,1,,CHEMBL617873,,20033,17394,,Striatum,B,,,Intermediate,,,
3265,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,2435.0,D,1,,CHEMBL617874,,20033,17394,,Striatum,B,,,Intermediate,,,
3266,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,2116.0,D,1,,CHEMBL619067,,20033,13961,,Ileum,F,,,Intermediate,,,
3267,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,2116.0,D,1,,CHEMBL619068,,20033,13961,,Ileum,F,,,Intermediate,,,
3268,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,2116.0,D,1,,CHEMBL619069,,20033,13961,,Ileum,F,,,Intermediate,,,
3269,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,D,1,,CHEMBL619070,,20033,16946,,,B,,,Intermediate,,,
3270,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,D,1,,CHEMBL619071,,20033,16946,,,B,,,Intermediate,,,
3271,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619072,,20033,15034,,,F,,,Intermediate,,,
3272,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,D,1,,CHEMBL619073,,20033,15034,,,F,,,Intermediate,,,
3273,BAO_0000019,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619074,,20033,12918,,,F,,,Intermediate,,,
3274,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619075,,20033,16946,,,B,,,Intermediate,,,
3275,BAO_0000357,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,2435.0,D,1,,CHEMBL619076,,20033,17394,,Striatum,B,,,Intermediate,,,
3276,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,2435.0,D,1,,CHEMBL619077,,20033,15034,,Striatum,B,,,Intermediate,,,
3277,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,D,1,,CHEMBL619078,,20033,5094,,Striatum,B,,,Intermediate,,,
3278,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,D,1,,CHEMBL619079,,20033,5094,,Striatum,B,,,Intermediate,,,
3279,BAO_0000221,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,2116.0,D,1,,CHEMBL619080,,20033,17358,,Ileum,B,,,Intermediate,,,
3280,BAO_0000357,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,D,1,,CHEMBL619081,,20033,12953,,,B,,,Expert,,,
3281,BAO_0000357,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,D,1,,CHEMBL619082,,20033,12953,,,B,,,Intermediate,,,
3282,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,D,1,,CHEMBL619083,,20033,12953,,,B,,,Intermediate,,,
3283,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,D,1,,CHEMBL619084,,20033,12953,,,B,,,Intermediate,,,
3284,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,D,1,,CHEMBL859397,,20033,273,,Ileum,F,,,Intermediate,,,
3285,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,2116.0,D,1,,CHEMBL619085,,20033,12918,,Ileum,F,,,Intermediate,,,
3286,BAO_0000221,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,2116.0,D,1,,CHEMBL619086,,20033,12919,,Ileum,F,,,Intermediate,,,
3287,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,2116.0,D,1,,CHEMBL619087,,20033,273,,Ileum,F,,,Intermediate,,,
3288,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,D,1,,CHEMBL619088,,20033,273,,Ileum,F,,,Intermediate,,,
3289,BAO_0000357,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,D,1,,CHEMBL619089,,20033,13181,,,B,,,Intermediate,,,
3290,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL619090,,168,13181,,,B,,,Autocuration,,,
3291,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619091,,20033,15034,,,F,,,Intermediate,,,
3292,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619092,,20033,5033,,,B,,,Intermediate,,,
3293,BAO_0000019,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,D,1,,CHEMBL619093,,20033,1980,,,B,,,Intermediate,,,
3294,BAO_0000219,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,H,1,HEK293,CHEMBL619094,,168,13181,,,B,,,Autocuration,,722.0,
3295,BAO_0000019,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,D,1,,CHEMBL619095,,20033,14287,,,B,,,Intermediate,,,
3296,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,D,1,,CHEMBL857988,,20033,1317,,,B,,,Intermediate,,,
3297,BAO_0000357,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,D,1,,CHEMBL619096,,20033,15316,,,B,,,Intermediate,,,
3298,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,2435.0,D,1,,CHEMBL619097,,20033,16429,,Striatum,B,,,Intermediate,,,
3299,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,10000000.0,D,1,,CHEMBL619098,,20033,14818,,Hippocampus,B,,,Intermediate,,,
3300,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,D,1,,CHEMBL619751,,20033,15194,,,B,,,Intermediate,,,
3301,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,D,1,,CHEMBL619752,,20033,15194,,,B,,,Intermediate,,,
3302,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,2116.0,D,1,,CHEMBL875096,,20033,13961,,Ileum,F,,,Intermediate,,,
3303,BAO_0000357,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,H,1,,CHEMBL619004,,108,5486,,,B,,,Autocuration,,,
3304,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL619005,,168,16209,,,B,,,Autocuration,,,
3305,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL619006,,168,17085,,,B,,,Autocuration,,,
3306,BAO_0000219,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,H,1,HeLa,CHEMBL619007,,168,4199,,,B,,,Autocuration,,308.0,
3307,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL619008,,168,15146,,,B,,,Autocuration,,,
3308,BAO_0000357,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL619009,,168,5213,,,B,,,Autocuration,,,
3309,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,H,1,HeLa,CHEMBL619010,,168,4829,,,B,,,Autocuration,,308.0,
3310,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,H,1,,CHEMBL619011,,10622,17358,,,B,,,Autocuration,,,
3311,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,H,1,,CHEMBL619012,,10622,17358,,,B,,,Autocuration,,,
3312,BAO_0000219,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,H,1,,CHEMBL619013,,10622,16946,,,B,,,Autocuration,,,
3313,BAO_0000357,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,H,1,,CHEMBL619014,,10622,17358,,,B,,,Autocuration,,,
3314,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,2081.0,H,1,,CHEMBL857503,,11249,268,,Cardiac atrium,F,,,Autocuration,,,
3315,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,2081.0,H,1,,CHEMBL619015,,11249,268,,Cardiac atrium,F,,,Autocuration,,,
3316,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL619016,,11249,15086,,,B,,,Autocuration,,,
3317,BAO_0000221,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,10000000.0,H,1,,CHEMBL619017,,11249,14875,,Hippocampus,B,,,Autocuration,,,
3318,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,10000000.0,H,1,,CHEMBL619018,,168,13267,,Hippocampus,B,,,Autocuration,,,
3319,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,H,1,,CHEMBL619019,,168,13047,,,B,,,Autocuration,,,
3320,BAO_0000357,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619020,,10623,1650,,,B,,,Expert,,,
3321,BAO_0000019,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,H,1,,CHEMBL619021,,10623,567,,,F,,,Autocuration,,,
3322,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,H,1,,CHEMBL619022,,10623,17358,,,B,,,Autocuration,,,
3323,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,H,1,,CHEMBL619023,,10623,188,,,B,,,Autocuration,,,
3324,BAO_0000019,lntrinsic activity relative to 5-HT receptor,,H,1,,CHEMBL619024,,10623,670,,,F,,,Autocuration,,,
3325,BAO_0000019,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,H,1,,CHEMBL619025,,10623,204,,,F,,,Autocuration,,,
3326,BAO_0000019,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,H,1,,CHEMBL619026,,10623,1946,,,F,,,Expert,,,
3327,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,H,1,,CHEMBL619027,,10623,6398,,,F,,,Autocuration,,,
3328,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,H,1,,CHEMBL619028,,10623,6398,,,F,,,Autocuration,,,
3329,BAO_0000019,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,H,1,,CHEMBL619029,,10623,17358,,,F,,,Autocuration,,,
3330,BAO_0000019,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,H,1,,CHEMBL619030,,10623,6398,,,F,,,Autocuration,,,
3331,BAO_0000357,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,H,1,,CHEMBL619031,,10623,11752,,,B,,,Expert,,,
3332,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,H,1,,CHEMBL619032,,10623,809,,,F,,,Autocuration,,,
3333,BAO_0000357,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL619033,,10623,14178,,,B,,,Expert,,,
3334,BAO_0000357,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,H,1,,CHEMBL619034,,10623,567,,,B,,,Autocuration,,,
3335,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,H,1,,CHEMBL619035,,10623,1946,,,B,,,Autocuration,,,
3336,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,H,1,,CHEMBL619036,,10623,1946,,,B,,,Autocuration,,,
3337,BAO_0000019,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,D,1,,CHEMBL619037,,10623,13961,,,B,,,Expert,,,
3338,BAO_0000249,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,2435.0,H,1,,CHEMBL619038,,10623,6238,,Striatum,B,,,Autocuration,,,
3339,BAO_0000249,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,H,1,,CHEMBL619039,,10623,14290,,,B,,,Autocuration,,,
3340,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,H,1,,CHEMBL619040,,10623,14290,,,B,,,Expert,,,
3341,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,2435.0,D,1,,CHEMBL619041,,10623,809,,Striatum,B,,,Expert,,,
3342,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,2435.0,H,1,,CHEMBL619042,,10623,1578,,Striatum,B,,,Autocuration,,,
3343,BAO_0000249,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,2435.0,H,1,,CHEMBL619043,,10623,16709,,Striatum,B,,,Expert,,,
3344,BAO_0000019,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,2435.0,H,1,,CHEMBL619044,,10623,1946,,Striatum,B,,,Expert,,,
3345,BAO_0000249,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,2435.0,H,1,,CHEMBL619045,,10623,15253,,Striatum,B,,,Expert,,,
3346,BAO_0000249,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,2435.0,H,1,,CHEMBL619046,,10623,4535,,Striatum,B,,,Expert,,,
3347,BAO_0000249,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,H,1,,CHEMBL619047,,10623,13961,,,B,,,Expert,,,
3348,BAO_0000221,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,955.0,H,1,,CHEMBL619048,,10623,17358,,Brain,F,,,Autocuration,,,
3349,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,H,1,,CHEMBL859398,,10623,15847,,,F,,,Autocuration,,,
3350,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,H,1,,CHEMBL619049,,10623,15847,,,F,,,Autocuration,,,
3351,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,H,1,,CHEMBL857886,,10623,670,,,F,,,Autocuration,,,
3352,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,H,1,,CHEMBL619050,,10623,670,,,F,,,Autocuration,,,
3353,BAO_0000019,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,H,1,,CHEMBL620591,,10623,1317,,,F,,,Autocuration,,,
3354,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,D,1,,CHEMBL620592,,10623,12936,,,B,,,Expert,,,
3355,BAO_0000249,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,2435.0,H,1,,CHEMBL620593,,10623,4535,,Striatum,B,,,Expert,,,
3356,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,D,1,,CHEMBL620594,,10623,14424,,,F,,,Expert,,,
3357,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,H,1,,CHEMBL875079,,10623,14424,,,F,,,Expert,,,
3358,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,H,1,,CHEMBL620595,,10623,14424,,,F,,,Expert,,,
3359,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,D,1,,CHEMBL620596,,10623,14424,,,F,,,Expert,,,
3360,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,H,1,,CHEMBL620597,,10623,14424,,,F,,,Autocuration,,,
3361,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,H,1,,CHEMBL620598,,10623,14424,,,F,,,Expert,,,
3362,BAO_0000218,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,H,1,,CHEMBL620599,,10623,14424,,,F,,,Expert,,,
3363,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,H,1,,CHEMBL620600,,10623,14424,,,F,,,Autocuration,,,
3364,BAO_0000019,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,H,1,,CHEMBL620601,,168,1980,,,F,,,Autocuration,,,
3365,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,H,1,,CHEMBL620602,,168,4639,,,F,,,Autocuration,,,
3366,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620603,,168,17358,,,B,,,Autocuration,,,
3367,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,H,1,,CHEMBL620604,,168,17358,,,B,,,Autocuration,,,
3368,BAO_0000357,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,H,1,,CHEMBL620605,,168,17358,,,B,,,Autocuration,,,
3369,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620606,,168,1558,,,B,,,Autocuration,,,
3370,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,H,1,,CHEMBL620607,,168,17358,,,F,,,Autocuration,,,
3371,BAO_0000357,In vitro binding affinity towards 5-HT4 receptor was determined,,H,1,,CHEMBL620608,,168,16117,,,B,,,Autocuration,,,
3372,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,H,1,,CHEMBL620609,,168,17358,,,F,,,Autocuration,,,
3373,BAO_0000019,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620610,,168,17358,,,F,,,Autocuration,,,
3374,BAO_0000357,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620611,,168,17358,,,B,,,Autocuration,,,
3375,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,H,1,,CHEMBL620612,,168,17358,,,B,,,Autocuration,,,
3376,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,H,1,,CHEMBL620613,,168,17358,,,B,,,Autocuration,,,
3377,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,H,1,,CHEMBL620614,,168,17358,,,B,,,Autocuration,,,
3378,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 4 receptor,,H,1,,CHEMBL620615,,168,1274,,,B,,,Expert,,,
3379,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,H,1,,CHEMBL857075,,104698,10728,Brain membranes,,B,,,Autocuration,,,
3380,BAO_0000249,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,H,1,,CHEMBL620616,,104698,11695,Brain membranes,,B,,,Autocuration,,,
3381,BAO_0000249,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,H,1,,CHEMBL619411,,104698,11695,Brain membranes,,B,,,Autocuration,,,
3382,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,H,1,,CHEMBL619412,,104698,12490,,,B,,,Autocuration,,,
3383,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL619413,,104698,11828,,,B,,,Autocuration,,,
3384,BAO_0000221,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,10000000.0,H,1,,CHEMBL619414,,104698,12253,,Hippocampus,B,,,Autocuration,,,
3385,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,H,1,,CHEMBL619415,,104698,10561,,,B,,,Autocuration,,,
3386,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,H,1,,CHEMBL619416,,104698,10561,,,B,,,Autocuration,,,
3387,BAO_0000019,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,H,1,,CHEMBL619417,,104698,14432,,,F,,,Autocuration,,,
3388,BAO_0000223,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL619418,,104698,12936,,,B,,,Autocuration,,,
3389,BAO_0000223,Binding affinity against 5-Hydroxytryptamine 3 receptor,,D,1,,CHEMBL619419,,104698,1274,,,B,,,Autocuration,,,
3390,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,H,1,,CHEMBL619420,,104698,1980,,,B,,,Autocuration,,,
3391,BAO_0000249,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,H,1,,CHEMBL619421,,104698,670,,,B,,,Autocuration,,,
3392,BAO_0000019,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,D,1,,CHEMBL619422,,104698,968,,,B,,,Autocuration,,,
3393,BAO_0000019,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,H,1,,CHEMBL619423,,104698,14287,,,B,,,Autocuration,,,
3394,BAO_0000019,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,H,1,,CHEMBL875080,,104698,567,,,B,,,Autocuration,,,
3395,BAO_0000019,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,H,1,,CHEMBL619424,,104698,13267,,,B,,,Autocuration,,,
3396,BAO_0000249,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,H,1,,CHEMBL619425,,104698,14826,,,B,,,Autocuration,,,
3397,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,H,1,,CHEMBL619426,,104698,15194,,,B,,,Autocuration,,,
3398,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,H,1,,CHEMBL619427,,104698,15194,,,B,,,Autocuration,,,
3399,BAO_0000223,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,D,1,,CHEMBL619645,,104698,10394,,,B,,,Autocuration,,,
3400,BAO_0000249,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,D,1,,CHEMBL619646,,10576,13657,,,B,,,Expert,,,
3401,BAO_0000221,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,955.0,H,1,,CHEMBL619647,,12020,1879,,Brain,F,,,Autocuration,,,
3402,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL619648,,12020,1879,,,F,,,Autocuration,,,
3403,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,H,1,,CHEMBL619165,,12020,1879,,,F,,,Autocuration,,,
3404,BAO_0000218,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620719,In vivo,12020,204,,,F,,,Autocuration,,,
3405,BAO_0000019,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,H,1,,CHEMBL872924,,12020,1879,,,B,,,Autocuration,,,
3406,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620720,,12020,1879,,,B,,,Autocuration,,,
3407,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,H,1,,CHEMBL620721,,12020,1879,,,B,,,Autocuration,,,
3408,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,H,1,,CHEMBL620722,,12020,1879,,,B,,,Autocuration,,,
3409,BAO_0000019,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,H,1,,CHEMBL620723,,104698,10641,,,B,,,Autocuration,,,
3410,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,H,1,,CHEMBL620724,,12020,773,,,B,,,Autocuration,,,
3411,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,H,1,,CHEMBL620725,,104698,11952,,,B,,,Autocuration,,,
3412,BAO_0000019,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,D,1,,CHEMBL620726,,12020,14145,,,F,,,Autocuration,,,
3413,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620727,,144,17066,,,B,,,Expert,,,
3414,BAO_0000223,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,H,1,,CHEMBL620728,,104714,6398,,,B,,,Autocuration,,,
3415,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,U,1,,CHEMBL620729,,22226,10321,,,B,,,Autocuration,,,
3416,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,H,1,,CHEMBL858288,,104714,511,,,F,,,Autocuration,,,
3417,BAO_0000223,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620730,,104714,4639,,,B,,,Autocuration,,,
3418,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL620731,,104714,4639,,,B,,,Autocuration,,,
3419,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,H,1,,CHEMBL620732,,104714,4639,,,F,,,Autocuration,,,
3420,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,H,1,,CHEMBL618042,,104714,4639,,,F,,,Autocuration,,,
3421,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,H,1,,CHEMBL618043,,104714,4639,,,F,,,Autocuration,,,
3422,BAO_0000223,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618044,,104714,1558,,,B,,,Autocuration,,,
3423,BAO_0000019,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,H,1,,CHEMBL618045,,104714,268,,,F,,,Autocuration,,,
3424,BAO_0000223,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,H,1,,CHEMBL618046,,104714,2474,,,B,,,Autocuration,,,
3425,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,H,1,,CHEMBL618047,,104714,5067,,,F,,,Autocuration,,,
3426,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,H,1,,CHEMBL875084,,104714,5067,,,F,,,Autocuration,,,
3427,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,H,1,,CHEMBL618048,,104714,5067,,,F,,,Autocuration,,,
3428,BAO_0000223,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,H,1,,CHEMBL618049,,104714,5067,,,B,,,Autocuration,,,
3429,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,H,1,,CHEMBL619764,,104714,5067,,,F,,,Autocuration,,,
3430,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,H,1,,CHEMBL619765,,104714,5067,,,F,,,Autocuration,,,
3431,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,H,1,,CHEMBL619766,,104714,5067,,,F,,,Autocuration,,,
3432,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,H,1,,CHEMBL619767,,104714,5067,,,B,,,Autocuration,,,
3433,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,H,1,,CHEMBL619768,,104714,5067,,,B,,,Autocuration,,,
3434,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,H,1,,CHEMBL619769,,104714,5067,,,F,,,Autocuration,,,
3435,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,H,1,,CHEMBL619770,,104714,5067,,,B,,,Autocuration,,,
3436,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL619771,,104714,5067,,,B,,,Autocuration,,,
3437,BAO_0000219,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,H,1,,CHEMBL619772,,104714,14331,,,B,,,Autocuration,,,
3438,BAO_0000223,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,H,1,,CHEMBL619773,,104714,5067,,,B,,,Autocuration,,,
3439,BAO_0000219,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,H,1,NG108-15,CHEMBL619774,,104714,6179,,,B,,,Autocuration,,433.0,
3440,BAO_0000019,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,H,1,,CHEMBL875083,,104714,4265,,,B,,,Autocuration,,,
3441,BAO_0000219,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,H,1,NG108-15,CHEMBL620718,,104714,4265,,,B,,,Autocuration,,433.0,
3442,BAO_0000223,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,H,1,,CHEMBL618127,,104714,17358,,,B,,,Autocuration,,,
3443,BAO_0000223,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,H,1,,CHEMBL618128,,104714,17358,,,B,,,Autocuration,,,
3444,BAO_0000219,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,H,1,,CHEMBL618129,In vitro,104714,13628,,,B,,,Autocuration,,,
3445,BAO_0000223,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,H,1,,CHEMBL618130,,104714,4612,,,B,,,Autocuration,,,
3446,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,H,1,,CHEMBL618131,,104714,17358,,,F,,,Autocuration,,,
3447,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,H,1,,CHEMBL618132,,104714,4639,,,F,,,Autocuration,,,
3448,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,H,1,,CHEMBL618133,,104714,4639,,,F,,,Autocuration,,,
3449,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,H,1,,CHEMBL618134,,104714,4639,,,F,,,Autocuration,,,
3450,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,H,1,,CHEMBL618135,,104714,4639,,,F,,,Autocuration,,,
3451,BAO_0000223,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,H,1,,CHEMBL618136,,104714,511,,,B,,,Autocuration,,,
3452,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618137,,104714,1479,,,B,,,Autocuration,,,
3453,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,H,1,,CHEMBL618138,,104714,1317,,,B,,,Autocuration,,,
3454,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,H,1,,CHEMBL618139,,104714,12146,,,B,,,Autocuration,,,
3455,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,H,1,,CHEMBL618140,,104714,12146,,,B,,,Autocuration,,,
3456,BAO_0000223,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,H,1,,CHEMBL618141,,104714,13969,,,B,,,Autocuration,,,
3457,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,H,1,,CHEMBL873478,,108,13392,,,B,,,Expert,,,
3458,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618142,,104698,13392,,,B,,,Autocuration,,,
3459,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618143,,144,14159,,,B,,,Autocuration,,,
3460,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618144,,144,1558,,,B,,,Autocuration,,,
3461,BAO_0000357,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618145,,144,16655,,,B,,,Autocuration,,,
3462,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,H,1,,CHEMBL618146,,104714,13020,,,B,,,Autocuration,,,
3463,BAO_0000223,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,H,1,,CHEMBL618147,,104714,13021,,,B,,,Autocuration,,,
3464,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,H,1,,CHEMBL618148,,104714,13020,,,B,,,Autocuration,,,
3465,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,H,1,,CHEMBL618149,,144,10321,,,B,,,Autocuration,,,
3466,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL872927,,144,15818,,,B,,,Autocuration,,,
3467,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL618150,,144,15818,,,B,,,Autocuration,,,
3468,BAO_0000357,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,H,1,,CHEMBL618151,,144,17358,,,B,,,Autocuration,,,
3469,BAO_0000357,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL875094,,144,2222,,,B,,,Autocuration,,,
3470,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,H,1,,CHEMBL618152,,144,10322,,,B,,,Autocuration,,,
3471,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,H,1,,CHEMBL618153,,144,16117,,,B,,,Autocuration,,,
3472,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,H,1,,CHEMBL618888,,144,17200,,,B,,,Autocuration,,,
3473,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,H,1,,CHEMBL618889,,144,17358,,,F,,,Autocuration,,,
3474,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,H,1,,CHEMBL618890,,144,16700,,,B,,,Autocuration,,,
3475,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,H,1,,CHEMBL618891,,144,1980,,,B,,,Autocuration,,,
3476,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,H,1,,CHEMBL619054,,144,1980,,,B,,,Autocuration,,,
3477,BAO_0000223,Binding affinity against the 5-hydroxytryptamine 3 receptor,,H,1,,CHEMBL619055,,104714,12409,,,B,,,Autocuration,,,
3478,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,,H,1,,CHEMBL619056,,144,4365,,,B,,,Autocuration,,,
3479,BAO_0000019,Percent efficacy against 5-hydroxytryptamine 3A receptor,,H,1,,CHEMBL619057,,144,4365,,,F,,,Autocuration,,,
3480,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,,H,1,,CHEMBL619058,,144,4365,,,B,,,Autocuration,,,
3481,BAO_0000219,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,D,1,Oocytes,CHEMBL619059,,12020,6769,,,F,,,Expert,,,
3482,BAO_0000219,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,D,1,Oocytes,CHEMBL619060,,12020,6769,,,F,,,Expert,,,
3483,BAO_0000219,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,D,1,Oocytes,CHEMBL875095,,12020,6769,,,F,,,Expert,,,
3484,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,2116.0,D,1,,CHEMBL619061,,20033,809,,Ileum,F,,,Intermediate,,,
3485,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,2116.0,D,1,,CHEMBL619062,,20033,809,,Ileum,F,,,Intermediate,,,
3486,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,D,1,,CHEMBL619063,,20033,14290,,,F,,,Intermediate,,,
3487,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,2116.0,D,1,,CHEMBL619064,,20033,17358,,Ileum,B,,,Intermediate,,,
3488,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,D,1,,CHEMBL619065,,20033,17358,,,B,,,Intermediate,,,
3489,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,2116.0,D,1,,CHEMBL619066,,20033,17358,,Ileum,B,,,Intermediate,,,
3490,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,2116.0,H,1,,CHEMBL619775,,10209,17386,,Ileum,B,,,Autocuration,,,
3491,BAO_0000357,Affinity against 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619776,,10209,3269,,,B,,,Autocuration,,,
3492,BAO_0000224,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,H,1,,CHEMBL619777,,104841,7721,,,B,,,Autocuration,,,
3493,BAO_0000224,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,H,1,,CHEMBL619778,,104841,7721,,,B,,,Autocuration,,,
3494,BAO_0000221,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,2116.0,H,1,,CHEMBL619779,,104841,9117,,Ileum,B,,,Autocuration,,,
3495,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,H,1,,CHEMBL619780,,104841,7721,,,B,,,Autocuration,,,
3496,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,H,1,,CHEMBL619166,,104841,7721,,,B,,,Autocuration,,,
3497,BAO_0000019,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,H,1,,CHEMBL619167,,104841,15796,,,F,,,Autocuration,,,
3498,BAO_0000019,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,H,1,,CHEMBL619168,,104841,15796,,,F,,,Autocuration,,,
3499,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,2081.0,D,1,,CHEMBL619169,,168,15650,,Cardiac atrium,B,,,Expert,,,
3500,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,2081.0,D,1,,CHEMBL619170,,168,15650,,Cardiac atrium,B,,,Expert,,,
3501,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,D,1,,CHEMBL619171,,104841,6866,,,F,,,Autocuration,,,
3502,BAO_0000219,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",2081.0,D,1,,CHEMBL619172,,168,15650,,Cardiac atrium,F,,,Expert,,,
3503,BAO_0000019,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,U,1,,CHEMBL619173,,22226,10063,,,B,,,Autocuration,,,
3504,BAO_0000019,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,U,1,,CHEMBL619174,,22226,12665,,,B,,,Autocuration,,,
3505,BAO_0000019,5-hydroxytryptamine receptor binding affinity was determined in rats,,H,1,,CHEMBL619175,,104705,7504,,,B,,,Autocuration,,,
3506,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine receptor.,,H,1,,CHEMBL619176,,104705,7504,,,B,,,Autocuration,,,
3507,BAO_0000019,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,H,1,,CHEMBL619177,,104705,7038,,,B,,,Autocuration,,,
3508,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,H,1,,CHEMBL619178,,104705,7626,,,B,,,Autocuration,,,
3509,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,H,1,,CHEMBL619179,,104705,7626,,,B,,,Autocuration,,,
3510,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,945.0,H,1,,CHEMBL619180,,104705,7185,,Stomach,F,,,Autocuration,,,
3511,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,945.0,H,1,,CHEMBL619181,,104705,7185,,Stomach,F,,,Autocuration,,,
3512,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,H,1,,CHEMBL619182,,104705,7185,,,F,,,Autocuration,,,
3513,BAO_0000224,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,H,1,,CHEMBL619183,,104705,6960,,,B,,,Autocuration,,,
3514,BAO_0000224,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,H,1,,CHEMBL619184,,104705,6960,,,B,,,Autocuration,,,
3515,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10000000.0,H,1,,CHEMBL619185,,10576,12416,,Hippocampus,B,,,Autocuration,,,
3516,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine transporter.,,H,1,,CHEMBL619186,,12198,15753,,,B,,,Expert,,,
3517,BAO_0000019,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,H,1,,CHEMBL619187,,104705,8062,,,B,,,Autocuration,,,
3518,BAO_0000019,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,D,1,,CHEMBL619188,,104705,9036,,,B,,,Autocuration,,,
3519,BAO_0000224,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,D,1,,CHEMBL619189,,104705,15067,,,B,,,Autocuration,,,
3520,BAO_0000019,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,955.0,D,1,,CHEMBL619190,,12198,15753,,Brain,F,,,Expert,,,
3521,BAO_0000221,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,2037.0,D,1,,CHEMBL619191,,12198,15753,,Cerebellum,F,,,Expert,,,
3522,BAO_0000019,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,D,1,,CHEMBL619192,,104705,15295,,,B,,,Autocuration,,,
3523,BAO_0000224,Percent binding affinity against 5-hydroxytryptamine receptor,,D,1,,CHEMBL619193,,104705,6347,,,B,,,Autocuration,,,
3524,BAO_0000019,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,U,1,,CHEMBL619194,,22226,6763,,,B,,,Autocuration,,,
3525,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,D,1,,CHEMBL619195,,104705,12092,,,B,,,Autocuration,,,
3526,BAO_0000224,Affinity against 5-hydroxytryptamine receptor was determined,,D,1,,CHEMBL619196,,104705,1579,,,B,,,Autocuration,,,
3527,BAO_0000019,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,945.0,D,1,,CHEMBL619197,,104705,1579,,Stomach,B,,,Autocuration,,,
3528,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,D,1,,CHEMBL619198,In vitro,121,5963,,,B,,,Expert,,,
3529,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,D,1,,CHEMBL875081,In vitro,121,5963,,,B,,,Expert,,,
3530,BAO_0000357,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,H,1,,CHEMBL884712,,18065,5030,,,B,,,Autocuration,,,
3531,BAO_0000357,Inhibition of 5-hydroxytryptamine reuptake,,H,1,,CHEMBL884710,,121,15796,,,B,,,Expert,,,
3532,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,H,1,,CHEMBL619199,,18065,15413,,,F,,,Autocuration,,,
3533,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,H,1,,CHEMBL619200,,18065,15413,,,F,,,Autocuration,,,
3534,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,H,1,,CHEMBL619201,,18065,15413,,,F,,,Autocuration,,,
3535,BAO_0000019,Tested for 5-hydroxytryptamine receptor uptake,,H,1,,CHEMBL619202,,18065,12409,,,F,,,Autocuration,,,
3536,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,D,1,CHO,CHEMBL619203,,51,16909,,,B,,,Expert,,449.0,
3537,BAO_0000019,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,D,1,,CHEMBL619204,,51,16909,,,F,,,Expert,,,
3538,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,H,1,,CHEMBL619205,,10576,15629,,,B,,,Autocuration,,,
3539,BAO_0000357,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,H,1,,CHEMBL619206,,10576,15629,,,B,,,Autocuration,,,
3540,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,H,1,,CHEMBL619207,,10576,15629,,,B,,,Expert,,,
3541,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,2435.0,H,1,,CHEMBL619208,,10825,10034,,Striatum,F,,,Autocuration,,,
3542,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,2435.0,H,1,,CHEMBL619209,,10825,10034,,Striatum,F,,,Autocuration,,,
3543,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,2435.0,H,1,,CHEMBL619210,,10825,10034,,Striatum,F,,,Autocuration,,,
3544,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,2435.0,H,1,,CHEMBL619211,,10825,10034,,Striatum,F,,,Autocuration,,,
3545,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,2435.0,H,1,,CHEMBL619212,,10825,10034,,Striatum,F,,,Autocuration,,,
3546,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,2435.0,H,1,,CHEMBL620681,,10825,10034,,Striatum,F,,,Autocuration,,,
3547,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,2435.0,H,1,,CHEMBL620682,,10825,10034,,Striatum,F,,,Autocuration,,,
3548,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,2435.0,H,1,,CHEMBL620683,,10825,10034,,Striatum,F,,,Autocuration,,,
3549,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,2435.0,H,1,,CHEMBL620684,,10825,10034,,Striatum,F,,,Autocuration,,,
3550,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,2435.0,H,1,,CHEMBL620685,,10825,10034,,Striatum,F,,,Autocuration,,,
3551,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,2435.0,H,1,,CHEMBL620686,,10825,10034,,Striatum,F,,,Autocuration,,,
3552,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,349.0,H,1,,CHEMBL620687,,10825,10034,,Limbic system,F,,,Autocuration,,,
3553,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,349.0,H,1,,CHEMBL620688,,10825,10034,,Limbic system,F,,,Autocuration,,,
3554,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,349.0,H,1,,CHEMBL620689,,10825,10034,,Limbic system,F,,,Autocuration,,,
3555,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,349.0,H,1,,CHEMBL620690,,10825,10034,,Limbic system,F,,,Autocuration,,,
3556,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,349.0,H,1,,CHEMBL620691,,10825,10034,,Limbic system,F,,,Autocuration,,,
3557,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,349.0,H,1,,CHEMBL620692,,10825,10034,,Limbic system,F,,,Autocuration,,,
3558,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,349.0,H,1,,CHEMBL620693,,10825,10034,,Limbic system,F,,,Autocuration,,,
3559,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620694,,168,1274,,,B,,,Expert,,,
3560,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,H,1,,CHEMBL857986,,168,17358,,,F,,,Autocuration,,,
3561,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,H,1,,CHEMBL620695,,168,14532,,,B,,,Autocuration,,,
3562,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620696,,168,16989,,,B,,,Expert,,,
3563,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,H,1,,CHEMBL620697,,168,17200,,,B,,,Autocuration,,,
3564,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor,,H,1,,CHEMBL620698,,168,15779,,,B,,,Autocuration,,,
3565,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,H,1,,CHEMBL620699,,168,15779,,,B,,,Autocuration,,,
3566,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,H,1,,CHEMBL620700,,168,15779,,,B,,,Autocuration,,,
3567,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,H,1,COS-7,CHEMBL620701,,168,15650,,,B,,,Autocuration,,643.0,
3568,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,H,1,COS-7,CHEMBL875082,,168,15650,,,B,,,Autocuration,,643.0,
3569,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,H,1,COS-7,CHEMBL620702,,168,15650,,,B,,,Autocuration,,643.0,
3570,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,H,1,COS-7,CHEMBL620703,,168,15650,,,B,,,Autocuration,,643.0,
3571,BAO_0000219,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,H,1,C6,CHEMBL620704,,168,17046,,,B,,,Autocuration,,673.0,
3572,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,H,1,C6,CHEMBL620705,,168,17046,,,B,,,Expert,,673.0,
3573,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,H,1,C6,CHEMBL620706,,168,15650,,,B,,,Expert,,673.0,
3574,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,H,1,C6,CHEMBL620707,,168,17046,,,B,,,Expert,,673.0,
3575,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5 receptor,,H,1,,CHEMBL620708,,10624,17066,,,B,,,Expert,,,
3576,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,H,1,,CHEMBL620709,,105,17200,,,B,,,Autocuration,,,
3577,BAO_0000357,Binding affinity against 5-hydroxytryptamine 5A receptor,,D,1,,CHEMBL620710,,10624,16146,,,B,,,Expert,,,
3578,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL620711,,10624,15250,,,B,,,Autocuration,,449.0,
3579,BAO_0000357,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,D,1,,CHEMBL620712,,10624,6491,,,B,,,Expert,,,
3580,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,D,1,,CHEMBL620713,,10624,17066,,,B,,,Expert,,,
3581,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,D,1,,CHEMBL620714,,10624,17066,,,B,,,Expert,,,
3582,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,D,1,,CHEMBL620715,,10624,4234,,,B,,,Expert,,,
3583,BAO_0000357,Binding affinity towards 5-HT5A receptor,,H,1,,CHEMBL620716,,10624,6013,,,B,,,Autocuration,,,
3584,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,H,1,,CHEMBL620717,,10624,17175,,,B,,,Expert,,,
3585,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,H,1,,CHEMBL618072,,10624,15818,,,B,,,Autocuration,,,
3586,BAO_0000357,Binding affinity towards cloned human 5-HT5A receptor was determined,,H,1,,CHEMBL857987,,10624,6166,,,B,,,Autocuration,,,
3587,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,1,HEK293,CHEMBL618073,,10624,15779,,,B,,,Autocuration,,722.0,
3588,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,H,1,HEK293,CHEMBL618074,,10624,15779,,,B,,,Autocuration,,722.0,
3589,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,H,1,HEK293,CHEMBL618075,,10624,5213,,,B,,,Autocuration,,722.0,
3590,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,D,1,,CHEMBL618076,,10625,17066,,,B,,,Expert,,,
3591,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,D,1,,CHEMBL618077,,10625,17066,,,B,,,Expert,,,
3592,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,D,1,,CHEMBL618078,,10625,17066,,,B,,,Expert,,,
3593,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,D,1,,CHEMBL881821,,10625,17066,,,B,,,Expert,,,
3594,BAO_0000357,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,D,1,,CHEMBL618079,,10625,17066,,,B,,,Expert,,,
3595,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,H,1,,CHEMBL618080,,10625,17175,,,B,,,Expert,,,
3596,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,H,1,HEK293,CHEMBL618081,,10576,16190,,,B,,,Autocuration,,722.0,
3597,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,H,1,HEK293,CHEMBL618082,,10626,16190,,,B,,,Autocuration,,722.0,
3598,BAO_0000357,Binding affinity towards 5-HT5a receptor,,H,1,,CHEMBL618083,,10624,4820,,,B,,,Expert,,,
3599,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor,,D,1,,CHEMBL618084,,10624,17066,,,B,,,Expert,,,
3600,BAO_0000357,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,H,1,,CHEMBL618085,,10624,17066,,,B,,,Expert,,,
3601,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,H,1,,CHEMBL618086,,10624,17175,,,B,,,Expert,,,
3602,BAO_0000357,Binding affinities against 5-hydroxytryptamine 5A receptor,,H,1,,CHEMBL875092,,10624,16633,,,B,,,Autocuration,,,
3603,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 5A receptor,,H,1,,CHEMBL618087,,10624,16633,,,B,,,Autocuration,,,
3604,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,H,1,,CHEMBL872926,,10624,16700,,,B,,,Autocuration,,,
3605,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,H,1,,CHEMBL618088,,104714,4639,,,F,,,Autocuration,,,
3606,BAO_0000223,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,H,1,,CHEMBL618089,,104714,5486,,,B,,,Autocuration,,,
3607,BAO_0000357,Inhibition of human 5-hydroxytryptamine 6 receptor,,D,1,,CHEMBL618090,,10627,16146,,,B,,,Expert,,,
3608,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,D,1,,CHEMBL618091,,10627,17273,,,B,,,Expert,,,
3609,BAO_0000357,Inhibition against human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL618092,,10627,17687,,,B,,,Autocuration,,,
3610,BAO_0000357,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,D,1,,CHEMBL618093,,10627,6491,,,B,,,Expert,,,
3611,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,H,1,HeLa,CHEMBL618094,,10627,16190,,,B,,,Expert,,308.0,
3612,BAO_0000357,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,D,1,,CHEMBL618095,,10627,17066,,,B,,,Expert,,,
3613,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,D,1,,CHEMBL875093,,10627,17066,,,B,,,Expert,,,
3614,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,D,1,,CHEMBL618096,,10627,17066,,,B,,,Expert,,,
3615,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,D,1,,CHEMBL618118,,10627,17066,,,B,,,Expert,,,
3616,BAO_0000357,Binding affinity against 5-hydroxytryptamine 6 receptor,,D,1,,CHEMBL618119,,10627,3555,,,B,,,Expert,,,
3617,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL618120,,10627,5808,,,B,,,Expert,,,
3618,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL618121,,10627,6013,,,B,,,Autocuration,,,
3619,BAO_0000219,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,H,1,HEK293,CHEMBL618122,,10627,15818,,,B,,,Expert,,722.0,
3620,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,H,1,,CHEMBL618123,,10627,16209,,,B,,,Autocuration,,,
3621,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,H,1,HEK293,CHEMBL618124,,10627,3935,,,B,,,Expert,,722.0,
3622,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL618125,,10627,15818,,,B,,,Autocuration,,,
3623,BAO_0000219,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,D,1,HEK293,CHEMBL618126,,10627,3805,,,B,,,Expert,,722.0,
3624,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,H,1,,CHEMBL618236,,10627,16441,,,B,,,Expert,,,
3625,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,H,1,,CHEMBL618237,,10627,16441,,,B,,,Expert,,,
3626,BAO_0000219,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,H,1,COS-7,CHEMBL618238,,10627,6786,,,B,,,Expert,,643.0,
3627,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,D,1,,CHEMBL618239,,10627,4234,,,B,,,Expert,,,
3628,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL618240,,10627,17085,,,B,,,Autocuration,,,
3629,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,H,1,,CHEMBL618241,,10627,17200,,,B,,,Autocuration,,,
3630,BAO_0000219,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,H,1,HEK293,CHEMBL859399,,10627,17451,,,B,,,Autocuration,,722.0,
3631,BAO_0000019,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,H,1,,CHEMBL618242,,10627,3935,,,F,,,Autocuration,,,
3632,BAO_0000357,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL857991,,10627,5033,,,B,,,Autocuration,,,
3633,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL619951,,10627,4540,,,B,,,Expert,,,
3634,BAO_0000219,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,D,1,HeLa,CHEMBL619952,,10627,4540,,,B,,,Expert,,308.0,
3635,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,D,1,HeLa,CHEMBL619953,,10627,4540,,,B,,,Expert,,308.0,
3636,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,H,1,HeLa,CHEMBL619954,,10627,17296,,,B,,,Autocuration,,308.0,
3637,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,H,1,HeLa,CHEMBL619955,,10627,17296,,,B,,,Autocuration,,308.0,
3638,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,H,1,HeLa,CHEMBL619956,,10627,17296,,,B,,,Autocuration,,308.0,
3639,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,H,1,CHO,CHEMBL619957,,10627,15779,,,B,,,Autocuration,,449.0,
3640,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,1,HEK293,CHEMBL619958,,10627,15779,,,B,,,Autocuration,,722.0,
3641,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,H,1,HEK293,CHEMBL620627,,10627,15779,,,B,,,Autocuration,,722.0,
3642,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,H,1,HEK293,CHEMBL620628,,10627,15779,,,B,,,Autocuration,,722.0,
3643,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,H,1,HeLa,CHEMBL620629,,10627,15779,,,B,,,Autocuration,,308.0,
3644,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620630,,10627,6166,,,B,,,Autocuration,,,
3645,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,H,1,HeLa,CHEMBL620782,,10627,17451,,,B,,,Autocuration,,308.0,
3646,BAO_0000357,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620783,,10627,15316,,,B,,,Autocuration,,,
3647,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620784,,10627,4199,,,B,,,Expert,,,
3648,BAO_0000219,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,H,1,HeLa,CHEMBL620785,,10627,15146,,,B,,,Expert,,308.0,
3649,BAO_0000357,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,H,1,,CHEMBL857992,,10627,5213,,,B,,,Autocuration,,,
3650,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,H,1,,CHEMBL620786,,10627,16429,,,B,,,Autocuration,,,
3651,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,H,1,HeLa,CHEMBL620787,,10627,14818,,,B,,,Autocuration,,308.0,
3652,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,H,1,HeLa,CHEMBL620788,,10627,4829,,,B,,,Autocuration,,308.0,
3653,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,H,1,HeLa,CHEMBL620789,,10627,4829,,,B,,,Autocuration,,308.0,
3654,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,H,1,HeLa,CHEMBL620790,,10627,4829,,,B,,,Autocuration,,308.0,
3655,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL620791,,10628,15250,,,B,,,Autocuration,,449.0,
3656,BAO_0000019,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,H,1,,CHEMBL620792,,10628,14423,,,B,,,Autocuration,,,
3657,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620793,,10628,15086,,,B,,,Autocuration,,,
3658,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,H,1,,CHEMBL620794,,10628,4342,,,B,,,Autocuration,,,
3659,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,D,1,HeLa,CHEMBL620795,,10627,16190,,,B,,,Autocuration,,308.0,
3660,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620796,,10627,4820,,,B,,,Expert,,,
3661,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,H,1,,CHEMBL620797,,10627,4639,,,B,,,Autocuration,,,
3662,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,D,1,,CHEMBL620798,,10627,17066,,,F,,,Expert,,,
3663,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,H,1,,CHEMBL620799,,10627,6011,,,B,,,Autocuration,,,
3664,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620800,,10627,17066,,,B,,,Expert,,,
3665,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,H,1,,CHEMBL620801,,10627,17515,,,B,,,Autocuration,,,
3666,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL875100,,10627,5014,,,B,,,Autocuration,,,
3667,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,H,1,,CHEMBL620802,,10627,4373,,,B,,,Autocuration,,,
3668,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620803,,10627,17066,,,F,,,Expert,,,
3669,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,H,1,,CHEMBL620804,,10627,17066,,,F,,,Expert,,,
3670,BAO_0000357,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,H,1,,CHEMBL620805,,10627,4373,,,B,,,Autocuration,,,
3671,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620806,,10627,4687,,,B,,,Autocuration,,,
3672,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,H,1,,CHEMBL620807,,10627,16946,,,B,,,Autocuration,,,
3673,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,H,1,,CHEMBL620808,,10627,16946,,,B,,,Autocuration,,,
3674,BAO_0000357,Binding affinities against 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620809,,10627,16633,,,B,,,Autocuration,,,
3675,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620810,,10627,16633,,,B,,,Autocuration,,,
3676,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor,,D,1,,CHEMBL620811,,10627,17066,,,B,,,Expert,,,
3677,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,H,1,,CHEMBL620812,,10627,16700,,,B,,,Autocuration,,,
3678,BAO_0000357,Affinity against 5-hydroxytryptamine 6 receptor,,H,1,,CHEMBL620813,,10627,3269,,,B,,,Autocuration,,,
3679,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,H,1,,CHEMBL620814,,10627,5486,,,B,,,Autocuration,,,
3680,BAO_0000357,Inhibition of human 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL620815,,10209,16146,,,B,,,Expert,,,
3681,BAO_0000219,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,H,1,HEK293,CHEMBL620816,,10209,5014,,,B,,,Autocuration,,722.0,
3682,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620817,,10209,15463,,,B,,,Autocuration,,,
3683,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,H,1,,CHEMBL620818,,10209,3805,,,B,,,Autocuration,,,
3684,BAO_0000219,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,H,1,HEK293,CHEMBL620819,,10209,5014,,,B,,,Expert,,722.0,
3685,BAO_0000357,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,D,1,,CHEMBL620820,,10209,6491,,,B,,,Expert,,,
3686,BAO_0000219,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,H,1,CHO,CHEMBL620821,,10209,16190,,,B,,,Autocuration,,449.0,
3687,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL620822,,10209,17066,,,B,,,Expert,,,
3688,BAO_0000357,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL620823,,10209,17066,,,B,,,Expert,,,
3689,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL620824,,10209,3555,,,B,,,Expert,,,
3690,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,H,1,CHO,CHEMBL620825,,10209,6588,,,B,,,Expert,,449.0,
3691,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,H,1,,CHEMBL872930,,10209,15463,,,B,,,Autocuration,,,
3692,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620826,,10209,6013,,,B,,,Autocuration,,,
3693,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL620827,,10209,16209,,,B,,,Autocuration,,,
3694,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620828,,10209,3935,,,B,,,Autocuration,,,
3695,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620829,,10209,15818,,,B,,,Autocuration,,,
3696,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,H,1,HEK293,CHEMBL620830,,10209,5014,,,B,,,Expert,,722.0,
3697,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,H,1,,CHEMBL620831,,10209,16441,,,B,,,Expert,,,
3698,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,H,1,,CHEMBL620832,,10209,16441,,,B,,,Expert,,,
3699,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL621548,,10209,4234,,,B,,,Expert,,,
3700,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL621549,,10209,17085,,,B,,,Autocuration,,,
3701,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,H,1,,CHEMBL621550,,10209,17200,,,B,,,Autocuration,,,
3702,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,H,1,CHO,CHEMBL621551,,10209,17451,,,B,,,Autocuration,,449.0,
3703,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,H,1,,CHEMBL621552,,10209,17085,,,B,,,Autocuration,,,
3704,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL857077,,10209,5104,,,B,,,Autocuration,,,
3705,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,H,1,,CHEMBL618158,,10209,5104,,,B,,,Autocuration,,,
3706,BAO_0000219,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,D,1,COS-7,CHEMBL618159,,10209,5033,,,B,,,Expert,,643.0,
3707,BAO_0000219,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,H,1,COS-7,CHEMBL875101,,10209,5486,,,B,,,Autocuration,,643.0,
3708,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,D,1,HEK293,CHEMBL618160,,10209,4540,,,B,,,Expert,,722.0,
3709,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,H,1,,CHEMBL618161,,10209,6166,,,B,,,Expert,,,
3710,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,H,1,HEK293,CHEMBL618162,,10209,17342,,,B,,,Expert,,722.0,
3711,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,H,1,,CHEMBL618163,,10209,17342,,,B,,,Expert,,,
3712,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 human receptors,,H,1,,CHEMBL618164,,10209,17296,,,B,,,Autocuration,,,
3713,BAO_0000219,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,H,1,,CHEMBL618165,,10209,16429,,,B,,,Expert,,,
3714,BAO_0000219,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,H,1,HEK293,CHEMBL618166,,10209,15779,,,B,,,Autocuration,,722.0,
3715,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,H,1,HEK293,CHEMBL857989,,10209,15779,,,B,,,Autocuration,,722.0,
3716,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,H,1,HEK293,CHEMBL619888,,10209,15779,,,B,,,Autocuration,,722.0,
3717,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,H,1,HEK293,CHEMBL619889,,10209,15779,,,B,,,Autocuration,,722.0,
3718,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,H,1,HEK293,CHEMBL619890,,10209,15779,,,B,,,Autocuration,,722.0,
3719,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,H,1,CHO,CHEMBL619891,,10209,17451,,,B,,,Autocuration,,449.0,
3720,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,H,1,HEK293,CHEMBL619892,,10209,4199,,,B,,,Autocuration,,722.0,
3721,BAO_0000219,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,D,1,HEK293,CHEMBL619893,,10209,4199,,,B,,,Expert,,722.0,
3722,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,H,1,HEK293,CHEMBL619894,,10209,4199,,,B,,,Autocuration,,722.0,
3723,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,D,1,HEK293,CHEMBL619895,,10209,3680,,,B,,,Intermediate,,722.0,
3724,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,D,1,,CHEMBL619896,,10209,3680,,,B,,,Intermediate,,,
3725,BAO_0000219,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,H,1,COS-7,CHEMBL619897,,10209,15316,,,B,,,Autocuration,,643.0,
3726,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,H,1,HEK293,CHEMBL619898,,10209,15146,,,B,,,Autocuration,,722.0,
3727,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,H,1,HEK293,CHEMBL619899,,10209,5213,,,B,,,Expert,,722.0,
3728,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,H,1,HEK293,CHEMBL619900,,10209,5213,,,B,,,Autocuration,,722.0,
3729,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,D,1,HEK293,CHEMBL619901,,10209,14818,,,B,,,Expert,,722.0,
3730,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,H,1,HEK293,CHEMBL620580,,10209,14818,,,B,,,Autocuration,,722.0,
3731,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,H,1,HEK293,CHEMBL620581,,10209,14818,,,B,,,Autocuration,,722.0,
3732,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,H,1,HEK293,CHEMBL620733,,10209,4829,,,B,,,Autocuration,,722.0,
3733,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,D,1,,CHEMBL620734,,10209,17200,,,B,,,Autocuration,,,
3734,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,D,1,,CHEMBL620735,,10022,17066,,,B,,,Expert,,,
3735,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,H,1,,CHEMBL620736,,10209,14025,,,B,,,Autocuration,,,
3736,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,H,1,CHO,CHEMBL620737,,11923,15250,,,B,,,Autocuration,,449.0,
3737,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,H,1,CHO,CHEMBL620738,,11923,16372,,,B,,,Autocuration,,449.0,
3738,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,H,1,CHO,CHEMBL620739,,11923,16372,,,B,,,Autocuration,,449.0,
3739,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,H,1,CHO,CHEMBL620740,,11923,16372,,,B,,,Autocuration,,449.0,
3740,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,H,1,CHO,CHEMBL620741,,11923,16372,,,B,,,Autocuration,,449.0,
3741,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,H,1,CHO,CHEMBL620742,,11923,16372,,,B,,,Autocuration,,449.0,
3742,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,H,1,CHO,CHEMBL620743,,11923,16372,,,B,,,Autocuration,,449.0,
3743,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,H,1,CHO,CHEMBL620744,,11923,16372,,,B,,,Autocuration,,449.0,
3744,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,H,1,CHO,CHEMBL620745,,11923,16372,,,B,,,Autocuration,,449.0,
3745,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,H,1,CHO,CHEMBL620746,,11923,16372,,,B,,,Autocuration,,449.0,
3746,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,H,1,CHO,CHEMBL620747,,11923,16372,,,B,,,Autocuration,,449.0,
3747,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,H,1,CHO,CHEMBL620748,,11923,16372,,,B,,,Autocuration,,449.0,
3748,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,H,1,CHO,CHEMBL620749,,11923,16372,,,B,,,Autocuration,,449.0,
3749,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620750,,11923,17066,,,B,,,Expert,,,
3750,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,D,1,,CHEMBL620751,,11923,17066,,,B,,,Expert,,,
3751,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620752,,11923,17386,,,B,,,Expert,,,
3752,BAO_0000019,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,H,1,,CHEMBL872929,,11923,14423,,,B,,,Autocuration,,,
3753,BAO_0000357,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,D,1,,CHEMBL620753,,11923,15874,,,B,,,Expert,,,
3754,BAO_0000357,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL620754,,11923,15874,,,B,,,Expert,,,
3755,BAO_0000219,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,D,1,CHO,CHEMBL620755,,11923,16372,,,B,,,Expert,,449.0,
3756,BAO_0000357,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,H,1,,CHEMBL620756,,11923,4622,,,B,,,Autocuration,,,
3757,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL620757,,11923,15086,,,B,,,Autocuration,,,
3758,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,H,1,CHO,CHEMBL620758,,11923,16372,,,B,,,Autocuration,,449.0,
3759,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,H,1,CHO,CHEMBL620759,,11923,16372,,,B,,,Autocuration,,449.0,
3760,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,H,1,CHO,CHEMBL620760,,11923,16372,,,B,,,Autocuration,,449.0,
3761,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,H,1,CHO,CHEMBL620761,,11923,16372,,,B,,,Autocuration,,449.0,
3762,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,2116.0,H,1,,CHEMBL620762,,11923,17386,,Ileum,F,,,Autocuration,,,
3763,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,2116.0,H,1,,CHEMBL620763,,11923,17386,,Ileum,F,,,Autocuration,,,
3764,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,2116.0,H,1,,CHEMBL620764,,11923,17386,,Ileum,F,,,Autocuration,,,
3765,BAO_0000249,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,D,1,,CHEMBL857990,,11923,5831,Membranes,,B,,,Expert,,,
3766,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,H,1,,CHEMBL620765,,11923,4342,,,B,,,Autocuration,,,
3767,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,H,1,,CHEMBL620766,,11923,17319,,,B,,,Expert,,,
3768,BAO_0000019,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,1898.0,H,1,,CHEMBL620767,,11923,17342,,Hypothalamus,B,,,Expert,,,
3769,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,H,1,,CHEMBL620768,,11923,17342,,,B,,,Autocuration,,,
3770,BAO_0000249,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,1898.0,H,1,,CHEMBL619051,,11923,3680,,Hypothalamus,B,,,Expert,,,
3771,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619052,,11923,3680,,,B,,,Expert,,,
3772,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,D,1,HEK293,CHEMBL619053,,11923,17319,,,F,,,Expert,,722.0,
3773,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,D,1,HEK293,CHEMBL619703,,11923,17319,,,F,,,Expert,,722.0,
3774,BAO_0000219,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,D,1,HEK293,CHEMBL619704,,11923,17319,,,F,,,Autocuration,,722.0,
3775,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619851,,10209,4820,,,B,,,Expert,,,
3776,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,H,1,,CHEMBL619852,,10209,4639,,,B,,,Autocuration,,,
3777,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,H,1,,CHEMBL619853,,10209,6011,,,B,,,Autocuration,,,
3778,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,D,1,,CHEMBL619854,,10209,17066,,,B,,,Expert,,,
3779,BAO_0000357,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619855,,10209,17066,,,B,,,Expert,,,
3780,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,H,1,,CHEMBL619856,,10209,17515,,,B,,,Autocuration,,,
3781,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,H,1,,CHEMBL619857,,10209,4373,,,B,,,Autocuration,,,
3782,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,H,1,,CHEMBL619858,,10209,17066,,,F,,,Expert,,,
3783,BAO_0000357,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,H,1,,CHEMBL619859,,10209,4373,,,B,,,Autocuration,,,
3784,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,H,1,,CHEMBL619860,,10209,4373,,,B,,,Autocuration,,,
3785,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619861,,10209,4687,,,B,,,Autocuration,,,
3786,BAO_0000357,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619862,,10209,17342,,,B,,,Expert,,,
3787,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,H,1,,CHEMBL619863,,10209,16946,,,B,,,Autocuration,,,
3788,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,H,1,,CHEMBL619864,,10209,16946,,,B,,,Autocuration,,,
3789,BAO_0000357,Binding affinities against 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL872928,,10209,16633,,,B,,,Autocuration,,,
3790,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619865,,10209,16633,,,B,,,Autocuration,,,
3791,BAO_0000357,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,H,1,,CHEMBL619866,,10209,17066,,,B,,,Expert,,,
3792,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,H,1,,CHEMBL619867,,10209,16700,,,B,,,Autocuration,,,
3793,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,2116.0,H,1,,CHEMBL619868,,10209,17386,,Ileum,B,,,Autocuration,,,
3794,BAO_0000019,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,H,1,,CHEMBL619869,,55,14080,,,F,,,Autocuration,,,
3795,BAO_0000019,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,D,1,,CHEMBL619870,,55,14080,,,F,,,Expert,,,
3796,BAO_0000357,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,H,1,,CHEMBL619871,,55,409,,,B,,,Autocuration,,,
3797,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme,,H,1,,CHEMBL619872,,55,409,,,B,,,Autocuration,,,
3798,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,H,1,,CHEMBL619873,,55,409,,,B,,,Autocuration,,,
3799,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,178.0,H,1,,CHEMBL619874,,55,11090,,Blood,B,,,Expert,,,
3800,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,178.0,H,1,,CHEMBL619875,,55,11090,,Blood,B,,,Expert,,,
3801,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,H,1,,CHEMBL619876,,55,948,,,B,,,Autocuration,,,
3802,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,H,1,,CHEMBL619877,,55,948,,,B,,,Autocuration,,,
3803,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,H,1,,CHEMBL619878,,55,13622,,,F,,,Expert,,,
3804,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,178.0,H,1,,CHEMBL619879,,55,13622,,Blood,F,,,Autocuration,,,
3805,BAO_0000357,In vitro inhibition of 5-lipoxygenase from human polymorphs,,H,1,,CHEMBL619880,,55,9637,,,B,,,Autocuration,,,
3806,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,H,1,,CHEMBL619881,,55,11320,,,B,,,Autocuration,,,
3807,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,H,1,,CHEMBL619882,,55,11320,,,B,,,Expert,,,
3808,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,H,1,,CHEMBL619883,,55,6838,,,B,,,Autocuration,,,
3809,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),178.0,D,1,,CHEMBL619884,,55,17667,,Blood,B,,,Expert,,,
3810,BAO_0000357,In vitro potency against human 5-Lipoxygenase,,H,1,,CHEMBL619885,,55,12703,,,B,,,Autocuration,,,
3811,BAO_0000019,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,D,1,,CHEMBL619886,,55,14312,,,F,,,Expert,,,
3812,BAO_0000019,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,178.0,H,1,,CHEMBL619887,,55,14312,,Blood,F,,,Autocuration,,,
3813,BAO_0000019,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,H,1,,CHEMBL875097,,55,5364,,,F,,,Autocuration,,,
3814,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,H,1,,CHEMBL618001,,55,951,,,B,,,Autocuration,,,
3815,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,H,1,,CHEMBL618002,,55,951,,,B,,,Autocuration,,,
3816,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,H,1,,CHEMBL618003,,55,951,,,B,,,Autocuration,,,
3817,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,H,1,,CHEMBL618004,,55,951,,,B,,,Autocuration,,,
3818,BAO_0000219,Inhibition of human 5-lipoxygenase in human cells,,H,1,,CHEMBL618005,,55,12365,,,B,,,Autocuration,,,
3819,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase,,H,1,,CHEMBL618006,,55,10603,,,B,,,Expert,,,
3820,BAO_0000019,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,H,1,,CHEMBL875086,,55,10501,,,B,,,Autocuration,,,
3821,BAO_0000357,Inhibition of 5-lipoxygenase from human whole blood,178.0,H,1,,CHEMBL618007,,55,12281,,Blood,B,,,Expert,,,
3822,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,H,1,,CHEMBL618008,,55,2567,,,B,,,Autocuration,,,
3823,BAO_0000219,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,H,1,,CHEMBL618009,,55,2567,,,B,,,Autocuration,,,
3824,BAO_0000357,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,H,1,,CHEMBL618010,,55,10193,,,B,,,Expert,,,
3825,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,H,1,,CHEMBL618011,,55,10193,,,B,,,Autocuration,,,
3826,BAO_0000357,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,H,1,,CHEMBL618012,,55,13623,,,B,,,Expert,,,
3827,BAO_0000357,Tested against 5-lipoxygenase,,H,1,,CHEMBL882927,,55,12780,,,B,,,Autocuration,,,
3828,BAO_0000357,Tested for activity against 5-Lipoxygenase (5-LO),,H,1,,CHEMBL618013,,55,12780,,,B,,,Autocuration,,,
3829,BAO_0000357,Tested for activity against 5-lipoxygenase,,H,1,,CHEMBL618014,,55,12780,,,B,,,Autocuration,,,
3830,BAO_0000357,Tested for inhibition of 5-HPETE production by human 5-LO,,H,1,,CHEMBL618015,,55,11966,,,B,,,Autocuration,,,
3831,BAO_0000019,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,H,1,,CHEMBL618016,,55,5364,,,F,,,Autocuration,,,
3832,BAO_0000357,Inhibition of Human 5-lipoxygenase,,H,1,,CHEMBL618017,,55,13165,,,B,,,Expert,,,
3833,BAO_0000019,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,H,1,,CHEMBL618018,,55,5364,,,B,,,Autocuration,,,
3834,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL875087,,55,11311,,,B,,,Autocuration,,,
3835,BAO_0000219,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL618019,,55,11311,,,B,,,Autocuration,,,
3836,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,H,1,,CHEMBL618020,,55,14863,,,B,,,Autocuration,,,
3837,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,H,1,,CHEMBL618021,,55,14863,,,B,,,Autocuration,,,
3838,BAO_0000357,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),178.0,H,1,,CHEMBL618022,,55,11087,,Blood,B,,,Autocuration,,,
3839,BAO_0000357,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,H,1,,CHEMBL618023,,55,455,,,B,,,Autocuration,,,
3840,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,H,1,,CHEMBL618024,,55,13183,,,B,,,Autocuration,,,
3841,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,H,1,,CHEMBL873950,,55,10319,,,B,,,Expert,,,
3842,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,H,1,,CHEMBL618025,,55,10193,,,B,,,Autocuration,,,
3843,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,H,1,,CHEMBL618026,,55,951,,,B,,,Autocuration,,,
3844,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,H,1,,CHEMBL618027,,55,951,,,B,,,Autocuration,,,
3845,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,H,1,,CHEMBL618028,,55,951,,,B,,,Autocuration,,,
3846,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,H,1,,CHEMBL618029,,55,951,,,B,,,Autocuration,,,
3847,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,H,1,,CHEMBL618030,,55,9859,,,B,,,Expert,,,
3848,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,H,1,,CHEMBL618031,,55,9859,,,B,,,Expert,,,
3849,BAO_0000357,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,H,1,,CHEMBL618032,,55,9859,,,B,,,Autocuration,,,
3850,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,H,1,,CHEMBL618033,,55,2567,,,B,,,Autocuration,,,
3851,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,H,1,,CHEMBL618034,,55,10193,,,B,,,Autocuration,,,
3852,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,H,1,,CHEMBL875088,,55,10193,,,B,,,Autocuration,,,
3853,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,H,1,,CHEMBL618035,,55,949,,,B,,,Autocuration,,,
3854,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,H,1,,CHEMBL618036,,55,949,,,B,,,Autocuration,,,
3855,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,H,1,,CHEMBL618037,,55,10603,,,B,,,Expert,,,
3856,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,H,1,,CHEMBL618038,,55,10603,,,B,,,Expert,,,
3857,BAO_0000019,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,H,1,,CHEMBL618761,,55,10603,,,F,,,Autocuration,,,
3858,BAO_0000357,Inhibition of lipoxygenase at the concentration of 0.1 uM,,H,1,,CHEMBL618762,,55,10603,,,B,,,Expert,,,
3859,BAO_0000357,Inhibition of lipoxygenase at the concentration of 1 uM,,H,1,,CHEMBL618763,,55,10603,,,B,,,Expert,,,
3860,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,H,1,,CHEMBL618764,,55,10193,,,B,,,Autocuration,,,
3861,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LOX),,D,1,,CHEMBL618765,,55,14580,,,B,,,Expert,,,
3862,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,,H,1,,CHEMBL618766,,17087,11090,,,B,,,Expert,,,
3863,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,,H,1,,CHEMBL618767,,17087,11090,,,B,,,Expert,,,
3864,BAO_0000357,Inhibitory activity against lipoxygenase-2 in mice,,H,1,,CHEMBL619380,,17087,6339,,,B,,,Autocuration,,,
3865,BAO_0000357,Inhibitory activity against murine lipoxygenase-2.,,H,1,,CHEMBL619381,,17087,6339,,,B,,,Expert,,,
3866,BAO_0000357,Inhibition of 5-lipoxygenase from mouse macrophage,,D,1,,CHEMBL619382,,17087,12281,,,B,,,Expert,,,
3867,BAO_0000357,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,H,1,,CHEMBL619383,,17087,11311,,,B,,,Autocuration,,,
3868,BAO_0000019,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,H,1,,CHEMBL619384,,55,11089,,,B,,,Autocuration,,,
3869,BAO_0000019,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,H,1,,CHEMBL619385,,55,10091,,,B,,,Autocuration,,,
3870,BAO_0000019,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,H,1,,CHEMBL882928,,55,14352,,,B,,,Autocuration,,,
3871,BAO_0000019,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,D,1,,CHEMBL619386,,12166,13329,,,B,,,Expert,,,
3872,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,H,1,,CHEMBL619387,,12166,13329,,,B,,,Autocuration,,,
3873,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,H,1,,CHEMBL619388,,12166,13329,,,B,,,Autocuration,,,
3874,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,H,1,,CHEMBL619389,,12166,13329,,,B,,,Autocuration,,,
3875,BAO_0000019,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,H,1,,CHEMBL619390,,12166,13329,,,B,,,Expert,,,
3876,BAO_0000019,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,H,1,,CHEMBL619391,,12166,13329,,,B,,,Expert,,,
3877,BAO_0000019,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,H,1,,CHEMBL619392,,12166,13329,,,B,,,Autocuration,,,
3878,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,H,1,,CHEMBL619393,,12166,11311,,,B,,,Autocuration,,,
3879,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,H,1,,CHEMBL619394,,12166,11311,,,B,,,Autocuration,,,
3880,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,H,1,RBL-1,CHEMBL619395,,12166,105,,,B,,,Autocuration,,702.0,
3881,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,H,1,RBL-1,CHEMBL619396,,12166,105,,,B,,,Autocuration,,702.0,
3882,BAO_0000357,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,H,1,,CHEMBL619397,,12166,9138,,,B,,,Autocuration,,,
3883,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,H,1,,CHEMBL619398,,12166,9138,,,B,,,Autocuration,,,
3884,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,H,1,,CHEMBL619399,,12166,9138,,,B,,,Autocuration,,,
3885,BAO_0000357,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,H,1,,CHEMBL619400,,12166,14427,,,B,,,Autocuration,,,
3886,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,H,1,,CHEMBL619401,,12166,13329,,,B,,,Autocuration,,,
3887,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,H,1,,CHEMBL619402,,12166,13329,,,B,,,Autocuration,,,
3888,BAO_0000219,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,D,1,RBL-2H3,CHEMBL619403,,12166,14427,,,B,,,Expert,,663.0,
3889,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,H,1,,CHEMBL619404,,12166,14427,,,B,,,Autocuration,,,
3890,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,H,1,,CHEMBL619405,,12166,14427,,,B,,,Autocuration,,,
3891,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,H,1,RBL-1,CHEMBL619406,,12166,10293,,,B,,,Expert,,702.0,
3892,BAO_0000219,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,D,1,RBL-1,CHEMBL619407,,12166,338,,,B,,,Expert,,702.0,
3893,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,H,1,,CHEMBL619408,,12166,303,,,B,,,Autocuration,,,
3894,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,H,1,RBL-1,CHEMBL619409,,12166,303,,,B,,,Autocuration,,702.0,
3895,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,H,1,RBL-1,CHEMBL619410,,12166,9247,,,B,,,Expert,,702.0,
3896,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,H,1,RBL-1,CHEMBL619753,,12166,9247,,,B,,,Autocuration,,702.0,
3897,BAO_0000219,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,H,1,RBL-1,CHEMBL619754,,12166,137,,,B,,,Autocuration,,702.0,
3898,BAO_0000357,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,H,1,,CHEMBL619903,,12166,11481,,,B,,,Expert,,,
3899,BAO_0000357,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,H,1,,CHEMBL619904,,12166,11481,,,B,,,Expert,,,
3900,BAO_0000357,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,H,1,,CHEMBL619905,,12166,9029,,,B,,,Expert,,,
3901,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,H,1,,CHEMBL619906,,12166,1701,,,B,,,Autocuration,,,
3902,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,H,1,,CHEMBL619907,,12166,1701,,,B,,,Autocuration,,,
3903,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,H,1,,CHEMBL619908,,12166,1701,,,B,,,Autocuration,,,
3904,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,H,1,,CHEMBL619909,,12166,1701,,,B,,,Autocuration,,,
3905,BAO_0000219,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,H,1,RBL-1,CHEMBL619910,,12166,13358,,,F,,,Expert,,702.0,
3906,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,H,1,RBL-1,CHEMBL882929,,12166,1175,,,B,,,Expert,,702.0,
3907,BAO_0000219,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,H,1,RBL-1,CHEMBL619911,,12166,8797,,,B,,,Expert,,702.0,
3908,BAO_0000019,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,H,1,,CHEMBL619912,,12166,8797,,,B,,,Autocuration,,,
3909,BAO_0000357,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,D,1,,CHEMBL619913,,12166,577,,,B,,,Expert,,,
3910,BAO_0000219,In vitro inhibitory activity against RBL-1 5-LO,,H,1,RBL-1,CHEMBL619914,,12166,9295,,,B,,,Expert,,702.0,
3911,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,H,1,RBL-1,CHEMBL619915,,12166,9295,,,B,,,Autocuration,,702.0,
3912,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,H,1,RBL-1,CHEMBL619916,,12166,9295,,,B,,,Autocuration,,702.0,
3913,BAO_0000218,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,H,1,,CHEMBL619917,,12166,9295,,,B,,,Autocuration,,,
3914,BAO_0000357,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,H,1,,CHEMBL619918,,12166,9295,,,B,,,Autocuration,,,
3915,BAO_0000218,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,H,1,,CHEMBL619919,,12166,216,,,B,,,Autocuration,,,
3916,BAO_0000219,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,H,1,RBL-1,CHEMBL883710,,12166,11090,,,B,,,Autocuration,,702.0,
3917,BAO_0000019,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,178.0,H,1,,CHEMBL619920,,12166,11090,,Blood,B,,,Autocuration,,,
3918,BAO_0000357,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,H,1,,CHEMBL619921,,12166,10091,,,B,,,Expert,,,
3919,BAO_0000019,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,H,1,,CHEMBL619922,,12166,10274,,,F,,,Autocuration,,,
3920,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,H,1,,CHEMBL619923,,12166,13622,,,F,,,Autocuration,,,
3921,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,H,1,RBL-1,CHEMBL619924,,12166,12118,,,B,,,Expert,,702.0,
3922,BAO_0000357,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,H,1,,CHEMBL619925,,12166,12576,,,B,,,Expert,,,
3923,BAO_0000219,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,H,1,RBL-1,CHEMBL619926,,12166,9546,,,B,,,Expert,,702.0,
3924,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,H,1,RBL-1,CHEMBL619927,,12166,9521,,,B,,,Autocuration,,702.0,
3925,BAO_0000219,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,H,1,RBL-1,CHEMBL619928,,12166,10626,,,B,,,Expert,,702.0,
3926,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase,,H,1,RBL-1,CHEMBL619929,,12166,9225,,,B,,,Autocuration,,702.0,
3927,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,H,1,RBL-1,CHEMBL875089,,12166,9225,,,B,,,Autocuration,,702.0,
3928,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,H,1,RBL-1,CHEMBL619930,,12166,9225,,,B,,,Autocuration,,702.0,
3929,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,H,1,RBL-1,CHEMBL619931,,12166,9225,,,B,,,Autocuration,,702.0,
3930,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,H,1,RBL-1,CHEMBL619932,,12166,9225,,,B,,,Autocuration,,702.0,
3931,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,H,1,RBL-1,CHEMBL619933,,12166,9225,,,B,,,Autocuration,,702.0,
3932,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,H,1,RBL-1,CHEMBL619934,,12166,9225,,,B,,,Autocuration,,702.0,
3933,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,H,1,RBL-1,CHEMBL619935,,12166,9225,,,B,,,Autocuration,,702.0,
3934,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,H,1,RBL-1,CHEMBL619936,,12166,9225,,,B,,,Autocuration,,702.0,
3935,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,H,1,RBL-1,CHEMBL619937,,12166,9225,,,B,,,Autocuration,,702.0,
3936,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,H,1,RBL-1,CHEMBL619938,,12166,9225,,,B,,,Autocuration,,702.0,
3937,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,H,1,RBL-1,CHEMBL619939,,12166,9225,,,B,,,Autocuration,,702.0,
3938,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,H,1,RBL-1,CHEMBL619940,,12166,9225,,,B,,,Autocuration,,702.0,
3939,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,H,1,RBL-1,CHEMBL875090,,12166,9225,,,B,,,Autocuration,,702.0,
3940,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,H,1,RBL-1,CHEMBL619941,,12166,9225,,,B,,,Autocuration,,702.0,
3941,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,H,1,RBL-1,CHEMBL619942,,12166,9225,,,B,,,Autocuration,,702.0,
3942,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,H,1,RBL-1,CHEMBL883711,,12166,9225,,,B,,,Autocuration,,702.0,
3943,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,H,1,RBL-1,CHEMBL619943,,12166,9225,,,B,,,Autocuration,,702.0,
3944,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,H,1,RBL-1,CHEMBL619944,,12166,9225,,,B,,,Autocuration,,702.0,
3945,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,H,1,RBL-1,CHEMBL619945,,12166,9225,,,B,,,Autocuration,,702.0,
3946,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,H,1,RBL-1,CHEMBL619946,,12166,9225,,,B,,,Autocuration,,702.0,
3947,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,H,1,RBL-1,CHEMBL619947,,12166,9225,,,B,,,Autocuration,,702.0,
3948,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,H,1,RBL-1,CHEMBL619948,,12166,9225,,,B,,,Autocuration,,702.0,
3949,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,H,1,RBL-1,CHEMBL619949,,12166,9225,,,B,,,Autocuration,,702.0,
3950,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,H,1,,CHEMBL619950,,12166,9401,,,B,,,Expert,,,
3951,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,H,1,,CHEMBL618050,,12166,10325,,,B,,,Autocuration,,,
3952,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,H,1,RBL-2H3,CHEMBL875091,,12166,1556,,,F,,,Expert,,663.0,
3953,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,H,1,RBL-2H3,CHEMBL618051,,12166,1556,,,F,,,Expert,,663.0,
3954,BAO_0000219,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,D,1,RBL-1,CHEMBL618052,,12166,961,,,B,,,Expert,,702.0,
3955,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,H,1,,CHEMBL618053,,12166,6838,,,B,,,Autocuration,,,
3956,BAO_0000019,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,H,1,,CHEMBL618054,,12166,10325,,,B,,,Expert,,,
3957,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,D,1,RBL-1,CHEMBL618055,,12166,9209,,,B,,,Expert,,702.0,
3958,BAO_0000219,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,H,1,RBL-1,CHEMBL618056,,12166,11520,,,B,,,Expert,,702.0,
3959,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined,,H,1,,CHEMBL618057,,12166,137,,,B,,,Autocuration,,,
3960,BAO_0000219,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,H,1,RBL-1,CHEMBL618058,,12166,4717,,,B,,,Autocuration,,702.0,
3961,BAO_0000219,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,H,1,RBL-1,CHEMBL618059,,12166,10636,,,B,,,Expert,,702.0,
3962,BAO_0000019,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,D,1,,CHEMBL618060,,12166,14312,,,F,,,Expert,,,
3963,BAO_0000219,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,H,1,RBL-1,CHEMBL618061,,12166,1203,,,B,,,Autocuration,,702.0,
3964,BAO_0000019,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,H,1,,CHEMBL618062,,12166,1203,,,B,,,Autocuration,,,
3965,BAO_0000219,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,H,1,RBL-1,CHEMBL618063,,12166,13622,,,B,,,Expert,,702.0,
3966,BAO_0000357,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,H,1,,CHEMBL618064,,12166,9793,,,B,,,Autocuration,,,
3967,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,D,1,RBL-1,CHEMBL618065,,12166,1143,,,B,,,Expert,,702.0,
3968,BAO_0000219,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,D,1,RBL-1,CHEMBL618066,,12166,11854,,,B,,,Expert,,702.0,
3969,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,H,1,RBL-1,CHEMBL618067,,12166,3595,,,B,,,Autocuration,,702.0,
3970,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,H,1,RBL-1,CHEMBL618068,,12166,3595,,,B,,,Autocuration,,702.0,
3971,BAO_0000219,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,D,1,RBL-1,CHEMBL618069,,12166,10501,,,B,,,Expert,,702.0,
3972,BAO_0000219,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,1,RBL-1,CHEMBL618070,,12166,12526,,,B,,,Expert,,702.0,
3973,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,349.0,H,1,,CHEMBL618071,,10825,10034,,Limbic system,F,,,Autocuration,,,
3974,BAO_0000019,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,349.0,H,1,,CHEMBL619247,,10825,10034,,Limbic system,F,,,Autocuration,,,
3975,BAO_0000019,Approximate dose levels for a half maximal reduction of 5-HTP levels,,H,1,,CHEMBL619248,,10825,10034,,,F,,,Autocuration,,,
3976,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,H,1,,CHEMBL619249,,10576,10046,,Hippocampus,B,,,Autocuration,,,
3977,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,H,1,,CHEMBL619250,,10576,10046,,Hippocampus,B,,,Autocuration,,,
3978,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,H,1,,CHEMBL619251,,10577,10046,,,B,,,Autocuration,,,
3979,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,178.0,H,1,,CHEMBL619252,,55,12079,,Blood,F,,,Autocuration,,,
3980,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,178.0,H,1,,CHEMBL619253,,55,12079,,Blood,F,,,Autocuration,,,
3981,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL619254,,12166,11311,,,B,,,Autocuration,,,
3982,BAO_0000219,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,H,1,,CHEMBL619255,,17140,12338,,,B,,,Expert,,,
3983,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,H,1,,CHEMBL619256,,17140,12143,,,B,,,Expert,,,
3984,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,H,1,,CHEMBL875418,,17140,12143,,,B,,,Autocuration,,,
3985,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,H,1,,CHEMBL619257,,17140,12143,,,B,,,Expert,,,
3986,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,H,1,,CHEMBL619258,,17140,12143,,,B,,,Autocuration,,,
3987,BAO_0000357,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,H,1,,CHEMBL619259,,17140,12365,,,B,,,Expert,,,
3988,BAO_0000357,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,H,1,,CHEMBL619260,,17140,13500,,,B,,,Expert,,,
3989,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619261,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3990,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619263,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3991,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619264,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3992,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619265,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3993,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619266,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3994,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619902,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3995,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620058,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3996,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620059,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3997,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620060,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3998,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620061,In vivo,55,12832,,Blood,F,,,Autocuration,,,
3999,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL620062,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4000,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620063,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4001,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620064,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4002,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620065,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4003,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL620066,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4004,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620067,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4005,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620068,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4006,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620069,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4007,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL620070,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4008,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620071,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4009,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620072,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4010,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620036,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4011,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL857702,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4012,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620037,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4013,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620038,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4014,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620039,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4015,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL620040,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4016,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620041,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4017,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620042,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4018,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620043,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4019,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL620044,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4020,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620045,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4021,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620046,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4022,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620047,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4023,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,H,1,,CHEMBL620048,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4024,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL857703,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4025,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,H,1,,CHEMBL620049,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4026,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620050,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4027,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620051,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4028,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619213,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4029,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619214,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4030,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619804,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4031,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619805,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4032,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619806,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4033,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619807,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4034,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL619808,In vivo,55,12832,,Blood,F,,,Autocuration,,,
4035,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,H,1,,CHEMBL619809,,55,3595,,,B,,,Autocuration,,,
4036,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,H,1,,CHEMBL619810,,55,3595,,,B,,,Autocuration,,,
4037,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,H,1,,CHEMBL619811,,55,3595,,,B,,,Autocuration,,,
4038,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,H,1,,CHEMBL620769,,55,3595,,,B,,,Autocuration,,,
4039,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,H,1,,CHEMBL620770,,55,3595,,,B,,,Autocuration,,,
4040,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,H,1,,CHEMBL620771,,55,3595,,,B,,,Autocuration,,,
4041,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,H,1,,CHEMBL620772,,55,3595,,,B,,,Autocuration,,,
4042,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,H,1,,CHEMBL620773,,55,3595,,,B,,,Autocuration,,,
4043,BAO_0000357,Ability to inhibit 5-lipoxygenase in guinea pig,,H,1,,CHEMBL620774,,55,9203,,,B,,,Autocuration,,,
4044,BAO_0000357,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,H,1,,CHEMBL620775,,55,82,,,B,,,Expert,,,
4045,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,H,1,,CHEMBL620776,,55,11090,,,B,,,Autocuration,,,
4046,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",178.0,H,1,,CHEMBL620777,,55,12832,,Blood,B,,,Autocuration,,,
4047,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,H,1,,CHEMBL620778,,55,1065,,,B,,,Autocuration,,,
4048,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,H,1,,CHEMBL620779,,55,1065,,,B,,,Autocuration,,,
4049,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,H,1,,CHEMBL621500,,55,12832,,,B,,,Expert,,,
4050,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,H,1,,CHEMBL621501,,55,12832,,,B,,,Expert,,,
4051,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,H,1,,CHEMBL618098,,55,12832,,,B,,,Autocuration,,,
4052,BAO_0000019,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,H,1,,CHEMBL618099,,55,10504,,,B,,,Autocuration,,,
4053,BAO_0000357,Inhibitory activity against 5-lipoxygenase,,H,1,,CHEMBL618100,,55,7788,,,B,,,Autocuration,,,
4054,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,H,1,,CHEMBL618101,,55,10001,,,B,,,Autocuration,,,
4055,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,H,1,,CHEMBL618102,,55,10193,,,B,,,Autocuration,,,
4056,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,H,1,,CHEMBL618103,,55,13243,,,B,,,Autocuration,,,
4057,BAO_0000357,Inhibitory activity uM,,H,1,,CHEMBL618104,,55,13243,,,B,,,Autocuration,,,
4058,BAO_0000219,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,H,1,,CHEMBL883712,,55,969,,,B,,,Autocuration,,,
4059,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,,H,1,,CHEMBL618105,,55,10001,,,B,,,Autocuration,,,
4060,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,H,1,,CHEMBL618106,,55,7788,,,B,,,Autocuration,,,
4061,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,H,1,,CHEMBL618107,,55,10001,,,B,,,Autocuration,,,
4062,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,H,1,,CHEMBL618108,,55,10193,,,B,,,Autocuration,,,
4063,BAO_0000357,Inhibitory activity uM,,H,1,,CHEMBL618109,,55,13243,,,B,,,Autocuration,,,
4064,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,H,1,,CHEMBL618110,,55,13243,,,B,,,Autocuration,,,
4065,BAO_0000357,Inhibitory activity uM,,H,1,,CHEMBL618111,,55,13243,,,B,,,Expert,,,
4066,BAO_0000019,Inhibitory activity uM,,H,1,,CHEMBL618112,,55,13243,,,F,,,Autocuration,,,
4067,BAO_0000019,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,H,1,,CHEMBL618113,,55,10504,,,B,,,Autocuration,,,
4068,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,H,1,,CHEMBL618114,,55,7788,,,B,,,Autocuration,,,
4069,BAO_0000221,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,2116.0,H,1,,CHEMBL620871,,55,10546,,Ileum,F,,,Expert,,,
4070,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,H,1,,CHEMBL620872,,55,13183,,,B,,,Autocuration,,,
4071,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,H,1,,CHEMBL620873,,55,13183,,,B,,,Autocuration,,,
4072,BAO_0000357,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,H,1,,CHEMBL620874,,55,2578,,,B,,,Autocuration,,,
4073,BAO_0000357,In vitro inhibition of human 5-Lipoxygenase.,,H,1,,CHEMBL620875,,55,12780,,,B,,,Expert,,,
4074,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,2107.0,U,1,,CHEMBL620876,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4075,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,2107.0,U,1,,CHEMBL620877,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4076,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,2107.0,U,1,,CHEMBL857854,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4077,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,2107.0,U,1,,CHEMBL620878,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4078,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,2107.0,U,1,,CHEMBL620879,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4079,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,2107.0,U,1,,CHEMBL620880,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4080,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,2107.0,U,1,,CHEMBL620881,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4081,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,2107.0,U,1,,CHEMBL620882,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4082,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,2107.0,U,1,,CHEMBL620883,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4083,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,2107.0,U,1,,CHEMBL620884,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4084,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,2107.0,U,1,,CHEMBL620885,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4085,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,2107.0,U,1,,CHEMBL620886,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4086,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,2107.0,U,1,,CHEMBL620887,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4087,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,2107.0,U,1,,CHEMBL618039,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4088,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,2107.0,U,1,,CHEMBL618040,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4089,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,2107.0,U,1,,CHEMBL618041,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4090,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",2107.0,U,1,,CHEMBL618216,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4091,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",2107.0,U,1,,CHEMBL618217,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4092,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,2107.0,U,1,,CHEMBL618218,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4093,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,2107.0,U,1,,CHEMBL618219,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4094,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,2107.0,U,1,,CHEMBL618220,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4095,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,2107.0,U,1,,CHEMBL618221,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4096,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,2107.0,U,1,,CHEMBL618222,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4097,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,2107.0,U,1,,CHEMBL618223,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4098,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,2107.0,U,1,,CHEMBL618224,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4099,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,2107.0,U,1,,CHEMBL618225,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4100,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,2107.0,U,1,,CHEMBL618226,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4101,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,2107.0,U,1,,CHEMBL618227,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4102,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,2107.0,U,1,,CHEMBL618228,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4103,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,2107.0,U,1,,CHEMBL618229,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4104,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,2107.0,U,1,,CHEMBL618230,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4105,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,2107.0,U,1,,CHEMBL618231,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4106,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,2107.0,U,1,,CHEMBL618232,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4107,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,2107.0,U,1,,CHEMBL618233,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4108,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,2107.0,U,1,,CHEMBL618234,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4109,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,2107.0,U,1,,CHEMBL618235,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4110,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,2107.0,U,1,,CHEMBL618115,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4111,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,2107.0,U,1,,CHEMBL618116,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4112,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,2107.0,U,1,,CHEMBL618117,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4113,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,2107.0,U,1,,CHEMBL619968,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4114,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,2107.0,U,1,,CHEMBL619969,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4115,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,2107.0,U,1,,CHEMBL619970,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4116,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,2107.0,U,1,,CHEMBL619971,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4117,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,2107.0,U,1,,CHEMBL619972,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4118,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,2107.0,U,1,,CHEMBL619973,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4119,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,2107.0,U,1,,CHEMBL619974,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4120,BAO_0000251,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,2107.0,U,1,,CHEMBL619975,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4121,BAO_0000251,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,U,1,,CHEMBL619976,,22226,7411,Microsomes,,B,,,Autocuration,,,
4122,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",2107.0,U,1,,CHEMBL619977,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4123,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",2107.0,U,1,,CHEMBL619978,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4124,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",2107.0,U,1,,CHEMBL619979,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4125,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",2107.0,U,1,,CHEMBL619980,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4126,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",2107.0,U,1,,CHEMBL619981,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4127,BAO_0000219,In vitro inhibition of 7226/S myeloma cancer cell line,,N,1,RPMI-8226,CHEMBL619982,,80433,10797,,,F,,,Intermediate,,741.0,
4128,BAO_0000219,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,N,1,BEL-7404 tumor cell line,CHEMBL619983,,80698,6881,,,F,,,Intermediate,,993.0,
4129,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,N,1,786-0,CHEMBL620031,,80640,3838,,,F,,,Intermediate,,391.0,
4130,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,N,1,786-0,CHEMBL620032,,80640,3838,,,F,,,Intermediate,,391.0,
4131,BAO_0000219,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,N,1,V79,CHEMBL620033,,81264,12981,,,F,,,Expert,,505.0,
4132,BAO_0000219,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,N,1,V79,CHEMBL620034,,81264,12981,,,F,,,Expert,,505.0,
4133,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,N,1,7800C1 cell line,CHEMBL620035,,80635,7653,,,F,,,Intermediate,,1119.0,
4134,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,N,1,7800C1 cell line,CHEMBL618318,,80635,7653,,,F,,,Intermediate,,1119.0,
4135,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,N,1,7800C1 cell line,CHEMBL618319,,80635,7653,,,F,,,Intermediate,,1119.0,
4136,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,N,1,7800C1 cell line,CHEMBL618320,,80635,7653,,,F,,,Intermediate,,1119.0,
4137,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,N,1,7800C1 cell line,CHEMBL618321,,80635,7653,,,F,,,Intermediate,,1119.0,
4138,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,N,1,7800C1 cell line,CHEMBL883118,,80635,7653,,,F,,,Intermediate,,1119.0,
4139,BAO_0000219,In vitro antitumor activity against renal 786-0 tumor cell lines,,N,1,786-0,CHEMBL883795,,80640,17229,,,F,,,Intermediate,,391.0,
4140,BAO_0000219,Cytotoxic activity against 786-0 Renal cancer cell line,,N,1,786-0,CHEMBL618322,,80640,12858,,,F,,,Intermediate,,391.0,
4141,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,N,1,786-0,CHEMBL618323,,80640,16325,,,F,,,Intermediate,,391.0,
4142,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,N,1,786-0,CHEMBL618324,,80640,16325,,,F,,,Intermediate,,391.0,
4143,BAO_0000219,In vitro antitumor activity against human renal 786-0 cell line,,N,1,786-0,CHEMBL618325,,80640,5858,,,F,,,Intermediate,,391.0,
4144,BAO_0000219,Inhibition of Renal cancer in 786-0 cancer cell lines,,N,1,786-0,CHEMBL875416,,80640,16325,,,F,,,Intermediate,,391.0,
4145,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,N,1,786-0,CHEMBL618326,,80640,14696,,,F,,,Intermediate,,391.0,
4146,BAO_0000219,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,N,1,786-0,CHEMBL618327,,80640,3786,,,F,,,Intermediate,,391.0,
4147,BAO_0000219,inhibition of the growth of renal cancer(786-0) cell line,,N,1,786-0,CHEMBL619215,,80640,14696,,,F,,,Intermediate,,391.0,
4148,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,N,1,786-0,CHEMBL619216,,80640,14769,,,F,,,Intermediate,,391.0,
4149,BAO_0000219,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,N,1,786-0,CHEMBL619217,,80640,15354,,,F,,,Intermediate,,391.0,
4150,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor,,N,1,786-0,CHEMBL619218,,80640,14255,,,F,,,Intermediate,,391.0,
4151,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,N,1,786-0,CHEMBL619219,,80640,14255,,,F,,,Intermediate,,391.0,
4152,BAO_0000219,The IC50 value was measured on 786-0 cell line in renal tumor type.,,N,1,786-0,CHEMBL619220,,80640,14255,,,F,,,Intermediate,,391.0,
4153,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,N,1,786-0,CHEMBL619221,,80640,14696,,,F,,,Intermediate,,391.0,
4154,BAO_0000219,Tested for cytotoxic activity against renal cancer 786-0 cell line,,N,1,786-0,CHEMBL619222,,80640,12016,,,F,,,Intermediate,,391.0,
4155,BAO_0000219,Compound was tested for growth inhibitory activity against 786-0 cell line,,N,1,786-0,CHEMBL857454,,80640,2597,,,F,,,Intermediate,,391.0,
4156,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,H,1,RBL-1,CHEMBL619223,,12166,12526,,,B,,,Autocuration,,702.0,
4157,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,H,1,RBL-1,CHEMBL619224,,12166,12526,,,B,,,Autocuration,,702.0,
4158,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,H,1,,CHEMBL619225,,12166,14799,,,B,,,Autocuration,,,
4159,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,H,1,RBL-1,CHEMBL619226,,12166,3595,,,B,,,Expert,,702.0,
4160,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,H,1,RBL-1,CHEMBL619227,,12166,3595,,,B,,,Expert,,702.0,
4161,BAO_0000357,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,H,1,,CHEMBL619228,,12166,12767,,,B,,,Autocuration,,,
4162,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,H,1,,CHEMBL619229,,12166,10997,,,B,,,Autocuration,,,
4163,BAO_0000219,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,H,1,RBL-1,CHEMBL619230,,12166,11388,,,B,,,Autocuration,,702.0,
4164,BAO_0000357,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,H,1,,CHEMBL619231,,12166,167,,,B,,,Autocuration,,,
4165,BAO_0000357,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,H,1,,CHEMBL619232,,12166,167,,,B,,,Autocuration,,,
4166,BAO_0000357,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,H,1,,CHEMBL619233,,12166,13744,,,B,,,Expert,,,
4167,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,H,1,,CHEMBL619234,,12166,1630,,,B,,,Autocuration,,,
4168,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,H,1,,CHEMBL619235,,12166,1630,,,B,,,Autocuration,,,
4169,BAO_0000019,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,D,1,,CHEMBL619236,,12166,969,,,B,,,Expert,,,
4170,BAO_0000219,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,H,1,RBL-1,CHEMBL619237,,12166,13621,,,B,,,Autocuration,,702.0,
4171,BAO_0000357,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,H,1,,CHEMBL619238,,12166,10089,,,B,,,Autocuration,,,
4172,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,H,1,,CHEMBL619239,,12166,10193,,,B,,,Expert,,,
4173,BAO_0000357,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,H,1,,CHEMBL619240,,12166,11966,,,B,,,Autocuration,,,
4174,BAO_0000019,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,H,1,,CHEMBL875417,,12166,12251,,,B,,,Autocuration,,,
4175,BAO_0000219,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,H,1,RBL-1,CHEMBL619241,,12166,211,,,B,,,Autocuration,,702.0,
4176,BAO_0000019,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,H,1,,CHEMBL619242,,12166,12251,,,F,,,Expert,,,
4177,BAO_0000219,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,H,1,RBL-1,CHEMBL883796,,12166,12495,,,B,,,Autocuration,,702.0,
4178,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase,,H,1,,CHEMBL619243,,12166,414,,,B,,,Autocuration,,,
4179,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,H,1,,CHEMBL619244,,12166,414,,,B,,,Autocuration,,,
4180,BAO_0000019,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,H,1,,CHEMBL619245,,12166,10325,,,B,,,Expert,,,
4181,BAO_0000019,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,H,1,,CHEMBL619246,,12166,11966,,,B,,,Expert,,,
4182,BAO_0000219,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,H,1,RBL-1,CHEMBL619984,,12166,165,,,B,,,Expert,,702.0,
4183,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,H,1,RBL-1,CHEMBL619985,,12166,165,,,B,,,Autocuration,,702.0,
4184,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,H,1,RBL-1,CHEMBL619986,,12166,165,,,B,,,Autocuration,,702.0,
4185,BAO_0000219,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,H,1,RBL-1,CHEMBL619987,,12166,165,,,B,,,Expert,,702.0,
4186,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,H,1,,CHEMBL619988,,12166,11311,,,B,,,Autocuration,,,
4187,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,H,1,RBL-1,CHEMBL619989,,12166,11311,,,B,,,Autocuration,,702.0,
4188,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,H,1,RBL-1,CHEMBL619990,,12166,11311,,,B,,,Autocuration,,702.0,
4189,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL619991,,12166,11311,,,B,,,Autocuration,,,
4190,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,H,1,,CHEMBL619992,,12166,11311,,,B,,,Autocuration,,,
4191,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,H,1,,CHEMBL619993,In vivo,12166,11311,,,B,,,Autocuration,,,
4192,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,H,1,RBL-2H3,CHEMBL619994,,12166,11311,,,F,,,Autocuration,,663.0,
4193,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,H,1,RBL-2H3,CHEMBL619995,,12166,11311,,,F,,,Autocuration,,663.0,
4194,BAO_0000019,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,H,1,,CHEMBL619996,,12166,11311,,,B,,,Autocuration,,,
4195,BAO_0000019,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,H,1,,CHEMBL619997,,12166,11732,,,B,,,Autocuration,,,
4196,BAO_0000019,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,H,1,,CHEMBL619998,,12166,11732,,,B,,,Expert,,,
4197,BAO_0000019,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,H,1,,CHEMBL619999,,12166,11087,,,B,,,Expert,,,
4198,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,H,1,,CHEMBL620000,,12166,11087,,,B,,,Autocuration,,,
4199,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,H,1,RBL-1,CHEMBL620001,,12166,11087,,,B,,,Autocuration,,702.0,
4200,BAO_0000357,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,D,1,,CHEMBL620002,,12166,11087,,,B,,,Expert,,,
4201,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,H,1,RBL-1,CHEMBL620003,,12166,496,,,B,,,Autocuration,,702.0,
4202,BAO_0000219,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,H,1,RBL-1,CHEMBL620004,,12166,13986,,,F,,,Expert,,702.0,
4203,BAO_0000357,Compound was evaluated for the inhibition of 5-lipoxygenase,,H,1,,CHEMBL874063,,12166,11520,,,B,,,Autocuration,,,
4204,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,H,1,RBL-1,CHEMBL620005,,12166,10293,,,B,,,Autocuration,,702.0,
4205,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,H,1,RBL-1,CHEMBL620006,,12166,303,,,B,,,Autocuration,,702.0,
4206,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,H,1,RBL-1,CHEMBL620007,,12166,303,,,B,,,Autocuration,,702.0,
4207,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,H,1,RBL-1,CHEMBL620008,,12166,9247,,,B,,,Autocuration,,702.0,
4208,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,D,1,RBL-1,CHEMBL620009,,12166,9247,,,B,,,Expert,,702.0,
4209,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,H,1,RBL-1,CHEMBL620010,,12166,9247,,,B,,,Autocuration,,702.0,
4210,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,H,1,RBL-1,CHEMBL620011,,12166,9247,,,B,,,Autocuration,,702.0,
4211,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,H,1,RBL-1,CHEMBL620677,,12166,9247,,,B,,,Autocuration,,702.0,
4212,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,H,1,RBL-1,CHEMBL620678,,12166,9247,,,B,,,Autocuration,,702.0,
4213,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,H,1,RBL-1,CHEMBL620679,,12166,9247,,,B,,,Autocuration,,702.0,
4214,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,H,1,RBL-1,CHEMBL620680,,12166,9247,,,B,,,Autocuration,,702.0,
4215,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,,D,1,,CHEMBL620838,,12166,11481,,,B,,,Expert,,,
4216,BAO_0000357,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,H,1,,CHEMBL620839,,12166,105,,,B,,,Autocuration,,,
4217,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,H,1,,CHEMBL620840,,12166,9029,,,B,,,Expert,,,
4218,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,H,1,RBL-1,CHEMBL620841,,12166,1175,,,B,,,Expert,,702.0,
4219,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,H,1,RBL-1,CHEMBL620842,,12166,12118,,,B,,,Autocuration,,702.0,
4220,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,H,1,RBL-1,CHEMBL620843,,12166,12118,,,B,,,Autocuration,,702.0,
4221,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,H,1,RBL-1,CHEMBL620844,,12166,12118,,,B,,,Autocuration,,702.0,
4222,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,H,1,RBL-1,CHEMBL620845,,12166,9225,,,B,,,Autocuration,,702.0,
4223,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,H,1,,CHEMBL620846,,12166,9401,,,B,,,Autocuration,,,
4224,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,H,1,,CHEMBL873951,,12166,137,,,B,,,Autocuration,,,
4225,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,H,1,,CHEMBL620847,,12166,137,,,B,,,Autocuration,,,
4226,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,H,1,RBL-1,CHEMBL620848,,12166,4717,,,B,,,Autocuration,,702.0,
4227,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,H,1,RBL-1,CHEMBL620849,,12166,3595,,,B,,,Autocuration,,702.0,
4228,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,H,1,RBL-1,CHEMBL620850,,12166,10501,,,B,,,Autocuration,,702.0,
4229,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,H,1,RBL-1,CHEMBL620851,,12166,10501,,,B,,,Autocuration,,702.0,
4230,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,H,1,RBL-1,CHEMBL620852,,12166,10501,,,B,,,Autocuration,,702.0,
4231,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,1,RBL-1,CHEMBL875098,,12166,12526,,,B,,,Autocuration,,702.0,
4232,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,D,1,RBL-1,CHEMBL620853,,12166,14799,,,B,,,Expert,,702.0,
4233,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,H,1,,CHEMBL620854,,12166,14799,,,B,,,Autocuration,,,
4234,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,H,1,RBL-1,CHEMBL620855,,12166,3595,,,B,,,Autocuration,,702.0,
4235,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,H,1,RBL-1,CHEMBL839884,,12166,3595,,,B,,,Expert,,702.0,
4236,BAO_0000219,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,1,RBL-1,CHEMBL620856,,12166,12526,,,B,,,Autocuration,,702.0,
4237,BAO_0000219,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,1,RBL-1,CHEMBL620857,,12166,12526,,,B,,,Autocuration,,702.0,
4238,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,H,1,,CHEMBL620858,,12166,10193,,,B,,,Autocuration,,,
4239,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,H,1,,CHEMBL620859,,12166,10193,,,B,,,Autocuration,,,
4240,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,H,1,,CHEMBL620860,,12166,10193,,,B,,,Autocuration,,,
4241,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,H,1,,CHEMBL620861,,12166,10193,,,B,,,Autocuration,,,
4242,BAO_0000357,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,H,1,,CHEMBL620862,,12166,9138,,,B,,,Expert,,,
4243,BAO_0000357,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,H,1,,CHEMBL620863,,12166,9138,,,B,,,Autocuration,,,
4244,BAO_0000019,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,H,1,,CHEMBL620864,,12166,11966,,,B,,,Autocuration,,,
4245,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,H,1,RBL-1,CHEMBL620865,,12166,165,,,B,,,Autocuration,,702.0,
4246,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,H,1,RBL-1,CHEMBL620866,,12166,165,,,B,,,Autocuration,,702.0,
4247,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,H,1,RBL-2H3,CHEMBL620867,,12166,11311,,,B,,,Autocuration,,663.0,
4248,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,H,1,RBL-2H3,CHEMBL620868,,12166,11311,,,B,,,Autocuration,,663.0,
4249,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,H,1,RBL-2H3,CHEMBL620869,,12166,11311,,,F,,,Autocuration,,663.0,
4250,BAO_0000019,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,H,1,,CHEMBL873952,,12166,11311,,,F,,,Autocuration,,,
4251,BAO_0000357,The compound was tested for inhibition of isolated 5-lipoxygenase,,H,1,,CHEMBL875099,,12166,11311,,,B,,,Autocuration,,,
4252,BAO_0000219,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,H,1,RBL-2H3,CHEMBL620870,,12166,11311,,,F,,,Autocuration,,663.0,
4253,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,H,1,,CHEMBL618261,,12166,11087,,,B,,,Autocuration,,,
4254,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,H,1,,CHEMBL618262,,12166,11087,,,B,,,Autocuration,,,
4255,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,H,1,,CHEMBL619428,,12166,11087,,,B,,,Autocuration,,,
4256,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,H,1,,CHEMBL619429,,12166,11087,,,B,,,Autocuration,,,
4257,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,H,1,,CHEMBL619430,,12166,11087,,,B,,,Autocuration,,,
4258,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,H,1,RBL-1,CHEMBL620017,,12166,496,,,B,,,Autocuration,,702.0,
4259,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,H,1,RBL-1,CHEMBL620018,,12166,496,,,B,,,Autocuration,,702.0,
4260,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,H,1,RBL-1,CHEMBL620019,,12166,13986,,,F,,,Autocuration,,702.0,
4261,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,H,1,RBL-1,CHEMBL620020,,12166,13986,,,F,,,Autocuration,,702.0,
4262,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,H,1,RBL-1,CHEMBL620021,,12166,13986,,,F,,,Autocuration,,702.0,
4263,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,H,1,RBL-1,CHEMBL620022,,12166,13986,,,F,,,Autocuration,,702.0,
4264,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,H,1,RBL-1,CHEMBL620023,,12166,13986,,,F,,,Autocuration,,702.0,
4265,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,H,1,RBL-1,CHEMBL620024,,12166,13986,,,F,,,Autocuration,,702.0,
4266,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,H,1,RBL-1,CHEMBL620025,,12166,13986,,,F,,,Autocuration,,702.0,
4267,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,H,1,RBL-1,CHEMBL620026,,12166,13986,,,F,,,Autocuration,,702.0,
4268,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,H,1,RBL-1,CHEMBL620027,,12166,13986,,,F,,,Autocuration,,702.0,
4269,BAO_0000019,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,D,1,,CHEMBL620028,,12166,13986,,,F,,,Expert,,,
4270,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,H,1,,CHEMBL620029,,12166,10193,,,B,,,Autocuration,,,
4271,BAO_0000357,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,H,1,,CHEMBL620030,,12166,9295,,,B,,,Autocuration,,,
4272,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,H,1,RBL-1,CHEMBL875415,,12166,4717,,,B,,,Autocuration,,702.0,
4273,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,H,1,RBL-1,CHEMBL618256,,12166,4717,,,B,,,Autocuration,,702.0,
4274,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,H,1,RBL-1,CHEMBL618257,,12166,11854,,,B,,,Autocuration,,702.0,
4275,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,H,1,RBL-1,CHEMBL618258,,12166,11854,,,B,,,Autocuration,,702.0,
4276,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,H,1,RBL-1,CHEMBL618259,,12166,11854,,,B,,,Autocuration,,702.0,
4277,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,H,1,,CHEMBL618260,,12166,10193,,,B,,,Autocuration,,,
4278,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,H,1,RBL-1,CHEMBL618215,,12166,9295,,,B,,,Autocuration,,702.0,
4279,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,H,1,RBL-1,CHEMBL618390,,12166,9295,,,B,,,Autocuration,,702.0,
4280,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,H,1,RBL-1,CHEMBL618391,,12166,9295,,,B,,,Autocuration,,702.0,
4281,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,H,1,RBL-1,CHEMBL618392,,12166,9295,,,B,,,Autocuration,,702.0,
4282,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,H,1,RBL-1,CHEMBL618393,,12166,165,,,B,,,Autocuration,,702.0,
4283,BAO_0000219,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,H,1,,CHEMBL618394,,12166,11311,,,B,,,Autocuration,,,
4284,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,H,1,RBL-1,CHEMBL618395,,12166,10489,,,B,,,Expert,,702.0,
4285,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,D,1,RBL-1,CHEMBL618396,,12166,10489,,,B,,,Expert,,702.0,
4286,BAO_0000219,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,D,1,RBL-1,CHEMBL858253,,12166,10489,,,B,,,Expert,,702.0,
4287,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,D,1,,CHEMBL618397,,12166,14799,,,B,,,Autocuration,,,
4288,BAO_0000357,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,H,1,,CHEMBL618398,,12054,9295,,,B,,,Autocuration,,,
4289,BAO_0000019,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,U,1,,CHEMBL618399,,22226,16811,,,B,,,Autocuration,,,
4290,BAO_0000357,In vitro inhibition of 5-Lipoxygenase; Inactive.,,H,1,,CHEMBL618400,,55,168,,,B,,,Expert,,,
4291,BAO_0000357,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,H,1,,CHEMBL618401,,55,6309,,,B,,,Autocuration,,,
4292,BAO_0000357,Inhibitory concentration against 5-lipoxygenase; No inhibition,,H,1,,CHEMBL618402,,55,6309,,,B,,,Autocuration,,,
4293,BAO_0000219,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,H,1,RBL-1,CHEMBL876400,,55,3092,,,B,,,Autocuration,,702.0,
4294,BAO_0000357,Inhibitory activity against 5-lipoxygenase.,,H,1,,CHEMBL618403,,55,168,,,B,,,Expert,,,
4295,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,H,1,,CHEMBL618404,,55,168,,,B,,,Autocuration,,,
4296,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,H,1,,CHEMBL618405,,55,168,,,B,,,Autocuration,,,
4297,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,H,1,,CHEMBL618406,,55,168,,,B,,,Autocuration,,,
4298,BAO_0000019,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,H,1,,CHEMBL618407,,55,12338,,,F,,,Expert,,,
4299,BAO_0000357,Tested for the inhibitory activity against 5-lipoxygenase,,H,1,,CHEMBL618408,,55,4501,,,B,,,Autocuration,,,
4300,BAO_0000357,Compound was tested for its inhibitory activity against 5-lipoxygenase,,H,1,,CHEMBL618409,,55,1132,,,B,,,Autocuration,,,
4301,BAO_0000357,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,H,1,,CHEMBL618410,,55,2117,,,B,,,Autocuration,,,
4302,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,H,1,,CHEMBL618411,,55,168,,,B,,,Autocuration,,,
4303,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,H,1,,CHEMBL618412,,55,168,,,B,,,Autocuration,,,
4304,BAO_0000219,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,H,1,RBL-1,CHEMBL618413,,12166,13575,,,B,,,Autocuration,,702.0,
4305,BAO_0000357,,,H,1,,CHEMBL618414,,12166,11089,,,B,,,Autocuration,,,
4306,BAO_0000357,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,H,1,,CHEMBL618415,,10102,216,,,B,,,Autocuration,,,
4307,BAO_0000019,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,H,1,,CHEMBL618416,,10102,13165,,,B,,,Autocuration,,,
4308,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,H,1,,CHEMBL876401,,10102,3278,,,B,,,Autocuration,,,
4309,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,H,1,,CHEMBL618417,,10102,3278,,,B,,,Expert,,,
4310,BAO_0000357,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,H,1,,CHEMBL618418,,10102,11966,,,B,,,Autocuration,,,
4311,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,H,1,,CHEMBL618419,,10102,175,,,B,,,Autocuration,,,
4312,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,H,1,,CHEMBL618420,,10102,175,,,B,,,Autocuration,,,
4313,BAO_0000357,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,H,1,,CHEMBL618421,,10102,13449,,,B,,,Autocuration,,,
4314,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,H,1,,CHEMBL618422,,11238,12014,,,B,,,Autocuration,,,
4315,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,H,1,,CHEMBL618423,,11238,12014,,,B,,,Autocuration,,,
4316,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,H,1,,CHEMBL618424,,11238,12014,,,B,,,Autocuration,,,
4317,BAO_0000220,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,S,1,,CHEMBL618425,,100284,99,,,B,,,Intermediate,,,
4318,BAO_0000019,The dark toxicity against 543 human galactophore carcinoma cells,,U,1,,CHEMBL618426,,22226,4349,,,F,,,Autocuration,,,
4319,BAO_0000219,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,N,1,Panel (56 tumour cell lines),CHEMBL618427,,80623,4071,,,F,,,Expert,,390.0,
4320,BAO_0000219,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,N,1,5637,CHEMBL618428,,80008,17589,,,F,,,Expert,,345.0,
4321,BAO_0000219,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,N,1,5637,CHEMBL618429,,80008,15002,,,F,,,Intermediate,,345.0,
4322,BAO_0000219,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,N,1,5637,CHEMBL618430,,80008,13958,,,F,,,Intermediate,,345.0,
4323,BAO_0000219,Growth inhibition against human 5637 cell lines,,N,1,5637,CHEMBL618431,,80008,17589,,,F,,,Expert,,345.0,
4324,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells.,,N,1,5637,CHEMBL883799,,80008,16748,,,F,,,Expert,,345.0,
4325,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,,N,1,5637,CHEMBL618432,,80008,16747,,,F,,,Intermediate,,345.0,
4326,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,,N,1,5637,CHEMBL618433,,80008,16747,,,F,,,Intermediate,,345.0,
4327,BAO_0000357,In vitro inhibition of bovine trypsin(Trp).,,D,1,,CHEMBL618434,,10443,15285,,,B,,,Expert,,,
4328,BAO_0000219,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,H,1,CV-1,CHEMBL618435,,240,3726,,,B,,,Expert,,407.0,
4329,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,H,1,,CHEMBL876402,,10577,5033,,,B,,,Autocuration,,,
4330,BAO_0000019,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,H,1,,CHEMBL618436,,104698,11756,,,F,,,Autocuration,,,
4331,BAO_0000218,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,U,1,,CHEMBL618437,In vivo,22226,11953,,,F,,,Autocuration,,,
4332,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,D,1,,CHEMBL618438,,20033,5033,,,B,,,Intermediate,,,
4333,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,H,1,,CHEMBL883800,,17045,11347,Microsomes,,A,,,Expert,,,
4334,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,H,1,,CHEMBL618439,,17045,11347,Microsomes,,A,,,Expert,,,
4335,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,U,1,,CHEMBL618440,,22226,1229,,,F,,,Intermediate,,,
4336,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,U,1,,CHEMBL618441,,22226,1229,,,F,,,Intermediate,,,
4337,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,H,1,,CHEMBL618442,,11938,17588,,,B,,,Expert,,,
4338,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,H,1,,CHEMBL618443,,11938,17588,,,B,,,Autocuration,,,
4339,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,H,1,,CHEMBL619158,,11938,17588,,,B,,,Expert,,,
4340,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,H,1,,CHEMBL620974,,11938,17588,,,B,,,Autocuration,,,
4341,BAO_0000357,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,H,1,,CHEMBL620975,,11938,16485,,,B,,,Autocuration,,,
4342,BAO_0000019,Average inhibitory concentration against 60 human cell lines was reported,,U,1,,CHEMBL620976,,22226,4337,,,F,,,Intermediate,,,
4343,BAO_0000019,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,U,1,,CHEMBL620977,,22226,4112,,,F,,,Expert,,,
4344,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,N,1,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620978,,80315,16160,,,F,,,Intermediate,,542.0,
4345,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,N,1,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620979,,80315,16160,,,F,,,Intermediate,,542.0,
4346,BAO_0000219,In vitro mean growth inhibitory activity against 60-cell panel,,N,1,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620980,,80315,17376,,,F,,,Expert,,542.0,
4347,BAO_0000219,In vitro mean growth lethal concentration against 60-cell panel,,N,1,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620981,,80315,17376,,,F,,,Expert,,542.0,
4348,BAO_0000219,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,N,1,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620982,,80315,17376,,,F,,,Expert,,542.0,
4349,BAO_0000219,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,N,1,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620983,,80315,17376,,,F,,,Expert,,542.0,
4350,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,H,1,,CHEMBL620984,,104775,3241,,,F,,,Autocuration,,,
4351,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,H,1,,CHEMBL620985,,104775,3241,,,F,,,Autocuration,,,
4352,BAO_0000357,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,H,1,,CHEMBL620986,,275,3725,,,B,,,Expert,,,
4353,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,N,1,,CHEMBL620987,,50425,10805,,,F,,,Expert,,,
4354,BAO_0000218,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,N,1,,CHEMBL620988,,50425,10805,,,F,,,Expert,,,
4355,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,N,1,,CHEMBL620989,,50425,10805,,,F,,,Expert,,,
4356,BAO_0000218,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,N,1,,CHEMBL620990,,50425,10805,,,F,,,Expert,,,
4357,BAO_0000218,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,N,1,,CHEMBL620991,,50425,10805,,,F,,,Intermediate,,,
4358,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,N,1,6C3HED,CHEMBL620992,,80628,10144,,,F,,,Intermediate,,850.0,
4359,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,N,1,6C3HED,CHEMBL620993,,80628,10144,,,F,,,Intermediate,,850.0,
4360,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,N,1,6C3HED,CHEMBL620994,,80628,10144,,,F,,,Intermediate,,850.0,
4361,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,N,1,6C3HED,CHEMBL620995,,80628,10144,,,F,,,Intermediate,,850.0,
4362,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,N,1,6C3HED,CHEMBL620996,,80628,10144,,,F,,,Intermediate,,850.0,
4363,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,N,1,6C3HED,CHEMBL875581,,80628,10144,,,F,,,Intermediate,,850.0,
4364,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,U,1,,CHEMBL620997,In vivo,22224,10685,,,F,,,Autocuration,,,
4365,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,U,1,,CHEMBL620998,In vivo,22224,10685,,,F,,,Autocuration,,,
4366,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,U,1,,CHEMBL620999,In vivo,22224,10685,,,F,,,Autocuration,,,
4367,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,U,1,,CHEMBL621000,In vivo,22224,10685,,,F,,,Autocuration,,,
4368,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,U,1,,CHEMBL621001,In vivo,22224,10685,,,F,,,Autocuration,,,
4369,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,U,1,,CHEMBL621002,In vivo,22224,10685,,,F,,,Autocuration,,,
4370,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,U,1,,CHEMBL621003,In vivo,22224,10685,,,F,,,Autocuration,,,
4371,BAO_0000218,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,U,1,,CHEMBL621004,In vivo,22224,10685,,,F,,,Autocuration,,,
4372,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,U,1,,CHEMBL621005,In vivo,22224,10685,,,F,,,Autocuration,,,
4373,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,U,1,,CHEMBL621006,In vivo,22224,10685,,,F,,,Autocuration,,,
4374,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,U,1,,CHEMBL621007,In vivo,22224,10685,,,F,,,Autocuration,,,
4375,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,U,1,,CHEMBL621008,,22224,10144,,,F,,,Autocuration,,,
4376,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,U,1,,CHEMBL621009,,22224,10144,,,F,,,Autocuration,,,
4377,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,U,1,,CHEMBL857705,,22224,10144,,,F,,,Autocuration,,,
4378,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,U,1,,CHEMBL619828,,22224,10144,,,F,,,Autocuration,,,
4379,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,U,1,,CHEMBL619829,,22224,10685,,,F,,,Autocuration,,,
4380,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,U,1,,CHEMBL619830,,22224,10685,,,F,,,Autocuration,,,
4381,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,U,1,,CHEMBL619831,,22224,10685,,,F,,,Autocuration,,,
4382,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,U,1,,CHEMBL619832,,22224,10685,,,F,,,Autocuration,,,
4383,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,U,1,,CHEMBL619833,,22224,10685,,,A,,,Autocuration,,,
4384,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,U,1,,CHEMBL619834,,22224,10685,,,A,,,Autocuration,,,
4385,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,U,1,,CHEMBL619835,,22224,10685,,,A,,,Autocuration,,,
4386,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,U,1,,CHEMBL619836,,22224,10685,,,A,,,Autocuration,,,
4387,BAO_0000218,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,N,1,6C3HED,CHEMBL619837,,80628,8831,,,F,,,Intermediate,,850.0,
4388,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,U,1,,CHEMBL619838,In vivo,22224,11704,,,F,,,Autocuration,,,
4389,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,N,1,,CHEMBL619839,,50594,11704,,,A,,,Intermediate,,,
4390,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,N,1,6C3HED,CHEMBL619840,In vivo,80628,10685,,,F,,,Intermediate,,850.0,
4391,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,N,1,6C3HED,CHEMBL619841,In vivo,80628,10685,,,F,,,Intermediate,,850.0,
4392,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,N,1,6C3HED,CHEMBL857704,,80628,11368,,,F,,,Expert,,850.0,
4393,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,N,1,6C3HED,CHEMBL619842,,80628,11368,,,F,,,Intermediate,,850.0,
4394,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,N,1,6C3HED,CHEMBL619843,,80628,11368,,,F,,,Expert,,850.0,
4395,BAO_0000019,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,U,1,,CHEMBL619844,,22226,17763,,,B,,,Autocuration,,,
4396,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,2107.0,U,1,,CHEMBL857855,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4397,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,2107.0,U,1,,CHEMBL619845,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4398,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,2107.0,U,1,,CHEMBL619846,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4399,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,2107.0,U,1,,CHEMBL619847,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4400,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,2107.0,U,1,,CHEMBL619848,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4401,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,2107.0,U,1,,CHEMBL620893,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4402,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,2107.0,U,1,,CHEMBL620894,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4403,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,2107.0,U,1,,CHEMBL620895,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4404,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,2107.0,U,1,,CHEMBL620896,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4405,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,2107.0,U,1,,CHEMBL620897,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4406,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,2107.0,U,1,,CHEMBL620898,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4407,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,2107.0,U,1,,CHEMBL620899,,22226,7411,Microsomes,Liver,B,,,Autocuration,,,
4408,BAO_0000218,The apparent total plasma clearance in monkey,1969.0,U,1,,CHEMBL620900,In vivo,22224,347,,Plasma,A,,,Autocuration,,,
4409,BAO_0000218,Compound was evaluated for Hepatic clearance in monkey,,U,1,,CHEMBL620901,In vivo,22224,3341,,,A,,,Autocuration,,,
4410,BAO_0000218,Lower clearance in monkey (i.v.) at 0.5 mpk,,U,1,,CHEMBL620902,In vivo,22224,17853,,,A,,,Autocuration,,,
4411,BAO_0000218,Plasma clearance in rhesus monkey,,U,1,,CHEMBL620903,In vivo,22224,4514,,,A,,,Autocuration,,,
4412,BAO_0000218,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,U,1,,CHEMBL620904,In vivo,22224,6062,,,A,,,Autocuration,,,
4413,BAO_0000218,Plasma clearance of compound was determined in monkey,,U,1,,CHEMBL620905,In vivo,22224,6821,,,A,,,Autocuration,,,
4414,BAO_0000218,Plasma clearance was calculated in rhesus monkey,,U,1,,CHEMBL620906,In vivo,22224,6057,,,A,,,Autocuration,,,
4415,BAO_0000218,Plasma clearance in rhesus monkey,,U,1,,CHEMBL875420,In vivo,22224,5145,,,A,,,Autocuration,,,
4416,BAO_0000218,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,1,,CHEMBL620907,In vivo,22224,6641,,,A,,,Autocuration,,,
4417,BAO_0000218,Plasma clearance was evaluated in rhesus,,U,1,,CHEMBL620908,In vivo,22224,5472,,,A,,,Autocuration,,,
4418,BAO_0000218,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,U,1,,CHEMBL620909,In vivo,22224,4257,,,A,,,Autocuration,,,
4419,BAO_0000218,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,U,1,,CHEMBL620910,In vivo,22224,5546,,,A,,,Autocuration,,,
4420,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,1,,CHEMBL620911,In vivo,22224,5334,,,A,,,Autocuration,,,
4421,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,1,,CHEMBL620912,In vivo,22224,5334,,,A,,,Autocuration,,,
4422,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,U,1,,CHEMBL620913,In vivo,22224,17509,,,A,,,Autocuration,,,
4423,BAO_0000218,Cmax in monkey after administration of 1 mg/kg iv,,U,1,,CHEMBL620914,In vivo,22224,6535,,,A,,,Autocuration,,,
4424,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rhesus,,U,1,,CHEMBL620915,In vivo,22224,5668,,,A,,,Autocuration,,,
4425,BAO_0000218,Cmax in cynomolgus monkey by iv administration,,U,1,,CHEMBL620916,In vivo,22224,5922,,,A,,,Autocuration,,,
4426,BAO_0000218,Cmax in cynomolgus monkey by po administration,,U,1,,CHEMBL620917,In vivo,22224,5922,,,A,,,Autocuration,,,
4427,BAO_0000218,Cmax value evaluated in monkey,,U,1,,CHEMBL620918,In vivo,22224,6078,,,A,,,Autocuration,,,
4428,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,1,,CHEMBL620919,In vivo,22224,2661,,,A,,,Autocuration,,,
4429,BAO_0000218,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,1969.0,U,1,,CHEMBL620920,In vivo,22224,3249,,Plasma,A,,,Autocuration,,,
4430,BAO_0000218,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,1969.0,U,1,,CHEMBL620921,In vivo,22224,3249,,Plasma,A,,,Autocuration,,,
4431,BAO_0000218,Maximal plasma concentration in squirrel monkeys,1969.0,U,1,,CHEMBL620922,In vivo,22224,5553,,Plasma,A,,,Autocuration,,,
4432,BAO_0000218,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,1,,CHEMBL620923,In vivo,22224,1916,,,A,,,Autocuration,,,
4433,BAO_0000218,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,1969.0,U,1,,CHEMBL620924,In vivo,22224,6227,,Plasma,A,,,Autocuration,,,
4434,BAO_0000218,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,1,,CHEMBL620925,In vivo,22224,4809,,,A,,,Autocuration,,,
4435,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,U,1,,CHEMBL620926,In vivo,22224,5355,,,A,,,Autocuration,,,
4436,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,U,1,,CHEMBL620927,In vivo,22224,5355,,,A,,,Autocuration,,,
4437,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,U,1,,CHEMBL620928,In vivo,22224,5355,,,A,,,Autocuration,,,
4438,BAO_0000218,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,U,1,,CHEMBL620929,In vivo,22224,5355,,,A,,,Autocuration,,,
4439,BAO_0000218,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,1969.0,U,1,,CHEMBL620930,In vivo,22224,6221,,Plasma,A,,,Autocuration,,,
4440,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,U,1,,CHEMBL620931,,22224,167,,,A,,,Autocuration,,,
4441,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,U,1,,CHEMBL620932,,22224,167,,,A,,,Autocuration,,,
4442,BAO_0000218,Absolute bioavailability was evaluated in monkey,,U,1,,CHEMBL620933,In vivo,22224,4257,,,A,,,Autocuration,,,
4443,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,U,1,,CHEMBL620934,In vivo,22224,6221,,,A,,,Autocuration,,,
4444,BAO_0000218,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,U,1,,CHEMBL620935,In vivo,22224,17667,,,A,,,Autocuration,,,
4445,BAO_0000218,Bioavailability of compound was determined in rhesus monkey,,U,1,,CHEMBL620936,In vivo,22224,17267,,,A,,,Autocuration,,,
4446,BAO_0000218,Bioavailability determined after oral administration in marmoset,,U,1,,CHEMBL620937,In vivo,22224,4256,,,A,,,Autocuration,,,
4447,BAO_0000218,Oral bioavailability in cynomolgus monkey,,U,1,,CHEMBL620938,In vivo,22224,4256,,,A,,,Autocuration,,,
4448,BAO_0000218,Bioavailability in monkey (p.o.) at 2.0 mpk,,U,1,,CHEMBL620939,In vivo,22224,17853,,,A,,,Autocuration,,,
4449,BAO_0000218,Bioavailability was evaluated after oral administration in monkey,,U,1,,CHEMBL620940,In vivo,22224,16365,,,A,,,Autocuration,,,
4450,BAO_0000218,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,1,,CHEMBL620941,In vivo,22224,1916,,,A,,,Autocuration,,,
4451,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,1,,CHEMBL620942,In vivo,22224,5334,,,A,,,Autocuration,,,
4452,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,1,,CHEMBL620943,In vivo,22224,5334,,,A,,,Autocuration,,,
4453,BAO_0000218,Bioavailability of the compound was determined in monkey,,U,1,,CHEMBL620944,In vivo,22224,17592,,,A,,,Autocuration,,,
4454,BAO_0000218,Bioavailability in squirrel monkey (dose 5 mg/kg),,U,1,,CHEMBL620945,In vivo,22224,1399,,,A,,,Autocuration,,,
4455,BAO_0000218,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,1,,CHEMBL620946,In vivo,22224,4809,,,A,,,Autocuration,,,
4456,BAO_0000218,Oral bioavailability in monkey,,U,1,,CHEMBL620947,In vivo,22224,3341,,,A,,,Autocuration,,,
4457,BAO_0000218,Compound was tested for bioavailability in squirrel monkey,,U,1,,CHEMBL620948,In vivo,22224,64,,,A,,,Autocuration,,,
4458,BAO_0000218,Oral bioavailability in Rhesus monkey,,U,1,,CHEMBL620949,In vivo,22224,5005,,,A,,,Autocuration,,,
4459,BAO_0000218,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,U,1,,CHEMBL620950,In vivo,22224,5005,,,A,,,Autocuration,,,
4460,BAO_0000218,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,U,1,,CHEMBL620951,In vivo,22224,5237,,,A,,,Autocuration,,,
4461,BAO_0000218,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,U,1,,CHEMBL620952,In vivo,22224,5237,,,A,,,Autocuration,,,
4462,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),,U,1,,CHEMBL875421,In vivo,22224,5302,,,A,,,Autocuration,,,
4463,BAO_0000218,Oral bioavailability of compound at 5 mg/kg in monkey,,U,1,,CHEMBL620953,In vivo,22224,17667,,,A,,,Autocuration,,,
4464,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,N,1,,CHEMBL873491,In vivo,50588,6161,,,A,,,Intermediate,,,
4465,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,N,1,,CHEMBL620954,In vivo,50588,6161,,,A,,,Intermediate,,,
4466,BAO_0000218,Plasma half life determined,1969.0,N,1,,CHEMBL620955,,50588,3854,,Plasma,A,,,Intermediate,,,
4467,BAO_0000218,Plasma half life in dog,1969.0,N,1,,CHEMBL618097,,50588,993,,Plasma,A,,,Intermediate,,,
4468,BAO_0000218,Plasma half-life in Beagle dogs,1969.0,N,1,,CHEMBL618268,,50588,4514,,Plasma,A,,,Intermediate,,,
4469,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1969.0,N,1,,CHEMBL618269,In vivo,50588,5334,,Plasma,A,,,Intermediate,,,
4470,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1969.0,N,1,,CHEMBL618270,In vivo,50588,5334,,Plasma,A,,,Intermediate,,,
4471,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,N,1,,CHEMBL618271,In vivo,50588,1466,,,A,,,Intermediate,,,
4472,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,N,1,,CHEMBL873493,In vivo,50588,1466,,,A,,,Intermediate,,,
4473,BAO_0000218,Tested for the half life period in dog,,N,1,,CHEMBL621031,,50588,5313,,,A,,,Intermediate,,,
4474,BAO_0000218,Tested for the half life period in dog at dosage of 10 mpk,,N,1,,CHEMBL621032,In vivo,50588,5313,,,A,,,Intermediate,,,
4475,BAO_0000218,The compound was tested for half life in dog,,N,1,,CHEMBL621033,,50588,3880,,,A,,,Intermediate,,,
4476,BAO_0000218,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1969.0,N,1,,CHEMBL621034,,50588,3639,,Plasma,A,,,Intermediate,,,
4477,BAO_0000218,The half life was determined,,N,1,,CHEMBL621035,,50588,3880,,,A,,,Intermediate,,,
4478,BAO_0000218,The plasma half-life in dogs,1969.0,N,1,,CHEMBL621036,,50588,3918,,Plasma,A,,,Intermediate,,,
4479,BAO_0000218,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1969.0,N,1,,CHEMBL621037,,50588,16452,,Plasma,A,,,Intermediate,,,
4480,BAO_0000218,Half life in dog,,N,1,,CHEMBL619812,,50588,17796,,,A,,,Intermediate,,,
4481,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,N,1,,CHEMBL619813,In vivo,50588,5983,,,A,,,Intermediate,,,
4482,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,N,1,,CHEMBL873335,In vivo,50588,1466,,,A,,,Intermediate,,,
4483,BAO_0000218,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL619814,In vivo,50588,16456,,,A,,,Intermediate,,,
4484,BAO_0000218,Cmax in ferrets after 30 mg/kg oral dose,,N,1,,CHEMBL619815,In vivo,50506,6113,,,A,,,Expert,,,
4485,BAO_0000218,Emesis in ferrets at 30 mg/kg oral dose,,N,1,,CHEMBL619816,In vivo,50506,6113,,,F,,,Expert,,,
4486,BAO_0000218,Bioavailability in cynomolgus monkey,,U,1,,CHEMBL619817,In vivo,22224,17796,,,A,,,Autocuration,,,
4487,BAO_0000218,Volume of distribution in cynomolgus,,N,1,,CHEMBL619818,In vivo,100710,17796,,,A,,,Intermediate,,,
4488,BAO_0000218,AUC tested in guinea pig when 3 mg/kg dose was given perorally,1969.0,U,1,,CHEMBL619819,,22224,5308,,Plasma,A,,,Autocuration,,,
4489,BAO_0000218,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,U,1,,CHEMBL619820,,22224,4877,,,A,,,Autocuration,,,
4490,BAO_0000218,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,U,1,,CHEMBL875419,,22224,4876,,,A,,,Autocuration,,,
4491,BAO_0000218,AUC in guinea pig after 3mg/kg oral dose,1969.0,U,1,,CHEMBL619821,In vivo,22224,4878,,Plasma,A,,,Autocuration,,,
4492,BAO_0000218,Bioavailability in guinea pig was tested,,U,1,,CHEMBL619822,In vivo,22224,5308,,,A,,,Autocuration,,,
4493,BAO_0000218,Tested for oral bioavailability in guinea pig at 5 mg/kg,,U,1,,CHEMBL619823,In vivo,22224,4877,,,A,,,Autocuration,,,
4494,BAO_0000218,Tested for the oral bioavailability of the compound,,U,1,,CHEMBL619824,In vivo,22224,4876,,,A,,,Autocuration,,,
4495,BAO_0000218,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,U,1,,CHEMBL619825,In vivo,22224,4876,,,A,,,Autocuration,,,
4496,BAO_0000218,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,U,1,,CHEMBL619826,In vivo,22224,5308,,,A,,,Autocuration,,,
4497,BAO_0000218,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,2048.0,U,1,,CHEMBL619827,In vivo,22224,4877,,Lung,A,,,Autocuration,,,
4498,BAO_0000218,Cmax in guinea pig after 3mg/kg oral dose,,U,1,,CHEMBL618167,In vivo,22224,4878,,,A,,,Autocuration,,,
4499,BAO_0000019,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,178.0,U,1,,CHEMBL618168,,22224,5689,,Blood,A,,,Autocuration,,,
4500,BAO_0000019,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,955.0,U,1,,CHEMBL618169,,22224,5689,,Brain,A,,,Autocuration,,,
4501,BAO_0000019,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,U,1,,CHEMBL618170,,22224,5689,,,A,,,Autocuration,,,
4502,BAO_0000019,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,160.0,U,1,,CHEMBL618171,,22224,5689,,Intestine,A,,,Autocuration,,,
4503,BAO_0000019,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,2113.0,U,1,,CHEMBL618172,,22224,5689,,Kidney,A,,,Autocuration,,,
4504,BAO_0000019,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,2107.0,U,1,,CHEMBL618173,,22224,5689,,Liver,A,,,Autocuration,,,
4505,BAO_0000019,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,U,1,,CHEMBL618174,,22224,5689,,,A,,,Autocuration,,,
4506,BAO_0000019,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,2106.0,U,1,,CHEMBL875408,,22224,5689,,Spleen,A,,,Autocuration,,,
4507,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),,U,1,,CHEMBL839827,In vivo,22224,14465,,,A,,,Autocuration,,,
4508,BAO_0000019,Partition coefficient was measured as -log (counts per min ),,U,1,,CHEMBL618175,,22224,5689,,,A,,,Autocuration,,,
4509,BAO_0000218,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,U,1,,CHEMBL618176,In vivo,22224,611,,,A,,,Autocuration,,,
4510,BAO_0000218,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,U,1,,CHEMBL618177,In vivo,22224,611,,,A,,,Autocuration,,,
4511,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),,U,1,,CHEMBL618178,In vivo,22224,14465,,,A,,,Autocuration,,,
4512,BAO_0000218,"Tested for the half life period of the compound, intravenously",,U,1,,CHEMBL618179,In vivo,22224,4876,,,A,,,Autocuration,,,
4513,BAO_0000019,Half-life was measured,,U,1,,CHEMBL873489,,22224,5689,,,A,,,Autocuration,,,
4514,BAO_0000019,The time required for onset of inotropy after addition of a single dose of delta F75,,U,1,,CHEMBL618180,,22224,7515,,,A,,,Autocuration,,,
4515,BAO_0000218,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,U,1,,CHEMBL618181,In vivo,22224,17667,,,A,,,Autocuration,,,
4516,BAO_0000218,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,U,1,,CHEMBL618182,In vivo,22224,17667,,,A,,,Autocuration,,,
4517,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,U,1,,CHEMBL618183,In vivo,22224,4727,,,A,,,Autocuration,,,
4518,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,1,,CHEMBL618184,In vivo,50594,10107,,,A,,,Intermediate,,,
4519,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,1,,CHEMBL618185,In vivo,50594,10107,,,A,,,Intermediate,,,
4520,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,1,,CHEMBL618186,In vivo,50594,10107,,,A,,,Intermediate,,,
4521,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,1,,CHEMBL618187,In vivo,50594,10107,,,A,,,Intermediate,,,
4522,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,N,1,,CHEMBL618188,In vivo,50594,10107,,,A,,,Intermediate,,,
4523,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,1,,CHEMBL875409,In vivo,50594,10107,,,A,,,Intermediate,,,
4524,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,1,,CHEMBL618189,In vivo,50594,10107,,,A,,,Intermediate,,,
4525,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,178.0,N,1,,CHEMBL618190,In vivo,50594,3655,,Blood,A,,,Intermediate,,,
4526,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,178.0,N,1,,CHEMBL618191,In vivo,50594,3655,,Blood,A,,,Intermediate,,,
4527,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,178.0,N,1,,CHEMBL618192,In vivo,50594,3655,,Blood,A,,,Intermediate,,,
4528,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,10000001.0,N,1,,CHEMBL618193,In vivo,50594,3655,,Bone,A,,,Intermediate,,,
4529,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,10000001.0,N,1,,CHEMBL618194,In vivo,50594,3655,,Bone,A,,,Intermediate,,,
4530,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,10000001.0,N,1,,CHEMBL618195,In vivo,50594,3655,,Bone,A,,,Intermediate,,,
4531,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,955.0,N,1,,CHEMBL618196,In vivo,50594,3655,,Brain,A,,,Intermediate,,,
4532,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,955.0,N,1,,CHEMBL618197,In vivo,50594,3655,,Brain,A,,,Intermediate,,,
4533,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,955.0,N,1,,CHEMBL618198,In vivo,50594,3655,,Brain,A,,,Intermediate,,,
4534,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,948.0,N,1,,CHEMBL618199,In vivo,50594,3655,,Heart,A,,,Intermediate,,,
4535,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,948.0,N,1,,CHEMBL618200,In vivo,50594,3655,,Heart,A,,,Intermediate,,,
4536,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,948.0,N,1,,CHEMBL618201,In vivo,50594,3655,,Heart,A,,,Intermediate,,,
4537,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,160.0,N,1,,CHEMBL618202,In vivo,50594,3655,,Intestine,A,,,Intermediate,,,
4538,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,160.0,N,1,,CHEMBL618203,In vivo,50594,3655,,Intestine,A,,,Intermediate,,,
4539,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,160.0,N,1,,CHEMBL618204,In vivo,50594,3655,,Intestine,A,,,Intermediate,,,
4540,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,2113.0,N,1,,CHEMBL618205,In vivo,50594,3655,,Kidney,A,,,Intermediate,,,
4541,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,2113.0,N,1,,CHEMBL618206,In vivo,50594,3655,,Kidney,A,,,Intermediate,,,
4542,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,2113.0,N,1,,CHEMBL618207,In vivo,50594,3655,,Kidney,A,,,Intermediate,,,
4543,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,2107.0,N,1,,CHEMBL618208,In vivo,50594,3655,,Liver,A,,,Intermediate,,,
4544,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,2107.0,N,1,,CHEMBL618932,In vivo,50594,3655,,Liver,A,,,Intermediate,,,
4545,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,2107.0,N,1,,CHEMBL618933,In vivo,50594,3655,,Liver,A,,,Intermediate,,,
4546,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,2048.0,N,1,,CHEMBL618934,In vivo,50594,3655,,Lung,A,,,Intermediate,,,
4547,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,2048.0,N,1,,CHEMBL618935,In vivo,50594,3655,,Lung,A,,,Intermediate,,,
4548,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,2048.0,N,1,,CHEMBL618936,In vivo,50594,3655,,Lung,A,,,Intermediate,,,
4549,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,2385.0,N,1,,CHEMBL618937,In vivo,50594,3655,,Muscle tissue,A,,,Intermediate,,,
4550,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,2385.0,N,1,,CHEMBL618938,In vivo,50594,3655,,Muscle tissue,A,,,Intermediate,,,
4551,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,2385.0,N,1,,CHEMBL619104,In vivo,50594,3655,,Muscle tissue,A,,,Intermediate,,,
4552,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,2106.0,N,1,,CHEMBL619105,In vivo,50594,3655,,Spleen,A,,,Intermediate,,,
4553,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,2106.0,N,1,,CHEMBL619106,In vivo,50594,3655,,Spleen,A,,,Intermediate,,,
4554,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,2106.0,N,1,,CHEMBL619107,In vivo,50594,3655,,Spleen,A,,,Intermediate,,,
4555,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,945.0,N,1,,CHEMBL875410,In vivo,50594,3655,,Stomach,A,,,Intermediate,,,
4556,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,945.0,N,1,,CHEMBL619108,In vivo,50594,3655,,Stomach,A,,,Intermediate,,,
4557,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,945.0,N,1,,CHEMBL619109,In vivo,50594,3655,,Stomach,A,,,Intermediate,,,
4558,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,N,1,,CHEMBL619110,In vivo,50594,16597,,,A,,,Intermediate,,,
4559,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,N,1,,CHEMBL619111,In vivo,50594,16597,,,F,,,Intermediate,,,
4560,BAO_0000218,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,N,1,,CHEMBL619112,In vivo,50594,16597,,,A,,,Intermediate,,,
4561,BAO_0000218,MRT value at a dose of 10 mg/kg peroral administration in mice.,,N,1,,CHEMBL619113,In vivo,50594,16597,,,A,,,Intermediate,,,
4562,BAO_0000218,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,N,1,,CHEMBL619114,In vivo,50594,17764,,,A,,,Intermediate,,,
4563,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,N,1,,CHEMBL619115,In vivo,50594,17764,,,F,,,Intermediate,,,
4564,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,N,1,A2780,CHEMBL619116,,81034,3830,,,F,,,Intermediate,,478.0,
4565,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,N,1,A2780,CHEMBL619117,,81034,3829,,,F,,,Intermediate,,478.0,
4566,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell lines.,,N,1,A2780,CHEMBL619118,,81034,2040,,,F,,,Intermediate,,478.0,
4567,BAO_0000219,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,N,1,A2780,CHEMBL619119,,81034,15684,,,F,,,Intermediate,,478.0,
4568,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,N,1,A2780,CHEMBL619120,,81034,15684,,,F,,,Intermediate,,478.0,
4569,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,N,1,A2780,CHEMBL619121,,81034,15684,,,F,,,Intermediate,,478.0,
4570,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,N,1,A2780,CHEMBL619122,,81034,15684,,,F,,,Intermediate,,478.0,
4571,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,N,1,A2780,CHEMBL619123,,81034,15684,,,F,,,Intermediate,,478.0,
4572,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,N,1,A2780,CHEMBL619124,,81034,15684,,,F,,,Intermediate,,478.0,
4573,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,,N,1,A2780,CHEMBL619125,,81034,2859,,,F,,,Intermediate,,478.0,
4574,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780,,N,1,A2780,CHEMBL875411,,81034,5618,,,F,,,Intermediate,,478.0,
4575,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,N,1,A2780,CHEMBL619126,,81034,15684,,,F,,,Intermediate,,478.0,
4576,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,N,1,A2780,CHEMBL619127,,81034,15684,,,F,,,Intermediate,,478.0,
4577,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,N,1,A2780,CHEMBL619128,,81034,15684,,,F,,,Intermediate,,478.0,
4578,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,N,1,A2780,CHEMBL619129,,81034,15684,,,F,,,Intermediate,,478.0,
4579,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,N,1,A2780,CHEMBL619130,,81034,2113,,,F,,,Intermediate,,478.0,
4580,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,N,1,A2780,CHEMBL619131,,81034,2113,,,F,,,Intermediate,,478.0,
4581,BAO_0000219,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,N,1,A2780,CHEMBL619132,,81034,16745,,,F,,,Intermediate,,478.0,
4582,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,N,1,A2780,CHEMBL619133,,81034,16597,,,F,,,Expert,,478.0,
4583,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,N,1,A2780,CHEMBL619134,,81034,15684,,,F,,,Intermediate,,478.0,
4584,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,N,1,A2780,CHEMBL619135,,81034,15684,,,F,,,Intermediate,,478.0,
4585,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,N,1,A2780,CHEMBL619136,,81034,2040,,,F,,,Intermediate,,478.0,
4586,BAO_0000219,Relative resistance factor in A2780 cisplatin-resistant line,,N,1,A2780,CHEMBL619137,,81034,2040,,,F,,,Intermediate,,478.0,
4587,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,N,1,A2780,CHEMBL883713,,81034,16165,,,F,,,Intermediate,,478.0,
4588,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,N,1,A2780,CHEMBL875412,,81034,16165,,,F,,,Intermediate,,478.0,
4589,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,N,1,A2780,CHEMBL619138,,81034,16597,,,F,,,Expert,,478.0,
4590,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,N,1,A2780,CHEMBL619262,,81034,16597,,,F,,,Expert,,478.0,
4591,BAO_0000219,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,N,1,A2780,CHEMBL619139,,81034,3992,,,F,,,Intermediate,,478.0,
4592,BAO_0000219,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,N,1,A2780,CHEMBL619140,,81034,10553,,,F,,,Intermediate,,478.0,
4593,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,N,1,A2780,CHEMBL619141,,81034,15608,,,F,,,Intermediate,,478.0,
4594,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,N,1,A2780,CHEMBL619142,,81034,15608,,,F,,,Intermediate,,478.0,
4595,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,N,1,A2780,CHEMBL619143,,81034,15608,,,F,,,Intermediate,,478.0,
4596,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,N,1,A2780,CHEMBL619144,,81034,15608,,,F,,,Intermediate,,478.0,
4597,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,N,1,A2780,CHEMBL619145,,81034,15608,,,F,,,Intermediate,,478.0,
4598,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,N,1,A2780,CHEMBL619146,,81034,15608,,,F,,,Intermediate,,478.0,
4599,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,N,1,A2780,CHEMBL619147,,81034,15569,,,F,,,Intermediate,,478.0,
4600,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line,,N,1,A2780,CHEMBL619148,,81034,17420,,,F,,,Intermediate,,478.0,
4601,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,N,1,A2780,CHEMBL619149,,81034,17420,,,F,,,Intermediate,,478.0,
4602,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,N,1,A2780,CHEMBL619150,,81034,15099,,,F,,,Intermediate,,478.0,
4603,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,N,1,A2780,CHEMBL619151,,81034,15099,,,F,,,Intermediate,,478.0,
4604,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,N,1,A2780,CHEMBL883794,,81034,17672,,,F,,,Intermediate,,478.0,
4605,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,N,1,A2780,CHEMBL619152,,81034,17672,,,F,,,Intermediate,,478.0,
4606,BAO_0000219,In vitro cytotoxicity against A2780ADR cell line,,N,1,A2780,CHEMBL619153,,81034,17270,,,F,,,Intermediate,,478.0,
4607,BAO_0000219,In vitro cytotoxicity against A2780CIS cell line,,N,1,A2780,CHEMBL619154,,81034,17270,,,F,,,Intermediate,,478.0,
4608,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,N,1,A2780,CHEMBL619155,,81034,5574,,,F,,,Intermediate,,478.0,
4609,BAO_0000219,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,N,1,A2780,CHEMBL619156,,81034,2113,,,F,,,Intermediate,,478.0,
4610,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,1,A2780,CHEMBL619157,,81034,16913,,,F,,,Intermediate,,478.0,
4611,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,1,A2780,CHEMBL619797,,81034,16913,,,F,,,Intermediate,,478.0,
4612,BAO_0000218,Oral bioavailability of compound in rhesus macaques,,U,1,,CHEMBL619798,In vivo,22224,17839,,,A,,,Autocuration,,,
4613,BAO_0000218,Oral bioavailability in monkey,,U,1,,CHEMBL619799,In vivo,22224,6821,,,A,,,Autocuration,,,
4614,BAO_0000218,Oral bioavailability evaluated in monkey,,U,1,,CHEMBL619800,In vivo,22224,6078,,,A,,,Autocuration,,,
4615,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,U,1,,CHEMBL619801,In vivo,22224,6535,,,A,,,Autocuration,,,
4616,BAO_0000218,Oral bioavailability in Rhesus monkey,,U,1,,CHEMBL619802,In vivo,22224,4449,,,A,,,Autocuration,,,
4617,BAO_0000218,Oral bioavailability was calculated in rhesus monkey,,U,1,,CHEMBL619803,In vivo,22224,6057,,,A,,,Autocuration,,,
4618,BAO_0000218,Oral bioavailability in cynomolgus monkey,,U,1,,CHEMBL619965,In vivo,22224,5922,,,A,,,Autocuration,,,
4619,BAO_0000218,Oral bioavailability in monkey,,U,1,,CHEMBL619966,In vivo,22224,5940,,,A,,,Autocuration,,,
4620,BAO_0000218,Oral bioavailability in monkey,,U,1,,CHEMBL619967,In vivo,22224,6265,,,A,,,Autocuration,,,
4621,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg),,U,1,,CHEMBL620073,In vivo,22224,6265,,,A,,,Autocuration,,,
4622,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),,U,1,,CHEMBL620074,In vivo,22224,6265,,,A,,,Autocuration,,,
4623,BAO_0000218,Oral bioavailability in monkey,,U,1,,CHEMBL620075,In vivo,22224,5940,,,A,,,Autocuration,,,
4624,BAO_0000218,Oral bioavailability in monkey,,U,1,,CHEMBL620076,In vivo,22224,5940,,,A,,,Autocuration,,,
4625,BAO_0000218,Oral bioavailability in rhesus monkey,,U,1,,CHEMBL620077,In vivo,22224,4514,,,A,,,Autocuration,,,
4626,BAO_0000218,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,U,1,,CHEMBL620078,In vivo,22224,5546,,,A,,,Autocuration,,,
4627,BAO_0000218,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,U,1,,CHEMBL620079,In vivo,22224,5553,,,A,,,Autocuration,,,
4628,BAO_0000218,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,1,,CHEMBL620080,In vivo,22224,6641,,,A,,,Autocuration,,,
4629,BAO_0000218,Oral bioavailability in Rhesus monkey,,U,1,,CHEMBL620081,In vivo,22224,5472,,,A,,,Autocuration,,,
4630,BAO_0000218,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,U,1,,CHEMBL620082,In vivo,22224,5668,,,A,,,Autocuration,,,
4631,BAO_0000218,Oral bioavailability in monkey at 10 mg/kg of the compound,,U,1,,CHEMBL620083,In vivo,22224,5711,,,A,,,Autocuration,,,
4632,BAO_0000218,Bioavailability in Rhesus monkey,,U,1,,CHEMBL620084,In vivo,22224,5145,,,A,,,Autocuration,,,
4633,BAO_0000218,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL620085,,22224,3443,,,A,,,Autocuration,,,
4634,BAO_0000218,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL874595,,22224,3443,,,A,,,Autocuration,,,
4635,BAO_0000218,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,U,1,,CHEMBL873352,In vivo,22224,3249,,,A,,,Autocuration,,,
4636,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,U,1,,CHEMBL620086,In vivo,22224,3249,,,A,,,Autocuration,,,
4637,BAO_0000218,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,U,1,,CHEMBL620087,In vivo,22224,5355,,,A,,,Autocuration,,,
4638,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,U,1,,CHEMBL620088,In vivo,22224,5355,,,A,,,Autocuration,,,
4639,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,U,1,,CHEMBL620089,In vivo,22224,5355,,,A,,,Autocuration,,,
4640,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,1,,CHEMBL620090,In vivo,22224,4809,,,A,,,Autocuration,,,
4641,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,1,,CHEMBL620091,In vivo,22224,4809,,,A,,,Autocuration,,,
4642,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,U,1,,CHEMBL620092,,22224,14294,Microsomes,,A,,,Autocuration,,,
4643,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,U,1,,CHEMBL620093,,22224,14294,Microsomes,,A,,,Autocuration,,,
4644,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,U,1,,CHEMBL620094,,22224,14294,Microsomes,,A,,,Autocuration,,,
4645,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,U,1,,CHEMBL620095,,22224,14294,Microsomes,,A,,,Autocuration,,,
4646,BAO_0000218,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL620096,In vivo,22224,3443,,,A,,,Autocuration,,,
4647,BAO_0000218,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL620097,In vivo,22224,3443,,,A,,,Autocuration,,,
4648,BAO_0000019,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,U,1,,CHEMBL620098,,22224,11271,,,A,,,Autocuration,,,
4649,BAO_0000218,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL620099,,22224,3443,,,A,,,Autocuration,,,
4650,BAO_0000218,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL620100,,22224,3443,,,A,,,Autocuration,,,
4651,BAO_0000019,Elimination Half-life of compound was determined in monkey,,U,1,,CHEMBL620101,,22224,6821,,,A,,,Autocuration,,,
4652,BAO_0000019,Half life of compound was determined in rhesus monkey,,U,1,,CHEMBL620102,,22224,17267,,,A,,,Autocuration,,,
4653,BAO_0000366,Half life in monkey plasma,1969.0,U,1,,CHEMBL620103,,22224,5819,,Plasma,A,,,Autocuration,,,
4654,BAO_0000366,Half life in monkey plasma; Not detected,1969.0,U,1,,CHEMBL620104,,22224,5819,,Plasma,A,,,Autocuration,,,
4655,BAO_0000218,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,1,,CHEMBL874596,In vivo,22224,1916,,,A,,,Autocuration,,,
4656,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,U,1,,CHEMBL873490,In vivo,22224,17509,,,A,,,Autocuration,,,
4657,BAO_0000019,Terminal half life of the compound.,,U,1,,CHEMBL620105,,22224,1399,,,A,,,Autocuration,,,
4658,BAO_0000218,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,1,,CHEMBL620780,In vivo,22224,1916,,,A,,,Autocuration,,,
4659,BAO_0000218,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,1,,CHEMBL620781,In vivo,22224,4809,,,A,,,Autocuration,,,
4660,BAO_0000218,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,U,1,,CHEMBL620956,,22224,5546,,,A,,,Autocuration,,,
4661,BAO_0000218,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1088.0,U,1,,CHEMBL620957,,22224,3443,,Urine,A,,,Autocuration,,,
4662,BAO_0000218,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1088.0,U,1,,CHEMBL620958,,22224,3443,,Urine,A,,,Autocuration,,,
4663,BAO_0000218,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,U,1,,CHEMBL620959,In vivo,22224,4257,,,A,,,Autocuration,,,
4664,BAO_0000218,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,U,1,,CHEMBL620960,In vivo,22224,6221,,,A,,,Autocuration,,,
4665,BAO_0000218,Volume of distribution was evaluated in rhesus,,U,1,,CHEMBL620961,In vivo,22224,5472,,,A,,,Autocuration,,,
4666,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,U,1,,CHEMBL620962,In vivo,22224,4727,,,A,,,Autocuration,,,
4667,BAO_0000218,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,U,1,,CHEMBL620963,In vivo,22224,4727,,,A,,,Autocuration,,,
4668,BAO_0000218,Bioavailability in hamster was determined,,U,1,,CHEMBL620964,In vivo,22224,4727,,,A,,,Autocuration,,,
4669,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,U,1,,CHEMBL620965,In vivo,22224,4727,,,A,,,Autocuration,,,
4670,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,U,1,,CHEMBL620966,In vivo,22224,4727,,,A,,,Autocuration,,,
4671,BAO_0000221,Half life of compound was determined in hamster blood,178.0,U,1,,CHEMBL620967,,22224,4727,,Blood,A,,,Autocuration,,,
4672,BAO_0000019,Michaelis-Menten constant of the compound.,,U,1,,CHEMBL620968,,22224,1452,,,A,,,Autocuration,,,
4673,BAO_0000019,Vmax value was measured at 0 uM concentration of silyl ether.,,U,1,,CHEMBL874597,,22224,1452,,,A,,,Autocuration,,,
4674,BAO_0000019,Vmax value was measured at 10 uM concentration of silyl ether.,,U,1,,CHEMBL620969,,22224,1452,,,A,,,Autocuration,,,
4675,BAO_0000019,Vmax value was measured at 5 uM concentration of silyl ether.,,U,1,,CHEMBL620970,,22224,1452,,,A,,,Autocuration,,,
4676,BAO_0000357,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,D,1,,CHEMBL620971,,235,11706,,,B,,,Expert,,,
4677,BAO_0000218,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,U,1,,CHEMBL620972,,22224,1916,,,A,,,Autocuration,,,
4678,BAO_0000019,Compound was evaluated for area under the curve expressed as (h*ug/ml),,U,1,,CHEMBL620973,,22224,17791,,,A,,,Autocuration,,,
4679,BAO_0000019,Active metabolite of ifosfamide determined in humans; A-Active,,U,1,,CHEMBL618243,,22224,7766,,,A,,,Autocuration,,,
4680,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,U,1,,CHEMBL618244,,22224,6567,,,A,,,Autocuration,,,
4681,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,U,1,,CHEMBL618245,,22224,6567,,,A,,,Autocuration,,,
4682,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,U,1,,CHEMBL618246,,22224,6567,,,A,,,Autocuration,,,
4683,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,U,1,,CHEMBL618247,,22224,6567,,,A,,,Autocuration,,,
4684,BAO_0000218,Compound was evaluated for oral bioavailability in human,,U,1,,CHEMBL618248,,22224,17791,,,A,,,Autocuration,,,
4685,BAO_0000019,Metabolite of ifosfamide determined in urine; NF-Not found,1088.0,U,1,,CHEMBL618249,,22224,7766,,Urine,A,,,Autocuration,,,
4686,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,U,1,,CHEMBL618250,,22224,6852,,,A,,,Autocuration,,,
4687,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,U,1,,CHEMBL874598,,22224,6852,,,A,,,Autocuration,,,
4688,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,U,1,,CHEMBL618251,,22224,6852,,,A,,,Autocuration,,,
4689,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,U,1,,CHEMBL618252,,22224,6852,,,A,,,Autocuration,,,
4690,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,U,1,,CHEMBL618253,,22224,6852,,,A,,,Autocuration,,,
4691,BAO_0000019,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,U,1,,CHEMBL618254,,22224,6852,,,A,,,Autocuration,,,
4692,BAO_0000019,Percent of compound in healthy individuals (Group D),,U,1,,CHEMBL618255,,22224,6852,,,A,,,Autocuration,,,
4693,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,2107.0,U,1,,CHEMBL618983,,22224,4397,Microsomes,Liver,A,,,Autocuration,,,
4694,BAO_0000019,Binding towards human plasma protein at 10 uM,,U,1,,CHEMBL618984,,22224,17409,,,A,,,Autocuration,,,
4695,BAO_0000019,Binding towards human plasma protein at 100 uM,,U,1,,CHEMBL618985,,22224,17409,,,A,,,Autocuration,,,
4696,BAO_0000019,Human plasma protein binding activity was determined,,U,1,,CHEMBL618986,,22224,17176,,,A,,,Autocuration,,,
4697,BAO_0000019,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,U,1,,CHEMBL618987,,22224,15444,,,A,,,Autocuration,,,
4698,BAO_0000019,Percent binding of compound towards human plasma protein was determined,,U,1,,CHEMBL618988,,22224,17267,,,A,,,Autocuration,,,
4699,BAO_0000251,Plasma clearance in human liver microsomes,2107.0,U,1,,CHEMBL618989,In vitro,22224,5944,Microsomes,Liver,A,,,Autocuration,,,
4700,BAO_0000251,In vitro intrinsic clearance in human liver microsome,2107.0,U,1,,CHEMBL618990,In vitro,22224,5668,Microsomes,Liver,A,,,Autocuration,,,
4701,BAO_0000251,In vitro intrinsic clearance in human liver microsome,2107.0,U,1,,CHEMBL618991,In vitro,22224,5669,Microsomes,Liver,A,,,Autocuration,,,
4702,BAO_0000251,In vitro microsome metabolism clearance in human was determined,,U,1,,CHEMBL876725,In vitro,22224,5041,Microsomes,,A,,,Autocuration,,,
4703,BAO_0000251,In vitro microsome metabolism clearance in human was determined; High,,U,1,,CHEMBL618992,In vitro,22224,5041,Microsomes,,A,,,Autocuration,,,
4704,BAO_0000251,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,U,1,,CHEMBL618993,In vitro,22224,5041,Microsomes,,A,,,Autocuration,,,
4705,BAO_0000251,Pharmacokinetic property (clearance) in human liver microsome,2107.0,U,1,,CHEMBL618994,In vitro,22224,5676,Microsomes,Liver,A,,,Autocuration,,,
4706,BAO_0000251,Plasma clearance in human liver microsomes,2107.0,U,1,,CHEMBL618995,In vitro,22224,5944,Microsomes,Liver,A,,,Autocuration,,,
4707,BAO_0000251,In vitro clearance in human liver microsomes,2107.0,U,1,,CHEMBL618996,In vitro,22224,17538,Microsomes,Liver,A,,,Autocuration,,,
4708,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,2107.0,U,1,,CHEMBL618997,In vitro,22224,6331,Microsomes,Liver,A,,,Autocuration,,,
4709,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,2107.0,U,1,,CHEMBL618998,In vitro,22224,5948,Microsomes,Liver,A,,,Autocuration,,,
4710,BAO_0000218,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,U,1,,CHEMBL618999,In vivo,22224,5965,,,A,,,Autocuration,,,
4711,BAO_0000218,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,U,1,,CHEMBL620223,In vivo,22224,1916,,,A,,,Autocuration,,,
4712,BAO_0000218,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,U,1,,CHEMBL620224,,22224,5965,,,A,,,Autocuration,,,
4713,BAO_0000019,Stability in human plasma 2 hr after incubation expressed as percent concentration,,U,1,,CHEMBL620225,,22224,1299,,,A,,,Autocuration,,,
4714,BAO_0000019,Stability in human plasma 4 hr after incubation expressed as percent concentration,,U,1,,CHEMBL620226,,22224,1299,,,A,,,Autocuration,,,
4715,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL620227,,22224,7766,,Urine,A,,,Autocuration,,,
4716,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL876726,,22224,7766,,Urine,A,,,Autocuration,,,
4717,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL620228,,22224,7766,,Urine,A,,,Autocuration,,,
4718,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL620229,,22224,7766,,Urine,A,,,Autocuration,,,
4719,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,N,1,,CHEMBL620230,In vivo,50594,17764,,,F,,,Intermediate,,,
4720,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,N,1,,CHEMBL620231,In vivo,50594,17764,,,F,,,Intermediate,,,
4721,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,N,1,,CHEMBL620232,In vivo,50594,17764,,,F,,,Intermediate,,,
4722,BAO_0000218,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,N,1,,CHEMBL620233,In vivo,50594,17764,,,F,,,Intermediate,,,
4723,BAO_0000218,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,N,1,,CHEMBL620234,,50594,14294,,,A,,,Intermediate,,,
4724,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,N,1,,CHEMBL620235,,50594,14294,,,A,,,Intermediate,,,
4725,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,N,1,,CHEMBL620236,,50594,14294,,,A,,,Intermediate,,,
4726,BAO_0000218,In vitro metabolic potential in mouse liver microsomes,2107.0,N,1,,CHEMBL620237,,50594,6251,,Liver,A,,,Intermediate,,,
4727,BAO_0000218,Ability of compound to bind to plasma protein was evaluated in HSA cells,,N,1,,CHEMBL620238,,50594,17582,,,A,,,Intermediate,,,
4728,BAO_0000218,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),2369.0,N,1,,CHEMBL620239,,50594,17811,,Adrenal gland,A,,,Intermediate,,,
4729,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,955.0,N,1,,CHEMBL620240,,50594,17811,,Brain,A,,,Intermediate,,,
4730,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,955.0,N,1,,CHEMBL620241,,50594,17811,,Brain,A,,,Intermediate,,,
4731,BAO_0000218,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,N,1,,CHEMBL876727,,50594,17811,,,A,,,Intermediate,,,
4732,BAO_0000218,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),2113.0,N,1,,CHEMBL620242,,50594,17811,,Kidney,A,,,Intermediate,,,
4733,BAO_0000218,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,N,1,,CHEMBL620243,,50594,17811,,,A,,,Intermediate,,,
4734,BAO_0000218,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,N,1,,CHEMBL620244,,50594,5288,,,A,,,Intermediate,,,
4735,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1977.0,N,1,,CHEMBL620245,,50594,2717,,Serum,A,,,Intermediate,,,
4736,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1977.0,N,1,,CHEMBL620246,,50594,2717,,Serum,A,,,Intermediate,,,
4737,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1977.0,N,1,,CHEMBL620247,,50594,2717,,Serum,A,,,Intermediate,,,
4738,BAO_0000218,Half life of compound was determined in plasma of mice at 24 mg/Kg,1969.0,N,1,,CHEMBL620248,In vivo,50594,17753,,Plasma,A,,,Intermediate,,,
4739,BAO_0000218,Half life of compound was determined in plasma of mice at 40 mg/Kg,1969.0,N,1,,CHEMBL873497,In vivo,50594,17753,,Plasma,A,,,Intermediate,,,
4740,BAO_0000218,Half life of compound was determined in plasma of mice at 5 mg/Kg,1969.0,N,1,,CHEMBL620249,In vivo,50594,17753,,Plasma,A,,,Intermediate,,,
4741,BAO_0000218,Half life after intraperitoneal administration in mice at 18 uM/kg,,N,1,,CHEMBL620250,In vivo,50594,17764,,,F,,,Intermediate,,,
4742,BAO_0000218,Half life after intraperitoneal administration in mice at 23 uM/kg,,N,1,,CHEMBL620251,In vivo,50594,17764,,,F,,,Intermediate,,,
4743,BAO_0000218,Half life after intraperitoneal administration in mice at 25 uM/kg,,N,1,,CHEMBL620252,In vivo,50594,17764,,,F,,,Intermediate,,,
4744,BAO_0000218,Half life after intraperitoneal administration in mice at 26 uM/kg,,N,1,,CHEMBL620253,In vivo,50594,17764,,,F,,,Intermediate,,,
4745,BAO_0000218,Half life after intravenous administration in mice at 23 uM/kg,,N,1,,CHEMBL620254,In vivo,50594,17764,,,F,,,Intermediate,,,
4746,BAO_0000218,Half life after intravenous administration in mice at 24 uM/kg,,N,1,,CHEMBL620255,In vivo,50594,17764,,,A,,,Intermediate,,,
4747,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,N,1,,CHEMBL620256,In vivo,50594,16597,,,A,,,Intermediate,,,
4748,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,N,1,,CHEMBL876728,In vivo,50594,2675,,,A,,,Intermediate,,,
4749,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after oral administration,,N,1,,CHEMBL620257,In vivo,50594,2675,,,A,,,Intermediate,,,
4750,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,N,1,,CHEMBL620258,In vivo,50594,16597,,,A,,,Intermediate,,,
4751,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,N,1,,CHEMBL620259,In vivo,50594,4890,,,A,,,Intermediate,,,
4752,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,N,1,,CHEMBL620260,In vivo,50594,429,,,A,,,Intermediate,,,
4753,BAO_0000218,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,178.0,N,1,,CHEMBL620261,In vivo,50594,17837,,Blood,A,,,Intermediate,,,
4754,BAO_0000218,Half life at a dose of 10 mg/kg intravenous administration in mice.,,N,1,,CHEMBL620262,In vivo,50594,16597,,,A,,,Intermediate,,,
4755,BAO_0000218,Half life at a dose of 10 mg/kg peroral administration in mice.,,N,1,,CHEMBL620263,In vivo,50594,16597,,,A,,,Intermediate,,,
4756,BAO_0000218,Half life in ob/ob mice,,N,1,,CHEMBL620264,,50594,6619,,,A,,,Intermediate,,,
4757,BAO_0000218,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,N,1,,CHEMBL620265,In vivo,50594,4066,,,A,,,Intermediate,,,
4758,BAO_0000218,Half-life was measured in mouse,,N,1,,CHEMBL620266,,50594,4239,,,A,,,Intermediate,,,
4759,BAO_0000218,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,N,1,,CHEMBL620267,In vivo,50594,5969,,,A,,,Intermediate,,,
4760,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,N,1,,CHEMBL619364,,50594,8999,,,A,,,Intermediate,,,
4761,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,N,1,,CHEMBL619365,,50594,8999,,,A,,,Intermediate,,,
4762,BAO_0000218,T2 in brain of mice at the oral dose of 50 mg/kg,955.0,N,1,,CHEMBL619366,,50594,17641,,Brain,A,,,Intermediate,,,
4763,BAO_0000218,T2 in kidney of mice at the oral dose of 50 mg/kg,2113.0,N,1,,CHEMBL619367,,50594,17641,,Kidney,A,,,Intermediate,,,
4764,BAO_0000218,T2 in liver of mice at the oral dose of 50 mg/kg,2107.0,N,1,,CHEMBL619368,,50594,17641,,Liver,A,,,Intermediate,,,
4765,BAO_0000218,T2 in lungs of mice at the oral dose of 50 mg/kg,2048.0,N,1,,CHEMBL619369,,50594,17641,,Lung,A,,,Intermediate,,,
4766,BAO_0000218,T2 in spleen of mice at the oral dose of 50 mg/kg,2106.0,N,1,,CHEMBL876729,,50594,17641,,Spleen,A,,,Intermediate,,,
4767,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,N,1,,CHEMBL619370,In vivo,50594,16597,,,A,,,Intermediate,,,
4768,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,N,1,,CHEMBL619371,In vivo,50594,4890,,,A,,,Intermediate,,,
4769,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,N,1,,CHEMBL619372,In vivo,50594,429,,,A,,,Intermediate,,,
4770,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,N,1,,CHEMBL620012,In vivo,50594,429,,,A,,,Intermediate,,,
4771,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,N,1,,CHEMBL620013,In vivo,50594,5969,,,A,,,Intermediate,,,
4772,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,1,A2780,CHEMBL620014,,81034,16913,,,F,,,Intermediate,,478.0,
4773,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,1,A2780,CHEMBL620015,,81034,16913,,,F,,,Intermediate,,478.0,
4774,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,1,A2780,CHEMBL621010,,81034,16913,,,F,,,Intermediate,,478.0,
4775,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,1,A2780,CHEMBL621011,,81034,16913,,,F,,,Intermediate,,478.0,
4776,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,1,A2780,CHEMBL621012,,81034,16913,,,F,,,Intermediate,,478.0,
4777,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,1,A2780,CHEMBL621013,,81034,16913,,,F,,,Intermediate,,478.0,
4778,BAO_0000219,In vitro cytotoxicity against A2780TAX cell line,,N,1,A2780,CHEMBL621014,,81034,17270,,,F,,,Intermediate,,478.0,
4779,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780cis,,N,1,A2780cisR,CHEMBL618154,,80017,5618,,,F,,,Intermediate,,481.0,
4780,BAO_0000219,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,N,1,A2780,CHEMBL618155,,81034,17777,,,F,,,Expert,,478.0,
4781,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,N,1,A2780cisR,CHEMBL618156,,80017,16112,,,F,,,Intermediate,,481.0,
4782,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,N,1,A2780cisR,CHEMBL618157,,80017,15748,,,F,,,Intermediate,,481.0,
4783,BAO_0000219,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,N,1,A2780,CHEMBL618328,,81034,6633,,,F,,,Intermediate,,478.0,
4784,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,N,1,A2780,CHEMBL618329,,81034,16930,,,F,,,Intermediate,,478.0,
4785,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,N,1,A2780,CHEMBL618330,,81034,17496,,,F,,,Intermediate,,478.0,
4786,BAO_0000219,In vitro antitumor activity against A2780cisR cell line.,,N,1,A2780,CHEMBL618331,,81034,12989,,,F,,,Expert,,478.0,
4787,BAO_0000219,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,N,1,A2780,CHEMBL618332,,81034,4840,,,F,,,Intermediate,,478.0,
4788,BAO_0000219,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,N,1,A2780,CHEMBL618333,,81034,12989,,,F,,,Expert,,478.0,
4789,BAO_0000219,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,N,1,A2780cisR,CHEMBL618334,,80017,16745,,,F,,,Intermediate,,481.0,
4790,BAO_0000219,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,N,1,A2780,CHEMBL618335,,81034,16597,,,F,,,Expert,,478.0,
4791,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,D,1,,CHEMBL618336,,11736,16547,,,B,,,Expert,,,
4792,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,H,1,,CHEMBL618337,,11736,16547,,,F,,,Expert,,,
4793,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,D,1,,CHEMBL618338,,11736,16547,,,F,,,Expert,,,
4794,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,D,1,HEK293,CHEMBL618339,,278,15856,,,F,,,Expert,,722.0,
4795,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,D,1,HEK293,CHEMBL618340,,278,15856,,,F,,,Expert,,722.0,
4796,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,D,1,,CHEMBL618341,,11831,16547,,,B,,,Expert,,,
4797,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,H,1,,CHEMBL618342,,11831,16547,,,F,,,Expert,,,
4798,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,D,1,,CHEMBL618343,,11831,16547,,,F,,,Expert,,,
4799,BAO_0000357,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,H,1,,CHEMBL621038,,280,17402,,,B,,,Expert,,,
4800,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,U,1,T-cells,CHEMBL621039,,22226,11746,,,F,,,Autocuration,,574.0,
4801,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,U,1,T-cells,CHEMBL621040,,22226,11746,,,F,,,Autocuration,,574.0,
4802,BAO_0000219,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,N,1,A-375,CHEMBL621041,,80018,5455,,,F,,,Intermediate,,455.0,
4803,BAO_0000219,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,N,1,A-375,CHEMBL621042,,80018,2068,,,F,,,Intermediate,,455.0,
4804,BAO_0000219,In vitro antitumor activity against A375cell line extracted form melanoma,,N,1,A-375,CHEMBL621043,,80018,2683,,,F,,,Intermediate,,455.0,
4805,BAO_0000219,Inhibition of cell growth in (A375) melan cell line,,N,1,A-375,CHEMBL621044,,80018,15313,,,F,,,Expert,,455.0,
4806,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,N,1,A-375,CHEMBL621045,,80018,13739,,,F,,,Intermediate,,455.0,
4807,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,N,1,A-375,CHEMBL621046,,80018,13739,,,F,,,Intermediate,,455.0,
4808,BAO_0000219,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,N,1,A-375,CHEMBL621047,,80018,14750,,,F,,,Intermediate,,455.0,
4809,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,,N,1,A-427,CHEMBL621048,,80019,14777,,,F,,,Intermediate,,797.0,
4810,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,,N,1,A-427,CHEMBL883798,,80019,14777,,,F,,,Intermediate,,797.0,
4811,BAO_0000219,Cytotoxicity against lung carcinoma A427 tumor cell lines,,N,1,A-427,CHEMBL621049,,80019,17672,,,F,,,Intermediate,,797.0,
4812,BAO_0000219,Inhibition of large cell lung carcinoma (A427),,N,1,A-427,CHEMBL621050,,80019,14368,,,F,,,Intermediate,,797.0,
4813,BAO_0000219,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,N,1,A-427,CHEMBL621051,,80019,14368,,,F,,,Intermediate,,797.0,
4814,BAO_0000219,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,N,1,A-427,CHEMBL621052,,80019,13866,,,F,,,Intermediate,,797.0,
4815,BAO_0000219,Inhibitory concentration in human lung carcinoma A427 cell line,,N,1,A-427,CHEMBL621053,,80019,2545,,,F,,,Intermediate,,797.0,
4816,BAO_0000219,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,N,1,A-427,CHEMBL621054,,80019,2545,,,F,,,Intermediate,,797.0,
4817,BAO_0000218,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,U,1,,CHEMBL621055,In vivo,22224,6062,,,A,,,Autocuration,,,
4818,BAO_0000218,Tested for volume of distribution upon iv administration to african green monkey,,U,1,,CHEMBL876398,In vivo,22224,4578,,,A,,,Autocuration,,,
4819,BAO_0000218,Volume of distribution in monkey,,U,1,,CHEMBL621056,In vivo,22224,17592,,,A,,,Autocuration,,,
4820,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,1,,CHEMBL621057,In vivo,22224,5005,,,A,,,Autocuration,,,
4821,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,U,1,,CHEMBL621058,In vivo,22224,5005,,,A,,,Autocuration,,,
4822,BAO_0000218,Pharmacokinetic property(Vdss) in cynomolgus monkey,,U,1,,CHEMBL621059,In vivo,22224,5922,,,A,,,Autocuration,,,
4823,BAO_0000218,The distribution volume after intravenous administration in cynomolgus monkeys,,U,1,,CHEMBL621060,In vivo,22224,5355,,,A,,,Autocuration,,,
4824,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,U,1,,CHEMBL621061,In vivo,22224,5355,,,A,,,Autocuration,,,
4825,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,U,1,,CHEMBL621062,In vivo,22224,5355,,,A,,,Autocuration,,,
4826,BAO_0000218,Volume displacement was calculated in rhesus monkey,,U,1,,CHEMBL621063,In vivo,22224,6057,,,A,,,Autocuration,,,
4827,BAO_0000218,Volume of distribution in steady state was determined in rhesus monkey,,U,1,,CHEMBL621064,In vivo,22224,5145,,,A,,,Autocuration,,,
4828,BAO_0000218,Volume of distribution of compound was determined in monkey,,U,1,,CHEMBL621065,In vivo,22224,6821,,,A,,,Autocuration,,,
4829,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,1,,CHEMBL621066,In vivo,22224,5334,,,A,,,Autocuration,,,
4830,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,1,,CHEMBL621067,In vivo,22224,5334,,,A,,,Autocuration,,,
4831,BAO_0000218,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,1,,CHEMBL621068,In vivo,22224,6641,,,A,,,Autocuration,,,
4832,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,1,,CHEMBL876399,In vivo,22224,2661,,,A,,,Autocuration,,,
4833,BAO_0000218,Volume distribution in monkey after administration of 1 mg/kg iv,,U,1,,CHEMBL621069,In vivo,22224,6535,,,A,,,Autocuration,,,
4834,BAO_0000218,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,1,,CHEMBL621070,In vivo,22224,4809,,,A,,,Autocuration,,,
4835,BAO_0000218,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,U,1,,CHEMBL621071,In vivo,22224,6062,,,A,,,Autocuration,,,
4836,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL621072,In vivo,22224,3443,,,A,,,Autocuration,,,
4837,BAO_0000218,Oral systemic bioavailability upon iv administration to african green monkey,,U,1,,CHEMBL618209,In vivo,22224,4578,,,A,,,Autocuration,,,
4838,BAO_0000218,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,1,,CHEMBL618210,In vivo,22224,4809,,,A,,,Autocuration,,,
4839,BAO_0000019,Baboon plasma free fraction. ,,U,1,,CHEMBL618211,,22224,11271,,,A,,,Autocuration,,,
4840,BAO_0000218,Area under the curve was calculated in rhesus monkey after iv administration,,U,1,,CHEMBL618212,,22224,6057,,,A,,,Autocuration,,,
4841,BAO_0000019,Area under the curve was calculated in rhesus monkey after peroral administration,,U,1,,CHEMBL618213,,22224,6057,,,A,,,Autocuration,,,
4842,BAO_0000019,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,U,1,,CHEMBL618214,,22224,17853,,,A,,,Autocuration,,,
4843,BAO_0000218,Half life period in monkey after 5 mg/kg dose,,U,1,,CHEMBL873492,In vivo,22224,5302,,,A,,,Autocuration,,,
4844,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,U,1,,CHEMBL618272,In vivo,22224,4257,,,A,,,Autocuration,,,
4845,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,U,1,,CHEMBL618273,In vivo,22224,4257,,,A,,,Autocuration,,,
4846,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1969.0,U,1,,CHEMBL618274,In vivo,22224,13501,,Plasma,A,,,Autocuration,,,
4847,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,U,1,,CHEMBL618275,In vivo,22224,5394,,,A,,,Autocuration,,,
4848,BAO_0000218,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,1,,CHEMBL618276,In vivo,22224,2661,,,A,,,Autocuration,,,
4849,BAO_0000019,Compound was evaluated for terminal half life in monkey,,U,1,,CHEMBL618277,,22224,3341,,,A,,,Autocuration,,,
4850,BAO_0000218,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,U,1,,CHEMBL618278,In vivo,22224,3045,,,A,,,Autocuration,,,
4851,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,U,1,,CHEMBL618279,In vivo,22224,5005,,Plasma,A,,,Autocuration,,,
4852,BAO_0000019,Half life of compound was determined in squirrel monkey,,U,1,,CHEMBL618280,,22224,4847,,,A,,,Autocuration,,,
4853,BAO_0000218,Half life after iv administration in cynomolgus monkey,,U,1,,CHEMBL618281,In vivo,22224,4256,,,A,,,Autocuration,,,
4854,BAO_0000218,Half life in monkey plasma after administration of 1 mg/kg iv,1969.0,U,1,,CHEMBL618282,In vivo,22224,6535,,Plasma,A,,,Autocuration,,,
4855,BAO_0000019,Half life was calculated in rhesus monkey,,U,1,,CHEMBL618283,,22224,6057,,,A,,,Autocuration,,,
4856,BAO_0000019,Half life in monkey,,U,1,,CHEMBL618284,,22224,17592,,,A,,,Autocuration,,,
4857,BAO_0000218,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,1,,CHEMBL618285,In vivo,22224,6641,,,A,,,Autocuration,,,
4858,BAO_0000019,Half life was evaluated in rhesus,,U,1,,CHEMBL618286,,22224,5472,,,A,,,Autocuration,,,
4859,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,U,1,,CHEMBL618287,In vivo,22224,6221,,,A,,,Autocuration,,,
4860,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in Rhesus,,U,1,,CHEMBL618288,In vivo,22224,5668,,,A,,,Autocuration,,,
4861,BAO_0000218,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,1,,CHEMBL876393,In vivo,22224,4809,,,A,,,Autocuration,,,
4862,BAO_0000218,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,U,1,,CHEMBL618289,In vivo,22224,5546,,,A,,,Autocuration,,,
4863,BAO_0000218,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,U,1,,CHEMBL618290,In vivo,22224,5553,,,A,,,Autocuration,,,
4864,BAO_0000019,Half-life was calculated in monkey,,U,1,,CHEMBL618291,,22224,6078,,,A,,,Autocuration,,,
4865,BAO_0000019,Half-life in Squirrel monkey,,U,1,,CHEMBL618292,,22224,5147,,,A,,,Autocuration,,,
4866,BAO_0000019,Half-life in rhesus monkey,,U,1,,CHEMBL618293,,22224,5145,,,A,,,Autocuration,,,
4867,BAO_0000218,Half-life was measured in monkey after an iv dose of 1 mg/kg,,U,1,,CHEMBL618294,In vivo,22224,6062,,,A,,,Autocuration,,,
4868,BAO_0000218,Half-life period after intravenous administration in cynomolgus monkeys,,U,1,,CHEMBL618295,In vivo,22224,5355,,,A,,,Autocuration,,,
4869,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys,,U,1,,CHEMBL618296,In vivo,22224,5355,,,A,,,Autocuration,,,
4870,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,U,1,,CHEMBL618297,In vivo,22224,5355,,,A,,,Autocuration,,,
4871,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL618298,,22224,7766,,Urine,A,,,Autocuration,,,
4872,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL618299,,22224,7766,,Urine,A,,,Autocuration,,,
4873,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL618300,,22224,7766,,Urine,A,,,Autocuration,,,
4874,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,U,1,,CHEMBL618301,,22224,7766,,Urine,A,,,Autocuration,,,
4875,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1088.0,U,1,,CHEMBL618302,,22224,7766,,Urine,A,,,Autocuration,,,
4876,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1088.0,U,1,,CHEMBL876394,,22224,7766,,Urine,A,,,Autocuration,,,
4877,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1088.0,U,1,,CHEMBL618303,,22224,7766,,Urine,A,,,Autocuration,,,
4878,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1088.0,U,1,,CHEMBL618304,,22224,7766,,Urine,A,,,Autocuration,,,
4879,BAO_0000218,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,U,1,,CHEMBL618305,In vivo,22224,1916,,,A,,,Autocuration,,,
4880,BAO_0000218,Oral bioavailability in human,,U,1,,CHEMBL618306,In vivo,22224,16643,,,A,,,Autocuration,,,
4881,BAO_0000019,Compound was tested for human plasma protein binding,,U,1,,CHEMBL618307,,22224,17248,,,A,,,Autocuration,,,
4882,BAO_0000019,Compound was tested for human plasma protein binding; Not determined,,U,1,,CHEMBL618308,,22224,17248,,,A,,,Autocuration,,,
4883,BAO_0000019,Protein binding activity of compound in human plasma; % Free,,U,1,,CHEMBL618309,,22224,6241,,,A,,,Autocuration,,,
4884,BAO_0000019,Unbound fraction (plasma),,U,1,,CHEMBL618310,,22224,17716,,,A,,,Autocuration,,,
4885,BAO_0000366,Half life for the hydrolysis of compound in human blood serum,1969.0,U,1,,CHEMBL873353,,22224,17605,,Plasma,A,,,Autocuration,,,
4886,BAO_0000366,Half life period in human plasma using phosphate buffer (0.08 M),1969.0,U,1,,CHEMBL618311,,22224,17625,,Plasma,A,,,Autocuration,,,
4887,BAO_0000366,Half life period in human plasma using phosphate buffer (0.1 M),1969.0,U,1,,CHEMBL618312,,22224,17625,,Plasma,A,,,Autocuration,,,
4888,BAO_0000366,Half-life in human plasma was determined,1969.0,U,1,,CHEMBL618313,,22224,17747,,Plasma,A,,,Autocuration,,,
4889,BAO_0000019,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,U,1,,CHEMBL618314,,22224,15613,,,A,,,Autocuration,,,
4890,BAO_0000019,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,U,1,,CHEMBL618315,,22224,354,,,A,,,Autocuration,,,
4891,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,U,1,,CHEMBL618316,,22224,3741,,,A,,,Autocuration,,,
4892,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,U,1,,CHEMBL618317,,22224,3741,,,A,,,Autocuration,,,
4893,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,U,1,,CHEMBL620138,,22224,3741,,,A,,,Autocuration,,,
4894,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL858280,,22224,17599,,,A,,,Autocuration,,,
4895,BAO_0000019,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,U,1,,CHEMBL620139,,22224,5486,,,A,,,Autocuration,,,
4896,BAO_0000251,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,U,1,,CHEMBL620140,,22224,5600,Microsomes,,A,,,Autocuration,,,
4897,BAO_0000019,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,U,1,,CHEMBL620141,,22224,14294,,,A,,,Autocuration,,,
4898,BAO_0000019,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,U,1,,CHEMBL620142,,22224,14294,,,A,,,Autocuration,,,
4899,BAO_0000019,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,U,1,,CHEMBL620143,,22224,14294,,,A,,,Autocuration,,,
4900,BAO_0000251,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,U,1,,CHEMBL620144,,22224,14294,Microsomes,,A,,,Autocuration,,,
4901,BAO_0000251,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,U,1,,CHEMBL620145,,22224,14294,Microsomes,,A,,,Autocuration,,,
4902,BAO_0000251,Metabolism of compound in human microsomes; Trace,,U,1,,CHEMBL620146,,22224,14294,Microsomes,,A,,,Autocuration,,,
4903,BAO_0000251,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,2107.0,U,1,,CHEMBL620147,,22224,6260,Microsomes,Liver,A,,,Autocuration,,,
4904,BAO_0000251,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,U,1,,CHEMBL620148,,22224,6187,Microsomes,,A,,,Autocuration,,,
4905,BAO_0000251,In vitro metabolic potential in human liver microsomes,2107.0,U,1,,CHEMBL620149,,22224,6251,Microsomes,Liver,A,,,Autocuration,,,
4906,BAO_0000019,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,U,1,,CHEMBL876412,,22224,3246,,,A,,,Autocuration,,,
4907,BAO_0000019,Tested for human plasma protein binding of the compound; Not tested,,U,1,,CHEMBL619352,,22224,17313,,,A,,,Autocuration,,,
4908,BAO_0000019,Compound was tested for percent protein binding (PB) in human,,U,1,,CHEMBL619353,,22224,6227,,,A,,,Autocuration,,,
4909,BAO_0000019,Protein binding in human plasma,1969.0,U,1,,CHEMBL619354,,22224,5530,,Plasma,A,,,Autocuration,,,
4910,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,,U,1,,CHEMBL619355,,22224,6108,,,A,,,Autocuration,,,
4911,BAO_0000019,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,U,1,,CHEMBL619356,,22224,6108,,,A,,,Autocuration,,,
4912,BAO_0000019,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,U,1,,CHEMBL619357,,22224,2774,,,A,,,Autocuration,,,
4913,BAO_0000019,In vitro rate of absorption observed as Caco-2 permeability in humans,,U,1,,CHEMBL619358,,22224,16643,,,A,,,Autocuration,,,
4914,BAO_0000219,Cellular permeability of compound was determined in Caco-2 cells; High,,U,1,Caco-2,CHEMBL619359,,22224,17582,,,A,,,Autocuration,,495.0,
4915,BAO_0000219,Permeability in Caco-2 cells of compound,,U,1,Caco-2,CHEMBL619360,,22224,6838,,,A,,,Autocuration,,495.0,
4916,BAO_0000019,Permeability coefficient (A to B) in Caco-2 cell,,U,1,,CHEMBL619361,,22224,6108,,,A,,,Autocuration,,,
4917,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,,U,1,,CHEMBL619362,,22224,6108,,,A,,,Autocuration,,,
4918,BAO_0000019,Permeability coefficient (Papp) (Caco-2 cell monolayer),,U,1,,CHEMBL619363,,22224,6108,,,A,,,Autocuration,,,
4919,BAO_0000019,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,U,1,,CHEMBL618942,,22224,2146,,,A,,,Autocuration,,,
4920,BAO_0000019,Compound was tested for protein binding in human plasma,,U,1,,CHEMBL618943,,22224,4514,,,A,,,Autocuration,,,
4921,BAO_0000019,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,U,1,,CHEMBL618944,,22224,6108,,,A,,,Autocuration,,,
4922,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,1088.0,U,1,,CHEMBL618945,,22224,7766,,Urine,A,,,Autocuration,,,
4923,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,N,1,,CHEMBL618946,In vivo,50594,5969,,,A,,,Intermediate,,,
4924,BAO_0000218,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,1,,CHEMBL876413,In vivo,50594,3277,,,A,,,Intermediate,,,
4925,BAO_0000218,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,N,1,,CHEMBL618947,In vivo,50594,3802,,,A,,,Intermediate,,,
4926,BAO_0000218,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1969.0,N,1,,CHEMBL618948,In vivo,50594,2862,,Plasma,A,,,Intermediate,,,
4927,BAO_0000218,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1969.0,N,1,,CHEMBL618949,In vivo,50594,6348,,Plasma,A,,,Intermediate,,,
4928,BAO_0000218,Tmax after intraperitoneal administration in mice at 23 uM/kg,,N,1,,CHEMBL618950,In vivo,50594,17764,,,F,,,Intermediate,,,
4929,BAO_0000218,Tmax after oral administration at 30 mg/kg in ICR mouse,,N,1,,CHEMBL618951,In vivo,50594,5781,,,A,,,Intermediate,,,
4930,BAO_0000218,Tmax after peroral administration in mice at 2.4 uM/kg,,N,1,,CHEMBL618952,In vivo,50594,17764,,,A,,,Intermediate,,,
4931,BAO_0000218,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,N,1,,CHEMBL618953,In vivo,50594,4066,,,A,,,Intermediate,,,
4932,BAO_0000218,Tmax in brain of mice at the oral dose of 50 mg/kg,955.0,N,1,,CHEMBL618954,In vivo,50594,17641,,Brain,A,,,Intermediate,,,
4933,BAO_0000218,Tmax in kidney of mice at the oral dose of 50 mg/kg,2113.0,N,1,,CHEMBL618955,In vivo,50594,17641,,Kidney,A,,,Intermediate,,,
4934,BAO_0000218,Tmax in liver of mice at the oral dose of 50 mg/kg,2107.0,N,1,,CHEMBL618956,In vivo,50594,17641,,Liver,A,,,Intermediate,,,
4935,BAO_0000218,Tmax in lungs of mice at the oral dose of 50 mg/kg,2048.0,N,1,,CHEMBL618957,In vivo,50594,17641,,Lung,A,,,Intermediate,,,
4936,BAO_0000218,Tmax in mice at 18 uM/kg i.p. administration,,N,1,,CHEMBL618958,In vivo,50594,17764,,,F,,,Intermediate,,,
4937,BAO_0000218,Tmax in mice at 23 uM/kg i.v. administration,,N,1,,CHEMBL618959,In vivo,50594,17764,,,F,,,Intermediate,,,
4938,BAO_0000218,Tmax in mice at 25 uM/kg i.p. administration,,N,1,,CHEMBL618960,In vivo,50594,17764,,,F,,,Intermediate,,,
4939,BAO_0000218,Tmax in mice at 26 uM/kg i.p. administration,,N,1,,CHEMBL876723,In vivo,50594,17764,,,F,,,Intermediate,,,
4940,BAO_0000218,Tmax in spleen of mice at the oral dose of 50 mg/kg,2106.0,N,1,,CHEMBL618961,In vivo,50594,17641,,Spleen,A,,,Intermediate,,,
4941,BAO_0000218,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,N,1,,CHEMBL618962,In vivo,50594,16597,,,A,,,Intermediate,,,
4942,BAO_0000218,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,N,1,,CHEMBL618963,In vivo,50594,16597,,,A,,,Intermediate,,,
4943,BAO_0000218,Tmax value in IRC mice,,N,1,,CHEMBL618964,,50594,5951,,,A,,,Intermediate,,,
4944,BAO_0000218,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,N,1,,CHEMBL618965,In vivo,50594,5506,,,A,,,Intermediate,,,
4945,BAO_0000218,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,N,1,,CHEMBL618966,In vivo,50594,5506,,,A,,,Intermediate,,,
4946,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1088.0,N,1,,CHEMBL618967,,50594,429,,Urine,A,,,Intermediate,,,
4947,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1088.0,N,1,,CHEMBL618968,,50594,429,,Urine,A,,,Intermediate,,,
4948,BAO_0000218,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1088.0,N,1,,CHEMBL618969,,50594,4066,,Urine,A,,,Intermediate,,,
4949,BAO_0000218,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,N,1,,CHEMBL618970,,50594,17734,,,A,,,Intermediate,,,
4950,BAO_0000218,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,N,1,,CHEMBL618971,,50594,17734,,,A,,,Intermediate,,,
4951,BAO_0000218,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,N,1,,CHEMBL618972,In vivo,50594,6062,,,A,,,Intermediate,,,
4952,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,N,1,,CHEMBL618973,In vivo,50594,5969,,,A,,,Intermediate,,,
4953,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,N,1,,CHEMBL618974,In vivo,50594,5969,,,A,,,Intermediate,,,
4954,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,N,1,,CHEMBL618975,In vivo,50594,5969,,,A,,,Intermediate,,,
4955,BAO_0000218,Vd in mice,,N,1,,CHEMBL618976,In vivo,50594,5980,,,A,,,Intermediate,,,
4956,BAO_0000218,Volume of distribution in mouse,,N,1,,CHEMBL618977,In vivo,50594,17592,,,A,,,Intermediate,,,
4957,BAO_0000218,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,1,,CHEMBL876724,In vivo,50594,6348,,,A,,,Intermediate,,,
4958,BAO_0000218,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,N,1,,CHEMBL618978,In vivo,50594,17753,,,A,,,Intermediate,,,
4959,BAO_0000218,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,N,1,,CHEMBL618979,In vivo,50594,17753,,,A,,,Intermediate,,,
4960,BAO_0000218,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,N,1,,CHEMBL618980,In vivo,50594,17753,,,A,,,Intermediate,,,
4961,BAO_0000218,Pharmacokinetic property (vdss) was measured in mouse,,N,1,,CHEMBL618981,In vivo,50594,4239,,,A,,,Intermediate,,,
4962,BAO_0000218,Value distribution upon iv administration in mouse,,N,1,,CHEMBL618982,In vivo,50594,2862,,,A,,,Intermediate,,,
4963,BAO_0000218,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,N,1,,CHEMBL620150,In vivo,50594,17734,,,A,,,Intermediate,,,
4964,BAO_0000218,Volume of distribution was evaluated in mice after intravenous administration,,N,1,,CHEMBL620151,In vivo,50594,2675,,,A,,,Intermediate,,,
4965,BAO_0000218,Volume of distribution was evaluated in mice after oral administration,,N,1,,CHEMBL620152,In vivo,50594,2675,,,A,,,Intermediate,,,
4966,BAO_0000218,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,N,1,,CHEMBL620153,In vivo,50594,17837,,,A,,,Intermediate,,,
4967,BAO_0000218,Steady state volume of distribution was determined in mice,,N,1,,CHEMBL876395,In vivo,50594,5727,,,A,,,Intermediate,,,
4968,BAO_0000218,Volume distribution (steady state) of compound was determined in mouse,,N,1,,CHEMBL620154,In vivo,50594,17852,,,A,,,Intermediate,,,
4969,BAO_0000218,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,N,1,,CHEMBL620155,In vivo,50594,17764,,,A,,,Intermediate,,,
4970,BAO_0000218,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,N,1,,CHEMBL620156,In vivo,50594,16597,,,A,,,Intermediate,,,
4971,BAO_0000218,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,N,1,,CHEMBL620157,In vivo,50594,6062,,,A,,,Intermediate,,,
4972,BAO_0000218,Biodistribution of compound (oxidized form) in in kidney tissue,2113.0,N,1,,CHEMBL620158,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
4973,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,178.0,N,1,,CHEMBL620159,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
4974,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",178.0,N,1,,CHEMBL620160,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
4975,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",178.0,N,1,,CHEMBL620161,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
4976,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,N,1,A-427,CHEMBL620162,,80019,10708,,,F,,,Intermediate,,797.0,
4977,BAO_0000219,Inhibition of A431 human squamous cell carcinoma cell proliferation,,N,1,A-431,CHEMBL620163,,80852,16597,,,F,,,Expert,,500.0,
4978,BAO_0000219,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,N,1,A-431,CHEMBL620833,,80852,16062,,,F,,,Expert,,500.0,
4979,BAO_0000219,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,N,1,A-431,CHEMBL876396,,80852,16062,,,F,,,Expert,,500.0,
4980,BAO_0000219,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,N,1,A-431,CHEMBL620834,,80852,16958,,,F,,,Expert,,500.0,
4981,BAO_0000219,Inhibition of A431 human carcinoma cell proliferation,,N,1,A-431,CHEMBL620835,,80852,6700,,,F,,,Expert,,500.0,
4982,BAO_0000219,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,N,1,A-431,CHEMBL620836,,80852,17226,,,F,,,Expert,,500.0,
4983,BAO_0000219,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,N,1,A-431,CHEMBL620837,,80852,6828,,,F,,,Intermediate,,500.0,
4984,BAO_0000219,In vitro cytotoxicity against epidermoid carcinoma cell line,,N,1,A-431,CHEMBL621017,,80852,12314,,,F,,,Intermediate,,500.0,
4985,BAO_0000218,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,D,1,A-431,CHEMBL621018,,9,13412,,,F,,,Expert,,500.0,
4986,BAO_0000219,Antiproliferative activity of compound was measured on human tumor cell line A431.,,N,1,A-431,CHEMBL621019,,80852,13299,,,F,,,Intermediate,,500.0,
4987,BAO_0000219,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,N,1,A-431,CHEMBL621020,,80852,17420,,,F,,,Intermediate,,500.0,
4988,BAO_0000219,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,N,1,A-431,CHEMBL621021,,80852,13678,,,F,,,Intermediate,,500.0,
4989,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,H,1,A-431,CHEMBL621022,,9,14171,,,F,,,Expert,,500.0,
4990,BAO_0000219,Tested for antiproliferative activity against human A431 cells,,N,1,A-431,CHEMBL621023,,80852,6333,,,F,,,Expert,,500.0,
4991,BAO_0000219,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,D,1,A-431,CHEMBL621024,,9,2356,,,F,,,Expert,,500.0,
4992,BAO_0000219,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,N,1,A-431,CHEMBL621025,,80852,15578,,,F,,,Expert,,500.0,
4993,BAO_0000219,Inhibition of A431 cell proliferation,,N,1,A-431,CHEMBL621026,,80852,5126,,,F,,,Expert,,500.0,
4994,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells,,N,1,A-431,CHEMBL621027,,80852,6844,,,F,,,Expert,,500.0,
4995,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,N,1,A-431,CHEMBL876397,,80852,6844,,,F,,,Expert,,500.0,
4996,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,N,1,A-431,CHEMBL883797,,80852,4925,,,F,,,Intermediate,,500.0,
4997,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,N,1,A-431,CHEMBL621028,,80852,4925,,,F,,,Intermediate,,500.0,
4998,BAO_0000219,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,N,1,A-431,CHEMBL621029,,80852,13978,,,F,,,Intermediate,,500.0,
4999,BAO_0000219,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,N,1,A-431,CHEMBL621030,,80852,16786,,,F,,,Intermediate,,500.0,
5000,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,H,1,A-431,CHEMBL621147,,9,13412,,,F,,,Expert,,500.0,
5001,BAO_0000218,In vivo antiproliferative activity against A431 cell line,,N,1,A-431,CHEMBL621148,,80852,17824,,,F,,,Intermediate,,500.0,
5002,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,D,1,A-431,CHEMBL621149,,9,12751,,,F,,,Expert,,500.0,
5003,BAO_0000219,Inhibition of A431 human epidermoid carcinoma cell proliferation,,N,1,A-431,CHEMBL621150,,80852,12380,,,F,,,Expert,,500.0,
5004,BAO_0000219,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,D,1,A-431,CHEMBL621151,,9,4959,,,F,,,Expert,,500.0,
5005,BAO_0000219,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,N,1,A-431,CHEMBL621152,,80852,6333,,,F,,,Intermediate,,500.0,
5006,BAO_0000219,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,N,1,A-431,CHEMBL621153,,80852,6333,,,F,,,Intermediate,,500.0,
5007,BAO_0000219,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,N,1,A-431,CHEMBL884000,,80852,6333,,,F,,,Intermediate,,500.0,
5008,BAO_0000019,Inhibition of EGFR overexpressing A431 cell proliferation,,D,1,,CHEMBL621154,,9,5296,,,F,,,Expert,,,
5009,BAO_0000219,Inhibition of A431 cell proliferation,,N,1,A-431,CHEMBL621155,,80852,12624,,,F,,,Expert,,500.0,
5010,BAO_0000219,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,D,1,A-431,CHEMBL621156,,9,14926,,,F,,,Expert,,500.0,
5011,BAO_0000219,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,D,1,A-431,CHEMBL621157,,9,14926,,,F,,,Expert,,500.0,
5012,BAO_0000219,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,H,1,A-431,CHEMBL621158,,9,14926,,,F,,,Expert,,500.0,
5013,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,N,1,A-431,CHEMBL621159,,80852,15144,,,F,,,Intermediate,,500.0,
5014,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,N,1,A-431,CHEMBL621160,,80852,15144,,,F,,,Intermediate,,500.0,
5015,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,N,1,A-431,CHEMBL621161,,80852,5245,,,F,,,Intermediate,,500.0,
5016,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,N,1,A-431,CHEMBL621162,,80852,5245,,,F,,,Intermediate,,500.0,
5017,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,N,1,A-431,CHEMBL621163,,80852,5245,,,F,,,Intermediate,,500.0,
5018,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,N,1,A-431,CHEMBL621164,,80852,5245,,,F,,,Intermediate,,500.0,
5019,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,N,1,A-431,CHEMBL621165,,80852,5245,,,F,,,Intermediate,,500.0,
5020,BAO_0000019,Half-life period in cynomolgus monkey,,U,1,,CHEMBL619159,,22224,5922,,,A,,,Autocuration,,,
5021,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1969.0,U,1,,CHEMBL619160,In vitro,22224,1116,,Plasma,A,,,Autocuration,,,
5022,BAO_0000218,Longer half-life in monkey (i.v.) at 0.5 mpk,,U,1,,CHEMBL619161,In vivo,22224,17853,,,A,,,Autocuration,,,
5023,BAO_0000366,Plasma half life in monkey,1969.0,U,1,,CHEMBL619162,,22224,993,,Plasma,A,,,Autocuration,,,
5024,BAO_0000366,Plasma half-life in rhesus monkey,1969.0,U,1,,CHEMBL619163,,22224,4514,,Plasma,A,,,Autocuration,,,
5025,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1969.0,U,1,,CHEMBL619164,In vivo,22224,5334,,Plasma,A,,,Autocuration,,,
5026,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1969.0,U,1,,CHEMBL619320,In vivo,22224,5334,,Plasma,A,,,Autocuration,,,
5027,BAO_0000218,Tested for half life upon iv administration to african green monkey,,U,1,,CHEMBL619321,In vivo,22224,4578,,,A,,,Autocuration,,,
5028,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,1,,CHEMBL873336,In vivo,22224,2661,,,A,,,Autocuration,,,
5029,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,U,1,,CHEMBL619322,In vivo,22224,5355,,,A,,,Autocuration,,,
5030,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,U,1,,CHEMBL619323,In vivo,22224,5355,,,A,,,Autocuration,,,
5031,BAO_0000218,The time for peak concentration value after oral administration in cynomolgus monkeys,,U,1,,CHEMBL619324,In vivo,22224,5355,,,A,,,Autocuration,,,
5032,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,U,1,,CHEMBL619325,,22224,11271,,,A,,,Autocuration,,,
5033,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,U,1,,CHEMBL876411,,22224,11271,,,A,,,Autocuration,,,
5034,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,U,1,,CHEMBL619326,,22224,11271,,,A,,,Autocuration,,,
5035,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,U,1,,CHEMBL619327,,22224,11271,,,A,,,Autocuration,,,
5036,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,U,1,,CHEMBL619328,,22224,11271,,,A,,,Autocuration,,,
5037,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,U,1,,CHEMBL619329,,22224,11271,,,A,,,Autocuration,,,
5038,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,U,1,,CHEMBL619330,,22224,11271,,,A,,,Autocuration,,,
5039,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,U,1,,CHEMBL619331,,22224,11271,,,A,,,Autocuration,,,
5040,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,U,1,,CHEMBL619332,,22224,11271,,,A,,,Autocuration,,,
5041,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,U,1,,CHEMBL619333,,22224,11271,,,A,,,Autocuration,,,
5042,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,U,1,,CHEMBL619334,,22224,11271,,,A,,,Autocuration,,,
5043,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,U,1,,CHEMBL619335,,22224,11271,,,A,,,Autocuration,,,
5044,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,U,1,,CHEMBL619336,,22224,11271,,,A,,,Autocuration,,,
5045,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,U,1,,CHEMBL619337,,22224,11271,,,A,,,Autocuration,,,
5046,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,U,1,,CHEMBL619338,,22224,11271,,,A,,,Autocuration,,,
5047,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,U,1,,CHEMBL619339,,22224,11271,,,A,,,Autocuration,,,
5048,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),,N,1,,CHEMBL619340,In vivo,50597,5809,,,A,,,Intermediate,,,
5049,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL873496,In vivo,50597,17720,,Plasma,A,,,Intermediate,,,
5050,BAO_0000218,AUC value in rat after IV administration at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL619341,,50597,3546,,Plasma,A,,,Intermediate,,,
5051,BAO_0000218,AUC value in rat after oral administration at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL619342,,50597,3546,,Plasma,A,,,Intermediate,,,
5052,BAO_0000218,Cmax value in rat after oral administration at a dose of 10 mg/kg,,N,1,,CHEMBL619343,In vivo,50597,3546,,,A,,,Intermediate,,,
5053,BAO_0000218,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,N,1,,CHEMBL619344,In vivo,50597,3546,,,A,,,Intermediate,,,
5054,BAO_0000218,Tmax value in rat after oral administration at a dose of 10 mg/kg,,N,1,,CHEMBL619345,In vivo,50597,3546,,,A,,,Intermediate,,,
5055,BAO_0000218,Vc value in rat after IV administration at a dose of 10 mg/kg,,N,1,,CHEMBL619346,,50597,3546,,,A,,,Intermediate,,,
5056,BAO_0000218,Half life period in rat after IV administration at a dose of 10 mg/kg,,N,1,,CHEMBL619347,In vivo,50597,3546,,,A,,,Intermediate,,,
5057,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,U,1,,CHEMBL619348,,22224,10625,,,A,,,Autocuration,,,
5058,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,U,1,,CHEMBL619349,,22224,10625,,,A,,,Autocuration,,,
5059,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,U,1,,CHEMBL619350,,22224,10625,,,A,,,Autocuration,,,
5060,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,U,1,,CHEMBL619351,,22224,10625,,,A,,,Autocuration,,,
5061,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,U,1,,CHEMBL875953,,22224,10625,,,A,,,Autocuration,,,
5062,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,U,1,,CHEMBL621716,,22224,10625,,,A,,,Autocuration,,,
5063,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,U,1,,CHEMBL621717,,22224,10625,,,A,,,Autocuration,,,
5064,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,U,1,,CHEMBL621718,,22224,10625,,,A,,,Autocuration,,,
5065,BAO_0000019,Area under curve after 1 mpk peroral administration to beagles,,U,1,,CHEMBL621719,,22224,3510,,,A,,,Autocuration,,,
5066,BAO_0000019,Area under curve after 2 mpk peroral administration to beagles,,U,1,,CHEMBL621720,,22224,3510,,,A,,,Autocuration,,,
5067,BAO_0000218,Cmax value after 1 mpk peroral administration to beagles,,U,1,,CHEMBL621721,In vivo,22224,3510,,,A,,,Autocuration,,,
5068,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,1088.0,U,1,,CHEMBL621722,,22224,7766,,Urine,A,,,Autocuration,,,
5069,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,1088.0,U,1,,CHEMBL621723,,22224,7766,,Urine,A,,,Autocuration,,,
5070,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,1088.0,U,1,,CHEMBL621724,,22224,7766,,Urine,A,,,Autocuration,,,
5071,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,1088.0,U,1,,CHEMBL623443,,22224,7766,,Urine,A,,,Autocuration,,,
5072,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,1088.0,U,1,,CHEMBL623444,,22224,7766,,Urine,A,,,Autocuration,,,
5073,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,1088.0,U,1,,CHEMBL623445,,22224,7766,,Urine,A,,,Autocuration,,,
5074,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,1088.0,U,1,,CHEMBL623446,,22224,7766,,Urine,A,,,Autocuration,,,
5075,BAO_0000251,Metabolic stability observed at 30 min after administration in human liver microsomes,2107.0,U,1,,CHEMBL623447,,22224,16643,Microsomes,Liver,A,,,Autocuration,,,
5076,BAO_0000019,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,U,1,,CHEMBL623448,,22224,6852,,,A,,,Autocuration,,,
5077,BAO_0000019,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,U,1,,CHEMBL623449,,22224,6852,,,A,,,Autocuration,,,
5078,BAO_0000019,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,U,1,,CHEMBL623450,,22224,6852,,,A,,,Autocuration,,,
5079,BAO_0000251,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",2107.0,U,1,,CHEMBL623451,,22224,6567,Microsomes,Liver,A,,,Autocuration,,,
5080,BAO_0000019,Metabolic stability (% remaining at 30 mins) in human S9.,,U,1,,CHEMBL623452,,22224,6570,,,A,,,Autocuration,,,
5081,BAO_0000019,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,U,1,,CHEMBL623453,,22224,6570,,,A,,,Autocuration,,,
5082,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes,2107.0,U,1,,CHEMBL623454,,22224,5237,Microsomes,Liver,A,,,Autocuration,,,
5083,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,2107.0,U,1,,CHEMBL623455,,22224,5237,Microsomes,Liver,A,,,Autocuration,,,
5084,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,2107.0,U,1,,CHEMBL624371,,22224,5237,Microsomes,Liver,A,,,Autocuration,,,
5085,BAO_0000218,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,U,1,,CHEMBL624372,,22224,5202,,,A,,,Autocuration,,,
5086,BAO_0000019,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,U,1,,CHEMBL624373,,22224,5481,,,A,,,Autocuration,,,
5087,BAO_0000019,Percent remaining in human plasma after incubation for 60 min at 37 C.,,U,1,,CHEMBL624374,,22224,5481,,,A,,,Autocuration,,,
5088,BAO_0000019,The percent remaining in human plasma after 30 min was determined,,U,1,,CHEMBL624556,,22224,3956,,,A,,,Autocuration,,,
5089,BAO_0000366,Conversion rate of the prodrug in human plasma,1969.0,U,1,,CHEMBL624557,,22224,5074,,Plasma,A,,,Autocuration,,,
5090,BAO_0000366,Conversion rate of the prodrug in human plasma; ND means no data,1969.0,U,1,,CHEMBL624558,,22224,5074,,Plasma,A,,,Autocuration,,,
5091,BAO_0000221,Half life of compound was determined in human blood,178.0,U,1,,CHEMBL624559,,22224,4727,,Blood,A,,,Autocuration,,,
5092,BAO_0000019,Half life of compound was determined in man with once daily dosing,,U,1,,CHEMBL624560,,22224,5965,,,A,,,Autocuration,,,
5093,BAO_0000251,Half life in human microsomes,,U,1,,CHEMBL624561,In vitro,22224,5732,Microsomes,,A,,,Autocuration,,,
5094,BAO_0000366,Half life in human plasma,1969.0,U,1,,CHEMBL624562,,22224,5819,,Plasma,A,,,Autocuration,,,
5095,BAO_0000366,Half life in human plasma; Not detected,1969.0,U,1,,CHEMBL624563,,22224,5819,,Plasma,A,,,Autocuration,,,
5096,BAO_0000218,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,U,1,,CHEMBL624564,In vivo,22224,1916,,,A,,,Autocuration,,,
5097,BAO_0000251,Half-life for oxidative metabolic stability was determined using rat liver microsomes,2107.0,U,1,,CHEMBL624565,In vitro,22224,6597,Microsomes,Liver,A,,,Autocuration,,,
5098,BAO_0000366,Half-life in human plasma,1969.0,U,1,,CHEMBL875152,,22224,5229,,Plasma,A,,,Autocuration,,,
5099,BAO_0000366,Half-life of the parent prodrug in plasma,1969.0,U,1,,CHEMBL624566,,22224,5229,,Plasma,A,,,Autocuration,,,
5100,BAO_0000366,In vitro half life in human plasma was determined,1969.0,U,1,,CHEMBL873805,In vitro,22224,2192,,Plasma,A,,,Autocuration,,,
5101,BAO_0000251,The compound was tested In Vitro for half life in human liver microsomes.,2107.0,U,1,,CHEMBL624567,In vitro,22224,3032,Microsomes,Liver,A,,,Autocuration,,,
5102,BAO_0000218,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,U,1,,CHEMBL624568,In vivo,22224,1916,,,A,,,Autocuration,,,
5103,BAO_0000218,Observed volume of distribution,,U,1,,CHEMBL624569,In vivo,22224,17716,,,A,,,Autocuration,,,
5104,BAO_0000218,Oral bioavailability in human,,U,1,,CHEMBL624570,In vivo,22224,15778,,,A,,,Autocuration,,,
5105,BAO_0000019,Tested for human plasma protein binding of the compound,,U,1,,CHEMBL624571,,22224,17313,,,A,,,Autocuration,,,
5106,BAO_0000019,"First order rate constant, k was determined in human plasma",,U,1,,CHEMBL624572,,22224,4231,,,A,,,Autocuration,,,
5107,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,,U,1,,CHEMBL624573,,22224,4755,,,A,,,Autocuration,,,
5108,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,,U,1,,CHEMBL875153,,22224,4755,,,A,,,Autocuration,,,
5109,BAO_0000251,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,2107.0,U,1,,CHEMBL624574,,22224,16907,Microsomes,Liver,A,,,Autocuration,,,
5110,BAO_0000019,The compound was tested for the plasma binding in human,,U,1,,CHEMBL624575,,22224,10839,,,A,,,Autocuration,,,
5111,BAO_0000019,Plasma protein binding (human),,U,1,,CHEMBL624576,,22224,10839,,,A,,,Autocuration,,,
5112,BAO_0000251,Compound was evaluated for half-life in human liver microsomes,2107.0,U,1,,CHEMBL624577,In vitro,22224,3199,Microsomes,Liver,A,,,Autocuration,,,
5113,BAO_0000221,Half life measured in vitro for its stability in human blood,178.0,U,1,,CHEMBL624578,In vitro,22224,1345,,Blood,A,,,Autocuration,,,
5114,BAO_0000019,Half life in human serum,1977.0,U,1,,CHEMBL622796,,22224,4297,,Serum,A,,,Autocuration,,,
5115,BAO_0000019,Half life in human serum; ND=not determined,1977.0,U,1,,CHEMBL622797,,22224,4297,,Serum,A,,,Autocuration,,,
5116,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 1,,U,1,,CHEMBL622798,,22224,4297,,,A,,,Autocuration,,,
5117,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 2,,U,1,,CHEMBL622799,,22224,4297,,,A,,,Autocuration,,,
5118,BAO_0000366,Half life of the in human plasma,1969.0,U,1,,CHEMBL622800,,22224,4231,,Plasma,A,,,Autocuration,,,
5119,BAO_0000220,Half life period in human hepatic S9 fraction was determined,,U,1,,CHEMBL622801,In vitro,22224,5633,S9,,A,,,Autocuration,,,
5120,BAO_0000251,Half life period in human liver microsome was determined,2107.0,U,1,,CHEMBL622802,In vitro,22224,5633,Microsomes,Liver,A,,,Autocuration,,,
5121,BAO_0000019,Half life period was determined; 6-7,,U,1,,CHEMBL622803,,22224,17791,,,A,,,Autocuration,,,
5122,BAO_0000019,Half life period was evaluated in human,,U,1,,CHEMBL875154,,22224,17791,,,A,,,Autocuration,,,
5123,BAO_0000366,Half life time in human plasma,1969.0,U,1,,CHEMBL622804,,22224,3160,,Plasma,A,,,Autocuration,,,
5124,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",955.0,N,1,,CHEMBL622805,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5125,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",948.0,N,1,,CHEMBL622611,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5126,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",948.0,N,1,,CHEMBL622612,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5127,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",2113.0,N,1,,CHEMBL875160,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5128,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",2113.0,N,1,,CHEMBL622613,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5129,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2113.0,N,1,,CHEMBL622614,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5130,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",2107.0,N,1,,CHEMBL622615,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
5131,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,2107.0,N,1,,CHEMBL622616,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
5132,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2107.0,N,1,,CHEMBL622617,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
5133,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,2106.0,N,1,,CHEMBL622618,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
5134,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",2106.0,N,1,,CHEMBL622619,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
5135,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2106.0,N,1,,CHEMBL622620,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
5136,BAO_0000218,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,N,1,,CHEMBL622621,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5137,BAO_0000218,Biodistribution of compound (oxidized form) in blood tissue,178.0,N,1,,CHEMBL622622,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
5138,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",178.0,N,1,,CHEMBL622623,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
5139,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",178.0,N,1,,CHEMBL622624,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
5140,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",178.0,N,1,,CHEMBL622625,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
5141,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",178.0,N,1,,CHEMBL622626,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
5142,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",178.0,N,1,,CHEMBL622627,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
5143,BAO_0000218,Biodistribution of compound (oxidized form) in brain tissue of mice,955.0,N,1,,CHEMBL622628,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5144,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",955.0,N,1,,CHEMBL622629,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5145,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,N,1,,CHEMBL622630,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5146,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",955.0,N,1,,CHEMBL622631,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5147,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",955.0,N,1,,CHEMBL622632,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5148,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",955.0,N,1,,CHEMBL622633,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
5149,BAO_0000218,Biodistribution of compound (oxidized form) in heart tissue of mice,948.0,N,1,,CHEMBL622634,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5150,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",948.0,N,1,,CHEMBL622635,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5151,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",948.0,N,1,,CHEMBL875161,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5152,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",948.0,N,1,,CHEMBL622636,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5153,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",948.0,N,1,,CHEMBL623335,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5154,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",948.0,N,1,,CHEMBL623336,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
5155,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2113.0,N,1,,CHEMBL623337,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5156,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",2113.0,N,1,,CHEMBL623338,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5157,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",2113.0,N,1,,CHEMBL623339,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5158,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2113.0,N,1,,CHEMBL623524,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5159,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",2113.0,N,1,,CHEMBL623525,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
5160,BAO_0000218,Biodistribution of compound (oxidized form) in liver tissue,2107.0,N,1,,CHEMBL623526,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
5161,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2107.0,N,1,,CHEMBL623527,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
5162,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2107.0,N,1,,CHEMBL623528,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
5163,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,N,1,A-431,CHEMBL624615,,80852,5245,,,F,,,Intermediate,,500.0,
5164,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,N,1,A-431,CHEMBL621672,,80852,5245,,,F,,,Intermediate,,500.0,
5165,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,N,1,A-431,CHEMBL621673,,80852,16289,,,F,,,Expert,,500.0,
5166,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,N,1,A-431,CHEMBL621674,,80852,16289,,,F,,,Expert,,500.0,
5167,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,D,1,A-431,CHEMBL884002,,9,16093,,,F,,,Expert,,500.0,
5168,BAO_0000219,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,N,1,A-431,CHEMBL621850,,80852,16825,,,F,,,Intermediate,,500.0,
5169,BAO_0000219,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,N,1,A-431,CHEMBL621851,,80852,4848,,,F,,,Intermediate,,500.0,
5170,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,D,1,A-431,CHEMBL621852,,9,14827,,,F,,,Expert,,500.0,
5171,BAO_0000219,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,D,1,A-431,CHEMBL621853,,9,14827,,,F,,,Expert,,500.0,
5172,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,N,1,A-431,CHEMBL621854,,80852,16289,,,F,,,Expert,,500.0,
5173,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,N,1,A-431,CHEMBL621855,,80852,16289,,,F,,,Expert,,500.0,
5174,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,N,1,A-431,CHEMBL623724,,80852,16289,,,F,,,Expert,,500.0,
5175,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,N,1,A-431,CHEMBL623725,,80852,16289,,,F,,,Expert,,500.0,
5176,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,N,1,A-431,CHEMBL623726,,80852,16289,,,F,,,Expert,,500.0,
5177,BAO_0000219,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,D,1,A-431,CHEMBL623727,,9,16289,,,F,,,Expert,,500.0,
5178,BAO_0000219,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,H,1,A-431,CHEMBL623728,,9,16289,,,F,,,Expert,,500.0,
5179,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,N,1,A-431,CHEMBL623729,,80852,16289,,,F,,,Expert,,500.0,
5180,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,N,1,A-431,CHEMBL623730,,80852,16289,,,F,,,Expert,,500.0,
5181,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,N,1,A-431,CHEMBL623731,,80852,16289,,,F,,,Expert,,500.0,
5182,BAO_0000218,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,1,A-431,CHEMBL623732,,80852,14555,,,F,,,Expert,,500.0,
5183,BAO_0000218,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,1,A-431,CHEMBL623733,,80852,14555,,,F,,,Expert,,500.0,
5184,BAO_0000218,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,1,A-431,CHEMBL623734,,80852,14555,,,F,,,Expert,,500.0,
5185,BAO_0000218,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,1,A-431,CHEMBL623735,,80852,14555,,,F,,,Expert,,500.0,
5186,BAO_0000219,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,N,1,A-431,CHEMBL623736,,80852,1937,,,F,,,Expert,,500.0,
5187,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,N,1,A-431,CHEMBL623737,,80852,13739,,,F,,,Intermediate,,500.0,
5188,BAO_0000219,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,N,1,A-431,CHEMBL623738,,80852,3558,,,F,,,Intermediate,,500.0,
5189,BAO_0000219,Dose giving a 50% decrease in the living cell number (A437 cells),,N,1,A-431,CHEMBL875168,,80852,3558,,,F,,,Intermediate,,500.0,
5190,BAO_0000219,In vitro inhibitory concentration against proliferation of A459 cell line.,,N,1,A549,CHEMBL623739,,80682,17686,,,F,,,Expert,,646.0,
5191,BAO_0000219,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,N,1,A549,CHEMBL623740,,80682,5305,,,F,,,Intermediate,,646.0,
5192,BAO_0000219,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,N,1,A549,CHEMBL624424,,80682,3614,,,F,,,Intermediate,,646.0,
5193,BAO_0000219,In vitro antitumor activity against renal A498 tumor cell lines,,N,1,A498,CHEMBL624425,,80021,17229,,,F,,,Intermediate,,624.0,
5194,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,N,1,A498,CHEMBL624426,,80021,15935,,,F,,,Intermediate,,624.0,
5195,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,N,1,A498,CHEMBL624427,,80021,15935,,,F,,,Intermediate,,624.0,
5196,BAO_0000219,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,N,1,A498,CHEMBL624428,,80021,15560,,,F,,,Intermediate,,624.0,
5197,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,N,1,A498,CHEMBL624429,,80021,13891,,,F,,,Intermediate,,624.0,
5198,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,N,1,A498,CHEMBL624620,,80021,13891,,,F,,,Intermediate,,624.0,
5199,BAO_0000219,Cytotoxicity on kidney carcinoma (A-498) cell line,,N,1,A498,CHEMBL624621,,80021,13788,,,F,,,Intermediate,,624.0,
5200,BAO_0000219,Compound was evaluated against Human cell line renal A498,,N,1,A498,CHEMBL624622,,80021,15403,,,F,,,Intermediate,,624.0,
5201,BAO_0000219,Compound was tested for inhibition of A498 human renal cancer cell line,,N,1,A498,CHEMBL624623,,80021,1009,,,F,,,Intermediate,,624.0,
5202,BAO_0000219,Growth inhibitory activity against A498 human cancer cell line,,N,1,A498,CHEMBL874365,,80021,1043,,,F,,,Intermediate,,624.0,
5203,BAO_0000219,In vitro antitumor activity against human renal A498 cell line,,N,1,A498,CHEMBL624624,,80021,5858,,,F,,,Intermediate,,624.0,
5204,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line,,N,1,A498,CHEMBL624625,,80021,5958,,,F,,,Intermediate,,624.0,
5205,BAO_0000219,In vitro cytotoxic activity against human renal cancer (A498) cell line,,N,1,A498,CHEMBL624626,,80021,5506,,,F,,,Intermediate,,624.0,
5206,BAO_0000219,Tested for cytostatic activity against renal A498 cell line,,N,1,A498,CHEMBL624627,,80021,12781,,,F,,,Intermediate,,624.0,
5207,BAO_0000219,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,N,1,A498,CHEMBL883157,,80021,14399,,,F,,,Intermediate,,624.0,
5208,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,N,1,A498,CHEMBL624628,,80021,5958,,,F,,,Expert,,624.0,
5209,BAO_0000218,Cmax value after 2 mpk peroral administration to beagles,,U,1,,CHEMBL624629,In vivo,22224,3510,,,A,,,Autocuration,,,
5210,BAO_0000218,Bioavailability,,U,1,,CHEMBL623551,In vivo,22224,3510,,,A,beagle,,Autocuration,,,
5211,BAO_0000218,Bioavailability after 1 mpk peroral administration to beagles,,U,1,,CHEMBL623552,In vivo,22224,3510,,,A,beagle,,Autocuration,,,
5212,BAO_0000218,Bioavailability after 2 mpk peroral administration to beagles,,U,1,,CHEMBL623553,In vivo,22224,3510,,,A,beagle,,Autocuration,,,
5213,BAO_0000019,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,U,1,,CHEMBL623554,,22224,3085,,,A,,,Autocuration,,,
5214,BAO_0000019,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,U,1,,CHEMBL623555,,22224,3085,,,A,,,Autocuration,,,
5215,BAO_0000019,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,U,1,,CHEMBL623556,,22224,3085,,,A,,,Autocuration,,,
5216,BAO_0000019,Solubility against bovine alpha-chymotrypsin,,U,1,,CHEMBL623557,,22224,9372,,,A,,,Autocuration,,,
5217,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,U,1,,CHEMBL623558,,22224,3085,,,A,,,Autocuration,,,
5218,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,U,1,,CHEMBL623559,,22224,3085,,,A,,,Autocuration,,,
5219,BAO_0000221,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,2106.0,U,1,,CHEMBL623560,,22224,1469,,Spleen,A,,,Autocuration,,,
5220,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,U,1,,CHEMBL623561,,22224,4297,,,A,,,Autocuration,,,
5221,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,U,1,,CHEMBL623562,,22224,4297,,,A,,,Autocuration,,,
5222,BAO_0000019,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,U,1,,CHEMBL623563,,22224,17585,,,A,,,Autocuration,,,
5223,BAO_0000221,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,2106.0,U,1,,CHEMBL623564,,22224,1336,,Spleen,A,,,Autocuration,,,
5224,BAO_0000019,Half life in presence of 2 mg/mL BSA at pH 8.8,,U,1,,CHEMBL873806,,22224,3085,,,A,,,Autocuration,,,
5225,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,U,1,,CHEMBL623565,,22224,2857,,,A,,,Autocuration,,,
5226,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,U,1,,CHEMBL623566,,22224,2857,,,A,,,Autocuration,,,
5227,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,U,1,,CHEMBL623567,,22224,2857,,,A,,,Autocuration,,,
5228,BAO_0000019,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,U,1,,CHEMBL623568,,22224,1540,,,A,,,Autocuration,,,
5229,BAO_0000218,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1969.0,N,1,,CHEMBL623569,,50588,6316,,Plasma,A,,,Intermediate,,,
5230,BAO_0000218,AUC after administration at 100 mg/kg/day in dogs,1969.0,N,1,,CHEMBL623570,,50588,17594,,Plasma,A,,,Intermediate,,,
5231,BAO_0000218,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1969.0,N,1,,CHEMBL624254,,50588,4953,,Plasma,A,,,Intermediate,,,
5232,BAO_0000218,AUC value after 15 mg/kg iv dose in Dogs,1969.0,N,1,,CHEMBL624255,,50588,16907,,Plasma,A,,,Intermediate,,,
5233,BAO_0000218,AUC value after 30 mg/kg po dose in Dogs,1969.0,N,1,,CHEMBL624256,,50588,16907,,Plasma,A,,,Intermediate,,,
5234,BAO_0000218,AUC value after administration of 4 mg/Kg oral dose in dog,1969.0,N,1,,CHEMBL624257,,50588,2959,,Plasma,A,,,Intermediate,,,
5235,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1969.0,N,1,,CHEMBL624258,,50588,17594,,Plasma,A,,,Intermediate,,,
5236,BAO_0000218,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,N,1,,CHEMBL875277,,50588,5356,,,A,,,Intermediate,,,
5237,BAO_0000218,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,N,1,,CHEMBL622667,,50588,16807,,,A,,,Intermediate,,,
5238,BAO_0000218,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,N,1,,CHEMBL622668,,50588,4527,,,A,,,Intermediate,,,
5239,BAO_0000218,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,N,1,,CHEMBL622669,,50588,4527,,,A,,,Intermediate,,,
5240,BAO_0000218,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,N,1,,CHEMBL622670,,50588,15660,,,A,,,Intermediate,,,
5241,BAO_0000218,Area under curve determined in dogs after oral administration of 10 mg/kg,,N,1,,CHEMBL622671,,50588,15660,,,A,,,Intermediate,,,
5242,BAO_0000218,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,1,,CHEMBL622672,,50588,5802,,,A,,,Intermediate,,,
5243,BAO_0000218,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL622673,,50588,3598,,,A,,,Expert,,,
5244,BAO_0000218,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL622674,,50588,3598,,,A,,,Expert,,,
5245,BAO_0000218,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,N,1,,CHEMBL622675,,50588,5944,,,A,,,Intermediate,,,
5246,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,N,1,,CHEMBL622676,,50588,5944,,,A,,,Intermediate,,,
5247,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,N,1,,CHEMBL622677,,50588,5944,,,A,,,Intermediate,,,
5248,BAO_0000218,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,N,1,,CHEMBL622678,,50588,5944,,,A,,,Intermediate,,,
5249,BAO_0000218,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,N,1,,CHEMBL622679,,50588,4186,,,A,,,Intermediate,,,
5250,BAO_0000218,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,1,,CHEMBL622680,,50588,5007,,,A,,,Intermediate,,,
5251,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in dog,,N,1,,CHEMBL622681,,50588,5668,,,A,,,Intermediate,,,
5252,BAO_0000218,Area under curve was determine after peroral administration at 5 mpk in dog,,N,1,,CHEMBL875278,,50588,5668,,,A,,,Intermediate,,,
5253,BAO_0000218,Area under curve was determined,,N,1,,CHEMBL622682,,50588,5006,,,A,,,Intermediate,,,
5254,BAO_0000218,Area under curve in dogs,,N,1,,CHEMBL622683,,50588,5006,,,A,,,Intermediate,,,
5255,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration,,N,1,,CHEMBL622684,,50588,3771,,,A,,,Intermediate,,,
5256,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,N,1,,CHEMBL622685,,50588,3771,,,A,,,Intermediate,,,
5257,BAO_0000218,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,N,1,,CHEMBL622686,,50588,3771,,,A,,,Intermediate,,,
5258,BAO_0000218,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,1,,CHEMBL618344,,50588,1916,,,A,,,Intermediate,,,
5259,BAO_0000218,Area under curve value in dog at a dose of 5 mg/kg,,N,1,,CHEMBL875582,,50588,5302,,,A,,,Intermediate,,,
5260,BAO_0000218,Area under curve was determined after 0.1 mg/kg iv administration in dog,,N,1,,CHEMBL618345,,50588,5600,,,A,,,Intermediate,,,
5261,BAO_0000218,Area under curve was determined after 0.3 mg/kg po administration in dog,,N,1,,CHEMBL618346,,50588,5600,,,A,,,Intermediate,,,
5262,BAO_0000218,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,N,1,,CHEMBL618347,,50588,17764,,,A,,,Intermediate,,,
5263,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,N,1,,CHEMBL618348,,50588,4368,,,A,,,Intermediate,,,
5264,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,U,1,,CHEMBL618349,,22224,5318,,,A,,,Autocuration,,,
5265,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,U,1,,CHEMBL618350,,22224,5318,,,A,,,Autocuration,,,
5266,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,U,1,,CHEMBL618351,,22224,5318,,,A,,,Autocuration,,,
5267,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,U,1,,CHEMBL618352,,22224,5318,,,A,,,Autocuration,,,
5268,BAO_0000221,Time taken to reduce 50% of the concentration of compound in blood plasma,178.0,U,1,,CHEMBL873494,,22224,14518,,Blood,A,,,Autocuration,,,
5269,BAO_0000366,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1969.0,U,1,,CHEMBL618353,,22224,2209,,Plasma,A,,,Autocuration,,,
5270,BAO_0000366,Half life in human plasma,1969.0,U,1,,CHEMBL618354,,22224,6787,,Plasma,A,,,Autocuration,,,
5271,BAO_0000366,Half life in human plasma was reported,1969.0,U,1,,CHEMBL875583,,22224,4898,,Plasma,A,,,Autocuration,,,
5272,BAO_0000019,Half life in human serum,1977.0,U,1,,CHEMBL618355,,22224,6072,,Serum,A,,,Autocuration,,,
5273,BAO_0000366,Half life upon exposure to human plasma,1969.0,U,1,,CHEMBL618356,,22224,16907,,Plasma,A,,,Autocuration,,,
5274,BAO_0000251,t1/2 in human microsomes,,U,1,,CHEMBL618357,In vitro,22224,5656,Microsomes,,A,,,Autocuration,,,
5275,BAO_0000366,Half life period in 80% human plasma at 37 degree Centigrade,1969.0,U,1,,CHEMBL618358,,22224,4755,,Plasma,A,,,Autocuration,,,
5276,BAO_0000221,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),14.0,U,1,,CHEMBL618359,,22224,17503,,Zone of skin,A,,,Autocuration,,,
5277,BAO_0000366,Half-life measured in in vitro Cathepsin B assay in human plasma,1969.0,U,1,,CHEMBL618360,In vitro,22224,12357,,Plasma,A,,,Autocuration,,,
5278,BAO_0000019,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,U,1,,CHEMBL618361,,22224,3076,,,A,,,Autocuration,,,
5279,BAO_0000251,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,2107.0,U,1,,CHEMBL618362,In vitro,22224,6410,Microsomes,Liver,A,,,Autocuration,,,
5280,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1969.0,U,1,,CHEMBL618363,,22224,3741,,Plasma,A,,,Autocuration,,,
5281,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1969.0,U,1,,CHEMBL618364,,22224,3741,,Plasma,A,,,Autocuration,,,
5282,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1969.0,U,1,,CHEMBL875584,,22224,3741,,Plasma,A,,,Autocuration,,,
5283,BAO_0000019,Half-life in the CEM cell extracts,,U,1,,CHEMBL618365,,22224,1540,,,A,,,Autocuration,,,
5284,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,1969.0,U,1,,CHEMBL873495,,22224,2905,,Plasma,A,,,Autocuration,,,
5285,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,1969.0,U,1,,CHEMBL618366,,22224,2905,,Plasma,A,,,Autocuration,,,
5286,BAO_0000019,Half-life was determined,,U,1,,CHEMBL618367,,22224,5523,,,A,,,Autocuration,,,
5287,BAO_0000221,Half-life (human blood stability),178.0,U,1,,CHEMBL618368,,22224,1499,,Blood,A,,,Autocuration,,,
5288,BAO_0000221,Half-life (human blood stability); no data,178.0,U,1,,CHEMBL618369,,22224,1499,,Blood,A,,,Autocuration,,,
5289,BAO_0000366,Half-life in human plasma,1969.0,U,1,,CHEMBL618370,,22224,17065,,Plasma,A,,,Autocuration,,,
5290,BAO_0000019,CYP3A4 metabolism half-life (t1/2),,U,1,,CHEMBL618371,,22224,6861,,,A,,,Autocuration,,,
5291,BAO_0000221,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),178.0,U,1,,CHEMBL618372,,22224,1499,,Blood,A,,,Autocuration,,,
5292,BAO_0000366,In vitro half life in human plasma,1969.0,U,1,,CHEMBL618373,In vitro,22224,530,,Plasma,A,,,Autocuration,,,
5293,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1969.0,U,1,,CHEMBL618374,In vitro,22224,1116,,Plasma,A,,,Autocuration,,,
5294,BAO_0000366,In vitro hydrolysis in human plasma,1969.0,U,1,,CHEMBL618375,In vitro,22224,6695,,Plasma,A,,,Autocuration,,,
5295,BAO_0000366,In vitro hydrolysis in human plasma; no data,1969.0,U,1,,CHEMBL618376,In vitro,22224,6695,,Plasma,A,,,Autocuration,,,
5296,BAO_0000251,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,2107.0,U,1,,CHEMBL618377,In vitro,22224,10,Microsomes,Liver,A,,,Autocuration,,,
5297,BAO_0000366,Plasma half life in human,1969.0,U,1,,CHEMBL618378,,22224,993,,Plasma,A,,,Autocuration,,,
5298,BAO_0000366,Stability after incubation with human plasma (at 37 degree C),1969.0,U,1,,CHEMBL618379,,22224,15429,,Plasma,A,,,Autocuration,,,
5299,BAO_0000366,T1/2 was evaluated in human plasma,1969.0,U,1,,CHEMBL618380,,22224,1675,,Plasma,A,,,Autocuration,,,
5300,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1969.0,U,1,,CHEMBL618381,,22224,2209,,Plasma,A,,,Autocuration,,,
5301,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",1969.0,U,1,,CHEMBL618382,,22224,2209,,Plasma,A,,,Autocuration,,,
5302,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,U,1,,CHEMBL618383,,22224,5318,,,A,,,Autocuration,,,
5303,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,U,1,,CHEMBL618384,In vitro,22224,2412,,,A,,,Autocuration,,,
5304,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,U,1,,CHEMBL618385,In vitro,22224,2412,,,A,,,Autocuration,,,
5305,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,1969.0,U,1,,CHEMBL619099,,22224,2906,,Plasma,A,,,Autocuration,,,
5306,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,1969.0,U,1,,CHEMBL619100,,22224,2906,,Plasma,A,,,Autocuration,,,
5307,BAO_0000019,Time taken for 50% to be consumed by serum PON1 was determined,,U,1,,CHEMBL619101,,22224,5495,,,A,,,Autocuration,,,
5308,BAO_0000019,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,U,1,,CHEMBL619102,,22224,5495,,,A,,,Autocuration,,,
5309,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,2107.0,U,1,,CHEMBL619103,,22224,4397,Microsomes,Liver,A,,,Autocuration,,,
5310,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,1,,CHEMBL619268,,22224,2413,,,A,,,Autocuration,,,
5311,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,1,,CHEMBL619269,,22224,2413,,,A,,,Autocuration,,,
5312,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,1,,CHEMBL619270,,22224,2413,,,A,,,Autocuration,,,
5313,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,1,,CHEMBL619271,,22224,2413,,,A,,,Autocuration,,,
5314,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,1,,CHEMBL875585,,22224,2413,,,A,,,Autocuration,,,
5315,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,1,,CHEMBL619272,,22224,2413,,,A,,,Autocuration,,,
5316,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line 786-0,,N,1,786-0,CHEMBL619273,,80640,6058,,,F,,,Intermediate,,391.0,
5317,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,N,1,786-0,CHEMBL619274,,80640,17708,,,F,,,Intermediate,,391.0,
5318,BAO_0000219,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,N,1,786-0,CHEMBL619275,,80640,14017,,,F,,,Expert,,391.0,
5319,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,N,1,786-0,CHEMBL619276,,80640,16818,,,F,,,Intermediate,,391.0,
5320,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,N,1,786-0,CHEMBL619277,,80640,16818,,,F,,,Intermediate,,391.0,
5321,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,N,1,786-0,CHEMBL619278,,80640,16818,,,F,,,Intermediate,,391.0,
5322,BAO_0000219,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,N,1,786-0,CHEMBL619279,,80640,11970,,,F,,,Intermediate,,391.0,
5323,BAO_0000219,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,N,1,786-0,CHEMBL858458,,80640,12400,,,F,,,Intermediate,,391.0,
5324,BAO_0000219,Cytotoxic effect on renal cancer line 786-0,,N,1,786-0,CHEMBL619280,,80640,12888,,,F,,,Expert,,391.0,
5325,BAO_0000219,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,N,1,786-0,CHEMBL619281,,80640,15300,,,F,,,Intermediate,,391.0,
5326,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,N,1,786-0,CHEMBL619282,,80640,14769,,,F,,,Intermediate,,391.0,
5327,BAO_0000219,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,N,1,786-0,CHEMBL619283,,80640,15895,,,F,,,Intermediate,,391.0,
5328,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,N,1,786-0,CHEMBL619284,,80640,17376,,,F,,,Intermediate,,391.0,
5329,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,N,1,786-0,CHEMBL619285,,80640,14882,,,F,,,Intermediate,,391.0,
5330,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,N,1,786-0,CHEMBL619286,,80640,14882,,,F,,,Intermediate,,391.0,
5331,BAO_0000219,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,N,1,786-0,CHEMBL619287,,80640,15176,,,F,,,Intermediate,,391.0,
5332,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,N,1,786-0,CHEMBL857455,,80640,12696,,,F,,,Intermediate,,391.0,
5333,BAO_0000219,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,N,1,786-0,CHEMBL883801,,80640,2496,,,F,,,Intermediate,,391.0,
5334,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,N,1,791T cell line,CHEMBL619288,,80641,11831,,,F,,,Intermediate,,972.0,
5335,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,N,1,791T cell line,CHEMBL619289,,80641,11831,,,F,,,Intermediate,,972.0,
5336,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,N,1,791T cell line,CHEMBL619290,,80641,11831,,,F,,,Intermediate,,972.0,
5337,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,N,1,791T cell line,CHEMBL619291,,80641,11831,,,F,,,Intermediate,,972.0,
5338,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,N,1,791T cell line,CHEMBL619292,,80641,11831,,,F,,,Intermediate,,972.0,
5339,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,N,1,791T cell line,CHEMBL619293,,80641,11831,,,F,,,Intermediate,,972.0,
5340,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,N,1,791T cell line,CHEMBL619294,,80641,11831,,,F,,,Intermediate,,972.0,
5341,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,N,1,791T cell line,CHEMBL619295,,80641,11831,,,F,,,Intermediate,,972.0,
5342,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,N,1,791T cell line,CHEMBL619296,,80641,11831,,,F,,,Intermediate,,972.0,
5343,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,N,1,791T cell line,CHEMBL619297,,80641,11831,,,F,,,Intermediate,,972.0,
5344,BAO_0000219,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,N,1,786-0,CHEMBL619298,,80640,12782,,,F,,,Intermediate,,391.0,
5345,BAO_0000019,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,U,1,,CHEMBL619299,,22226,1229,,,F,,,Intermediate,,,
5346,BAO_0000219,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,N,1,RPMI-8226,CHEMBL619300,,80433,15313,,,F,,,Expert,,741.0,
5347,BAO_0000219,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,N,1,RPMI-8226,CHEMBL619301,,80433,15313,,,F,,,Expert,,741.0,
5348,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,N,1,RPMI-8226,CHEMBL619302,,80433,11544,,,F,,,Intermediate,,741.0,
5349,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,N,1,RPMI-8226,CHEMBL619303,,80433,9424,,,F,,,Intermediate,,741.0,
5350,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,N,1,RPMI-8226,CHEMBL619304,,80433,9424,,,F,,,Intermediate,,741.0,
5351,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL857706,,80433,9424,,,F,,,Intermediate,,741.0,
5352,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL619305,,80433,9424,,,F,,,Intermediate,,741.0,
5353,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL619306,,80433,9424,,,F,,,Intermediate,,741.0,
5354,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL619307,,80433,9424,,,F,,,Intermediate,,741.0,
5355,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL619308,,80433,9424,,,F,,,Intermediate,,741.0,
5356,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL619309,,80433,9424,,,F,,,Intermediate,,741.0,
5357,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL619310,,80433,9424,,,F,,,Intermediate,,741.0,
5358,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,N,1,A498,CHEMBL619311,,80021,14769,,,F,,,Intermediate,,624.0,
5359,BAO_0000219,Compound was tested for the growth inhibition of A498 renal tumor cell line,,N,1,A498,CHEMBL619312,,80021,15354,,,F,,,Intermediate,,624.0,
5360,BAO_0000219,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,N,1,A498,CHEMBL619313,,80021,17445,,,F,,,Intermediate,,624.0,
5361,BAO_0000219,In vitro inhibitory concentration against renal cancer cell line A498,,N,1,A498,CHEMBL619314,,80021,4337,,,F,,,Intermediate,,624.0,
5362,BAO_0000219,Cytotoxicity against A 498 tumor cell line,,N,1,A498,CHEMBL619959,,80021,15277,,,F,,,Intermediate,,624.0,
5363,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line,,N,1,A498,CHEMBL619960,,80021,4812,,,F,,,Intermediate,,624.0,
5364,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,N,1,A498,CHEMBL619961,,80021,4812,,,F,,,Intermediate,,624.0,
5365,BAO_0000219,Inhibitory dose required against A498 human tumor cell lines,,N,1,A498,CHEMBL619962,,80021,4995,,,F,,,Intermediate,,624.0,
5366,BAO_0000219,Anticancer activity against one renal cancer (A498 cell line),,N,1,A498,CHEMBL875586,,80021,5847,,,F,,,Intermediate,,624.0,
5367,BAO_0000219,In vitro cytotoxicity against melanoma A498 cell line,,N,1,A498,CHEMBL619963,,80021,6557,,,F,,,Intermediate,,624.0,
5368,BAO_0000219,Compound was tested for growth inhibitory activity against A498 cell line,,N,1,A498,CHEMBL619964,,80021,2597,,,F,,,Intermediate,,624.0,
5369,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line A498,,N,1,A498,CHEMBL620108,,80021,6058,,,F,,,Intermediate,,624.0,
5370,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,N,1,A498,CHEMBL620109,,80021,17708,,,F,,,Intermediate,,624.0,
5371,BAO_0000219,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,N,1,A498,CHEMBL620110,,80021,15176,,,F,,,Intermediate,,624.0,
5372,BAO_0000219,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,N,1,A498,CHEMBL620111,,80021,15300,,,F,,,Intermediate,,624.0,
5373,BAO_0000219,Tested for cytotoxicity against A498 cell lines in renal cancer,,N,1,A498,CHEMBL620112,,80021,11970,,,F,,,Intermediate,,624.0,
5374,BAO_0000219,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,N,1,A498,CHEMBL620113,,80021,12400,,,F,,,Intermediate,,624.0,
5375,BAO_0000219,Cytotoxic effect on renal cancer lines A498,,N,1,A498,CHEMBL620114,,80021,12888,,,F,,,Expert,,624.0,
5376,BAO_0000219,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,N,1,A498,CHEMBL620115,,80021,3030,,,F,,,Intermediate,,624.0,
5377,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,N,1,A498,CHEMBL620116,,80021,14769,,,F,,,Intermediate,,624.0,
5378,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,N,1,A498,CHEMBL620117,,80021,17376,,,F,,,Intermediate,,624.0,
5379,BAO_0000219,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,N,1,A498,CHEMBL620118,,80021,16558,,,F,,,Intermediate,,624.0,
5380,BAO_0000219,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,N,1,A498,CHEMBL620119,,80021,5194,,,F,,,Intermediate,,624.0,
5381,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,N,1,A498,CHEMBL620120,,80021,10708,,,F,,,Intermediate,,624.0,
5382,BAO_0000219,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,N,1,A549,CHEMBL620121,,80682,16880,,,F,,,Expert,,646.0,
5383,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line,,N,1,A549,CHEMBL620122,,80682,10196,,,F,,,Intermediate,,646.0,
5384,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,N,1,A549,CHEMBL620123,,80682,10196,,,F,,,Intermediate,,646.0,
5385,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,N,1,A549,CHEMBL620124,,80682,10196,,,F,,,Intermediate,,646.0,
5386,BAO_0000219,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,N,1,A549,CHEMBL620125,,80682,12083,,,F,,,Intermediate,,646.0,
5387,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,N,1,A549,CHEMBL620126,,80682,16464,,,F,,,Expert,,646.0,
5388,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,1,A549,CHEMBL883027,,80682,16464,,,F,,,Intermediate,,646.0,
5389,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line,,N,1,A549,CHEMBL620127,,80682,16470,,,F,,,Expert,,646.0,
5390,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,N,1,A549,CHEMBL620128,,80682,16470,,,F,,,Intermediate,,646.0,
5391,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line),,N,1,A549,CHEMBL620129,,80682,16470,,,F,,,Intermediate,,646.0,
5392,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,N,1,A549,CHEMBL620130,,80682,16470,,,F,,,Intermediate,,646.0,
5393,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,N,1,A549,CHEMBL620131,,80682,16582,,,F,,,Expert,,646.0,
5394,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,N,1,A549,CHEMBL620132,,80682,15935,,,F,,,Intermediate,,646.0,
5395,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,N,1,A549,CHEMBL620133,,80682,15935,,,F,,,Intermediate,,646.0,
5396,BAO_0000219,Inhibition of A549 human lung carcinoma cell proliferation,,N,1,A549,CHEMBL620134,,80682,16597,,,F,,,Expert,,646.0,
5397,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,,N,1,A549,CHEMBL620135,,80682,17376,,,F,,,Intermediate,,646.0,
5398,BAO_0000219,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,N,1,A549,CHEMBL620136,,80682,16496,,,F,,,Intermediate,,646.0,
5399,BAO_0000219,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,N,1,A549,CHEMBL620137,,80682,16152,,,F,,,Intermediate,,646.0,
5400,BAO_0000219,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,N,1,A549,CHEMBL620268,,80682,16152,,,F,,,Intermediate,,646.0,
5401,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,1,A549,CHEMBL620269,,80682,16464,,,F,,,Intermediate,,646.0,
5402,BAO_0000219,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,N,1,A549,CHEMBL620270,,80682,2288,,,F,,,Intermediate,,646.0,
5403,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,N,1,A549,CHEMBL620271,,80682,17350,,,F,,,Intermediate,,646.0,
5404,BAO_0000219,Inhibition of A549 cancer cell proliferation,,N,1,A549,CHEMBL620272,,80682,4090,,,F,,,Expert,,646.0,
5405,BAO_0000219,Inhibition of A549 cancer cell proliferation (Not tested),,N,1,A549,CHEMBL620273,,80682,4090,,,F,,,Expert,,646.0,
5406,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,N,1,A549,CHEMBL620274,,80682,17350,,,F,,,Intermediate,,646.0,
5407,BAO_0000219,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,N,1,A549,CHEMBL620275,,80682,4197,,,F,,,Intermediate,,646.0,
5408,BAO_0000219,Antiproliferative potency determined as inhibitory concentration against A549 cells,,N,1,A549,CHEMBL620276,,80682,17072,,,F,,,Intermediate,,646.0,
5409,BAO_0000219,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,N,1,A549,CHEMBL620277,,80682,17072,,,F,,,Intermediate,,646.0,
5410,BAO_0000219,Cytotoxicity against Renal cell lines A549 was determined,,N,1,A549,CHEMBL620278,,80682,5194,,,F,,,Intermediate,,646.0,
5411,BAO_0000218,Area under curve was determined in dog after a 3 mg/kg of oral dose,,N,1,,CHEMBL620279,,50588,4257,,,A,,,Intermediate,,,
5412,BAO_0000218,Area under curve was determined in dog after oral administration at 1 mg/kg,,N,1,,CHEMBL620280,,50588,6123,,,A,,,Intermediate,,,
5413,BAO_0000218,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,N,1,,CHEMBL620281,,50588,1337,,,A,,,Intermediate,,,
5414,BAO_0000218,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,N,1,,CHEMBL620282,,50588,1337,,,A,,,Intermediate,,,
5415,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,N,1,,CHEMBL621134,,50588,8833,,,A,,,Intermediate,,,
5416,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,N,1,,CHEMBL621135,,50588,8833,,,A,,,Intermediate,,,
5417,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,N,1,,CHEMBL621136,,50588,8833,,,A,,,Intermediate,,,
5418,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,N,1,,CHEMBL621137,,50588,8833,,,A,,,Intermediate,,,
5419,BAO_0000218,Area under plasma concentration time curve in dog upon oral administration,1969.0,N,1,,CHEMBL621138,,50588,17657,,Plasma,A,,,Intermediate,,,
5420,BAO_0000218,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1969.0,N,1,,CHEMBL875587,,50588,17650,,Plasma,A,,,Intermediate,,,
5421,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,N,1,,CHEMBL621139,,50588,1977,,,A,,,Intermediate,,,
5422,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,N,1,,CHEMBL621140,,50588,1977,,,A,,,Intermediate,,,
5423,BAO_0000218,Area under the curve for the compound was obtained when tested in dog,,N,1,,CHEMBL621141,,50588,3132,,,A,,,Intermediate,,,
5424,BAO_0000218,Area under the curve at a dose of 1 mg/kg,,N,1,,CHEMBL621142,,50588,5473,,,A,,,Intermediate,,,
5425,BAO_0000218,Area under the curve at a dose of 1 mg/kg (oral),,N,1,,CHEMBL621143,,50588,5474,,,A,,,Intermediate,,,
5426,BAO_0000218,Area under the curve at i.v. dose of 0.2 mg/kg,,N,1,,CHEMBL621144,,50588,5474,,,A,,,Intermediate,,,
5427,BAO_0000218,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,N,1,,CHEMBL621145,,50588,6062,,,A,,,Intermediate,,,
5428,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,N,1,,CHEMBL621146,,50588,4709,,,A,,,Intermediate,,,
5429,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,N,1,,CHEMBL622567,,50588,2652,,,A,,,Intermediate,,,
5430,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,N,1,,CHEMBL622568,,50588,2652,,,A,,,Intermediate,,,
5431,BAO_0000218,Compound was evaluated for area under the curve in dog blood.,,N,1,,CHEMBL622569,,50588,2877,,,A,,,Intermediate,,,
5432,BAO_0000218,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,N,1,,CHEMBL622570,,50588,5444,,,A,,,Intermediate,,,
5433,BAO_0000218,AUC in dog after oral dose (1 mg/kg),1969.0,N,1,,CHEMBL622571,,50588,5130,,Plasma,A,,,Intermediate,,,
5434,BAO_0000218,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,N,1,,CHEMBL622572,,50588,6265,,,A,,,Intermediate,,,
5435,BAO_0000218,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,N,1,,CHEMBL622573,,50588,4657,,,A,,,Intermediate,,,
5436,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to dogs,,N,1,,CHEMBL622574,,50588,16367,,,A,,,Intermediate,,,
5437,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to dogs,,N,1,,CHEMBL622575,,50588,16367,,,A,,,Intermediate,,,
5438,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,N,1,,CHEMBL622576,,50588,9579,,,A,,,Intermediate,,,
5439,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,N,1,,CHEMBL622577,,50588,9579,,,A,,,Intermediate,,,
5440,BAO_0000218,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,N,1,,CHEMBL622578,,50588,5983,,,A,,,Intermediate,,,
5441,BAO_0000218,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,N,1,,CHEMBL622579,,50588,6241,,,A,,,Intermediate,,,
5442,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,N,1,,CHEMBL622580,,50588,5313,,,A,,,Intermediate,,,
5443,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,N,1,,CHEMBL622581,,50588,5313,,,A,,,Intermediate,,,
5444,BAO_0000218,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,1,,CHEMBL622582,,50588,6642,,,A,,,Intermediate,,,
5445,BAO_0000218,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,1,,CHEMBL622583,,50588,6642,,,A,,,Intermediate,,,
5446,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),,N,1,,CHEMBL622584,,50588,6641,,,A,,,Intermediate,,,
5447,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),,N,1,,CHEMBL622585,,50588,6642,,,A,,,Intermediate,,,
5448,BAO_0000218,Compound was evaluated for oral bioavailability in dog; 90-100,,N,1,,CHEMBL622586,,50588,17791,,,A,,,Intermediate,,,
5449,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,N,1,,CHEMBL623281,,50588,17655,,,A,,,Intermediate,,,
5450,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,N,1,,CHEMBL623282,,50588,17655,,,A,,,Intermediate,,,
5451,BAO_0000218,PAPP (membrane permeability) in dog kidney cell monolayer assay,,N,1,,CHEMBL623283,,50588,6596,,,A,,,Intermediate,,,
5452,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623284,,50588,3880,,,A,,,Intermediate,,,
5453,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,N,1,,CHEMBL623285,,50588,16367,,,A,,,Intermediate,,,
5454,BAO_0000218,Plasma protein binding towards dog plasma at 10 uM,1969.0,N,1,,CHEMBL623463,,50588,17409,,Plasma,A,,,Intermediate,,,
5455,BAO_0000218,Plasma protein binding towards dog plasma at 100 uM,1969.0,N,1,,CHEMBL875952,,50588,17409,,Plasma,A,,,Intermediate,,,
5456,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),,N,1,,CHEMBL621705,In vivo,50588,2959,,,A,,,Intermediate,,,
5457,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,N,1,,CHEMBL621706,In vivo,50588,13501,,,A,,,Intermediate,,,
5458,BAO_0000218,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,N,1,,CHEMBL621707,In vivo,50588,4527,,,A,,,Intermediate,,,
5459,BAO_0000218,Bioavailability in dogs,,N,1,,CHEMBL621708,In vivo,50588,15145,,,A,,,Intermediate,,,
5460,BAO_0000218,Bioavailability,,N,1,,CHEMBL621709,In vivo,50588,4219,,,A,,,Intermediate,,,
5461,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,N,1,,CHEMBL621710,In vivo,50588,17538,,,A,,,Intermediate,,,
5462,BAO_0000218,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,N,1,,CHEMBL621711,In vivo,50588,17538,,,A,,,Intermediate,,,
5463,BAO_0000218,Bioavailability in dog (dose 10.0 mg/kg p.o.),,N,1,,CHEMBL621712,In vivo,50588,1466,,,A,,,Intermediate,,,
5464,BAO_0000218,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,N,1,,CHEMBL621713,In vivo,50588,17650,,,A,,,Intermediate,,,
5465,BAO_0000218,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,N,1,,CHEMBL621714,In vivo,50588,3132,,,A,,,Intermediate,,,
5466,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,1,,CHEMBL621715,,22224,2413,,,A,,,Autocuration,,,
5467,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,2107.0,U,1,,CHEMBL623717,,22224,2413,,Liver,A,,,Autocuration,,,
5468,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,2107.0,U,1,,CHEMBL623718,,22224,2413,,Liver,A,,,Autocuration,,,
5469,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,2107.0,U,1,,CHEMBL623719,,22224,2413,,Liver,A,,,Autocuration,,,
5470,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,1,,CHEMBL623720,,22224,2413,,,A,,,Autocuration,,,
5471,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,1,,CHEMBL623721,,22224,2413,,,A,,,Autocuration,,,
5472,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,2385.0,U,1,,CHEMBL623722,,22224,2413,,Muscle tissue,A,,,Autocuration,,,
5473,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,2385.0,U,1,,CHEMBL623723,,22224,2413,,Muscle tissue,A,,,Autocuration,,,
5474,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,2385.0,U,1,,CHEMBL618543,,22224,2413,,Muscle tissue,A,,,Autocuration,,,
5475,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,2106.0,U,1,,CHEMBL618544,,22224,2413,,Spleen,A,,,Autocuration,,,
5476,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,2106.0,U,1,,CHEMBL875155,,22224,2413,,Spleen,A,,,Autocuration,,,
5477,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,1,,CHEMBL618545,,22224,2413,,,A,,,Autocuration,,,
5478,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,1,,CHEMBL618546,,22224,2413,,,A,,,Autocuration,,,
5479,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,1,,CHEMBL623529,,22224,2413,,,A,,,Autocuration,,,
5480,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,1,,CHEMBL623530,,22224,2413,,,A,,,Autocuration,,,
5481,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,1,,CHEMBL621764,,22224,2413,,,A,,,Autocuration,,,
5482,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,U,1,,CHEMBL621765,,22224,17827,,,A,,,Autocuration,,,
5483,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),2037.0,U,1,,CHEMBL621766,,22224,17827,,Cerebellum,A,,,Autocuration,,,
5484,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1870.0,U,1,,CHEMBL621767,,22224,17827,,Frontal cortex,A,,,Autocuration,,,
5485,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,U,1,,CHEMBL621768,,22224,17827,,,A,,,Autocuration,,,
5486,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),2435.0,U,1,,CHEMBL621769,,22224,17827,,Striatum,A,,,Autocuration,,,
5487,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,U,1,,CHEMBL621770,,22224,17827,,,A,,,Autocuration,,,
5488,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),2037.0,U,1,,CHEMBL621771,,22224,17827,,Cerebellum,A,,,Autocuration,,,
5489,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1870.0,U,1,,CHEMBL621772,,22224,17827,,Frontal cortex,A,,,Autocuration,,,
5490,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,U,1,,CHEMBL621773,,22224,17827,,,A,,,Autocuration,,,
5491,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),2435.0,U,1,,CHEMBL621774,,22224,17827,,Striatum,A,,,Autocuration,,,
5492,BAO_0000218,Compound was evaluated for oral bioavailability in rats,,U,1,,CHEMBL621775,,22224,17791,,,A,,,Autocuration,,,
5493,BAO_0000218,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,1969.0,U,1,,CHEMBL621776,In vivo,22224,17667,,Plasma,A,,,Autocuration,,,
5494,BAO_0000019,Half life period was evaluated in monkey,,U,1,,CHEMBL621777,,22224,17791,,,A,,,Autocuration,,,
5495,BAO_0000218,Half-life in rhesus monkeys by intravenous administration of dose,,U,1,,CHEMBL875162,In vivo,22224,110,,,A,,,Autocuration,,,
5496,BAO_0000218,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1969.0,N,1,,CHEMBL621778,,50594,5781,,Plasma,A,,,Intermediate,,,
5497,BAO_0000218,AUC after intraperitoneal administration of 100 mg/kg in mice,1969.0,N,1,,CHEMBL621779,,50594,17734,,Plasma,A,,,Intermediate,,,
5498,BAO_0000218,AUC value was determined after oral administration,1969.0,N,1,,CHEMBL622479,,50594,17718,,Plasma,A,,,Intermediate,,,
5499,BAO_0000218,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,N,1,,CHEMBL622480,,50594,4573,,,A,,,Intermediate,,,
5500,BAO_0000218,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,1,,CHEMBL622481,,50594,3277,,,A,,,Intermediate,,,
5501,BAO_0000218,Area under curve by ioral administration in mouse,,N,1,,CHEMBL622482,,50594,2862,,,A,,,Intermediate,,,
5502,BAO_0000218,Area under curve by iv administration in mouse,,N,1,,CHEMBL622483,,50594,2862,,,A,,,Intermediate,,,
5503,BAO_0000218,Area under curve at 0-8 hr in IRC mice after peroral administration,,N,1,,CHEMBL622484,,50594,5951,,,A,,,Intermediate,,,
5504,BAO_0000218,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,N,1,,CHEMBL622641,,50594,17729,,,A,,,Intermediate,,,
5505,BAO_0000218,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,N,1,,CHEMBL622642,,50594,17728,,,A,,,Intermediate,,,
5506,BAO_0000218,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,N,1,,CHEMBL622643,,50594,17728,,,A,,,Intermediate,,,
5507,BAO_0000218,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,N,1,,CHEMBL622644,,50594,17729,,,A,,,Intermediate,,,
5508,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,N,1,RPMI-8226,CHEMBL622645,,80433,9424,,,F,,,Intermediate,,741.0,
5509,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,N,1,RPMI-8226,CHEMBL622646,,80433,9424,,,F,,,Intermediate,,741.0,
5510,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL621238,,80433,9424,,,F,,,Intermediate,,741.0,
5511,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL621239,,80433,9424,,,F,,,Intermediate,,741.0,
5512,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL621240,,80433,9424,,,F,,,Intermediate,,741.0,
5513,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL621241,,80433,9424,,,F,,,Intermediate,,741.0,
5514,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL621242,,80433,9424,,,F,,,Intermediate,,741.0,
5515,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL620350,,80433,9424,,,F,,,Intermediate,,741.0,
5516,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,N,1,RPMI-8226,CHEMBL620351,,80433,9424,,,F,,,Intermediate,,741.0,
5517,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,N,1,RPMI-8226,CHEMBL620352,,80433,9424,,,F,,,Intermediate,,741.0,
5518,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL620353,,80433,9424,,,F,,,Intermediate,,741.0,
5519,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL620354,,80433,9424,,,F,,,Intermediate,,741.0,
5520,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL620355,,80433,9424,,,F,,,Intermediate,,741.0,
5521,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL620356,,80433,9424,,,F,,,Intermediate,,741.0,
5522,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,N,1,RPMI-8226,CHEMBL620357,,80433,9424,,,F,,,Intermediate,,741.0,
5523,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,N,1,RPMI-8226,CHEMBL620358,,80433,9424,,,F,,,Intermediate,,741.0,
5524,BAO_0000219,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,N,1,RPMI-8226,CHEMBL620359,,80433,9424,,,F,,,Expert,,741.0,
5525,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,N,1,RPMI-8226,CHEMBL620360,,80433,11544,,,F,,,Intermediate,,741.0,
5526,BAO_0000219,Cytotoxicity of compound against 8226/DOX1V cells,,N,1,RPMI-8226,CHEMBL620361,,80433,17378,,,F,,,Intermediate,,741.0,
5527,BAO_0000219,Cytotoxicity of compound against 8226/S cells,,N,1,RPMI-8226,CHEMBL620362,,80433,17378,,,F,,,Intermediate,,741.0,
5528,BAO_0000219,Inhibitory concentration against 8226 myeloma cancer cell line,,N,1,RPMI-8226,CHEMBL620363,,80433,17079,,,F,,,Intermediate,,741.0,
5529,BAO_0000219,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,N,1,RPMI-8226,CHEMBL620364,,80433,17079,,,F,,,Intermediate,,741.0,
5530,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,N,1,833K,CHEMBL620365,,80647,13466,,,F,,,Intermediate,,854.0,
5531,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,N,1,833K,CHEMBL620366,,80647,13466,,,F,,,Intermediate,,854.0,
5532,BAO_0000219,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,N,1,833K,CHEMBL620367,,80647,2392,,,F,,,Expert,,854.0,
5533,BAO_0000219,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,N,1,833K,CHEMBL620368,,80647,2392,,,F,,,Intermediate,,854.0,
5534,BAO_0000019,Inhibitory activity against caspase-1,,U,1,,CHEMBL620369,,22226,6608,,,B,,,Autocuration,,,
5535,BAO_0000357,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,H,1,,CHEMBL620370,,45,10199,,,B,,,Autocuration,,,
5536,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,N,1,8701-BC,CHEMBL620371,,80648,17749,,,F,,,Intermediate,,705.0,
5537,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,N,1,8701-BC,CHEMBL620372,,80648,17749,,,F,,,Intermediate,,705.0,
5538,BAO_0000019,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,U,1,,CHEMBL876492,,22226,1229,,,F,,,Intermediate,,,
5539,BAO_0000019,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,U,1,,CHEMBL620373,,22226,1229,,,F,,,Intermediate,,,
5540,BAO_0000019,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,U,1,,CHEMBL620374,,22226,1229,,,F,,,Intermediate,,,
5541,BAO_0000019,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,U,1,,CHEMBL620375,,22226,6390,,,B,,,Autocuration,,,
5542,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,U,1,,CHEMBL857902,,22226,16219,,,F,,,Autocuration,,,
5543,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,U,1,,CHEMBL620376,,22226,16219,,,F,,,Autocuration,,,
5544,BAO_0000357,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,H,1,,CHEMBL620377,,11922,17043,,,B,,,Autocuration,,,
5545,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,,N,1,KB ,CHEMBL620378,,81115,6929,,,F,,,Intermediate,,324.0,
5546,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,,N,1,KB ,CHEMBL620379,,81115,6929,,,A,,,Intermediate,,324.0,
5547,BAO_0000219,In vitro cytotoxicity of compound was tested against 9KB cells.,,U,1,,CHEMBL620380,,22226,7083,,,F,,,Autocuration,,,
5548,BAO_0000219,Cytotoxic concentration against 9L cells was determined on day 3,,N,1,9L,CHEMBL884006,,80653,12446,,,F,,,Intermediate,,392.0,
5549,BAO_0000219,Tested in vitro for anticancer activity against 9L cells,,N,1,9L,CHEMBL620381,,80653,15345,,,F,,,Expert,,392.0,
5550,BAO_0000219,Tested in vitro for anticancer activity against 9L cells; Not determined,,N,1,9L,CHEMBL620382,,80653,15345,,,F,,,Expert,,392.0,
5551,BAO_0000219,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,N,1,A549,CHEMBL620383,,80682,6301,,,F,,,Intermediate,,646.0,
5552,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,N,1,A549,CHEMBL876493,,80682,4833,,,F,,,Intermediate,,646.0,
5553,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,N,1,A549,CHEMBL620384,,80682,4833,,,F,,,Intermediate,,646.0,
5554,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,N,1,A549,CHEMBL620385,,80682,4833,,,F,,,Intermediate,,646.0,
5555,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line,,N,1,A549,CHEMBL620386,,80682,13330,,,F,,,Expert,,646.0,
5556,BAO_0000219,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,D,1,A549,CHEMBL620387,,25,17517,,,F,,,Expert,,646.0,
5557,BAO_0000219,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,D,1,A549,CHEMBL621404,,25,17517,,,F,,,Expert,,646.0,
5558,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma",,N,1,A549,CHEMBL621405,,80682,14425,,,F,,,Intermediate,,646.0,
5559,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma.",,N,1,A549,CHEMBL621406,,80682,14425,,,F,,,Intermediate,,646.0,
5560,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL621407,,80682,5228,,,F,,,Expert,,646.0,
5561,BAO_0000219,Cytotoxic activity against human lung cancer A549 cell line was determined,,N,1,A549,CHEMBL621408,,80682,5351,,,F,,,Intermediate,,646.0,
5562,BAO_0000219,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,N,1,A549,CHEMBL885345,,80682,12198,,,F,,,Expert,,646.0,
5563,BAO_0000219,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,N,1,A549,CHEMBL621409,,80682,13891,,,F,,,Intermediate,,646.0,
5564,BAO_0000219,Cytotoxicity in A549 (human carcinoma) cell line.,,N,1,A549,CHEMBL876034,,80682,5677,,,F,,,Expert,,646.0,
5565,BAO_0000219,Cytotoxicity on lung carcinoma (A-549) cell line,,N,1,A549,CHEMBL621410,,80682,13788,,,F,,,Intermediate,,646.0,
5566,BAO_0000219,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,N,1,A549,CHEMBL621411,,80682,13384,,,F,,,Expert,,646.0,
5567,BAO_0000219,Effective dose of compound against replication of A549 cell line was evaluated,,N,1,A549,CHEMBL621412,,80682,6726,,,F,,,Intermediate,,646.0,
5568,BAO_0000219,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,N,1,A549,CHEMBL621413,,80682,3455,,,F,,,Expert,,646.0,
5569,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,N,1,A549,CHEMBL621414,,80682,5726,,,F,,,Intermediate,,646.0,
5570,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,N,1,A549,CHEMBL621415,,80682,5726,,,F,,,Intermediate,,646.0,
5571,BAO_0000219,The compound was evaluated for antiproliferative activity against A549 cell line,,N,1,A549,CHEMBL621416,,80682,3936,,,F,,,Intermediate,,646.0,
5572,BAO_0000219,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,N,1,A549,CHEMBL621417,,80682,14991,,,F,,,Intermediate,,646.0,
5573,BAO_0000219,Concentration required for growth inhibition of human lung carcinoma cell line A549,,N,1,A549,CHEMBL621418,,80682,5243,,,F,,,Intermediate,,646.0,
5574,BAO_0000219,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,N,1,A549,CHEMBL621419,,80682,12858,,,F,,,Intermediate,,646.0,
5575,BAO_0000219,Growth inhibition against A549 cell line was evaluated,,N,1,A549,CHEMBL621420,,80682,6776,,,F,,,Intermediate,,646.0,
5576,BAO_0000219,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,N,1,A549,CHEMBL875823,,80682,16558,,,F,,,Intermediate,,646.0,
5577,BAO_0000219,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,N,1,A549,CHEMBL621421,,80682,4583,,,F,,,Expert,,646.0,
5578,BAO_0000219,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,N,1,A549,CHEMBL621422,,80682,13514,,,F,,,Intermediate,,646.0,
5579,BAO_0000219,Chemosensitivity against DT-diaphorase rich A549 cell lines,,N,1,A549,CHEMBL884014,,80682,15166,,,F,,,Expert,,646.0,
5580,BAO_0000219,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,N,1,A549,CHEMBL621423,,80682,13873,,,F,,,Intermediate,,646.0,
5581,BAO_0000219,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,N,1,A549,CHEMBL621424,,80682,6447,,,F,,,Expert,,646.0,
5582,BAO_0000219,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,N,1,A549,CHEMBL621425,,80682,2068,,,F,,,Intermediate,,646.0,
5583,BAO_0000219,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,N,1,A549,CHEMBL621426,,80682,1863,,,F,,,Expert,,646.0,
5584,BAO_0000219,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,N,1,A549,CHEMBL621427,,80682,13873,,,F,,,Intermediate,,646.0,
5585,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,N,1,A549,CHEMBL621428,,80682,13873,,,F,,,Intermediate,,646.0,
5586,BAO_0000219,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,N,1,A549,CHEMBL621429,,80682,13873,,,F,,,Expert,,646.0,
5587,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,N,1,A549,CHEMBL621430,,80682,579,,,F,,,Intermediate,,646.0,
5588,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,N,1,A549,CHEMBL621431,,80682,579,,,F,,,Intermediate,,646.0,
5589,BAO_0000219,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,N,1,A549,CHEMBL621432,,80682,4584,,,F,,,Intermediate,,646.0,
5590,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,N,1,A549,CHEMBL621433,,80682,5421,,,F,,,Expert,,646.0,
5591,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,N,1,A549,CHEMBL875824,,80682,5421,,,F,,,Intermediate,,646.0,
5592,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,N,1,A549,CHEMBL621434,,80682,5421,,,F,,,Intermediate,,646.0,
5593,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,N,1,A549,CHEMBL621435,,80682,5421,,,F,,,Intermediate,,646.0,
5594,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,N,1,A549,CHEMBL621436,,80682,14188,,,F,,,Intermediate,,646.0,
5595,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,N,1,A549,CHEMBL621437,,80682,14188,,,F,,,Intermediate,,646.0,
5596,BAO_0000219,Compound was tested for the growth inhibition of A549 lung tumor cell line,,N,1,A549,CHEMBL621438,,80682,15354,,,F,,,Intermediate,,646.0,
5597,BAO_0000219,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,N,1,A549,CHEMBL621439,,80682,14253,,,F,,,Expert,,646.0,
5598,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,N,1,A549,CHEMBL621440,,80682,13873,,,F,,,Intermediate,,646.0,
5599,BAO_0000218,Oral bioavailability in dog (conscious),,N,1,,CHEMBL621441,In vivo,50588,3043,,,A,,,Intermediate,,,
5600,BAO_0000218,Compound was evaluated for the oral bioavailability after oral administration in dog.,,N,1,,CHEMBL621442,In vivo,50588,3045,,,A,,,Intermediate,,,
5601,BAO_0000218,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,N,1,,CHEMBL621443,In vivo,50588,3022,,,A,,,Intermediate,,,
5602,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621444,In vivo,50588,4453,,,A,,,Intermediate,,,
5603,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL625133,In vivo,50588,1696,,,A,,,Intermediate,,,
5604,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL625134,In vivo,50588,5045,,,A,,,Intermediate,,,
5605,BAO_0000218,Oral bioavailability in dog (fasted),,N,1,,CHEMBL625135,In vivo,50588,5356,,,A,,,Intermediate,,,
5606,BAO_0000218,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,N,1,,CHEMBL625136,In vivo,50588,17764,,,A,,,Intermediate,,,
5607,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL625137,In vivo,50588,6448,,,A,,,Intermediate,,,
5608,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL625138,In vivo,50588,1475,,,A,,,Intermediate,,,
5609,BAO_0000218,Percent bioavailability in dog,,N,1,,CHEMBL625139,In vivo,50588,3788,,,A,,,Intermediate,,,
5610,BAO_0000218,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,N,1,,CHEMBL872264,In vivo,50588,3639,,,A,,,Intermediate,,,
5611,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL625140,In vivo,50588,13397,,,A,,,Intermediate,,,
5612,BAO_0000218,The compound was evaluated for bioavailability in dogs; 34-44,,N,1,,CHEMBL624436,In vivo,50588,2137,,,A,,,Intermediate,,,
5613,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),,N,1,,CHEMBL624437,In vivo,50588,2959,,,A,,,Intermediate,,,
5614,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL872261,In vivo,50588,6448,,,A,,,Intermediate,,,
5615,BAO_0000218,8 hour trough Blood level in dog was measured after administration of compound,,N,1,,CHEMBL624438,,50588,6084,,,A,,,Intermediate,,,
5616,BAO_0000218,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1969.0,N,1,,CHEMBL624439,In vivo,50588,3639,,Plasma,A,,,Intermediate,,,
5617,BAO_0000218,C24 after oral administration at 5 mg/kg,,N,1,,CHEMBL624440,,50588,6316,,,A,,,Intermediate,,,
5618,BAO_0000218,Clearance after oral and iv dosing in dogs,,N,1,,CHEMBL624441,,50588,5238,,,A,,,Intermediate,,,
5619,BAO_0000218,Clearance of the drug was measured in the plasma of dog,1969.0,N,1,,CHEMBL624442,,50588,17796,,Plasma,A,,,Intermediate,,,
5620,BAO_0000218,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,N,1,,CHEMBL624443,,50588,2652,,,A,,,Intermediate,,,
5621,BAO_0000218,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,N,1,,CHEMBL624444,In vivo,50588,5654,,,A,,,Intermediate,,,
5622,BAO_0000218,Clearance of compound was determined in dogs,,N,1,,CHEMBL624445,In vivo,50588,6621,,,A,,,Intermediate,,,
5623,BAO_0000218,Clearance on i.v. administration of 2 mg/kg was measured in dog,,N,1,,CHEMBL624446,In vivo,50588,6505,,,A,,,Intermediate,,,
5624,BAO_0000218,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,1,,CHEMBL624447,In vivo,50588,5802,,,A,,,Intermediate,,,
5625,BAO_0000218,Plasma clearance in dog was determined,,N,1,,CHEMBL624448,In vivo,50588,17267,,,A,,,Intermediate,,,
5626,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,1,,CHEMBL624449,In vivo,50588,4521,,,A,,,Intermediate,,,
5627,BAO_0000218,Plasma clearance in dog after administration of 0.25 mg/kg iv,,N,1,,CHEMBL624450,In vivo,50588,6535,,,A,,,Intermediate,,,
5628,BAO_0000218,Plasma clearance in dog after administration of 1 mg/kg iv,,N,1,,CHEMBL875942,In vivo,50588,6535,,,A,,,Intermediate,,,
5629,BAO_0000218,Plasma clearance in dogs,,N,1,,CHEMBL624451,In vivo,50588,6535,,,A,,,Intermediate,,,
5630,BAO_0000218,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,N,1,,CHEMBL624452,In vivo,50588,5542,,,A,,,Intermediate,,,
5631,BAO_0000218,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,N,1,,CHEMBL624453,In vivo,50588,5199,,,A,,,Intermediate,,,
5632,BAO_0000218,Plasma clearance after 15 mg/kg iv dose in Dogs,,N,1,,CHEMBL624454,In vivo,50588,16907,,,A,,,Intermediate,,,
5633,BAO_0000218,Plasma clearance after 30 mg/kg po dose in Dogs,,N,1,,CHEMBL624455,In vivo,50588,16907,,,A,,,Intermediate,,,
5634,BAO_0000218,Plasma administration to dogs,,N,1,,CHEMBL624456,In vivo,50588,16367,,,A,,,Intermediate,,,
5635,BAO_0000218,Plasma clearance was determined,,N,1,,CHEMBL624457,In vivo,50588,5505,,,A,,,Intermediate,,,
5636,BAO_0000218,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,N,1,,CHEMBL624458,In vivo,50588,6215,,,A,,,Intermediate,,,
5637,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,N,1,,CHEMBL624459,In vivo,50588,1466,,,A,,,Intermediate,,,
5638,BAO_0000251,Intrinsic clearance in human liver microsomes,2107.0,S,1,,CHEMBL624460,In vitro,102164,5007,Microsomes,Liver,A,,,Intermediate,,,
5639,BAO_0000251,Intrinsic clearance in human liver microsomes,2107.0,S,1,,CHEMBL624461,In vitro,102164,5007,Microsomes,Liver,A,,,Intermediate,,,
5640,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,1,,CHEMBL875943,In vivo,50588,16452,,,A,,,Intermediate,,,
5641,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,N,1,,CHEMBL624462,In vivo,50588,16452,,,A,,,Intermediate,,,
5642,BAO_0000218,Clearance in dog (dose 1 mg/kg i.v.),,N,1,,CHEMBL624463,In vivo,50588,16452,,,A,,,Intermediate,,,
5643,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,N,1,,CHEMBL624464,In vivo,50588,6221,,,A,,,Intermediate,,,
5644,BAO_0000218,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,1,,CHEMBL624465,In vivo,50588,5007,,,A,,,Intermediate,,,
5645,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in dog,,N,1,,CHEMBL624466,In vivo,50588,5668,,,A,,,Intermediate,,,
5646,BAO_0000218,Plasma clearance after peroral administration at 5 mpk in dog,,N,1,,CHEMBL624467,In vivo,50588,5668,,,A,,,Intermediate,,,
5647,BAO_0000218,Plasma clearance after peroral administration at 5 mg/kg in dog,,N,1,,CHEMBL624468,In vivo,50588,5668,,,A,,,Intermediate,,,
5648,BAO_0000218,Plasma clearance was measured in dog,,N,1,,CHEMBL624469,In vivo,50588,15660,,,A,,,Intermediate,,,
5649,BAO_0000218,Plasma clearance was measured in dog,,N,1,,CHEMBL624470,In vivo,50588,15660,,,A,,,Intermediate,,,
5650,BAO_0000218,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,N,1,,CHEMBL624471,In vivo,50588,5983,,,A,,,Intermediate,,,
5651,BAO_0000218,Total clearance was determined after 0.1 mg/kg iv administration in dog,,N,1,,CHEMBL624472,In vivo,50588,5600,,,A,,,Intermediate,,,
5652,BAO_0000218,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,N,1,,CHEMBL622775,In vivo,50588,17764,,,A,,,Intermediate,,,
5653,BAO_0000218,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,N,1,,CHEMBL622776,In vivo,50588,6039,,,A,,,Intermediate,,,
5654,BAO_0000218,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,N,1,,CHEMBL622777,In vivo,50588,6039,,,A,,,Intermediate,,,
5655,BAO_0000218,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,N,1,,CHEMBL622778,In vivo,50588,6039,,,A,,,Intermediate,,,
5656,BAO_0000218,Clearance by intravenous administration of 1.2 mg/kg in dog,,N,1,,CHEMBL622779,In vivo,50588,4368,,,A,,,Intermediate,,,
5657,BAO_0000218,Clearance by iv administration in dogs at a dose of 1 mg/kg,,N,1,,CHEMBL622780,In vivo,50588,4305,,,A,,,Intermediate,,,
5658,BAO_0000218,Clearance value was evaluated in dog plasma,1969.0,N,1,,CHEMBL622781,In vivo,50588,1918,,Plasma,A,,,Intermediate,,,
5659,BAO_0000218,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,N,1,,CHEMBL622782,In vivo,50588,6005,,,A,,,Intermediate,,,
5660,BAO_0000218,Compound was tested for plasma clearance in dog,1969.0,N,1,,CHEMBL622783,In vivo,50588,4839,,Plasma,A,,,Intermediate,,,
5661,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in dog,,N,1,,CHEMBL622784,In vivo,50588,4239,,,A,,,Intermediate,,,
5662,BAO_0000218,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,N,1,,CHEMBL622785,,50594,17729,,,A,,,Intermediate,,,
5663,BAO_0000218,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,N,1,,CHEMBL622786,,50594,17728,,,A,,,Intermediate,,,
5664,BAO_0000218,Area under curve value in mouse at a dose of 10 mg/kg,,N,1,,CHEMBL622787,,50594,5302,,,A,,,Intermediate,,,
5665,BAO_0000218,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,N,1,,CHEMBL875949,,50594,5506,,,A,,,Intermediate,,,
5666,BAO_0000218,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,N,1,,CHEMBL622788,,50594,5506,,,A,,,Intermediate,,,
5667,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,N,1,,CHEMBL622789,,50594,17764,,,F,,,Intermediate,,,
5668,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,N,1,,CHEMBL622790,,50594,17764,,,F,,,Intermediate,,,
5669,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,N,1,,CHEMBL622791,,50594,17764,,,F,,,Intermediate,,,
5670,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,N,1,,CHEMBL622792,,50594,17764,,,F,,,Intermediate,,,
5671,BAO_0000218,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,N,1,,CHEMBL622793,,50594,17764,,,A,,,Intermediate,,,
5672,BAO_0000218,Area under curve was determined for the compound at 24 mg/Kg,,N,1,,CHEMBL622794,,50594,17753,,,A,,,Intermediate,,,
5673,BAO_0000218,Area under curve was determined for the compound at 40 mg/Kg,,N,1,,CHEMBL622795,,50594,17753,,,A,,,Intermediate,,,
5674,BAO_0000218,Area under curve was determined for the compound at 5 mg/Kg,,N,1,,CHEMBL621803,,50594,17753,,,A,,,Intermediate,,,
5675,BAO_0000218,Area under the curve for the compound is obtained at dose 25 mg/kg,,N,1,,CHEMBL621804,,50594,3132,,,A,,,Intermediate,,,
5676,BAO_0000218,Area under the curve for the compound was obtained when tested in mouse,,N,1,,CHEMBL621805,,50594,3132,,,A,,,Intermediate,,,
5677,BAO_0000218,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,N,1,,CHEMBL621806,,50594,17837,,,A,,,Intermediate,,,
5678,BAO_0000218,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,N,1,,CHEMBL621807,,50594,17837,,,A,,,Intermediate,,,
5679,BAO_0000218,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,N,1,,CHEMBL621808,,50594,6062,,,A,,,Intermediate,,,
5680,BAO_0000218,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,N,1,,CHEMBL621809,,50594,4066,,,A,,,Intermediate,,,
5681,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,N,1,,CHEMBL621810,,50594,16597,,,A,,,Intermediate,,,
5682,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,N,1,,CHEMBL875164,,50594,14239,,,A,,,Intermediate,,,
5683,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,N,1,,CHEMBL621811,,50594,14239,,,A,,,Intermediate,,,
5684,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,N,1,,CHEMBL621812,,50594,4890,,,A,,,Intermediate,,,
5685,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,N,1,,CHEMBL621813,,50594,429,,,A,,,Intermediate,,,
5686,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,N,1,,CHEMBL621814,,50594,429,,,A,,,Intermediate,,,
5687,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,N,1,,CHEMBL621815,,50594,5969,,,A,,,Intermediate,,,
5688,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,N,1,,CHEMBL621816,,50594,5969,,,A,,,Intermediate,,,
5689,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,N,1,,CHEMBL621817,,50594,5969,,,A,,,Intermediate,,,
5690,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,N,1,,CHEMBL621818,,50594,6091,,,A,,,Intermediate,,,
5691,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,N,1,,CHEMBL621819,,50594,6091,,,A,,,Intermediate,,,
5692,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,N,1,,CHEMBL621820,,50594,6091,,,A,,,Intermediate,,,
5693,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,N,1,,CHEMBL621821,,50594,6091,,,A,,,Intermediate,,,
5694,BAO_0000218,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,N,1,,CHEMBL621822,,50594,6178,,,A,,,Intermediate,,,
5695,BAO_0000218,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,N,1,,CHEMBL619474,,50594,6178,,,A,,,Intermediate,,,
5696,BAO_0000218,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,N,1,,CHEMBL619475,,50594,6619,,,A,,,Intermediate,,,
5697,BAO_0000218,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,N,1,,CHEMBL619476,,50594,6619,,,A,,,Intermediate,,,
5698,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,N,1,,CHEMBL619477,,50594,3760,,,A,,,Intermediate,,,
5699,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,N,1,,CHEMBL619478,,50594,3760,,,A,,,Intermediate,,,
5700,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,N,1,,CHEMBL619479,,50594,3760,,,A,,,Intermediate,,,
5701,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,N,1,,CHEMBL619480,,50594,3760,,,A,,,Intermediate,,,
5702,BAO_0000218,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,N,1,,CHEMBL619481,,50594,3192,,,A,,,Intermediate,,,
5703,BAO_0000218,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,N,1,,CHEMBL619482,,50594,3192,,,A,,,Intermediate,,,
5704,BAO_0000218,Area under the curve was evaluated in mice after intravenous administration,,N,1,,CHEMBL619483,,50594,2675,,,A,,,Intermediate,,,
5705,BAO_0000218,Area under the curve was evaluated in mice after oral administration,,N,1,,CHEMBL619484,,50594,2675,,,A,,,Intermediate,,,
5706,BAO_0000218,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1969.0,N,1,,CHEMBL619485,,50594,16597,,Plasma,A,,,Intermediate,,,
5707,BAO_0000218,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1969.0,N,1,,CHEMBL619486,,50594,16597,,Plasma,A,,,Intermediate,,,
5708,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,N,1,,CHEMBL619487,,50594,16597,,,A,,,Intermediate,,,
5709,BAO_0000218,AUMC after intraperitoneal administration of 100 mg/kg in mice,,N,1,,CHEMBL619488,,50594,17734,,,A,,,Intermediate,,,
5710,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,178.0,N,1,,CHEMBL620106,In vivo,50594,7767,,Blood,A,,,Intermediate,,,
5711,BAO_0000219,The compound was tested in vitro for anticancer activity against 9L cells,,N,1,9L,CHEMBL620107,,80653,15345,,,F,,,Intermediate,,392.0,
5712,BAO_0000019,Anti proliferation activity determined; Weak effect,,U,1,,CHEMBL620283,,22226,2181,,,F,,,Autocuration,,,
5713,BAO_0000219,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,U,1,,CHEMBL875176,,22226,2181,,,F,,,Autocuration,,,
5714,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,U,1,,CHEMBL620284,,22226,2181,,,F,,,Autocuration,,,
5715,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,U,1,,CHEMBL623515,,22226,2181,,,F,,,Autocuration,,,
5716,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method,,U,1,,CHEMBL623516,,22226,10486,,,F,,,Autocuration,,,
5717,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method.,,U,1,,CHEMBL623517,,22226,10486,,,F,,,Autocuration,,,
5718,BAO_0000019,Partition coefficient (logD6.5),,U,1,,CHEMBL857878,,22224,15508,,,A,,,Autocuration,,,
5719,BAO_0000219,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,N,1,A2780,CHEMBL623518,,81034,5242,,,F,,,Expert,,478.0,
5720,BAO_0000219,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,N,1,A-375,CHEMBL624195,,80018,16167,,,F,,,Intermediate,,455.0,
5721,BAO_0000219,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,N,1,A-431,CHEMBL624196,,80852,4782,,,F,,,Expert,,500.0,
5722,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,D,1,A-431,CHEMBL624197,,9,16093,,,F,,,Expert,,500.0,
5723,BAO_0000219,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,N,1,A498,CHEMBL624198,,80021,2596,,,F,,,Intermediate,,624.0,
5724,BAO_0000219,in vitro cytotoxicity against A 498 cancer cell line,,N,1,A498,CHEMBL621287,,80021,2596,,,F,,,Intermediate,,624.0,
5725,BAO_0000219,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,N,1,A498,CHEMBL621288,,80021,3239,,,F,,,Intermediate,,624.0,
5726,BAO_0000219,Cytotoxic activity against A 498 renal cancer cell lines.,,N,1,A498,CHEMBL876496,,80021,1847,,,F,,,Intermediate,,624.0,
5727,BAO_0000219,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,N,1,A498,CHEMBL621289,,80021,10553,,,F,,,Intermediate,,624.0,
5728,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,U,1,,CHEMBL621290,,22226,16219,,,F,,,Autocuration,,,
5729,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,U,1,,CHEMBL621291,,22226,16219,,,F,,,Autocuration,,,
5730,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,U,1,,CHEMBL621292,,22226,16219,,,F,,,Autocuration,,,
5731,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,U,1,,CHEMBL621293,,22226,16219,,,F,,,Autocuration,,,
5732,BAO_0000219,Inhibitory concentration required against A 549 lung cancer cell line,,N,1,A549,CHEMBL621294,,80682,4782,,,F,,,Intermediate,,646.0,
5733,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,N,1,A549,CHEMBL621295,,80682,11805,,,F,,,Intermediate,,646.0,
5734,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,N,1,A549,CHEMBL884007,,80682,11805,,,F,,,Intermediate,,646.0,
5735,BAO_0000219,In vitro cytotoxicity against lung cancer A 549 cell lines,,N,1,A549,CHEMBL621296,,80682,2007,,,F,,,Intermediate,,646.0,
5736,BAO_0000219,Compound was tested for its cytotoxicity against A 549 cell line,,N,1,A549,CHEMBL621297,,80682,4594,,,F,,,Intermediate,,646.0,
5737,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,N,1,A549,CHEMBL839828,,80682,6018,,,F,,,Expert,,646.0,
5738,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,N,1,A549,CHEMBL620397,,80682,6018,,,F,,,Intermediate,,646.0,
5739,BAO_0000219,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,N,1,A549,CHEMBL620398,,80682,3599,,,F,,,Expert,,646.0,
5740,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,N,1,A549,CHEMBL620399,,80682,2551,,,F,,,Intermediate,,646.0,
5741,BAO_0000219,In vitro inhibition of A549 (human lung cancer) cell growth.,,N,1,A549,CHEMBL620400,,80682,16132,,,F,,,Expert,,646.0,
5742,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,N,1,A549,CHEMBL620401,,80682,16132,,,F,,,Intermediate,,646.0,
5743,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,N,1,A549,CHEMBL620402,,80682,2551,,,F,,,Expert,,646.0,
5744,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,N,1,A549,CHEMBL620403,,80682,2551,,,F,,,Expert,,646.0,
5745,BAO_0000218,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,U,1,,CHEMBL620404,,22226,11913,,,F,,,Autocuration,,,
5746,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,H,1,,CHEMBL620405,In vivo,104694,12621,,,F,,,Autocuration,,,
5747,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,H,1,,CHEMBL620406,In vivo,104694,12621,,,F,,,Autocuration,,,
5748,BAO_0000218,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,H,1,,CHEMBL620407,In vivo,104694,12621,,,F,,,Autocuration,,,
5749,BAO_0000218,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,H,1,,CHEMBL620408,In vivo,104694,12621,,,F,,,Autocuration,,,
5750,BAO_0000218,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,H,1,,CHEMBL620409,In vivo,104694,12621,,,F,,,Autocuration,,,
5751,BAO_0000219,Inhibition of A-498 human Renal cell proliferation,,N,1,A498,CHEMBL620410,,80021,3600,,,F,,,Expert,,624.0,
5752,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,U,1,,CHEMBL620411,,22226,1796,,,F,,,Autocuration,,,
5753,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,U,1,,CHEMBL620412,,22226,1796,,,F,,,Autocuration,,,
5754,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,U,1,,CHEMBL876596,,22226,1796,,,F,,,Autocuration,,,
5755,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,N,1,A 172,CHEMBL620413,,80012,16464,,,F,,,Expert,,622.0,
5756,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,1,A 172,CHEMBL620414,,80012,16464,,,F,,,Intermediate,,622.0,
5757,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,1,A 172,CHEMBL620415,,80012,16464,,,F,,,Intermediate,,622.0,
5758,BAO_0000219,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,N,1,A549,CHEMBL620416,,80682,13617,,,F,,,Expert,,646.0,
5759,BAO_0000219,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,N,1,A549,CHEMBL620417,,80682,4584,,,F,,,Intermediate,,646.0,
5760,BAO_0000219,Cytotoxic activity evaluated against A549 tumor cells,,N,1,A549,CHEMBL620418,,80682,13799,,,F,,,Expert,,646.0,
5761,BAO_0000219,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,N,1,A549,CHEMBL620419,,80682,16726,,,F,,,Intermediate,,646.0,
5762,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,N,1,A549,CHEMBL620420,,80682,16109,,,F,,,Intermediate,,646.0,
5763,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,N,1,A549,CHEMBL620421,,80682,16109,,,F,,,Intermediate,,646.0,
5764,BAO_0000219,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,N,1,A549,CHEMBL620422,,80682,15474,,,F,,,Intermediate,,646.0,
5765,BAO_0000219,Cytotoxicity of compound against A549 cell line,,N,1,A549,CHEMBL620423,,80682,6851,,,F,,,Intermediate,,646.0,
5766,BAO_0000219,Cytotoxicity against human lung cell carcinoma A549 cell line,,N,1,A549,CHEMBL620424,,80682,17534,,,F,,,Expert,,646.0,
5767,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,N,1,A549,CHEMBL620425,,80682,2621,,,F,,,Intermediate,,646.0,
5768,BAO_0000219,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,N,1,A549,CHEMBL620426,,80682,830,,,F,,,Intermediate,,646.0,
5769,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,N,1,A549,CHEMBL620427,,80682,14255,,,F,,,Intermediate,,646.0,
5770,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,N,1,A549,CHEMBL620428,,80682,14255,,,F,,,Intermediate,,646.0,
5771,BAO_0000219,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,N,1,A549,CHEMBL620429,,80682,1590,,,F,,,Intermediate,,646.0,
5772,BAO_0000219,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,N,1,A549,CHEMBL620430,,80682,6146,,,F,,,Expert,,646.0,
5773,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL839887,,80682,17427,,,F,,,Expert,,646.0,
5774,BAO_0000219,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,N,1,A549,CHEMBL620431,,80682,5280,,,F,,,Intermediate,,646.0,
5775,BAO_0000219,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,N,1,A549,CHEMBL884010,,80682,16786,,,F,,,Intermediate,,646.0,
5776,BAO_0000219,In vitro cytotoxicity against A549 (human lung cancer),,N,1,A549,CHEMBL620538,,80682,5895,,,F,,,Intermediate,,646.0,
5777,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL620539,,80682,14297,,,F,,,Expert,,646.0,
5778,BAO_0000218,In vivo antiproliferative activity against A549 cell line,,N,1,A549,CHEMBL623373,,80682,17824,,,F,,,Intermediate,,646.0,
5779,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549),,N,1,A549,CHEMBL623374,,80682,14368,,,F,,,Intermediate,,646.0,
5780,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,N,1,A549,CHEMBL623375,,80682,14368,,,F,,,Intermediate,,646.0,
5781,BAO_0000219,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,N,1,A549,CHEMBL623376,,80682,14254,,,F,,,Intermediate,,646.0,
5782,BAO_0000219,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,N,1,A549,CHEMBL623377,,80682,15897,,,F,,,Intermediate,,646.0,
5783,BAO_0000219,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,N,1,A549,CHEMBL623378,,80682,13866,,,F,,,Intermediate,,646.0,
5784,BAO_0000219,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,N,1,A549,CHEMBL623379,,80682,13370,,,F,,,Intermediate,,646.0,
5785,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,,N,1,A549,CHEMBL623380,,80682,4862,,,F,,,Intermediate,,646.0,
5786,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,N,1,A549,CHEMBL623381,,80682,4862,,,F,,,Intermediate,,646.0,
5787,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,N,1,A549,CHEMBL623382,,80682,4862,,,F,,,Intermediate,,646.0,
5788,BAO_0000219,Inhibitory concentration against A549 (lung cancer) cell line,,N,1,A549,CHEMBL623383,,80682,15970,,,F,,,Intermediate,,646.0,
5789,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL623384,,80682,17713,,,F,,,Expert,,646.0,
5790,BAO_0000219,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,N,1,A549,CHEMBL623385,,80682,4833,,,F,,,Intermediate,,646.0,
5791,BAO_0000219,Activity against A549 cancer cell line.,,N,1,A549,CHEMBL623386,,80682,13736,,,F,,,Expert,,646.0,
5792,BAO_0000219,The compound was evaluated for cytotoxicity against A549 cell line,,N,1,A549,CHEMBL884105,,80682,4312,,,F,,,Intermediate,,646.0,
5793,BAO_0000219,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,N,1,A549,CHEMBL623387,,80682,5421,,,F,,,Intermediate,,646.0,
5794,BAO_0000219,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,N,1,A549,CHEMBL621568,,80682,5421,,,F,,,Intermediate,,646.0,
5795,BAO_0000219,Growth inhibitory activity was measured for human A549 tumor cell line.,,N,1,A549,CHEMBL621569,,80682,14717,,,F,,,Intermediate,,646.0,
5796,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,,N,1,A549,CHEMBL621570,,80682,4634,,,F,,,Intermediate,,646.0,
5797,BAO_0000219,Inhibitory activity against A549 cell line; inactive,,N,1,A549,CHEMBL621571,,80682,1149,,,F,,,Intermediate,,646.0,
5798,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,N,1,A549,CHEMBL621572,,80682,5421,,,F,,,Expert,,646.0,
5799,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,N,1,A549,CHEMBL621573,,80682,5421,,,F,,,Expert,,646.0,
5800,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,N,1,A549,CHEMBL621574,,80682,5421,,,F,,,Intermediate,,646.0,
5801,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,N,1,A549,CHEMBL621575,,80682,3320,,,F,,,Intermediate,,646.0,
5802,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,N,1,A549,CHEMBL621576,,80682,3320,,,F,,,Intermediate,,646.0,
5803,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,N,1,A549,CHEMBL621577,,80682,3320,,,F,,,Intermediate,,646.0,
5804,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,N,1,A549,CHEMBL621578,,80682,3320,,,F,,,Intermediate,,646.0,
5805,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,N,1,A549,CHEMBL621579,,80682,3320,,,F,,,Intermediate,,646.0,
5806,BAO_0000219,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,N,1,A549,CHEMBL621580,,80682,5726,,,F,,,Intermediate,,646.0,
5807,BAO_0000218,Plasma clearance (in vivo) in mongrel dogs was determined,,N,1,,CHEMBL621581,In vivo,50588,17800,,,A,,,Intermediate,,,
5808,BAO_0000218,Plasma clearance was measured in dog,,N,1,,CHEMBL621582,In vivo,50588,5985,,,A,,,Intermediate,,,
5809,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,N,1,,CHEMBL621583,In vivo,50588,5530,,,A,,,Intermediate,,,
5810,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,N,1,,CHEMBL621584,In vivo,50588,5530,,,A,,,Intermediate,,,
5811,BAO_0000218,Tested for plasma clearance in dog,1969.0,N,1,,CHEMBL621585,In vivo,50588,4839,,Plasma,A,,,Intermediate,,,
5812,BAO_0000218,The compound was tested for clearance in dog plasma.,,N,1,,CHEMBL621586,In vivo,50588,3639,,,A,,,Intermediate,,,
5813,BAO_0000218,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,N,1,,CHEMBL875835,In vivo,50588,4838,,,A,,,Intermediate,,,
5814,BAO_0000218,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,N,1,,CHEMBL621587,In vivo,50588,4137,,,A,,,Intermediate,,,
5815,BAO_0000218,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1969.0,N,1,,CHEMBL621588,In vivo,50588,5017,,Plasma,A,,,Intermediate,,,
5816,BAO_0000218,In vitro clearance in dog liver microsomes,2107.0,N,1,,CHEMBL621589,In vitro,50588,17538,Microsomes,Liver,A,,,Intermediate,,,
5817,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,N,1,,CHEMBL621590,In vivo,50588,6161,,,A,,,Intermediate,,,
5818,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,N,1,,CHEMBL621591,In vivo,50588,6161,,,A,,,Intermediate,,,
5819,BAO_0000218,Plasma clearance in dog,,N,1,,CHEMBL621592,In vivo,50588,1696,,,A,,,Intermediate,,,
5820,BAO_0000218,Clearance rate in dog,,N,1,,CHEMBL621593,In vivo,50588,6762,,,A,,,Intermediate,,,
5821,BAO_0000218,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1969.0,N,1,,CHEMBL621594,In vivo,50588,5932,,Plasma,A,,,Intermediate,,,
5822,BAO_0000218,Clearance in dogs,,N,1,,CHEMBL621595,In vivo,50588,6305,,,A,,,Intermediate,,,
5823,BAO_0000218,Plasma clearance in dogs,,N,1,,CHEMBL621596,In vivo,50588,4942,,,A,,,Intermediate,,,
5824,BAO_0000218,Plasma clearance was determined,,N,1,,CHEMBL621597,In vivo,50588,4219,,,A,,,Intermediate,,,
5825,BAO_0000218,Lower clearance in dog (i.v.) at 0.5 mpk,,N,1,,CHEMBL621598,In vivo,50588,17853,,,A,,,Intermediate,,,
5826,BAO_0000218,Plasma clearance in Beagle dogs,,N,1,,CHEMBL621599,In vivo,50588,4514,,,A,,,Intermediate,,,
5827,BAO_0000218,Plasma clearance (Clp) in dog,,N,1,,CHEMBL875836,In vivo,50588,6448,,,A,,,Intermediate,,,
5828,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,N,1,,CHEMBL621600,In vivo,50588,6227,,,A,,,Intermediate,,,
5829,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog was determined,,N,1,,CHEMBL621601,In vivo,50588,6227,,,A,,,Intermediate,,,
5830,BAO_0000218,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,N,1,,CHEMBL618474,In vivo,50588,6062,,,A,,,Intermediate,,,
5831,BAO_0000218,Plasma clearance of compound was determined in dog,,N,1,,CHEMBL618475,In vivo,50588,6821,,,A,,,Intermediate,,,
5832,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in dog,,N,1,,CHEMBL624524,In vivo,50588,4709,,,A,,,Intermediate,,,
5833,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,N,1,,CHEMBL624525,In vivo,50588,4521,,,A,,,Intermediate,,,
5834,BAO_0000218,Plasma clearance in dog was determined,,N,1,,CHEMBL624526,In vivo,50588,5374,,,A,,,Intermediate,,,
5835,BAO_0000218,Plasma clearance was calculated in dog,,N,1,,CHEMBL624527,In vivo,50588,6057,,,A,,,Intermediate,,,
5836,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in dog,,N,1,,CHEMBL624528,In vivo,50588,4727,,,A,,,Intermediate,,,
5837,BAO_0000218,Plasma clearance in dog,,N,1,,CHEMBL624529,In vivo,50588,5145,,,A,,,Intermediate,,,
5838,BAO_0000218,Plasma clearance in dog,,N,1,,CHEMBL624530,In vivo,50588,17657,,,A,,,Intermediate,,,
5839,BAO_0000218,Plasma clearance in dog; Unable to calculate,,N,1,,CHEMBL624531,In vivo,50588,17657,,,A,,,Intermediate,,,
5840,BAO_0000218,Plasma clearance in rhesus monkey,,N,1,,CHEMBL624532,In vivo,50588,5145,,,A,,,Intermediate,,,
5841,BAO_0000218,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,1,,CHEMBL624533,In vivo,50588,6642,,,A,,,Intermediate,,,
5842,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,1,,CHEMBL624534,In vivo,50588,6641,,,A,,,Intermediate,,,
5843,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,1,,CHEMBL624535,In vivo,50588,6642,,,A,,,Intermediate,,,
5844,BAO_0000218,Plasma clearance was evaluated in dog,,N,1,,CHEMBL624536,In vivo,50588,5472,,,A,,,Intermediate,,,
5845,BAO_0000218,Plasma clearance was evaluated in dog; Not tested,,N,1,,CHEMBL624537,In vivo,50588,5472,,,A,,,Intermediate,,,
5846,BAO_0000218,Plasma clearance was evaluated in rhesus,,N,1,,CHEMBL624538,In vivo,50588,5472,,,A,,,Intermediate,,,
5847,BAO_0000218,Plasma clearance was evaluated in rhesus; Not tested,,N,1,,CHEMBL624539,In vivo,50588,5472,,,A,,,Intermediate,,,
5848,BAO_0000218,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,N,1,,CHEMBL624540,In vivo,50588,4257,,,A,,,Intermediate,,,
5849,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL624541,In vivo,50588,6679,,,A,,,Intermediate,,,
5850,BAO_0000218,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,N,1,,CHEMBL624542,In vivo,50588,5546,,,A,,,Intermediate,,,
5851,BAO_0000218,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,1,,CHEMBL624543,In vivo,50588,6348,,,A,,,Intermediate,,,
5852,BAO_0000218,Clearance value at a dose of 0.2 mg/kg i.v.,,N,1,,CHEMBL624544,In vivo,50588,5474,,,A,,,Intermediate,,,
5853,BAO_0000218,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1969.0,N,1,,CHEMBL624545,In vivo,50588,6316,,Plasma,A,,,Intermediate,,,
5854,BAO_0000218,Cmax after oral dose of compound at 3 mg/kg in dogs,,N,1,,CHEMBL624546,In vivo,50588,17594,,,A,,,Intermediate,,,
5855,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in dogs,,N,1,,CHEMBL875957,In vivo,50588,17594,,,A,,,Intermediate,,,
5856,BAO_0000218,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,1,,CHEMBL624547,In vivo,50588,5802,,,A,,,Intermediate,,,
5857,BAO_0000218,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,N,1,,CHEMBL624548,In vivo,50588,6535,,,A,,,Intermediate,,,
5858,BAO_0000218,Cmax in dog after administration of 1 mg/kg iv,,N,1,,CHEMBL624549,In vivo,50588,6535,,,A,,,Intermediate,,,
5859,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1969.0,N,1,,CHEMBL624550,In vivo,50588,1466,,Plasma,A,,,Intermediate,,,
5860,BAO_0000218,Cmax on p.o. administration of 10 mg/kg was measured in dog,,N,1,,CHEMBL621613,In vivo,50588,6505,,,A,,,Intermediate,,,
5861,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in dog,,N,1,,CHEMBL621614,In vivo,50588,5668,,,A,,,Intermediate,,,
5862,BAO_0000218,Cmax was determine after peroral administration at 5 mpk in dog,,N,1,,CHEMBL623431,In vivo,50588,5668,,,A,,,Intermediate,,,
5863,BAO_0000218,Cmax was determine after peroral administration at 5 mg/kg in dog,,N,1,,CHEMBL623432,In vivo,50588,5668,,,A,,,Intermediate,,,
5864,BAO_0000218,Cmax after 0.3 mg/kg po administration in dog,,N,1,,CHEMBL623433,In vivo,50588,5600,,,A,,,Intermediate,,,
5865,BAO_0000218,Cmax after peroral administration in dogs at 2.4 uM/kg,,N,1,,CHEMBL623434,In vivo,50588,17764,,,A,,,Intermediate,,,
5866,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg,,N,1,,CHEMBL623435,In vivo,50588,6123,,,A,,,Intermediate,,,
5867,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,N,1,,CHEMBL623436,In vivo,50588,6123,,,A,,,Intermediate,,,
5868,BAO_0000218,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,N,1,,CHEMBL875958,In vivo,50588,6757,,,A,,,Intermediate,,,
5869,BAO_0000218,Cmax value after 15 mg/kg iv dose in Dogs,,N,1,,CHEMBL623437,In vivo,50588,16907,,,A,,,Intermediate,,,
5870,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,178.0,N,1,,CHEMBL623438,In vivo,50594,7767,,Blood,A,,,Intermediate,,,
5871,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,178.0,N,1,,CHEMBL623439,In vivo,50594,7767,,Blood,A,,,Intermediate,,,
5872,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10000001.0,N,1,,CHEMBL623440,In vivo,50594,7767,,Bone,A,,,Intermediate,,,
5873,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10000001.0,N,1,,CHEMBL623441,In vivo,50594,7767,,Bone,A,,,Intermediate,,,
5874,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10000001.0,N,1,,CHEMBL623442,In vivo,50594,7767,,Bone,A,,,Intermediate,,,
5875,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,1,,CHEMBL623469,In vivo,50594,7767,,,A,,,Intermediate,,,
5876,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,1,,CHEMBL623470,In vivo,50594,7767,,,A,,,Intermediate,,,
5877,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,1,,CHEMBL623471,In vivo,50594,7767,,,A,,,Intermediate,,,
5878,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,948.0,N,1,,CHEMBL623472,In vivo,50594,7767,,Heart,A,,,Intermediate,,,
5879,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,948.0,N,1,,CHEMBL623473,In vivo,50594,7767,,Heart,A,,,Intermediate,,,
5880,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,948.0,N,1,,CHEMBL623474,In vivo,50594,7767,,Heart,A,,,Intermediate,,,
5881,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2113.0,N,1,,CHEMBL623475,In vivo,50594,7767,,Kidney,A,,,Intermediate,,,
5882,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2113.0,N,1,,CHEMBL623476,In vivo,50594,7767,,Kidney,A,,,Intermediate,,,
5883,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2113.0,N,1,,CHEMBL623477,In vivo,50594,7767,,Kidney,A,,,Intermediate,,,
5884,BAO_0000218,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,160.0,N,1,,CHEMBL621896,In vivo,50594,7767,,Intestine,A,,,Intermediate,,,
5885,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,160.0,N,1,,CHEMBL621897,In vivo,50594,7767,,Intestine,A,,,Intermediate,,,
5886,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,160.0,N,1,,CHEMBL621898,In vivo,50594,7767,,Intestine,A,,,Intermediate,,,
5887,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2107.0,N,1,,CHEMBL621899,In vivo,50594,7767,,Liver,A,,,Intermediate,,,
5888,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2107.0,N,1,,CHEMBL621900,In vivo,50594,7767,,Liver,A,,,Intermediate,,,
5889,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2107.0,N,1,,CHEMBL621901,In vivo,50594,7767,,Liver,A,,,Intermediate,,,
5890,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2048.0,N,1,,CHEMBL621902,In vivo,50594,7767,,Lung,A,,,Intermediate,,,
5891,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2048.0,N,1,,CHEMBL621903,In vivo,50594,7767,,Lung,A,,,Intermediate,,,
5892,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2048.0,N,1,,CHEMBL622587,In vivo,50594,7767,,Lung,A,,,Intermediate,,,
5893,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2385.0,N,1,,CHEMBL620285,In vivo,50594,7767,,Muscle tissue,A,,,Intermediate,,,
5894,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2385.0,N,1,,CHEMBL875285,In vivo,50594,7767,,Muscle tissue,A,,,Intermediate,,,
5895,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2385.0,N,1,,CHEMBL620286,In vivo,50594,7767,,Muscle tissue,A,,,Intermediate,,,
5896,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,1,,CHEMBL620287,In vivo,50594,7767,,,A,,,Intermediate,,,
5897,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,1,,CHEMBL620288,In vivo,50594,7767,,,A,,,Intermediate,,,
5898,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,1,,CHEMBL620289,In vivo,50594,7767,,,A,,,Intermediate,,,
5899,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,160.0,N,1,,CHEMBL620290,In vivo,50594,7767,,Intestine,A,,,Intermediate,,,
5900,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,160.0,N,1,,CHEMBL620291,In vivo,50594,7767,,Intestine,A,,,Intermediate,,,
5901,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,160.0,N,1,,CHEMBL620292,In vivo,50594,7767,,Intestine,A,,,Intermediate,,,
5902,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2106.0,N,1,,CHEMBL620293,In vivo,50594,7767,,Spleen,A,,,Intermediate,,,
5903,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2106.0,N,1,,CHEMBL620294,In vivo,50594,7767,,Spleen,A,,,Intermediate,,,
5904,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2106.0,N,1,,CHEMBL618614,In vivo,50594,7767,,Spleen,A,,,Intermediate,,,
5905,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,945.0,N,1,,CHEMBL618615,In vivo,50594,7767,,Stomach,A,,,Intermediate,,,
5906,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,945.0,N,1,,CHEMBL618616,In vivo,50594,7767,,Stomach,A,,,Intermediate,,,
5907,BAO_0000219,Cytotoxicity against A-172 human tumor cell lines,,N,1,A 172,CHEMBL618617,,80012,2036,,,F,,,Expert,,622.0,
5908,BAO_0000219,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,N,1,A 172,CHEMBL618618,,80012,2357,,,F,,,Intermediate,,622.0,
5909,BAO_0000219,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,N,1,A204,CHEMBL618619,,80014,1457,,,F,,,Intermediate,,623.0,
5910,BAO_0000219,Tested for antiproliferative activity against A-2780 tumoral cell line,,N,1,A2780,CHEMBL618620,,81034,4379,,,F,,,Intermediate,,478.0,
5911,BAO_0000219,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,N,1,A-375,CHEMBL618621,,80018,1093,,,F,,,Intermediate,,455.0,
5912,BAO_0000219,Tested in vitro against A-375 cell line human melanoma,,N,1,A-375,CHEMBL618622,,80018,12152,,,F,,,Intermediate,,455.0,
5913,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,N,1,A-427,CHEMBL618623,,80019,16464,,,F,,,Expert,,797.0,
5914,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,1,A-427,CHEMBL618624,,80019,16464,,,F,,,Intermediate,,797.0,
5915,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,N,1,A-427,CHEMBL618625,,80019,16582,,,F,,,Expert,,797.0,
5916,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,1,A-427,CHEMBL618626,,80019,16464,,,F,,,Intermediate,,797.0,
5917,BAO_0000219,Antitumor activity on A-427 lung carcinoma cell lines,,N,1,A-427,CHEMBL618627,,80019,10413,,,F,,,Intermediate,,797.0,
5918,BAO_0000219,Cytotoxic activity against human A-427 lung tumor cell line,,N,1,A-427,CHEMBL618628,,80019,6418,,,F,,,Intermediate,,797.0,
5919,BAO_0000219,In vitro antitumor effects against human A-427 cell lines.,,N,1,A-427,CHEMBL618629,,80019,17134,,,F,,,Expert,,797.0,
5920,BAO_0000219,In vitro inhibition of A-427 (human lung cancer) cell growth.,,N,1,A-427,CHEMBL618630,,80019,16132,,,F,,,Expert,,797.0,
5921,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,N,1,A-427,CHEMBL618631,,80019,16132,,,F,,,Intermediate,,797.0,
5922,BAO_0000219,Cytotoxic activity of compound against A-427 lung human tumor cell line,,N,1,A-427,CHEMBL618632,,80019,16780,,,F,,,Intermediate,,797.0,
5923,BAO_0000219,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,N,1,A-431,CHEMBL618633,,80852,4085,,,F,,,Expert,,500.0,
5924,BAO_0000219,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,N,1,A498,CHEMBL619315,,80021,1276,,,F,,,Intermediate,,624.0,
5925,BAO_0000219,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,N,1,A498,CHEMBL619316,,80021,3498,,,F,,,Expert,,624.0,
5926,BAO_0000219,Cytotoxicity against human kidney carcinoma A-498cell lines,,N,1,A498,CHEMBL619317,,80021,1169,,,F,,,Intermediate,,624.0,
5927,BAO_0000219,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,N,1,A498,CHEMBL619318,,80021,4450,,,F,,,Intermediate,,624.0,
5928,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,N,1,A498,CHEMBL619319,,80021,3311,,,F,,,Intermediate,,624.0,
5929,BAO_0000219,Antitumor cytotoxic activity against A-498 cell line was determined,,N,1,A498,CHEMBL619739,,80021,4461,,,F,,,Intermediate,,624.0,
5930,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,N,1,A498,CHEMBL619740,,80021,3311,,,F,,,Intermediate,,624.0,
5931,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,N,1,A498,CHEMBL883158,,80021,3311,,,F,,,Intermediate,,624.0,
5932,BAO_0000219,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,N,1,A498,CHEMBL884012,,80021,1457,,,F,,,Intermediate,,624.0,
5933,BAO_0000219,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,N,1,A498,CHEMBL619741,,80021,3664,,,F,,,Intermediate,,624.0,
5934,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,N,1,A498,CHEMBL619742,,80021,15895,,,F,,,Intermediate,,624.0,
5935,BAO_0000219,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,N,1,A549,CHEMBL876610,,80682,11843,,,F,,,Intermediate,,646.0,
5936,BAO_0000219,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,N,1,A549,CHEMBL619743,,80682,11843,,,F,,,Intermediate,,646.0,
5937,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line,,N,1,A549,CHEMBL619744,,80682,17705,,,F,,,Intermediate,,646.0,
5938,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,N,1,A549,CHEMBL619745,,80682,17705,,,F,,,Intermediate,,646.0,
5939,BAO_0000219,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,N,1,A549,CHEMBL619746,,80682,4369,,,F,,,Intermediate,,646.0,
5940,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,N,1,A549,CHEMBL619747,,80682,4369,,,F,,,Intermediate,,646.0,
5941,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,N,1,A549,CHEMBL619748,,80682,4369,,,F,,,Intermediate,,646.0,
5942,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,N,1,A549,CHEMBL619749,,80682,4369,,,F,,,Intermediate,,646.0,
5943,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,N,1,A549,CHEMBL619750,,80682,4369,,,F,,,Intermediate,,646.0,
5944,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,N,1,A549,CHEMBL624014,,80682,4369,,,F,,,Intermediate,,646.0,
5945,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,N,1,A549,CHEMBL624015,,80682,4369,,,F,,,Intermediate,,646.0,
5946,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,N,1,A549,CHEMBL885344,,80682,4787,,,F,,,Expert,,646.0,
5947,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,N,1,A549,CHEMBL623224,,80682,4787,,,F,,,Intermediate,,646.0,
5948,BAO_0000219,Cytotoxic activity against A-549 cell line,,N,1,A549,CHEMBL623225,,80682,6513,,,F,,,Intermediate,,646.0,
5949,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,N,1,A549,CHEMBL622698,,80682,6690,,,F,,,Intermediate,,646.0,
5950,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,N,1,A549,CHEMBL622699,,80682,6690,,,F,,,Intermediate,,646.0,
5951,BAO_0000219,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,N,1,A549,CHEMBL622700,,80682,12263,,,F,,,Expert,,646.0,
5952,BAO_0000219,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,N,1,A549,CHEMBL622701,,80682,1054,,,F,,,Intermediate,,646.0,
5953,BAO_0000219,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,N,1,A549,CHEMBL622702,,80682,1359,,,F,,,Intermediate,,646.0,
5954,BAO_0000219,Cytotoxic activity against human lung carcinoma (A-549) cell line,,N,1,A549,CHEMBL622703,,80682,3547,,,F,,,Intermediate,,646.0,
5955,BAO_0000219,Cytotoxic activity towards A-549 cells,,N,1,A549,CHEMBL622704,,80682,5771,,,F,,,Expert,,646.0,
5956,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",,N,1,A549,CHEMBL622705,,80682,14425,,,F,,,Intermediate,,646.0,
5957,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma",,N,1,A549,CHEMBL622706,,80682,14425,,,F,,,Intermediate,,646.0,
5958,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",,N,1,A549,CHEMBL622707,,80682,14425,,,F,,,Intermediate,,646.0,
5959,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,N,1,A549,CHEMBL622708,,80682,14425,,,F,,,Intermediate,,646.0,
5960,BAO_0000219,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,N,1,A549,CHEMBL622709,,80682,5280,,,F,,,Intermediate,,646.0,
5961,BAO_0000219,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,N,1,A549,CHEMBL622710,,80682,15176,,,F,,,Intermediate,,646.0,
5962,BAO_0000219,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,N,1,A549,CHEMBL622711,,80682,15300,,,F,,,Intermediate,,646.0,
5963,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,1,A549,CHEMBL622712,,80682,17824,,,F,,,Intermediate,,646.0,
5964,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,1,A549,CHEMBL622713,,80682,17824,,,F,,,Intermediate,,646.0,
5965,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,1,A549,CHEMBL622714,,80682,17824,,,F,,,Intermediate,,646.0,
5966,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,1,A549,CHEMBL622715,,80682,17824,,,F,,,Intermediate,,646.0,
5967,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,1,A549,CHEMBL622716,,80682,17824,,,F,,,Intermediate,,646.0,
5968,BAO_0000219,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,N,1,A549,CHEMBL622717,,80682,17824,,,F,,,Intermediate,,646.0,
5969,BAO_0000218,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,N,1,A549,CHEMBL622718,,80682,17528,,,F,,,Intermediate,,646.0,
5970,BAO_0000219,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,N,1,A549,CHEMBL622719,,80682,6870,,,F,,,Expert,,646.0,
5971,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,N,1,A549,CHEMBL622720,,80682,6870,,,F,,,Intermediate,,646.0,
5972,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,N,1,A549,CHEMBL622721,,80682,6870,,,F,,,Intermediate,,646.0,
5973,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,N,1,A549,CHEMBL622722,,80682,6870,,,F,,,Intermediate,,646.0,
5974,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,N,1,A549,CHEMBL876030,,80682,16726,,,F,,,Intermediate,,646.0,
5975,BAO_0000219,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,N,1,A549,CHEMBL620206,,80682,6170,,,F,,,Intermediate,,646.0,
5976,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,N,1,A549,CHEMBL620207,,80682,6583,,,F,,,Expert,,646.0,
5977,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,N,1,A549,CHEMBL620208,,80682,6583,,,F,,,Expert,,646.0,
5978,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,N,1,A549,CHEMBL620209,,80682,6583,,,F,,,Expert,,646.0,
5979,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,N,1,A549,CHEMBL620210,,80682,6583,,,F,,,Expert,,646.0,
5980,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,N,1,A549,CHEMBL621639,,80682,6583,,,F,,,Expert,,646.0,
5981,BAO_0000219,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,N,1,A549,CHEMBL621640,,80682,17321,,,F,,,Intermediate,,646.0,
5982,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,N,1,A549,CHEMBL621641,,80682,17528,,,F,,,Expert,,646.0,
5983,BAO_0000219,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,N,1,A549,CHEMBL621642,,80682,12888,,,F,,,Expert,,646.0,
5984,BAO_0000219,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,N,1,A549,CHEMBL621643,,80682,4312,,,F,,,Intermediate,,646.0,
5985,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,N,1,A549,CHEMBL621644,,80682,4312,,,F,,,Intermediate,,646.0,
5986,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,N,1,A549,CHEMBL621645,,80682,4312,,,F,,,Intermediate,,646.0,
5987,BAO_0000219,In vitro antiproliferative activity against A549 cell line,,N,1,A549,CHEMBL621646,,80682,17737,,,F,,,Intermediate,,646.0,
5988,BAO_0000219,Synergism with indomethacin in A549 cells,,N,1,A549,CHEMBL621647,,80682,6630,,,F,,,Intermediate,,646.0,
5989,BAO_0000219,Synergism with tolmetin in A549 cells,,N,1,A549,CHEMBL621648,,80682,6630,,,F,,,Intermediate,,646.0,
5990,BAO_0000219,Synergism with sulindac in A549 cells,,N,1,A549,CHEMBL621649,,80682,6630,,,F,,,Intermediate,,646.0,
5991,BAO_0000219,Antagonism of indomethacin in A549 cells,,N,1,A549,CHEMBL621650,,80682,6630,,,F,,,Intermediate,,646.0,
5992,BAO_0000219,Antagonism of sulindac in A549 cells,,N,1,A549,CHEMBL621651,,80682,6630,,,F,,,Intermediate,,646.0,
5993,BAO_0000219,Antagonism of tolmetin in A549 cells,,N,1,A549,CHEMBL621652,,80682,6630,,,F,,,Intermediate,,646.0,
5994,BAO_0000219,Synergism with indomethacin in A549 cells,,N,1,A549,CHEMBL621653,,80682,6630,,,F,,,Intermediate,,646.0,
5995,BAO_0000219,Synergism with sulindac in A549 cells,,N,1,A549,CHEMBL621654,,80682,6630,,,F,,,Intermediate,,646.0,
5996,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,N,1,A549,CHEMBL621655,,80682,6630,,,F,,,Intermediate,,646.0,
5997,BAO_0000218,Cmax value after 30 mg/kg po dose in Dogs,,N,1,,CHEMBL621656,In vivo,50588,16907,,,A,,,Intermediate,,,
5998,BAO_0000218,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,N,1,,CHEMBL621657,In vivo,50588,5944,,,A,,,Intermediate,,,
5999,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,N,1,,CHEMBL621658,In vivo,50588,5944,,,A,,,Intermediate,,,
6000,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,N,1,,CHEMBL621659,In vivo,50588,5944,,,A,,,Intermediate,,,
6001,BAO_0000218,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,N,1,,CHEMBL621660,In vivo,50588,5944,,,A,,,Intermediate,,,
6002,BAO_0000218,Cmax value after administration of 4 mg/Kg oral dose in dog,,N,1,,CHEMBL621661,In vivo,50588,2959,,,A,,,Intermediate,,,
6003,BAO_0000218,Cmax value in dog,,N,1,,CHEMBL621662,In vivo,50588,6241,,,A,,,Intermediate,,,
6004,BAO_0000218,Cmax value in dogs after oral administration at 1 mg/kg,,N,1,,CHEMBL621663,In vivo,50588,6241,,,A,,,Intermediate,,,
6005,BAO_0000218,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,N,1,,CHEMBL621664,In vivo,50588,2652,,,A,,,Intermediate,,,
6006,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1969.0,N,1,,CHEMBL621665,In vivo,50588,1806,,Plasma,A,,,Intermediate,,,
6007,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1969.0,N,1,,CHEMBL621666,In vivo,50588,1806,,Plasma,A,,,Intermediate,,,
6008,BAO_0000218,Concentration maxima after oral dosing in dogs,,N,1,,CHEMBL621667,In vivo,50588,1021,,,A,,,Intermediate,,,
6009,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,,N,1,,CHEMBL876738,In vivo,50588,1021,,,A,,,Intermediate,,,
6010,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,,N,1,,CHEMBL621668,In vivo,50588,1021,,,A,,,Intermediate,,,
6011,BAO_0000218,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,N,1,,CHEMBL621669,In vivo,50588,5444,,,A,,,Intermediate,,,
6012,BAO_0000218,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,N,1,,CHEMBL621670,In vivo,50588,5444,,,A,,,Intermediate,,,
6013,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog,,N,1,,CHEMBL621671,In vivo,50588,5444,,,A,,,Intermediate,,,
6014,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,N,1,,CHEMBL622360,In vivo,50588,5444,,,A,,,Intermediate,,,
6015,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,N,1,,CHEMBL622361,In vivo,50588,5444,,,A,,,Intermediate,,,
6016,BAO_0000218,Cmax in dog plasma after oral dose (1 mg/kg),1969.0,N,1,,CHEMBL622362,In vivo,50588,5130,,Plasma,A,,,Intermediate,,,
6017,BAO_0000218,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1969.0,N,1,,CHEMBL622363,In vivo,50588,3249,,Plasma,A,,,Intermediate,,,
6018,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg,1969.0,N,1,,CHEMBL622364,In vivo,50588,5473,,Plasma,A,,,Intermediate,,,
6019,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg (oral),1969.0,N,1,,CHEMBL622365,In vivo,50588,5474,,Plasma,A,,,Intermediate,,,
6020,BAO_0000218,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1969.0,N,1,,CHEMBL622533,In vivo,50588,4657,,Plasma,A,,,Intermediate,,,
6021,BAO_0000218,Maximum concentration of compound in dog was evaluated.,,N,1,,CHEMBL622534,In vivo,50588,3031,,,A,,,Intermediate,,,
6022,BAO_0000218,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,N,1,,CHEMBL622535,In vivo,50588,4527,,,A,,,Intermediate,,,
6023,BAO_0000218,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,N,1,,CHEMBL876739,In vivo,50588,4186,,,A,,,Intermediate,,,
6024,BAO_0000218,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,1,,CHEMBL622536,In vivo,50588,5007,,,A,,,Intermediate,,,
6025,BAO_0000218,Maximum concentration obtained in dog plasma was determined,1969.0,N,1,,CHEMBL622537,In vivo,50588,3132,,Plasma,A,,,Intermediate,,,
6026,BAO_0000218,Maximum concentration was determined,,N,1,,CHEMBL622538,In vivo,50588,5006,,,A,,,Intermediate,,,
6027,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in dog,,N,1,,CHEMBL627867,In vivo,50588,4727,,,A,,,Intermediate,,,
6028,BAO_0000218,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,1,,CHEMBL627868,In vivo,50588,1916,,,A,,,Intermediate,,,
6029,BAO_0000218,Maximum concentration was evaluated in dog plasma,1969.0,N,1,,CHEMBL627869,In vivo,50588,1918,,Plasma,A,,,Intermediate,,,
6030,BAO_0000218,Maximum concentration was evaluated after 75 min after administration in dog,,N,1,,CHEMBL627870,In vivo,50588,3045,,,A,,,Intermediate,,,
6031,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 17b,1969.0,N,1,,CHEMBL627871,In vivo,50588,9579,,Plasma,A,,,Intermediate,,,
6032,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 2b,1969.0,N,1,,CHEMBL627872,In vivo,50588,9579,,Plasma,A,,,Intermediate,,,
6033,BAO_0000218,Maximum plasma concentration in dog,1969.0,N,1,,CHEMBL627873,In vivo,50588,933,,Plasma,A,,,Intermediate,,,
6034,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1969.0,N,1,,CHEMBL627874,In vivo,50588,17839,,Plasma,A,,,Intermediate,,,
6035,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1969.0,N,1,,CHEMBL627875,In vivo,50588,17839,,Plasma,A,,,Intermediate,,,
6036,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1969.0,N,1,,CHEMBL627876,In vivo,50588,17839,,Plasma,A,,,Intermediate,,,
6037,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1969.0,N,1,,CHEMBL627877,In vivo,50588,17839,,Plasma,A,,,Intermediate,,,
6038,BAO_0000218,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1969.0,N,1,,CHEMBL627878,In vivo,50588,6348,,Plasma,A,,,Intermediate,,,
6039,BAO_0000218,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL627879,In vivo,50588,16367,,Plasma,A,,,Intermediate,,,
6040,BAO_0000218,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1969.0,N,1,,CHEMBL875355,In vivo,50588,1337,,Plasma,A,,,Intermediate,,,
6041,BAO_0000218,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1969.0,N,1,,CHEMBL627880,In vivo,50588,1337,,Plasma,A,,,Intermediate,,,
6042,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1969.0,N,1,,CHEMBL627881,In vivo,50588,5199,,Plasma,A,,,Intermediate,,,
6043,BAO_0000218,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1969.0,N,1,,CHEMBL627882,In vivo,50588,17650,,Plasma,A,,,Intermediate,,,
6044,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1969.0,N,1,,CHEMBL627883,In vivo,50588,6679,,Plasma,A,,,Intermediate,,,
6045,BAO_0000218,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1969.0,N,1,,CHEMBL628526,In vivo,50588,5356,,Plasma,A,,,Intermediate,,,
6046,BAO_0000218,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1969.0,N,1,,CHEMBL628527,In vivo,50588,5356,,Plasma,A,,,Intermediate,,,
6047,BAO_0000218,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1969.0,N,1,,CHEMBL628528,In vivo,50588,6227,,Plasma,A,,,Intermediate,,,
6048,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1969.0,N,1,,CHEMBL628529,In vivo,50588,6227,,Plasma,A,,,Intermediate,,,
6049,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1969.0,N,1,,CHEMBL628530,In vivo,50588,6227,,Plasma,A,,,Intermediate,,,
6050,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1969.0,N,1,,CHEMBL625243,In vivo,50588,6227,,Plasma,A,,,Intermediate,,,
6051,BAO_0000218,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL625244,In vivo,50588,3598,,Plasma,A,,,Expert,,,
6052,BAO_0000218,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,N,1,,CHEMBL625245,In vivo,50588,4368,,,A,,,Intermediate,,,
6053,BAO_0000218,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,N,1,,CHEMBL625246,In vivo,50588,6265,,,A,,,Intermediate,,,
6054,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,945.0,N,1,,CHEMBL625247,In vivo,50594,7767,,Stomach,A,,,Intermediate,,,
6055,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1088.0,N,1,,CHEMBL625248,In vivo,50594,7767,,Urine,A,,,Intermediate,,,
6056,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1088.0,N,1,,CHEMBL625249,In vivo,50594,7767,,Urine,A,,,Intermediate,,,
6057,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1088.0,N,1,,CHEMBL625250,In vivo,50594,7767,,Urine,A,,,Intermediate,,,
6058,BAO_0000218,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,N,1,,CHEMBL625251,,50594,17811,,,A,,,Intermediate,,,
6059,BAO_0000218,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,N,1,,CHEMBL875356,,50594,17811,,,A,,,Intermediate,,,
6060,BAO_0000218,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,N,1,,CHEMBL625252,,50594,17827,,,A,,,Intermediate,,,
6061,BAO_0000218,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),178.0,N,1,,CHEMBL625253,,50594,17827,,Blood,A,,,Intermediate,,,
6062,BAO_0000218,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,N,1,,CHEMBL625254,,50594,17827,,,A,,,Intermediate,,,
6063,BAO_0000218,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,N,1,,CHEMBL625255,,50594,17827,,,A,,,Intermediate,,,
6064,BAO_0000218,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,N,1,,CHEMBL625256,,50594,17827,,,A,,,Intermediate,,,
6065,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),178.0,N,1,,CHEMBL625257,,50594,17827,,Blood,A,,,Intermediate,,,
6066,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),178.0,N,1,,CHEMBL625258,,50594,17827,,Blood,A,,,Intermediate,,,
6067,BAO_0000218,Compound was evaluated for washout rate in mice (Radiolabeled compound),,N,1,,CHEMBL625259,,50594,17827,,,A,,,Intermediate,,,
6068,BAO_0000218,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,N,1,,CHEMBL625260,,50594,17827,,,A,,,Intermediate,,,
6069,BAO_0000218,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,N,1,,CHEMBL625261,,50594,17827,,,A,,,Intermediate,,,
6070,BAO_0000218,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,N,1,,CHEMBL625262,,50594,17827,,,A,,,Intermediate,,,
6071,BAO_0000218,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,N,1,,CHEMBL622639,,50594,17827,,,A,,,Intermediate,,,
6072,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,N,1,,CHEMBL622640,,50594,17257,,,A,,,Intermediate,,,
6073,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,N,1,,CHEMBL622812,,50594,17257,,,A,,,Intermediate,,,
6074,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,N,1,,CHEMBL622813,,50594,17257,,,A,,,Intermediate,,,
6075,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,N,1,,CHEMBL622814,,50594,17257,,,A,,,Intermediate,,,
6076,BAO_0000218,Time at maximum activity in mice (Radiolabeled compound),,N,1,,CHEMBL622815,,50594,17827,,,A,,,Intermediate,,,
6077,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,N,1,,CHEMBL625342,,50594,3760,,,A,,,Intermediate,,,
6078,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,N,1,,CHEMBL625343,,50594,3760,,,A,,,Intermediate,,,
6079,BAO_0000218,Binding towards mouse plasma protein at 10 uM,,N,1,,CHEMBL877591,,50594,17409,,,A,,,Intermediate,,,
6080,BAO_0000218,Binding towards mouse plasma protein at 100 uM,,N,1,,CHEMBL625344,,50594,17409,,,A,,,Intermediate,,,
6081,BAO_0000218,Bioavailability was evaluated in mice after intravenous administration,,N,1,,CHEMBL625345,In vivo,50594,2675,,,A,,,Intermediate,,,
6082,BAO_0000218,Bioavailability was evaluated in mice after oral administration,,N,1,,CHEMBL625346,In vivo,50594,2675,,,A,,,Intermediate,,,
6083,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,N,1,,CHEMBL625347,In vivo,50594,3132,,,A,,,Intermediate,,,
6084,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,N,1,,CHEMBL625348,In vivo,50594,3132,,,A,,,Intermediate,,,
6085,BAO_0000218,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,N,1,,CHEMBL625349,In vivo,50594,16597,,,A,,,Intermediate,,,
6086,BAO_0000218,Oral bioavailability in mouse,,N,1,,CHEMBL625350,In vivo,50594,2862,,,A,,,Intermediate,,,
6087,BAO_0000218,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,N,1,,CHEMBL882952,In vivo,50594,17764,,,A,,,Intermediate,,,
6088,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,955.0,N,1,,CHEMBL625351,In vivo,50594,846,,Brain,A,,,Intermediate,,,
6089,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,955.0,N,1,,CHEMBL625352,In vivo,50594,846,,Brain,A,,,Intermediate,,,
6090,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,955.0,N,1,,CHEMBL877592,In vivo,50594,846,,Brain,A,,,Intermediate,,,
6091,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,955.0,N,1,,CHEMBL625353,In vivo,50594,846,,Brain,A,,,Intermediate,,,
6092,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,955.0,N,1,,CHEMBL625354,In vivo,50594,846,,Brain,A,,,Intermediate,,,
6093,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,955.0,N,1,,CHEMBL626019,In vivo,50594,846,,Brain,A,,,Intermediate,,,
6094,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,948.0,N,1,,CHEMBL626020,In vivo,50594,846,,Heart,A,,,Intermediate,,,
6095,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,948.0,N,1,,CHEMBL626021,In vivo,50594,846,,Heart,A,,,Intermediate,,,
6096,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,948.0,N,1,,CHEMBL626022,In vivo,50594,846,,Heart,A,,,Intermediate,,,
6097,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,948.0,N,1,,CHEMBL626192,In vivo,50594,846,,Heart,A,,,Intermediate,,,
6098,BAO_0000219,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,N,1,A549,CHEMBL626193,,80682,1276,,,F,,,Intermediate,,646.0,
6099,BAO_0000219,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,N,1,A549,CHEMBL626194,,80682,3498,,,F,,,Expert,,646.0,
6100,BAO_0000219,Cytotoxicity against human lung carcinoma A-549 cell lines,,N,1,A549,CHEMBL626195,,80682,1169,,,F,,,Intermediate,,646.0,
6101,BAO_0000219,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,N,1,A549,CHEMBL626196,,80682,4450,,,F,,,Intermediate,,646.0,
6102,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549,,N,1,A549,CHEMBL626197,,80682,358,,,F,,,Intermediate,,646.0,
6103,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,N,1,A549,CHEMBL626198,,80682,358,,,F,,,Intermediate,,646.0,
6104,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,N,1,A549,CHEMBL626199,,80682,358,,,F,,,Intermediate,,646.0,
6105,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,N,1,A549,CHEMBL626200,,80682,358,,,F,,,Intermediate,,646.0,
6106,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,N,1,A549,CHEMBL626201,,80682,358,,,F,,,Intermediate,,646.0,
6107,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,N,1,A549,CHEMBL626202,,80682,358,,,F,,,Intermediate,,646.0,
6108,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,N,1,A549,CHEMBL626203,,80682,358,,,F,,,Intermediate,,646.0,
6109,BAO_0000219,In vitro cytotoxicity against A-549 human lung cancer cells,,N,1,A549,CHEMBL626204,,80682,15167,,,F,,,Intermediate,,646.0,
6110,BAO_0000219,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,N,1,A549,CHEMBL624701,,80682,4139,,,F,,,Intermediate,,646.0,
6111,BAO_0000219,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,N,1,A549,CHEMBL624702,,80682,833,,,F,,,Intermediate,,646.0,
6112,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,N,1,A549,CHEMBL624703,,80682,15718,,,F,,,Expert,,646.0,
6113,BAO_0000219,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,N,1,A549,CHEMBL624704,,80682,12373,,,F,,,Intermediate,,646.0,
6114,BAO_0000219,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,N,1,A549,CHEMBL624705,,80682,637,,,F,,,Intermediate,,646.0,
6115,BAO_0000219,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,N,1,A549,CHEMBL624706,,80682,14867,,,F,,,Expert,,646.0,
6116,BAO_0000219,Antitumor cytotoxic activity against A-549 cell line was determined,,N,1,A549,CHEMBL624707,,80682,4461,,,F,,,Intermediate,,646.0,
6117,BAO_0000219,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,N,1,A549,CHEMBL624708,,80682,5406,,,F,,,Intermediate,,646.0,
6118,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,N,1,A549,CHEMBL624709,,80682,4457,,,F,,,Intermediate,,646.0,
6119,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL884107,,80682,1386,,,F,,,Expert,,646.0,
6120,BAO_0000219,Antitumoral activity was assayed against A-549 cell line,,N,1,A549,CHEMBL624710,,80682,3265,,,F,,,Intermediate,,646.0,
6121,BAO_0000219,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,N,1,A549,CHEMBL624711,,80682,2359,,,F,,,Intermediate,,646.0,
6122,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,N,1,A549,CHEMBL624712,,80682,4457,,,F,,,Intermediate,,646.0,
6123,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL624713,,80682,12454,,,F,,,Expert,,646.0,
6124,BAO_0000219,Compound was tested for inhibition of cell growth of A-549 cells,,N,1,A549,CHEMBL624714,,80682,1481,,,F,,,Intermediate,,646.0,
6125,BAO_0000219,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,N,1,A549,CHEMBL624715,,80682,1750,,,F,,,Intermediate,,646.0,
6126,BAO_0000219,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,N,1,A549,CHEMBL624716,,80682,5065,,,F,,,Intermediate,,646.0,
6127,BAO_0000219,In vitro cytotoxicity against A549-human lung carcinoma cells.,,N,1,A549,CHEMBL619505,,80682,808,,,F,,,Expert,,646.0,
6128,BAO_0000219,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,N,1,A549,CHEMBL619506,,80682,16364,,,F,,,Expert,,646.0,
6129,BAO_0000219,Cytotoxic activity against A-549 cell lines.,,N,1,A549,CHEMBL619507,,80682,1847,,,F,,,Intermediate,,646.0,
6130,BAO_0000219,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,N,1,A549,CHEMBL619508,,80682,1747,,,F,,,Expert,,646.0,
6131,BAO_0000219,Cytotoxicity against human A549 non small cell lung cell lines,,N,1,A549,CHEMBL619509,,80682,1003,,,F,,,Intermediate,,646.0,
6132,BAO_0000219,Inhibition of cell growth in (A-549) lung cell line,,N,1,A549,CHEMBL619510,,80682,15313,,,F,,,Expert,,646.0,
6133,BAO_0000219,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,N,1,A549,CHEMBL619511,,80682,3122,,,F,,,Intermediate,,646.0,
6134,BAO_0000219,In vitro antitumor activity against A-549 tumor cells.,,N,1,A549,CHEMBL619512,,80682,16049,,,F,,,Intermediate,,646.0,
6135,BAO_0000219,In vitro antitumor effects against human A-549 cell lines.,,N,1,A549,CHEMBL619513,,80682,17134,,,F,,,Expert,,646.0,
6136,BAO_0000219,In vitro cytotoxic activity of compound against A-549 cell line,,N,1,A549,CHEMBL619514,,80682,6406,,,F,,,Intermediate,,646.0,
6137,BAO_0000219,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,N,1,A549,CHEMBL619515,,80682,627,,,F,,,Intermediate,,646.0,
6138,BAO_0000219,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,N,1,A549,CHEMBL619516,,80682,12307,,,F,,,Intermediate,,646.0,
6139,BAO_0000219,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,N,1,A549,CHEMBL884005,,80682,17861,,,F,,,Intermediate,,646.0,
6140,BAO_0000219,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,N,1,A549,CHEMBL619517,,80682,6682,,,F,,,Expert,,646.0,
6141,BAO_0000219,Inhibitory concentration of compound against A-549 cell line,,N,1,A549,CHEMBL619518,,80682,6663,,,F,,,Intermediate,,646.0,
6142,BAO_0000219,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,N,1,A549,CHEMBL619519,,80682,2454,,,F,,,Intermediate,,646.0,
6143,BAO_0000219,cytotoxic activity against leukemia (A-549) cancer cell line,,N,1,A549,CHEMBL876489,,80682,14709,,,F,,,Intermediate,,646.0,
6144,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,N,1,A549,CHEMBL619520,,80682,15718,,,F,,,Expert,,646.0,
6145,BAO_0000219,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,N,1,A549,CHEMBL619521,,80682,15718,,,F,,,Intermediate,,646.0,
6146,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,N,1,A549,CHEMBL619522,,80682,17130,,,F,,,Intermediate,,646.0,
6147,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,N,1,A549,CHEMBL619523,,80682,17130,,,F,,,Intermediate,,646.0,
6148,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,N,1,A549,CHEMBL619524,,80682,17130,,,F,,,Intermediate,,646.0,
6149,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,N,1,A549,CHEMBL619525,,80682,17130,,,F,,,Intermediate,,646.0,
6150,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,N,1,A549,CHEMBL619526,,80682,6630,,,F,,,Intermediate,,646.0,
6151,BAO_0000219,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,N,1,A549,CHEMBL619527,,80682,16726,,,F,,,Intermediate,,646.0,
6152,BAO_0000219,Cytotoxicity against A549 cells; No cytotoxicity,,N,1,A549,CHEMBL619528,,80682,17846,,,F,,,Intermediate,,646.0,
6153,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines,,N,1,A549,CHEMBL619529,,80682,3415,,,F,,,Expert,,646.0,
6154,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,N,1,A549,CHEMBL619530,,80682,3415,,,F,,,Expert,,646.0,
6155,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,,N,1,A549,CHEMBL876490,,80682,5609,,,F,,,Intermediate,,646.0,
6156,BAO_0000219,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,N,1,A549,CHEMBL619531,,80682,17206,,,F,,,Intermediate,,646.0,
6157,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619532,,80682,17206,,,F,,,Intermediate,,646.0,
6158,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619533,,80682,17206,,,F,,,Intermediate,,646.0,
6159,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619534,,80682,17206,,,F,,,Intermediate,,646.0,
6160,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,N,1,A549,CHEMBL620164,,80682,17206,,,F,,,Intermediate,,646.0,
6161,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,N,1,A549,CHEMBL620165,,80682,17206,,,F,,,Intermediate,,646.0,
6162,BAO_0000219,Inhibition of A549 human lung tumor cell proliferation,,N,1,A549,CHEMBL620166,,80682,16295,,,F,,,Expert,,646.0,
6163,BAO_0000219,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,N,1,A549,CHEMBL620167,,80682,16825,,,F,,,Intermediate,,646.0,
6164,BAO_0000219,In vitro cytotoxicity against human tumor cell line A549,,N,1,A549,CHEMBL620168,,80682,3439,,,F,,,Expert,,646.0,
6165,BAO_0000219,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,N,1,A549,CHEMBL620338,,80682,10870,,,F,,,Intermediate,,646.0,
6166,BAO_0000219,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,N,1,A549,CHEMBL620339,,80682,4845,,,F,,,Intermediate,,646.0,
6167,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,N,1,A549,CHEMBL620340,,80682,5822,,,F,,,Intermediate,,646.0,
6168,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,N,1,A549,CHEMBL620341,,80682,5822,,,F,,,Intermediate,,646.0,
6169,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,N,1,A549,CHEMBL876491,,80682,5822,,,F,,,Intermediate,,646.0,
6170,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,N,1,A549,CHEMBL620342,,80682,16381,,,F,,,Intermediate,,646.0,
6171,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,N,1,A549,CHEMBL620343,,80682,16381,,,F,,,Intermediate,,646.0,
6172,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,N,1,A549,CHEMBL620344,,80682,16381,,,F,,,Intermediate,,646.0,
6173,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,,N,1,A549,CHEMBL620345,,80682,5609,,,F,,,Intermediate,,646.0,
6174,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,N,1,A549,CHEMBL620346,,80682,4644,,,F,,,Intermediate,,646.0,
6175,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,N,1,A549,CHEMBL620347,,80682,4644,,,F,,,Intermediate,,646.0,
6176,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,N,1,A549,CHEMBL620348,,80682,4644,,,F,,,Intermediate,,646.0,
6177,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,N,1,A549,CHEMBL620349,,80682,4644,,,F,,,Intermediate,,646.0,
6178,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,N,1,A549,CHEMBL618667,,80682,5822,,,F,,,Intermediate,,646.0,
6179,BAO_0000219,Percentage inhibition of human lung carcinoma (A549) cell lines,,N,1,A549,CHEMBL618668,,80682,3415,,,F,,,Expert,,646.0,
6180,BAO_0000219,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,N,1,A549,CHEMBL876031,,80682,16726,,,F,,,Intermediate,,646.0,
6181,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,N,1,A549,CHEMBL618759,,80682,17206,,,F,,,Intermediate,,646.0,
6182,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,N,1,A549,CHEMBL618760,,80682,17206,,,F,,,Intermediate,,646.0,
6183,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,N,1,A549,CHEMBL619000,,80682,17206,,,F,,,Intermediate,,646.0,
6184,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,N,1,A549,CHEMBL619001,,80682,17206,,,F,,,Intermediate,,646.0,
6185,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,N,1,A549,CHEMBL619002,,80682,17206,,,F,,,Intermediate,,646.0,
6186,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,N,1,A549,CHEMBL619003,,80682,17206,,,F,,,Intermediate,,646.0,
6187,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,N,1,A549,CHEMBL619597,,80682,17206,,,F,,,Intermediate,,646.0,
6188,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,N,1,A549,CHEMBL619598,,80682,17206,,,F,,,Intermediate,,646.0,
6189,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,N,1,A549,CHEMBL619599,,80682,17206,,,F,,,Intermediate,,646.0,
6190,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,N,1,A549,CHEMBL619600,,80682,17206,,,F,,,Intermediate,,646.0,
6191,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,N,1,A549,CHEMBL619601,,80682,16726,,,F,,,Intermediate,,646.0,
6192,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619602,,80682,17206,,,F,,,Intermediate,,646.0,
6193,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619603,,80682,17206,,,F,,,Intermediate,,646.0,
6194,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619604,,80682,17206,,,F,,,Intermediate,,646.0,
6195,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619605,,80682,17206,,,F,,,Intermediate,,646.0,
6196,BAO_0000218,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,N,1,,CHEMBL619606,In vivo,50588,6084,,,A,,,Intermediate,,,
6197,BAO_0000218,Pharmacokinetic activity (Cmax) in dog,,N,1,,CHEMBL876032,In vivo,50588,6084,,,A,,,Intermediate,,,
6198,BAO_0000218,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,N,1,,CHEMBL619607,In vivo,50588,4809,,,A,,,Intermediate,,,
6199,BAO_0000218,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,N,1,,CHEMBL619608,In vivo,50588,5983,,,A,,,Intermediate,,,
6200,BAO_0000218,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,N,1,,CHEMBL619609,In vivo,50588,6251,,,A,,,Intermediate,,,
6201,BAO_0000218,Cmax in dog plasma after 30mg/kg oral dose,1969.0,N,1,,CHEMBL619610,In vivo,50588,5932,,Plasma,A,,,Intermediate,,,
6202,BAO_0000218,Tested for the peak blood level in dog,178.0,N,1,,CHEMBL619611,In vivo,50588,4273,,Blood,A,,,Intermediate,,,
6203,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,N,1,,CHEMBL619612,In vivo,50588,5313,,,A,,,Intermediate,,,
6204,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,N,1,,CHEMBL619613,In vivo,50588,5313,,,A,,,Intermediate,,,
6205,BAO_0000218,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,178.0,N,1,,CHEMBL619614,In vivo,50588,6221,,Blood,A,,,Intermediate,,,
6206,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,N,1,,CHEMBL619615,,50588,4709,,,A,,,Intermediate,,,
6207,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,N,1,,CHEMBL619616,,50588,167,,,A,,,Intermediate,,,
6208,BAO_0000218,Final plasma concentration in dogs after oral administration at 1 mg/kg,1969.0,N,1,,CHEMBL619617,,50588,6241,,Plasma,A,,,Intermediate,,,
6209,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,N,1,,CHEMBL619618,,50588,344,,,A,,,Intermediate,,,
6210,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,N,1,,CHEMBL876033,,50588,344,,,A,,,Intermediate,,,
6211,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,N,1,,CHEMBL619619,,50588,344,,,A,,,Intermediate,,,
6212,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,N,1,,CHEMBL619620,,50588,2189,,,A,,,Intermediate,,,
6213,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1088.0,N,1,,CHEMBL619621,,50588,2189,,Urine,A,,,Intermediate,,,
6214,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1088.0,N,1,,CHEMBL619622,,50588,2189,,Urine,A,,,Intermediate,,,
6215,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1088.0,N,1,,CHEMBL618874,,50588,2189,,Urine,A,,,Intermediate,,,
6216,BAO_0000218,Absolute bioavailability was evaluated in dog,,N,1,,CHEMBL618875,In vivo,50588,4257,,,A,,,Intermediate,,,
6217,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,N,1,,CHEMBL618876,In vivo,50588,6221,,,A,,,Intermediate,,,
6218,BAO_0000218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,N,1,,CHEMBL618877,In vivo,50588,6215,,,A,,,Intermediate,,,
6219,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL618878,In vivo,50588,17267,,,A,,,Intermediate,,,
6220,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL618879,In vivo,50588,6621,,,A,,,Intermediate,,,
6221,BAO_0000218,Bioavailability after intravenous administration in dogs,,N,1,,CHEMBL618880,In vivo,50588,3854,,,A,,,Intermediate,,,
6222,BAO_0000218,Bioavailability after peroral administration in dogs,,N,1,,CHEMBL618881,In vivo,50588,3854,,,A,,,Intermediate,,,
6223,BAO_0000218,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,N,1,,CHEMBL618882,In vivo,50588,5007,,,A,,,Intermediate,,,
6224,BAO_0000218,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,N,1,,CHEMBL624226,In vivo,50588,4333,,,A,,,Intermediate,,,
6225,BAO_0000218,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1969.0,N,1,,CHEMBL624227,In vivo,50588,4333,,Plasma,A,,,Intermediate,,,
6226,BAO_0000218,Bioavailability,,N,1,,CHEMBL624228,In vivo,50588,5006,,,A,,,Intermediate,,,
6227,BAO_0000218,Bioavailability,,N,1,,CHEMBL624229,In vivo,50588,5199,,,A,,,Intermediate,,,
6228,BAO_0000218,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,N,1,,CHEMBL624230,In vivo,50588,4368,,,A,,,Intermediate,,,
6229,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL624231,In vivo,50588,3771,,,A,,,Intermediate,,,
6230,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL624232,In vivo,50588,4953,,,A,,,Intermediate,,,
6231,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL625127,In vivo,50588,5064,,,A,,,Intermediate,,,
6232,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL625128,In vivo,50588,17657,,,A,,,Intermediate,,,
6233,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL621675,In vivo,50588,17796,,,A,,,Intermediate,,,
6234,BAO_0000218,Bioavailability in dog (p.o.) at 2.0 mpk,,N,1,,CHEMBL621676,In vivo,50588,17853,,,A,,,Intermediate,,,
6235,BAO_0000218,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,N,1,,CHEMBL621677,In vivo,50588,4521,,,A,,,Intermediate,,,
6236,BAO_0000218,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,1,,CHEMBL621678,In vivo,50588,4521,,,A,,,Intermediate,,,
6237,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL621679,In vivo,50588,5006,,,A,,,Intermediate,,,
6238,BAO_0000218,Bioavailability was evaluated after oral administration in dog,,N,1,,CHEMBL621680,In vivo,50588,16365,,,A,,,Intermediate,,,
6239,BAO_0000218,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,1,,CHEMBL621681,In vivo,50588,1916,,,A,,,Intermediate,,,
6240,BAO_0000218,Bioavailability was evaluated in dog,,N,1,,CHEMBL876740,In vivo,50588,1918,,,A,,,Intermediate,,,
6241,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL621682,In vivo,50588,4239,,,A,,,Intermediate,,,
6242,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL621683,In vivo,50588,6505,,,A,,,Intermediate,,,
6243,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,N,1,,CHEMBL621684,In vivo,50588,5334,,,A,,,Intermediate,,,
6244,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,N,1,,CHEMBL621685,In vivo,50588,5334,,,A,,,Intermediate,,,
6245,BAO_0000218,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,N,1,,CHEMBL621686,In vivo,50588,4809,,,A,,,Intermediate,,,
6246,BAO_0000218,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,1,,CHEMBL621687,In vivo,50588,6348,,,A,,,Intermediate,,,
6247,BAO_0000218,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,N,1,,CHEMBL621688,In vivo,50588,6005,,,A,,,Intermediate,,,
6248,BAO_0000218,Bioavailability of compound in dog was determined after peroral administration,,N,1,,CHEMBL621689,In vivo,50588,17804,,,A,,,Intermediate,,,
6249,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621690,In vivo,50588,3184,,,A,,,Intermediate,,,
6250,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,N,1,,CHEMBL621691,In vivo,50588,1806,,,A,,,Intermediate,,,
6251,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,N,1,,CHEMBL875941,In vivo,50588,1806,,,A,,,Intermediate,,,
6252,BAO_0000218,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,N,1,,CHEMBL621692,In vivo,50588,1806,,,A,,,Intermediate,,,
6253,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL621693,In vivo,50588,4839,,,A,,,Intermediate,,,
6254,BAO_0000218,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,N,1,,CHEMBL621694,In vivo,50588,5017,,,A,,,Intermediate,,,
6255,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,948.0,N,1,,CHEMBL621695,In vivo,50594,846,,Heart,A,,,Intermediate,,,
6256,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,948.0,N,1,,CHEMBL621696,In vivo,50594,846,,Heart,A,,,Intermediate,,,
6257,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,2113.0,N,1,,CHEMBL621697,In vivo,50594,846,,Kidney,A,,,Intermediate,,,
6258,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,2113.0,N,1,,CHEMBL621698,In vivo,50594,846,,Kidney,A,,,Intermediate,,,
6259,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,2113.0,N,1,,CHEMBL623420,In vivo,50594,846,,Kidney,A,,,Intermediate,,,
6260,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,2113.0,N,1,,CHEMBL623421,In vivo,50594,846,,Kidney,A,,,Intermediate,,,
6261,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,2113.0,N,1,,CHEMBL623422,In vivo,50594,846,,Kidney,A,,,Intermediate,,,
6262,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,2113.0,N,1,,CHEMBL623423,In vivo,50594,846,,Kidney,A,,,Intermediate,,,
6263,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,2107.0,N,1,,CHEMBL623424,In vivo,50594,846,,Liver,A,,,Intermediate,,,
6264,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,2107.0,N,1,,CHEMBL623425,In vivo,50594,846,,Liver,A,,,Intermediate,,,
6265,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,2107.0,N,1,,CHEMBL623426,In vivo,50594,846,,Liver,A,,,Intermediate,,,
6266,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,2107.0,N,1,,CHEMBL623427,In vivo,50594,846,,Liver,A,,,Intermediate,,,
6267,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,2107.0,N,1,,CHEMBL623428,In vivo,50594,846,,Liver,A,,,Intermediate,,,
6268,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,2107.0,N,1,,CHEMBL875947,In vivo,50594,846,,Liver,A,,,Intermediate,,,
6269,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,2048.0,N,1,,CHEMBL623429,In vivo,50594,846,,Lung,A,,,Intermediate,,,
6270,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,2048.0,N,1,,CHEMBL623430,In vivo,50594,846,,Lung,A,,,Intermediate,,,
6271,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,2048.0,N,1,,CHEMBL622588,In vivo,50594,846,,Lung,A,,,Intermediate,,,
6272,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,2048.0,N,1,,CHEMBL622589,In vivo,50594,846,,Lung,A,,,Intermediate,,,
6273,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,2048.0,N,1,,CHEMBL622751,In vivo,50594,846,,Lung,A,,,Intermediate,,,
6274,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,2048.0,N,1,,CHEMBL622752,In vivo,50594,846,,Lung,A,,,Intermediate,,,
6275,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,N,1,CCRF S-180,CHEMBL622753,,50594,6599,,,A,,,Intermediate,,42.0,
6276,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,N,1,CCRF S-180,CHEMBL622647,,50594,6599,,,A,,,Intermediate,,42.0,
6277,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,N,1,CCRF S-180,CHEMBL875163,,50594,6599,,,A,,,Intermediate,,42.0,
6278,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,N,1,CCRF S-180,CHEMBL622648,,50594,6599,,,A,,,Intermediate,,42.0,
6279,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,N,1,CCRF S-180,CHEMBL622649,,50594,6599,,,A,,,Intermediate,,42.0,
6280,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,955.0,N,1,CCRF S-180,CHEMBL622650,,50594,6599,,Brain,A,,,Intermediate,,42.0,
6281,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,955.0,N,1,CCRF S-180,CHEMBL622651,,50594,6599,,Brain,A,,,Intermediate,,42.0,
6282,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,955.0,N,1,CCRF S-180,CHEMBL622652,,50594,6599,,Brain,A,,,Intermediate,,42.0,
6283,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,955.0,N,1,CCRF S-180,CHEMBL622653,,50594,6599,,Brain,A,,,Intermediate,,42.0,
6284,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,955.0,N,1,CCRF S-180,CHEMBL622654,,50594,6599,,Brain,A,,,Intermediate,,42.0,
6285,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,948.0,N,1,CCRF S-180,CHEMBL622655,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6286,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,948.0,N,1,CCRF S-180,CHEMBL622656,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6287,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,948.0,N,1,CCRF S-180,CHEMBL622657,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6288,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,948.0,N,1,CCRF S-180,CHEMBL622658,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6289,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,948.0,N,1,CCRF S-180,CHEMBL622659,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6290,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,2113.0,N,1,CCRF S-180,CHEMBL624630,,50594,6599,,Kidney,A,,,Intermediate,,42.0,
6291,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,2113.0,N,1,CCRF S-180,CHEMBL624631,,50594,6599,,Kidney,A,,,Intermediate,,42.0,
6292,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,2113.0,N,1,CCRF S-180,CHEMBL624632,,50594,6599,,Kidney,A,,,Intermediate,,42.0,
6293,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,N,1,A549,CHEMBL624633,,80682,17130,,,F,,,Intermediate,,646.0,
6294,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,N,1,A549,CHEMBL624634,,80682,17130,,,F,,,Intermediate,,646.0,
6295,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,N,1,A549,CHEMBL624635,,80682,17130,,,F,,,Intermediate,,646.0,
6296,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,N,1,A549,CHEMBL624636,,80682,17130,,,F,,,Intermediate,,646.0,
6297,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL857055,,80682,3263,,,F,,,Expert,,646.0,
6298,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,N,1,A549,CHEMBL624637,,80682,6663,,,F,,,Expert,,646.0,
6299,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,N,1,A549,CHEMBL624638,,80682,6663,,,F,,,Expert,,646.0,
6300,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,N,1,A549,CHEMBL874366,,80682,6663,,,F,,,Expert,,646.0,
6301,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,N,1,A549,CHEMBL624639,,80682,6663,,,F,,,Expert,,646.0,
6302,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,N,1,A549,CHEMBL624640,,80682,6663,,,F,,,Expert,,646.0,
6303,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,N,1,A549,CHEMBL624641,,80682,6663,,,F,,,Intermediate,,646.0,
6304,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,N,1,A549,CHEMBL624642,,80682,6663,,,F,,,Intermediate,,646.0,
6305,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,N,1,A549,CHEMBL624643,,80682,6663,,,F,,,Intermediate,,646.0,
6306,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,N,1,A549,CHEMBL624644,,80682,6663,,,F,,,Intermediate,,646.0,
6307,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,N,1,A549,CHEMBL624645,,80682,6663,,,F,,,Intermediate,,646.0,
6308,BAO_0000219,The compound was evaluated for its cytotoxic potency against A-549 cell line,,N,1,A549,CHEMBL619445,,80682,3983,,,F,,,Intermediate,,646.0,
6309,BAO_0000219,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,N,1,A549,CHEMBL839886,,80682,11141,,,F,,,Expert,,646.0,
6310,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line.,,N,1,A549,CHEMBL619446,,80682,5076,,,F,,,Intermediate,,646.0,
6311,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,N,1,A549,CHEMBL619447,,80682,3311,,,F,,,Intermediate,,646.0,
6312,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,N,1,A549,CHEMBL619448,,80682,3311,,,F,,,Intermediate,,646.0,
6313,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,N,1,A549,CHEMBL619449,,80682,3311,,,F,,,Intermediate,,646.0,
6314,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,N,1,A549,CHEMBL619450,,80682,5076,,,F,,,Intermediate,,646.0,
6315,BAO_0000219,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,N,1,A549,CHEMBL619451,,80682,4150,,,F,,,Intermediate,,646.0,
6316,BAO_0000219,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,N,1,A549,CHEMBL619452,,80682,2150,,,F,,,Expert,,646.0,
6317,BAO_0000219,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,N,1,A549,CHEMBL619453,,80682,4644,,,F,,,Intermediate,,646.0,
6318,BAO_0000219,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,N,1,A549,CHEMBL874367,,80682,263,,,F,,,Intermediate,,646.0,
6319,BAO_0000219,Cytotoxic concentration against A-549 tumor cells.,,N,1,A549,CHEMBL619454,,80682,11333,,,F,,,Intermediate,,646.0,
6320,BAO_0000219,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,N,1,A549,CHEMBL619455,,80682,11333,,,F,,,Intermediate,,646.0,
6321,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,N,1,A549,CHEMBL619456,,80682,15895,,,F,,,Intermediate,,646.0,
6322,BAO_0000218,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,N,1,,CHEMBL619457,,50191,16677,,,F,,,Expert,,,
6323,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),,N,1,,CHEMBL619458,,50192,10624,,,F,,,Intermediate,,,
6324,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,,N,1,,CHEMBL619459,,50274,16717,,,F,,,Expert,,,
6325,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,,N,1,,CHEMBL619460,,50274,16717,,,F,,,Expert,,,
6326,BAO_0000218,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,N,1,,CHEMBL619461,,50416,5513,,,F,,,Intermediate,,,
6327,BAO_0000218,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,N,1,,CHEMBL619462,,50416,15962,,,F,,,Intermediate,,,
6328,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),,N,1,,CHEMBL620388,,50416,15962,,,F,,,Intermediate,,,
6329,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),,N,1,,CHEMBL620389,,50416,15962,,,F,,,Intermediate,,,
6330,BAO_0000218,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,N,1,,CHEMBL620390,,50416,15962,,,F,,,Intermediate,,,
6331,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,,N,1,,CHEMBL620391,,50416,16717,,,F,,,Expert,,,
6332,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,,N,1,,CHEMBL621073,,50416,16717,,,F,,,Expert,,,
6333,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,N,1,,CHEMBL621074,,50296,8117,,,F,,,Intermediate,,,
6334,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,N,1,,CHEMBL621075,,50366,8117,,,F,,,Intermediate,,,
6335,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,N,1,,CHEMBL619554,,50535,15472,,,F,,,Intermediate,,,
6336,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,N,1,,CHEMBL619555,,50535,15472,,,F,,,Intermediate,,,
6337,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,N,1,,CHEMBL619556,,50169,16443,,,F,,,Intermediate,,,
6338,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,N,1,,CHEMBL619557,,50169,16443,,,F,,,Intermediate,,,
6339,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,N,1,,CHEMBL619558,,50169,16443,,,F,,,Intermediate,,,
6340,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619559,,80682,17206,,,F,,,Intermediate,,646.0,
6341,BAO_0000219,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619560,,80682,17206,,,F,,,Intermediate,,646.0,
6342,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,N,1,A549,CHEMBL619561,,80682,16381,,,F,,,Intermediate,,646.0,
6343,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,N,1,A549,CHEMBL619562,,80682,16381,,,F,,,Intermediate,,646.0,
6344,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,N,1,A549,CHEMBL619563,,80682,16381,,,F,,,Intermediate,,646.0,
6345,BAO_0000219,GI values against A549 cells (lung cancer),,N,1,A549,CHEMBL857457,,80682,16381,,,F,,,Intermediate,,646.0,
6346,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,N,1,A549,CHEMBL619564,,80682,17206,,,F,,,Intermediate,,646.0,
6347,BAO_0000219,Inhibitory activity against A549 human adenocarcinoma,,N,1,A549,CHEMBL619565,,80682,16325,,,F,,,Intermediate,,646.0,
6348,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,N,1,A549,CHEMBL619566,,80682,10708,,,F,,,Intermediate,,646.0,
6349,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,N,1,A549,CHEMBL619567,,80682,10708,,,F,,,Intermediate,,646.0,
6350,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,,N,1,A549,CHEMBL619568,,80682,17376,,,F,,,Intermediate,,646.0,
6351,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,N,1,A549,CHEMBL619569,,80682,17376,,,F,,,Intermediate,,646.0,
6352,BAO_0000219,Cytotoxicity against human A549 lung cells,,N,1,A549,CHEMBL619570,,80682,17488,,,F,,,Intermediate,,646.0,
6353,BAO_0000218,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,N,1,A549,CHEMBL619571,,80682,17404,,,F,,,Intermediate,,646.0,
6354,BAO_0000219,Growth inhibition of A549 (human lung carcinoma) cell line.,,N,1,A549,CHEMBL619572,,80682,10958,,,F,,,Expert,,646.0,
6355,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line.,,N,1,A549,CHEMBL619573,,80682,17099,,,F,,,Expert,,646.0,
6356,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,N,1,A549,CHEMBL619574,,80682,17099,,,F,,,Intermediate,,646.0,
6357,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,N,1,A549,CHEMBL619575,,80682,4096,,,F,,,Intermediate,,646.0,
6358,BAO_0000219,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,N,1,A549,CHEMBL619576,,80682,4096,,,F,,,Expert,,646.0,
6359,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,N,1,A549,CHEMBL619577,,80682,4096,,,F,,,Intermediate,,646.0,
6360,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture,,N,1,A549,CHEMBL619578,,80682,2525,,,F,,,Intermediate,,646.0,
6361,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,N,1,A549,CHEMBL884009,,80682,2525,,,F,,,Intermediate,,646.0,
6362,BAO_0000219,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,N,1,A549,CHEMBL619579,,80682,5302,,,F,,,Intermediate,,646.0,
6363,BAO_0000219,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,N,1,A549,CHEMBL619580,,80682,16325,,,F,,,Intermediate,,646.0,
6364,BAO_0000219,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,N,1,A549,CHEMBL619581,,80682,16939,,,F,,,Intermediate,,646.0,
6365,BAO_0000219,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,N,1,A549,CHEMBL619582,,80682,17229,,,F,,,Intermediate,,646.0,
6366,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,N,1,A549,CHEMBL619583,,80682,17380,,,F,,,Intermediate,,646.0,
6367,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,N,1,A549,CHEMBL876502,,80682,17380,,,F,,,Intermediate,,646.0,
6368,BAO_0000219,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,N,1,A549,CHEMBL619584,,80682,1903,,,F,,,Intermediate,,646.0,
6369,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,N,1,A549,CHEMBL619585,,80682,3838,,,F,,,Intermediate,,646.0,
6370,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,N,1,A549,CHEMBL619586,,80682,14696,,,F,,,Intermediate,,646.0,
6371,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,N,1,A549,CHEMBL619587,,80682,3838,,,F,,,Intermediate,,646.0,
6372,BAO_0000219,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,N,1,A549,CHEMBL619588,,80682,1522,,,F,,,Intermediate,,646.0,
6373,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,N,1,A549,CHEMBL619589,,80682,12400,,,F,,,Intermediate,,646.0,
6374,BAO_0000219,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,N,1,A549,CHEMBL619590,,80682,14696,,,F,,,Intermediate,,646.0,
6375,BAO_0000219,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,N,1,A549,CHEMBL619591,,80682,14769,,,F,,,Intermediate,,646.0,
6376,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,N,1,A549,CHEMBL619592,,80682,14696,,,F,,,Intermediate,,646.0,
6377,BAO_0000219,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,N,1,A549,CHEMBL619593,,80682,1888,,,F,,,Intermediate,,646.0,
6378,BAO_0000219,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,N,1,A549,CHEMBL620217,,80682,12016,,,F,,,Intermediate,,646.0,
6379,BAO_0000219,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,N,1,A549,CHEMBL620218,,80682,6058,,,F,,,Intermediate,,646.0,
6380,BAO_0000219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,N,1,A549,CHEMBL620219,,80682,17708,,,F,,,Intermediate,,646.0,
6381,BAO_0000219,Antitumor activity against A549/ATCC cell line,,N,1,A549,CHEMBL620220,,80682,12301,,,F,,,Intermediate,,646.0,
6382,BAO_0000219,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,N,1,A549,CHEMBL625141,,80682,11970,,,F,,,Intermediate,,646.0,
6383,BAO_0000219,In vitro cytotoxicity against A549/ATCC cell line.,,N,1,A549,CHEMBL625142,,80682,11818,,,F,,,Expert,,646.0,
6384,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,N,1,A549,CHEMBL625143,,80682,12400,,,F,,,Intermediate,,646.0,
6385,BAO_0000219,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,N,1,A549,CHEMBL625144,,80682,3381,,,F,,,Intermediate,,646.0,
6386,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,N,1,A549,CHEMBL622474,,80682,17376,,,F,,,Intermediate,,646.0,
6387,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,N,1,A549,CHEMBL884104,,80682,10708,,,F,,,Intermediate,,646.0,
6388,BAO_0000219,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,U,1,,CHEMBL622475,,22226,2964,,,F,,,Autocuration,,,
6389,BAO_0000218,Compound was tested for oral bioavailability in dogs,,U,1,,CHEMBL622476,In vivo,22224,5005,,,A,,,Intermediate,,,
6390,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,N,1,,CHEMBL875831,In vivo,50588,6229,,,A,,,Intermediate,,,
6391,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,N,1,,CHEMBL622477,In vivo,50588,6229,,,A,,,Intermediate,,,
6392,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL622478,In vivo,50588,5374,,,A,,,Intermediate,,,
6393,BAO_0000218,Compound was tested for the oral bioavailability in dog; No availability,,N,1,,CHEMBL623172,In vivo,50588,5374,,,A,,,Intermediate,,,
6394,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,N,1,,CHEMBL623173,In vivo,50588,6265,,,A,,,Intermediate,,,
6395,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,N,1,,CHEMBL623174,In vivo,50588,5654,,,A,,,Intermediate,,,
6396,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,N,1,,CHEMBL623175,In vivo,50588,5654,,,A,,,Intermediate,,,
6397,BAO_0000218,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,N,1,,CHEMBL623340,In vivo,50588,16456,,,A,,,Intermediate,,,
6398,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,N,1,,CHEMBL623341,In vivo,50588,5302,,,A,,,Intermediate,,,
6399,BAO_0000218,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,N,1,,CHEMBL623342,In vivo,50588,3624,,,A,,,Intermediate,,,
6400,BAO_0000218,Oral bioavailability of active FTIs in dogs,,N,1,,CHEMBL623343,In vivo,50588,16452,,,A,,,Intermediate,,,
6401,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,N,1,,CHEMBL623344,In vivo,50588,5802,,,A,,,Intermediate,,,
6402,BAO_0000218,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL623345,In vivo,50588,3598,,,A,,,Expert,,,
6403,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL875832,In vivo,50588,17839,,,A,,,Intermediate,,,
6404,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623346,In vivo,50588,6762,,,A,,,Intermediate,,,
6405,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623347,In vivo,50588,6821,,,A,,,Intermediate,,,
6406,BAO_0000218,Oral bioavailability of compound was determined in dog; Not tested,,N,1,,CHEMBL623348,In vivo,50588,6821,,,A,,,Intermediate,,,
6407,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623349,In vivo,50588,5210,,,A,,,Intermediate,,,
6408,BAO_0000218,Oral bioavailability (10 mg/kg) was determined in dog,,N,1,,CHEMBL623350,In vivo,50588,6227,,,A,,,Intermediate,,,
6409,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL623351,In vivo,50588,761,,,A,,,Intermediate,,,
6410,BAO_0000218,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,N,1,,CHEMBL623352,In vivo,50588,761,,,A,,,Intermediate,,,
6411,BAO_0000218,Oral bioavailability administered in solution in rats,,N,1,,CHEMBL623353,In vivo,50588,761,,,A,,,Intermediate,,,
6412,BAO_0000218,Oral bioavailability after 30 mg/kg po dose in Dogs,,N,1,,CHEMBL875833,In vivo,50588,16907,,,A,,,Intermediate,,,
6413,BAO_0000218,Oral bioavailability at a dose of 1 mg/kg in dogs,,N,1,,CHEMBL623354,In vivo,50588,5474,,,A,,,Intermediate,,,
6414,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg p.o.),,N,1,,CHEMBL623355,In vivo,50588,6535,,,A,,,Intermediate,,,
6415,BAO_0000218,Oral bioavailability in Dog; ND = not determined,,N,1,,CHEMBL623356,In vivo,50588,6535,,,A,,,Intermediate,,,
6416,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623357,In vivo,50588,3352,,,A,,,Intermediate,,,
6417,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623358,In vivo,50588,6168,,,A,,,Intermediate,,,
6418,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623359,In vivo,50588,5988,,,A,,,Intermediate,,,
6419,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623360,In vivo,50588,4942,,,A,,,Intermediate,,,
6420,BAO_0000218,Oral bioavailability in dogs; No data,,N,1,,CHEMBL623361,In vivo,50588,4942,,,A,,,Intermediate,,,
6421,BAO_0000218,Oral bioavailability measured in dogs,,N,1,,CHEMBL623362,In vivo,50588,14541,,,A,,,Intermediate,,,
6422,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623363,In vivo,50588,4449,,,A,,,Intermediate,,,
6423,BAO_0000218,Oral bioavailability was calculated in dog,,N,1,,CHEMBL623364,In vivo,50588,6057,,,A,,,Intermediate,,,
6424,BAO_0000218,Oral bioavailability after 0.3 mg/kg po administration in dog,,N,1,,CHEMBL875834,In vivo,50588,5600,,,A,,,Intermediate,,,
6425,BAO_0000218,Oral bioavailability in dog (i.v. dosing),,N,1,,CHEMBL623365,In vivo,50588,5542,,,A,,,Intermediate,,,
6426,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623366,In vivo,50588,5542,,,A,,,Intermediate,,,
6427,BAO_0000218,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,N,1,,CHEMBL623367,In vivo,50588,5546,,,A,,,Intermediate,,,
6428,BAO_0000218,Oral bioavailability in Beagle dogs,,N,1,,CHEMBL623368,In vivo,50588,4514,,,A,,,Intermediate,,,
6429,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623369,In vivo,50588,3624,,,A,,,Intermediate,,,
6430,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623370,In vivo,50588,3854,,,A,,,Intermediate,,,
6431,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623371,In vivo,50588,5836,,,A,,,Intermediate,,,
6432,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL623372,In vivo,50588,5940,,,A,,,Intermediate,,,
6433,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621351,In vivo,50588,6168,,,A,,,Intermediate,,,
6434,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621352,In vivo,50588,6227,,,A,,,Intermediate,,,
6435,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621353,In vivo,50588,6251,,,A,,,Intermediate,,,
6436,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621354,In vivo,50588,6448,,,A,,,Intermediate,,,
6437,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621355,In vivo,50588,6647,,,A,,,Intermediate,,,
6438,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621356,In vivo,50588,5940,,,A,,,Intermediate,,,
6439,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621357,In vivo,50588,933,,,A,,,Intermediate,,,
6440,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621358,In vivo,50588,5210,,,A,,,Intermediate,,,
6441,BAO_0000218,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,N,1,,CHEMBL621359,In vivo,50588,6642,,,A,,,Intermediate,,,
6442,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,N,1,,CHEMBL621360,In vivo,50588,6641,,,A,,,Intermediate,,,
6443,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,N,1,,CHEMBL621361,In vivo,50588,6642,,,A,,,Intermediate,,,
6444,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621362,In vivo,50588,5472,,,A,,,Intermediate,,,
6445,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621363,In vivo,50588,5985,,,A,,,Intermediate,,,
6446,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621364,In vivo,50588,15660,,,A,,,Intermediate,,,
6447,BAO_0000218,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,N,1,,CHEMBL621166,In vivo,50588,5530,,,A,,,Intermediate,,,
6448,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg i.v.),,N,1,,CHEMBL621167,In vivo,50588,5530,,,A,,,Intermediate,,,
6449,BAO_0000218,Oral bioavailability (F) in dogs,,N,1,,CHEMBL621168,In vivo,50588,6305,,,A,,,Intermediate,,,
6450,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL621169,In vivo,50588,5210,,,A,,,Intermediate,,,
6451,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL875950,In vivo,50588,5238,,,A,,,Intermediate,,,
6452,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,N,1,,CHEMBL621170,In vivo,50588,5668,,,A,,,Intermediate,,,
6453,BAO_0000218,Oral bioavailability after peroral administration at 5 mpk in Dog,,N,1,,CHEMBL621171,In vivo,50588,5668,,,A,,,Intermediate,,,
6454,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,N,1,,CHEMBL621172,In vivo,50588,5668,,,A,,,Intermediate,,,
6455,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,N,1,,CHEMBL621173,In vivo,50588,6084,,,A,,,Intermediate,,,
6456,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,2113.0,N,1,CCRF S-180,CHEMBL621174,,50594,6599,,Kidney,A,,,Intermediate,,42.0,
6457,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,2113.0,N,1,CCRF S-180,CHEMBL621175,,50594,6599,,Kidney,A,,,Intermediate,,42.0,
6458,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,2107.0,N,1,CCRF S-180,CHEMBL621176,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6459,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,2107.0,N,1,CCRF S-180,CHEMBL621177,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6460,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,2107.0,N,1,CCRF S-180,CHEMBL621178,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6461,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,2107.0,N,1,CCRF S-180,CHEMBL621179,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6462,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,2107.0,N,1,CCRF S-180,CHEMBL621180,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6463,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,2048.0,N,1,CCRF S-180,CHEMBL875951,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6464,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,2048.0,N,1,CCRF S-180,CHEMBL621181,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6465,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,2048.0,N,1,CCRF S-180,CHEMBL621182,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6466,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,2048.0,N,1,CCRF S-180,CHEMBL621183,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6467,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,2048.0,N,1,CCRF S-180,CHEMBL621184,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6468,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,N,1,CCRF S-180,CHEMBL621185,,50594,6599,,,A,,,Intermediate,,42.0,
6469,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,N,1,CCRF S-180,CHEMBL621186,,50594,6599,,,A,,,Intermediate,,42.0,
6470,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,N,1,CCRF S-180,CHEMBL621187,,50594,6599,,,A,,,Intermediate,,42.0,
6471,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,N,1,CCRF S-180,CHEMBL621188,,50594,6599,,,A,,,Intermediate,,42.0,
6472,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,N,1,CCRF S-180,CHEMBL621189,,50594,6599,,,A,,,Intermediate,,42.0,
6473,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,2106.0,N,1,CCRF S-180,CHEMBL621190,,50594,6599,,Spleen,A,,,Intermediate,,42.0,
6474,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,2106.0,N,1,CCRF S-180,CHEMBL618520,,50594,6599,,Spleen,A,,,Intermediate,,42.0,
6475,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,2106.0,N,1,CCRF S-180,CHEMBL621739,,50594,6599,,Spleen,A,,,Intermediate,,42.0,
6476,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,2106.0,N,1,CCRF S-180,CHEMBL621740,,50594,6599,,Spleen,A,,,Intermediate,,42.0,
6477,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,2106.0,N,1,CCRF S-180,CHEMBL621741,,50594,6599,,Spleen,A,,,Intermediate,,42.0,
6478,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,N,1,CCRF S-180,CHEMBL621742,,50594,6599,,,A,,,Intermediate,,42.0,
6479,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,N,1,CCRF S-180,CHEMBL621743,,50594,6599,,,A,,,Intermediate,,42.0,
6480,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,N,1,CCRF S-180,CHEMBL621744,,50594,6599,,,A,,,Intermediate,,42.0,
6481,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,N,1,CCRF S-180,CHEMBL621745,,50594,6599,,,A,,,Intermediate,,42.0,
6482,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,N,1,CCRF S-180,CHEMBL621746,,50594,6599,,,A,,,Intermediate,,42.0,
6483,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,N,1,CCRF S-180,CHEMBL621747,,50594,6599,,,A,,,Intermediate,,42.0,
6484,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,N,1,CCRF S-180,CHEMBL621748,,50594,6599,,,A,,,Intermediate,,42.0,
6485,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,N,1,CCRF S-180,CHEMBL621749,,50594,6599,,,A,,,Intermediate,,42.0,
6486,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,N,1,CCRF S-180,CHEMBL621750,,50594,6599,,,A,,,Intermediate,,42.0,
6487,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,N,1,CCRF S-180,CHEMBL621751,,50594,6599,,,A,,,Intermediate,,42.0,
6488,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,948.0,N,1,CCRF S-180,CHEMBL621752,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6489,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,948.0,N,1,CCRF S-180,CHEMBL621753,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6490,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,948.0,N,1,CCRF S-180,CHEMBL875955,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6491,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,948.0,N,1,CCRF S-180,CHEMBL621754,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6492,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,948.0,N,1,CCRF S-180,CHEMBL621755,,50594,6599,,Heart,A,,,Intermediate,,42.0,
6493,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,2107.0,N,1,CCRF S-180,CHEMBL621756,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6494,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,2107.0,N,1,CCRF S-180,CHEMBL624199,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6495,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,2107.0,N,1,CCRF S-180,CHEMBL624200,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6496,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,2107.0,N,1,CCRF S-180,CHEMBL624375,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6497,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,2107.0,N,1,CCRF S-180,CHEMBL624376,,50594,6599,,Liver,A,,,Intermediate,,42.0,
6498,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,2048.0,N,1,CCRF S-180,CHEMBL624377,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6499,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,2048.0,N,1,CCRF S-180,CHEMBL624378,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6500,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,1,,CHEMBL857901,,50067,12269,,,F,,,Intermediate,,,
6501,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,1,,CHEMBL875274,,50067,12269,,,F,,,Intermediate,,,
6502,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,1,,CHEMBL624379,,50067,12269,,,F,,,Intermediate,,,
6503,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,1,,CHEMBL624380,,50067,12269,,,F,,,Intermediate,,,
6504,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),,N,1,,CHEMBL624381,,50192,10624,,,F,,,Intermediate,,,
6505,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,N,1,,CHEMBL624382,,50714,17216,,,F,,,Intermediate,,,
6506,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,N,1,,CHEMBL624383,,50714,17216,,,F,,,Intermediate,,,
6507,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii 631,,N,1,,CHEMBL624384,,50296,9560,,,F,,,Intermediate,,,
6508,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii B74,,N,1,,CHEMBL624385,,50296,9560,,,F,,,Intermediate,,,
6509,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,N,1,,CHEMBL624386,,50296,9560,,,F,,,Intermediate,,,
6510,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,N,1,,CHEMBL624387,,50296,9560,,,F,,,Intermediate,,,
6511,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii 631,,N,1,,CHEMBL624388,,50296,9560,,,F,,,Intermediate,,,
6512,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/9,,N,1,,CHEMBL624389,,50296,9560,,,F,,,Intermediate,,,
6513,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii B74,,N,1,,CHEMBL624390,,50296,9560,,,F,,,Intermediate,,,
6514,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/3,,N,1,,CHEMBL875275,,50296,9560,,,F,,,Intermediate,,,
6515,BAO_0000218,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,N,1,,CHEMBL624391,,50056,114,,,F,,,Intermediate,,,
6516,BAO_0000218,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,N,1,,CHEMBL623636,,50056,114,,,F,,,Intermediate,,,
6517,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,N,1,,CHEMBL623637,,50532,10841,,,F,,,Intermediate,,,
6518,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,N,1,,CHEMBL623638,,50532,10841,,,F,,,Intermediate,,,
6519,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,N,1,,CHEMBL623639,,50532,10841,,,F,,,Intermediate,,,
6520,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,N,1,,CHEMBL623640,,50532,10841,,,F,,,Intermediate,,,
6521,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,N,1,,CHEMBL623641,,50532,10841,,,F,,,Intermediate,,,
6522,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,N,1,,CHEMBL623642,,50532,10841,,,F,,,Intermediate,,,
6523,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,N,1,,CHEMBL623643,,50532,10841,,,F,,,Intermediate,,,
6524,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,N,1,,CHEMBL623644,,50532,10841,,,F,,,Intermediate,,,
6525,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,N,1,,CHEMBL623645,,50532,10841,,,F,,,Intermediate,,,
6526,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,N,1,,CHEMBL623646,,50532,10841,,,F,,,Intermediate,,,
6527,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,N,1,,CHEMBL623647,,50532,10841,,,F,,,Intermediate,,,
6528,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,N,1,,CHEMBL623648,,50532,10841,,,F,,,Intermediate,,,
6529,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,N,1,,CHEMBL623649,,50366,8117,,,F,,,Intermediate,,,
6530,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,N,1,,CHEMBL623650,,50366,8117,,,F,,,Intermediate,,,
6531,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,N,1,,CHEMBL623651,,50366,9560,,,F,,,Intermediate,,,
6532,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-100,,N,1,,CHEMBL623652,,50366,9560,,,F,,,Expert,,,
6533,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-626,,N,1,,CHEMBL623653,,50366,9560,,,F,,,Intermediate,,,
6534,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus T14V,,N,1,,CHEMBL623654,,50366,9560,,,F,,,Intermediate,,,
6535,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 8A06,,N,1,,CHEMBL623655,,50366,9560,,,F,,,Intermediate,,,
6536,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100,,N,1,,CHEMBL623656,,50366,9560,,,F,,,Intermediate,,,
6537,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,N,1,,CHEMBL623657,,50366,9560,,,F,,,Expert,,,
6538,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,N,1,,CHEMBL623658,,50366,9560,,,F,,,Intermediate,,,
6539,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,N,1,,CHEMBL623659,,50366,9560,,,F,,,Intermediate,,,
6540,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 626,,N,1,,CHEMBL623660,,50366,9560,,,F,,,Intermediate,,,
6541,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus T14V,,N,1,,CHEMBL623661,,50366,9560,,,F,,,Intermediate,,,
6542,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,N,1,,CHEMBL875281,,50535,10986,,,F,,,Intermediate,,,
6543,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,N,1,,CHEMBL623662,,50535,10986,,,F,,,Intermediate,,,
6544,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,N,1,,CHEMBL623663,,50535,10986,,,F,,,Intermediate,,,
6545,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,N,1,,CHEMBL623664,,50535,10986,,,F,,,Intermediate,,,
6546,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,N,1,,CHEMBL623665,,50535,10986,,,F,,,Intermediate,,,
6547,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,N,1,A673,CHEMBL621856,,80023,10708,,,F,,,Intermediate,,165.0,
6548,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,N,1,A704,CHEMBL620432,,80661,10708,,,F,,,Intermediate,,645.0,
6549,BAO_0000219,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,U,1,,CHEMBL620433,,22226,416,,,F,,,Autocuration,,,
6550,BAO_0000219,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,N,1,A9,CHEMBL620434,,80024,14354,,,F,,,Intermediate,,625.0,
6551,BAO_0000219,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,N,1,A9,CHEMBL620435,,80024,14354,,,F,,,Intermediate,,625.0,
6552,BAO_0000219,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,N,1,A9,CHEMBL620436,,80024,5116,,,F,,,Intermediate,,625.0,
6553,BAO_0000219,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,N,1,A9,CHEMBL876597,,80024,5116,,,F,,,Intermediate,,625.0,
6554,BAO_0000219,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,N,1,Human ovarian carcinoma cell line,CHEMBL620437,,81037,15694,,,F,,,Expert,,874.0,
6555,BAO_0000219,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,N,1,A9,CHEMBL620438,,80024,13038,,,F,,,Expert,,625.0,
6556,BAO_0000219,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,N,1,A9,CHEMBL620439,,80024,13038,,,F,,,Expert,,625.0,
6557,BAO_0000219,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,N,1,A9,CHEMBL619657,,80024,10923,,,F,,,Expert,,625.0,
6558,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,N,1,A9,CHEMBL619658,,80024,10923,,,F,,,Intermediate,,625.0,
6559,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,N,1,A9,CHEMBL619659,,80024,10923,,,F,,,Intermediate,,625.0,
6560,BAO_0000019,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,H,1,,CHEMBL619660,,10649,10923,,,F,,,Expert,,,
6561,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,N,1,A9,CHEMBL619661,,80024,10923,,,F,,,Intermediate,,625.0,
6562,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,N,1,A9,CHEMBL619662,,80024,10923,,,F,,,Intermediate,,625.0,
6563,BAO_0000219,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,N,1,AA6,CHEMBL619663,,80663,8158,,,F,,,Intermediate,,975.0,
6564,BAO_0000219,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,U,1,,CHEMBL619664,,22226,15494,,,F,,,Autocuration,,,
6565,BAO_0000219,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,U,1,,CHEMBL619665,,22226,15494,,,F,,,Autocuration,,,
6566,BAO_0000219,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,N,1,AA5,CHEMBL883244,,80662,12348,,,F,,,Intermediate,,974.0,
6567,BAO_0000219,Cytotoxicity was measured against AA5/HIV-1(IIIB),,N,1,AA5,CHEMBL884011,,80662,12348,,,F,,,Intermediate,,974.0,
6568,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,N,1,AA5,CHEMBL619666,,80662,2726,,,F,,,Intermediate,,974.0,
6569,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,N,1,U-937,CHEMBL619667,,80566,2726,,,F,,,Intermediate,,379.0,
6570,BAO_0000219,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,N,1,UV4,CHEMBL619668,,80578,10747,,,F,,,Intermediate,,274.0,
6571,BAO_0000219,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,N,1,CHO-AA8,CHEMBL619669,,80089,11005,,,F,,,Expert,,185.0,
6572,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6,,N,1,CHO-AA8,CHEMBL876608,,80089,12687,,,F,,,Intermediate,,185.0,
6573,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6.,,N,1,CHO-AA8,CHEMBL619670,,80089,12687,,,F,,,Intermediate,,185.0,
6574,BAO_0000219,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,N,1,CHO-AA8,CHEMBL619671,,80089,12687,,,F,,,Intermediate,,185.0,
6575,BAO_0000219,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,N,1,CHO-AA8,CHEMBL619672,,80089,12687,,,F,,,Intermediate,,185.0,
6576,BAO_0000219,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,N,1,CHO-AA8,CHEMBL619673,,80089,12687,,,F,,,Intermediate,,185.0,
6577,BAO_0000219,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,N,1,CHO-AA8,CHEMBL619674,,80089,13436,,,F,,,Intermediate,,185.0,
6578,BAO_0000219,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,N,1,CHO-AA8,CHEMBL619675,,80089,13435,,,F,,,Intermediate,,185.0,
6579,BAO_0000219,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,N,1,CHO-AA8,CHEMBL619676,,80089,13302,,,F,,,Intermediate,,185.0,
6580,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,N,1,CHO-AA8,CHEMBL619677,,80089,12687,,,F,,,Intermediate,,185.0,
6581,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,N,1,CHO-AA8,CHEMBL619678,,80089,12687,,,A,,,Intermediate,,185.0,
6582,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,N,1,CHO-AA8,CHEMBL619679,,80089,12687,,,A,,,Intermediate,,185.0,
6583,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,N,1,CHO-AA8,CHEMBL619680,,80089,12878,,,A,,,Expert,,185.0,
6584,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,N,1,CHO-AA8,CHEMBL621457,,80089,12878,,,A,,,Intermediate,,185.0,
6585,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,N,1,CHO-AA8,CHEMBL876609,,80089,14367,,,F,,,Expert,,185.0,
6586,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,N,1,CHO-AA8,CHEMBL621458,,80089,14367,,,F,,,Intermediate,,185.0,
6587,BAO_0000219,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,N,1,CHO-AA8,CHEMBL621459,,80089,12398,,,F,,,Expert,,185.0,
6588,BAO_0000219,Aerobic growth inhibition in Chinese hamster cell line AA8,,N,1,CHO-AA8,CHEMBL621460,,80089,12878,,,F,,,Expert,,185.0,
6589,BAO_0000219,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,N,1,CHO-AA8,CHEMBL621461,,80089,13820,,,F,,,Expert,,185.0,
6590,BAO_0000219,Inhibition of growth under aerobic conditions in AA8 cells,,N,1,CHO-AA8,CHEMBL621462,,80089,13436,,,F,,,Expert,,185.0,
6591,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,N,1,,CHEMBL621463,In vivo,50588,6084,,,A,,,Intermediate,,,
6592,BAO_0000218,Oral bioavailability in dog at 10 mg/kg of the compound,,N,1,,CHEMBL621464,In vivo,50588,5711,,,A,,,Intermediate,,,
6593,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,N,1,,CHEMBL621465,In vivo,50588,4353,,,A,,,Intermediate,,,
6594,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,N,1,,CHEMBL621466,In vivo,50588,4353,,,A,,,Intermediate,,,
6595,BAO_0000218,Oral bioavailability in dog (mongrel),,N,1,,CHEMBL621467,In vivo,50588,17800,,,A,,,Intermediate,,,
6596,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,N,1,,CHEMBL621468,In vivo,50588,3994,,,A,,,Intermediate,,,
6597,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,N,1,,CHEMBL876734,In vivo,50588,3994,,,F,,,Intermediate,,,
6598,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL618476,In vivo,50588,5145,,,A,,,Intermediate,,,
6599,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,N,1,,CHEMBL618477,In vivo,50588,16452,,,A,,,Intermediate,,,
6600,BAO_0000218,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,N,1,,CHEMBL618478,In vivo,50588,16452,,,A,,,Intermediate,,,
6601,BAO_0000218,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,N,1,,CHEMBL618479,In vivo,50588,5983,,,A,,,Intermediate,,,
6602,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL618480,In vivo,50588,4273,,,A,,,Intermediate,,,
6603,BAO_0000218,Bioavailability in dog (dose 3-10 mg/kg),,N,1,,CHEMBL618481,In vivo,50588,12500,,,A,,,Intermediate,,,
6604,BAO_0000218,The compound was tested for bioavailability of compound in plasma of dog; Complete,1969.0,N,1,,CHEMBL618482,In vivo,50588,12500,,Plasma,A,,,Intermediate,,,
6605,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL618483,In vivo,50588,3639,,,A,,,Intermediate,,,
6606,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL618484,In vivo,50588,3880,,,A,,,Intermediate,,,
6607,BAO_0000218,Bioavailability in dog,,N,1,,CHEMBL618485,In vivo,50588,4838,,,A,,,Intermediate,,,
6608,BAO_0000218,oral bioavailability was measured in dogs,,N,1,,CHEMBL618486,In vivo,50588,15600,,,A,,,Intermediate,,,
6609,BAO_0000218,Compound was tested for plasma protein binding in dog; Not determined,,N,1,,CHEMBL618487,,50588,17248,,,A,,,Intermediate,,,
6610,BAO_0000218,Compound was tested for plasma protein binding of dog,,N,1,,CHEMBL618488,,50588,17248,,,A,,,Intermediate,,,
6611,BAO_0000218,Compound was tested for plasma protein binding of dog; Not determined,,N,1,,CHEMBL876735,,50588,17248,,,A,,,Intermediate,,,
6612,BAO_0000218,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,N,1,,CHEMBL618489,,50588,17443,,,A,,,Intermediate,,,
6613,BAO_0000218,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,N,1,,CHEMBL618490,In vivo,50588,4186,,,A,,,Intermediate,,,
6614,BAO_0000218,Half life was determined,,N,1,,CHEMBL618491,,50588,3749,,,A,,,Intermediate,,,
6615,BAO_0000218,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,N,1,,CHEMBL618492,In vivo,50588,3249,,,A,,,Intermediate,,,
6616,BAO_0000218,Half life was evaluated in dog,,N,1,,CHEMBL873354,,50588,3022,,,A,,,Intermediate,,,
6617,BAO_0000218,Half life was determined,,N,1,,CHEMBL618493,,50588,3749,,,A,,,Intermediate,,,
6618,BAO_0000218,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,1,,CHEMBL618494,In vivo,50588,2517,,,A,,,Intermediate,,,
6619,BAO_0000218,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),948.0,N,1,,CHEMBL618495,In vivo,50588,2517,,Heart,A,,,Intermediate,,,
6620,BAO_0000218,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),2113.0,N,1,,CHEMBL618496,In vivo,50588,2517,,Kidney,A,,,Intermediate,,,
6621,BAO_0000218,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),2107.0,N,1,,CHEMBL618497,In vivo,50588,2517,,Liver,A,,,Intermediate,,,
6622,BAO_0000218,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),2048.0,N,1,,CHEMBL618498,In vivo,50588,2517,,Lung,A,,,Intermediate,,,
6623,BAO_0000218,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),2106.0,N,1,,CHEMBL618499,In vivo,50588,2517,,Spleen,A,,,Intermediate,,,
6624,BAO_0000218,LogP in dog,,N,1,,CHEMBL876736,,50588,3639,,,A,,,Intermediate,,,
6625,BAO_0000218,Partition coefficient (logP),,N,1,,CHEMBL618500,,50588,6227,,,A,,,Intermediate,,,
6626,BAO_0000218,Partition coefficient in dog,,N,1,,CHEMBL857831,,50588,6227,,,A,,,Intermediate,,,
6627,BAO_0000218,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,N,1,,CHEMBL618501,In vivo,50588,17764,,,A,,,Intermediate,,,
6628,BAO_0000218,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,N,1,,CHEMBL618502,In vivo,50588,4809,,,A,,,Intermediate,,,
6629,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,N,1,,CHEMBL618503,,50588,5600,,,A,,,Intermediate,,,
6630,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,N,1,,CHEMBL618504,,50588,14294,,,A,,,Intermediate,,,
6631,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,N,1,,CHEMBL618505,,50588,14294,,,A,,,Intermediate,,,
6632,BAO_0000218,Metabolism of compound in dog S9 microsomes; Trace,,N,1,,CHEMBL618506,,50588,14294,,,A,,,Intermediate,,,
6633,BAO_0000218,In vitro metabolic potential in dog liver microsomes,2107.0,N,1,,CHEMBL618507,,50588,6251,,Liver,A,,,Intermediate,,,
6634,BAO_0000218,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,N,1,,CHEMBL876737,In vivo,50588,3748,,,A,,,Intermediate,,,
6635,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL618508,In vivo,50588,2713,,,A,,,Intermediate,,,
6636,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL618509,In vivo,50588,6512,,,A,,,Intermediate,,,
6637,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL618510,In vivo,50588,6679,,,A,,,Intermediate,,,
6638,BAO_0000218,The compound was tested for bioavailability in dogs,,N,1,,CHEMBL618511,In vivo,50588,3749,,,A,,,Intermediate,,,
6639,BAO_0000218,The compound was tested for oral bioavailability in dogs,,N,1,,CHEMBL618512,In vivo,50588,3749,,,A,,,Intermediate,,,
6640,BAO_0000218,Oral bioavailability in dog,,N,1,,CHEMBL618513,In vivo,50588,6742,,,A,,,Intermediate,,,
6641,BAO_0000218,Compound was tested for percent protein binding (PB) in dog,,N,1,,CHEMBL618514,,50588,6227,,,A,,,Intermediate,,,
6642,BAO_0000218,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,N,1,,CHEMBL620052,,50588,6874,,,A,,,Intermediate,,,
6643,BAO_0000218,Compound was evaluated for plasma clearance.,1969.0,N,1,,CHEMBL620053,In vivo,50588,2877,,Plasma,A,,,Intermediate,,,
6644,BAO_0000218,The compound was tested for plasma clearance in dog,1969.0,N,1,,CHEMBL620054,In vivo,50588,12500,,Plasma,A,,,Intermediate,,,
6645,BAO_0000218,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1969.0,N,1,,CHEMBL620055,In vivo,50588,12500,,Plasma,A,,,Intermediate,,,
6646,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,N,1,,CHEMBL620056,,50588,4709,,,A,,,Intermediate,,,
6647,BAO_0000218,In vitro relative rate of metabolism was determined in dog liver microsomes,2107.0,N,1,,CHEMBL620057,,50588,5542,,Liver,A,,,Intermediate,,,
6648,BAO_0000218,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,N,1,,CHEMBL618939,In vivo,50588,17594,,,A,,,Intermediate,,,
6649,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,N,1,,CHEMBL618940,In vivo,50588,2652,,,A,,,Intermediate,,,
6650,BAO_0000218,Half life after intravenous administration in dogs at 1.2 uM/kg,,N,1,,CHEMBL618941,In vivo,50588,17764,,,A,,,Intermediate,,,
6651,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,2048.0,N,1,CCRF S-180,CHEMBL624473,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6652,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,2048.0,N,1,CCRF S-180,CHEMBL624474,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6653,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,2048.0,N,1,CCRF S-180,CHEMBL624475,,50594,6599,,Lung,A,,,Intermediate,,42.0,
6654,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,N,1,CCRF S-180,CHEMBL624476,,50594,6599,,,A,,,Intermediate,,42.0,
6655,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,N,1,CCRF S-180,CHEMBL623478,,50594,6599,,,A,,,Intermediate,,42.0,
6656,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,N,1,CCRF S-180,CHEMBL623479,,50594,6599,,,A,,,Intermediate,,42.0,
6657,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,N,1,CCRF S-180,CHEMBL623480,,50594,6599,,,A,,,Intermediate,,42.0,
6658,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,N,1,CCRF S-180,CHEMBL623481,,50594,6599,,,A,,,Intermediate,,42.0,
6659,BAO_0000218,C2 in brain of mice at the oral dose of 50 mg/kg,955.0,N,1,,CHEMBL623482,,50594,17641,,Brain,A,,,Intermediate,,,
6660,BAO_0000218,C2 in kidney of mice at the oral dose of 50 mg/kg,2113.0,N,1,,CHEMBL623483,,50594,17641,,Kidney,A,,,Intermediate,,,
6661,BAO_0000218,C2 in liver of mice at the oral dose of 50 mg/kg,2107.0,N,1,,CHEMBL623484,,50594,17641,,Liver,A,,,Intermediate,,,
6662,BAO_0000218,C2 in lungs of mice at the oral dose of 50 mg/kg,2048.0,N,1,,CHEMBL623485,,50594,17641,,Lung,A,,,Intermediate,,,
6663,BAO_0000218,C2 in spleen of mice at the oral dose of 50 mg/kg,2106.0,N,1,,CHEMBL623486,,50594,17641,,Spleen,A,,,Intermediate,,,
6664,BAO_0000218,Plasma clearance in mouse,,N,1,,CHEMBL623487,In vivo,50594,17852,,,A,,,Intermediate,,,
6665,BAO_0000218,Clearance of compound after intravenous administration in mice at 24 uM/kg,,N,1,,CHEMBL623488,In vivo,50594,17764,,,A,,,Intermediate,,,
6666,BAO_0000218,Clearance from mouse blood following i.v. administration of 10 mg/kg,,N,1,,CHEMBL623489,In vivo,50594,17837,,,A,,,Intermediate,,,
6667,BAO_0000218,Clearance was evaluated in mice after intravenous administration,,N,1,,CHEMBL875157,In vivo,50594,2675,,,A,,,Intermediate,,,
6668,BAO_0000218,Clearance was evaluated in mice after oral administration,,N,1,,CHEMBL623490,In vivo,50594,2675,,,A,,,Intermediate,,,
6669,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in mouse,,N,1,,CHEMBL623491,In vivo,50594,4239,,,A,,,Intermediate,,,
6670,BAO_0000218,Plasma clearance of compound was determined at 40 mg/Kg,,N,1,,CHEMBL623492,In vivo,50594,17753,,,A,,,Intermediate,,,
6671,BAO_0000218,Plasma clearance of at 24 mg/Kg,,N,1,,CHEMBL623493,In vivo,50594,17753,,,A,,,Intermediate,,,
6672,BAO_0000218,Plasma clearance at 24 mg/Kg,,N,1,,CHEMBL623494,In vivo,50594,17753,,,A,,,Intermediate,,,
6673,BAO_0000218,Plasma clearance at 5 mg/Kg,,N,1,,CHEMBL623495,In vivo,50594,17753,,,A,,,Intermediate,,,
6674,BAO_0000218,Plasma clearance in mice,,N,1,,CHEMBL623496,In vivo,50594,5727,,,A,,,Intermediate,,,
6675,BAO_0000218,Plasma clearance value upon iv administration in mouse,,N,1,,CHEMBL623497,In vivo,50594,2862,,,A,,,Intermediate,,,
6676,BAO_0000218,Total plasma clearance in mice,1969.0,N,1,,CHEMBL623498,In vivo,50594,5980,,Plasma,A,,,Intermediate,,,
6677,BAO_0000218,Clearance in mouse,,N,1,,CHEMBL623499,In vivo,50594,17592,,,A,,,Intermediate,,,
6678,BAO_0000218,Clearance value was determined,,N,1,,CHEMBL623500,In vivo,50594,17718,,,A,,,Intermediate,,,
6679,BAO_0000218,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,N,1,,CHEMBL623501,In vivo,50594,16597,,,A,,,Intermediate,,,
6680,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL875158,,22229,17384,,,P,,,Intermediate,,,
6681,BAO_0000218,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,N,1,,CHEMBL623502,In vivo,50594,6062,,,A,,,Intermediate,,,
6682,BAO_0000218,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,N,1,,CHEMBL623503,In vivo,50594,17734,,,A,,,Intermediate,,,
6683,BAO_0000218,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,1,,CHEMBL623504,In vivo,50594,6348,,,A,,,Intermediate,,,
6684,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,N,1,,CHEMBL623505,In vivo,50594,5969,,,A,,,Intermediate,,,
6685,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,N,1,,CHEMBL623506,In vivo,50594,5969,,,A,,,Intermediate,,,
6686,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,N,1,,CHEMBL623507,In vivo,50594,5969,,,A,,,Intermediate,,,
6687,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,N,1,,CHEMBL623508,In vivo,50594,16597,,,A,,,Intermediate,,,
6688,BAO_0000218,Cmax after oral administration at 30 mg/kg in ICR mouse,,N,1,,CHEMBL623509,In vivo,50594,5781,,,A,,,Intermediate,,,
6689,BAO_0000218,Cmax after peroral administration in mice at 2.4 uM/kg,,N,1,,CHEMBL875159,In vivo,50594,17764,,,A,,,Intermediate,,,
6690,BAO_0000218,Cmax in brain of mice at the oral dose of 50 mg/kg,955.0,N,1,,CHEMBL623510,In vivo,50594,17641,,Brain,A,,,Intermediate,,,
6691,BAO_0000218,Cmax in kidney of mice at the oral dose of 50 mg/kg,2113.0,N,1,,CHEMBL623511,In vivo,50594,17641,,Kidney,A,,,Intermediate,,,
6692,BAO_0000218,Cmax in liver of mice at the oral dose of 50 mg/kg,2107.0,N,1,,CHEMBL623512,In vivo,50594,17641,,Liver,A,,,Intermediate,,,
6693,BAO_0000218,Cmax in lungs of mice at the oral dose of 50 mg/kg,2048.0,N,1,,CHEMBL623513,In vivo,50594,17641,,Lung,A,,,Intermediate,,,
6694,BAO_0000218,Cmax in mice at 18 uM/kg i.p. administration,,N,1,,CHEMBL623514,In vivo,50594,17764,,,F,,,Intermediate,,,
6695,BAO_0000218,Cmax in mice at 23 uM/kg i.v. administration,,N,1,,CHEMBL622609,In vivo,50594,17764,,,F,,,Intermediate,,,
6696,BAO_0000218,Cmax in mice at 24 uM/kg i.p. administration,,N,1,,CHEMBL622610,In vivo,50594,17764,,,F,,,Intermediate,,,
6697,BAO_0000218,Cmax in mice at 25 uM/kg i.p. administration,,N,1,,CHEMBL621823,In vivo,50594,17764,,,F,,,Intermediate,,,
6698,BAO_0000218,Cmax in mice at 26 uM/kg i.p. administration,,N,1,,CHEMBL621824,In vivo,50594,17764,,,F,,,Intermediate,,,
6699,BAO_0000218,Cmax in spleen of mice at the oral dose of 50 mg/kg,2106.0,N,1,,CHEMBL621825,In vivo,50594,17641,,Spleen,A,,,Intermediate,,,
6700,BAO_0000218,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,N,1,,CHEMBL621826,In vivo,50594,16597,,,A,,,Intermediate,,,
6701,BAO_0000218,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,N,1,,CHEMBL621827,In vivo,50594,16597,,,A,,,Intermediate,,,
6702,BAO_0000218,Cmax value was determined,,N,1,,CHEMBL621828,In vivo,50594,5727,,,A,,,Intermediate,,,
6703,BAO_0000218,Cmax value in IRC mice,,N,1,,CHEMBL621829,In vivo,50594,5951,,,A,,,Intermediate,,,
6704,BAO_0000218,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,N,1,,CHEMBL621830,In vivo,50594,5506,,,A,,,Intermediate,,,
6705,BAO_0000218,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,N,1,,CHEMBL621831,In vivo,50594,5506,,,A,,,Intermediate,,,
6706,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1969.0,N,1,,CHEMBL621832,In vivo,50594,14239,,Plasma,A,,,Intermediate,,,
6707,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1969.0,N,1,,CHEMBL624579,In vivo,50594,4890,,Plasma,A,,,Intermediate,,,
6708,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,N,1,,CHEMBL624580,In vivo,50594,429,,,A,,,Intermediate,,,
6709,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,N,1,,CHEMBL624581,,50535,10986,,,F,,,Intermediate,,,
6710,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,N,1,,CHEMBL624582,,50535,10986,,,F,,,Intermediate,,,
6711,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,N,1,,CHEMBL624583,,50535,10986,,,F,,,Intermediate,,,
6712,BAO_0000219,Inhibitory activity against human tumor cell line A0375 melanoma.,,N,1,A-375,CHEMBL624584,,80018,13227,,,F,,,Intermediate,,455.0,
6713,BAO_0000249,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,D,1,,CHEMBL624585,,12512,4481,Brain membranes,,B,,,Expert,,,
6714,BAO_0000019,Forskolin-induced cAMP production at human A1 adenosine receptor,,D,1,,CHEMBL875165,,114,16931,,,F,,,Expert,,,
6715,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,H,1,CHO,CHEMBL619490,,114,3850,,,F,,,Autocuration,,449.0,
6716,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,H,1,CHO,CHEMBL619491,,114,3850,,,F,,,Autocuration,,449.0,
6717,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,H,1,CHO,CHEMBL619492,,114,3850,,,F,,,Expert,,449.0,
6718,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,H,1,CHO,CHEMBL619493,,114,3850,,,F,,,Expert,,449.0,
6719,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,H,1,CHO,CHEMBL619494,,114,3850,,,F,,,Autocuration,,449.0,
6720,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,H,1,CHO,CHEMBL619495,,114,3850,,,F,,,Autocuration,,449.0,
6721,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,H,1,CHO,CHEMBL619496,,114,3850,,,F,,,Autocuration,,449.0,
6722,BAO_0000219,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,D,1,CHO,CHEMBL619497,,114,3850,,,F,,,Expert,,449.0,
6723,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,H,1,CHO,CHEMBL619498,,114,3850,,,F,,,Autocuration,,449.0,
6724,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,H,1,CHO,CHEMBL619499,,114,3850,,,F,,,Autocuration,,449.0,
6725,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,H,1,CHO,CHEMBL619500,,114,3850,,,F,,,Expert,,449.0,
6726,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,H,1,CHO,CHEMBL619501,,114,3850,,,F,,,Autocuration,,449.0,
6727,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,H,1,CHO,CHEMBL619502,,114,3850,,,F,,,Expert,,449.0,
6728,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,H,1,CHO,CHEMBL619503,,114,3850,,,F,,,Autocuration,,449.0,
6729,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,H,1,CHO,CHEMBL619504,,114,3850,,,F,,,Autocuration,,449.0,
6730,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,H,1,CHO,CHEMBL621298,,114,3850,,,F,,,Autocuration,,449.0,
6731,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,H,1,CHO,CHEMBL621299,,114,3850,,,F,,,Expert,,449.0,
6732,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,H,1,CHO,CHEMBL621300,,114,3850,,,F,,,Autocuration,,449.0,
6733,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,H,1,CHO,CHEMBL621301,,114,3850,,,F,,,Autocuration,,449.0,
6734,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,H,1,CHO,CHEMBL621302,,114,3850,,,F,,,Expert,,449.0,
6735,BAO_0000219,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,N,1,A10,CHEMBL621303,,80013,12680,,,F,,,Intermediate,,164.0,
6736,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,U,1,A10,CHEMBL621304,,22226,1313,,,F,,,Autocuration,,164.0,
6737,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,U,1,A10,CHEMBL621305,,22226,1313,,,F,,,Autocuration,,164.0,
6738,BAO_0000219,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,N,1,A10,CHEMBL621306,,80013,17567,,,F,,,Intermediate,,164.0,
6739,BAO_0000219,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,N,1,A10,CHEMBL618444,,80013,17567,,,F,,,Intermediate,,164.0,
6740,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,N,1,A10,CHEMBL618445,,80013,11819,,,F,,,Intermediate,,164.0,
6741,BAO_0000219,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,N,1,CHO-AA8,CHEMBL618446,,80089,13436,,,F,,,Intermediate,,185.0,
6742,BAO_0000219,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,N,1,CHO-AA8,CHEMBL618447,,80089,12687,,,F,,,Intermediate,,185.0,
6743,BAO_0000219,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,N,1,CHO-AA8,CHEMBL618448,,80089,12651,,,F,,,Intermediate,,185.0,
6744,BAO_0000219,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,N,1,CHO-AA8,CHEMBL618449,,80089,13300,,,F,,,Intermediate,,185.0,
6745,BAO_0000219,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,N,1,CHO-AA8,CHEMBL618637,,80089,15296,,,F,,,Intermediate,,185.0,
6746,BAO_0000219,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,N,1,CHO-AA8,CHEMBL618638,,80089,15328,,,F,,,Intermediate,,185.0,
6747,BAO_0000219,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,N,1,CHO-AA8,CHEMBL618639,,80089,13302,,,F,,,Intermediate,,185.0,
6748,BAO_0000219,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,N,1,CHO-AA8,CHEMBL618640,,80089,14367,,,F,,,Expert,,185.0,
6749,BAO_0000219,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,N,1,CHO-AA8,CHEMBL618641,,80089,17002,,,F,,,Expert,,185.0,
6750,BAO_0000219,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,N,1,CHO-AA8,CHEMBL618642,,80089,13436,,,F,,,Intermediate,,185.0,
6751,BAO_0000219,Inhibitory activity against aerobic growth of AA8 cells.,,N,1,CHO-AA8,CHEMBL618643,,80089,13435,,,F,,,Intermediate,,185.0,
6752,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,N,1,CHO-AA8,CHEMBL884013,,80089,10503,,,A,,,Intermediate,,185.0,
6753,BAO_0000219,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,N,1,CHO-AA8,CHEMBL622723,,80089,10503,,,F,,,Expert,,185.0,
6754,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,N,1,CHO-AA8,CHEMBL622724,,80089,10503,,,F,,,Intermediate,,185.0,
6755,BAO_0000219,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,N,1,CHO-AA8,CHEMBL622725,,80089,15090,,,F,,,Expert,,185.0,
6756,BAO_0000219,Cytotoxicity against AA8 cell line,,N,1,CHO-AA8,CHEMBL622726,,80089,10368,,,F,,,Expert,,185.0,
6757,BAO_0000219,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,N,1,CHO-AA8,CHEMBL622727,,80089,12651,,,F,,,Intermediate,,185.0,
6758,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,N,1,CHO-AA8,CHEMBL622728,,80089,12687,,,A,,,Intermediate,,185.0,
6759,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,N,1,CHO-AA8,CHEMBL622729,,80089,12687,,,F,,,Intermediate,,185.0,
6760,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,N,1,CHO-AA8,CHEMBL622730,,80089,12687,,,A,,,Intermediate,,185.0,
6761,BAO_0000219,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,N,1,CHO-AA8,CHEMBL622731,,80089,1890,,,F,,,Intermediate,,185.0,
6762,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,N,1,CHO-AA8,CHEMBL622732,,80089,10747,,,F,,,Intermediate,,185.0,
6763,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,N,1,CHO-AA8,CHEMBL622733,,80089,10747,,,F,,,Intermediate,,185.0,
6764,BAO_0000218,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,U,1,,CHEMBL622734,,22224,11616,,,F,,,Autocuration,,,
6765,BAO_0000219,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,N,1,CHO-AA8,CHEMBL622735,,80089,11616,,,F,,,Expert,,185.0,
6766,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,U,1,CHO-AA8,CHEMBL618746,,22224,3471,,,F,,,Autocuration,,185.0,
6767,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,U,1,CHO-AA8,CHEMBL618747,,22224,3471,,,F,,,Autocuration,,185.0,
6768,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,U,1,CHO-AA8,CHEMBL620540,,22224,3471,,,F,,,Autocuration,,185.0,
6769,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,U,1,CHO-AA8,CHEMBL620541,,22224,3471,,,F,,,Autocuration,,185.0,
6770,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,U,1,CHO-AA8,CHEMBL620542,,22224,3471,,,F,,,Autocuration,,185.0,
6771,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,U,1,CHO-AA8,CHEMBL620543,,22224,3471,,,F,,,Autocuration,,185.0,
6772,BAO_0000219,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,U,1,CHO-AA8,CHEMBL618832,,22224,3471,,,F,,,Autocuration,,185.0,
6773,BAO_0000219,Concentration required to reduce AA8 cell survival by 10%,,N,1,CHO-AA8,CHEMBL618833,,80089,11616,,,F,,,Expert,,185.0,
6774,BAO_0000219,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,U,1,CHO-AA8,CHEMBL618834,,22224,2656,,,F,,,Autocuration,,185.0,
6775,BAO_0000219,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,U,1,CHO-AA8,CHEMBL618835,,22224,10518,,,F,,,Autocuration,,185.0,
6776,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,U,1,CHO-AA8,CHEMBL618836,,22224,10518,,,F,,,Autocuration,,185.0,
6777,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,U,1,CHO-AA8,CHEMBL618837,,22224,10518,,,F,,,Autocuration,,185.0,
6778,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,U,1,CHO-AA8,CHEMBL618838,,22224,10518,,,F,,,Autocuration,,185.0,
6779,BAO_0000219,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,U,1,CHO-AA8,CHEMBL618839,,22224,16156,,,F,,,Autocuration,,185.0,
6780,BAO_0000219,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,U,1,CHO-AA8,CHEMBL618840,,22224,2656,,,F,,,Autocuration,,185.0,
6781,BAO_0000019,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,U,1,,CHEMBL618841,,22224,11005,,,F,,,Autocuration,,,
6782,BAO_0000219,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,U,1,CHO-AA8,CHEMBL618842,,22224,11942,,,F,,,Autocuration,,185.0,
6783,BAO_0000219,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,U,1,CHO-AA8,CHEMBL618843,,22224,2128,,,F,,,Autocuration,,185.0,
6784,BAO_0000218,Half life period after 15 mg/kg iv dose in Dogs,,N,1,,CHEMBL618844,In vivo,50588,16907,,,A,,,Intermediate,,,
6785,BAO_0000218,Half life period after 30 mg/kg po dose in Dogs,,N,1,,CHEMBL618845,In vivo,50588,16907,,,A,,,Intermediate,,,
6786,BAO_0000218,Half life was measured after oral 2b administration (tested in 6 dogs),,N,1,,CHEMBL618846,In vivo,50588,9579,,,A,,,Intermediate,,,
6787,BAO_0000218,Half life was measured in dog after oral 17b administration,,N,1,,CHEMBL618847,In vivo,50588,9579,,,A,,,Intermediate,,,
6788,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,N,1,,CHEMBL618848,In vivo,50588,9579,,,A,,,Intermediate,,,
6789,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,N,1,,CHEMBL618849,In vivo,50588,9579,,,A,,,Intermediate,,,
6790,BAO_0000218,Tmax value after 15 mg/kg iv dose in Dogs,,N,1,,CHEMBL618850,In vivo,50588,16907,,,A,,,Intermediate,,,
6791,BAO_0000218,Tmax value after 30 mg/kg po dose in Dogs,,N,1,,CHEMBL618851,In vivo,50588,16907,,,A,,,Intermediate,,,
6792,BAO_0000218,Compound was evaluated for its half life when administered intravenously in dog,,N,1,,CHEMBL873815,In vivo,50588,3184,,,A,,,Intermediate,,,
6793,BAO_0000218,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1969.0,N,1,,CHEMBL618852,In vivo,50588,5017,,Plasma,A,,,Intermediate,,,
6794,BAO_0000218,Elimination Half-life of compound was determined in dog,,N,1,,CHEMBL618853,,50588,6821,,,A,,,Intermediate,,,
6795,BAO_0000218,Half life of compound in dog following oral administration,,N,1,,CHEMBL618854,In vivo,50588,17839,,,A,,,Intermediate,,,
6796,BAO_0000218,Half life of compound was determined in dog,,N,1,,CHEMBL618855,,50588,17267,,,A,,,Intermediate,,,
6797,BAO_0000218,Half life of compound was determined in dog blood,178.0,N,1,,CHEMBL618856,,50588,4727,,Blood,A,,,Intermediate,,,
6798,BAO_0000218,Half life after oral and iv dosing in dogs,,N,1,,CHEMBL875827,In vivo,50588,5238,,,A,,,Intermediate,,,
6799,BAO_0000218,Half life in dogs in hours,,N,1,,CHEMBL618857,,50588,4942,,,A,,,Intermediate,,,
6800,BAO_0000218,Half life on i.v. administration of 2 mg/kg was measured in dog,,N,1,,CHEMBL618858,In vivo,50588,6505,,,A,,,Intermediate,,,
6801,BAO_0000218,t1/2 in dog after oral dose (1 mg/kg),,N,1,,CHEMBL618859,In vivo,50588,5130,,,A,,,Intermediate,,,
6802,BAO_0000218,Half life was evaluated in dog,,N,1,,CHEMBL618860,,50588,1475,,,A,,,Intermediate,,,
6803,BAO_0000218,Half life period of compound was determined after intravenous administration at 2 mg/kg,,N,1,,CHEMBL618861,In vivo,50588,17804,,,A,,,Intermediate,,,
6804,BAO_0000218,Half life period of compound was determined after peroral administration at 2 mg/kg,,N,1,,CHEMBL622539,In vivo,50588,17804,,,A,,,Intermediate,,,
6805,BAO_0000218,Half life period (10 mg/kg) was determined in dog,,N,1,,CHEMBL622540,In vivo,50588,6084,,,A,,,Intermediate,,,
6806,BAO_0000218,Half life period (10 mg/kg) was determined in dog,,N,1,,CHEMBL873803,In vivo,50588,6084,,,A,,,Intermediate,,,
6807,BAO_0000218,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,N,1,,CHEMBL873804,In vivo,50588,5542,,,A,,,Intermediate,,,
6808,BAO_0000218,Half life period by po administration in dog at a dose of 0.3 mg/kg,,N,1,,CHEMBL624311,In vivo,50588,5542,,,A,,,Intermediate,,,
6809,BAO_0000218,Half life period in dog,,N,1,,CHEMBL624312,,50588,6084,,,A,,,Intermediate,,,
6810,BAO_0000218,Half life period in dogs after oral administration at 1 mg/kg,,N,1,,CHEMBL624313,In vivo,50588,6241,,,A,,,Intermediate,,,
6811,BAO_0000218,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,1,,CHEMBL624314,In vivo,50588,1916,,,A,,,Intermediate,,,
6812,BAO_0000218,Half-life of compound was determined in dogs,,N,1,,CHEMBL624315,,50588,6621,,,A,,,Intermediate,,,
6813,BAO_0000218,Half-life in dog plasma,1969.0,N,1,,CHEMBL624316,,50588,1696,,Plasma,A,,,Intermediate,,,
6814,BAO_0000218,Half-life in mongrel dogs was determined,,N,1,,CHEMBL624317,,50588,17800,,,A,,,Intermediate,,,
6815,BAO_0000218,Half-life in dog upon oral administration,,N,1,,CHEMBL624318,In vivo,50588,17657,,,A,,,Intermediate,,,
6816,BAO_0000218,Half-life in dog upon oral administration; Unable to calculate,,N,1,,CHEMBL624319,In vivo,50588,17657,,,A,,,Intermediate,,,
6817,BAO_0000218,Half-life was measured in dog,,N,1,,CHEMBL624496,,50588,4239,,,A,,,Intermediate,,,
6818,BAO_0000218,Half-life was measured in dog,,N,1,,CHEMBL624497,,50588,5985,,,A,,,Intermediate,,,
6819,BAO_0000218,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,N,1,,CHEMBL624498,,50588,9932,,,A,,,Intermediate,,,
6820,BAO_0000218,Oral half life was determined,,N,1,,CHEMBL624499,In vivo,50588,5199,,,A,,,Intermediate,,,
6821,BAO_0000218,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1969.0,N,1,,CHEMBL624500,In vivo,50588,5199,,Plasma,A,,,Intermediate,,,
6822,BAO_0000218,Plasma half life was evaluated,1969.0,N,1,,CHEMBL624501,,50588,1475,,Plasma,A,,,Intermediate,,,
6823,BAO_0000218,Plasma half life was evaluated in Dog,1969.0,N,1,,CHEMBL623666,,50588,1475,,Plasma,A,,,Intermediate,,,
6824,BAO_0000218,Plasma half life was evaluated in dog,1969.0,N,1,,CHEMBL623667,,50588,1475,,Plasma,A,,,Intermediate,,,
6825,BAO_0000218,T1/2 (Half-life) was after oral administration at 5 mg/kg,,N,1,,CHEMBL623668,In vivo,50588,6316,,,A,,,Intermediate,,,
6826,BAO_0000218,Tested for the half life value in dog,,N,1,,CHEMBL623669,,50588,4883,,,A,,,Intermediate,,,
6827,BAO_0000218,Maximum time at the dose of 2 mg/kg in dog,,N,1,,CHEMBL623670,In vivo,50588,4727,,,A,,,Intermediate,,,
6828,BAO_0000218,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,1,,CHEMBL623671,In vivo,50588,1916,,,A,,,Intermediate,,,
6829,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,178.0,N,1,,CHEMBL875945,In vivo,50588,1337,,Blood,A,,,Intermediate,,,
6830,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,178.0,N,1,,CHEMBL623672,In vivo,50588,1337,,Blood,A,,,Intermediate,,,
6831,BAO_0000218,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,N,1,,CHEMBL623673,In vivo,50588,6265,,,A,,,Intermediate,,,
6832,BAO_0000218,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,N,1,,CHEMBL623674,In vivo,50588,4809,,,A,,,Intermediate,,,
6833,BAO_0000218,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,N,1,,CHEMBL623675,In vivo,50588,5983,,,A,,,Intermediate,,,
6834,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,N,1,,CHEMBL872526,,50588,5313,,,A,,,Intermediate,,,
6835,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,N,1,,CHEMBL623676,In vivo,50588,5313,,,A,,,Intermediate,,,
6836,BAO_0000218,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1969.0,N,1,,CHEMBL623677,In vivo,50588,17650,,Plasma,A,,,Intermediate,,,
6837,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1969.0,N,1,,CHEMBL623678,In vivo,50588,5199,,Plasma,A,,,Intermediate,,,
6838,BAO_0000218,Time taken for maximum plasma concentration in dog,1969.0,N,1,,CHEMBL623679,,50588,933,,Plasma,A,,,Intermediate,,,
6839,BAO_0000218,Time to reach Cmax after oral administration to dogs,,N,1,,CHEMBL623680,In vivo,50588,16367,,,A,,,Intermediate,,,
6840,BAO_0000218,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1969.0,N,1,,CHEMBL623681,In vivo,50588,6348,,Plasma,A,,,Intermediate,,,
6841,BAO_0000218,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,N,1,,CHEMBL623682,In vivo,50588,6316,,,A,,,Intermediate,,,
6842,BAO_0000218,Tmax after peroral administration (1 mg/kg) was determined in dog,,N,1,,CHEMBL623683,In vivo,50588,6215,,,A,,,Intermediate,,,
6843,BAO_0000218,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL623684,In vivo,50588,3598,,,A,,,Expert,,,
6844,BAO_0000218,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,N,1,,CHEMBL622745,In vivo,50588,4527,,,A,,,Intermediate,,,
6845,BAO_0000218,Tmax after peroral administration in dogs at 2.4 uM/kg,,N,1,,CHEMBL622746,In vivo,50588,17764,,,A,,,Intermediate,,,
6846,BAO_0000218,In vivo Cmax in mice at dose of 100 mg/kg,,N,1,,CHEMBL622747,In vivo,50594,5969,,,A,,,Intermediate,,,
6847,BAO_0000218,In vivo Cmax in mice at dose of 50 mg/kg,,N,1,,CHEMBL622748,In vivo,50594,5969,,,A,,,Intermediate,,,
6848,BAO_0000218,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,N,1,,CHEMBL622749,In vivo,50594,4573,,,A,,,Intermediate,,,
6849,BAO_0000218,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1969.0,N,1,,CHEMBL622750,In vivo,50594,3277,,Plasma,A,,,Intermediate,,,
6850,BAO_0000218,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1969.0,N,1,,CHEMBL623411,In vivo,50594,17734,,Plasma,A,,,Intermediate,,,
6851,BAO_0000218,Maximum concentration obtained in mouse plasma was determined,1969.0,N,1,,CHEMBL875946,In vivo,50594,3132,,Plasma,A,,,Intermediate,,,
6852,BAO_0000218,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1969.0,N,1,,CHEMBL623412,In vivo,50594,3132,,Plasma,A,,,Intermediate,,,
6853,BAO_0000218,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1969.0,N,1,,CHEMBL623413,In vivo,50594,6348,,Plasma,A,,,Intermediate,,,
6854,BAO_0000218,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1969.0,N,1,,CHEMBL623414,In vivo,50594,17729,,Plasma,A,,,Intermediate,,,
6855,BAO_0000218,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1969.0,N,1,,CHEMBL623415,In vivo,50594,17729,,Plasma,A,,,Intermediate,,,
6856,BAO_0000218,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1969.0,N,1,,CHEMBL623416,In vivo,50594,17729,,Plasma,A,,,Intermediate,,,
6857,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1969.0,N,1,,CHEMBL623417,In vivo,50594,17728,,Plasma,A,,,Intermediate,,,
6858,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1969.0,N,1,,CHEMBL623418,In vivo,50594,17728,,Plasma,A,,,Intermediate,,,
6859,BAO_0000218,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1969.0,N,1,,CHEMBL623419,In vivo,50594,17728,,Plasma,A,,,Intermediate,,,
6860,BAO_0000218,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,N,1,,CHEMBL622816,In vivo,50594,4066,,,A,,,Intermediate,,,
6861,BAO_0000218,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,N,1,,CHEMBL623313,In vivo,50594,6178,,,A,,,Intermediate,,,
6862,BAO_0000218,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,N,1,,CHEMBL623314,In vivo,50594,6178,,,A,,,Intermediate,,,
6863,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,N,1,,CHEMBL876788,In vivo,50594,3760,,,A,,,Intermediate,,,
6864,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,N,1,,CHEMBL623315,In vivo,50594,3760,,,A,,,Intermediate,,,
6865,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,N,1,,CHEMBL623316,In vivo,50594,3760,,,A,,,Intermediate,,,
6866,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,N,1,,CHEMBL623317,In vivo,50594,3760,,,A,,,Intermediate,,,
6868,BAO_0000218,Cmax in male mice after 2 mg/kg oral dose,,N,1,,CHEMBL623319,In vivo,50594,5961,,,A,,,Intermediate,,,
6869,BAO_0000218,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,N,1,,CHEMBL623320,In vivo,50594,6137,,,A,,,Intermediate,,,
6870,BAO_0000218,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,N,1,,CHEMBL623321,In vivo,50594,3802,,,A,,,Intermediate,,,
6871,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,N,1,,CHEMBL623322,,50594,3535,,,A,,,Intermediate,,,
6872,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,N,1,,CHEMBL623323,,50594,3535,,,A,,,Intermediate,,,
6873,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,N,1,,CHEMBL623324,,50594,3535,,,A,,,Intermediate,,,
6874,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,N,1,,CHEMBL623325,,50594,3535,,,A,,,Intermediate,,,
6875,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,N,1,,CHEMBL623326,,50594,3535,,,A,,,Intermediate,,,
6876,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,N,1,,CHEMBL623327,,50594,3535,,,A,,,Intermediate,,,
6877,BAO_0000218,Maximum concentration in plasma upon oral administration in mouse,1969.0,N,1,,CHEMBL623328,,50594,2862,,Plasma,A,,,Intermediate,,,
6878,BAO_0000218,Maximum plasma concentration was evaluated in mice after oral administration,1969.0,N,1,,CHEMBL623329,,50594,2675,,Plasma,A,,,Intermediate,,,
6879,BAO_0000218,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1969.0,N,1,,CHEMBL623330,In vivo,50594,2675,,Plasma,A,,,Intermediate,,,
6880,BAO_0000218,Dose at which the compound induced fecal excretion in mice,,N,1,,CHEMBL876789,,50594,5399,,,A,,,Intermediate,,,
6893,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,N,1,A10,CHEMBL623333,,80013,11819,,,F,,,Expert,,164.0,
6894,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,N,1,A10,CHEMBL623334,,80013,11819,,,F,,,Expert,,164.0,
6895,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,N,1,A10,CHEMBL627536,,80013,11819,,,F,,,Expert,,164.0,
6896,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,N,1,A10,CHEMBL627537,,80013,11819,,,F,,,Expert,,164.0,
6897,BAO_0000219,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,N,1,A10,CHEMBL627538,,80013,16361,,,F,,,Intermediate,,164.0,
6898,BAO_0000219,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,N,1,A121,CHEMBL884106,,80655,2288,,,F,,,Intermediate,,393.0,
6899,BAO_0000219,Anticancer activity against human ovarian carcinoma A121 cells,,N,1,A121,CHEMBL625294,,80655,10404,,,F,,,Intermediate,,393.0,
6900,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,N,1,A121,CHEMBL625295,,80655,14790,,,F,,,Intermediate,,393.0,
6901,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,N,1,A121,CHEMBL625296,,80655,14790,,,F,,,Intermediate,,393.0,
6902,BAO_0000219,Growth inhibition of human ovarian carcinoma (A121) cell line,,N,1,A121,CHEMBL625297,,80655,14253,,,F,,,Expert,,393.0,
6903,BAO_0000219,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,N,1,A121,CHEMBL625298,,80655,13617,,,F,,,Expert,,393.0,
6904,BAO_0000219,Cytotoxicity against human A121 ovarian cells,,N,1,A121,CHEMBL625960,,80655,1003,,,F,,,Intermediate,,393.0,
6905,BAO_0000219,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,N,1,A121,CHEMBL625961,,80655,830,,,F,,,Intermediate,,393.0,
6906,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma A21,,N,1,A121,CHEMBL625962,,80655,12307,,,F,,,Intermediate,,393.0,
6907,BAO_0000219,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,N,1,A121,CHEMBL624717,,80655,14254,,,F,,,Intermediate,,393.0,
6908,BAO_0000219,Inhibitory activity of compound against human A121 ovarian cell line.,,N,1,A121,CHEMBL624718,,80655,13370,,,F,,,Intermediate,,393.0,
6909,BAO_0000219,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,N,1,A121,CHEMBL624719,,80655,14790,,,F,,,Intermediate,,393.0,
6910,BAO_0000219,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,N,1,A121,CHEMBL624720,,80655,3614,,,F,,,Intermediate,,393.0,
6911,BAO_0000219,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,N,1,A 172,CHEMBL624721,,80012,2664,,,F,,,Intermediate,,622.0,
6912,BAO_0000219,In vitro cytotoxicity against A172 human tumor cell lines.,,N,1,A 172,CHEMBL624722,,80012,2037,,,F,,,Expert,,622.0,
6913,BAO_0000219,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,N,1,A 172,CHEMBL877597,,80012,14539,,,F,,,Intermediate,,622.0,
6914,BAO_0000219,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,N,1,A 172,CHEMBL624723,,80012,2836,,,F,,,Intermediate,,622.0,
6915,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,N,1,A 172,CHEMBL624724,,80012,10708,,,F,,,Intermediate,,622.0,
6916,BAO_0000224,Association constant against A2 adenosine receptor,,H,1,,CHEMBL624725,,104729,8975,,,B,,,Autocuration,,,
6917,BAO_0000219,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,N,1,A2,CHEMBL624726,,80656,7645,,,F,,,Intermediate,,1085.0,
6918,BAO_0000224,Ratio of Ki for adenosine A2 and A1 receptor binding,,D,1,,CHEMBL857535,,104713,11377,,,B,,,Autocuration,,,
6919,BAO_0000219,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,N,1,A204,CHEMBL624727,,80014,13528,,,F,,,Expert,,623.0,
6920,BAO_0000219,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,N,1,A204,CHEMBL624728,,80014,10160,,,F,,,Expert,,623.0,
6921,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,N,1,A2058,CHEMBL624729,,80015,15144,,,F,,,Intermediate,,404.0,
6922,BAO_0000219,Growth inhibition against Human squamous cell line(A 253),,N,1,A253 cell line,CHEMBL624730,,80657,13160,,,F,,,Intermediate,,973.0,
6923,BAO_0000219,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,N,1,A253 cell line,CHEMBL624731,,80657,12898,,,F,,,Intermediate,,973.0,
6924,BAO_0000219,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,N,1,A253 cell line,CHEMBL624732,,80657,13069,,,F,,,Intermediate,,973.0,
6925,BAO_0000219,Growth inhibition of A253 cell lines.,,N,1,A253 cell line,CHEMBL883245,,80657,15984,,,F,,,Intermediate,,973.0,
6926,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,N,1,A253 cell line,CHEMBL624733,,80657,15564,,,F,,,Intermediate,,973.0,
6927,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,N,1,A253 cell line,CHEMBL624734,,80657,15564,,,F,,,Intermediate,,973.0,
6928,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,N,1,A253 cell line,CHEMBL624735,,80657,15564,,,F,,,Intermediate,,973.0,
6929,BAO_0000219,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,N,1,A2780,CHEMBL621780,,81034,4720,,,F,,,Intermediate,,478.0,
6930,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,N,1,A2780,CHEMBL877598,,81034,16112,,,F,,,Intermediate,,478.0,
6931,BAO_0000219,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,N,1,A2780,CHEMBL621781,,81034,16597,,,F,,,Expert,,478.0,
6932,BAO_0000219,Cytotoxicity against human cancer cell lines A2780 (ovarian),,N,1,A2780,CHEMBL621782,,81034,16378,,,F,,,Intermediate,,478.0,
6933,BAO_0000219,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,N,1,A2780,CHEMBL621783,,81034,16085,,,F,,,Expert,,478.0,
6934,BAO_0000219,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,N,1,A2780,CHEMBL621784,,81034,16317,,,F,,,Intermediate,,478.0,
6935,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,N,1,A2780,CHEMBL621785,,81034,15748,,,F,,,Intermediate,,478.0,
6936,BAO_0000219,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,N,1,A2780,CHEMBL621968,,81034,16597,,,F,,,Expert,,478.0,
6937,BAO_0000219,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,N,1,A2780,CHEMBL621969,,81034,16597,,,F,,,Expert,,478.0,
6938,BAO_0000219,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,N,1,A2780,CHEMBL621970,,81034,16597,,,F,,,Expert,,478.0,
6939,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,N,1,A2780,CHEMBL621971,,81034,15608,,,F,,,Intermediate,,478.0,
6940,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,N,1,A2780,CHEMBL621972,,81034,15608,,,F,,,Intermediate,,478.0,
6941,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,N,1,A2780,CHEMBL884108,,81034,15608,,,F,,,Intermediate,,478.0,
6942,BAO_0000019,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,U,1,,CHEMBL623826,,22224,15296,,,F,,,Autocuration,,,
6943,BAO_0000219,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,U,1,CHO-AA8,CHEMBL623827,,22224,10251,,,A,,,Autocuration,,185.0,
6944,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,U,1,CHO-AA8,CHEMBL623828,,22224,10251,,,F,,,Autocuration,,185.0,
6945,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,U,1,CHO-AA8,CHEMBL623829,,22224,10251,,,F,,,Autocuration,,185.0,
6946,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,U,1,CHO-AA8,CHEMBL623830,,22224,10251,,,F,,,Autocuration,,185.0,
6947,BAO_0000019,Growth inhibition against CHO-derived cell line AA8,,U,1,,CHEMBL623831,,22224,11858,,,F,,,Autocuration,,,
6948,BAO_0000219,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,U,1,CHO-AA8,CHEMBL623832,,22224,11858,,,F,,,Autocuration,,185.0,
6949,BAO_0000219,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,N,1,CHO-AA8,CHEMBL623833,,80089,11616,,,F,,,Expert,,185.0,
6950,BAO_0000219,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,N,1,CHO-AA8,CHEMBL623834,,80089,11616,,,F,,,Expert,,185.0,
6951,BAO_0000219,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,U,1,CHO-AA8,CHEMBL623835,,22224,10518,,,F,,,Autocuration,,185.0,
6952,BAO_0000219,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,U,1,CHO-AA8,CHEMBL623836,,22224,11396,,,F,,,Autocuration,,185.0,
6953,BAO_0000219,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,U,1,CHO-AA8,CHEMBL623837,,22224,10518,,,F,,,Autocuration,,185.0,
6954,BAO_0000219,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,N,1,CHO-AA8,CHEMBL623838,,80089,11616,,,F,,,Expert,,185.0,
6955,BAO_0000019,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,H,1,,CHEMBL623839,,12675,14837,,,F,,,Autocuration,,,
6956,BAO_0000019,Number of binding sites (n) of isolated serum protein AAG,,H,1,,CHEMBL623840,,12675,14837,,,F,,,Autocuration,,,
6957,BAO_0000225,Association constant for binding to AATT duplex,,M,1,,CHEMBL623841,,22222,16037,,,B,,,Intermediate,,,
6958,BAO_0000219,Inhibition of ABAE human fibroblast cell proliferation,,N,1,ABAE,CHEMBL623842,,100090,16597,,,F,,,Expert,,416.0,
6959,BAO_0000218,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,N,1,AC755,CHEMBL623843,,80668,8831,,,F,,,Intermediate,,1064.0,
6960,BAO_0000218,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,D,1,,CHEMBL618669,,102444,13419,,,F,,,Expert,,,
6961,BAO_0000218,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,D,1,,CHEMBL618670,In vivo,102444,13419,,,F,,,Expert,,,
6962,BAO_0000357,Inhibitory activity against angiotensin-converting enzyme (ACE).,,H,1,,CHEMBL618671,,69,15778,,,B,,,Autocuration,,,
6963,BAO_0000357,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,H,1,,CHEMBL618672,,69,15778,,,B,,,Autocuration,,,
6964,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,N,1,ACH-2 cell line,CHEMBL618673,,80669,12988,,,F,,,Intermediate,,978.0,
6965,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,N,1,ACH-2 cell line,CHEMBL618674,,80669,12988,,,F,,,Intermediate,,978.0,
6966,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,U,1,T cell line,CHEMBL618675,,22224,12988,,,F,,,Autocuration,,998.0,
6967,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,U,1,T cell line,CHEMBL618676,,22224,12988,,,F,,,Autocuration,,998.0,
6968,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,U,1,T cell line,CHEMBL618677,,22224,12988,,,F,,,Autocuration,,998.0,
6969,BAO_0000219,Inhibition of growth of renal cancer ACHN cell line,,N,1,ACHN,CHEMBL618678,,80025,11843,,,F,,,Intermediate,,626.0,
6970,BAO_0000219,Inhibition of growth of ACHN renal cancer cell line,,N,1,ACHN,CHEMBL618679,,80025,16939,,,F,,,Intermediate,,626.0,
6971,BAO_0000219,Inhibitory concentration required against ACHN renal cancer cell line,,N,1,ACHN,CHEMBL618680,,80025,4782,,,F,,,Intermediate,,626.0,
6972,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line,,N,1,ACHN,CHEMBL618681,,80025,6310,,,F,,,Expert,,626.0,
6973,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,N,1,ACHN,CHEMBL618682,,80025,6310,,,F,,,Intermediate,,626.0,
6974,BAO_0000219,Cytotoxic activity against ACHN Renal cancer cell line,,N,1,ACHN,CHEMBL618683,,80025,12858,,,F,,,Intermediate,,626.0,
6975,BAO_0000219,Cytotoxicity evaluation against ACHN renal cancer cells,,N,1,ACHN,CHEMBL618684,,80025,17380,,,F,,,Intermediate,,626.0,
6976,BAO_0000219,In vitro antitumor activity against human renal ACHN cell line,,N,1,ACHN,CHEMBL618685,,80025,5858,,,F,,,Intermediate,,626.0,
6977,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,N,1,ACHN,CHEMBL876499,,80025,3838,,,F,,,Intermediate,,626.0,
6978,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,N,1,ACHN,CHEMBL618686,,80025,3838,,,F,,,Intermediate,,626.0,
6979,BAO_0000219,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,N,1,ACHN,CHEMBL618687,,80025,5406,,,F,,,Intermediate,,626.0,
6980,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,N,1,ACHN,CHEMBL618688,,80025,4071,,,F,,,Intermediate,,626.0,
6981,BAO_0000219,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,N,1,ACHN,CHEMBL618689,,80025,4071,,,F,,,Expert,,626.0,
6982,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,N,1,ACHN,CHEMBL618690,,80025,4071,,,F,,,Intermediate,,626.0,
6983,BAO_0000219,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,N,1,ACHN,CHEMBL618691,,80025,15002,,,F,,,Intermediate,,626.0,
6984,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,N,1,ACHN,CHEMBL619373,,80025,14769,,,F,,,Intermediate,,626.0,
6985,BAO_0000219,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,N,1,ACHN,CHEMBL884008,,80025,13958,,,F,,,Intermediate,,626.0,
6986,BAO_0000219,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,N,1,ACHN,CHEMBL619374,,80025,1665,,,F,,,Intermediate,,626.0,
6987,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,N,1,ACHN,CHEMBL619375,,80025,15354,,,F,,,Intermediate,,626.0,
6988,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,N,1,ACHN,CHEMBL619376,,80025,15354,,,F,,,Intermediate,,626.0,
6989,BAO_0000219,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,N,1,ACHN,CHEMBL619377,,80025,13978,,,F,,,Intermediate,,626.0,
6990,BAO_0000219,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,N,1,ACHN,CHEMBL619378,,80025,6798,,,F,,,Intermediate,,626.0,
6991,BAO_0000218,Tmax value after administration of 4 mg/Kg oral dose in dog,,N,1,,CHEMBL872527,In vivo,50588,2959,,,A,,,Intermediate,,,
6992,BAO_0000218,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,N,1,,CHEMBL876500,,50588,9932,,,A,,,Intermediate,,,
6993,BAO_0000218,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,N,1,,CHEMBL619379,,50588,5546,,,A,,,Intermediate,,,
6994,BAO_0000218,Volume distribution after 15 mg/kg iv dose in Dogs,,N,1,,CHEMBL619538,In vivo,50588,16907,,,A,,,Intermediate,,,
6995,BAO_0000218,Volume distribution after 30 mg/kg po dose in Dogs,,N,1,,CHEMBL619539,In vivo,50588,16907,,,A,,,Intermediate,,,
6996,BAO_0000218,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,N,1,,CHEMBL619540,In vivo,50588,4257,,,A,,,Intermediate,,,
6997,BAO_0000218,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,N,1,,CHEMBL619541,In vivo,50588,4305,,,A,,,Intermediate,,,
6998,BAO_0000218,Volume of distribution was evaluated in dog,,N,1,,CHEMBL619542,In vivo,50588,5472,,,A,,,Intermediate,,,
6999,BAO_0000218,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,N,1,,CHEMBL619543,In vivo,50588,6062,,,A,,,Intermediate,,,
7000,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL619544,,50588,3598,,,A,,,Expert,,,
7001,BAO_0000218,The compound was tested for volume of distribution in dog,,N,1,,CHEMBL619545,In vivo,50588,12500,,,A,,,Intermediate,,,
7002,BAO_0000218,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,N,1,,CHEMBL619546,In vivo,50588,12500,,,A,,,Intermediate,,,
7003,BAO_0000218,Vd (1 mg/kg) was determined in dog (in vivo),,N,1,,CHEMBL619547,In vivo,50588,6227,,,A,,,Intermediate,,,
7004,BAO_0000218,Vd in dog,,N,1,,CHEMBL619548,In vivo,50588,6227,,,A,,,Intermediate,,,
7005,BAO_0000218,Volume distribution was determined,,N,1,,CHEMBL619549,In vivo,50588,4219,,,A,,,Intermediate,,,
7006,BAO_0000218,Volume of distribution in dog,,N,1,,CHEMBL619550,In vivo,50588,1696,,,A,,,Intermediate,,,
7007,BAO_0000218,Volume of distribution by as 4 fold increase by iv administration in dogs,,N,1,,CHEMBL876501,In vivo,50588,5542,,,A,,,Intermediate,,,
7008,BAO_0000218,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,N,1,,CHEMBL619551,In vivo,50588,5199,,,A,,,Intermediate,,,
7009,BAO_0000218,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,1,,CHEMBL619552,In vivo,50588,6348,,,A,,,Intermediate,,,
7010,BAO_0000218,Volume distribution at the dose of 2 mg/kg in dog,,N,1,,CHEMBL619553,In vivo,50588,4727,,,A,,,Intermediate,,,
7011,BAO_0000218,Steady state volume of distribution was determined,,N,1,,CHEMBL618722,In vivo,50588,16367,,,A,,,Intermediate,,,
7012,BAO_0000218,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,N,1,,CHEMBL618723,In vivo,50588,2652,,,A,,,Intermediate,,,
7013,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,1,,CHEMBL618724,In vivo,50588,16452,,,A,,,Intermediate,,,
7014,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,N,1,,CHEMBL618725,In vivo,50588,16452,,,A,,,Intermediate,,,
7015,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,N,1,,CHEMBL618726,In vivo,50588,16452,,,A,,,Intermediate,,,
7016,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,N,1,,CHEMBL618727,In vivo,50588,5334,,,A,,,Intermediate,,,
7017,BAO_0000218,Pharmacokinetic property (vdss) was measured in dog,,N,1,,CHEMBL624233,In vivo,50588,4239,,,A,,,Intermediate,,,
7018,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,N,1,,CHEMBL624234,In vivo,50588,4709,,,A,,,Intermediate,,,
7019,BAO_0000218,Vdss was determined after iv 0.1 mg/kg administration in dog,,N,1,,CHEMBL624235,In vivo,50588,5600,,,A,,,Intermediate,,,
7020,BAO_0000218,Volume displacement was calculated in dog,,N,1,,CHEMBL624236,In vivo,50588,6057,,,A,,,Intermediate,,,
7021,BAO_0000218,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,N,1,,CHEMBL624237,In vivo,50588,5654,,,A,,,Intermediate,,,
7022,BAO_0000218,Volume distribution constant was determined,,N,1,,CHEMBL624238,In vivo,50588,5505,,,A,,,Intermediate,,,
7023,BAO_0000218,Volume distribution at a dose of 1 uM/kg in dog was determined,,N,1,,CHEMBL624239,In vivo,50588,4527,,,A,,,Intermediate,,,
7024,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,N,1,,CHEMBL875829,In vivo,50588,4521,,,A,,,Intermediate,,,
7025,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,1,,CHEMBL624240,In vivo,50588,4521,,,A,,,Intermediate,,,
7026,BAO_0000218,Volume distribution (Vdss) was measured in dog,,N,1,,CHEMBL624241,In vivo,50588,15660,,,A,,,Intermediate,,,
7027,BAO_0000218,Volume distribution (Vdss) was measured in dog,,N,1,,CHEMBL624242,In vivo,50588,15660,,,A,,,Intermediate,,,
7028,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL624243,In vivo,50588,6679,,,A,,,Intermediate,,,
7029,BAO_0000218,Volume of distribution in steady state was determined in dog,,N,1,,CHEMBL624244,In vivo,50588,5145,,,A,,,Intermediate,,,
7030,BAO_0000218,Volume of distribution of compound was determined in dog,,N,1,,CHEMBL624245,In vivo,50588,6821,,,A,,,Intermediate,,,
7031,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,N,1,,CHEMBL624246,In vivo,50588,4137,,,A,,,Intermediate,,,
7032,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,N,1,,CHEMBL624247,In vivo,50588,5334,,,A,,,Intermediate,,,
7033,BAO_0000218,Volume of distribution (Vdss) was measured in dog,,N,1,,CHEMBL624248,In vivo,50588,15660,,,A,,,Intermediate,,,
7034,BAO_0000218,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,1,,CHEMBL624249,In vivo,50588,6642,,,A,,,Intermediate,,,
7035,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,1,,CHEMBL624250,In vivo,50588,6641,,,A,,,Intermediate,,,
7036,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,1,,CHEMBL624251,In vivo,50588,6642,,,A,,,Intermediate,,,
7037,BAO_0000218,Maximum rate of depolarization of the upstroke of the action potential,,N,1,,CHEMBL624252,,50588,11659,,,A,,,Intermediate,,,
7038,BAO_0000218,Steady state volume distribution in dog,,N,1,,CHEMBL624253,In vivo,50588,6448,,,A,,,Intermediate,,,
7039,BAO_0000218,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,N,1,,CHEMBL624950,In vivo,50588,5474,,,A,,,Intermediate,,,
7040,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,N,1,,CHEMBL624951,In vivo,50588,1466,,,A,,,Intermediate,,,
7041,BAO_0000218,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,N,1,,CHEMBL875830,In vivo,50588,6535,,,A,,,Intermediate,,,
7042,BAO_0000218,Volume distribution in dog after administration of 1 mg/kg iv,,N,1,,CHEMBL624952,In vivo,50588,6535,,,A,,,Intermediate,,,
7043,BAO_0000218,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,N,1,,CHEMBL624953,In vivo,50588,17764,,,A,,,Intermediate,,,
7044,BAO_0000218,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,N,1,,CHEMBL624954,In vivo,50588,6215,,,A,,,Intermediate,,,
7045,BAO_0000218,Vss on i.v. administration of 2 mg/kg was measured in dog,,N,1,,CHEMBL624955,In vivo,50588,6505,,,A,,,Intermediate,,,
7046,BAO_0000218,Vss was determined,,N,1,,CHEMBL624956,,50588,3639,,,A,,,Intermediate,,,
7047,BAO_0000218,Vss in dog,,N,1,,CHEMBL625129,,50588,3639,,,A,,,Intermediate,,,
7048,BAO_0000218,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,N,1,,CHEMBL625130,In vivo,50588,6062,,,A,,,Intermediate,,,
7049,BAO_0000218,Volume distribution in dogs,,N,1,,CHEMBL625131,In vivo,50588,4942,,,A,,,Intermediate,,,
7050,BAO_0000218,Volume of distribution in dog,,N,1,,CHEMBL625132,In vivo,50588,17796,,,A,,,Intermediate,,,
7051,BAO_0000218,Tested for the oral bioavailability in dog,,N,1,,CHEMBL872263,In vivo,50588,4883,,,A,,,Intermediate,,,
7060,BAO_0000218,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,N,1,,CHEMBL624336,In vivo,50594,17837,,,A,,,Intermediate,,,
7061,BAO_0000218,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,N,1,,CHEMBL624337,In vivo,50594,17729,,,A,,,Intermediate,,,
7062,BAO_0000218,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,N,1,,CHEMBL624338,In vivo,50594,17729,,,A,,,Intermediate,,,
7063,BAO_0000218,Bioavailability was measured in mouse,,N,1,,CHEMBL624339,In vivo,50594,4239,,,A,,,Intermediate,,,
7064,BAO_0000218,Bioavailability in mouse,,N,1,,CHEMBL624340,In vivo,50594,17592,,,A,,,Intermediate,,,
7065,BAO_0000218,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,1,,CHEMBL624341,In vivo,50594,6348,,,A,,,Intermediate,,,
7066,BAO_0000218,Bioavailability in mouse,,N,1,,CHEMBL624342,In vivo,50594,2801,,,A,,,Intermediate,,,
7067,BAO_0000218,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,N,1,,CHEMBL624343,In vivo,50594,2801,,,A,,,Intermediate,,,
7068,BAO_0000218,Oral bioavailability in mouse,,N,1,,CHEMBL624344,In vivo,50594,17718,,,A,,,Intermediate,,,
7069,BAO_0000218,Oral availability at 50 mg/kg po in male mice,,N,1,,CHEMBL624345,In vivo,50594,5727,,,A,,,Intermediate,,,
7070,BAO_0000218,Oral bioavailability in mouse (dose 10 mg/kg),,N,1,,CHEMBL624346,In vivo,50594,5302,,,A,,,Intermediate,,,
7071,BAO_0000218,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL624347,In vivo,50594,3598,,,A,,,Expert,,,
7072,BAO_0000218,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,N,1,,CHEMBL624348,In vivo,50594,5961,,,A,,,Intermediate,,,
7074,BAO_0000218,Oral bioavailability in mouse,,N,1,,CHEMBL622754,In vivo,50594,6091,,,A,,,Intermediate,,,
7075,BAO_0000218,Oral bioavailability in vivo in mice;ND=Not determined,,N,1,,CHEMBL622755,In vivo,50594,6091,,,A,,,Intermediate,,,
7076,BAO_0000218,Oral bioavailability in mouse at 10 mg/kg of the compound,,N,1,,CHEMBL622756,In vivo,50594,5711,,,A,,,Intermediate,,,
7077,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,N,1,,CHEMBL622757,In vivo,50594,17728,,,A,,,Intermediate,,,
7078,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,N,1,,CHEMBL622758,In vivo,50594,17728,,,A,,,Intermediate,,,
7079,BAO_0000218,Tested for bioavailability of the compound,,N,1,,CHEMBL622759,In vivo,50594,3802,,,A,,,Intermediate,,,
7080,BAO_0000218,Tested for half life at the dose of 10 mg/kg when administered intravenously,,N,1,,CHEMBL622760,In vivo,50594,3802,,,A,,,Intermediate,,,
7081,BAO_0000218,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1969.0,N,1,,CHEMBL622761,,50594,14029,,Plasma,A,,,Intermediate,,,
7082,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma. ,1969.0,N,1,,CHEMBL622762,,50594,14029,,Plasma,A,,,Intermediate,,,
7083,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1969.0,N,1,,CHEMBL622763,,50594,14029,,Plasma,A,,,Intermediate,,,
7084,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1969.0,N,1,,CHEMBL622764,,50594,14029,,Plasma,A,,,Intermediate,,,
7085,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1969.0,N,1,,CHEMBL622765,,50594,14029,,Plasma,A,,,Intermediate,,,
7086,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,N,1,,CHEMBL622766,,50594,17753,,,F,,,Intermediate,,,
7087,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,N,1,,CHEMBL622767,,50594,17753,,,A,,,Intermediate,,,
7088,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,N,1,,CHEMBL622768,,50594,17753,,,A,,,Intermediate,,,
7089,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,178.0,N,1,,CHEMBL875948,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7090,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,178.0,N,1,,CHEMBL622769,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7091,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,178.0,N,1,,CHEMBL622770,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7092,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,178.0,N,1,,CHEMBL622771,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7093,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,178.0,N,1,,CHEMBL622772,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7094,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,178.0,N,1,,CHEMBL622773,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7095,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,178.0,N,1,,CHEMBL622774,In vivo,50594,10107,,Blood,A,,,Intermediate,,,
7096,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10000001.0,N,1,,CHEMBL621725,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7097,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10000001.0,N,1,,CHEMBL621726,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7098,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,N,1,A2780,CHEMBL621727,,81034,15608,,,F,,,Intermediate,,478.0,
7099,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,N,1,A2780,CHEMBL622413,,81034,3290,,,F,,,Expert,,478.0,
7100,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,,N,1,A2780,CHEMBL622414,,81034,2859,,,F,,,Intermediate,,478.0,
7101,BAO_0000219,Inhibition of A2780 cell clonogenic assay,,N,1,A2780,CHEMBL622415,,81034,15688,,,F,,,Expert,,478.0,
7102,BAO_0000219,Cytotoxic effect on ovarian cancer cell line (A2780),,N,1,A2780,CHEMBL884001,,81034,5642,,,F,,,Expert,,478.0,
7103,BAO_0000219,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,N,1,A2780,CHEMBL622416,,81034,6633,,,F,,,Intermediate,,478.0,
7104,BAO_0000219,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,N,1,A2780,CHEMBL622417,,81034,3906,,,F,,,Intermediate,,478.0,
7105,BAO_0000219,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,N,1,A2780,CHEMBL622590,,81034,6788,,,F,,,Expert,,478.0,
7106,BAO_0000219,Antiproliferative activity against human A2780 cells,,N,1,A2780,CHEMBL622591,,81034,17582,,,F,,,Expert,,478.0,
7107,BAO_0000219,Inhibition of human A2780 cell proliferation,,N,1,A2780,CHEMBL622592,,81034,17764,,,F,,,Expert,,478.0,
7108,BAO_0000219,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,N,1,A2780,CHEMBL622593,,81034,17764,,,F,,,Expert,,478.0,
7109,BAO_0000219,Inhibition of human A2780 cell proliferation (No data),,N,1,A2780,CHEMBL622594,,81034,17764,,,F,,,Expert,,478.0,
7110,BAO_0000219,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,N,1,A2780,CHEMBL622595,,81034,2815,,,F,,,Intermediate,,478.0,
7111,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780,,N,1,A2780,CHEMBL622596,,81034,16930,,,F,,,Intermediate,,478.0,
7112,BAO_0000219,Growth inhibition against A2780 wild-type ovarian cell lines,,N,1,A2780,CHEMBL622597,,81034,17777,,,F,,,Expert,,478.0,
7113,BAO_0000219,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,N,1,A2780,CHEMBL622598,,81034,17777,,,F,,,Intermediate,,478.0,
7114,BAO_0000019,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,D,1,,CHEMBL622599,,104766,16936,,,F,,,Autocuration,,,
7115,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,N,1,A2780,CHEMBL622600,,81034,13759,,,F,,,Intermediate,,478.0,
7116,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,N,1,A2780,CHEMBL622601,,81034,13759,,,F,,,Intermediate,,478.0,
7117,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,N,1,A2780,CHEMBL622602,,81034,13759,,,F,,,Intermediate,,478.0,
7118,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,N,1,A2780,CHEMBL622603,,81034,13759,,,F,,,Intermediate,,478.0,
7119,BAO_0000219,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,N,1,A2780,CHEMBL622604,,81034,15292,,,F,,,Intermediate,,478.0,
7120,BAO_0000219,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,N,1,A2780,CHEMBL622605,,81034,15292,,,F,,,Intermediate,,478.0,
7121,BAO_0000219,In vitro inhibition of human ovarian cell line A2780,,N,1,A2780,CHEMBL622606,,81034,15069,,,F,,,Expert,,478.0,
7122,BAO_0000219,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,N,1,A2780,CHEMBL619463,,81034,15069,,,F,,,Expert,,478.0,
7123,BAO_0000219,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,N,1,A2780,CHEMBL619464,,81034,14073,,,F,,,Intermediate,,478.0,
7124,BAO_0000219,Concentration required to inhibit A2780-cell growth by 50%,,N,1,A2780,CHEMBL619465,,81034,14553,,,F,,,Expert,,478.0,
7125,BAO_0000219,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,N,1,A2780,CHEMBL619466,,81034,13040,,,F,,,Expert,,478.0,
7126,BAO_0000219,Cytotoxic effect on human ovarian (A2780) cancer cell line,,N,1,A2780,CHEMBL619467,,81034,6891,,,F,,,Expert,,478.0,
7127,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,N,1,A2780,CHEMBL619468,,81034,15569,,,F,,,Intermediate,,478.0,
7128,BAO_0000219,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,N,1,A2780,CHEMBL619469,,81034,14190,,,F,,,Expert,,478.0,
7129,BAO_0000219,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,N,1,A2780,CHEMBL619470,,81034,15014,,,F,,,Expert,,478.0,
7130,BAO_0000219,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,N,1,A2780,CHEMBL619471,,81034,15014,,,F,,,Intermediate,,478.0,
7131,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780 cell line,,N,1,A2780,CHEMBL619472,,81034,17496,,,F,,,Intermediate,,478.0,
7132,BAO_0000219,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,N,1,A2780,CHEMBL619473,,81034,13617,,,F,,,Intermediate,,478.0,
7133,BAO_0000219,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,N,1,A2780,CHEMBL874368,,81034,13617,,,F,,,Intermediate,,478.0,
7134,BAO_0000219,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,N,1,A2780,CHEMBL884003,,81034,13617,,,F,,,Intermediate,,478.0,
7135,BAO_0000219,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,N,1,A2780,CHEMBL622690,,81034,13617,,,F,,,Intermediate,,478.0,
7136,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,N,1,A2780,CHEMBL622691,,81034,17672,,,F,,,Intermediate,,478.0,
7137,BAO_0000219,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,N,1,A2780,CHEMBL622692,,81034,4544,,,F,,,Intermediate,,478.0,
7138,BAO_0000219,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,N,1,A2780,CHEMBL623406,,81034,4544,,,F,,,Intermediate,,478.0,
7139,BAO_0000219,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,N,1,A2780,CHEMBL884004,,81034,16317,,,F,,,Intermediate,,478.0,
7140,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,N,1,A2780,CHEMBL623407,,81034,15099,,,F,,,Intermediate,,478.0,
7141,BAO_0000219,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,N,1,A2780,CHEMBL623408,,81034,13978,,,F,,,Intermediate,,478.0,
7142,BAO_0000219,In vitro antitumor activity against A2780 cell line.,,N,1,A2780,CHEMBL623409,,81034,12989,,,F,,,Expert,,478.0,
7143,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,N,1,A2780,CHEMBL623410,,81034,5574,,,F,,,Intermediate,,478.0,
7144,BAO_0000219,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,N,1,A2780,CHEMBL623576,,81034,13528,,,F,,,Expert,,478.0,
7145,BAO_0000219,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,N,1,ACHN,CHEMBL623577,,80025,12782,,,F,,,Intermediate,,626.0,
7146,BAO_0000219,The IC50 value was measured on ACHN cell line in renal tumor type.,,N,1,ACHN,CHEMBL623578,,80025,14255,,,F,,,Intermediate,,626.0,
7147,BAO_0000219,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,N,1,ACHN,CHEMBL623579,,80025,16364,,,F,,,Intermediate,,626.0,
7148,BAO_0000219,In vitro lethal concentration against most sensitive ACHN cell line,,N,1,ACHN,CHEMBL623580,,80025,17376,,,F,,,Expert,,626.0,
7149,BAO_0000219,Tested for cytotoxic activity against renal cancer ACHN cell line,,N,1,ACHN,CHEMBL623581,,80025,12016,,,F,,,Intermediate,,626.0,
7150,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line ACHN,,N,1,ACHN,CHEMBL857456,,80025,6058,,,F,,,Intermediate,,626.0,
7151,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,N,1,ACHN,CHEMBL623582,,80025,17708,,,F,,,Intermediate,,626.0,
7152,BAO_0000219,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,N,1,ACHN,CHEMBL623583,,80025,15176,,,F,,,Intermediate,,626.0,
7153,BAO_0000219,In vitro anticancer activity against ACHN renal cancer cell line,,N,1,ACHN,CHEMBL623584,,80025,2806,,,F,,,Intermediate,,626.0,
7154,BAO_0000219,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,N,1,ACHN,CHEMBL623585,,80025,15300,,,F,,,Intermediate,,626.0,
7155,BAO_0000219,Percent selectivity was evaluated in renal ACHN cell lines,,N,1,ACHN,CHEMBL623586,,80025,16364,,,F,,,Intermediate,,626.0,
7156,BAO_0000219,In vitro inhibitory activity against renal ACHN cancer cell line,,N,1,ACHN,CHEMBL623587,,80025,13859,,,F,,,Intermediate,,626.0,
7157,BAO_0000219,Tested for cytotoxicity against ACHN cell lines in renal cancer,,N,1,ACHN,CHEMBL875279,,80025,11970,,,F,,,Intermediate,,626.0,
7158,BAO_0000219,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,N,1,ACHN,CHEMBL623588,,80025,2450,,,F,,,Intermediate,,626.0,
7159,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,N,1,ACHN,CHEMBL623589,,80025,12696,,,F,,,Intermediate,,626.0,
7160,BAO_0000219,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,N,1,ACHN,CHEMBL623590,,80025,12400,,,F,,,Intermediate,,626.0,
7161,BAO_0000219,Cytotoxic effect on renal cancer line ACHN,,N,1,ACHN,CHEMBL623591,,80025,12888,,,F,,,Expert,,626.0,
7162,BAO_0000219,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,N,1,ACHN,CHEMBL623592,,80025,3156,,,F,,,Intermediate,,626.0,
7163,BAO_0000219,In vitro inhibition of Renal Cancer ACHN cell lines,,N,1,ACHN,CHEMBL623593,,80025,3381,,,F,,,Intermediate,,626.0,
7164,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells,,N,1,ACHN,CHEMBL623594,,80025,16747,,,F,,,Intermediate,,626.0,
7165,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells.,,N,1,ACHN,CHEMBL621833,,80025,16748,,,F,,,Expert,,626.0,
7166,BAO_0000219,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,N,1,ACHN,CHEMBL621834,,80025,12062,,,F,,,Intermediate,,626.0,
7167,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,N,1,ACHN,CHEMBL621835,,80025,14769,,,F,,,Intermediate,,626.0,
7168,BAO_0000219,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,N,1,ACHN,CHEMBL621836,,80025,15895,,,F,,,Intermediate,,626.0,
7169,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,N,1,ACHN,CHEMBL621837,,80025,17376,,,F,,,Intermediate,,626.0,
7170,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,N,1,ACHN,CHEMBL875280,,80025,14882,,,F,,,Intermediate,,626.0,
7171,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,N,1,ACHN,CHEMBL621838,,80025,14882,,,F,,,Intermediate,,626.0,
7172,BAO_0000219,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,N,1,ACHN,CHEMBL621839,,80025,15661,,,F,,,Intermediate,,626.0,
7173,BAO_0000019,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,U,1,,CHEMBL621840,,22224,9680,,,A,,,Autocuration,,,
7174,BAO_0000019,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,H,1,,CHEMBL621841,,10647,14579,,,F,,,Autocuration,,,
7175,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,N,1,HEL,CHEMBL622979,,50529,17290,,,F,,,Expert,,468.0,
7176,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,N,1,,CHEMBL876595,,50529,17290,,,F,,,Intermediate,,,
7177,BAO_0000357,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,H,1,,CHEMBL620221,,12159,15891,,,B,,,Autocuration,,,
7178,BAO_0000357,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,H,1,,CHEMBL620222,,12159,15890,,,B,,,Autocuration,,,
7179,BAO_0000219,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,N,1,ADDP cell line,CHEMBL620506,,80670,3801,,,F,,,Intermediate,,979.0,
7180,BAO_0000219,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,N,1,ADJ/PC6,CHEMBL620507,,80671,9222,,,F,,,Intermediate,,980.0,
7181,BAO_0000219,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,N,1,ADJ/PC6,CHEMBL620508,,80671,9222,,,F,,,Intermediate,,980.0,
7182,BAO_0000219,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,N,1,ADJ/PC6,CHEMBL620509,,80671,7257,,,F,,,Intermediate,,980.0,
7183,BAO_0000219,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,N,1,ADJ/PC6,CHEMBL620510,,80671,7257,,,F,,,Intermediate,,980.0,
7184,BAO_0000219,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,N,1,ADJ/PC6,CHEMBL620511,,80671,7257,,,A,,,Intermediate,,980.0,
7185,BAO_0000219,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,N,1,ADJ/PC6,CHEMBL620512,,80671,8084,,,F,,,Intermediate,,980.0,
7186,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,U,1,,CHEMBL620513,,22224,14943,,,F,,,Autocuration,,,
7187,BAO_0000019,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,U,1,,CHEMBL620514,,22224,14943,,,F,,,Autocuration,,,
7188,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,U,1,,CHEMBL620515,,22224,14943,,,F,,,Autocuration,,,
7189,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,U,1,,CHEMBL620516,In vivo,22224,10524,,,A,,,Autocuration,,,
7190,BAO_0000218,AUC value in dog after IV administration at a dose of 5 mg/kg,1969.0,N,1,,CHEMBL620517,,50588,3546,,Plasma,A,,,Intermediate,,,
7191,BAO_0000218,AUC value in dog after oral administration at a dose of 5 mg/kg,1969.0,N,1,,CHEMBL620518,,50588,3546,,Plasma,A,,,Intermediate,,,
7192,BAO_0000218,Cmax value in dog after oral administration at a dose of 5 mg/kg,,N,1,,CHEMBL620519,In vivo,50588,3546,,,A,,,Intermediate,,,
7193,BAO_0000218,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,N,1,,CHEMBL621386,In vivo,50588,3546,,,A,,,Intermediate,,,
7194,BAO_0000218,Tmax value in dog after oral administration at a dose of 5 mg/kg,,N,1,,CHEMBL621387,In vivo,50588,3546,,,A,,,Intermediate,,,
7195,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in dog,,N,1,,CHEMBL621388,In vivo,50588,3184,,,A,,,Intermediate,,,
7196,BAO_0000218,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL621389,In vivo,50588,16456,,,A,,,Intermediate,,,
7197,BAO_0000218,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,N,1,,CHEMBL621390,In vivo,50588,4809,,,A,,,Intermediate,,,
7198,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL621391,,22229,4219,,,P,,,Intermediate,,,
7199,BAO_0000218,Half life in dog,,N,1,,CHEMBL621392,,50588,3748,,,A,,,Intermediate,,,
7200,BAO_0000218,Time taken for EC90 was determined when tested in dog,,N,1,,CHEMBL621393,,50588,3132,,,A,,,Intermediate,,,
7201,BAO_0000218,Half life (iv) was determined,,N,1,,CHEMBL621394,,50588,4219,,,A,,,Intermediate,,,
7202,BAO_0000218,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,2107.0,N,1,,CHEMBL621395,,50588,16907,,Liver,A,,,Intermediate,,,
7203,BAO_0000218,Area under the curve was calculated in dog after iv administration,,N,1,,CHEMBL621396,,50588,6057,,,A,,,Intermediate,,,
7204,BAO_0000218,Area under the curve was calculated in dog after peroral administration,,N,1,,CHEMBL621397,,50588,6057,,,A,,,Intermediate,,,
7205,BAO_0000218,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,N,1,,CHEMBL621398,,50588,17853,,,A,,,Intermediate,,,
7206,BAO_0000218,pKa was evaluated in dog,,N,1,,CHEMBL618818,,50588,3639,,,A,,,Intermediate,,,
7207,BAO_0000218,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,N,1,,CHEMBL618819,,50588,14541,,,A,,,Intermediate,,,
7208,BAO_0000218,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL618820,In vivo,50588,16456,,,A,,,Intermediate,,,
7209,BAO_0000218,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL873810,In vivo,50588,16456,,,A,,,Intermediate,,,
7210,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,N,1,,CHEMBL876606,In vivo,50588,2652,,,A,,,Intermediate,,,
7211,BAO_0000218,Compound was evaluated for the half-life (t 1/2) in hours,,N,1,,CHEMBL618821,,50588,3624,,,A,,,Intermediate,,,
7212,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,178.0,N,1,,CHEMBL618822,In vivo,50588,1337,,Blood,A,,,Intermediate,,,
7213,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,178.0,N,1,,CHEMBL618823,In vivo,50588,1337,,Blood,A,,,Intermediate,,,
7214,BAO_0000218,Half life after intravenous administration of 1 mg/kg in dog,,N,1,,CHEMBL618824,In vivo,50588,4709,,,A,,,Intermediate,,,
7215,BAO_0000218,Half life was measured in dog,,N,1,,CHEMBL618825,,50588,15660,,,A,,,Intermediate,,,
7216,BAO_0000218,Half life period in dog after 5 mg/kg dose,,N,1,,CHEMBL618826,In vivo,50588,5302,,,A,,,Intermediate,,,
7217,BAO_0000218,Half life period was evaluated in dog; 4-4.8,,N,1,,CHEMBL618827,,50588,17791,,,A,,,Intermediate,,,
7218,BAO_0000218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,1,,CHEMBL618828,In vivo,50588,6348,,,A,,,Intermediate,,,
7219,BAO_0000218,Half-life was determined in dog after a3 mg/kg of iv dose,,N,1,,CHEMBL618829,In vivo,50588,4257,,,A,,,Intermediate,,,
7220,BAO_0000218,Half-life was determined,,N,1,,CHEMBL618830,,50588,3771,,,A,,,Intermediate,,,
7221,BAO_0000218,Half life in dogs,,N,1,,CHEMBL618831,,50588,6305,,,A,,,Intermediate,,,
7222,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1969.0,N,1,,CHEMBL619489,In vivo,50588,13501,,Plasma,A,,,Intermediate,,,
7223,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,N,1,,CHEMBL619649,In vivo,50588,17594,,,A,,,Intermediate,,,
7224,BAO_0000218,Compound was evaluated for the half life period after iv administration in Beagle dog.,,N,1,,CHEMBL876607,In vivo,50588,3045,,,A,,,Intermediate,,,
7225,BAO_0000218,Compound was evaluated for the half life period after oral administration in conscious dog.,,N,1,,CHEMBL619650,In vivo,50588,3043,,,A,,,Intermediate,,,
7226,BAO_0000218,Compound was tested for half life in dog,,N,1,,CHEMBL619651,,50588,4839,,,A,,,Intermediate,,,
7227,BAO_0000218,Compound was tested for its half life in dog,,N,1,,CHEMBL619652,,50588,4839,,,A,,,Intermediate,,,
7228,BAO_0000218,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,1,,CHEMBL619653,In vivo,50588,5802,,,A,,,Intermediate,,,
7229,BAO_0000218,Half life of compound in dog was determined,,N,1,,CHEMBL619654,,50588,17839,,,A,,,Intermediate,,,
7230,BAO_0000218,Half life (iv) was determined,,N,1,,CHEMBL619655,In vivo,50588,4219,,,A,,,Intermediate,,,
7231,BAO_0000218,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),178.0,N,1,,CHEMBL619656,,50588,13966,,Blood,A,,,Intermediate,,,
7232,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1969.0,N,1,,CHEMBL873812,In vivo,50588,3994,,Plasma,A,,,Intermediate,,,
7233,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1969.0,N,1,,CHEMBL621365,In vivo,50588,3994,,Plasma,F,,,Intermediate,,,
7234,BAO_0000218,Half life in dog,,N,1,,CHEMBL621366,,50588,4453,,,A,,,Intermediate,,,
7235,BAO_0000218,Half life in dog plasma,1969.0,N,1,,CHEMBL621367,,50588,6535,,Plasma,A,,,Intermediate,,,
7236,BAO_0000218,Half life in dog plasma after administration of 0.25 mg/kg iv,1969.0,N,1,,CHEMBL621368,In vivo,50588,6535,,Plasma,A,,,Intermediate,,,
7237,BAO_0000218,Half life in dog plasma after administration of 1 mg/kg iv,1969.0,N,1,,CHEMBL621369,In vivo,50588,6535,,Plasma,A,,,Intermediate,,,
7238,BAO_0000218,Half life in dog plasma was determined at dose 10 mg/kg,1969.0,N,1,,CHEMBL621370,In vivo,50588,3132,,Plasma,A,,,Intermediate,,,
7239,BAO_0000218,Half life in dog was determined,,N,1,,CHEMBL621371,,50588,5374,,,A,,,Intermediate,,,
7240,BAO_0000218,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,1,,CHEMBL621372,In vivo,50588,5007,,,A,,,Intermediate,,,
7241,BAO_0000218,Half life upon exposure to human plasma,1969.0,N,1,,CHEMBL621373,,50588,16907,,Plasma,A,,,Intermediate,,,
7242,BAO_0000218,Half life was calculated in dog,,N,1,,CHEMBL621374,,50588,6057,,,A,,,Intermediate,,,
7243,BAO_0000218,Half life was determined,,N,1,,CHEMBL621375,,50588,5006,,,A,,,Intermediate,,,
7244,BAO_0000218,Half life was determined,,N,1,,CHEMBL621376,,50588,5473,,,A,,,Intermediate,,,
7245,BAO_0000218,Half life by intravenous administration of 1.2 mg/kg in dog,,N,1,,CHEMBL619624,In vivo,50588,4368,,,A,,,Intermediate,,,
7246,BAO_0000218,Half life in dog,,N,1,,CHEMBL875840,,50588,6448,,,A,,,Intermediate,,,
7247,BAO_0000218,Half life in dog after intra venous administration of the compound,,N,1,,CHEMBL619625,,50588,4353,,,A,,,Intermediate,,,
7248,BAO_0000218,Half life in dog after intra venous administration of the compound; ND means Not determined,,N,1,,CHEMBL619626,,50588,4353,,,A,,,Intermediate,,,
7249,BAO_0000218,Half life in dog after po administration of the compound,,N,1,,CHEMBL619627,In vivo,50588,4353,,,A,,,Intermediate,,,
7250,BAO_0000218,Half life in dog after po administration of the compound; ND means Not determined,,N,1,,CHEMBL873817,In vivo,50588,4353,,,A,,,Intermediate,,,
7251,BAO_0000218,Half life in dog at the single oral dose of 1 mg/kg,,N,1,,CHEMBL619628,In vivo,50588,6265,,,A,,,Intermediate,,,
7252,BAO_0000218,Half life in dogs,,N,1,,CHEMBL619629,,50588,5006,,,A,,,Intermediate,,,
7253,BAO_0000218,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,N,1,,CHEMBL619630,In vivo,50588,5356,,,A,,,Intermediate,,,
7254,BAO_0000218,Half life in rat,,N,1,,CHEMBL619631,,50588,405,,,A,,,Intermediate,,,
7255,BAO_0000218,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,1,,CHEMBL619632,In vivo,50588,6642,,,A,,,Intermediate,,,
7256,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10000001.0,N,1,,CHEMBL619633,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7257,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10000001.0,N,1,,CHEMBL875841,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7258,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10000001.0,N,1,,CHEMBL619634,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7259,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10000001.0,N,1,,CHEMBL619635,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7260,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10000001.0,N,1,,CHEMBL619636,In vivo,50594,10107,,Bone,A,,,Intermediate,,,
7261,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10000004.0,N,1,,CHEMBL619637,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7262,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10000004.0,N,1,,CHEMBL619638,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7263,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10000004.0,N,1,,CHEMBL619639,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7264,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10000004.0,N,1,,CHEMBL619640,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7265,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10000004.0,N,1,,CHEMBL619641,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7266,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10000004.0,N,1,,CHEMBL619642,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7267,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10000004.0,N,1,,CHEMBL619643,In vivo,50594,10107,,Gut,A,,,Intermediate,,,
7268,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,948.0,N,1,,CHEMBL619644,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7269,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,948.0,N,1,,CHEMBL621112,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7270,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,948.0,N,1,,CHEMBL621113,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7271,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,948.0,N,1,,CHEMBL621114,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7272,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,948.0,N,1,,CHEMBL621115,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7273,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,948.0,N,1,,CHEMBL621116,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7274,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,948.0,N,1,,CHEMBL621117,In vivo,50594,10107,,Heart,A,,,Intermediate,,,
7275,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2113.0,N,1,,CHEMBL621118,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7276,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,2113.0,N,1,,CHEMBL621119,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7277,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2113.0,N,1,,CHEMBL621120,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7278,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2113.0,N,1,,CHEMBL621757,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7279,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2113.0,N,1,,CHEMBL621758,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7280,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2113.0,N,1,,CHEMBL621759,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7281,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2113.0,N,1,,CHEMBL621760,In vivo,50594,10107,,Kidney,A,,,Intermediate,,,
7282,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2107.0,N,1,,CHEMBL621761,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7283,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,2107.0,N,1,,CHEMBL621762,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7284,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2107.0,N,1,,CHEMBL621763,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7285,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2107.0,N,1,,CHEMBL624502,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7286,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2107.0,N,1,,CHEMBL624503,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7287,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2107.0,N,1,,CHEMBL624504,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7288,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2107.0,N,1,,CHEMBL624505,In vivo,50594,10107,,Liver,A,,,Intermediate,,,
7289,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2048.0,N,1,,CHEMBL624506,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7290,BAO_0000219,In vitro cytotoxicity against A2780 (human ovarian cancer),,N,1,A2780,CHEMBL624507,,81034,5895,,,F,,,Intermediate,,478.0,
7291,BAO_0000219,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,N,1,A2780,CHEMBL624508,,81034,6338,,,F,,,Intermediate,,478.0,
7292,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,N,1,A2780,CHEMBL624509,,81034,15163,,,F,,,Intermediate,,478.0,
7293,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,N,1,A2780,CHEMBL624510,,81034,15163,,,F,,,Intermediate,,478.0,
7294,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,N,1,A2780,CHEMBL875956,,81034,15000,,,F,,,Expert,,478.0,
7295,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,N,1,A2780,CHEMBL839885,,81034,15000,,,F,,,Expert,,478.0,
7296,BAO_0000219,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,N,1,A2780,CHEMBL624511,,81034,14729,,,F,,,Expert,,478.0,
7297,BAO_0000219,In vitro cytotoxicity against A2780 cell line,,N,1,A2780,CHEMBL624512,,81034,17270,,,F,,,Intermediate,,478.0,
7298,BAO_0000219,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,N,1,A2780,CHEMBL624513,,81034,5685,,,F,,,Intermediate,,478.0,
7299,BAO_0000219,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,N,1,A2780,CHEMBL624514,,81034,3563,,,F,,,Intermediate,,478.0,
7300,BAO_0000218,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,N,1,A2780,CHEMBL618547,,81034,17753,,,F,,,Intermediate,,478.0,
7301,BAO_0000219,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,N,1,A2780,CHEMBL618548,,81034,16317,,,F,,,Intermediate,,478.0,
7302,BAO_0000219,Inhibition of tubulin polymerization in analogy of ca.,,N,1,A2780,CHEMBL618549,,81034,16936,,,F,,,Intermediate,,478.0,
7303,BAO_0000219,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,N,1,A2780,CHEMBL618550,,81034,3801,,,F,,,Intermediate,,478.0,
7304,BAO_0000219,Cytotoxic effect in ovarian cancer cell line (A2780),,N,1,A2780,CHEMBL618551,,81034,6181,,,F,,,Expert,,478.0,
7305,BAO_0000219,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,N,1,A2780,CHEMBL618552,,81034,5318,,,F,,,Intermediate,,478.0,
7306,BAO_0000219,Tested for the cytotoxicity in A2780 ovarian cell line,,N,1,A2780,CHEMBL618553,,81034,4840,,,F,,,Intermediate,,478.0,
7307,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,N,1,A2780,CHEMBL618554,,81034,15748,,,F,,,Intermediate,,478.0,
7308,BAO_0000219,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,N,1,A2780,CHEMBL618555,,81034,15748,,,F,,,Intermediate,,478.0,
7309,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,N,1,A2780cisR,CHEMBL618556,,80017,15748,,,F,,,Intermediate,,481.0,
7310,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,N,1,A2780cisR,CHEMBL618557,,80017,15748,,,F,,,Intermediate,,481.0,
7311,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,N,1,A2780cisR,CHEMBL618558,,80017,15748,,,F,,,Intermediate,,481.0,
7312,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,N,1,A2780cisR,CHEMBL618559,,80017,15748,,,F,,,Intermediate,,481.0,
7313,BAO_0000218,In vivo log of cells killed after administration of compound in A2780 cell line,,N,1,A2780,CHEMBL618560,,81034,17753,,,F,,,Intermediate,,478.0,
7314,BAO_0000218,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,N,1,A2780,CHEMBL618561,In vivo,81034,17753,,,F,,,Intermediate,,478.0,
7315,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,N,1,A2780,CHEMBL618562,,81034,16936,,,F,,,Intermediate,,478.0,
7316,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,N,1,A2780,CHEMBL618563,,81034,16936,,,F,,,Intermediate,,478.0,
7317,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,N,1,A2780,CHEMBL618564,,81034,16936,,,F,,,Intermediate,,478.0,
7318,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,N,1,A2780,CHEMBL618565,,81034,16936,,,F,,,Intermediate,,478.0,
7319,BAO_0000218,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,N,1,A2780,CHEMBL618566,,81034,17528,,,F,,,Intermediate,,478.0,
7320,BAO_0000219,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,N,1,A2780,CHEMBL618567,,81034,6633,,,F,,,Intermediate,,478.0,
7321,BAO_0000219,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,N,1,A2780,CHEMBL618568,,81034,15000,,,F,,,Expert,,478.0,
7322,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,N,1,A2780,CHEMBL618569,,81034,17528,,,F,,,Expert,,478.0,
7323,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,N,1,A2780,CHEMBL621857,,81034,16936,,,F,,,Intermediate,,478.0,
7324,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,N,1,A2780,CHEMBL621858,,81034,16936,,,F,,,Intermediate,,478.0,
7325,BAO_0000219,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,N,1,A2780,CHEMBL621859,,81034,16936,,,F,,,Intermediate,,478.0,
7326,BAO_0000219,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,N,1,A2780,CHEMBL621860,,81034,16936,,,F,,,Intermediate,,478.0,
7327,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,N,1,A2780,CHEMBL621861,,81034,16936,,,F,,,Intermediate,,478.0,
7328,BAO_0000219,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,N,1,A2780,CHEMBL621862,,81034,16936,,,F,,,Expert,,478.0,
7329,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,N,1,A2780,CHEMBL621863,,81034,16936,,,F,,,Intermediate,,478.0,
7330,BAO_0000219,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,N,1,A2780,CHEMBL621864,,81034,16936,,,F,,,Intermediate,,478.0,
7331,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,N,1,A2780,CHEMBL621865,,81034,16936,,,F,,,Intermediate,,478.0,
7332,BAO_0000219,In vitro antiproliferative activity against A2780 cell line,,N,1,A2780,CHEMBL621866,,81034,17737,,,F,,,Intermediate,,478.0,
7333,BAO_0000219,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,N,1,A2780,CHEMBL621867,,81034,17764,,,F,,,Expert,,478.0,
7334,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,N,1,A2780,CHEMBL621868,,81034,3830,,,F,,,Intermediate,,478.0,
7335,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,N,1,A2780,CHEMBL875282,,81034,3829,,,F,,,Intermediate,,478.0,
7336,BAO_0000218,Vc value in dog after IV administration at a dose of 5 mg/kg,,N,1,,CHEMBL621869,,50588,3546,,,A,,,Intermediate,,,
7337,BAO_0000218,Half life period in dog after IV administration at a dose of 5 mg/kg,,N,1,,CHEMBL621870,In vivo,50588,3546,,,A,,,Intermediate,,,
7338,BAO_0000019,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,U,1,,CHEMBL621871,,22224,5668,,,A,,,Autocuration,,,
7339,BAO_0000218,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1969.0,U,1,,CHEMBL621243,,22224,3443,,Plasma,A,,,Autocuration,,,
7340,BAO_0000218,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1969.0,U,1,,CHEMBL621244,,22224,3443,,Plasma,A,,,Autocuration,,,
7341,BAO_0000218,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,U,1,,CHEMBL621245,In vivo,22224,4256,,,A,,,Autocuration,,,
7342,BAO_0000218,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,U,1,,CHEMBL621246,In vivo,22224,4256,,,A,,,Autocuration,,,
7343,BAO_0000218,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,U,1,,CHEMBL621247,In vivo,22224,4256,,,A,,,Autocuration,,,
7344,BAO_0000218,Oral Bioavailability in rat,,U,1,,CHEMBL618386,In vivo,22224,4256,,,A,,,Autocuration,,,
7345,BAO_0000218,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,1,,CHEMBL618387,,22224,1916,,,A,,,Autocuration,,,
7346,BAO_0000218,Area under curve value in monkey at a dose of 5 mg/kg,,U,1,,CHEMBL618388,,22224,5302,,,A,,,Autocuration,,,
7347,BAO_0000218,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,U,1,,CHEMBL618389,,22224,4257,,,A,,,Autocuration,,,
7348,BAO_0000019,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,U,1,,CHEMBL618574,,22224,5355,,,A,,,Autocuration,,,
7349,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,U,1,,CHEMBL618575,,22224,5355,,,A,,,Autocuration,,,
7350,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,U,1,,CHEMBL618576,,22224,5355,,,A,,,Autocuration,,,
7351,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,U,1,,CHEMBL618577,,22224,6078,,,A,,,Autocuration,,,
7352,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,U,1,,CHEMBL876487,,22224,6078,,,A,,,Autocuration,,,
7353,BAO_0000218,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,U,1,,CHEMBL618578,,22224,6062,,,A,,,Autocuration,,,
7354,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,1,,CHEMBL618579,,22224,2661,,,A,,,Autocuration,,,
7355,BAO_0000019,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,1,,CHEMBL618580,,22224,2661,,,A,,,Autocuration,,,
7356,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,U,1,,CHEMBL618581,,22224,5394,,,A,,,Autocuration,,,
7357,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,U,1,,CHEMBL618582,,22224,4397,,,A,,,Autocuration,,,
7358,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,U,1,,CHEMBL618583,,22224,17509,,,A,,,Autocuration,,,
7359,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,U,1,,CHEMBL618584,,22224,17509,,,A,,,Autocuration,,,
7360,BAO_0000218,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,U,1,,CHEMBL618585,In vivo,22224,6641,,,A,,,Autocuration,,,
7361,BAO_0000218,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,U,1,,CHEMBL618586,,22224,5355,,,A,,,Autocuration,,,
7362,BAO_0000218,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL618587,In vivo,22224,3443,,,A,,,Autocuration,,,
7363,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,1,,CHEMBL618588,In vivo,22224,3443,,,A,,,Autocuration,,,
7364,BAO_0000019,Binding towards monkey plasma protein at 10 uM,,U,1,,CHEMBL618589,,22224,17409,,,A,,,Autocuration,,,
7365,BAO_0000019,Binding towards monkey plasma protein at 100 uM,,U,1,,CHEMBL618590,,22224,17409,,,A,,,Autocuration,,,
7366,BAO_0000218,Apparent bioavailability in squirrel monkey was determined,,U,1,,CHEMBL872262,In vivo,22224,1052,,,A,,,Autocuration,,,
7367,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,U,1,,CHEMBL618591,In vivo,22224,13501,,,A,,,Autocuration,,,
7368,BAO_0000218,Bioavailability in monkey (dose 2 mg/kg),,U,1,,CHEMBL618592,In vivo,22224,17509,,,A,,,Autocuration,,,
7369,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,U,1,,CHEMBL876488,In vivo,22224,5394,,,A,,,Autocuration,,,
7370,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,1,,CHEMBL618593,In vivo,22224,2661,,,A,,,Autocuration,,,
7371,BAO_0000218,Bioavailability in monkey (i.d. dosing),,U,1,,CHEMBL618594,In vivo,22224,11219,,,A,,,Autocuration,,,
7372,BAO_0000218,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,U,1,,CHEMBL618595,In vivo,22224,3045,,,A,,,Autocuration,,,
7373,BAO_0000019,Clearance of the drug was measured in cynomolgus,,U,1,,CHEMBL621469,,22224,17796,,,A,,,Autocuration,,,
7374,BAO_0000218,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,U,1,,CHEMBL621470,In vivo,22224,1399,,,A,,,Autocuration,,,
7375,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,1,,CHEMBL621471,In vivo,22224,2661,,,A,,,Autocuration,,,
7376,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,U,1,,CHEMBL621472,In vivo,22224,5005,,Plasma,A,,,Autocuration,,,
7377,BAO_0000218,Plasma clearance in rhesus monkey was determined,,U,1,,CHEMBL621473,In vivo,22224,17267,,,A,,,Autocuration,,,
7378,BAO_0000218,Plasma clearance in monkey after administration of 1 mg/kg iv,,U,1,,CHEMBL621474,In vivo,22224,6535,,,A,,,Autocuration,,,
7379,BAO_0000218,Plasma clearance in cynomolgus monkey,,U,1,,CHEMBL621475,In vivo,22224,5922,,,A,,,Autocuration,,,
7380,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,U,1,,CHEMBL621476,In vivo,22224,6221,,,A,,,Autocuration,,,
7381,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rhesus,,U,1,,CHEMBL624290,In vivo,22224,5668,,,A,,,Autocuration,,,
7382,BAO_0000218,The total clearance was determined after intravenous administration in cynomolgus monkeys,,U,1,,CHEMBL624291,In vivo,22224,5355,,,A,,,Autocuration,,,
7383,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,U,1,,CHEMBL624292,In vivo,22224,5355,,,A,,,Autocuration,,,
7384,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,U,1,,CHEMBL624293,In vivo,22224,5355,,,A,,,Autocuration,,,
7385,BAO_0000218,Tested for Clearance upon iv administration to african green monkey,,U,1,,CHEMBL624294,In vivo,22224,4578,,,A,,,Autocuration,,,
7386,BAO_0000218,Clearance in monkey,,U,1,,CHEMBL624295,In vivo,22224,17592,,,A,,,Autocuration,,,
7387,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,1,,CHEMBL624296,In vivo,50588,6641,,,A,,,Intermediate,,,
7388,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,1,,CHEMBL624297,In vivo,50588,6642,,,A,,,Intermediate,,,
7389,BAO_0000218,Half life was evaluated after intravenous administration to dogs,,N,1,,CHEMBL624298,In vivo,50588,16367,,,A,,,Intermediate,,,
7390,BAO_0000218,Half life was evaluated in dog,,N,1,,CHEMBL624299,,50588,5472,,,A,,,Intermediate,,,
7391,BAO_0000218,Half life was evaluated in dog,,N,1,,CHEMBL624300,,50588,5474,,,A,,,Intermediate,,,
7392,BAO_0000218,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,N,1,,CHEMBL624301,In vivo,50588,5654,,,A,,,Intermediate,,,
7393,BAO_0000218,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,N,1,,CHEMBL624302,In vivo,50588,6227,,,A,,,Intermediate,,,
7394,BAO_0000218,Half life period after intravenous administration in dog,,N,1,,CHEMBL876026,In vivo,50588,6227,,,A,,,Intermediate,,,
7395,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in dog was determined,,N,1,,CHEMBL624303,In vivo,50588,6221,,,A,,,Intermediate,,,
7396,BAO_0000218,Half life period at a dose of 1 uM/kg in dog was determined,,N,1,,CHEMBL624304,,50588,4527,,,A,,,Intermediate,,,
7397,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in dog,,N,1,,CHEMBL624305,In vivo,50588,5668,,,A,,,Intermediate,,,
7398,BAO_0000218,Half life period was determine after peroral administration at 5 mpk in dog,,N,1,,CHEMBL624306,In vivo,50588,5668,,,A,,,Intermediate,,,
7399,BAO_0000218,Half life period was determined,,N,1,,CHEMBL624307,,50588,3854,,,A,,,Intermediate,,,
7400,BAO_0000218,Half life period was determined,,N,1,,CHEMBL624308,,50588,5505,,,A,,,Intermediate,,,
7401,BAO_0000218,Half life period by iv administration in dog at a dose of 6 mg/kg,,N,1,,CHEMBL624309,In vivo,50588,6251,,,A,,,Intermediate,,,
7402,BAO_0000218,Half life period was evaluated in dog,,N,1,,CHEMBL624310,,50588,1918,,,A,,,Intermediate,,,
7403,BAO_0000218,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,N,1,,CHEMBL625003,In vivo,50588,5546,,,A,,,Intermediate,,,
7404,BAO_0000218,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,N,1,,CHEMBL625004,In vivo,50588,4809,,,A,,,Intermediate,,,
7405,BAO_0000218,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,N,1,,CHEMBL625005,In vivo,50588,6215,,,A,,,Intermediate,,,
7406,BAO_0000218,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,N,1,,CHEMBL873813,In vivo,50588,4527,,,A,,,Intermediate,,,
7407,BAO_0000218,Half-life after oral dose of compound at 3 mg/kg in dogs,,N,1,,CHEMBL625006,In vivo,50588,17594,,,A,,,Intermediate,,,
7408,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,N,1,,CHEMBL625007,In vivo,50588,17839,,,A,,,Intermediate,,,
7409,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,N,1,,CHEMBL876027,In vivo,50588,17839,,,A,,,Intermediate,,,
7410,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,N,1,,CHEMBL625008,In vivo,50588,17839,,,A,,,Intermediate,,,
7411,BAO_0000218,Half-life of compound in dog following p.o. administration of 1 mg/kg,,N,1,,CHEMBL625009,In vivo,50588,17839,,,A,,,Intermediate,,,
7412,BAO_0000218,Half-life of compound in plasma of dog was determined,1969.0,N,1,,CHEMBL625010,,50588,5210,,Plasma,A,,,Intermediate,,,
7413,BAO_0000218,Half-life of compound was determined in dogs,,N,1,,CHEMBL625011,,50588,5210,,,A,,,Intermediate,,,
7414,BAO_0000218,Half-life after administration of 4 mg/Kg oral dose in dog,,N,1,,CHEMBL621553,In vivo,50588,2959,,,A,,,Intermediate,,,
7415,BAO_0000218,Half-life after intravenous administration of 1 mg/kg/h in dog,,N,1,,CHEMBL621554,In vivo,50588,4137,,,A,,,Intermediate,,,
7416,BAO_0000218,Half-life in Dog,,N,1,,CHEMBL621555,,50588,5064,,,A,,,Intermediate,,,
7417,BAO_0000218,Half-life in Dog,,N,1,,CHEMBL621556,,50588,5147,,,A,,,Intermediate,,,
7418,BAO_0000218,Half-life in dog,,N,1,,CHEMBL621557,,50588,5145,,,A,,,Intermediate,,,
7419,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg,,N,1,,CHEMBL621558,In vivo,50588,6123,,,A,,,Intermediate,,,
7420,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,N,1,,CHEMBL621559,In vivo,50588,6123,,,A,,,Intermediate,,,
7421,BAO_0000218,Half-life in dogs,,N,1,,CHEMBL621560,,50588,4333,,,A,,,Intermediate,,,
7422,BAO_0000218,Half-life in dogs; ND indicates not determined,,N,1,,CHEMBL876028,,50588,4333,,,A,,,Intermediate,,,
7423,BAO_0000218,Half-life in plasma of dog,1969.0,N,1,,CHEMBL621561,,50588,12500,,Plasma,A,,,Intermediate,,,
7424,BAO_0000218,Half-life in plasma of dog at dose of 3-10 mgkg,1969.0,N,1,,CHEMBL621562,,50588,12500,,Plasma,A,,,Intermediate,,,
7425,BAO_0000218,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,N,1,,CHEMBL621563,In vivo,50588,6005,,,A,,,Intermediate,,,
7426,BAO_0000218,Half-life was measured in dog after an iv dose of 1 mg/kg,,N,1,,CHEMBL621564,In vivo,50588,6062,,,A,,,Intermediate,,,
7427,BAO_0000218,Half-life was measured in dogs after an oral dose of 10 uM/kg,,N,1,,CHEMBL621565,In vivo,50588,17650,,,A,,,Intermediate,,,
7428,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,N,1,,CHEMBL621566,In vivo,50588,5530,,,A,,,Intermediate,,,
7429,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,N,1,,CHEMBL621567,In vivo,50588,5530,,,A,,,Intermediate,,,
7430,BAO_0000218,Half-life of the compound after 0.3 mg/kg po administration in dog,,N,1,,CHEMBL622978,In vivo,50588,5600,,,A,,,Intermediate,,,
7431,BAO_0000218,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,N,1,,CHEMBL873814,In vivo,50588,6039,,,A,,,Intermediate,,,
7432,BAO_0000218,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,N,1,,CHEMBL623219,In vivo,50588,6039,,,A,,,Intermediate,,,
7433,BAO_0000218,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,N,1,,CHEMBL624477,In vivo,50588,6039,,,A,,,Intermediate,,,
7434,BAO_0000218,t1/2 in dog,,N,1,,CHEMBL624478,,50588,6227,,,A,,,Intermediate,,,
7435,BAO_0000218,Half-life period measured in dogs,,N,1,,CHEMBL624479,,50588,14541,,,A,,,Intermediate,,,
7436,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,N,1,,CHEMBL624480,In vivo,50588,4521,,,A,,,Intermediate,,,
7437,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,1,,CHEMBL623595,In vivo,50588,4521,,,A,,,Intermediate,,,
7438,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL623596,In vivo,50588,6679,,,A,,,Intermediate,,,
7439,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1969.0,N,1,,CHEMBL623597,In vitro,50588,1116,,Plasma,A,,,Intermediate,,,
7440,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog,,N,1,,CHEMBL623598,In vivo,50588,5444,,,A,,,Intermediate,,,
7441,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,N,1,,CHEMBL623599,In vivo,50588,5444,,,A,,,Intermediate,,,
7442,BAO_0000218,Longer half-life in dog (i.v.) at 0.5 mpk,,N,1,,CHEMBL623600,In vivo,50588,17853,,,A,,,Intermediate,,,
7443,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,N,1,,CHEMBL623601,In vivo,50588,4353,,,A,,,Intermediate,,,
7444,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,1,,CHEMBL623602,In vivo,50588,16452,,,A,,,Intermediate,,,
7445,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,N,1,,CHEMBL623603,In vivo,50588,16452,,,A,,,Intermediate,,,
7446,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,N,1,,CHEMBL623604,In vivo,50588,16452,,,A,,,Intermediate,,,
7447,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,2048.0,N,1,,CHEMBL623605,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7448,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2048.0,N,1,,CHEMBL623606,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7449,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2048.0,N,1,,CHEMBL623607,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7450,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2048.0,N,1,,CHEMBL623608,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7451,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2048.0,N,1,,CHEMBL623609,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7452,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2048.0,N,1,,CHEMBL623610,In vivo,50594,10107,,Lung,A,,,Intermediate,,,
7453,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2385.0,N,1,,CHEMBL623611,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7454,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,2385.0,N,1,,CHEMBL623612,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7455,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2385.0,N,1,,CHEMBL623613,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7456,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2385.0,N,1,,CHEMBL623614,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7457,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2385.0,N,1,,CHEMBL623615,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7458,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2385.0,N,1,,CHEMBL623616,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7459,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2385.0,N,1,,CHEMBL623617,In vivo,50594,10107,,Muscle tissue,A,,,Intermediate,,,
7460,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,14.0,N,1,,CHEMBL875944,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7461,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,14.0,N,1,,CHEMBL623618,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7462,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,14.0,N,1,,CHEMBL623619,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7463,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,14.0,N,1,,CHEMBL623620,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7464,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,14.0,N,1,,CHEMBL623621,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7465,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,14.0,N,1,,CHEMBL623622,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7466,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,14.0,N,1,,CHEMBL623623,In vivo,50594,10107,,Zone of skin,A,,,Intermediate,,,
7467,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2106.0,N,1,,CHEMBL623624,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7468,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,2106.0,N,1,,CHEMBL618521,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7469,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2106.0,N,1,,CHEMBL618522,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7470,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2106.0,N,1,,CHEMBL618523,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7471,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2106.0,N,1,,CHEMBL618524,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7472,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2106.0,N,1,,CHEMBL618525,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7473,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2106.0,N,1,,CHEMBL624586,In vivo,50594,10107,,Spleen,A,,,Intermediate,,,
7474,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,945.0,N,1,,CHEMBL624587,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7475,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,945.0,N,1,,CHEMBL624588,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7476,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,945.0,N,1,,CHEMBL624589,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7477,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,945.0,N,1,,CHEMBL624590,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7478,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,945.0,N,1,,CHEMBL624591,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7479,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,945.0,N,1,,CHEMBL624592,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7480,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,945.0,N,1,,CHEMBL624593,In vivo,50594,10107,,Stomach,A,,,Intermediate,,,
7481,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL624594,In vivo,50597,4689,,,A,,,Intermediate,,,
7482,BAO_0000218,Tested for the bioavailability in rat,,N,1,,CHEMBL624595,In vivo,50597,4950,,,A,,,Intermediate,,,
7483,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,1,,CHEMBL624596,In vivo,50597,5328,,,A,,,Intermediate,,,
7484,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL624597,In vivo,50597,406,,,A,,,Intermediate,,,
7485,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL624598,In vivo,50597,12500,,,A,,,Intermediate,,,
7486,BAO_0000218,Bioavailability in rat (dose 3-10 mg/kg),,N,1,,CHEMBL624599,In vivo,50597,12500,,,A,,,Intermediate,,,
7487,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL875166,In vivo,50597,5247,,,A,,,Intermediate,,,
7488,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,N,1,,CHEMBL624600,In vivo,50597,4186,,Plasma,A,,,Intermediate,,,
7489,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1969.0,N,1,,CHEMBL624601,In vivo,50597,4186,,Plasma,A,,,Intermediate,,,
7490,BAO_0000218,Half life after oral administration was determined in rats at 6 mg/kg,,N,1,,CHEMBL624602,In vivo,50597,6647,,,A,,,Intermediate,,,
7491,BAO_0000218,Half life was determined,,N,1,,CHEMBL624603,,50597,6484,,,A,,,Intermediate,,,
7492,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,N,1,,CHEMBL624604,In vivo,50597,3249,,,A,,,Intermediate,,,
7493,BAO_0000218,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1969.0,N,1,,CHEMBL624605,In vivo,50597,6281,,Plasma,A,,,Intermediate,,,
7494,BAO_0000218,Half life in rats,,N,1,,CHEMBL624606,,50597,3307,,,A,,,Intermediate,,,
7495,BAO_0000218,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,178.0,N,1,,CHEMBL624607,In vivo,50597,12058,,Blood,A,,,Intermediate,,,
7496,BAO_0000218,Hill coefficient of the compound,,N,1,,CHEMBL624608,,50597,8833,,,A,,,Intermediate,,,
7497,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,178.0,N,1,,CHEMBL624609,,50597,3193,,Blood,A,,,Intermediate,,,
7498,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,178.0,N,1,,CHEMBL624610,,50597,3193,,Blood,A,,,Intermediate,,,
7499,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,178.0,N,1,,CHEMBL624611,,50597,3193,,Blood,A,,,Intermediate,,,
7500,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,178.0,N,1,,CHEMBL624612,,50597,3193,,Blood,A,,,Intermediate,,,
7501,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,178.0,N,1,,CHEMBL875167,,50597,3193,,Blood,A,,,Intermediate,,,
7502,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,178.0,N,1,,CHEMBL624613,,50597,3193,,Blood,A,,,Intermediate,,,
7503,BAO_0000218,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",178.0,N,1,,CHEMBL624614,,50597,3193,,Blood,A,,,Intermediate,,,
7504,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,N,1,,CHEMBL624392,,50597,5960,,,A,,,Intermediate,,,
7505,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,955.0,N,1,,CHEMBL624393,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
7506,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,955.0,N,1,,CHEMBL624394,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
7507,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,955.0,N,1,,CHEMBL624395,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
7508,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,955.0,N,1,,CHEMBL624396,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
7509,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,955.0,N,1,,CHEMBL624397,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
7510,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,2046.0,N,1,,CHEMBL624398,In vivo,50597,13950,,Thyroid gland,A,,,Intermediate,,,
7511,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,2046.0,N,1,,CHEMBL624399,In vivo,50597,13950,,Thyroid gland,A,,,Intermediate,,,
7512,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,2046.0,N,1,,CHEMBL624400,In vivo,50597,13950,,Thyroid gland,A,,,Intermediate,,,
7513,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,2046.0,N,1,,CHEMBL624401,In vivo,50597,13950,,Thyroid gland,A,,,Intermediate,,,
7514,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,2046.0,N,1,,CHEMBL624402,In vivo,50597,13950,,Thyroid gland,A,,,Intermediate,,,
7515,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,178.0,N,1,,CHEMBL624403,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7516,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,178.0,N,1,,CHEMBL624404,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7517,BAO_0000218,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,178.0,N,1,,CHEMBL624405,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7518,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10000001.0,N,1,,CHEMBL624406,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7519,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,10000001.0,N,1,,CHEMBL624407,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7520,BAO_0000218,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,10000001.0,N,1,,CHEMBL624408,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7521,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,948.0,N,1,,CHEMBL618644,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7522,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,948.0,N,1,,CHEMBL618645,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7523,BAO_0000218,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,948.0,N,1,,CHEMBL618646,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7524,BAO_0000218,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2113.0,N,1,,CHEMBL618647,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7525,BAO_0000218,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,2113.0,N,1,,CHEMBL618648,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7526,BAO_0000218,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,2113.0,N,1,,CHEMBL618649,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7527,BAO_0000218,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2107.0,N,1,,CHEMBL618650,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7528,BAO_0000218,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,2107.0,N,1,,CHEMBL618651,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7529,BAO_0000218,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,2107.0,N,1,,CHEMBL876497,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7530,BAO_0000218,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2048.0,N,1,,CHEMBL618652,In vivo,50597,9866,,Lung,A,,,Intermediate,,,
7531,BAO_0000218,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,2048.0,N,1,,CHEMBL618653,In vivo,50597,9866,,Lung,A,,,Intermediate,,,
7532,BAO_0000218,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,2048.0,N,1,,CHEMBL618654,In vivo,50597,9866,,Lung,A,,,Intermediate,,,
7533,BAO_0000218,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,N,1,,CHEMBL618655,,50597,6351,,,A,,,Intermediate,,,
7534,BAO_0000218,Compound was tested for solubility in water,,N,1,,CHEMBL618656,,50597,1465,,,A,,,Intermediate,,,
7535,BAO_0000100,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,U,1,,CHEMBL618657,,22229,5182,,,P,,,Intermediate,,,
7536,BAO_0000218,Solubility was determined,,N,1,,CHEMBL618658,,50597,17847,,,A,,,Intermediate,,,
7537,BAO_0000218,solubility in water (ug/mL) at 37 degree C.,,N,1,,CHEMBL618659,,50597,15339,,,A,,,Intermediate,,,
7538,BAO_0000218,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,N,1,,CHEMBL618660,,50597,5202,,,A,,,Intermediate,,,
7539,BAO_0000218,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,N,1,,CHEMBL618661,,50597,1088,,,A,,,Intermediate,,,
7540,BAO_0000218,Half life in rats,,N,1,,CHEMBL873807,,50597,3169,,,A,,,Intermediate,,,
7541,BAO_0000218,Half life in Dawley rat,,N,1,,CHEMBL618662,,50597,5353,,,A,,,Intermediate,,,
7542,BAO_0000218,Half life period after 3 mg/kg iv administration,,N,1,,CHEMBL618663,In vivo,50597,2864,,,A,,,Intermediate,,,
7543,BAO_0000218,Half life period after 3 mg/kg iv administration in rat,,N,1,,CHEMBL618664,In vivo,50597,2864,,,A,,,Intermediate,,,
7544,BAO_0000218,Half life period after 3 mg/kg iv administration in the rat,,N,1,,CHEMBL618665,In vivo,50597,2864,,,A,,,Intermediate,,,
7545,BAO_0000218,Half life period in female Sprague-Dawley rats,,N,1,,CHEMBL876498,,50597,6362,,,A,,,Intermediate,,,
7546,BAO_0000218,Half life period in rat,,N,1,,CHEMBL618666,,50597,6249,,,A,,,Intermediate,,,
7547,BAO_0000218,Half-life in rats was determined,,N,1,,CHEMBL620440,,50597,3169,,,A,,,Intermediate,,,
7548,BAO_0000218,Half-life in rats with metabolic oxidation,,N,1,,CHEMBL620441,,50597,3169,,,A,,,Intermediate,,,
7549,BAO_0000218,Half-life in rats,,N,1,,CHEMBL620442,,50597,3169,,,A,,,Intermediate,,,
7550,BAO_0000218,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,1,,CHEMBL620443,In vivo,50597,17260,,,A,,,Intermediate,,,
7551,BAO_0000218,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,1,,CHEMBL620444,In vivo,50597,17260,,,A,,,Intermediate,,,
7552,BAO_0000218,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,1,,CHEMBL620445,In vivo,50597,17260,,,A,,,Intermediate,,,
7553,BAO_0000218,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,1,,CHEMBL620446,In vivo,50597,17260,,,A,,,Intermediate,,,
7554,BAO_0000218,Biological half-life measured in plasma of rat,1969.0,N,1,,CHEMBL620447,,50597,2879,,Plasma,A,,,Intermediate,,,
7555,BAO_0000218,Biological half-life measured in plasma of rat; 22-25,1969.0,N,1,,CHEMBL621129,,50597,2879,,Plasma,A,,,Intermediate,,,
7556,BAO_0000218,Biological half-life measured in plasma of rat; 9-16,1969.0,N,1,,CHEMBL621130,,50597,2879,,Plasma,A,,,Intermediate,,,
7557,BAO_0000218,Compound was evaluated for its half life when administered intravenously in rat,,N,1,,CHEMBL873808,In vivo,50597,3184,,,A,,,Intermediate,,,
7558,BAO_0000218,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,N,1,,CHEMBL876598,In vivo,50597,4891,,,A,,,Intermediate,,,
7559,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,N,1,,CHEMBL621131,In vivo,50597,429,,,A,,,Intermediate,,,
7560,BAO_0000218,Half life (T1/2) after oral administration in rat,,N,1,,CHEMBL621132,In vivo,50597,5656,,,A,,,Intermediate,,,
7561,BAO_0000218,Half life of compound after iv administration of 20 mg/kg dose in rat,,N,1,,CHEMBL621133,In vivo,50597,4413,,,A,,,Intermediate,,,
7562,BAO_0000218,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL621312,In vivo,50597,3598,,,A,,,Expert,,,
7563,BAO_0000218,Half life of compound was determined in rat,,N,1,,CHEMBL621313,,50597,17267,,,A,,,Intermediate,,,
7564,BAO_0000218,Half life of compound was determined in rat blood,178.0,N,1,,CHEMBL621314,,50597,4727,,Blood,A,,,Intermediate,,,
7565,BAO_0000218,Half life at 1 mg/kg was determined in rat,,N,1,,CHEMBL621315,In vivo,50597,17651,,,A,,,Intermediate,,,
7566,BAO_0000218,Half life at 10 mg/kg was determined in rat,,N,1,,CHEMBL621316,In vivo,50597,17651,,,A,,,Intermediate,,,
7567,BAO_0000218,Half life in rats,,N,1,,CHEMBL621317,,50597,401,,,A,,,Intermediate,,,
7568,BAO_0000218,Half life in rats in hours,,N,1,,CHEMBL621318,,50597,4942,,,A,,,Intermediate,,,
7569,BAO_0000218,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,N,1,,CHEMBL621319,In vivo,50597,17735,,,A,,,Intermediate,,,
7570,BAO_0000218,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,N,1,,CHEMBL621377,In vivo,50597,6056,,,A,,,Intermediate,,,
7571,BAO_0000218,Half life was determined,,N,1,,CHEMBL621378,,50597,5213,,,A,,,Intermediate,,,
7572,BAO_0000218,Half life after i.v. administration,,N,1,,CHEMBL876599,In vivo,50597,6616,,,A,,,Intermediate,,,
7573,BAO_0000218,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,N,1,,CHEMBL621379,In vivo,50597,5937,,,A,,,Intermediate,,,
7574,BAO_0000218,Half life in rat plasma,1969.0,N,1,,CHEMBL621380,,50597,5819,,Plasma,A,,,Intermediate,,,
7575,BAO_0000218,Half life in rat plasma; Not detected,1969.0,N,1,,CHEMBL621381,,50597,5819,,Plasma,A,,,Intermediate,,,
7576,BAO_0000218,Half life in rats,,N,1,,CHEMBL618515,,50597,6803,,,A,,,Intermediate,,,
7577,BAO_0000218,Half life period of compound was determined after peroral administration,,N,1,,CHEMBL618516,In vivo,50597,17804,,,A,,,Intermediate,,,
7578,BAO_0000218,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,N,1,,CHEMBL618517,In vivo,50597,17804,,,A,,,Intermediate,,,
7579,BAO_0000218,Half life period in rat,,N,1,,CHEMBL618518,,50597,5948,,,A,,,Intermediate,,,
7580,BAO_0000218,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,N,1,,CHEMBL618519,In vivo,50597,1916,,,A,,,Intermediate,,,
7581,BAO_0000218,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,N,1,,CHEMBL618698,In vivo,50597,1916,,,A,,,Intermediate,,,
7582,BAO_0000218,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,N,1,,CHEMBL618862,In vivo,50597,1916,,,A,,,Intermediate,,,
7583,BAO_0000218,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL618863,In vivo,50597,4890,,,A,,,Intermediate,,,
7584,BAO_0000218,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,N,1,,CHEMBL618864,In vivo,50597,17764,,,A,,,Intermediate,,,
7585,BAO_0000218,Half life time in rat the dose of 2 mg/kg,,N,1,,CHEMBL618865,In vivo,50597,4727,,,A,,,Intermediate,,,
7586,BAO_0000218,Half-life 24 hr after 10 mg/kg iv administration in rats,,N,1,,CHEMBL618866,In vivo,50597,17509,,,A,,,Intermediate,,,
7587,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in rats,,N,1,,CHEMBL618867,In vivo,50597,17509,,,A,,,Intermediate,,,
7588,BAO_0000218,Half-life consistent with the observed metabolic steady state in rats,,N,1,,CHEMBL875828,,50597,6597,,,A,,,Intermediate,,,
7589,BAO_0000218,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,N,1,,CHEMBL618868,In vivo,50597,17735,,,A,,,Intermediate,,,
7590,BAO_0000218,Half-life for oxidative metabolic stability was determined using male human,,N,1,,CHEMBL618869,,50597,6597,,,A,,,Intermediate,,,
7591,BAO_0000218,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,N,1,,CHEMBL618870,In vivo,50597,17670,,,A,,,Intermediate,,,
7592,BAO_0000218,Half-life in rat plasma,1969.0,N,1,,CHEMBL618871,,50597,1696,,Plasma,A,,,Intermediate,,,
7593,BAO_0000218,Half-life in rat plasma was determined,1969.0,N,1,,CHEMBL618872,,50597,1742,,Plasma,A,,,Intermediate,,,
7594,BAO_0000218,Half-life in rats was determined,,N,1,,CHEMBL873816,,50597,17800,,,A,,,Intermediate,,,
7595,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,U,1,,CHEMBL618873,,22224,12923,,,A,,,Autocuration,,,
7596,BAO_0000019,Area under curve after oral dose of 0.1 mg//kg,,U,1,,CHEMBL621602,,22224,11954,,,A,,,Autocuration,,,
7597,BAO_0000218,Area under curve after oral dose of 0.3 mg/kg,,U,1,,CHEMBL621603,,22224,11954,,,A,,,Autocuration,,,
7598,BAO_0000218,Area under curve after oral dose of 1 mg/kg,,U,1,,CHEMBL621604,,22224,11954,,,A,,,Autocuration,,,
7599,BAO_0000218,Area under curve after oral dose of 10 mg/kg,,U,1,,CHEMBL621605,,22224,11954,,,A,,,Autocuration,,,
7600,BAO_0000218,Area under curve after oral dose of 23.4 mg/kg,,U,1,,CHEMBL621606,,22224,11954,,,A,,,Autocuration,,,
7601,BAO_0000218,Area under curve after oral dose of 3 mg/kg,,U,1,,CHEMBL621607,,22224,11954,,,A,,,Autocuration,,,
7602,BAO_0000218,Area under curve after oral dose of 3.87 mg/kg,,U,1,,CHEMBL621608,,22224,11954,,,A,,,Autocuration,,,
7603,BAO_0000019,Area under curve was determined,,U,1,,CHEMBL621609,,22224,5237,,,A,,,Autocuration,,,
7604,BAO_0000218,Area under curve at a dose of 10 mg/kg,,U,1,,CHEMBL621610,,22224,4026,,,A,,,Autocuration,,,
7605,BAO_0000218,Area under curve was determined; ND=No data,,N,1,,CHEMBL621611,,50597,5237,,,A,,,Intermediate,,,
7606,BAO_0000218,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,N,1,,CHEMBL621612,,50597,14793,,,A,,,Intermediate,,,
7607,BAO_0000218,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,N,1,,CHEMBL622308,,50597,14793,,,A,,,Intermediate,,,
7608,BAO_0000218,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,N,1,,CHEMBL622309,,50597,14793,,,A,,,Intermediate,,,
7609,BAO_0000218,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,N,1,,CHEMBL622310,,50597,14793,,,A,,,Intermediate,,,
7610,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,N,1,,CHEMBL622311,,50597,14793,,,A,,,Intermediate,,,
7611,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,N,1,,CHEMBL622312,,50597,14793,,,A,,,Intermediate,,,
7612,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,N,1,,CHEMBL622931,,50597,14793,,,A,,,Intermediate,,,
7613,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,N,1,,CHEMBL622932,,50597,14793,,,A,,,Intermediate,,,
7614,BAO_0000218,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1969.0,N,1,,CHEMBL622736,,50597,14793,,Plasma,A,,,Intermediate,,,
7615,BAO_0000218,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1969.0,N,1,,CHEMBL622737,,50597,14793,,Plasma,A,,,Intermediate,,,
7616,BAO_0000218,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1969.0,N,1,,CHEMBL622738,,50597,14793,,Plasma,A,,,Intermediate,,,
7617,BAO_0000218,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1969.0,N,1,,CHEMBL622739,,50597,14793,,Plasma,A,,,Intermediate,,,
7618,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1969.0,N,1,,CHEMBL622740,,50597,14793,,Plasma,A,,,Intermediate,,,
7619,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1969.0,N,1,,CHEMBL622741,,50597,14793,,Plasma,A,,,Intermediate,,,
7620,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1969.0,N,1,,CHEMBL622742,,50597,14793,,Plasma,A,,,Intermediate,,,
7621,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1969.0,N,1,,CHEMBL622743,,50597,14793,,Plasma,A,,,Intermediate,,,
7622,BAO_0000218,AUC in mice,1969.0,N,1,,CHEMBL622744,,50594,11637,,Plasma,A,,,Intermediate,,,
7623,BAO_0000019,Area under curve was measured from the graph obtained from concentration Vs time,,U,1,,CHEMBL624134,,22224,11149,,,A,,,Autocuration,,,
7624,BAO_0000019,Area under curve value of compound per hour after oral administration,,U,1,,CHEMBL624135,,22224,10016,,,A,,,Autocuration,,,
7625,BAO_0000218,Area under curve was determined after oral administration in rats,,N,1,,CHEMBL624136,,50597,17796,,,A,,,Intermediate,,,
7626,BAO_0000218,Area under curve was determined after oral administration in rats; No data,,N,1,,CHEMBL624137,,50597,17796,,,A,,,Intermediate,,,
7627,BAO_0000218,Area under curve was determined after oral administration in rats;No data,,N,1,,CHEMBL624320,,50597,17796,,,A,,,Intermediate,,,
7628,BAO_0000218,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,N,1,,CHEMBL624321,,50588,12923,,,A,,,Intermediate,,,
7629,BAO_0000218,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,N,1,,CHEMBL624322,,50597,15372,,,A,,,Intermediate,,,
7630,BAO_0000218,Area under curve was determined for the compound after iv dose of 5.06 in rats,,N,1,,CHEMBL624323,,50597,15372,,,A,,,Intermediate,,,
7631,BAO_0000218,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,N,1,,CHEMBL624324,,50597,15372,,,A,,,Intermediate,,,
7632,BAO_0000218,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,N,1,,CHEMBL624325,,50597,15372,,,A,,,Intermediate,,,
7633,BAO_0000218,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,N,1,,CHEMBL624326,,50597,15372,,,A,,,Intermediate,,,
7634,BAO_0000218,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,N,1,,CHEMBL624327,,50597,15372,,,A,,,Intermediate,,,
7635,BAO_0000218,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,N,1,,CHEMBL624328,,50597,15372,,,A,,,Intermediate,,,
7636,BAO_0000218,Area under curve was determined in Dogs after peroral administration,,N,1,,CHEMBL627848,,50588,14169,,,A,,,Intermediate,,,
7637,BAO_0000218,Area under curve was determined in Rats after peroral administration,,N,1,,CHEMBL627849,,50597,14169,,,A,,,Intermediate,,,
7638,BAO_0000218,Area under curve was determined in carotid blood of rat when administered intradermally,,N,1,,CHEMBL627850,,50597,14258,,,A,,,Intermediate,,,
7639,BAO_0000218,Area under curve was determined in portal blood of rat when administered intradermally,,N,1,,CHEMBL627851,,50597,14258,,,A,,,Intermediate,,,
7640,BAO_0000218,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL627852,,50594,15011,,,A,,,Intermediate,,,
7641,BAO_0000218,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL627853,,50594,15011,,,A,,,Intermediate,,,
7642,BAO_0000218,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,N,1,,CHEMBL627854,,50594,15011,,,A,,,Intermediate,,,
7643,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL627855,,50594,15011,,,A,,,Intermediate,,,
7644,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,N,1,,CHEMBL627856,,50594,15011,,,A,,,Intermediate,,,
7645,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL875339,,50594,15011,,,A,,,Intermediate,,,
7646,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,N,1,,CHEMBL627857,,50594,15011,,,A,,,Intermediate,,,
7647,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,2106.0,N,1,,CHEMBL627858,In vivo,50597,11195,,Spleen,A,,,Intermediate,,,
7648,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,178.0,N,1,,CHEMBL627859,,50597,10130,,Blood,A,,,Intermediate,,,
7649,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,955.0,N,1,,CHEMBL627860,,50597,10130,,Brain,A,,,Intermediate,,,
7650,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,948.0,N,1,,CHEMBL627019,,50597,10130,,Heart,A,,,Intermediate,,,
7651,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,2107.0,N,1,,CHEMBL627020,,50597,10130,,Liver,A,,,Intermediate,,,
7652,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,2048.0,N,1,,CHEMBL627021,,50597,10130,,Lung,A,,,Intermediate,,,
7653,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,2385.0,N,1,,CHEMBL627022,,50597,10130,,Muscle tissue,A,,,Intermediate,,,
7654,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,N,1,,CHEMBL627023,,50597,10130,,,A,,,Intermediate,,,
7655,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,2106.0,N,1,,CHEMBL627024,,50597,10130,,Spleen,A,,,Intermediate,,,
7656,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,2046.0,N,1,,CHEMBL627025,,50597,10130,,Thyroid gland,A,,,Intermediate,,,
7657,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,2113.0,N,1,,CHEMBL627026,,50597,10130,,Kidney,A,,,Intermediate,,,
7658,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,178.0,N,1,,CHEMBL627027,,50597,10130,,Blood,A,,,Intermediate,,,
7659,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,955.0,N,1,,CHEMBL627028,,50597,10130,,Brain,A,,,Intermediate,,,
7660,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,948.0,N,1,,CHEMBL627029,,50597,10130,,Heart,A,,,Intermediate,,,
7661,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,2113.0,N,1,,CHEMBL627030,,50597,10130,,Kidney,A,,,Intermediate,,,
7662,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,2107.0,N,1,,CHEMBL627031,,50597,10130,,Liver,A,,,Intermediate,,,
7663,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,2048.0,N,1,,CHEMBL627032,,50597,10130,,Lung,A,,,Intermediate,,,
7664,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,2385.0,N,1,,CHEMBL627033,,50597,10130,,Muscle tissue,A,,,Intermediate,,,
7665,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,N,1,,CHEMBL627034,,50597,10130,,,A,,,Intermediate,,,
7666,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,2106.0,N,1,,CHEMBL627035,,50597,10130,,Spleen,A,,,Intermediate,,,
7667,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,2046.0,N,1,,CHEMBL627036,,50597,10130,,Thyroid gland,A,,,Intermediate,,,
7668,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,178.0,N,1,,CHEMBL875340,,50597,10130,,Blood,A,,,Intermediate,,,
7669,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,948.0,N,1,,CHEMBL627037,,50597,10130,,Heart,A,,,Intermediate,,,
7670,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,2113.0,N,1,,CHEMBL627038,,50597,10130,,Kidney,A,,,Intermediate,,,
7671,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,2107.0,N,1,,CHEMBL627039,,50597,10130,,Liver,A,,,Intermediate,,,
7672,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,2385.0,N,1,,CHEMBL627040,,50597,10130,,Muscle tissue,A,,,Intermediate,,,
7673,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,2106.0,N,1,,CHEMBL624663,,50597,10130,,Spleen,A,,,Intermediate,,,
7674,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,2046.0,N,1,,CHEMBL625963,,50597,10130,,Thyroid gland,A,,,Intermediate,,,
7675,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,955.0,N,1,,CHEMBL876799,,50597,10130,,Brain,A,,,Intermediate,,,
7676,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,2048.0,N,1,,CHEMBL626133,,50597,10130,,Lung,A,,,Intermediate,,,
7677,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,N,1,,CHEMBL626134,,50597,10130,,,A,,,Intermediate,,,
7678,BAO_0000218,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,N,1,,CHEMBL626135,,50597,6295,,,A,,,Intermediate,,,
7679,BAO_0000218,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,N,1,,CHEMBL626136,,50597,6296,,,A,,,Intermediate,,,
7680,BAO_0000218,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,N,1,,CHEMBL626137,,50597,6296,,,A,,,Intermediate,,,
7681,BAO_0000218,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,N,1,,CHEMBL626138,,50597,6295,,,A,,,Intermediate,,,
7682,BAO_0000218,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,N,1,,CHEMBL626139,,50597,6296,,,A,,,Intermediate,,,
7683,BAO_0000218,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,1,,CHEMBL626140,In vivo,50597,17260,,,A,,,Intermediate,,,
7684,BAO_0000218,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,1,,CHEMBL626141,In vivo,50597,17260,,,A,,,Intermediate,,,
7685,BAO_0000218,C24h in rat p.o. at 20 mg/kg concentration,,N,1,,CHEMBL626142,,50597,17686,,,A,,,Intermediate,,,
7686,BAO_0000218,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2385.0,N,1,,CHEMBL627930,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
7687,BAO_0000218,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,2385.0,N,1,,CHEMBL627931,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
7688,BAO_0000218,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,2385.0,N,1,,CHEMBL627932,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
7689,BAO_0000218,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2106.0,N,1,,CHEMBL627933,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
7690,BAO_0000218,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,2106.0,N,1,,CHEMBL627934,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
7691,BAO_0000218,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,2106.0,N,1,,CHEMBL627935,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
7692,BAO_0000218,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,178.0,N,1,,CHEMBL627936,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7693,BAO_0000218,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,178.0,N,1,,CHEMBL627937,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7694,BAO_0000218,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,178.0,N,1,,CHEMBL627938,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7695,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,178.0,N,1,,CHEMBL627939,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7696,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,178.0,N,1,,CHEMBL627940,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7697,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,178.0,N,1,,CHEMBL627941,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7698,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,178.0,N,1,,CHEMBL876800,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7699,BAO_0000218,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,178.0,N,1,,CHEMBL627942,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7700,BAO_0000218,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,178.0,N,1,,CHEMBL627943,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7701,BAO_0000218,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,178.0,N,1,,CHEMBL627944,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7702,BAO_0000218,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,178.0,N,1,,CHEMBL627945,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7703,BAO_0000218,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,178.0,N,1,,CHEMBL628584,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7704,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 15 min,178.0,N,1,,CHEMBL628585,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7705,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,178.0,N,1,,CHEMBL628586,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7706,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 30 min,178.0,N,1,,CHEMBL628587,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7707,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,178.0,N,1,,CHEMBL628588,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7708,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,178.0,N,1,,CHEMBL628589,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7709,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,178.0,N,1,,CHEMBL625304,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7710,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,178.0,N,1,,CHEMBL625305,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7711,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,178.0,N,1,,CHEMBL625306,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7712,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,178.0,N,1,,CHEMBL625307,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7713,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,178.0,N,1,,CHEMBL625308,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7714,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,178.0,N,1,,CHEMBL627740,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7715,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,178.0,N,1,,CHEMBL627741,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7716,BAO_0000218,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,178.0,N,1,,CHEMBL627742,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7717,BAO_0000218,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,178.0,N,1,,CHEMBL627743,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7718,BAO_0000218,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,178.0,N,1,,CHEMBL627744,In vivo,50597,9866,,Blood,A,,,Intermediate,,,
7719,BAO_0000218,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,10000001.0,N,1,,CHEMBL627745,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7720,BAO_0000218,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,10000001.0,N,1,,CHEMBL627746,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7721,BAO_0000218,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,10000001.0,N,1,,CHEMBL627747,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7722,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,10000001.0,N,1,,CHEMBL876810,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7723,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,10000001.0,N,1,,CHEMBL627748,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7724,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,10000001.0,N,1,,CHEMBL627749,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7725,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,10000001.0,N,1,,CHEMBL627750,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7726,BAO_0000218,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,10000001.0,N,1,,CHEMBL618728,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7727,BAO_0000218,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,10000001.0,N,1,,CHEMBL618729,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7728,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 15 min,10000001.0,N,1,,CHEMBL618730,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7729,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,10000001.0,N,1,,CHEMBL618731,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7730,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 30 min,10000001.0,N,1,,CHEMBL618732,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7731,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,10000001.0,N,1,,CHEMBL618733,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7732,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,10000001.0,N,1,,CHEMBL618734,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7733,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,10000001.0,N,1,,CHEMBL618735,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7734,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,10000001.0,N,1,,CHEMBL876602,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7735,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,10000001.0,N,1,,CHEMBL618736,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7736,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,10000001.0,N,1,,CHEMBL618737,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7737,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,10000001.0,N,1,,CHEMBL618738,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7738,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,10000001.0,N,1,,CHEMBL618739,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7739,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,10000001.0,N,1,,CHEMBL618740,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7740,BAO_0000218,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,10000001.0,N,1,,CHEMBL618741,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7741,BAO_0000218,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,10000001.0,N,1,,CHEMBL618742,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7742,BAO_0000218,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,10000001.0,N,1,,CHEMBL618743,In vivo,50597,9866,,Bone,A,,,Intermediate,,,
7743,BAO_0000218,Half-life from rat plasma at a single oral dose of 25 mg/kg,1969.0,N,1,,CHEMBL618744,In vivo,50597,17752,,Plasma,A,,,Intermediate,,,
7744,BAO_0000218,Half-life in male rat,,N,1,,CHEMBL618745,,50597,5610,,,A,,,Intermediate,,,
7745,BAO_0000218,Half-life in rat after peroral administration at 10 mg/kg concentration,,N,1,,CHEMBL620479,In vivo,50597,5939,,,A,,,Intermediate,,,
7746,BAO_0000218,Half-life in rat after peroral administration at 5 mg/kg concentration,,N,1,,CHEMBL620480,In vivo,50597,5939,,,A,,,Intermediate,,,
7747,BAO_0000218,Half-life in rat at a dose of 3 mg/kg,,N,1,,CHEMBL620481,In vivo,50597,17771,,,A,,,Intermediate,,,
7748,BAO_0000218,Half-life was evaluated in rats,,N,1,,CHEMBL620482,,50597,1974,,,A,,,Intermediate,,,
7749,BAO_0000218,Half-life was measured in rat,,N,1,,CHEMBL876603,,50597,4239,,,A,,,Intermediate,,,
7750,BAO_0000218,Half-life period for the compound was determined in rats at 50 mg/kg dose,,N,1,,CHEMBL620483,In vivo,50597,6681,,,A,,,Intermediate,,,
7751,BAO_0000218,Half-life period in rats after intravenous administration at 5 mg/kg,,N,1,,CHEMBL620484,In vivo,50597,17752,,,A,,,Intermediate,,,
7752,BAO_0000218,Half-life period in rat at 10 mg/kg,,N,1,,CHEMBL620485,In vivo,50597,6046,,,A,,,Intermediate,,,
7753,BAO_0000218,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,N,1,,CHEMBL620486,In vivo,50597,6685,,,A,,,Intermediate,,,
7754,BAO_0000218,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,N,1,,CHEMBL620487,In vivo,50597,6685,,,A,,,Intermediate,,,
7755,BAO_0000218,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,N,1,,CHEMBL620488,In vivo,50597,6685,,,A,,,Intermediate,,,
7756,BAO_0000218,Half-life time in rat the dose of 2 mg/kg,,N,1,,CHEMBL620489,In vivo,50597,4727,,,A,,,Intermediate,,,
7757,BAO_0000218,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,N,1,,CHEMBL620490,In vivo,50597,1088,,,A,,,Intermediate,,,
7758,BAO_0000218,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,N,1,,CHEMBL620491,In vivo,50597,5610,,,A,,,Intermediate,,,
7759,BAO_0000218,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1969.0,N,1,,CHEMBL876604,In vivo,50597,3032,,Plasma,A,,,Intermediate,,,
7760,BAO_0000218,Oral half life was determined,,N,1,,CHEMBL620492,In vivo,50597,5199,,,A,,,Intermediate,,,
7761,BAO_0000218,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,N,1,,CHEMBL620493,In vivo,50597,14941,,,A,,,Intermediate,,,
7762,BAO_0000218,Pharmacokinetic property (t1/2) in rat,,N,1,,CHEMBL620494,In vivo,50597,4408,,,A,,,Intermediate,,,
7763,BAO_0000218,Plasma elimination half-life was determined,1969.0,N,1,,CHEMBL620495,,50597,2552,,Plasma,A,,,Intermediate,,,
7764,BAO_0000218,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1969.0,N,1,,CHEMBL620496,In vivo,50597,5199,,Plasma,A,,,Intermediate,,,
7765,BAO_0000218,Plasma half life was observed after intravenous administration in rat,1969.0,N,1,,CHEMBL620497,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
7766,BAO_0000218,Plasma half-life was determined,1969.0,N,1,,CHEMBL620498,,50597,1465,,Plasma,A,,,Intermediate,,,
7767,BAO_0000218,Plasma half-life following oral administration in Fisher rats,1969.0,N,1,,CHEMBL620499,In vivo,50597,1446,,Plasma,A,,,Intermediate,,,
7768,BAO_0000218,Plasma half-life in rat,1969.0,N,1,,CHEMBL620500,,50597,6824,,Plasma,A,,,Intermediate,,,
7769,BAO_0000218,Plasmatic Half-life after intravenous administration to rat,1969.0,N,1,,CHEMBL873809,In vivo,50597,17533,,Plasma,A,,,Intermediate,,,
7770,BAO_0000218,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,N,1,,CHEMBL620501,In vivo,50597,5979,,,A,,,Intermediate,,,
7771,BAO_0000218,Terminal half life after intravenous administration (1 mg/kg) in rat,,N,1,,CHEMBL620502,In vivo,50597,4689,,,A,,,Intermediate,,,
7772,BAO_0000218,Terminal half life in Rat at a oral dose of 5 mg/kg,,N,1,,CHEMBL620503,In vivo,50597,4689,,,A,,,Intermediate,,,
7773,BAO_0000218,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,N,1,,CHEMBL620504,In vivo,50597,2463,,,A,,,Intermediate,,,
7774,BAO_0000218,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,N,1,,CHEMBL876605,In vivo,50597,4883,,,A,,,Intermediate,,,
7775,BAO_0000218,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,N,1,,CHEMBL620505,In vivo,50597,4883,,,A,,,Intermediate,,,
7776,BAO_0000218,plasma half life was observed after intravenous administration in rat,1969.0,N,1,,CHEMBL873811,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
7777,BAO_0000218,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL624016,In vivo,50597,3598,,,A,,,Expert,,,
7778,BAO_0000218,Half life of compound determined in rat,,N,1,,CHEMBL624017,,50597,4576,,,A,,,Intermediate,,,
7779,BAO_0000218,Mean residence time determined in rat,,N,1,,CHEMBL624018,,50597,4576,,,A,,,Intermediate,,,
7780,BAO_0000218,Plasma half life determined in rat,,N,1,,CHEMBL624019,,50597,4576,,,A,,,Intermediate,,,
7781,BAO_0000218,Compound was evaluated for Tmax in brain after intravenous administration in male rats,955.0,N,1,,CHEMBL624020,In vivo,50597,4910,,Brain,A,,,Intermediate,,,
7782,BAO_0000218,Compound was evaluated for pharmacokinetic parameter maximum time period,,N,1,,CHEMBL624201,In vivo,50597,4891,,,A,,,Intermediate,,,
7783,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,N,1,,CHEMBL872528,In vivo,50597,429,,,A,,,Intermediate,,,
7784,BAO_0000218,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624202,In vivo,50597,5974,,,A,,,Intermediate,,,
7785,BAO_0000218,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624203,In vivo,50597,5974,,,A,,,Intermediate,,,
7786,BAO_0000218,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624350,In vivo,50597,5974,,,A,,,Intermediate,,,
7787,BAO_0000218,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL621320,In vivo,50597,5974,,,A,,,Intermediate,,,
7788,BAO_0000218,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,N,1,,CHEMBL621321,In vivo,50597,17582,,,A,,,Intermediate,,,
7789,BAO_0000218,Maximum time (Tmax) required to reach Cmax in rats,,N,1,,CHEMBL621322,,50597,4026,,,A,,,Intermediate,,,
7790,BAO_0000218,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL621323,In vivo,50597,4890,,,A,,,Intermediate,,,
7791,BAO_0000218,Maximum time of clearance of compound in rats after peroral administration,,N,1,,CHEMBL621324,In vivo,50597,6571,,,A,,,Intermediate,,,
7792,BAO_0000218,Maximum time at the dose of 2 mg/kg in rat,,N,1,,CHEMBL621325,,50597,4727,,,A,,,Intermediate,,,
7793,BAO_0000218,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1969.0,N,1,,CHEMBL875837,In vivo,50597,17651,,Plasma,A,,,Intermediate,,,
7794,BAO_0000218,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1969.0,N,1,,CHEMBL621326,In vivo,50597,17651,,Plasma,A,,,Intermediate,,,
7795,BAO_0000218,Tmax in Guinea pig (PO dose),,N,1,,CHEMBL621327,In vivo,50597,14465,,,A,,,Intermediate,,,
7796,BAO_0000218,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,N,1,,CHEMBL621328,In vivo,50597,14941,,,A,,,Intermediate,,,
7797,BAO_0000218,Pharmacokinetic parameter (Tmax) in rat,,N,1,,CHEMBL621329,In vivo,50597,5960,,,A,,,Intermediate,,,
7798,BAO_0000218,Pharmacokinetic parameter (Tmax) was estimated,,N,1,,CHEMBL621330,In vivo,50597,5022,,,A,,,Intermediate,,,
7799,BAO_0000218,Pharmacokinetic property (Tmax) in rat,,N,1,,CHEMBL621331,In vivo,50597,4408,,,A,,,Intermediate,,,
7800,BAO_0000218,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,N,1,,CHEMBL621332,In vivo,50597,5983,,,A,,,Intermediate,,,
7801,BAO_0000218,T max in Rat at a oral dose of 5 mg/kg,,N,1,,CHEMBL621333,In vivo,50597,4689,,,A,,,Intermediate,,,
7802,BAO_0000218,T max was determined at 10 mg/kg po dose in rats,,N,1,,CHEMBL621334,In vivo,50597,2792,,,A,,,Intermediate,,,
7803,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,N,1,,CHEMBL621335,,50594,15011,,,A,,,Intermediate,,,
7804,BAO_0000218,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,N,1,,CHEMBL621336,,50588,14180,,,A,,,Intermediate,,,
7805,BAO_0000218,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,N,1,,CHEMBL621337,,50597,14180,,,A,,,Intermediate,,,
7806,BAO_0000218,Area under curve was measured after i.v. administration into Beagle dog.,,N,1,,CHEMBL621338,,50588,14599,,,A,,,Intermediate,,,
7807,BAO_0000218,Area under curve was measured after iv administration into Beagle dog,,N,1,,CHEMBL875838,,50588,14599,,,A,,,Intermediate,,,
7808,BAO_0000218,Area under curve was measured after po administration into Beagle dog,,N,1,,CHEMBL621339,,50588,14599,,,A,,,Intermediate,,,
7809,BAO_0000218,Area under curve was measured after po administration into Beagle dog.,,N,1,,CHEMBL621340,,50588,14599,,,A,,,Intermediate,,,
7810,BAO_0000218,Area under curve was measured at peroral dose of 3 mg/kg,,U,1,,CHEMBL621341,,22224,15675,,,A,,,Autocuration,,,
7811,BAO_0000019,Area under curve was measured by using concentration Vs time,,U,1,,CHEMBL621342,,22224,12706,,,A,,,Autocuration,,,
7812,BAO_0000019,Area under curve was measured by using concentration Vs time; not tested,,U,1,,CHEMBL621343,,22224,12706,,,A,,,Autocuration,,,
7813,BAO_0000218,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,N,1,,CHEMBL621344,,50594,9750,,,A,,,Intermediate,,,
7814,BAO_0000218,Area under curve(AUC) was measured in mice after oral administration.,,N,1,,CHEMBL621345,,50594,9750,,,A,,,Intermediate,,,
7815,BAO_0000019,Area under curve(AUC) value of the compound,,U,1,,CHEMBL621346,,22224,14691,,,A,,,Autocuration,,,
7816,BAO_0000218,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,U,1,,CHEMBL621347,,22224,14691,,,A,,,Autocuration,,,
7817,BAO_0000218,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,N,1,,CHEMBL621348,,50588,14691,,,A,,,Intermediate,,,
7818,BAO_0000019,Area under curve(carotid artery) was determined by the availability in blood,178.0,U,1,,CHEMBL621349,,22224,2939,,Blood,A,,,Autocuration,,,
7819,BAO_0000019,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,178.0,U,1,,CHEMBL621350,,22224,2939,,Blood,A,,,Autocuration,,,
7820,BAO_0000019,Area under curve(carotid artery) was determined by the availability in blood; No data,178.0,U,1,,CHEMBL875839,,22224,2939,,Blood,A,,,Autocuration,,,
7821,BAO_0000019,Area under curve(portal vein) was determined by the availability in blood,178.0,U,1,,CHEMBL620211,,22224,2939,,Blood,A,,,Autocuration,,,
7822,BAO_0000019,Area under curve(portal vein) was determined by the availability in blood; ND means no data,178.0,U,1,,CHEMBL620212,,22224,2939,,Blood,A,,,Autocuration,,,
7823,BAO_0000019,Area under curve(portal vein) was determined by the availability in blood; No data,178.0,U,1,,CHEMBL620213,,22224,2939,,Blood,A,,,Autocuration,,,
7824,BAO_0000218,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1969.0,N,1,,CHEMBL620214,,50797,9552,,Plasma,A,,,Intermediate,,,
7825,BAO_0000218,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1969.0,N,1,,CHEMBL620215,,50797,9552,,Plasma,A,,,Intermediate,,,
7826,BAO_0000218,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1969.0,N,1,,CHEMBL620216,,50797,9552,,Plasma,A,,,Intermediate,,,
7827,BAO_0000218,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1969.0,N,1,,CHEMBL620888,,50588,9552,,Plasma,A,,,Intermediate,,,
7828,BAO_0000218,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1969.0,N,1,,CHEMBL620889,,50588,9552,,Plasma,A,,,Intermediate,,,
7829,BAO_0000019,Area under plasma concentration vs time curve observed in rats for 0-3 h,1969.0,U,1,,CHEMBL620890,,22224,9552,,Plasma,A,,,Autocuration,,,
7830,BAO_0000218,Area under plasma time curve determined in male rat,1969.0,N,1,,CHEMBL620891,,50597,11911,,Plasma,A,,,Intermediate,,,
7831,BAO_0000019,Area under the MAP curve measured over 5 min.,,U,1,,CHEMBL620892,,22224,16618,,,A,,,Autocuration,,,
7832,BAO_0000218,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,N,1,,CHEMBL621079,,50594,14387,,,A,,,Intermediate,,,
7833,BAO_0000218,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,N,1,,CHEMBL621080,,50594,14387,,,A,,,Intermediate,,,
7834,BAO_0000218,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,N,1,,CHEMBL621081,,50588,12836,,,A,,,Intermediate,,,
7835,BAO_0000218,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,N,1,,CHEMBL621082,,100712,12836,,,A,,,Intermediate,,,
7836,BAO_0000218,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,N,1,,CHEMBL621083,,50597,12836,,,A,,,Intermediate,,,
7837,BAO_0000218,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,N,1,,CHEMBL621084,,50588,14339,,,A,,,Intermediate,,,
7838,BAO_0000218,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,N,1,,CHEMBL621085,,50588,14339,,,A,,,Intermediate,,,
7839,BAO_0000218,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,N,1,,CHEMBL621086,,50588,14339,,,A,,,Intermediate,,,
7840,BAO_0000218,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,N,1,,CHEMBL621087,,50588,10524,,,A,,,Intermediate,,,
7841,BAO_0000218,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,N,1,,CHEMBL622607,,50588,9994,,,A,,,Intermediate,,,
7842,BAO_0000218,Serum AUC in marmosets (IV dose),,N,1,,CHEMBL622608,,50588,11325,,,A,,,Intermediate,,,
7843,BAO_0000019,Area under the curve after intravenous administration at a dose of 10 umol/kg,,U,1,,CHEMBL624481,,22224,12536,,,A,,,Autocuration,,,
7844,BAO_0000019,Area under the curve after intravenous administration at a dose of 2 umol/kg,,U,1,,CHEMBL624482,,22224,12536,,,A,,,Autocuration,,,
7845,BAO_0000019,Area under the curve after intravenous administration at a dose of 4 umol/kg,,U,1,,CHEMBL624483,,22224,12536,,,A,,,Autocuration,,,
7846,BAO_0000019,Area under the curve after intravenous administration at a dose of 40 umol/kg,,U,1,,CHEMBL624484,,22224,12536,,,A,,,Autocuration,,,
7847,BAO_0000019,Area under the curve after intravenous administration at a dose of 5 umol/kg,,U,1,,CHEMBL624485,,22224,12536,,,A,,,Autocuration,,,
7848,BAO_0000218,Area under the curve for fumarate salt was evaluated in F344 Rats.,,N,1,,CHEMBL624486,,50597,15556,,,A,,,Intermediate,,,
7849,BAO_0000019,Area under the curve for the compound was calculated.,,U,1,,CHEMBL624487,,22224,2809,,,A,,,Autocuration,,,
7850,BAO_0000019,Area under the curve in concentration/ time,,U,1,,CHEMBL624488,,22224,9511,,,A,,,Autocuration,,,
7851,BAO_0000218,Area under the curve administered intraintestinal in rats.,,N,1,,CHEMBL624489,,50597,12818,,,A,,,Intermediate,,,
7852,BAO_0000218,Area under the curve administered intravenously in rats.,,N,1,,CHEMBL625184,,50597,12818,,,A,,,Intermediate,,,
7853,BAO_0000019,Area under the curve during intravenous administration,,U,1,,CHEMBL625185,,22224,15118,,,A,,,Autocuration,,,
7854,BAO_0000019,Area under the curve during intravenous administration; Not determined,,U,1,,CHEMBL875954,,22224,15118,,,A,,,Autocuration,,,
7855,BAO_0000019,Area under the curve during systemic administration,,U,1,,CHEMBL625186,,22224,15118,,,A,,,Autocuration,,,
7856,BAO_0000019,Area under the curve during systemic administration; Not determined,,U,1,,CHEMBL625187,,22224,15118,,,A,,,Autocuration,,,
7857,BAO_0000019,Area under the curve was calculated for the compound.,,U,1,,CHEMBL625188,,22224,2632,,,A,,,Autocuration,,,
7858,BAO_0000218,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,N,1,,CHEMBL625189,,50588,14346,,,A,,,Intermediate,,,
7859,BAO_0000218,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,N,1,,CHEMBL625190,,50588,14346,,,A,,,Intermediate,,,
7860,BAO_0000218,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,N,1,,CHEMBL621733,,50597,14346,,,A,,,Intermediate,,,
7861,BAO_0000218,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,N,1,,CHEMBL621734,,50597,14346,,,A,,,Intermediate,,,
7862,BAO_0000218,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,N,1,,CHEMBL621735,,50597,11149,,,A,,,Intermediate,,,
7863,BAO_0000218,Clearance of the drug was measured in the plasma of rat; No data,1969.0,N,1,,CHEMBL621736,,50597,17796,,Plasma,A,,,Intermediate,,,
7864,BAO_0000218,The pharmacokinetic parameter plasma clearance in vivo in rats,1969.0,N,1,,CHEMBL621737,,50597,5247,,Plasma,A,,,Intermediate,,,
7865,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in rat,,N,1,,CHEMBL621738,,50597,4727,,,A,,,Intermediate,,,
7866,BAO_0000218,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,1,,CHEMBL622806,In vivo,50597,5654,,,A,,,Intermediate,,,
7867,BAO_0000218,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,1,,CHEMBL623519,In vivo,50597,5654,,,A,,,Intermediate,,,
7868,BAO_0000218,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,1,,CHEMBL623520,In vivo,50597,17260,,,A,,,Intermediate,,,
7869,BAO_0000218,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,1,,CHEMBL623521,In vivo,50597,17065,,,A,,,Intermediate,,,
7870,BAO_0000218,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,1,,CHEMBL623522,In vivo,50597,17671,,,A,,,Intermediate,,,
7871,BAO_0000218,Clearance rate in rat,,N,1,,CHEMBL623523,In vivo,50597,6672,,,A,,,Intermediate,,,
7872,BAO_0000218,Clearance rate in rat,,N,1,,CHEMBL623690,In vivo,50597,6673,,,A,,,Intermediate,,,
7873,BAO_0000218,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL623691,In vivo,50597,5978,,,A,,,Intermediate,,,
7874,BAO_0000218,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL623692,In vivo,50597,5978,,,A,,,Intermediate,,,
7875,BAO_0000218,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL623693,In vivo,50597,5978,,,A,,,Intermediate,,,
7876,BAO_0000218,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL623694,In vivo,50597,5978,,,A,,,Intermediate,,,
7877,BAO_0000218,Clearance of compound after iv administration of 20 mg/kg dose in rat,,N,1,,CHEMBL623695,In vivo,50597,4413,,,A,,,Intermediate,,,
7878,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,N,1,,CHEMBL623696,In vivo,50597,2661,,,A,,,Intermediate,,,
7879,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,N,1,,CHEMBL623697,In vivo,50597,2661,,,A,,,Intermediate,,,
7880,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,U,1,,CHEMBL623698,In vivo,22224,5005,,Plasma,A,,,Intermediate,,,
7881,BAO_0000218,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1969.0,U,1,,CHEMBL623699,In vivo,22224,5005,,Plasma,A,,,Intermediate,,,
7882,BAO_0000218,Mean (%CV) PK parameters for CL(mL/min/kg).,,N,1,,CHEMBL623700,In vivo,50597,15765,,,A,,,Intermediate,,,
7883,BAO_0000218,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,N,1,,CHEMBL623701,In vivo,50597,3747,,,A,,,Intermediate,,,
7884,BAO_0000218,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1969.0,N,1,,CHEMBL623702,In vivo,50597,16366,,Plasma,A,,,Intermediate,,,
7885,BAO_0000218,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,N,1,,CHEMBL623703,In vivo,50597,4199,,,A,,,Intermediate,,,
7886,BAO_0000218,Plasma clearance in rat was determined,,N,1,,CHEMBL623704,In vivo,50597,17267,,,A,,,Intermediate,,,
7887,BAO_0000218,Plasma clearance in rat after administration of 2 mg/kg iv,,N,1,,CHEMBL623705,In vivo,50597,6535,,,A,,,Intermediate,,,
7888,BAO_0000218,Plasma clearance in rat after administration of 2 mg/kg iv,,N,1,,CHEMBL623706,In vivo,50597,6535,,,A,,,Intermediate,,,
7889,BAO_0000218,Plasma clearance was determined,,N,1,,CHEMBL623707,In vivo,50597,5041,,,A,,,Intermediate,,,
7890,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL623708,In vivo,50597,5960,,,A,,,Intermediate,,,
7891,BAO_0000218,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,N,1,,CHEMBL623709,In vivo,50597,5937,,,A,,,Intermediate,,,
7892,BAO_0000218,Plasma clearance in rat by iv administration,,N,1,,CHEMBL623710,In vivo,50597,5871,,,A,,,Intermediate,,,
7893,BAO_0000218,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,N,1,,CHEMBL623711,In vivo,50597,5874,,,A,,,Intermediate,,,
7894,BAO_0000218,Plasma clearance in rat p.o.,,N,1,,CHEMBL623712,In vivo,50597,6504,,,A,,,Intermediate,,,
7895,BAO_0000218,Plasma clearance in rats,,N,1,,CHEMBL623713,In vivo,50597,6803,,,A,,,Intermediate,,,
7896,BAO_0000218,Plasma clearance was determined; ND denotes no data,,N,1,,CHEMBL623714,In vivo,50597,5041,,,A,,,Intermediate,,,
7897,BAO_0000218,Plasma clearance was determined; ND denotes not determined,,N,1,,CHEMBL623715,In vivo,50597,5041,,,A,,,Intermediate,,,
7898,BAO_0000218,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,N,1,,CHEMBL623716,In vivo,50597,1916,,,A,,,Intermediate,,,
7899,BAO_0000218,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,N,1,,CHEMBL622980,In vivo,50597,5199,,,A,,,Intermediate,,,
7900,BAO_0000218,Plasma administration to rats,,N,1,,CHEMBL622981,In vivo,50597,16367,,,A,,,Intermediate,,,
7901,BAO_0000218,Plasma clearance of the compound in female Sprague-Dawley rats,,N,1,,CHEMBL622982,In vivo,50597,6362,,,A,,,Intermediate,,,
7902,BAO_0000218,Plasma clearance was observed after intravenous administration in rat,,N,1,,CHEMBL622983,In vivo,50597,15662,,,A,,,Intermediate,,,
7903,BAO_0000218,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,N,1,,CHEMBL622984,In vivo,50597,6215,,,A,,,Intermediate,,,
7904,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,N,1,,CHEMBL622985,In vivo,50597,1466,,,A,,,Intermediate,,,
7905,BAO_0000218,plasma clearance was observed after intravenous administration in rat,1969.0,N,1,,CHEMBL623631,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
7906,BAO_0000218,In vivo CL/F determined,,N,1,,CHEMBL623632,In vivo,50597,4723,,,A,,,Intermediate,,,
7907,BAO_0000218,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1969.0,N,1,,CHEMBL623633,In vivo,50597,2792,,Plasma,A,,,Intermediate,,,
7908,BAO_0000218,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1969.0,N,1,,CHEMBL623634,In vivo,50597,2792,,Plasma,A,,,Intermediate,,,
7909,BAO_0000218,Compound was tested for the lower blood clearance in rat,,N,1,,CHEMBL623635,In vivo,50597,5213,,,A,,,Intermediate,,,
7910,BAO_0000218,Evaluated for the low clearance in rat (in vivo),,N,1,,CHEMBL621195,In vivo,50597,4687,,,A,,,Intermediate,,,
7911,BAO_0000218,Pharmacokinetic property (CLb)of the compound was determined in rat,,N,1,,CHEMBL621196,In vivo,50597,3371,,,A,,,Intermediate,,,
7912,BAO_0000218,Rapid clearance after intravenous administration in rat was determined,,N,1,,CHEMBL875287,In vivo,50597,4690,,,A,,,Intermediate,,,
7913,BAO_0000218,Clearance measured in rat,,N,1,,CHEMBL621197,In vivo,50597,5702,,,A,,,Intermediate,,,
7914,BAO_0000218,Compound was evaluated for plasma clearance in rat,1969.0,N,1,,CHEMBL621198,In vivo,50597,740,,Plasma,A,,,Intermediate,,,
7915,BAO_0000218,Low plasma clearance was calculated in rat,1969.0,N,1,,CHEMBL621199,In vivo,50597,4853,,Plasma,A,,,Intermediate,,,
7916,BAO_0000218,Pharmacokinetic property (Clp) in rat,,N,1,,CHEMBL621200,In vivo,50597,5789,,,A,,,Intermediate,,,
7917,BAO_0000218,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,N,1,,CHEMBL621201,In vivo,50597,4527,,,A,,,Intermediate,,,
7918,BAO_0000218,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,N,1,,CHEMBL621202,In vivo,50597,4527,,,A,,,Intermediate,,,
7919,BAO_0000218,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,N,1,,CHEMBL621203,In vivo,50597,6518,,,A,,,Intermediate,,,
7920,BAO_0000218,Plasma clearance after IV dosing at 1 mg/kg in rat,,N,1,,CHEMBL621204,In vivo,50597,6518,,,A,,,Intermediate,,,
7921,BAO_0000218,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,948.0,N,1,,CHEMBL621205,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7922,BAO_0000218,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,948.0,N,1,,CHEMBL621206,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7923,BAO_0000218,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,948.0,N,1,,CHEMBL621207,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7924,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,948.0,N,1,,CHEMBL621208,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7925,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,948.0,N,1,,CHEMBL621209,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7926,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,948.0,N,1,,CHEMBL876484,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7927,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,948.0,N,1,,CHEMBL621210,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7928,BAO_0000218,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,948.0,N,1,,CHEMBL621211,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7929,BAO_0000218,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,948.0,N,1,,CHEMBL621212,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7930,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 15 min,948.0,N,1,,CHEMBL621213,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7931,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,948.0,N,1,,CHEMBL621214,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7932,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 30 min,948.0,N,1,,CHEMBL621215,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7933,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,948.0,N,1,,CHEMBL621216,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7934,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,948.0,N,1,,CHEMBL621217,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7935,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,948.0,N,1,,CHEMBL621218,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7936,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,948.0,N,1,,CHEMBL621219,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7937,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,948.0,N,1,,CHEMBL621220,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7938,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,948.0,N,1,,CHEMBL621221,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7939,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,948.0,N,1,,CHEMBL621222,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7940,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,948.0,N,1,,CHEMBL621223,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7941,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,948.0,N,1,,CHEMBL876485,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7942,BAO_0000218,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,948.0,N,1,,CHEMBL621224,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7943,BAO_0000218,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,948.0,N,1,,CHEMBL621225,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7944,BAO_0000218,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,948.0,N,1,,CHEMBL621226,In vivo,50597,9866,,Heart,A,,,Intermediate,,,
7945,BAO_0000218,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,2113.0,N,1,,CHEMBL621227,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7946,BAO_0000218,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,2113.0,N,1,,CHEMBL621228,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7947,BAO_0000218,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,2113.0,N,1,,CHEMBL621229,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7948,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,2113.0,N,1,,CHEMBL621230,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7949,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,2113.0,N,1,,CHEMBL621231,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7950,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,2113.0,N,1,,CHEMBL621232,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7951,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,2113.0,N,1,,CHEMBL621233,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7952,BAO_0000218,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,2113.0,N,1,,CHEMBL621234,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7953,BAO_0000218,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,2113.0,N,1,,CHEMBL621235,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7954,BAO_0000218,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,2113.0,N,1,,CHEMBL621236,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7955,BAO_0000218,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,2113.0,N,1,,CHEMBL621237,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7956,BAO_0000218,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,2113.0,N,1,,CHEMBL876486,In vivo,50597,9866,,Kidney,A,,,Intermediate,,,
7957,BAO_0000218,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,160.0,N,1,,CHEMBL622436,In vivo,50597,9866,,Intestine,A,,,Intermediate,,,
7958,BAO_0000218,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,160.0,N,1,,CHEMBL622437,In vivo,50597,9866,,Intestine,A,,,Intermediate,,,
7959,BAO_0000218,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,160.0,N,1,,CHEMBL622438,In vivo,50597,9866,,Intestine,A,,,Intermediate,,,
7960,BAO_0000218,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,2107.0,N,1,,CHEMBL622439,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7961,BAO_0000218,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,2107.0,N,1,,CHEMBL622440,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7962,BAO_0000218,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,2107.0,N,1,,CHEMBL622441,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7963,BAO_0000218,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,2107.0,N,1,,CHEMBL622442,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7964,BAO_0000218,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,2107.0,N,1,,CHEMBL622443,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7965,BAO_0000218,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,2107.0,N,1,,CHEMBL622444,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7966,BAO_0000218,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,2107.0,N,1,,CHEMBL622445,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7967,BAO_0000218,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,2107.0,N,1,,CHEMBL622446,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7968,BAO_0000218,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,2107.0,N,1,,CHEMBL622447,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7969,BAO_0000218,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,2107.0,N,1,,CHEMBL622448,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7970,BAO_0000218,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,2107.0,N,1,,CHEMBL622449,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7971,BAO_0000218,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,2107.0,N,1,,CHEMBL622450,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7972,BAO_0000218,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,2107.0,N,1,,CHEMBL622451,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7973,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 15 min,2107.0,N,1,,CHEMBL622452,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7974,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,2107.0,N,1,,CHEMBL622453,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7975,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 30 min,2107.0,N,1,,CHEMBL622454,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7976,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,2107.0,N,1,,CHEMBL622455,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7977,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,2107.0,N,1,,CHEMBL876024,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
7978,BAO_0000218,T max was determined at 3 mg/kg po dose in rats,,N,1,,CHEMBL622456,In vivo,50597,2792,,,A,,,Intermediate,,,
7979,BAO_0000218,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL622457,In vivo,50597,15078,,,A,,,Intermediate,,,
7980,BAO_0000218,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL622458,In vivo,50597,15078,,,A,,,Intermediate,,,
7981,BAO_0000218,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,N,1,,CHEMBL622459,,50597,15022,,,A,,,Intermediate,,,
7982,BAO_0000218,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,N,1,,CHEMBL873343,,50597,15022,,,A,,,Intermediate,,,
7983,BAO_0000218,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,N,1,,CHEMBL622460,,50597,15022,,,A,,,Intermediate,,,
7984,BAO_0000218,Time for maximum plasma concentration determined in rat,1969.0,N,1,,CHEMBL622461,,50597,4576,,Plasma,A,,,Intermediate,,,
7985,BAO_0000218,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1969.0,N,1,,CHEMBL622462,In vivo,50597,6681,,Plasma,A,,,Intermediate,,,
7986,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,N,1,,CHEMBL622463,In vivo,50597,16365,,,A,,,Intermediate,,,
7987,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,N,1,,CHEMBL622464,In vivo,50597,16365,,,A,,,Intermediate,,,
7988,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,N,1,,CHEMBL622465,In vivo,50597,16365,,,A,,,Intermediate,,,
7989,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,N,1,,CHEMBL622466,In vivo,50597,16365,,,A,,,Intermediate,,,
7990,BAO_0000218,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,N,1,,CHEMBL622467,In vivo,50597,16365,,,A,,,Intermediate,,,
7991,BAO_0000218,Time of maximum plasma concentration in rat,1969.0,N,1,,CHEMBL622468,,50597,6824,,Plasma,A,,,Intermediate,,,
7992,BAO_0000218,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1969.0,N,1,,CHEMBL876025,,50597,6685,,Plasma,A,,,Intermediate,,,
7993,BAO_0000218,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1969.0,N,1,,CHEMBL622469,,50597,6685,,Plasma,A,,,Intermediate,,,
7994,BAO_0000218,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1969.0,N,1,,CHEMBL622470,,50597,6685,,Plasma,A,,,Intermediate,,,
7995,BAO_0000218,Time required to reach maximum concentration (Cmax) after oral administration in rat,,N,1,,CHEMBL622471,In vivo,50597,15662,,,A,,,Intermediate,,,
7996,BAO_0000218,Time required to reach maximum concentration in rat plasma,1969.0,N,1,,CHEMBL622472,,50597,1742,,Plasma,A,,,Intermediate,,,
7997,BAO_0000218,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1969.0,N,1,,CHEMBL622473,In vivo,50597,2774,,Plasma,A,,,Intermediate,,,
7998,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1969.0,N,1,,CHEMBL624282,In vivo,50597,5199,,Plasma,A,,,Intermediate,,,
7999,BAO_0000218,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,N,1,,CHEMBL624283,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
8000,BAO_0000218,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,N,1,,CHEMBL624284,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
8001,BAO_0000218,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1969.0,N,1,,CHEMBL624285,In vivo,50597,1916,,Plasma,A,,,Intermediate,,,
8002,BAO_0000218,Time to reach Cmax after oral administration to rats,,N,1,,CHEMBL624286,In vivo,50597,16367,,,A,,,Intermediate,,,
8003,BAO_0000218,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,N,1,,CHEMBL624287,In vivo,50597,16366,,,A,,,Intermediate,,,
8004,BAO_0000218,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,N,1,,CHEMBL624288,,50597,216,,,A,,,Intermediate,,,
8005,BAO_0000218,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1969.0,N,1,,CHEMBL624289,In vivo,50597,6410,,Plasma,A,,,Intermediate,,,
8006,BAO_0000218,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1969.0,N,1,,CHEMBL873344,In vivo,50597,6410,,Plasma,A,,,Intermediate,,,
8007,BAO_0000218,Tmax after peroral administration (10 mg/kg) was determined in rat,,N,1,,CHEMBL619623,In vivo,50597,6215,,,A,,,Intermediate,,,
8008,BAO_0000218,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL621399,In vivo,50597,3598,,,A,,,Expert,,,
8009,BAO_0000218,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,N,1,,CHEMBL621400,In vivo,50597,4527,,,A,,,Intermediate,,,
8010,BAO_0000218,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,N,1,,CHEMBL621401,In vivo,50597,17670,,,A,,,Intermediate,,,
8011,BAO_0000218,Tmax was determined,,N,1,,CHEMBL621402,,50597,1465,,,A,,,Intermediate,,,
8012,BAO_0000218,Tmax was determined,,N,1,,CHEMBL621403,,50597,2552,,,A,,,Intermediate,,,
8013,BAO_0000218,Tmax after oral administration in rat,,N,1,,CHEMBL621121,In vivo,50597,5656,,,A,,,Intermediate,,,
8014,BAO_0000218,Tmax after peroral administration in rats at 2.4 uM/kg,,N,1,,CHEMBL872525,In vivo,50597,17764,,,A,,,Intermediate,,,
8015,BAO_0000218,Tmax in male rat,,N,1,,CHEMBL621122,,50597,5610,,,A,,,Intermediate,,,
8016,BAO_0000218,Tmax in rat at 10 mg/kg,,N,1,,CHEMBL621123,In vivo,50597,6046,,,A,,,Intermediate,,,
8017,BAO_0000218,Tmax in rat by po administration at a dose of 40 mg/kg,,N,1,,CHEMBL621124,In vivo,50597,5874,,,A,,,Intermediate,,,
8018,BAO_0000218,Tmax in rats,,N,1,,CHEMBL621125,,50597,17596,,,A,,,Intermediate,,,
8019,BAO_0000218,Tmax was measured in rats after peroral administration at 5 mg/kg,,N,1,,CHEMBL621126,In vivo,50597,17804,,,A,,,Intermediate,,,
8020,BAO_0000218,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,N,1,,CHEMBL621127,In vivo,50597,1908,,,A,,,Intermediate,,,
8021,BAO_0000218,Tmax value after administration of 20 mg/Kg oral dose in rat,,N,1,,CHEMBL621128,In vivo,50597,2959,,,A,,,Intermediate,,,
8022,BAO_0000218,Tmax value at a dose of 10 mg/kg in male SD rats,,N,1,,CHEMBL618263,In vivo,50597,6757,,,A,,,Intermediate,,,
8023,BAO_0000218,Tmax value at a dose of 100 mg/kg in male SD rats,,N,1,,CHEMBL618264,In vivo,50597,6757,,,A,,,Intermediate,,,
8024,BAO_0000218,Tmax value at a dose of 50 mg/kg in male SD rats,,N,1,,CHEMBL618265,In vivo,50597,6757,,,A,,,Intermediate,,,
8025,BAO_0000218,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,N,1,,CHEMBL618266,In vivo,50597,4186,,Plasma,A,,,Intermediate,,,
8026,BAO_0000218,time required to reach maximum concentration (Cmax) after oral administration in rat,,N,1,,CHEMBL618267,In vivo,50597,15662,,,A,,,Intermediate,,,
8027,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1088.0,N,1,,CHEMBL618450,,50597,429,,Urine,A,,,Intermediate,,,
8028,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1088.0,N,1,,CHEMBL618451,,50597,429,,Urine,A,,,Intermediate,,,
8029,BAO_0000218,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,N,1,,CHEMBL618452,,50597,5546,,,A,,,Intermediate,,,
8030,BAO_0000218,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1088.0,N,1,,CHEMBL618453,,50597,3173,,Urine,A,,,Intermediate,,,
8031,BAO_0000218,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1088.0,N,1,,CHEMBL618454,,50597,3173,,Urine,A,,,Intermediate,,,
8032,BAO_0000218,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1088.0,N,1,,CHEMBL618455,,50597,3173,,Urine,A,,,Intermediate,,,
8033,BAO_0000218,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,N,1,,CHEMBL618456,In vivo,50597,4257,,,A,,,Intermediate,,,
8034,BAO_0000218,Compound distribution in rat tissues was determined,,N,1,,CHEMBL618457,In vivo,50597,6011,,,A,,,Intermediate,,,
8035,BAO_0000218,Volume of distribution was evaluated in rat,,N,1,,CHEMBL618458,In vivo,50597,5472,,,A,,,Intermediate,,,
8036,BAO_0000218,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,N,1,,CHEMBL618459,,50597,14346,,,A,,,Intermediate,,,
8037,BAO_0000218,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,N,1,,CHEMBL876733,,50597,14346,,,A,,,Intermediate,,,
8038,BAO_0000218,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,N,1,,CHEMBL618460,,50588,14346,,,A,,,Intermediate,,,
8039,BAO_0000218,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,N,1,,CHEMBL618461,,50597,14346,,,A,,,Intermediate,,,
8040,BAO_0000019,Area under the curve was determined after oral administration (300 uM/Kg),,U,1,,CHEMBL618462,,22224,15469,,,A,,,Autocuration,,,
8041,BAO_0000218,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,N,1,,CHEMBL618463,,50597,14346,,,A,,,Intermediate,,,
8042,BAO_0000218,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,N,1,,CHEMBL618464,,50597,14346,,,A,,,Intermediate,,,
8043,BAO_0000218,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,N,1,,CHEMBL618465,,50597,14346,,,A,,,Intermediate,,,
8044,BAO_0000218,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,N,1,,CHEMBL618466,,50597,14346,,,A,,,Intermediate,,,
8045,BAO_0000218,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,N,1,,CHEMBL618467,,50597,14346,,,A,,,Intermediate,,,
8046,BAO_0000218,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,N,1,,CHEMBL618468,,50597,15372,,,A,,,Intermediate,,,
8047,BAO_0000218,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1969.0,N,1,,CHEMBL618469,,50588,12935,,Plasma,A,,,Intermediate,,,
8048,BAO_0000218,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1969.0,N,1,,CHEMBL618470,,50588,12935,,Plasma,A,,,Intermediate,,,
8049,BAO_0000218,Plasma drug AUC in rat (PO dose),,U,1,,CHEMBL618471,,22224,14813,,,A,,,Autocuration,,,
8050,BAO_0000218,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,N,1,,CHEMBL618472,,50594,15792,,,A,,,Intermediate,,,
8051,BAO_0000218,Area under was determined at a dose of 30 mg/kg,,U,1,,CHEMBL618473,,22224,3579,,,A,,,Autocuration,,,
8052,BAO_0000218,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,N,1,,CHEMBL621699,,50506,12487,,,A,,,Intermediate,,,
8053,BAO_0000218,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,N,1,,CHEMBL621700,,50597,12487,,,A,,,Intermediate,,,
8054,BAO_0000218,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,N,1,,CHEMBL621701,,50597,12487,,,A,,,Intermediate,,,
8055,BAO_0000218,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,N,1,,CHEMBL621702,,50506,12487,,,A,,,Intermediate,,,
8056,BAO_0000218,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,N,1,,CHEMBL621703,,50588,12487,,,A,,,Intermediate,,,
8057,BAO_0000218,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,N,1,,CHEMBL621704,,50588,12487,,,A,,,Intermediate,,,
8058,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,N,1,,CHEMBL624259,,50597,12902,,,A,,,Intermediate,,,
8059,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,N,1,,CHEMBL624260,,50597,12902,,,A,,,Intermediate,,,
8060,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,N,1,,CHEMBL624430,,50597,12902,,,A,,,Intermediate,,,
8061,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,N,1,,CHEMBL624431,,50597,12902,,,A,,,Intermediate,,,
8062,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,N,1,,CHEMBL624432,,50597,12902,,,A,,,Intermediate,,,
8063,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,N,1,,CHEMBL624433,,50597,12902,,,A,,,Intermediate,,,
8064,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,N,1,,CHEMBL624434,,50597,12902,,,A,,,Intermediate,,,
8065,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,N,1,,CHEMBL624435,,50597,12902,,,A,,,Intermediate,,,
8066,BAO_0000218,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,N,1,,CHEMBL618570,,50594,12745,,,A,,,Intermediate,,,
8067,BAO_0000218,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,1,,CHEMBL618571,,50594,12745,,,A,,,Intermediate,,,
8068,BAO_0000218,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,N,1,,CHEMBL618572,,50594,12745,,,A,,,Intermediate,,,
8069,BAO_0000218,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,1,,CHEMBL618573,,50594,12745,,,A,,,Intermediate,,,
8070,BAO_0000218,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,N,1,,CHEMBL619267,,50594,12745,,,A,,,Intermediate,,,
8071,BAO_0000218,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,1,,CHEMBL619431,,50594,12745,,,A,,,Intermediate,,,
8072,BAO_0000218,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,N,1,,CHEMBL619432,,50594,12745,,,A,,,Intermediate,,,
8073,BAO_0000218,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,1,,CHEMBL619433,,50594,12745,,,A,,,Intermediate,,,
8074,BAO_0000218,AUC in mice after oral dose (50 mg/kg),1969.0,U,1,,CHEMBL619434,,22224,13298,,Plasma,A,,,Autocuration,,,
8075,BAO_0000218,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1977.0,N,1,,CHEMBL619435,,50594,12226,,Serum,A,,,Intermediate,,,
8076,BAO_0000019,AUC (0-4 hr) ug/ml/h,1969.0,U,1,,CHEMBL619436,,22224,12634,,Plasma,A,,,Autocuration,,,
8077,BAO_0000218,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,N,1,,CHEMBL619437,,50597,14810,,,A,,,Intermediate,,,
8078,BAO_0000218,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,U,1,,CHEMBL619438,,22224,13889,,,A,,,Autocuration,,,
8079,BAO_0000218,Compound was evaluated for Area under curve in mice,,N,1,,CHEMBL619439,,50594,10018,,,A,,,Intermediate,,,
8080,BAO_0000218,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,N,1,,CHEMBL619440,,50597,8758,,,A,,,Intermediate,,,
8081,BAO_0000218,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,U,1,,CHEMBL619441,,22224,8758,,,F,,,Autocuration,,,
8082,BAO_0000218,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,N,1,,CHEMBL619442,,50597,8758,,,A,,,Intermediate,,,
8083,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,U,1,,CHEMBL875156,,22224,2249,,,A,,,Autocuration,,,
8084,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,U,1,,CHEMBL619443,,22224,2249,,,A,,,Autocuration,,,
8085,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,U,1,,CHEMBL619444,,22224,2249,,,A,,,Autocuration,,,
8086,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,U,1,,CHEMBL623464,,22224,2249,,,A,,,Autocuration,,,
8087,BAO_0000218,Compound was evaluated for area under curve when administered through oral route in mouse,,N,1,,CHEMBL623465,,50594,15115,,,A,,,Intermediate,,,
8088,BAO_0000218,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,N,1,,CHEMBL623466,In vivo,50597,6518,,,A,,,Intermediate,,,
8089,BAO_0000218,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,N,1,,CHEMBL623467,In vivo,50597,6518,,,A,,,Intermediate,,,
8090,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL623468,In vivo,50597,6249,,,A,,,Intermediate,,,
8091,BAO_0000218,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,N,1,,CHEMBL622660,In vivo,50597,2463,,,A,,,Intermediate,,,
8092,BAO_0000218,Plasma clearance rate in Sprague-Dawley rats,,N,1,,CHEMBL622661,In vivo,50597,4969,,,A,,,Intermediate,,,
8093,BAO_0000218,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,1,,CHEMBL622662,In vivo,50597,17720,,,F,,,Intermediate,,,
8094,BAO_0000218,Pharmacokinetic property (total body clearance) in rat,,N,1,,CHEMBL622663,In vivo,50597,3457,,,A,,,Intermediate,,,
8095,BAO_0000218,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,N,1,,CHEMBL622664,In vivo,50597,5983,,,A,,,Intermediate,,,
8096,BAO_0000218,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,N,1,,CHEMBL622665,,50597,6295,,,A,,,Intermediate,,,
8097,BAO_0000218,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,N,1,,CHEMBL622666,,50597,6296,,,A,,,Intermediate,,,
8098,BAO_0000218,Cl in rat i.v. at 2 mg/kg concentration,,N,1,,CHEMBL621615,In vivo,50597,17686,,,A,,,Intermediate,,,
8099,BAO_0000218,Clearance of compound after intravenous administration in rats at 24 uM/kg,,N,1,,CHEMBL621616,In vivo,50597,17764,,,A,,,Intermediate,,,
8100,BAO_0000218,Clearance was determined,,N,1,,CHEMBL621617,In vivo,50597,5503,,,A,,,Intermediate,,,
8101,BAO_0000218,Clearance by intravenous administration of 3.4 mg/kg in rat,,N,1,,CHEMBL621618,In vivo,50597,4368,,,A,,,Intermediate,,,
8102,BAO_0000218,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,N,1,,CHEMBL621619,In vivo,50597,6005,,,A,,,Intermediate,,,
8103,BAO_0000218,Clearance rate after i.v. administration in rats,,N,1,,CHEMBL621620,In vivo,50597,5031,,,A,,,Intermediate,,,
8104,BAO_0000218,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL621786,In vivo,50597,4890,,,A,,,Intermediate,,,
8105,BAO_0000218,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,N,1,,CHEMBL621787,In vivo,50597,5182,,,A,,,Intermediate,,,
8106,BAO_0000218,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,N,1,,CHEMBL621788,In vivo,50597,5979,,,A,,,Intermediate,,,
8107,BAO_0000218,Clearance (Cl) after oral administration in rat,,N,1,,CHEMBL621789,In vivo,50597,5656,,,A,,,Intermediate,,,
8108,BAO_0000218,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,N,1,,CHEMBL621790,In vivo,50597,17804,,,A,,,Intermediate,,,
8109,BAO_0000218,Compound was tested for plasma clearance in rat,1969.0,N,1,,CHEMBL621791,In vivo,50597,4839,,Plasma,A,,,Intermediate,,,
8110,BAO_0000218,In vitro microsome metabolism clearance in rat was determined,,N,1,,CHEMBL621792,In vitro,50597,5041,Microsomes,,A,,,Intermediate,,,
8111,BAO_0000218,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,N,1,,CHEMBL621793,In vitro,50597,5041,Microsomes,,A,,,Intermediate,,,
8112,BAO_0000218,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL621794,In vivo,50597,5974,,,A,,,Intermediate,,,
8113,BAO_0000218,In vivo plasma clearance was determined,1969.0,N,1,,CHEMBL621795,In vivo,50597,5496,,Plasma,A,,,Intermediate,,,
8114,BAO_0000218,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,N,1,,CHEMBL621796,In vivo,50597,5739,,,A,,,Intermediate,,,
8115,BAO_0000218,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,2107.0,N,1,Hepatocyte,CHEMBL621797,In vivo,50597,5676,,Liver,A,,,Intermediate,,401.0,
8116,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in rat,,N,1,,CHEMBL621798,In vivo,50597,4239,,,A,,,Intermediate,,,
8117,BAO_0000218,Pharmacokinetic property (clearance) in rat i.v.,,N,1,,CHEMBL621799,In vivo,50597,5676,,,A,,,Intermediate,,,
8118,BAO_0000218,"Plasma Clearance was evaluated in rats, iv",,N,1,,CHEMBL621800,In vivo,50597,1918,,,A,,,Intermediate,,,
8119,BAO_0000218,Plasma clearance (in vivo) in rats was determined,,N,1,,CHEMBL621801,In vivo,50597,17800,,,A,,,Intermediate,,,
8120,BAO_0000218,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,N,1,,CHEMBL621802,In vivo,50597,6056,,,A,,,Intermediate,,,
8121,BAO_0000218,Plasma clearance was determined,,N,1,,CHEMBL618596,In vivo,50597,5496,,,A,,,Intermediate,,,
8122,BAO_0000218,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,N,1,,CHEMBL618597,In vivo,50597,5939,,,A,,,Intermediate,,,
8123,BAO_0000218,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,N,1,,CHEMBL618598,In vivo,50597,5939,,,A,,,Intermediate,,,
8124,BAO_0000218,Plasma clearance in rats,,N,1,,CHEMBL618599,In vivo,50597,17752,,,A,,,Intermediate,,,
8125,BAO_0000218,Plasma clearance rate determined in rat,,N,1,,CHEMBL618600,In vivo,50597,4576,,,A,,,Intermediate,,,
8126,BAO_0000218,Plasma clearance was determined in rat,,N,1,,CHEMBL618601,In vivo,50597,6011,,,A,,,Intermediate,,,
8127,BAO_0000218,Plasma clearance was determined,,N,1,,CHEMBL618602,In vivo,50597,5510,,,A,,,Intermediate,,,
8128,BAO_0000218,Plasma clearance value in rat,,N,1,,CHEMBL618603,In vivo,50597,5948,,,A,,,Intermediate,,,
8129,BAO_0000218,Clearance rate constant using isolated perfused rat liver (IPRL) assay,2107.0,N,1,,CHEMBL618604,Ex vivo,50597,6125,,Liver,A,,,Intermediate,,,
8130,BAO_0000218,Clearance in rat,,N,1,,CHEMBL618605,In vivo,50597,4839,,,A,,,Intermediate,,,
8131,BAO_0000218,Total body clearance in rat i.v. at 2 mg/kg concentration,,N,1,,CHEMBL618606,In vivo,50597,17686,,,A,,,Intermediate,,,
8132,BAO_0000218,Clearance of compound in rats after intravenous administration,,N,1,,CHEMBL618607,In vivo,50597,6571,,,A,,,Intermediate,,,
8133,BAO_0000218,Clearance after iv administration to rats,,N,1,,CHEMBL618608,In vivo,50597,3364,,,A,,,Intermediate,,,
8134,BAO_0000218,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,N,1,,CHEMBL618609,In vivo,50597,13569,,,A,,,Intermediate,,,
8135,BAO_0000218,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,N,1,,CHEMBL618610,In vivo,50597,13569,,,A,,,Intermediate,,,
8136,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,N,1,,CHEMBL618611,In vivo,50597,13569,,,A,,,Intermediate,,,
8137,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,N,1,,CHEMBL618612,In vivo,50597,13569,,,A,,,Intermediate,,,
8138,BAO_0000218,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,N,1,,CHEMBL618613,In vivo,50597,13569,,,A,,,Intermediate,,,
8139,BAO_0000218,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,N,1,,CHEMBL621076,In vivo,50597,13569,,,A,,,Intermediate,,,
8140,BAO_0000218,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,N,1,,CHEMBL621077,In vivo,50597,13569,,,A,,,Intermediate,,,
8141,BAO_0000218,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,N,1,,CHEMBL621078,In vivo,50597,17670,,,A,,,Intermediate,,,
8142,BAO_0000218,Clearance in rat,,N,1,,CHEMBL621251,In vivo,50597,5970,,,A,,,Intermediate,,,
8143,BAO_0000218,Clearance in rat after oral administration at 10 mg/kg,,N,1,,CHEMBL621252,In vivo,50597,6495,,,A,,,Intermediate,,,
8144,BAO_0000218,Clearance in rat.,,N,1,,CHEMBL621253,In vivo,50597,4590,,,A,,,Intermediate,,,
8145,BAO_0000218,Clearance rate following an oral dose of 20 mg/kg in rats,,N,1,,CHEMBL621254,In vivo,50597,6193,,,A,,,Intermediate,,,
8146,BAO_0000218,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,N,1,,CHEMBL621255,In vivo,50597,2832,,,A,,,Intermediate,,,
8147,BAO_0000218,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1969.0,N,1,,CHEMBL621256,In vivo,50597,1052,,Plasma,A,,,Intermediate,,,
8148,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,2107.0,N,1,,CHEMBL621257,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8149,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,2107.0,N,1,,CHEMBL621258,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8150,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,2107.0,N,1,,CHEMBL621259,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8151,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,2107.0,N,1,,CHEMBL621260,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8152,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,2107.0,N,1,,CHEMBL876494,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8153,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,2107.0,N,1,,CHEMBL621261,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8154,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,2107.0,N,1,,CHEMBL621262,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8155,BAO_0000218,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,2107.0,N,1,,CHEMBL621263,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8156,BAO_0000218,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,2107.0,N,1,,CHEMBL621264,In vivo,50597,9866,,Liver,A,,,Intermediate,,,
8157,BAO_0000218,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,2385.0,N,1,,CHEMBL621265,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8158,BAO_0000218,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,2385.0,N,1,,CHEMBL621266,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8159,BAO_0000218,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,2385.0,N,1,,CHEMBL621267,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8160,BAO_0000218,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,2385.0,N,1,,CHEMBL621268,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8161,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,2385.0,N,1,,CHEMBL621269,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8162,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,2385.0,N,1,,CHEMBL621270,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8163,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,2385.0,N,1,,CHEMBL621271,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8164,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,2385.0,N,1,,CHEMBL621272,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8165,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,2385.0,N,1,,CHEMBL621273,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8166,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,2385.0,N,1,,CHEMBL621274,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8167,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,2385.0,N,1,,CHEMBL876495,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8168,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,2385.0,N,1,,CHEMBL621275,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8169,BAO_0000218,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,2385.0,N,1,,CHEMBL621276,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8170,BAO_0000218,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,2385.0,N,1,,CHEMBL621277,In vivo,50597,9866,,Muscle tissue,A,,,Intermediate,,,
8171,BAO_0000218,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,160.0,N,1,,CHEMBL621278,In vivo,50597,9866,,Intestine,A,,,Intermediate,,,
8172,BAO_0000218,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,160.0,N,1,,CHEMBL621279,In vivo,50597,9866,,Intestine,A,,,Intermediate,,,
8173,BAO_0000218,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),160.0,N,1,,CHEMBL621280,In vivo,50597,9866,,Intestine,A,,,Intermediate,,,
8174,BAO_0000218,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,2106.0,N,1,,CHEMBL621281,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8175,BAO_0000218,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,2106.0,N,1,,CHEMBL621282,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8176,BAO_0000218,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,2106.0,N,1,,CHEMBL621283,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8177,BAO_0000218,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,2106.0,N,1,,CHEMBL621284,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8178,BAO_0000218,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,2106.0,N,1,,CHEMBL621285,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8179,BAO_0000218,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,2106.0,N,1,,CHEMBL621286,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8180,BAO_0000218,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,2106.0,N,1,,CHEMBL623220,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8181,BAO_0000218,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,2106.0,N,1,,CHEMBL623221,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8182,BAO_0000218,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,2106.0,N,1,,CHEMBL876029,In vivo,50597,9866,,Spleen,A,,,Intermediate,,,
8183,BAO_0000218,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,945.0,N,1,,CHEMBL623222,In vivo,50597,9866,,Stomach,A,,,Intermediate,,,
8184,BAO_0000218,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,945.0,N,1,,CHEMBL623223,In vivo,50597,9866,,Stomach,A,,,Intermediate,,,
8185,BAO_0000218,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,945.0,N,1,,CHEMBL621445,In vivo,50597,9866,,Stomach,A,,,Intermediate,,,
8186,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,178.0,N,1,,CHEMBL621446,In vivo,50597,13950,,Blood,A,,,Intermediate,,,
8187,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,178.0,N,1,,CHEMBL621447,In vivo,50597,13950,,Blood,A,,,Intermediate,,,
8188,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,178.0,N,1,,CHEMBL619681,In vivo,50597,13950,,Blood,A,,,Intermediate,,,
8189,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,178.0,N,1,,CHEMBL619682,In vivo,50597,13950,,Blood,A,,,Intermediate,,,
8190,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,178.0,N,1,,CHEMBL619683,In vivo,50597,13950,,Blood,A,,,Intermediate,,,
8191,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,955.0,N,1,,CHEMBL619684,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
8192,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,955.0,N,1,,CHEMBL619685,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
8193,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,955.0,N,1,,CHEMBL619686,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
8194,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,955.0,N,1,,CHEMBL619687,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
8195,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,955.0,N,1,,CHEMBL619688,In vivo,50597,13950,,Brain,A,,,Intermediate,,,
8196,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,948.0,N,1,,CHEMBL619689,In vivo,50597,13950,,Heart,A,,,Intermediate,,,
8197,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,948.0,N,1,,CHEMBL619690,In vivo,50597,13950,,Heart,A,,,Intermediate,,,
8198,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,948.0,N,1,,CHEMBL619691,In vivo,50597,13950,,Heart,A,,,Intermediate,,,
8199,BAO_0000218,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,N,1,,CHEMBL619692,In vivo,50597,6062,,,A,,,Intermediate,,,
8200,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL619693,,50597,3598,,,A,,,Expert,,,
8201,BAO_0000218,Vc value after IV dose at a dose of 5 mg/kg in rats.,,N,1,,CHEMBL619694,In vivo,50597,1908,,,A,,,Intermediate,,,
8202,BAO_0000218,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,N,1,,CHEMBL619695,In vivo,50597,17596,,,A,,,Intermediate,,,
8203,BAO_0000218,Compound was evaluated for pharmacokinetic parameter volume of distribution,,N,1,,CHEMBL619696,In vivo,50597,4891,,,A,,,Intermediate,,,
8204,BAO_0000218,Compound was evaluated for volume of distribution in rat,,N,1,,CHEMBL619697,In vivo,50597,740,,,A,,,Intermediate,,,
8205,BAO_0000218,Steady state volume distribution was determined; steady state(ss),,N,1,,CHEMBL619698,In vivo,50597,16366,,,A,,,Intermediate,,,
8206,BAO_0000218,Steady state volume of distribution after iv administration to rats,,N,1,,CHEMBL619699,In vivo,50597,3364,,,A,,,Intermediate,,,
8207,BAO_0000218,Steady state volume of distribution dosing at 3 mg/kg iv,,N,1,,CHEMBL619700,In vivo,50597,2552,,,A,,,Intermediate,,,
8208,BAO_0000218,The compound was evaluated for volume of distribution in rat,,N,1,,CHEMBL619701,In vivo,50597,406,,,A,,,Intermediate,,,
8209,BAO_0000218,The compound was tested for volume of distribution in rat,,N,1,,CHEMBL619702,In vivo,50597,12500,,,A,,,Intermediate,,,
8210,BAO_0000218,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,N,1,,CHEMBL620335,In vivo,50597,12500,,,A,,,Intermediate,,,
8211,BAO_0000218,Volume distribution (VD) after oral administration in rat,,N,1,,CHEMBL620336,In vivo,50597,5656,,,A,,,Intermediate,,,
8212,BAO_0000218,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,1,,CHEMBL620337,In vivo,50597,17671,,,A,,,Intermediate,,,
8213,BAO_0000218,Volume distribution in rat,,N,1,,CHEMBL620520,In vivo,50597,1094,,,A,,,Intermediate,,,
8214,BAO_0000218,Volume distribution in rat,,N,1,,CHEMBL620521,In vivo,50597,5833,,,A,,,Intermediate,,,
8215,BAO_0000218,Volume distribution in rat after peroral administration at 10 mg/kg,,N,1,,CHEMBL875825,In vivo,50597,5939,,,A,,,Intermediate,,,
8216,BAO_0000218,Volume distribution in rat after peroral administration at 5 mg/kg,,N,1,,CHEMBL620522,In vivo,50597,5939,,,A,,,Intermediate,,,
8217,BAO_0000218,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,N,1,,CHEMBL620523,In vivo,50597,6005,,,A,,,Intermediate,,,
8218,BAO_0000218,Volume of distribution in rat.,,N,1,,CHEMBL620524,In vivo,50597,1696,,,A,,,Intermediate,,,
8219,BAO_0000218,Volume of distribution in rat,,N,1,,CHEMBL620525,In vivo,50597,6672,,,A,,,Intermediate,,,
8220,BAO_0000218,Volume of distribution in rat,,N,1,,CHEMBL620526,In vivo,50597,6673,,,A,,,Intermediate,,,
8221,BAO_0000218,Volume of distribution in rat by iv administration,,N,1,,CHEMBL620527,In vivo,50597,5871,,,A,,,Intermediate,,,
8222,BAO_0000218,Volume of distribution in rats,,N,1,,CHEMBL620528,In vivo,50597,6803,,,A,,,Intermediate,,,
8223,BAO_0000218,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,N,1,,CHEMBL620529,In vivo,50597,5199,,,A,,,Intermediate,,,
8224,BAO_0000218,Volume distribution at the dose of 2 mg/kg in rat,,N,1,,CHEMBL620530,,50597,4727,,,A,,,Intermediate,,,
8225,BAO_0000218,Steady state volume of distribution was determined,,N,1,,CHEMBL620531,In vivo,50597,16367,,,A,,,Intermediate,,,
8226,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,1,,CHEMBL620532,In vivo,22224,5005,,,A,,,Intermediate,,,
8227,BAO_0000218,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,U,1,,CHEMBL620533,In vivo,22224,5005,,,A,,,Intermediate,,,
8228,BAO_0000218,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,U,1,,CHEMBL620534,In vivo,22224,5005,,,A,,,Intermediate,,,
8229,BAO_0000218,Mean (%CV) PK parameters for Vdss(mL/kg).,,N,1,,CHEMBL620535,In vivo,50597,15765,,,A,,,Intermediate,,,
8230,BAO_0000218,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,N,1,,CHEMBL875826,In vivo,50597,2792,,,A,,,Intermediate,,,
8231,BAO_0000218,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,N,1,,CHEMBL620536,In vivo,50597,2792,,,A,,,Intermediate,,,
8232,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,N,1,,CHEMBL620537,In vivo,50597,5334,,,A,,,Intermediate,,,
8233,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,N,1,,CHEMBL618526,In vivo,50597,5334,,,A,,,Intermediate,,,
8234,BAO_0000218,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,N,1,,CHEMBL618527,In vivo,50597,5739,,,A,,,Intermediate,,,
8235,BAO_0000218,Pharmacokinetic property (Vdss) in rat,,N,1,,CHEMBL618528,In vivo,50597,5789,,,A,,,Intermediate,,,
8236,BAO_0000218,Pharmacokinetic property (vdss) was measured in rat,,N,1,,CHEMBL618529,In vivo,50597,4239,,,A,,,Intermediate,,,
8237,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,N,1,,CHEMBL618530,In vivo,50597,4709,,,A,,,Intermediate,,,
8238,BAO_0000218,Volume of distribution in rat,,N,1,,CHEMBL618531,In vivo,50597,6642,,,A,,,Intermediate,,,
8239,BAO_0000218,The pharmacokinetic parameter volume of distribution in vivo in rats,,N,1,,CHEMBL618532,In vivo,50597,5247,,,A,,,Intermediate,,,
8240,BAO_0000218,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,1,,CHEMBL618533,In vivo,50597,17720,,,F,,,Intermediate,,,
8241,BAO_0000218,Vdss in rat i.v. at 2 mg/kg concentration,,N,1,,CHEMBL618534,In vivo,50597,17686,,,A,,,Intermediate,,,
8242,BAO_0000218,Volume distribution after intravenous administration (1 mg/kg) in rat,,N,1,,CHEMBL618535,In vivo,50597,4689,,,A,,,Intermediate,,,
8243,BAO_0000218,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,1,,CHEMBL618536,In vivo,50597,5654,,,A,,,Intermediate,,,
8244,BAO_0000218,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,1,,CHEMBL618537,In vivo,50597,5654,,,A,,,Intermediate,,,
8245,BAO_0000218,Volume distribution at a dose of 10 uM/kg in rat was determined,,N,1,,CHEMBL618538,In vivo,50597,4527,,,A,,,Intermediate,,,
8246,BAO_0000218,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,1,,CHEMBL618539,In vivo,50597,4521,,,A,,,Intermediate,,,
8247,BAO_0000218,Volume distribution was calculated in rat,,N,1,,CHEMBL618540,In vivo,50597,6057,,,A,,,Intermediate,,,
8248,BAO_0000218,Volume distribution was determined,,N,1,,CHEMBL618541,In vivo,50597,5510,,,A,,,Intermediate,,,
8249,BAO_0000218,Volume of distribution after intravenous administration was evaluated in rat,,N,1,,CHEMBL618542,In vivo,50597,2938,,,A,,,Intermediate,,,
8250,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL622544,In vivo,50597,6679,,,A,,,Intermediate,,,
8251,BAO_0000218,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,N,1,,CHEMBL622545,In vivo,50597,6685,,,A,,,Intermediate,,,
8252,BAO_0000218,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,N,1,,CHEMBL622546,In vivo,50597,6685,,,A,,,Intermediate,,,
8253,BAO_0000218,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,N,1,,CHEMBL622547,In vivo,50597,6685,,,A,,,Intermediate,,,
8254,BAO_0000218,Volume of distribution in steady state was determined in rat,,N,1,,CHEMBL622548,In vivo,50597,5145,,,A,,,Intermediate,,,
8255,BAO_0000218,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,N,1,,CHEMBL622549,In vivo,50597,6467,,,A,,,Intermediate,,,
8256,BAO_0000218,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,N,1,,CHEMBL622550,In vivo,50597,6467,,,A,,,Intermediate,,,
8257,BAO_0000218,Compound was evaluated for area under curve when administered through oral route to mouse,,N,1,,CHEMBL622551,,50594,15115,,,A,,,Intermediate,,,
8258,BAO_0000218,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,N,1,,CHEMBL622552,,50597,8758,,,A,,,Intermediate,,,
8259,BAO_0000218,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,N,1,,CHEMBL622553,,50597,8758,,,A,,,Intermediate,,,
8260,BAO_0000218,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,U,1,,CHEMBL622554,In vivo,22224,8267,,,F,,,Autocuration,,,
8261,BAO_0000218,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,N,1,,CHEMBL622555,,50588,8267,,,A,,,Intermediate,,,
8262,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,N,1,,CHEMBL622556,,50594,14239,,,A,,,Intermediate,,,
8263,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,N,1,,CHEMBL622557,,50594,14239,,,A,,,Intermediate,,,
8264,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,178.0,N,1,,CHEMBL622558,,50594,10754,,Blood,A,,,Intermediate,,,
8265,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,178.0,N,1,,CHEMBL622559,,50594,10754,,Blood,A,,,Intermediate,,,
8266,BAO_0000218,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,N,1,,CHEMBL622560,,50588,10754,,,A,,,Intermediate,,,
8267,BAO_0000218,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,N,1,,CHEMBL622561,,50597,14681,,,A,,,Intermediate,,,
8268,BAO_0000218,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,N,1,,CHEMBL622562,,50597,14681,,,A,,,Intermediate,,,
8269,BAO_0000218,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,N,1,,CHEMBL622563,,50597,14681,,,A,,,Intermediate,,,
8270,BAO_0000019,Concentration of compound in Central nervous system,,U,1,,CHEMBL622564,,22224,13118,,,A,,,Autocuration,,,
8271,BAO_0000019,Concentration of compound in Central nervous system; Not detectable,,U,1,,CHEMBL622565,,22224,13118,,,A,,,Autocuration,,,
8272,BAO_0000218,"Concentration of diester in the blood, following oral administration in mice",,N,1,,CHEMBL622566,,50594,13318,,,A,,,Intermediate,,,
8273,BAO_0000218,"Concentration of monoester in the blood, following oral administration in mice",,N,1,,CHEMBL624515,,50594,13318,,,A,,,Intermediate,,,
8274,BAO_0000218,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,N,1,,CHEMBL624516,,50594,13318,,,A,,,Intermediate,,,
8275,BAO_0000019,Evaluated for Pharmacokinetic property: Area under the curve,,U,1,,CHEMBL624517,,22224,15692,,,A,,,Autocuration,,,
8276,BAO_0000218,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,N,1,,CHEMBL624518,,50594,14839,,,A,,,Intermediate,,,
8277,BAO_0000218,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,N,1,,CHEMBL624519,,100710,14839,,,A,,,Intermediate,,,
8278,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,N,1,,CHEMBL624520,,100710,14839,,,A,,,Intermediate,,,
8279,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,N,1,,CHEMBL624521,,100710,14839,,,A,,,Intermediate,,,
8280,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,N,1,,CHEMBL624522,,100710,14839,,,A,,,Intermediate,,,
8281,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,N,1,,CHEMBL624523,,100710,14839,,,A,,,Intermediate,,,
8282,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,N,1,,CHEMBL624409,,100710,14839,,,A,,,Intermediate,,,
8283,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,N,1,,CHEMBL624410,,100710,14839,,,A,,,Intermediate,,,
8284,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,N,1,,CHEMBL624411,,100710,14839,,,A,,,Intermediate,,,
8285,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,N,1,,CHEMBL623531,,100710,14839,,,A,,,Intermediate,,,
8286,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,N,1,,CHEMBL623532,,100710,14839,,,A,,,Intermediate,,,
8287,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,N,1,,CHEMBL623533,,100710,14839,,,A,,,Intermediate,,,
8288,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,N,1,,CHEMBL623534,,100710,14839,,,A,,,Intermediate,,,
8289,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,N,1,,CHEMBL623535,,50594,14839,,,A,,,Intermediate,,,
8290,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,N,1,,CHEMBL623536,,50594,14839,,,A,,,Intermediate,,,
8291,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,N,1,,CHEMBL623537,,50594,14839,,,A,,,Intermediate,,,
8292,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,N,1,,CHEMBL623538,,50594,14839,,,A,,,Intermediate,,,
8293,BAO_0000218,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,N,1,,CHEMBL623539,,50594,14839,,,A,,,Intermediate,,,
8294,BAO_0000218,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,N,1,,CHEMBL623540,,50594,14839,,,A,,,Intermediate,,,
8295,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,N,1,,CHEMBL623541,,50594,14839,,,A,,,Intermediate,,,
8296,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,N,1,,CHEMBL623542,,50594,14839,,,A,,,Intermediate,,,
8297,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,N,1,,CHEMBL623543,,50594,14839,,,A,,,Intermediate,,,
8298,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,N,1,,CHEMBL623544,,50594,14839,,,A,,,Intermediate,,,
8299,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,N,1,,CHEMBL623545,,50594,14839,,,A,,,Intermediate,,,
8300,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,N,1,,CHEMBL623546,,50594,14839,,,A,,,Intermediate,,,
8301,BAO_0000218,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1969.0,N,1,,CHEMBL623547,In vivo,50597,5408,,Plasma,A,,,Intermediate,,,
8302,BAO_0000218,High i.v. clearance in Dawley rats,,N,1,,CHEMBL623548,In vivo,50597,6827,,,A,,,Intermediate,,,
8303,BAO_0000218,In vitro clearance in rat liver microsomes,2107.0,N,1,,CHEMBL623549,In vitro,50597,17538,Microsomes,Liver,A,,,Intermediate,,,
8304,BAO_0000218,Intrinsic clearance in rat liver microsomes was determined,2107.0,N,1,,CHEMBL623550,In vitro,50597,6331,Microsomes,Liver,A,,,Intermediate,,,
8305,BAO_0000218,Intrinsic clearance in rat hepatocytes was determined,2107.0,N,1,Hepatocyte,CHEMBL875276,In vitro,50597,5948,,Liver,A,,,Intermediate,,401.0,
8306,BAO_0000218,Plasma Clearance was determined,,N,1,,CHEMBL621872,In vivo,50597,4026,,,A,,,Intermediate,,,
8307,BAO_0000218,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,N,1,,CHEMBL621873,In vivo,50597,6647,,,A,,,Intermediate,,,
8308,BAO_0000218,Plasma clearance in rat.,,N,1,,CHEMBL621874,In vivo,50597,1696,,,A,,,Intermediate,,,
8309,BAO_0000218,Plasma clearance in rats,,N,1,,CHEMBL621875,In vivo,50597,6597,,,A,,,Intermediate,,,
8310,BAO_0000218,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,N,1,,CHEMBL621876,In vivo,50597,347,,,A,,,Intermediate,,,
8311,BAO_0000218,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,N,1,,CHEMBL621877,In vivo,50597,16423,,,A,,,Intermediate,,,
8312,BAO_0000218,Plasma clearance was measured in rat,,N,1,,CHEMBL621878,In vivo,50597,2879,,,A,,,Intermediate,,,
8313,BAO_0000218,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,N,1,,CHEMBL621879,In vivo,50597,4883,,,A,,,Intermediate,,,
8314,BAO_0000218,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1969.0,N,1,,CHEMBL621880,In vivo,50597,5328,,Plasma,A,,,Intermediate,,,
8315,BAO_0000218,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,N,1,,CHEMBL621881,In vivo,50597,5160,,,A,,,Intermediate,,,
8316,BAO_0000218,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,1,,CHEMBL621882,In vivo,50597,17582,,,A,,,Intermediate,,,
8317,BAO_0000218,Total clearance at 1 mg/kg was determined in rat,,N,1,,CHEMBL875283,In vivo,50597,17651,,,A,,,Intermediate,,,
8318,BAO_0000218,Total clearance at 10 mg/kg was determined in rat,,N,1,,CHEMBL621883,In vivo,50597,17651,,,A,,,Intermediate,,,
8319,BAO_0000218,Clearance in rat,,N,1,,CHEMBL621884,In vivo,50597,6596,,,A,,,Intermediate,,,
8320,BAO_0000218,Plasma clearance rate determined in rats,,N,1,,CHEMBL621885,In vivo,50597,4796,,,A,,,Intermediate,,,
8321,BAO_0000218,Clearance of compound in rat was evaluated,,N,1,,CHEMBL621886,In vivo,50597,6850,,,A,,,Intermediate,,,
8322,BAO_0000218,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1969.0,N,1,,CHEMBL621887,In vivo,50597,5932,,Plasma,A,,,Intermediate,,,
8323,BAO_0000218,Pharmacokinetic property (blood clearance) in rat,,N,1,,CHEMBL621888,In vivo,50597,3371,,,A,,,Intermediate,,,
8324,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL621889,In vivo,50597,2083,,,A,,,Intermediate,,,
8325,BAO_0000218,Plasma clearance in rats,,N,1,,CHEMBL621890,In vivo,50597,4942,,,A,,,Intermediate,,,
8326,BAO_0000218,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,2107.0,N,1,,CHEMBL621891,In vitro,50597,6838,Microsomes,Liver,A,,,Intermediate,,,
8327,BAO_0000218,Clearance in Dawley rat,,N,1,,CHEMBL621892,In vivo,50597,5353,,,A,,,Intermediate,,,
8328,BAO_0000218,Clearance rat,,N,1,,CHEMBL621893,In vivo,50597,6641,,,A,,,Intermediate,,,
8329,BAO_0000218,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,N,1,,CHEMBL621894,In vivo,50597,6641,,,A,,,Intermediate,,,
8330,BAO_0000218,Clearance rat; Not determined,,N,1,,CHEMBL621895,In vivo,50597,6641,,,A,,,Intermediate,,,
8331,BAO_0000218,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,N,1,,CHEMBL875284,In vivo,50597,6444,,,A,,,Intermediate,,,
8332,BAO_0000218,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,N,1,,CHEMBL618699,In vivo,50597,6444,,,A,,,Intermediate,,,
8333,BAO_0000218,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,N,1,,CHEMBL618700,In vivo,50597,6444,,,A,,,Intermediate,,,
8334,BAO_0000218,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,N,1,,CHEMBL618701,In vivo,50597,6211,,,A,,,Intermediate,,,
8335,BAO_0000218,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1969.0,N,1,,CHEMBL876600,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
8336,BAO_0000218,Clearance of compound in rat after 1 mg/kg i.v. administration,,N,1,,CHEMBL618702,In vivo,50597,6570,,,A,,,Intermediate,,,
8337,BAO_0000218,Compound was evaluated for Hepatic clearance in rat,,N,1,,CHEMBL618703,In vivo,50597,3341,,,A,,,Intermediate,,,
8338,BAO_0000218,In vivo clearance after 5 mg/kg dose,,N,1,,CHEMBL618704,In vivo,50597,4891,,,A,,,Intermediate,,,
8339,BAO_0000218,Compound was tested for plasma clearance in rats,1969.0,N,1,,CHEMBL618705,In vivo,50597,1094,,Plasma,A,,,Intermediate,,,
8340,BAO_0000218,Hepatic clearance after intravenous administration was evaluated in rat,,N,1,,CHEMBL618706,In vivo,50597,2938,,,A,,,Intermediate,,,
8341,BAO_0000218,Lower clearance in rat (i.v.) at 0.5 mpk,,N,1,,CHEMBL618707,In vivo,50597,17853,,,A,,,Intermediate,,,
8342,BAO_0000218,Pharmacokinetic parameter expressed as plasma clearance in rat,1969.0,N,1,,CHEMBL618708,In vivo,50597,6049,,Plasma,A,,,Intermediate,,,
8343,BAO_0000218,Pharmacokinetic property (Clp) in rat,,N,1,,CHEMBL618709,In vivo,50597,5789,,,A,,,Intermediate,,,
8344,BAO_0000218,Plasma clearance in Sprague-Dawley rats,,N,1,,CHEMBL618710,In vivo,50597,4514,,,A,,,Intermediate,,,
8345,BAO_0000218,Plasma clearance (Clp) in rat,,N,1,,CHEMBL618711,In vivo,50597,6448,,,A,,,Intermediate,,,
8346,BAO_0000218,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,N,1,,CHEMBL618712,In vivo,50597,6062,,,A,,,Intermediate,,,
8347,BAO_0000218,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,N,1,,CHEMBL618713,In vivo,50597,5710,,,A,,,Intermediate,,,
8348,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in rat,,N,1,,CHEMBL618714,In vivo,50597,4709,,,A,,,Intermediate,,,
8349,BAO_0000218,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,1,,CHEMBL618715,In vivo,50597,4521,,,A,,,Intermediate,,,
8350,BAO_0000218,Plasma clearance in rat was determined,,N,1,,CHEMBL618716,In vivo,50597,1742,,,A,,,Intermediate,,,
8351,BAO_0000218,Plasma clearance measured in rat,,N,1,,CHEMBL876601,In vivo,50597,6057,,,A,,,Intermediate,,,
8352,BAO_0000218,Plasma clearance was calculated in rat,,N,1,,CHEMBL618717,In vivo,50597,6057,,,A,,,Intermediate,,,
8353,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL618718,In vivo,50597,5145,,,A,,,Intermediate,,,
8354,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL618719,In vivo,50597,5833,,,A,,,Intermediate,,,
8355,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL618720,In vivo,50597,6453,,,A,,,Intermediate,,,
8356,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL618721,In vivo,50597,6640,,,A,,,Intermediate,,,
8357,BAO_0000218,Plasma clearance in rats,,N,1,,CHEMBL621477,In vivo,50597,6305,,,A,,,Intermediate,,,
8358,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL621478,In vivo,50597,6642,,,A,,,Intermediate,,,
8359,BAO_0000218,Plasma clearance was evaluated in rat,,N,1,,CHEMBL621479,In vivo,50597,5472,,,A,,,Intermediate,,,
8360,BAO_0000218,Plasma clearance was evaluated in rat; Not tested,,N,1,,CHEMBL621480,In vivo,50597,5472,,,A,,,Intermediate,,,
8361,BAO_0000218,Plasma clearance rate was determined for the compound in rat,,N,1,,CHEMBL621481,In vivo,50597,5144,,,A,,,Intermediate,,,
8362,BAO_0000218,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,N,1,,CHEMBL621482,In vivo,50597,6685,,,A,,,Intermediate,,,
8363,BAO_0000218,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,N,1,,CHEMBL621483,In vivo,50597,6685,,,A,,,Intermediate,,,
8364,BAO_0000218,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,N,1,,CHEMBL621484,In vivo,50597,6685,,,A,,,Intermediate,,,
8365,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,948.0,N,1,,CHEMBL621485,In vivo,50597,13950,,Heart,A,,,Intermediate,,,
8366,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,948.0,N,1,,CHEMBL621486,In vivo,50597,13950,,Heart,A,,,Intermediate,,,
8367,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,160.0,N,1,,CHEMBL621487,In vivo,50597,13950,,Intestine,A,,,Intermediate,,,
8368,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,160.0,N,1,,CHEMBL621488,In vivo,50597,13950,,Intestine,A,,,Intermediate,,,
8369,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,160.0,N,1,,CHEMBL621489,In vivo,50597,13950,,Intestine,A,,,Intermediate,,,
8370,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,160.0,N,1,,CHEMBL621490,In vivo,50597,13950,,Intestine,A,,,Intermediate,,,
8371,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,160.0,N,1,,CHEMBL621491,In vivo,50597,13950,,Intestine,A,,,Intermediate,,,
8372,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2113.0,N,1,,CHEMBL621492,In vivo,50597,13950,,Kidney,A,,,Intermediate,,,
8373,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,2113.0,N,1,,CHEMBL621493,In vivo,50597,13950,,Kidney,A,,,Intermediate,,,
8374,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,2113.0,N,1,,CHEMBL621494,In vivo,50597,13950,,Kidney,A,,,Intermediate,,,
8375,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,2113.0,N,1,,CHEMBL621495,In vivo,50597,13950,,Kidney,A,,,Intermediate,,,
8376,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,2113.0,N,1,,CHEMBL621496,In vivo,50597,13950,,Kidney,A,,,Intermediate,,,
8377,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2107.0,N,1,,CHEMBL621497,In vivo,50597,13950,,Liver,A,,,Intermediate,,,
8378,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,2107.0,N,1,,CHEMBL621498,In vivo,50597,13950,,Liver,A,,,Intermediate,,,
8379,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,2107.0,N,1,,CHEMBL621499,In vivo,50597,13950,,Liver,A,,,Intermediate,,,
8380,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,2107.0,N,1,,CHEMBL618634,In vivo,50597,13950,,Liver,A,,,Intermediate,,,
8381,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,2107.0,N,1,,CHEMBL618635,In vivo,50597,13950,,Liver,A,,,Intermediate,,,
8382,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2048.0,N,1,,CHEMBL618636,In vivo,50597,13950,,Lung,A,,,Intermediate,,,
8383,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,2048.0,N,1,,CHEMBL619737,In vivo,50597,13950,,Lung,A,,,Intermediate,,,
8384,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,2048.0,N,1,,CHEMBL619738,In vivo,50597,13950,,Lung,A,,,Intermediate,,,
8385,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,2048.0,N,1,,CHEMBL624329,In vivo,50597,13950,,Lung,A,,,Intermediate,,,
8386,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,2048.0,N,1,,CHEMBL624330,In vivo,50597,13950,,Lung,A,,,Intermediate,,,
8387,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2385.0,N,1,,CHEMBL624331,In vivo,50597,13950,,Muscle tissue,A,,,Intermediate,,,
8388,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,2385.0,N,1,,CHEMBL624332,In vivo,50597,13950,,Muscle tissue,A,,,Intermediate,,,
8389,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,2385.0,N,1,,CHEMBL624333,In vivo,50597,13950,,Muscle tissue,A,,,Intermediate,,,
8390,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,2385.0,N,1,,CHEMBL624334,In vivo,50597,13950,,Muscle tissue,A,,,Intermediate,,,
8391,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,2385.0,N,1,,CHEMBL624335,In vivo,50597,13950,,Muscle tissue,A,,,Intermediate,,,
8392,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2106.0,N,1,,CHEMBL620016,In vivo,50597,13950,,Spleen,A,,,Intermediate,,,
8393,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,2106.0,N,1,,CHEMBL620169,In vivo,50597,13950,,Spleen,A,,,Intermediate,,,
8394,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,2106.0,N,1,,CHEMBL620170,In vivo,50597,13950,,Spleen,A,,,Intermediate,,,
8395,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,2106.0,N,1,,CHEMBL620171,In vivo,50597,13950,,Spleen,A,,,Intermediate,,,
8396,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,2106.0,N,1,,CHEMBL620172,In vivo,50597,13950,,Spleen,A,,,Intermediate,,,
8397,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,945.0,N,1,,CHEMBL620173,In vivo,50597,13950,,Stomach,A,,,Intermediate,,,
8398,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,945.0,N,1,,CHEMBL620174,In vivo,50597,13950,,Stomach,A,,,Intermediate,,,
8399,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,945.0,N,1,,CHEMBL620175,In vivo,50597,13950,,Stomach,A,,,Intermediate,,,
8400,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,945.0,N,1,,CHEMBL620176,In vivo,50597,13950,,Stomach,A,,,Intermediate,,,
8401,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,945.0,N,1,,CHEMBL620177,In vivo,50597,13950,,Stomach,A,,,Intermediate,,,
8402,BAO_0000218,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,2037.0,N,1,,CHEMBL620178,,50597,13950,,Cerebellum,A,,,Intermediate,,,
8403,BAO_0000218,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,2037.0,N,1,,CHEMBL620179,,50597,13950,,Cerebellum,A,,,Intermediate,,,
8404,BAO_0000218,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,1,,CHEMBL620180,,50597,13950,,,A,,,Intermediate,,,
8405,BAO_0000218,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,N,1,,CHEMBL620181,In vivo,50597,6570,,,A,,,Intermediate,,,
8406,BAO_0000218,Volume of distribution of compound in rats after intravenous administration,,N,1,,CHEMBL620182,In vivo,50597,6571,,,A,,,Intermediate,,,
8407,BAO_0000218,Volume of distribution in rat,,N,1,,CHEMBL620183,In vivo,50597,6453,,,A,,,Intermediate,,,
8408,BAO_0000218,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,N,1,,CHEMBL620184,In vivo,50597,6444,,,A,,,Intermediate,,,
8409,BAO_0000218,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,N,1,,CHEMBL620185,In vivo,50597,6444,,,A,,,Intermediate,,,
8410,BAO_0000218,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,N,1,,CHEMBL620186,In vivo,50597,6444,,,A,,,Intermediate,,,
8411,BAO_0000218,Volume of distribution was determined in Dawley rat,,N,1,,CHEMBL620187,In vivo,50597,5353,,,A,,,Intermediate,,,
8412,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,N,1,,CHEMBL620188,In vivo,50597,5334,,,A,,,Intermediate,,,
8413,BAO_0000218,Volume of distribution was reported in Sprague-Dawley rat,,N,1,,CHEMBL620189,In vivo,50597,5334,,,A,,,Intermediate,,,
8414,BAO_0000218,Volumes of distribution in rat after peroral administration,,N,1,,CHEMBL620190,In vivo,50597,6641,,,A,,,Intermediate,,,
8415,BAO_0000218,Volumes of distribution in rat after po administration,,N,1,,CHEMBL620191,In vivo,50597,6641,,,A,,,Intermediate,,,
8416,BAO_0000218,Volumes of distribution in rat after po administration; Not determined,,N,1,,CHEMBL620192,In vivo,50597,6641,,,A,,,Intermediate,,,
8417,BAO_0000218,Pharmacokinetic property (Volume) in rat i.v.,,N,1,,CHEMBL620193,In vivo,50597,5676,,,A,,,Intermediate,,,
8418,BAO_0000218,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,N,1,,CHEMBL620194,In vivo,50597,6410,,,A,,,Intermediate,,,
8419,BAO_0000218,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,N,1,,CHEMBL876730,In vivo,50597,17670,,,A,,,Intermediate,,,
8420,BAO_0000218,Volume distribution in rat after oral administration at 10 mg/kg,,N,1,,CHEMBL620195,In vivo,50597,6495,,,A,,,Intermediate,,,
8421,BAO_0000218,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL620196,In vivo,50597,5408,,,A,,,Intermediate,,,
8422,BAO_0000218,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,N,1,,CHEMBL620197,In vivo,50597,4883,,,A,,,Intermediate,,,
8423,BAO_0000218,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,N,1,,CHEMBL620198,In vivo,50597,6647,,,A,,,Intermediate,,,
8424,BAO_0000218,Volume of distribution in rats,,N,1,,CHEMBL620199,In vivo,50597,6495,,,A,,,Intermediate,,,
8425,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,N,1,,CHEMBL620200,In vivo,50597,2661,,,A,,,Intermediate,,,
8426,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,N,1,,CHEMBL620201,In vivo,50597,2661,,,A,,,Intermediate,,,
8427,BAO_0000218,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL620202,In vivo,50597,5974,,,A,,,Intermediate,,,
8428,BAO_0000218,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL620203,In vivo,50597,5974,,,A,,,Intermediate,,,
8429,BAO_0000218,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,N,1,,CHEMBL620204,In vivo,50597,5974,,,A,,,Intermediate,,,
8430,BAO_0000218,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL620205,In vivo,50597,5974,,,A,,,Intermediate,,,
8431,BAO_0000218,Pharmacokinetic parameter (Vss) in rat,,N,1,,CHEMBL624664,In vivo,50597,5960,,,A,,,Intermediate,,,
8432,BAO_0000218,Pharmacokinetic property (Volume) in rat i.v.,,N,1,,CHEMBL624665,In vivo,50597,5676,,,A,,,Intermediate,,,
8433,BAO_0000218,Pharmacokinetic property (Vss) in rat,,N,1,,CHEMBL624666,,50597,5948,,,A,,,Intermediate,,,
8434,BAO_0000218,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,N,1,,CHEMBL624667,In vivo,50597,5979,,,A,,,Intermediate,,,
8435,BAO_0000218,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL624668,In vivo,50597,5978,,,A,,,Intermediate,,,
8436,BAO_0000218,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL624669,In vivo,50597,5978,,,A,,,Intermediate,,,
8437,BAO_0000218,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL624670,In vivo,50597,5978,,,A,,,Intermediate,,,
8438,BAO_0000218,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL624671,In vivo,50597,5978,,,A,,,Intermediate,,,
8439,BAO_0000218,Steady state volume distribution in rat,,N,1,,CHEMBL624672,In vivo,50597,6448,,,A,,,Intermediate,,,
8440,BAO_0000218,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1969.0,N,1,,CHEMBL624673,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
8441,BAO_0000218,Steady state volume of distribution determined in rat,,N,1,,CHEMBL624674,In vivo,50597,4576,,,A,,,Intermediate,,,
8442,BAO_0000218,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,1,,CHEMBL624675,In vivo,50597,17582,,,A,,,Intermediate,,,
8443,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,N,1,,CHEMBL621728,In vivo,50597,1466,,,A,,,Intermediate,,,
8444,BAO_0000218,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,N,1,,CHEMBL621729,,50597,5182,,,A,,,Intermediate,,,
8445,BAO_0000218,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,N,1,,CHEMBL621730,,50597,5182,,,A,,,Intermediate,,,
8446,BAO_0000218,Volume distribution in rat after administration of 2 mg/kg iv,,N,1,,CHEMBL621731,In vivo,50597,6535,,,A,,,Intermediate,,,
8447,BAO_0000218,Volume distribution in rat after administration of 2 mg/kg iv,,N,1,,CHEMBL621732,In vivo,50597,6535,,,A,,,Intermediate,,,
8448,BAO_0000218,Volume in steady state distribution value was determined,,N,1,,CHEMBL621908,In vivo,50597,5041,,,A,,,Intermediate,,,
8449,BAO_0000218,Volume in steady state distribution value was determined; ND denotes no data,,N,1,,CHEMBL875347,In vivo,50597,5041,,,A,,,Intermediate,,,
8450,BAO_0000218,Volume in steady state distribution value was determined; ND denotes not determined,,N,1,,CHEMBL621909,In vivo,50597,5041,,,A,,,Intermediate,,,
8451,BAO_0000218,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,1,,CHEMBL621910,In vivo,50597,17065,,,A,,,Intermediate,,,
8452,BAO_0000218,Volume of distribution at steady state was evaluated in rats,,N,1,,CHEMBL621911,In vivo,50597,6597,,,A,,,Intermediate,,,
8453,BAO_0000218,Volume of distribution at steady state was observed after intravenous administration in rat,,N,1,,CHEMBL621912,In vivo,50597,15662,,,A,,,Intermediate,,,
8454,BAO_0000218,Volume of distribution in steady state was determined in rat,,N,1,,CHEMBL621913,In vivo,50597,6485,,,A,,,Intermediate,,,
8455,BAO_0000218,Volume of distribution in steady state was determined in rat,,N,1,,CHEMBL621914,In vivo,50597,17655,,,A,,,Intermediate,,,
8456,BAO_0000218,Volume of distribution after i.v. administration,,N,1,,CHEMBL621915,In vivo,50597,6616,,,A,,,Intermediate,,,
8457,BAO_0000218,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,N,1,,CHEMBL621916,In vivo,50597,1916,,,A,,,Intermediate,,,
8458,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",2107.0,N,1,,CHEMBL621917,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
8459,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2107.0,N,1,,CHEMBL621918,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
8460,BAO_0000218,Biodistribution of compound (oxidized form) in spleen tissue,2106.0,N,1,,CHEMBL621919,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8461,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2106.0,N,1,,CHEMBL621920,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8462,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",2106.0,N,1,,CHEMBL621921,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8463,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2106.0,N,1,,CHEMBL622401,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8464,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2106.0,N,1,,CHEMBL875348,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8465,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",2106.0,N,1,,CHEMBL622402,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8466,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,178.0,N,1,,CHEMBL622403,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
8467,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",178.0,N,1,,CHEMBL622404,In vivo,50594,16438,,Blood,A,,,Intermediate,,,
8468,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,955.0,N,1,,CHEMBL622405,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
8469,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",955.0,N,1,,CHEMBL622406,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
8470,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,N,1,,CHEMBL622407,In vivo,50594,16438,,Brain,A,,,Intermediate,,,
8471,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,948.0,N,1,,CHEMBL622408,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
8472,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",948.0,N,1,,CHEMBL622409,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
8473,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",948.0,N,1,,CHEMBL622410,In vivo,50594,16438,,Heart,A,,,Intermediate,,,
8474,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,2113.0,N,1,,CHEMBL622411,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
8475,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",2113.0,N,1,,CHEMBL627864,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
8476,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2113.0,N,1,,CHEMBL627865,In vivo,50594,16438,,Kidney,A,,,Intermediate,,,
8477,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,2107.0,N,1,,CHEMBL627866,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
8478,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2107.0,N,1,,CHEMBL627751,In vivo,50594,16438,,Liver,A,,,Intermediate,,,
8479,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,2106.0,N,1,,CHEMBL627752,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8480,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",2106.0,N,1,,CHEMBL627753,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8481,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2106.0,N,1,,CHEMBL627754,In vivo,50594,16438,,Spleen,A,,,Intermediate,,,
8482,BAO_0000218,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,N,1,,CHEMBL627755,,50594,12467,,,A,,,Intermediate,,,
8483,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),955.0,N,1,,CHEMBL627756,In vivo,50594,17208,,Brain,A,,,Intermediate,,,
8484,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),955.0,N,1,,CHEMBL627757,In vivo,50594,17208,,Brain,A,,,Intermediate,,,
8485,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),955.0,N,1,,CHEMBL627758,In vivo,50594,17208,,Brain,A,,,Intermediate,,,
8486,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),955.0,N,1,,CHEMBL627759,In vivo,50594,17208,,Brain,A,,,Intermediate,,,
8487,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),955.0,N,1,,CHEMBL627760,In vivo,50594,17208,,Brain,A,,,Intermediate,,,
8488,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),955.0,N,1,,CHEMBL627761,In vivo,50594,17208,,Brain,A,,,Intermediate,,,
8489,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),948.0,N,1,,CHEMBL876811,In vivo,50594,17208,,Heart,A,,,Intermediate,,,
8490,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),948.0,N,1,,CHEMBL627762,In vivo,50594,17208,,Heart,A,,,Intermediate,,,
8491,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),948.0,N,1,,CHEMBL627763,In vivo,50594,17208,,Heart,A,,,Intermediate,,,
8492,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),948.0,N,1,,CHEMBL627764,In vivo,50594,17208,,Heart,A,,,Intermediate,,,
8493,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),948.0,N,1,,CHEMBL627765,In vivo,50594,17208,,Heart,A,,,Intermediate,,,
8494,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),948.0,N,1,,CHEMBL627766,In vivo,50594,17208,,Heart,A,,,Intermediate,,,
8495,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),2113.0,N,1,,CHEMBL627767,In vivo,50594,17208,,Kidney,A,,,Intermediate,,,
8496,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),2113.0,N,1,,CHEMBL627768,In vivo,50594,17208,,Kidney,A,,,Intermediate,,,
8497,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),2113.0,N,1,,CHEMBL628422,In vivo,50594,17208,,Kidney,A,,,Intermediate,,,
8498,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),2113.0,N,1,,CHEMBL628423,In vivo,50594,17208,,Kidney,A,,,Intermediate,,,
8499,BAO_0000218,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,N,1,,CHEMBL628424,In vivo,50597,5089,,,A,,,Intermediate,,,
8500,BAO_0000218,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,N,1,,CHEMBL628425,In vivo,50597,5089,,,A,,,Intermediate,,,
8501,BAO_0000218,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,N,1,,CHEMBL628426,In vivo,50597,4257,,,A,,,Intermediate,,,
8502,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL628427,In vivo,50597,6679,,,A,,,Intermediate,,,
8503,BAO_0000218,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,N,1,,CHEMBL626938,In vivo,50597,5546,,,A,,,Intermediate,,,
8504,BAO_0000218,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,N,1,,CHEMBL626939,In vivo,50597,6141,,,A,,,Intermediate,,,
8505,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,N,1,,CHEMBL626940,In vivo,50597,5334,,,A,,,Intermediate,,,
8506,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,N,1,,CHEMBL626941,In vivo,50597,5334,,,A,,,Intermediate,,,
8507,BAO_0000218,Plasma clearance was reported in Sprague-Dawley rat,,N,1,,CHEMBL626942,In vivo,50597,5334,,,A,,,Intermediate,,,
8508,BAO_0000218,Plasma clearance after intravenous administration (1 mg/kg) in rat,,N,1,,CHEMBL876812,In vivo,50597,4689,,,A,,,Intermediate,,,
8509,BAO_0000218,Plasma clearance of compound in rats was evaluated,,N,1,,CHEMBL626943,In vivo,50597,6848,,,A,,,Intermediate,,,
8510,BAO_0000218,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,N,1,,CHEMBL626944,In vivo,50597,6848,,,A,,,Intermediate,,,
8511,BAO_0000218,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,N,1,,CHEMBL626945,In vivo,50597,6467,,,A,,,Intermediate,,,
8512,BAO_0000218,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,N,1,,CHEMBL626946,In vivo,50597,6467,,,A,,,Intermediate,,,
8513,BAO_0000218,Plasma clearance rate in Sprague-Dawley rats,,N,1,,CHEMBL626856,In vivo,50597,4956,,,A,,,Intermediate,,,
8514,BAO_0000218,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,N,1,,CHEMBL626857,In vivo,50597,5529,,,A,,,Intermediate,,,
8515,BAO_0000218,The compound was evaluated for plasma clearance in rat,1969.0,N,1,,CHEMBL626858,In vivo,50597,406,,Plasma,A,,,Intermediate,,,
8516,BAO_0000218,Total plasma clearance in rat,1969.0,N,1,,CHEMBL627018,In vivo,50597,17655,,Plasma,A,,,Intermediate,,,
8517,BAO_0000218,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,178.0,N,1,,CHEMBL625331,In vivo,50597,3293,,Blood,A,,,Intermediate,,,
8518,BAO_0000218,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,178.0,N,1,,CHEMBL625332,In vivo,50597,4075,,Blood,A,,,Intermediate,,,
8519,BAO_0000218,C max was determined at 10 mg/kg po dose in rats,,N,1,,CHEMBL877590,In vivo,50597,2792,,,A,,,Intermediate,,,
8520,BAO_0000218,C max was determined at 3 mg/kg po dose in rats,,N,1,,CHEMBL625333,In vivo,50597,2792,,,A,,,Intermediate,,,
8521,BAO_0000218,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,N,1,,CHEMBL625334,In vivo,50597,17594,,,A,,,Intermediate,,,
8522,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in rats,,N,1,,CHEMBL625335,In vivo,50597,17594,,,A,,,Intermediate,,,
8523,BAO_0000218,Cmax of compound at 5 mg/kg after po administration was determined in rat,,N,1,,CHEMBL625336,In vivo,50597,4762,,,A,,,Intermediate,,,
8524,BAO_0000218,Cmax 24 hr after 10 mg/kg oral administration in rats,,N,1,,CHEMBL625337,In vivo,50597,17509,,,A,,,Intermediate,,,
8525,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in rats,,N,1,,CHEMBL625338,In vivo,50597,17509,,,A,,,Intermediate,,,
8526,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1969.0,N,1,,CHEMBL625339,In vivo,50597,1466,,Plasma,A,,,Intermediate,,,
8527,BAO_0000218,Cmax in rat after administration of 2 mg/kg iv,,N,1,,CHEMBL625340,In vivo,50597,6535,,,A,,,Intermediate,,,
8528,BAO_0000218,Cmax in rat after administration of 2 mg/kg iv,,N,1,,CHEMBL625341,In vivo,50597,6535,,,A,,,Intermediate,,,
8529,BAO_0000218,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,N,1,,CHEMBL622687,In vivo,50597,3169,,,A,,,Intermediate,,,
8530,BAO_0000218,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1969.0,N,1,,CHEMBL622688,In vivo,50597,6515,,Plasma,A,,,Intermediate,,,
8531,BAO_0000218,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,178.0,N,1,,CHEMBL622689,In vivo,50597,11149,,Blood,A,,,Intermediate,,,
8532,BAO_0000218,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,178.0,N,1,,CHEMBL620295,In vivo,50597,11149,,Blood,A,,,Intermediate,,,
8533,BAO_0000218,Cmax after 10 mg/kg oral administration in rat,,N,1,,CHEMBL620296,In vivo,50597,17858,,,A,,,Intermediate,,,
8534,BAO_0000218,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,N,1,,CHEMBL620297,In vivo,50597,6518,,,A,,,Intermediate,,,
8535,BAO_0000218,Cmax after IV dosing at 1 mg/kg in rat; no data,,N,1,,CHEMBL620298,In vivo,50597,6518,,,A,,,Intermediate,,,
8536,BAO_0000218,Cmax after oral administration at 20 mpk in rats,,N,1,,CHEMBL620299,In vivo,50597,4426,,,A,,,Intermediate,,,
8537,BAO_0000218,Cmax after oral administration at 20 mpk in rats; Not performed.,,N,1,,CHEMBL620300,In vivo,50597,4426,,,A,,,Intermediate,,,
8538,BAO_0000218,Cmax after oral administration at 20 mpk in rats d; Not performed.,,N,1,,CHEMBL620301,In vivo,50597,4426,,,A,,,Intermediate,,,
8539,BAO_0000218,Cmax after oral administration in rat,,N,1,,CHEMBL620302,In vivo,50597,5656,,,A,,,Intermediate,,,
8540,BAO_0000218,Cmax after oral administration at a dose of 2 mg/kg in rat,,N,1,,CHEMBL620303,In vivo,50597,6518,,,A,,,Intermediate,,,
8541,BAO_0000218,Cmax after oral administration at a dose of 4 mg/kg in rat,,N,1,,CHEMBL620304,In vivo,50597,6518,,,A,,,Intermediate,,,
8542,BAO_0000218,Cmax in rats after 20 mg/kg oral dose,,N,1,,CHEMBL620305,In vivo,50597,6113,,,A,,,Intermediate,,,
8543,BAO_0000218,Cmax after peroral administration in rats at 2.4 uM/kg,,N,1,,CHEMBL620306,In vivo,50597,17764,,,A,,,Intermediate,,,
8544,BAO_0000218,Cmax at the dose of 2 mg/Kg administered perorally in rats,,N,1,,CHEMBL620307,In vivo,50597,4756,,,A,,,Intermediate,,,
8545,BAO_0000218,Cmax at the dose of 5 mg/Kg administered perorally in rats,,N,1,,CHEMBL620308,In vivo,50597,4756,,,A,,,Intermediate,,,
8546,BAO_0000218,Cmax by administering at 20 mg/kg p.o. in rats,,N,1,,CHEMBL620309,In vivo,50597,6402,,,A,,,Intermediate,,,
8547,BAO_0000218,Cmax in male rat,,N,1,,CHEMBL620310,In vivo,50597,5610,,,A,,,Intermediate,,,
8548,BAO_0000218,Cmax in rat,,N,1,,CHEMBL620311,In vivo,50597,5207,,,A,,,Intermediate,,,
8549,BAO_0000218,Cmax in rat,,N,1,,CHEMBL620312,In vivo,50597,6011,,,A,,,Intermediate,,,
8550,BAO_0000218,Cmax in rat,,N,1,,CHEMBL620313,In vivo,50597,6504,,,A,,,Intermediate,,,
8551,BAO_0000218,Cmax in rat at 10 mg/kg,,N,1,,CHEMBL620314,In vivo,50597,6046,,,A,,,Intermediate,,,
8552,BAO_0000218,Cmax in rat at the dose of 1 mg/kg i.v.,,N,1,,CHEMBL620315,In vivo,50597,6504,,,A,,,Intermediate,,,
8553,BAO_0000218,Cmax in rat by po administration at a dose of 40 mg/kg,,N,1,,CHEMBL620316,In vivo,50597,5874,,,A,,,Intermediate,,,
8554,BAO_0000218,Cmax in rat p.o. at 20 mg/kg concentration,,N,1,,CHEMBL620317,In vivo,50597,17686,,,A,,,Intermediate,,,
8555,BAO_0000218,Cmax in rats,,N,1,,CHEMBL620318,In vivo,50597,5836,,,A,,,Intermediate,,,
8556,BAO_0000218,Cmax in rats,,N,1,,CHEMBL620319,In vivo,50597,17596,,,A,,,Intermediate,,,
8557,BAO_0000218,Cmax was evaluated after 20 uM/kg of peroral administration,,N,1,,CHEMBL620320,In vivo,50597,16423,,,A,,,Intermediate,,,
8558,BAO_0000218,Cmax was measured in rats after peroral administration at 3 mg/kg,,N,1,,CHEMBL620321,In vivo,50597,17804,,,A,,,Intermediate,,,
8559,BAO_0000218,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,N,1,,CHEMBL620322,In vivo,50597,1908,,,A,,,Intermediate,,,
8560,BAO_0000218,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,1,,CHEMBL620323,,50597,13950,,,A,,,Intermediate,,,
8561,BAO_0000218,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1870.0,N,1,,CHEMBL620324,,50597,13950,,Frontal cortex,A,,,Intermediate,,,
8562,BAO_0000218,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1870.0,N,1,,CHEMBL620325,,50597,13950,,Frontal cortex,A,,,Intermediate,,,
8563,BAO_0000218,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,10000000.0,N,1,,CHEMBL620326,,50597,13950,,Hippocampus,A,,,Intermediate,,,
8564,BAO_0000218,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,10000000.0,N,1,,CHEMBL620327,,50597,13950,,Hippocampus,A,,,Intermediate,,,
8565,BAO_0000218,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,1,,CHEMBL620328,,50597,13950,,,A,,,Intermediate,,,
8566,BAO_0000218,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,1,,CHEMBL620329,,50597,13950,,,A,,,Intermediate,,,
8567,BAO_0000218,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1891.0,N,1,,CHEMBL620330,,50597,13950,,Midbrain,A,,,Intermediate,,,
8568,BAO_0000218,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1891.0,N,1,,CHEMBL875286,,50597,13950,,Midbrain,A,,,Intermediate,,,
8569,BAO_0000218,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,1,,CHEMBL620331,,50597,13950,,,A,,,Intermediate,,,
8570,BAO_0000218,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,1,,CHEMBL620332,,50597,13950,,,A,,,Intermediate,,,
8571,BAO_0000218,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,2435.0,N,1,,CHEMBL620333,,50597,13950,,Striatum,A,,,Intermediate,,,
8572,BAO_0000218,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,2435.0,N,1,,CHEMBL620334,,50597,13950,,Striatum,A,,,Intermediate,,,
8573,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,178.0,N,1,,CHEMBL621015,,50597,16434,,Blood,A,,,Intermediate,,,
8574,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,178.0,N,1,,CHEMBL621016,,50597,16434,,Blood,A,,,Intermediate,,,
8575,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,178.0,N,1,,CHEMBL621191,,50597,16434,,Blood,A,,,Intermediate,,,
8576,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,178.0,N,1,,CHEMBL621192,,50597,16434,,Blood,A,,,Intermediate,,,
8577,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,178.0,N,1,,CHEMBL621193,,50597,16434,,Blood,A,,,Intermediate,,,
8578,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,178.0,N,1,,CHEMBL621194,,50597,16434,,Blood,A,,,Intermediate,,,
8579,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,178.0,N,1,,CHEMBL624204,,50597,16434,,Blood,A,,,Intermediate,,,
8580,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,178.0,N,1,,CHEMBL624205,,50597,16434,,Blood,A,,,Intermediate,,,
8581,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,178.0,N,1,,CHEMBL624206,,50597,16435,,Blood,A,,,Intermediate,,,
8582,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,178.0,N,1,,CHEMBL624207,,50597,16435,,Blood,A,,,Intermediate,,,
8583,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,178.0,N,1,,CHEMBL624208,,50597,16435,,Blood,A,,,Intermediate,,,
8584,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,178.0,N,1,,CHEMBL624209,,50597,16435,,Blood,A,,,Intermediate,,,
8585,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,178.0,N,1,,CHEMBL624210,,50597,16435,,Blood,A,,,Intermediate,,,
8586,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,178.0,N,1,,CHEMBL624211,,50597,16435,,Blood,A,,,Intermediate,,,
8587,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,178.0,N,1,,CHEMBL624212,,50597,16435,,Blood,A,,,Intermediate,,,
8588,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,178.0,N,1,,CHEMBL624213,,50597,16435,,Blood,A,,,Intermediate,,,
8589,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,178.0,N,1,,CHEMBL876611,,50597,16434,,Blood,A,,,Intermediate,,,
8590,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,178.0,N,1,,CHEMBL624214,,50597,16434,,Blood,A,,,Intermediate,,,
8591,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,178.0,N,1,,CHEMBL624215,,50597,16434,,Blood,A,,,Intermediate,,,
8592,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,178.0,N,1,,CHEMBL624216,,50597,16435,,Blood,A,,,Intermediate,,,
8593,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,178.0,N,1,,CHEMBL624217,,50597,16435,,Blood,A,,,Intermediate,,,
8594,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,178.0,N,1,,CHEMBL624218,,50597,16435,,Blood,A,,,Intermediate,,,
8595,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,178.0,N,1,,CHEMBL624219,,50597,16435,,Blood,A,,,Intermediate,,,
8596,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,178.0,N,1,,CHEMBL624220,,50597,16435,,Blood,A,,,Intermediate,,,
8597,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,178.0,N,1,,CHEMBL624221,,50597,16435,,Blood,A,,,Intermediate,,,
8598,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,1,,CHEMBL624222,,50597,16434,,,A,,,Intermediate,,,
8599,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,1,,CHEMBL624223,,50597,16434,,,A,,,Intermediate,,,
8600,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,1,,CHEMBL624224,,50597,16434,,,A,,,Intermediate,,,
8601,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,1,,CHEMBL624225,,50597,16434,,,A,,,Intermediate,,,
8602,BAO_0000218,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,N,1,,CHEMBL622420,In vivo,50597,17764,,,A,,,Intermediate,,,
8603,BAO_0000218,Volume of steady state distribution after i.v. administration in rats,,N,1,,CHEMBL622421,In vivo,50597,5031,,,A,,,Intermediate,,,
8604,BAO_0000218,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,N,1,,CHEMBL622422,In vivo,50597,6215,,,A,,,Intermediate,,,
8605,BAO_0000218,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,1,,CHEMBL622423,In vivo,50597,17671,,,A,,,Intermediate,,,
8606,BAO_0000218,Vss was determined,,N,1,,CHEMBL622424,In vivo,50597,17752,,,A,,,Intermediate,,,
8607,BAO_0000218,Vss in rat,,N,1,,CHEMBL622425,In vivo,50597,6596,,,A,,,Intermediate,,,
8608,BAO_0000218,Vss was evaluated after 10 uM/kg of intra arterial administration,,N,1,,CHEMBL876612,In vivo,50597,16423,,,A,,,Intermediate,,,
8609,BAO_0000218,volume of distribution at steady state was observed after intravenous administration in rat,,N,1,,CHEMBL622426,In vivo,50597,15662,,,A,,,Intermediate,,,
8610,BAO_0000218,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,N,1,,CHEMBL622427,In vivo,50597,6062,,,A,,,Intermediate,,,
8611,BAO_0000218,Pharmacokinetic (PK) parameter Vz in rat,,N,1,,CHEMBL622428,In vivo,50597,5874,,,A,,,Intermediate,,,
8612,BAO_0000218,Volume distribution in rats,,N,1,,CHEMBL622429,In vivo,50597,4942,,,A,,,Intermediate,,,
8613,BAO_0000218,Volume of distribution in rat; No data,,N,1,,CHEMBL622430,In vivo,50597,17796,,,A,,,Intermediate,,,
8614,BAO_0000218,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL622431,In vivo,50597,4890,,,A,,,Intermediate,,,
8615,BAO_0000218,% absorption predicted from in vitro rat ileum transport studies,2116.0,N,1,,CHEMBL622432,,50597,15765,,Ileum,A,,,Intermediate,,,
8616,BAO_0000218,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,N,1,,CHEMBL622433,In vivo,50597,13569,,,A,,,Intermediate,,,
8617,BAO_0000218,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,N,1,,CHEMBL622434,In vivo,50597,13569,,,A,,,Intermediate,,,
8618,BAO_0000218,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,N,1,,CHEMBL622435,In vivo,50597,13569,,,A,,,Intermediate,,,
8619,BAO_0000218,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,N,1,,CHEMBL618748,In vivo,50597,13569,,,A,,,Intermediate,,,
8620,BAO_0000218,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,N,1,,CHEMBL618749,In vivo,50597,13569,,,A,,,Intermediate,,,
8621,BAO_0000218,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,N,1,,CHEMBL618750,In vivo,50597,13569,,,A,,,Intermediate,,,
8622,BAO_0000218,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,N,1,,CHEMBL618751,In vivo,50597,13569,,,A,,,Intermediate,,,
8623,BAO_0000218,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,N,1,,CHEMBL618752,In vivo,50597,13569,,,A,,,Intermediate,,,
8624,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618753,In vivo,50597,4576,,,A,,,Intermediate,,,
8625,BAO_0000218,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1969.0,N,1,,CHEMBL618754,In vivo,50597,750,,Plasma,A,,,Intermediate,,,
8626,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618755,In vivo,50597,750,,,A,,,Intermediate,,,
8627,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618756,In vivo,50597,4590,,,A,,,Intermediate,,,
8628,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618757,In vivo,50597,1716,,,A,,,Intermediate,,,
8629,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL618758,In vivo,50597,1974,,,A,,,Intermediate,,,
8630,BAO_0000218,Oral bioavailability in rat (dose 30 mg/kg),,N,1,,CHEMBL621088,In vivo,50597,4502,,,A,,,Intermediate,,,
8631,BAO_0000218,Pharmacokinetic property (cLogP) in rat,,N,1,,CHEMBL621089,,50597,3371,,,A,,,Intermediate,,,
8632,BAO_0000218,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,178.0,N,1,,CHEMBL621090,,50597,9099,,Blood,F,,,Intermediate,,,
8633,BAO_0000218,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,178.0,N,1,,CHEMBL621091,,50597,9099,,Blood,F,,,Intermediate,,,
8634,BAO_0000218,Clearance in rat.,,N,1,,CHEMBL876731,In vivo,50597,4590,,,A,,,Intermediate,,,
8635,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in rat,,N,1,,CHEMBL621092,In vivo,50597,3184,,,A,,,Intermediate,,,
8636,BAO_0000218,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL621093,In vivo,50597,16456,,,A,,,Intermediate,,,
8637,BAO_0000218,Blood: Brain distribution ratio is determined in rat,,N,1,,CHEMBL621094,,50597,4199,,,A,,,Intermediate,,,
8638,BAO_0000218,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,N,1,,CHEMBL621095,,50597,4199,,,A,,,Intermediate,,,
8639,BAO_0000218,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,N,1,,CHEMBL621096,,50597,4199,,,A,,,Intermediate,,,
8640,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,N,1,,CHEMBL621097,In vivo,50597,8677,,Kidney,A,,,Intermediate,,,
8641,BAO_0000218,Percent dose excreted in 0-48 hours administered ip to male rat,,N,1,,CHEMBL621098,,50597,7449,,,F,,,Intermediate,,,
8642,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),2037.0,N,1,,CHEMBL621099,,50597,11977,,Cerebellum,A,,,Intermediate,,,
8643,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),2037.0,N,1,,CHEMBL621100,,50597,11977,,Cerebellum,A,,,Intermediate,,,
8644,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),2037.0,N,1,,CHEMBL621101,,50597,11977,,Cerebellum,A,,,Intermediate,,,
8645,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),2037.0,N,1,,CHEMBL621102,,50597,11977,,Cerebellum,A,,,Intermediate,,,
8646,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),2037.0,N,1,,CHEMBL876732,,50597,11977,,Cerebellum,A,,,Intermediate,,,
8647,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL621103,,50597,11977,,,A,,,Intermediate,,,
8648,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL621104,,50597,11977,,,A,,,Intermediate,,,
8649,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,1,,CHEMBL621105,,50597,11977,,,A,,,Intermediate,,,
8650,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL621106,,50597,11977,,,A,,,Intermediate,,,
8651,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL621107,,50597,11977,,,A,,,Intermediate,,,
8652,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL621108,,50597,11977,,,A,,,Intermediate,,,
8653,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL621109,,50597,11977,,,A,,,Intermediate,,,
8654,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),2113.0,N,1,,CHEMBL621110,In vivo,50594,17208,,Kidney,A,,,Intermediate,,,
8655,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),2113.0,N,1,,CHEMBL621111,In vivo,50594,17208,,Kidney,A,,,Intermediate,,,
8656,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),2107.0,N,1,,CHEMBL622541,In vivo,50594,17208,,Liver,A,,,Intermediate,,,
8657,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),2107.0,N,1,,CHEMBL622542,In vivo,50594,17208,,Liver,A,,,Intermediate,,,
8658,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),2107.0,N,1,,CHEMBL622543,In vivo,50594,17208,,Liver,A,,,Intermediate,,,
8659,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),2107.0,N,1,,CHEMBL624412,In vivo,50594,17208,,Liver,A,,,Intermediate,,,
8660,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),2107.0,N,1,,CHEMBL624413,In vivo,50594,17208,,Liver,A,,,Intermediate,,,
8661,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),2107.0,N,1,,CHEMBL624414,In vivo,50594,17208,,Liver,A,,,Intermediate,,,
8662,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),2048.0,N,1,,CHEMBL624415,In vivo,50594,17208,,Lung,A,,,Intermediate,,,
8663,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),2048.0,N,1,,CHEMBL624416,In vivo,50594,17208,,Lung,A,,,Intermediate,,,
8664,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),2048.0,N,1,,CHEMBL624417,In vivo,50594,17208,,Lung,A,,,Intermediate,,,
8665,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),2048.0,N,1,,CHEMBL624418,In vivo,50594,17208,,Lung,A,,,Intermediate,,,
8666,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),2048.0,N,1,,CHEMBL624419,In vivo,50594,17208,,Lung,A,,,Intermediate,,,
8667,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),2048.0,N,1,,CHEMBL624420,In vivo,50594,17208,,Lung,A,,,Intermediate,,,
8668,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),2385.0,N,1,,CHEMBL624421,In vivo,50594,17208,,Muscle tissue,A,,,Intermediate,,,
8669,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),2385.0,N,1,,CHEMBL624422,In vivo,50594,17208,,Muscle tissue,A,,,Intermediate,,,
8670,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),2385.0,N,1,,CHEMBL624423,In vivo,50594,17208,,Muscle tissue,A,,,Intermediate,,,
8671,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),2385.0,N,1,,CHEMBL625123,In vivo,50594,17208,,Muscle tissue,A,,,Intermediate,,,
8672,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),2385.0,N,1,,CHEMBL625124,In vivo,50594,17208,,Muscle tissue,A,,,Intermediate,,,
8673,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),2385.0,N,1,,CHEMBL625125,In vivo,50594,17208,,Muscle tissue,A,,,Intermediate,,,
8674,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),14.0,N,1,,CHEMBL625126,In vivo,50594,17208,,Zone of skin,A,,,Intermediate,,,
8675,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),14.0,N,1,,CHEMBL626947,In vivo,50594,17208,,Zone of skin,A,,,Intermediate,,,
8676,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),14.0,N,1,,CHEMBL626948,In vivo,50594,17208,,Zone of skin,A,,,Intermediate,,,
8677,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),14.0,N,1,,CHEMBL626949,In vivo,50594,17208,,Zone of skin,A,,,Intermediate,,,
8678,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),14.0,N,1,,CHEMBL626950,In vivo,50594,17208,,Zone of skin,A,,,Intermediate,,,
8679,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),14.0,N,1,,CHEMBL626951,In vivo,50594,17208,,Zone of skin,A,,,Intermediate,,,
8680,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),2106.0,N,1,,CHEMBL626952,In vivo,50594,17208,,Spleen,A,,,Intermediate,,,
8681,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),2106.0,N,1,,CHEMBL626953,In vivo,50594,17208,,Spleen,A,,,Intermediate,,,
8682,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),2106.0,N,1,,CHEMBL626954,In vivo,50594,17208,,Spleen,A,,,Intermediate,,,
8683,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),2106.0,N,1,,CHEMBL626955,In vivo,50594,17208,,Spleen,A,,,Intermediate,,,
8684,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),2106.0,N,1,,CHEMBL626956,In vivo,50594,17208,,Spleen,A,,,Intermediate,,,
8685,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),2106.0,N,1,,CHEMBL626957,In vivo,50594,17208,,Spleen,A,,,Intermediate,,,
8686,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),178.0,N,1,,CHEMBL626958,In vivo,50594,17208,,Blood,A,,,Intermediate,,,
8687,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),178.0,N,1,,CHEMBL626959,In vivo,50594,17208,,Blood,A,,,Intermediate,,,
8688,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),178.0,N,1,,CHEMBL626960,In vivo,50594,17208,,Blood,A,,,Intermediate,,,
8689,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),178.0,N,1,,CHEMBL626961,In vivo,50594,17208,,Blood,A,,,Intermediate,,,
8690,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),178.0,N,1,,CHEMBL627589,In vivo,50594,17208,,Blood,A,,,Intermediate,,,
8691,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),178.0,N,1,,CHEMBL627590,In vivo,50594,17208,,Blood,A,,,Intermediate,,,
8692,BAO_0000218,Time taken for EC90 was determined when tested in mouse,,N,1,,CHEMBL627591,,50594,3132,,,A,,,Intermediate,,,
8693,BAO_0000218,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,N,1,,CHEMBL627592,,50594,3132,,,A,,,Intermediate,,,
8694,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,N,1,,CHEMBL627593,In vivo,50594,16597,,,A,,,Intermediate,,,
8695,BAO_0000218,Half life in mice,,N,1,,CHEMBL627594,,50594,5727,,,A,,,Intermediate,,,
8696,BAO_0000218,Half life period in mouse after 10 mg/Kg dose,,N,1,,CHEMBL876813,In vivo,50594,5302,,,A,,,Intermediate,,,
8697,BAO_0000218,Half life period in mouse after 10 mg/kg dose,,N,1,,CHEMBL627595,In vivo,50594,5302,,,A,,,Intermediate,,,
8698,BAO_0000218,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,1,,CHEMBL627596,In vivo,50594,6348,,,A,,,Intermediate,,,
8699,BAO_0000218,Cmax value at 5 mg/kg po was determined in rat,,N,1,,CHEMBL627597,In vivo,50597,5964,,,A,,,Intermediate,,,
8700,BAO_0000218,Cmax value evaluated in rat,,N,1,,CHEMBL627598,In vivo,50597,6078,,,A,,,Intermediate,,,
8701,BAO_0000218,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,955.0,N,1,,CHEMBL627599,In vivo,50597,5206,,Brain,A,,,Intermediate,,,
8702,BAO_0000218,Cmax value after administration of 20 mg/Kg oral dose in rat,,N,1,,CHEMBL627600,In vivo,50597,2959,,,A,,,Intermediate,,,
8703,BAO_0000218,Cmax value at 1 mg/kg po in rat,,N,1,,CHEMBL627601,In vivo,50597,5964,,,A,,,Intermediate,,,
8704,BAO_0000218,Cmax value at 5 mg/kg po in rat,,N,1,,CHEMBL627776,In vivo,50597,5964,,,A,,,Intermediate,,,
8705,BAO_0000218,Cmax value at a dose of 10 mg/kg in male SD rats,,N,1,,CHEMBL627777,In vivo,50597,6757,,,A,,,Intermediate,,,
8706,BAO_0000218,Cmax value at a dose of 100 mg/kg in male SD rats,,N,1,,CHEMBL627778,In vivo,50597,6757,,,A,,,Intermediate,,,
8707,BAO_0000218,Cmax value at a dose of 50 mg/kg in male SD rats,,N,1,,CHEMBL627779,In vivo,50597,6757,,,A,,,Intermediate,,,
8708,BAO_0000218,Cmax value in rats at 10 mg/kg,,N,1,,CHEMBL876814,In vivo,50597,17617,,,A,,,Intermediate,,,
8709,BAO_0000218,Cmax value was evaluated in rats at a dose of 20 mg/kg,,N,1,,CHEMBL627780,In vivo,50597,1445,,,A,,,Intermediate,,,
8710,BAO_0000218,Cmax value was determined after peroral administration of 20 mg/kg in rat,,N,1,,CHEMBL627781,In vivo,50597,6082,,,A,,,Intermediate,,,
8711,BAO_0000218,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,N,1,,CHEMBL627782,In vivo,50597,1446,,,A,,,Intermediate,,,
8712,BAO_0000218,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1969.0,N,1,,CHEMBL627783,In vivo,50597,5407,,Plasma,A,,,Intermediate,,,
8713,BAO_0000218,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1969.0,N,1,,CHEMBL627784,In vivo,50597,2690,,Plasma,A,,,Intermediate,,,
8714,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,N,1,,CHEMBL627785,In vivo,50597,2661,,,A,,,Intermediate,,,
8715,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,N,1,,CHEMBL627786,In vivo,50597,2661,,,A,,,Intermediate,,,
8716,BAO_0000218,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1969.0,N,1,,CHEMBL627787,In vivo,50597,4891,,Plasma,A,,,Intermediate,,,
8717,BAO_0000218,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1969.0,N,1,,CHEMBL627788,In vivo,50597,2807,,Plasma,A,,,Intermediate,,,
8718,BAO_0000218,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1969.0,N,1,,CHEMBL626579,In vivo,50597,2807,,Plasma,A,,,Intermediate,,,
8719,BAO_0000218,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1969.0,N,1,,CHEMBL626580,In vivo,50597,2807,,Plasma,A,,,Intermediate,,,
8720,BAO_0000218,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,N,1,,CHEMBL876815,In vivo,50597,3634,,,A,,,Intermediate,,,
8721,BAO_0000218,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1969.0,N,1,,CHEMBL626581,In vivo,50597,1881,,Plasma,A,,,Intermediate,,,
8722,BAO_0000218,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1969.0,N,1,,CHEMBL626582,In vivo,50597,1881,,Plasma,A,,,Intermediate,,,
8723,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,N,1,,CHEMBL626583,In vivo,50597,429,,,A,,,Intermediate,,,
8724,BAO_0000218,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL626205,In vivo,50597,5974,,,A,,,Intermediate,,,
8725,BAO_0000218,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL626206,In vivo,50597,5974,,,A,,,Intermediate,,,
8726,BAO_0000218,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL626207,In vivo,50597,5974,,,A,,,Intermediate,,,
8727,BAO_0000218,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL623882,In vivo,50597,5974,,,A,,,Intermediate,,,
8728,BAO_0000218,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,N,1,,CHEMBL623883,In vivo,50597,17582,,,A,,,Intermediate,,,
8729,BAO_0000218,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,N,1,,CHEMBL623884,In vivo,50597,17582,,,A,,,Intermediate,,,
8730,BAO_0000218,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1969.0,N,1,,CHEMBL623885,In vivo,50597,3032,,Plasma,A,,,Intermediate,,,
8731,BAO_0000218,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1969.0,N,1,,CHEMBL623886,In vivo,50597,6295,,Plasma,A,,,Intermediate,,,
8732,BAO_0000218,Maximal concentration in rat was determined,,N,1,,CHEMBL623887,In vivo,50597,6619,,,A,,,Intermediate,,,
8733,BAO_0000218,Maximal concentration after i.v. administration,,N,1,,CHEMBL623888,In vivo,50597,6616,,,A,,,Intermediate,,,
8734,BAO_0000218,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL623889,In vivo,50597,3249,,Plasma,A,,,Intermediate,,,
8735,BAO_0000218,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1969.0,N,1,,CHEMBL623890,In vivo,50597,17791,,Plasma,A,,,Intermediate,,,
8736,BAO_0000218,Cmax in rat plasma after oral dose (50 mg/Kg),1969.0,N,1,,CHEMBL623891,In vivo,50597,17791,,Plasma,A,,,Intermediate,,,
8737,BAO_0000218,Maximal plasma concentration was determined.,1969.0,N,1,,CHEMBL623892,In vivo,50597,1360,,Plasma,A,,,Intermediate,,,
8738,BAO_0000218,Maximal plasma drug concentration was determined,1969.0,N,1,,CHEMBL623893,In vivo,50597,2552,,Plasma,A,,,Intermediate,,,
8739,BAO_0000218,Maximal concentration in rats after peroral administration,,N,1,,CHEMBL877616,In vivo,50597,6571,,,A,,,Intermediate,,,
8740,BAO_0000218,Maximum concentration in rat after 2 mg/kg peroral administration,,N,1,,CHEMBL623894,In vivo,50597,6570,,,A,,,Intermediate,,,
8741,BAO_0000218,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1969.0,N,1,,CHEMBL623895,In vivo,50597,6567,,Plasma,A,,,Intermediate,,,
8742,BAO_0000218,Maximum concentration of compound in rat was evaluated.,,N,1,,CHEMBL623896,In vivo,50597,3031,,,A,,,Intermediate,,,
8743,BAO_0000218,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,N,1,,CHEMBL623897,In vivo,50597,3436,,,A,,,Intermediate,,,
8744,BAO_0000218,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,N,1,,CHEMBL623898,In vivo,50597,3436,,,A,,,Intermediate,,,
8745,BAO_0000218,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,N,1,,CHEMBL623899,In vivo,50597,2083,,,A,,,Intermediate,,,
8746,BAO_0000218,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,N,1,,CHEMBL623900,In vivo,50597,3436,,,A,,,Intermediate,,,
8747,BAO_0000218,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,N,1,,CHEMBL623901,In vivo,50597,4527,,,A,,,Intermediate,,,
8748,BAO_0000218,Maximum concentration was evaluated in rats,,N,1,,CHEMBL623902,In vivo,50597,1974,,,A,,,Intermediate,,,
8749,BAO_0000218,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1359.0,N,1,,CHEMBL623903,In vivo,50597,3307,,Cerebrospinal fluid,A,,,Intermediate,,,
8750,BAO_0000218,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1969.0,N,1,,CHEMBL623904,In vivo,50597,3307,,Plasma,A,,,Intermediate,,,
8751,BAO_0000218,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1969.0,N,1,,CHEMBL877617,In vivo,50597,1916,,Plasma,A,,,Intermediate,,,
8752,BAO_0000218,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,N,1,,CHEMBL623905,In vivo,50597,1500,,,A,,,Intermediate,,,
8753,BAO_0000218,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,N,1,,CHEMBL623906,In vivo,50597,1500,,,A,,,Intermediate,,,
8754,BAO_0000218,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,N,1,,CHEMBL623907,In vivo,50597,4186,,Plasma,A,,,Intermediate,,,
8755,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,1,,CHEMBL623908,,50597,16434,,,A,,,Intermediate,,,
8756,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,N,1,,CHEMBL623909,,50597,16434,,,A,,,Intermediate,,,
8757,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,1,,CHEMBL623910,,50597,16434,,,A,,,Intermediate,,,
8758,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,1,,CHEMBL623911,,50597,16434,,,A,,,Intermediate,,,
8759,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,1,,CHEMBL623912,,50597,16435,,,A,,,Intermediate,,,
8760,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,1,,CHEMBL624616,,50597,16435,,,A,,,Intermediate,,,
8761,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,1,,CHEMBL624617,,50597,16435,,,A,,,Intermediate,,,
8762,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,1,,CHEMBL624618,,50597,16435,,,A,,,Intermediate,,,
8763,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,1,,CHEMBL624619,,50597,16435,,,A,,,Intermediate,,,
8764,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,1,,CHEMBL624794,,50597,16435,,,A,,,Intermediate,,,
8765,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,1,,CHEMBL624795,,50597,16435,,,A,,,Intermediate,,,
8766,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,1,,CHEMBL623921,,50597,16435,,,A,,,Intermediate,,,
8767,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,1,,CHEMBL623922,,50597,16434,,,A,,,Intermediate,,,
8768,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,1,,CHEMBL623923,,50597,16434,,,A,,,Intermediate,,,
8769,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,1,,CHEMBL623924,,50597,16434,,,A,,,Intermediate,,,
8770,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,1,,CHEMBL623925,,50597,16435,,,A,,,Intermediate,,,
8771,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,1,,CHEMBL623926,,50597,16435,,,A,,,Intermediate,,,
8772,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,1,,CHEMBL623927,,50597,16435,,,A,,,Intermediate,,,
8773,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,1,,CHEMBL623928,,50597,16435,,,A,,,Intermediate,,,
8774,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,1,,CHEMBL623929,,50597,16435,,,A,,,Intermediate,,,
8775,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,1,,CHEMBL623930,,50597,16435,,,A,,,Intermediate,,,
8776,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,955.0,N,1,,CHEMBL623931,,50597,16434,,Brain,A,,,Intermediate,,,
8777,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,955.0,N,1,,CHEMBL622165,,50597,16434,,Brain,A,,,Intermediate,,,
8778,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,955.0,N,1,,CHEMBL621249,,50597,16434,,Brain,A,,,Intermediate,,,
8779,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,955.0,N,1,,CHEMBL621250,,50597,16434,,Brain,A,,,Intermediate,,,
8780,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,955.0,N,1,,CHEMBL621448,,50597,16434,,Brain,A,,,Intermediate,,,
8781,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,955.0,N,1,,CHEMBL621449,,50597,16434,,Brain,A,,,Intermediate,,,
8782,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,955.0,N,1,,CHEMBL621450,,50597,16434,,Brain,A,,,Intermediate,,,
8783,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,955.0,N,1,,CHEMBL621451,,50597,16434,,Brain,A,,,Intermediate,,,
8784,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,955.0,N,1,,CHEMBL621452,,50597,16435,,Brain,A,,,Intermediate,,,
8785,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,955.0,N,1,,CHEMBL621453,,50597,16435,,Brain,A,,,Intermediate,,,
8786,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,955.0,N,1,,CHEMBL621454,,50597,16435,,Brain,A,,,Intermediate,,,
8787,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,955.0,N,1,,CHEMBL621455,,50597,16435,,Brain,A,,,Intermediate,,,
8788,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,955.0,N,1,,CHEMBL621456,,50597,16435,,Brain,A,,,Intermediate,,,
8789,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,955.0,N,1,,CHEMBL625145,,50597,16435,,Brain,A,,,Intermediate,,,
8790,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,955.0,N,1,,CHEMBL875847,,50597,16435,,Brain,A,,,Intermediate,,,
8791,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,955.0,N,1,,CHEMBL625146,,50597,16435,,Brain,A,,,Intermediate,,,
8792,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,955.0,N,1,,CHEMBL625147,,50597,16434,,Brain,A,,,Intermediate,,,
8793,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,955.0,N,1,,CHEMBL625148,,50597,16434,,Brain,A,,,Intermediate,,,
8794,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,955.0,N,1,,CHEMBL625149,,50597,16434,,Brain,A,,,Intermediate,,,
8795,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,955.0,N,1,,CHEMBL625150,,50597,16435,,Brain,A,,,Intermediate,,,
8796,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,955.0,N,1,,CHEMBL625151,,50597,16435,,Brain,A,,,Intermediate,,,
8797,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,955.0,N,1,,CHEMBL625152,,50597,16435,,Brain,A,,,Intermediate,,,
8798,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,955.0,N,1,,CHEMBL625153,,50597,16435,,Brain,A,,,Intermediate,,,
8799,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,955.0,N,1,,CHEMBL625154,,50597,16435,,Brain,A,,,Intermediate,,,
8800,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,955.0,N,1,,CHEMBL625155,,50597,16435,,Brain,A,,,Intermediate,,,
8801,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,1,,CHEMBL625156,,50597,11977,,,A,,,Intermediate,,,
8802,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,1,,CHEMBL624354,,50597,11977,,,A,,,Intermediate,,,
8803,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),10000000.0,N,1,,CHEMBL624355,,50597,11977,,Hippocampus,A,,,Intermediate,,,
8804,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),10000000.0,N,1,,CHEMBL624356,,50597,11977,,Hippocampus,A,,,Intermediate,,,
8805,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),10000000.0,N,1,,CHEMBL624357,,50597,11977,,Hippocampus,A,,,Intermediate,,,
8806,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),10000000.0,N,1,,CHEMBL624358,,50597,11977,,Hippocampus,A,,,Intermediate,,,
8807,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),2435.0,N,1,,CHEMBL624359,,50597,11977,,Striatum,A,,,Intermediate,,,
8808,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),2435.0,N,1,,CHEMBL624360,,50597,11977,,Striatum,A,,,Intermediate,,,
8809,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),2435.0,N,1,,CHEMBL624361,,50597,11977,,Striatum,A,,,Intermediate,,,
8810,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),2435.0,N,1,,CHEMBL624362,,50597,11977,,Striatum,A,,,Intermediate,,,
8811,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),2435.0,N,1,,CHEMBL624363,,50597,11977,,Striatum,A,,,Intermediate,,,
8812,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),178.0,N,1,,CHEMBL624364,In vivo,50597,11977,,Blood,A,,,Intermediate,,,
8813,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),178.0,N,1,,CHEMBL624365,In vivo,50597,11977,,Blood,A,,,Intermediate,,,
8814,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),178.0,N,1,,CHEMBL624366,In vivo,50597,11977,,Blood,A,,,Intermediate,,,
8815,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),178.0,N,1,,CHEMBL624367,In vivo,50597,11977,,Blood,A,,,Intermediate,,,
8816,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),955.0,N,1,,CHEMBL624368,In vivo,50597,11977,,Brain,A,,,Intermediate,,,
8817,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),955.0,N,1,,CHEMBL624369,In vivo,50597,11977,,Brain,A,,,Intermediate,,,
8818,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),955.0,N,1,,CHEMBL624370,In vivo,50597,11977,,Brain,A,,,Intermediate,,,
8819,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),955.0,N,1,,CHEMBL625069,In vivo,50597,11977,,Brain,A,,,Intermediate,,,
8820,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),955.0,N,1,,CHEMBL625070,In vivo,50597,11977,,Brain,A,,,Intermediate,,,
8821,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),948.0,N,1,,CHEMBL626051,In vivo,50597,11977,,Heart,A,,,Intermediate,,,
8822,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),948.0,N,1,,CHEMBL626052,In vivo,50597,11977,,Heart,A,,,Intermediate,,,
8823,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),948.0,N,1,,CHEMBL626053,In vivo,50597,11977,,Heart,A,,,Intermediate,,,
8824,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),948.0,N,1,,CHEMBL626054,In vivo,50597,11977,,Heart,A,,,Intermediate,,,
8825,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),948.0,N,1,,CHEMBL626055,In vivo,50597,11977,,Heart,A,,,Intermediate,,,
8826,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2113.0,N,1,,CHEMBL626056,In vivo,50597,11977,,Kidney,A,,,Intermediate,,,
8827,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2113.0,N,1,,CHEMBL626057,In vivo,50597,11977,,Kidney,A,,,Intermediate,,,
8828,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2113.0,N,1,,CHEMBL625193,In vivo,50597,11977,,Kidney,A,,,Intermediate,,,
8829,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2113.0,N,1,,CHEMBL625194,In vivo,50597,11977,,Kidney,A,,,Intermediate,,,
8830,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2107.0,N,1,,CHEMBL625195,In vivo,50597,11977,,Liver,A,,,Intermediate,,,
8831,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2107.0,N,1,,CHEMBL625196,In vivo,50597,11977,,Liver,A,,,Intermediate,,,
8832,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2107.0,N,1,,CHEMBL625197,In vivo,50597,11977,,Liver,A,,,Intermediate,,,
8833,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2107.0,N,1,,CHEMBL625198,In vivo,50597,11977,,Liver,A,,,Intermediate,,,
8834,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2107.0,N,1,,CHEMBL627929,In vivo,50597,11977,,Liver,A,,,Intermediate,,,
8835,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2048.0,N,1,,CHEMBL627074,In vivo,50597,11977,,Lung,A,,,Intermediate,,,
8836,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2048.0,N,1,,CHEMBL627075,In vivo,50597,11977,,Lung,A,,,Intermediate,,,
8837,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2048.0,N,1,,CHEMBL627076,In vivo,50597,11977,,Lung,A,,,Intermediate,,,
8838,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2048.0,N,1,,CHEMBL627077,In vivo,50597,11977,,Lung,A,,,Intermediate,,,
8839,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2048.0,N,1,,CHEMBL627078,In vivo,50597,11977,,Lung,A,,,Intermediate,,,
8840,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),2385.0,N,1,,CHEMBL627079,In vivo,50597,11977,,Muscle tissue,A,,,Intermediate,,,
8841,BAO_0000218,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,N,1,,CHEMBL873824,In vivo,50594,4573,,,A,,,Intermediate,,,
8842,BAO_0000218,Half life in mouse plasma was determined at dose 25 mg/kg,1969.0,N,1,,CHEMBL627080,In vivo,50594,3132,,Plasma,A,,,Intermediate,,,
8843,BAO_0000218,Half life was determined,,N,1,,CHEMBL627081,,50594,17718,,,A,,,Intermediate,,,
8844,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,N,1,,CHEMBL627082,In vivo,50594,17728,,,A,,,Intermediate,,,
8845,BAO_0000218,Half-life in male mice after 1 mg/kg intravenous dose,,N,1,,CHEMBL627083,In vivo,50594,5961,,,A,,,Intermediate,,,
8847,BAO_0000218,Half life in mice plasma,1969.0,N,1,,CHEMBL627085,,50594,17731,,Plasma,A,,,Intermediate,,,
8848,BAO_0000218,Half life in mouse,,N,1,,CHEMBL627086,,50594,17592,,,A,,,Intermediate,,,
8849,BAO_0000218,Half life in mouse plasma at dose 25 mg/kg,1969.0,N,1,,CHEMBL627087,In vivo,50594,3132,,Plasma,A,,,Intermediate,,,
8850,BAO_0000218,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,N,1,,CHEMBL627088,In vivo,50594,17729,,,A,,,Intermediate,,,
8851,BAO_0000218,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,N,1,,CHEMBL627089,In vivo,50594,17729,,,A,,,Intermediate,,,
8852,BAO_0000218,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,N,1,,CHEMBL627090,In vivo,50594,17729,,,A,,,Intermediate,,,
8853,BAO_0000218,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,1,,CHEMBL627091,In vivo,50594,3277,,,A,,,Intermediate,,,
8854,BAO_0000218,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,N,1,,CHEMBL627092,In vivo,50594,3760,,,A,,,Intermediate,,,
8855,BAO_0000218,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,N,1,,CHEMBL876785,In vivo,50594,3760,,,A,,,Intermediate,,,
8856,BAO_0000218,Half-life by iv administration in mouse,,N,1,,CHEMBL627093,In vivo,50594,2862,,,A,,,Intermediate,,,
8857,BAO_0000218,Half-life by oral administration in mouse,,N,1,,CHEMBL627094,In vivo,50594,2862,,,A,,,Intermediate,,,
8858,BAO_0000218,Half-life in mice,,N,1,,CHEMBL627095,,50594,5980,,,A,,,Intermediate,,,
8859,BAO_0000218,Half-life using mouse brain homogenate,955.0,N,1,,CHEMBL627096,,50594,6159,,Brain,A,,,Intermediate,,,
8860,BAO_0000218,Half-life was measured in mice,,N,1,,CHEMBL627097,,50594,6254,,,A,,,Intermediate,,,
8861,BAO_0000218,Half-life was measured in mouse after an iv dose of 1 mg/kg,,N,1,,CHEMBL627098,In vivo,50594,6062,,,A,,,Intermediate,,,
8862,BAO_0000218,Half-life period was determined in mouse blood,178.0,N,1,,CHEMBL627099,,50594,1574,,Blood,A,,,Intermediate,,,
8863,BAO_0000218,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",955.0,N,1,,CHEMBL627100,,50594,56,,Brain,A,,,Intermediate,,,
8864,BAO_0000218,Plasma half life in mouse,1969.0,N,1,,CHEMBL627101,,50594,993,,Plasma,A,,,Intermediate,,,
8865,BAO_0000218,Stability of the peptide in the presence of mouse serum,,N,1,,CHEMBL627102,,50594,6652,,,A,,,Intermediate,,,
8866,BAO_0000218,Terminal half life of compound was determined in mouse,,N,1,,CHEMBL627103,,50594,17852,,,A,,,Intermediate,,,
8867,BAO_0000218,Terminal half life was evaluated in mice after intravenous administration,,N,1,,CHEMBL627104,In vivo,50594,2675,,,A,,,Intermediate,,,
8868,BAO_0000218,Terminal half life was evaluated in mice after oral administration,,N,1,,CHEMBL627105,In vivo,50594,2675,,,A,,,Intermediate,,,
8869,BAO_0000218,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,N,1,,CHEMBL876786,,50594,499,,,A,,,Intermediate,,,
8870,BAO_0000218,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,N,1,,CHEMBL873825,,50594,499,,,A,,,Intermediate,,,
8871,BAO_0000218,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,N,1,,CHEMBL627106,,50594,499,,,A,,,Intermediate,,,
8872,BAO_0000218,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,N,1,,CHEMBL626336,In vivo,50594,14239,,,A,,,Intermediate,,,
8873,BAO_0000218,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,N,1,,CHEMBL877462,In vivo,50594,5506,,,A,,,Intermediate,,,
8874,BAO_0000218,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,N,1,,CHEMBL626337,In vivo,50594,5506,,,A,,,Intermediate,,,
8875,BAO_0000218,Half life after intraperitoneal administration of 100 mg/kg in mice,,N,1,,CHEMBL626338,,50594,17734,,,A,,,Intermediate,,,
8876,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,N,1,,CHEMBL626339,In vivo,50594,17728,,,A,,,Intermediate,,,
8877,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,N,1,,CHEMBL626340,In vivo,50594,17728,,,A,,,Intermediate,,,
8878,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,N,1,,CHEMBL625377,In vivo,50594,17728,,,A,,,Intermediate,,,
8879,BAO_0000218,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,N,1,,CHEMBL625378,In vivo,50594,17728,,,A,,,Intermediate,,,
8880,BAO_0000218,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,N,1,,CHEMBL625379,In vivo,50594,17728,,,A,,,Intermediate,,,
8881,BAO_0000251,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,U,1,,CHEMBL625380,,22224,14294,Microsomes,,A,,,Autocuration,,,
8882,BAO_0000251,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,U,1,,CHEMBL625381,,22224,14294,Microsomes,,A,,,Autocuration,,,
8883,BAO_0000019,Stability to porcine renal DHP-I,,U,1,,CHEMBL625382,,22224,6056,,,A,,,Autocuration,,,
8884,BAO_0000218,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,U,1,,CHEMBL873828,In vivo,22224,1317,,,A,,,Autocuration,,,
8885,BAO_0000218,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,U,1,,CHEMBL625383,In vivo,22224,1317,,,A,,,Autocuration,,,
8886,BAO_0000019,Half-life of the parent prodrug in porcine esterase solution,,U,1,,CHEMBL625384,,22224,5229,,,A,,,Autocuration,,,
8887,BAO_0000019,"First order rate constant, k was determined in in pig liver Esterase",,U,1,,CHEMBL625385,,22224,4231,,,A,,,Autocuration,,,
8888,BAO_0000221,Half life of the in pig liver Esterase,2107.0,U,1,,CHEMBL625386,,22224,4231,,Liver,A,,,Autocuration,,,
8889,BAO_0000221,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,2107.0,U,1,,CHEMBL623571,,22224,5318,,Liver,A,,,Autocuration,,,
8890,BAO_0000221,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,2107.0,U,1,,CHEMBL623572,,22224,5318,,Liver,A,,,Autocuration,,,
8891,BAO_0000221,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,2107.0,U,1,,CHEMBL623573,,22224,5318,,Liver,A,,,Autocuration,,,
8892,BAO_0000221,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,2107.0,U,1,,CHEMBL623574,,22224,3305,,Liver,A,,,Autocuration,,,
8893,BAO_0000221,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,2107.0,U,1,,CHEMBL623575,,22224,3305,,Liver,A,,,Autocuration,,,
8894,BAO_0000221,Half-life in the presence of pig liver esterase(PLE) was evaluated.,2107.0,U,1,,CHEMBL623749,,22224,2842,,Liver,A,,,Autocuration,,,
8895,BAO_0000221,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,2107.0,U,1,,CHEMBL623750,,22224,2842,,Liver,A,,,Autocuration,,,
8896,BAO_0000221,Half-life in vitro in pig liver,2107.0,U,1,,CHEMBL623751,In vitro,22224,889,,Liver,A,,,Autocuration,,,
8897,BAO_0000221,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,2107.0,U,1,,CHEMBL623752,,22224,1904,,Liver,A,,,Autocuration,,,
8898,BAO_0000218,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1969.0,N,1,,CHEMBL623753,In vivo,50597,4186,,Plasma,A,,,Intermediate,,,
8899,BAO_0000218,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1969.0,N,1,,CHEMBL623754,In vivo,50597,2774,,Plasma,A,,,Intermediate,,,
8900,BAO_0000218,Maximum concentration in rat plasma was determined,1969.0,N,1,,CHEMBL623755,In vivo,50597,1742,,Plasma,A,,,Intermediate,,,
8901,BAO_0000218,Maximum concentration in rats,,N,1,,CHEMBL623756,In vivo,50597,3169,,,A,,,Intermediate,,,
8902,BAO_0000218,Maximum concentration in rats at 1-2 hours,,N,1,,CHEMBL623757,In vivo,50597,3169,,,A,,,Intermediate,,,
8903,BAO_0000218,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,N,1,,CHEMBL623758,In vivo,50597,2081,,,A,,,Intermediate,,,
8904,BAO_0000218,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,955.0,N,1,,CHEMBL623759,In vivo,50597,3307,,Brain,A,,,Intermediate,,,
8905,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in rat,,N,1,,CHEMBL623760,In vivo,50597,4727,,,A,,,Intermediate,,,
8906,BAO_0000218,Maximum concentration was evaluated in rats,,N,1,,CHEMBL623761,In vivo,50597,6597,,,A,,,Intermediate,,,
8907,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1969.0,N,1,,CHEMBL623762,In vivo,50597,16365,,Plasma,A,,,Intermediate,,,
8908,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1969.0,N,1,,CHEMBL877594,In vivo,50597,16365,,Plasma,A,,,Intermediate,,,
8909,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1969.0,N,1,,CHEMBL623763,In vivo,50597,16365,,Plasma,A,,,Intermediate,,,
8910,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1969.0,N,1,,CHEMBL623764,In vivo,50597,16365,,Plasma,A,,,Intermediate,,,
8911,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1969.0,N,1,,CHEMBL623765,In vivo,50597,16365,,Plasma,A,,,Intermediate,,,
8912,BAO_0000218,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,178.0,N,1,,CHEMBL623766,In vivo,50597,2591,,Blood,A,,,Intermediate,,,
8913,BAO_0000218,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,178.0,N,1,,CHEMBL623767,In vivo,50597,2591,,Blood,A,,,Intermediate,,,
8914,BAO_0000218,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,178.0,N,1,,CHEMBL623768,In vivo,50597,2591,,Blood,A,,,Intermediate,,,
8915,BAO_0000218,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623769,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8916,BAO_0000218,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623770,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8917,BAO_0000218,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623771,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8918,BAO_0000218,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623772,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8919,BAO_0000218,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623773,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8920,BAO_0000218,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623774,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8921,BAO_0000218,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,N,1,,CHEMBL623775,In vivo,50597,5978,,Plasma,A,,,Intermediate,,,
8922,BAO_0000218,Cmax in rat (PO dose),,N,1,,CHEMBL623776,In vivo,50597,14465,,,A,,,Intermediate,,,
8923,BAO_0000218,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1969.0,N,1,,CHEMBL622191,In vivo,50597,4723,,Plasma,A,,,Intermediate,,,
8924,BAO_0000218,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1969.0,N,1,,CHEMBL622192,In vivo,50597,4723,,Plasma,A,,,Intermediate,,,
8925,BAO_0000218,Maximum plasma concentration determined in rat,1969.0,N,1,,CHEMBL622193,In vivo,50597,4576,,Plasma,A,,,Intermediate,,,
8926,BAO_0000218,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,N,1,,CHEMBL622194,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
8927,BAO_0000218,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,N,1,,CHEMBL622195,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
8928,BAO_0000218,Maximum plasma concentration in rat,1969.0,N,1,,CHEMBL622196,In vivo,50597,6824,,Plasma,A,,,Intermediate,,,
8929,BAO_0000218,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1969.0,N,1,,CHEMBL622197,In vivo,50597,17065,,Plasma,A,,,Intermediate,,,
8930,BAO_0000218,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1969.0,N,1,,CHEMBL622198,In vivo,50597,2932,,Plasma,A,,,Intermediate,,,
8931,BAO_0000218,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1969.0,N,1,,CHEMBL622199,In vivo,50597,2932,,Plasma,A,,,Intermediate,,,
8932,BAO_0000218,Maximum plasma concentration of compound was measured in rat,1969.0,N,1,,CHEMBL622200,In vivo,50597,2879,,Plasma,A,,,Intermediate,,,
8933,BAO_0000218,Maximum plasma concentration after 20 mg/kg oral administration in rat,1969.0,N,1,,CHEMBL622201,In vivo,50597,2864,,Plasma,A,,,Intermediate,,,
8934,BAO_0000218,Maximum plasma concentration after oral administration to rats,1969.0,N,1,,CHEMBL623990,In vivo,50597,16367,,Plasma,A,,,Intermediate,,,
8935,BAO_0000218,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1969.0,N,1,,CHEMBL623991,In vivo,50597,17717,,Plasma,A,,,Intermediate,,,
8936,BAO_0000218,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1969.0,N,1,,CHEMBL623992,In vivo,50597,17717,,Plasma,A,,,Intermediate,,,
8937,BAO_0000218,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1969.0,N,1,,CHEMBL623993,In vivo,50597,17717,,Plasma,A,,,Intermediate,,,
8938,BAO_0000218,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1969.0,N,1,,CHEMBL623994,In vivo,50597,17717,,Plasma,A,,,Intermediate,,,
8939,BAO_0000218,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL623995,In vivo,50597,17720,,Plasma,F,,,Intermediate,,,
8940,BAO_0000218,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL623996,In vivo,50597,17720,,Plasma,F,,,Intermediate,,,
8941,BAO_0000218,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL623997,In vivo,50597,17720,,Plasma,F,,,Intermediate,,,
8942,BAO_0000218,Maximum plasma concentration dosed orally in rats,1969.0,N,1,,CHEMBL623998,In vivo,50597,4516,,Plasma,A,,,Intermediate,,,
8943,BAO_0000218,Maximum plasma concentration dosed orally in rats after 6 hours,1969.0,N,1,,CHEMBL623999,In vivo,50597,4516,,Plasma,A,,,Intermediate,,,
8944,BAO_0000218,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1969.0,N,1,,CHEMBL624000,In vivo,50597,4516,,Plasma,A,,,Intermediate,,,
8945,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1969.0,N,1,,CHEMBL624001,In vivo,50597,5199,,Plasma,A,,,Intermediate,,,
8946,BAO_0000218,Maximum plasma concentration in rat after po administration,1969.0,N,1,,CHEMBL624002,In vivo,50597,17538,,Plasma,A,,,Intermediate,,,
8947,BAO_0000218,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1969.0,N,1,,CHEMBL624003,In vivo,50597,6685,,Plasma,A,,,Intermediate,,,
8948,BAO_0000218,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1969.0,N,1,,CHEMBL624004,In vivo,50597,6685,,Plasma,A,,,Intermediate,,,
8949,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,948.0,N,1,,CHEMBL624005,,50597,16434,,Heart,A,,,Intermediate,,,
8950,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,948.0,N,1,,CHEMBL624006,,50597,16434,,Heart,A,,,Intermediate,,,
8951,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,948.0,N,1,,CHEMBL624007,,50597,16434,,Heart,A,,,Intermediate,,,
8952,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,948.0,N,1,,CHEMBL624008,,50597,16434,,Heart,A,,,Intermediate,,,
8953,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,948.0,N,1,,CHEMBL624009,,50597,16434,,Heart,A,,,Intermediate,,,
8954,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,948.0,N,1,,CHEMBL874387,,50597,16434,,Heart,A,,,Intermediate,,,
8955,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,948.0,N,1,,CHEMBL624010,,50597,16434,,Heart,A,,,Intermediate,,,
8956,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,948.0,N,1,,CHEMBL624011,,50597,16434,,Heart,A,,,Intermediate,,,
8957,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,948.0,N,1,,CHEMBL624012,,50597,16435,,Heart,A,,,Intermediate,,,
8958,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,948.0,N,1,,CHEMBL624013,,50597,16435,,Heart,A,,,Intermediate,,,
8959,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,948.0,N,1,,CHEMBL624736,,50597,16435,,Heart,A,,,Intermediate,,,
8960,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,948.0,N,1,,CHEMBL624737,,50597,16435,,Heart,A,,,Intermediate,,,
8961,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,948.0,N,1,,CHEMBL624738,,50597,16434,,Heart,A,,,Intermediate,,,
8962,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,948.0,N,1,,CHEMBL624739,,50597,16434,,Heart,A,,,Intermediate,,,
8963,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,948.0,N,1,,CHEMBL624740,,50597,16434,,Heart,A,,,Intermediate,,,
8964,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,948.0,N,1,,CHEMBL624896,,50597,16435,,Heart,A,,,Intermediate,,,
8965,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,948.0,N,1,,CHEMBL624897,,50597,16435,,Heart,A,,,Intermediate,,,
8966,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,948.0,N,1,,CHEMBL624108,,50597,16435,,Heart,A,,,Intermediate,,,
8967,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,948.0,N,1,,CHEMBL624109,,50597,16435,,Heart,A,,,Intermediate,,,
8968,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,948.0,N,1,,CHEMBL624110,,50597,16435,,Heart,A,,,Intermediate,,,
8969,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,948.0,N,1,,CHEMBL624111,,50597,16435,,Heart,A,,,Intermediate,,,
8970,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,948.0,N,1,,CHEMBL624112,,50597,16435,,Heart,A,,,Intermediate,,,
8971,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,948.0,N,1,,CHEMBL624113,,50597,16435,,Heart,A,,,Intermediate,,,
8972,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,948.0,N,1,,CHEMBL619709,,50597,16435,,Heart,A,,,Intermediate,,,
8973,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,948.0,N,1,,CHEMBL619710,,50597,16435,,Heart,A,,,Intermediate,,,
8974,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2113.0,N,1,,CHEMBL619711,,50597,16434,,Kidney,A,,,Intermediate,,,
8975,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2113.0,N,1,,CHEMBL619712,,50597,16434,,Kidney,A,,,Intermediate,,,
8976,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2113.0,N,1,,CHEMBL619713,,50597,16434,,Kidney,A,,,Intermediate,,,
8977,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2113.0,N,1,,CHEMBL619714,,50597,16434,,Kidney,A,,,Intermediate,,,
8978,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2113.0,N,1,,CHEMBL619715,,50597,16434,,Kidney,A,,,Intermediate,,,
8979,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2113.0,N,1,,CHEMBL619716,,50597,16434,,Kidney,A,,,Intermediate,,,
8980,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2113.0,N,1,,CHEMBL619717,,50597,16434,,Kidney,A,,,Intermediate,,,
8981,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2113.0,N,1,,CHEMBL619718,,50597,16434,,Kidney,A,,,Intermediate,,,
8982,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2113.0,N,1,,CHEMBL619719,,50597,16435,,Kidney,A,,,Intermediate,,,
8983,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2113.0,N,1,,CHEMBL875329,,50597,16435,,Kidney,A,,,Intermediate,,,
8984,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2113.0,N,1,,CHEMBL619720,,50597,16435,,Kidney,A,,,Intermediate,,,
8985,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2113.0,N,1,,CHEMBL619721,,50597,16435,,Kidney,A,,,Intermediate,,,
8986,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2113.0,N,1,,CHEMBL619722,,50597,16435,,Kidney,A,,,Intermediate,,,
8987,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2113.0,N,1,,CHEMBL619723,,50597,16435,,Kidney,A,,,Intermediate,,,
8988,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2113.0,N,1,,CHEMBL619724,,50597,16435,,Kidney,A,,,Intermediate,,,
8989,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2113.0,N,1,,CHEMBL619725,,50597,16435,,Kidney,A,,,Intermediate,,,
8990,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2113.0,N,1,,CHEMBL619726,,50597,16434,,Kidney,A,,,Intermediate,,,
8991,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2113.0,N,1,,CHEMBL619727,,50597,16434,,Kidney,A,,,Intermediate,,,
8992,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2113.0,N,1,,CHEMBL619728,,50597,16434,,Kidney,A,,,Intermediate,,,
8993,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2113.0,N,1,,CHEMBL619729,,50597,16435,,Kidney,A,,,Intermediate,,,
8994,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2385.0,N,1,,CHEMBL619730,In vivo,50597,11977,,Muscle tissue,A,,,Intermediate,,,
8995,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2385.0,N,1,,CHEMBL619731,In vivo,50597,11977,,Muscle tissue,A,,,Intermediate,,,
8996,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2385.0,N,1,,CHEMBL619732,In vivo,50597,11977,,Muscle tissue,A,,,Intermediate,,,
8997,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2385.0,N,1,,CHEMBL619733,In vivo,50597,11977,,Muscle tissue,A,,,Intermediate,,,
8998,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2385.0,N,1,,CHEMBL619734,In vivo,50597,11977,,Muscle tissue,A,,,Intermediate,,,
8999,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),14.0,N,1,,CHEMBL619735,In vivo,50597,11977,,Zone of skin,A,,,Intermediate,,,
9000,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),14.0,N,1,,CHEMBL875330,In vivo,50597,11977,,Zone of skin,A,,,Intermediate,,,
9001,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),14.0,N,1,,CHEMBL628465,In vivo,50597,11977,,Zone of skin,A,,,Intermediate,,,
9002,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),14.0,N,1,,CHEMBL628466,In vivo,50597,11977,,Zone of skin,A,,,Intermediate,,,
9003,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),14.0,N,1,,CHEMBL628467,In vivo,50597,11977,,Zone of skin,A,,,Intermediate,,,
9004,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2106.0,N,1,,CHEMBL628468,In vivo,50597,11977,,Spleen,A,,,Intermediate,,,
9005,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2106.0,N,1,,CHEMBL628469,In vivo,50597,11977,,Spleen,A,,,Intermediate,,,
9006,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2106.0,N,1,,CHEMBL628470,In vivo,50597,11977,,Spleen,A,,,Intermediate,,,
9007,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2106.0,N,1,,CHEMBL628471,In vivo,50597,11977,,Spleen,A,,,Intermediate,,,
9008,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2106.0,N,1,,CHEMBL628472,In vivo,50597,11977,,Spleen,A,,,Intermediate,,,
9009,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2046.0,N,1,,CHEMBL625191,In vivo,50597,11977,,Thyroid gland,A,,,Intermediate,,,
9010,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2046.0,N,1,,CHEMBL625192,In vivo,50597,11977,,Thyroid gland,A,,,Intermediate,,,
9011,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2046.0,N,1,,CHEMBL875337,In vivo,50597,11977,,Thyroid gland,A,,,Intermediate,,,
9012,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2046.0,N,1,,CHEMBL626341,In vivo,50597,11977,,Thyroid gland,A,,,Intermediate,,,
9013,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2046.0,N,1,,CHEMBL626342,In vivo,50597,11977,,Thyroid gland,A,,,Intermediate,,,
9014,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2107.0,N,1,,CHEMBL621943,In vivo,50597,11977,,Liver,A,,,Intermediate,,,
9015,BAO_0000218,Half life in rats,,N,1,,CHEMBL621944,,50597,3748,,,A,,,Intermediate,,,
9016,BAO_0000218,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,N,1,,CHEMBL621945,,50597,15765,,,A,,,Intermediate,,,
9017,BAO_0000218,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,N,1,,CHEMBL621946,,50597,4871,,,A,,,Intermediate,,,
9018,BAO_0000218,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,N,1,,CHEMBL621947,,50597,4871,,,A,,,Intermediate,,,
9019,BAO_0000218,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,N,1,,CHEMBL621948,,50597,4872,,,A,,,Intermediate,,,
9020,BAO_0000218,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,N,1,,CHEMBL621949,,50597,4872,,,A,,,Intermediate,,,
9021,BAO_0000218,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,N,1,,CHEMBL621950,,50597,5413,,,A,,,Intermediate,,,
9022,BAO_0000218,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,N,1,,CHEMBL621951,,50597,5413,,,A,,,Intermediate,,,
9023,BAO_0000218,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,178.0,N,1,,CHEMBL621952,In vivo,50597,15272,,Blood,A,,,Intermediate,,,
9024,BAO_0000218,Stability (%) in rat liver microsomes,2107.0,N,1,,CHEMBL621953,,50597,4689,,Liver,A,,,Intermediate,,,
9025,BAO_0000218,Area under curve was calculated after intravenous administration,,N,1,,CHEMBL621954,,50597,6057,,,A,,,Intermediate,,,
9026,BAO_0000218,Area under the curve was calculated after iv administration in rat,,N,1,,CHEMBL621955,,50597,6057,,,A,,,Intermediate,,,
9027,BAO_0000218,Area under the curve was calculated in rat after peroral administration,,N,1,,CHEMBL621956,,50597,6057,,,A,,,Intermediate,,,
9028,BAO_0000218,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,N,1,,CHEMBL621957,,50597,6211,,,A,,,Intermediate,,,
9029,BAO_0000218,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,N,1,,CHEMBL621958,,50597,5710,,,A,,,Intermediate,,,
9030,BAO_0000218,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,N,1,,CHEMBL621959,,50597,5710,,,A,,,Intermediate,,,
9031,BAO_0000218,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,N,1,,CHEMBL621960,,50597,17853,,,A,,,Intermediate,,,
9032,BAO_0000218,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,N,1,,CHEMBL621961,,50597,17853,,,A,,,Intermediate,,,
9033,BAO_0000218,p value of the compound,,N,1,,CHEMBL621962,,50597,15765,,,A,,,Intermediate,,,
9034,BAO_0000218,p value of the compound,,N,1,,CHEMBL876787,,50597,15765,,,F,,,Intermediate,,,
9035,BAO_0000218,p value of the compound,,N,1,,CHEMBL621963,,50597,15765,,,A,,,Intermediate,,,
9036,BAO_0000218,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL622637,,50597,6175,,Stomach,A,,,Intermediate,,,
9037,BAO_0000218,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL622638,,50597,6175,,Stomach,A,,,Intermediate,,,
9038,BAO_0000218,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL626561,,50597,6175,,Stomach,A,,,Intermediate,,,
9039,BAO_0000019,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,U,1,,CHEMBL626562,,22224,7991,,,F,,,Autocuration,,,
9040,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,U,1,,CHEMBL626563,,22224,429,,,A,,,Autocuration,,,
9041,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,U,1,,CHEMBL626564,,22224,429,,,A,,,Autocuration,,,
9042,BAO_0000218,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,U,1,,CHEMBL626565,In vivo,22224,6253,,,A,,,Autocuration,,,
9043,BAO_0000218,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,U,1,,CHEMBL626566,In vivo,22224,6253,,,A,,,Autocuration,,,
9044,BAO_0000218,Clearance rate in rabbits,,U,1,,CHEMBL626567,In vivo,22224,3615,,,A,,,Autocuration,,,
9045,BAO_0000218,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,U,1,,CHEMBL626568,In vivo,22224,4059,,,A,,,Autocuration,,,
9046,BAO_0000218,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,U,1,,CHEMBL626569,In vivo,22224,5124,,,A,,,Autocuration,,,
9047,BAO_0000218,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,U,1,,CHEMBL626570,In vivo,22224,5124,,,A,,,Autocuration,,,
9048,BAO_0000218,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,U,1,,CHEMBL626571,In vivo,22224,5124,,,A,,,Autocuration,,,
9049,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,U,1,,CHEMBL626572,In vivo,22224,429,,,A,,,Autocuration,,,
9050,BAO_0000218,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1969.0,U,1,,CHEMBL626573,In vivo,22224,4059,,Plasma,A,,,Autocuration,,,
9051,BAO_0000251,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,2107.0,U,1,,CHEMBL626574,,22224,9659,Microsomes,Liver,A,,,Autocuration,,,
9052,BAO_0000251,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,2107.0,U,1,,CHEMBL626575,,22224,9659,Microsomes,Liver,A,,,Autocuration,,,
9053,BAO_0000218,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,U,1,,CHEMBL626576,,22224,3639,,,A,,,Autocuration,,,
9054,BAO_0000218,Dose at which bioavailability of perorally administered compound was tested in rabbit,,U,1,,CHEMBL626577,,22224,3639,,,A,,,Autocuration,,,
9055,BAO_0000218,The compound was tested for its bioavailability in rabbit (by oral dosage).,,U,1,,CHEMBL626578,In vivo,22224,3639,,,A,,,Autocuration,,,
9056,BAO_0000218,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,U,1,,CHEMBL625263,In vivo,22224,5124,,,A,,,Autocuration,,,
9057,BAO_0000218,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,U,1,,CHEMBL625264,In vivo,22224,5124,,,A,,,Autocuration,,,
9058,BAO_0000218,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,U,1,,CHEMBL625265,In vivo,22224,5124,,,A,,,Autocuration,,,
9059,BAO_0000251,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,U,1,,CHEMBL625266,,22224,14294,Microsomes,,A,,,Autocuration,,,
9060,BAO_0000251,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,U,1,,CHEMBL876796,,22224,14294,Microsomes,,A,,,Autocuration,,,
9061,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,U,1,,CHEMBL625267,In vivo,22224,429,,,A,,,Autocuration,,,
9062,BAO_0000218,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1969.0,U,1,,CHEMBL625268,In vivo,22224,5124,,Plasma,A,,,Autocuration,,,
9063,BAO_0000218,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1969.0,U,1,,CHEMBL625269,In vivo,22224,5124,,Plasma,A,,,Autocuration,,,
9064,BAO_0000218,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1969.0,U,1,,CHEMBL624689,In vivo,22224,5124,,Plasma,A,,,Autocuration,,,
9065,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,U,1,,CHEMBL624690,In vivo,22224,429,,,A,,,Autocuration,,,
9066,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1088.0,U,1,,CHEMBL624691,,22224,429,,Urine,A,,,Autocuration,,,
9067,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1088.0,U,1,,CHEMBL624692,,22224,429,,Urine,A,,,Autocuration,,,
9068,BAO_0000218,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,U,1,,CHEMBL624693,In vivo,22224,4059,,,A,,,Autocuration,,,
9069,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,U,1,,CHEMBL624694,In vivo,22224,4137,,,A,,,Autocuration,,,
9070,BAO_0000221,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,U,1,,CHEMBL877596,In vitro,22224,11672,,,A,,,Autocuration,,,
9071,BAO_0000019,Time within which only 10% of the drug was degraded,,U,1,,CHEMBL624695,,22224,12886,,,A,,,Autocuration,,,
9072,BAO_0000221,Half life period in rabbit liver homogenate,2107.0,U,1,,CHEMBL624696,,22224,3853,,Liver,A,,,Autocuration,,,
9073,BAO_0000019,Half life value in rabbits,,U,1,,CHEMBL624697,,22224,3615,,,A,,,Autocuration,,,
9074,BAO_0000218,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,178.0,U,1,,CHEMBL624698,In vivo,22224,6253,,Blood,A,,,Autocuration,,,
9075,BAO_0000218,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,178.0,U,1,,CHEMBL624699,In vivo,22224,6253,,Blood,A,,,Autocuration,,,
9076,BAO_0000218,Half-life period in rabbits following intravenous administration at 2 mg/kg,,U,1,,CHEMBL624700,In vivo,22224,6077,,,A,,,Autocuration,,,
9077,BAO_0000218,AUC 0-8 hr value in rats at 10 mg/kg,1969.0,N,1,,CHEMBL622903,,50597,17617,,Plasma,A,,,Intermediate,,,
9078,BAO_0000218,AUC after administration at 2000 mg/kg/day in rats,1969.0,N,1,,CHEMBL622904,,50597,17594,,Plasma,A,,,Intermediate,,,
9079,BAO_0000218,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1969.0,N,1,,CHEMBL622905,,50597,6149,,Plasma,A,,,Intermediate,,,
9080,BAO_0000218,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1969.0,N,1,,CHEMBL622906,,50597,17260,,Plasma,A,,,Intermediate,,,
9081,BAO_0000218,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1969.0,N,1,,CHEMBL622907,,50597,17260,,Plasma,A,,,Intermediate,,,
9082,BAO_0000218,AUC in rat after oral administration at 10.5 mg/kg dose,1969.0,N,1,,CHEMBL622908,,50597,6644,,Plasma,A,,,Intermediate,,,
9083,BAO_0000218,AUC in rat after oral administration at 11.2 mg/kg dose,1969.0,N,1,,CHEMBL622909,,50597,6644,,Plasma,A,,,Intermediate,,,
9084,BAO_0000218,AUC in rat after oral administration at 9.7 mg/kg dose,1969.0,N,1,,CHEMBL622910,,50597,6644,,Plasma,A,,,Intermediate,,,
9085,BAO_0000218,AUC in rat brain after oral administration at 10 mg/kg,955.0,N,1,,CHEMBL622911,,50597,6495,,Brain,A,,,Intermediate,,,
9086,BAO_0000218,AUC in rat p.o.,1969.0,N,1,,CHEMBL622912,,50597,6504,,Plasma,A,,,Intermediate,,,
9087,BAO_0000218,AUC in rat p.o. at 20 mg/kg concentration,1969.0,N,1,,CHEMBL622913,,50597,17686,,Plasma,A,,,Intermediate,,,
9088,BAO_0000218,AUC in rat plasma after oral administration at 10 mg/kg,1969.0,N,1,,CHEMBL622914,,50597,6495,,Plasma,A,,,Intermediate,,,
9089,BAO_0000218,AUC in rats,1969.0,N,1,,CHEMBL622915,,50597,216,,Plasma,A,,,Intermediate,,,
9090,BAO_0000218,AUC value after IV dose at a dose of 5 mg/kg in rats.,1969.0,N,1,,CHEMBL622916,,50597,1908,,Plasma,A,,,Intermediate,,,
9091,BAO_0000218,AUC value after oral dose at a dose of 10 mg/kg in rats.,1969.0,N,1,,CHEMBL622917,,50597,1908,,Plasma,A,,,Intermediate,,,
9092,BAO_0000218,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1969.0,N,1,,CHEMBL622918,In vivo,50597,6685,,Plasma,A,,,Intermediate,,,
9093,BAO_0000218,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1969.0,N,1,,CHEMBL622919,In vivo,50597,216,,Plasma,A,,,Intermediate,,,
9094,BAO_0000218,Maximum plasma concentration was evaluated in rat,1969.0,N,1,,CHEMBL622920,In vivo,50597,6049,,Plasma,A,,,Intermediate,,,
9095,BAO_0000218,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1969.0,N,1,,CHEMBL622921,In vivo,50597,2463,,Plasma,A,,,Intermediate,,,
9096,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1969.0,N,1,,CHEMBL622922,In vivo,50597,6679,,Plasma,A,,,Intermediate,,,
9097,BAO_0000218,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1969.0,N,1,,CHEMBL622923,In vivo,50597,6681,,Plasma,A,,,Intermediate,,,
9098,BAO_0000218,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1969.0,N,1,,CHEMBL877604,In vivo,50597,4890,,Plasma,A,,,Intermediate,,,
9099,BAO_0000218,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1969.0,N,1,,CHEMBL622924,In vivo,50597,6410,,Plasma,A,,,Intermediate,,,
9100,BAO_0000218,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1969.0,N,1,,CHEMBL622925,In vivo,50597,6410,,Plasma,A,,,Intermediate,,,
9101,BAO_0000218,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1969.0,N,1,,CHEMBL622926,In vivo,50597,16366,,Plasma,A,,,Intermediate,,,
9102,BAO_0000218,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL623625,In vivo,50597,6227,,Plasma,A,,,Intermediate,,,
9103,BAO_0000218,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL623626,In vivo,50597,3598,,Plasma,A,,,Expert,,,
9104,BAO_0000218,Maximum plasma drug concentration was determined,1969.0,N,1,,CHEMBL623627,In vivo,50597,1465,,Plasma,A,,,Intermediate,,,
9105,BAO_0000218,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,N,1,,CHEMBL623628,In vivo,50597,4368,,,A,,,Intermediate,,,
9106,BAO_0000218,Mean peak plasma concentration was observed after intravenous administration in rat,1969.0,N,1,,CHEMBL623629,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
9107,BAO_0000218,Mean peak plasma concentration was observed after oral administration in rat,1969.0,N,1,,CHEMBL623630,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
9108,BAO_0000218,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,N,1,,CHEMBL623804,In vivo,50597,5355,,,A,,,Intermediate,,,
9109,BAO_0000218,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,N,1,,CHEMBL623805,In vivo,50597,5355,,,A,,,Intermediate,,,
9110,BAO_0000218,Peak oral plasma concentration was determined in rats by oral administration,1969.0,N,1,,CHEMBL623806,In vivo,50597,1567,,Plasma,A,,,Intermediate,,,
9111,BAO_0000218,Peak plasma concentration (Cmax) was determined,1969.0,N,1,,CHEMBL623807,In vivo,50597,4026,,Plasma,A,,,Intermediate,,,
9112,BAO_0000218,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1969.0,N,1,,CHEMBL623808,In vivo,50597,6193,,Plasma,A,,,Intermediate,,,
9113,BAO_0000218,Peak plasma concentration (Cmax) in rats,1969.0,N,1,,CHEMBL623809,In vivo,50597,4026,,Plasma,A,,,Intermediate,,,
9114,BAO_0000218,Peak plasma concentration at 1 mg/kg peroral administration,1969.0,N,1,,CHEMBL623810,In vivo,50597,6485,,Plasma,A,,,Intermediate,,,
9115,BAO_0000218,Peak plasma concentration in rat,1969.0,N,1,,CHEMBL623811,In vivo,50597,17655,,Plasma,A,,,Intermediate,,,
9116,BAO_0000218,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1969.0,N,1,,CHEMBL623812,In vivo,50597,14941,,Plasma,A,,,Intermediate,,,
9117,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,N,1,,CHEMBL877605,In vivo,50597,5394,,,A,,,Intermediate,,,
9118,BAO_0000218,Pharmacokinetic property (Cmax) in rat,,N,1,,CHEMBL623813,In vivo,50597,4408,,,A,,,Intermediate,,,
9119,BAO_0000218,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,N,1,,CHEMBL623814,In vivo,50597,5983,,,A,,,Intermediate,,,
9120,BAO_0000218,Cmax in rat after 3mg/kg oral dose,,N,1,,CHEMBL623815,In vivo,50597,4878,,,A,,,Intermediate,,,
9121,BAO_0000218,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,N,1,,CHEMBL623816,In vivo,50597,5862,,,A,Sprague-Dawley,,Intermediate,,,
9122,BAO_0000218,Cmax in rats after 20 mg/kg oral dose,,N,1,,CHEMBL623145,In vivo,50597,4517,,,A,,,Intermediate,,,
9123,BAO_0000218,Cmax in rat plasma after 30mg/kg oral dose,1969.0,N,1,,CHEMBL623146,In vivo,50597,5932,,Plasma,A,,,Intermediate,,,
9124,BAO_0000218,Plasma concentration after oral administration of 100 mg/kg to rats,1969.0,N,1,,CHEMBL623147,In vivo,50597,5436,,Plasma,A,,,Intermediate,,,
9125,BAO_0000218,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,955.0,N,1,,CHEMBL623042,In vivo,50597,4910,,Brain,A,,,Intermediate,,,
9126,BAO_0000218,Tested for the Cmax in rat at 10 mg/kg per orally,,N,1,,CHEMBL623043,In vivo,50597,4950,,,A,,,Intermediate,,,
9127,BAO_0000218,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL623044,In vivo,50597,15078,,,A,,,Intermediate,,,
9128,BAO_0000218,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL623045,In vivo,50597,15078,,,A,,,Intermediate,,,
9129,BAO_0000218,Bioavailability as oral Cmax in rats at 30 mins,,N,1,,CHEMBL623046,In vivo,50597,3360,,,A,,,Intermediate,,,
9130,BAO_0000218,Bioavailability as oral Cmax in rats at 6hr,,N,1,,CHEMBL623226,In vivo,50597,3360,,,A,,,Intermediate,,,
9131,BAO_0000218,The maximum concentration of compound was measured at the dose of 100 umol/kg,,N,1,,CHEMBL623227,In vivo,50597,15022,,,A,,,Intermediate,,,
9132,BAO_0000218,The maximum concentration of compound was measured at the dose of 300 umol/kg,,N,1,,CHEMBL623228,In vivo,50597,15022,,,A,,,Intermediate,,,
9133,BAO_0000218,The maximum concentration of compound was measured at the dose of 30 umol/kg,,N,1,,CHEMBL623229,In vivo,50597,15022,,,A,,,Intermediate,,,
9134,BAO_0000218,The maximum plasma levels for the compounds were determined by LC-MS.,1969.0,N,1,,CHEMBL623230,In vivo,50597,5160,,Plasma,A,,,Intermediate,,,
9135,BAO_0000218,mean peak plasma concentration was observed after intravenous administration in rat,1969.0,N,1,,CHEMBL623231,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
9136,BAO_0000218,mean peak plasma concentration was observed after oral administration in rat,1969.0,N,1,,CHEMBL623232,In vivo,50597,15662,,Plasma,A,,,Intermediate,,,
9137,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,N,1,,CHEMBL623233,,50597,4709,,,A,,,Intermediate,,,
9138,BAO_0000218,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,N,1,,CHEMBL623234,,50597,3535,,,A,,,Intermediate,,,
9139,BAO_0000218,Concentration in plasma (portal) following oral dose in rats at 1 hr,,N,1,,CHEMBL623235,,50597,3535,,,A,,,Intermediate,,,
9140,BAO_0000218,Concentration in plasma (portal) following oral dose in rats at 2 hr,,N,1,,CHEMBL623236,,50597,3535,,,A,,,Intermediate,,,
9141,BAO_0000218,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,N,1,,CHEMBL623237,,50597,3535,,,A,,,Intermediate,,,
9142,BAO_0000218,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,N,1,,CHEMBL623238,,50597,3535,,,A,,,Intermediate,,,
9143,BAO_0000218,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,N,1,,CHEMBL623239,,50597,3535,,,A,,,Intermediate,,,
9144,BAO_0000218,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1969.0,U,1,,CHEMBL623240,In vivo,22224,5005,,Plasma,A,,,Intermediate,,,
9145,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1898.0,N,1,,CHEMBL623241,,50597,6326,,Hypothalamus,A,,,Intermediate,,,
9146,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1898.0,N,1,,CHEMBL623242,,50597,6326,,Hypothalamus,A,,,Intermediate,,,
9147,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,N,1,,CHEMBL874394,,50597,6326,,,A,,,Intermediate,,,
9148,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,N,1,,CHEMBL623243,,50597,6326,,,A,,,Intermediate,,,
9149,BAO_0000218,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL623244,,50597,17411,,,A,,,Intermediate,,,
9150,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2113.0,N,1,,CHEMBL623245,,50597,16435,,Kidney,A,,,Intermediate,,,
9151,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2113.0,N,1,,CHEMBL623246,,50597,16435,,Kidney,A,,,Intermediate,,,
9152,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2113.0,N,1,,CHEMBL623247,,50597,16435,,Kidney,A,,,Intermediate,,,
9153,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2113.0,N,1,,CHEMBL623248,,50597,16435,,Kidney,A,,,Intermediate,,,
9154,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2113.0,N,1,,CHEMBL623249,,50597,16435,,Kidney,A,,,Intermediate,,,
9155,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2107.0,N,1,,CHEMBL625072,,50597,16434,,Liver,A,,,Intermediate,,,
9156,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2107.0,N,1,,CHEMBL625073,,50597,16434,,Liver,A,,,Intermediate,,,
9157,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2107.0,N,1,,CHEMBL625074,,50597,16434,,Liver,A,,,Intermediate,,,
9158,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2107.0,N,1,,CHEMBL625075,,50597,16434,,Liver,A,,,Intermediate,,,
9159,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,2107.0,N,1,,CHEMBL625076,,50597,16434,,Liver,A,,,Intermediate,,,
9160,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2107.0,N,1,,CHEMBL625077,,50597,16434,,Liver,A,,,Intermediate,,,
9161,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2107.0,N,1,,CHEMBL625078,,50597,16434,,Liver,A,,,Intermediate,,,
9162,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2107.0,N,1,,CHEMBL874395,,50597,16434,,Liver,A,,,Intermediate,,,
9163,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2107.0,N,1,,CHEMBL625079,,50597,16435,,Liver,A,,,Intermediate,,,
9164,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2107.0,N,1,,CHEMBL625080,,50597,16435,,Liver,A,,,Intermediate,,,
9165,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2107.0,N,1,,CHEMBL625081,,50597,16435,,Liver,A,,,Intermediate,,,
9166,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2107.0,N,1,,CHEMBL625082,,50597,16435,,Liver,A,,,Intermediate,,,
9167,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2107.0,N,1,,CHEMBL625083,,50597,16435,,Liver,A,,,Intermediate,,,
9168,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2107.0,N,1,,CHEMBL625084,,50597,16435,,Liver,A,,,Intermediate,,,
9169,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2107.0,N,1,,CHEMBL625085,,50597,16435,,Liver,A,,,Intermediate,,,
9170,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2107.0,N,1,,CHEMBL625086,,50597,16435,,Liver,A,,,Intermediate,,,
9171,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2107.0,N,1,,CHEMBL625087,,50597,16434,,Liver,A,,,Intermediate,,,
9172,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2107.0,N,1,,CHEMBL625088,,50597,16434,,Liver,A,,,Intermediate,,,
9173,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2107.0,N,1,,CHEMBL622205,,50597,16434,,Liver,A,,,Intermediate,,,
9174,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2107.0,N,1,,CHEMBL622206,,50597,16435,,Liver,A,,,Intermediate,,,
9175,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2107.0,N,1,,CHEMBL622207,,50597,16435,,Liver,A,,,Intermediate,,,
9176,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2107.0,N,1,,CHEMBL622366,,50597,16435,,Liver,A,,,Intermediate,,,
9177,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2107.0,N,1,,CHEMBL622367,,50597,16435,,Liver,A,,,Intermediate,,,
9178,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2107.0,N,1,,CHEMBL875331,,50597,16435,,Liver,A,,,Intermediate,,,
9179,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2107.0,N,1,,CHEMBL622368,,50597,16435,,Liver,A,,,Intermediate,,,
9180,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2048.0,N,1,,CHEMBL622369,,50597,16434,,Lung,A,,,Intermediate,,,
9181,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2048.0,N,1,,CHEMBL622370,,50597,16434,,Lung,A,,,Intermediate,,,
9182,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2048.0,N,1,,CHEMBL622371,,50597,16434,,Lung,A,,,Intermediate,,,
9183,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2048.0,N,1,,CHEMBL622372,,50597,16434,,Lung,A,,,Intermediate,,,
9184,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2048.0,N,1,,CHEMBL622373,,50597,16434,,Lung,A,,,Intermediate,,,
9185,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2048.0,N,1,,CHEMBL622374,,50597,16434,,Lung,A,,,Intermediate,,,
9186,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2048.0,N,1,,CHEMBL622375,,50597,16434,,Lung,A,,,Intermediate,,,
9187,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,2048.0,N,1,,CHEMBL622376,,50597,16434,,Lung,A,,,Intermediate,,,
9188,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2048.0,N,1,,CHEMBL622377,,50597,16435,,Lung,A,,,Intermediate,,,
9189,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2048.0,N,1,,CHEMBL622378,,50597,16435,,Lung,A,,,Intermediate,,,
9190,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2048.0,N,1,,CHEMBL622379,,50597,16435,,Lung,A,,,Intermediate,,,
9191,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2048.0,N,1,,CHEMBL622380,,50597,16435,,Lung,A,,,Intermediate,,,
9192,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2048.0,N,1,,CHEMBL622381,,50597,16435,,Lung,A,,,Intermediate,,,
9193,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2048.0,N,1,,CHEMBL622382,,50597,16435,,Lung,A,,,Intermediate,,,
9194,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,2048.0,N,1,,CHEMBL622383,,50597,16434,,Lung,A,,,Intermediate,,,
9195,BAO_0000218,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL875332,,50597,6175,,Stomach,A,,,Intermediate,,,
9196,BAO_0000218,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL622384,,50597,6175,,Stomach,A,,,Intermediate,,,
9197,BAO_0000218,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL622385,,50597,6175,,Stomach,A,,,Intermediate,,,
9198,BAO_0000218,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,N,1,,CHEMBL622386,,50597,6175,,Stomach,A,,,Intermediate,,,
9199,BAO_0000218,The compound was tested for the plasma binding in rat,,N,1,,CHEMBL622387,,50597,10839,,,A,,,Intermediate,,,
9200,BAO_0000218,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,N,1,,CHEMBL622388,,50597,16459,,,A,,,Intermediate,,,
9201,BAO_0000218,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,N,1,,CHEMBL622389,,50597,16459,,,A,,,Intermediate,,,
9202,BAO_0000218,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,N,1,,CHEMBL622390,,50597,16459,,,A,,,Intermediate,,,
9203,BAO_0000218,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,N,1,,CHEMBL622391,,50597,16459,,,A,,,Intermediate,,,
9204,BAO_0000218,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,N,1,,CHEMBL622392,,50597,16459,,,A,,,Intermediate,,,
9205,BAO_0000218,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,N,1,,CHEMBL622393,,50597,16459,,,A,,,Intermediate,,,
9206,BAO_0000218,Plasma level at 2 hr after administration of the compound,,N,1,,CHEMBL622394,,50597,3278,,,A,,,Intermediate,,,
9207,BAO_0000218,plasma level at 2 hr after administration of the compound,,N,1,,CHEMBL622395,,50597,3278,,,A,,,Intermediate,,,
9208,BAO_0000218,Stability in rat serum measured as % recovery at 1 min,1977.0,N,1,,CHEMBL622396,,50597,4684,,Serum,A,,,Intermediate,,,
9209,BAO_0000218,Stability in rat serum measured as % recovery at 10 min,1977.0,N,1,,CHEMBL624894,,50597,4684,,Serum,A,,,Intermediate,,,
9210,BAO_0000218,Stability in rat serum measured as % recovery at 10 mins,1977.0,N,1,,CHEMBL624895,,50597,4684,,Serum,A,,,Intermediate,,,
9211,BAO_0000218,Stability in rat serum measured as % recovery at 2 hr,1977.0,N,1,,CHEMBL624058,,50597,4684,,Serum,A,,,Intermediate,,,
9212,BAO_0000218,Stability in rat serum measured as % recovery at 3 min,1977.0,N,1,,CHEMBL624059,,50597,4684,,Serum,A,,,Intermediate,,,
9213,BAO_0000218,Stability in rat serum measured as % recovery at 3 mins,1977.0,N,1,,CHEMBL624060,,50597,4684,,Serum,A,,,Intermediate,,,
9214,BAO_0000218,Stability in rat serum measured as % recovery at 5 min,1977.0,N,1,,CHEMBL624061,,50597,4684,,Serum,A,,,Intermediate,,,
9215,BAO_0000218,Stability in rat serum measured as % recovery at 5 mins,1977.0,N,1,,CHEMBL624062,,50597,4684,,Serum,A,,,Intermediate,,,
9216,BAO_0000218,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL624063,In vivo,50597,16456,,,A,,,Intermediate,,,
9217,BAO_0000218,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL624064,In vivo,50597,16456,,,A,,,Intermediate,,,
9218,BAO_0000218,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1969.0,N,1,,CHEMBL624065,,50597,723,,Plasma,A,,,Intermediate,,,
9219,BAO_0000218,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1969.0,N,1,,CHEMBL624066,,50597,723,,Plasma,A,,,Intermediate,,,
9220,BAO_0000218,Half life tested in mature male rat at a dose of 30 mg/kg,,N,1,,CHEMBL877490,In vivo,50597,5160,,,A,,,Intermediate,,,
9221,BAO_0000218,Half life after intravenous administration of 1 mg/kg in rat,,N,1,,CHEMBL874442,In vivo,50597,4709,,,A,,,Intermediate,,,
9222,BAO_0000218,Half life period after administration (30 mg/kg) in rat,,N,1,,CHEMBL626890,In vivo,50597,5633,,,A,,,Intermediate,,,
9223,BAO_0000218,Half life period in rat after 5 mg/Kg dose,,N,1,,CHEMBL626891,In vivo,50597,5302,,,A,,,Intermediate,,,
9224,BAO_0000218,Half life period in rat after 5 mg/kg dose,,N,1,,CHEMBL626892,In vivo,50597,5302,,,A,,,Intermediate,,,
9225,BAO_0000218,Half life period was determined,,N,1,,CHEMBL626893,,50597,17791,,,A,,,Intermediate,,,
9226,BAO_0000218,Half life period was evaluated in rat,,N,1,,CHEMBL626894,,50597,17791,,,A,,,Intermediate,,,
9227,BAO_0000218,Half life period was evaluated in rat; 0.5-1.0,,N,1,,CHEMBL626895,,50597,17791,,,A,,,Intermediate,,,
9228,BAO_0000218,Half life period was evaluated in rat; 5.9-7.5,,N,1,,CHEMBL626896,,50597,17791,,,A,,,Intermediate,,,
9229,BAO_0000218,Half-life in rat plasma,1969.0,N,1,,CHEMBL626897,,50597,14512,,Plasma,A,,,Intermediate,,,
9230,BAO_0000218,Half-life time in rat was determined,,N,1,,CHEMBL626898,,50597,6230,,,A,,,Intermediate,,,
9231,BAO_0000218,Terminal half-life after iv administration to rats,,N,1,,CHEMBL626899,In vivo,50597,3364,,,A,,,Intermediate,,,
9232,BAO_0000218,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,N,1,,CHEMBL626900,In vivo,50597,6874,,,A,,,Intermediate,,,
9233,BAO_0000218,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,N,1,,CHEMBL626901,,50597,857,,,A,,,Intermediate,,,
9234,BAO_0000218,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,N,1,,CHEMBL626902,In vivo,50597,858,,,A,,,Intermediate,,,
9235,BAO_0000218,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,N,1,,CHEMBL626903,In vivo,50597,858,,,A,,,Intermediate,,,
9236,BAO_0000218,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,N,1,,CHEMBL874443,In vivo,50597,5355,,,A,,,Intermediate,,,
9237,BAO_0000218,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,N,1,,CHEMBL626904,In vivo,50597,5355,,,A,,,Intermediate,,,
9238,BAO_0000218,Half life in rats,,N,1,,CHEMBL626905,,50597,6305,,,A,,,Intermediate,,,
9239,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1969.0,N,1,,CHEMBL873830,In vivo,50597,13501,,Plasma,A,,,Intermediate,,,
9240,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,N,1,,CHEMBL626906,In vivo,50597,17594,,,A,,,Intermediate,,,
9241,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,N,1,,CHEMBL631076,In vivo,50597,4186,,Plasma,A,,,Intermediate,,,
9242,BAO_0000218,Biological half-life was measured in plasma of rats,1969.0,N,1,,CHEMBL631077,,50597,2932,,Plasma,A,,,Intermediate,,,
9243,BAO_0000218,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,1,,CHEMBL631078,In vivo,50597,17065,,,A,,,Intermediate,,,
9244,BAO_0000218,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,N,1,,CHEMBL631079,In vivo,50597,15765,,,A,,,Intermediate,,,
9245,BAO_0000218,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,N,1,,CHEMBL631080,In vivo,50597,2713,,,A,,,Intermediate,,,
9246,BAO_0000218,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,N,1,,CHEMBL631081,In vivo,50597,2661,,,A,,,Intermediate,,,
9247,BAO_0000218,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,N,1,,CHEMBL631239,In vivo,50597,2661,,,A,,,Intermediate,,,
9248,BAO_0000218,Compound was evaluated for plasma half life in rat,1969.0,N,1,,CHEMBL631240,,50597,740,,Plasma,A,,,Intermediate,,,
9249,BAO_0000218,AUC value at a dose of 5 mg/kg (p.o.) in rats,1969.0,N,1,,CHEMBL631241,,50597,6597,,Plasma,A,,,Intermediate,,,
9250,BAO_0000218,AUC value after administration of 20 mg/Kg oral dose in rat,1969.0,N,1,,CHEMBL631242,,50597,2959,,Plasma,A,,,Intermediate,,,
9251,BAO_0000218,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1969.0,N,1,,CHEMBL631243,,50597,17594,,Plasma,A,,,Intermediate,,,
9252,BAO_0000218,AUC0-96 after administration at 50 mg/kg,1969.0,N,1,,CHEMBL874444,,50597,17596,,Plasma,A,,,Intermediate,,,
9253,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1969.0,N,1,,CHEMBL631244,,50597,17594,,Plasma,A,,,Intermediate,,,
9254,BAO_0000218,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,N,1,,CHEMBL631245,,50597,3293,,,A,,,Intermediate,,,
9255,BAO_0000218,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,N,1,,CHEMBL627162,,50597,6757,,,A,,,Intermediate,,,
9256,BAO_0000218,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,N,1,,CHEMBL627163,,50597,6757,,,A,,,Intermediate,,,
9257,BAO_0000218,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,N,1,,CHEMBL627164,,50597,6757,,,A,,,Intermediate,,,
9258,BAO_0000218,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,2113.0,N,1,,CHEMBL627165,,50597,5979,,Kidney,A,,,Intermediate,,,
9259,BAO_0000218,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,N,1,,CHEMBL627166,,50597,5979,,,A,,,Intermediate,,,
9260,BAO_0000218,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,N,1,,CHEMBL627167,,50597,5979,,,A,,,Intermediate,,,
9261,BAO_0000218,Area under curve (AUC) at a dose of 30 mg/kg in rats,,N,1,,CHEMBL627822,,50597,4026,,,A,,,Intermediate,,,
9262,BAO_0000218,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,N,1,,CHEMBL627823,,50597,5355,,,A,,,Intermediate,,,
9263,BAO_0000218,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,N,1,,CHEMBL627824,,50597,5355,,,A,,,Intermediate,,,
9264,BAO_0000218,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,N,1,,CHEMBL627825,,50597,5355,,,A,,,Intermediate,,,
9265,BAO_0000218,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,N,1,,CHEMBL627826,,50597,5633,,,A,,,Intermediate,,,
9266,BAO_0000218,Area under curve (Pharmacokinetic property) was determined,,N,1,,CHEMBL627827,,50597,1716,,,A,,,Intermediate,,,
9267,BAO_0000218,Area under curve (Pharmacokinetic property) of the compound; Not determined,,N,1,,CHEMBL627828,,50597,1716,,,A,,,Intermediate,,,
9268,BAO_0000218,Area under curve after intravenous administration (1 mg/kg) in rat,,N,1,,CHEMBL627829,,50597,4689,,,A,,,Intermediate,,,
9269,BAO_0000218,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,N,1,,CHEMBL627830,,50597,4527,,,A,,,Intermediate,,,
9270,BAO_0000218,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,N,1,,CHEMBL627831,,50597,4527,,,A,,,Intermediate,,,
9271,BAO_0000218,Area under curve in male SD rats was observed after oral administration in rat,,N,1,,CHEMBL627832,,50597,15662,,,A,,,Intermediate,,,
9272,BAO_0000218,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,N,1,,CHEMBL627833,,50597,4413,,,A,,,Intermediate,,,
9273,BAO_0000218,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL627834,,50597,3598,,,A,,,Expert,,,
9274,BAO_0000218,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL628004,,50597,3598,,,A,,,Expert,,,
9275,BAO_0000218,Area under curve at 5 mg/kg po was determined in rat,,N,1,,CHEMBL628005,,50597,5964,,,A,,,Intermediate,,,
9276,BAO_0000218,Area under curve in Rat at a oral dose of 5 mg/kg,,N,1,,CHEMBL628006,,50597,4689,,,A,,,Intermediate,,,
9277,BAO_0000218,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,N,1,,CHEMBL628007,,50597,4186,,,A,,,Intermediate,,,
9278,BAO_0000218,Area under curve was determined,,N,1,,CHEMBL625676,,50597,5510,,,A,,,Intermediate,,,
9279,BAO_0000218,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,N,1,,CHEMBL631309,,50597,17858,,,A,,,Intermediate,,,
9280,BAO_0000218,Area under curve after intravenous administration at 3 mg/kg,,N,1,,CHEMBL631310,,50597,17804,,,A,,,Intermediate,,,
9281,BAO_0000218,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,N,1,,CHEMBL631311,,50597,6106,,,A,,,Intermediate,,,
9282,BAO_0000218,Area under curve at 4 hr in rat,,N,1,,CHEMBL631312,,50597,5964,,,A,,,Intermediate,,,
9283,BAO_0000218,Area under curve at a dose of 30 mg/kg,,N,1,,CHEMBL631313,,50597,4026,,,A,,,Intermediate,,,
9284,BAO_0000218,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,N,1,,CHEMBL631314,,50597,4756,,,A,,,Intermediate,,,
9285,BAO_0000218,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,N,1,,CHEMBL631315,,50597,4756,,,A,,,Intermediate,,,
9286,BAO_0000218,Area under curve for a 2-mpk po dose in SD rats,,N,1,,CHEMBL631316,,50597,5862,,,A,,,Intermediate,,,
9287,BAO_0000218,Area under curve in SD rats,,N,1,,CHEMBL631317,,50597,5862,,,A,,,Intermediate,,,
9288,BAO_0000218,Area under curve in rat after oral administration at 13 mg/kg dose,,N,1,,CHEMBL874471,,50597,6644,,,A,,,Intermediate,,,
9289,BAO_0000218,Area under curve in rat by po administration at 0-24 hr,,N,1,,CHEMBL631318,,50597,5871,,,A,,,Intermediate,,,
9290,BAO_0000218,Area under curve in rat plasma,1969.0,N,1,,CHEMBL631319,,50597,5919,,Plasma,A,,,Intermediate,,,
9291,BAO_0000218,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,N,1,,CHEMBL631320,,50597,5939,,,A,,,Intermediate,,,
9292,BAO_0000218,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,N,1,,CHEMBL631321,,50597,5939,,,A,,,Intermediate,,,
9293,BAO_0000218,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,N,1,,CHEMBL631322,,50597,10,,,A,,,Intermediate,,,
9294,BAO_0000218,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,N,1,,CHEMBL631323,,50597,11149,,,A,,,Intermediate,,,
9295,BAO_0000218,Area under curve value in rat at a dose of 5 mg/kg,,N,1,,CHEMBL631324,,50597,5302,,,A,,,Intermediate,,,
9296,BAO_0000218,Area under curve was determined after oral administration in rats,,N,1,,CHEMBL631325,,50597,17796,,,A,,,Intermediate,,,
9297,BAO_0000218,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL631326,,50597,4890,,,A,,,Intermediate,,,
9298,BAO_0000218,Area under curve was determined after peroral administration in rat,,N,1,,CHEMBL631327,,50597,6011,,,A,,,Intermediate,,,
9299,BAO_0000218,Area under curve was determined at a dose 30 mpk administered orally.,,N,1,,CHEMBL631328,,50597,5375,,,A,,,Intermediate,,,
9300,BAO_0000218,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,N,1,,CHEMBL631329,,50597,17764,,,A,,,Intermediate,,,
9301,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,N,1,,CHEMBL627217,,50597,4368,,,A,,,Intermediate,,,
9302,BAO_0000218,Area under curve was determined in male rat,,N,1,,CHEMBL626352,,50597,5610,,,A,,,Intermediate,,,
9303,BAO_0000218,Area under curve was determined in rat after PO administration,,N,1,,CHEMBL626353,,50597,5833,,,A,,,Intermediate,,,
9304,BAO_0000218,Area under curve was determined in rat after a 3 mg/kg of oral dose,,N,1,,CHEMBL626354,,50597,4257,,,A,,,Intermediate,,,
9305,BAO_0000218,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,N,1,,CHEMBL626355,,50597,5937,,,A,,,Intermediate,,,
9306,BAO_0000218,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,N,1,,CHEMBL626356,,50597,5932,,,A,,,Intermediate,,,
9307,BAO_0000218,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,N,1,,CHEMBL626357,,50597,5932,,,A,,,Intermediate,,,
9308,BAO_0000218,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL626358,,50597,17411,,,A,,,Intermediate,,,
9309,BAO_0000218,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL626359,,50597,17411,,,A,,,Intermediate,,,
9310,BAO_0000218,Peak plasma concentration in rat at a dose of 3 mg/kg,1969.0,N,1,,CHEMBL626360,,50597,17771,,Plasma,A,,,Intermediate,,,
9311,BAO_0000218,Plasma concentration at 2 hr in rats was evaluated.,,N,1,,CHEMBL626361,,50597,1628,,,A,,,Intermediate,,,
9312,BAO_0000218,Plasma concentration at 2 hr in rats was evaluated; Not available,,N,1,,CHEMBL626362,,50597,1628,,,A,,,Intermediate,,,
9313,BAO_0000218,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL626363,,50597,17411,,,A,,,Intermediate,,,
9314,BAO_0000218,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,N,1,,CHEMBL626970,,50597,4910,,,A,,,Intermediate,,,
9315,BAO_0000218,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,N,1,,CHEMBL626971,,50597,4910,,,A,,,Intermediate,,,
9316,BAO_0000218,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,N,1,,CHEMBL626972,,50597,4910,,Plasma,A,,,Intermediate,,,
9317,BAO_0000218,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,N,1,,CHEMBL626973,,50597,4910,,Plasma,A,,,Intermediate,,,
9318,BAO_0000218,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,N,1,,CHEMBL626974,,50597,4910,,Plasma,A,,,Intermediate,,,
9319,BAO_0000218,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,N,1,,CHEMBL874592,,50597,4910,,Plasma,A,,,Intermediate,,,
9320,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,N,1,,CHEMBL626975,,50597,5510,,,A,,,Intermediate,,,
9321,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,N,1,,CHEMBL626976,,50597,5510,,,A,,,Intermediate,,,
9322,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,N,1,,CHEMBL626977,,50597,5510,,,A,,,Intermediate,,,
9323,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,N,1,,CHEMBL626978,,50597,5510,,,A,,,Intermediate,,,
9324,BAO_0000218,PK study was carried to determine the relative absorption ranking in rat.,,N,1,,CHEMBL626979,,50597,16427,,,A,,,Intermediate,,,
9325,BAO_0000218,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1969.0,N,1,,CHEMBL626980,In vivo,50597,4689,,Plasma,A,,,Intermediate,,,
9326,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",178.0,N,1,,CHEMBL626981,,50597,11450,,Blood,A,,,Intermediate,,,
9327,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",178.0,N,1,,CHEMBL626982,,50597,11450,,Blood,A,,,Intermediate,,,
9328,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",178.0,N,1,,CHEMBL626983,,50597,11450,,Blood,A,,,Intermediate,,,
9329,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",178.0,N,1,,CHEMBL622522,,50597,11450,,Blood,A,,,Intermediate,,,
9330,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",178.0,N,1,,CHEMBL622523,,50597,11450,,Blood,A,,,Intermediate,,,
9331,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",178.0,N,1,,CHEMBL622524,,50597,11450,,Blood,A,,,Intermediate,,,
9332,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",955.0,N,1,,CHEMBL622525,,50597,11450,,Brain,A,,,Intermediate,,,
9333,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",955.0,N,1,,CHEMBL622526,,50597,11450,,Brain,A,,,Intermediate,,,
9334,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",955.0,N,1,,CHEMBL619849,,50597,11450,,Brain,A,,,Intermediate,,,
9335,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",955.0,N,1,,CHEMBL619850,,50597,11450,,Brain,A,,,Intermediate,,,
9336,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",955.0,N,1,,CHEMBL623864,,50597,11450,,Brain,A,,,Intermediate,,,
9337,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",955.0,N,1,,CHEMBL623865,,50597,11450,,Brain,A,,,Intermediate,,,
9338,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",948.0,N,1,,CHEMBL623866,,50597,11450,,Heart,A,,,Intermediate,,,
9339,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",948.0,N,1,,CHEMBL623867,,50597,11450,,Heart,A,,,Intermediate,,,
9340,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",948.0,N,1,,CHEMBL877615,,50597,11450,,Heart,A,,,Intermediate,,,
9341,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",948.0,N,1,,CHEMBL623868,,50597,11450,,Heart,A,,,Intermediate,,,
9342,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",948.0,N,1,,CHEMBL623869,,50597,11450,,Heart,A,,,Intermediate,,,
9343,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",948.0,N,1,,CHEMBL623870,,50597,11450,,Heart,A,,,Intermediate,,,
9344,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,2048.0,N,1,,CHEMBL623871,,50597,16434,,Lung,A,,,Intermediate,,,
9345,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2048.0,N,1,,CHEMBL623872,,50597,16434,,Lung,A,,,Intermediate,,,
9346,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2048.0,N,1,,CHEMBL622129,,50597,16435,,Lung,A,,,Intermediate,,,
9347,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2048.0,N,1,,CHEMBL622130,,50597,16435,,Lung,A,,,Intermediate,,,
9348,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2048.0,N,1,,CHEMBL622131,,50597,16435,,Lung,A,,,Intermediate,,,
9349,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2048.0,N,1,,CHEMBL622132,,50597,16435,,Lung,A,,,Intermediate,,,
9350,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2048.0,N,1,,CHEMBL622133,,50597,16435,,Lung,A,,,Intermediate,,,
9351,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2048.0,N,1,,CHEMBL622134,,50597,16435,,Lung,A,,,Intermediate,,,
9352,BAO_0000218,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2048.0,N,1,,CHEMBL622135,,50597,16435,,Lung,A,,,Intermediate,,,
9353,BAO_0000218,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2048.0,N,1,,CHEMBL622136,,50597,16435,,Lung,A,,,Intermediate,,,
9354,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2385.0,N,1,,CHEMBL622137,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9355,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2385.0,N,1,,CHEMBL622138,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9356,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2385.0,N,1,,CHEMBL623017,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9357,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2385.0,N,1,,CHEMBL623018,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9358,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2385.0,N,1,,CHEMBL623019,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9359,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2385.0,N,1,,CHEMBL623020,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9360,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,2385.0,N,1,,CHEMBL623021,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9361,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,2385.0,N,1,,CHEMBL623022,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9362,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2385.0,N,1,,CHEMBL623023,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9363,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2385.0,N,1,,CHEMBL623024,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9364,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2385.0,N,1,,CHEMBL623025,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9365,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2385.0,N,1,,CHEMBL620545,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9366,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2385.0,N,1,,CHEMBL620546,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9367,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2385.0,N,1,,CHEMBL620547,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9368,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2385.0,N,1,,CHEMBL620548,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9369,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2385.0,N,1,,CHEMBL620549,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9370,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2385.0,N,1,,CHEMBL620550,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9371,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,2385.0,N,1,,CHEMBL620551,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9372,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2385.0,N,1,,CHEMBL620552,,50597,16434,,Muscle tissue,A,,,Intermediate,,,
9373,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2385.0,N,1,,CHEMBL620553,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9374,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2385.0,N,1,,CHEMBL620554,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9375,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2385.0,N,1,,CHEMBL875845,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9376,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2385.0,N,1,,CHEMBL620555,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9377,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2385.0,N,1,,CHEMBL620556,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9378,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2385.0,N,1,,CHEMBL620557,,50597,16435,,Muscle tissue,A,,,Intermediate,,,
9379,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,1,,CHEMBL620558,,50597,16434,,,A,,,Intermediate,,,
9380,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,1,,CHEMBL620559,,50597,16434,,,A,,,Intermediate,,,
9381,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,1,,CHEMBL622939,,50597,16434,,,A,,,Intermediate,,,
9382,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,1,,CHEMBL622940,,50597,16434,,,A,,,Intermediate,,,
9383,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,1,,CHEMBL622941,,50597,16434,,,A,,,Intermediate,,,
9384,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,1,,CHEMBL622942,,50597,16434,,,A,,,Intermediate,,,
9385,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,1,,CHEMBL622943,,50597,16434,,,A,,,Intermediate,,,
9386,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,1,,CHEMBL622944,,50597,16434,,,A,,,Intermediate,,,
9387,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,1,,CHEMBL622945,,50597,16435,,,A,,,Intermediate,,,
9388,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,1,,CHEMBL622946,,50597,16435,,,A,,,Intermediate,,,
9389,BAO_0000218,Compound was evaluated for terminal half life in rat,,N,1,,CHEMBL622947,,50597,3341,,,A,,,Intermediate,,,
9390,BAO_0000218,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1969.0,N,1,,CHEMBL622948,In vivo,50597,3634,,Plasma,A,,,Intermediate,,,
9391,BAO_0000218,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1969.0,N,1,,CHEMBL622949,In vivo,50597,3634,,Plasma,A,,,Intermediate,,,
9392,BAO_0000218,Compound was tested for its half life in rat,,N,1,,CHEMBL622950,,50597,4839,,,A,,,Intermediate,,,
9393,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1969.0,U,1,,CHEMBL622951,In vivo,22224,5005,,Plasma,A,,,Intermediate,,,
9394,BAO_0000366,Compound was tested for its plasma half life in Sprague Dawley rats,1969.0,U,1,,CHEMBL622952,,22224,5005,,Plasma,A,,,Intermediate,,,
9395,BAO_0000366,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1969.0,U,1,,CHEMBL622953,,22224,5005,,Plasma,A,,,Intermediate,,,
9396,BAO_0000218,Compound was tested for plasma half-life period in rat,1969.0,N,1,,CHEMBL873818,,50597,1094,,Plasma,A,,,Intermediate,,,
9397,BAO_0000218,Elimination half life after i.v. administration of compound in rats,,N,1,,CHEMBL622954,In vivo,50597,5031,,,A,,,Intermediate,,,
9398,BAO_0000218,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,N,1,,CHEMBL622955,In vivo,50597,6518,,,A,,,Intermediate,,,
9399,BAO_0000218,Elimination half-life after IV dosing at 1 mg/kg in rat,,N,1,,CHEMBL875229,In vivo,50597,6518,,,A,,,Intermediate,,,
9400,BAO_0000218,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,N,1,,CHEMBL622956,In vivo,50597,6518,,,A,,,Intermediate,,,
9401,BAO_0000218,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,N,1,,CHEMBL622957,In vivo,50597,6518,,,A,,,Intermediate,,,
9402,BAO_0000218,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,955.0,N,1,,CHEMBL622958,In vivo,50597,5408,,Brain,A,,,Intermediate,,,
9403,BAO_0000218,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1969.0,N,1,,CHEMBL622959,In vivo,50597,5408,,Plasma,A,,,Intermediate,,,
9404,BAO_0000218,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,955.0,N,1,,CHEMBL622960,In vivo,50597,5408,,Brain,A,,,Intermediate,,,
9405,BAO_0000218,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1969.0,N,1,,CHEMBL622961,In vivo,50597,5408,,Plasma,A,,,Intermediate,,,
9406,BAO_0000218,Evaluated for the half life in rat (in vivo),,N,1,,CHEMBL622962,In vivo,50597,4687,,,A,,,Intermediate,,,
9407,BAO_0000218,Hafl life in rat,,N,1,,CHEMBL622963,,50597,6640,,,A,,,Intermediate,,,
9408,BAO_0000218,Hafl life rat,,N,1,,CHEMBL622964,,50597,6640,,,A,,,Intermediate,,,
9409,BAO_0000218,Hafl life rat,,N,1,,CHEMBL622965,,50597,6641,,,A,,,Intermediate,,,
9410,BAO_0000218,Hafl life rat; Not determined,,N,1,,CHEMBL622966,,50597,6640,,,A,,,Intermediate,,,
9411,BAO_0000218,Hafl life rat; Not determined,,N,1,,CHEMBL622967,,50597,6641,,,A,,,Intermediate,,,
9412,BAO_0000218,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2113.0,N,1,,CHEMBL622968,In vivo,50597,17411,,Kidney,A,,,Intermediate,,,
9413,BAO_0000218,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2107.0,N,1,,CHEMBL622969,In vivo,50597,17411,,Liver,A,,,Intermediate,,,
9414,BAO_0000218,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2048.0,N,1,,CHEMBL875327,In vivo,50597,17411,,Lung,A,,,Intermediate,,,
9415,BAO_0000218,Half life in rat after 1 mg/kg i.v. administration,,N,1,,CHEMBL628638,In vivo,50597,6570,,,A,,,Intermediate,,,
9416,BAO_0000218,Half life in rat after 2 mg/kg peroral administration,,N,1,,CHEMBL628639,In vivo,50597,6570,,,A,,,Intermediate,,,
9417,BAO_0000218,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL625840,In vivo,50597,17411,,,A,,,Intermediate,,,
9418,BAO_0000218,Half life of 10 mg/kg oral dose determined in rats,,N,1,,CHEMBL625841,In vivo,50597,4722,,,A,,,Intermediate,,,
9419,BAO_0000218,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL625842,In vivo,50597,5978,,,A,,,Intermediate,,,
9420,BAO_0000218,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL625843,In vivo,50597,5978,,,A,,,Intermediate,,,
9421,BAO_0000218,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL625844,In vivo,50597,5978,,,A,,,Intermediate,,,
9422,BAO_0000218,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL873822,In vivo,50597,5978,,,A,,,Intermediate,,,
9423,BAO_0000218,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL625845,In vivo,50597,5978,,,A,,,Intermediate,,,
9424,BAO_0000218,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL627059,In vivo,50597,5978,,,A,,,Intermediate,,,
9425,BAO_0000218,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL627060,In vivo,50597,5978,,,A,,,Intermediate,,,
9426,BAO_0000218,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL627061,In vivo,50597,5978,,,A,,,Intermediate,,,
9427,BAO_0000218,Half life of compound at 5 mg/kg after po administration was determined in rat,,N,1,,CHEMBL627709,In vivo,50597,4762,,,A,,,Intermediate,,,
9428,BAO_0000218,Half life of compound determined after intravenous administration to rat,,N,1,,CHEMBL627710,In vivo,50597,5327,,,A,,,Intermediate,,,
9429,BAO_0000218,Half life of compound was determined in rat,,N,1,,CHEMBL627711,,50597,4847,,,A,,,Intermediate,,,
9430,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL627712,In vivo,50597,17720,,Plasma,A,,,Intermediate,,,
9431,BAO_0000218,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL627713,In vivo,50597,4723,,,A,,,Intermediate,,,
9432,BAO_0000218,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL627714,In vivo,50597,4723,,,A,,,Intermediate,,,
9433,BAO_0000218,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,U,1,,CHEMBL627889,In vivo,22224,4256,,,A,,,Intermediate,,,
9434,BAO_0000218,Half life determined in rat by intravenous administration,,U,1,,CHEMBL627890,In vivo,22224,4256,,,A,,,Intermediate,,,
9435,BAO_0000218,Half life determined in rats after iv administration,,N,1,,CHEMBL627891,In vivo,50597,4722,,,A,,,Intermediate,,,
9436,BAO_0000218,Half life in rat plasma after administration of 2 mg/kg iv,1969.0,N,1,,CHEMBL627892,In vivo,50597,6535,,Plasma,A,,,Intermediate,,,
9437,BAO_0000218,Half life in rat plasma after administration of 2 mg/kg iv,1969.0,N,1,,CHEMBL627893,In vivo,50597,6535,,Plasma,A,,,Intermediate,,,
9438,BAO_0000218,Half life in rat plasma was determined,1969.0,N,1,,CHEMBL627894,,50597,1435,,Plasma,A,,,Intermediate,,,
9439,BAO_0000218,Half life in rat plasma was determined; NA means not applicable,1969.0,N,1,,CHEMBL627895,,50597,1435,,Plasma,A,,,Intermediate,,,
9440,BAO_0000218,Half life in rat was tested,,N,1,,CHEMBL627896,,50597,5206,,,A,,,Intermediate,,,
9441,BAO_0000218,Half life measured in rat plasma,1969.0,N,1,,CHEMBL627897,,50597,6080,,Plasma,A,,,Intermediate,,,
9442,BAO_0000218,Half life recorded in rats,,N,1,,CHEMBL627898,,50597,4449,,,A,,,Intermediate,,,
9443,BAO_0000218,Half life was calculated,,N,1,,CHEMBL627899,,50597,6057,,,A,,,Intermediate,,,
9444,BAO_0000218,Half life was calculated in rat,,N,1,,CHEMBL873823,,50597,6057,,,A,,,Intermediate,,,
9445,BAO_0000218,Half life was determined,,N,1,,CHEMBL627900,,50597,3747,,,A,,,Intermediate,,,
9446,BAO_0000218,Half life after 10 mg/kg oral administration in rat,,N,1,,CHEMBL627901,In vivo,50597,17858,,,A,,,Intermediate,,,
9447,BAO_0000218,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,N,1,,CHEMBL627902,In vivo,50597,16365,,,A,,,Intermediate,,,
9448,BAO_0000218,Half life after administering orally a dose of 30 mg/kg,,N,1,,CHEMBL627903,In vivo,50597,16365,,,A,,,Intermediate,,,
9449,BAO_0000218,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,N,1,,CHEMBL627904,,50597,5031,,,A,,,Intermediate,,,
9450,BAO_0000218,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,N,1,,CHEMBL627905,,50597,4722,,,A,,,Intermediate,,,
9451,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,N,1,,CHEMBL627906,,50597,6078,,,A,,,Intermediate,,,
9452,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,N,1,,CHEMBL627907,,50597,6078,,,A,,,Intermediate,,,
9453,BAO_0000218,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,N,1,,CHEMBL876783,,50597,6078,,,A,,,Intermediate,,,
9454,BAO_0000218,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,N,1,,CHEMBL627908,,50597,6078,,,A,,,Intermediate,,,
9455,BAO_0000218,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,1,,CHEMBL627909,,50597,17065,,,A,,,Intermediate,,,
9456,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,N,1,,CHEMBL627910,,50597,1353,,,A,,,Intermediate,,,
9457,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,N,1,,CHEMBL627911,,50597,1353,,,A,,,Intermediate,,,
9458,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,N,1,,CHEMBL627912,,50597,1353,,,A,,,Intermediate,,,
9459,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,N,1,,CHEMBL627913,,50597,1353,,,A,,,Intermediate,,,
9460,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,N,1,,CHEMBL627914,,50597,1353,,,A,,,Intermediate,,,
9461,BAO_0000218,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,N,1,,CHEMBL627915,,50597,16423,,,A,,,Intermediate,,,
9462,BAO_0000218,Area under the curve was evaluated after 20 uM/kg of peroral administration,,N,1,,CHEMBL627916,,50597,16423,,,A,,,Intermediate,,,
9463,BAO_0000218,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,N,1,,CHEMBL627917,,50597,6062,,,A,,,Intermediate,,,
9464,BAO_0000218,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,N,1,,CHEMBL627918,,50597,6056,,,A,,,Intermediate,,,
9465,BAO_0000218,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,N,1,,CHEMBL627919,,50597,5182,,,A,,,Intermediate,,,
9466,BAO_0000218,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,N,1,,CHEMBL627920,,50597,6410,,,A,,,Intermediate,,,
9467,BAO_0000218,Area under the curve was evaluated at an oral dose of 30 mg/kg,,N,1,,CHEMBL627921,,50597,6410,,,A,,,Intermediate,,,
9468,BAO_0000218,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL627922,,50597,4723,,,A,,,Intermediate,,,
9469,BAO_0000218,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL876784,,50597,4723,,,A,,,Intermediate,,,
9470,BAO_0000218,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL627923,,50597,4723,,,A,,,Intermediate,,,
9471,BAO_0000218,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL626208,,50597,4723,,,A,,,Intermediate,,,
9472,BAO_0000218,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL626209,,50597,4723,,,A,,,Intermediate,,,
9473,BAO_0000218,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL626210,,50597,4723,,,A,,,Intermediate,,,
9474,BAO_0000218,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1969.0,N,1,,CHEMBL627994,,50597,2463,,Plasma,A,,,Intermediate,,,
9475,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,N,1,,CHEMBL627995,,50597,4709,,,A,,,Intermediate,,,
9476,BAO_0000218,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,N,1,,CHEMBL627996,,50597,4075,,,A,,,Intermediate,,,
9477,BAO_0000218,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,N,1,,CHEMBL627997,,50597,5394,,,A,,,Intermediate,,,
9478,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,N,1,,CHEMBL627998,,50597,2661,,,A,,,Intermediate,,,
9479,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,N,1,,CHEMBL628640,,50597,2661,,,A,,,Intermediate,,,
9480,BAO_0000218,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,N,1,,CHEMBL628641,,50597,2661,,,A,,,Intermediate,,,
9481,BAO_0000218,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,N,1,,CHEMBL628642,,50597,2661,,,A,,,Intermediate,,,
9482,BAO_0000218,Compound was evaluated for area under the curve expressed as (h*ug/ml),,N,1,,CHEMBL628643,,50597,17791,,,A,,,Intermediate,,,
9483,BAO_0000218,Compound was tested for area under curve in rat,,N,1,,CHEMBL628644,,50597,2591,,,A,,,Intermediate,,,
9484,BAO_0000218,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,N,1,,CHEMBL628645,,50597,6567,,,A,,,Intermediate,,,
9485,BAO_0000218,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,N,1,,CHEMBL628646,,50597,6211,,,A,,,Intermediate,,,
9486,BAO_0000218,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,N,1,,CHEMBL628647,,50597,5529,,,A,,,Intermediate,,,
9487,BAO_0000218,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,N,1,,CHEMBL628648,,50597,5408,,,A,,,Intermediate,,,
9488,BAO_0000218,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,N,1,,CHEMBL625358,,50597,5408,,,A,,,Intermediate,,,
9489,BAO_0000218,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,N,1,,CHEMBL625359,,50597,5408,,,A,,,Intermediate,,,
9490,BAO_0000218,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,N,1,,CHEMBL625360,,50597,5408,,,A,,,Intermediate,,,
9491,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,N,1,,CHEMBL625361,,50597,429,,,A,,,Intermediate,,,
9492,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,N,1,,CHEMBL625362,,50597,429,,,A,,,Intermediate,,,
9493,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,N,1,,CHEMBL625363,,50597,429,,,A,,,Intermediate,,,
9494,BAO_0000218,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,N,1,,CHEMBL625364,,50597,4796,,,A,,,Intermediate,,,
9495,BAO_0000218,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL625365,,50597,5974,,,A,,,Intermediate,,,
9496,BAO_0000218,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL625366,,50597,5974,,,A,,,Intermediate,,,
9497,BAO_0000218,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL625367,,50597,5974,,,A,,,Intermediate,,,
9498,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",2113.0,N,1,,CHEMBL625368,,50597,11450,,Kidney,A,,,Intermediate,,,
9499,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",2113.0,N,1,,CHEMBL625369,,50597,11450,,Kidney,A,,,Intermediate,,,
9500,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",2113.0,N,1,,CHEMBL625370,,50597,11450,,Kidney,A,,,Intermediate,,,
9501,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",2113.0,N,1,,CHEMBL625371,,50597,11450,,Kidney,A,,,Intermediate,,,
9502,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",2113.0,N,1,,CHEMBL625372,,50597,11450,,Kidney,A,,,Intermediate,,,
9503,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",2113.0,N,1,,CHEMBL625373,,50597,11450,,Kidney,A,,,Intermediate,,,
9504,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",2107.0,N,1,,CHEMBL625374,,50597,11450,,Liver,A,,,Intermediate,,,
9505,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",2107.0,N,1,,CHEMBL877593,,50597,11450,,Liver,A,,,Intermediate,,,
9506,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",2107.0,N,1,,CHEMBL625375,,50597,11450,,Liver,A,,,Intermediate,,,
9507,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",2107.0,N,1,,CHEMBL625376,,50597,11450,,Liver,A,,,Intermediate,,,
9508,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",2107.0,N,1,,CHEMBL621973,,50597,11450,,Liver,A,,,Intermediate,,,
9509,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",2107.0,N,1,,CHEMBL621974,,50597,11450,,Liver,A,,,Intermediate,,,
9510,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",2048.0,N,1,,CHEMBL621975,,50597,11450,,Lung,A,,,Intermediate,,,
9511,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",2048.0,N,1,,CHEMBL622166,,50597,11450,,Lung,A,,,Intermediate,,,
9512,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",2048.0,N,1,,CHEMBL622167,,50597,11450,,Lung,A,,,Intermediate,,,
9513,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",2048.0,N,1,,CHEMBL622168,,50597,11450,,Lung,A,,,Intermediate,,,
9514,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",2048.0,N,1,,CHEMBL622169,,50597,11450,,Lung,A,,,Intermediate,,,
9515,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",2048.0,N,1,,CHEMBL622170,,50597,11450,,Lung,A,,,Intermediate,,,
9516,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",2046.0,N,1,,CHEMBL622171,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9517,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",2046.0,N,1,,CHEMBL622172,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9518,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",2046.0,N,1,,CHEMBL622173,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9519,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",2046.0,N,1,,CHEMBL622174,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9520,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",2046.0,N,1,,CHEMBL622175,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9521,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",2046.0,N,1,,CHEMBL622176,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9522,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",2046.0,N,1,,CHEMBL622177,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9523,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",2046.0,N,1,,CHEMBL622178,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9524,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",2046.0,N,1,,CHEMBL622179,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9525,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",2046.0,N,1,,CHEMBL622180,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9526,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,1,,CHEMBL622181,,50597,16435,,,A,,,Intermediate,,,
9527,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,1,,CHEMBL622182,,50597,16435,,,A,,,Intermediate,,,
9528,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,1,,CHEMBL622183,,50597,16435,,,A,,,Intermediate,,,
9529,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,1,,CHEMBL622184,,50597,16435,,,A,,,Intermediate,,,
9530,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,1,,CHEMBL622185,,50597,16435,,,A,,,Intermediate,,,
9531,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,1,,CHEMBL622186,,50597,16435,,,A,,,Intermediate,,,
9532,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,1,,CHEMBL622187,,50597,16434,,,A,,,Intermediate,,,
9533,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,N,1,,CHEMBL625002,,50597,16434,,,A,,,Intermediate,,,
9534,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,N,1,,CHEMBL622090,,50597,16434,,,A,,,Intermediate,,,
9535,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,1,,CHEMBL622091,,50597,16435,,,A,,,Intermediate,,,
9536,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,1,,CHEMBL622092,,50597,16435,,,A,,,Intermediate,,,
9537,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,1,,CHEMBL622093,,50597,16435,,,A,,,Intermediate,,,
9538,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,1,,CHEMBL622094,,50597,16435,,,A,,,Intermediate,,,
9539,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,1,,CHEMBL622095,,50597,16435,,,A,,,Intermediate,,,
9540,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,1,,CHEMBL622264,,50597,16435,,,A,,,Intermediate,,,
9541,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2106.0,N,1,,CHEMBL622265,,50597,16434,,Spleen,A,,,Intermediate,,,
9542,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2106.0,N,1,,CHEMBL622266,,50597,16434,,Spleen,A,,,Intermediate,,,
9543,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2106.0,N,1,,CHEMBL622267,,50597,16434,,Spleen,A,,,Intermediate,,,
9544,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2106.0,N,1,,CHEMBL622268,,50597,16434,,Spleen,A,,,Intermediate,,,
9545,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2106.0,N,1,,CHEMBL622269,,50597,16434,,Spleen,A,,,Intermediate,,,
9546,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2106.0,N,1,,CHEMBL625071,,50597,16434,,Spleen,A,,,Intermediate,,,
9547,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2106.0,N,1,,CHEMBL621621,,50597,16434,,Spleen,A,,,Intermediate,,,
9548,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2106.0,N,1,,CHEMBL621622,,50597,16434,,Spleen,A,,,Intermediate,,,
9549,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2106.0,N,1,,CHEMBL621623,,50597,16435,,Spleen,A,,,Intermediate,,,
9550,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2106.0,N,1,,CHEMBL621624,,50597,16435,,Spleen,A,,,Intermediate,,,
9551,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2106.0,N,1,,CHEMBL621625,,50597,16435,,Spleen,A,,,Intermediate,,,
9552,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2106.0,N,1,,CHEMBL621626,,50597,16435,,Spleen,A,,,Intermediate,,,
9553,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2106.0,N,1,,CHEMBL621627,,50597,16435,,Spleen,A,,,Intermediate,,,
9554,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2106.0,N,1,,CHEMBL621628,,50597,16435,,Spleen,A,,,Intermediate,,,
9555,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2106.0,N,1,,CHEMBL875328,,50597,16435,,Spleen,A,,,Intermediate,,,
9556,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2106.0,N,1,,CHEMBL621629,,50597,16435,,Spleen,A,,,Intermediate,,,
9557,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2106.0,N,1,,CHEMBL621630,,50597,16434,,Spleen,A,,,Intermediate,,,
9558,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2106.0,N,1,,CHEMBL621631,,50597,16434,,Spleen,A,,,Intermediate,,,
9559,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2106.0,N,1,,CHEMBL621632,,50597,16434,,Spleen,A,,,Intermediate,,,
9560,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2106.0,N,1,,CHEMBL621633,,50597,16435,,Spleen,A,,,Intermediate,,,
9561,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2106.0,N,1,,CHEMBL621634,,50597,16435,,Spleen,A,,,Intermediate,,,
9562,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2106.0,N,1,,CHEMBL621635,,50597,16435,,Spleen,A,,,Intermediate,,,
9563,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2106.0,N,1,,CHEMBL621636,,50597,16435,,Spleen,A,,,Intermediate,,,
9564,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2106.0,N,1,,CHEMBL621637,,50597,16435,,Spleen,A,,,Intermediate,,,
9565,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2106.0,N,1,,CHEMBL621638,,50597,16435,,Spleen,A,,,Intermediate,,,
9566,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,1,,CHEMBL618883,,50597,16434,,,A,,,Intermediate,,,
9567,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,1,,CHEMBL618884,,50597,16434,,,A,,,Intermediate,,,
9568,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,1,,CHEMBL628627,,50597,16434,,,A,,,Intermediate,,,
9569,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,1,,CHEMBL628628,,50597,16434,,,A,,,Intermediate,,,
9570,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,1,,CHEMBL628629,,50597,16434,,,A,,,Intermediate,,,
9571,BAO_0000218,Half life after administering orally a dose of 3 mg/kg,,N,1,,CHEMBL628630,In vivo,50597,16365,,,A,,,Intermediate,,,
9572,BAO_0000218,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,N,1,,CHEMBL628631,In vivo,50597,16365,,,A,,,Intermediate,,,
9573,BAO_0000218,Half life after administering intravenously a dose of 1 mg/kg,,N,1,,CHEMBL628632,In vivo,50597,16365,,,A,,,Intermediate,,,
9574,BAO_0000218,Half life after oral dosing in rats,,N,1,,CHEMBL628633,In vivo,50597,526,,,A,,,Intermediate,,,
9575,BAO_0000218,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,N,1,,CHEMBL628634,In vivo,50597,16365,,,A,,,Intermediate,,,
9576,BAO_0000218,Half life by intravenous administration of 3.4 mg/kg in rat,,N,1,,CHEMBL627789,In vivo,50597,4368,,,A,,,Intermediate,,,
9577,BAO_0000218,Half life in rat,,N,1,,CHEMBL627790,,50597,3371,,,A,,,Intermediate,,,
9578,BAO_0000218,Half life in rat,,N,1,,CHEMBL627791,,50597,6448,,,A,,,Intermediate,,,
9579,BAO_0000218,Half life in rat,,N,1,,CHEMBL627792,,50597,6453,,,A,,,Intermediate,,,
9580,BAO_0000218,Half life in rat after intravenous administration of the compound,,N,1,,CHEMBL627793,In vivo,50597,4353,,,A,,,Intermediate,,,
9581,BAO_0000218,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1969.0,N,1,,CHEMBL627794,In vivo,50597,4353,,Plasma,A,,,Intermediate,,,
9582,BAO_0000218,Half life in rat after po administration of the compound,,N,1,,CHEMBL627795,In vivo,50597,4353,,,A,,,Intermediate,,,
9583,BAO_0000218,Half life in rat after po administration of the compound; ND means Not determined,,N,1,,CHEMBL627796,In vivo,50597,4353,,,A,,,Intermediate,,,
9584,BAO_0000218,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1969.0,N,1,,CHEMBL875335,In vivo,50597,4353,,Plasma,A,,,Intermediate,,,
9585,BAO_0000218,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1969.0,N,1,,CHEMBL627797,In vivo,50597,4353,,Plasma,A,,,Intermediate,,,
9586,BAO_0000218,Half life in rat i.v.,,N,1,,CHEMBL627798,In vivo,50597,5789,,,A,,,Intermediate,,,
9587,BAO_0000218,Half life in rat i.v. at 2 mg/kg concentration,,N,1,,CHEMBL627799,In vivo,50597,17686,,,A,,,Intermediate,,,
9588,BAO_0000218,Half life in rats,,N,1,,CHEMBL627800,,50597,6495,,,A,,,Intermediate,,,
9589,BAO_0000218,Half life in rats after intravenous administration,,N,1,,CHEMBL627801,In vivo,50597,484,,,A,,,Intermediate,,,
9590,BAO_0000218,Half life in rats at the dose of 1.0 mpk by i.v. administration,,N,1,,CHEMBL627802,In vivo,50597,6467,,,A,,,Intermediate,,,
9591,BAO_0000218,Half life in rat,,N,1,,CHEMBL627803,,50597,6642,,,A,,,Expert,,,
9592,BAO_0000218,Half life was evaluated after intravenous administration to rats,,N,1,,CHEMBL873820,In vivo,50597,16367,,,A,,,Intermediate,,,
9593,BAO_0000218,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,N,1,,CHEMBL627804,,50597,1369,,,A,,,Intermediate,,,
9594,BAO_0000218,Half life was evaluated in rat,,N,1,,CHEMBL627805,,50597,5472,,,A,,,Intermediate,,,
9595,BAO_0000218,Half life was evaluated in rat,,N,1,,CHEMBL627806,,50597,6049,,,A,,,Intermediate,,,
9596,BAO_0000218,Half life was evaluated in rat; Not tested,,N,1,,CHEMBL627107,,50597,5472,,,A,,,Intermediate,,,
9597,BAO_0000218,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,N,1,,CHEMBL627108,In vivo,50597,16366,,,A,,,Intermediate,,,
9598,BAO_0000218,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,N,1,,CHEMBL627109,In vivo,50597,11149,,,A,,,Intermediate,,,
9599,BAO_0000218,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,178.0,N,1,,CHEMBL627110,In vivo,50597,11149,,Blood,A,,,Intermediate,,,
9600,BAO_0000218,Half life was measured in monkey at dose of 10 mg/kg by po administration,,U,1,,CHEMBL627111,In vivo,22224,2891,,,A,,,Intermediate,,,
9601,BAO_0000218,Half life was measured in monkey at dose of 10 mg/kg by po administration,,U,1,,CHEMBL627112,In vivo,22224,2891,,,A,,,Intermediate,,,
9602,BAO_0000218,Half life was measured in rat at dose of 30 mg/kg by iv administration,,U,1,,CHEMBL627113,In vivo,22224,2891,,,A,,,Intermediate,,,
9603,BAO_0000218,Half life was measured in rat at dose of 30 mg/kg by po administration,,U,1,,CHEMBL627114,In vivo,22224,2891,,,A,,,Intermediate,,,
9604,BAO_0000218,Half life (t1/2) was determined,,N,1,,CHEMBL627115,,50597,4026,,,A,,,Intermediate,,,
9605,BAO_0000218,Half life period at a dose of 10 uM/kg in rat was determined,,N,1,,CHEMBL627116,,50597,4527,,,A,,,Intermediate,,,
9606,BAO_0000218,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,N,1,,CHEMBL627117,In vivo,50597,4527,,,A,,,Intermediate,,,
9607,BAO_0000218,Half life period was determined,,N,1,,CHEMBL627118,,50597,5503,,,A,,,Intermediate,,,
9608,BAO_0000218,Half life period after intravenous administration at 20 mpk in rats,,N,1,,CHEMBL627119,In vivo,50597,4426,,,A,,,Intermediate,,,
9609,BAO_0000218,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,N,1,,CHEMBL627120,In vivo,50597,4426,,,A,,,Intermediate,,,
9610,BAO_0000218,Half life period after intravenous administration in rat,,N,1,,CHEMBL626922,In vivo,50597,6109,,,A,,,Intermediate,,,
9611,BAO_0000218,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,1,,CHEMBL626923,In vivo,50597,5654,,,A,,,Intermediate,,,
9612,BAO_0000218,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,1,,CHEMBL626924,In vivo,50597,5654,,,A,,,Intermediate,,,
9613,BAO_0000218,Half life period in 80% rat plasma at 37 degree Centigrade,1969.0,N,1,,CHEMBL626925,,50597,4755,,Plasma,A,,,Intermediate,,,
9614,BAO_0000218,Half life period in SD rats,,N,1,,CHEMBL626926,,50597,5862,,,A,,,Intermediate,,,
9615,BAO_0000218,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1969.0,N,1,,CHEMBL626927,,50597,1515,,Plasma,A,,,Intermediate,,,
9616,BAO_0000218,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1969.0,N,1,,CHEMBL626928,,50597,1515,,Plasma,A,,,Intermediate,,,
9617,BAO_0000218,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,N,1,,CHEMBL626929,,50597,1515,,Plasma,A,,,Intermediate,,,
9618,BAO_0000218,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,N,1,,CHEMBL626930,,50597,1515,,Plasma,A,,,Intermediate,,,
9619,BAO_0000218,Half life period in rat,,N,1,,CHEMBL626931,,50597,5960,,,A,,,Intermediate,,,
9620,BAO_0000218,Half life period in rat,,N,1,,CHEMBL626932,,50597,6103,,,A,,,Intermediate,,,
9621,BAO_0000218,Half life period in rat,,N,1,,CHEMBL626933,,50597,6317,,,A,,,Intermediate,,,
9622,BAO_0000218,Half life period in rat after oral administration at 10.5 mg/kg dose,,N,1,,CHEMBL873826,In vivo,50597,6644,,,A,,,Intermediate,,,
9623,BAO_0000218,Half life period in rat after oral administration at 11.2 mg/kg dose,,N,1,,CHEMBL626934,In vivo,50597,6644,,,A,,,Intermediate,,,
9624,BAO_0000218,Half life period in rat after oral administration at 13 mg/kg dose,,N,1,,CHEMBL626935,In vivo,50597,6644,,,A,,,Intermediate,,,
9625,BAO_0000218,Half life period in rat after oral administration at 9.7 mg/kg dose,,N,1,,CHEMBL626936,In vivo,50597,6644,,,A,,,Intermediate,,,
9626,BAO_0000218,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL626937,,50597,5974,,,A,,,Intermediate,,,
9627,BAO_0000218,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,N,1,,CHEMBL625906,,50597,6295,,,A,,,Intermediate,,,
9628,BAO_0000218,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,N,1,,CHEMBL625907,,50597,6296,,,A,,,Intermediate,,,
9629,BAO_0000218,PK study was carried to determine AUC (area under curve) value in rat,,N,1,,CHEMBL625908,,50597,16427,,,A,,,Intermediate,,,
9630,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to rats,,N,1,,CHEMBL625909,,50597,16367,,,A,,,Intermediate,,,
9631,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to rats,,N,1,,CHEMBL625910,,50597,16367,,,A,,,Intermediate,,,
9632,BAO_0000218,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,N,1,,CHEMBL625911,,50597,16365,,,A,,,Intermediate,,,
9633,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,N,1,,CHEMBL625912,,50597,16365,,,A,,,Intermediate,,,
9634,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,N,1,,CHEMBL626538,,50597,16365,,,A,,,Intermediate,,,
9635,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,N,1,,CHEMBL876794,,50597,16365,,,A,,,Intermediate,,,
9636,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,N,1,,CHEMBL626539,,50597,16365,,,A,,,Intermediate,,,
9637,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,N,1,,CHEMBL626540,,50597,16365,,,A,,,Intermediate,,,
9638,BAO_0000218,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,N,1,,CHEMBL626541,,50597,5394,,,A,,,Intermediate,,,
9639,BAO_0000218,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,N,1,,CHEMBL626542,,50597,5394,,,A,,,Intermediate,,,
9640,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,N,1,,CHEMBL626543,,50597,2792,,,A,,,Intermediate,,,
9641,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,N,1,,CHEMBL626544,,50597,2792,,,A,,,Intermediate,,,
9642,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,N,1,,CHEMBL626545,,50597,2792,,,A,,,Intermediate,,,
9643,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,N,1,,CHEMBL626546,,50597,2792,,,A,,,Intermediate,,,
9644,BAO_0000218,Pharmacokinetic parameter area under curve was reported,,N,1,,CHEMBL626547,,50597,5334,,,A,,,Intermediate,,,
9645,BAO_0000218,Pharmacokinetic property (AUC) in rat,,N,1,,CHEMBL626548,,50597,4408,,,A,,,Intermediate,,,
9646,BAO_0000218,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,N,1,,CHEMBL626549,,50597,5983,,,A,,,Intermediate,,,
9647,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,N,1,,CHEMBL626550,,50597,4397,,,A,,,Intermediate,,,
9648,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,N,1,,CHEMBL626551,,50597,4397,,,A,,,Intermediate,,,
9649,BAO_0000218,Pharmacokinetic property was determined,,N,1,,CHEMBL623777,,50597,5491,,,A,,,Intermediate,,,
9650,BAO_0000218,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,N,1,,CHEMBL623778,,50597,5491,,,A,,,Intermediate,,,
9651,BAO_0000218,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,N,1,,CHEMBL623779,,50597,5491,,,A,,,Intermediate,,,
9652,BAO_0000218,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,N,1,,CHEMBL623780,,50597,4199,,Plasma,A,,,Intermediate,,,
9653,BAO_0000218,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,N,1,,CHEMBL622015,,50597,4199,,Plasma,A,,,Intermediate,,,
9654,BAO_0000218,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,N,1,,CHEMBL622016,,50597,4199,,Plasma,A,,,Intermediate,,,
9655,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,N,1,,CHEMBL622017,,50597,5173,,,A,,,Intermediate,,,
9656,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,N,1,,CHEMBL622018,,50597,5173,,,A,,,Intermediate,,,
9657,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,N,1,,CHEMBL622019,,50597,5173,,,A,,,Intermediate,,,
9658,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,N,1,,CHEMBL622020,,50597,5173,,,A,,,Intermediate,,,
9659,BAO_0000218,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,N,1,,CHEMBL622021,,50597,16366,,,A,,,Intermediate,,,
9660,BAO_0000218,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,N,1,,CHEMBL622022,,50597,16366,,,A,,,Intermediate,,,
9661,BAO_0000218,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,N,1,,CHEMBL622023,,50597,5327,,,A,,,Intermediate,,,
9662,BAO_0000218,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,N,1,,CHEMBL622024,,50597,6681,,,A,,,Intermediate,,,
9663,BAO_0000218,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,N,1,,CHEMBL622693,,50597,12873,,,A,,,Intermediate,,,
9664,BAO_0000218,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,N,1,,CHEMBL622694,,50597,12873,,,A,,,Intermediate,,,
9665,BAO_0000218,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,N,1,,CHEMBL622695,,50597,6685,,,A,,,Intermediate,,,
9666,BAO_0000218,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,N,1,,CHEMBL622696,,50597,6685,,,A,,,Intermediate,,,
9667,BAO_0000218,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,N,1,,CHEMBL622697,,50597,6685,,,A,,,Intermediate,,,
9668,BAO_0000218,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,N,1,,CHEMBL622874,,50597,6619,,,A,,,Intermediate,,,
9669,BAO_0000218,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,N,1,,CHEMBL622875,,50597,6619,,,A,,,Intermediate,,,
9670,BAO_0000218,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,N,1,,CHEMBL622876,,50597,10363,,,A,,,Intermediate,,,
9671,BAO_0000218,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,N,1,,CHEMBL622877,,50597,4796,,,A,,,Intermediate,,,
9672,BAO_0000218,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,N,1,,CHEMBL622878,,50597,4910,,,A,,,Intermediate,,,
9673,BAO_0000218,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1969.0,N,1,,CHEMBL622879,,50597,4910,,Plasma,A,,,Intermediate,,,
9674,BAO_0000218,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,N,1,,CHEMBL877602,,50597,4839,,,A,,,Intermediate,,,
9675,BAO_0000218,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL622880,,50597,15078,,,A,,,Intermediate,,,
9676,BAO_0000218,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL622881,,50597,15078,,,A,,,Intermediate,,,
9677,BAO_0000218,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL622882,,50597,15078,,,A,,,Intermediate,,,
9678,BAO_0000218,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL622883,,50597,15078,,,A,,,Intermediate,,,
9679,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",2046.0,N,1,,CHEMBL622884,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9680,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",2046.0,N,1,,CHEMBL622885,,50597,11450,,Thyroid gland,A,,,Intermediate,,,
9681,BAO_0000218,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,N,1,,CHEMBL622886,,50597,8151,,,A,,,Intermediate,,,
9682,BAO_0000218,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,N,1,,CHEMBL622887,,50597,8151,,,A,,,Intermediate,,,
9683,BAO_0000218,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,N,1,,CHEMBL622888,,50597,8151,,Urine,A,,,Intermediate,,,
9684,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",178.0,N,1,,CHEMBL622889,In vivo,50597,8677,,Blood,A,,,Intermediate,,,
9685,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",178.0,N,1,,CHEMBL622890,In vivo,50597,8677,,Blood,A,,,Intermediate,,,
9686,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",178.0,N,1,,CHEMBL622891,In vivo,50597,8677,,Blood,A,,,Intermediate,,,
9687,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",178.0,N,1,,CHEMBL877603,In vivo,50597,8677,,Blood,A,,,Intermediate,,,
9688,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",955.0,N,1,,CHEMBL622892,In vivo,50597,8677,,Brain,A,,,Intermediate,,,
9689,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",955.0,N,1,,CHEMBL622893,In vivo,50597,8677,,Brain,A,,,Intermediate,,,
9690,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",955.0,N,1,,CHEMBL622894,In vivo,50597,8677,,Brain,A,,,Intermediate,,,
9691,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",955.0,N,1,,CHEMBL622895,In vivo,50597,8677,,Brain,A,,,Intermediate,,,
9692,BAO_0000218,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,955.0,N,1,,CHEMBL622896,In vivo,50597,8677,,Brain,A,,,Intermediate,,,
9693,BAO_0000218,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",948.0,N,1,,CHEMBL622897,In vivo,50597,8677,,Heart,A,,,Intermediate,,,
9694,BAO_0000218,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",948.0,N,1,,CHEMBL622898,In vivo,50597,8677,,Heart,A,,,Intermediate,,,
9695,BAO_0000218,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",948.0,N,1,,CHEMBL622899,In vivo,50597,8677,,Heart,A,,,Intermediate,,,
9696,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,N,1,,CHEMBL622900,In vivo,50597,8677,,Kidney,A,,,Intermediate,,,
9697,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2113.0,N,1,,CHEMBL624114,In vivo,50597,8677,,Kidney,A,,,Intermediate,,,
9698,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,N,1,,CHEMBL624115,In vivo,50597,8677,,Kidney,A,,,Intermediate,,,
9699,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2113.0,N,1,,CHEMBL624116,In vivo,50597,8677,,Kidney,A,,,Intermediate,,,
9700,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2107.0,N,1,,CHEMBL624117,In vivo,50597,8677,,Liver,A,,,Intermediate,,,
9701,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2107.0,N,1,,CHEMBL624118,In vivo,50597,8677,,Liver,A,,,Intermediate,,,
9702,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2107.0,N,1,,CHEMBL624119,In vivo,50597,8677,,Liver,A,,,Intermediate,,,
9703,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2107.0,N,1,,CHEMBL624120,In vivo,50597,8677,,Liver,A,,,Intermediate,,,
9704,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2048.0,N,1,,CHEMBL624121,In vivo,50597,8677,,Lung,A,,,Intermediate,,,
9705,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2048.0,N,1,,CHEMBL624122,In vivo,50597,8677,,Lung,A,,,Intermediate,,,
9706,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2048.0,N,1,,CHEMBL624123,In vivo,50597,8677,,Lung,A,,,Intermediate,,,
9707,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2048.0,N,1,,CHEMBL624124,In vivo,50597,8677,,Lung,A,,,Intermediate,,,
9708,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,N,1,,CHEMBL624125,In vivo,50597,8677,,Muscle tissue,A,,,Intermediate,,,
9709,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2385.0,N,1,,CHEMBL624126,In vivo,50597,8677,,Muscle tissue,A,,,Intermediate,,,
9710,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,N,1,,CHEMBL624127,In vivo,50597,8677,,Muscle tissue,A,,,Intermediate,,,
9711,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2385.0,N,1,,CHEMBL624128,In vivo,50597,8677,,Muscle tissue,A,,,Intermediate,,,
9712,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",14.0,N,1,,CHEMBL624129,In vivo,50597,8677,,Zone of skin,A,,,Intermediate,,,
9713,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",14.0,N,1,,CHEMBL624130,In vivo,50597,8677,,Zone of skin,A,,,Intermediate,,,
9714,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",14.0,N,1,,CHEMBL622340,In vivo,50597,8677,,Zone of skin,A,,,Intermediate,,,
9715,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",14.0,N,1,,CHEMBL622341,In vivo,50597,8677,,Zone of skin,A,,,Intermediate,,,
9716,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",160.0,N,1,,CHEMBL622342,In vivo,50597,8677,,Intestine,A,,,Intermediate,,,
9717,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",160.0,N,1,,CHEMBL622343,In vivo,50597,8677,,Intestine,A,,,Intermediate,,,
9718,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",160.0,N,1,,CHEMBL622344,In vivo,50597,8677,,Intestine,A,,,Intermediate,,,
9719,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",160.0,N,1,,CHEMBL622345,In vivo,50597,8677,,Intestine,A,,,Intermediate,,,
9720,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2106.0,N,1,,CHEMBL622346,In vivo,50597,8677,,Spleen,A,,,Intermediate,,,
9721,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2106.0,N,1,,CHEMBL622347,In vivo,50597,8677,,Spleen,A,,,Intermediate,,,
9722,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2106.0,N,1,,CHEMBL622348,In vivo,50597,8677,,Spleen,A,,,Intermediate,,,
9723,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2106.0,N,1,,CHEMBL622349,In vivo,50597,8677,,Spleen,A,,,Intermediate,,,
9724,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,1,,CHEMBL622350,,50597,16434,,,A,,,Intermediate,,,
9725,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,1,,CHEMBL622351,,50597,16434,,,A,,,Intermediate,,,
9726,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,1,,CHEMBL622352,,50597,16434,,,A,,,Intermediate,,,
9727,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,1,,CHEMBL622353,,50597,16435,,,A,,,Intermediate,,,
9728,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,1,,CHEMBL622354,,50597,16435,,,A,,,Intermediate,,,
9729,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,1,,CHEMBL622355,,50597,16435,,,A,,,Intermediate,,,
9730,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,1,,CHEMBL622356,,50597,16435,,,A,,,Intermediate,,,
9731,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,1,,CHEMBL622357,,50597,16435,,,A,,,Intermediate,,,
9732,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,1,,CHEMBL622358,,50597,16435,,,A,,,Intermediate,,,
9733,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,1,,CHEMBL622359,,50597,16435,,,A,,,Intermediate,,,
9734,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,1,,CHEMBL874393,,50597,16435,,,A,,,Intermediate,,,
9735,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,1,,CHEMBL622872,,50597,16434,,,A,,,Intermediate,,,
9736,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,1,,CHEMBL622873,,50597,16434,,,A,,,Intermediate,,,
9737,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,1,,CHEMBL623047,,50597,16434,,,A,,,Intermediate,,,
9738,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,1,,CHEMBL623048,,50597,16435,,,A,,,Intermediate,,,
9739,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,1,,CHEMBL623049,,50597,16435,,,A,,,Intermediate,,,
9740,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,1,,CHEMBL623050,,50597,16435,,,A,,,Intermediate,,,
9741,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,1,,CHEMBL623051,,50597,16435,,,A,,,Intermediate,,,
9742,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,1,,CHEMBL623052,,50597,16435,,,A,,,Intermediate,,,
9743,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,1,,CHEMBL626343,,50597,16435,,,A,,,Intermediate,,,
9744,BAO_0000218,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,1,,CHEMBL626344,,50597,16434,,,A,,,Intermediate,,,
9745,BAO_0000218,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,1,,CHEMBL626345,,50597,16434,,,A,,,Intermediate,,,
9746,BAO_0000218,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,1,,CHEMBL626346,,50597,16434,,,A,,,Intermediate,,,
9747,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,1,,CHEMBL626347,,50597,16434,,,A,,,Intermediate,,,
9748,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,1,,CHEMBL626348,,50597,16434,,,A,,,Intermediate,,,
9749,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,1,,CHEMBL626349,,50597,16434,,,A,,,Intermediate,,,
9750,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,1,,CHEMBL626350,,50597,16435,,,F,,,Intermediate,,,
9751,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,1,,CHEMBL626351,,50597,16435,,,A,,,Intermediate,,,
9752,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,1,,CHEMBL627650,,50597,16435,,,A,,,Intermediate,,,
9753,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,1,,CHEMBL627651,,50597,16435,,,F,,,Intermediate,,,
9754,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,1,,CHEMBL627652,,50597,16435,,,A,,,Intermediate,,,
9755,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,1,,CHEMBL627653,,50597,16435,,,A,,,Intermediate,,,
9756,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,N,1,,CHEMBL627654,,50597,13091,,,A,,,Intermediate,,,
9757,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,N,1,,CHEMBL627835,,50597,13091,,,A,,,Intermediate,,,
9758,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,N,1,,CHEMBL627836,,50597,13091,,,A,,,Intermediate,,,
9759,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,N,1,,CHEMBL627837,,50597,13091,,,A,,,Intermediate,,,
9760,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,N,1,,CHEMBL627838,,50597,13091,,,A,,,Intermediate,,,
9761,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,N,1,,CHEMBL875338,,50597,13091,,,A,,,Intermediate,,,
9762,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,N,1,,CHEMBL627839,,50597,13091,,,A,,,Intermediate,,,
9763,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,N,1,,CHEMBL627840,,50597,13091,,,A,,,Intermediate,,,
9764,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,N,1,,CHEMBL627841,,50597,13091,,,A,,,Intermediate,,,
9765,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,N,1,,CHEMBL627842,,50597,13091,,,A,,,Intermediate,,,
9766,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,N,1,,CHEMBL627843,,50597,13091,,,A,,,Intermediate,,,
9767,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,N,1,,CHEMBL627844,,50597,13091,,,A,,,Intermediate,,,
9768,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,N,1,,CHEMBL627845,,50597,13091,,,A,,,Intermediate,,,
9769,BAO_0000218,Half life period in rat by iv administration at a dose of 3 mg/kg,,N,1,,CHEMBL627846,In vivo,50597,5874,,,A,,,Intermediate,,,
9770,BAO_0000218,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1969.0,N,1,,CHEMBL627847,,50597,1515,,Plasma,A,,,Intermediate,,,
9771,BAO_0000218,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1969.0,N,1,,CHEMBL873821,,50597,1515,,Plasma,A,,,Intermediate,,,
9772,BAO_0000218,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,N,1,,CHEMBL626079,,50597,1515,,Plasma,A,,,Intermediate,,,
9773,BAO_0000218,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,N,1,,CHEMBL626080,,50597,1515,,Plasma,A,,,Intermediate,,,
9774,BAO_0000218,Half life period was evaluated in rat plasma,1969.0,N,1,,CHEMBL626081,,50597,5491,,Plasma,A,,,Intermediate,,,
9775,BAO_0000218,Half life period was evaluated in rat plasma; Not tested,1969.0,N,1,,CHEMBL875344,,50597,5491,,Plasma,A,,,Intermediate,,,
9776,BAO_0000218,Half life period was evaluated in rats,,N,1,,CHEMBL626082,,50597,1918,,,A,,,Intermediate,,,
9777,BAO_0000218,"Half life period was evaluated in rats, iv",,N,1,,CHEMBL626250,In vivo,50597,1918,,,A,,,Intermediate,,,
9778,BAO_0000218,Half life period after intravenous administration at 5 mg/kg in rat,,N,1,,CHEMBL626251,In vivo,50597,6113,,,A,,,Intermediate,,,
9779,BAO_0000218,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,N,1,,CHEMBL626252,In vivo,50597,5546,,,A,,,Intermediate,,,
9780,BAO_0000218,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,N,1,,CHEMBL626253,In vivo,50597,5553,,,A,,,Intermediate,,,
9781,BAO_0000218,Half life stability of compound was evaluated in rat plasma,1969.0,N,1,,CHEMBL626254,,50597,4188,,Plasma,A,,,Intermediate,,,
9782,BAO_0000218,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,N,1,,CHEMBL626255,In vivo,50597,6215,,,A,,,Intermediate,,,
9783,BAO_0000218,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,N,1,,CHEMBL626256,In vivo,50597,6141,,,A,,,Intermediate,,,
9784,BAO_0000218,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,N,1,,CHEMBL626257,In vivo,50597,5182,,,A,,,Intermediate,,,
9785,BAO_0000218,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,N,1,,CHEMBL626258,In vivo,50597,5182,,,A,,,Intermediate,,,
9786,BAO_0000218,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,N,1,,CHEMBL626259,In vivo,50597,5710,,,A,,,Intermediate,,,
9787,BAO_0000218,Half in rat i.v.,,N,1,,CHEMBL626260,In vivo,50597,5789,,,A,,,Intermediate,,,
9788,BAO_0000218,Half period in rat after intravenous administration,,N,1,,CHEMBL875345,In vivo,50597,6011,,,A,,,Intermediate,,,
9789,BAO_0000218,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,N,1,,CHEMBL626261,In vivo,50597,17594,,,A,,,Intermediate,,,
9790,BAO_0000218,Half-life measured in in vitro Cathepsin B assay in rat liver,2107.0,N,1,,CHEMBL626262,In vitro,50597,12357,,Liver,A,,,Intermediate,,,
9791,BAO_0000218,Half-life of compound was determined in rats,,N,1,,CHEMBL626263,,50597,5210,,,A,,,Intermediate,,,
9792,BAO_0000218,Half-life at 10 mg/kg in rat upon intravenous administration,,N,1,,CHEMBL625270,In vivo,50597,17596,,,A,,,Intermediate,,,
9793,BAO_0000218,Half-life determined in rat,,N,1,,CHEMBL625271,,50597,6672,,,A,,,Intermediate,,,
9794,BAO_0000218,Half-life determined in rat,,N,1,,CHEMBL625272,,50597,6673,,,A,,,Intermediate,,,
9795,BAO_0000218,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,955.0,N,1,,CHEMBL625273,In vivo,50597,4910,,Brain,A,,,Intermediate,,,
9796,BAO_0000218,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1969.0,N,1,,CHEMBL625274,,50597,3741,,Plasma,A,,,Intermediate,,,
9797,BAO_0000218,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,1,,CHEMBL625275,In vivo,50597,17671,,,A,,,Intermediate,,,
9798,BAO_0000218,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1969.0,N,1,,CHEMBL625276,In vivo,50597,4910,,Plasma,A,,,Intermediate,,,
9799,BAO_0000218,Half-life in rat plasma,1969.0,N,1,,CHEMBL625277,,50597,17537,,Plasma,A,,,Intermediate,,,
9800,BAO_0000218,Half-life in rat plasma was determined,1969.0,N,1,,CHEMBL625278,,50597,4965,,Plasma,A,,,Intermediate,,,
9801,BAO_0000218,Half-life in rat plasma; Not tested,1969.0,N,1,,CHEMBL625279,,50597,17537,,Plasma,A,,,Intermediate,,,
9802,BAO_0000218,Half-life in rat serum,1977.0,N,1,,CHEMBL625280,,50597,6124,,Serum,A,,,Intermediate,,,
9803,BAO_0000218,Half-life in rat serum; na is not available,1977.0,N,1,,CHEMBL876797,,50597,6124,,Serum,A,,,Intermediate,,,
9804,BAO_0000218,Half-life was calculated in rat,,N,1,,CHEMBL625281,,50597,6078,,,A,,,Intermediate,,,
9805,BAO_0000218,Half-life was calculated in rat plasma,1969.0,N,1,,CHEMBL873827,,50597,17668,,Plasma,A,,,Intermediate,,,
9806,BAO_0000218,Half-life was determined,,N,1,,CHEMBL625282,,50597,3185,,,A,,,Intermediate,,,
9807,BAO_0000218,Half-life was determined,,N,1,,CHEMBL625283,,50597,4883,,,A,,,Intermediate,,,
9808,BAO_0000218,Half-life after administration of 20 mg/Kg oral dose in rat,,N,1,,CHEMBL625284,In vivo,50597,2959,,,A,,,Intermediate,,,
9809,BAO_0000218,Half-life after administration of 3.2 mg/kg intravenously in male rat,,N,1,,CHEMBL625285,In vivo,50597,4029,,,A,,,Intermediate,,,
9810,BAO_0000218,Half-life after intravenous administration in female rat,,N,1,,CHEMBL625286,In vivo,50597,4029,,,A,,,Intermediate,,,
9811,BAO_0000218,Half-life after intravenous administration in male rat,,N,1,,CHEMBL625287,In vivo,50597,4029,,,A,,,Intermediate,,,
9812,BAO_0000218,Half-life after intravenous dose in rat,,N,1,,CHEMBL625288,In vivo,50597,6180,,,A,,,Intermediate,,,
9813,BAO_0000218,Half-life in a rat liver homogenate preparation,2107.0,N,1,,CHEMBL625289,,50597,1557,,Liver,A,,,Intermediate,,,
9814,BAO_0000218,Half-life in plasma of rat,1969.0,N,1,,CHEMBL625290,,50597,12500,,Plasma,A,,,Intermediate,,,
9815,BAO_0000218,Half-life in plasma of rat at dose of 3-10 mgkg,1969.0,N,1,,CHEMBL876798,,50597,12500,,Plasma,A,,,Intermediate,,,
9816,BAO_0000218,Half-life in rat,,N,1,,CHEMBL625291,,50597,5064,,,A,,,Intermediate,,,
9817,BAO_0000218,Half-life in rat,,N,1,,CHEMBL625292,,50597,5145,,,A,,,Intermediate,,,
9818,BAO_0000218,Half-life in rat,,N,1,,CHEMBL625293,,50597,5147,,,A,,,Intermediate,,,
9819,BAO_0000218,Half-life in rat,,N,1,,CHEMBL622832,,50597,5833,,,A,,,Intermediate,,,
9820,BAO_0000218,Half-life in rat,,N,1,,CHEMBL622833,,50597,6596,,,A,,,Intermediate,,,
9821,BAO_0000218,Half-life in rat,,N,1,,CHEMBL622834,,50597,17655,,,A,,,Intermediate,,,
9822,BAO_0000218,Half-life in rat after oral administration at 10 mg/kg,,N,1,,CHEMBL622835,In vivo,50597,6495,,,A,,,Intermediate,,,
9823,BAO_0000218,Half-life in rat after po administration at a dose of 10 mg/kg,,N,1,,CHEMBL622836,In vivo,50597,17538,,,A,,,Intermediate,,,
9824,BAO_0000218,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,N,1,,CHEMBL622837,In vivo,50597,17538,,,A,,,Intermediate,,,
9825,BAO_0000218,Half-life in rat at 3 mg/kg dose administered intravenously,,N,1,,CHEMBL622838,In vivo,50597,10,,,A,,,Intermediate,,,
9826,BAO_0000218,Half-life in rat brain homogenate,955.0,N,1,,CHEMBL622839,,50597,17669,,Brain,A,,,Intermediate,,,
9827,BAO_0000218,Half-life in rat plasma,1969.0,N,1,,CHEMBL622840,,50597,17065,,Plasma,A,,,Intermediate,,,
9828,BAO_0000218,Half-life in rats,,N,1,,CHEMBL622841,,50597,4333,,,A,,,Intermediate,,,
9829,BAO_0000218,Half-life in Dawley rats,,N,1,,CHEMBL622842,,50597,6827,,,A,,,Intermediate,,,
9830,BAO_0000218,Half-life in vitro in rat plasma,1969.0,N,1,,CHEMBL622843,In vitro,50597,889,,Plasma,A,,,Intermediate,,,
9831,BAO_0000218,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1969.0,N,1,,CHEMBL622844,In vitro,50597,889,,Plasma,A,,,Intermediate,,,
9832,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,N,1,,CHEMBL622845,,50597,3747,,,A,,,Intermediate,,,
9833,BAO_0000218,The area under the curve of compound was measured at the dose of 100 umol/kg,,N,1,,CHEMBL622846,,50597,15022,,,A,,,Intermediate,,,
9834,BAO_0000218,The area under the curve of compound was measured at the dose of 300 umol/kg,,N,1,,CHEMBL622847,,50597,15022,,,A,,,Intermediate,,,
9835,BAO_0000218,The area under the curve of compound was measured at the dose of 30 umol/kg,,N,1,,CHEMBL622848,,50597,15022,,,A,,,Intermediate,,,
9836,BAO_0000218,Bioavailability as oral AUC in rats,,N,1,,CHEMBL622849,In vivo,50597,3360,,,A,,,Intermediate,,,
9837,BAO_0000218,The plasma concentration versus time curve (AUC) was determined,1969.0,N,1,,CHEMBL622850,,50597,5334,,Plasma,A,,,Intermediate,,,
9838,BAO_0000218,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL876807,,50597,17411,,,A,,,Intermediate,,,
9839,BAO_0000218,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL622851,,50597,17411,,,A,,,Intermediate,,,
9840,BAO_0000218,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL622852,,50597,17411,,,A,,,Intermediate,,,
9841,BAO_0000218,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,N,1,,CHEMBL622853,,50597,6570,,,A,,,Intermediate,,,
9842,BAO_0000218,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,N,1,,CHEMBL622854,,50597,6570,,,A,,,Intermediate,,,
9843,BAO_0000218,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,1,,CHEMBL622855,,50597,17411,,,A,,,Intermediate,,,
9844,BAO_0000218,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1969.0,N,1,,CHEMBL622856,,50597,14941,,Plasma,A,,,Intermediate,,,
9845,BAO_0000218,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1969.0,N,1,,CHEMBL622857,,50597,14941,,Plasma,A,,,Intermediate,,,
9846,BAO_0000218,AUC in rat after po administration at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL622858,,50597,17538,,Plasma,A,,,Intermediate,,,
9847,BAO_0000218,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1969.0,N,1,,CHEMBL622859,,50597,17752,,Plasma,A,,,Intermediate,,,
9848,BAO_0000218,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,N,1,,CHEMBL622860,,50597,17509,,,A,,,Intermediate,,,
9849,BAO_0000218,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,N,1,,CHEMBL622861,,50597,17509,,,A,,,Intermediate,,,
9850,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,N,1,,CHEMBL622862,,50597,17509,,,A,,,Intermediate,,,
9851,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,N,1,,CHEMBL622863,,50597,17509,,,A,,,Intermediate,,,
9852,BAO_0000218,Area under curve value 6 hr after po administration in rat,,N,1,,CHEMBL623817,,50597,17509,,,A,,,Intermediate,,,
9853,BAO_0000218,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,1,,CHEMBL623818,,50597,17717,,,A,,,Intermediate,,,
9854,BAO_0000218,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,N,1,,CHEMBL623819,,50597,17717,,,A,,,Intermediate,,,
9855,BAO_0000218,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,1,,CHEMBL623820,,50597,17717,,,A,,,Intermediate,,,
9856,BAO_0000218,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,N,1,,CHEMBL623821,,50597,17717,,,A,,,Intermediate,,,
9857,BAO_0000218,AUC normalized for dose (AUCN) in rat,1969.0,N,1,,CHEMBL623822,,50597,6642,,Plasma,A,,,Intermediate,,,
9858,BAO_0000218,Area under curve in rat after p.o. administration,,N,1,,CHEMBL623823,,50597,6640,,,A,,,Intermediate,,,
9859,BAO_0000218,Area under curve in rat after p.o. administration,,N,1,,CHEMBL623824,,50597,6641,,,A,,,Intermediate,,,
9860,BAO_0000218,Area under curve in rat after p.o. administration; Not determined,,N,1,,CHEMBL623825,,50597,6641,,,A,,,Intermediate,,,
9861,BAO_0000218,Area under curve in rat after peroral administration,,N,1,,CHEMBL622070,,50597,6641,,,A,,,Intermediate,,,
9862,BAO_0000218,Area under curve (carotid artery) value of the compound,,N,1,,CHEMBL622071,,50597,3603,,,A,,,Intermediate,,,
9863,BAO_0000218,Bioavailability expressed as the area under curve of rat carotid artery,,N,1,,CHEMBL622072,,50597,3550,,,A,,,Intermediate,,,
9864,BAO_0000218,Area under curve in male SD rats was observed after intravenous administration in rat,,N,1,,CHEMBL622073,,50597,15662,,,A,,,Intermediate,,,
9865,BAO_0000218,Area under curve of the compound was determined,,N,1,,CHEMBL622074,,50597,17720,,,A,,,Intermediate,,,
9866,BAO_0000218,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,N,1,,CHEMBL622075,,50597,5407,,,A,,,Intermediate,,,
9867,BAO_0000218,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1969.0,N,1,,CHEMBL622076,,50597,17752,,Plasma,A,,,Intermediate,,,
9868,BAO_0000218,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1969.0,N,1,,CHEMBL622077,,50597,17752,,Plasma,A,,,Intermediate,,,
9869,BAO_0000218,Area under curve (portal vein) value of the compound,,N,1,,CHEMBL622078,,50597,3603,,,A,,,Intermediate,,,
9870,BAO_0000218,Bioavailability expressed as the area under curve of rat portal vein,,N,1,,CHEMBL622079,,50597,3550,,,A,,,Intermediate,,,
9871,BAO_0000218,Area Under plasma concentration time curve in rat upon peroral administration,1969.0,N,1,,CHEMBL622080,,50597,17655,,Plasma,A,,,Intermediate,,,
9872,BAO_0000218,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,N,1,,CHEMBL877612,,50597,17582,,,A,,,Intermediate,,,
9873,BAO_0000218,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,N,1,,CHEMBL622081,,50597,17582,,,A,,,Intermediate,,,
9874,BAO_0000218,Compound was evaluated for oral bioavailability in rats,,N,1,,CHEMBL622082,,50597,17791,,,A,,,Intermediate,,,
9875,BAO_0000218,Compound was evaluated for oral bioavailability in rats after iv administration,,N,1,,CHEMBL622083,,50597,17791,,,A,,,Intermediate,,,
9876,BAO_0000218,Compound was evaluated for oral bioavailability in rats; 30-80,,N,1,,CHEMBL622084,,50597,17791,,,A,,,Intermediate,,,
9877,BAO_0000218,Compound was evaluated for oral bioavailability in rats; 50-60,,N,1,,CHEMBL622085,,50597,17791,,,A,,,Intermediate,,,
9878,BAO_0000218,Compound was evaluated for oral bioavailability in rats; no data,,N,1,,CHEMBL622086,,50597,17791,,,A,,,Intermediate,,,
9879,BAO_0000218,Compound was evaluated for oral bioavailability in rats; peptide,,N,1,,CHEMBL622087,,50597,17791,,,A,,,Intermediate,,,
9880,BAO_0000218,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",178.0,N,1,,CHEMBL622088,,50597,7768,,Blood,A,,,Intermediate,,,
9881,BAO_0000218,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",178.0,N,1,,CHEMBL622089,,50597,7768,,Blood,A,,,Intermediate,,,
9882,BAO_0000218,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",178.0,N,1,,CHEMBL623685,,50597,7768,,Blood,A,,,Intermediate,,,
9883,BAO_0000218,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",178.0,N,1,,CHEMBL623686,,50597,7768,,Blood,A,,,Intermediate,,,
9884,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",945.0,N,1,,CHEMBL623687,In vivo,50597,8677,,Stomach,A,,,Intermediate,,,
9885,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",945.0,N,1,,CHEMBL623688,In vivo,50597,8677,,Stomach,A,,,Intermediate,,,
9886,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",945.0,N,1,,CHEMBL623689,In vivo,50597,8677,,Stomach,A,,,Intermediate,,,
9887,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",945.0,N,1,,CHEMBL622485,In vivo,50597,8677,,Stomach,A,,,Intermediate,,,
9888,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2046.0,N,1,,CHEMBL622486,In vivo,50597,8677,,Thyroid gland,A,,,Intermediate,,,
9889,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2046.0,N,1,,CHEMBL877613,In vivo,50597,8677,,Thyroid gland,A,,,Intermediate,,,
9890,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2046.0,N,1,,CHEMBL622487,In vivo,50597,8677,,Thyroid gland,A,,,Intermediate,,,
9891,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2046.0,N,1,,CHEMBL622488,In vivo,50597,8677,,Thyroid gland,A,,,Intermediate,,,
9892,BAO_0000218,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",948.0,N,1,,CHEMBL622489,In vivo,50597,8677,,Heart,A,,,Intermediate,,,
9893,BAO_0000218,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,N,1,,CHEMBL622490,,50597,6899,,Urine,A,,,Intermediate,,,
9894,BAO_0000218,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1088.0,N,1,,CHEMBL622491,,50597,6899,,Urine,A,,,Intermediate,,,
9895,BAO_0000218,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,2107.0,N,1,,CHEMBL622492,,50597,6899,,Liver,A,,,Intermediate,,,
9896,BAO_0000218,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,N,1,,CHEMBL622493,,50597,6899,,Urine,A,,,Intermediate,,,
9897,BAO_0000218,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1088.0,N,1,,CHEMBL622494,,50597,6899,,Urine,A,,,Intermediate,,,
9898,BAO_0000218,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,N,1,,CHEMBL622495,,50597,8677,,Muscle tissue,A,,,Intermediate,,,
9899,BAO_0000218,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,N,1,,CHEMBL622496,,50597,6899,,,A,,,Intermediate,,,
9900,BAO_0000218,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,N,1,,CHEMBL622497,,50597,6899,,Urine,A,,,Intermediate,,,
9901,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,N,1,,CHEMBL622498,,50597,2189,,,A,,,Intermediate,,,
9902,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1088.0,N,1,,CHEMBL624918,,50597,2189,,Urine,A,,,Intermediate,,,
9903,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1088.0,N,1,,CHEMBL624919,,50597,2189,,Urine,A,,,Intermediate,,,
9904,BAO_0000218,Biodistribution of compound in rat blood after 5 min of administration,178.0,N,1,,CHEMBL624920,In vivo,50597,10839,,Blood,A,,,Intermediate,,,
9905,BAO_0000218,Biodistribution of compound in rat blood after 5 min of administration.,178.0,N,1,,CHEMBL624921,In vivo,50597,10839,,Blood,A,,,Intermediate,,,
9906,BAO_0000218,Biodistribution of compound in rat brain after 5 min of administration,955.0,N,1,,CHEMBL624922,In vivo,50597,10839,,Brain,A,,,Intermediate,,,
9907,BAO_0000218,Biodistribution of compound in rat heart after 5 min of administration,948.0,N,1,,CHEMBL624923,In vivo,50597,10839,,Heart,A,,,Intermediate,,,
9908,BAO_0000218,Biodistribution of compound in rat heart after 5 min of administration.,948.0,N,1,,CHEMBL624924,In vivo,50597,10839,,Heart,A,,,Intermediate,,,
9909,BAO_0000218,Biodistribution of compound in rat kidney after 5 min of administration,2113.0,N,1,,CHEMBL624925,In vivo,50597,10839,,Kidney,A,,,Intermediate,,,
9910,BAO_0000218,Biodistribution of compound in rat kidney after 5 min of administration.,2113.0,N,1,,CHEMBL624926,In vivo,50597,10839,,Kidney,A,,,Intermediate,,,
9911,BAO_0000218,Biodistribution of compound in rat liver after 5 min of administration,2107.0,N,1,,CHEMBL624927,In vivo,50597,10839,,Liver,A,,,Intermediate,,,
9912,BAO_0000218,Biodistribution of compound in rat liver after 5 min of administration.,2107.0,N,1,,CHEMBL874402,In vivo,50597,10839,,Liver,A,,,Intermediate,,,
9913,BAO_0000218,Biodistribution of compound in rat lung after 5 min of administration,2048.0,N,1,,CHEMBL624928,In vivo,50597,10839,,Lung,A,,,Intermediate,,,
9914,BAO_0000218,Biodistribution of compound in rat lung after 5 min of administration.,2048.0,N,1,,CHEMBL624929,In vivo,50597,10839,,Lung,A,,,Intermediate,,,
9915,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration,2385.0,N,1,,CHEMBL624930,In vivo,50597,10839,,Muscle tissue,A,,,Intermediate,,,
9916,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration.,2385.0,N,1,,CHEMBL624931,In vivo,50597,10839,,Muscle tissue,A,,,Intermediate,,,
9917,BAO_0000218,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,948.0,N,1,,CHEMBL624932,,50597,4043,,Heart,A,,,Intermediate,,,
9918,BAO_0000218,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,948.0,N,1,,CHEMBL624933,,50597,4043,,Heart,A,,,Intermediate,,,
9919,BAO_0000218,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2107.0,N,1,,CHEMBL624934,,50597,4043,,Liver,A,,,Intermediate,,,
9920,BAO_0000218,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2107.0,N,1,,CHEMBL624935,,50597,4043,,Liver,A,,,Intermediate,,,
9921,BAO_0000218,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,1,,CHEMBL624936,,50597,4043,,,A,,,Intermediate,,,
9922,BAO_0000218,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,1,,CHEMBL624937,,50597,4043,,,A,,,Intermediate,,,
9923,BAO_0000218,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2106.0,N,1,,CHEMBL624938,,50597,4043,,Spleen,A,,,Intermediate,,,
9924,BAO_0000218,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2106.0,N,1,,CHEMBL624939,,50597,4043,,Spleen,A,,,Intermediate,,,
9925,BAO_0000218,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,1,,CHEMBL624940,,50597,4043,,,A,,,Intermediate,,,
9926,BAO_0000218,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,1,,CHEMBL874403,,50597,4043,,,A,,,Intermediate,,,
9927,BAO_0000218,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,N,1,,CHEMBL624941,,50597,1446,,,A,,,Intermediate,,,
9928,BAO_0000218,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1088.0,N,1,,CHEMBL624942,,50597,9971,,Urine,A,,,Intermediate,,,
9929,BAO_0000218,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1088.0,N,1,,CHEMBL624943,,50597,9971,,Urine,A,,,Intermediate,,,
9930,BAO_0000218,% Bioavailability after 1 day of the drug administration in rats,,N,1,,CHEMBL624944,In vivo,50597,5765,,,A,,,Intermediate,,,
9931,BAO_0000218,% Bioavailability after 4 day of the drug administration in rats,,N,1,,CHEMBL624945,In vivo,50597,5765,,,A,,,Intermediate,,,
9932,BAO_0000218,Absolute bioavailability was evaluated in rat,,N,1,,CHEMBL624946,In vivo,50597,4257,,,A,,,Intermediate,,,
9933,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,N,1,,CHEMBL624947,,50597,13091,,,A,,,Intermediate,,,
9934,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,N,1,,CHEMBL624948,,50597,13091,,,A,,,Intermediate,,,
9935,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,N,1,,CHEMBL624949,,50597,13091,,,A,,,Intermediate,,,
9936,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,2113.0,N,1,,CHEMBL622025,,50597,13091,,Kidney,A,,,Intermediate,,,
9937,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,2113.0,N,1,,CHEMBL622026,,50597,13091,,Kidney,A,,,Intermediate,,,
9938,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,2113.0,N,1,,CHEMBL622027,,50597,13091,,Kidney,A,,,Intermediate,,,
9939,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,2113.0,N,1,,CHEMBL622028,,50597,13091,,Kidney,A,,,Intermediate,,,
9940,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,2107.0,N,1,,CHEMBL622029,,50597,13091,,Liver,A,,,Intermediate,,,
9941,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,2107.0,N,1,,CHEMBL622208,,50597,13091,,Liver,A,,,Intermediate,,,
9942,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,2107.0,N,1,,CHEMBL622209,,50597,13091,,Liver,A,,,Intermediate,,,
9943,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,2107.0,N,1,,CHEMBL622210,,50597,13091,,Liver,A,,,Intermediate,,,
9944,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,N,1,,CHEMBL622211,,50597,13091,,,A,,,Intermediate,,,
9945,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,N,1,,CHEMBL622212,,50597,13091,,,A,,,Intermediate,,,
9946,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,N,1,,CHEMBL622213,,50597,13091,,,A,,,Intermediate,,,
9947,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,N,1,,CHEMBL874404,,50597,13091,,,A,,,Intermediate,,,
9948,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,2385.0,N,1,,CHEMBL620452,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9949,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,2385.0,N,1,,CHEMBL620453,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9950,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,2385.0,N,1,,CHEMBL620454,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9951,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,2385.0,N,1,,CHEMBL624067,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9952,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,N,1,,CHEMBL624068,,50597,13091,,,A,,,Intermediate,,,
9953,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,992.0,N,1,,CHEMBL624069,,50597,13091,,Female gonad,A,,,Intermediate,,,
9954,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,992.0,N,1,,CHEMBL624070,,50597,13091,,Female gonad,A,,,Intermediate,,,
9955,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,992.0,N,1,,CHEMBL624071,,50597,13091,,Female gonad,A,,,Intermediate,,,
9956,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,995.0,N,1,,CHEMBL624072,,50597,13091,,Uterus,A,,,Intermediate,,,
9957,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,995.0,N,1,,CHEMBL624073,,50597,13091,,Uterus,A,,,Intermediate,,,
9958,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,995.0,N,1,,CHEMBL624788,,50597,13091,,Uterus,A,,,Intermediate,,,
9959,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,995.0,N,1,,CHEMBL624789,,50597,13091,,Uterus,A,,,Intermediate,,,
9960,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,N,1,,CHEMBL624790,,50597,13091,,,A,,,Intermediate,,,
9961,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,N,1,,CHEMBL624791,,50597,13091,,,A,,,Intermediate,,,
9962,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,N,1,,CHEMBL624792,,50597,13091,,,A,,,Intermediate,,,
9963,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,N,1,,CHEMBL624793,,50597,13091,,,A,,,Intermediate,,,
9964,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,2385.0,N,1,,CHEMBL877491,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9965,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,2385.0,N,1,,CHEMBL624957,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9966,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,2385.0,N,1,,CHEMBL624958,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9967,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,2385.0,N,1,,CHEMBL624959,,50597,13091,,Muscle tissue,A,,,Intermediate,,,
9968,BAO_0000218,Dissociation constant was determined,,N,1,,CHEMBL624960,,50597,11977,,,A,,,Intermediate,,,
9969,BAO_0000218,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,N,1,,CHEMBL624961,,50597,14941,,,A,,,Intermediate,,,
9970,BAO_0000218,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL624962,,50597,15078,,,A,,,Intermediate,,,
9971,BAO_0000218,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL624963,,50597,15078,,,A,,,Intermediate,,,
9972,BAO_0000218,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,N,1,,CHEMBL624964,,50597,4755,,,A,,,Intermediate,,,
9973,BAO_0000218,LogP value was evaluated in the in situ rat gut perfusion assay,,N,1,,CHEMBL624965,,50597,589,,,A,,,Intermediate,,,
9974,BAO_0000218,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,1,,CHEMBL624966,In vivo,50597,17582,,,A,,,Intermediate,,,
9975,BAO_0000218,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,N,1,,CHEMBL624967,In vivo,50597,5031,,,A,,,Intermediate,,,
9976,BAO_0000218,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,N,1,,CHEMBL624968,In vivo,50597,17764,,,A,,,Intermediate,,,
9977,BAO_0000218,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,1,,CHEMBL624969,,50597,17720,,,A,,,Intermediate,,,
9978,BAO_0000218,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,N,1,,CHEMBL624970,,50597,2862,,,F,,,Expert,,,
9979,BAO_0000218,Half-life was evaluated after 10 uM/kg of intra arterial administration,,N,1,,CHEMBL624971,,50597,16423,,,A,,,Intermediate,,,
9980,BAO_0000218,Half-life was evaluated after 20 uM/kg of peroral administration,,N,1,,CHEMBL624972,In vivo,50597,16423,,,A,,,Intermediate,,,
9981,BAO_0000218,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,N,1,,CHEMBL624973,In vivo,50597,6005,,,A,,,Intermediate,,,
9982,BAO_0000218,Half-life was evaluated in plasma of rat,1969.0,N,1,,CHEMBL624974,,50597,2938,,Plasma,A,,,Intermediate,,,
9983,BAO_0000218,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,N,1,,CHEMBL624975,In vivo,50597,6410,,,A,,,Intermediate,,,
9984,BAO_0000218,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,N,1,,CHEMBL877492,In vivo,50597,6410,,,A,,,Intermediate,,,
9985,BAO_0000218,Half-life was measured in rat after an iv dose of 1 mg/kg,,N,1,,CHEMBL624976,In vivo,50597,6062,,,A,,,Intermediate,,,
9986,BAO_0000218,Half-life period of compound in rats after peroral administration,,N,1,,CHEMBL624977,In vivo,50597,6571,,,A,,,Intermediate,,,
9987,BAO_0000218,Half-life period of compound was measured in rat plasma.,1969.0,N,1,,CHEMBL626848,,50597,3136,,Plasma,A,,,Intermediate,,,
9988,BAO_0000218,Half-life period of compound was measured in rat plasma; ND is not determined,1969.0,N,1,,CHEMBL626849,,50597,3136,,Plasma,A,,,Intermediate,,,
9989,BAO_0000218,Half-life period of compound was measured in rat plasma; not determined,1969.0,N,1,,CHEMBL626850,,50597,3136,,Plasma,A,,,Intermediate,,,
9990,BAO_0000218,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,1,,CHEMBL626851,In vivo,50597,4521,,,A,,,Intermediate,,,
9991,BAO_0000218,Half-life period in rat by iv administration,,N,1,,CHEMBL626852,In vivo,50597,5871,,,A,,,Intermediate,,,
9992,BAO_0000218,Half-life period in rats following intravenous administration at 2 mg/kg,,N,1,,CHEMBL626853,In vivo,50597,6077,,,A,,,Intermediate,,,
9993,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL626854,In vivo,50597,6679,,,A,,,Intermediate,,,
9994,BAO_0000218,Half-life period was determined for the compound in rat,,N,1,,CHEMBL627486,,50597,5144,,,A,,,Intermediate,,,
9995,BAO_0000218,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,N,1,,CHEMBL627487,In vivo,50597,4498,,,A,,,Intermediate,,,
9996,BAO_0000218,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,N,1,,CHEMBL627488,In vivo,50597,4498,,,A,,,Intermediate,,,
9997,BAO_0000218,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,N,1,,CHEMBL627489,In vivo,50597,1908,,,A,,,Intermediate,,,
9998,BAO_0000218,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,N,1,,CHEMBL627490,In vivo,50597,6211,,,A,,,Intermediate,,,
9999,BAO_0000218,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,N,1,,CHEMBL873829,In vivo,50597,5529,,,A,,,Intermediate,,,
10000,BAO_0000218,Half-life was determined in rat at a dose of 1 mpk i.v.,,N,1,,CHEMBL627655,In vivo,50597,6444,,,A,,,Intermediate,,,
10001,BAO_0000218,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,N,1,,CHEMBL625994,In vivo,50597,6444,,,A,,,Intermediate,,,
10002,BAO_0000218,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,N,1,,CHEMBL625995,In vivo,50597,6444,,,A,,,Intermediate,,,
10003,BAO_0000218,Half-life in rat,,N,1,,CHEMBL625996,,50597,5207,,,A,,,Intermediate,,,
10004,BAO_0000218,In vitro half life in rat plasma,1969.0,N,1,,CHEMBL625850,In vitro,50597,530,,Plasma,A,,,Intermediate,,,
10005,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1969.0,N,1,,CHEMBL625851,In vitro,50597,1116,,Plasma,A,,,Intermediate,,,
10006,BAO_0000218,In vitro half life in rat,,N,1,,CHEMBL625852,In vitro,50597,3219,,,A,,,Intermediate,,,
10007,BAO_0000218,In vivo half life period after intravenous administration in rat,,N,1,,CHEMBL625853,In vivo,50597,6109,,,A,,,Intermediate,,,
10008,BAO_0000218,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,1,,CHEMBL625854,In vivo,50597,17582,,,A,,,Intermediate,,,
10009,BAO_0000218,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,N,1,,CHEMBL874450,In vivo,50597,17582,,,A,,,Intermediate,,,
10010,BAO_0000218,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL625855,In vivo,50597,5974,,,A,,,Intermediate,,,
10011,BAO_0000218,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL625856,In vivo,50597,5974,,,A,,,Intermediate,,,
10012,BAO_0000218,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL625857,In vivo,50597,5974,,,A,,,Intermediate,,,
10013,BAO_0000218,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL873831,In vivo,50597,5974,,,A,,,Intermediate,,,
10014,BAO_0000218,Longer half-life in rat (i.v.) at 0.5 mpk,,N,1,,CHEMBL625858,In vivo,50597,17853,,,A,,,Intermediate,,,
10015,BAO_0000218,Longer half-life in rat (p.o.) at 2.0 mpk,,N,1,,CHEMBL625859,In vivo,50597,17853,,,A,,,Intermediate,,,
10016,BAO_0000218,Pharmacokinetic property (half life) in rat,,N,1,,CHEMBL625860,,50597,3457,,,A,,,Intermediate,,,
10017,BAO_0000218,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,N,1,,CHEMBL625861,In vivo,50597,2792,,,A,,,Intermediate,,,
10018,BAO_0000218,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,N,1,,CHEMBL625862,In vivo,50597,2792,,,A,,,Intermediate,,,
10019,BAO_0000218,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,N,1,,CHEMBL625863,In vivo,50597,2792,,,A,,,Intermediate,,,
10020,BAO_0000218,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,N,1,,CHEMBL625864,In vivo,50597,2792,,,A,,,Intermediate,,,
10021,BAO_0000218,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,N,1,,CHEMBL625865,In vivo,50597,5739,,,A,,,Intermediate,,,
10022,BAO_0000218,Pharmacokinetic half time was determined intravenously in rats.,,N,1,,CHEMBL625866,In vivo,50597,15765,,,A,,,Intermediate,,,
10023,BAO_0000218,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1969.0,N,1,,CHEMBL625867,In vivo,50597,6567,,Plasma,A,,,Intermediate,,,
10024,BAO_0000218,Plasma half life of hydrolysis of the compound,1969.0,N,1,,CHEMBL625868,,50597,2448,,Plasma,A,,,Intermediate,,,
10025,BAO_0000218,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1969.0,N,1,,CHEMBL625869,In vivo,50597,5423,,Plasma,A,,,Intermediate,,,
10026,BAO_0000218,Plasma half life period was calculated in rat,1969.0,N,1,,CHEMBL874451,,50597,4853,,Plasma,A,,,Intermediate,,,
10027,BAO_0000218,Plasma half-life in Sprague-Dawley rats,1969.0,N,1,,CHEMBL625870,,50597,4514,,Plasma,A,,,Intermediate,,,
10028,BAO_0000218,Plasma half-life in Sprague-Dawley rats; Not determined,1969.0,N,1,,CHEMBL625871,,50597,4514,,Plasma,A,,,Intermediate,,,
10029,BAO_0000218,Plasma half-life in rats,1969.0,N,1,,CHEMBL625872,,50597,1500,,Plasma,A,,,Intermediate,,,
10030,BAO_0000218,Plasma half-life in rats; <MQL,1969.0,N,1,,CHEMBL625873,,50597,1500,,Plasma,A,,,Intermediate,,,
10031,BAO_0000218,Plasma half-life period (0-8 h) was determined,1969.0,N,1,,CHEMBL625874,,50597,5334,,Plasma,A,,,Intermediate,,,
10032,BAO_0000218,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1969.0,N,1,,CHEMBL625875,,50597,5334,,Plasma,A,,,Intermediate,,,
10033,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1969.0,N,1,,CHEMBL625876,In vivo,50597,5334,,Plasma,A,,,Intermediate,,,
10034,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1969.0,N,1,,CHEMBL631258,In vivo,50597,5334,,Plasma,A,,,Intermediate,,,
10035,BAO_0000218,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1969.0,N,1,,CHEMBL631259,,50597,4956,,Plasma,A,,,Intermediate,,,
10036,BAO_0000218,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1969.0,N,1,,CHEMBL631260,,50597,4956,,Plasma,A,,,Intermediate,,,
10037,BAO_0000218,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",178.0,N,1,,CHEMBL631261,,50597,7768,,Blood,A,,,Intermediate,,,
10038,BAO_0000218,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",178.0,N,1,,CHEMBL631262,,50597,7768,,Blood,A,,,Intermediate,,,
10039,BAO_0000218,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",178.0,N,1,,CHEMBL631263,,50597,7768,,Blood,A,,,Intermediate,,,
10040,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,N,1,,CHEMBL631264,,50597,7768,,,A,,,Intermediate,,,
10041,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,N,1,,CHEMBL631265,,50597,7768,,,A,,,Intermediate,,,
10042,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,N,1,,CHEMBL631266,,50597,7768,,,A,,,Intermediate,,,
10043,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,N,1,,CHEMBL631267,,50597,7768,,,A,,,Intermediate,,,
10044,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,N,1,,CHEMBL631268,,50597,7768,,,A,,,Intermediate,,,
10045,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,N,1,,CHEMBL631269,,50597,7768,,,A,,,Intermediate,,,
10046,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,N,1,,CHEMBL631270,,50597,7768,,,A,,,Intermediate,,,
10047,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",948.0,N,1,,CHEMBL631271,,50597,7768,,Heart,A,,,Intermediate,,,
10048,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",948.0,N,1,,CHEMBL631272,,50597,7768,,Heart,A,,,Intermediate,,,
10049,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",948.0,N,1,,CHEMBL631273,,50597,7768,,Heart,A,,,Intermediate,,,
10050,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",948.0,N,1,,CHEMBL631274,,50597,7768,,Heart,A,,,Intermediate,,,
10051,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",948.0,N,1,,CHEMBL631275,,50597,7768,,Heart,A,,,Intermediate,,,
10052,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",948.0,N,1,,CHEMBL626984,,50597,7768,,Heart,A,,,Intermediate,,,
10053,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",948.0,N,1,,CHEMBL626985,,50597,7768,,Heart,A,,,Intermediate,,,
10054,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",2107.0,N,1,,CHEMBL626986,,50597,7768,,Liver,A,,,Intermediate,,,
10055,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",2107.0,N,1,,CHEMBL626987,,50597,7768,,Liver,A,,,Intermediate,,,
10056,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",2107.0,N,1,,CHEMBL626988,,50597,7768,,Liver,A,,,Intermediate,,,
10057,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",2107.0,N,1,,CHEMBL626989,,50597,7768,,Liver,A,,,Intermediate,,,
10058,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",2107.0,N,1,,CHEMBL626990,,50597,7768,,Liver,A,,,Intermediate,,,
10059,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",2107.0,N,1,,CHEMBL626991,,50597,7768,,Liver,A,,,Intermediate,,,
10060,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",2107.0,N,1,,CHEMBL626992,,50597,7768,,Liver,A,,,Intermediate,,,
10061,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",2048.0,N,1,,CHEMBL626993,,50597,7768,,Lung,A,,,Intermediate,,,
10062,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",2048.0,N,1,,CHEMBL874593,,50597,7768,,Lung,A,,,Intermediate,,,
10063,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",2048.0,N,1,,CHEMBL626994,,50597,7768,,Lung,A,,,Intermediate,,,
10064,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",2048.0,N,1,,CHEMBL626995,,50597,7768,,Lung,A,,,Intermediate,,,
10065,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",2048.0,N,1,,CHEMBL626190,,50597,7768,,Lung,A,,,Intermediate,,,
10066,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",2048.0,N,1,,CHEMBL626191,,50597,7768,,Lung,A,,,Intermediate,,,
10067,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",2048.0,N,1,,CHEMBL626364,,50597,7768,,Lung,A,,,Intermediate,,,
10068,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",2046.0,N,1,,CHEMBL626365,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10069,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",2046.0,N,1,,CHEMBL626366,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10070,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",2046.0,N,1,,CHEMBL626367,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10071,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",2046.0,N,1,,CHEMBL626368,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10072,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",2046.0,N,1,,CHEMBL626369,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10073,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",2046.0,N,1,,CHEMBL626370,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10074,BAO_0000218,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,N,1,,CHEMBL626371,In vivo,50597,4498,,,A,,,Intermediate,,,
10075,BAO_0000218,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,N,1,,CHEMBL626372,In vivo,50597,4498,,,A,,,Intermediate,,,
10076,BAO_0000218,Bioavailability after a dose of 10 mg/kg p.o.,,N,1,,CHEMBL626373,In vivo,50597,3603,,,A,,,Intermediate,,,
10077,BAO_0000218,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,N,1,,CHEMBL626374,In vivo,50597,6215,,,A,,,Intermediate,,,
10078,BAO_0000218,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,N,1,,CHEMBL626375,In vivo,50597,5710,,,A,,,Intermediate,,,
10079,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,N,1,,CHEMBL626376,In vivo,50597,5710,,,A,,,Intermediate,,,
10080,BAO_0000218,Bioavailability in rat po was determined,,N,1,,CHEMBL626377,In vivo,50597,5676,,,A,,,Intermediate,,,
10081,BAO_0000218,Bioavailability of compound at 10 mg/kg in rat after oral administration,,N,1,,CHEMBL626378,In vivo,50597,17667,,,A,,,Intermediate,,,
10082,BAO_0000218,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,N,1,,CHEMBL626379,In vivo,50597,17667,,,A,,,Intermediate,,,
10083,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,1,,CHEMBL626380,In vivo,50597,6848,,,A,,,Intermediate,,,
10084,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,1,,CHEMBL626381,In vivo,50597,6848,,,A,,,Intermediate,,,
10085,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL626382,In vivo,50597,17267,,,A,,,Intermediate,,,
10086,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (female),,N,1,,CHEMBL626383,In vivo,50597,6362,,,A,,,Intermediate,,,
10087,BAO_0000218,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,1,,CHEMBL874652,In vivo,50597,17671,,,A,,,Intermediate,,,
10088,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,N,1,,CHEMBL626384,In vivo,50597,17671,,,A,,,Intermediate,,,
10089,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,N,1,,CHEMBL626385,In vivo,50597,4333,,,A,,,Intermediate,,,
10090,BAO_0000218,Bioavailability in rat at an oral dose of 2 mg/kg,,N,1,,CHEMBL626386,In vivo,50597,6077,,,A,,,Intermediate,,,
10091,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL626387,In vivo,50597,3278,,,A,,,Intermediate,,,
10092,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL626388,In vivo,50597,5964,,,A,,,Intermediate,,,
10093,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL626389,In vivo,50597,4884,,,A,,,Intermediate,,,
10094,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL626390,In vivo,50597,4905,,,A,,,Intermediate,,,
10095,BAO_0000218,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,N,1,,CHEMBL626391,In vivo,50597,4884,,,A,,,Intermediate,,,
10096,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL626392,In vivo,50597,6850,,,A,,,Intermediate,,,
10097,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL626393,In vivo,50597,2864,,,A,,,Intermediate,,,
10098,BAO_0000218,Bioavailability was determined in rat,,N,1,,CHEMBL623026,In vivo,50597,5780,,,A,,,Intermediate,,,
10099,BAO_0000218,Bioavailability,,N,1,,CHEMBL623027,In vivo,50597,1465,,,A,,,Intermediate,,,
10100,BAO_0000218,Bioavailability,,N,1,,CHEMBL623028,In vivo,50597,5199,,,A,,,Intermediate,,,
10101,BAO_0000218,Bioavailability in rat after 1 day dosing,,N,1,,CHEMBL623029,In vivo,50597,5765,,,A,,,Intermediate,,,
10102,BAO_0000218,Bioavailability in rat after 4 day dosing,,N,1,,CHEMBL623030,In vivo,50597,5765,,,A,,,Intermediate,,,
10103,BAO_0000218,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,N,1,,CHEMBL623031,In vivo,50597,6518,,,A,,,Intermediate,,,
10104,BAO_0000218,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,N,1,,CHEMBL623032,In vivo,50597,6518,,,A,,,Intermediate,,,
10105,BAO_0000218,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,N,1,,CHEMBL623033,In vivo,50597,6518,,,A,,,Intermediate,,,
10106,BAO_0000218,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,N,1,,CHEMBL623034,In vivo,50597,6518,,,A,,,Intermediate,,,
10107,BAO_0000218,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,N,1,,CHEMBL623035,In vivo,50597,2083,,,A,,,Intermediate,,,
10108,BAO_0000218,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,1,,CHEMBL623036,In vivo,50597,17260,,,A,,,Intermediate,,,
10109,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,1,,CHEMBL623037,In vivo,50597,4956,,,A,,,Intermediate,,,
10110,BAO_0000218,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,N,1,,CHEMBL623038,In vivo,50597,4368,,,A,,,Intermediate,,,
10111,BAO_0000218,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1969.0,N,1,,CHEMBL874385,In vivo,50597,17752,,Plasma,A,,,Intermediate,,,
10112,BAO_0000218,Bioavailability in rat (Fisher) (fasted),,N,1,,CHEMBL623039,In vivo,50597,1446,,,A,,,Intermediate,,,
10113,BAO_0000218,Bioavailability in monkey after po administration of 10 mg/kg dose,,U,1,,CHEMBL623040,In vivo,22224,2891,,,A,,,Intermediate,,,
10114,BAO_0000218,Oral bioavailability in monkey (dose 10 mg/kg),,U,1,,CHEMBL623041,In vivo,22224,2891,,,A,,,Intermediate,,,
10115,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL623741,In vivo,50597,6672,,,A,,,Intermediate,,,
10116,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL623742,In vivo,50597,6673,,,A,,,Intermediate,,,
10117,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL623743,In vivo,50597,17655,,,A,,,Intermediate,,,
10118,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL623744,In vivo,50597,17796,,,A,,,Intermediate,,,
10119,BAO_0000218,Bioavailability in rat (dose 2.0 mg/kg p.o.),,N,1,,CHEMBL623745,In vivo,50597,17853,,,A,,,Intermediate,,,
10120,BAO_0000218,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,N,1,,CHEMBL623746,In vivo,50597,4521,,,A,,,Intermediate,,,
10121,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg p.o.),,N,1,,CHEMBL623747,In vivo,50597,4940,,,A,,,Intermediate,,,
10122,BAO_0000218,Bioavailability in rat after po administration of 30 mg/kg dose,,U,1,,CHEMBL623748,In vivo,22224,2891,,,A,,,Intermediate,,,
10123,BAO_0000218,Bioavailability in rat after po administration of 30 mg/kg dose,,U,1,,CHEMBL623916,In vivo,22224,2891,,,A,,,Intermediate,,,
10124,BAO_0000218,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,1,,CHEMBL623917,In vivo,50597,4521,,,A,,,Intermediate,,,
10125,BAO_0000218,Bioavailability in rat (dose 2 mg/kg i.v.),,N,1,,CHEMBL623918,In vivo,50597,17686,,,A,,,Intermediate,,,
10126,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL874386,In vivo,50597,17796,,,A,,,Intermediate,,,
10127,BAO_0000218,Bioavailability in rat; Only traces detected in rat plasma,1969.0,N,1,,CHEMBL623919,In vivo,50597,17796,,Plasma,A,,,Intermediate,,,
10128,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL623920,In vivo,50597,5064,,,A,,,Intermediate,,,
10129,BAO_0000218,Bioavailability upon oral administration of compound,,N,1,,CHEMBL623148,In vivo,50597,5147,,,A,,,Intermediate,,,
10130,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,N,1,,CHEMBL623149,In vivo,50597,1916,,,A,,,Intermediate,,,
10131,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL623150,In vivo,50597,6049,,,A,,,Intermediate,,,
10132,BAO_0000218,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,N,1,,CHEMBL623151,In vivo,50597,1445,,,A,,,Intermediate,,,
10133,BAO_0000218,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,N,1,,CHEMBL623152,In vivo,50597,1445,,,A,,,Intermediate,,,
10134,BAO_0000218,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,N,1,,CHEMBL623153,,50597,2862,,,F,,,Expert,,,
10135,BAO_0000218,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,N,1,,CHEMBL623154,,50597,2862,,,F,,,Expert,,,
10136,BAO_0000218,In vitro and metabolic stability was determined,,N,1,,CHEMBL623155,,50597,4194,,,A,,,Intermediate,,,
10137,BAO_0000218,In vitro metabolic stability in rat hepatocytes,,N,1,,CHEMBL623156,,50597,4194,,,A,,,Intermediate,,,
10138,BAO_0000218,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,N,1,,CHEMBL623157,,50597,5486,,,A,,,Intermediate,,,
10139,BAO_0000218,Metabolic rate for compound was observed in rat hepatocytes,2107.0,N,1,Hepatocyte,CHEMBL623158,In vitro,50597,17582,,Liver,A,,,Intermediate,,401.0,
10140,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,N,1,,CHEMBL623159,,50597,5600,,,A,,,Intermediate,,,
10141,BAO_0000218,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,N,1,,CHEMBL874390,,50597,14294,,,A,,,Intermediate,,,
10142,BAO_0000218,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,N,1,,CHEMBL623160,,50597,14294,,,A,,,Intermediate,,,
10143,BAO_0000218,Metabolism of compound in rat S9 microsomes; Trace,,N,1,,CHEMBL623161,,50597,14294,,,A,,,Intermediate,,,
10144,BAO_0000218,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,N,1,,CHEMBL623162,,50597,17847,,,A,,,Intermediate,,,
10145,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,N,1,,CHEMBL623163,,50597,11020,,,A,,,Intermediate,,,
10146,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,N,1,,CHEMBL623164,,50597,11020,,,A,,,Intermediate,,,
10147,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,N,1,,CHEMBL623165,,50597,11020,,,A,,,Intermediate,,,
10148,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,N,1,,CHEMBL623166,,50597,11020,,,A,,,Intermediate,,,
10149,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,N,1,,CHEMBL624983,,50597,11020,,,A,,,Intermediate,,,
10150,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,N,1,,CHEMBL624984,,50597,11020,,,A,,,Intermediate,,,
10151,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,N,1,,CHEMBL624985,,50597,11020,,,A,,,Intermediate,,,
10152,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,N,1,,CHEMBL622970,,50597,11020,,,A,,,Intermediate,,,
10153,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,N,1,,CHEMBL622971,,50597,11020,,,A,,,Intermediate,,,
10154,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,N,1,,CHEMBL622972,,50597,11020,,,A,,,Intermediate,,,
10155,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,N,1,,CHEMBL622973,,50597,11020,,,A,,,Intermediate,,,
10156,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,N,1,,CHEMBL622974,,50597,11020,,,A,,,Intermediate,,,
10157,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,N,1,,CHEMBL622975,,50597,11020,,,A,,,Intermediate,,,
10158,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,N,1,,CHEMBL622976,,50597,11020,,,A,,,Intermediate,,,
10159,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,N,1,,CHEMBL622977,,50597,11020,,,A,,,Intermediate,,,
10160,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,N,1,,CHEMBL624351,,50597,11020,,,A,,,Intermediate,,,
10161,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,N,1,,CHEMBL624352,,50597,11020,,,A,,,Intermediate,,,
10162,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,N,1,,CHEMBL624353,,50597,11020,,,A,,,Intermediate,,,
10163,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,N,1,,CHEMBL622397,,50597,11020,,,A,,,Intermediate,,,
10164,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,N,1,,CHEMBL622398,,50597,11020,,,A,,,Intermediate,,,
10165,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,N,1,,CHEMBL622399,,50597,11020,,,A,,,Intermediate,,,
10166,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,N,1,,CHEMBL622400,,50597,11020,,,A,,,Intermediate,,,
10167,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,N,1,,CHEMBL628428,,50597,11020,,,A,,,Intermediate,,,
10168,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,N,1,,CHEMBL628590,,50597,11020,,,A,,,Intermediate,,,
10169,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,N,1,,CHEMBL628591,,50597,11020,,,A,,,Intermediate,,,
10170,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,N,1,,CHEMBL628592,,50597,11020,,,A,,,Intermediate,,,
10171,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,N,1,,CHEMBL628593,,50597,11020,,,A,,,Intermediate,,,
10172,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,N,1,,CHEMBL875333,,50597,11020,,,A,,,Intermediate,,,
10173,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,N,1,,CHEMBL628594,,50597,11020,,,A,,,Intermediate,,,
10174,BAO_0000218,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1969.0,N,1,,CHEMBL628595,,50597,4969,,Plasma,A,,,Intermediate,,,
10175,BAO_0000218,Stability in rat plasma was determined,1969.0,N,1,,CHEMBL628596,,50597,6737,,Plasma,A,,,Intermediate,,,
10176,BAO_0000218,Stability in rat plasma was determined; ND= no data,1969.0,N,1,,CHEMBL628597,,50597,6737,,Plasma,A,,,Intermediate,,,
10177,BAO_0000218,Tested for plasma half life period in rat (0-8 hr),1969.0,N,1,,CHEMBL628598,,50597,5089,,Plasma,A,,,Intermediate,,,
10178,BAO_0000218,Tested for plasma half life period in rat (0-8 hr); Not determined,1969.0,N,1,,CHEMBL628599,,50597,5089,,Plasma,A,,,Intermediate,,,
10179,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,N,1,,CHEMBL628600,In vivo,50597,1466,,,A,,,Intermediate,,,
10180,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,N,1,,CHEMBL628601,In vivo,50597,1466,,,A,,,Intermediate,,,
10181,BAO_0000218,Tested for the half life in rat,,N,1,,CHEMBL628602,,50597,4950,,,A,,,Intermediate,,,
10182,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,N,1,,CHEMBL628603,In vitro,50597,2412,,,A,,,Intermediate,,,
10183,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,N,1,,CHEMBL628604,In vitro,50597,2412,,,A,,,Intermediate,,,
10184,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,N,1,,CHEMBL628605,In vitro,50597,2412,,,A,,,Intermediate,,,
10185,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,N,1,,CHEMBL628606,In vitro,50597,2412,,,A,,,Intermediate,,,
10186,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,N,1,,CHEMBL628607,In vitro,50597,2412,,,A,,,Intermediate,,,
10187,BAO_0000218,The biological half life the compound was measured at the dose of 100 umol/kg,,N,1,,CHEMBL628608,,50597,15022,,,A,,,Intermediate,,,
10188,BAO_0000218,The biological half life the compound was measured at the dose of 30 umol/kg,,N,1,,CHEMBL628609,,50597,15022,,,A,,,Intermediate,,,
10189,BAO_0000218,The compound was evaluated for plasma half life period in rat,1969.0,N,1,,CHEMBL628610,,50597,406,,Plasma,A,,,Intermediate,,,
10190,BAO_0000218,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL873819,In vivo,50597,15078,,,A,,,Intermediate,,,
10191,BAO_0000218,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL628611,In vivo,50597,15078,,,A,,,Intermediate,,,
10192,BAO_0000218,The pharmacokinetic parameter half-life period in vivo in rats,,N,1,,CHEMBL628612,In vivo,50597,5247,,,A,,,Intermediate,,,
10193,BAO_0000218,"The pharmacokinetic property, Half-life was determined",,N,1,,CHEMBL628613,In vivo,50597,5041,,,A,,,Intermediate,,,
10194,BAO_0000218,"The pharmacokinetic property, Half-life in rat in vivo",,N,1,,CHEMBL628614,In vivo,50597,5041,,,A,,,Intermediate,,,
10195,BAO_0000218,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,N,1,,CHEMBL628615,In vivo,50597,5041,,,A,,,Intermediate,,,
10196,BAO_0000218,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,N,1,,CHEMBL628616,In vivo,50597,5041,,,A,,,Intermediate,,,
10197,BAO_0000218,The plasma half life period in rats,1969.0,N,1,,CHEMBL627924,,50597,3918,,Plasma,A,,,Intermediate,,,
10198,BAO_0000218,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,2107.0,N,1,,CHEMBL627925,,50597,2906,,Liver,A,,,Intermediate,,,
10199,BAO_0000218,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,N,1,,CHEMBL627926,In vivo,50597,6467,,,A,,,Intermediate,,,
10200,BAO_0000218,t1/2 (apparent elimination)of the compound was determined,,N,1,,CHEMBL627927,,50597,5510,,,A,,,Intermediate,,,
10201,BAO_0000218,t1/2 value in rat,,N,1,,CHEMBL627928,,50597,3788,,,A,,,Intermediate,,,
10202,BAO_0000218,Half life in rat,,N,1,,CHEMBL627539,,50597,17796,,,A,,,Intermediate,,,
10203,BAO_0000218,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1969.0,N,1,,CHEMBL876790,In vivo,50597,12873,,Plasma,A,,,Intermediate,,,
10204,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,N,1,,CHEMBL858186,In vivo,50597,5983,,,A,,,Intermediate,,,
10205,BAO_0000218,Half-life period in fasted rats,,N,1,,CHEMBL627540,,50597,15765,,,A,,,Intermediate,,,
10206,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,N,1,,CHEMBL627541,In vivo,50597,2661,,,A,,,Intermediate,,,
10207,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,N,1,,CHEMBL627715,In vivo,50597,2661,,,A,,,Intermediate,,,
10208,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,N,1,,CHEMBL627716,In vivo,50597,429,,,A,,,Intermediate,,,
10209,BAO_0000218,Maximum time required to achieve Cmax was determined in rat,,N,1,,CHEMBL627717,,50597,17655,,,A,,,Intermediate,,,
10210,BAO_0000218,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,1,,CHEMBL627718,In vivo,50597,17717,,,A,,,Intermediate,,,
10211,BAO_0000218,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,1,,CHEMBL627719,In vivo,50597,17717,,,A,,,Intermediate,,,
10212,BAO_0000218,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,N,1,,CHEMBL627720,In vivo,50597,17717,,,A,,,Intermediate,,,
10213,BAO_0000218,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,N,1,,CHEMBL627721,In vivo,50597,6570,,,A,,,Intermediate,,,
10214,BAO_0000218,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,N,1,,CHEMBL627722,In vivo,50597,6570,,,A,,,Intermediate,,,
10215,BAO_0000218,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL627723,In vivo,50597,5978,,,A,,,Intermediate,,,
10216,BAO_0000218,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL626058,In vivo,50597,5978,,,A,,,Intermediate,,,
10217,BAO_0000218,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL626059,In vivo,50597,5978,,,A,,,Intermediate,,,
10218,BAO_0000218,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL626060,In vivo,50597,5978,,,A,,,Intermediate,,,
10219,BAO_0000218,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL626061,In vivo,50597,17720,,Plasma,A,,,Intermediate,,,
10220,BAO_0000218,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL876791,In vivo,50597,4723,,,A,,,Intermediate,,,
10221,BAO_0000218,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,1,,CHEMBL626062,In vivo,50597,4723,,,A,,,Intermediate,,,
10222,BAO_0000218,Tmax at the dose of 2 mg/Kg administered perorally in rats,,N,1,,CHEMBL626063,In vivo,50597,4756,,,A,,,Intermediate,,,
10223,BAO_0000218,Tmax at the dose of 5 mg/Kg administered perorally in rats,,N,1,,CHEMBL626064,In vivo,50597,4756,,,A,,,Intermediate,,,
10224,BAO_0000218,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL626065,In vivo,50597,17720,,Plasma,A,,,Intermediate,,,
10225,BAO_0000218,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1969.0,N,1,,CHEMBL626066,In vivo,50597,17720,,Plasma,A,,,Intermediate,,,
10226,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,N,1,,CHEMBL626067,In vivo,50597,1466,,,A,,,Intermediate,,,
10227,BAO_0000218,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,N,1,,CHEMBL626068,,50597,7449,,,F,,,Intermediate,,,
10228,BAO_0000218,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,N,1,,CHEMBL626069,,50597,7449,,,F,,,Intermediate,,,
10229,BAO_0000218,Percent total excretion of 3-methoxyacetaminophen glucuronide,,N,1,,CHEMBL626070,,50597,7449,,,F,,,Intermediate,,,
10230,BAO_0000218,Percent total excretion of N-methoxyacetaminophen glucuronide,,N,1,,CHEMBL626071,,50597,7449,,,F,,,Intermediate,,,
10231,BAO_0000218,Percent total excretion of N-methoxyacetaminophen sulfate,,N,1,,CHEMBL626072,,50597,7449,,,F,,,Intermediate,,,
10232,BAO_0000218,Percent total excretion of acetaminophen,,N,1,,CHEMBL626073,,50597,7449,,,F,,,Intermediate,,,
10233,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",2046.0,N,1,,CHEMBL626741,,50597,7768,,Thyroid gland,A,,,Intermediate,,,
10234,BAO_0000218,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,N,1,,CHEMBL626742,,50597,17655,,,A,,,Intermediate,,,
10235,BAO_0000218,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,N,1,,CHEMBL626743,,50597,17735,,,A,,,Intermediate,,,
10236,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,N,1,,CHEMBL876792,,50597,5960,,,A,,,Intermediate,,,
10237,BAO_0000218,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,N,1,,CHEMBL626744,,50597,17735,,,A,,,Intermediate,,,
10238,BAO_0000218,Compound was tested for antidiuretic activity in rats,,N,1,,CHEMBL626745,,50597,7116,,,A,,,Intermediate,,,
10239,BAO_0000218,AUC in rat after 3mg/kg oral dose,1969.0,N,1,,CHEMBL626746,In vivo,50597,4878,,Plasma,A,,,Intermediate,,,
10240,BAO_0000218,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,N,1,,CHEMBL626747,,50597,5939,,,A,,,Intermediate,,,
10241,BAO_0000218,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,N,1,,CHEMBL626748,,50597,5939,,,A,,,Intermediate,,,
10242,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to rats,,N,1,,CHEMBL626749,,50597,16367,,,A,,,Intermediate,,,
10243,BAO_0000218,Oral Bioavailability was determined,,N,1,,CHEMBL626750,,50597,16366,,,A,,,Intermediate,,,
10244,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL626751,,50597,4426,,,A,,,Intermediate,,,
10245,BAO_0000218,Oral bioavailability in rat; Not performed.,,N,1,,CHEMBL626913,,50597,4426,,,A,,,Intermediate,,,
10246,BAO_0000218,Bioavailability,,N,1,,CHEMBL626914,,50597,5041,,,A,,,Intermediate,,,
10247,BAO_0000218,Bioavailability was determined; ND denotes no data,,N,1,,CHEMBL626915,,50597,5041,,,A,,,Intermediate,,,
10248,BAO_0000218,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,N,1,,CHEMBL626916,,50597,1500,,,A,,,Intermediate,,,
10249,BAO_0000218,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,N,1,,CHEMBL626917,,50597,1500,,,A,,,Intermediate,,,
10250,BAO_0000218,Binding towards rat plasma protein at 10 uM,,N,1,,CHEMBL626918,,50597,17409,,,A,,,Intermediate,,,
10251,BAO_0000218,Binding towards rat plasma protein at 100 uM,,N,1,,CHEMBL626919,,50597,17409,,,A,,,Intermediate,,,
10252,BAO_0000218,Bioavailability in rat (dose 20 mg/kg p.o.),,N,1,,CHEMBL626920,In vivo,50597,2959,,,A,,,Intermediate,,,
10253,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,N,1,,CHEMBL621976,In vivo,50597,13501,,,A,,,Intermediate,,,
10254,BAO_0000218,Bioavailability in rat after 5 mg/kg oral gavage,,N,1,,CHEMBL877599,In vivo,50597,6567,,,A,,,Intermediate,,,
10255,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL621977,In vivo,50597,6571,,,A,,,Intermediate,,,
10256,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v.),,N,1,,CHEMBL621978,In vivo,50597,6715,,,A,,,Intermediate,,,
10257,BAO_0000218,Bioavailability in rat (dose 3 mg/kg p.o.),,N,1,,CHEMBL621979,In vivo,50597,6715,,,A,,,Intermediate,,,
10258,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL621980,In vivo,50597,2932,,,A,,,Intermediate,,,
10259,BAO_0000218,Bioavailability of the compound in rats after administration of 30 mg/kg,,N,1,,CHEMBL621981,In vivo,50597,4171,,,A,,,Intermediate,,,
10260,BAO_0000218,Bioavailability after administration of 10 mg/kg in rats,,N,1,,CHEMBL621982,In vivo,50597,17509,,,A,,,Intermediate,,,
10261,BAO_0000218,Bioavailability after administration of 2 mg/kg in rats,,N,1,,CHEMBL882953,In vivo,50597,17509,,,A,,,Intermediate,,,
10262,BAO_0000218,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,N,1,,CHEMBL621983,In vivo,50597,4527,,,A,,,Intermediate,,,
10263,BAO_0000218,Bioavailability in dogs was determined; high,,N,1,,CHEMBL621984,In vivo,50597,4026,,,A,,,Intermediate,,,
10264,BAO_0000218,Bioavailability in monkey after intravenous administration at 1 mpk,,N,1,,CHEMBL621985,In vivo,50597,6659,,,A,,,Intermediate,,,
10265,BAO_0000218,Bioavailability in monkey after peroral administration at 10 mpk,,N,1,,CHEMBL621986,In vivo,50597,6659,,,A,,,Intermediate,,,
10266,BAO_0000218,Bioavailability in rat after intravenous administration at 1 mpk,,N,1,,CHEMBL621987,In vivo,50597,6659,,,A,,,Intermediate,,,
10267,BAO_0000218,Bioavailability in rat after intravenous administration at 2 mpk,,N,1,,CHEMBL877600,In vivo,50597,6659,,,F,,,Intermediate,,,
10268,BAO_0000218,Bioavailability in rat after peroral administration at 30 mpk,,N,1,,CHEMBL621988,In vivo,50597,6659,,,A,,,Intermediate,,,
10269,BAO_0000218,Bioavailability in rat after peroral administration at at 100 mpk,,N,1,,CHEMBL621989,In vivo,50597,6659,,,F,,,Intermediate,,,
10270,BAO_0000218,Bioavailability in rats was evaluated,,N,1,,CHEMBL621990,In vivo,50597,6597,,,A,,,Intermediate,,,
10271,BAO_0000218,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,N,1,,CHEMBL621991,In vivo,50597,1202,,,A,,,Intermediate,,,
10272,BAO_0000218,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,N,1,,CHEMBL621992,In vivo,50597,1202,,,A,,,Intermediate,,,
10273,BAO_0000218,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,N,1,,CHEMBL621993,In vivo,50597,1202,,,A,,,Intermediate,,,
10274,BAO_0000218,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,N,1,,CHEMBL621994,In vivo,50597,1202,,,A,,,Intermediate,,,
10275,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL621995,In vivo,50597,5207,,,A,,,Intermediate,,,
10276,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL621996,In vivo,50597,5970,,,A,,,Intermediate,,,
10277,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),,N,1,,CHEMBL621997,In vivo,50597,17538,,,A,,,Intermediate,,,
10278,BAO_0000218,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,N,1,,CHEMBL621998,In vivo,50597,17538,,,A,,,Intermediate,,,
10279,BAO_0000218,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,N,1,,CHEMBL621999,In vivo,50597,1466,,,A,,,Intermediate,,,
10280,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622000,In vivo,50597,2879,,,A,,,Intermediate,,,
10281,BAO_0000218,Bioavailability was measured in rat after oral administration; 2-4,,N,1,,CHEMBL622001,In vivo,50597,2879,,,A,,,Intermediate,,,
10282,BAO_0000218,Bioavailability was measured in rat after oral administration; 3-7,,N,1,,CHEMBL622002,In vivo,50597,2879,,,A,,,Intermediate,,,
10283,BAO_0000218,Bioavailability in rat (intraduodenal administration),,N,1,,CHEMBL622003,In vivo,50597,3777,,,A,,,Intermediate,,,
10284,BAO_0000218,Bioavailability in rat (intraduodenal administration),,N,1,,CHEMBL877601,In vivo,50597,3777,,,A,,,Intermediate,,,
10285,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL624871,In vivo,50597,3777,,,A,,,Intermediate,,,
10286,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622004,In vivo,50597,3777,,,A,,,Intermediate,,,
10287,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,N,1,,CHEMBL882954,In vivo,50597,5423,,,A,,,Intermediate,,,
10288,BAO_0000218,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,N,1,,CHEMBL622005,In vivo,50597,16365,,,A,,,Intermediate,,,
10289,BAO_0000218,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,N,1,,CHEMBL622006,In vivo,50597,16365,,,A,,,Intermediate,,,
10290,BAO_0000218,Bioavailability was measured in rat,,N,1,,CHEMBL622007,In vivo,50597,4239,,,A,,,Intermediate,,,
10291,BAO_0000218,Bioavailability was reported,,N,1,,CHEMBL622008,In vivo,50597,5438,,,A,,,Intermediate,,,
10292,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,1,,CHEMBL622009,In vivo,50597,5334,,,A,,,Intermediate,,,
10293,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,1,,CHEMBL622010,In vivo,50597,5334,,,A,,,Intermediate,,,
10294,BAO_0000218,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,N,1,,CHEMBL622011,In vivo,50597,4199,,,A,,,Intermediate,,,
10295,BAO_0000218,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,N,1,,CHEMBL622012,In vivo,50597,4199,,,A,,,Intermediate,,,
10296,BAO_0000218,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,N,1,,CHEMBL622013,In vivo,50597,4199,,,A,,,Intermediate,,,
10297,BAO_0000218,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,1,,CHEMBL622014,In vivo,50597,4890,,,A,,,Intermediate,,,
10298,BAO_0000218,Bioavailability was determined at 3 mg/kg po dose in rats,,N,1,,CHEMBL624749,In vivo,50597,2792,,,A,,,Intermediate,,,
10299,BAO_0000218,Oral bioavailability in rat (dose 2 mg/kg),,N,1,,CHEMBL624750,In vivo,50597,5529,,,A,,,Intermediate,,,
10300,BAO_0000218,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,N,1,,CHEMBL624751,In vivo,50597,6685,,,A,,,Intermediate,,,
10301,BAO_0000218,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,N,1,,CHEMBL624752,In vivo,50597,6685,,,A,,,Intermediate,,,
10302,BAO_0000218,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,N,1,,CHEMBL624753,In vivo,50597,6685,,,A,,,Intermediate,,,
10303,BAO_0000218,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,N,1,,CHEMBL624754,In vivo,50597,6005,,,A,,,Intermediate,,,
10304,BAO_0000218,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,N,1,,CHEMBL624755,In vivo,50597,6410,,,A,,,Intermediate,,,
10305,BAO_0000218,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,N,1,,CHEMBL624756,In vivo,50597,6410,,,A,,,Intermediate,,,
10306,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL624757,In vivo,50597,6103,,,A,,,Intermediate,,,
10307,BAO_0000218,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,N,1,,CHEMBL624758,In vivo,50597,6410,,,A,,,Intermediate,,,
10308,BAO_0000218,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,N,1,,CHEMBL622270,In vivo,50597,6410,,,A,,,Intermediate,,,
10309,BAO_0000218,Bioavailability in rat (Sprague-Dawley),,N,1,,CHEMBL622271,In vivo,50597,5353,,,A,,,Intermediate,,,
10310,BAO_0000218,Bioavailability in rat at the dose of 2 mg/kg,,N,1,,CHEMBL622272,In vivo,50597,4727,,,A,,,Intermediate,,,
10311,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622273,In vivo,50597,17804,,,A,,,Intermediate,,,
10312,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),,N,1,,CHEMBL622274,In vivo,50597,5809,,,A,,,Intermediate,,,
10313,BAO_0000218,Bioavailability value of compound in rats was determined after peroral administration,,N,1,,CHEMBL622275,In vivo,50597,17804,,,A,,,Intermediate,,,
10314,BAO_0000218,Oral bioavailability in rat (dose 20 mg/kg),,N,1,,CHEMBL622276,In vivo,50597,3634,,,A,,,Intermediate,,,
10315,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622277,In vivo,50597,3341,,,A,,,Intermediate,,,
10316,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg),,N,1,,CHEMBL622278,In vivo,50597,2690,,,A,,,Intermediate,,,
10317,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622279,In vivo,50597,3184,,,A,,,Intermediate,,,
10318,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622280,In vivo,50597,740,,,A,,,Intermediate,,,
10319,BAO_0000218,Compound was evaluated for oral bioavailability in rats; 15-27 %,,N,1,,CHEMBL624083,In vivo,50597,1806,,,A,,,Intermediate,,,
10320,BAO_0000218,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,N,1,,CHEMBL624084,In vivo,50597,4891,,,A,,,Intermediate,,,
10321,BAO_0000218,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,N,1,,CHEMBL624085,In vivo,50597,3634,,,A,,,Intermediate,,,
10322,BAO_0000218,Compound was tested for bioavailability in rats,,N,1,,CHEMBL624086,In vivo,50597,64,,,A,,,Intermediate,,,
10323,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL624087,In vivo,50597,4839,,,A,,,Intermediate,,,
10324,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL624088,In vivo,50597,1094,,,A,,,Intermediate,,,
10325,BAO_0000218,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,U,1,,CHEMBL624089,In vivo,22224,5005,,,A,,,Intermediate,,,
10326,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,U,1,,CHEMBL624090,In vivo,22224,5005,,,A,,,Intermediate,,,
10327,BAO_0000218,Evaluated for the bioavailability in rat (in vivo),,N,1,,CHEMBL624091,In vivo,50597,4687,,,A,,,Intermediate,,,
10328,BAO_0000218,F value of compound in rats was determined after peroral administration,,N,1,,CHEMBL624092,In vivo,50597,17804,,,A,,,Intermediate,,,
10329,BAO_0000218,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624093,In vivo,50597,5974,,,A,,,Intermediate,,,
10330,BAO_0000218,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624094,In vivo,50597,5974,,,A,,,Intermediate,,,
10331,BAO_0000218,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624095,In vivo,50597,5974,,,A,,,Intermediate,,,
10332,BAO_0000218,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,1,,CHEMBL624096,In vivo,50597,5974,,,A,,,Intermediate,,,
10333,BAO_0000218,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,N,1,,CHEMBL624097,In vivo,50597,1088,,,A,,,Intermediate,,,
10334,BAO_0000218,Maximum fall in carotid flow in rat,,N,1,,CHEMBL624098,In vivo,50597,1742,,,A,,,Intermediate,,,
10335,BAO_0000218,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,N,1,,CHEMBL874392,In vivo,50597,4689,,,A,,,Intermediate,,,
10336,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg),,N,1,,CHEMBL624099,In vivo,50597,2463,,,A,,,Intermediate,,,
10337,BAO_0000218,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,1,,CHEMBL624100,In vivo,50597,5654,,,A,,,Intermediate,,,
10338,BAO_0000218,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,1,,CHEMBL624101,In vivo,50597,5654,,,A,,,Intermediate,,,
10339,BAO_0000218,Oral bioavailability in rat (male Wistar),,N,1,,CHEMBL624102,In vivo,50597,6874,,,A,,,Intermediate,,,
10340,BAO_0000218,Oral bioavailability after administration (30 mg/kg) in rat; good,,N,1,,CHEMBL624103,In vivo,50597,5633,,,A,,,Intermediate,,,
10341,BAO_0000218,Oral bioavailability at the dose of 2 mg/kg in rat,,N,1,,CHEMBL624104,In vivo,50597,5496,,,A,,,Intermediate,,,
10342,BAO_0000218,Oral bioavailability determined in rats,,N,1,,CHEMBL624105,In vivo,50597,2358,,,A,,,Intermediate,,,
10343,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,N,1,,CHEMBL624106,In vivo,50597,16456,,,A,,,Intermediate,,,
10344,BAO_0000218,Oral bioavailability in rat (dose single 10 mg/kg),,N,1,,CHEMBL624107,In vivo,50597,5302,,,A,,,Intermediate,,,
10345,BAO_0000218,Oral bioavailability in rat (dose single 10 mg/kg),,N,1,,CHEMBL623943,In vivo,50597,5302,,,A,,,Intermediate,,,
10346,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg,,N,1,,CHEMBL623944,In vivo,50597,5302,,,A,,,Intermediate,,,
10347,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,N,1,,CHEMBL623945,,50597,11020,,,A,,,Intermediate,,,
10348,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,N,1,,CHEMBL623946,,50597,11020,,,A,,,Intermediate,,,
10349,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,N,1,,CHEMBL623947,,50597,11020,,,A,,,Intermediate,,,
10350,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,N,1,,CHEMBL623948,,50597,11020,,,A,,,Intermediate,,,
10351,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,N,1,,CHEMBL623949,,50597,11020,,,A,,,Intermediate,,,
10352,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,N,1,,CHEMBL623950,,50597,11020,,,A,,,Intermediate,,,
10353,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,N,1,,CHEMBL874398,,50597,11020,,,A,,,Intermediate,,,
10354,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,N,1,,CHEMBL623951,,50597,11020,,,A,,,Intermediate,,,
10355,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,N,1,,CHEMBL623952,,50597,11020,,,A,,,Intermediate,,,
10356,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,N,1,,CHEMBL623953,,50597,11020,,,A,,,Intermediate,,,
10357,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,N,1,,CHEMBL623954,,50597,11020,,,A,,,Intermediate,,,
10358,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,N,1,,CHEMBL623955,,50597,11020,,,A,,,Intermediate,,,
10359,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,N,1,,CHEMBL623956,,50597,11020,,,A,,,Intermediate,,,
10360,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,N,1,,CHEMBL627807,,50597,11020,,,A,,,Intermediate,,,
10361,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,N,1,,CHEMBL627808,,50597,11020,,,A,,,Intermediate,,,
10362,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,N,1,,CHEMBL627809,,50597,11020,,,A,,,Intermediate,,,
10363,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,N,1,,CHEMBL627810,,50597,11020,,,A,,,Intermediate,,,
10364,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,N,1,,CHEMBL627811,,50597,11020,,,A,,,Intermediate,,,
10365,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,N,1,,CHEMBL627812,,50597,11020,,,A,,,Intermediate,,,
10366,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,N,1,,CHEMBL627813,,50597,11020,,,A,,,Intermediate,,,
10367,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,N,1,,CHEMBL627814,,50597,11020,,,A,,,Intermediate,,,
10368,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,N,1,,CHEMBL875336,,50597,11020,,,A,,,Intermediate,,,
10369,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,N,1,,CHEMBL627815,,50597,11020,,,A,,,Intermediate,,,
10370,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,N,1,,CHEMBL627816,,50597,11020,,,A,,,Intermediate,,,
10371,BAO_0000218,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,N,1,,CHEMBL627817,,50597,11020,,,A,,,Intermediate,,,
10372,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,N,1,,CHEMBL627818,,50597,11020,,,A,,,Intermediate,,,
10373,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,N,1,,CHEMBL627819,,50597,11020,,,A,,,Intermediate,,,
10374,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,N,1,,CHEMBL627820,,50597,11020,,,A,,,Intermediate,,,
10375,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,N,1,,CHEMBL627821,,50597,11020,,,A,,,Intermediate,,,
10376,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,N,1,,CHEMBL628464,,50597,11020,,,A,,,Intermediate,,,
10377,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,N,1,,CHEMBL626239,,50597,11020,,,A,,,Intermediate,,,
10378,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,N,1,,CHEMBL626240,,50597,11020,,,A,,,Intermediate,,,
10379,BAO_0000218,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,N,1,,CHEMBL626241,,50597,11020,,,A,,,Intermediate,,,
10380,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,N,1,,CHEMBL626242,,50597,11020,,,A,,,Intermediate,,,
10381,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,N,1,,CHEMBL626243,,50597,11020,,,A,,,Intermediate,,,
10382,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,N,1,,CHEMBL626244,,50597,11020,,,A,,,Intermediate,,,
10383,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,N,1,,CHEMBL626907,,50597,11020,,,A,,,Intermediate,,,
10384,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,N,1,,CHEMBL626908,,50597,11020,,,A,,,Intermediate,,,
10385,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,N,1,,CHEMBL626909,,50597,11020,,,A,,,Intermediate,,,
10386,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,N,1,,CHEMBL626910,,50597,11020,,,A,,,Intermediate,,,
10387,BAO_0000218,Percent total excretion of acetaminophen cysteine conjugate,,N,1,,CHEMBL875342,,50597,7449,,,F,,,Intermediate,,,
10388,BAO_0000218,Percent total excretion of acetaminophen glucuronide,,N,1,,CHEMBL626911,,50597,7449,,,F,,,Intermediate,,,
10389,BAO_0000218,Percent total excretion of acetaminophen sulfate,,N,1,,CHEMBL626912,,50597,7449,,,F,,,Intermediate,,,
10390,BAO_0000218,Percent total excretion of acetaminophen-mercapturic acid,,N,1,,CHEMBL627065,,50597,7449,,,F,,,Intermediate,,,
10391,BAO_0000218,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1088.0,N,1,,CHEMBL627066,,50597,3172,,Urine,A,,,Intermediate,,,
10392,BAO_0000218,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,1,,CHEMBL627067,In vivo,50597,16456,,,A,,,Intermediate,,,
10393,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration,2385.0,U,1,,CHEMBL627068,In vivo,22224,10839,,Muscle tissue,A,,,Autocuration,,,
10394,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration.,2385.0,U,1,,CHEMBL627069,In vivo,22224,10839,,Muscle tissue,A,,,Autocuration,,,
10395,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,1,,CHEMBL627070,In vivo,22224,5334,,,A,,,Autocuration,,,
10396,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,1,,CHEMBL627071,In vivo,22224,5334,,,A,,,Autocuration,,,
10397,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,1,,CHEMBL627072,In vivo,22224,5334,,,A,,,Autocuration,,,
10398,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,1,,CHEMBL627073,In vivo,22224,5334,,,A,,,Autocuration,,,
10399,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,1,,CHEMBL625387,In vivo,22224,5334,,,A,,,Autocuration,,,
10400,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,1,,CHEMBL625388,In vivo,22224,5334,,,A,,,Autocuration,,,
10401,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1969.0,U,1,,CHEMBL625389,In vivo,22224,5334,,Plasma,A,,,Autocuration,,,
10402,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1969.0,U,1,,CHEMBL875343,In vivo,22224,5334,,Plasma,A,,,Autocuration,,,
10403,BAO_0000218,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,N,1,,CHEMBL876795,,50497,1735,,,A,,,Intermediate,,,
10404,BAO_0000218,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,N,1,,CHEMBL626552,,50497,1469,,,A,,,Intermediate,,,
10405,BAO_0000218,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,N,1,,CHEMBL626553,,50497,1336,,,A,,,Intermediate,,,
10406,BAO_0000366,The human biological plasma half life of the compound,1969.0,U,1,,CHEMBL626554,,22224,12403,,Plasma,A,,,Autocuration,,,
10407,BAO_0000218,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,N,1,,CHEMBL626555,,50597,8151,,Urine,A,,,Intermediate,,,
10408,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,N,1,,CHEMBL626556,,50597,8004,,,A,,,Intermediate,,,
10409,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,N,1,,CHEMBL626557,,50597,8004,,,A,,,Intermediate,,,
10410,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,N,1,,CHEMBL626558,,50597,8004,,,A,,,Intermediate,,,
10411,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,N,1,,CHEMBL626559,,50597,8004,,,A,,,Intermediate,,,
10412,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,N,1,,CHEMBL626560,,50597,8004,,,A,,,Intermediate,,,
10413,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,N,1,,CHEMBL876803,,50597,8004,,,A,,,Intermediate,,,
10414,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,N,1,,CHEMBL627964,,50597,8004,,,A,,,Intermediate,,,
10415,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,N,1,,CHEMBL627965,,50597,8004,,,A,,,Intermediate,,,
10416,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,N,1,,CHEMBL627966,,50597,8004,,,A,,,Intermediate,,,
10417,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,N,1,,CHEMBL627967,,50597,8004,,,A,,,Intermediate,,,
10418,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,N,1,,CHEMBL627968,,50597,8004,,,A,,,Intermediate,,,
10419,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,N,1,,CHEMBL627969,,50597,8004,,,A,,,Intermediate,,,
10420,BAO_0000218,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,N,1,,CHEMBL627970,,50597,8004,,,A,,,Intermediate,,,
10421,BAO_0000218,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,178.0,N,1,,CHEMBL627971,,50597,8004,,Blood,A,,,Intermediate,,,
10422,BAO_0000218,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,178.0,N,1,,CHEMBL627972,,50597,8004,,Blood,A,,,Intermediate,,,
10423,BAO_0000357,Dissociation constant against binding to human cyclophilin A,,D,1,,CHEMBL856029,,180,15917,,,B,,,Expert,,,
10424,BAO_0000019,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,H,1,,CHEMBL627973,,11591,12396,,,B,,,Expert,,,
10425,BAO_0000019,-Log C was determined by performing the electroshock minimum test,,U,1,,CHEMBL627974,,22224,7065,,,A,,,Autocuration,,,
10426,BAO_0000019,-Log C was determined by performing the foot shock test,,U,1,,CHEMBL627975,,22224,7065,,,A,,,Autocuration,,,
10427,BAO_0000019,-Log C was determined by performing the incl screen test,,U,1,,CHEMBL627976,,22224,7065,,,A,,,Autocuration,,,
10428,BAO_0000019,-Log C was determined by performing the maximum electroshock test,,U,1,,CHEMBL627977,,22224,7065,,,A,,,Autocuration,,,
10429,BAO_0000019,-Log C was determined by performing the pentylenetetrazole test,,U,1,,CHEMBL627978,,22224,7065,,,A,,,Autocuration,,,
10430,BAO_0000019,Tested for experimental arotinoid inhibitory dose,,U,1,,CHEMBL627979,,22224,12415,,,A,,,Autocuration,,,
10431,BAO_0000019,Negative log transformed activity,,U,1,,CHEMBL876804,,22224,10256,,,A,,,Autocuration,,,
10432,BAO_0000019,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,U,1,,CHEMBL627980,,22224,7991,,,A,,,Autocuration,,,
10433,BAO_0000218,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,N,1,,CHEMBL627981,,50512,14342,,,A,,,Intermediate,,,
10434,BAO_0000218,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,N,1,,CHEMBL627982,,50512,14342,,,A,,,Intermediate,,,
10435,BAO_0000218,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,N,1,,CHEMBL627983,,50512,14342,,,A,,,Intermediate,,,
10436,BAO_0000218,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,2116.0,N,1,,CHEMBL627984,,50512,14342,,Ileum,A,,,Intermediate,,,
10437,BAO_0000100,Solubility in water was determined; values expressed as -log,,U,1,,CHEMBL627985,,22229,6047,,,P,,,Autocuration,,,
10438,BAO_0000019,Ratio of Kcat to that of Km was determined,,U,1,,CHEMBL627986,,22224,17269,,,A,,,Autocuration,,,
10439,BAO_0000019,Observed first order rate constant,,U,1,,CHEMBL627987,,22224,10026,,,A,,,Autocuration,,,
10440,BAO_0000019,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,U,1,,CHEMBL627988,,22224,14583,,,A,,,Autocuration,,,
10441,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,N,1,,CHEMBL627989,In vivo,50597,2661,,,A,,,Intermediate,,,
10442,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,N,1,,CHEMBL627990,In vivo,50597,2661,,,A,,,Intermediate,,,
10443,BAO_0000218,Oral Bioavailability after administration of 10 mg/kg in male rat,,N,1,,CHEMBL876805,In vivo,50597,4029,,,A,,,Intermediate,,,
10444,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,N,1,,CHEMBL627991,In vivo,50597,17735,,,A,,,Intermediate,,,
10445,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL627992,In vivo,50597,4576,,,A,,,Intermediate,,,
10446,BAO_0000218,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,N,1,,CHEMBL627993,In vivo,50597,17582,,,A,,,Intermediate,,,
10447,BAO_0000218,Oral bioavailability at 1 mg/kg was determined in rat,,N,1,,CHEMBL622817,In vivo,50597,17651,,,A,,,Intermediate,,,
10448,BAO_0000218,Oral bioavailability at 10 mg/kg was determined in rat,,N,1,,CHEMBL622818,In vivo,50597,17651,,,A,,,Intermediate,,,
10449,BAO_0000218,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,N,1,,CHEMBL622819,In vivo,50597,17670,,,A,,,Intermediate,,,
10450,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL872267,In vivo,50597,5045,,,A,,,Intermediate,,,
10451,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622820,In vivo,50597,1696,,,A,,,Intermediate,,,
10452,BAO_0000218,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,N,1,,CHEMBL622821,In vivo,50597,17764,,,A,,,Intermediate,,,
10453,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622822,In vivo,50597,6448,,,A,,,Intermediate,,,
10454,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622823,In vivo,50597,6596,,,A,,,Intermediate,,,
10455,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622824,In vivo,50597,17547,,,A,,,Intermediate,,,
10456,BAO_0000218,Oral bioavailability in rat at a dose of 3 mg/kg,,N,1,,CHEMBL622825,In vivo,50597,17771,,,A,,,Intermediate,,,
10457,BAO_0000218,Oral bioavailability in rat after oral administration at 10 mg/kg,,N,1,,CHEMBL622901,In vivo,50597,6495,,,A,,,Intermediate,,,
10458,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622902,In vivo,50597,4558,,,A,,,Intermediate,,,
10459,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL621844,In vivo,50597,17596,,,A,,,Intermediate,,,
10460,BAO_0000218,Oral bioavailability in Dawley rats,,N,1,,CHEMBL621845,In vivo,50597,6827,,,A,,,Intermediate,,,
10461,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL621846,In vivo,50597,4026,,,A,,,Intermediate,,,
10462,BAO_0000218,Oral bioavailability in rat (dose 30 mg/kg),,N,1,,CHEMBL621847,In vivo,50597,10,,,A,,,Intermediate,,,
10463,BAO_0000218,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,N,1,,CHEMBL877609,In vivo,50597,17717,,,A,,,Intermediate,,,
10464,BAO_0000218,Bioavailability in rat (dose 3 mg/kg i.v.),,N,1,,CHEMBL621848,In vivo,50597,17717,,,A,,,Intermediate,,,
10465,BAO_0000218,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,N,1,,CHEMBL621849,In vivo,50597,17717,,,A,,,Intermediate,,,
10466,BAO_0000218,Oral bioavailability in rat (dose 60 mg/kg p.o.),,N,1,,CHEMBL622030,In vivo,50597,17717,,,A,,,Intermediate,,,
10467,BAO_0000218,Percent oral bioavailability determined in rats,,N,1,,CHEMBL622031,In vivo,50597,4796,,,A,,,Intermediate,,,
10468,BAO_0000218,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,N,1,,CHEMBL622032,In vivo,50597,4883,,,A,,,Intermediate,,,
10469,BAO_0000218,The compound was evaluated for bioavailability in rats; 32-51,,N,1,,CHEMBL622033,In vivo,50597,2137,,,A,,,Intermediate,,,
10470,BAO_0000218,Bioavailability in rat (dose 20 mg/kg p.o.),,N,1,,CHEMBL622034,In vivo,50597,2959,,,A,,,Intermediate,,,
10471,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622035,In vivo,50597,1361,,,A,,,Intermediate,,,
10472,BAO_0000218,Bioavailability percent in rat at the dose of 2 mg/kg,,N,1,,CHEMBL882966,In vivo,50597,4727,,,A,,,Intermediate,,,
10473,BAO_0000218,Bioavailability was evaluated after 20 uM/kg of peroral administration,,N,1,,CHEMBL622036,In vivo,50597,16423,,,A,,,Intermediate,,,
10474,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622037,In vivo,50597,5206,,,A,,,Intermediate,,,
10475,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622038,In vivo,50597,6448,,,A,,,Intermediate,,,
10476,BAO_0000218,Bioavailability in rats,,N,1,,CHEMBL622039,In vivo,50597,17723,,,A,,,Intermediate,,,
10477,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,178.0,N,1,,CHEMBL622040,In vivo,50597,17738,,Blood,A,,,Intermediate,,,
10478,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,178.0,N,1,,CHEMBL622041,In vivo,50597,17738,,Blood,A,,,Intermediate,,,
10479,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,178.0,N,1,,CHEMBL622042,In vivo,50597,17738,,Blood,A,,,Intermediate,,,
10480,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,178.0,N,1,,CHEMBL622043,In vivo,50597,17738,,Blood,A,,,Intermediate,,,
10481,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,178.0,N,1,,CHEMBL622044,In vivo,50597,17738,,Blood,A,,,Intermediate,,,
10482,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,10000001.0,N,1,,CHEMBL622045,In vivo,50597,17738,,Bone,A,,,Intermediate,,,
10483,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,10000001.0,N,1,,CHEMBL622046,In vivo,50597,17738,,Bone,A,,,Intermediate,,,
10484,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,10000001.0,N,1,,CHEMBL622047,In vivo,50597,17738,,Bone,A,,,Intermediate,,,
10485,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,10000001.0,N,1,,CHEMBL877610,In vivo,50597,17738,,Bone,A,,,Intermediate,,,
10486,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,955.0,N,1,,CHEMBL622048,In vivo,50597,17738,,Brain,A,,,Intermediate,,,
10487,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,955.0,N,1,,CHEMBL622049,In vivo,50597,17738,,Brain,A,,,Intermediate,,,
10488,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,955.0,N,1,,CHEMBL622050,In vivo,50597,17738,,Brain,A,,,Intermediate,,,
10489,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,955.0,N,1,,CHEMBL622051,In vivo,50597,17738,,Brain,A,,,Intermediate,,,
10490,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,N,1,,CHEMBL622052,In vivo,50597,17738,,,A,,,Intermediate,,,
10491,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,N,1,,CHEMBL622053,In vivo,50597,17738,,,A,,,Intermediate,,,
10492,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,N,1,,CHEMBL622054,In vivo,50597,17738,,,A,,,Intermediate,,,
10493,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,N,1,,CHEMBL622055,In vivo,50597,17738,,,A,,,Intermediate,,,
10494,BAO_0000218,Oral bioavailability in rats was determined; High,,N,1,,CHEMBL622056,In vivo,50597,5237,,,A,,,Intermediate,,,
10495,BAO_0000218,Oral bioavailability in the rat was determined,,N,1,,CHEMBL622057,In vivo,50597,5503,,,A,,,Intermediate,,,
10496,BAO_0000218,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,N,1,,CHEMBL628008,In vivo,50597,15765,,,A,,,Intermediate,,,
10497,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,N,1,,CHEMBL622058,In vivo,50597,15660,,,A,,,Intermediate,,,
10498,BAO_0000218,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL622059,In vivo,50597,5978,,,A,,,Intermediate,,,
10499,BAO_0000218,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL622060,In vivo,50597,5978,,,A,,,Intermediate,,,
10500,BAO_0000218,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL622061,In vivo,50597,5978,,,A,,,Intermediate,,,
10501,BAO_0000218,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,1,,CHEMBL622062,In vivo,50597,5978,,,A,,,Intermediate,,,
10502,BAO_0000218,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,N,1,,CHEMBL622063,In vivo,50597,5656,,,A,,,Intermediate,,,
10503,BAO_0000218,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,1,,CHEMBL877611,In vivo,50597,3598,,,A,,,Expert,,,
10504,BAO_0000218,Oral bioavailability of compound in Sprague Dawley rats,,N,1,,CHEMBL622064,In vivo,50597,4216,,,A,,,Intermediate,,,
10505,BAO_0000218,Oral bioavailability of compound in rat,,N,1,,CHEMBL622065,In vivo,50597,17839,,,A,,,Intermediate,,,
10506,BAO_0000218,Oral bioavailability in rat (dose 2 mg/kg),,N,1,,CHEMBL622066,In vivo,50597,6570,,,A,,,Intermediate,,,
10507,BAO_0000218,Oral bioavailability of compound in rat was determined,,N,1,,CHEMBL622067,In vivo,50597,5334,,,A,,,Intermediate,,,
10508,BAO_0000218,Oral bioavailability of compound in rats,,N,1,,CHEMBL622068,In vivo,50597,6886,,,A,,,Intermediate,,,
10509,BAO_0000218,Oral bioavailability of compound was determined in rats,,N,1,,CHEMBL622069,In vivo,50597,5210,,,A,,,Intermediate,,,
10510,BAO_0000218,Oral bioavailability at a dose of 30 mg/kg in rats,,N,1,,CHEMBL624796,In vivo,50597,4170,,,A,,,Intermediate,,,
10511,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),,N,1,,CHEMBL624797,In vivo,50597,6028,,,A,,,Intermediate,,,
10512,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),,N,1,,CHEMBL623053,In vivo,50597,6028,,,A,,,Intermediate,,,
10513,BAO_0000218,Oral bioavailability evaluated in rat,,N,1,,CHEMBL623054,In vivo,50597,6078,,,A,,,Intermediate,,,
10514,BAO_0000218,Oral bioavailability in fasted rat,,N,1,,CHEMBL623055,In vivo,50597,6168,,,A,,,Intermediate,,,
10515,BAO_0000218,Oral bioavailability in fed rat,,N,1,,CHEMBL623056,In vivo,50597,6168,,,A,,,Intermediate,,,
10516,BAO_0000218,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,N,1,,CHEMBL623057,In vivo,50597,5160,,,A,,,Intermediate,,,
10517,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623058,In vivo,50597,6057,,,A,,,Intermediate,,,
10518,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg p.o.),,N,1,,CHEMBL623059,In vivo,50597,6535,,,A,,,Intermediate,,,
10519,BAO_0000218,Oral bioavailability in rat after administration of 10 mg/kg po,,N,1,,CHEMBL623060,In vivo,50597,6535,,,A,,,Intermediate,,,
10520,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623061,In vivo,50597,4194,,,A,,,Intermediate,,,
10521,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623062,In vivo,50597,6230,,,A,,,Intermediate,,,
10522,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623063,In vivo,50597,6619,,,A,,,Intermediate,,,
10523,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623064,In vivo,50597,17607,,,A,,,Intermediate,,,
10524,BAO_0000218,Oral bioavailability in ratrs,,N,1,,CHEMBL623065,In vivo,50597,4942,,,A,,,Intermediate,,,
10525,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623066,In vivo,50597,4942,,,A,,,Intermediate,,,
10526,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623067,In vivo,50597,6646,,,A,,,Intermediate,,,
10527,BAO_0000218,Oral bioavailability in rats was determined; High,,N,1,,CHEMBL623068,In vivo,50597,5237,,,A,,,Intermediate,,,
10528,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623069,In vivo,50597,6646,,,A,,,Intermediate,,,
10529,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623070,In vivo,50597,4449,,,A,,,Intermediate,,,
10530,BAO_0000218,Oral bioavailability was calculated in rat,,N,1,,CHEMBL623071,In vivo,50597,6057,,,A,,,Intermediate,,,
10531,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL623072,In vivo,50597,2552,,,A,,,Intermediate,,,
10532,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL623073,In vivo,50597,5496,,,A,,,Intermediate,,,
10533,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL623074,In vivo,50597,6484,,,A,,,Intermediate,,,
10534,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL623075,In vivo,50597,6485,,,A,,,Intermediate,,,
10535,BAO_0000218,Oral bioavailability after i.v. administration,,N,1,,CHEMBL623076,In vivo,50597,6616,,,A,,,Intermediate,,,
10536,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,1,,CHEMBL623077,In vivo,50597,4969,,,A,,,Intermediate,,,
10537,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley),,N,1,,CHEMBL623078,In vivo,50597,5862,,,A,,,Intermediate,,,
10538,BAO_0000218,Oral bioavailability in Sprague-Dawley rats,,N,1,,CHEMBL623079,In vivo,50597,4514,,,A,,,Intermediate,,,
10539,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,1,,CHEMBL623080,In vivo,50597,4514,,,A,,,Intermediate,,,
10540,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,1,,CHEMBL623081,In vivo,50597,4514,,,A,,,Intermediate,,,
10541,BAO_0000218,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,N,1,,CHEMBL623082,In vivo,50597,5546,,,A,,,Intermediate,,,
10542,BAO_0000218,Oral bioavailability in fasted rat,,N,1,,CHEMBL874400,In vivo,50597,6168,,,A,,,Intermediate,,,
10543,BAO_0000218,Oral bioavailability in fed rat,,N,1,,CHEMBL623083,In vivo,50597,6168,,,A,,,Intermediate,,,
10544,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623084,In vivo,50597,3624,,,A,,,Intermediate,,,
10545,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623085,In vivo,50597,5213,,,A,,,Intermediate,,,
10546,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623086,In vivo,50597,5496,,,A,,,Intermediate,,,
10547,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623087,In vivo,50597,5553,,,A,,,Intermediate,,,
10548,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623088,In vivo,50597,5833,,,A,,,Intermediate,,,
10549,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623089,In vivo,50597,5836,,,A,,,Intermediate,,,
10550,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623090,In vivo,50597,5865,,,A,,,Intermediate,,,
10551,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623091,In vivo,50597,5960,,,A,,,Intermediate,,,
10552,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623092,In vivo,50597,6249,,,A,,,Intermediate,,,
10553,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623093,In vivo,50597,6448,,,A,,,Intermediate,,,
10554,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL874401,In vivo,50597,6453,,,A,,,Intermediate,,,
10555,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623094,In vivo,50597,6640,,,A,,,Intermediate,,,
10556,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL623095,In vivo,50597,17607,,,A,,,Intermediate,,,
10557,BAO_0000218,Oral bioavailability in rat after peroral administration at 10 mg/kg,,N,1,,CHEMBL623096,In vivo,50597,5939,,,A,,,Intermediate,,,
10558,BAO_0000218,Oral bioavailability in rat after peroral administration at 5 mg/kg,,N,1,,CHEMBL624913,In vivo,50597,5939,,,A,,,Intermediate,,,
10559,BAO_0000218,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,N,1,,CHEMBL624914,In vivo,50597,6281,,,A,,,Intermediate,,,
10560,BAO_0000218,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,N,1,,CHEMBL624915,In vivo,50597,5874,,,A,,,Intermediate,,,
10561,BAO_0000218,Oral bioavailability in rat; Not measured,,N,1,,CHEMBL624916,In vivo,50597,5213,,,A,,,Intermediate,,,
10562,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL624917,In vivo,50597,4964,,,A,,,Intermediate,,,
10563,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,N,1,,CHEMBL625157,,50597,11020,,,A,,,Intermediate,,,
10564,BAO_0000218,In vitro metabolic potential in rat liver microsomes,2107.0,N,1,,CHEMBL625158,,50597,6251,,Liver,A,,,Intermediate,,,
10565,BAO_0000218,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,N,1,,CHEMBL625159,In vivo,50597,1568,,,A,,,Intermediate,,,
10566,BAO_0000218,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,N,1,,CHEMBL625160,In vivo,50597,3032,,,A,,,Intermediate,,,
10567,BAO_0000218,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,N,1,,CHEMBL625161,In vivo,50597,3748,,,A,,,Intermediate,,,
10568,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL625162,In vivo,50597,401,,,A,,,Intermediate,,,
10569,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL625163,In vivo,50597,6512,,,A,,,Intermediate,,,
10570,BAO_0000218,Oral bioavailability in rats at 10 mg/kg,,N,1,,CHEMBL625164,In vivo,50597,17617,,,A,,,Intermediate,,,
10571,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,1,,CHEMBL625165,In vivo,50597,6679,,,A,,,Intermediate,,,
10572,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL625166,In vivo,50597,6742,,,A,,,Intermediate,,,
10573,BAO_0000218,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,N,1,,CHEMBL625167,,50597,589,,,A,,,Intermediate,,,
10574,BAO_0000218,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,N,1,,CHEMBL625168,,50597,589,,,A,,,Intermediate,,,
10575,BAO_0000218,Plasma clearance of the compound,,N,1,,CHEMBL625169,In vivo,50597,3185,,,A,,,Intermediate,,,
10576,BAO_0000218,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,N,1,,CHEMBL626264,In vivo,50597,17596,,,A,,,Intermediate,,,
10577,BAO_0000218,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,N,1,,CHEMBL626265,In vivo,50597,2713,,,A,,,Intermediate,,,
10578,BAO_0000218,The compound was tested for plasma clearance in rat,1969.0,N,1,,CHEMBL626266,In vivo,50597,12500,,Plasma,A,,,Intermediate,,,
10579,BAO_0000218,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1969.0,N,1,,CHEMBL626267,In vivo,50597,12500,,Plasma,A,,,Intermediate,,,
10580,BAO_0000218,Plasma concentration upon oral administration of 1 mg/Kg in rats,,N,1,,CHEMBL626268,,50597,2713,,,A,,,Intermediate,,,
10581,BAO_0000218,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,N,1,,CHEMBL626269,,50597,1446,,,A,,,Intermediate,,,
10582,BAO_0000218,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,N,1,,CHEMBL626270,,50597,6227,,,A,,,Intermediate,,,
10583,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,N,1,,CHEMBL626271,,50597,4709,,,A,,,Intermediate,,,
10584,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,N,1,,CHEMBL626272,,50597,5510,,,A,,,Intermediate,,,
10585,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,N,1,,CHEMBL626273,,50597,5510,,,A,,,Intermediate,,,
10586,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,N,1,,CHEMBL875346,,50597,5510,,,A,,,Intermediate,,,
10587,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,N,1,,CHEMBL626274,,50597,5510,,,A,,,Intermediate,,,
10588,BAO_0000218,Compound was tested for protein binding in rat plasma,,N,1,,CHEMBL626275,,50597,4514,,,A,,,Intermediate,,,
10589,BAO_0000218,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,N,1,,CHEMBL624646,,50597,2713,,,A,,,Intermediate,,,
10590,BAO_0000218,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,N,1,,CHEMBL624647,,50597,2713,,,A,,,Intermediate,,,
10591,BAO_0000218,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,2107.0,N,1,,CHEMBL624648,,50597,5340,,Liver,A,,,Intermediate,,,
10592,BAO_0000218,Area under curve ratio was determined (po/iv) in rat,,N,1,,CHEMBL624649,,50597,12058,,,A,,,Intermediate,,,
10593,BAO_0000218,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,N,1,,CHEMBL624650,,50597,11195,,,A,,,Intermediate,,,
10594,BAO_0000218,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,N,1,,CHEMBL624651,,50597,11195,,,A,,,Intermediate,,,
10595,BAO_0000218,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,N,1,,CHEMBL624652,,50597,11195,,,A,,,Intermediate,,,
10596,BAO_0000218,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,N,1,,CHEMBL624653,,50597,6495,,,A,,,Intermediate,,,
10597,BAO_0000218,Ratio of AUCbrain to AUCplasma,,N,1,,CHEMBL624654,,50597,6078,,,A,,,Intermediate,,,
10598,BAO_0000218,Ratio of brain to plasma,,N,1,,CHEMBL624655,,50597,5656,,,A,,,Intermediate,,,
10599,BAO_0000218,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,N,1,,CHEMBL624656,,50597,4910,,,A,,,Intermediate,,,
10600,BAO_0000218,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,N,1,,CHEMBL624657,,50597,4910,,,A,,,Intermediate,,,
10601,BAO_0000218,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,N,1,,CHEMBL624658,,50597,4910,,,A,,,Intermediate,,,
10602,BAO_0000218,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,N,1,,CHEMBL624659,,50597,10130,,,A,,,Intermediate,,,
10603,BAO_0000218,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,N,1,,CHEMBL624660,,50597,10130,,,A,,,Intermediate,,,
10604,BAO_0000218,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,N,1,,CHEMBL624661,,50597,10130,,,A,,,Intermediate,,,
10605,BAO_0000218,Steady state brain :blood ratio was determined,,N,1,,CHEMBL624662,,50597,5213,,,A,,,Intermediate,,,
10606,BAO_0000218,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,N,1,,CHEMBL625199,,50597,4910,,,A,,,Intermediate,,,
10607,BAO_0000218,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,N,1,,CHEMBL625200,,50597,4910,,,A,,,Intermediate,,,
10608,BAO_0000218,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,N,1,,CHEMBL625201,,50597,4910,,,A,,,Intermediate,,,
10609,BAO_0000218,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,N,1,,CHEMBL625202,,50597,4910,,,A,,,Intermediate,,,
10610,BAO_0000218,Percentage recovery after 3h incubation with rat hapatocytes was determined,,N,1,,CHEMBL625203,,50597,2083,,,A,,,Intermediate,,,
10611,BAO_0000218,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,N,1,,CHEMBL625204,,50597,2082,,,A,,,Intermediate,,,
10612,BAO_0000218,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,N,1,,CHEMBL625205,,50597,2082,,,A,,,Intermediate,,,
10613,BAO_0000218,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,N,1,,CHEMBL625206,,50597,6351,,,A,,,Intermediate,,,
10614,BAO_0000019,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,U,1,,CHEMBL625207,,22224,14583,,,A,,,Autocuration,,,
10615,BAO_0000019,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,U,1,,CHEMBL625208,,22224,14583,,,A,,,Autocuration,,,
10616,BAO_0000218,In vivo absorption in Caco-2 cell line monolayers was determined,,N,1,Caco-2,CHEMBL625209,,50587,4608,,,A,,,Intermediate,,495.0,
10617,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625210,,22229,13668,,,P,,,Autocuration,,,
10618,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in Rat,,N,1,,CHEMBL625211,,50597,5669,,,A,,,Intermediate,,,
10619,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,N,1,,CHEMBL625212,,50797,5669,,,A,,,Intermediate,,,
10620,BAO_0000218,Area under curve was determine after peroral administration at 160 mpk in Rat,,N,1,,CHEMBL625213,,50597,5669,,,A,,,Intermediate,,,
10621,BAO_0000218,Area under curve was determine after peroral administration at 20 mpk in Rat,,N,1,,CHEMBL625214,,50597,5669,,,A,,,Intermediate,,,
10622,BAO_0000218,Area under curve was determine after peroral administration at 50 mpk in Rat,,N,1,,CHEMBL874542,,50597,5669,,,A,,,Intermediate,,,
10623,BAO_0000100,Calculated partition coefficient (clogP) (AlogP),,U,1,,CHEMBL625215,,22229,6472,,,P,,,Autocuration,,,
10624,BAO_0000019,Activated partial thromboplastin time measured,,U,1,,CHEMBL625216,,22224,15106,,,A,,,Autocuration,,,
10625,BAO_0000100,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,U,1,,CHEMBL625217,,22224,15207,,,P,,,Autocuration,,,
10626,BAO_0000100,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,U,1,,CHEMBL625218,,22224,15207,,,P,,,Autocuration,,,
10627,BAO_0000218,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1969.0,N,1,,CHEMBL622864,,50588,13941,,Plasma,A,,,Intermediate,,,
10628,BAO_0000218,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1969.0,N,1,,CHEMBL622865,,50597,13941,,Plasma,A,,,Intermediate,,,
10629,BAO_0000218,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1969.0,N,1,,CHEMBL622866,,50597,13941,,Plasma,A,,,Intermediate,,,
10630,BAO_0000218,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1969.0,N,1,,CHEMBL622867,,50588,13941,,Plasma,A,,,Intermediate,,,
10631,BAO_0000218,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1969.0,N,1,,CHEMBL876808,,50512,15240,,Plasma,A,,,Intermediate,,,
10632,BAO_0000019,AUC in brain,955.0,U,1,,CHEMBL627725,,22224,10655,,Brain,A,,,Autocuration,,,
10633,BAO_0000019,AUC in serum,1977.0,U,1,,CHEMBL627726,,22224,10655,,Serum,A,,,Autocuration,,,
10634,BAO_0000019,AUC was determined,1969.0,U,1,,CHEMBL627727,,22224,6504,,Plasma,A,,,Autocuration,,,
10635,BAO_0000019,AUC of the compound.,1969.0,U,1,,CHEMBL627728,,22224,10615,,Plasma,A,,,Autocuration,,,
10636,BAO_0000019,AUC value (0-4 hr),1969.0,U,1,,CHEMBL627729,,22224,10353,,Plasma,A,,,Autocuration,,,
10637,BAO_0000019,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1969.0,U,1,,CHEMBL627730,,22224,14907,,Plasma,A,,,Autocuration,,,
10638,BAO_0000019,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1969.0,U,1,,CHEMBL627731,,22224,14907,,Plasma,A,,,Autocuration,,,
10639,BAO_0000019,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1969.0,U,1,,CHEMBL627732,,22224,14907,,Plasma,A,,,Autocuration,,,
10640,BAO_0000019,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1969.0,U,1,,CHEMBL627733,,22224,14907,,Plasma,A,,,Autocuration,,,
10641,BAO_0000218,AUC(area under curve) was determined after intravenous administration in rats,1969.0,N,1,,CHEMBL627734,,50597,16359,,Plasma,A,,,Intermediate,,,
10642,BAO_0000218,AUC(area under curve) was determined after oral administration in rats,1969.0,N,1,,CHEMBL627735,,50597,16359,,Plasma,A,,,Intermediate,,,
10643,BAO_0000218,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1969.0,N,1,,CHEMBL627736,,50512,15240,,Plasma,A,,,Intermediate,,,
10644,BAO_0000218,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1969.0,N,1,,CHEMBL876809,,50597,15240,,Plasma,A,,,Intermediate,,,
10645,BAO_0000019,Area Under Curve after oral dosing of 100 uM/Kg,,U,1,,CHEMBL627737,,22224,15469,,,A,,,Autocuration,,,
10646,BAO_0000019,Area Under Curve after oral dosing of 30 uM/Kg,,U,1,,CHEMBL627738,,22224,15469,,,A,,,Autocuration,,,
10647,BAO_0000019,Area Under Curve was measured by ploting the graph between concentration verses time,,U,1,,CHEMBL627739,,22224,13520,,,A,,,Autocuration,,,
10648,BAO_0000218,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,N,1,,CHEMBL626143,,50588,17025,,,A,,,Intermediate,,,
10649,BAO_0000218,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,U,1,,CHEMBL626144,,22224,17025,,,A,,,Autocuration,,,
10650,BAO_0000218,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,N,1,,CHEMBL626145,,50592,17025,,,A,,,Intermediate,,,
10651,BAO_0000218,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,N,1,,CHEMBL626146,,50597,17025,,,A,,,Intermediate,,,
10652,BAO_0000218,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,178.0,N,1,,CHEMBL626147,,50597,12032,,Blood,A,,,Intermediate,,,
10653,BAO_0000019,Area under curve (AUC) was determined,,U,1,,CHEMBL626148,,22224,10291,,,A,,,Autocuration,,,
10654,BAO_0000218,Area under curve (AUC) following ip administration at 1 mg/kg,,U,1,,CHEMBL626149,,22224,5767,,,A,,,Autocuration,,,
10655,BAO_0000019,Area under curve (AUC) was determined; ND is Not determined,,U,1,,CHEMBL626150,,22224,1434,,,A,,,Autocuration,,,
10656,BAO_0000218,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,N,1,,CHEMBL626151,,50588,14925,,,A,,,Intermediate,,,
10657,BAO_0000218,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,N,1,,CHEMBL626152,,50588,14925,,,A,,,Intermediate,,,
10658,BAO_0000218,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,N,1,,CHEMBL626153,,50588,14925,,,A,,,Intermediate,,,
10659,BAO_0000019,Area under curve (AUR) was determined,,U,1,,CHEMBL626154,,22224,1434,,,A,,,Autocuration,,,
10660,BAO_0000019,Area under curve at 1 uM/dg administered intravenously,,U,1,,CHEMBL626155,,22224,11883,,,A,,,Autocuration,,,
10661,BAO_0000019,Area under curve at 10 uM/dg administered perorally,,U,1,,CHEMBL626156,,22224,11883,,,A,,,Autocuration,,,
10662,BAO_0000019,Area under curve at 2 uM/dg administered intravenously,,U,1,,CHEMBL626157,,22224,11883,,,A,,,Autocuration,,,
10663,BAO_0000019,Area under curve at 20 uM/dg administered perorally,,U,1,,CHEMBL626158,,22224,11883,,,A,,,Autocuration,,,
10664,BAO_0000218,Area under curve at a peroral dose of 3 mg/kg in dog,,N,1,,CHEMBL626159,,50588,15233,,,A,,,Intermediate,,,
10665,BAO_0000218,Area under curve at a peroral dose of 3 mg/kg in rat,,N,1,,CHEMBL626160,,50597,15233,,,A,,,Intermediate,,,
10666,BAO_0000218,Area under curve at an iv dose of 1 mg/kg in dog,,N,1,,CHEMBL626161,,50588,15233,,,A,,,Intermediate,,,
10667,BAO_0000218,Area under curve at an iv dose of 1 mg/kg in rat,,N,1,,CHEMBL626162,,50597,15233,,,A,,,Intermediate,,,
10668,BAO_0000019,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,U,1,,CHEMBL626163,,22224,12978,,,A,,,Autocuration,,,
10669,BAO_0000019,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,U,1,,CHEMBL626164,,22224,12978,,,A,,,Autocuration,,,
10670,BAO_0000218,Area under curve measured as conc vs time after intravenous administration to mice.,,N,1,,CHEMBL626165,,50594,11355,,,A,,,Intermediate,,,
10671,BAO_0000218,Area under curve measured as conc vs time after peroral administration to mice.,,N,1,,CHEMBL626166,,50594,11355,,,A,,,Intermediate,,,
10672,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,N,1,,CHEMBL626167,,50588,12923,,,A,,,Intermediate,,,
10673,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,N,1,,CHEMBL626168,,50588,12923,,,A,,,Intermediate,,,
10674,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,N,1,,CHEMBL877463,,50588,12923,,,A,,,Intermediate,,,
10675,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,N,1,,CHEMBL626169,,50588,12923,,,A,,,Intermediate,,,
10676,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,948.0,N,1,,CHEMBL626170,In vivo,50597,17738,,Heart,A,,,Intermediate,,,
10677,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,948.0,N,1,,CHEMBL626171,In vivo,50597,17738,,Heart,A,,,Intermediate,,,
10678,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,948.0,N,1,,CHEMBL626172,In vivo,50597,17738,,Heart,A,,,Intermediate,,,
10679,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,948.0,N,1,,CHEMBL626173,In vivo,50597,17738,,Heart,A,,,Intermediate,,,
10680,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,2113.0,N,1,,CHEMBL626174,In vivo,50597,17738,,Kidney,A,,,Intermediate,,,
10681,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,2113.0,N,1,,CHEMBL626175,In vivo,50597,17738,,Kidney,A,,,Intermediate,,,
10682,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,2113.0,N,1,,CHEMBL626176,In vivo,50597,17738,,Kidney,A,,,Intermediate,,,
10683,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,2113.0,N,1,,CHEMBL626177,In vivo,50597,17738,,Kidney,A,,,Intermediate,,,
10684,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,2113.0,N,1,,CHEMBL622499,In vivo,50597,17738,,Kidney,A,,,Intermediate,,,
10685,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,2107.0,N,1,,CHEMBL622500,In vivo,50597,17738,,Liver,A,,,Intermediate,,,
10686,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,2107.0,N,1,,CHEMBL622501,In vivo,50597,17738,,Liver,A,,,Intermediate,,,
10687,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,2107.0,N,1,,CHEMBL622502,In vivo,50597,17738,,Liver,A,,,Intermediate,,,
10688,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,2107.0,N,1,,CHEMBL622503,In vivo,50597,17738,,Liver,A,,,Intermediate,,,
10689,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,2107.0,N,1,,CHEMBL877614,In vivo,50597,17738,,Liver,A,,,Intermediate,,,
10690,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,2048.0,N,1,,CHEMBL624839,In vivo,50597,17738,,Lung,A,,,Intermediate,,,
10691,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,2048.0,N,1,,CHEMBL624840,In vivo,50597,17738,,Lung,A,,,Intermediate,,,
10692,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,2048.0,N,1,,CHEMBL624841,In vivo,50597,17738,,Lung,A,,,Intermediate,,,
10693,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,2048.0,N,1,,CHEMBL624842,In vivo,50597,17738,,Lung,A,,,Intermediate,,,
10694,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,2385.0,N,1,,CHEMBL624843,In vivo,50597,17738,,Muscle tissue,A,,,Intermediate,,,
10695,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,2385.0,N,1,,CHEMBL624844,In vivo,50597,17738,,Muscle tissue,A,,,Intermediate,,,
10696,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,2385.0,N,1,,CHEMBL624845,In vivo,50597,17738,,Muscle tissue,A,,,Intermediate,,,
10697,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,2385.0,N,1,,CHEMBL621904,In vivo,50597,17738,,Muscle tissue,A,,,Intermediate,,,
10698,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,178.0,N,1,,CHEMBL621905,In vivo,50597,11195,,Blood,A,,,Intermediate,,,
10699,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,178.0,N,1,,CHEMBL874382,In vivo,50597,11195,,Blood,A,,,Intermediate,,,
10700,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,178.0,N,1,,CHEMBL621906,In vivo,50597,11195,,Blood,A,,,Intermediate,,,
10701,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,955.0,N,1,,CHEMBL621907,In vivo,50597,11195,,Brain,A,,,Intermediate,,,
10702,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,955.0,N,1,,CHEMBL622096,In vivo,50597,11195,,Brain,A,,,Intermediate,,,
10703,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,955.0,N,1,,CHEMBL622097,In vivo,50597,11195,,Brain,A,,,Intermediate,,,
10704,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,948.0,N,1,,CHEMBL622098,In vivo,50597,11195,,Heart,A,,,Intermediate,,,
10705,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,948.0,N,1,,CHEMBL622099,In vivo,50597,11195,,Heart,A,,,Intermediate,,,
10706,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,948.0,N,1,,CHEMBL622100,In vivo,50597,11195,,Heart,A,,,Intermediate,,,
10707,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,2113.0,N,1,,CHEMBL622101,In vivo,50597,11195,,Kidney,A,,,Intermediate,,,
10708,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,2113.0,N,1,,CHEMBL622102,In vivo,50597,11195,,Kidney,A,,,Intermediate,,,
10709,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,2113.0,N,1,,CHEMBL622103,In vivo,50597,11195,,Kidney,A,,,Intermediate,,,
10710,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,2107.0,N,1,,CHEMBL622104,In vivo,50597,11195,,Liver,A,,,Intermediate,,,
10711,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,2107.0,N,1,,CHEMBL622105,In vivo,50597,11195,,Liver,A,,,Intermediate,,,
10712,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,2107.0,N,1,,CHEMBL622106,In vivo,50597,11195,,Liver,A,,,Intermediate,,,
10713,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,2048.0,N,1,,CHEMBL622107,In vivo,50597,11195,,Lung,A,,,Intermediate,,,
10714,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,2048.0,N,1,,CHEMBL622108,In vivo,50597,11195,,Lung,A,,,Intermediate,,,
10715,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,2048.0,N,1,,CHEMBL622109,In vivo,50597,11195,,Lung,A,,,Intermediate,,,
10716,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,2385.0,N,1,,CHEMBL622110,In vivo,50597,11195,,Muscle tissue,A,,,Intermediate,,,
10717,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,2385.0,N,1,,CHEMBL622111,In vivo,50597,11195,,Muscle tissue,A,,,Intermediate,,,
10718,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,2385.0,N,1,,CHEMBL874383,In vivo,50597,11195,,Muscle tissue,A,,,Intermediate,,,
10719,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,14.0,N,1,,CHEMBL622112,In vivo,50597,11195,,Zone of skin,A,,,Intermediate,,,
10720,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,14.0,N,1,,CHEMBL622113,In vivo,50597,11195,,Zone of skin,A,,,Intermediate,,,
10721,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,14.0,N,1,,CHEMBL622114,In vivo,50597,11195,,Zone of skin,A,,,Intermediate,,,
10722,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,2106.0,N,1,,CHEMBL622115,In vivo,50597,11195,,Spleen,A,,,Intermediate,,,
10723,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,2106.0,N,1,,CHEMBL622116,In vivo,50597,11195,,Spleen,A,,,Intermediate,,,
10724,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622117,In vivo,50597,6193,,,A,,,Intermediate,,,
10725,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622118,In vivo,50597,6803,,,A,,,Intermediate,,,
10726,BAO_0000218,Oral bioavailability in rats at 6 mg/kg,,N,1,,CHEMBL622119,In vivo,50597,6647,,,A,,,Intermediate,,,
10727,BAO_0000218,Oral bioavailability in rat (dose 6 mg/kg),,N,1,,CHEMBL622120,In vivo,50597,6647,,,A,,,Intermediate,,,
10728,BAO_0000218,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,N,1,,CHEMBL622121,In vivo,50597,6647,,,A,,,Intermediate,,,
10729,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622122,In vivo,50597,6640,,,A,,,Intermediate,,,
10730,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622123,In vivo,50597,6641,,,A,,,Intermediate,,,
10731,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL622124,In vivo,50597,6641,,,A,,,Intermediate,,,
10732,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL622125,In vivo,50597,6642,,,A,,,Intermediate,,,
10733,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL622126,In vivo,50597,5472,,,A,,,Intermediate,,,
10734,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,1,,CHEMBL620455,In vivo,50597,6141,,,A,,,Intermediate,,,
10735,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620456,In vivo,50597,4390,,,A,,,Intermediate,,,
10736,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620457,In vivo,50597,5472,,,A,,,Intermediate,,,
10737,BAO_0000218,Oral bioavailability was evaluated; Not tested,,N,1,,CHEMBL620458,In vivo,50597,5472,,,A,,,Intermediate,,,
10738,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL620459,In vivo,50597,5438,,,A,,,Intermediate,,,
10739,BAO_0000218,Oral bioavailability in rat by oral dosing,,N,1,,CHEMBL620460,In vivo,50597,4883,,,A,,,Intermediate,,,
10740,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg p.o.),,N,1,,CHEMBL620461,In vivo,50597,1908,,,A,,,Intermediate,,,
10741,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley),,N,1,,CHEMBL620462,In vivo,50597,4853,,,A,,,Intermediate,,,
10742,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,1,,CHEMBL620463,In vivo,50597,4853,,,A,,,Intermediate,,,
10743,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,1,,CHEMBL620464,In vivo,50597,4853,,,A,,,Intermediate,,,
10744,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,1,,CHEMBL620465,In vivo,50597,4853,,,A,,,Intermediate,,,
10745,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,N,1,,CHEMBL620466,In vivo,50597,4853,,,A,,,Intermediate,,,
10746,BAO_0000218,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,N,1,,CHEMBL620467,In vivo,50597,4853,,,A,,,Intermediate,,,
10747,BAO_0000218,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,N,1,,CHEMBL620468,In vivo,50597,4853,,,A,,,Intermediate,,,
10748,BAO_0000218,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,N,1,,CHEMBL620469,In vivo,50597,12873,,,A,,,Intermediate,,,
10749,BAO_0000218,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,N,1,,CHEMBL620470,In vivo,50597,12873,,,A,,,Intermediate,,,
10750,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620471,In vivo,50597,3169,,,A,,,Intermediate,,,
10751,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620472,In vivo,50597,6305,,,A,,,Intermediate,,,
10752,BAO_0000218,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,N,1,,CHEMBL620473,In vivo,50597,4762,,,A,,,Intermediate,,,
10753,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620474,In vivo,50597,17847,,,A,,,Intermediate,,,
10754,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,N,1,,CHEMBL620475,In vivo,50597,6211,,,A,,,Intermediate,,,
10755,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620476,In vivo,50597,6011,,,A,,,Intermediate,,,
10756,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL620477,In vivo,50597,6317,,,A,,,Intermediate,,,
10757,BAO_0000218,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,N,1,,CHEMBL620478,In vivo,50597,6644,,,A,,,Intermediate,,,
10758,BAO_0000218,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,N,1,,CHEMBL618768,In vivo,50597,6644,,,A,,,Intermediate,,,
10759,BAO_0000218,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,N,1,,CHEMBL618769,In vivo,50597,6644,,,A,,,Intermediate,,,
10760,BAO_0000218,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,N,1,,CHEMBL618770,In vivo,50597,6644,,,A,,,Intermediate,,,
10761,BAO_0000218,Oral bioavailability (dose 20 mg/kg p.o.),,N,1,,CHEMBL618771,In vivo,50597,6113,,,A,,,Intermediate,,,
10762,BAO_0000218,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,N,1,,CHEMBL618772,In vivo,50597,5937,,,A,,,Intermediate,,,
10763,BAO_0000218,Oral bioavailability in rat at 10 mg/kg of the compound,,N,1,,CHEMBL618773,In vivo,50597,5711,,,A,,,Intermediate,,,
10764,BAO_0000218,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,N,1,,CHEMBL875842,In vivo,50597,17717,,,A,,,Intermediate,,,
10765,BAO_0000218,Bioavailability in rat (dose 3 mg/kg i.v.),,N,1,,CHEMBL618774,In vivo,50597,17717,,,A,,,Intermediate,,,
10766,BAO_0000218,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,N,1,,CHEMBL618775,In vivo,50597,17717,,,A,,,Intermediate,,,
10767,BAO_0000218,Oral bioavailability in rat (dose 60 mg/kg p.o.),,N,1,,CHEMBL618776,In vivo,50597,17717,,,A,,,Intermediate,,,
10768,BAO_0000218,Percent bioavailability (F) in rats after iv administration,,N,1,,CHEMBL618777,In vivo,50597,4722,,,A,,,Intermediate,,,
10769,BAO_0000218,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,N,1,,CHEMBL618778,In vivo,50597,4722,,,A,,,Intermediate,,,
10770,BAO_0000218,Bioavailability in rat (dose 5 uM/kg p.o.),,N,1,,CHEMBL618779,In vivo,50597,4353,,,A,,,Intermediate,,,
10771,BAO_0000218,Oral bioavailability,,N,1,,CHEMBL618780,In vivo,50597,15662,,,A,,,Intermediate,,,
10772,BAO_0000218,Bioavailability in rat (dose 2 mg/kg p.o.),,N,1,,CHEMBL618781,In vivo,50597,4756,,,A,,,Intermediate,,,
10773,BAO_0000218,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,N,1,,CHEMBL618782,In vivo,50597,4756,,,A,,,Intermediate,,,
10774,BAO_0000218,Oral bioavailability in rat (dose 20 mg/kg),,N,1,,CHEMBL618783,In vivo,50597,3436,,,A,,,Intermediate,,,
10775,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618784,In vivo,50597,17800,,,A,,,Intermediate,,,
10776,BAO_0000218,Percent oral bioavailability evaluated in rat,,N,1,,CHEMBL618785,In vivo,50597,15762,,,A,,,Intermediate,,,
10777,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618786,In vivo,50597,5089,,,A,,,Intermediate,,,
10778,BAO_0000218,Percent oral bioavailability in rat; Not determined,,N,1,,CHEMBL618787,In vivo,50597,5089,,,A,,,Intermediate,,,
10779,BAO_0000218,Oral bioavailability in rat,,N,1,,CHEMBL618788,In vivo,50597,3185,,,A,,,Intermediate,,,
10780,BAO_0000218,Bioavailability in rat,,N,1,,CHEMBL618789,In vivo,50597,5145,,,A,,,Intermediate,,,
10781,BAO_0000218,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,N,1,,CHEMBL618790,In vivo,50597,3457,,,A,,,Intermediate,,,
10782,BAO_0000218,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,N,1,,CHEMBL618791,In vivo,50597,3457,,,A,,,Intermediate,,,
10783,BAO_0000218,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,N,1,,CHEMBL875843,In vivo,50597,5983,,,A,,,Intermediate,,,
10784,BAO_0000218,Oral bioavailability in rat (dose 20 mg/kg p.o.),,N,1,,CHEMBL618792,In vivo,50597,5739,,,A,,,Intermediate,,,
10785,BAO_0000218,Cmax at a dose of 30 mg/kg in rat,,N,1,,CHEMBL623395,In vivo,50597,3579,,,A,,,Intermediate,,,
10786,BAO_0000218,Cmax in monkeys at a dose of 1 mg/kg,,U,1,,CHEMBL623396,In vivo,22224,17788,,,A,,,Autocuration,,,
10787,BAO_0000218,Cmax in rat,,N,1,,CHEMBL623397,In vivo,50597,14956,,,A,,,Intermediate,,,
10788,BAO_0000218,Cmax in rats at a dose of 1 mg/kg,,N,1,,CHEMBL623398,In vivo,50597,17788,,,A,,,Intermediate,,,
10789,BAO_0000218,Cmax was measured in mice after an oral dose of 50 mg/kg.,,N,1,,CHEMBL623399,In vivo,50594,9750,,,A,,,Intermediate,,,
10790,BAO_0000218,"Cmax value at a dose of 12.7 uM/kg, po",,U,1,,CHEMBL623400,In vivo,22224,12767,,,A,,,Autocuration,,,
10791,BAO_0000218,"Cmax value at a dose of 6.3 uM/kg, iv",,U,1,,CHEMBL623401,In vivo,22224,12767,,,A,,,Autocuration,,,
10792,BAO_0000218,"Cmax value at a dose of 7.1 uM/kg, iv",,U,1,,CHEMBL623402,In vivo,22224,12767,,,A,,,Autocuration,,,
10793,BAO_0000218,Cmax value of compound was determined after 1 hr,,U,1,,CHEMBL623403,In vivo,22224,12703,,,A,,,Autocuration,,,
10794,BAO_0000218,Cmax value of the compound,,U,1,,CHEMBL623404,In vivo,22224,15778,,,A,,,Autocuration,,,
10795,BAO_0000218,Cmax value administered intraintestinal in rats.,,N,1,,CHEMBL625997,In vivo,50597,12818,,,A,,,Intermediate,,,
10796,BAO_0000218,Cmax value administered perorally was determined in rat; Not determined,,N,1,,CHEMBL625998,In vivo,50597,14964,,,A,,,Intermediate,,,
10797,BAO_0000218,Cmax value at the dose of 2.3 mg/kg,,U,1,,CHEMBL625999,In vivo,22224,15808,,,A,,,Autocuration,,,
10798,BAO_0000218,Cmax value at the dose of 5 mg/kg,,U,1,,CHEMBL626000,In vivo,22224,15808,,,A,,,Autocuration,,,
10799,BAO_0000218,Cmax value in the period of 8 hr after dosing. ,,U,1,,CHEMBL626001,In vivo,22224,15778,,,A,,,Autocuration,,,
10800,BAO_0000218,Cmax value at a oral dose of 20 mg/kg; Not tested,,U,1,,CHEMBL626002,In vivo,22224,3715,,,A,,,Autocuration,,,
10801,BAO_0000218,Cmax value at a oral dose of 20 mg/kg,,U,1,,CHEMBL626003,In vivo,22224,3715,,,A,,,Autocuration,,,
10802,BAO_0000218,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,N,1,,CHEMBL626004,In vivo,50597,1446,,,A,,,Intermediate,,,
10803,BAO_0000218,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,N,1,,CHEMBL626005,In vivo,50512,15240,,,A,,,Intermediate,,,
10804,BAO_0000218,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,N,1,,CHEMBL626006,In vivo,50597,15240,,,A,,,Intermediate,,,
10805,BAO_0000218,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1969.0,N,1,,CHEMBL626007,In vivo,50597,14810,,Plasma,A,,,Intermediate,,,
10806,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1969.0,N,1,,CHEMBL626008,In vivo,50594,14239,,Plasma,A,,,Intermediate,,,
10807,BAO_0000218,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,2107.0,N,1,,CHEMBL626009,In vivo,50588,12555,,Liver,A,,,Intermediate,,,
10808,BAO_0000218,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,N,1,,CHEMBL626010,In vivo,50588,10754,,,A,,,Intermediate,,,
10809,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,178.0,N,1,,CHEMBL626011,In vivo,50594,10754,,Blood,A,,,Intermediate,,,
10810,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,178.0,N,1,,CHEMBL626012,In vivo,50594,10754,,Blood,A,,,Intermediate,,,
10811,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,178.0,N,1,,CHEMBL626013,In vivo,50594,10754,,Blood,A,,,Intermediate,,,
10812,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,178.0,N,1,,CHEMBL626014,In vivo,50594,10754,,Blood,A,,,Intermediate,,,
10813,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,178.0,N,1,,CHEMBL877496,In vivo,50594,10754,,Blood,A,,,Intermediate,,,
10814,BAO_0000218,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,N,1,,CHEMBL626015,In vivo,50588,14600,,,F,,,Intermediate,,,
10815,BAO_0000218,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,N,1,,CHEMBL626016,In vivo,50588,14600,,,F,,,Intermediate,,,
10816,BAO_0000218,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,N,1,,CHEMBL626017,In vivo,50588,14600,,,F,,,Intermediate,,,
10817,BAO_0000218,Bioavailability as maximal plasma concentration in dogs,1969.0,N,1,,CHEMBL626018,In vivo,50588,13543,,Plasma,A,,,Intermediate,,,
10818,BAO_0000218,Bioavailability as maximal plasma concentration in dogs,1969.0,N,1,,CHEMBL626692,In vivo,50588,13543,,Plasma,A,,,Intermediate,,,
10819,BAO_0000218,Bioavailability as maximal plasma concentration in rats,1969.0,N,1,,CHEMBL626693,In vivo,50597,13543,,Plasma,A,,,Intermediate,,,
10820,BAO_0000218,Bioavailability as maximal plasma concentration in rats,1969.0,U,1,,CHEMBL626694,In vivo,22224,13543,,Plasma,A,,,Autocuration,,,
10821,BAO_0000218,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,N,1,,CHEMBL626695,In vivo,50588,14600,,Blood,A,,,Intermediate,,,
10822,BAO_0000218,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,N,1,,CHEMBL626696,In vivo,50588,14600,,Blood,A,,,Intermediate,,,
10823,BAO_0000218,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,N,1,,CHEMBL626697,In vivo,50588,14600,,Blood,A,,,Intermediate,,,
10824,BAO_0000218,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,178.0,N,1,,CHEMBL626859,In vivo,50588,14600,,Blood,A,,,Intermediate,,,
10825,BAO_0000218,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,N,1,,CHEMBL626860,In vivo,50588,14600,,Blood,A,,,Intermediate,,,
10826,BAO_0000218,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,N,1,,CHEMBL626861,In vivo,50588,14600,,Blood,A,,,Intermediate,,,
10827,BAO_0000218,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,N,1,,CHEMBL626296,In vivo,50597,14681,,,A,,,Intermediate,,,
10828,BAO_0000218,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,U,1,,CHEMBL626297,In vivo,22224,15905,,,A,,,Autocuration,,,
10829,BAO_0000218,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1969.0,U,1,,CHEMBL626298,In vivo,22224,15905,,Plasma,A,,,Autocuration,,,
10830,BAO_0000218,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1969.0,N,1,,CHEMBL626299,In vivo,50597,13304,,Plasma,A,,,Intermediate,,,
10831,BAO_0000218,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1969.0,N,1,,CHEMBL626300,In vivo,50597,15137,,Plasma,A,,,Intermediate,,,
10832,BAO_0000218,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1969.0,N,1,,CHEMBL626301,In vivo,50597,15137,,Plasma,A,,,Intermediate,,,
10833,BAO_0000218,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1969.0,N,1,,CHEMBL626962,In vivo,50597,15137,,Plasma,A,,,Intermediate,,,
10834,BAO_0000218,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1969.0,N,1,,CHEMBL626963,In vivo,50597,15137,,Plasma,A,,,Intermediate,,,
10835,BAO_0000218,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1969.0,N,1,,CHEMBL626964,In vivo,50597,15137,,Plasma,A,,,Intermediate,,,
10836,BAO_0000218,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1969.0,N,1,,CHEMBL626965,In vivo,100710,14839,,Plasma,A,,,Intermediate,,,
10837,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,N,1,,CHEMBL626966,In vivo,50594,14839,,Plasma,A,,,Intermediate,,,
10838,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,N,1,,CHEMBL626967,In vivo,50594,14839,,Plasma,A,,,Intermediate,,,
10839,BAO_0000218,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1969.0,N,1,,CHEMBL626968,In vivo,100710,14839,,Plasma,A,,,Intermediate,,,
10840,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,948.0,N,1,,CHEMBL626969,,50597,8418,,Heart,A,,,Intermediate,,,
10841,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,948.0,N,1,,CHEMBL627126,,50597,8418,,Heart,A,,,Intermediate,,,
10842,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,948.0,N,1,,CHEMBL631276,,50597,8418,,Heart,A,,,Intermediate,,,
10843,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,948.0,N,1,,CHEMBL631277,,50597,8418,,Heart,A,,,Intermediate,,,
10844,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,948.0,N,1,,CHEMBL631278,,50597,8418,,Heart,A,,,Intermediate,,,
10845,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,948.0,N,1,,CHEMBL874457,,50597,8418,,Heart,A,,,Intermediate,,,
10846,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,948.0,N,1,,CHEMBL631279,,50597,8418,,Heart,A,,,Intermediate,,,
10847,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,948.0,N,1,,CHEMBL631280,,50597,8418,,Heart,A,,,Intermediate,,,
10848,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,948.0,N,1,,CHEMBL631281,,50597,8418,,Heart,A,,,Intermediate,,,
10849,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,948.0,N,1,,CHEMBL631968,,50597,8418,,Heart,A,,,Intermediate,,,
10850,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,948.0,N,1,,CHEMBL631969,,50597,8418,,Heart,A,,,Intermediate,,,
10851,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,948.0,N,1,,CHEMBL631970,,50597,8418,,Heart,A,,,Intermediate,,,
10852,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,948.0,N,1,,CHEMBL631971,,50597,8418,,Heart,A,,,Intermediate,,,
10853,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,948.0,N,1,,CHEMBL631972,,50597,8418,,Heart,A,,,Intermediate,,,
10854,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,948.0,N,1,,CHEMBL630435,,50597,8418,,Heart,A,,,Intermediate,,,
10855,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,948.0,N,1,,CHEMBL630436,,50597,8418,,Heart,A,,,Intermediate,,,
10856,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,948.0,N,1,,CHEMBL630437,,50597,8418,,Heart,A,,,Intermediate,,,
10857,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,948.0,N,1,,CHEMBL630438,,50597,8418,,Heart,A,,,Intermediate,,,
10858,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,948.0,N,1,,CHEMBL630439,,50597,8418,,Heart,A,,,Intermediate,,,
10859,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,2113.0,N,1,,CHEMBL630440,,50597,8418,,Kidney,A,,,Intermediate,,,
10860,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,2113.0,N,1,,CHEMBL630441,,50597,8418,,Kidney,A,,,Intermediate,,,
10861,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,2113.0,N,1,,CHEMBL630442,,50597,8418,,Kidney,A,,,Intermediate,,,
10862,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,2113.0,N,1,,CHEMBL625234,,50597,8418,,Kidney,A,,,Intermediate,,,
10863,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,2113.0,N,1,,CHEMBL625235,,50597,8418,,Kidney,A,,,Intermediate,,,
10864,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,2113.0,N,1,,CHEMBL625236,,50597,8418,,Kidney,A,,,Intermediate,,,
10865,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,2113.0,N,1,,CHEMBL625237,,50597,8418,,Kidney,A,,,Intermediate,,,
10866,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,2113.0,N,1,,CHEMBL626125,,50597,8418,,Kidney,A,,,Intermediate,,,
10867,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,2113.0,N,1,,CHEMBL626126,,50597,8418,,Kidney,A,,,Intermediate,,,
10868,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,2113.0,N,1,,CHEMBL626127,,50597,8418,,Kidney,A,,,Intermediate,,,
10869,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,2113.0,N,1,,CHEMBL626128,,50597,8418,,Kidney,A,,,Intermediate,,,
10870,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,2113.0,N,1,,CHEMBL626129,,50597,8418,,Kidney,A,,,Intermediate,,,
10871,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,2113.0,N,1,,CHEMBL626130,,50597,8418,,Kidney,A,,,Intermediate,,,
10872,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,2113.0,N,1,,CHEMBL626131,,50597,8418,,Kidney,A,,,Intermediate,,,
10873,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,2113.0,N,1,,CHEMBL626132,,50597,8418,,Kidney,A,,,Intermediate,,,
10874,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,2113.0,N,1,,CHEMBL626752,,50597,8418,,Kidney,A,,,Intermediate,,,
10875,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,2113.0,N,1,,CHEMBL626753,,50597,8418,,Kidney,A,,,Intermediate,,,
10876,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,2113.0,N,1,,CHEMBL626754,,50597,8418,,Kidney,A,,,Intermediate,,,
10877,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,2113.0,N,1,,CHEMBL626755,,50597,8418,,Kidney,A,,,Intermediate,,,
10878,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,2107.0,N,1,,CHEMBL626756,,50597,8418,,Liver,A,,,Intermediate,,,
10879,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,2107.0,N,1,,CHEMBL626757,,50597,8418,,Liver,A,,,Intermediate,,,
10880,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,2107.0,N,1,,CHEMBL626758,,50597,8418,,Liver,A,,,Intermediate,,,
10881,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,2107.0,N,1,,CHEMBL626759,,50597,8418,,Liver,A,,,Intermediate,,,
10882,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,2107.0,N,1,,CHEMBL626760,,50597,8418,,Liver,A,,,Intermediate,,,
10883,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL626394,,50588,6996,,,A,,,Intermediate,,,
10884,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,N,1,,CHEMBL626395,,50588,6996,,,A,,,Intermediate,,,
10885,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL626396,,50588,6996,,,A,,,Intermediate,,,
10886,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL626397,,50588,6996,,,A,,,Intermediate,,,
10887,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,N,1,,CHEMBL626398,,50588,6996,,,A,,,Intermediate,,,
10888,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL626399,,50588,6996,,,A,,,Intermediate,,,
10889,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,N,1,,CHEMBL874653,,50597,6996,,,A,,,Intermediate,,,
10890,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL626400,,50597,6996,,,A,,,Intermediate,,,
10891,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL626401,,50597,6996,,,A,,,Intermediate,,,
10892,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL626402,,50597,6996,,,A,,,Intermediate,,,
10893,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL626403,,50597,6996,,,A,,,Intermediate,,,
10894,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL626404,,50597,6996,,,A,,,Intermediate,,,
10895,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,N,1,,CHEMBL626405,,50597,6996,,,A,,,Intermediate,,,
10896,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL625529,,50597,6996,,,A,,,Intermediate,,,
10897,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL625530,,50597,6996,,,A,,,Intermediate,,,
10898,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL625531,,50597,6996,,,A,,,Intermediate,,,
10899,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL625532,,50597,6996,,,A,,,Intermediate,,,
10900,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL625533,,50597,6996,,,A,,,Intermediate,,,
10901,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,N,1,,CHEMBL875474,,50597,6996,,,A,,,Intermediate,,,
10902,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL625534,,50597,6996,,,A,,,Intermediate,,,
10903,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL625535,,50597,6996,,,A,,,Intermediate,,,
10904,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL625536,,50597,6996,,,A,,,Intermediate,,,
10905,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL625537,,50597,6996,,,A,,,Intermediate,,,
10906,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL625538,,50597,6996,,,A,,,Intermediate,,,
10907,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,N,1,,CHEMBL625539,,50597,6996,,,A,,,Intermediate,,,
10908,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL625540,,50597,6996,,,A,,,Intermediate,,,
10909,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL625541,,50597,6996,,,A,,,Intermediate,,,
10910,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL625542,,50597,6996,,,A,,,Intermediate,,,
10911,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL625543,,50597,6996,,,A,,,Intermediate,,,
10912,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL625544,,50597,6996,,,A,,,Intermediate,,,
10913,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,N,1,,CHEMBL625545,,50588,6996,,,A,,,Intermediate,,,
10914,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL625546,,50588,6996,,,A,,,Intermediate,,,
10915,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,N,1,,CHEMBL625547,,50588,6996,,,A,,,Intermediate,,,
10916,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL625548,,50588,6996,,,A,,,Intermediate,,,
10917,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL625549,,50588,6996,,,A,,,Intermediate,,,
10918,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL625550,,50588,6996,,,A,,,Intermediate,,,
10919,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL625551,,50588,6996,,,A,,,Intermediate,,,
10920,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL875475,,50588,6996,,,A,,,Intermediate,,,
10921,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL625552,,50588,6996,,,A,,,Intermediate,,,
10922,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL625553,,50588,6996,,,A,,,Intermediate,,,
10923,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL625554,,50588,6996,,,A,,,Intermediate,,,
10924,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,N,1,,CHEMBL625555,,50588,6996,,,A,,,Intermediate,,,
10925,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL625556,,50588,6996,,,A,,,Intermediate,,,
10926,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,N,1,,CHEMBL624986,,50588,6996,,,A,,,Intermediate,,,
10927,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL624987,,50588,6996,,,A,,,Intermediate,,,
10928,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL624988,,50588,6996,,,A,,,Intermediate,,,
10929,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1637.0,N,1,,CHEMBL624989,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10930,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1637.0,N,1,,CHEMBL624990,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10931,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1637.0,N,1,,CHEMBL874391,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10932,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1637.0,N,1,,CHEMBL624991,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10933,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1637.0,N,1,,CHEMBL624992,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10934,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1637.0,N,1,,CHEMBL624993,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10935,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1637.0,N,1,,CHEMBL624994,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10936,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1637.0,N,1,,CHEMBL624995,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10937,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1637.0,N,1,,CHEMBL624996,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10938,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1637.0,N,1,,CHEMBL624997,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10939,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1637.0,N,1,,CHEMBL624998,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10940,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1637.0,N,1,,CHEMBL624999,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10941,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1637.0,N,1,,CHEMBL882955,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10942,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1637.0,N,1,,CHEMBL625000,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10943,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1637.0,N,1,,CHEMBL625001,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10944,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1637.0,N,1,,CHEMBL625089,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10945,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1637.0,N,1,,CHEMBL625090,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10946,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1637.0,N,1,,CHEMBL625091,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10947,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1637.0,N,1,,CHEMBL625092,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10948,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1637.0,N,1,,CHEMBL625093,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10949,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1637.0,N,1,,CHEMBL625094,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10950,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1637.0,N,1,,CHEMBL625095,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
10951,BAO_0000218,Compound was evaluated for its bioavailability in the dogs,,N,1,,CHEMBL625096,In vivo,50588,2249,,,A,,,Intermediate,,,
10952,BAO_0000218,Compound was evaluated for its bioavailability in the rats,,N,1,,CHEMBL625097,In vivo,50597,2249,,,A,,,Intermediate,,,
10953,BAO_0000218,Compound was evaluated for oral bioavailability,,U,1,,CHEMBL882956,In vivo,22224,17515,,,A,,,Autocuration,,,
10954,BAO_0000218,Compound was evaluated for percentage of Oral bioavailability in rats,,N,1,,CHEMBL625098,In vivo,50597,14541,,,A,,,Intermediate,,,
10955,BAO_0000218,Bioavailability in guinea pig,,U,1,,CHEMBL625099,In vivo,22224,12797,,,A,,,Autocuration,,,
10956,BAO_0000218,Compound was evaluated for the oral bioavailability in rat,,N,1,,CHEMBL625100,In vivo,50597,12797,,,A,,,Intermediate,,,
10957,BAO_0000218,Compound was evaluated for the oral bioavailability in dog,,N,1,,CHEMBL625101,In vivo,50588,12797,,,A,,,Intermediate,,,
10958,BAO_0000218,Compound was evaluated for the oral bioavailability in rat,,N,1,,CHEMBL874396,In vivo,50597,12797,,,A,,,Intermediate,,,
10959,BAO_0000218,Bioavailability in dog (dosed i.v.),,U,1,,CHEMBL625102,In vivo,22224,11727,,,F,,,Autocuration,,,
10960,BAO_0000218,Compound was tested for in vivo bioavailability in dog,,N,1,,CHEMBL625103,In vivo,50588,13249,,,A,,,Intermediate,,,
10961,BAO_0000218,Compound was tested for in vivo bioavailability in hamsters,,N,1,,CHEMBL625104,In vivo,100712,13249,,,A,,,Intermediate,,,
10962,BAO_0000218,Compound was tested for in vivo bioavailability in monkey,,U,1,,CHEMBL625105,In vivo,22224,13249,,,A,,,Autocuration,,,
10963,BAO_0000218,Compound was tested for in vivo bioavailability in rat,,N,1,,CHEMBL625106,In vivo,50597,13249,,,A,,,Intermediate,,,
10964,BAO_0000218,Oral bioavailability in mouse,,U,1,,CHEMBL625107,In vivo,22224,9552,,,A,,,Autocuration,,,
10965,BAO_0000218,Compound was tested for percent of oral bioavailability in mice; 56-74,,N,1,,CHEMBL625108,In vivo,50594,9552,,,A,,,Intermediate,,,
10966,BAO_0000218,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,U,1,,CHEMBL625109,In vivo,22224,14839,,,A,,,Autocuration,,,
10967,BAO_0000218,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,U,1,,CHEMBL625110,In vivo,22224,14839,,,A,,,Autocuration,,,
10968,BAO_0000218,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,U,1,,CHEMBL625111,In vivo,22224,14839,,,A,,,Autocuration,,,
10969,BAO_0000218,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,N,1,,CHEMBL625112,In vivo,50594,14839,,,A,,,Intermediate,,,
10970,BAO_0000218,Oral bioavailability in nude mice,,N,1,,CHEMBL875334,In vivo,50594,14839,,,A,,,Intermediate,,,
10971,BAO_0000218,Bioavailability in monkey (i.d. dosing),,U,1,,CHEMBL628617,In vivo,22224,11219,,,A,,,Autocuration,,,
10972,BAO_0000218,Bioavailability in rat,,U,1,,CHEMBL628618,In vivo,22224,9552,,,A,,,Autocuration,,,
10973,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,U,1,,CHEMBL628619,In vivo,22224,11732,,,A,,,Autocuration,,,
10974,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,U,1,,CHEMBL628620,In vivo,22224,11732,,,A,,,Autocuration,,,
10975,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,N,1,,CHEMBL628621,In vivo,100710,14839,,,A,,,Intermediate,,,
10976,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,N,1,,CHEMBL628622,In vivo,100710,14839,,,A,,,Intermediate,,,
10977,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,N,1,,CHEMBL628623,In vivo,100710,14839,,,A,,,Intermediate,,,
10978,BAO_0000218,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1969.0,N,1,,CHEMBL628624,In vivo,100710,14839,,Plasma,A,,,Intermediate,,,
10979,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,N,1,,CHEMBL628625,In vivo,50594,14839,,Plasma,A,,,Intermediate,,,
10980,BAO_0000218,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1969.0,N,1,,CHEMBL628626,In vivo,100710,14839,,Plasma,A,,,Intermediate,,,
10981,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,N,1,,CHEMBL627041,In vivo,50594,14839,,Plasma,A,,,Intermediate,,,
10982,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,N,1,,CHEMBL627042,In vivo,50594,14839,,Plasma,A,,,Intermediate,,,
10983,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,N,1,,CHEMBL627043,In vivo,50594,14839,,Plasma,A,,,Intermediate,,,
10984,BAO_0000218,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1969.0,U,1,,CHEMBL627044,In vivo,22224,13932,,Plasma,A,,,Autocuration,,,
10985,BAO_0000218,Cmax in mouse plasma,1969.0,N,1,,CHEMBL627045,In vivo,50594,11637,,Plasma,A,,,Intermediate,,,
10986,BAO_0000218,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1969.0,U,1,,CHEMBL627046,In vivo,22224,11637,,Plasma,A,,,Autocuration,,,
10987,BAO_0000218,Maximal plasma concentration in rat,1969.0,N,1,,CHEMBL627047,In vivo,50597,13960,,Plasma,A,,,Intermediate,,,
10988,BAO_0000218,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1969.0,N,1,,CHEMBL627048,In vivo,50597,15905,,Plasma,A,,,Intermediate,,,
10989,BAO_0000218,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,N,1,,CHEMBL627049,In vivo,50597,14062,,,A,,,Intermediate,,,
10990,BAO_0000218,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,N,1,,CHEMBL627050,In vivo,50597,14062,,,A,,,Intermediate,,,
10991,BAO_0000218,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,N,1,,CHEMBL627051,In vivo,50597,14062,,,A,,,Intermediate,,,
10992,BAO_0000218,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,N,1,,CHEMBL627052,In vivo,50597,14062,,,A,,,Intermediate,,,
10993,BAO_0000218,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,N,1,,CHEMBL627053,In vivo,50597,14062,,,A,,,Intermediate,,,
10994,BAO_0000218,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,N,1,,CHEMBL627054,In vivo,50597,14062,,,A,,,Intermediate,,,
10995,BAO_0000218,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL627055,In vivo,50594,15011,,,A,,,Intermediate,,,
10996,BAO_0000218,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL627056,In vivo,50594,15011,,,A,,,Intermediate,,,
10997,BAO_0000218,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,N,1,,CHEMBL627057,In vivo,50594,15011,,,A,,,Intermediate,,,
10998,BAO_0000218,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL627058,In vivo,50594,15011,,,A,,,Intermediate,,,
10999,BAO_0000218,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,N,1,,CHEMBL626211,In vivo,50594,15011,,,A,,,Intermediate,,,
11000,BAO_0000218,Maximum Concentration of the compound.,,U,1,,CHEMBL626212,In vivo,22224,10291,,,A,,,Autocuration,,,
11001,BAO_0000218,Maximum Concentration was measured after iv administration into Beagle dog,,N,1,,CHEMBL626213,In vivo,50588,14599,,,A,,,Intermediate,,,
11002,BAO_0000218,Maximum Concentration was measured after iv administration into Beagle dog.,,N,1,,CHEMBL626214,In vivo,50588,14599,,,A,,,Intermediate,,,
11003,BAO_0000218,Maximum Concentration was measured after po administration into Beagle dog,,N,1,,CHEMBL626215,In vivo,50588,14599,,,A,,,Intermediate,,,
11004,BAO_0000218,Maximum Concentration was measured after po administration into Beagle dog.,,N,1,,CHEMBL626216,In vivo,50588,14599,,,A,,,Intermediate,,,
11005,BAO_0000218,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,178.0,U,1,,CHEMBL626217,In vivo,22224,12767,,Blood,A,,,Autocuration,,,
11006,BAO_0000218,Maximum blood level reached after an iv dose of 12.2 uM/kg,178.0,U,1,,CHEMBL626218,In vivo,22224,12767,,Blood,A,,,Autocuration,,,
11007,BAO_0000218,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,178.0,U,1,,CHEMBL626219,In vivo,22224,12767,,Blood,A,,,Autocuration,,,
11008,BAO_0000218,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,178.0,U,1,,CHEMBL626220,In vivo,22224,12767,,Blood,A,,,Autocuration,,,
11009,BAO_0000218,Maximum blood level reached after an oral dose of 5.0 mg/kg,178.0,U,1,,CHEMBL626221,In vivo,22224,12767,,Blood,A,,,Autocuration,,,
11010,BAO_0000218,Maximum blood level reached at dose of 10.6 uM/kg orally,178.0,U,1,,CHEMBL626222,In vivo,22224,12767,,Blood,A,,,Autocuration,,,
11011,BAO_0000218,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,N,1,,CHEMBL626223,In vivo,50512,14706,,,A,,,Intermediate,,,
11012,BAO_0000218,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,N,1,,CHEMBL626224,In vivo,50512,14706,,,A,,,Intermediate,,,
11013,BAO_0000218,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,955.0,N,1,,CHEMBL626225,In vivo,50597,14793,,Brain,A,,,Intermediate,,,
11014,BAO_0000218,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,955.0,N,1,,CHEMBL626226,In vivo,50597,14793,,Brain,A,,,Intermediate,,,
11015,BAO_0000218,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,955.0,N,1,,CHEMBL626227,In vivo,50597,14793,,Brain,A,,,Intermediate,,,
11016,BAO_0000218,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,955.0,N,1,,CHEMBL626228,In vivo,50597,14793,,Brain,A,,,Intermediate,,,
11017,BAO_0000218,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,N,1,,CHEMBL626229,In vivo,50597,14793,,,A,,,Intermediate,,,
11018,BAO_0000218,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,N,1,,CHEMBL626921,In vivo,50597,14793,,,A,,,Intermediate,,,
11019,BAO_0000218,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,N,1,,CHEMBL876793,In vivo,50597,14793,,,A,,,Intermediate,,,
11020,BAO_0000218,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,N,1,,CHEMBL625309,In vivo,50597,14793,,,A,,,Intermediate,,,
11021,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,N,1,,CHEMBL625310,In vivo,50278,10524,,,A,,,Intermediate,,,
11022,BAO_0000218,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,U,1,,CHEMBL625311,In vivo,22224,11871,,,A,,,Autocuration,,,
11023,BAO_0000218,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,N,1,,CHEMBL625312,In vivo,50597,11871,,,A,,,Intermediate,,,
11024,BAO_0000218,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,U,1,,CHEMBL625313,In vivo,22224,3437,,,A,,,Autocuration,,,
11025,BAO_0000218,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,N,1,,CHEMBL625314,In vivo,50594,12038,,,A,,,Intermediate,,,
11026,BAO_0000218,Maximum concentration in male rats after iv administration of 20 mg/kg,,N,1,,CHEMBL625315,In vivo,50597,12038,,,A,,,Intermediate,,,
11027,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,2107.0,N,1,,CHEMBL625316,,50597,8418,,Liver,A,,,Intermediate,,,
11028,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,2107.0,N,1,,CHEMBL625317,,50597,8418,,Liver,A,,,Intermediate,,,
11029,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,2107.0,N,1,,CHEMBL625318,,50597,8418,,Liver,A,,,Intermediate,,,
11030,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,2107.0,N,1,,CHEMBL625319,,50597,8418,,Liver,A,,,Intermediate,,,
11031,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,2107.0,N,1,,CHEMBL625320,,50597,8418,,Liver,A,,,Intermediate,,,
11032,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,2107.0,N,1,,CHEMBL625321,,50597,8418,,Liver,A,,,Intermediate,,,
11033,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,2107.0,N,1,,CHEMBL625322,,50597,8418,,Liver,A,,,Intermediate,,,
11034,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,2107.0,N,1,,CHEMBL876801,,50597,8418,,Liver,A,,,Intermediate,,,
11035,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,2107.0,N,1,,CHEMBL625323,,50597,8418,,Liver,A,,,Intermediate,,,
11036,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,2107.0,N,1,,CHEMBL625324,,50597,8418,,Liver,A,,,Intermediate,,,
11037,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,2107.0,N,1,,CHEMBL625325,,50597,8418,,Liver,A,,,Intermediate,,,
11038,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,2107.0,N,1,,CHEMBL625326,,50597,8418,,Liver,A,,,Intermediate,,,
11039,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,2107.0,N,1,,CHEMBL625327,,50597,8418,,Liver,A,,,Intermediate,,,
11040,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,2107.0,N,1,,CHEMBL625328,,50597,8418,,Liver,A,,,Intermediate,,,
11041,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,2048.0,N,1,,CHEMBL625329,,50597,8418,,Lung,A,,,Intermediate,,,
11042,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,2048.0,N,1,,CHEMBL625330,,50597,8418,,Lung,A,,,Intermediate,,,
11043,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,2048.0,N,1,,CHEMBL627774,,50597,8418,,Lung,A,,,Intermediate,,,
11044,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,2048.0,N,1,,CHEMBL627775,,50597,8418,,Lung,A,,,Intermediate,,,
11045,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,2048.0,N,1,,CHEMBL627949,,50597,8418,,Lung,A,,,Intermediate,,,
11046,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,2048.0,N,1,,CHEMBL627950,,50597,8418,,Lung,A,,,Intermediate,,,
11047,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,2048.0,N,1,,CHEMBL627951,,50597,8418,,Lung,A,,,Intermediate,,,
11048,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,2048.0,N,1,,CHEMBL627952,,50597,8418,,Lung,A,,,Intermediate,,,
11049,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,2048.0,N,1,,CHEMBL627953,,50597,8418,,Lung,A,,,Intermediate,,,
11050,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,2048.0,N,1,,CHEMBL627954,,50597,8418,,Lung,A,,,Intermediate,,,
11051,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,2048.0,N,1,,CHEMBL627955,,50597,8418,,Lung,A,,,Intermediate,,,
11052,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,2048.0,N,1,,CHEMBL627956,,50597,8418,,Lung,A,,,Intermediate,,,
11053,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,2048.0,N,1,,CHEMBL876802,,50597,8418,,Lung,A,,,Intermediate,,,
11054,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,2048.0,N,1,,CHEMBL627957,,50597,8418,,Lung,A,,,Intermediate,,,
11055,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,2048.0,N,1,,CHEMBL627958,,50597,8418,,Lung,A,,,Intermediate,,,
11056,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,2048.0,N,1,,CHEMBL627959,,50597,8418,,Lung,A,,,Intermediate,,,
11057,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,2048.0,N,1,,CHEMBL627960,,50597,8418,,Lung,A,,,Intermediate,,,
11058,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,2048.0,N,1,,CHEMBL627961,,50597,8418,,Lung,A,,,Intermediate,,,
11059,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,2048.0,N,1,,CHEMBL627962,,50597,8418,,Lung,A,,,Intermediate,,,
11060,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,N,1,,CHEMBL627963,,50597,9796,,,A,,,Intermediate,,,
11061,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,N,1,,CHEMBL624759,,50597,9796,,,A,,,Intermediate,,,
11062,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,N,1,,CHEMBL624760,,50597,9796,,,A,,,Intermediate,,,
11063,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,N,1,,CHEMBL624761,,50597,9796,,,A,,,Intermediate,,,
11064,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,N,1,,CHEMBL877607,,50597,9796,,,A,,,Intermediate,,,
11065,BAO_0000218,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,2107.0,N,1,,CHEMBL624762,,50597,9796,,Liver,A,,,Intermediate,,,
11066,BAO_0000218,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,N,1,,CHEMBL624763,,50597,9796,,Liver,A,,,Intermediate,,,
11067,BAO_0000218,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,2107.0,N,1,,CHEMBL624764,,50597,9796,,Liver,A,,,Intermediate,,,
11068,BAO_0000218,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,N,1,,CHEMBL624765,,50597,9796,,Liver,A,,,Intermediate,,,
11069,BAO_0000218,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,N,1,,CHEMBL624766,,50597,9796,,Liver,A,,,Intermediate,,,
11070,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL624767,,50588,6996,,,A,,,Intermediate,,,
11071,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,N,1,,CHEMBL624768,,50588,6996,,,A,,,Intermediate,,,
11072,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL624769,,50588,6996,,,A,,,Intermediate,,,
11073,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL624770,,50588,6996,,,A,,,Intermediate,,,
11074,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,N,1,,CHEMBL624771,,50588,6996,,,A,,,Intermediate,,,
11075,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL624772,,50588,6996,,,A,,,Intermediate,,,
11076,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,N,1,,CHEMBL624773,,50597,6996,,,A,,,Intermediate,,,
11077,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL624774,,50597,6996,,,A,,,Intermediate,,,
11078,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL624775,,50597,6996,,,A,,,Intermediate,,,
11079,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL624776,,50597,6996,,,A,,,Intermediate,,,
11080,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL624777,,50597,6996,,,A,,,Intermediate,,,
11081,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL624778,,50597,6996,,,A,,,Intermediate,,,
11082,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,N,1,,CHEMBL624779,,50597,6996,,,A,,,Intermediate,,,
11083,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL624780,,50597,6996,,,A,,,Intermediate,,,
11084,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL624781,,50597,6996,,,A,,,Intermediate,,,
11085,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL877608,,50597,6996,,,A,,,Intermediate,,,
11086,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL624782,,50597,6996,,,A,,,Intermediate,,,
11087,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL624783,,50597,6996,,,A,,,Intermediate,,,
11088,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,N,1,,CHEMBL624784,,50597,6996,,,A,,,Intermediate,,,
11089,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL624785,,50597,6996,,,A,,,Intermediate,,,
11090,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL624786,,50597,6996,,,A,,,Intermediate,,,
11091,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL624787,,50597,6996,,,A,,,Intermediate,,,
11092,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL628676,,50597,6996,,,A,,,Intermediate,,,
11093,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,N,1,,CHEMBL621842,,50597,6996,,,A,,,Intermediate,,,
11094,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL621843,,50597,6996,,,A,,,Intermediate,,,
11095,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL623873,,50597,6996,,,A,,,Intermediate,,,
11096,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL623874,,50597,6996,,,A,,,Intermediate,,,
11097,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL623875,,50597,6996,,,A,,,Intermediate,,,
11098,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL623876,,50597,6996,,,A,,,Intermediate,,,
11099,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,N,1,,CHEMBL623877,,50588,6996,,,A,,,Intermediate,,,
11100,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL623878,,50588,6996,,,A,,,Intermediate,,,
11101,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,N,1,,CHEMBL623879,,50588,6996,,,A,,,Intermediate,,,
11102,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL623880,,50588,6996,,,A,,,Intermediate,,,
11103,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL623881,,50588,6996,,,A,,,Intermediate,,,
11104,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL623957,,50588,6996,,,A,,,Intermediate,,,
11105,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL623958,,50588,6996,,,A,,,Intermediate,,,
11106,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL623959,,50588,6996,,,A,,,Intermediate,,,
11107,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL623960,,50588,6996,,,A,,,Intermediate,,,
11108,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL623961,,50588,6996,,,A,,,Intermediate,,,
11109,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL623962,,50588,6996,,,A,,,Intermediate,,,
11110,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,N,1,,CHEMBL624676,,50588,6996,,,A,,,Intermediate,,,
11111,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL624677,,50588,6996,,,A,,,Intermediate,,,
11112,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,N,1,,CHEMBL624678,,50588,6996,,,A,,,Intermediate,,,
11113,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL624679,,50588,6996,,,A,,,Intermediate,,,
11114,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL624680,,50588,6996,,,A,,,Intermediate,,,
11115,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,U,1,,CHEMBL624849,In vivo,22224,11732,,,A,,,Autocuration,,,
11116,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,U,1,,CHEMBL624850,In vivo,22224,11732,,,A,,,Autocuration,,,
11117,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,U,1,,CHEMBL874399,In vivo,22224,11732,,,A,,,Autocuration,,,
11118,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,U,1,,CHEMBL624851,In vivo,22224,11732,,,A,,,Autocuration,,,
11119,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,U,1,,CHEMBL624852,In vivo,22224,11732,,,A,,,Autocuration,,,
11120,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),,U,1,,CHEMBL624853,In vivo,22224,13359,,,A,,,Autocuration,,,
11121,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley),,U,1,,CHEMBL624854,In vivo,22224,16618,,,A,,,Autocuration,,,
11122,BAO_0000218,Oral bioavailability in rat,,U,1,,CHEMBL624855,In vivo,22224,13960,,,A,,,Autocuration,,,
11123,BAO_0000218,Oral bioavailability in rats was determined in vivo,,U,1,,CHEMBL624856,In vivo,22224,13917,,,A,,,Autocuration,,,
11124,BAO_0000218,Oral bioavailability in dog,,U,1,,CHEMBL882957,In vivo,22224,14266,,,A,,,Autocuration,,,
11125,BAO_0000218,Oral bioavailability of compound in monkey,,U,1,,CHEMBL624857,In vivo,22224,12359,,,A,,,Autocuration,,,
11126,BAO_0000218,Oral bioavailability of compound in rat,,N,1,,CHEMBL622202,In vivo,50597,12359,,,A,,,Intermediate,,,
11127,BAO_0000218,Bioavailability in rat of PMEA prodrug,,U,1,,CHEMBL622203,In vivo,22224,12359,,,A,,,Autocuration,,,
11128,BAO_0000218,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,N,1,,CHEMBL625522,In vivo,50597,12359,,,A,,,Intermediate,,,
11129,BAO_0000218,Serum conc at 3 hours following 25 mg/kg dose,,U,1,,CHEMBL622868,In vivo,22224,10791,,,A,,,Autocuration,,,
11130,BAO_0000218,Urine conc 0-5 hours following 25 mg/kg dose,1088.0,U,1,,CHEMBL622869,In vivo,22224,10791,,Urine,A,,,Autocuration,,,
11131,BAO_0000218,Urine conc 0-24 hours following 25 mg/kg dose,1088.0,U,1,,CHEMBL622870,In vivo,22224,10791,,Urine,A,,,Autocuration,,,
11132,BAO_0000218,Oral bioavailability in African green monkeys; 20-25,,U,1,,CHEMBL622871,In vivo,22224,138,,,A,,,Autocuration,,,
11133,BAO_0000218,Oral bioavailability in cynomolgus monkey.,,N,1,,CHEMBL620560,In vivo,100710,14521,,,A,,,Intermediate,,,
11134,BAO_0000218,Oral bioavailability in dog,,U,1,,CHEMBL620561,In vivo,22224,13953,,,A,,,Autocuration,,,
11135,BAO_0000218,Oral bioavailability in dog at 10 mg/kg oral dose,,N,1,,CHEMBL620562,In vivo,50588,12836,,,A,,,Intermediate,,,
11136,BAO_0000218,Oral bioavailability in hamster at 10 mg/kg oral dose,,N,1,,CHEMBL620563,In vivo,100712,12836,,,A,,,Intermediate,,,
11137,BAO_0000218,Oral bioavailability in rat at 10 mg/kg oral dose,,N,1,,CHEMBL620564,In vivo,50597,12836,,,A,,,Intermediate,,,
11138,BAO_0000218,Oral bioavailability in rat,,U,1,,CHEMBL872265,In vivo,22224,14521,,,A,,,Autocuration,,,
11139,BAO_0000218,Oral bioavailability in rat,,U,1,,CHEMBL620565,In vivo,22224,13953,,,A,,,Autocuration,,,
11140,BAO_0000218,Oral bioavailability,,U,1,,CHEMBL620566,In vivo,22224,6799,,,A,,,Autocuration,,,
11141,BAO_0000218,Oral bioavailability was determined; range 49-102%,,U,1,,CHEMBL620567,In vivo,22224,11311,,,A,,,Autocuration,,,
11142,BAO_0000218,Oral bioavailability was determined in dogs,,N,1,,CHEMBL620568,In vivo,50588,4013,,,A,,,Intermediate,,,
11143,BAO_0000218,Oral bioavailability in rat,,U,1,,CHEMBL620569,In vivo,22224,4013,,,A,,,Autocuration,,,
11144,BAO_0000218,Oral bioavailability,,U,1,,CHEMBL620570,In vivo,22224,17591,,,A,,,Autocuration,,,
11145,BAO_0000218,Oral bioavailability was determined; Not orally available,,U,1,,CHEMBL620571,In vivo,22224,17591,,,A,,,Autocuration,,,
11146,BAO_0000218,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,N,1,,CHEMBL620572,In vivo,50594,15011,,,A,,,Intermediate,,,
11147,BAO_0000218,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,U,1,,CHEMBL620573,In vivo,22224,15011,,,A,,,Autocuration,,,
11148,BAO_0000218,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,U,1,,CHEMBL620574,In vivo,22224,15011,,,A,,,Autocuration,,,
11149,BAO_0000218,Oral bioavailability in Rhesus monkey,,U,1,,CHEMBL620575,In vivo,22224,9552,,,A,,,Autocuration,,,
11150,BAO_0000218,Oral bioavailability in dog (female mongrel),,U,1,,CHEMBL620576,In vivo,22224,9552,,,A,,,Autocuration,,,
11151,BAO_0000218,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,U,1,,CHEMBL875846,In vivo,22224,3639,,,A,,,Autocuration,,,
11152,BAO_0000218,Oral bioavailability in dog,,U,1,,CHEMBL620577,In vivo,22224,13397,,,A,,,Autocuration,,,
11153,BAO_0000218,Percentage Bioavailability was evaluated.,,U,1,,CHEMBL620578,In vivo,22224,3031,,,A,,,Autocuration,,,
11154,BAO_0000218,Bioavailability in rat administered i.d.,,U,1,,CHEMBL620579,In vivo,22224,12818,,,A,,,Autocuration,,,
11155,BAO_0000218,Bioavailability,,U,1,,CHEMBL621248,In vivo,22224,4847,,,A,,,Autocuration,,,
11156,BAO_0000218,Bioavailability in dog (male Beagle) i.v. administration,,U,1,,CHEMBL625390,In vivo,22224,12421,,,A,,,Autocuration,,,
11157,BAO_0000218,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,U,1,,CHEMBL625391,In vivo,22224,11966,,,A,,,Autocuration,,,
11158,BAO_0000218,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,U,1,,CHEMBL872266,In vivo,22224,11218,,,A,,,Autocuration,,,
11159,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (male),,U,1,,CHEMBL625392,In vivo,22224,13129,,,A,,,Autocuration,,,
11160,BAO_0000218,The oral bioavailability was measured on rats after oral administration,,N,1,,CHEMBL625393,In vivo,50597,12350,,,A,,,Intermediate,,,
11161,BAO_0000218,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,N,1,,CHEMBL625394,In vivo,50597,2231,,,A,,,Intermediate,,,
11162,BAO_0000218,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,N,1,,CHEMBL625395,In vivo,50797,2231,,,A,,,Intermediate,,,
11163,BAO_0000218,Bioavailability in rat (dose 10 mg/kg i.d.),,U,1,,CHEMBL625396,In vivo,22224,12187,,,A,,,Autocuration,,,
11164,BAO_0000218,Bioavailability in dog (male Beagle) i.v. administration,,U,1,,CHEMBL625397,In vivo,22224,12421,,,A,,,Autocuration,,,
11165,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL625398,In vivo,50594,13256,,,A,,,Intermediate,,,
11166,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,N,1,,CHEMBL625399,In vivo,50594,13256,,Blood,A,,,Intermediate,,,
11167,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,N,1,,CHEMBL626074,In vivo,50594,13256,,Cerebellum,A,,,Intermediate,,,
11168,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL626075,In vivo,50594,13256,,,A,,,Intermediate,,,
11169,BAO_0000218,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1969.0,N,1,,CHEMBL626076,In vivo,50597,2231,,Plasma,A,,,Intermediate,,,
11170,BAO_0000218,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1969.0,N,1,,CHEMBL626077,In vivo,50797,2231,,Plasma,A,,,Intermediate,,,
11171,BAO_0000218,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),178.0,N,1,,CHEMBL626078,In vivo,50597,12178,,Blood,A,,,Intermediate,,,
11172,BAO_0000218,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),178.0,U,1,,CHEMBL625846,In vivo,22224,12178,,Blood,A,,,Autocuration,,,
11173,BAO_0000218,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),178.0,U,1,,CHEMBL625847,In vivo,22224,12178,,Blood,A,,,Autocuration,,,
11174,BAO_0000218,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,N,1,,CHEMBL625848,In vivo,50597,15633,,,A,,,Expert,,,
11175,BAO_0000218,Maximum concentration of compound in plasma administered orally to rats,1969.0,N,1,,CHEMBL625849,In vivo,50597,14258,,Plasma,A,,,Intermediate,,,
11176,BAO_0000218,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1969.0,N,1,,CHEMBL626023,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
11177,BAO_0000218,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1969.0,N,1,,CHEMBL626024,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
11178,BAO_0000218,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1969.0,N,1,,CHEMBL626025,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
11179,BAO_0000218,Maximum concentration after 10 mg/kg by oral administration,,U,1,,CHEMBL626026,In vivo,22224,5566,,,A,,,Autocuration,,,
11180,BAO_0000218,Maximum concentration at a dose of 1.5 mg/kg,,U,1,,CHEMBL626027,In vivo,22224,16935,,,A,,,Autocuration,,,
11181,BAO_0000218,Maximum concentration at a dose of 2.0 mg/kg,,U,1,,CHEMBL626028,In vivo,22224,16935,,,A,,,Autocuration,,,
11182,BAO_0000218,Maximum concentration in dog plasma,1969.0,N,1,,CHEMBL626029,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
11183,BAO_0000218,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1969.0,U,1,,CHEMBL626030,In vivo,22224,12536,,Plasma,A,,,Autocuration,,,
11184,BAO_0000218,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1969.0,U,1,,CHEMBL626031,In vivo,22224,12536,,Plasma,A,,,Autocuration,,,
11185,BAO_0000218,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1969.0,U,1,,CHEMBL626032,In vivo,22224,12536,,Plasma,A,,,Autocuration,,,
11186,BAO_0000218,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1969.0,U,1,,CHEMBL626033,In vivo,22224,12536,,Plasma,A,,,Autocuration,,,
11187,BAO_0000218,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1969.0,U,1,,CHEMBL626034,In vivo,22224,12536,,Plasma,A,,,Autocuration,,,
11188,BAO_0000218,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1969.0,N,1,,CHEMBL626035,In vivo,50588,9994,,Plasma,A,,,Intermediate,,,
11189,BAO_0000218,Maximum concentration in plasma at Tmax,1969.0,U,1,,CHEMBL626036,In vivo,22224,1434,,Plasma,A,,,Autocuration,,,
11190,BAO_0000218,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1969.0,N,1,,CHEMBL626037,In vivo,50588,12836,,Plasma,A,,,Expert,,,
11191,BAO_0000218,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1969.0,N,1,,CHEMBL626038,In vivo,100712,12836,,Plasma,A,,,Intermediate,,,
11192,BAO_0000218,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1969.0,N,1,,CHEMBL626039,In vivo,50597,12836,,Plasma,A,,,Intermediate,,,
11193,BAO_0000218,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1969.0,N,1,,CHEMBL626040,In vivo,50597,12545,,Plasma,A,,,Intermediate,,,
11194,BAO_0000218,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1969.0,N,1,,CHEMBL626041,In vivo,50592,13856,,Plasma,A,,,Intermediate,,,
11195,BAO_0000218,Maximum concentration was calculated,,U,1,,CHEMBL626042,In vivo,22224,3550,,,A,,,Autocuration,,,
11196,BAO_0000218,Maximum concentration was calculated.,,U,1,,CHEMBL626043,In vivo,22224,2632,,,A,,,Autocuration,,,
11197,BAO_0000218,Maximum concentration at a peroral dose of 10 mg/kg,,U,1,,CHEMBL626044,In vivo,22224,5566,,,A,,,Autocuration,,,
11198,BAO_0000218,Maximum concentration of the drug at 10 uM/dg administered perorally,,U,1,,CHEMBL626045,In vivo,22224,11883,,,A,,,Autocuration,,,
11199,BAO_0000218,Maximum concentration of the drug at 2 uM/dg administered intravenously,,U,1,,CHEMBL626046,In vivo,22224,11883,,,A,,,Autocuration,,,
11200,BAO_0000218,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1969.0,N,1,,CHEMBL626047,In vivo,50588,14122,,Plasma,A,,,Intermediate,,,
11201,BAO_0000218,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1969.0,N,1,,CHEMBL626048,In vivo,100712,14122,,Plasma,A,,,Intermediate,,,
11202,BAO_0000218,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1969.0,N,1,,CHEMBL626049,In vivo,50597,14122,,Plasma,A,,,Intermediate,,,
11203,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1969.0,N,1,,CHEMBL626050,In vivo,50597,12542,,Plasma,A,,,Intermediate,,,
11204,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1969.0,N,1,,CHEMBL874541,In vivo,50588,12542,,Plasma,A,,,Intermediate,,,
11205,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1969.0,N,1,,CHEMBL622826,In vivo,100712,12542,,Plasma,A,,,Intermediate,,,
11206,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1969.0,N,1,,CHEMBL622827,In vivo,100712,12542,,Plasma,A,,,Intermediate,,,
11207,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1969.0,N,1,,CHEMBL622828,In vivo,50597,12542,,Plasma,A,,,Intermediate,,,
11208,BAO_0000218,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1969.0,N,1,,CHEMBL622829,In vivo,50597,14080,,Plasma,A,,,Intermediate,,,
11209,BAO_0000218,Maximum concentration reached following intravenous administration in male rat,,N,1,,CHEMBL876806,In vivo,50597,11911,,,A,,,Intermediate,,,
11210,BAO_0000218,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,N,1,,CHEMBL622830,In vivo,50588,13204,,,A,,,Intermediate,,,
11211,BAO_0000218,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,N,1,,CHEMBL622831,In vivo,50597,13204,,,A,,,Intermediate,,,
11212,BAO_0000218,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,N,1,,CHEMBL626794,In vivo,50588,14346,,,A,,,Intermediate,,,
11213,BAO_0000218,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,N,1,,CHEMBL626795,In vivo,50597,14346,,,A,,,Intermediate,,,
11214,BAO_0000218,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,N,1,,CHEMBL626796,In vivo,50597,14346,,,A,,,Intermediate,,,
11215,BAO_0000218,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,N,1,,CHEMBL626797,In vivo,50597,14346,,,A,,,Intermediate,,,
11216,BAO_0000218,Maximum drug concentration is determined after oral dosing in rats.,,N,1,,CHEMBL626798,In vivo,50597,14127,,,A,,,Intermediate,,,
11217,BAO_0000218,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,N,1,,CHEMBL626799,In vivo,50588,14339,,,A,,,Intermediate,,,
11218,BAO_0000218,Maximum observed concentration in oral (5 mg/kg) fed dogs,,N,1,,CHEMBL626800,In vivo,50588,14339,,,A,,,Intermediate,,,
11219,BAO_0000218,Maximum plasma concentration,1969.0,U,1,,CHEMBL626801,In vivo,22224,13494,,Plasma,A,,,Autocuration,,,
11220,BAO_0000218,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1969.0,N,1,,CHEMBL876816,In vivo,50597,14925,,Plasma,A,,,Intermediate,,,
11221,BAO_0000218,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1969.0,N,1,,CHEMBL626802,In vivo,50597,14474,,Plasma,A,,,Intermediate,,,
11222,BAO_0000218,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1969.0,N,1,,CHEMBL626803,In vivo,50588,14474,,Plasma,A,,,Intermediate,,,
11223,BAO_0000218,Maximum plasma concentration following oral administration of 30 umol/kg,1969.0,U,1,,CHEMBL626804,In vivo,22224,13917,,Plasma,A,,,Autocuration,,,
11224,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1969.0,N,1,,CHEMBL626805,,50597,9796,,Plasma,A,,,Intermediate,,,
11225,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1969.0,N,1,,CHEMBL626309,,50597,9796,,Plasma,A,,,Intermediate,,,
11226,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1969.0,N,1,,CHEMBL626310,,50597,9796,,Plasma,A,,,Intermediate,,,
11227,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1969.0,N,1,,CHEMBL626311,,50597,9796,,Plasma,A,,,Intermediate,,,
11228,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1969.0,N,1,,CHEMBL626312,,50597,9796,,Plasma,A,,,Intermediate,,,
11229,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,N,1,,CHEMBL626313,,50597,9796,,Uterus,A,,,Intermediate,,,
11230,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,995.0,N,1,,CHEMBL626314,,50597,9796,,Uterus,A,,,Intermediate,,,
11231,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,995.0,N,1,,CHEMBL626315,,50597,9796,,Uterus,A,,,Intermediate,,,
11232,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,N,1,,CHEMBL626316,,50597,9796,,Uterus,A,,,Intermediate,,,
11233,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,N,1,,CHEMBL626317,,50597,9796,,Uterus,A,,,Intermediate,,,
11234,BAO_0000218,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,N,1,,CHEMBL626318,,50597,8363,,,A,,,Intermediate,,,
11235,BAO_0000218,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,N,1,,CHEMBL626319,,50597,8363,,,A,,,Intermediate,,,
11236,BAO_0000218,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,N,1,,CHEMBL626320,,50597,8363,,,A,,,Intermediate,,,
11237,BAO_0000218,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,N,1,,CHEMBL875053,,50597,8363,,,A,,,Intermediate,,,
11238,BAO_0000218,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,N,1,,CHEMBL626321,,50597,8363,,,A,,,Intermediate,,,
11239,BAO_0000218,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,N,1,,CHEMBL626322,,50597,8363,,,A,,,Intermediate,,,
11240,BAO_0000218,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,N,1,,CHEMBL626323,,50597,8363,,,A,,,Intermediate,,,
11241,BAO_0000218,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,N,1,,CHEMBL626324,,50597,8363,,,A,,,Intermediate,,,
11242,BAO_0000218,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,N,1,,CHEMBL626325,,50597,8363,,,A,,,Intermediate,,,
11243,BAO_0000218,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,N,1,,CHEMBL626326,,50597,8363,,,A,,,Intermediate,,,
11244,BAO_0000218,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,N,1,,CHEMBL626327,,50597,8363,,,A,,,Intermediate,,,
11245,BAO_0000218,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,N,1,,CHEMBL626328,,50597,8363,,,A,,,Intermediate,,,
11246,BAO_0000218,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626329,,50597,8684,,Blood,A,,,Intermediate,,,
11247,BAO_0000218,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626330,,50597,8684,,Blood,A,,,Intermediate,,,
11248,BAO_0000218,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626331,,50597,8684,,Blood,A,,,Intermediate,,,
11249,BAO_0000218,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626332,,50597,8684,,Blood,A,,,Intermediate,,,
11250,BAO_0000218,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626333,,50597,8684,,Blood,A,,,Intermediate,,,
11251,BAO_0000218,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626334,,50597,8684,,Blood,A,,,Intermediate,,,
11252,BAO_0000218,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL626335,,50597,8684,,Blood,A,,,Intermediate,,,
11253,BAO_0000218,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",178.0,N,1,,CHEMBL624798,,50597,8684,,Blood,A,,,Intermediate,,,
11254,BAO_0000218,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624799,,50597,8684,,Brain,A,,,Intermediate,,,
11255,BAO_0000218,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624800,,50597,8684,,Brain,A,,,Intermediate,,,
11256,BAO_0000218,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624801,,50597,8684,,Brain,A,,,Intermediate,,,
11257,BAO_0000218,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624802,,50597,8684,,Brain,A,,,Intermediate,,,
11258,BAO_0000218,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624803,,50597,8684,,Brain,A,,,Intermediate,,,
11259,BAO_0000218,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624804,,50597,8684,,Brain,A,,,Intermediate,,,
11260,BAO_0000218,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624805,,50597,8684,,Brain,A,,,Intermediate,,,
11261,BAO_0000218,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",955.0,N,1,,CHEMBL624806,,50597,8684,,Brain,A,,,Intermediate,,,
11262,BAO_0000218,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624807,,50597,8684,,,A,,,Intermediate,,,
11263,BAO_0000218,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624808,,50597,8684,,,A,,,Intermediate,,,
11264,BAO_0000218,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624809,,50597,8684,,,A,,,Intermediate,,,
11265,BAO_0000218,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624810,,50597,8684,,,A,,,Intermediate,,,
11266,BAO_0000218,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL877618,,50597,8684,,,A,,,Intermediate,,,
11267,BAO_0000218,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624811,,50597,8684,,,A,,,Intermediate,,,
11268,BAO_0000218,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624812,,50597,8684,,,A,,,Intermediate,,,
11269,BAO_0000218,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624813,,50597,8684,,,A,,,Intermediate,,,
11270,BAO_0000218,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624814,,50597,8684,,,A,,,Intermediate,,,
11271,BAO_0000218,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624815,,50597,8684,,,A,,,Intermediate,,,
11272,BAO_0000218,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624816,,50597,8684,,,A,,,Intermediate,,,
11273,BAO_0000218,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624817,,50597,8684,,,A,,,Intermediate,,,
11274,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL624818,,50588,6996,,,A,,,Intermediate,,,
11275,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,N,1,,CHEMBL624819,,50588,6996,,,A,,,Intermediate,,,
11276,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL624820,,50588,6996,,,A,,,Intermediate,,,
11277,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL624821,,50588,6996,,,A,,,Intermediate,,,
11278,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,N,1,,CHEMBL624822,,50588,6996,,,A,,,Intermediate,,,
11279,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL624823,,50588,6996,,,A,,,Intermediate,,,
11280,BAO_0000218,Observed diffusion coefficient in organic solvent for Escherichia coli,,N,1,,CHEMBL624824,,50212,15599,,,A,,,Intermediate,,,
11281,BAO_0000218,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",178.0,N,1,,CHEMBL624825,,50597,9614,,Blood,A,,,Intermediate,,,
11282,BAO_0000218,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",178.0,N,1,,CHEMBL624826,,50597,9614,,Blood,A,,,Intermediate,,,
11283,BAO_0000218,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2081.0,N,1,,CHEMBL876817,,50597,9614,,Cardiac atrium,A,,,Intermediate,,,
11284,BAO_0000218,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2081.0,N,1,,CHEMBL624827,,50597,9614,,Cardiac atrium,A,,,Intermediate,,,
11285,BAO_0000218,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,1,,CHEMBL624828,,50597,9614,,,A,,,Intermediate,,,
11286,BAO_0000218,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,1,,CHEMBL624829,,50597,9614,,,A,,,Intermediate,,,
11287,BAO_0000218,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2107.0,N,1,,CHEMBL624830,,50597,9614,,Liver,A,,,Intermediate,,,
11288,BAO_0000218,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2107.0,N,1,,CHEMBL624831,,50597,9614,,Liver,A,,,Intermediate,,,
11289,BAO_0000218,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2081.0,N,1,,CHEMBL624832,,50597,9614,,Cardiac atrium,A,,,Intermediate,,,
11290,BAO_0000218,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2081.0,N,1,,CHEMBL624833,,50597,9614,,Cardiac atrium,A,,,Intermediate,,,
11291,BAO_0000218,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,1,,CHEMBL624834,,50597,9614,,,A,,,Intermediate,,,
11292,BAO_0000218,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,1,,CHEMBL624835,,50597,9614,,,A,,,Intermediate,,,
11293,BAO_0000218,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2106.0,N,1,,CHEMBL624836,,50597,9614,,Spleen,A,,,Intermediate,,,
11294,BAO_0000218,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2106.0,N,1,,CHEMBL624837,,50597,9614,,Spleen,A,,,Intermediate,,,
11295,BAO_0000218,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,178.0,N,1,,CHEMBL624838,,50597,9071,,Blood,A,,,Intermediate,,,
11296,BAO_0000218,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,178.0,N,1,,CHEMBL622188,,50597,9071,,Blood,A,,,Intermediate,,,
11297,BAO_0000218,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,948.0,N,1,,CHEMBL622189,,50597,9071,,Heart,A,,,Intermediate,,,
11298,BAO_0000218,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,948.0,N,1,,CHEMBL622190,,50597,9071,,Heart,A,,,Intermediate,,,
11299,BAO_0000218,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,948.0,N,1,,CHEMBL625170,,50597,9071,,Heart,A,,,Intermediate,,,
11300,BAO_0000218,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,2113.0,N,1,,CHEMBL625171,,50597,9071,,Kidney,A,,,Intermediate,,,
11301,BAO_0000218,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,2113.0,N,1,,CHEMBL625172,,50597,9071,,Kidney,A,,,Intermediate,,,
11302,BAO_0000218,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,2113.0,N,1,,CHEMBL625173,,50597,9071,,Kidney,A,,,Intermediate,,,
11303,BAO_0000218,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,2107.0,N,1,,CHEMBL625174,,50597,9071,,Liver,A,,,Intermediate,,,
11304,BAO_0000218,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,2107.0,N,1,,CHEMBL625175,,50597,9071,,Liver,A,,,Intermediate,,,
11305,BAO_0000218,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,2107.0,N,1,,CHEMBL625176,,50597,9071,,Liver,A,,,Intermediate,,,
11306,BAO_0000218,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,2048.0,N,1,,CHEMBL625177,,50597,9071,,Lung,A,,,Intermediate,,,
11307,BAO_0000218,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,2048.0,N,1,,CHEMBL625178,,50597,9071,,Lung,A,,,Intermediate,,,
11308,BAO_0000218,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,2048.0,N,1,,CHEMBL625179,,50597,9071,,Lung,A,,,Intermediate,,,
11309,BAO_0000218,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,2048.0,N,1,,CHEMBL625180,,50597,9071,,Lung,A,,,Intermediate,,,
11310,BAO_0000218,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,U,1,,CHEMBL625181,,22224,10677,,,A,,,Autocuration,,,
11311,BAO_0000218,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1088.0,N,1,,CHEMBL625182,,50594,9750,,Urine,A,,,Intermediate,,,
11312,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,1,,CHEMBL625183,,50597,8319,,,A,,,Intermediate,,,
11313,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,1,,CHEMBL875848,,50597,8319,,,A,,,Intermediate,,,
11314,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,1,,CHEMBL622260,,50597,8319,,,A,,,Intermediate,,,
11315,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,1,,CHEMBL622261,,50597,8319,,,A,,,Intermediate,,,
11316,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,1,,CHEMBL622262,,50597,8319,,,A,,,Intermediate,,,
11317,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,N,1,,CHEMBL622263,,50597,8319,,Kidney,A,,,Intermediate,,,
11318,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,N,1,,CHEMBL622418,,50597,8319,,Kidney,A,,,Intermediate,,,
11319,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,2107.0,N,1,,CHEMBL622419,,50597,8319,,Liver,A,,,Intermediate,,,
11320,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL623388,In vivo,50594,13256,,,A,,,Intermediate,,,
11321,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,N,1,,CHEMBL623389,In vivo,50594,13256,,Liver,A,,,Intermediate,,,
11322,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL623390,In vivo,50594,13256,,,A,,,Intermediate,,,
11323,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL623391,In vivo,50594,13256,,,A,,,Intermediate,,,
11324,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,N,1,,CHEMBL623392,In vivo,50594,13256,,Blood,A,,,Intermediate,,,
11325,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,N,1,,CHEMBL623393,In vivo,50594,13256,,Cerebellum,A,,,Intermediate,,,
11326,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL623394,In vivo,50594,13256,,,A,,,Intermediate,,,
11327,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL618885,In vivo,50594,13256,,,A,,,Intermediate,,,
11328,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,N,1,,CHEMBL618886,In vivo,50594,13256,,Liver,A,,,Intermediate,,,
11329,BAO_0000218,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL618887,In vivo,50594,13256,,,A,,,Intermediate,,,
11330,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL619535,In vivo,50594,13256,,,A,,,Intermediate,,,
11331,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,N,1,,CHEMBL619536,In vivo,50594,13256,,Blood,A,,,Intermediate,,,
11332,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,N,1,,CHEMBL619537,In vivo,50594,13256,,Cerebellum,A,,,Intermediate,,,
11333,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL619705,In vivo,50594,13256,,,A,,,Intermediate,,,
11334,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL619706,In vivo,50594,13256,,,A,,,Intermediate,,,
11335,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,N,1,,CHEMBL619707,In vivo,50594,13256,,Liver,A,,,Intermediate,,,
11336,BAO_0000218,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL619708,In vivo,50594,13256,,,A,,,Intermediate,,,
11337,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL625219,In vivo,50594,13256,,,A,,,Intermediate,,,
11338,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,N,1,,CHEMBL625220,In vivo,50594,13256,,Blood,A,,,Intermediate,,,
11339,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,N,1,,CHEMBL625221,In vivo,50594,13256,,Cerebellum,A,,,Intermediate,,,
11340,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL625222,In vivo,50594,13256,,,A,,,Intermediate,,,
11341,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL625223,In vivo,50594,13256,,,A,,,Intermediate,,,
11342,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,N,1,,CHEMBL625224,In vivo,50594,13256,,Liver,A,,,Intermediate,,,
11343,BAO_0000218,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,1,,CHEMBL625225,In vivo,50594,13256,,,A,,,Intermediate,,,
11344,BAO_0000218,Biodistribution in Rat blood after 24 hours of iv administration,178.0,N,1,,CHEMBL625226,In vivo,50597,8829,,Blood,A,,,Intermediate,,,
11345,BAO_0000218,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,178.0,N,1,,CHEMBL625227,In vivo,50597,8829,,Blood,A,,,Intermediate,,,
11346,BAO_0000218,Biodistribution in Rat blood after 30 minutes of iv administration,178.0,N,1,,CHEMBL625228,In vivo,50597,8829,,Blood,A,,,Intermediate,,,
11347,BAO_0000218,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,178.0,N,1,,CHEMBL875354,In vivo,50597,8829,,Blood,A,,,Intermediate,,,
11348,BAO_0000218,Biodistribution in Rat blood after 5 minutes of iv administration,178.0,N,1,,CHEMBL625229,In vivo,50597,8829,,Blood,A,,,Intermediate,,,
11349,BAO_0000218,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,178.0,N,1,,CHEMBL625230,In vivo,50597,8829,,Blood,A,,,Intermediate,,,
11350,BAO_0000218,Biodistribution in Rat heart after 24 hours of iv administration,948.0,N,1,,CHEMBL625231,In vivo,50597,8829,,Heart,A,,,Intermediate,,,
11351,BAO_0000218,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,948.0,N,1,,CHEMBL625900,In vivo,50597,8829,,Heart,A,,,Intermediate,,,
11352,BAO_0000218,Biodistribution in Rat heart after 30 minutes of iv administration,948.0,N,1,,CHEMBL625901,In vivo,50597,8829,,Heart,A,,,Intermediate,,,
11353,BAO_0000218,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,948.0,N,1,,CHEMBL625902,In vivo,50597,8829,,Heart,A,,,Intermediate,,,
11354,BAO_0000218,Biodistribution in Rat heart after 5 minutes of iv administration,948.0,N,1,,CHEMBL625903,In vivo,50597,8829,,Heart,A,,,Intermediate,,,
11355,BAO_0000218,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,948.0,N,1,,CHEMBL625904,In vivo,50597,8829,,Heart,A,,,Intermediate,,,
11356,BAO_0000218,Biodistribution in Rat liver after 24 hours of iv administration,2107.0,N,1,,CHEMBL625905,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11357,BAO_0000218,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,2107.0,N,1,,CHEMBL627861,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11358,BAO_0000218,Biodistribution in Rat liver after 30 minutes of iv administration,2107.0,N,1,,CHEMBL627862,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11359,BAO_0000218,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,2107.0,N,1,,CHEMBL627863,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11360,BAO_0000218,Biodistribution in Rat liver after 30 minutes of iv administration,2107.0,N,1,,CHEMBL627769,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11361,BAO_0000218,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1969.0,N,1,,CHEMBL627770,In vivo,50588,13249,,Plasma,A,,,Intermediate,,,
11362,BAO_0000218,Cmax in cynomolgus monkey (PO dose),,N,1,,CHEMBL627771,In vivo,100710,13622,,,A,,,Intermediate,,,
11363,BAO_0000218,Cmax in rat (PO dose),,N,1,,CHEMBL627772,In vivo,50597,13622,,,A,,,Intermediate,,,
11364,BAO_0000218,Cmax in rat (PO dose),,N,1,,CHEMBL627773,In vivo,50597,13622,,,A,,,Intermediate,,,
11365,BAO_0000218,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1969.0,N,1,,CHEMBL621922,In vivo,50597,13494,,Plasma,A,,,Intermediate,,,
11366,BAO_0000218,Cmax in rat plasma after oral dose (10 mg/kg),1969.0,N,1,,CHEMBL621923,In vivo,50597,12170,,Plasma,A,,,Intermediate,,,
11367,BAO_0000218,Cmax in plasma after oral dose (10 mg/kg),1969.0,U,1,,CHEMBL621924,In vivo,22224,12170,,Plasma,A,,,Autocuration,,,
11368,BAO_0000218,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1969.0,N,1,,CHEMBL621925,In vivo,50588,17025,,Plasma,A,,,Intermediate,,,
11369,BAO_0000218,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,1969.0,U,1,,CHEMBL621926,In vivo,22224,17025,,Plasma,A,,,Autocuration,,,
11370,BAO_0000218,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1969.0,N,1,,CHEMBL621927,In vivo,50592,17025,,Plasma,A,,,Intermediate,,,
11371,BAO_0000218,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1969.0,N,1,,CHEMBL621928,In vivo,50597,17025,,Plasma,A,,,Intermediate,,,
11372,BAO_0000218,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1969.0,N,1,,CHEMBL621929,In vivo,50597,14187,,Plasma,A,,,Intermediate,,,
11373,BAO_0000218,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1969.0,N,1,,CHEMBL621930,In vivo,50594,14816,,Plasma,A,,,Intermediate,,,
11374,BAO_0000218,Maximum plasma concentration after oral dosing in rat,1969.0,N,1,,CHEMBL621931,In vivo,50597,17820,,Plasma,A,,,Intermediate,,,
11375,BAO_0000218,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621932,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11376,BAO_0000218,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621933,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11377,BAO_0000218,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1969.0,N,1,,CHEMBL621934,In vivo,50588,14691,,Plasma,A,,,Intermediate,,,
11378,BAO_0000218,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1969.0,N,1,,CHEMBL621935,In vivo,50588,14691,,Plasma,A,,,Intermediate,,,
11379,BAO_0000218,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1969.0,N,1,,CHEMBL621936,In vivo,50597,13375,,Plasma,A,,,Intermediate,,,
11380,BAO_0000218,Maximum plasma concentration was determined,1969.0,U,1,,CHEMBL621937,In vivo,22224,6236,,Plasma,A,,,Autocuration,,,
11381,BAO_0000218,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621938,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11382,BAO_0000218,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621939,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11383,BAO_0000218,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621940,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11384,BAO_0000218,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621941,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11385,BAO_0000218,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL621942,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11386,BAO_0000218,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL626178,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11387,BAO_0000218,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL626179,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11388,BAO_0000218,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,1969.0,U,1,,CHEMBL626180,In vivo,22224,14380,,Plasma,A,,,Autocuration,,,
11389,BAO_0000218,Plasma Cmax in rat (PO dose),1969.0,N,1,,CHEMBL626181,In vivo,50597,13622,,Plasma,A,,,Intermediate,,,
11390,BAO_0000218,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,N,1,,CHEMBL626182,In vivo,50597,15372,,,A,,,Intermediate,,,
11391,BAO_0000218,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,N,1,,CHEMBL626183,In vivo,50597,15372,,,A,,,Intermediate,,,
11392,BAO_0000218,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,N,1,,CHEMBL626184,In vivo,50597,15372,,,A,,,Intermediate,,,
11393,BAO_0000218,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,N,1,,CHEMBL626185,In vivo,50597,15372,,,A,,,Intermediate,,,
11394,BAO_0000218,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1969.0,N,1,,CHEMBL626186,In vivo,50588,14925,,Plasma,A,,,Intermediate,,,
11395,BAO_0000218,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1969.0,N,1,,CHEMBL877589,In vivo,50588,14925,,Plasma,A,,,Intermediate,,,
11396,BAO_0000218,Maximum concentration of the drug at 1 uM/dg administered intravenously,,U,1,,CHEMBL626187,In vivo,22224,11883,,,A,,,Autocuration,,,
11397,BAO_0000218,Maximum concentration of the drug at 20 uM/dg administered perorally,,U,1,,CHEMBL626188,In vivo,22224,11883,,,A,,,Autocuration,,,
11398,BAO_0000218,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,U,1,,CHEMBL626189,In vivo,22224,13391,,,A,,,Autocuration,,,
11399,BAO_0000218,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,U,1,,CHEMBL626855,In vivo,22224,13391,,Blood,A,,,Autocuration,,,
11400,BAO_0000218,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,178.0,U,1,,CHEMBL623781,In vivo,22224,13391,,Blood,A,,,Autocuration,,,
11401,BAO_0000218,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,U,1,,CHEMBL623782,In vivo,22224,13391,,Blood,A,,,Autocuration,,,
11402,BAO_0000218,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1969.0,N,1,,CHEMBL623783,In vivo,50597,16360,,Plasma,A,,,Intermediate,,,
11403,BAO_0000218,Cmax in dog plasma after 1mg/kg oral dose,1969.0,N,1,,CHEMBL623784,In vivo,50588,3673,,Plasma,A,,,Intermediate,,,
11404,BAO_0000218,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1969.0,N,1,,CHEMBL623785,In vivo,50588,14431,,Plasma,A,,,Intermediate,,,
11405,BAO_0000218,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1969.0,N,1,,CHEMBL623786,In vivo,50597,14431,,Plasma,A,,,Intermediate,,,
11406,BAO_0000218,Oral maximum concentration in rat,,N,1,,CHEMBL623787,In vivo,50597,14964,,,A,,,Intermediate,,,
11407,BAO_0000218,Oral maximum concentration in rat,,N,1,,CHEMBL623788,In vivo,50597,14964,,,A,,,Intermediate,,,
11408,BAO_0000218,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1969.0,N,1,,CHEMBL623789,In vivo,50594,14209,,Plasma,A,,,Intermediate,,,
11409,BAO_0000218,Peak concentration in blood after intravenous administration to mice,178.0,N,1,,CHEMBL623790,In vivo,50594,11355,,Blood,A,,,Intermediate,,,
11410,BAO_0000218,Peak concentration in blood after peroral administration to mice,178.0,N,1,,CHEMBL623791,In vivo,50594,11355,,Blood,A,,,Intermediate,,,
11411,BAO_0000218,Peak concentration in rat plasma was determined,1969.0,N,1,,CHEMBL623792,In vivo,50597,11966,,Plasma,A,,,Intermediate,,,
11412,BAO_0000218,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,1969.0,U,1,,CHEMBL623793,In vivo,22224,8918,,Plasma,A,,,Autocuration,,,
11413,BAO_0000218,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1969.0,N,1,,CHEMBL623794,In vivo,50594,8918,,Plasma,A,,,Intermediate,,,
11414,BAO_0000218,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1969.0,N,1,,CHEMBL623795,In vivo,50597,8918,,Plasma,A,,,Intermediate,,,
11415,BAO_0000218,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623796,,50597,8684,,,A,,,Intermediate,,,
11416,BAO_0000218,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL623797,,50597,8684,,,A,,,Intermediate,,,
11417,BAO_0000218,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623798,,50597,8684,,,A,,,Intermediate,,,
11418,BAO_0000218,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623799,,50597,8684,,,A,,,Intermediate,,,
11419,BAO_0000218,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624490,,50597,8684,,Intestine,A,,,Intermediate,,,
11420,BAO_0000218,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624491,,50597,8684,,Intestine,A,,,Intermediate,,,
11421,BAO_0000218,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624492,,50597,8684,,Intestine,A,,,Intermediate,,,
11422,BAO_0000218,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624493,,50597,8684,,Intestine,A,,,Intermediate,,,
11423,BAO_0000218,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL877595,,50597,8684,,Intestine,A,,,Intermediate,,,
11424,BAO_0000218,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624494,,50597,8684,,Intestine,A,,,Intermediate,,,
11425,BAO_0000218,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624495,,50597,8684,,Intestine,A,,,Intermediate,,,
11426,BAO_0000218,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",160.0,N,1,,CHEMBL624681,,50597,8684,,Intestine,A,,,Intermediate,,,
11427,BAO_0000218,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624682,,50597,8684,,,A,,,Intermediate,,,
11428,BAO_0000218,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624683,,50597,8684,,,A,,,Intermediate,,,
11429,BAO_0000218,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624684,,50597,8684,,,A,,,Intermediate,,,
11430,BAO_0000218,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624685,,50597,8684,,,A,,,Intermediate,,,
11431,BAO_0000218,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624686,,50597,8684,,,A,,,Intermediate,,,
11432,BAO_0000218,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624687,,50597,8684,,,A,,,Intermediate,,,
11433,BAO_0000218,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624688,,50597,8684,,,A,,,Intermediate,,,
11434,BAO_0000218,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL627161,,50597,8684,,,A,,,Intermediate,,,
11435,BAO_0000218,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL622127,,50597,8684,,,A,,,Intermediate,,,
11436,BAO_0000218,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL622128,,50597,8684,,,A,,,Intermediate,,,
11437,BAO_0000218,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL874384,,50597,8684,,,A,,,Intermediate,,,
11438,BAO_0000218,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624898,,50597,8684,,,A,,,Intermediate,,,
11439,BAO_0000218,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624899,,50597,8684,,,A,,,Intermediate,,,
11440,BAO_0000218,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624900,,50597,8684,,,A,,,Intermediate,,,
11441,BAO_0000218,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624901,,50597,8684,,,A,,,Intermediate,,,
11442,BAO_0000218,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624902,,50597,8684,,,A,,,Intermediate,,,
11443,BAO_0000218,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624903,,50597,8684,,,A,,,Intermediate,,,
11444,BAO_0000218,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624904,,50597,8684,,,A,,,Intermediate,,,
11445,BAO_0000218,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624905,,50597,8684,,,A,,,Intermediate,,,
11446,BAO_0000218,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624906,,50597,8684,,,A,,,Intermediate,,,
11447,BAO_0000218,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624907,,50597,8684,,,A,,,Intermediate,,,
11448,BAO_0000218,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL624908,,50597,8684,,,A,,,Intermediate,,,
11449,BAO_0000218,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624909,,50597,8684,,,A,,,Intermediate,,,
11450,BAO_0000218,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL624910,,50597,8684,,,A,,,Intermediate,,,
11451,BAO_0000218,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL624911,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11452,BAO_0000218,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL874388,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11453,BAO_0000218,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL624912,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11454,BAO_0000218,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL622930,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11455,BAO_0000218,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL623121,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11456,BAO_0000218,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL623122,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11457,BAO_0000218,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL623123,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11458,BAO_0000218,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",2385.0,N,1,,CHEMBL623124,,50597,8684,,Muscle tissue,A,,,Intermediate,,,
11459,BAO_0000218,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL623125,,50597,8684,,,A,,,Intermediate,,,
11460,BAO_0000218,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623126,,50597,8684,,,A,,,Intermediate,,,
11461,BAO_0000218,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623127,,50597,8684,,,A,,,Intermediate,,,
11462,BAO_0000218,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL623128,,50597,8684,,,A,,,Intermediate,,,
11463,BAO_0000218,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623129,,50597,8684,,,A,,,Intermediate,,,
11464,BAO_0000218,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL623130,,50597,8684,,,A,,,Intermediate,,,
11465,BAO_0000218,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623131,,50597,8684,,,A,,,Intermediate,,,
11466,BAO_0000218,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL623132,,50597,8684,,,A,,,Intermediate,,,
11467,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,2107.0,N,1,,CHEMBL623133,,50597,8319,,Liver,A,,,Intermediate,,,
11468,BAO_0000218,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,1,,CHEMBL623134,,50597,8319,,,A,,,Intermediate,,,
11469,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,1,,CHEMBL874389,,50597,8319,,,A,,,Intermediate,,,
11470,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,1,,CHEMBL623135,,50597,8319,,,A,,,Intermediate,,,
11471,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,1,,CHEMBL623136,,50597,8319,,,A,,,Intermediate,,,
11472,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,1,,CHEMBL623137,,50597,8319,,,A,,,Intermediate,,,
11473,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,1,,CHEMBL623138,,50597,8319,,,A,,,Intermediate,,,
11474,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,N,1,,CHEMBL623139,,50597,8319,,Kidney,A,,,Intermediate,,,
11475,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,N,1,,CHEMBL623140,,50597,8319,,Kidney,A,,,Intermediate,,,
11476,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,2107.0,N,1,,CHEMBL623141,,50597,8319,,Liver,A,,,Intermediate,,,
11477,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,2107.0,N,1,,CHEMBL623142,,50597,8319,,Liver,A,,,Intermediate,,,
11478,BAO_0000218,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,1,,CHEMBL623143,,50597,8319,,,A,,,Intermediate,,,
11479,BAO_0000218,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1088.0,N,1,,CHEMBL623144,,50594,14571,,Urine,A,,,Intermediate,,,
11480,BAO_0000218,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1088.0,N,1,,CHEMBL623405,,50597,14571,,Urine,A,,,Intermediate,,,
11481,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624074,,50597,8319,,,A,,,Intermediate,,,
11482,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,1,,CHEMBL624075,,50597,8319,,,A,,,Intermediate,,,
11483,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624076,,50597,8319,,,A,,,Intermediate,,,
11484,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,1,,CHEMBL624077,,50597,8319,,,A,,,Intermediate,,,
11485,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624078,,50597,8319,,,A,,,Intermediate,,,
11486,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,N,1,,CHEMBL624079,,50597,8319,,Kidney,A,,,Intermediate,,,
11487,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,N,1,,CHEMBL624261,,50597,8319,,Kidney,A,,,Intermediate,,,
11488,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,N,1,,CHEMBL624262,,50597,8319,,,A,,,Intermediate,,,
11489,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624263,,50597,8319,,,A,,,Intermediate,,,
11490,BAO_0000218,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624264,,50597,8319,,,A,,,Intermediate,,,
11491,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624265,,50597,8319,,,A,,,Intermediate,,,
11492,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,1,,CHEMBL624266,,50597,8319,,,A,,,Intermediate,,,
11493,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624267,,50597,8319,,,A,,,Intermediate,,,
11494,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,1,,CHEMBL624268,,50597,8319,,,A,,,Intermediate,,,
11495,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,1,,CHEMBL875227,,50597,8319,,,A,,,Intermediate,,,
11496,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,N,1,,CHEMBL624269,,50597,8319,,Kidney,A,,,Intermediate,,,
11497,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,N,1,,CHEMBL624270,,50597,8319,,Kidney,A,,,Intermediate,,,
11498,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,N,1,,CHEMBL624271,,50597,8319,,,A,,,Intermediate,,,
11499,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624272,,50597,8319,,,A,,,Intermediate,,,
11500,BAO_0000218,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,1,,CHEMBL624273,,50597,8319,,,A,,,Intermediate,,,
11501,BAO_0000218,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1088.0,N,1,,CHEMBL624274,,50597,12064,,Urine,A,,,Intermediate,,,
11502,BAO_0000218,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1088.0,N,1,,CHEMBL624275,,50597,12064,,Urine,A,,,Intermediate,,,
11503,BAO_0000218,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1088.0,N,1,,CHEMBL624276,,50597,12064,,Urine,A,,,Intermediate,,,
11504,BAO_0000218,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1088.0,N,1,,CHEMBL624277,,50597,12038,,Urine,A,,,Intermediate,,,
11505,BAO_0000019,% dose converted to 2-amino-5-chlorophenyl sulfate,,U,1,,CHEMBL624278,,22224,14314,,,A,,,Autocuration,,,
11506,BAO_0000019,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,U,1,,CHEMBL624279,,22224,14314,,,A,,,Autocuration,,,
11507,BAO_0000218,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1988.0,N,1,,CHEMBL624280,,50597,11488,,Feces,A,,,Intermediate,,,
11508,BAO_0000218,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1988.0,N,1,,CHEMBL624281,,50597,11488,,Feces,A,,,Intermediate,,,
11509,BAO_0000218,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1988.0,N,1,,CHEMBL622933,,50597,11488,,Feces,A,,,Intermediate,,,
11510,BAO_0000218,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1988.0,N,1,,CHEMBL622934,,50597,11488,,Feces,A,,,Intermediate,,,
11511,BAO_0000218,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,2107.0,N,1,,CHEMBL622935,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11512,BAO_0000218,Biodistribution in Rat liver after 5 minutes of iv administration,2107.0,N,1,,CHEMBL622936,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11513,BAO_0000218,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,2107.0,N,1,,CHEMBL875228,In vivo,50597,8829,,Liver,A,,,Intermediate,,,
11514,BAO_0000218,Biodistribution in Rat lung after 24 hours of iv administration,2048.0,N,1,,CHEMBL622937,In vivo,50597,8829,,Lung,A,,,Intermediate,,,
11515,BAO_0000218,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,2048.0,N,1,,CHEMBL622938,In vivo,50597,8829,,Lung,A,,,Intermediate,,,
11516,BAO_0000218,Biodistribution in Rat lung after 30 minutes of iv administration,2048.0,N,1,,CHEMBL619736,In vivo,50597,8829,,Lung,A,,,Intermediate,,,
11517,BAO_0000218,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,2048.0,N,1,,CHEMBL625117,In vivo,50597,8829,,Lung,A,,,Intermediate,,,
11518,BAO_0000218,Biodistribution in Rat lung after 5 minutes of iv administration,2048.0,N,1,,CHEMBL625118,In vivo,50597,8829,,Lung,A,,,Intermediate,,,
11519,BAO_0000218,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,2048.0,N,1,,CHEMBL625119,In vivo,50597,8829,,Lung,A,,,Intermediate,,,
11520,BAO_0000218,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",2037.0,N,1,,CHEMBL625120,In vivo,50597,14972,,Cerebellum,A,,,Intermediate,,,
11521,BAO_0000218,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,N,1,,CHEMBL625121,In vivo,50597,14972,,,A,,,Intermediate,,,
11522,BAO_0000218,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",10000006.0,N,1,,CHEMBL625122,In vivo,50597,14972,,Thalamus,A,,,Intermediate,,,
11523,BAO_0000218,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,178.0,N,1,,CHEMBL622204,In vivo,50597,14608,,Blood,A,,,Intermediate,,,
11524,BAO_0000218,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,178.0,N,1,,CHEMBL877503,In vivo,50597,14608,,Blood,A,,,Intermediate,,,
11525,BAO_0000218,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,178.0,N,1,,CHEMBL627127,In vivo,50597,14608,,Blood,A,,,Intermediate,,,
11526,BAO_0000218,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,10000000.0,U,1,,CHEMBL627128,In vivo,22224,14608,,Hippocampus,A,,,Autocuration,,,
11527,BAO_0000218,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,10000000.0,U,1,,CHEMBL627129,In vivo,22224,14608,,Hippocampus,A,,,Autocuration,,,
11528,BAO_0000218,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,10000000.0,U,1,,CHEMBL627130,In vivo,22224,14608,,Hippocampus,A,,,Autocuration,,,
11529,BAO_0000218,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,955.0,N,1,,CHEMBL627131,In vivo,50597,14608,,Brain,A,,,Intermediate,,,
11530,BAO_0000218,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,955.0,N,1,,CHEMBL627132,In vivo,50597,14608,,Brain,A,,,Intermediate,,,
11531,BAO_0000218,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,955.0,N,1,,CHEMBL627133,In vivo,50597,14608,,Brain,A,,,Intermediate,,,
11532,BAO_0000218,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,2037.0,N,1,,CHEMBL627134,In vivo,50597,14608,,Cerebellum,A,,,Intermediate,,,
11533,BAO_0000218,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,2037.0,N,1,,CHEMBL627135,In vivo,50597,14608,,Cerebellum,A,,,Intermediate,,,
11534,BAO_0000218,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,2037.0,N,1,,CHEMBL627136,In vivo,50597,14608,,Cerebellum,A,,,Intermediate,,,
11535,BAO_0000218,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,1,,CHEMBL628435,In vivo,50597,14608,,,A,,,Intermediate,,,
11536,BAO_0000218,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,1,,CHEMBL628436,In vivo,50597,14608,,,A,,,Intermediate,,,
11537,BAO_0000218,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,1,,CHEMBL628437,In vivo,50597,14608,,,A,,,Intermediate,,,
11538,BAO_0000218,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,948.0,N,1,,CHEMBL628438,In vivo,50597,14608,,Heart,A,,,Intermediate,,,
11539,BAO_0000218,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,948.0,N,1,,CHEMBL628439,In vivo,50597,14608,,Heart,A,,,Intermediate,,,
11540,BAO_0000218,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,948.0,N,1,,CHEMBL628440,In vivo,50597,14608,,Heart,A,,,Intermediate,,,
11541,BAO_0000218,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,10000000.0,N,1,,CHEMBL628441,In vivo,50597,14608,,Hippocampus,A,,,Intermediate,,,
11542,BAO_0000218,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,10000000.0,N,1,,CHEMBL628442,In vivo,50597,14608,,Hippocampus,A,,,Intermediate,,,
11543,BAO_0000218,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,10000000.0,N,1,,CHEMBL628443,In vivo,50597,14608,,Hippocampus,A,,,Intermediate,,,
11544,BAO_0000218,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,2113.0,N,1,,CHEMBL628444,In vivo,50597,14608,,Kidney,A,,,Intermediate,,,
11545,BAO_0000218,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,2113.0,N,1,,CHEMBL628445,In vivo,50597,14608,,Kidney,A,,,Intermediate,,,
11546,BAO_0000218,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,2113.0,N,1,,CHEMBL877504,In vivo,50597,14608,,Kidney,A,,,Intermediate,,,
11547,BAO_0000218,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,2107.0,N,1,,CHEMBL628446,In vivo,50597,14608,,Liver,A,,,Intermediate,,,
11548,BAO_0000218,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,2107.0,N,1,,CHEMBL626874,In vivo,50597,14608,,Liver,A,,,Intermediate,,,
11549,BAO_0000218,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,2107.0,N,1,,CHEMBL626875,In vivo,50597,14608,,Liver,A,,,Intermediate,,,
11550,BAO_0000218,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,2048.0,N,1,,CHEMBL626876,In vivo,50597,14608,,Lung,A,,,Intermediate,,,
11551,BAO_0000218,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,2048.0,N,1,,CHEMBL626877,In vivo,50597,14608,,Lung,A,,,Intermediate,,,
11552,BAO_0000218,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,2048.0,N,1,,CHEMBL626878,In vivo,50597,14608,,Lung,A,,,Intermediate,,,
11553,BAO_0000218,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,2385.0,N,1,,CHEMBL626879,In vivo,50597,14608,,Muscle tissue,A,,,Intermediate,,,
11554,BAO_0000218,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,1969.0,U,1,,CHEMBL626880,In vivo,22224,8918,,Plasma,A,,,Autocuration,,,
11555,BAO_0000218,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1969.0,N,1,,CHEMBL626881,In vivo,50594,8918,,Plasma,A,,,Intermediate,,,
11556,BAO_0000218,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1969.0,N,1,,CHEMBL626882,In vivo,50597,8918,,Plasma,A,,,Intermediate,,,
11557,BAO_0000218,Peak plasma concentration was measured in dogs,1969.0,N,1,,CHEMBL626883,In vivo,50588,14470,,Plasma,A,,,Intermediate,,,
11558,BAO_0000218,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,1,,CHEMBL626884,In vivo,50597,14393,,,A,,,Intermediate,,,
11559,BAO_0000218,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,N,1,,CHEMBL626885,In vivo,50597,14886,,,A,,,Intermediate,,,
11560,BAO_0000218,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,N,1,,CHEMBL626886,In vivo,50597,14886,,,A,,,Intermediate,,,
11561,BAO_0000218,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,N,1,,CHEMBL626887,In vivo,50597,14886,,,A,,,Intermediate,,,
11562,BAO_0000218,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,1,,CHEMBL626888,In vivo,50597,14393,,,A,,,Intermediate,,,
11563,BAO_0000218,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,N,1,,CHEMBL626889,In vivo,50588,13465,,,A,,,Intermediate,,,
11564,BAO_0000218,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,U,1,,CHEMBL626761,In vivo,22224,13465,,,A,,,Autocuration,,,
11565,BAO_0000218,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,N,1,,CHEMBL626762,In vivo,50588,13465,,,A,,,Intermediate,,,
11566,BAO_0000218,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,N,1,,CHEMBL626763,In vivo,50588,13465,,,A,,,Intermediate,,,
11567,BAO_0000218,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,N,1,,CHEMBL626764,In vivo,50597,13465,,,A,,,Intermediate,,,
11568,BAO_0000218,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,N,1,,CHEMBL626765,In vivo,50597,13465,,,A,,,Intermediate,,,
11569,BAO_0000218,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,N,1,,CHEMBL626766,In vivo,50588,13465,,,A,,,Intermediate,,,
11570,BAO_0000218,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,N,1,,CHEMBL626767,In vivo,50597,13465,,,A,,,Intermediate,,,
11571,BAO_0000218,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,N,1,,CHEMBL626768,In vivo,50597,13465,,,A,,,Intermediate,,,
11572,BAO_0000218,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,N,1,,CHEMBL626769,In vivo,50588,13465,,,A,,,Intermediate,,,
11573,BAO_0000218,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,N,1,,CHEMBL874463,In vivo,50588,13465,,,A,,,Intermediate,,,
11574,BAO_0000218,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,U,1,,CHEMBL626770,In vivo,22224,13465,,,A,,,Autocuration,,,
11575,BAO_0000218,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,U,1,,CHEMBL626771,In vivo,22224,13465,,,A,,,Autocuration,,,
11576,BAO_0000218,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,N,1,,CHEMBL626772,In vivo,50597,13465,,,A,,,Intermediate,,,
11577,BAO_0000218,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,N,1,,CHEMBL626773,In vivo,100710,14731,,,A,,,Intermediate,,,
11578,BAO_0000218,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,N,1,,CHEMBL626774,In vivo,50594,14731,,,A,,,Intermediate,,,
11579,BAO_0000218,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,N,1,,CHEMBL626775,In vivo,50588,13376,,,A,,,Intermediate,,,
11580,BAO_0000218,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,N,1,,CHEMBL626776,In vivo,50588,13376,,,A,,,Intermediate,,,
11581,BAO_0000218,Maximum concentration (Cmax) in rat when administered orally,,N,1,,CHEMBL626777,In vivo,50597,14443,,,A,,,Intermediate,,,
11582,BAO_0000218,Maximal concentration in monkey plasma after 25 mg/kg oral dose,1969.0,U,1,,CHEMBL626778,In vivo,22224,13465,,Plasma,A,,,Autocuration,,,
11583,BAO_0000218,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,U,1,,CHEMBL626779,In vivo,22224,16359,,,A,,,Autocuration,,,
11584,BAO_0000218,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,U,1,,CHEMBL626780,In vivo,22224,16359,,,A,,,Autocuration,,,
11585,BAO_0000218,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,1969.0,U,1,,CHEMBL626781,In vivo,22224,15618,,Plasma,A,,,Autocuration,,,
11586,BAO_0000218,Pharmacokinetic profile Cmax was evaluated in rats,,N,1,,CHEMBL632164,In vivo,50597,14554,,,A,,,Intermediate,,,
11587,BAO_0000218,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,N,1,,CHEMBL632165,In vivo,50588,11537,,,A,,,Intermediate,,,
11588,BAO_0000218,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,N,1,,CHEMBL632166,In vivo,50594,11537,,,A,,,Intermediate,,,
11589,BAO_0000218,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,N,1,,CHEMBL632167,In vivo,50588,11537,,,A,,,Intermediate,,,
11590,BAO_0000218,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,N,1,,CHEMBL632168,In vivo,50594,11537,,,A,,,Intermediate,,,
11591,BAO_0000218,Cmax in rat plasma,1969.0,U,1,,CHEMBL632169,In vivo,22224,2021,,Plasma,A,,,Autocuration,,,
11592,BAO_0000218,Cmax in dog plasma after 30mg/kg oral dose,1969.0,N,1,,CHEMBL632170,In vivo,50588,5932,,Plasma,A,,,Intermediate,,,
11593,BAO_0000218,Cmax in rat plasma after 30mg/kg oral dose,1969.0,N,1,,CHEMBL632171,In vivo,50597,5932,,Plasma,A,,,Intermediate,,,
11594,BAO_0000218,Plasma level in rats at 30 mg/kg,1969.0,N,1,,CHEMBL632172,In vivo,50597,17320,,Plasma,A,,,Intermediate,,,
11595,BAO_0000218,Tested for maximum plasma concentration in mice,1969.0,N,1,,CHEMBL632173,In vivo,50594,15831,,Plasma,A,,,Intermediate,,,
11596,BAO_0000218,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL632174,In vivo,50597,15078,,,A,,,Intermediate,,,
11597,BAO_0000218,The Cmax values in female wistar rats.,,N,1,,CHEMBL632175,In vivo,50597,14941,,,A,,,Intermediate,,,
11598,BAO_0000218,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1969.0,N,1,,CHEMBL632176,In vivo,50588,15343,,Plasma,A,,,Intermediate,,,
11599,BAO_0000218,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1969.0,N,1,,CHEMBL632177,In vivo,50597,15343,,Plasma,A,,,Intermediate,,,
11600,BAO_0000218,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1969.0,N,1,,CHEMBL632178,In vivo,50597,14856,,Plasma,A,,,Intermediate,,,
11601,BAO_0000218,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,N,1,,CHEMBL632179,In vivo,50597,13129,,,A,,,Intermediate,,,
11602,BAO_0000218,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,178.0,N,1,,CHEMBL632180,In vivo,50597,13098,,Blood,A,,,Intermediate,,,
11603,BAO_0000218,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,178.0,N,1,,CHEMBL632181,In vivo,50597,13098,,Blood,A,,,Intermediate,,,
11604,BAO_0000218,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,178.0,N,1,,CHEMBL632182,In vivo,50597,13098,,Blood,A,,,Intermediate,,,
11605,BAO_0000218,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,178.0,U,1,,CHEMBL632183,In vivo,22224,15478,,Blood,A,,,Autocuration,,,
11606,BAO_0000218,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,N,1,,CHEMBL632184,In vivo,50588,15341,,,A,,,Intermediate,,,
11607,BAO_0000218,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,N,1,,CHEMBL874470,In vivo,50597,15341,,,A,,,Intermediate,,,
11608,BAO_0000218,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL631302,,50597,8684,,,A,,,Intermediate,,,
11609,BAO_0000218,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL631303,,50597,8684,,,A,,,Intermediate,,,
11610,BAO_0000218,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL631304,,50597,8684,,,A,,,Intermediate,,,
11611,BAO_0000218,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL631305,,50597,8684,,,A,,,Intermediate,,,
11612,BAO_0000218,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL631306,,50597,8684,,,A,,,Intermediate,,,
11613,BAO_0000218,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,N,1,,CHEMBL631307,,50597,8684,,,A,,,Intermediate,,,
11614,BAO_0000218,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL631308,,50597,8684,,,A,,,Intermediate,,,
11615,BAO_0000218,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,N,1,,CHEMBL625557,,50597,8684,,,A,,,Intermediate,,,
11616,BAO_0000218,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625558,,50597,8684,,Spleen,A,,,Intermediate,,,
11617,BAO_0000218,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625559,,50597,8684,,Spleen,A,,,Intermediate,,,
11618,BAO_0000218,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625560,,50597,8684,,Spleen,A,,,Intermediate,,,
11619,BAO_0000218,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625561,,50597,8684,,Spleen,A,,,Intermediate,,,
11620,BAO_0000218,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625562,,50597,8684,,Spleen,A,,,Intermediate,,,
11621,BAO_0000218,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL875320,,50597,8684,,Spleen,A,,,Intermediate,,,
11622,BAO_0000218,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625563,,50597,8684,,Spleen,A,,,Intermediate,,,
11623,BAO_0000218,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",2106.0,N,1,,CHEMBL625564,,50597,8684,,Spleen,A,,,Intermediate,,,
11624,BAO_0000218,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL625565,,50597,8684,,Uterus,A,,,Intermediate,,,
11625,BAO_0000218,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL625566,,50597,8684,,Uterus,A,,,Intermediate,,,
11626,BAO_0000218,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL625567,,50597,8684,,Uterus,A,,,Intermediate,,,
11627,BAO_0000218,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL625568,,50597,8684,,Uterus,A,,,Intermediate,,,
11628,BAO_0000218,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL628217,,50597,8684,,Uterus,A,,,Intermediate,,,
11629,BAO_0000218,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL628218,,50597,8684,,Uterus,A,,,Intermediate,,,
11630,BAO_0000218,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL628219,,50597,8684,,Uterus,A,,,Intermediate,,,
11631,BAO_0000218,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",995.0,N,1,,CHEMBL628220,,50597,8684,,Uterus,A,,,Intermediate,,,
11632,BAO_0000019,Distribution in the blood after 120 min of intravenous administration,,U,1,,CHEMBL628221,,22224,8926,,,A,,,Autocuration,,,
11633,BAO_0000019,Distribution in the blood after 15 min of intravenous administration,,U,1,,CHEMBL628222,,22224,8926,,,A,,,Autocuration,,,
11634,BAO_0000019,Distribution in the blood after 30 min of intravenous administration,,U,1,,CHEMBL628223,,22224,8926,,,A,,,Autocuration,,,
11635,BAO_0000019,Distribution in the blood after 5 min of intravenous administration,,U,1,,CHEMBL628224,,22224,8926,,,A,,,Autocuration,,,
11636,BAO_0000019,Distribution in the blood after 60 min of intravenous administration,,U,1,,CHEMBL628225,,22224,8926,,,A,,,Autocuration,,,
11637,BAO_0000019,Distribution in the blood after 90 min of intravenous administration,,U,1,,CHEMBL628226,,22224,8926,,,A,,,Autocuration,,,
11638,BAO_0000019,Distribution in the bone after 120 min of intravenous administration,,U,1,,CHEMBL628227,,22224,8926,,,A,,,Autocuration,,,
11639,BAO_0000019,Distribution in the bone after 15 min of intravenous administration,,U,1,,CHEMBL875481,,22224,8926,,,A,,,Autocuration,,,
11640,BAO_0000019,Distribution in the bone after 30 min of intravenous administration,,U,1,,CHEMBL628228,,22224,8926,,,A,,,Autocuration,,,
11641,BAO_0000019,Distribution in the bone after 5 min of intravenous administration,,U,1,,CHEMBL628229,,22224,8926,,,A,,,Autocuration,,,
11642,BAO_0000019,Distribution in the bone after 60 min of intravenous administration,,U,1,,CHEMBL628230,,22224,8926,,,A,,,Autocuration,,,
11643,BAO_0000019,Distribution in the bone after 90 min of intravenous administration,,U,1,,CHEMBL628231,,22224,8926,,,A,,,Autocuration,,,
11644,BAO_0000019,Distribution in the heart after 120 min of intravenous administration,,U,1,,CHEMBL628232,,22224,8926,,,A,,,Autocuration,,,
11645,BAO_0000019,Distribution in the heart after 15 min of intravenous administration,,U,1,,CHEMBL628233,,22224,8926,,,A,,,Autocuration,,,
11646,BAO_0000019,Distribution in the heart after 30 min of intravenous administration,,U,1,,CHEMBL628234,,22224,8926,,,A,,,Autocuration,,,
11647,BAO_0000019,Distribution in the heart after 5 min of intravenous administration,,U,1,,CHEMBL628235,,22224,8926,,,A,,,Autocuration,,,
11648,BAO_0000019,Distribution in the heart after 60 min of intravenous administration,,U,1,,CHEMBL628236,,22224,8926,,,A,,,Autocuration,,,
11649,BAO_0000019,Distribution in the heart after 90 min of intravenous administration,,U,1,,CHEMBL628237,,22224,8926,,,A,,,Autocuration,,,
11650,BAO_0000019,Distribution in the kidneys after 120 min of intravenous administration,,U,1,,CHEMBL628238,,22224,8926,,,A,,,Autocuration,,,
11651,BAO_0000019,Distribution in the kidneys after 15 min of intravenous administration,,U,1,,CHEMBL628239,,22224,8926,,,A,,,Autocuration,,,
11652,BAO_0000019,Distribution in the kidneys after 30 min of intravenous administration,,U,1,,CHEMBL628240,,22224,8926,,,A,,,Autocuration,,,
11653,BAO_0000019,Distribution in the kidneys after 5 min of intravenous administration,,U,1,,CHEMBL628241,,22224,8926,,,A,,,Autocuration,,,
11654,BAO_0000019,Distribution in the kidneys after 60 min of intravenous administration,,U,1,,CHEMBL628242,,22224,8926,,,A,,,Autocuration,,,
11655,BAO_0000019,Distribution in the kidneys after 90 min of intravenous administration,,U,1,,CHEMBL875482,,22224,8926,,,A,,,Autocuration,,,
11656,BAO_0000019,Distribution in the liver after 120 min of intravenous administration,,U,1,,CHEMBL628243,,22224,8926,,,A,,,Autocuration,,,
11657,BAO_0000019,Distribution in the liver after 15 min of intravenous administration,,U,1,,CHEMBL628244,,22224,8926,,,A,,,Autocuration,,,
11658,BAO_0000019,Distribution in the liver after 30 min of intravenous administration,,U,1,,CHEMBL628245,,22224,8926,,,A,,,Autocuration,,,
11659,BAO_0000019,Distribution in the liver after 5 min of intravenous administration,,U,1,,CHEMBL628246,,22224,8926,,,A,,,Autocuration,,,
11660,BAO_0000019,Distribution in the liver after 60 min of intravenous administration,,U,1,,CHEMBL628247,,22224,8926,,,A,,,Autocuration,,,
11661,BAO_0000019,Distribution in the liver after 90 min of intravenous administration,,U,1,,CHEMBL628248,,22224,8926,,,A,,,Autocuration,,,
11662,BAO_0000019,Distribution in the lung after 120 min of intravenous administration,,U,1,,CHEMBL628249,,22224,8926,,,A,,,Autocuration,,,
11663,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,N,1,,CHEMBL625452,,50594,14839,,,A,,,Intermediate,,,
11664,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,N,1,,CHEMBL625453,,50594,14839,,,A,,,Intermediate,,,
11665,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,N,1,,CHEMBL625454,,50594,14839,,,A,,,Intermediate,,,
11666,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,N,1,,CHEMBL623844,,50594,14839,,,A,,,Intermediate,,,
11667,BAO_0000218,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,N,1,,CHEMBL623845,,50597,12178,,,A,,,Intermediate,,,
11668,BAO_0000218,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,N,1,,CHEMBL623846,,50597,12178,,,A,,,Intermediate,,,
11669,BAO_0000218,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,U,1,,CHEMBL623847,,22224,12178,,,A,,,Autocuration,,,
11670,BAO_0000218,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,1,,CHEMBL623848,,100710,12186,,,A,,,Intermediate,,,
11671,BAO_0000218,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,N,1,,CHEMBL623849,,100710,12186,,,A,,,Intermediate,,,
11672,BAO_0000218,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,1,,CHEMBL623850,,100710,12186,,,A,,,Intermediate,,,
11673,BAO_0000218,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,N,1,,CHEMBL623851,,100710,12186,,,A,,,Intermediate,,,
11674,BAO_0000218,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,U,1,,CHEMBL623852,,22224,12187,,,A,,,Autocuration,,,
11675,BAO_0000218,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,N,1,,CHEMBL624551,,50506,12187,,,A,,,Intermediate,,,
11676,BAO_0000218,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,N,1,,CHEMBL624552,,50506,12187,,,A,,,Intermediate,,,
11677,BAO_0000218,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,U,1,,CHEMBL624553,,22224,12187,,,A,,,Autocuration,,,
11678,BAO_0000218,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,U,1,,CHEMBL624554,,22224,12187,,,A,,,Autocuration,,,
11679,BAO_0000218,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,N,1,,CHEMBL624555,,50597,12187,,,A,,,Intermediate,,,
11680,BAO_0000218,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,N,1,,CHEMBL624741,,50597,12187,,,A,,,Intermediate,,,
11681,BAO_0000218,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,N,1,,CHEMBL624742,,50588,14122,,,A,,,Intermediate,,,
11682,BAO_0000218,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,N,1,,CHEMBL624743,,100712,14122,,,A,,,Intermediate,,,
11683,BAO_0000218,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,N,1,,CHEMBL877606,,50597,14122,,,A,,,Intermediate,,,
11684,BAO_0000218,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,U,1,,CHEMBL624744,,22224,13391,,,A,,,Autocuration,,,
11685,BAO_0000218,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,U,1,,CHEMBL624745,,22224,13391,,Blood,A,,,Autocuration,,,
11686,BAO_0000218,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,178.0,U,1,,CHEMBL624746,,22224,13391,,Blood,A,,,Autocuration,,,
11687,BAO_0000218,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,U,1,,CHEMBL624747,,22224,13391,,Blood,A,,,Autocuration,,,
11688,BAO_0000019,Oral absorption expressed as Area under curve was determined,,U,1,,CHEMBL624748,,22224,16360,,,A,,,Autocuration,,,
11689,BAO_0000218,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,N,1,,CHEMBL622504,,50588,3673,,,A,,,Intermediate,,,
11690,BAO_0000218,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,N,1,,CHEMBL622505,,50588,14122,,,A,,,Intermediate,,,
11691,BAO_0000218,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,N,1,,CHEMBL622506,,100712,14122,,,A,,,Intermediate,,,
11692,BAO_0000218,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,N,1,,CHEMBL622507,,100712,14122,,,A,,,Intermediate,,,
11693,BAO_0000218,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,N,1,,CHEMBL622508,,50597,14122,,,A,,,Intermediate,,,
11694,BAO_0000019,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,U,1,,CHEMBL622509,,22224,13889,,,A,,,Autocuration,,,
11695,BAO_0000218,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,1,,CHEMBL622510,,50597,14393,,,A,,,Intermediate,,,
11696,BAO_0000218,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,N,1,,CHEMBL622511,,50597,17279,,,A,,,Intermediate,,,
11697,BAO_0000218,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,N,1,,CHEMBL622512,,100710,14548,,,A,,,Intermediate,,,
11698,BAO_0000218,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,N,1,,CHEMBL622513,,100710,14548,,,A,,,Intermediate,,,
11699,BAO_0000218,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,N,1,,CHEMBL622514,,100710,14548,,,A,,,Intermediate,,,
11700,BAO_0000218,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,N,1,,CHEMBL622515,,50588,14548,,,A,,,Intermediate,,,
11701,BAO_0000218,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,N,1,,CHEMBL622516,,50588,14548,,,A,,,Intermediate,,,
11702,BAO_0000218,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,N,1,,CHEMBL622517,,50597,14548,,,A,,,Intermediate,,,
11703,BAO_0000218,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,N,1,,CHEMBL622518,,50597,14548,,,A,,,Intermediate,,,
11704,BAO_0000218,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,N,1,,CHEMBL622519,,50597,14548,,,A,,,Intermediate,,,
11705,BAO_0000218,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,2385.0,N,1,,CHEMBL622520,In vivo,50597,14608,,Muscle tissue,A,,,Intermediate,,,
11706,BAO_0000218,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,2385.0,N,1,,CHEMBL622521,In vivo,50597,14608,,Muscle tissue,A,,,Intermediate,,,
11707,BAO_0000218,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,14.0,N,1,,CHEMBL625113,In vivo,50594,14608,,Zone of skin,A,,,Intermediate,,,
11708,BAO_0000218,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,14.0,N,1,,CHEMBL625114,In vivo,50597,14608,,Zone of skin,A,,,Intermediate,,,
11709,BAO_0000218,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,14.0,N,1,,CHEMBL874397,In vivo,50597,14608,,Zone of skin,A,,,Intermediate,,,
11710,BAO_0000218,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,2106.0,N,1,,CHEMBL625115,In vivo,50597,14608,,Spleen,A,,,Intermediate,,,
11711,BAO_0000218,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,2106.0,N,1,,CHEMBL625116,In vivo,50597,14608,,Spleen,A,,,Intermediate,,,
11712,BAO_0000218,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,2106.0,N,1,,CHEMBL623932,In vivo,50597,14608,,Spleen,A,,,Intermediate,,,
11713,BAO_0000218,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,2435.0,N,1,,CHEMBL623933,In vivo,50597,14608,,Striatum,A,,,Intermediate,,,
11714,BAO_0000218,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,2435.0,N,1,,CHEMBL623934,In vivo,50597,14608,,Striatum,A,,,Intermediate,,,
11715,BAO_0000218,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,2435.0,N,1,,CHEMBL623935,In vivo,50597,14608,,Striatum,A,,,Intermediate,,,
11716,BAO_0000218,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,2046.0,N,1,,CHEMBL623936,In vivo,50597,14608,,Thyroid gland,A,,,Intermediate,,,
11717,BAO_0000218,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,2046.0,N,1,,CHEMBL623937,In vivo,50597,14608,,Thyroid gland,A,,,Intermediate,,,
11718,BAO_0000218,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,2046.0,N,1,,CHEMBL623938,In vivo,50597,14608,,Thyroid gland,A,,,Intermediate,,,
11719,BAO_0000218,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,1,,CHEMBL623939,,50594,15383,,,A,,,Intermediate,,,
11720,BAO_0000218,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,N,1,,CHEMBL623940,,50594,15383,,,A,,,Intermediate,,,
11721,BAO_0000218,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,1,,CHEMBL623941,,50594,15383,,,A,,,Intermediate,,,
11722,BAO_0000218,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,1,,CHEMBL627216,,50594,15383,,,A,,,Intermediate,,,
11723,BAO_0000218,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,1,,CHEMBL623942,,50594,15383,,,A,,,Intermediate,,,
11724,BAO_0000218,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,955.0,N,1,,CHEMBL618793,,50594,15383,,Brain,A,,,Intermediate,,,
11725,BAO_0000218,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,955.0,N,1,,CHEMBL618794,,50594,15383,,Brain,A,,,Intermediate,,,
11726,BAO_0000218,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,955.0,N,1,,CHEMBL618795,,50594,15383,,Brain,A,,,Intermediate,,,
11727,BAO_0000218,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,1,,CHEMBL618796,,50594,15383,,,A,,,Intermediate,,,
11728,BAO_0000218,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,1,,CHEMBL618797,,50594,15383,,,A,,,Intermediate,,,
11729,BAO_0000218,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,2113.0,N,1,,CHEMBL618798,,50594,15383,,Kidney,A,,,Intermediate,,,
11730,BAO_0000218,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2113.0,N,1,,CHEMBL618799,,50594,15383,,Kidney,A,,,Intermediate,,,
11731,BAO_0000218,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2113.0,N,1,,CHEMBL618800,,50594,15383,,Kidney,A,,,Intermediate,,,
11732,BAO_0000218,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2113.0,N,1,,CHEMBL618801,,50594,15383,,Kidney,A,,,Intermediate,,,
11733,BAO_0000218,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2113.0,N,1,,CHEMBL618802,,50594,15383,,Kidney,A,,,Intermediate,,,
11734,BAO_0000218,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2113.0,N,1,,CHEMBL618803,,50594,15383,,Kidney,A,,,Intermediate,,,
11735,BAO_0000218,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,2107.0,N,1,,CHEMBL618804,,50594,15383,,Liver,A,,,Intermediate,,,
11736,BAO_0000218,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2107.0,N,1,,CHEMBL618805,,50594,15383,,Liver,A,,,Intermediate,,,
11737,BAO_0000218,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2107.0,N,1,,CHEMBL618806,,50594,15383,,Liver,A,,,Intermediate,,,
11738,BAO_0000218,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2107.0,N,1,,CHEMBL618807,,50594,15383,,Liver,A,,,Intermediate,,,
11739,BAO_0000218,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2107.0,N,1,,CHEMBL618808,,50594,15383,,Liver,A,,,Intermediate,,,
11740,BAO_0000218,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2107.0,N,1,,CHEMBL618809,,50594,15383,,Liver,A,,,Intermediate,,,
11741,BAO_0000218,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2385.0,N,1,,CHEMBL618810,,50594,15383,,Muscle tissue,A,,,Intermediate,,,
11742,BAO_0000218,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2385.0,N,1,,CHEMBL618811,,50594,15383,,Muscle tissue,A,,,Intermediate,,,
11743,BAO_0000218,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2385.0,N,1,,CHEMBL875844,,50594,15383,,Muscle tissue,A,,,Intermediate,,,
11744,BAO_0000218,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2385.0,N,1,,CHEMBL618812,,50594,15383,,Muscle tissue,A,,,Intermediate,,,
11745,BAO_0000218,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2385.0,N,1,,CHEMBL618813,,50594,15383,,Muscle tissue,A,,,Intermediate,,,
11746,BAO_0000218,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,1,,CHEMBL618814,,50594,15383,,,A,,,Intermediate,,,
11747,BAO_0000218,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,1,,CHEMBL618815,,50594,15383,,,A,,,Intermediate,,,
11748,BAO_0000218,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,1,,CHEMBL618816,,50594,15383,,,A,,,Intermediate,,,
11749,BAO_0000218,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,1,,CHEMBL618817,,50594,15383,,,A,,,Intermediate,,,
11750,BAO_0000218,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,1,,CHEMBL620544,,50594,15383,,,A,,,Intermediate,,,
11751,BAO_0000218,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,N,1,,CHEMBL626230,In vivo,50597,15341,,,A,,,Intermediate,,,
11752,BAO_0000218,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,N,1,,CHEMBL626231,In vivo,50597,15341,,,A,,,Intermediate,,,
11753,BAO_0000218,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,N,1,,CHEMBL626232,In vivo,50597,15341,,,A,,,Intermediate,,,
11754,BAO_0000218,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1969.0,N,1,,CHEMBL626233,In vivo,50588,14906,,Plasma,A,,,Intermediate,,,
11755,BAO_0000218,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1969.0,N,1,,CHEMBL626234,In vivo,50597,14906,,Plasma,A,,,Intermediate,,,
11756,BAO_0000218,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1969.0,N,1,,CHEMBL875341,In vivo,50597,14906,,Plasma,A,,,Intermediate,,,
11757,BAO_0000218,The maximum plasma concentration (100 mg/kg) administered orally in human,1969.0,N,1,,CHEMBL626235,In vivo,50587,14215,,Plasma,A,,,Intermediate,,,
11758,BAO_0000218,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,1969.0,U,1,,CHEMBL626236,In vivo,22224,14215,,Plasma,A,,,Autocuration,,,
11759,BAO_0000218,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,1969.0,U,1,,CHEMBL626237,In vivo,22224,14215,,Plasma,A,,,Autocuration,,,
11760,BAO_0000218,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1969.0,N,1,,CHEMBL626238,In vivo,50588,14215,,Plasma,A,,,Intermediate,,,
11761,BAO_0000218,The maximum plasma concentration (200 mg/kg) administered orally in human,1969.0,N,1,,CHEMBL622412,In vivo,50587,14215,,Plasma,A,,,Intermediate,,,
11762,BAO_0000218,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1969.0,N,1,,CHEMBL623114,In vivo,50597,14215,,Plasma,A,,,Intermediate,,,
11763,BAO_0000218,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,1969.0,U,1,,CHEMBL623115,In vivo,22224,14215,,Plasma,A,,,Autocuration,,,
11764,BAO_0000218,The maximum plasma concentration (25 mg/kg) administered orally in monkey,1969.0,U,1,,CHEMBL623116,In vivo,22224,14215,,Plasma,A,,,Autocuration,,,
11765,BAO_0000218,The maximum plasma concentration (30 mg/kg) administered orally in dog,1969.0,U,1,,CHEMBL623117,In vivo,22224,14215,,Plasma,A,,,Autocuration,,,
11766,BAO_0000218,The maximum plasma concentration (400 mg/kg) administered orally in human,1969.0,N,1,,CHEMBL623118,In vivo,50587,14215,,Plasma,A,,,Intermediate,,,
11767,BAO_0000218,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1969.0,N,1,,CHEMBL623119,In vivo,50597,14215,,Plasma,A,,,Intermediate,,,
11768,BAO_0000218,The maximum plasma concentration (50 mg/kg) administered orally in rat,1969.0,N,1,,CHEMBL623120,In vivo,50597,14215,,Plasma,A,,,Intermediate,,,
11769,BAO_0000218,The maximum plasma concentration (800 mg/kg) administered orally in human,1969.0,N,1,,CHEMBL623286,In vivo,50587,14215,,Plasma,A,,,Intermediate,,,
11770,BAO_0000218,The maximum plasma concentration was measured on rats,1969.0,N,1,,CHEMBL623287,In vivo,50597,14067,,Plasma,A,,,Intermediate,,,
11771,BAO_0000218,The maximum plasma concentration was measured on rats after oral administration,1969.0,N,1,,CHEMBL623288,In vivo,50597,12350,,Plasma,A,,,Intermediate,,,
11772,BAO_0000218,Plasma drug Cmax in rat (PO dose),1969.0,N,1,,CHEMBL623289,In vivo,50597,14813,,Plasma,A,,,Intermediate,,,
11773,BAO_0000218,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,U,1,,CHEMBL623290,In vivo,22224,12536,,,A,,,Autocuration,,,
11774,BAO_0000218,maximum Plasma concentration in Dog was determined after Peroral administration,1969.0,N,1,,CHEMBL623291,In vivo,50588,14169,,Plasma,A,,,Intermediate,,,
11775,BAO_0000218,maximum Plasma concentration in Rats was determined after Peroral administration,1969.0,N,1,,CHEMBL623292,In vivo,50597,14169,,Plasma,A,,,Intermediate,,,
11776,BAO_0000218,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1969.0,N,1,,CHEMBL623293,In vivo,50588,15604,,Plasma,A,,,Intermediate,,,
11777,BAO_0000218,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1969.0,U,1,,CHEMBL623294,In vivo,22224,15604,,Plasma,A,,,Autocuration,,,
11778,BAO_0000218,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1969.0,N,1,,CHEMBL623295,In vivo,50597,15604,,Plasma,A,,,Intermediate,,,
11779,BAO_0000218,maximum concentration was measured when administered through oral route in mice,,N,1,,CHEMBL623296,In vivo,50594,14387,,,A,,,Intermediate,,,
11780,BAO_0000218,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,N,1,,CHEMBL875349,,50594,15115,,,A,,,Intermediate,,,
11781,BAO_0000019,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,U,1,,CHEMBL623297,,22224,15115,,,A,,,Autocuration,,,
11782,BAO_0000019,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,U,1,,CHEMBL623298,,22224,15115,,,A,,,Autocuration,,,
11783,BAO_0000019,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,U,1,,CHEMBL623299,,22224,15115,,,A,,,Autocuration,,,
11784,BAO_0000218,Pharmacokinetic parameter was evaluated in rats,,N,1,,CHEMBL623300,,50597,16359,,,A,,,Intermediate,,,
11785,BAO_0000218,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,N,1,,CHEMBL623301,,50594,12829,,,A,,,Intermediate,,,
11786,BAO_0000218,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,N,1,,CHEMBL623302,,50594,12829,,,A,,,Intermediate,,,
11787,BAO_0000218,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,N,1,,CHEMBL623303,,50594,12829,,,A,,,Intermediate,,,
11788,BAO_0000218,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,N,1,,CHEMBL623304,,50594,12829,,,A,,,Intermediate,,,
11789,BAO_0000218,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,N,1,,CHEMBL623305,,50594,12829,,,A,,,Intermediate,,,
11790,BAO_0000218,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1969.0,N,1,,CHEMBL623306,,50597,15137,,Plasma,A,,,Intermediate,,,
11791,BAO_0000218,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1969.0,N,1,,CHEMBL623307,,50597,15137,,Plasma,A,,,Intermediate,,,
11792,BAO_0000218,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1969.0,N,1,,CHEMBL623308,,50597,15137,,Plasma,A,,,Intermediate,,,
11793,BAO_0000218,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1969.0,N,1,,CHEMBL623309,,50594,15137,,Plasma,A,,,Intermediate,,,
11794,BAO_0000218,Plasma Concentration after 120 min of oral administration to mice,,N,1,,CHEMBL623310,,50594,13509,,,A,,,Intermediate,,,
11795,BAO_0000218,Plasma Concentration after 30 min of oral administration to mice,,N,1,,CHEMBL623311,,50594,13509,,,A,,,Intermediate,,,
11796,BAO_0000218,Plasma Concentration after 60 min of oral administration to mice,,N,1,,CHEMBL623312,,100710,13509,,,A,,,Intermediate,,,
11797,BAO_0000218,Plasma Concentration after 60 min of oral administration to mice; Not determined,,N,1,,CHEMBL875350,,50594,13509,,,A,,,Intermediate,,,
11798,BAO_0000218,Plasma Concentration after 90 min of oral administration to mice,,N,1,,CHEMBL628635,,50594,13509,,,A,,,Intermediate,,,
11799,BAO_0000218,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,N,1,,CHEMBL628636,,50597,12064,,,A,,,Intermediate,,,
11800,BAO_0000218,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,N,1,,CHEMBL628637,,50597,12064,,,A,,,Intermediate,,,
11801,BAO_0000218,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,N,1,,CHEMBL628058,,50597,12064,,,A,,,Intermediate,,,
11802,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,N,1,,CHEMBL628059,,50597,10677,,,A,,,Intermediate,,,
11803,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,N,1,,CHEMBL628060,,50597,10677,,,A,,,Intermediate,,,
11804,BAO_0000019,Distribution in the lung after 15 min of intravenous administration,,U,1,,CHEMBL628061,,22224,8926,,,A,,,Autocuration,,,
11805,BAO_0000019,Distribution in the lung after 30 min of intravenous administration,,U,1,,CHEMBL628062,,22224,8926,,,A,,,Autocuration,,,
11806,BAO_0000019,Distribution in the lung after 5 min of intravenous administration,,U,1,,CHEMBL628063,,22224,8926,,,A,,,Autocuration,,,
11807,BAO_0000019,Distribution in the lung after 60 min of intravenous administration,,U,1,,CHEMBL628064,,22224,8926,,,A,,,Autocuration,,,
11808,BAO_0000019,Distribution in the lung after 90 min of intravenous administration,,U,1,,CHEMBL628065,,22224,8926,,,A,,,Autocuration,,,
11809,BAO_0000019,Distribution in the muscle after 120 min of intravenous administration,2385.0,U,1,,CHEMBL628066,,22224,8926,,Muscle tissue,A,,,Autocuration,,,
11810,BAO_0000019,Distribution in the muscle after 15 min of intravenous administration,2385.0,U,1,,CHEMBL628067,,22224,8926,,Muscle tissue,A,,,Autocuration,,,
11811,BAO_0000218,Distribution in the muscle after 30 min of intravenous administration,2385.0,N,1,,CHEMBL874646,,50594,8926,,Muscle tissue,A,,,Intermediate,,,
11812,BAO_0000019,Distribution in the muscle after 5 min of intravenous administration,2385.0,U,1,,CHEMBL628068,,22224,8926,,Muscle tissue,A,,,Autocuration,,,
11813,BAO_0000019,Distribution in the muscle after 60 min of intravenous administration,2385.0,U,1,,CHEMBL628069,,22224,8926,,Muscle tissue,A,,,Autocuration,,,
11814,BAO_0000019,Distribution in the muscle after 90 min of intravenous administration,2385.0,U,1,,CHEMBL628070,,22224,8926,,Muscle tissue,A,,,Autocuration,,,
11815,BAO_0000019,Distribution in the spleen after 120 min of intravenous administration,2106.0,U,1,,CHEMBL628071,,22224,8926,,Spleen,A,,,Autocuration,,,
11816,BAO_0000019,Distribution in the spleen after 15 min of intravenous administration,2106.0,U,1,,CHEMBL628072,,22224,8926,,Spleen,A,,,Autocuration,,,
11817,BAO_0000019,Distribution in the spleen after 30 min of intravenous administration,2106.0,U,1,,CHEMBL628073,,22224,8926,,Spleen,A,,,Autocuration,,,
11818,BAO_0000019,Distribution in the spleen after 5 min of intravenous administration,2106.0,U,1,,CHEMBL628074,,22224,8926,,Spleen,A,,,Autocuration,,,
11819,BAO_0000019,Distribution in the spleen after 60 min of intravenous administration,2106.0,U,1,,CHEMBL628075,,22224,8926,,Spleen,A,,,Autocuration,,,
11820,BAO_0000019,Distribution in the spleen after 90 min of intravenous administration,2106.0,U,1,,CHEMBL628076,,22224,8926,,Spleen,A,,,Autocuration,,,
11821,BAO_0000218,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1235.0,N,1,,CHEMBL628077,,50597,7570,,Adrenal cortex,A,,,Intermediate,,,
11822,BAO_0000218,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,178.0,N,1,,CHEMBL628078,,50597,7570,,Blood,A,,,Intermediate,,,
11823,BAO_0000218,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,2107.0,N,1,,CHEMBL628079,,50597,7570,,Liver,A,,,Intermediate,,,
11824,BAO_0000218,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,992.0,N,1,,CHEMBL628080,,50597,7570,,Female gonad,A,,,Intermediate,,,
11825,BAO_0000218,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,2046.0,N,1,,CHEMBL628081,,50597,7570,,Thyroid gland,A,,,Intermediate,,,
11826,BAO_0000218,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1235.0,N,1,,CHEMBL628082,,50597,7570,,Adrenal cortex,A,,,Intermediate,,,
11827,BAO_0000218,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,178.0,N,1,,CHEMBL874647,,50597,7570,,Blood,A,,,Intermediate,,,
11828,BAO_0000218,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,2107.0,N,1,,CHEMBL626406,,50597,7570,,Liver,A,,,Intermediate,,,
11829,BAO_0000218,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,992.0,N,1,,CHEMBL626407,,50597,7570,,Female gonad,A,,,Intermediate,,,
11830,BAO_0000218,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,2046.0,N,1,,CHEMBL626408,,50597,7570,,Thyroid gland,A,,,Intermediate,,,
11831,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",178.0,N,1,,CHEMBL626409,,50597,8608,,Blood,A,,,Intermediate,,,
11832,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",178.0,N,1,,CHEMBL626410,,50597,8608,,Blood,A,,,Intermediate,,,
11833,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",178.0,N,1,,CHEMBL626411,,50597,8608,,Blood,A,,,Intermediate,,,
11834,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",178.0,N,1,,CHEMBL626412,,50597,8608,,Blood,A,,,Intermediate,,,
11835,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",178.0,N,1,,CHEMBL626413,,50597,8608,,Blood,A,,,Intermediate,,,
11836,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",178.0,N,1,,CHEMBL626414,,50597,8608,,Blood,A,,,Intermediate,,,
11837,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",178.0,N,1,,CHEMBL626415,,50597,8608,,Blood,A,,,Intermediate,,,
11838,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",178.0,N,1,,CHEMBL626416,,50597,8608,,Blood,A,,,Intermediate,,,
11839,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",178.0,N,1,,CHEMBL627062,,50597,8608,,Blood,A,,,Intermediate,,,
11840,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",178.0,N,1,,CHEMBL627063,,50597,8608,,Blood,A,,,Intermediate,,,
11841,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",178.0,N,1,,CHEMBL627064,,50597,8608,,Blood,A,,,Intermediate,,,
11842,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",178.0,N,1,,CHEMBL627227,,50597,8608,,Blood,A,,,Intermediate,,,
11843,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",178.0,N,1,,CHEMBL627228,,50597,8608,,Blood,A,,,Intermediate,,,
11844,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",178.0,N,1,,CHEMBL627229,,50597,8608,,Blood,A,,,Intermediate,,,
11845,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",178.0,N,1,,CHEMBL625792,,50597,8608,,Blood,A,,,Intermediate,,,
11846,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",178.0,N,1,,CHEMBL625793,,50597,8608,,Blood,A,,,Intermediate,,,
11847,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",178.0,N,1,,CHEMBL625794,,50597,8608,,Blood,A,,,Intermediate,,,
11848,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",178.0,N,1,,CHEMBL625795,,50597,8608,,Blood,A,,,Intermediate,,,
11849,BAO_0000218,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,N,1,,CHEMBL625796,,50594,13792,,,A,,,Intermediate,,,
11850,BAO_0000218,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,N,1,,CHEMBL625797,,50588,13376,,,A,,,Intermediate,,,
11851,BAO_0000218,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,N,1,,CHEMBL625798,,50588,13376,,,A,,,Intermediate,,,
11852,BAO_0000218,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,U,1,,CHEMBL875613,,22224,14380,,,A,,,Autocuration,,,
11853,BAO_0000218,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,U,1,,CHEMBL625799,,22224,14380,,,A,,,Autocuration,,,
11854,BAO_0000218,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,U,1,,CHEMBL625800,,22224,14380,,,A,,,Autocuration,,,
11855,BAO_0000218,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,U,1,,CHEMBL625801,,22224,14380,,,A,,,Autocuration,,,
11856,BAO_0000218,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,U,1,,CHEMBL625802,,22224,14380,,,A,,,Autocuration,,,
11857,BAO_0000218,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,U,1,,CHEMBL625803,,22224,14380,,,A,,,Autocuration,,,
11858,BAO_0000019,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,U,1,,CHEMBL625804,,22224,14380,,,A,,,Autocuration,,,
11859,BAO_0000218,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,U,1,,CHEMBL622530,,22224,14380,,,A,,,Autocuration,,,
11860,BAO_0000218,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,N,1,,CHEMBL622531,,50594,13701,,,A,,,Intermediate,,,
11861,BAO_0000218,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,N,1,,CHEMBL622532,,50594,13701,,,A,,,Intermediate,,,
11862,BAO_0000218,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,N,1,,CHEMBL623176,,50594,13701,,,A,,,Intermediate,,,
11863,BAO_0000218,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,N,1,,CHEMBL623177,,50594,13701,,,A,,,Intermediate,,,
11864,BAO_0000218,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,N,1,,CHEMBL623178,,50594,13701,,,A,,,Intermediate,,,
11865,BAO_0000218,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,N,1,,CHEMBL623179,,50594,13701,,,A,,,Intermediate,,,
11866,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,N,1,,CHEMBL623180,,50594,13701,,,A,,,Intermediate,,,
11867,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,N,1,,CHEMBL623181,,50594,13701,,,A,,,Intermediate,,,
11868,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,N,1,,CHEMBL624131,,50594,13701,,,A,,,Intermediate,,,
11869,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,N,1,,CHEMBL624132,,50594,13701,,,A,,,Intermediate,,,
11870,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,N,1,,CHEMBL624133,,50594,13701,,,A,,,Intermediate,,,
11871,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,N,1,,CHEMBL624846,,50594,13701,,,A,,,Intermediate,,,
11872,BAO_0000218,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,N,1,,CHEMBL624847,,50594,13701,,,A,,,Intermediate,,,
11873,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,N,1,,CHEMBL624848,,50594,13701,,,A,,,Intermediate,,,
11874,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,N,1,,CHEMBL625012,,50594,13701,,,A,,,Intermediate,,,
11875,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,N,1,,CHEMBL625013,,50594,13701,,,A,,,Intermediate,,,
11876,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,N,1,,CHEMBL625014,,50594,13701,,,A,,,Intermediate,,,
11877,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,N,1,,CHEMBL625015,,50594,13701,,,A,,,Intermediate,,,
11878,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,N,1,,CHEMBL625016,,50594,13701,,,A,,,Intermediate,,,
11879,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,N,1,,CHEMBL625017,,50594,13701,,,A,,,Intermediate,,,
11880,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,N,1,,CHEMBL625018,,50594,13701,,,A,,,Intermediate,,,
11881,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,N,1,,CHEMBL625019,,50594,13701,,,A,,,Intermediate,,,
11882,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,N,1,,CHEMBL625020,,50594,13701,,,A,,,Intermediate,,,
11883,BAO_0000218,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,N,1,,CHEMBL625021,,50594,13701,,,A,,,Intermediate,,,
11884,BAO_0000218,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,1,,CHEMBL625022,,50597,14393,,,A,,,Intermediate,,,
11885,BAO_0000218,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,N,1,,CHEMBL625023,,50594,14731,,,A,,,Intermediate,,,
11886,BAO_0000218,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,N,1,,CHEMBL625024,,100710,14731,,,A,,,Intermediate,,,
11887,BAO_0000218,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,N,1,,CHEMBL627626,,100710,14731,,,A,,,Intermediate,,,
11888,BAO_0000218,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,955.0,U,1,,CHEMBL627627,,22224,13758,,Brain,A,,,Autocuration,,,
11889,BAO_0000218,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,1977.0,U,1,,CHEMBL627628,,22224,13758,,Serum,A,,,Autocuration,,,
11890,BAO_0000218,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,955.0,U,1,,CHEMBL627629,,22224,13758,,Brain,A,,,Autocuration,,,
11891,BAO_0000218,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,1977.0,U,1,,CHEMBL627630,,22224,13758,,Serum,A,,,Autocuration,,,
11892,BAO_0000019,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,U,1,,CHEMBL627631,,22224,16359,,,A,,,Autocuration,,,
11893,BAO_0000218,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,U,1,,CHEMBL629515,,22224,16359,,,A,,,Autocuration,,,
11894,BAO_0000218,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2106.0,N,1,,CHEMBL629516,,50594,15383,,Spleen,A,,,Intermediate,,,
11895,BAO_0000218,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2106.0,N,1,,CHEMBL629517,,50594,15383,,Spleen,A,,,Intermediate,,,
11896,BAO_0000218,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2106.0,N,1,,CHEMBL629518,,50594,15383,,Spleen,A,,,Intermediate,,,
11897,BAO_0000218,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,1,,CHEMBL877499,,50594,15383,,,A,,,Intermediate,,,
11898,BAO_0000218,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,1,,CHEMBL629519,,50594,15383,,,A,,,Intermediate,,,
11899,BAO_0000218,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,1,,CHEMBL629520,,50594,15383,,,A,,,Intermediate,,,
11900,BAO_0000218,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,1,,CHEMBL629521,,50594,15383,,,A,,,Intermediate,,,
11901,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,N,1,,CHEMBL629522,,50594,14439,,,A,,,Intermediate,,,
11902,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,N,1,,CHEMBL629523,,50594,14439,,,A,,,Intermediate,,,
11903,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,N,1,,CHEMBL629524,,50594,14439,,,A,,,Intermediate,,,
11904,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,N,1,,CHEMBL629525,,50594,14439,,,A,,,Intermediate,,,
11905,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,N,1,,CHEMBL629526,,50594,14439,,,A,,,Intermediate,,,
11906,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,N,1,,CHEMBL629527,,50594,14439,,,A,,,Intermediate,,,
11907,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,N,1,,CHEMBL629528,,50594,14439,,,A,,,Intermediate,,,
11908,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,N,1,,CHEMBL629529,,50594,14439,,,A,,,Intermediate,,,
11909,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,N,1,,CHEMBL629530,,50594,14439,,,A,,,Intermediate,,,
11910,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,N,1,,CHEMBL629531,,50594,14439,,,A,,,Intermediate,,,
11911,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,N,1,,CHEMBL628656,,50594,14439,,,A,,,Intermediate,,,
11912,BAO_0000218,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,N,1,,CHEMBL628657,,50594,14439,,,A,,,Intermediate,,,
11913,BAO_0000218,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,N,1,,CHEMBL628658,In vivo,50597,13751,,,A,,,Intermediate,,,
11914,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,1,,CHEMBL628659,In vivo,50597,13751,,,A,,,Intermediate,,,
11915,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,1,,CHEMBL877500,In vivo,50597,13751,,,A,,,Intermediate,,,
11916,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,1,,CHEMBL628660,In vivo,50597,13751,,,A,,,Intermediate,,,
11917,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,1,,CHEMBL628661,In vivo,50597,13751,,,A,,,Intermediate,,,
11918,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,1,,CHEMBL628662,In vivo,50597,13751,,,A,,,Intermediate,,,
11919,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,1,,CHEMBL628663,In vivo,50597,13751,,,A,,,Intermediate,,,
11920,BAO_0000218,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,1,,CHEMBL628664,In vivo,50597,13751,,,A,,,Intermediate,,,
11921,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628665,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11922,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628666,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11923,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628667,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11924,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628668,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11925,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628669,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11926,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628670,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11927,BAO_0000218,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",178.0,N,1,,CHEMBL628671,In vivo,50597,13751,,Blood,A,,,Intermediate,,,
11928,BAO_0000218,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",10000001.0,N,1,,CHEMBL628672,In vivo,50597,13751,,Bone,A,,,Intermediate,,,
11929,BAO_0000218,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",10000001.0,N,1,,CHEMBL630300,In vivo,50597,13751,,Bone,A,,,Intermediate,,,
11930,BAO_0000218,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",10000001.0,N,1,,CHEMBL629787,In vivo,50597,13751,,Bone,A,,,Intermediate,,,
11931,BAO_0000218,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",10000001.0,N,1,,CHEMBL629788,In vivo,50597,13751,,Bone,A,,,Intermediate,,,
11932,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629789,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
11933,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629790,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
11934,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629791,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
11935,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629792,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
11936,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629793,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
11937,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629794,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
11938,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,N,1,,CHEMBL874459,,50597,10677,,,A,,,Intermediate,,,
11939,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,N,1,,CHEMBL629795,,50597,10677,,,A,,,Intermediate,,,
11940,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,N,1,,CHEMBL629796,,50597,10677,,,A,,,Intermediate,,,
11941,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,N,1,,CHEMBL629797,,50597,10677,,,A,,,Intermediate,,,
11942,BAO_0000218,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,N,1,,CHEMBL629798,,50597,10677,,,A,,,Intermediate,,,
11943,BAO_0000218,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2369.0,N,1,,CHEMBL629799,In vivo,50597,10911,,Adrenal gland,A,,,Intermediate,,,
11944,BAO_0000218,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2369.0,N,1,,CHEMBL629800,In vivo,50597,10911,,Adrenal gland,A,,,Intermediate,,,
11945,BAO_0000218,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2369.0,N,1,,CHEMBL629801,In vivo,50597,10911,,Adrenal gland,A,,,Intermediate,,,
11946,BAO_0000218,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,2369.0,N,1,,CHEMBL629802,In vivo,50597,10911,,Adrenal gland,A,,,Intermediate,,,
11947,BAO_0000218,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2369.0,N,1,,CHEMBL629803,In vivo,50597,10911,,Adrenal gland,A,,,Intermediate,,,
11948,BAO_0000218,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,178.0,N,1,,CHEMBL629804,In vivo,50597,10911,,Blood,A,,,Intermediate,,,
11949,BAO_0000218,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,178.0,N,1,,CHEMBL629805,In vivo,50597,10911,,Blood,A,,,Intermediate,,,
11950,BAO_0000218,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,178.0,N,1,,CHEMBL629806,In vivo,50597,10911,,Blood,A,,,Intermediate,,,
11951,BAO_0000218,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,178.0,N,1,,CHEMBL629807,In vivo,50597,10911,,Blood,A,,,Intermediate,,,
11952,BAO_0000218,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,178.0,N,1,,CHEMBL629808,In vivo,50597,10911,,Blood,A,,,Intermediate,,,
11953,BAO_0000218,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,955.0,N,1,,CHEMBL629809,In vivo,50597,10911,,Brain,A,,,Intermediate,,,
11954,BAO_0000218,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,955.0,N,1,,CHEMBL629810,In vivo,50597,10911,,Brain,A,,,Intermediate,,,
11955,BAO_0000218,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,955.0,N,1,,CHEMBL629811,In vivo,50597,10911,,Brain,A,,,Intermediate,,,
11956,BAO_0000218,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,955.0,N,1,,CHEMBL629812,In vivo,50597,10911,,Brain,A,,,Intermediate,,,
11957,BAO_0000218,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,955.0,N,1,,CHEMBL629813,In vivo,50597,10911,,Brain,A,,,Intermediate,,,
11958,BAO_0000218,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,955.0,N,1,,CHEMBL874460,In vivo,50597,10911,,Brain,A,,,Intermediate,,,
11959,BAO_0000218,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,1,,CHEMBL629814,In vivo,50597,10911,,,A,,,Intermediate,,,
11960,BAO_0000218,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,1,,CHEMBL629815,In vivo,50597,10911,,,A,,,Intermediate,,,
11961,BAO_0000218,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,1,,CHEMBL629816,In vivo,50597,10911,,,A,,,Intermediate,,,
11962,BAO_0000218,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,1,,CHEMBL629817,In vivo,50597,10911,,,A,,,Intermediate,,,
11963,BAO_0000218,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2113.0,N,1,,CHEMBL626643,In vivo,50597,10911,,Kidney,A,,,Intermediate,,,
11964,BAO_0000218,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2113.0,N,1,,CHEMBL626644,In vivo,50597,10911,,Kidney,A,,,Intermediate,,,
11965,BAO_0000218,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2113.0,N,1,,CHEMBL626806,In vivo,50597,10911,,Kidney,A,,,Intermediate,,,
11966,BAO_0000218,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2113.0,N,1,,CHEMBL626807,In vivo,50597,10911,,Kidney,A,,,Intermediate,,,
11967,BAO_0000218,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2107.0,N,1,,CHEMBL627261,In vivo,50597,10911,,Liver,A,,,Intermediate,,,
11968,BAO_0000218,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2107.0,N,1,,CHEMBL627262,In vivo,50597,10911,,Liver,A,,,Intermediate,,,
11969,BAO_0000218,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2107.0,N,1,,CHEMBL627263,In vivo,50597,10911,,Liver,A,,,Intermediate,,,
11970,BAO_0000218,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2107.0,N,1,,CHEMBL627264,In vivo,50597,10911,,Liver,A,,,Intermediate,,,
11971,BAO_0000218,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2048.0,N,1,,CHEMBL627265,In vivo,50597,10911,,Lung,A,,,Intermediate,,,
11972,BAO_0000218,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2048.0,N,1,,CHEMBL627266,In vivo,50597,10911,,Lung,A,,,Intermediate,,,
11973,BAO_0000218,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2048.0,N,1,,CHEMBL627267,In vivo,50597,10911,,Lung,A,,,Intermediate,,,
11974,BAO_0000218,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2048.0,N,1,,CHEMBL627268,In vivo,50597,10911,,Lung,A,,,Intermediate,,,
11975,BAO_0000218,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2385.0,N,1,,CHEMBL627269,In vivo,50597,10911,,Muscle tissue,A,,,Intermediate,,,
11976,BAO_0000218,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2385.0,N,1,,CHEMBL627270,In vivo,50597,10911,,Muscle tissue,A,,,Intermediate,,,
11977,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,N,1,,CHEMBL627271,,50597,8608,,,A,,,Intermediate,,,
11978,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,N,1,,CHEMBL627946,,50597,8608,,,A,,,Intermediate,,,
11979,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,N,1,,CHEMBL875472,,50597,8608,,,A,,,Intermediate,,,
11980,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,N,1,,CHEMBL627947,,50597,8608,,,A,,,Intermediate,,,
11981,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,N,1,,CHEMBL627948,,50597,8608,,,A,,,Intermediate,,,
11982,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,N,1,,CHEMBL628113,,50597,8608,,,A,,,Intermediate,,,
11983,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,N,1,,CHEMBL628114,,50597,8608,,,A,,,Intermediate,,,
11984,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,N,1,,CHEMBL628115,,50597,8608,,,A,,,Intermediate,,,
11985,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,N,1,,CHEMBL628116,,50597,8608,,,A,,,Intermediate,,,
11986,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,N,1,,CHEMBL628117,,50597,8608,,,A,,,Intermediate,,,
11987,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,N,1,,CHEMBL628118,,50597,8608,,,A,,,Intermediate,,,
11988,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,N,1,,CHEMBL628119,,50597,8608,,,A,,,Intermediate,,,
11989,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,N,1,,CHEMBL628120,,50597,8608,,,A,,,Intermediate,,,
11990,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,N,1,,CHEMBL628121,,50597,8608,,,A,,,Intermediate,,,
11991,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,N,1,,CHEMBL628122,,50597,8608,,,A,,,Intermediate,,,
11992,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,N,1,,CHEMBL627297,,50597,8608,,,A,,,Intermediate,,,
11993,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,N,1,,CHEMBL627298,,50597,8608,,,A,,,Intermediate,,,
11994,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,N,1,,CHEMBL627299,,50597,8608,,,A,,,Intermediate,,,
11995,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,N,1,,CHEMBL627300,,50597,8608,,,A,,,Intermediate,,,
11996,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,N,1,,CHEMBL627301,,50597,8608,,,A,,,Intermediate,,,
11997,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,N,1,,CHEMBL627302,,50597,8608,,,A,,,Intermediate,,,
11998,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,N,1,,CHEMBL627303,,50597,8608,,,A,,,Intermediate,,,
11999,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,N,1,,CHEMBL627304,,50597,8608,,,A,,,Intermediate,,,
12000,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,N,1,,CHEMBL627305,,50597,8608,,,A,,,Intermediate,,,
12001,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,N,1,,CHEMBL627306,,50597,8608,,,A,,,Intermediate,,,
12002,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,N,1,,CHEMBL623982,,50597,8608,,,A,,,Intermediate,,,
12003,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,N,1,,CHEMBL623983,,50597,8608,,,A,,,Intermediate,,,
12004,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,N,1,,CHEMBL623984,,50597,8608,,,A,,,Intermediate,,,
12005,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,N,1,,CHEMBL623985,,50597,8608,,,A,,,Intermediate,,,
12006,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,N,1,,CHEMBL623986,,50597,8608,,,A,,,Intermediate,,,
12007,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,N,1,,CHEMBL623987,,50597,8608,,,A,,,Intermediate,,,
12008,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,N,1,,CHEMBL623988,,50597,8608,,,A,,,Intermediate,,,
12009,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,N,1,,CHEMBL623989,,50597,8608,,,A,,,Intermediate,,,
12010,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,N,1,,CHEMBL622215,,50597,8608,,,A,,,Intermediate,,,
12011,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,N,1,,CHEMBL622216,,50597,8608,,,A,,,Intermediate,,,
12012,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,N,1,,CHEMBL877481,,50597,8608,,,A,,,Intermediate,,,
12013,BAO_0000218,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,U,1,,CHEMBL622217,,22224,16359,,,A,,,Autocuration,,,
12014,BAO_0000218,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,N,1,,CHEMBL622218,,50594,13701,,,A,,,Intermediate,,,
12015,BAO_0000218,Pharmacokinetic profile AUC was evaluated in rats,,N,1,,CHEMBL622219,,50597,14554,,,A,,,Intermediate,,,
12016,BAO_0000019,Pharmacokinetic property (Area under curve),,U,1,,CHEMBL622220,,22224,6241,,,A,,,Autocuration,,,
12017,BAO_0000218,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,N,1,,CHEMBL622221,,50588,11537,,,A,,,Intermediate,,,
12018,BAO_0000218,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,N,1,,CHEMBL622222,,50594,11537,,,A,,,Intermediate,,,
12019,BAO_0000218,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,N,1,,CHEMBL622223,,50588,11537,,,A,,,Intermediate,,,
12020,BAO_0000218,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,N,1,,CHEMBL622224,,50594,11537,,,A,,,Intermediate,,,
12021,BAO_0000019,Plasma concentration (AUC) was determined,,U,1,,CHEMBL622225,,22224,13118,,,A,,,Autocuration,,,
12022,BAO_0000019,Plasma concentration (AUC) was determined; Not detectable,,U,1,,CHEMBL622226,,22224,13118,,,A,,,Autocuration,,,
12023,BAO_0000218,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,N,1,,CHEMBL624154,,50512,9562,,,A,,,Intermediate,,,
12024,BAO_0000218,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,N,1,,CHEMBL624155,,50597,10363,,,A,,,Intermediate,,,
12025,BAO_0000218,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,N,1,,CHEMBL624156,,50597,10363,,,A,,,Intermediate,,,
12026,BAO_0000218,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,N,1,,CHEMBL624157,,50597,10363,,,A,,,Intermediate,,,
12027,BAO_0000218,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,N,1,,CHEMBL624158,,50597,10363,,,A,,,Intermediate,,,
12028,BAO_0000218,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,N,1,,CHEMBL624159,,50597,12504,,,A,,,Intermediate,,,
12029,BAO_0000218,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,N,1,,CHEMBL624160,,50597,12504,,,A,,,Intermediate,,,
12030,BAO_0000218,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,N,1,,CHEMBL624161,,50597,12504,,,A,,,Intermediate,,,
12031,BAO_0000218,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,N,1,,CHEMBL624162,,50597,12504,,,A,,,Intermediate,,,
12032,BAO_0000218,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,N,1,,CHEMBL624163,,50588,13317,,,A,,,Intermediate,,,
12033,BAO_0000218,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL624164,,50597,15078,,,A,,,Intermediate,,,
12034,BAO_0000218,The AUC(0-infinity) values in female wistar rats.,,N,1,,CHEMBL624165,,50597,14941,,,A,,,Intermediate,,,
12035,BAO_0000218,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL624166,,50597,15078,,,A,,,Intermediate,,,
12036,BAO_0000218,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,N,1,,CHEMBL624167,,50597,15078,,,A,,,Intermediate,,,
12037,BAO_0000218,The AUC(0-t)values in female wistar rats.,,N,1,,CHEMBL624168,,50597,14941,,,A,,,Intermediate,,,
12038,BAO_0000218,The Area under the concentration time curve of compound was measured on rats,,N,1,,CHEMBL624169,,50597,14067,,,A,,,Intermediate,,,
12039,BAO_0000218,The area under curve (100 mg/kg) administered orally in humans,,N,1,,CHEMBL624170,,50587,14215,,,A,,,Intermediate,,,
12040,BAO_0000218,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,U,1,,CHEMBL624171,,22224,14215,,,A,,,Autocuration,,,
12041,BAO_0000218,The area under curve (12.5 mg/kg) administered intravenously in monkey,,U,1,,CHEMBL624172,,22224,14215,,,A,,,Autocuration,,,
12042,BAO_0000218,The area under curve (15 mg/kg) administered intravenously in dog,,N,1,,CHEMBL624173,,50588,14215,,,A,,,Intermediate,,,
12043,BAO_0000218,The area under curve (200 mg/kg) administered orally in humans,,N,1,,CHEMBL877488,,50587,14215,,,A,,,Intermediate,,,
12044,BAO_0000218,The area under curve (25 mg/kg) administered intravenously in rat,,N,1,,CHEMBL624174,,50597,14215,,,A,,,Intermediate,,,
12045,BAO_0000218,The area under curve (25 mg/kg) administered orally in marmoset,,U,1,,CHEMBL624175,,22224,14215,,,A,,,Autocuration,,,
12046,BAO_0000218,The area under curve (25 mg/kg) administered orally in monkey,,U,1,,CHEMBL624176,,22224,14215,,,A,,,Autocuration,,,
12047,BAO_0000218,The area under curve (30 mg/kg) administered orally in dog,,N,1,,CHEMBL624177,,50588,14215,,,A,,,Intermediate,,,
12048,BAO_0000218,The area under curve (400 mg/kg) administered orally in humans,,N,1,,CHEMBL624178,,50587,14215,,,A,,,Intermediate,,,
12049,BAO_0000218,The area under curve (50 mg/kg) administered orally in fasted rat,,N,1,,CHEMBL624179,,50597,14215,,,A,,,Intermediate,,,
12050,BAO_0000218,The area under curve (50 mg/kg) administered orally in rat,,N,1,,CHEMBL627689,,50597,14215,,,A,,,Intermediate,,,
12051,BAO_0000218,The area under curve (800 mg/kg) administered orally in humans,,N,1,,CHEMBL627690,,50587,14215,,,A,,,Intermediate,,,
12052,BAO_0000019,The compound was evaluated for area under the curve,,U,1,,CHEMBL627691,,22224,11324,,,A,,,Autocuration,,,
12053,BAO_0000019,The compound was evaluated for area under the curve in marmosets,,U,1,,CHEMBL627692,,22224,11324,,,A,,,Autocuration,,,
12054,BAO_0000019,The compound was evaluated for area under the curve in marmosets,,U,1,,CHEMBL627693,,22224,11324,,,A,,,Autocuration,,,
12055,BAO_0000218,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,N,1,,CHEMBL627694,,50597,13875,,,A,,,Intermediate,,,
12056,BAO_0000218,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,N,1,,CHEMBL627695,,50597,13875,,,A,,,Intermediate,,,
12057,BAO_0000218,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,U,1,,CHEMBL627696,,22224,13875,,,A,,,Autocuration,,,
12058,BAO_0000218,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,N,1,,CHEMBL627697,,50597,13875,,,A,,,Intermediate,,,
12059,BAO_0000218,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,N,1,,CHEMBL627698,,50597,13875,,,A,,,Intermediate,,,
12060,BAO_0000218,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,N,1,,CHEMBL627699,,50597,13875,,,A,,,Intermediate,,,
12061,BAO_0000218,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,N,1,,CHEMBL627700,,50597,13807,,,A,,,Intermediate,,,
12062,BAO_0000218,Total drug exposure is determined after oral dosing in rats.,,N,1,,CHEMBL627701,,50597,14127,,,A,,,Intermediate,,,
12063,BAO_0000218,Total drug exposure (5 mg/kg) when administered intravenously,,U,1,,CHEMBL627702,,22224,15116,,,A,,,Autocuration,,,
12064,BAO_0000218,Total drug exposure (5 mg/kg) when administered orally,,U,1,,CHEMBL627703,,22224,15116,,,A,,,Autocuration,,,
12065,BAO_0000218,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,U,1,,CHEMBL626873,,22224,15604,,,A,,,Autocuration,,,
12066,BAO_0000218,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,N,1,,CHEMBL629583,,50597,15604,,,A,,,Intermediate,,,
12067,BAO_0000218,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,N,1,,CHEMBL629584,,50588,15604,,,A,,,Intermediate,,,
12068,BAO_0000218,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,N,1,,CHEMBL629585,,50588,15604,,,A,,,Intermediate,,,
12069,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629586,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
12070,BAO_0000218,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",955.0,N,1,,CHEMBL629587,In vivo,50597,13751,,Brain,A,,,Intermediate,,,
12071,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,1,,CHEMBL629588,In vivo,50597,13751,,,A,,,Intermediate,,,
12072,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,1,,CHEMBL629589,In vivo,50597,13751,,,A,,,Intermediate,,,
12073,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,1,,CHEMBL629590,In vivo,50597,13751,,,A,,,Intermediate,,,
12074,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,1,,CHEMBL629591,In vivo,50597,13751,,,A,,,Intermediate,,,
12075,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,1,,CHEMBL629592,In vivo,50597,13751,,,A,,,Intermediate,,,
12076,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,1,,CHEMBL629593,In vivo,50597,13751,,,A,,,Intermediate,,,
12077,BAO_0000218,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,1,,CHEMBL629594,In vivo,50597,13751,,,A,,,Intermediate,,,
12078,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",948.0,N,1,,CHEMBL629595,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12079,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",948.0,N,1,,CHEMBL630290,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12080,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",948.0,N,1,,CHEMBL627137,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12081,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",948.0,N,1,,CHEMBL627138,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12082,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",948.0,N,1,,CHEMBL627139,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12083,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",948.0,N,1,,CHEMBL627140,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12084,BAO_0000218,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",948.0,N,1,,CHEMBL627141,In vivo,50597,13751,,Heart,A,,,Intermediate,,,
12085,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL627142,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12086,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL627143,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12087,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL874449,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12088,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL627144,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12089,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL627145,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12090,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL627146,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12091,BAO_0000218,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",2113.0,N,1,,CHEMBL627147,In vivo,50597,13751,,Kidney,A,,,Intermediate,,,
12092,BAO_0000218,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL627148,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12093,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL627149,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12094,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL632160,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12095,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL632161,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12096,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL632162,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12097,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL632163,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12098,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL874469,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12099,BAO_0000218,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",2048.0,N,1,,CHEMBL627182,In vivo,50597,13751,,Lung,A,,,Intermediate,,,
12100,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627183,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12101,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627184,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12102,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627185,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12103,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627186,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12104,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627187,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12105,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627188,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12106,BAO_0000218,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",2385.0,N,1,,CHEMBL627189,In vivo,50597,13751,,Muscle tissue,A,,,Intermediate,,,
12107,BAO_0000218,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,1,,CHEMBL627190,In vivo,50597,13751,,,A,,,Intermediate,,,
12108,BAO_0000218,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL627191,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12109,BAO_0000218,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL627192,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12110,BAO_0000218,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL627193,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12111,BAO_0000218,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,2385.0,N,1,,CHEMBL874590,In vivo,50597,10911,,Muscle tissue,A,,,Intermediate,,,
12112,BAO_0000218,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2385.0,N,1,,CHEMBL627194,In vivo,50597,10911,,Muscle tissue,A,,,Intermediate,,,
12113,BAO_0000218,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2385.0,N,1,,CHEMBL627195,In vivo,50597,10911,,Muscle tissue,A,,,Intermediate,,,
12114,BAO_0000218,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,992.0,N,1,,CHEMBL627196,In vivo,50597,10911,,Female gonad,A,,,Intermediate,,,
12115,BAO_0000218,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,992.0,N,1,,CHEMBL627197,In vivo,50597,10911,,Female gonad,A,,,Intermediate,,,
12116,BAO_0000218,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,992.0,N,1,,CHEMBL627198,In vivo,50597,10911,,Female gonad,A,,,Intermediate,,,
12117,BAO_0000218,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,992.0,N,1,,CHEMBL627199,In vivo,50597,10911,,Female gonad,A,,,Intermediate,,,
12118,BAO_0000218,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,992.0,N,1,,CHEMBL627200,In vivo,50597,10911,,Female gonad,A,,,Intermediate,,,
12119,BAO_0000218,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1969.0,N,1,,CHEMBL627201,In vivo,50597,10911,,Plasma,A,,,Intermediate,,,
12120,BAO_0000218,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1969.0,N,1,,CHEMBL627202,In vivo,50597,10911,,Plasma,A,,,Intermediate,,,
12121,BAO_0000218,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1969.0,N,1,,CHEMBL627203,In vivo,50597,10911,,Plasma,A,,,Intermediate,,,
12122,BAO_0000218,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1969.0,N,1,,CHEMBL627204,In vivo,50597,10911,,Plasma,A,,,Intermediate,,,
12123,BAO_0000218,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2106.0,N,1,,CHEMBL627205,In vivo,50597,10911,,Spleen,A,,,Intermediate,,,
12124,BAO_0000218,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2106.0,N,1,,CHEMBL627206,In vivo,50597,10911,,Spleen,A,,,Intermediate,,,
12125,BAO_0000218,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2106.0,N,1,,CHEMBL627207,In vivo,50597,10911,,Spleen,A,,,Intermediate,,,
12126,BAO_0000218,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2106.0,N,1,,CHEMBL627208,In vivo,50597,10911,,Spleen,A,,,Intermediate,,,
12127,BAO_0000218,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2046.0,N,1,,CHEMBL627209,In vivo,50597,10911,,Thyroid gland,A,,,Intermediate,,,
12128,BAO_0000218,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2046.0,N,1,,CHEMBL627210,In vivo,50597,10911,,Thyroid gland,A,,,Intermediate,,,
12129,BAO_0000218,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2046.0,N,1,,CHEMBL627211,In vivo,50597,10911,,Thyroid gland,A,,,Intermediate,,,
12130,BAO_0000218,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2046.0,N,1,,CHEMBL627212,In vivo,50597,10911,,Thyroid gland,A,,,Intermediate,,,
12131,BAO_0000218,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,995.0,N,1,,CHEMBL627213,In vivo,50597,10911,,Uterus,A,,,Intermediate,,,
12132,BAO_0000218,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,995.0,N,1,,CHEMBL626599,In vivo,50597,10911,,Uterus,A,,,Intermediate,,,
12133,BAO_0000218,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,995.0,N,1,,CHEMBL626600,In vivo,50597,10911,,Uterus,A,,,Intermediate,,,
12134,BAO_0000218,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,995.0,N,1,,CHEMBL626601,In vivo,50597,10911,,Uterus,A,,,Intermediate,,,
12135,BAO_0000019,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,U,1,,CHEMBL627484,,22224,8081,,,A,,,Autocuration,,,
12136,BAO_0000218,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1969.0,N,1,,CHEMBL627485,,100710,17248,,Plasma,A,,,Intermediate,,,
12137,BAO_0000218,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1969.0,N,1,,CHEMBL628147,,100710,17248,,Plasma,A,,,Intermediate,,,
12138,BAO_0000218,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1969.0,N,1,,CHEMBL628148,,100710,17248,,Plasma,A,,,Intermediate,,,
12139,BAO_0000218,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1969.0,N,1,,CHEMBL628149,,50588,17248,,Plasma,A,,,Intermediate,,,
12140,BAO_0000218,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1969.0,N,1,,CHEMBL628150,,50588,17248,,Plasma,A,,,Intermediate,,,
12141,BAO_0000218,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1969.0,N,1,,CHEMBL628318,,50588,17248,,Plasma,A,,,Intermediate,,,
12142,BAO_0000218,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1969.0,N,1,,CHEMBL628319,,50588,17248,,Plasma,A,,,Intermediate,,,
12143,BAO_0000218,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,N,1,,CHEMBL875609,,50588,15592,,,A,,,Intermediate,,,
12144,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,U,1,,CHEMBL628320,,22224,7040,,,A,,,Autocuration,,,
12145,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,U,1,,CHEMBL628321,,22224,7040,,,A,,,Autocuration,,,
12146,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,U,1,,CHEMBL628322,,22224,7040,,,A,,,Autocuration,,,
12147,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,U,1,,CHEMBL628323,,22224,7040,,,A,,,Autocuration,,,
12148,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,U,1,,CHEMBL628324,,22224,7040,,,A,,,Autocuration,,,
12149,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,U,1,,CHEMBL628325,,22224,7040,,,A,,,Autocuration,,,
12150,BAO_0000019,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,U,1,,CHEMBL628326,,22224,7040,,,A,,,Autocuration,,,
12151,BAO_0000218,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1236.0,N,1,,CHEMBL628327,,50588,9614,,Adrenal medulla,A,,,Intermediate,,,
12152,BAO_0000218,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1236.0,N,1,,CHEMBL628328,,50588,9614,,Adrenal medulla,A,,,Intermediate,,,
12153,BAO_0000218,"Concentration of compound in blood of dog 1, after administering intravenously",178.0,N,1,,CHEMBL628329,,50588,9614,,Blood,A,,,Intermediate,,,
12154,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",2107.0,N,1,,CHEMBL628330,,50597,8608,,Liver,A,,,Intermediate,,,
12155,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",2107.0,N,1,,CHEMBL628331,,50597,8608,,Liver,A,,,Intermediate,,,
12156,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",2107.0,N,1,,CHEMBL628332,,50597,8608,,Liver,A,,,Intermediate,,,
12157,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",2107.0,N,1,,CHEMBL628333,,50597,8608,,Liver,A,,,Intermediate,,,
12158,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",2107.0,N,1,,CHEMBL628334,,50597,8608,,Liver,A,,,Intermediate,,,
12159,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",2107.0,N,1,,CHEMBL628335,,50597,8608,,Liver,A,,,Intermediate,,,
12160,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",2107.0,N,1,,CHEMBL628336,,50597,8608,,Liver,A,,,Intermediate,,,
12161,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",2107.0,N,1,,CHEMBL628337,,50597,8608,,Liver,A,,,Intermediate,,,
12162,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",2107.0,N,1,,CHEMBL628338,,50597,8608,,Liver,A,,,Intermediate,,,
12163,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",2107.0,N,1,,CHEMBL875610,,50597,8608,,Liver,A,,,Intermediate,,,
12164,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",2107.0,N,1,,CHEMBL628339,,50597,8608,,Liver,A,,,Intermediate,,,
12165,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",2107.0,N,1,,CHEMBL628340,,50597,8608,,Liver,A,,,Intermediate,,,
12166,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",2107.0,N,1,,CHEMBL628341,,50597,8608,,Liver,A,,,Intermediate,,,
12167,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",2107.0,N,1,,CHEMBL622214,,50597,8608,,Liver,A,,,Intermediate,,,
12168,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",2107.0,N,1,,CHEMBL623167,,50597,8608,,Liver,A,,,Intermediate,,,
12169,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",2107.0,N,1,,CHEMBL623168,,50597,8608,,Liver,A,,,Intermediate,,,
12170,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",2107.0,N,1,,CHEMBL623169,,50597,8608,,Liver,A,,,Intermediate,,,
12171,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",2107.0,N,1,,CHEMBL623170,,50597,8608,,Liver,A,,,Intermediate,,,
12172,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",2048.0,N,1,,CHEMBL627224,,50597,8608,,Lung,A,,,Intermediate,,,
12173,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",2048.0,N,1,,CHEMBL875634,,50597,8608,,Lung,A,,,Intermediate,,,
12174,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",2048.0,N,1,,CHEMBL627225,,50597,8608,,Lung,A,,,Intermediate,,,
12175,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",2048.0,N,1,,CHEMBL627226,,50597,8608,,Lung,A,,,Intermediate,,,
12176,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",2048.0,N,1,,CHEMBL626083,,50597,8608,,Lung,A,,,Intermediate,,,
12177,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",2048.0,N,1,,CHEMBL626084,,50597,8608,,Lung,A,,,Intermediate,,,
12178,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",2048.0,N,1,,CHEMBL626085,,50597,8608,,Lung,A,,,Intermediate,,,
12179,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",2048.0,N,1,,CHEMBL626086,,50597,8608,,Lung,A,,,Intermediate,,,
12180,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",2048.0,N,1,,CHEMBL626087,,50597,8608,,Lung,A,,,Intermediate,,,
12181,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",2048.0,N,1,,CHEMBL626088,,50597,8608,,Lung,A,,,Intermediate,,,
12182,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",2048.0,N,1,,CHEMBL626089,,50597,8608,,Lung,A,,,Intermediate,,,
12183,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",2048.0,N,1,,CHEMBL626090,,50597,8608,,Lung,A,,,Intermediate,,,
12184,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",2048.0,N,1,,CHEMBL626091,,50597,8608,,Lung,A,,,Intermediate,,,
12185,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",2048.0,N,1,,CHEMBL626092,,50597,8608,,Lung,A,,,Intermediate,,,
12186,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",2048.0,N,1,,CHEMBL626093,,50597,8608,,Lung,A,,,Intermediate,,,
12187,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",2048.0,N,1,,CHEMBL626094,,50597,8608,,Lung,A,,,Intermediate,,,
12188,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",2048.0,N,1,,CHEMBL626095,,50597,8608,,Lung,A,,,Intermediate,,,
12189,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",2048.0,N,1,,CHEMBL626096,,50597,8608,,Lung,A,,,Intermediate,,,
12190,BAO_0000218,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,U,1,,CHEMBL626097,,22224,15604,,,A,,,Autocuration,,,
12191,BAO_0000218,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,N,1,,CHEMBL626098,,50597,15604,,,A,,,Intermediate,,,
12192,BAO_0000218,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,1969.0,U,1,,CHEMBL626099,,22224,1806,,Plasma,A,,,Autocuration,,,
12193,BAO_0000218,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,1969.0,U,1,,CHEMBL626100,,22224,1806,,Plasma,A,,,Autocuration,,,
12194,BAO_0000218,AUC 0-inf in dog,1969.0,N,1,,CHEMBL626101,,50588,17237,,Plasma,A,,,Intermediate,,,
12195,BAO_0000218,AUC 0-inf in guinea pig,1969.0,N,1,,CHEMBL626102,,50512,17237,,Plasma,A,,,Intermediate,,,
12196,BAO_0000218,AUC 0-t in dog,1969.0,N,1,,CHEMBL626103,,50588,17237,,Plasma,A,,,Intermediate,,,
12197,BAO_0000218,AUC 0-t in guinea pig,1969.0,N,1,,CHEMBL628391,,50512,17237,,Plasma,A,,,Intermediate,,,
12198,BAO_0000218,The compound was tested for brain to plasma partition in rat,,N,1,,CHEMBL628392,,50597,15194,,,A,,,Intermediate,,,
12199,BAO_0000218,The compound was tested for brain to plasma partition in rat.,,N,1,,CHEMBL628393,,50597,15194,,,A,,,Intermediate,,,
12200,BAO_0000019,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,178.0,U,1,,CHEMBL628394,,22224,8787,,Blood,A,,,Autocuration,,,
12201,BAO_0000218,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,N,1,,CHEMBL628395,,50588,17025,,,A,,,Intermediate,,,
12202,BAO_0000218,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,U,1,,CHEMBL628396,,22224,17025,,,A,,,Autocuration,,,
12203,BAO_0000218,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,N,1,,CHEMBL628397,,50592,17025,,,A,,,Intermediate,,,
12204,BAO_0000218,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,N,1,,CHEMBL628398,,50597,17025,,,A,,,Intermediate,,,
12205,BAO_0000218,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,N,1,,CHEMBL628399,,50797,4236,,,A,,,Intermediate,,,
12206,BAO_0000218,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,N,1,,CHEMBL628400,,50588,15343,,,A,,,Intermediate,,,
12207,BAO_0000218,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,N,1,,CHEMBL874907,,50597,15343,,,A,,,Intermediate,,,
12208,BAO_0000019,Area under curve of the compound was determined,,U,1,,CHEMBL628401,,22224,17720,,,A,,,Autocuration,,,
12209,BAO_0000218,AUC in monkeys at a dose of 1 mg/kg,1969.0,U,1,,CHEMBL628402,,22224,17788,,Plasma,A,,,Autocuration,,,
12210,BAO_0000218,AUC in rats at a dose of 1 mg/kg,1969.0,N,1,,CHEMBL628403,,50597,17788,,Plasma,A,,,Intermediate,,,
12211,BAO_0000019,Compound was evaluated for the overall absorbance loss at pH of 2,,U,1,,CHEMBL628404,,22224,8778,,,A,,,Autocuration,,,
12212,BAO_0000019,Compound was evaluated for the overall absorbance loss at pH of 4,,U,1,,CHEMBL628405,,22224,8778,,,A,,,Autocuration,,,
12213,BAO_0000019,Compound was evaluated for the overall absorbance loss at pH of 7,,U,1,,CHEMBL628406,,22224,8778,,,A,,,Autocuration,,,
12214,BAO_0000218,Compound was evaluated for its absorption in the rats,,N,1,,CHEMBL628407,,50597,2249,,,A,,,Intermediate,,,
12215,BAO_0000218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1088.0,N,1,,CHEMBL628408,,50597,8881,,Urine,A,,,Intermediate,,,
12216,BAO_0000218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1088.0,N,1,,CHEMBL629171,,50597,8881,,Urine,A,,,Intermediate,,,
12217,BAO_0000218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1088.0,N,1,,CHEMBL629172,,50597,8881,,Urine,A,,,Intermediate,,,
12218,BAO_0000218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1088.0,N,1,,CHEMBL629173,,50597,8881,,Urine,A,,,Intermediate,,,
12219,BAO_0000218,In vitro percent permeability into rat ileum,,N,1,,CHEMBL629174,,50597,15286,,,A,,,Intermediate,,,
12220,BAO_0000218,In vitro percent permeability into rat ileum; Range is 10-17,,N,1,,CHEMBL629175,,50597,15286,,,A,,,Intermediate,,,
12221,BAO_0000218,In vitro percent permeability into rat ileum; Range is 10-18,,N,1,,CHEMBL629176,,50597,15286,,,A,,,Intermediate,,,
12222,BAO_0000218,In vitro percent permeability into rat ileum; Range is 10-19,,N,1,,CHEMBL629177,,50597,15286,,,A,,,Intermediate,,,
12223,BAO_0000218,In vitro percent permeability into rat ileum; Range is 12-15,,N,1,,CHEMBL629178,,50597,15286,,,A,,,Intermediate,,,
12224,BAO_0000218,In vitro percent permeability into rat ileum; Range is 13-19,,N,1,,CHEMBL631869,,50597,15286,,,A,,,Intermediate,,,
12225,BAO_0000218,In vitro percent permeability into rat ileum; Range is 14-17,,N,1,,CHEMBL631870,,50597,15286,,,A,,,Intermediate,,,
12226,BAO_0000218,In vitro percent permeability into rat ileum; Range is 15-18,,N,1,,CHEMBL631871,,50597,15286,,,A,,,Intermediate,,,
12227,BAO_0000218,In vitro percent permeability into rat ileum; Range is 2-5,,N,1,,CHEMBL631872,,50597,15286,,,A,,,Intermediate,,,
12228,BAO_0000221,In vitro percent permeability into rat ileum; Range is 23-42,2116.0,U,1,,CHEMBL875775,,22224,15286,,Ileum,A,,,Autocuration,,,
12229,BAO_0000218,In vitro percent permeability into rat ileum; Range is 28-36,,N,1,,CHEMBL631873,,50597,15286,,,A,,,Intermediate,,,
12230,BAO_0000218,In vitro percent permeability into rat ileum; Range is 29-35,,N,1,,CHEMBL631874,,50597,15286,,,A,,,Intermediate,,,
12231,BAO_0000218,In vitro percent permeability into rat ileum; Range is 46-66,,N,1,,CHEMBL631875,,50597,15286,,,A,,,Intermediate,,,
12232,BAO_0000218,In vitro percent permeability into rat ileum; Range is 50-68,,N,1,,CHEMBL631876,,50597,15286,,,A,,,Intermediate,,,
12233,BAO_0000218,In vitro percent permeability into rat ileum; Range is 78-81,,N,1,,CHEMBL631877,,50597,15286,,,A,,,Intermediate,,,
12234,BAO_0000218,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,N,1,,CHEMBL631878,,50597,15286,,,A,,,Intermediate,,,
12235,BAO_0000218,In vitro percent permeability into rat ileum; nd indicates not detected,,N,1,,CHEMBL631879,,50597,15286,,,A,,,Intermediate,,,
12236,BAO_0000218,In vitro percent permeability into rat ileum; nt indicates not detected,,N,1,,CHEMBL631880,,50597,15286,,,A,,,Intermediate,,,
12237,BAO_0000218,In vitro percent permeability into rat ileum; nt indicates not tested,,N,1,,CHEMBL631881,,50597,15286,,,A,,,Intermediate,,,
12238,BAO_0000218,Compound was tested for oral absorption in bile-duct cannulated rats,,N,1,,CHEMBL631882,,50597,13770,,,A,,,Intermediate,,,
12239,BAO_0000218,Compound was tested for oral absorption in bile-duct cannulated rats.,,N,1,,CHEMBL630749,,50597,13770,,,A,,,Intermediate,,,
12240,BAO_0000218,Oral absorption using Caco-2 cell monolayers.,,N,1,,CHEMBL630750,,50587,5202,,,A,,,Intermediate,,,
12241,BAO_0000218,Percent of the drug absorbed after administration to humans was determined,,N,1,,CHEMBL630253,,50587,14920,,,A,,,Intermediate,,,
12242,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1969.0,N,1,,CHEMBL630254,,50597,14103,,Plasma,A,,,Intermediate,,,
12243,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1969.0,N,1,,CHEMBL630255,,50597,14103,,Plasma,A,,,Intermediate,,,
12244,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1969.0,N,1,,CHEMBL630256,,50597,14103,,Plasma,A,,,Intermediate,,,
12245,BAO_0000218,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL875781,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12246,BAO_0000218,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL630257,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12247,BAO_0000218,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",2107.0,N,1,,CHEMBL630258,In vivo,50597,13751,,Liver,A,,,Intermediate,,,
12248,BAO_0000218,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,N,1,,CHEMBL630259,,50597,15807,,,A,,,Intermediate,,,
12249,BAO_0000218,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",2435.0,N,1,,CHEMBL630260,,50597,15807,,Striatum,A,,,Intermediate,,,
12250,BAO_0000218,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",2435.0,N,1,,CHEMBL630261,,50597,15807,,Striatum,A,,,Intermediate,,,
12251,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,N,1,,CHEMBL630262,,50597,14950,,,A,,,Intermediate,,,
12252,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,N,1,,CHEMBL630263,,50597,14950,,,A,,,Intermediate,,,
12253,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,N,1,,CHEMBL630264,,50597,14950,,,A,,,Intermediate,,,
12254,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,N,1,,CHEMBL630265,,50597,14950,,,A,,,Intermediate,,,
12255,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,N,1,,CHEMBL630266,,50597,14950,,,A,,,Intermediate,,,
12256,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,2113.0,N,1,,CHEMBL630267,,50597,14950,,Kidney,A,,,Intermediate,,,
12257,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,2113.0,N,1,,CHEMBL630268,,50597,14950,,Kidney,A,,,Intermediate,,,
12258,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,N,1,,CHEMBL630269,,50597,14950,,,A,,,Intermediate,,,
12259,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,N,1,,CHEMBL630270,,50597,14950,,,A,,,Intermediate,,,
12260,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,2048.0,N,1,,CHEMBL630141,,50597,14950,,Lung,A,,,Intermediate,,,
12261,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,2048.0,N,1,,CHEMBL630142,,50597,14950,,Lung,A,,,Intermediate,,,
12262,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,2385.0,N,1,,CHEMBL630143,,50597,14950,,Muscle tissue,A,,,Intermediate,,,
12263,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,2385.0,N,1,,CHEMBL630144,,50597,14950,,Muscle tissue,A,,,Intermediate,,,
12264,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,2367.0,N,1,,CHEMBL630145,,50597,14950,,Prostate gland,A,,,Intermediate,,,
12265,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,2367.0,N,1,,CHEMBL630146,,50597,14950,,Prostate gland,A,,,Intermediate,,,
12266,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,N,1,,CHEMBL630147,,50597,14950,,,A,,,Intermediate,,,
12267,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,N,1,,CHEMBL630148,,50597,14950,,,A,,,Intermediate,,,
12268,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,N,1,,CHEMBL630149,,50597,14950,,,A,,,Intermediate,,,
12269,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,2106.0,N,1,,CHEMBL630150,,50597,14950,,Spleen,A,,,Intermediate,,,
12270,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,2106.0,N,1,,CHEMBL630151,,50597,14950,,Spleen,A,,,Intermediate,,,
12271,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,2046.0,N,1,,CHEMBL632031,,50597,14950,,Thyroid gland,A,,,Intermediate,,,
12272,BAO_0000218,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,2046.0,N,1,,CHEMBL632032,,50597,14950,,Thyroid gland,A,,,Intermediate,,,
12273,BAO_0000218,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,N,1,,CHEMBL632033,,50597,14950,,,A,,,Intermediate,,,
12274,BAO_0000218,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,N,1,,CHEMBL632034,,50597,14950,,,A,,,Intermediate,,,
12275,BAO_0000218,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,2385.0,N,1,,CHEMBL632035,,50597,14950,,Muscle tissue,A,,,Intermediate,,,
12276,BAO_0000218,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,N,1,,CHEMBL632036,,50597,14950,,,A,,,Intermediate,,,
12277,BAO_0000218,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,2046.0,N,1,,CHEMBL632037,,50597,14950,,Thyroid gland,A,,,Intermediate,,,
12278,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,178.0,N,1,,CHEMBL632038,,50597,8631,,Blood,A,,,Intermediate,,,
12279,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,178.0,N,1,,CHEMBL632039,,50597,8631,,Blood,A,,,Intermediate,,,
12280,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,178.0,N,1,,CHEMBL632040,,50597,8631,,Blood,A,,,Intermediate,,,
12281,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,178.0,N,1,,CHEMBL632041,,50597,8631,,Blood,A,,,Intermediate,,,
12282,BAO_0000218,"Concentration of compound in blood of dog 2, after administering intravenously",178.0,N,1,,CHEMBL632042,,50588,9614,,Blood,A,,,Intermediate,,,
12283,BAO_0000218,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,N,1,,CHEMBL632043,,50588,9614,,,A,,,Intermediate,,,
12284,BAO_0000218,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,N,1,,CHEMBL632044,,50588,9614,,,A,,,Intermediate,,,
12285,BAO_0000218,"Concentration of compound in liver of dog 1, after administering intravenously",2107.0,N,1,,CHEMBL632045,,50588,9614,,Liver,A,,,Intermediate,,,
12286,BAO_0000218,"Concentration of compound in liver of dog 2, after administering intravenously",2107.0,N,1,,CHEMBL632046,,50588,9614,,Liver,A,,,Intermediate,,,
12287,BAO_0000218,"Concentration of compound in lung of dog 1, after administering intravenously",2048.0,N,1,,CHEMBL632047,,50588,9614,,Lung,A,,,Intermediate,,,
12288,BAO_0000218,"Concentration of compound in lung of dog 2, after administering intravenously",2048.0,N,1,,CHEMBL632048,,50588,9614,,Lung,A,,,Intermediate,,,
12289,BAO_0000218,"Concentration of compound in muscle of dog 1, after administering intravenously",2385.0,N,1,,CHEMBL632049,,50588,9614,,Muscle tissue,A,,,Intermediate,,,
12290,BAO_0000218,"Concentration of compound in muscle of dog 2, after administering intravenously",2385.0,N,1,,CHEMBL876418,,50588,9614,,Muscle tissue,A,,,Intermediate,,,
12291,BAO_0000218,"Concentration of compound in spleen of dog 1,after administering intravenously",2106.0,N,1,,CHEMBL632050,,50588,9614,,Spleen,A,,,Intermediate,,,
12292,BAO_0000218,"Concentration of compound in spleen of dog 2, after administering intravenously",2106.0,N,1,,CHEMBL632051,,50588,9614,,Spleen,A,,,Intermediate,,,
12293,BAO_0000218,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,U,1,,CHEMBL632052,,22224,10353,,,F,,,Autocuration,,,
12294,BAO_0000218,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,U,1,,CHEMBL632053,,22224,10353,,,F,,,Autocuration,,,
12295,BAO_0000218,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,U,1,,CHEMBL632054,,22224,10353,,,A,,,Autocuration,,,
12296,BAO_0000218,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,U,1,,CHEMBL632055,,22224,10353,,,F,,,Autocuration,,,
12297,BAO_0000218,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,U,1,,CHEMBL631181,,22224,10353,,,F,,,Autocuration,,,
12298,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,U,1,,CHEMBL631182,,22224,9196,,,A,,,Autocuration,,,
12299,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,U,1,,CHEMBL631183,,22224,9196,,,A,,,Autocuration,,,
12300,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL631184,,22224,9196,,,A,,,Autocuration,,,
12301,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL629774,,22224,9196,,,A,,,Autocuration,,,
12302,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,1,,CHEMBL629775,,22224,9196,,,A,,,Autocuration,,,
12303,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL876549,,22224,9196,,,A,,,Autocuration,,,
12304,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL628172,,22224,9196,,,A,,,Autocuration,,,
12305,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,U,1,,CHEMBL628173,,22224,9196,,,A,,,Autocuration,,,
12306,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,U,1,,CHEMBL628174,,22224,9196,,,A,,,Autocuration,,,
12307,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,U,1,,CHEMBL628175,,22224,9196,,,A,,,Autocuration,,,
12308,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL628176,,22224,9196,,,A,,,Autocuration,,,
12309,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL628177,,22224,9196,,,A,,,Autocuration,,,
12310,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL628178,,22224,9196,,,A,,,Autocuration,,,
12311,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,U,1,,CHEMBL628179,,22224,9196,,,A,,,Autocuration,,,
12312,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,U,1,,CHEMBL628180,,22224,9196,,,A,,,Autocuration,,,
12313,BAO_0000218,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,U,1,,CHEMBL628181,,22224,9196,,,A,,,Autocuration,,,
12314,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL628182,,22224,9196,,,A,,,Autocuration,,,
12315,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,1,,CHEMBL628183,,22224,9196,,,A,,,Autocuration,,,
12316,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,U,1,,CHEMBL628184,,22224,9196,,,A,,,Autocuration,,,
12317,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL628185,,22224,9196,,,A,,,Autocuration,,,
12318,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL875617,,22224,9196,,,A,,,Autocuration,,,
12319,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,U,1,,CHEMBL628186,,22224,9196,,,A,,,Autocuration,,,
12320,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL628187,,22224,9196,,,A,,,Autocuration,,,
12321,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL628188,,22224,9196,,,A,,,Autocuration,,,
12322,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,U,1,,CHEMBL628189,,22224,9196,,,A,,,Autocuration,,,
12323,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,U,1,,CHEMBL628190,,22224,9196,,,A,,,Autocuration,,,
12324,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL628191,,22224,9196,,,A,,,Autocuration,,,
12325,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,U,1,,CHEMBL626513,,22224,9196,,,A,,,Autocuration,,,
12326,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",2046.0,N,1,,CHEMBL626514,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12327,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",2046.0,N,1,,CHEMBL626515,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12328,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",2046.0,N,1,,CHEMBL626516,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12329,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",2046.0,N,1,,CHEMBL626517,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12330,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",2046.0,N,1,,CHEMBL626518,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12331,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",2046.0,N,1,,CHEMBL626519,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12332,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",2046.0,N,1,,CHEMBL626520,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12333,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",2046.0,N,1,,CHEMBL626521,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12334,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",2046.0,N,1,,CHEMBL626522,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12335,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",2046.0,N,1,,CHEMBL626523,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12336,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",2046.0,N,1,,CHEMBL626524,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12337,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",2046.0,N,1,,CHEMBL626688,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12338,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",2046.0,N,1,,CHEMBL626689,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12339,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",2046.0,N,1,,CHEMBL626690,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12340,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",2046.0,N,1,,CHEMBL626691,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12341,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",2046.0,N,1,,CHEMBL627319,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12342,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",2046.0,N,1,,CHEMBL624052,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12343,BAO_0000218,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",2046.0,N,1,,CHEMBL624053,,50597,8608,,Thyroid gland,A,,,Intermediate,,,
12344,BAO_0000218,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,1,,CHEMBL624054,,50597,8085,,,A,,,Intermediate,,,
12345,BAO_0000218,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,1,,CHEMBL624055,,50597,8085,,,A,,,Intermediate,,,
12346,BAO_0000218,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,1,,CHEMBL624056,,50597,8085,,,A,,,Intermediate,,,
12347,BAO_0000218,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL624057,,50597,8085,,Uterus,A,,,Intermediate,,,
12348,BAO_0000218,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL622281,,50597,8085,,Uterus,A,,,Intermediate,,,
12349,BAO_0000218,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL622282,,50597,8085,,Uterus,A,,,Intermediate,,,
12350,BAO_0000218,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL622283,,50597,8085,,Uterus,A,,,Intermediate,,,
12351,BAO_0000218,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL622284,,50597,8085,,Uterus,A,,,Intermediate,,,
12352,BAO_0000218,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL622285,,50597,8085,,Uterus,A,,,Intermediate,,,
12353,BAO_0000218,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,N,1,,CHEMBL622286,,50597,8085,,Uterus,A,,,Intermediate,,,
12354,BAO_0000100,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,U,1,,CHEMBL622287,,22224,7657,,,P,,,Autocuration,,,
12355,BAO_0000218,Partition coefficient (logD7.4),,N,1,,CHEMBL622288,,50594,8935,,,A,,,Intermediate,,,
12356,BAO_0000218,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,N,1,,CHEMBL622289,,50594,13792,,,A,,,Intermediate,,,
12357,BAO_0000218,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",955.0,N,1,,CHEMBL622290,,50594,13792,,Brain,A,,,Intermediate,,,
12358,BAO_0000218,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,N,1,,CHEMBL622291,,50594,13792,,,A,,,Intermediate,,,
12359,BAO_0000218,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,955.0,N,1,,CHEMBL622292,,50594,13792,,Brain,A,,,Intermediate,,,
12360,BAO_0000218,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,N,1,,CHEMBL622293,,50594,13792,,,A,,,Intermediate,,,
12361,BAO_0000218,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",955.0,N,1,,CHEMBL622294,,50594,13792,,Brain,A,,,Intermediate,,,
12362,BAO_0000218,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,N,1,,CHEMBL622295,,50594,13792,,,A,,,Intermediate,,,
12363,BAO_0000218,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,955.0,N,1,,CHEMBL622296,,50597,13792,,Brain,A,,,Intermediate,,,
12364,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1969.0,N,1,,CHEMBL874409,,50597,14103,,Plasma,A,,,Intermediate,,,
12365,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1969.0,N,1,,CHEMBL622297,,50597,14103,,Plasma,A,,,Intermediate,,,
12366,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1969.0,N,1,,CHEMBL622298,,50597,14103,,Plasma,A,,,Intermediate,,,
12367,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1969.0,N,1,,CHEMBL622299,,50597,14103,,Plasma,A,,,Intermediate,,,
12368,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1969.0,N,1,,CHEMBL622300,,50597,14103,,Plasma,A,,,Intermediate,,,
12369,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1969.0,N,1,,CHEMBL622301,,50597,14103,,Plasma,A,,,Intermediate,,,
12370,BAO_0000218,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1969.0,N,1,,CHEMBL622302,,50597,14103,,Plasma,A,,,Intermediate,,,
12371,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1969.0,N,1,,CHEMBL622303,,50597,14103,,Plasma,A,,,Intermediate,,,
12372,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1969.0,N,1,,CHEMBL622304,,50597,14103,,Plasma,A,,,Intermediate,,,
12373,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1969.0,N,1,,CHEMBL622305,,50597,14103,,Plasma,A,,,Intermediate,,,
12374,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1969.0,N,1,,CHEMBL622306,,50597,14103,,Plasma,A,,,Intermediate,,,
12375,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1969.0,N,1,,CHEMBL626864,,50597,14103,,Plasma,A,,,Intermediate,,,
12376,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1969.0,N,1,,CHEMBL626865,,50597,14103,,Plasma,A,,,Intermediate,,,
12377,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1969.0,N,1,,CHEMBL626866,,50597,14103,,Plasma,A,,,Intermediate,,,
12378,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1969.0,N,1,,CHEMBL626867,,50597,14103,,Plasma,A,,,Intermediate,,,
12379,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1969.0,N,1,,CHEMBL626868,,50597,14103,,Plasma,A,,,Intermediate,,,
12380,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1969.0,N,1,,CHEMBL626869,,50597,14103,,Plasma,A,,,Intermediate,,,
12381,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1969.0,N,1,,CHEMBL626870,,50597,14103,,Plasma,A,,,Intermediate,,,
12382,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1969.0,N,1,,CHEMBL626871,,50597,14103,,Plasma,A,,,Intermediate,,,
12383,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1969.0,N,1,,CHEMBL626872,,50597,14103,,Plasma,A,,,Intermediate,,,
12384,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1969.0,N,1,,CHEMBL632185,,50597,14103,,Plasma,A,,,Intermediate,,,
12385,BAO_0000218,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1969.0,N,1,,CHEMBL632186,,50597,14103,,Plasma,A,,,Intermediate,,,
12386,BAO_0000019,Amount of acetic acid produced by the compound,,U,1,,CHEMBL629310,,22224,12904,,,A,,,Autocuration,,,
12387,BAO_0000019,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,U,1,,CHEMBL629311,,22224,12904,,,A,,,Autocuration,,,
12388,BAO_0000218,Log of (Cbrain/Cblood) in rats,,N,1,,CHEMBL629312,,50597,9663,,,A,,,Intermediate,,,
12389,BAO_0000221,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,U,1,,CHEMBL629313,,22224,7652,,,A,,,Autocuration,,,
12390,BAO_0000221,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,U,1,,CHEMBL629314,,22224,7652,,,A,,,Autocuration,,,
12391,BAO_0000221,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,U,1,,CHEMBL629315,,22224,7652,,,A,,,Autocuration,,,
12392,BAO_0000219,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,U,1,,CHEMBL629316,,22224,7652,,,B,,,Autocuration,,,
12393,BAO_0000221,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,U,1,,CHEMBL629317,,22224,7652,,,A,,,Autocuration,,,
12394,BAO_0000019,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,U,1,,CHEMBL629318,,22224,7652,,,A,,,Autocuration,,,
12395,BAO_0000019,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,U,1,,CHEMBL877497,,22224,7652,,,A,,,Autocuration,,,
12396,BAO_0000019,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,U,1,,CHEMBL629319,,22224,7652,,,A,,,Autocuration,,,
12397,BAO_0000019,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,U,1,,CHEMBL629320,,22224,7652,,,A,,,Autocuration,,,
12398,BAO_0000019,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,U,1,,CHEMBL629496,,22224,7652,,,A,,,Autocuration,,,
12399,BAO_0000019,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,U,1,,CHEMBL629497,,22224,7652,,,A,,,Autocuration,,,
12400,BAO_0000019,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,U,1,,CHEMBL629498,,22224,7652,,,A,,,Autocuration,,,
12401,BAO_0000019,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,U,1,,CHEMBL629499,,22224,7652,,,A,,,Autocuration,,,
12402,BAO_0000019,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,U,1,,CHEMBL629500,,22224,7652,,,A,,,Autocuration,,,
12403,BAO_0000019,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,U,1,,CHEMBL629501,,22224,7652,,,A,,,Autocuration,,,
12404,BAO_0000019,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,U,1,,CHEMBL629502,,22224,7652,,,A,,,Autocuration,,,
12405,BAO_0000218,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,U,1,,CHEMBL629503,In vivo,22224,8267,,,F,,,Autocuration,,,
12406,BAO_0000218,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,N,1,,CHEMBL629504,,50588,8267,,,A,,,Intermediate,,,
12407,BAO_0000019,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,U,1,,CHEMBL629505,,22224,14479,,,A,,,Autocuration,,,
12408,BAO_0000019,Compound was evaluated for total body clearance,,U,1,,CHEMBL629506,,22224,17515,,,A,,,Autocuration,,,
12409,BAO_0000019,Compound was evaluated for volume of distribution at steady state,,U,1,,CHEMBL629507,,22224,17515,,,A,,,Autocuration,,,
12410,BAO_0000019,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,U,1,,CHEMBL877498,,22224,8142,,,A,,,Autocuration,,,
12411,BAO_0000019,Percentage of the diamine which is monoprotonated at pH 7.4,,U,1,,CHEMBL629508,,22224,14849,,,A,,,Autocuration,,,
12412,BAO_0000019,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,U,1,,CHEMBL629509,,22224,7653,,,A,,,Autocuration,,,
12413,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,178.0,N,1,,CHEMBL629510,,50597,8631,,Blood,A,,,Intermediate,,,
12414,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,N,1,,CHEMBL629511,,50597,8631,,Blood,A,,,Intermediate,,,
12415,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,N,1,,CHEMBL629512,,50597,8631,,Blood,A,,,Intermediate,,,
12416,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,N,1,,CHEMBL629513,,50597,8631,,Blood,A,,,Intermediate,,,
12417,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,178.0,N,1,,CHEMBL629514,,50597,8631,,Blood,A,,,Intermediate,,,
12418,BAO_0000218,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,N,1,,CHEMBL628447,,50597,8631,,Blood,A,,,Intermediate,,,
12419,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,178.0,N,1,,CHEMBL628448,,50597,8631,,Blood,A,,,Intermediate,,,
12420,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,178.0,N,1,,CHEMBL628449,,50597,8631,,Blood,A,,,Intermediate,,,
12421,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,178.0,N,1,,CHEMBL631119,,50597,8631,,Blood,A,,,Intermediate,,,
12422,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,178.0,N,1,,CHEMBL631120,,50597,8631,,Blood,A,,,Intermediate,,,
12423,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,178.0,N,1,,CHEMBL631121,,50597,8631,,Blood,A,,,Intermediate,,,
12424,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,178.0,N,1,,CHEMBL874458,,50597,8631,,Blood,A,,,Intermediate,,,
12425,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,N,1,,CHEMBL631122,,50597,8631,,Blood,A,,,Intermediate,,,
12426,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,N,1,,CHEMBL631123,,50597,8631,,Blood,A,,,Intermediate,,,
12427,BAO_0000218,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,N,1,,CHEMBL631124,,50597,8631,,Blood,A,,,Intermediate,,,
12428,BAO_0000218,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,N,1,,CHEMBL631125,,50597,8631,,Blood,A,,,Intermediate,,,
12429,BAO_0000218,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,N,1,,CHEMBL631290,,50597,8631,,Blood,A,,,Intermediate,,,
12430,BAO_0000218,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,N,1,,CHEMBL631291,,50597,8631,,Blood,A,,,Intermediate,,,
12431,BAO_0000218,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,N,1,,CHEMBL631292,,50597,8631,,Blood,A,,,Intermediate,,,
12432,BAO_0000218,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,N,1,,CHEMBL631293,,50597,8631,,Blood,A,,,Intermediate,,,
12433,BAO_0000218,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,N,1,,CHEMBL631294,,50597,8631,,Blood,A,,,Intermediate,,,
12434,BAO_0000218,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,N,1,,CHEMBL631295,,50597,8631,,Blood,A,,,Intermediate,,,
12435,BAO_0000218,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,178.0,N,1,,CHEMBL631296,,50597,8631,,Blood,A,,,Intermediate,,,
12436,BAO_0000218,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,N,1,,CHEMBL631297,,50597,8631,,Blood,A,,,Intermediate,,,
12437,BAO_0000218,Maximum biodistribution (Bmax) was determined.,,U,1,,CHEMBL631298,,22224,10263,,,A,,,Autocuration,,,
12438,BAO_0000218,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,N,1,,CHEMBL631299,,50594,12364,,,A,,,Intermediate,,,
12439,BAO_0000218,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,N,1,,CHEMBL631300,,50594,12364,,,A,,,Intermediate,,,
12440,BAO_0000218,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,N,1,,CHEMBL631301,,50594,12364,,,A,,,Intermediate,,,
12441,BAO_0000218,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,N,1,,CHEMBL630291,,50594,12364,,,A,,,Intermediate,,,
12442,BAO_0000218,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,1,,CHEMBL630292,,22224,14793,,,A,,,Autocuration,,,
12443,BAO_0000218,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,U,1,,CHEMBL630293,,22224,14793,,,A,,,Autocuration,,,
12444,BAO_0000218,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,U,1,,CHEMBL630294,,22224,14793,,,A,,,Autocuration,,,
12445,BAO_0000218,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,U,1,,CHEMBL630295,,22224,14793,,,A,,,Autocuration,,,
12446,BAO_0000218,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,U,1,,CHEMBL630296,,22224,14793,,,A,,,Autocuration,,,
12447,BAO_0000218,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,U,1,,CHEMBL626782,,22224,14793,,,A,,,Autocuration,,,
12448,BAO_0000218,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,U,1,,CHEMBL626783,,22224,14793,,,A,,,Autocuration,,,
12449,BAO_0000218,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,1,,CHEMBL626784,,22224,14793,,,A,,,Autocuration,,,
12450,BAO_0000218,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,U,1,,CHEMBL626785,,22224,14793,,,A,,,Autocuration,,,
12451,BAO_0000218,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,U,1,,CHEMBL626786,,22224,14793,,,A,,,Autocuration,,,
12452,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL626787,,22224,9196,,,A,,,Autocuration,,,
12453,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,U,1,,CHEMBL626788,,22224,9196,,,A,,,Autocuration,,,
12454,BAO_0000218,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL625927,,22224,9196,,,A,,,Autocuration,,,
12455,BAO_0000218,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL625928,,50597,8374,,Blood,A,,,Intermediate,,,
12456,BAO_0000218,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,N,1,,CHEMBL625929,,50597,8374,,Blood,A,,,Intermediate,,,
12457,BAO_0000218,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,178.0,N,1,,CHEMBL625930,,50597,8374,,Blood,A,,,Intermediate,,,
12458,BAO_0000218,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",178.0,N,1,,CHEMBL625931,,50597,8374,,Blood,A,,,Intermediate,,,
12459,BAO_0000218,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,178.0,N,1,,CHEMBL627230,,50597,8374,,Blood,A,,,Intermediate,,,
12460,BAO_0000218,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627231,,50597,8374,,Blood,A,,,Intermediate,,,
12461,BAO_0000218,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,N,1,,CHEMBL627232,,50597,8374,,Blood,A,,,Intermediate,,,
12462,BAO_0000218,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,178.0,N,1,,CHEMBL627233,,50597,8374,,Blood,A,,,Intermediate,,,
12463,BAO_0000218,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL875470,,50597,8374,,Blood,A,,,Intermediate,,,
12464,BAO_0000218,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627234,,50597,8374,,Blood,A,,,Intermediate,,,
12465,BAO_0000218,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627235,,50597,8374,,Blood,A,,,Intermediate,,,
12466,BAO_0000218,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627236,,50597,8374,,Blood,A,,,Intermediate,,,
12467,BAO_0000218,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627237,,50597,8374,,Blood,A,,,Intermediate,,,
12468,BAO_0000218,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627238,,50597,8374,,Blood,A,,,Intermediate,,,
12469,BAO_0000218,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627239,,50597,8374,,Blood,A,,,Intermediate,,,
12470,BAO_0000218,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627240,,50597,8374,,Blood,A,,,Intermediate,,,
12471,BAO_0000218,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627241,,50597,8374,,Blood,A,,,Intermediate,,,
12472,BAO_0000218,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627242,,50597,8374,,Blood,A,,,Intermediate,,,
12473,BAO_0000218,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,178.0,N,1,,CHEMBL627243,,50597,8374,,Blood,A,,,Intermediate,,,
12474,BAO_0000218,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,N,1,,CHEMBL627244,,50597,8374,,Blood,A,,,Intermediate,,,
12475,BAO_0000218,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627245,,50597,8374,,Blood,A,,,Intermediate,,,
12476,BAO_0000218,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627246,,50597,8374,,Blood,A,,,Intermediate,,,
12477,BAO_0000218,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627247,,50597,8374,,Blood,A,,,Intermediate,,,
12478,BAO_0000218,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627248,,50597,8374,,Blood,A,,,Intermediate,,,
12479,BAO_0000218,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627249,,50597,8374,,Blood,A,,,Intermediate,,,
12480,BAO_0000218,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL625569,,50597,8374,,Blood,A,,,Intermediate,,,
12481,BAO_0000218,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL625570,,50597,8374,,Blood,A,,,Intermediate,,,
12482,BAO_0000218,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL625571,,50597,8374,,Blood,A,,,Intermediate,,,
12483,BAO_0000218,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,N,1,,CHEMBL625572,,50597,8374,,Blood,A,,,Intermediate,,,
12484,BAO_0000218,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,N,1,,CHEMBL625573,,50597,8374,,Blood,A,,,Intermediate,,,
12485,BAO_0000218,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,178.0,N,1,,CHEMBL625574,,50597,8374,,Blood,A,,,Intermediate,,,
12486,BAO_0000218,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,N,1,,CHEMBL626245,,50597,8374,,Blood,A,,,Intermediate,,,
12487,BAO_0000218,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL626246,,50597,8374,,Blood,A,,,Intermediate,,,
12488,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL626247,,22224,9196,,,A,,,Autocuration,,,
12489,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,1,,CHEMBL626248,,22224,9196,,,A,,,Autocuration,,,
12490,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,U,1,,CHEMBL626249,,22224,9196,,,A,,,Autocuration,,,
12491,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL626420,,22224,9196,,,A,,,Autocuration,,,
12492,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,U,1,,CHEMBL626421,,22224,9196,,,A,,,Autocuration,,,
12493,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,U,1,,CHEMBL626422,,22224,9196,,,A,,,Autocuration,,,
12494,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL626423,,22224,9196,,,A,,,Autocuration,,,
12495,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL626424,,22224,9196,,,A,,,Autocuration,,,
12496,BAO_0000218,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,N,1,,CHEMBL626425,,50588,12023,,,A,,,Intermediate,,,
12497,BAO_0000218,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,N,1,,CHEMBL875476,,50597,12023,,,A,,,Intermediate,,,
12498,BAO_0000218,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,N,1,,CHEMBL626426,,100710,12023,,,A,,,Intermediate,,,
12499,BAO_0000100,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,U,1,,CHEMBL626427,,22224,10580,,,P,,,Autocuration,,,
12500,BAO_0000100,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,U,1,,CHEMBL626428,,22224,10580,,,P,,,Autocuration,,,
12501,BAO_0000019,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,U,1,,CHEMBL626429,,22224,16032,,,A,,,Autocuration,,,
12502,BAO_0000019,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,1088.0,U,1,,CHEMBL625025,,22224,16032,,Urine,A,,,Autocuration,,,
12503,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,178.0,N,1,,CHEMBL625026,,50597,8594,,Blood,A,,,Intermediate,,,
12504,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,178.0,N,1,,CHEMBL625027,,50597,8594,,Blood,A,,,Intermediate,,,
12505,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,178.0,N,1,,CHEMBL874410,,50597,8594,,Blood,A,,,Intermediate,,,
12506,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,178.0,N,1,,CHEMBL625028,,50597,8594,,Blood,A,,,Intermediate,,,
12507,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,178.0,N,1,,CHEMBL625029,,50597,8594,,Blood,A,,,Intermediate,,,
12508,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,178.0,N,1,,CHEMBL625030,,50597,8594,,Blood,A,,,Intermediate,,,
12509,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,178.0,N,1,,CHEMBL625031,,50597,8594,,Blood,A,,,Intermediate,,,
12510,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,178.0,N,1,,CHEMBL625032,,50597,8594,,Blood,A,,,Intermediate,,,
12511,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,178.0,N,1,,CHEMBL625033,,50597,8594,,Blood,A,,,Intermediate,,,
12512,BAO_0000218,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,178.0,N,1,,CHEMBL625034,,50597,8594,,Blood,A,,,Intermediate,,,
12513,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,948.0,N,1,,CHEMBL624872,,50597,8594,,Heart,A,,,Intermediate,,,
12514,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,948.0,N,1,,CHEMBL624873,,50597,8594,,Heart,A,,,Intermediate,,,
12515,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,948.0,N,1,,CHEMBL624874,,50597,8594,,Heart,A,,,Intermediate,,,
12516,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,948.0,N,1,,CHEMBL624875,,50597,8594,,Heart,A,,,Intermediate,,,
12517,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,948.0,N,1,,CHEMBL624876,,50597,8594,,Heart,A,,,Intermediate,,,
12518,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,948.0,N,1,,CHEMBL624877,,50597,8594,,Heart,A,,,Intermediate,,,
12519,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,948.0,N,1,,CHEMBL624878,,50597,8594,,Heart,A,,,Intermediate,,,
12520,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,948.0,N,1,,CHEMBL624879,,50597,8594,,Heart,A,,,Intermediate,,,
12521,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,948.0,N,1,,CHEMBL624880,,50597,8594,,Heart,A,,,Intermediate,,,
12522,BAO_0000218,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,948.0,N,1,,CHEMBL624881,,50597,8594,,Heart,A,,,Intermediate,,,
12523,BAO_0000218,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",948.0,N,1,,CHEMBL624882,,50597,8594,,Heart,A,,,Intermediate,,,
12524,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL624883,,50597,8594,,Kidney,A,,,Intermediate,,,
12525,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2113.0,N,1,,CHEMBL624884,,50597,8594,,Kidney,A,,,Intermediate,,,
12526,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL624885,,50597,8594,,Kidney,A,,,Intermediate,,,
12527,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2113.0,N,1,,CHEMBL624886,,50597,8594,,Kidney,A,,,Intermediate,,,
12528,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL624887,,50597,8594,,Kidney,A,,,Intermediate,,,
12529,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2113.0,N,1,,CHEMBL624888,,50597,8594,,Kidney,A,,,Intermediate,,,
12530,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL624889,,50597,8594,,Kidney,A,,,Intermediate,,,
12531,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,2113.0,N,1,,CHEMBL624890,,50597,8594,,Kidney,A,,,Intermediate,,,
12532,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL621964,,50597,8594,,Kidney,A,,,Intermediate,,,
12533,BAO_0000218,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL621965,,50597,8594,,Kidney,A,,,Intermediate,,,
12534,BAO_0000218,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL621966,,50597,8594,,Liver,A,,,Intermediate,,,
12535,BAO_0000218,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2107.0,N,1,,CHEMBL621967,,50597,8594,,Liver,A,,,Intermediate,,,
12536,BAO_0000218,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL622164,,50597,8594,,Liver,A,,,Intermediate,,,
12537,BAO_0000019,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,U,1,,CHEMBL623097,,22224,7653,,,A,,,Autocuration,,,
12538,BAO_0000019,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,U,1,,CHEMBL623098,,22224,7653,,,A,,,Autocuration,,,
12539,BAO_0000019,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,U,1,,CHEMBL623099,,22224,7653,,,A,,,Autocuration,,,
12540,BAO_0000019,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,U,1,,CHEMBL623100,,22224,7653,,,A,,,Autocuration,,,
12541,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,N,1,,CHEMBL628673,,50597,9104,,,A,,,Intermediate,,,
12542,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,N,1,,CHEMBL628674,,50597,9104,,,A,,,Intermediate,,,
12543,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,N,1,,CHEMBL628675,,50597,9104,,,A,,,Intermediate,,,
12544,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,N,1,,CHEMBL627644,,50597,9104,,,A,,,Intermediate,,,
12545,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,N,1,,CHEMBL627645,,50597,9104,,,A,,,Intermediate,,,
12546,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,N,1,,CHEMBL627646,,50597,9104,,,A,,,Intermediate,,,
12547,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,N,1,,CHEMBL627647,,50597,9104,,,A,,,Intermediate,,,
12548,BAO_0000218,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,N,1,,CHEMBL627648,,50597,9104,,,A,,,Intermediate,,,
12549,BAO_0000218,Free level in rat plasma,,N,1,,CHEMBL627649,,50597,12902,,,A,,,Intermediate,,,
12550,BAO_0000019,Level reaching in blood plasma of rat or human was determined,,U,1,,CHEMBL628313,,22224,6614,,,A,,,Autocuration,,,
12551,BAO_0000218,Log (Cbrain/Cblood) in rats,,N,1,,CHEMBL628314,,50597,9663,,,A,,,Intermediate,,,
12552,BAO_0000019,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,U,1,,CHEMBL628315,,22224,17658,,,A,,,Autocuration,,,
12553,BAO_0000019,Mean percentage of compound transport through membrane; expressed as membrane transport,,U,1,,CHEMBL628316,,22224,17658,,,A,,,Autocuration,,,
12554,BAO_0000218,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,U,1,,CHEMBL628317,,22224,14314,,,A,,,Autocuration,,,
12555,BAO_0000019,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,U,1,,CHEMBL628473,,22224,7385,,,A,,,Autocuration,,,
12556,BAO_0000019,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,U,1,,CHEMBL628474,,22224,7385,,,A,,,Autocuration,,,
12557,BAO_0000019,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,U,1,,CHEMBL628475,,22224,7385,,,A,,,Autocuration,,,
12558,BAO_0000019,Net water uptake by a carrier mediated transport (%cm) mechanism,,U,1,,CHEMBL628476,,22224,1329,,,A,,,Autocuration,,,
12559,BAO_0000218,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,U,1,,CHEMBL628477,,22224,12187,,,A,,,Autocuration,,,
12560,BAO_0000218,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,N,1,,CHEMBL628478,,50506,12187,,,A,,,Intermediate,,,
12561,BAO_0000218,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,N,1,,CHEMBL628479,,50506,12187,,,A,,,Intermediate,,,
12562,BAO_0000218,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,U,1,,CHEMBL628480,,22224,12187,,,A,,,Autocuration,,,
12563,BAO_0000218,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,U,1,,CHEMBL628481,,22224,12187,,,A,,,Autocuration,,,
12564,BAO_0000218,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,N,1,,CHEMBL628482,,50597,12187,,,A,,,Intermediate,,,
12565,BAO_0000218,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,N,1,,CHEMBL628483,,50597,12187,,,A,,,Intermediate,,,
12566,BAO_0000218,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1969.0,N,1,,CHEMBL628484,,50597,9278,,Plasma,A,,,Intermediate,,,
12567,BAO_0000218,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,N,1,,CHEMBL628485,,50597,9278,,Plasma,A,,,Intermediate,,,
12568,BAO_0000218,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1969.0,N,1,,CHEMBL628486,,100710,9278,,Plasma,A,,,Intermediate,,,
12569,BAO_0000218,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1969.0,N,1,,CHEMBL628487,,50587,9278,,Plasma,A,,,Intermediate,,,
12570,BAO_0000218,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1969.0,N,1,,CHEMBL628488,,50597,9278,,Plasma,A,,,Intermediate,,,
12571,BAO_0000218,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,N,1,,CHEMBL628489,,50597,9278,,Plasma,A,,,Intermediate,,,
12572,BAO_0000218,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,N,1,,CHEMBL628490,,50597,9278,,Plasma,A,,,Intermediate,,,
12573,BAO_0000218,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,1,,CHEMBL628491,,100710,12186,,,A,,,Intermediate,,,
12574,BAO_0000218,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,1,,CHEMBL877507,,100710,12186,,,A,,,Intermediate,,,
12575,BAO_0000218,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,U,1,,CHEMBL628492,,22224,12186,,,A,,,Autocuration,,,
12576,BAO_0000019,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,U,1,,CHEMBL628493,,22224,12041,,,A,,,Autocuration,,,
12577,BAO_0000019,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,U,1,,CHEMBL628494,,22224,12041,,,A,,,Autocuration,,,
12578,BAO_0000019,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,U,1,,CHEMBL628495,,22224,12041,,,A,,,Autocuration,,,
12579,BAO_0000218,Permeability in Caco-2 assay at 10E-6,,N,1,,CHEMBL628496,,50587,6737,,,A,,,Intermediate,,,
12580,BAO_0000218,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,955.0,U,1,,CHEMBL628497,,22224,13758,,Brain,A,,,Autocuration,,,
12581,BAO_0000218,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,955.0,U,1,,CHEMBL628498,,22224,13758,,Brain,A,,,Autocuration,,,
12582,BAO_0000019,Plasma protein binding was determined,,U,1,,CHEMBL628499,,22224,5676,,,A,,,Autocuration,,,
12583,BAO_0000218,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,U,1,,CHEMBL627656,,22224,14793,,,A,,,Autocuration,,,
12584,BAO_0000218,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,1,,CHEMBL627657,,22224,14793,,,A,,,Autocuration,,,
12585,BAO_0000218,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,U,1,,CHEMBL626808,,22224,14793,,,A,,,Autocuration,,,
12586,BAO_0000218,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,U,1,,CHEMBL626809,,22224,14793,,,A,,,Autocuration,,,
12587,BAO_0000218,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,U,1,,CHEMBL626810,,22224,14793,,,A,,,Autocuration,,,
12588,BAO_0000218,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,1,,CHEMBL626811,,22224,14793,,,A,,,Autocuration,,,
12589,BAO_0000218,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,U,1,,CHEMBL874465,,22224,14793,,,A,,,Autocuration,,,
12590,BAO_0000218,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,U,1,,CHEMBL626812,,22224,14793,,,A,,,Autocuration,,,
12591,BAO_0000218,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,U,1,,CHEMBL626813,,22224,14793,,,A,,,Autocuration,,,
12592,BAO_0000218,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,U,1,,CHEMBL626814,,22224,14793,,,A,,,Autocuration,,,
12593,BAO_0000019,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,U,1,,CHEMBL626815,,22224,14000,,,A,,,Autocuration,,,
12594,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL628566,,22224,5948,,,A,,,Autocuration,,,
12595,BAO_0000100,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,U,1,,CHEMBL628567,,22229,13824,,,P,,,Autocuration,,,
12596,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL628568,,22229,10778,,,P,,,Autocuration,,,
12597,BAO_0000218,C max in dog,,N,1,,CHEMBL628569,In vivo,50588,17237,,,A,,,Intermediate,,,
12598,BAO_0000218,C max in guinea pig,,N,1,,CHEMBL628570,In vivo,50512,17237,,,A,,,Intermediate,,,
12599,BAO_0000218,C max value was evaluated,,U,1,,CHEMBL628571,In vivo,22224,2809,,,A,,,Autocuration,,,
12600,BAO_0000218,Cmax value after oral dose of 0.1 mg//kg,,U,1,,CHEMBL628572,In vivo,22224,11954,,,A,,,Autocuration,,,
12601,BAO_0000218,Cmax value after oral dose of 0.3 mg/kg,,U,1,,CHEMBL628573,In vivo,22224,11954,,,A,,,Autocuration,,,
12602,BAO_0000218,Cmax value after oral dose of 1 mg/kg,,U,1,,CHEMBL628574,In vivo,22224,11954,,,A,,,Autocuration,,,
12603,BAO_0000218,Cmax value after oral dose of 10 mg/kg,,U,1,,CHEMBL628575,In vivo,22224,11954,,,A,,,Autocuration,,,
12604,BAO_0000218,Cmax value after oral dose of 23.4 mg/kg,,U,1,,CHEMBL628576,In vivo,22224,11954,,,A,,,Autocuration,,,
12605,BAO_0000218,Cmax value after oral dose of 3 mg/kg,,U,1,,CHEMBL628577,In vivo,22224,11954,,,A,,,Autocuration,,,
12606,BAO_0000218,Cmax value after oral dose of 3.87 mg/kg,,U,1,,CHEMBL628578,In vivo,22224,11954,,,A,,,Autocuration,,,
12607,BAO_0000218,Cmax value in female Beagle dogs,,N,1,,CHEMBL874466,In vivo,50588,12768,,,A,,,Intermediate,,,
12608,BAO_0000218,Cmax value in male rats,,N,1,,CHEMBL628579,In vivo,50597,12768,,,A,,,Intermediate,,,
12609,BAO_0000218,Cmax value in rat plasma when administered 20 mg/kg perorally,1969.0,N,1,,CHEMBL628580,In vivo,50597,12780,,Plasma,A,,,Intermediate,,,
12610,BAO_0000218,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,N,1,,CHEMBL628581,In vivo,50588,15592,,Plasma,A,,,Intermediate,,,
12611,BAO_0000218,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,N,1,,CHEMBL628582,In vivo,50588,15592,,Plasma,A,,,Intermediate,,,
12612,BAO_0000218,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,N,1,,CHEMBL628583,,50588,17025,,,A,,,Intermediate,,,
12613,BAO_0000218,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,U,1,,CHEMBL625782,,22224,17025,,,A,,,Autocuration,,,
12614,BAO_0000218,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,N,1,,CHEMBL625783,,50592,17025,,,A,,,Intermediate,,,
12615,BAO_0000218,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,N,1,,CHEMBL625784,,50597,17025,,,A,,,Intermediate,,,
12616,BAO_0000218,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1969.0,N,1,,CHEMBL625785,,50797,4236,,Plasma,A,,,Intermediate,,,
12617,BAO_0000218,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,N,1,,CHEMBL625786,,50597,15791,,,A,,,Intermediate,,,
12618,BAO_0000019,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,U,1,,CHEMBL874467,,22224,11149,,,A,,,Autocuration,,,
12619,BAO_0000218,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,N,1,,CHEMBL625787,,50588,15592,,,A,,,Intermediate,,,
12620,BAO_0000218,cytotoxicity against HIV protease enzyme.,,N,1,,CHEMBL625964,,50677,15778,,,A,,,Intermediate,,,
12621,BAO_0000218,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,N,1,,CHEMBL625965,,50594,12745,,,A,,,Intermediate,,,
12622,BAO_0000218,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,N,1,,CHEMBL625966,,50594,12745,,,A,,,Intermediate,,,
12623,BAO_0000218,The plasma clearance in dog.,1969.0,N,1,,CHEMBL625967,In vivo,50588,13941,,Plasma,A,,,Intermediate,,,
12624,BAO_0000218,The plasma clearance in rat.,1969.0,N,1,,CHEMBL625968,In vivo,50597,13941,,Plasma,A,,,Intermediate,,,
12625,BAO_0000218,Clearance from plasma in male Sprague-Dawley rats,1969.0,N,1,,CHEMBL625969,In vivo,50597,16449,,Plasma,A,,,Intermediate,,,
12626,BAO_0000218,Clearance from plasma in male cynomolgus monkeys,1969.0,N,1,,CHEMBL625970,In vivo,100710,16449,,Plasma,A,,,Intermediate,,,
12627,BAO_0000218,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1969.0,N,1,,CHEMBL625971,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
12628,BAO_0000218,Clearance of compound in dog plasma,1969.0,N,1,,CHEMBL625972,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
12629,BAO_0000218,Clearance of compound in human plasma,1969.0,N,1,,CHEMBL625973,In vivo,50587,14224,,Plasma,A,,,Intermediate,,,
12630,BAO_0000218,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,N,1,,CHEMBL625974,In vivo,50588,14317,,,A,,,Intermediate,,,
12631,BAO_0000218,Clearance of compound when administered intravenously as an individual dose to a single dog.,,N,1,,CHEMBL625975,In vivo,50588,14317,,,A,,,Intermediate,,,
12632,BAO_0000218,"Clearance (10 mg/kg, intravenously) in dog plasma",1969.0,N,1,,CHEMBL625976,In vivo,50588,14224,,Plasma,A,,,Intermediate,,,
12633,BAO_0000218,Clearance value in dog,,N,1,,CHEMBL625977,In vivo,50588,17237,,,A,,,Intermediate,,,
12634,BAO_0000218,Clearance value in guinea pig,,N,1,,CHEMBL625978,In vivo,50512,17237,,,A,,,Intermediate,,,
12635,BAO_0000218,Clearance values in rats after iv administration.,,N,1,,CHEMBL874468,In vivo,50597,14187,,,A,,,Intermediate,,,
12636,BAO_0000218,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,1969.0,U,1,,CHEMBL625421,In vivo,22224,4806,,Plasma,A,,,Autocuration,,,
12637,BAO_0000218,In vivo clearance (5 mg/kg) was determined in rabbits,,N,1,,CHEMBL625422,In vivo,50592,15025,,,A,,,Intermediate,,,
12638,BAO_0000218,Plasma Clearance rate was determined for the compound in rats,,N,1,,CHEMBL625423,In vivo,50597,13197,,,A,,,Intermediate,,,
12639,BAO_0000218,Plasma Clearance rate was determined for the compound in squirrel monkeys,,U,1,,CHEMBL625424,In vivo,22224,13197,,,A,,,Autocuration,,,
12640,BAO_0000218,Plasma clearance in rat,,N,1,,CHEMBL625425,In vivo,50597,13960,,,A,,,Intermediate,,,
12641,BAO_0000218,Plasma clearance of the compound,,U,1,,CHEMBL625426,In vivo,22224,17820,,,A,,,Autocuration,,,
12642,BAO_0000218,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,N,1,,CHEMBL625427,In vivo,50512,14706,,,A,,,Intermediate,,,
12643,BAO_0000218,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,N,1,,CHEMBL625428,In vivo,50512,14706,,,A,,,Intermediate,,,
12644,BAO_0000218,Plasma clearance was determined,,U,1,,CHEMBL625429,In vivo,22224,6504,,,A,,,Autocuration,,,
12645,BAO_0000218,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,N,1,,CHEMBL625430,In vivo,50588,14925,,,A,,,Intermediate,,,
12646,BAO_0000218,Plasma clearance rate was determined for the compound in rats,,N,1,,CHEMBL625431,In vivo,50597,13197,,,A,,,Intermediate,,,
12647,BAO_0000218,Plasma clearance rate was determined for the compound in squirrel monkeys,,U,1,,CHEMBL627307,In vivo,22224,13197,,,A,,,Autocuration,,,
12648,BAO_0000218,Slow clearance (CL) was determined,,U,1,,CHEMBL627308,In vivo,22224,3437,,,A,,,Autocuration,,,
12649,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL627309,,22224,9196,,,A,,,Autocuration,,,
12650,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,U,1,,CHEMBL627310,,22224,9196,,,A,,,Autocuration,,,
12651,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,U,1,,CHEMBL627311,,22224,9196,,,A,,,Autocuration,,,
12652,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL627312,,22224,9196,,,A,,,Autocuration,,,
12653,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,U,1,,CHEMBL627313,,22224,9196,,,A,,,Autocuration,,,
12654,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,U,1,,CHEMBL627314,,22224,9196,,,A,,,Autocuration,,,
12655,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL627315,,22224,9196,,,A,,,Autocuration,,,
12656,BAO_0000218,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL627316,,22224,9196,,,A,,,Autocuration,,,
12657,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,1,,CHEMBL627317,,22224,9196,,,A,,,Autocuration,,,
12658,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,1,,CHEMBL627318,,22224,9196,,,A,,,Autocuration,,,
12659,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,U,1,,CHEMBL627999,,22224,9196,,,A,,,Autocuration,,,
12660,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,1,,CHEMBL628000,,22224,9196,,,A,,,Autocuration,,,
12661,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,U,1,,CHEMBL628001,,22224,9196,,,A,,,Autocuration,,,
12662,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL628002,,22224,9196,,,A,,,Autocuration,,,
12663,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,U,1,,CHEMBL625610,,22224,9196,,,A,,,Autocuration,,,
12664,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL625611,,22224,9196,,,A,,,Autocuration,,,
12665,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,U,1,,CHEMBL625612,,22224,9196,,,A,,,Autocuration,,,
12666,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,U,1,,CHEMBL625613,,22224,9196,,,A,,,Autocuration,,,
12667,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,1,,CHEMBL875479,,22224,9196,,,A,,,Autocuration,,,
12668,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,U,1,,CHEMBL625614,,22224,9196,,,A,,,Autocuration,,,
12669,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,U,1,,CHEMBL625615,,22224,9196,,,A,,,Autocuration,,,
12670,BAO_0000218,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,U,1,,CHEMBL626302,,22224,9196,,,A,,,Autocuration,,,
12671,BAO_0000218,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL626303,,50597,8374,,Blood,A,,,Intermediate,,,
12672,BAO_0000218,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,N,1,,CHEMBL627420,,50597,8374,,Blood,A,,,Intermediate,,,
12673,BAO_0000218,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,N,1,,CHEMBL627421,,50597,13477,,,A,,,Intermediate,,,
12674,BAO_0000218,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,N,1,,CHEMBL625695,,50597,13477,,,A,,,Intermediate,,,
12675,BAO_0000218,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,N,1,,CHEMBL625696,,50597,13477,,,A,,,Intermediate,,,
12676,BAO_0000218,Distribution of compound in mice brain was measured after 1 hr,955.0,N,1,,CHEMBL875606,,50594,10009,,Brain,A,,,Intermediate,,,
12677,BAO_0000218,Distribution of compound in mice brain was measured after 24 hr r,955.0,N,1,,CHEMBL625697,,50594,10009,,Brain,A,,,Intermediate,,,
12678,BAO_0000218,Distribution of compound in mice brain was measured after 2 hr,955.0,N,1,,CHEMBL625698,,50594,10009,,Brain,A,,,Intermediate,,,
12679,BAO_0000218,Distribution of compound in mice brain was measured after 3 hr,955.0,N,1,,CHEMBL625699,,50594,10009,,Brain,A,,,Intermediate,,,
12680,BAO_0000218,Distribution of compound in mice brain was measured after 6 hr,955.0,N,1,,CHEMBL625700,,50594,10009,,Brain,A,,,Intermediate,,,
12681,BAO_0000218,Distribution of compound in mice liver was measured after 1 hr,,N,1,,CHEMBL625701,,50594,10009,,,A,,,Intermediate,,,
12682,BAO_0000218,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,N,1,,CHEMBL625702,,50594,10009,,,A,,,Intermediate,,,
12683,BAO_0000218,Distribution of compound in mice liver was measured after 2 hr,,N,1,,CHEMBL625703,,50594,10009,,,A,,,Intermediate,,,
12684,BAO_0000218,Distribution of compound in mice liver was measured after 3 hr,,N,1,,CHEMBL625704,,50594,10009,,,A,,,Intermediate,,,
12685,BAO_0000218,Distribution of compound in mice liver was measured after 6 hr,,N,1,,CHEMBL625705,,50594,10009,,,A,,,Intermediate,,,
12686,BAO_0000218,Distribution in dog adrenal medulla 30 min after administration.,1236.0,N,1,,CHEMBL625706,,50588,8170,,Adrenal medulla,A,,,Intermediate,,,
12687,BAO_0000218,Distribution in dog adrenal medulla 72 hours after administration.,1236.0,N,1,,CHEMBL625707,,50588,8170,,Adrenal medulla,A,,,Intermediate,,,
12688,BAO_0000218,Distribution in female dog Ovary 24 hours after administration.,,N,1,,CHEMBL625708,,50588,8170,,,A,,,Intermediate,,,
12689,BAO_0000218,Distribution in female dog Ovary 72 hours after administration.,,N,1,,CHEMBL625709,,50588,8170,,,A,,,Intermediate,,,
12690,BAO_0000218,Distribution in female dog adipose 24 hours after administration.,,N,1,,CHEMBL624180,,50588,8170,,,A,,,Intermediate,,,
12691,BAO_0000218,Distribution in female dog adipose 72 hours after administration.,,N,1,,CHEMBL624181,,50588,8170,,,A,,,Intermediate,,,
12692,BAO_0000218,Distribution in female dog adrenal cortex 72 hours after administration.,1235.0,N,1,,CHEMBL624182,,50588,8170,,Adrenal cortex,A,,,Intermediate,,,
12693,BAO_0000218,Distribution in female dog adrenal cortex 72 hours after administration.,1235.0,N,1,,CHEMBL624183,,50588,8170,,Adrenal cortex,A,,,Intermediate,,,
12694,BAO_0000218,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2107.0,N,1,,CHEMBL624184,,50597,8594,,Liver,A,,,Intermediate,,,
12695,BAO_0000218,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL877489,,50597,8594,,Liver,A,,,Intermediate,,,
12696,BAO_0000218,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL624185,,50597,8594,,Liver,A,,,Intermediate,,,
12697,BAO_0000218,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL624186,,50597,8594,,Liver,A,,,Intermediate,,,
12698,BAO_0000218,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2107.0,N,1,,CHEMBL624187,,50597,8594,,Liver,A,,,Intermediate,,,
12699,BAO_0000218,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL624188,,50597,8594,,Liver,A,,,Intermediate,,,
12700,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL624189,,50597,8594,,Lung,A,,,Intermediate,,,
12701,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL624190,,50597,8594,,Lung,A,,,Intermediate,,,
12702,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2048.0,N,1,,CHEMBL624191,,50597,8594,,Lung,A,,,Intermediate,,,
12703,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL624192,,50597,8594,,Lung,A,,,Intermediate,,,
12704,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2048.0,N,1,,CHEMBL624193,,50597,8594,,Lung,A,,,Intermediate,,,
12705,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL624194,,50597,8594,,Lung,A,,,Intermediate,,,
12706,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2048.0,N,1,,CHEMBL624891,,50597,8594,,Lung,A,,,Intermediate,,,
12707,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL624892,,50597,8594,,Lung,A,,,Intermediate,,,
12708,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,2048.0,N,1,,CHEMBL624893,,50597,8594,,Lung,A,,,Intermediate,,,
12709,BAO_0000218,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL627632,,50597,8594,,Lung,A,,,Intermediate,,,
12710,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,1,,CHEMBL627633,,50597,8594,,,A,,,Intermediate,,,
12711,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,1,,CHEMBL627634,,50597,8594,,,A,,,Intermediate,,,
12712,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,1,,CHEMBL627635,,50597,8594,,,A,,,Intermediate,,,
12713,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,1,,CHEMBL627636,,50597,8594,,,A,,,Intermediate,,,
12714,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,1,,CHEMBL626816,,50597,8594,,,A,,,Intermediate,,,
12715,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,1,,CHEMBL626817,,50597,8594,,,A,,,Intermediate,,,
12716,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,1,,CHEMBL626818,,50597,8594,,,A,,,Intermediate,,,
12717,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,1,,CHEMBL626819,,50597,8594,,,A,,,Intermediate,,,
12718,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,1,,CHEMBL626820,,50597,8594,,,A,,,Intermediate,,,
12719,BAO_0000218,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,1,,CHEMBL626821,,50597,8594,,,A,,,Intermediate,,,
12720,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL626822,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12721,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL626823,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12722,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2046.0,N,1,,CHEMBL626824,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12723,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL626825,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12724,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2046.0,N,1,,CHEMBL626826,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12725,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL626827,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12726,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2046.0,N,1,,CHEMBL626828,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12727,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL626829,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12728,BAO_0000218,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL626830,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12729,BAO_0000218,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,1,,CHEMBL627150,,50597,8594,,,A,,,Intermediate,,,
12730,BAO_0000218,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,1,,CHEMBL627151,,50597,8594,,,A,,,Intermediate,,,
12731,BAO_0000218,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,1,,CHEMBL627152,,50597,8594,,,A,,,Intermediate,,,
12732,BAO_0000218,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,1,,CHEMBL627153,,50597,8594,,,A,,,Intermediate,,,
12733,BAO_0000019,Rate of acetate production by the compound was determined,,U,1,,CHEMBL627154,,22224,12904,,,A,,,Autocuration,,,
12734,BAO_0000019,Rate of acetate production by the compound was determined; Not determined,,U,1,,CHEMBL627155,,22224,12904,,,A,,,Autocuration,,,
12735,BAO_0000019,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,U,1,,CHEMBL627156,,22224,3730,,,A,,,Autocuration,,,
12736,BAO_0000019,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,U,1,,CHEMBL627157,,22224,3627,,,A,,,Autocuration,,,
12737,BAO_0000218,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,N,1,,CHEMBL627158,,50592,13799,,,A,,,Intermediate,,,
12738,BAO_0000218,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1969.0,N,1,,CHEMBL627159,,50592,13799,,Plasma,A,,,Intermediate,,,
12739,BAO_0000218,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,N,1,,CHEMBL627160,,50594,13799,,,A,,,Intermediate,,,
12740,BAO_0000218,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,N,1,,CHEMBL628540,,50597,13799,,,A,,,Intermediate,,,
12741,BAO_0000218,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1969.0,N,1,,CHEMBL628541,,50597,13799,,Plasma,A,,,Intermediate,,,
12742,BAO_0000218,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1969.0,N,1,,CHEMBL628542,,50597,13799,,Plasma,A,,,Intermediate,,,
12743,BAO_0000100,Solubility after at a pH 1.2,,U,1,,CHEMBL628543,,22229,6629,,,P,,,Autocuration,,,
12744,BAO_0000100,Solubility after at pH 1.2,,U,1,,CHEMBL628544,,22229,6629,,,P,,,Autocuration,,,
12745,BAO_0000100,Solubility after injection of water,,U,1,,CHEMBL628545,,22229,6629,,,P,,,Autocuration,,,
12746,BAO_0000019,Statistical significance of IC 50 values; Expressed as R value,,U,1,,CHEMBL628546,,22224,14000,,,A,,,Autocuration,,,
12747,BAO_0000019,Systemic availability with respect to methyldopa was determined,,U,1,,CHEMBL874455,,22224,8267,,,A,,,Autocuration,,,
12748,BAO_0000218,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,N,1,,CHEMBL628547,,50597,13799,,,A,,,Intermediate,,,
12749,BAO_0000218,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1969.0,N,1,,CHEMBL628548,,50597,13799,,Plasma,A,,,Intermediate,,,
12750,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1988.0,N,1,,CHEMBL628549,,50592,7132,,Feces,A,,,Intermediate,,,
12751,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1988.0,N,1,,CHEMBL628550,,50592,7132,,Feces,A,,,Intermediate,,,
12752,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1988.0,N,1,,CHEMBL628551,,50592,7132,,Feces,A,,,Intermediate,,,
12753,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1088.0,N,1,,CHEMBL628552,,50592,7132,,Urine,A,,,Intermediate,,,
12754,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1088.0,N,1,,CHEMBL628553,,50592,7132,,Urine,A,,,Intermediate,,,
12755,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1088.0,N,1,,CHEMBL628554,,50592,7132,,Urine,A,,,Intermediate,,,
12756,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1088.0,N,1,,CHEMBL628555,,50592,7132,,Urine,A,,,Intermediate,,,
12757,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1088.0,N,1,,CHEMBL628556,,50592,7132,,Urine,A,,,Intermediate,,,
12758,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",2113.0,N,1,,CHEMBL628557,,50592,7132,,Kidney,A,,,Intermediate,,,
12759,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1988.0,N,1,,CHEMBL628558,,50592,7132,,Feces,A,,,Intermediate,,,
12760,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1988.0,N,1,,CHEMBL628559,,50592,7132,,Feces,A,,,Intermediate,,,
12761,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1988.0,N,1,,CHEMBL628560,,50592,7132,,Feces,A,,,Intermediate,,,
12762,BAO_0000218,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1088.0,N,1,,CHEMBL874456,,50592,7132,,Urine,A,,,Intermediate,,,
12763,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1988.0,N,1,,CHEMBL628561,,50592,7132,,Feces,A,,,Intermediate,,,
12764,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1988.0,N,1,,CHEMBL628562,,50592,7132,,Feces,A,,,Intermediate,,,
12765,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1088.0,N,1,,CHEMBL628563,,50592,7132,,Urine,A,,,Intermediate,,,
12766,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1088.0,N,1,,CHEMBL628564,,50592,7132,,Urine,A,,,Intermediate,,,
12767,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1088.0,N,1,,CHEMBL628565,,50592,7132,,Urine,A,,,Intermediate,,,
12768,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1088.0,N,1,,CHEMBL631248,,50592,7132,,Urine,A,,,Intermediate,,,
12769,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1088.0,N,1,,CHEMBL631249,,50592,7132,,Urine,A,,,Intermediate,,,
12770,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",2113.0,N,1,,CHEMBL627214,,50592,7132,,Kidney,A,,,Intermediate,,,
12771,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1988.0,N,1,,CHEMBL874591,,50592,7132,,Feces,A,,,Intermediate,,,
12772,BAO_0000218,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1988.0,N,1,,CHEMBL627215,,50592,7132,,Feces,A,,,Intermediate,,,
12773,BAO_0000218,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1988.0,N,1,,CHEMBL625471,,50592,7132,,Feces,A,,,Intermediate,,,
12774,BAO_0000218,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,N,1,,CHEMBL625472,,50592,7132,,,A,,,Intermediate,,,
12775,BAO_0000218,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,N,1,,CHEMBL625473,,50592,7132,,,A,,,Intermediate,,,
12776,BAO_0000218,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,N,1,,CHEMBL625474,In vivo,50588,13317,,,A,,,Intermediate,,,
12777,BAO_0000218,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,N,1,,CHEMBL625475,In vivo,50588,15341,,,A,,,Intermediate,,,
12778,BAO_0000218,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,N,1,,CHEMBL625476,In vivo,50597,15341,,,A,,,Intermediate,,,
12779,BAO_0000218,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,N,1,,CHEMBL625477,In vivo,50597,15341,,,A,,,Intermediate,,,
12780,BAO_0000218,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,N,1,,CHEMBL625478,In vivo,50597,15341,,,A,,,Intermediate,,,
12781,BAO_0000218,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,N,1,,CHEMBL625479,In vitro,50597,12801,,esophageal tunica muscularis mucosae,A,,,Intermediate,,,
12782,BAO_0000218,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,N,1,,CHEMBL625480,In vitro,50597,12801,,esophageal tunica muscularis mucosae,A,,,Intermediate,,,
12783,BAO_0000218,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1969.0,N,1,,CHEMBL625481,In vivo,50597,14856,,Plasma,A,,,Intermediate,,,
12784,BAO_0000218,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,N,1,,CHEMBL625482,In vivo,50597,14062,,,A,,,Intermediate,,,
12785,BAO_0000218,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,N,1,,CHEMBL625483,In vivo,50597,14062,,,A,,,Intermediate,,,
12786,BAO_0000218,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,N,1,,CHEMBL625484,In vivo,50597,14062,,,A,,,Intermediate,,,
12787,BAO_0000218,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,N,1,,CHEMBL625485,In vivo,50597,14062,,,A,,,Intermediate,,,
12788,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1969.0,N,1,,CHEMBL625486,In vivo,50588,14346,,Plasma,A,,,Intermediate,,,
12789,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1969.0,N,1,,CHEMBL625487,In vivo,50597,14346,,Plasma,A,,,Intermediate,,,
12790,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1969.0,N,1,,CHEMBL625488,In vivo,50597,14346,,Plasma,A,,,Intermediate,,,
12791,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1969.0,N,1,,CHEMBL625489,In vivo,50597,14346,,Plasma,A,,,Intermediate,,,
12792,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1969.0,N,1,,CHEMBL625490,In vivo,50597,14346,,Plasma,A,,,Intermediate,,,
12793,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1969.0,N,1,,CHEMBL625491,In vivo,50588,14346,,Plasma,A,,,Intermediate,,,
12794,BAO_0000218,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1969.0,N,1,,CHEMBL625492,In vivo,50597,14346,,Plasma,A,,,Intermediate,,,
12795,BAO_0000218,plasma clearance in human,1969.0,N,1,,CHEMBL625493,In vivo,50587,15711,,Plasma,A,,,Intermediate,,,
12796,BAO_0000218,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,N,1,,CHEMBL625494,In vivo,50597,14886,,,A,,,Intermediate,,,
12797,BAO_0000218,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,N,1,,CHEMBL625495,In vivo,50597,14886,,,A,,,Intermediate,,,
12798,BAO_0000218,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,N,1,,CHEMBL625496,In vivo,50597,14886,,,A,,,Intermediate,,,
12799,BAO_0000100,1-Octanol/water partition coefficient measured at 7.4,,U,1,,CHEMBL625497,,22229,4115,,,P,,,Autocuration,,,
12800,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625498,,22229,13733,,,P,,,Autocuration,,,
12801,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL625499,,22224,12102,,,A,,,Autocuration,,,
12802,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625500,,22229,12676,,,P,,,Autocuration,,,
12803,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625501,,22229,13733,,,P,,,Autocuration,,,
12804,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625502,,22229,13740,,,P,,,Autocuration,,,
12805,BAO_0000100,Calculated partition coefficient (clogP) (relative to BAY K 8644),,U,1,,CHEMBL625503,,22229,12766,,,P,,,Autocuration,,,
12806,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625504,,22229,2764,,,P,,,Autocuration,,,
12807,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625505,,22229,12355,,,P,,,Autocuration,,,
12808,BAO_0000100,Calculated partition coefficient of the compound,,U,1,,CHEMBL625506,,22229,11314,,,P,,,Autocuration,,,
12809,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL625507,,22224,12706,,,A,,,Autocuration,,,
12810,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625508,,22229,12645,,,P,,,Autocuration,,,
12811,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625509,,22229,13668,,,P,,,Autocuration,,,
12812,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625510,,22229,12819,,,P,,,Autocuration,,,
12813,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL883125,,22229,13668,,,P,,,Autocuration,,,
12814,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625511,,22229,13017,,,P,,,Autocuration,,,
12815,BAO_0000019,Partition coefficient of the compound,,U,1,,CHEMBL874650,,22224,2448,,,A,,,Autocuration,,,
12816,BAO_0000019,Partition coefficient of the compound,,U,1,,CHEMBL625512,,22224,11526,,,A,,,Autocuration,,,
12817,BAO_0000019,Partition coefficient of compound was determined,,U,1,,CHEMBL625513,,22224,12426,,,A,,,Autocuration,,,
12818,BAO_0000019,Partition coefficient was determined,,U,1,,CHEMBL625514,,22224,2448,,,A,,,Autocuration,,,
12819,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625515,,22229,12001,,,P,,,Autocuration,,,
12820,BAO_0000100,partition coefficient of compound was determined,,U,1,,CHEMBL625516,,22229,12426,,,P,,,Autocuration,,,
12821,BAO_0000218,The total body administered intravenously in dog,,N,1,,CHEMBL625517,In vivo,50588,13204,,,A,,,Intermediate,,,
12822,BAO_0000218,The total body administered intravenously in rats,,N,1,,CHEMBL625518,In vivo,50597,13204,,,A,,,Intermediate,,,
12823,BAO_0000218,Time taken for the administration to female NIH mice weighing 25-30 g.,,N,1,,CHEMBL625519,,50594,13889,,,A,,,Intermediate,,,
12824,BAO_0000019,Time taken for the administration,,U,1,,CHEMBL625520,,22224,13889,,,A,,,Autocuration,,,
12825,BAO_0000218,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,N,1,,CHEMBL874651,In vivo,50588,17025,,,A,,,Intermediate,,,
12826,BAO_0000218,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,U,1,,CHEMBL625521,In vivo,22224,17025,,,A,,,Autocuration,,,
12827,BAO_0000218,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,N,1,,CHEMBL623171,In vivo,50592,17025,,,A,,,Intermediate,,,
12828,BAO_0000218,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,N,1,,CHEMBL623853,In vivo,50597,17025,,,A,,,Intermediate,,,
12829,BAO_0000019,Plasma clearance for the compound was determined.,,U,1,,CHEMBL623854,,22224,15067,,,A,,,Autocuration,,,
12830,BAO_0000100,CLog P value of the compound,,U,1,,CHEMBL874405,,22224,3091,,,P,,,Autocuration,,,
12831,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL623855,,22229,15592,,,P,,,Autocuration,,,
12832,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL623856,,22229,14738,,,P,,,Autocuration,,,
12833,BAO_0000100,ClogP value of the compound; nd ='no data',,U,1,,CHEMBL623857,,22224,14738,,,P,,,Autocuration,,,
12834,BAO_0000100,ClogP value of the compound; nd ='not determined',,U,1,,CHEMBL623858,,22224,14738,,,P,,,Autocuration,,,
12835,BAO_0000100,CLog P was determined,,U,1,,CHEMBL623859,,22224,6076,,,P,,,Autocuration,,,
12836,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL839829,,22229,17840,,,P,,,Autocuration,,,
12837,BAO_0000019,CLogP was calculated,,U,1,,CHEMBL623860,,22224,13589,,,A,,,Autocuration,,,
12838,BAO_0000019,CLogP value was determined,,U,1,,CHEMBL623861,,22224,17655,,,A,,,Autocuration,,,
12839,BAO_0000019,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,U,1,,CHEMBL623862,,22224,5867,,,A,,,Autocuration,,,
12840,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL874406,,22229,5867,,,P,,,Autocuration,,,
12841,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL623863,,22229,10783,,,P,,,Autocuration,,,
12842,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624021,,22229,14849,,,P,,,Autocuration,,,
12843,BAO_0000218,Distribution in female dog adrenal medulla 24 hours after administration.,1236.0,N,1,,CHEMBL624022,,50588,8170,,Adrenal medulla,A,,,Intermediate,,,
12844,BAO_0000218,Distribution in female dog adrenal medulla 72 hours after administration.,1236.0,N,1,,CHEMBL624023,,50588,8170,,Adrenal medulla,A,,,Intermediate,,,
12845,BAO_0000218,Distribution in female dog bile 24 hours after administration.,,N,1,,CHEMBL624024,,50588,8170,,,A,,,Intermediate,,,
12846,BAO_0000218,Distribution in female dog bile 72 hr after administration.,,N,1,,CHEMBL624025,,50588,8170,,,A,,,Intermediate,,,
12847,BAO_0000218,Distribution in female dog blood 24 hours after administration.,,N,1,,CHEMBL624026,,50588,8170,,,A,,,Intermediate,,,
12848,BAO_0000218,Distribution in female dog blood 72 hours after administration.,,N,1,,CHEMBL624027,,50588,8170,,,A,,,Intermediate,,,
12849,BAO_0000218,Distribution in female dog heart 24 hours after administration.,,N,1,,CHEMBL624028,,50588,8170,,,A,,,Intermediate,,,
12850,BAO_0000218,Distribution in female dog heart 72 hours after administration.,,N,1,,CHEMBL624029,,50588,8170,,,A,,,Intermediate,,,
12851,BAO_0000218,Distribution in female dog kidney 24 hours after administration.,,N,1,,CHEMBL624030,,50588,8170,,,A,,,Intermediate,,,
12852,BAO_0000218,Distribution in female dog kidney 72 hours after administration.,,N,1,,CHEMBL624031,,50588,8170,,,A,,,Intermediate,,,
12853,BAO_0000218,Distribution in female dog large intestine 24 hours after administration.,160.0,N,1,,CHEMBL624032,,50588,8170,,Intestine,A,,,Intermediate,,,
12854,BAO_0000218,Distribution in female dog large intestine 72 hours after administration.,160.0,N,1,,CHEMBL874407,,50588,8170,,Intestine,A,,,Intermediate,,,
12855,BAO_0000218,Distribution in female dog liver 24 hours after administration.,,N,1,,CHEMBL624033,,50588,8170,,,A,,,Intermediate,,,
12856,BAO_0000218,Distribution in female dog liver 72 hours after administration.,,N,1,,CHEMBL624034,,50588,8170,,,A,,,Intermediate,,,
12857,BAO_0000218,Distribution in female dog lung 24 hours after administration.,,N,1,,CHEMBL624035,,50588,8170,,,A,,,Intermediate,,,
12858,BAO_0000218,Distribution in female dog lung 72 hours after administration.,,N,1,,CHEMBL624036,,50588,8170,,,A,,,Intermediate,,,
12859,BAO_0000218,Distribution in female dog muscle 24 hours after administration.,2385.0,N,1,,CHEMBL624037,,50588,8170,,Muscle tissue,A,,,Intermediate,,,
12860,BAO_0000218,Distribution in female dog muscle 72 hours after administration.,2385.0,N,1,,CHEMBL624038,,50588,8170,,Muscle tissue,A,,,Intermediate,,,
12861,BAO_0000218,Distribution in female dog pancreas 24 hours after administration.,,N,1,,CHEMBL624039,,50588,8170,,,A,,,Intermediate,,,
12862,BAO_0000218,Distribution in female dog pancreas 72 hours after administration.,,N,1,,CHEMBL624040,,50588,8170,,,A,,,Intermediate,,,
12863,BAO_0000218,Distribution in female dog small intestine 24 hours after administration.,160.0,N,1,,CHEMBL624041,,50588,8170,,Intestine,A,,,Intermediate,,,
12864,BAO_0000218,Distribution in female dog small intestine 72 hours after administration.,160.0,N,1,,CHEMBL624042,,50588,8170,,Intestine,A,,,Intermediate,,,
12865,BAO_0000218,Distribution in female dog spleen 24 hours after administration.,2106.0,N,1,,CHEMBL624043,,50588,8170,,Spleen,A,,,Intermediate,,,
12866,BAO_0000218,Distribution in female dog spleen 72 hours after administration.,2106.0,N,1,,CHEMBL624044,,50588,8170,,Spleen,A,,,Intermediate,,,
12867,BAO_0000218,Distribution in female dog stomach 24 hours after administration.,945.0,N,1,,CHEMBL624045,,50588,8170,,Stomach,A,,,Intermediate,,,
12868,BAO_0000218,Distribution in female dog stomach 72 hours after administration.,945.0,N,1,,CHEMBL624046,,50588,8170,,Stomach,A,,,Intermediate,,,
12869,BAO_0000218,Distribution in female dog thyroid 24 hours after administration.,2046.0,N,1,,CHEMBL624047,,50588,8170,,Thyroid gland,A,,,Intermediate,,,
12870,BAO_0000218,Distribution in female dog thyroid 72 hours after administration.,2046.0,N,1,,CHEMBL624048,,50588,8170,,Thyroid gland,A,,,Intermediate,,,
12871,BAO_0000218,Distribution in female dog urine 24 hours after administration.,1088.0,N,1,,CHEMBL874408,,50588,8170,,Urine,A,,,Intermediate,,,
12872,BAO_0000218,Distribution in female dog urine 72 hr after administration.,1088.0,N,1,,CHEMBL624049,,50588,8170,,Urine,A,,,Intermediate,,,
12873,BAO_0000218,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,1969.0,U,1,,CHEMBL624050,,22224,14283,,Plasma,A,,,Autocuration,,,
12874,BAO_0000019,Plasma concentration at 7 hr after intravenous dosing,,U,1,,CHEMBL624051,,22224,5623,,,A,,,Autocuration,,,
12875,BAO_0000218,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,N,1,,CHEMBL623278,,50597,13477,,,A,,,Intermediate,,,
12876,BAO_0000218,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,N,1,,CHEMBL623279,,50597,13477,,,A,,,Intermediate,,,
12877,BAO_0000218,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,N,1,,CHEMBL623280,,50597,13477,,,A,,,Intermediate,,,
12878,BAO_0000218,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,N,1,,CHEMBL623963,,50597,13477,,,A,,,Intermediate,,,
12879,BAO_0000218,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,N,1,,CHEMBL623964,,50597,13477,,,A,,,Intermediate,,,
12880,BAO_0000218,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,N,1,,CHEMBL623965,,50597,13477,,,A,,,Intermediate,,,
12881,BAO_0000218,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,N,1,,CHEMBL623966,,50597,13477,,,A,,,Intermediate,,,
12882,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,N,1,,CHEMBL874415,,50597,13477,,,A,,,Intermediate,,,
12883,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,N,1,,CHEMBL623967,,50597,13477,,,A,,,Intermediate,,,
12884,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,N,1,,CHEMBL623968,,50597,13477,,,A,,,Intermediate,,,
12885,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,N,1,,CHEMBL623969,,50597,13477,,,A,,,Intermediate,,,
12886,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,N,1,,CHEMBL628409,,50597,13477,,,A,,,Intermediate,,,
12887,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,N,1,,CHEMBL628410,,50597,13477,,,A,,,Intermediate,,,
12888,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,N,1,,CHEMBL628411,,50597,13477,,,A,,,Intermediate,,,
12889,BAO_0000218,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,N,1,,CHEMBL628412,,50597,13477,,,A,,,Intermediate,,,
12890,BAO_0000019,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,U,1,,CHEMBL628413,,22224,12553,,,A,,,Autocuration,,,
12891,BAO_0000019,The concentration in plasmat; Not determined,1969.0,U,1,,CHEMBL628414,,22224,14548,,Plasma,A,,,Autocuration,,,
12892,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in blood,,N,1,,CHEMBL628415,,50597,14393,,,A,,,Intermediate,,,
12893,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,N,1,,CHEMBL628416,,50597,14393,,,A,,,Intermediate,,,
12894,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in heart,,N,1,,CHEMBL628417,,50597,14393,,,A,,,Intermediate,,,
12895,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in liver,2107.0,N,1,,CHEMBL874908,,50597,14393,,Liver,A,,,Intermediate,,,
12896,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in plasma,,N,1,,CHEMBL628418,,50597,14393,,,A,,,Intermediate,,,
12897,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,2385.0,N,1,,CHEMBL628419,,50597,14393,,Muscle tissue,A,,,Intermediate,,,
12898,BAO_0000218,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,N,1,,CHEMBL628420,,50597,14393,,,A,,,Intermediate,,,
12899,BAO_0000019,Water solubility at 37 degree C.,,U,1,,CHEMBL628421,,22224,1629,,,A,,,Autocuration,,,
12900,BAO_0000100,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,U,1,,CHEMBL626726,,22229,8194,,,P,,,Autocuration,,,
12901,BAO_0000100,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,U,1,,CHEMBL626727,,22229,8194,,,P,,,Autocuration,,,
12902,BAO_0000218,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,178.0,N,1,,CHEMBL626728,,50597,8594,,Blood,A,,,Intermediate,,,
12903,BAO_0000218,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,178.0,N,1,,CHEMBL626729,,50597,8594,,Blood,A,,,Intermediate,,,
12904,BAO_0000218,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,178.0,N,1,,CHEMBL626730,,50597,8594,,Blood,A,,,Intermediate,,,
12905,BAO_0000218,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,178.0,N,1,,CHEMBL626731,,50597,8594,,Blood,A,,,Intermediate,,,
12906,BAO_0000218,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,178.0,N,1,,CHEMBL626732,,50597,8594,,Blood,A,,,Intermediate,,,
12907,BAO_0000218,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,948.0,N,1,,CHEMBL626733,,50597,8594,,Heart,A,,,Intermediate,,,
12908,BAO_0000218,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,948.0,N,1,,CHEMBL626734,,50597,8594,,Heart,A,,,Intermediate,,,
12909,BAO_0000218,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,948.0,N,1,,CHEMBL626735,,50597,8594,,Heart,A,,,Intermediate,,,
12910,BAO_0000218,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,948.0,N,1,,CHEMBL874909,,50597,8594,,Heart,A,,,Intermediate,,,
12911,BAO_0000218,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,948.0,N,1,,CHEMBL626736,,50597,8594,,Heart,A,,,Intermediate,,,
12912,BAO_0000218,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL626737,,50597,8594,,Kidney,A,,,Intermediate,,,
12913,BAO_0000218,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL630999,,50597,8594,,Kidney,A,,,Intermediate,,,
12914,BAO_0000218,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL631000,,50597,8594,,Kidney,A,,,Intermediate,,,
12915,BAO_0000218,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL631001,,50597,8594,,Kidney,A,,,Intermediate,,,
12916,BAO_0000218,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2113.0,N,1,,CHEMBL631002,,50597,8594,,Kidney,A,,,Intermediate,,,
12917,BAO_0000218,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL631003,,50597,8594,,Liver,A,,,Intermediate,,,
12918,BAO_0000218,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL631004,,50597,8594,,Liver,A,,,Intermediate,,,
12919,BAO_0000218,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL631005,,50597,8594,,Liver,A,,,Intermediate,,,
12920,BAO_0000218,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL631006,,50597,8594,,Liver,A,,,Intermediate,,,
12921,BAO_0000218,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2107.0,N,1,,CHEMBL631007,,50597,8594,,Liver,A,,,Intermediate,,,
12922,BAO_0000218,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL631008,,50597,8594,,Lung,A,,,Intermediate,,,
12923,BAO_0000218,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL631009,,50597,8594,,Lung,A,,,Intermediate,,,
12924,BAO_0000218,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL631010,,50597,8594,,Lung,A,,,Intermediate,,,
12925,BAO_0000218,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL631011,,50597,8594,,Lung,A,,,Intermediate,,,
12926,BAO_0000218,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2048.0,N,1,,CHEMBL631012,,50597,8594,,Lung,A,,,Intermediate,,,
12927,BAO_0000218,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL630271,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12928,BAO_0000218,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL630272,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12929,BAO_0000218,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL630273,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12930,BAO_0000218,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL630274,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12931,BAO_0000218,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2046.0,N,1,,CHEMBL630275,,50597,8594,,Thyroid gland,A,,,Intermediate,,,
12932,BAO_0000218,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,N,1,,CHEMBL875782,,50597,8594,,,A,,,Intermediate,,,
12933,BAO_0000218,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,N,1,,CHEMBL630276,,50597,8594,,,A,,,Intermediate,,,
12934,BAO_0000218,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,N,1,,CHEMBL630277,,50597,8594,,,A,,,Intermediate,,,
12935,BAO_0000218,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,N,1,,CHEMBL630278,,50597,8594,,,A,,,Intermediate,,,
12936,BAO_0000218,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,N,1,,CHEMBL630279,,50597,8594,,,A,,,Intermediate,,,
12937,BAO_0000019,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,U,1,,CHEMBL630280,,22224,8151,,,A,,,Autocuration,,,
12938,BAO_0000019,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,U,1,,CHEMBL630281,,22224,8151,,,A,,,Autocuration,,,
12939,BAO_0000218,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,N,1,,CHEMBL630282,,50592,7132,,,A,,,Intermediate,,,
12940,BAO_0000218,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,N,1,,CHEMBL630283,,50592,7132,,,A,,,Intermediate,,,
12941,BAO_0000019,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,U,1,,CHEMBL630284,,22224,5797,,,A,,,Autocuration,,,
12942,BAO_0000019,Alkylating activity was determined,,U,1,,CHEMBL630285,,22224,7849,,,A,,,Autocuration,,,
12943,BAO_0000251,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,U,1,,CHEMBL630286,,22224,14220,Microsomes,,A,,,Autocuration,,,
12944,BAO_0000218,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,N,1,,CHEMBL630069,,50592,8650,,,A,,,Intermediate,,,
12945,BAO_0000218,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,N,1,,CHEMBL630070,,50592,8650,,,A,,,Intermediate,,,
12946,BAO_0000218,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,N,1,,CHEMBL630071,,50592,8650,,,A,,,Intermediate,,,
12947,BAO_0000218,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,N,1,,CHEMBL630072,,50592,8650,,,A,,,Intermediate,,,
12948,BAO_0000218,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,N,1,,CHEMBL875110,,50592,8650,,,A,,,Intermediate,,,
12949,BAO_0000218,Compound was tested for antidiuretic activity in rats,,N,1,,CHEMBL630073,,50597,7116,,,A,,,Intermediate,,,
12950,BAO_0000019,Compound was tested for inactivation kinetic values,,U,1,,CHEMBL630074,,22224,14131,,,A,,,Autocuration,,,
12951,BAO_0000218,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,U,1,,CHEMBL630075,In vivo,22224,7415,,,A,,,Autocuration,,,
12952,BAO_0000019,Dissociation rate calculated from the first-order equation using the t1/2 value,,U,1,,CHEMBL630076,,22224,13178,,,A,,,Autocuration,,,
12953,BAO_0000100,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,U,1,,CHEMBL630077,,22229,8815,,,P,,,Autocuration,,,
12954,BAO_0000100,Aqueous solubility was measured,,U,1,,CHEMBL630078,,22229,1450,,,P,,,Autocuration,,,
12955,BAO_0000100,Aqueous solubility was measured at a pH 4,,U,1,,CHEMBL630079,,22229,1450,,,P,,,Autocuration,,,
12956,BAO_0000100,Aqueous solubility (pH 7),,U,1,,CHEMBL630080,,22229,1450,,,P,,,Autocuration,,,
12957,BAO_0000100,Aqueous solubility was measured at a pH 9,,U,1,,CHEMBL630081,,22229,1450,,,P,,,Autocuration,,,
12958,BAO_0000019,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,U,1,,CHEMBL630082,,22224,12711,,,A,,,Autocuration,,,
12959,BAO_0000019,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,U,1,,CHEMBL630083,,22224,12711,,,A,,,Autocuration,,,
12960,BAO_0000019,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,U,1,,CHEMBL630084,,22224,12711,,,A,,,Autocuration,,,
12961,BAO_0000100,Aqueous solubility of the compound,,U,1,,CHEMBL629198,,22229,15032,,,P,,,Autocuration,,,
12962,BAO_0000100,Aqueous solubility at 37 degree Celsius at pH 7.38,,U,1,,CHEMBL629199,,22229,9964,,,P,,,Autocuration,,,
12963,BAO_0000100,Aqueous solubility in pH 7.4 phosphate buffer,,U,1,,CHEMBL629200,,22229,14962,,,P,,,Autocuration,,,
12964,BAO_0000218,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,N,1,,CHEMBL629201,,50588,12487,,,A,,,Intermediate,,,
12965,BAO_0000218,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,N,1,,CHEMBL629202,,50588,12487,,,A,,,Intermediate,,,
12966,BAO_0000218,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,N,1,,CHEMBL875111,,50587,10026,,,A,,,Intermediate,,,
12967,BAO_0000218,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,N,1,,CHEMBL629203,,50587,10026,,,A,,,Intermediate,,,
12968,BAO_0000218,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,N,1,,CHEMBL629204,,50587,10026,,,A,,,Intermediate,,,
12969,BAO_0000218,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,N,1,,CHEMBL629205,,50587,10026,,,A,,,Intermediate,,,
12970,BAO_0000218,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,N,1,,CHEMBL629206,,50587,10026,,,A,,,Intermediate,,,
12971,BAO_0000019,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,U,1,,CHEMBL631185,,22224,10026,,,A,,,Autocuration,,,
12972,BAO_0000218,Compound was evaluated for the average bile flow rat in rats,,N,1,,CHEMBL631186,,50597,7415,,,A,,,Intermediate,,,
12973,BAO_0000218,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,N,1,,CHEMBL631187,,50592,17025,,,A,,,Intermediate,,,
12974,BAO_0000218,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,N,1,,CHEMBL631188,,50592,17025,,,A,,,Intermediate,,,
12975,BAO_0000019,Average half life period was determined,,U,1,,CHEMBL876419,,22224,10184,,,A,,,Autocuration,,,
12976,BAO_0000019,Average half life period was determined,,U,1,,CHEMBL631189,,22224,10184,,,A,,,Autocuration,,,
12977,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,N,1,,CHEMBL631190,,50602,8613,,,A,,,Intermediate,,,
12978,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,N,1,,CHEMBL631191,,50602,8613,,,A,,,Intermediate,,,
12979,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,N,1,,CHEMBL631192,,50602,8613,,,A,,,Intermediate,,,
12980,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,N,1,,CHEMBL632400,,50602,8613,,,A,,,Intermediate,,,
12981,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,N,1,,CHEMBL630564,,50602,8613,,,A,,,Intermediate,,,
12982,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,N,1,,CHEMBL630565,,50602,8613,,,A,,,Intermediate,,,
12983,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,N,1,,CHEMBL630566,,50602,8613,,,A,,,Intermediate,,,
12984,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,N,1,,CHEMBL631229,,50602,8613,,,A,,,Intermediate,,,
12985,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,N,1,,CHEMBL631230,,50602,8613,,,A,,,Intermediate,,,
12986,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL876428,,22229,6030,,,P,,,Autocuration,,,
12987,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631231,,22229,6147,,,P,,,Autocuration,,,
12988,BAO_0000100,Calculated partition coefficient (clogP) (MacLogP),,U,1,,CHEMBL631232,,22229,14556,,,P,,,Autocuration,,,
12989,BAO_0000019,Hydrophilicity was determined,,U,1,,CHEMBL631233,,22224,768,,,A,,,Autocuration,,,
12990,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631234,,22229,14452,,,P,,,Autocuration,,,
12991,BAO_0000019,Increased absorption was determined,,U,1,,CHEMBL883126,,22224,5237,,,A,,,Autocuration,,,
12992,BAO_0000100,Lipophilicity value was evaluated,,U,1,,CHEMBL631235,,22224,14378,,,P,,,Autocuration,,,
12993,BAO_0000100,Log P value of the compound.,,U,1,,CHEMBL631236,,22224,14418,,,P,,,Autocuration,,,
12994,BAO_0000019,Partition coefficient of compound was determined,,U,1,,CHEMBL631237,,22224,5249,,,A,,,Autocuration,,,
12995,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631238,,22229,14621,,,P,,,Autocuration,,,
12996,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL876429,,22229,12542,,,P,,,Autocuration,,,
12997,BAO_0000019,Partition coefficient was measured by medchem software; Not calculated,,U,1,,CHEMBL631414,,22224,12542,,,A,,,Autocuration,,,
12998,BAO_0000100,Partition coefficient was measured by octanol-water using standard shake-flask method,,U,1,,CHEMBL631415,,22224,12542,,,P,,,Autocuration,,,
12999,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631416,,22229,15462,,,P,,,Autocuration,,,
13000,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL631417,,22224,14884,,,A,,,Autocuration,,,
13001,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631418,,22229,16526,,,P,,,Autocuration,,,
13002,BAO_0000100,The Octanol/Water partition coefficient CLogP,,U,1,,CHEMBL631419,,22229,13693,,,P,,,Autocuration,,,
13003,BAO_0000019,The pharmacokinetic parameter C Log p was reported,,U,1,,CHEMBL631420,,22224,13693,,,A,,,Autocuration,,,
13004,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631421,,22229,13779,,,P,,,Autocuration,,,
13005,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631422,,22229,14772,,,P,,,Autocuration,,,
13006,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL631423,,22229,14393,,,P,,,Autocuration,,,
13007,BAO_0000218,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL876430,In vivo,50597,14793,,Plasma,A,,,Intermediate,,,
13008,BAO_0000218,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL631424,In vivo,50597,14793,,Plasma,A,,,Intermediate,,,
13009,BAO_0000218,Compound was administered intravenously in dog to evaluate plasma clearance values,1969.0,N,1,,CHEMBL631425,In vivo,50588,13744,,Plasma,A,,,Intermediate,,,
13010,BAO_0000218,Compound was administered intravenously in monkey to evaluate plasma clearance values,1969.0,U,1,,CHEMBL631426,In vivo,22224,13744,,Plasma,A,,,Autocuration,,,
13011,BAO_0000218,Compound was administered intravenously in mouse to evaluate plasma clearance values,1969.0,N,1,,CHEMBL631427,In vivo,50594,13744,,Plasma,A,,,Intermediate,,,
13012,BAO_0000218,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1969.0,N,1,,CHEMBL631428,In vivo,50588,13207,,Plasma,A,,,Intermediate,,,
13013,BAO_0000218,Intrinsic clearance in Rhesus liver microsome,2107.0,N,1,,CHEMBL631429,In vitro,50797,5669,Microsomes,Liver,A,,,Intermediate,,,
13014,BAO_0000218,Intrinsic clearance in dog liver microsome,2107.0,N,1,,CHEMBL631430,In vitro,50588,5669,Microsomes,Liver,A,,,Intermediate,,,
13015,BAO_0000218,Intrinsic clearance in rat liver microsome,2107.0,N,1,,CHEMBL631431,In vitro,50597,5669,Microsomes,Liver,A,,,Intermediate,,,
13016,BAO_0000218,Low plasma clearance was calculated in rhesus monkey,1969.0,N,1,,CHEMBL631432,In vivo,50797,4853,,Plasma,A,,,Intermediate,,,
13017,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,1,,CHEMBL631433,In vivo,50588,16452,,,A,,,Intermediate,,,
13018,BAO_0000218,Plasma clearance after intravenous dose of 0.3 mg/kg,,U,1,,CHEMBL631434,In vivo,22224,11954,,,A,,,Autocuration,,,
13019,BAO_0000218,Plasma clearance after intravenous dose of 1 mg/kg,,U,1,,CHEMBL631435,In vivo,22224,11954,,,A,,,Autocuration,,,
13020,BAO_0000218,Plasma clearance after intravenous dose of 3 mg/kg,,U,1,,CHEMBL631436,In vivo,22224,11954,,,A,,,Autocuration,,,
13021,BAO_0000218,Plasma clearance after intravenous dose of 3.87 mg/kg,,U,1,,CHEMBL631437,In vivo,22224,11954,,,A,,,Autocuration,,,
13022,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rat,,N,1,,CHEMBL631438,In vivo,50597,5669,,,A,,,Intermediate,,,
13023,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rhesus,,N,1,,CHEMBL876431,In vivo,50797,5669,,,A,,,Intermediate,,,
13024,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in dog,,N,1,,CHEMBL631439,In vivo,50588,5669,,,A,,,Intermediate,,,
13025,BAO_0000218,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,N,1,,CHEMBL631440,In vivo,50597,13662,,,A,,,Intermediate,,,
13026,BAO_0000019,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,U,1,,CHEMBL631441,,22224,8272,,,A,,,Autocuration,,,
13027,BAO_0000019,Critical Micellar concentration was determined,,U,1,,CHEMBL631442,,22224,13410,,,A,,,Autocuration,,,
13028,BAO_0000019,Critical Micellar concentration of the compound. was determined,,U,1,,CHEMBL626525,,22224,13410,,,A,,,Autocuration,,,
13029,BAO_0000019,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,U,1,,CHEMBL627168,,22224,12628,,,A,,,Autocuration,,,
13030,BAO_0000019,Critical micellar concentration was measured in water by the dye solubilization method,,U,1,,CHEMBL875618,,22224,9675,,,A,,,Autocuration,,,
13031,BAO_0000019,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,U,1,,CHEMBL626612,,22224,12628,,,B,,,Autocuration,,,
13032,BAO_0000019,CMR value (relative to BAY K 8644),,U,1,,CHEMBL626613,,22224,12766,,,A,,,Autocuration,,,
13033,BAO_0000019,Carbamoylating activity was determined,,U,1,,CHEMBL626614,,22224,7849,,,A,,,Autocuration,,,
13034,BAO_0000218,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,U,1,,CHEMBL626615,,22224,12187,,,A,,,Autocuration,,,
13035,BAO_0000019,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,U,1,,CHEMBL626616,,22224,2040,,,A,,,Autocuration,,,
13036,BAO_0000019,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,U,1,,CHEMBL626617,,22224,2040,,,A,,,Autocuration,,,
13037,BAO_0000218,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1969.0,N,1,,CHEMBL626618,In vivo,50588,14180,,Plasma,A,,,Intermediate,,,
13038,BAO_0000218,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1969.0,N,1,,CHEMBL626619,In vivo,50597,14180,,Plasma,A,,,Intermediate,,,
13039,BAO_0000218,"Clearance rate at 0.46 mg/kg, iv, in dogs",,N,1,,CHEMBL626620,In vivo,50588,14474,,,A,,,Intermediate,,,
13040,BAO_0000218,"Clearance rate at 5.5 mg/kg, iv, in rat",,N,1,,CHEMBL626621,In vivo,50597,14474,,,A,,,Intermediate,,,
13041,BAO_0000218,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,N,1,,CHEMBL626622,In vivo,100710,14548,,,A,,,Intermediate,,,
13042,BAO_0000218,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,N,1,,CHEMBL626623,In vivo,100710,14548,,,A,,,Intermediate,,,
13043,BAO_0000218,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,N,1,,CHEMBL626624,In vivo,50588,14548,,,A,,,Intermediate,,,
13044,BAO_0000218,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,N,1,,CHEMBL626625,In vivo,50597,14548,,,A,,,Intermediate,,,
13045,BAO_0000218,Clearance rate constant using isolated perfused rat liver (IPRL) assay,2107.0,N,1,,CHEMBL626626,Ex vivo,50597,6125,,Liver,A,,,Intermediate,,,
13046,BAO_0000218,Tested for the total clearance of the compound,,U,1,,CHEMBL626627,In vivo,22224,6874,,,A,,,Autocuration,,,
13047,BAO_0000218,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,N,1,,CHEMBL626628,In vivo,50588,15343,,,A,,,Intermediate,,,
13048,BAO_0000218,Total body clearance was determined,,U,1,,CHEMBL626629,In vivo,22224,6236,,,A,,,Autocuration,,,
13049,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,N,1,,CHEMBL626630,,50597,11510,,,A,,,Intermediate,,,
13050,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,N,1,,CHEMBL626631,,50597,11510,,,A,,,Intermediate,,,
13051,BAO_0000100,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,U,1,,CHEMBL626632,,22229,8194,,,P,,,Autocuration,,,
13052,BAO_0000100,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,U,1,,CHEMBL626633,,22229,8194,,,P,,,Autocuration,,,
13053,BAO_0000100,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,U,1,,CHEMBL626634,,22229,8194,,,P,,,Autocuration,,,
13054,BAO_0000100,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,U,1,,CHEMBL626635,,22229,8194,,,P,,,Autocuration,,,
13055,BAO_0000100,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,U,1,,CHEMBL626636,,22229,8194,,,P,,,Autocuration,,,
13056,BAO_0000100,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,U,1,,CHEMBL626637,,22229,8194,,,P,,,Autocuration,,,
13057,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,N,1,,CHEMBL626638,,50339,13273,,,A,,,Intermediate,,,
13058,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,N,1,,CHEMBL626639,,50339,13273,,,A,,,Intermediate,,,
13059,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,N,1,,CHEMBL626640,,50339,13273,,,A,,,Intermediate,,,
13060,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,N,1,,CHEMBL626641,,50339,13273,,,A,,,Intermediate,,,
13061,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,N,1,,CHEMBL627272,,50339,13273,,,A,,,Intermediate,,,
13062,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,N,1,,CHEMBL627273,,50339,13273,,,A,,,Intermediate,,,
13063,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,N,1,,CHEMBL627441,,50339,13273,,,A,,,Intermediate,,,
13064,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,N,1,,CHEMBL628355,,50339,13273,,,A,,,Intermediate,,,
13065,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,N,1,,CHEMBL628356,,50339,13273,,,A,,,Intermediate,,,
13066,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,N,1,,CHEMBL628357,,50339,13273,,,A,,,Intermediate,,,
13067,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,N,1,,CHEMBL628358,,50339,13273,,,A,,,Intermediate,,,
13068,BAO_0000218,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,N,1,,CHEMBL622307,,50339,13273,,,A,,,Intermediate,,,
13069,BAO_0000019,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,U,1,,CHEMBL622527,,22224,13118,,,A,,,Autocuration,,,
13070,BAO_0000019,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,U,1,,CHEMBL622528,,22224,13118,,,A,,,Autocuration,,,
13071,BAO_0000019,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,U,1,,CHEMBL622529,,22224,13118,,,A,,,Autocuration,,,
13072,BAO_0000019,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,U,1,,CHEMBL622992,,22224,13118,,,A,,,Autocuration,,,
13073,BAO_0000019,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,U,1,,CHEMBL622993,,22224,13118,,,A,,,Autocuration,,,
13074,BAO_0000019,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,U,1,,CHEMBL622994,,22224,13118,,,A,,,Autocuration,,,
13075,BAO_0000218,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,N,1,,CHEMBL622995,,50597,10633,,,A,,,Intermediate,,,
13076,BAO_0000218,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,N,1,,CHEMBL622996,,50597,10633,,,A,,,Intermediate,,,
13077,BAO_0000218,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,N,1,,CHEMBL622997,,50597,10633,,,A,,,Intermediate,,,
13078,BAO_0000218,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,N,1,,CHEMBL622998,,50597,10633,,,A,,,Intermediate,,,
13079,BAO_0000218,Cp max following ip administration at 1 mg/kg,,U,1,,CHEMBL622999,,22224,5767,,,A,,,Autocuration,,,
13080,BAO_0000218,Maximum concentration in plasma was reported at 0.5 hour,1969.0,U,1,,CHEMBL623000,In vivo,22224,3302,,Plasma,A,,,Autocuration,,,
13081,BAO_0000218,Maximum concentration in plasma was reported at 2 hour,1969.0,U,1,,CHEMBL623001,In vivo,22224,3302,,Plasma,A,,,Autocuration,,,
13082,BAO_0000218,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,N,1,,CHEMBL623002,,50594,12467,,,A,,,Intermediate,,,
13083,BAO_0000100,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,U,1,,CHEMBL623003,,22229,11778,,,P,,,Autocuration,,,
13084,BAO_0000019,Steady state concentration was evaluated,,U,1,,CHEMBL623004,,22224,4321,,,A,,,Autocuration,,,
13085,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL623005,,22224,14884,,,A,,,Autocuration,,,
13086,BAO_0000019,Partition coefficient (logD7.4),,U,1,,CHEMBL623006,,22224,15234,,,A,,,Autocuration,,,
13087,BAO_0000218,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,2107.0,N,1,,CHEMBL623007,In vivo,50597,14198,,Liver,A,,,Intermediate,,,
13088,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,10000001.0,N,1,,CHEMBL623008,In vivo,50597,14198,,Bone,A,,,Intermediate,,,
13089,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,2037.0,N,1,,CHEMBL876654,In vivo,50597,14198,,Cerebellum,A,,,Intermediate,,,
13090,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,N,1,,CHEMBL623009,In vivo,50597,14198,,,A,,,Intermediate,,,
13091,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,N,1,,CHEMBL623010,In vivo,50597,14198,,,A,,,Intermediate,,,
13092,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,948.0,N,1,,CHEMBL623011,In vivo,50597,14198,,Heart,A,,,Intermediate,,,
13093,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,160.0,N,1,,CHEMBL623012,In vivo,50597,14198,,Intestine,A,,,Intermediate,,,
13094,BAO_0000019,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,U,1,,CHEMBL623013,,22224,8151,,,A,,,Autocuration,,,
13095,BAO_0000019,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,U,1,,CHEMBL623014,,22224,8151,,,A,,,Autocuration,,,
13096,BAO_0000019,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,1088.0,U,1,,CHEMBL623015,,22224,8151,,Urine,A,,,Autocuration,,,
13097,BAO_0000019,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,U,1,,CHEMBL623016,,22224,8151,,Urine,A,,,Autocuration,,,
13098,BAO_0000019,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,1088.0,U,1,,CHEMBL624858,,22224,8151,,Urine,A,,,Autocuration,,,
13099,BAO_0000218,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,N,1,,CHEMBL624859,,50597,8151,,,A,,,Intermediate,,,
13100,BAO_0000218,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,N,1,,CHEMBL624860,,50597,8151,,,A,,,Intermediate,,,
13101,BAO_0000218,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,N,1,,CHEMBL624861,,50597,8151,,,A,,,Intermediate,,,
13102,BAO_0000218,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,N,1,,CHEMBL624862,,50597,8151,,,A,,,Intermediate,,,
13103,BAO_0000218,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,N,1,,CHEMBL624863,,50597,8151,,,A,,,Intermediate,,,
13104,BAO_0000218,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,N,1,,CHEMBL876655,,50597,8151,,,A,,,Intermediate,,,
13105,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,N,1,,CHEMBL624864,,50588,6996,,,A,,,Intermediate,,,
13106,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,N,1,,CHEMBL624865,,50588,6996,,,A,,,Intermediate,,,
13107,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,N,1,,CHEMBL624866,,50588,6996,,,A,,,Intermediate,,,
13108,BAO_0000218,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,N,1,,CHEMBL624867,,50588,6996,,,F,,,Expert,,,
13109,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,N,1,,CHEMBL624868,,50588,6996,,,A,,,Intermediate,,,
13110,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,N,1,,CHEMBL628450,,50588,6996,,,A,,,Intermediate,,,
13111,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,N,1,,CHEMBL628451,,50588,6996,,,A,,,Intermediate,,,
13112,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,N,1,,CHEMBL628452,,50588,6996,,,A,,,Intermediate,,,
13113,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,N,1,,CHEMBL628453,,50588,6996,,,A,,,Intermediate,,,
13114,BAO_0000218,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,N,1,,CHEMBL628454,,50588,6996,,,A,,,Intermediate,,,
13115,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,N,1,,CHEMBL628455,,50588,6996,,,A,,,Intermediate,,,
13116,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,N,1,,CHEMBL628456,,50588,6996,,,A,,,Intermediate,,,
13117,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,N,1,,CHEMBL628457,,50588,6996,,,A,,,Intermediate,,,
13118,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,N,1,,CHEMBL877505,,50588,6996,,,A,,,Intermediate,,,
13119,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,N,1,,CHEMBL628458,,50588,6996,,,A,,,Intermediate,,,
13120,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,N,1,,CHEMBL628459,,50588,6996,,,A,,,Intermediate,,,
13121,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,N,1,,CHEMBL628460,,50588,6996,,,A,,,Intermediate,,,
13122,BAO_0000218,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,N,1,,CHEMBL628461,,50588,6996,,,A,,,Intermediate,,,
13123,BAO_0000218,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,U,1,,CHEMBL628462,,22224,6996,,,B,,,Autocuration,,,
13124,BAO_0000218,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,N,1,,CHEMBL628463,,50588,6996,,,A,,,Intermediate,,,
13125,BAO_0000218,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,N,1,,CHEMBL625666,,50597,6996,,,F,,,Expert,,,
13126,BAO_0000218,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,U,1,,CHEMBL625667,,22224,6996,,,B,,,Autocuration,,,
13127,BAO_0000218,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,N,1,,CHEMBL625668,,50597,6996,,,A,,,Expert,,,
13128,BAO_0000218,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,N,1,,CHEMBL625669,,50597,6996,,,A,,,Intermediate,,,
13129,BAO_0000019,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,U,1,,CHEMBL625670,,22224,7114,,,A,,,Autocuration,,,
13130,BAO_0000218,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,N,1,,CHEMBL625671,,50597,7114,,,A,,,Intermediate,,,
13131,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,N,1,,CHEMBL625672,,50602,8613,,,A,,,Intermediate,,,
13132,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,N,1,,CHEMBL625673,,50602,8613,,,A,,,Intermediate,,,
13133,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,N,1,,CHEMBL625674,,50602,8613,,,A,,,Intermediate,,,
13134,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,N,1,,CHEMBL625675,,50602,8613,,,A,,,Intermediate,,,
13135,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,N,1,,CHEMBL627637,,50602,8613,,,A,,,Intermediate,,,
13136,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,N,1,,CHEMBL627638,,50602,8613,,,A,,,Intermediate,,,
13137,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,N,1,,CHEMBL627639,,50602,8613,,,A,,,Intermediate,,,
13138,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,N,1,,CHEMBL627640,,50602,8613,,,A,,,Intermediate,,,
13139,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,N,1,,CHEMBL627641,,50602,8613,,,A,,,Intermediate,,,
13140,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,N,1,,CHEMBL627642,,50602,8613,,,A,,,Intermediate,,,
13141,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,N,1,,CHEMBL877506,,50602,8613,,,A,,,Intermediate,,,
13142,BAO_0000218,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,N,1,,CHEMBL627275,,50594,8613,,,A,,,Intermediate,,,
13143,BAO_0000218,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,N,1,,CHEMBL627643,,50506,11219,,,A,,,Intermediate,,,
13144,BAO_0000218,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,N,1,,CHEMBL631246,,50506,11219,,,A,,,Intermediate,,,
13145,BAO_0000218,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,N,1,,CHEMBL631247,,50506,11219,,,A,,,Intermediate,,,
13146,BAO_0000218,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,N,1,,CHEMBL629532,,50506,11219,,,A,,,Intermediate,,,
13147,BAO_0000218,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,N,1,,CHEMBL629533,,50506,11219,,,A,,,Intermediate,,,
13148,BAO_0000218,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,N,1,,CHEMBL629534,,50506,11219,,,A,,,Intermediate,,,
13149,BAO_0000218,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,N,1,,CHEMBL629535,,50506,11219,,,A,,,Intermediate,,,
13150,BAO_0000019,Pharmacokinetic parameter :drug bound to plasma was reported,,U,1,,CHEMBL625932,,22224,14837,,,A,,,Autocuration,,,
13151,BAO_0000019,compound was evaluated for drug bound in plasma,,U,1,,CHEMBL625933,,22224,14837,,,A,,,Autocuration,,,
13152,BAO_0000218,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,N,1,,CHEMBL625934,,50597,15343,,,A,,,Intermediate,,,
13153,BAO_0000218,Bioavailability,,U,1,,CHEMBL625935,,22224,13761,,,A,,,Autocuration,,,
13154,BAO_0000218,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,N,1,,CHEMBL625936,,50597,14810,,,A,,,Intermediate,,,
13155,BAO_0000218,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,N,1,,CHEMBL625937,,50597,14810,,,A,,,Intermediate,,,
13156,BAO_0000218,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,N,1,,CHEMBL625938,,50588,13249,,,A,,,Intermediate,,,
13157,BAO_0000218,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1970.0,N,1,,CHEMBL625939,,50597,9267,,Bile,A,,,Intermediate,,,
13158,BAO_0000218,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1970.0,N,1,,CHEMBL625940,,50597,9267,,Bile,A,,,Intermediate,,,
13159,BAO_0000218,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1970.0,N,1,,CHEMBL874464,,50597,9267,,Bile,A,,,Intermediate,,,
13160,BAO_0000218,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1970.0,N,1,,CHEMBL625941,,50597,9267,,Bile,A,,,Intermediate,,,
13161,BAO_0000218,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1970.0,N,1,,CHEMBL625942,,50597,9267,,Bile,A,,,Intermediate,,,
13162,BAO_0000218,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1970.0,N,1,,CHEMBL625943,,50597,9267,,Bile,A,,,Intermediate,,,
13163,BAO_0000218,In vitro protein binding in human serum at 5 ug/ml,1977.0,N,1,,CHEMBL625944,,50587,15549,,Serum,A,,,Intermediate,,,
13164,BAO_0000019,Serum protein binding ability was measured,,U,1,,CHEMBL625945,,22224,10929,,,A,,,Autocuration,,,
13165,BAO_0000019,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,U,1,,CHEMBL625946,,22224,15444,,,A,,,Autocuration,,,
13166,BAO_0000218,Oral bioavailability in dog,,U,1,,CHEMBL625947,In vivo,22224,12860,,,A,,,Autocuration,,,
13167,BAO_0000218,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,N,1,,CHEMBL625948,In vivo,50597,12170,,,A,,,Intermediate,,,
13168,BAO_0000218,Absolute oral bioavailability at an iv dose of 14 mg/kg,,U,1,,CHEMBL625949,In vivo,22224,15173,,,A,,,Autocuration,,,
13169,BAO_0000218,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,U,1,,CHEMBL625950,In vivo,22224,15173,,,A,,,Autocuration,,,
13170,BAO_0000218,Oral bioavailability (dose 15 mg/kg i.v.),,U,1,,CHEMBL625951,In vivo,22224,15173,,,A,,,Autocuration,,,
13171,BAO_0000218,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,U,1,,CHEMBL625952,In vivo,22224,15173,,,A,,,Autocuration,,,
13172,BAO_0000218,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,U,1,,CHEMBL625953,In vivo,22224,15173,,,A,,,Autocuration,,,
13173,BAO_0000218,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,U,1,,CHEMBL625954,In vivo,22224,15173,,,A,,,Autocuration,,,
13174,BAO_0000218,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,U,1,,CHEMBL882959,In vivo,22224,15173,,,A,,,Autocuration,,,
13175,BAO_0000218,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,N,1,,CHEMBL625955,In vivo,50588,11767,,,A,,,Intermediate,,,
13176,BAO_0000218,Bioavailability in ferret,,U,1,,CHEMBL625956,In vivo,22224,11219,,,A,,,Autocuration,,,
13177,BAO_0000218,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,N,1,,CHEMBL625957,In vivo,100710,12186,,,A,,,Intermediate,,,
13178,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,N,1,,CHEMBL625958,,50597,11510,,,A,,,Intermediate,,,
13179,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,N,1,,CHEMBL625959,,50597,11510,,,A,,,Intermediate,,,
13180,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,N,1,,CHEMBL626642,,50597,11510,,,A,,,Intermediate,,,
13181,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,N,1,,CHEMBL631330,,50597,11510,,,A,,,Intermediate,,,
13182,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,N,1,,CHEMBL631331,,50597,11510,,,A,,,Intermediate,,,
13183,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,N,1,,CHEMBL631332,,50597,11510,,,A,,,Intermediate,,,
13184,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,N,1,,CHEMBL631333,,50597,11510,,,A,,,Intermediate,,,
13185,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,N,1,,CHEMBL632018,,50597,11510,,,A,,,Intermediate,,,
13186,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,N,1,,CHEMBL632019,,50597,11510,,,A,,,Intermediate,,,
13187,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,N,1,,CHEMBL632020,,50597,11510,,,A,,,Intermediate,,,
13188,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,N,1,,CHEMBL632021,,50597,11510,,,A,,,Intermediate,,,
13189,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,N,1,,CHEMBL632022,,50597,11510,,,A,,,Intermediate,,,
13190,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,N,1,,CHEMBL632023,,50597,11510,,,A,,,Intermediate,,,
13191,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,N,1,,CHEMBL632024,,50597,11510,,,A,,,Intermediate,,,
13192,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,N,1,,CHEMBL874472,,50597,11510,,,A,,,Intermediate,,,
13193,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,N,1,,CHEMBL632025,,50597,11510,,,A,,,Intermediate,,,
13194,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,N,1,,CHEMBL632026,,50597,11510,,,A,,,Intermediate,,,
13195,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,N,1,,CHEMBL632027,,50597,11510,,,A,,,Intermediate,,,
13196,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,N,1,,CHEMBL632028,,50597,11510,,,A,,,Intermediate,,,
13197,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,N,1,,CHEMBL626430,,50597,11510,,,A,,,Intermediate,,,
13198,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,N,1,,CHEMBL626431,,50597,11510,,,A,,,Intermediate,,,
13199,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,N,1,,CHEMBL626432,,50597,11510,,,A,,,Intermediate,,,
13200,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,N,1,,CHEMBL626433,,50597,11510,,,A,,,Intermediate,,,
13201,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,N,1,,CHEMBL626434,,50597,11510,,,A,,,Intermediate,,,
13202,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,N,1,,CHEMBL627280,,50597,11510,,,A,,,Intermediate,,,
13203,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,N,1,,CHEMBL627281,,50597,11510,,,A,,,Intermediate,,,
13204,BAO_0000218,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,N,1,,CHEMBL627282,,50597,11510,,,A,,,Intermediate,,,
13205,BAO_0000019,Total body clearance was measured at given dose,,U,1,,CHEMBL627283,,22224,7199,,,A,,,Autocuration,,,
13206,BAO_0000218,Total body clearance was measured at given dose.,,U,1,,CHEMBL627284,,22224,7199,,,A,,,Autocuration,,,
13207,BAO_0000218,Metabolic clearance from the body in rat,,N,1,,CHEMBL627285,,50597,7095,,,A,,,Intermediate,,,
13208,BAO_0000218,Renal clearance from the body,,U,1,,CHEMBL627286,In vivo,22224,7095,,,A,,,Autocuration,,,
13209,BAO_0000218,Renal clearance from the body in rat,,N,1,,CHEMBL875477,In vivo,50597,7095,,,A,,,Intermediate,,,
13210,BAO_0000218,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,N,1,,CHEMBL627287,In vivo,50597,12528,,,A,,,Intermediate,,,
13211,BAO_0000218,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,N,1,,CHEMBL627288,In vivo,50588,12528,,,A,,,Intermediate,,,
13212,BAO_0000218,Total clearance from the body in rat,,N,1,,CHEMBL627289,,50597,7095,,,A,,,Intermediate,,,
13213,BAO_0000218,Clearance into cortex from rat plasma or PBS,1969.0,N,1,,CHEMBL627290,In vivo,50597,14223,,Plasma,A,,,Intermediate,,,
13214,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,U,1,,CHEMBL627291,In vivo,22224,13569,,,A,,,Autocuration,,,
13215,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,U,1,,CHEMBL627292,In vivo,22224,13569,,,A,,,Autocuration,,,
13216,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,U,1,,CHEMBL627293,In vivo,22224,13569,,,A,,,Autocuration,,,
13217,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,U,1,,CHEMBL627294,In vivo,22224,13569,,,A,,,Autocuration,,,
13218,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,U,1,,CHEMBL875478,In vivo,22224,13569,,,A,,,Autocuration,,,
13219,BAO_0000218,Clearance was determined,,U,1,,CHEMBL627295,In vivo,22224,13979,,,A,,,Autocuration,,,
13220,BAO_0000218,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,N,1,,CHEMBL627296,In vivo,50594,14315,,,A,,,Intermediate,,,
13221,BAO_0000218,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,N,1,,CHEMBL626119,In vivo,50592,14315,,,A,,,Intermediate,,,
13222,BAO_0000218,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,N,1,,CHEMBL626120,In vivo,50597,14315,,,A,,,Intermediate,,,
13223,BAO_0000218,Clearance in rat after iv dose (100 ug/kg),,N,1,,CHEMBL626121,In vivo,50597,12174,,,A,,,Intermediate,,,
13224,BAO_0000218,Clearance in guinea pig,,U,1,,CHEMBL626122,In vivo,22224,12797,,,A,,,Autocuration,,,
13225,BAO_0000218,Compound was evaluated for clearance in rat,,N,1,,CHEMBL626123,In vivo,50597,12797,,,A,,,Intermediate,,,
13226,BAO_0000218,Compound was evaluated for the clearance in dog,,N,1,,CHEMBL623456,In vivo,50588,12797,,,A,,,Intermediate,,,
13227,BAO_0000218,Compound was evaluated for the clearance in rat,,N,1,,CHEMBL623457,In vivo,50597,12797,,,A,,,Intermediate,,,
13228,BAO_0000218,Compound was tested in vivo for clearance after iv administration in the rat,,N,1,,CHEMBL623458,In vivo,50597,11500,,,A,,,Intermediate,,,
13229,BAO_0000218,IV clearance determined at an iv dose of 14 mg/kg,,U,1,,CHEMBL623459,In vivo,22224,15173,,,A,,,Autocuration,,,
13230,BAO_0000218,IV clearance determined at an iv dose of 15.2 mg/kg,,U,1,,CHEMBL875484,In vivo,22224,15173,,,A,,,Autocuration,,,
13231,BAO_0000218,IV clearance determined at an iv dose of 15 mg/kg,,U,1,,CHEMBL623460,In vivo,22224,15173,,,A,,,Autocuration,,,
13232,BAO_0000218,IV clearance determined at an peroral dose of 30 mg/kg.,,U,1,,CHEMBL623461,In vivo,22224,15173,,,A,,,Autocuration,,,
13233,BAO_0000218,IV clearance determined at an peroral dose of 30.2 mg/kg.,,U,1,,CHEMBL623462,In vivo,22224,15173,,,A,,,Autocuration,,,
13234,BAO_0000218,IV clearance determined at an peroral dose of 30.3 mg/kg.,,U,1,,CHEMBL627386,In vivo,22224,15173,,,A,,,Autocuration,,,
13235,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,2113.0,N,1,,CHEMBL627387,In vivo,50597,14198,,Kidney,A,,,Intermediate,,,
13236,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,2107.0,N,1,,CHEMBL627388,In vivo,50597,14198,,Liver,A,,,Intermediate,,,
13237,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,2048.0,N,1,,CHEMBL627389,In vivo,50597,14198,,Lung,A,,,Intermediate,,,
13238,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,2385.0,N,1,,CHEMBL627390,In vivo,50597,14198,,Muscle tissue,A,,,Intermediate,,,
13239,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1969.0,N,1,,CHEMBL627391,In vivo,50597,14198,,Plasma,A,,,Intermediate,,,
13240,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,N,1,,CHEMBL627392,In vivo,50597,14198,,,A,,,Intermediate,,,
13241,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,2106.0,N,1,,CHEMBL627393,In vivo,50597,14198,,Spleen,A,,,Intermediate,,,
13242,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,3126.0,N,1,,CHEMBL627394,In vivo,50597,14198,,Trachea,A,,,Intermediate,,,
13243,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,10000001.0,N,1,,CHEMBL627395,In vivo,50597,14198,,Bone,A,,,Intermediate,,,
13244,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,2037.0,N,1,,CHEMBL875485,In vivo,50597,14198,,Cerebellum,A,,,Intermediate,,,
13245,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,N,1,,CHEMBL627396,In vivo,50597,14198,,,A,,,Intermediate,,,
13246,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,N,1,,CHEMBL627397,In vivo,50597,14198,,,A,,,Intermediate,,,
13247,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,948.0,N,1,,CHEMBL627398,In vivo,50597,14198,,Heart,A,,,Intermediate,,,
13248,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,10000001.0,N,1,,CHEMBL627399,In vivo,50597,14198,,Bone,A,,,Intermediate,,,
13249,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,2113.0,N,1,,CHEMBL627400,In vivo,50597,14198,,Kidney,A,,,Intermediate,,,
13250,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,2107.0,N,1,,CHEMBL627401,In vivo,50597,14198,,Liver,A,,,Intermediate,,,
13251,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,2048.0,N,1,,CHEMBL627402,In vivo,50597,14198,,Lung,A,,,Intermediate,,,
13252,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,2385.0,N,1,,CHEMBL627403,In vivo,50597,14198,,Muscle tissue,A,,,Intermediate,,,
13253,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1969.0,N,1,,CHEMBL627404,In vivo,50597,14198,,Plasma,A,,,Intermediate,,,
13254,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,N,1,,CHEMBL623101,In vivo,50597,14198,,,A,,,Intermediate,,,
13255,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,2106.0,N,1,,CHEMBL877480,In vivo,50597,14198,,Spleen,A,,,Intermediate,,,
13256,BAO_0000218,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,3126.0,N,1,,CHEMBL623102,In vivo,50597,14198,,Trachea,A,,,Intermediate,,,
13257,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,10000001.0,N,1,,CHEMBL623103,In vivo,50597,14198,,Bone,A,,,Intermediate,,,
13258,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,2037.0,N,1,,CHEMBL623104,In vivo,50597,14198,,Cerebellum,A,,,Intermediate,,,
13259,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,N,1,,CHEMBL623105,In vivo,50597,14198,,,A,,,Intermediate,,,
13260,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,N,1,,CHEMBL623106,In vivo,50597,14198,,,A,,,Intermediate,,,
13261,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,948.0,N,1,,CHEMBL623107,In vivo,50597,14198,,Heart,A,,,Intermediate,,,
13262,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,160.0,N,1,,CHEMBL623108,In vivo,50597,14198,,Intestine,A,,,Intermediate,,,
13263,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,2113.0,N,1,,CHEMBL623109,In vivo,50597,14198,,Kidney,A,,,Intermediate,,,
13264,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,2107.0,N,1,,CHEMBL623110,In vivo,50597,14198,,Liver,A,,,Intermediate,,,
13265,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,2048.0,N,1,,CHEMBL623111,In vivo,50597,14198,,Lung,A,,,Intermediate,,,
13266,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,2385.0,N,1,,CHEMBL625060,In vivo,50597,14198,,Muscle tissue,A,,,Intermediate,,,
13267,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1969.0,N,1,,CHEMBL625061,In vivo,50597,14198,,Plasma,A,,,Intermediate,,,
13268,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,N,1,,CHEMBL625062,In vivo,50597,14198,,,A,,,Intermediate,,,
13269,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,2106.0,N,1,,CHEMBL625063,In vivo,50597,14198,,Spleen,A,,,Intermediate,,,
13270,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,3126.0,N,1,,CHEMBL625064,In vivo,50597,14198,,Trachea,A,,,Intermediate,,,
13271,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,10000001.0,N,1,,CHEMBL625065,In vivo,50597,14198,,Bone,A,,,Intermediate,,,
13272,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,2037.0,N,1,,CHEMBL625066,In vivo,50597,14198,,Cerebellum,A,,,Intermediate,,,
13273,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,N,1,,CHEMBL625067,In vivo,50597,14198,,,A,,,Intermediate,,,
13274,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,N,1,,CHEMBL625068,In vivo,50597,14198,,,A,,,Intermediate,,,
13275,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,948.0,N,1,,CHEMBL622159,In vivo,50597,14198,,Heart,A,,,Intermediate,,,
13276,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,160.0,N,1,,CHEMBL622160,In vivo,50597,14198,,Intestine,A,,,Intermediate,,,
13277,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,2113.0,N,1,,CHEMBL622161,In vivo,50597,14198,,Kidney,A,,,Intermediate,,,
13278,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,2048.0,N,1,,CHEMBL622162,In vivo,50597,14198,,Lung,A,,,Intermediate,,,
13279,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,2385.0,N,1,,CHEMBL622163,In vivo,50597,14198,,Muscle tissue,A,,,Intermediate,,,
13280,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1969.0,N,1,,CHEMBL622313,In vivo,50597,14198,,Plasma,A,,,Intermediate,,,
13281,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,N,1,,CHEMBL622314,In vivo,50597,14198,,,A,,,Intermediate,,,
13282,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,2106.0,N,1,,CHEMBL622315,In vivo,50597,14198,,Spleen,A,,,Intermediate,,,
13283,BAO_0000218,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,3126.0,N,1,,CHEMBL622316,In vivo,50597,14198,,Trachea,A,,,Intermediate,,,
13284,BAO_0000218,Normal diffusion coefficient in water for Escherichia coli,,N,1,,CHEMBL877486,,50212,15599,,,A,,,Intermediate,,,
13285,BAO_0000019,Average max percent decrease in RVR (renal vascular resistance) was determined,,U,1,,CHEMBL622317,,22224,8204,,,A,,,Autocuration,,,
13286,BAO_0000019,Average max percent decrease in RVR (renal vascular resistance) was determined.,,U,1,,CHEMBL622318,,22224,8204,,,A,,,Autocuration,,,
13287,BAO_0000019,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,U,1,,CHEMBL622319,,22224,6154,,,A,,,Autocuration,,,
13288,BAO_0000019,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,U,1,,CHEMBL622320,,22224,6154,,,A,,,Autocuration,,,
13289,BAO_0000019,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,U,1,,CHEMBL622321,,22224,6154,,,A,,,Autocuration,,,
13290,BAO_0000019,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,U,1,,CHEMBL622322,,22224,6154,,,A,,,Autocuration,,,
13291,BAO_0000019,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,U,1,,CHEMBL622323,,22224,7114,,,A,,,Autocuration,,,
13292,BAO_0000218,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,N,1,,CHEMBL622324,,50597,7114,,,A,,,Intermediate,,,
13293,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1088.0,N,1,,CHEMBL622325,,50588,8133,,Urine,A,,,Intermediate,,,
13294,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,N,1,,CHEMBL622326,,50588,8133,,Urine,A,,,Intermediate,,,
13295,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1088.0,N,1,,CHEMBL877487,,50588,8133,,Urine,A,,,Intermediate,,,
13296,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,N,1,,CHEMBL622327,,50588,8133,,Urine,A,,,Intermediate,,,
13297,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1088.0,N,1,,CHEMBL622328,,50588,8133,,Urine,A,,,Intermediate,,,
13298,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1088.0,N,1,,CHEMBL622329,,50588,8133,,Urine,A,,,Intermediate,,,
13299,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,N,1,,CHEMBL622330,,50588,8133,,Urine,A,,,Intermediate,,,
13300,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1088.0,N,1,,CHEMBL622331,,50588,8133,,Urine,A,,,Intermediate,,,
13301,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,N,1,,CHEMBL622332,,50588,8133,,Urine,A,,,Intermediate,,,
13302,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1088.0,N,1,,CHEMBL622333,,50588,8133,,Urine,A,,,Intermediate,,,
13303,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,U,1,,CHEMBL627658,,22224,8133,,Urine,A,,,Autocuration,,,
13304,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",1088.0,U,1,,CHEMBL630428,,22224,8133,,Urine,A,,,Autocuration,,,
13305,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,U,1,,CHEMBL630429,,22224,8133,,Urine,A,,,Autocuration,,,
13306,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",1088.0,U,1,,CHEMBL630430,,22224,8133,,Urine,A,,,Autocuration,,,
13307,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",1088.0,U,1,,CHEMBL630431,,22224,8133,,Urine,A,,,Autocuration,,,
13308,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,N,1,,CHEMBL630432,,50597,8133,,Urine,A,,,Intermediate,,,
13309,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1088.0,N,1,,CHEMBL630433,,50597,8133,,Urine,A,,,Intermediate,,,
13310,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1088.0,N,1,,CHEMBL630434,,50597,8133,,Urine,A,,,Intermediate,,,
13311,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1088.0,N,1,,CHEMBL629372,,50597,8133,,Urine,A,,,Intermediate,,,
13312,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1088.0,N,1,,CHEMBL629553,,50597,8133,,Urine,A,,,Intermediate,,,
13313,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1088.0,N,1,,CHEMBL629554,,50597,8133,,Urine,A,,,Intermediate,,,
13314,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1088.0,N,1,,CHEMBL874447,,50597,8133,,Urine,A,,,Intermediate,,,
13315,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1088.0,N,1,,CHEMBL629555,,50597,8133,,Urine,A,,,Intermediate,,,
13316,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1088.0,N,1,,CHEMBL629556,,50597,8133,,Urine,A,,,Intermediate,,,
13317,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1088.0,N,1,,CHEMBL629557,,50597,8133,,Urine,A,,,Intermediate,,,
13318,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1088.0,N,1,,CHEMBL629558,,50597,8133,,Urine,A,,,Intermediate,,,
13319,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1088.0,N,1,,CHEMBL629559,,50597,8133,,Urine,A,,,Intermediate,,,
13320,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1088.0,N,1,,CHEMBL629560,,50597,8133,,Urine,A,,,Intermediate,,,
13321,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1088.0,N,1,,CHEMBL629561,,50588,8133,,Urine,A,,,Intermediate,,,
13322,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,N,1,,CHEMBL629562,,50588,8133,,Urine,A,,,Intermediate,,,
13323,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1088.0,N,1,,CHEMBL629563,,50588,8133,,Urine,A,,,Intermediate,,,
13324,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,N,1,,CHEMBL629564,,50588,8133,,Urine,A,,,Intermediate,,,
13325,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1088.0,N,1,,CHEMBL629565,,50588,8133,,Urine,A,,,Intermediate,,,
13326,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,N,1,,CHEMBL629566,,50588,8133,,Urine,A,,,Intermediate,,,
13327,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,N,1,,CHEMBL629567,,50588,8133,,Urine,A,,,Intermediate,,,
13328,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1088.0,N,1,,CHEMBL629568,,50588,8133,,Urine,A,,,Intermediate,,,
13329,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1088.0,N,1,,CHEMBL629569,,50588,8133,,Urine,A,,,Intermediate,,,
13330,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1088.0,N,1,,CHEMBL629570,,50588,8133,,Urine,A,,,Intermediate,,,
13331,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,U,1,,CHEMBL629571,,22224,8133,,Urine,A,,,Autocuration,,,
13332,BAO_0000218,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,U,1,,CHEMBL629572,In vivo,22224,12170,,,A,,,Autocuration,,,
13333,BAO_0000218,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,U,1,,CHEMBL629573,In vivo,22224,12170,,,A,,,Autocuration,,,
13334,BAO_0000218,Bioavailability (dose 20 mg/kg),,U,1,,CHEMBL629574,In vivo,22224,4985,,,A,,,Autocuration,,,
13335,BAO_0000218,Bioavailability in dog,,U,1,,CHEMBL629575,In vivo,22224,15145,,,A,,,Autocuration,,,
13336,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (male),,U,1,,CHEMBL874448,In vivo,22224,14080,,,A,,,Autocuration,,,
13337,BAO_0000218,Bioavailability in monkey (dose 10 mg/kg i.d.),,U,1,,CHEMBL629576,In vivo,22224,11219,,,A,,,Autocuration,,,
13338,BAO_0000218,Bioavailability in rat,,U,1,,CHEMBL629577,In vivo,22224,15145,,,A,,,Autocuration,,,
13339,BAO_0000218,Bioavailability in rat,,U,1,,CHEMBL629578,In vivo,22224,15145,,,A,,,Autocuration,,,
13340,BAO_0000218,Bioavailability in dog (dose 3.0 mg/kg p.o.),,U,1,,CHEMBL629579,In vivo,22224,1202,,,A,,,Autocuration,,,
13341,BAO_0000218,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,U,1,,CHEMBL882958,In vivo,22224,1202,,,A,,,Autocuration,,,
13342,BAO_0000218,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,N,1,,CHEMBL629580,In vivo,50505,1202,,,A,,,Intermediate,,,
13343,BAO_0000218,Bioavailability,,U,1,,CHEMBL629581,In vivo,22224,4026,,,A,,,Autocuration,,,
13344,BAO_0000218,Bioavailability in squirrel monkey,,U,1,,CHEMBL629582,In vivo,22224,1492,,,A,,,Autocuration,,,
13345,BAO_0000218,Bioavailability was evaluated in dog,,N,1,,CHEMBL628522,In vivo,50588,12793,,,A,,,Intermediate,,,
13346,BAO_0000218,Bioavailability was evaluated in hamster,,N,1,,CHEMBL625432,In vivo,100712,12793,,,A,,,Intermediate,,,
13347,BAO_0000218,Bioavailability in rat,,U,1,,CHEMBL625433,In vivo,22224,12793,,,A,,,Autocuration,,,
13348,BAO_0000218,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1969.0,N,1,,CHEMBL625434,In vivo,50597,14793,,Plasma,A,,,Intermediate,,,
13349,BAO_0000218,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1969.0,N,1,,CHEMBL625435,In vivo,50597,14793,,Plasma,A,,,Intermediate,,,
13350,BAO_0000218,Bioavailability in rat (dose 10 mg/kg p.o.),,U,1,,CHEMBL625436,In vivo,22224,14793,,,A,,,Autocuration,,,
13351,BAO_0000218,Bioavailability was measured in cynomolgus monkeys.,,N,1,,CHEMBL874588,In vivo,100710,14731,,,A,,,Intermediate,,,
13352,BAO_0000218,Bioavailability was measured in nude mice.,,N,1,,CHEMBL625437,In vivo,50594,14731,,,A,,,Intermediate,,,
13353,BAO_0000218,Bioavailability in ferret (dose 10 mg/kg i.d.),,U,1,,CHEMBL625438,In vivo,22224,12187,,,A,,,Autocuration,,,
13354,BAO_0000218,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,U,1,,CHEMBL625439,In vivo,22224,12187,,,A,,,Autocuration,,,
13355,BAO_0000218,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,U,1,,CHEMBL625440,In vivo,22224,12187,,,A,,,Autocuration,,,
13356,BAO_0000218,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,U,1,,CHEMBL625441,In vivo,22224,12187,,,A,,,Autocuration,,,
13357,BAO_0000218,Bioavailability in rat (dose 10 mg/kg i.d.),,U,1,,CHEMBL625442,In vivo,22224,12187,,,A,,,Autocuration,,,
13358,BAO_0000218,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,N,1,,CHEMBL625443,In vivo,50597,12187,,,A,,,Intermediate,,,
13359,BAO_0000218,Bioavailability was determined; extremely poor,,U,1,,CHEMBL625444,In vivo,22224,17431,,,A,,,Autocuration,,,
13360,BAO_0000218,% bioavailability in mice after oral administration of prodrug,,N,1,,CHEMBL625445,In vivo,50594,13318,,,A,,,Intermediate,,,
13361,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,N,1,,CHEMBL625446,In vivo,50588,9025,,,A,,,Intermediate,,,
13362,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,N,1,,CHEMBL882960,In vivo,50588,9025,,,A,,,Intermediate,,,
13363,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,N,1,,CHEMBL625447,In vivo,50588,9025,,,A,,,Intermediate,,,
13364,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,N,1,,CHEMBL625448,In vivo,50588,9025,,,A,,,Intermediate,,,
13365,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,N,1,,CHEMBL625449,In vivo,50588,9025,,,A,,,Intermediate,,,
13366,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,N,1,,CHEMBL874589,In vivo,50588,9025,,,A,,,Intermediate,,,
13367,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,N,1,,CHEMBL625450,In vivo,50588,9025,,,A,,,Intermediate,,,
13368,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,N,1,,CHEMBL625451,In vivo,50588,9025,,,A,,,Intermediate,,,
13369,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,N,1,,CHEMBL626584,In vivo,50588,9025,,,A,,,Intermediate,,,
13370,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,N,1,,CHEMBL626585,In vivo,50588,9025,,,A,,,Intermediate,,,
13371,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,N,1,,CHEMBL626586,In vivo,50588,9025,,,A,,,Intermediate,,,
13372,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,N,1,,CHEMBL626587,In vivo,50588,9025,,,A,,,Intermediate,,,
13373,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,N,1,,CHEMBL626588,In vivo,50588,9025,,,A,,,Intermediate,,,
13374,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,N,1,,CHEMBL626589,In vivo,50588,9025,,,A,,,Intermediate,,,
13375,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,N,1,,CHEMBL626590,In vivo,50588,9025,,,A,,,Intermediate,,,
13376,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,N,1,,CHEMBL626591,In vivo,50588,9025,,,A,,,Intermediate,,,
13377,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,N,1,,CHEMBL627181,In vivo,50588,9025,,,A,,,Intermediate,,,
13378,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,N,1,,CHEMBL628083,In vivo,50588,9025,,,A,,,Intermediate,,,
13379,BAO_0000218,IV clearance determined at an peroral dose of 15 mg/kg.,,U,1,,CHEMBL628084,In vivo,22224,15173,,,A,,,Autocuration,,,
13380,BAO_0000218,Mouse oral clearance was measured against Hymenolepiasis nana.,,N,1,,CHEMBL628085,In vivo,50064,7732,,,F,,,Expert,,,
13381,BAO_0000218,Mouse oral clearance was measured against Nematospiroides dubius,,N,1,,CHEMBL628086,In vivo,50545,7732,,,F,,,Expert,,,
13382,BAO_0000218,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,U,1,,CHEMBL628087,In vivo,22224,7732,,,F,,,Autocuration,,,
13383,BAO_0000218,Mouse oral clearance was measured against N. nana; NT is Not Tested,,N,1,,CHEMBL628088,In vivo,50594,7732,,,A,,,Intermediate,,,
13384,BAO_0000218,Mouse oral clearance was measured against N. nana; NT is Not Tested,,U,1,,CHEMBL628089,In vivo,22224,7732,,,B,,,Autocuration,,,
13385,BAO_0000218,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL628090,In vivo,22224,8328,,,A,,,Autocuration,,,
13386,BAO_0000218,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL628091,In vivo,22224,8328,,,A,,,Autocuration,,,
13387,BAO_0000218,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL628092,In vivo,22224,8328,,,A,,,Autocuration,,,
13388,BAO_0000218,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL628093,In vivo,22224,8328,,,A,,,Autocuration,,,
13389,BAO_0000218,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL875607,In vivo,22224,8328,,,A,,,Autocuration,,,
13390,BAO_0000218,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL625710,In vivo,22224,8328,,,A,,,Autocuration,,,
13391,BAO_0000218,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL625711,In vivo,22224,8328,,,A,,,Autocuration,,,
13392,BAO_0000218,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL625712,In vivo,22224,8328,,,A,,,Autocuration,,,
13393,BAO_0000218,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,U,1,,CHEMBL625713,In vivo,22224,8328,,,A,,,Autocuration,,,
13394,BAO_0000218,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,N,1,,CHEMBL625714,In vivo,50588,13376,,,A,,,Intermediate,,,
13395,BAO_0000218,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,N,1,,CHEMBL625715,In vivo,50797,13477,,,A,,,Intermediate,,,
13396,BAO_0000218,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,N,1,,CHEMBL625716,In vivo,50597,13477,,,A,,,Intermediate,,,
13397,BAO_0000218,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,N,1,,CHEMBL625717,In vivo,50597,13477,,,A,,,Intermediate,,,
13398,BAO_0000218,Plasma clearance was determined for the compound in rats,,N,1,,CHEMBL625718,In vivo,50597,13313,,,A,,,Intermediate,,,
13399,BAO_0000218,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,N,1,,CHEMBL625719,In vivo,50597,12504,,,A,,,Intermediate,,,
13400,BAO_0000218,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,N,1,,CHEMBL625720,In vivo,50597,12504,,,A,,,Intermediate,,,
13401,BAO_0000218,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,N,1,,CHEMBL625721,In vivo,50597,12504,,,A,,,Intermediate,,,
13402,BAO_0000218,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,N,1,,CHEMBL625722,In vivo,50597,12504,,,A,,,Intermediate,,,
13403,BAO_0000218,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,N,1,,CHEMBL625723,In vivo,50597,13129,,,A,,,Intermediate,,,
13404,BAO_0000218,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,N,1,,CHEMBL625724,In vivo,50545,7732,,,A,,,Intermediate,,,
13405,BAO_0000218,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,N,1,,CHEMBL625725,In vivo,50545,7732,,,A,,,Intermediate,,,
13406,BAO_0000218,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,N,1,,CHEMBL625726,In vivo,50545,7732,,,A,,,Intermediate,,,
13407,BAO_0000218,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,N,1,,CHEMBL875608,In vivo,50545,7732,,,A,,,Intermediate,,,
13408,BAO_0000218,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,N,1,,CHEMBL625727,In vivo,50545,7732,,,A,,,Intermediate,,,
13409,BAO_0000218,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,1088.0,U,1,,CHEMBL625728,In vivo,22224,9278,,Urine,A,,,Autocuration,,,
13410,BAO_0000218,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,U,1,,CHEMBL625729,In vivo,22224,9278,,,A,,,Autocuration,,,
13411,BAO_0000218,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,U,1,,CHEMBL625730,In vivo,22224,9278,,,A,,,Autocuration,,,
13412,BAO_0000218,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1088.0,U,1,,CHEMBL625731,In vivo,22224,9278,,Urine,A,,,Autocuration,,,
13413,BAO_0000218,Urinary clearance was determined in rat at 25 mg/kg os dosage,1088.0,U,1,,CHEMBL626417,In vivo,22224,9278,,Urine,A,,,Autocuration,,,
13414,BAO_0000218,Urinary clearance was determined at 100 mg/kg oral dosage in human,1088.0,N,1,,CHEMBL626418,In vivo,50587,9278,,Urine,A,,,Intermediate,,,
13415,BAO_0000218,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1088.0,N,1,,CHEMBL626419,In vivo,50588,9278,,Urine,A,,,Intermediate,,,
13416,BAO_0000218,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1969.0,N,1,,CHEMBL626592,In vivo,50588,5932,,Plasma,A,,,Intermediate,,,
13417,BAO_0000218,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1969.0,N,1,,CHEMBL626593,In vivo,50597,5932,,Plasma,A,,,Intermediate,,,
13418,BAO_0000218,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,N,1,,CHEMBL626594,In vivo,50597,5182,,,A,,,Intermediate,,,
13419,BAO_0000218,Clearance rate in dogs,,N,1,,CHEMBL625035,In vivo,50588,10499,,,A,,,Intermediate,,,
13420,BAO_0000019,Compound was measured for intrinsic clearance,,U,1,,CHEMBL625036,In vitro,22224,6051,,,A,,,Autocuration,,,
13421,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625037,,22229,17508,,,P,,,Autocuration,,,
13422,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625038,,22229,6228,,,P,,,Autocuration,,,
13423,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625039,,22229,6231,,,P,,,Autocuration,,,
13424,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625040,,22229,17740,,,P,,,Autocuration,,,
13425,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625041,,22229,6495,,,P,,,Autocuration,,,
13426,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625042,,22229,2171,,,P,,,Autocuration,,,
13427,BAO_0000019,Partition coefficient of the compound,,U,1,,CHEMBL874411,,22224,3255,,,A,,,Autocuration,,,
13428,BAO_0000019,Permeability,,U,1,,CHEMBL625043,,22224,6821,,,A,,,Autocuration,,,
13429,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625044,,22229,2685,,,P,,,Autocuration,,,
13430,BAO_0000019,Partition coefficient (logD),,U,1,,CHEMBL625045,,22224,17584,,,A,,,Autocuration,,,
13431,BAO_0000100,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,U,1,,CHEMBL625046,,22229,13824,,,P,,,Autocuration,,,
13432,BAO_0000100,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,U,1,,CHEMBL625047,,22229,13824,,,P,,,Autocuration,,,
13433,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625048,,22229,16479,,,P,,,Autocuration,,,
13434,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625049,,22229,11997,,,P,,,Autocuration,,,
13435,BAO_0000100,Calculated logarithm of partition coefficient (P) was determined,,U,1,,CHEMBL625050,,22229,2988,,,P,,,Autocuration,,,
13436,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625051,,22229,931,,,P,,,Autocuration,,,
13437,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL874412,,22229,4381,,,P,,,Autocuration,,,
13438,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625052,,22229,4397,,,P,,,Autocuration,,,
13439,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL625053,,22229,5889,,,P,,,Autocuration,,,
13440,BAO_0000019,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,U,1,,CHEMBL623250,,22224,6154,,,A,,,Autocuration,,,
13441,BAO_0000019,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,U,1,,CHEMBL623251,,22224,6154,,,A,,,Autocuration,,,
13442,BAO_0000019,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,U,1,,CHEMBL623252,,22224,6154,,,A,,,Autocuration,,,
13443,BAO_0000019,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,U,1,,CHEMBL623253,,22224,6154,,,A,,,Autocuration,,,
13444,BAO_0000019,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,U,1,,CHEMBL623254,,22224,6154,,,A,,,Autocuration,,,
13445,BAO_0000019,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,U,1,,CHEMBL623255,,22224,6154,,,A,,,Autocuration,,,
13446,BAO_0000019,Percent degradation of compound at a pH of 1 over a 18 hr period,,U,1,,CHEMBL626831,,22224,6887,,,A,,,Autocuration,,,
13447,BAO_0000019,Percent degradation of compound at pH of 1 over an 18 hr period,,U,1,,CHEMBL877494,,22224,6887,,,A,,,Autocuration,,,
13448,BAO_0000019,Delta Logarithm of Partition Coefficient value was determined.,,U,1,,CHEMBL626832,,22224,14116,,,A,,,Autocuration,,,
13449,BAO_0000019,Delta logPoct-cyc,,U,1,,CHEMBL626833,,22224,11137,,,A,,,Autocuration,,,
13450,BAO_0000100,Lipophilicity estimated on reversed phase TLC,,U,1,,CHEMBL626834,,22224,7230,,,P,,,Autocuration,,,
13451,BAO_0000019,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,U,1,,CHEMBL626835,,22224,15741,,,A,,,Autocuration,,,
13452,BAO_0000019,Delta logPoct-cyc,,U,1,,CHEMBL626836,,22224,9663,,,A,,,Autocuration,,,
13453,BAO_0000100,Change in logarithm of partition coefficient of the compound,,U,1,,CHEMBL626837,,22229,9663,,,P,,,Autocuration,,,
13454,BAO_0000019,Delta logD (pH 6.5),,U,1,,CHEMBL626838,,22224,13807,,,A,,,Autocuration,,,
13455,BAO_0000100,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,U,1,,CHEMBL626839,,22224,13807,,,P,,,Autocuration,,,
13456,BAO_0000019,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,U,1,,CHEMBL626840,,22224,17425,,,A,,,Autocuration,,,
13457,BAO_0000019,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,U,1,,CHEMBL626841,,22224,12143,,,A,,,Autocuration,,,
13458,BAO_0000219,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,U,1,,CHEMBL626842,,22224,12608,,,A,,,Autocuration,,,
13459,BAO_0000219,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,U,1,,CHEMBL626843,,22224,12608,,,A,,,Autocuration,,,
13460,BAO_0000218,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,N,1,,CHEMBL626844,,50597,8649,,,A,,,Intermediate,,,
13461,BAO_0000218,Amount of deuterium retained was reported after normal workup in rats,,N,1,,CHEMBL877495,,50597,8649,,,A,,,Intermediate,,,
13462,BAO_0000218,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,N,1,,CHEMBL626845,,50597,8649,,,A,,,Intermediate,,,
13463,BAO_0000218,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,N,1,,CHEMBL626846,,50597,8649,,,A,,,Intermediate,,,
13464,BAO_0000218,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,N,1,,CHEMBL626847,,50597,8649,,,A,,,Intermediate,,,
13465,BAO_0000218,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,N,1,,CHEMBL628677,,50597,8649,,,A,,,Intermediate,,,
13466,BAO_0000218,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,N,1,,CHEMBL628678,,50597,8649,,,A,,,Intermediate,,,
13467,BAO_0000019,Compound was subjected to electrochemical oxidation,,U,1,,CHEMBL628679,,22224,9659,,,A,,,Autocuration,,,
13468,BAO_0000019,Compound was subjected to photochemical oxidation,,U,1,,CHEMBL628680,,22224,9659,,,A,,,Autocuration,,,
13469,BAO_0000019,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,U,1,,CHEMBL628681,,22224,9659,,,A,,,Autocuration,,,
13470,BAO_0000019,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,U,1,,CHEMBL628682,,22224,9659,,,A,,,Autocuration,,,
13471,BAO_0000019,Oxidation of compound by methemoglobin in presence of hydroperoxide,,U,1,,CHEMBL628683,,22224,9659,,,A,,,Autocuration,,,
13472,BAO_0000218,Percent diffusion through fuzzy rat skin after 48 h of incubation,,N,1,,CHEMBL628684,,50597,9607,,,A,,,Intermediate,,,
13473,BAO_0000100,Dissociation constant (pKa),,U,1,,CHEMBL877501,,22229,7057,,,P,,,Autocuration,,,
13474,BAO_0000100,Dissociation constant value of the compound; ND means not determined.,,U,1,,CHEMBL628685,,22224,7057,,,P,,,Autocuration,,,
13475,BAO_0000218,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,178.0,N,1,,CHEMBL628686,,50597,7911,,Blood,A,,,Intermediate,,,
13476,BAO_0000218,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,178.0,N,1,,CHEMBL628687,,50597,7911,,Blood,A,,,Intermediate,,,
13477,BAO_0000218,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,N,1,,CHEMBL628688,,50597,7911,,,A,,,Intermediate,,,
13478,BAO_0000218,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,N,1,,CHEMBL628689,,50597,7911,,,A,,,Intermediate,,,
13479,BAO_0000218,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,2107.0,N,1,,CHEMBL628690,,50597,7911,,Liver,A,,,Intermediate,,,
13480,BAO_0000218,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,2107.0,N,1,,CHEMBL629363,,50597,7911,,Liver,A,,,Intermediate,,,
13481,BAO_0000218,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,2106.0,N,1,,CHEMBL629364,,50597,7911,,Spleen,A,,,Intermediate,,,
13482,BAO_0000218,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,2106.0,N,1,,CHEMBL629365,,50597,7911,,Spleen,A,,,Intermediate,,,
13483,BAO_0000218,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,N,1,,CHEMBL629366,,50597,7911,,,A,,,Intermediate,,,
13484,BAO_0000218,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1088.0,N,1,,CHEMBL629367,,50597,7911,,Urine,A,,,Intermediate,,,
13485,BAO_0000218,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1988.0,N,1,,CHEMBL629368,,50597,7911,,Feces,A,,,Intermediate,,,
13486,BAO_0000218,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1088.0,N,1,,CHEMBL877502,,50597,7911,,Urine,A,,,Intermediate,,,
13487,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,2037.0,N,1,,CHEMBL629369,,50594,13792,,Cerebellum,A,,,Intermediate,,,
13488,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,955.0,N,1,,CHEMBL629370,,50594,13792,,Brain,A,,,Intermediate,,,
13489,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",1088.0,U,1,,CHEMBL629371,,22224,8133,,Urine,A,,,Autocuration,,,
13490,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,U,1,,CHEMBL626276,,22224,8133,,Urine,A,,,Autocuration,,,
13491,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1088.0,U,1,,CHEMBL626277,,22224,8133,,Urine,A,,,Autocuration,,,
13492,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1088.0,U,1,,CHEMBL631250,,22224,8133,,Urine,A,,,Autocuration,,,
13493,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,N,1,,CHEMBL631251,,50597,8133,,Urine,A,,,Intermediate,,,
13494,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1088.0,N,1,,CHEMBL631252,,50597,8133,,Urine,A,,,Intermediate,,,
13495,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1088.0,N,1,,CHEMBL631253,,50597,8133,,Urine,A,,,Intermediate,,,
13496,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1088.0,N,1,,CHEMBL631254,,50597,8133,,Urine,A,,,Intermediate,,,
13497,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1088.0,N,1,,CHEMBL631255,,50597,8133,,Urine,A,,,Intermediate,,,
13498,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1088.0,N,1,,CHEMBL631256,,50597,8133,,Urine,A,,,Intermediate,,,
13499,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1088.0,N,1,,CHEMBL631257,,50597,8133,,Urine,A,,,Intermediate,,,
13500,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1088.0,N,1,,CHEMBL628009,,50597,8133,,Urine,A,,,Intermediate,,,
13501,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1088.0,N,1,,CHEMBL628010,,50597,8133,,Urine,A,,,Intermediate,,,
13502,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1088.0,N,1,,CHEMBL628011,,50597,8133,,Urine,A,,,Intermediate,,,
13503,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1088.0,N,1,,CHEMBL628012,,50597,8133,,Urine,A,,,Intermediate,,,
13504,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1088.0,N,1,,CHEMBL628013,,50597,8133,,Urine,A,,,Intermediate,,,
13505,BAO_0000218,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1088.0,N,1,,CHEMBL628014,,50597,8133,,Urine,A,,,Intermediate,,,
13506,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1088.0,N,1,,CHEMBL628015,,50588,8133,,Urine,A,,,Intermediate,,,
13507,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,N,1,,CHEMBL628016,,50588,8133,,Urine,A,,,Intermediate,,,
13508,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1088.0,N,1,,CHEMBL874461,,50588,8133,,Urine,A,,,Intermediate,,,
13509,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,N,1,,CHEMBL628017,,50588,8133,,Urine,A,,,Intermediate,,,
13510,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1088.0,N,1,,CHEMBL628018,,50588,8133,,Urine,A,,,Intermediate,,,
13511,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,N,1,,CHEMBL628019,,50588,8133,,Urine,A,,,Intermediate,,,
13512,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,N,1,,CHEMBL628020,,50588,8133,,Urine,A,,,Intermediate,,,
13513,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1088.0,N,1,,CHEMBL628021,,50588,8133,,Urine,A,,,Intermediate,,,
13514,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1088.0,N,1,,CHEMBL628022,,50588,8133,,Urine,A,,,Intermediate,,,
13515,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1088.0,N,1,,CHEMBL628023,,50588,8133,,Urine,A,,,Intermediate,,,
13516,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,U,1,,CHEMBL628024,,22224,8133,,Urine,A,,,Autocuration,,,
13517,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",1088.0,U,1,,CHEMBL628025,,22224,8133,,Urine,A,,,Autocuration,,,
13518,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,U,1,,CHEMBL628026,,22224,8133,,Urine,A,,,Autocuration,,,
13519,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1088.0,U,1,,CHEMBL628027,,22224,8133,,Urine,A,,,Autocuration,,,
13520,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1088.0,U,1,,CHEMBL628028,,22224,8133,,Urine,A,,,Autocuration,,,
13521,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,N,1,,CHEMBL628029,,50597,8133,,Urine,A,,,Intermediate,,,
13522,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1088.0,N,1,,CHEMBL628030,,50597,8133,,Urine,A,,,Intermediate,,,
13523,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1088.0,N,1,,CHEMBL628031,,50597,8133,,Urine,A,,,Intermediate,,,
13524,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1088.0,N,1,,CHEMBL628032,,50597,8133,,Urine,A,,,Intermediate,,,
13525,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1088.0,N,1,,CHEMBL628033,,50597,8133,,Urine,A,,,Intermediate,,,
13526,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1088.0,N,1,,CHEMBL628034,,50597,8133,,Urine,A,,,Intermediate,,,
13527,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1088.0,N,1,,CHEMBL628035,,50597,8133,,Urine,A,,,Intermediate,,,
13528,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1088.0,N,1,,CHEMBL628036,,50597,8133,,Urine,A,,,Intermediate,,,
13529,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1088.0,N,1,,CHEMBL874462,,50597,8133,,Urine,A,,,Intermediate,,,
13530,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,N,1,,CHEMBL628037,In vivo,50588,9025,,,A,,,Intermediate,,,
13531,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,N,1,,CHEMBL628123,In vivo,50588,9025,,,A,,,Intermediate,,,
13532,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,N,1,,CHEMBL628124,In vivo,50588,9025,,,A,,,Intermediate,,,
13533,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,N,1,,CHEMBL628125,In vivo,50588,9025,,,A,,,Intermediate,,,
13534,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,N,1,,CHEMBL628126,In vivo,50588,9025,,,A,,,Intermediate,,,
13535,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,N,1,,CHEMBL628127,In vivo,50588,9025,,,A,,,Intermediate,,,
13536,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,N,1,,CHEMBL628128,In vivo,50588,9025,,,A,,,Intermediate,,,
13537,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,N,1,,CHEMBL628129,In vivo,50588,9025,,,A,,,Intermediate,,,
13538,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,N,1,,CHEMBL628130,In vivo,50588,9025,,,A,,,Intermediate,,,
13539,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,N,1,,CHEMBL628131,In vivo,50588,9025,,,A,,,Intermediate,,,
13540,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,N,1,,CHEMBL628132,In vivo,50588,9025,,,A,,,Intermediate,,,
13541,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,N,1,,CHEMBL628133,In vivo,50588,9025,,,A,,,Intermediate,,,
13542,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,N,1,,CHEMBL628134,In vivo,50588,9025,,,A,,,Intermediate,,,
13543,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,N,1,,CHEMBL628135,In vivo,50588,9025,,,A,,,Intermediate,,,
13544,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,N,1,,CHEMBL628136,In vivo,50588,9025,,,A,,,Intermediate,,,
13545,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,N,1,,CHEMBL628137,In vivo,50588,9025,,,A,,,Intermediate,,,
13546,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,N,1,,CHEMBL628138,In vivo,50588,9025,,,A,,,Intermediate,,,
13547,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,N,1,,CHEMBL628139,In vivo,50588,9025,,,A,,,Intermediate,,,
13548,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,N,1,,CHEMBL628140,In vivo,50588,9025,,,A,,,Intermediate,,,
13549,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,N,1,,CHEMBL628141,In vivo,50588,9025,,,A,,,Intermediate,,,
13550,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,N,1,,CHEMBL628142,In vivo,50588,9025,,,A,,,Intermediate,,,
13551,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,N,1,,CHEMBL628143,In vivo,50588,9025,,,A,,,Intermediate,,,
13552,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,N,1,,CHEMBL628144,In vivo,50588,9025,,,A,,,Intermediate,,,
13553,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,N,1,,CHEMBL628145,In vivo,50588,9025,,,A,,,Intermediate,,,
13554,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,N,1,,CHEMBL628146,In vivo,50588,9025,,,A,,,Intermediate,,,
13555,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,N,1,,CHEMBL625355,In vivo,50588,9025,,,A,,,Intermediate,,,
13556,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,N,1,,CHEMBL625356,In vivo,50588,9025,,,A,,,Intermediate,,,
13557,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,N,1,,CHEMBL625357,In vivo,50588,9025,,,A,,,Intermediate,,,
13558,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,N,1,,CHEMBL625527,In vivo,50588,9025,,,A,,,Intermediate,,,
13559,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,N,1,,CHEMBL875473,In vivo,50588,9025,,,A,,,Intermediate,,,
13560,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,N,1,,CHEMBL625528,In vivo,50588,9025,,,A,,,Intermediate,,,
13561,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,N,1,,CHEMBL626304,In vivo,50597,9025,,,A,,,Intermediate,,,
13562,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1637.0,N,1,,CHEMBL624138,In vivo,50588,9025,,Artery,A,,,Intermediate,,,
13563,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624139,,22229,6448,,,P,,,Autocuration,,,
13564,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624140,,22229,17221,,,P,,,Autocuration,,,
13565,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624141,,22229,6545,,,P,,,Autocuration,,,
13566,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624142,,22229,577,,,P,,,Autocuration,,,
13567,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624143,,22229,6285,,,P,,,Autocuration,,,
13568,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624144,,22229,6500,,,P,,,Autocuration,,,
13569,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624145,,22229,6716,,,P,,,Autocuration,,,
13570,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624146,,22229,13658,,,P,,,Autocuration,,,
13571,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624147,,22229,6549,,,P,,,Autocuration,,,
13572,BAO_0000100,Calculated partition coefficient (clogP) (MacLogP),,U,1,,CHEMBL883123,,22229,14685,,,P,,,Autocuration,,,
13573,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL624148,,22224,6893,,,A,,,Autocuration,,,
13574,BAO_0000019,Kinetic parameter was determined,,U,1,,CHEMBL874416,,22224,3687,,,A,,,Autocuration,,,
13575,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624149,,22229,4207,,,P,,,Autocuration,,,
13576,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL624150,,22229,4626,,,P,,,Autocuration,,,
13577,BAO_0000100,Lipophilicity was determined,,U,1,,CHEMBL624151,,22224,1021,,,P,,,Autocuration,,,
13578,BAO_0000100,Lipophilicity was determined,,U,1,,CHEMBL624152,,22224,3777,,,P,,,Autocuration,,,
13579,BAO_0000100,Lipophilicity was determined,,U,1,,CHEMBL622139,,22224,17533,,,P,,,Autocuration,,,
13580,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL622140,,22229,6524,,,P,,,Autocuration,,,
13581,BAO_0000100,Lipophilicity was determined,,U,1,,CHEMBL622141,,22224,17533,,,P,,,Autocuration,,,
13582,BAO_0000100,Lipophilicity in octanol-water,,U,1,,CHEMBL622142,,22224,6480,,,P,,,Autocuration,,,
13583,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL622143,,22229,17606,,,P,,,Autocuration,,,
13584,BAO_0000100,Octanol-water partition coefficient was determined,,U,1,,CHEMBL622144,,22229,6863,,,P,,,Autocuration,,,
13585,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL877473,,22224,1356,,,A,,,Autocuration,,,
13586,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL622145,,22229,3326,,,P,,,Autocuration,,,
13587,BAO_0000019,Partition coefficient was determined; ND means not determined,,U,1,,CHEMBL622146,,22224,1356,,,A,,,Autocuration,,,
13588,BAO_0000100,Calculated partition coefficient (clogP),,U,1,,CHEMBL622147,,22229,12984,,,P,,,Autocuration,,,
13589,BAO_0000019,Partition coefficient of the compound,,U,1,,CHEMBL622148,,22224,17363,,,A,,,Autocuration,,,
13590,BAO_0000019,Permeability was determined,,U,1,,CHEMBL883124,,22224,6827,,,A,,,Autocuration,,,
13591,BAO_0000100,The compound was evaluated for the partition coefficient,,U,1,,CHEMBL622149,,22229,261,,,P,,,Autocuration,,,
13592,BAO_0000019,Partition coefficient (logP),,U,1,,CHEMBL622150,,22224,2685,,,A,,,Autocuration,,,
13593,BAO_0000100,The lipophilicity was reported,,U,1,,CHEMBL622151,,22224,414,,,P,,,Autocuration,,,
13594,BAO_0000100,logarithm of the octanol-water partition coefficient for the compound,,U,1,,CHEMBL622152,,22229,15769,,,P,,,Autocuration,,,
13595,BAO_0000019,Clogp value was determined,,U,1,,CHEMBL622153,,22224,17248,,,A,,,Autocuration,,,
13596,BAO_0000218,Clp at a dose of 1.5 mg/kg,,U,1,,CHEMBL877474,In vivo,22224,16935,,,A,,,Autocuration,,,
13597,BAO_0000218,Clp at a dose of 2.0 mg/kg,,U,1,,CHEMBL622154,In vivo,22224,16935,,,A,,,Autocuration,,,
13598,BAO_0000218,"Clp, plasma clearance at a dose of 10 mg/kg",1969.0,U,1,,CHEMBL622155,In vivo,22224,14832,,Plasma,A,,,Autocuration,,,
13599,BAO_0000218,"Clp, plasma clearance at a dose of 50 mg/kg",1969.0,U,1,,CHEMBL622156,In vivo,22224,14832,,Plasma,A,,,Autocuration,,,
13600,BAO_0000218,Compound was tested for plasma clearance in rat,1969.0,N,1,,CHEMBL622157,In vivo,50597,2399,,Plasma,A,,,Intermediate,,,
13601,BAO_0000218,Compound was tested for plasma clearance in rat; Not determined,1969.0,N,1,,CHEMBL622158,In vivo,50597,2399,,Plasma,A,,,Intermediate,,,
13602,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,N,1,,CHEMBL622807,In vivo,50597,6227,,,A,,,Intermediate,,,
13603,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,N,1,,CHEMBL622808,In vivo,50797,6227,,,A,,,Intermediate,,,
13604,BAO_0000218,Plasma clearance by iv administration at a dose 0.003 ug/mL,,U,1,,CHEMBL622809,In vivo,22224,5623,,,A,,,Autocuration,,,
13605,BAO_0000218,Plasma clearance determined,,U,1,,CHEMBL622810,In vivo,22224,4854,,,A,,,Autocuration,,,
13606,BAO_0000218,Plasma clearance after iv administration at 3 mg/kg in hamster,,N,1,,CHEMBL876653,In vivo,100712,4493,,,A,,,Intermediate,,,
13607,BAO_0000218,Plasma clearance after iv administration at 4 mg/kg in hamster,,N,1,,CHEMBL622811,In vivo,100712,4493,,,A,,,Intermediate,,,
13608,BAO_0000218,Rate of clearance in rat was determined,,N,1,,CHEMBL622986,In vivo,50597,14956,,,A,,,Intermediate,,,
13609,BAO_0000218,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1969.0,N,1,,CHEMBL622987,In vivo,50597,15372,,Plasma,A,,,Intermediate,,,
13610,BAO_0000218,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1969.0,N,1,,CHEMBL622988,In vivo,50597,15372,,Plasma,A,,,Intermediate,,,
13611,BAO_0000218,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1969.0,N,1,,CHEMBL622989,In vivo,50597,15372,,Plasma,A,,,Intermediate,,,
13612,BAO_0000218,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1969.0,N,1,,CHEMBL622990,In vivo,50597,15372,,Plasma,A,,,Intermediate,,,
13613,BAO_0000218,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1969.0,U,1,,CHEMBL622991,In vivo,22224,15604,,Plasma,A,,,Autocuration,,,
13614,BAO_0000218,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1969.0,N,1,,CHEMBL622227,In vivo,50597,15604,,Plasma,A,,,Intermediate,,,
13615,BAO_0000218,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1969.0,N,1,,CHEMBL622228,In vivo,50588,15604,,Plasma,A,,,Intermediate,,,
13616,BAO_0000218,Clpl value in rat,,N,1,,CHEMBL622229,In vivo,50597,14964,,,A,,,Intermediate,,,
13617,BAO_0000218,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,N,1,,CHEMBL622230,In vivo,50512,15240,,,A,,,Intermediate,,,
13618,BAO_0000218,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,N,1,,CHEMBL622231,In vivo,50597,16449,,,A,,,Intermediate,,,
13619,BAO_0000218,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,N,1,,CHEMBL622232,In vivo,100710,16449,,,A,,,Intermediate,,,
13620,BAO_0000218,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,U,1,,CHEMBL622233,In vivo,22224,12902,,,A,,,Autocuration,,,
13621,BAO_0000218,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,U,1,,CHEMBL622234,In vivo,22224,12902,,,A,,,Autocuration,,,
13622,BAO_0000218,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,U,1,,CHEMBL622235,In vivo,22224,12902,,,A,,,Autocuration,,,
13623,BAO_0000218,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,U,1,,CHEMBL622236,In vivo,22224,12902,,,A,,,Autocuration,,,
13624,BAO_0000218,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,U,1,,CHEMBL622237,In vivo,22224,12902,,,A,,,Autocuration,,,
13625,BAO_0000218,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,U,1,,CHEMBL877482,In vivo,22224,12902,,,A,,,Autocuration,,,
13626,BAO_0000218,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,U,1,,CHEMBL622238,In vivo,22224,12902,,,A,,,Autocuration,,,
13627,BAO_0000218,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,U,1,,CHEMBL622239,In vivo,22224,12902,,,A,,,Autocuration,,,
13628,BAO_0000218,Cmax was calculated as maximum concentration reached in the blood,178.0,U,1,,CHEMBL622240,In vivo,22224,11149,,Blood,A,,,Autocuration,,,
13629,BAO_0000218,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,178.0,U,1,,CHEMBL622241,In vivo,22224,11149,,Blood,A,,,Autocuration,,,
13630,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rat,,N,1,,CHEMBL631013,In vivo,50597,5669,,,A,,,Intermediate,,,
13631,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rhesus,,N,1,,CHEMBL631014,In vivo,50797,5669,,,A,,,Intermediate,,,
13632,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in dog,,N,1,,CHEMBL631015,In vivo,50588,5669,,,A,,,Intermediate,,,
13633,BAO_0000218,Cmax was determine after peroral administration at 160 mpk in Rat,,N,1,,CHEMBL631016,In vivo,50597,5669,,,A,,,Intermediate,,,
13634,BAO_0000218,Cmax was determine after peroral administration at 20 mpk in Rat,,N,1,,CHEMBL631017,In vivo,50597,5669,,,A,,,Intermediate,,,
13635,BAO_0000218,Cmax was determine after peroral administration at 50 mpk in Rat,,N,1,,CHEMBL631018,In vivo,50597,5669,,,A,,,Intermediate,,,
13636,BAO_0000218,Cmax was determined,,U,1,,CHEMBL631019,In vivo,22224,4236,,,A,,,Autocuration,,,
13637,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,955.0,N,1,,CHEMBL875761,,50594,13792,,Brain,A,,,Intermediate,,,
13638,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,955.0,N,1,,CHEMBL631020,,50594,13792,,Brain,A,,,Intermediate,,,
13639,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,955.0,N,1,,CHEMBL631669,,50594,13792,,Brain,A,,,Intermediate,,,
13640,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,955.0,N,1,,CHEMBL631670,,50594,13792,,Brain,A,,,Intermediate,,,
13641,BAO_0000218,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,2435.0,N,1,,CHEMBL631671,,50594,13792,,Striatum,A,,,Intermediate,,,
13642,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,178.0,N,1,,CHEMBL631672,,50597,8418,,Blood,A,,,Intermediate,,,
13643,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,178.0,N,1,,CHEMBL631673,,50597,8418,,Blood,A,,,Intermediate,,,
13644,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,178.0,N,1,,CHEMBL631856,,50597,8418,,Blood,A,,,Intermediate,,,
13645,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,178.0,N,1,,CHEMBL631857,,50597,8418,,Blood,A,,,Intermediate,,,
13646,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,178.0,N,1,,CHEMBL631858,,50597,8418,,Blood,A,,,Intermediate,,,
13647,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,178.0,N,1,,CHEMBL631859,,50597,8418,,Blood,A,,,Intermediate,,,
13648,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,178.0,N,1,,CHEMBL631860,,50597,8418,,Blood,A,,,Intermediate,,,
13649,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,178.0,N,1,,CHEMBL631861,,50597,8418,,Blood,A,,,Intermediate,,,
13650,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,178.0,N,1,,CHEMBL631862,,50597,8418,,Blood,A,,,Intermediate,,,
13651,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,178.0,N,1,,CHEMBL631863,,50597,8418,,Blood,A,,,Intermediate,,,
13652,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,178.0,N,1,,CHEMBL631864,,50597,8418,,Blood,A,,,Intermediate,,,
13653,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,178.0,N,1,,CHEMBL631865,,50597,8418,,Blood,A,,,Intermediate,,,
13654,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,178.0,N,1,,CHEMBL631866,,50597,8418,,Blood,A,,,Intermediate,,,
13655,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,178.0,N,1,,CHEMBL629360,,50597,8418,,Blood,A,,,Intermediate,,,
13656,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,178.0,N,1,,CHEMBL629361,,50597,8418,,Blood,A,,,Intermediate,,,
13657,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,178.0,N,1,,CHEMBL629362,,50597,8418,,Blood,A,,,Intermediate,,,
13658,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,178.0,N,1,,CHEMBL630740,,50597,8418,,Blood,A,,,Intermediate,,,
13659,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,178.0,N,1,,CHEMBL630741,,50597,8418,,Blood,A,,,Intermediate,,,
13660,BAO_0000218,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,178.0,N,1,,CHEMBL630742,,50597,8418,,Blood,A,,,Intermediate,,,
13661,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,N,1,,CHEMBL630743,,50597,8418,,,A,,,Intermediate,,,
13662,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,N,1,,CHEMBL630744,,50597,8418,,,A,,,Intermediate,,,
13663,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,N,1,,CHEMBL630745,,50597,8418,,,A,,,Intermediate,,,
13664,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,N,1,,CHEMBL630746,,50597,8418,,,A,,,Intermediate,,,
13665,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,N,1,,CHEMBL630747,,50597,8418,,,A,,,Intermediate,,,
13666,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,N,1,,CHEMBL630748,,50597,8418,,,A,,,Intermediate,,,
13667,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,N,1,,CHEMBL632056,,50597,8418,,,A,,,Intermediate,,,
13668,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,N,1,,CHEMBL632057,,50597,8418,,,A,,,Intermediate,,,
13669,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,N,1,,CHEMBL632058,,50597,8418,,,A,,,Intermediate,,,
13670,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,N,1,,CHEMBL632059,,50597,8418,,,A,,,Intermediate,,,
13671,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,N,1,,CHEMBL632060,,50597,8418,,,A,,,Intermediate,,,
13672,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,N,1,,CHEMBL632061,,50597,8418,,,A,,,Intermediate,,,
13673,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,N,1,,CHEMBL629207,,50597,8418,,,A,,,Intermediate,,,
13674,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,N,1,,CHEMBL629208,,50597,8418,,,A,,,Intermediate,,,
13675,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,N,1,,CHEMBL629209,,50597,8418,,,A,,,Intermediate,,,
13676,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,N,1,,CHEMBL629210,,50597,8418,,,A,,,Intermediate,,,
13677,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,N,1,,CHEMBL629211,,50597,8418,,,A,,,Intermediate,,,
13678,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,N,1,,CHEMBL629212,,50597,8418,,,A,,,Intermediate,,,
13679,BAO_0000218,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,N,1,,CHEMBL629213,,50597,8418,,,A,,,Intermediate,,,
13680,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1088.0,N,1,,CHEMBL629214,,50597,8133,,Urine,A,,,Intermediate,,,
13681,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1088.0,N,1,,CHEMBL629215,,50597,8133,,Urine,A,,,Intermediate,,,
13682,BAO_0000218,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1088.0,N,1,,CHEMBL635154,,50597,8133,,Urine,A,,,Intermediate,,,
13683,BAO_0000218,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL629216,,50597,6996,,,A,,,Intermediate,,,
13684,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,N,1,,CHEMBL629217,,50597,6996,,,A,,,Intermediate,,,
13685,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL629218,,50597,6996,,,A,,,Intermediate,,,
13686,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL629219,,50597,6996,,,A,,,Intermediate,,,
13687,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL629220,,50597,6996,,,A,,,Intermediate,,,
13688,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL629221,,50597,6996,,,A,,,Intermediate,,,
13689,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL631127,,50597,6996,,,A,,,Intermediate,,,
13690,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,N,1,,CHEMBL631128,,50597,6996,,,A,,,Intermediate,,,
13691,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL631129,,50597,6996,,,A,,,Intermediate,,,
13692,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL631130,,50597,6996,,,A,,,Intermediate,,,
13693,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL631131,,50597,6996,,,A,,,Intermediate,,,
13694,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL631132,,50597,6996,,,A,,,Intermediate,,,
13695,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL631133,,50597,6996,,,A,,,Intermediate,,,
13696,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,N,1,,CHEMBL631134,,50597,6996,,,A,,,Intermediate,,,
13697,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL875120,,50597,6996,,,A,,,Intermediate,,,
13698,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL631135,,50597,6996,,,A,,,Intermediate,,,
13699,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL631136,,50597,6996,,,A,,,Intermediate,,,
13700,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL631137,,50597,6996,,,A,,,Intermediate,,,
13701,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL631138,,50597,6996,,,A,,,Intermediate,,,
13702,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,N,1,,CHEMBL631139,,50597,6996,,,A,,,Intermediate,,,
13703,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL631140,,50597,6996,,,A,,,Intermediate,,,
13704,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,1,,CHEMBL631141,,50597,6996,,,A,,,Intermediate,,,
13705,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,N,1,,CHEMBL631142,,50597,6996,,,A,,,Intermediate,,,
13706,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,N,1,,CHEMBL631143,,50597,6996,,,A,,,Intermediate,,,
13707,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,1,,CHEMBL631144,,50597,6996,,,A,,,Intermediate,,,
13708,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,N,1,,CHEMBL631145,,50588,6996,,,A,,,Intermediate,,,
13709,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL631146,,50588,6996,,,A,,,Intermediate,,,
13710,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,N,1,,CHEMBL631147,,50588,6996,,,A,,,Intermediate,,,
13711,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL631148,,50588,6996,,,A,,,Intermediate,,,
13712,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL631149,,50588,6996,,,A,,,Intermediate,,,
13713,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL631150,,50588,6996,,,A,,,Intermediate,,,
13714,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL631151,,50588,6996,,,A,,,Intermediate,,,
13715,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL631152,,50588,6996,,,A,,,Intermediate,,,
13716,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL631443,,50588,6996,,,A,,,Intermediate,,,
13717,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL631444,,50588,6996,,,A,,,Intermediate,,,
13718,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL631445,,50588,6996,,,A,,,Intermediate,,,
13719,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,N,1,,CHEMBL631446,,50588,6996,,,A,,,Intermediate,,,
13720,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,N,1,,CHEMBL631447,,50588,6996,,,A,,,Intermediate,,,
13721,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,N,1,,CHEMBL631448,,50588,6996,,,A,,,Intermediate,,,
13722,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,N,1,,CHEMBL631449,,50588,6996,,,A,,,Intermediate,,,
13723,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,N,1,,CHEMBL631450,,50588,6996,,,A,,,Intermediate,,,
13724,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,N,1,,CHEMBL629724,,50588,6996,,,A,,,Intermediate,,,
13725,BAO_0000218,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",14.0,N,1,,CHEMBL629725,In vivo,50594,9716,,Zone of skin,A,,,Intermediate,,,
13726,BAO_0000218,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",14.0,N,1,,CHEMBL629726,In vivo,50594,9716,,Zone of skin,A,,,Intermediate,,,
13727,BAO_0000218,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,N,1,,CHEMBL629727,In vivo,50594,9716,,Spleen,A,,,Intermediate,,,
13728,BAO_0000218,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,N,1,,CHEMBL630404,In vivo,50594,9716,,Spleen,A,,,Intermediate,,,
13729,BAO_0000218,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,N,1,,CHEMBL630405,In vivo,50594,9716,,Spleen,A,,,Intermediate,,,
13730,BAO_0000218,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,N,1,,CHEMBL630406,In vivo,50594,9716,,Spleen,A,,,Intermediate,,,
13731,BAO_0000218,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,N,1,,CHEMBL630407,In vivo,50594,9716,,Stomach,A,,,Intermediate,,,
13732,BAO_0000218,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,N,1,,CHEMBL630573,In vivo,50594,9716,,Stomach,A,,,Intermediate,,,
13733,BAO_0000218,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,N,1,,CHEMBL630574,In vivo,50594,9716,,Stomach,A,,,Intermediate,,,
13734,BAO_0000218,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,N,1,,CHEMBL630575,In vivo,50594,9716,,Stomach,A,,,Intermediate,,,
13735,BAO_0000218,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,1,,CHEMBL630576,In vivo,50594,9716,,,A,,,Intermediate,,,
13736,BAO_0000218,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,1,,CHEMBL630577,In vivo,50594,9716,,,A,,,Intermediate,,,
13737,BAO_0000218,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,1,,CHEMBL630578,In vivo,50594,9716,,,A,,,Intermediate,,,
13738,BAO_0000218,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,1,,CHEMBL630579,In vivo,50594,9716,,,A,,,Intermediate,,,
13739,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),2113.0,N,1,,CHEMBL630580,,50594,12192,,Kidney,A,,,Intermediate,,,
13740,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,2113.0,N,1,,CHEMBL630581,,50594,12192,,Kidney,A,,,Intermediate,,,
13741,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),2113.0,N,1,,CHEMBL630582,,50594,12192,,Kidney,A,,,Intermediate,,,
13742,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,N,1,,CHEMBL630583,,50594,12192,,,A,,,Intermediate,,,
13743,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,N,1,,CHEMBL630584,,50594,12192,,,A,,,Intermediate,,,
13744,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,N,1,,CHEMBL630585,,50594,12192,,,A,,,Intermediate,,,
13745,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,N,1,,CHEMBL630586,,50594,12192,,,A,,,Intermediate,,,
13746,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,N,1,,CHEMBL630587,,50594,12192,,,A,,,Intermediate,,,
13747,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,N,1,,CHEMBL630588,,50594,12192,,,A,,,Intermediate,,,
13748,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,N,1,,CHEMBL630589,,50594,12192,,,A,,,Intermediate,,,
13749,BAO_0000218,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,N,1,,CHEMBL630590,,50594,12192,,,A,,,Intermediate,,,
13750,BAO_0000019,Removal of 238-Plutonium(IV) in feces at 24 h,1988.0,U,1,,CHEMBL630591,,22224,12192,,Feces,A,,,Autocuration,,,
13751,BAO_0000019,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),1988.0,U,1,,CHEMBL630592,,22224,12192,,Feces,A,,,Autocuration,,,
13752,BAO_0000019,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,U,1,,CHEMBL630593,,22224,12192,,,A,,,Autocuration,,,
13753,BAO_0000019,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,U,1,,CHEMBL630594,,22224,12192,,,A,,,Autocuration,,,
13754,BAO_0000019,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),1088.0,U,1,,CHEMBL630595,,22224,12192,,Urine,A,,,Autocuration,,,
13755,BAO_0000019,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),1088.0,U,1,,CHEMBL630596,,22224,12192,,Urine,A,,,Autocuration,,,
13756,BAO_0000019,Removal of 238-Plutonium(IV) in urine after 0-24 h,1088.0,U,1,,CHEMBL630597,,22224,12192,,Urine,A,,,Autocuration,,,
13757,BAO_0000019,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),1088.0,U,1,,CHEMBL630598,,22224,12192,,Urine,A,,,Autocuration,,,
13758,BAO_0000019,Removal of 238-Plutonium(IV) in urine after 0-4 h,1088.0,U,1,,CHEMBL630599,,22224,12192,,Urine,A,,,Autocuration,,,
13759,BAO_0000019,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),1088.0,U,1,,CHEMBL630600,,22224,12192,,Urine,A,,,Autocuration,,,
13760,BAO_0000019,Removal of 238-Plutonium(IV) in urine after 4-24 h,1088.0,U,1,,CHEMBL630601,,22224,12192,,Urine,A,,,Autocuration,,,
13761,BAO_0000019,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),1088.0,U,1,,CHEMBL630602,,22224,12192,,Urine,A,,,Autocuration,,,
13762,BAO_0000019,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),1088.0,U,1,,CHEMBL630603,,22224,12192,,Urine,A,,,Autocuration,,,
13763,BAO_0000019,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),1088.0,U,1,,CHEMBL630604,,22224,12192,,Urine,A,,,Autocuration,,,
13764,BAO_0000218,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL624869,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
13765,BAO_0000218,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL624870,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
13766,BAO_0000218,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,N,1,,CHEMBL623189,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
13767,BAO_0000218,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL623190,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
13768,BAO_0000218,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL623191,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
13769,BAO_0000218,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL623192,In vivo,50597,12017,,,A,,,Intermediate,,,
13770,BAO_0000218,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL623193,In vivo,50597,12017,,,A,,,Intermediate,,,
13771,BAO_0000218,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,1,,CHEMBL623194,In vivo,50597,12017,,,A,,,Intermediate,,,
13772,BAO_0000218,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL623195,In vivo,50597,12017,,,A,,,Intermediate,,,
13773,BAO_0000218,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL623196,In vivo,50597,12017,,,A,,,Intermediate,,,
13774,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,N,1,,CHEMBL623197,,50597,11836,,,A,,,Intermediate,,,
13775,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,N,1,,CHEMBL623198,,50597,11836,,,A,,,Intermediate,,,
13776,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,N,1,,CHEMBL623199,,50597,11836,,,A,,,Intermediate,,,
13777,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623200,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13778,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623201,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13779,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623202,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13780,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623203,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13781,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623204,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13782,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,2385.0,N,1,,CHEMBL623205,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13783,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623206,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13784,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,2385.0,N,1,,CHEMBL623207,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13785,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,2385.0,N,1,,CHEMBL623208,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13786,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,2385.0,N,1,,CHEMBL623209,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13787,BAO_0000218,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,2385.0,N,1,,CHEMBL623210,,50597,11836,,Muscle tissue,A,,,Intermediate,,,
13788,BAO_0000218,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,N,1,,CHEMBL623211,,50597,11836,,,A,,,Intermediate,,,
13789,BAO_0000218,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,995.0,N,1,,CHEMBL623212,,50597,11836,,Uterus,A,,,Intermediate,,,
13790,BAO_0000019,Tested in vitro for intrinsic activity relative to quinpirole,,U,1,,CHEMBL623213,,22224,12640,,,A,,,Autocuration,,,
13791,BAO_0000019,"Relative ion enhancement, determined in pulsed ultrafiltration",,U,1,,CHEMBL623214,,22224,14218,,,A,,,Autocuration,,,
13792,BAO_0000019,% ionization at the pH 7.4 at 37 degree Centigrade,,U,1,,CHEMBL623215,,22224,11296,,,A,,,Autocuration,,,
13793,BAO_0000019,Percentage ionization was measured,,U,1,,CHEMBL623216,,22224,10929,,,A,,,Autocuration,,,
13794,BAO_0000218,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,N,1,,CHEMBL623217,,50591,13841,,,A,,,Intermediate,,,
13795,BAO_0000019,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,U,1,,CHEMBL623218,,22224,10431,,,A,,,Autocuration,,,
13796,BAO_0000019,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,U,1,,CHEMBL623913,,22224,10431,,,A,,,Autocuration,,,
13797,BAO_0000019,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,U,1,,CHEMBL623914,,22224,10431,,,A,,,Autocuration,,,
13798,BAO_0000100,Compound was evaluated for the partition coefficient in octanol/water,,U,1,,CHEMBL623915,,22229,8826,,,P,,,Autocuration,,,
13799,BAO_0000100,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,U,1,,CHEMBL624080,,22229,8826,,,P,,,Autocuration,,,
13800,BAO_0000019,Equilibrium constant measured by the pulse radiolysis at pH 7,,U,1,,CHEMBL624081,,22224,9884,,,A,,,Autocuration,,,
13801,BAO_0000218,In vitro hydrolytic rate constant determined in human blood,,N,1,,CHEMBL624082,,50587,9827,,,A,,,Intermediate,,,
13802,BAO_0000218,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,N,1,,CHEMBL625054,,50587,10009,,,A,,,Intermediate,,,
13803,BAO_0000019,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,U,1,,CHEMBL877485,,22224,10009,,,A,,,Autocuration,,,
13804,BAO_0000218,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,N,1,,CHEMBL625055,,50594,10009,,,A,,,Intermediate,,,
13805,BAO_0000218,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,N,1,,CHEMBL625056,,50594,10009,,,A,,,Intermediate,,,
13806,BAO_0000218,In vitro oxidation of compound in presence of human plasma,,N,1,,CHEMBL625057,,50587,10009,,,A,,,Intermediate,,,
13807,BAO_0000019,In vitro oxidation of compound in presence of hydrogen peroxide,,U,1,,CHEMBL625058,,22224,10009,,,A,,,Autocuration,,,
13808,BAO_0000218,In vitro oxidation of compound in presence of mouse brain homogenate,,N,1,,CHEMBL625059,,50594,10009,,,A,,,Intermediate,,,
13809,BAO_0000218,In vitro oxidation of compound in presence of mouse liver homogenate,,N,1,,CHEMBL629536,,50594,10009,,,A,,,Intermediate,,,
13810,BAO_0000218,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,N,1,,CHEMBL629537,,50597,11510,,,A,,,Intermediate,,,
13811,BAO_0000218,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,N,1,,CHEMBL629538,,50597,11510,,,A,,,Intermediate,,,
13812,BAO_0000218,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,N,1,,CHEMBL629539,,50597,11510,,,A,,,Intermediate,,,
13813,BAO_0000218,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,N,1,,CHEMBL874445,,50597,11510,,,A,,,Intermediate,,,
13814,BAO_0000218,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,N,1,,CHEMBL629540,,50597,11510,,,A,,,Intermediate,,,
13815,BAO_0000218,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,N,1,,CHEMBL629541,,50597,11510,,,A,,,Intermediate,,,
13816,BAO_0000218,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,N,1,,CHEMBL629542,,50597,11510,,,A,,,Intermediate,,,
13817,BAO_0000218,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,N,1,,CHEMBL630243,,50597,11510,,,A,,,Intermediate,,,
13818,BAO_0000218,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,N,1,,CHEMBL630244,,50597,11510,,,A,,,Intermediate,,,
13819,BAO_0000218,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,N,1,,CHEMBL630245,,50597,11510,,,A,,,Intermediate,,,
13820,BAO_0000218,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,N,1,,CHEMBL630246,,50597,11510,,,A,,,Intermediate,,,
13821,BAO_0000218,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,N,1,,CHEMBL630247,,50597,11510,,,A,,,Intermediate,,,
13822,BAO_0000218,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,N,1,,CHEMBL630248,,50597,11510,,,A,,,Intermediate,,,
13823,BAO_0000218,Biodistribution in rat blood at 240 minutes after dose administration.,178.0,N,1,,CHEMBL630249,In vivo,50597,13100,,Blood,A,,,Intermediate,,,
13824,BAO_0000218,Biodistribution in rat blood at 30 minutes after dose administration.,178.0,N,1,,CHEMBL630250,In vivo,50597,13100,,Blood,A,,,Intermediate,,,
13825,BAO_0000218,Biodistribution in rat blood at 360 minutes after dose administration.,178.0,N,1,,CHEMBL630251,In vivo,50597,13100,,Blood,A,,,Intermediate,,,
13826,BAO_0000218,Biodistribution in rat blood at 3 hr after dose administration.,178.0,N,1,,CHEMBL630252,In vivo,50597,13100,,Blood,A,,,Intermediate,,,
13827,BAO_0000218,Biodistribution in rat blood at 60 minutes after dose administration.,178.0,N,1,,CHEMBL630408,In vivo,50597,13100,,Blood,A,,,Intermediate,,,
13828,BAO_0000218,Biodistribution in rat cerebellum at 120 minutes after dose administration.,2037.0,N,1,,CHEMBL630409,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13829,BAO_0000218,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,2037.0,N,1,,CHEMBL874446,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13830,BAO_0000218,Biodistribution in rat cerebellum at 15 minutes after dose administration.,2037.0,N,1,,CHEMBL630410,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13831,BAO_0000218,Biodistribution in rat cerebellum at 240 minutes after dose administration.,2037.0,N,1,,CHEMBL630411,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13832,BAO_0000218,Biodistribution in rat cerebellum at 30 minutes after dose administration.,2037.0,N,1,,CHEMBL630412,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13833,BAO_0000218,Biodistribution in rat cerebellum at 360 minutes after dose administration.,2037.0,N,1,,CHEMBL630413,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13834,BAO_0000218,Biodistribution in rat cerebellum at 3 hr after dose administration.,2037.0,N,1,,CHEMBL630414,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13835,BAO_0000218,Biodistribution in rat cerebellum at 60 minutes after dose administration.,2037.0,N,1,,CHEMBL630415,In vivo,50597,13100,,Cerebellum,A,,,Intermediate,,,
13836,BAO_0000218,Biodistribution in rat cortex at 120 minutes after dose administration.,,N,1,,CHEMBL630416,In vivo,50597,13100,,,A,,,Intermediate,,,
13837,BAO_0000218,Biodistribution in rat cortex at 1440 minutes after dose administration.,,N,1,,CHEMBL630417,In vivo,50597,13100,,,A,,,Intermediate,,,
13838,BAO_0000218,Biodistribution in rat cortex at 15 minutes after dose administration.,,N,1,,CHEMBL630418,In vivo,50597,13100,,,A,,,Intermediate,,,
13839,BAO_0000218,Biodistribution in rat cortex at 240 minutes after dose administration.,,N,1,,CHEMBL630419,In vivo,50597,13100,,,A,,,Intermediate,,,
13840,BAO_0000218,Biodistribution in rat cortex at 30 minutes after dose administration.,,N,1,,CHEMBL630420,In vivo,50597,13100,,,A,,,Intermediate,,,
13841,BAO_0000218,Biodistribution in rat cortex at 360 minutes after dose administration.,,N,1,,CHEMBL630421,In vivo,50597,13100,,,A,,,Intermediate,,,
13842,BAO_0000218,Biodistribution in rat cortex at 3 hr after dose administration.,,N,1,,CHEMBL630422,In vivo,50597,13100,,,A,,,Intermediate,,,
13843,BAO_0000218,Biodistribution in rat cortex at 60 minutes after dose administration.,,N,1,,CHEMBL630423,In vivo,50597,13100,,,A,,,Intermediate,,,
13844,BAO_0000218,Biodistribution in rat heart at 120 minutes after dose administration.,948.0,N,1,,CHEMBL630424,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13845,BAO_0000218,Biodistribution in rat heart at 15 minutes after dose administration.,948.0,N,1,,CHEMBL630425,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13846,BAO_0000218,Biodistribution in rat heart at 240 minutes after dose administration.,948.0,N,1,,CHEMBL629462,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13847,BAO_0000218,Biodistribution in rat heart at 30 minutes after dose administration.,948.0,N,1,,CHEMBL630426,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13848,BAO_0000218,Biodistribution in rat heart at 360 minutes after dose administration.,948.0,N,1,,CHEMBL630427,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13849,BAO_0000218,Biodistribution in rat heart at 3 hr after dose administration.,948.0,N,1,,CHEMBL625877,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13850,BAO_0000218,Biodistribution in rat heart at 60 minutes after dose administration.,948.0,N,1,,CHEMBL625878,In vivo,50597,13100,,Heart,A,,,Intermediate,,,
13851,BAO_0000218,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,10000000.0,N,1,,CHEMBL625879,In vivo,50597,13100,,Hippocampus,A,,,Intermediate,,,
13852,BAO_0000218,Biodistribution in rat hippocampus at 240 minutes after dose administration.,10000000.0,N,1,,CHEMBL625880,In vivo,50597,13100,,Hippocampus,A,,,Intermediate,,,
13853,BAO_0000218,Biodistribution in rat hippocampus at 30 minutes after dose administration.,10000000.0,N,1,,CHEMBL625881,In vivo,50597,13100,,Hippocampus,A,,,Intermediate,,,
13854,BAO_0000218,Biodistribution in rat hippocampus at 360 minutes after dose administration.,10000000.0,N,1,,CHEMBL625882,In vivo,50597,13100,,Hippocampus,A,,,Intermediate,,,
13855,BAO_0000218,Biodistribution in rat hippocampus at 15 minutes after dose administration.,10000000.0,N,1,,CHEMBL625883,In vivo,50597,13100,,Hippocampus,A,,,Intermediate,,,
13856,BAO_0000218,Biodistribution in rat kidney at 120 minutes after dose administration.,2113.0,N,1,,CHEMBL625884,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13857,BAO_0000218,Biodistribution in rat kidney at 1440 minutes after dose administration.,2113.0,N,1,,CHEMBL625885,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13858,BAO_0000218,Biodistribution in rat kidney at 15 minutes after dose administration.,2113.0,N,1,,CHEMBL628649,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13859,BAO_0000218,Biodistribution in rat kidney at 240 minutes after dose administration.,2113.0,N,1,,CHEMBL628650,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13860,BAO_0000218,Biodistribution in rat kidney at 30 minutes after dose administration.,2113.0,N,1,,CHEMBL628651,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13861,BAO_0000218,Biodistribution in rat kidney at 360 minutes after dose administration.,2113.0,N,1,,CHEMBL628652,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13862,BAO_0000218,Biodistribution in rat kidney at 60 minutes after dose administration.,2113.0,N,1,,CHEMBL628653,In vivo,50597,13100,,Kidney,A,,,Intermediate,,,
13863,BAO_0000218,Biodistribution in rat liver at 120 minutes after dose administration.,2107.0,N,1,,CHEMBL628654,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13864,BAO_0000218,Biodistribution in rat liver at 1440 minutes after dose administration.,2107.0,N,1,,CHEMBL628655,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13865,BAO_0000218,Biodistribution in rat liver at 15 minutes after dose administration.,2107.0,N,1,,CHEMBL625238,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13866,BAO_0000218,Biodistribution in rat liver at 240 minutes after dose administration.,2107.0,N,1,,CHEMBL625239,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13867,BAO_0000218,Biodistribution in rat liver at 30 minutes after dose administration.,2107.0,N,1,,CHEMBL625240,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13868,BAO_0000218,Biodistribution in rat liver at 360 minutes after dose administration.,2107.0,N,1,,CHEMBL625241,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13869,BAO_0000218,Biodistribution in rat liver at 60 minutes after dose administration.,2107.0,N,1,,CHEMBL625242,In vivo,50597,13100,,Liver,A,,,Intermediate,,,
13870,BAO_0000218,Biodistribution in rat lung at 120 minutes after dose administration.,2048.0,N,1,,CHEMBL874587,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
13871,BAO_0000218,Biodistribution in rat lung at 1440 minutes after dose administration.,2048.0,N,1,,CHEMBL625405,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
13872,BAO_0000218,Biodistribution in rat lung at 15 minutes after dose administration.,2048.0,N,1,,CHEMBL625406,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
13873,BAO_0000218,Biodistribution in rat lung at 240 minutes after dose administration.,2048.0,N,1,,CHEMBL625407,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
13874,BAO_0000218,Biodistribution in rat lung at 30 minutes after dose administration.,2048.0,N,1,,CHEMBL625408,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
13875,BAO_0000218,Biodistribution in rat lung at 360 minutes after dose administration.,2048.0,N,1,,CHEMBL625409,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
13876,BAO_0000218,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1515.0,N,1,,CHEMBL625410,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13877,BAO_0000218,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1515.0,N,1,,CHEMBL625411,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13878,BAO_0000218,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1515.0,N,1,,CHEMBL625412,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13879,BAO_0000218,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1515.0,N,1,,CHEMBL625413,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13880,BAO_0000218,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1515.0,N,1,,CHEMBL625414,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13881,BAO_0000218,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1515.0,N,1,,CHEMBL625415,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13882,BAO_0000218,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1515.0,N,1,,CHEMBL625416,,50597,12361,,Thoracic aorta,A,,,Intermediate,,,
13883,BAO_0000218,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1088.0,N,1,,CHEMBL625417,,50597,12712,,Urine,A,,,Intermediate,,,
13884,BAO_0000218,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1988.0,N,1,,CHEMBL625418,,50597,7415,,Feces,A,,,Intermediate,,,
13885,BAO_0000218,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1088.0,N,1,,CHEMBL625419,,50597,7415,,Urine,A,,,Intermediate,,,
13886,BAO_0000218,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,N,1,,CHEMBL625420,,50597,7415,,,A,,,Intermediate,,,
13887,BAO_0000218,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,N,1,,CHEMBL626996,,50597,7415,,,A,,,Intermediate,,,
13888,BAO_0000218,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1988.0,N,1,,CHEMBL626997,,50597,7415,,Feces,A,,,Intermediate,,,
13889,BAO_0000218,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1088.0,N,1,,CHEMBL626998,,50597,7415,,Urine,A,,,Intermediate,,,
13890,BAO_0000218,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,N,1,,CHEMBL626999,,50597,7415,,,A,,,Intermediate,,,
13891,BAO_0000218,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,N,1,,CHEMBL627000,,50594,8050,,,A,,,Intermediate,,,
13892,BAO_0000218,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,N,1,,CHEMBL627001,,50594,8050,,,A,,,Intermediate,,,
13893,BAO_0000218,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,N,1,,CHEMBL627002,,50594,8050,,,A,,,Intermediate,,,
13894,BAO_0000218,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,N,1,,CHEMBL627003,,50594,8050,,,A,,,Intermediate,,,
13895,BAO_0000218,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1088.0,N,1,,CHEMBL627004,,50594,8050,,Urine,A,,,Intermediate,,,
13896,BAO_0000218,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1088.0,N,1,,CHEMBL627005,,50594,8050,,Urine,A,,,Intermediate,,,
13897,BAO_0000218,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1088.0,N,1,,CHEMBL874594,,50594,8050,,Urine,A,,,Intermediate,,,
13898,BAO_0000218,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1088.0,N,1,,CHEMBL627006,,50594,8050,,Urine,A,,,Intermediate,,,
13899,BAO_0000218,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1088.0,N,1,,CHEMBL627007,,50594,8050,,Urine,A,,,Intermediate,,,
13900,BAO_0000218,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1088.0,N,1,,CHEMBL627884,,50594,8050,,Urine,A,,,Intermediate,,,
13901,BAO_0000218,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1088.0,N,1,,CHEMBL627885,,50594,8050,,Urine,A,,,Intermediate,,,
13902,BAO_0000218,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1088.0,N,1,,CHEMBL627886,,50594,8050,,Urine,A,,,Intermediate,,,
13903,BAO_0000218,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1088.0,N,1,,CHEMBL627887,,50594,8050,,Urine,A,,,Intermediate,,,
13904,BAO_0000218,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1088.0,N,1,,CHEMBL627888,,50594,8050,,Urine,A,,,Intermediate,,,
13905,BAO_0000218,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1088.0,N,1,,CHEMBL628057,,50594,8050,,Urine,A,,,Intermediate,,,
13906,BAO_0000218,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1088.0,N,1,,CHEMBL627405,,50594,8050,,Urine,A,,,Intermediate,,,
13907,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,N,1,,CHEMBL627406,,50588,12582,,Urine,A,,,Intermediate,,,
13908,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,N,1,,CHEMBL627407,,50588,12582,,Urine,A,,,Intermediate,,,
13909,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,N,1,,CHEMBL627408,,50588,12582,,Urine,A,,,Intermediate,,,
13910,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,N,1,,CHEMBL627409,,50588,12582,,Urine,A,,,Intermediate,,,
13911,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,N,1,,CHEMBL875486,,50588,12582,,Urine,A,,,Intermediate,,,
13912,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627410,,50588,12582,,Urine,A,,,Intermediate,,,
13913,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,N,1,,CHEMBL627411,,50588,12582,,Urine,A,,,Intermediate,,,
13914,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,N,1,,CHEMBL627412,,50588,12582,,Urine,A,,,Intermediate,,,
13915,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,N,1,,CHEMBL627413,,50588,12582,,Urine,A,,,Intermediate,,,
13916,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,N,1,,CHEMBL627414,,50588,12582,,Urine,A,,,Intermediate,,,
13917,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627415,,50588,12582,,Urine,A,,,Intermediate,,,
13918,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1088.0,N,1,,CHEMBL627416,,50588,12582,,Urine,A,,,Intermediate,,,
13919,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,N,1,,CHEMBL627417,,50588,12582,,Urine,A,,,Intermediate,,,
13920,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,N,1,,CHEMBL627418,,50588,12582,,Urine,A,,,Intermediate,,,
13921,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627419,,50588,12582,,Urine,A,,,Intermediate,,,
13922,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1088.0,N,1,,CHEMBL627320,,50588,12582,,Urine,A,,,Intermediate,,,
13923,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627321,,50588,12582,,Urine,A,,,Intermediate,,,
13924,BAO_0000218,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL627322,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
13925,BAO_0000218,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL627323,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
13926,BAO_0000218,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,N,1,,CHEMBL627491,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
13927,BAO_0000218,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL627492,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
13928,BAO_0000218,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL627493,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
13929,BAO_0000218,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL627494,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
13930,BAO_0000218,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL627495,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
13931,BAO_0000218,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,N,1,,CHEMBL627496,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
13932,BAO_0000218,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL627497,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
13933,BAO_0000218,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL627498,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
13934,BAO_0000218,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL627499,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
13935,BAO_0000218,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL627500,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
13936,BAO_0000218,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,N,1,,CHEMBL627501,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
13937,BAO_0000218,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL625616,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
13938,BAO_0000218,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL625617,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
13939,BAO_0000218,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL625618,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
13940,BAO_0000218,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL625619,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
13941,BAO_0000218,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,N,1,,CHEMBL625620,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
13942,BAO_0000218,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL625621,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
13943,BAO_0000218,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL625622,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
13944,BAO_0000218,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL625788,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13945,BAO_0000218,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL625789,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13946,BAO_0000218,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,N,1,,CHEMBL625790,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13947,BAO_0000218,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL625791,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13948,BAO_0000218,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL622334,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13949,BAO_0000218,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,N,1,,CHEMBL622335,In vivo,50597,12017,,Thyroid gland,A,,,Intermediate,,,
13950,BAO_0000218,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,N,1,,CHEMBL622336,In vivo,50597,12017,,Thyroid gland,A,,,Intermediate,,,
13951,BAO_0000218,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2046.0,N,1,,CHEMBL622337,In vivo,50597,12017,,Thyroid gland,A,,,Intermediate,,,
13952,BAO_0000218,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,N,1,,CHEMBL622338,In vivo,50597,12017,,Thyroid gland,A,,,Intermediate,,,
13953,BAO_0000218,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,N,1,,CHEMBL622339,In vivo,50597,12017,,Thyroid gland,A,,,Intermediate,,,
13954,BAO_0000218,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL624153,In vivo,50597,12017,,,A,,,Intermediate,,,
13955,BAO_0000218,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL628430,In vivo,50597,12017,,,A,,,Intermediate,,,
13956,BAO_0000218,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,1,,CHEMBL628431,In vivo,50597,12017,,,A,,,Intermediate,,,
13957,BAO_0000218,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL628432,In vivo,50597,12017,,,A,,,Intermediate,,,
13958,BAO_0000218,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL628433,In vivo,50597,12017,,,A,,,Intermediate,,,
13959,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,N,1,,CHEMBL628434,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13960,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,N,1,,CHEMBL626789,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13961,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",2106.0,N,1,,CHEMBL626790,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13962,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,N,1,,CHEMBL626791,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13963,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,N,1,,CHEMBL626792,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13964,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,N,1,,CHEMBL626793,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
13965,BAO_0000218,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,N,1,,CHEMBL627436,,50597,11510,,,A,,,Intermediate,,,
13966,BAO_0000218,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,N,1,,CHEMBL627437,,50597,11510,,,A,,,Intermediate,,,
13967,BAO_0000218,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,N,1,,CHEMBL627438,,50597,11510,,,A,,,Intermediate,,,
13968,BAO_0000218,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,N,1,,CHEMBL627439,,50597,11510,,,A,,,Intermediate,,,
13969,BAO_0000218,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,N,1,,CHEMBL627440,,50597,11510,,,A,,,Intermediate,,,
13970,BAO_0000218,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,N,1,,CHEMBL627602,,50597,11510,,,A,,,Intermediate,,,
13971,BAO_0000218,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,N,1,,CHEMBL627603,,50597,11510,,,A,,,Intermediate,,,
13972,BAO_0000218,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,N,1,,CHEMBL627604,,50597,11510,,,A,,,Intermediate,,,
13973,BAO_0000218,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,N,1,,CHEMBL627605,,50597,11510,,,A,,,Intermediate,,,
13974,BAO_0000218,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,N,1,,CHEMBL627606,,50597,11510,,,A,,,Intermediate,,,
13975,BAO_0000218,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,N,1,,CHEMBL627607,,50597,11510,,,A,,,Intermediate,,,
13976,BAO_0000218,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,N,1,,CHEMBL627608,,50597,11510,,,A,,,Intermediate,,,
13977,BAO_0000218,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,N,1,,CHEMBL627609,,50597,11510,,,A,,,Intermediate,,,
13978,BAO_0000218,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,N,1,,CHEMBL627610,,50597,11510,,,A,,,Intermediate,,,
13979,BAO_0000218,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,N,1,,CHEMBL627611,,50597,11510,,,A,,,Intermediate,,,
13980,BAO_0000218,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,N,1,,CHEMBL627612,,50597,11510,,,A,,,Intermediate,,,
13981,BAO_0000100,Octanol:water partition coefficient is evaluated,,U,1,,CHEMBL627613,,22229,8362,,,P,,,Autocuration,,,
13982,BAO_0000100,Partition coefficient in 1-octanol/water system,,U,1,,CHEMBL627614,,22224,8257,,,P,,,Autocuration,,,
13983,BAO_0000100,Partition coefficient in 1-octanol/water system measured using radio active compounds,,U,1,,CHEMBL627615,,22224,8257,,,P,,,Autocuration,,,
13984,BAO_0000100,Partition coefficient in octanol/water system was determined,,U,1,,CHEMBL627616,,22224,9468,,,P,,,Autocuration,,,
13985,BAO_0000100,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,U,1,,CHEMBL627617,,22224,9468,,,P,,,Autocuration,,,
13986,BAO_0000019,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,U,1,,CHEMBL627618,,22224,10568,,,A,,,Autocuration,,,
13987,BAO_0000019,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,U,1,,CHEMBL627619,,22224,10568,,,A,,,Autocuration,,,
13988,BAO_0000019,Pseudo-first-order rate constant of the compound,,U,1,,CHEMBL627620,,22224,15359,,,A,,,Autocuration,,,
13989,BAO_0000019,Pseudo-first-order rate constant with 1-min time point,,U,1,,CHEMBL627621,,22224,15359,,,A,,,Autocuration,,,
13990,BAO_0000019,Pseudo-first-order rate constant without 1-min time point,,U,1,,CHEMBL627622,,22224,15359,,,A,,,Autocuration,,,
13991,BAO_0000019,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,U,1,,CHEMBL627623,,22224,10431,,,A,,,Autocuration,,,
13992,BAO_0000019,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,U,1,,CHEMBL627624,,22224,10431,,,A,,,Autocuration,,,
13993,BAO_0000019,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,U,1,,CHEMBL627625,,22224,10431,,,A,,,Autocuration,,,
13994,BAO_0000019,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,U,1,,CHEMBL628523,,22224,15704,,,A,,,Autocuration,,,
13995,BAO_0000019,The alkaline hydrolysis second order rate constant(K OH) of the compound,,U,1,,CHEMBL628524,,22224,15287,,,A,,,Autocuration,,,
13996,BAO_0000019,The efflux rate constant of the compound,,U,1,,CHEMBL628525,,22224,7516,,,A,,,Autocuration,,,
13997,BAO_0000019,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,U,1,,CHEMBL625732,,22224,12973,,,A,,,Autocuration,,,
13998,BAO_0000019,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,U,1,,CHEMBL625733,,22224,12973,,,A,,,Autocuration,,,
13999,BAO_0000019,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,U,1,,CHEMBL625734,,22224,12973,,,F,,,Autocuration,,,
14000,BAO_0000019,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,U,1,,CHEMBL625913,,22224,12973,,,A,,,Autocuration,,,
14001,BAO_0000019,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,U,1,,CHEMBL625914,,22224,8696,,,A,,,Autocuration,,,
14002,BAO_0000019,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,U,1,,CHEMBL625915,,22224,15052,,,A,,,Autocuration,,,
14003,BAO_0000019,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,U,1,,CHEMBL625916,,22224,15052,,,A,,,Autocuration,,,
14004,BAO_0000019,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,U,1,,CHEMBL625917,,22224,10503,,,A,,,Autocuration,,,
14005,BAO_0000019,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625918,,22224,8354,,,A,,,Autocuration,,,
14006,BAO_0000019,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625919,,22224,8354,,,A,,,Autocuration,,,
14007,BAO_0000019,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625920,,22224,8354,,,A,,,Autocuration,,,
14008,BAO_0000019,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL874453,,22224,8354,,,A,,,Autocuration,,,
14009,BAO_0000019,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625921,,22224,8354,,,A,,,Autocuration,,,
14010,BAO_0000019,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,U,1,,CHEMBL625922,,22224,10503,,,A,,,Autocuration,,,
14011,BAO_0000019,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625923,,22224,8354,,,A,,,Autocuration,,,
14012,BAO_0000019,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625924,,22224,8354,,,A,,,Autocuration,,,
14013,BAO_0000019,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625925,,22224,8354,,,A,,,Autocuration,,,
14014,BAO_0000019,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL625926,,22224,8354,,,A,,,Autocuration,,,
14015,BAO_0000218,Biodistribution in rat lung at 60 minutes after dose administration.,2048.0,N,1,,CHEMBL627704,In vivo,50597,13100,,Lung,A,,,Intermediate,,,
14016,BAO_0000218,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,N,1,,CHEMBL627705,In vivo,50597,13100,,,A,,,Intermediate,,,
14017,BAO_0000218,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,N,1,,CHEMBL627706,In vivo,50597,13100,,,A,,,Intermediate,,,
14018,BAO_0000218,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,N,1,,CHEMBL627707,In vivo,50597,13100,,,A,,,Intermediate,,,
14019,BAO_0000218,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,N,1,,CHEMBL627708,In vivo,50597,13100,,,A,,,Intermediate,,,
14020,BAO_0000218,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,N,1,,CHEMBL628361,In vivo,50597,13100,,,A,,,Intermediate,,,
14021,BAO_0000218,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,N,1,,CHEMBL628362,In vivo,50597,13100,,,A,,,Intermediate,,,
14022,BAO_0000218,Biodistribution in rat striatum at 120 minutes after dose administration.,2435.0,N,1,,CHEMBL628363,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14023,BAO_0000218,Biodistribution in rat striatum at 1440 minutes after dose administration.,2435.0,N,1,,CHEMBL628364,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14024,BAO_0000218,Biodistribution in rat striatum at 15 minutes after dose administration.,2435.0,N,1,,CHEMBL628365,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14025,BAO_0000218,Biodistribution in rat striatum at 240 minutes after dose administration.,2435.0,N,1,,CHEMBL874454,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14026,BAO_0000218,Biodistribution in rat striatum at 30 minutes after dose administration.,2435.0,N,1,,CHEMBL628531,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14027,BAO_0000218,Biodistribution in rat striatum at 360 minutes after dose administration.,2435.0,N,1,,CHEMBL628532,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14028,BAO_0000218,Biodistribution in rat striatum at 3 hr after dose administration.,2435.0,N,1,,CHEMBL628533,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14029,BAO_0000218,Biodistribution in rat striatum at 60 minutes after dose administration.,2435.0,N,1,,CHEMBL628534,In vivo,50597,13100,,Striatum,A,,,Intermediate,,,
14030,BAO_0000218,Biodistribution in rat thyroid at 120 minutes after dose administration.,2046.0,N,1,,CHEMBL628535,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14031,BAO_0000218,Biodistribution in rat thyroid at 1440 minutes after dose administration.,2046.0,N,1,,CHEMBL628536,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14032,BAO_0000218,Biodistribution in rat thyroid at 15 minutes after dose administration.,2046.0,N,1,,CHEMBL628537,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14033,BAO_0000218,Biodistribution in rat thyroid at 240 minutes after dose administration.,2046.0,N,1,,CHEMBL628538,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14034,BAO_0000218,Biodistribution in rat thyroid at 30 minutes after dose administration.,2046.0,N,1,,CHEMBL628539,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14035,BAO_0000218,Biodistribution in rat thyroid at 360 minutes after dose administration.,2046.0,N,1,,CHEMBL630297,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14036,BAO_0000218,Biodistribution in rat thyroid at 60 minutes after dose administration.,2046.0,N,1,,CHEMBL630298,In vivo,50597,13100,,Thyroid gland,A,,,Intermediate,,,
14037,BAO_0000218,Biodistribution in rest of brain of rat 120 minutes after dose administration.,955.0,N,1,,CHEMBL630299,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14038,BAO_0000218,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,955.0,N,1,,CHEMBL628094,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14039,BAO_0000218,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,955.0,N,1,,CHEMBL628095,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14040,BAO_0000218,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,955.0,N,1,,CHEMBL874648,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14041,BAO_0000218,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,955.0,N,1,,CHEMBL628096,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14042,BAO_0000218,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,955.0,N,1,,CHEMBL628097,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14043,BAO_0000218,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,955.0,N,1,,CHEMBL628098,In vivo,50597,13100,,Brain,A,,,Intermediate,,,
14044,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,U,1,,CHEMBL628099,,22224,13331,,,A,,,Autocuration,,,
14045,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,U,1,,CHEMBL628100,,22224,13331,,,A,,,Autocuration,,,
14046,BAO_0000019,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,U,1,,CHEMBL628101,,22224,13331,,,A,,,Autocuration,,,
14047,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,U,1,,CHEMBL628102,,22224,13331,,,A,,,Autocuration,,,
14048,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,U,1,,CHEMBL628103,,22224,13331,,,A,,,Autocuration,,,
14049,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,U,1,,CHEMBL628104,,22224,13331,,,A,,,Autocuration,,,
14050,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,U,1,,CHEMBL628105,,22224,13331,,,A,,,Autocuration,,,
14051,BAO_0000019,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,U,1,,CHEMBL628106,,22224,13331,,,A,,,Autocuration,,,
14052,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1088.0,N,1,,CHEMBL628107,,50597,10086,,Urine,A,,,Intermediate,,,
14053,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1088.0,U,1,,CHEMBL628108,,22224,10086,,Urine,F,,,Autocuration,,,
14054,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1088.0,N,1,,CHEMBL628109,,50597,10086,,Urine,A,,,Intermediate,,,
14055,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1088.0,U,1,,CHEMBL625299,,22224,10086,,Urine,F,,,Autocuration,,,
14056,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1088.0,N,1,,CHEMBL625300,,50597,10086,,Urine,A,,,Intermediate,,,
14057,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1088.0,N,1,,CHEMBL625301,,50597,10086,,Urine,A,,,Intermediate,,,
14058,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1088.0,N,1,,CHEMBL625302,,50597,10086,,Urine,A,,,Intermediate,,,
14059,BAO_0000218,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1088.0,N,1,,CHEMBL874649,,50597,10086,,Urine,A,,,Intermediate,,,
14060,BAO_0000218,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,N,1,,CHEMBL625303,,50597,13248,,,A,,,Intermediate,,,
14061,BAO_0000218,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,N,1,,CHEMBL625463,,50597,13248,,,A,,,Intermediate,,,
14062,BAO_0000218,In vitro metabolism in human liver microsomes,2107.0,N,1,,CHEMBL625464,,50587,14527,,Liver,A,,,Intermediate,,,
14063,BAO_0000218,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,N,1,,CHEMBL625465,,50587,3008,,,A,,,Intermediate,,,
14064,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1088.0,N,1,,CHEMBL625466,,50588,12582,,Urine,A,,,Intermediate,,,
14065,BAO_0000218,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,N,1,,CHEMBL625467,,50588,12582,,Urine,A,,,Intermediate,,,
14066,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1088.0,N,1,,CHEMBL625468,,50597,12582,,Urine,A,,,Intermediate,,,
14067,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,N,1,,CHEMBL625469,,50597,12582,,Urine,A,,,Intermediate,,,
14068,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,N,1,,CHEMBL625470,,50597,12582,,Urine,A,,,Intermediate,,,
14069,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,N,1,,CHEMBL632418,,50597,12582,,Urine,A,,,Intermediate,,,
14070,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627250,,50597,12582,,Urine,A,,,Intermediate,,,
14071,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,N,1,,CHEMBL627251,,50597,12582,,Urine,A,,,Intermediate,,,
14072,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,N,1,,CHEMBL627252,,50597,12582,,Urine,A,,,Intermediate,,,
14073,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,N,1,,CHEMBL627253,,50597,12582,,Urine,A,,,Intermediate,,,
14074,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,N,1,,CHEMBL627254,,50597,12582,,Urine,A,,,Intermediate,,,
14075,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,N,1,,CHEMBL875471,,50597,12582,,Urine,A,,,Intermediate,,,
14076,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,N,1,,CHEMBL627255,,50597,12582,,Urine,A,,,Intermediate,,,
14077,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,N,1,,CHEMBL627256,,50597,12582,,Urine,A,,,Intermediate,,,
14078,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,N,1,,CHEMBL627257,,50597,12582,,Urine,A,,,Intermediate,,,
14079,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,N,1,,CHEMBL627258,,50597,12582,,Urine,A,,,Intermediate,,,
14080,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,N,1,,CHEMBL627259,,50597,12582,,Urine,A,,,Intermediate,,,
14081,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,N,1,,CHEMBL627260,,50597,12582,,Urine,A,,,Intermediate,,,
14082,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,N,1,,CHEMBL623256,,50597,12582,,Urine,A,,,Intermediate,,,
14083,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,N,1,,CHEMBL874413,,50597,12582,,Urine,A,,,Intermediate,,,
14084,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,N,1,,CHEMBL623257,,50597,12582,,Urine,A,,,Intermediate,,,
14085,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,N,1,,CHEMBL623258,,50597,12582,,Urine,A,,,Intermediate,,,
14086,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,N,1,,CHEMBL623259,,50597,12582,,Urine,A,,,Intermediate,,,
14087,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,N,1,,CHEMBL623260,,50597,12582,,Urine,A,,,Intermediate,,,
14088,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,N,1,,CHEMBL623261,,50597,12582,,Urine,A,,,Intermediate,,,
14089,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,N,1,,CHEMBL623262,,50597,12582,,Urine,A,,,Intermediate,,,
14090,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,N,1,,CHEMBL623263,,50597,12582,,Urine,A,,,Intermediate,,,
14091,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,N,1,,CHEMBL623264,,50597,12582,,Urine,A,,,Intermediate,,,
14092,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1088.0,N,1,,CHEMBL623265,,50597,12582,,Urine,A,,,Intermediate,,,
14093,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,N,1,,CHEMBL623266,,50597,12582,,Urine,A,,,Intermediate,,,
14094,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,N,1,,CHEMBL623267,,50597,12582,,Urine,A,,,Intermediate,,,
14095,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,N,1,,CHEMBL623268,,50597,12582,,Urine,A,,,Intermediate,,,
14096,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,N,1,,CHEMBL623269,,50597,12582,,Urine,A,,,Intermediate,,,
14097,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,N,1,,CHEMBL623270,,50597,12582,,Urine,A,,,Intermediate,,,
14098,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1088.0,N,1,,CHEMBL623271,,50597,12582,,Urine,A,,,Intermediate,,,
14099,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,N,1,,CHEMBL623272,,50597,12582,,Urine,A,,,Intermediate,,,
14100,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,N,1,,CHEMBL623273,,50597,12582,,Urine,A,,,Intermediate,,,
14101,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,N,1,,CHEMBL623274,,50597,12582,,Urine,A,,,Intermediate,,,
14102,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,N,1,,CHEMBL874414,,50597,12582,,Urine,A,,,Intermediate,,,
14103,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,N,1,,CHEMBL623275,,50597,12582,,Urine,A,,,Intermediate,,,
14104,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,N,1,,CHEMBL629150,,50597,12582,,Urine,A,,,Intermediate,,,
14105,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL623276,,50597,12582,,Urine,A,,,Intermediate,,,
14106,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,N,1,,CHEMBL623277,,50597,12582,,Urine,A,,,Intermediate,,,
14107,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,N,1,,CHEMBL623112,,50597,12582,,Urine,A,,,Intermediate,,,
14108,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,N,1,,CHEMBL623113,,50597,12582,,Urine,A,,,Intermediate,,,
14109,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,N,1,,CHEMBL623800,,50597,12582,,Urine,A,,,Intermediate,,,
14110,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,N,1,,CHEMBL623801,,50597,12582,,Urine,A,,,Intermediate,,,
14111,BAO_0000218,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,N,1,,CHEMBL623802,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14112,BAO_0000218,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,N,1,,CHEMBL623803,In vivo,50597,12017,,Uterus,A,,,Intermediate,,,
14113,BAO_0000218,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,N,1,,CHEMBL623970,In vivo,50597,12017,,Uterus,A,,,Intermediate,,,
14114,BAO_0000218,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,N,1,,CHEMBL623971,In vivo,50597,12017,,Uterus,A,,,Intermediate,,,
14115,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),178.0,N,1,,CHEMBL623972,In vivo,50597,14045,,Blood,A,,,Intermediate,,,
14116,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),178.0,N,1,,CHEMBL623973,In vivo,50597,14045,,Blood,A,,,Intermediate,,,
14117,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),178.0,N,1,,CHEMBL623974,In vivo,50597,14045,,Blood,A,,,Intermediate,,,
14118,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),178.0,N,1,,CHEMBL623975,In vivo,50597,14045,,Blood,A,,,Intermediate,,,
14119,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),955.0,N,1,,CHEMBL623976,In vivo,50597,14045,,Brain,A,,,Intermediate,,,
14120,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),955.0,N,1,,CHEMBL623977,In vivo,50597,14045,,Brain,A,,,Intermediate,,,
14121,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),955.0,N,1,,CHEMBL623978,In vivo,50597,14045,,Brain,A,,,Intermediate,,,
14122,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),955.0,N,1,,CHEMBL623979,In vivo,50597,14045,,Brain,A,,,Intermediate,,,
14123,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,N,1,,CHEMBL623980,In vivo,50597,14045,,,A,,,Intermediate,,,
14124,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,N,1,,CHEMBL623981,In vivo,50597,14045,,,A,,,Intermediate,,,
14125,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,N,1,,CHEMBL626278,In vivo,50597,14045,,,A,,,Intermediate,,,
14126,BAO_0000218,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,N,1,,CHEMBL626279,In vivo,50597,14045,,,A,,,Intermediate,,,
14127,BAO_0000218,Biodistribution in mice bladder plus excreted urine was determined,,N,1,,CHEMBL626280,In vivo,50594,14045,,,A,,,Intermediate,,,
14128,BAO_0000218,"Percentage biodistribution in mouse blood, 10 minutes post injection",,N,1,,CHEMBL626281,,50594,14045,,,A,,,Intermediate,,,
14129,BAO_0000218,"Percentage biodistribution in mouse blood, 30 minutes post injection",,N,1,,CHEMBL626282,,50594,14045,,,A,,,Intermediate,,,
14130,BAO_0000218,"Percentage biodistribution in mouse blood, 5 minutes post injection",,N,1,,CHEMBL626283,,50594,14045,,,A,,,Intermediate,,,
14131,BAO_0000218,"Percentage biodistribution in mouse blood, 60 minutes post injection",,N,1,,CHEMBL626284,,50594,14045,,,A,,,Intermediate,,,
14132,BAO_0000218,"Percentage biodistribution in mouse brain, 10 minutes post injection",955.0,N,1,,CHEMBL626285,,50594,14045,,Brain,A,,,Intermediate,,,
14133,BAO_0000218,"Percentage biodistribution in mouse brain, 30 minutes post injection",955.0,N,1,,CHEMBL626286,,50594,14045,,Brain,A,,,Intermediate,,,
14134,BAO_0000218,"Percentage biodistribution in mouse brain, 5 minutes post injection",955.0,N,1,,CHEMBL626287,,50594,14045,,Brain,A,,,Intermediate,,,
14135,BAO_0000218,"Percentage biodistribution in mouse brain, 60 minutes post injection",955.0,N,1,,CHEMBL626288,,50594,14045,,Brain,A,,,Intermediate,,,
14136,BAO_0000218,"Percentage biodistribution in mouse heart, 10 minutes post injection",,N,1,,CHEMBL626289,,50594,14045,,,A,,,Intermediate,,,
14137,BAO_0000218,"Percentage biodistribution in mouse heart, 30 minutes post injection",,N,1,,CHEMBL626290,,50594,14045,,,A,,,Intermediate,,,
14138,BAO_0000218,"Percentage biodistribution in mouse heart, 5 minutes post injection",,N,1,,CHEMBL626291,,50594,14045,,,A,,,Intermediate,,,
14139,BAO_0000218,"Percentage biodistribution in mouse heart, 60 minutes post injection",,N,1,,CHEMBL839888,,50594,14045,,,A,,,Intermediate,,,
14140,BAO_0000218,"Percentage biodistribution in mouse intestine, 10 minutes post injection",160.0,N,1,,CHEMBL626292,,50594,14045,,Intestine,A,,,Intermediate,,,
14141,BAO_0000218,"Percentage biodistribution in mouse intestine, 30 minutes post injection",160.0,N,1,,CHEMBL626293,,50594,14045,,Intestine,A,,,Intermediate,,,
14142,BAO_0000218,"Percentage biodistribution in mouse intestine, 5 minutes post injection",160.0,N,1,,CHEMBL626294,,50594,14045,,Intestine,A,,,Intermediate,,,
14143,BAO_0000218,"Percentage biodistribution in mouse intestine, 60 minutes post injection",160.0,N,1,,CHEMBL626295,,50594,14045,,Intestine,A,,,Intermediate,,,
14144,BAO_0000218,"Percentage biodistribution in mouse liver, 10 minutes post injection",2107.0,N,1,,CHEMBL627659,,50594,14045,,Liver,A,,,Intermediate,,,
14145,BAO_0000218,"Percentage biodistribution in mouse liver, 30 minutes of post injection",2107.0,N,1,,CHEMBL627660,,50594,14045,,Liver,A,,,Intermediate,,,
14146,BAO_0000218,"Percentage biodistribution in mouse liver, 5 minutes post injection",2107.0,N,1,,CHEMBL627661,,50594,14045,,Liver,A,,,Intermediate,,,
14147,BAO_0000218,Biodistribution in mice liver at 60 minutes of post injection,2107.0,N,1,,CHEMBL627662,In vivo,50594,14045,,Liver,A,,,Intermediate,,,
14148,BAO_0000218,Biodistribution in mice lungs at 10 min of post injection,2048.0,N,1,,CHEMBL627663,In vivo,50594,14045,,Lung,A,,,Intermediate,,,
14149,BAO_0000218,"Percentage biodistribution in mouse lung, 30 minutes post injection",,N,1,,CHEMBL627664,,50594,14045,,,A,,,Intermediate,,,
14150,BAO_0000218,"Percentage biodistribution in mousee lung, 5 minutes post injection",,N,1,,CHEMBL627665,,50594,14045,,,A,,,Intermediate,,,
14151,BAO_0000218,Biodistribution in mice lungs at 60 min of post injection,2048.0,N,1,,CHEMBL627666,In vivo,50594,14045,,Lung,A,,,Intermediate,,,
14152,BAO_0000218,Percentage biodistribution in mouse spleen,2106.0,N,1,,CHEMBL627667,,50594,14045,,Spleen,A,,,Intermediate,,,
14153,BAO_0000218,Percentage biodistribution in mouse stomach,945.0,N,1,,CHEMBL627668,,50594,14045,,Stomach,A,,,Intermediate,,,
14154,BAO_0000218,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1088.0,N,1,,CHEMBL627669,,50594,11745,,Urine,A,,,Intermediate,,,
14155,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,1255.0,U,1,,CHEMBL627670,In vivo,22224,13257,,Urinary bladder,A,,,Autocuration,,,
14156,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,178.0,U,1,,CHEMBL627671,In vivo,22224,13257,,Blood,A,,,Autocuration,,,
14157,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,1474.0,U,1,,CHEMBL627672,In vivo,22224,13257,,Bone element,A,,,Autocuration,,,
14158,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,U,1,,CHEMBL627673,In vivo,22224,13257,,,A,,,Autocuration,,,
14159,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,2113.0,U,1,,CHEMBL627674,In vivo,22224,13257,,Kidney,A,,,Autocuration,,,
14160,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,2107.0,U,1,,CHEMBL627675,In vivo,22224,13257,,Liver,A,,,Autocuration,,,
14161,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,2048.0,U,1,,CHEMBL627676,In vivo,22224,13257,,Lung,A,,,Autocuration,,,
14162,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,2385.0,U,1,,CHEMBL627677,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14163,BAO_0000019,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL627678,,22224,8354,,,A,,,Autocuration,,,
14164,BAO_0000218,Affinity for protein binding expressed as association constant in fresh rat serum,1977.0,N,1,,CHEMBL627679,,50597,7095,,Serum,A,,,Intermediate,,,
14165,BAO_0000019,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,U,1,,CHEMBL627680,,22224,12185,,,A,,,Autocuration,,,
14166,BAO_0000019,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,U,1,,CHEMBL627681,,22224,12185,,,A,,,Autocuration,,,
14167,BAO_0000019,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,U,1,,CHEMBL627682,,22224,12185,,,A,,,Autocuration,,,
14168,BAO_0000019,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,U,1,,CHEMBL627683,,22224,12185,,,A,,,Autocuration,,,
14169,BAO_0000019,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,U,1,,CHEMBL627684,,22224,12686,,,A,,,Autocuration,,,
14170,BAO_0000019,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,U,1,,CHEMBL874441,,22224,12686,,,A,,,Autocuration,,,
14171,BAO_0000019,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,U,1,,CHEMBL627685,,22224,12686,,,A,,,Autocuration,,,
14172,BAO_0000019,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,U,1,,CHEMBL627686,,22224,12686,,,A,,,Autocuration,,,
14173,BAO_0000019,Apparent rate constant Koff for inactivation of dTMP synthase.,,U,1,,CHEMBL627687,,22224,8057,,,A,,,Autocuration,,,
14174,BAO_0000019,The irreversible inhibitor activity by second order rate equation.,,U,1,,CHEMBL627688,,22224,15778,,,A,,,Autocuration,,,
14175,BAO_0000218,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,N,1,,CHEMBL628038,,50597,12375,,,A,,,Intermediate,,,
14176,BAO_0000218,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,N,1,,CHEMBL628039,,50597,12375,,,A,,,Intermediate,,,
14177,BAO_0000218,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,N,1,,CHEMBL628040,,50597,12375,,,A,,,Intermediate,,,
14178,BAO_0000019,Dissociation rate calculated from the first-order equation using t1/2 value,,U,1,,CHEMBL628041,,22224,13588,,,A,,,Autocuration,,,
14179,BAO_0000019,The compound was tested for Binding constant against DNA,,U,1,,CHEMBL630226,,22224,15039,,,A,,,Autocuration,,,
14180,BAO_0000019,First order rate constant for cyclization of the compound,,U,1,,CHEMBL628042,,22224,9500,,,A,,,Autocuration,,,
14181,BAO_0000019,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,U,1,,CHEMBL625232,,22224,10014,,,A,,,Autocuration,,,
14182,BAO_0000019,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,U,1,,CHEMBL625233,,22224,10014,,,A,,,Autocuration,,,
14183,BAO_0000019,Hydrolysis rate constant was determined,,U,1,,CHEMBL625979,,22224,568,,,A,,,Autocuration,,,
14184,BAO_0000019,Observed first order rate constant,,U,1,,CHEMBL625980,,22224,10026,,,A,,,Autocuration,,,
14185,BAO_0000019,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,U,1,,CHEMBL625981,,22224,10281,,,A,,,Autocuration,,,
14186,BAO_0000019,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,U,1,,CHEMBL625982,,22224,10281,,,A,,,Autocuration,,,
14187,BAO_0000019,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,U,1,,CHEMBL625983,,22224,9680,,,A,,,Autocuration,,,
14188,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625984,,22224,13028,,,A,,,Autocuration,,,
14189,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625985,,22224,13028,,,A,,,Autocuration,,,
14190,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625986,,22224,13028,,,A,,,Autocuration,,,
14191,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625987,,22224,13028,,,A,,,Autocuration,,,
14192,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625988,,22224,13028,,,A,,,Autocuration,,,
14193,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625989,,22224,13028,,,A,,,Autocuration,,,
14194,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625990,,22224,13028,,,A,,,Autocuration,,,
14195,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625991,,22224,13028,,,A,,,Autocuration,,,
14196,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625992,,22224,13028,,,A,,,Autocuration,,,
14197,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL625993,,22224,13028,,,A,,,Autocuration,,,
14198,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL631973,,22224,13028,,,A,,,Autocuration,,,
14199,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632143,,22224,13028,,,A,,,Autocuration,,,
14200,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632144,,22224,13028,,,A,,,Autocuration,,,
14201,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632145,,22224,13028,,,A,,,Autocuration,,,
14202,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632146,,22224,13028,,,A,,,Autocuration,,,
14203,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632147,,22224,13028,,,A,,,Autocuration,,,
14204,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632148,,22224,13028,,,A,,,Autocuration,,,
14205,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632149,,22224,13028,,,A,,,Autocuration,,,
14206,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632150,,22224,13028,,,A,,,Autocuration,,,
14207,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL632151,,22224,13028,,,A,,,Autocuration,,,
14208,BAO_0000218,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,N,1,,CHEMBL632152,,50587,3008,,,A,,,Intermediate,,,
14209,BAO_0000218,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,N,1,,CHEMBL632153,,50587,4509,,,A,,,Intermediate,,,
14210,BAO_0000218,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,N,1,,CHEMBL632154,,50587,4509,,,A,,,Intermediate,,,
14211,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,N,1,,CHEMBL632155,,50602,8613,,,A,,,Intermediate,,,
14212,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,N,1,,CHEMBL632156,,50602,8613,,,A,,,Intermediate,,,
14213,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,N,1,,CHEMBL632157,,50602,8613,,,A,,,Intermediate,,,
14214,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,N,1,,CHEMBL632158,,50602,8613,,,A,,,Intermediate,,,
14215,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,N,1,,CHEMBL632159,,50602,8613,,,A,,,Intermediate,,,
14216,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,N,1,,CHEMBL626305,,50602,8613,,,A,,,Intermediate,,,
14217,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,N,1,,CHEMBL626306,,50602,8613,,,A,,,Intermediate,,,
14218,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,N,1,,CHEMBL626307,,50602,8613,,,A,,,Intermediate,,,
14219,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,N,1,,CHEMBL626308,,50602,8613,,,A,,,Intermediate,,,
14220,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,N,1,,CHEMBL626479,,50602,8613,,,A,,,Intermediate,,,
14221,BAO_0000218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,N,1,,CHEMBL626480,,50602,8613,,,A,,,Intermediate,,,
14222,BAO_0000100,Calculated partition coefficient (clogP) (MlogP),,U,1,,CHEMBL626481,,22229,6021,,,P,,,Autocuration,,,
14223,BAO_0000019,Equipotent potent ratio relative to carbachol (nicotinic activity),,U,1,,CHEMBL626482,,22224,9348,,,A,,,Autocuration,,,
14224,BAO_0000218,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,N,1,,CHEMBL626483,,50588,15592,,,A,,,Intermediate,,,
14225,BAO_0000218,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,N,1,,CHEMBL626484,,50588,15592,,,A,,,Intermediate,,,
14226,BAO_0000100,Solubility at pH 7.4 in micro g/mL;NA denotes available,,U,1,,CHEMBL626485,,22229,15592,,,P,,,Autocuration,,,
14227,BAO_0000100,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,U,1,,CHEMBL626486,,22229,15592,,,P,,,Autocuration,,,
14228,BAO_0000100,Solubility at pH 7.4 in ug/mL;NA denotes not available,,U,1,,CHEMBL626487,,22229,15592,,,P,,,Autocuration,,,
14229,BAO_0000218,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,N,1,,CHEMBL626488,In vivo,50588,15592,,Plasma,A,,,Intermediate,,,
14230,BAO_0000218,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1977.0,N,1,,CHEMBL626489,,50597,7095,,Serum,A,,,Intermediate,,,
14231,BAO_0000019,Area under the MAP curve measured over 5 min; ND means Not determined,,U,1,,CHEMBL626490,,22224,16618,,,A,,,Autocuration,,,
14232,BAO_0000100,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,U,1,,CHEMBL626491,,22224,16835,,,P,,,Autocuration,,,
14233,BAO_0000100,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,U,1,,CHEMBL626492,,22229,15284,,,P,,,Autocuration,,,
14234,BAO_0000019,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,U,1,,CHEMBL626493,,22224,15750,,,A,,,Autocuration,,,
14235,BAO_0000218,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,N,1,,CHEMBL626494,In vivo,50597,16618,,,A,,,Intermediate,,,
14236,BAO_0000218,Half life after oral tested,,U,1,,CHEMBL626495,In vivo,22224,16618,,,A,,,Autocuration,,,
14237,BAO_0000218,Half life was determined in plasma of rat; NT indicates not tested,1969.0,N,1,,CHEMBL626496,,50597,15812,,Plasma,A,,,Intermediate,,,
14238,BAO_0000218,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,N,1,,CHEMBL626497,In vivo,50597,16618,,,A,,,Intermediate,,,
14239,BAO_0000218,Oral bioavailability after oral tested,,U,1,,CHEMBL626498,In vivo,22224,16618,,,A,,,Autocuration,,,
14240,BAO_0000218,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,N,1,,CHEMBL626499,,50597,13098,,,A,,,Intermediate,,,
14241,BAO_0000218,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,N,1,,CHEMBL626500,,50597,13098,,,A,,,Intermediate,,,
14242,BAO_0000218,half life was determined in plasma of rat; NT indicates not tested,1969.0,N,1,,CHEMBL626501,,50597,15812,,Plasma,A,,,Intermediate,,,
14243,BAO_0000218,half life was determined in plasma of rat; NT means not tested,1969.0,N,1,,CHEMBL626502,,50597,15812,,Plasma,A,,,Intermediate,,,
14244,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,N,1,,CHEMBL626503,,50597,11510,,,A,,,Intermediate,,,
14245,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,N,1,,CHEMBL626504,,50597,11510,,,A,,,Intermediate,,,
14246,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,N,1,,CHEMBL626505,,50597,11510,,,A,,,Intermediate,,,
14247,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,N,1,,CHEMBL626506,,50597,11510,,,A,,,Intermediate,,,
14248,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,N,1,,CHEMBL626507,,50597,11510,,,A,,,Intermediate,,,
14249,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,N,1,,CHEMBL626508,,50597,11510,,,A,,,Intermediate,,,
14250,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,N,1,,CHEMBL626509,,50597,11510,,,A,,,Intermediate,,,
14251,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,N,1,,CHEMBL875480,,50597,11510,,,A,,,Intermediate,,,
14252,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,N,1,,CHEMBL626510,,50597,11510,,,A,,,Intermediate,,,
14253,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,N,1,,CHEMBL626511,,50597,11510,,,A,,,Intermediate,,,
14254,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,N,1,,CHEMBL626512,,50597,11510,,,A,,,Intermediate,,,
14255,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,N,1,,CHEMBL628208,,50597,11510,,,A,,,Intermediate,,,
14256,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,N,1,,CHEMBL628209,,50597,11510,,,A,,,Intermediate,,,
14257,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,N,1,,CHEMBL628210,,50597,11510,,,A,,,Intermediate,,,
14258,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,N,1,,CHEMBL628211,,50597,11510,,,A,,,Intermediate,,,
14259,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,N,1,,CHEMBL628212,,50597,11510,,,A,,,Intermediate,,,
14260,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,N,1,,CHEMBL628213,,50597,11510,,,A,,,Intermediate,,,
14261,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,N,1,,CHEMBL628214,,50597,12582,,Urine,A,,,Intermediate,,,
14262,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,N,1,,CHEMBL628215,,50597,12582,,Urine,A,,,Intermediate,,,
14263,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,N,1,,CHEMBL628216,,50597,12582,,Urine,A,,,Intermediate,,,
14264,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,N,1,,CHEMBL626595,,50597,12582,,Urine,A,,,Intermediate,,,
14265,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,N,1,,CHEMBL626596,,50597,12582,,Urine,A,,,Intermediate,,,
14266,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,N,1,,CHEMBL626597,,50597,12582,,Urine,A,,,Intermediate,,,
14267,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,N,1,,CHEMBL626598,,50597,12582,,Urine,A,,,Intermediate,,,
14268,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,N,1,,CHEMBL622242,,50597,12582,,Urine,A,,,Intermediate,,,
14269,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,N,1,,CHEMBL622243,,50597,12582,,Urine,A,,,Intermediate,,,
14270,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,N,1,,CHEMBL622244,,50597,12582,,Urine,A,,,Intermediate,,,
14271,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,N,1,,CHEMBL622245,,50597,12582,,Urine,A,,,Intermediate,,,
14272,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,N,1,,CHEMBL622246,,50597,12582,,Urine,A,,,Intermediate,,,
14273,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,N,1,,CHEMBL622247,,50597,12582,,Urine,A,,,Intermediate,,,
14274,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,N,1,,CHEMBL622248,,50597,12582,,Urine,A,,,Intermediate,,,
14275,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,N,1,,CHEMBL877483,,50597,12582,,Urine,A,,,Intermediate,,,
14276,BAO_0000218,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,N,1,,CHEMBL622249,,50597,12582,,Urine,A,,,Intermediate,,,
14277,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,N,1,,CHEMBL622250,,50588,12582,,Urine,A,,,Intermediate,,,
14278,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,N,1,,CHEMBL622251,,50588,12582,,Urine,A,,,Intermediate,,,
14279,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,N,1,,CHEMBL622252,,50588,12582,,Urine,A,,,Intermediate,,,
14280,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,N,1,,CHEMBL622253,,50588,12582,,Urine,A,,,Intermediate,,,
14281,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,N,1,,CHEMBL622254,,50588,12582,,Urine,A,,,Intermediate,,,
14282,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL622255,,50588,12582,,Urine,A,,,Intermediate,,,
14283,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,N,1,,CHEMBL622256,,50588,12582,,Urine,A,,,Intermediate,,,
14284,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,N,1,,CHEMBL622257,,50588,12582,,Urine,A,,,Intermediate,,,
14285,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,N,1,,CHEMBL622258,,50588,12582,,Urine,A,,,Intermediate,,,
14286,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,N,1,,CHEMBL622259,,50588,12582,,Urine,A,,,Intermediate,,,
14287,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,N,1,,CHEMBL622927,,50588,12582,,Urine,A,,,Intermediate,,,
14288,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,N,1,,CHEMBL622928,,50588,12582,,Urine,A,,,Intermediate,,,
14289,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,N,1,,CHEMBL622929,,50588,12582,,Urine,A,,,Intermediate,,,
14290,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1088.0,N,1,,CHEMBL623182,,50588,12582,,Urine,A,,,Intermediate,,,
14291,BAO_0000218,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,N,1,,CHEMBL623183,,50588,12582,,Urine,A,,,Intermediate,,,
14292,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,N,1,,CHEMBL623184,,50597,12582,,Urine,A,,,Intermediate,,,
14293,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,N,1,,CHEMBL623185,,50597,12582,,Urine,A,,,Intermediate,,,
14294,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,N,1,,CHEMBL877484,,50597,12582,,Urine,A,,,Intermediate,,,
14295,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627274,,50597,12582,,Urine,A,,,Intermediate,,,
14296,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,N,1,,CHEMBL623186,,50597,12582,,Urine,A,,,Intermediate,,,
14297,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,N,1,,CHEMBL623187,,50597,12582,,Urine,A,,,Intermediate,,,
14298,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,N,1,,CHEMBL623188,,50597,12582,,Urine,A,,,Intermediate,,,
14299,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,N,1,,CHEMBL628055,,50597,12582,,Urine,A,,,Intermediate,,,
14300,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,N,1,,CHEMBL628056,,50597,12582,,Urine,A,,,Intermediate,,,
14301,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,N,1,,CHEMBL628200,,50597,12582,,Urine,A,,,Intermediate,,,
14302,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,N,1,,CHEMBL628201,,50597,12582,,Urine,A,,,Intermediate,,,
14303,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,N,1,,CHEMBL628202,,50597,12582,,Urine,A,,,Intermediate,,,
14304,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,N,1,,CHEMBL628203,,50597,12582,,Urine,A,,,Intermediate,,,
14305,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,N,1,,CHEMBL628204,,50597,12582,,Urine,A,,,Intermediate,,,
14306,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,N,1,,CHEMBL628205,,50597,12582,,Urine,A,,,Intermediate,,,
14307,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,N,1,,CHEMBL628206,,50597,12582,,Urine,A,,,Intermediate,,,
14308,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),2367.0,U,1,,CHEMBL628207,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14309,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,2367.0,U,1,,CHEMBL627220,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14310,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,2385.0,U,1,,CHEMBL627221,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14311,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),2367.0,U,1,,CHEMBL627222,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14312,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,U,1,,CHEMBL627223,In vivo,22224,13257,,,A,,,Autocuration,,,
14313,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,2385.0,U,1,,CHEMBL632062,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14314,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,2106.0,U,1,,CHEMBL632063,In vivo,22224,13257,,Spleen,A,,,Autocuration,,,
14315,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,1255.0,U,1,,CHEMBL632064,In vivo,22224,13257,,Urinary bladder,A,,,Autocuration,,,
14316,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,178.0,U,1,,CHEMBL632065,In vivo,22224,13257,,Blood,A,,,Autocuration,,,
14317,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,1474.0,U,1,,CHEMBL632066,In vivo,22224,13257,,Bone element,A,,,Autocuration,,,
14318,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,U,1,,CHEMBL632067,In vivo,22224,13257,,,A,,,Autocuration,,,
14319,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,2113.0,U,1,,CHEMBL629188,In vivo,22224,13257,,Kidney,A,,,Autocuration,,,
14320,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,2107.0,U,1,,CHEMBL629189,In vivo,22224,13257,,Liver,A,,,Autocuration,,,
14321,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,2048.0,U,1,,CHEMBL629190,In vivo,22224,13257,,Lung,A,,,Autocuration,,,
14322,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,2385.0,U,1,,CHEMBL629191,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14323,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),2367.0,U,1,,CHEMBL629192,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14324,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,2385.0,U,1,,CHEMBL629193,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14325,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),2367.0,U,1,,CHEMBL629194,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14326,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,U,1,,CHEMBL629195,In vivo,22224,13257,,,A,,,Autocuration,,,
14327,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,2385.0,U,1,,CHEMBL629373,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14328,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,2106.0,U,1,,CHEMBL629374,In vivo,22224,13257,,Spleen,A,,,Autocuration,,,
14329,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,2367.0,U,1,,CHEMBL629375,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14330,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,1255.0,U,1,,CHEMBL629376,In vivo,22224,13257,,Urinary bladder,A,,,Autocuration,,,
14331,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,178.0,U,1,,CHEMBL629377,In vivo,22224,13257,,Blood,A,,,Autocuration,,,
14332,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,1474.0,U,1,,CHEMBL629378,In vivo,22224,13257,,Bone element,A,,,Autocuration,,,
14333,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,U,1,,CHEMBL629379,In vivo,22224,13257,,,A,,,Autocuration,,,
14334,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,2113.0,U,1,,CHEMBL629151,In vivo,22224,13257,,Kidney,A,,,Autocuration,,,
14335,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,2107.0,U,1,,CHEMBL629152,In vivo,22224,13257,,Liver,A,,,Autocuration,,,
14336,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,2048.0,U,1,,CHEMBL629153,In vivo,22224,13257,,Lung,A,,,Autocuration,,,
14337,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,2385.0,U,1,,CHEMBL629154,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14338,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),2367.0,U,1,,CHEMBL629155,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14339,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,2367.0,U,1,,CHEMBL629156,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14340,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,2385.0,U,1,,CHEMBL629157,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14341,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),2367.0,U,1,,CHEMBL629158,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14342,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,U,1,,CHEMBL629159,In vivo,22224,13257,,,A,,,Autocuration,,,
14343,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,2385.0,U,1,,CHEMBL629160,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14344,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,2106.0,U,1,,CHEMBL629161,In vivo,22224,13257,,Spleen,A,,,Autocuration,,,
14345,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,1255.0,U,1,,CHEMBL629162,In vivo,22224,13257,,Urinary bladder,A,,,Autocuration,,,
14346,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,178.0,U,1,,CHEMBL629163,In vivo,22224,13257,,Blood,A,,,Autocuration,,,
14347,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,1474.0,U,1,,CHEMBL629164,In vivo,22224,13257,,Bone element,A,,,Autocuration,,,
14348,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,U,1,,CHEMBL629165,In vivo,22224,13257,,,A,,,Autocuration,,,
14349,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,2107.0,U,1,,CHEMBL629166,In vivo,22224,13257,,Liver,A,,,Autocuration,,,
14350,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,2048.0,U,1,,CHEMBL629167,In vivo,22224,13257,,Lung,A,,,Autocuration,,,
14351,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,2385.0,U,1,,CHEMBL629168,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14352,BAO_0000019,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,U,1,,CHEMBL629169,,22224,2193,,,A,,,Autocuration,,,
14353,BAO_0000019,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,U,1,,CHEMBL629170,,22224,2193,,,A,,,Autocuration,,,
14354,BAO_0000019,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,U,1,,CHEMBL631153,,22224,2193,,,A,,,Autocuration,,,
14355,BAO_0000019,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,U,1,,CHEMBL875121,,22224,2193,,,A,,,Autocuration,,,
14356,BAO_0000019,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,U,1,,CHEMBL631154,,22224,2193,,,A,,,Autocuration,,,
14357,BAO_0000019,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,U,1,,CHEMBL631155,,22224,2193,,,A,,,Autocuration,,,
14358,BAO_0000019,Hydrolysis rate constant was determined,,U,1,,CHEMBL631156,,22224,568,,,A,,,Autocuration,,,
14359,BAO_0000019,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,U,1,,CHEMBL631157,,22224,9680,,,A,,,Autocuration,,,
14360,BAO_0000019,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,U,1,,CHEMBL631158,,22224,9680,,,A,,,Autocuration,,,
14361,BAO_0000019,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,U,1,,CHEMBL631159,,22224,9680,,,A,,,Autocuration,,,
14362,BAO_0000019,Observed second order rate constant,,U,1,,CHEMBL631160,,22224,10026,,,A,,,Autocuration,,,
14363,BAO_0000019,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,U,1,,CHEMBL631161,,22224,10281,,,A,,,Autocuration,,,
14364,BAO_0000019,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,U,1,,CHEMBL631162,,22224,10014,,,A,,,Autocuration,,,
14365,BAO_0000019,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,U,1,,CHEMBL630313,,22224,10014,,,A,,,Autocuration,,,
14366,BAO_0000019,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,U,1,,CHEMBL630314,,22224,9680,,,A,,,Autocuration,,,
14367,BAO_0000019,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,U,1,,CHEMBL630315,,22224,9680,,,A,,,Autocuration,,,
14368,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630316,,22224,13028,,,A,,,Autocuration,,,
14369,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630986,,22224,13028,,,A,,,Autocuration,,,
14370,BAO_0000019,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630987,,22224,13028,,,A,,,Autocuration,,,
14371,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630988,,22224,13028,,,A,,,Autocuration,,,
14372,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630989,,22224,13028,,,A,,,Autocuration,,,
14373,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630990,,22224,13028,,,A,,,Autocuration,,,
14374,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630991,,22224,13028,,,A,,,Autocuration,,,
14375,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630992,,22224,13028,,,A,,,Autocuration,,,
14376,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630993,,22224,13028,,,A,,,Autocuration,,,
14377,BAO_0000019,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,1,,CHEMBL630994,,22224,13028,,,A,,,Autocuration,,,
14378,BAO_0000218,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,N,1,,CHEMBL630995,,50597,10014,,,A,,,Intermediate,,,
14379,BAO_0000019,Association constant for compound at 31 degree C was determined,,U,1,,CHEMBL629252,,22224,9962,,,A,,,Autocuration,,,
14380,BAO_0000019,Calculated antagonist equilibrium dissociation constant of the compound,,U,1,,CHEMBL629253,,22224,12029,,,A,,,Autocuration,,,
14381,BAO_0000019,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,U,1,,CHEMBL629944,,22224,12029,,,A,,,Autocuration,,,
14382,BAO_0000218,Dissociation constants vs LTE4 on guinea pig trachea,3126.0,N,1,,CHEMBL629945,,50512,10583,,Trachea,A,,,Intermediate,,,
14383,BAO_0000019,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,U,1,,CHEMBL629946,,22224,568,,,A,,,Autocuration,,,
14384,BAO_0000019,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,U,1,,CHEMBL629947,,22224,568,,,A,,,Autocuration,,,
14385,BAO_0000019,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,U,1,,CHEMBL629948,,22224,568,,,A,,,Autocuration,,,
14386,BAO_0000019,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,U,1,,CHEMBL856024,,22224,568,,,A,,,Autocuration,,,
14387,BAO_0000019,Affinity constant KD value was derived from TMP,,U,1,,CHEMBL629949,,22224,7493,,,A,,,Autocuration,,,
14388,BAO_0000019,Apparent dissociation (binding) rate constant was evaluated,,U,1,,CHEMBL629950,,22224,8371,,,A,,,Autocuration,,,
14389,BAO_0000100,Dissociation constant (KD) of the compound,,U,1,,CHEMBL630127,,22224,13114,,,P,,,Autocuration,,,
14390,BAO_0000100,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,U,1,,CHEMBL630128,,22224,15515,,,P,,,Autocuration,,,
14391,BAO_0000100,Dissociation constant from ESR titration experiments,,U,1,,CHEMBL630129,,22224,522,,,P,,,Autocuration,,,
14392,BAO_0000019,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,U,1,,CHEMBL630130,,22224,13888,,,,,,Autocuration,,,
14393,BAO_0000100,Dissociation constant was evaluated.,,U,1,,CHEMBL875234,,22224,2616,,,P,,,Autocuration,,,
14394,BAO_0000100,Dissociation constant was reported,,U,1,,CHEMBL630131,,22224,3798,,,P,,,Autocuration,,,
14395,BAO_0000218,Dissociation constant was determined in rat pituitary cells.,,N,1,,CHEMBL630132,,50597,8731,,,A,,,Intermediate,,,
14396,BAO_0000019,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,U,1,,CHEMBL630133,,22224,11892,,,A,,,Autocuration,,,
14397,BAO_0000019,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,U,1,,CHEMBL630134,,22224,11892,,,A,,,Autocuration,,,
14398,BAO_0000019,Equilibrium dissociation constant of the compound,,U,1,,CHEMBL630135,,22224,2582,,,A,,,Autocuration,,,
14399,BAO_0000019,Equilibrium dissociation constant was determined,,U,1,,CHEMBL630136,,22224,11892,,,A,,,Autocuration,,,
14400,BAO_0000019,Kinetic constant KD was evaluated,,U,1,,CHEMBL630137,,22224,13396,,,A,,,Autocuration,,,
14401,BAO_0000019,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,U,1,,CHEMBL630138,,22224,603,,,A,,,Autocuration,,,
14402,BAO_0000019,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,U,1,,CHEMBL630139,,22224,15673,,,A,,,Autocuration,,,
14403,BAO_0000019,Rate constant for hydrolysis in aqueous acetone.,,U,1,,CHEMBL630140,,22224,10368,,,A,,,Autocuration,,,
14404,BAO_0000019,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,U,1,,CHEMBL875235,,22224,14228,,,A,,,Autocuration,,,
14405,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,N,1,,CHEMBL876439,,50597,11510,,,A,,,Intermediate,,,
14406,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,N,1,,CHEMBL630605,,50597,11510,,,A,,,Intermediate,,,
14407,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,N,1,,CHEMBL630606,,50597,11510,,,A,,,Intermediate,,,
14408,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,N,1,,CHEMBL630607,,50597,11510,,,A,,,Intermediate,,,
14409,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,N,1,,CHEMBL630608,,50597,11510,,,A,,,Intermediate,,,
14410,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,N,1,,CHEMBL630609,,50597,11510,,,A,,,Intermediate,,,
14411,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,N,1,,CHEMBL630610,,50597,11510,,,A,,,Intermediate,,,
14412,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,N,1,,CHEMBL630611,,50597,11510,,,A,,,Intermediate,,,
14413,BAO_0000218,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,N,1,,CHEMBL629552,,50597,11510,,,A,,,Intermediate,,,
14414,BAO_0000218,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,N,1,,CHEMBL629733,,50597,11510,,,A,,,Intermediate,,,
14415,BAO_0000218,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,N,1,,CHEMBL629734,,50597,11510,,,A,,,Intermediate,,,
14416,BAO_0000218,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,N,1,,CHEMBL629735,,50597,11510,,,A,,,Intermediate,,,
14417,BAO_0000218,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,N,1,,CHEMBL629736,,50597,11510,,,A,,,Intermediate,,,
14418,BAO_0000218,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,N,1,,CHEMBL629737,,50597,11510,,,A,,,Intermediate,,,
14419,BAO_0000218,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,N,1,,CHEMBL629738,,50597,11510,,,A,,,Intermediate,,,
14420,BAO_0000218,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,N,1,,CHEMBL629739,,50597,11510,,,A,,,Intermediate,,,
14421,BAO_0000218,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,N,1,,CHEMBL629740,,50597,11510,,,A,,,Intermediate,,,
14422,BAO_0000218,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,N,1,,CHEMBL629741,,50597,11510,,,A,,,Intermediate,,,
14423,BAO_0000218,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,N,1,,CHEMBL629742,,50597,11510,,,A,,,Intermediate,,,
14424,BAO_0000218,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,N,1,,CHEMBL629743,,50597,11510,,,A,,,Intermediate,,,
14425,BAO_0000218,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,N,1,,CHEMBL629744,,50597,11510,,,A,,,Intermediate,,,
14426,BAO_0000218,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,N,1,,CHEMBL629745,,50597,11510,,,A,,,Intermediate,,,
14427,BAO_0000218,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,N,1,,CHEMBL629746,,50597,11510,,,A,,,Intermediate,,,
14428,BAO_0000218,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,N,1,,CHEMBL629747,,50597,11510,,,A,,,Intermediate,,,
14429,BAO_0000218,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,N,1,,CHEMBL629748,,50597,11510,,,A,,,Intermediate,,,
14430,BAO_0000218,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,N,1,,CHEMBL629749,,50597,11510,,,A,,,Intermediate,,,
14431,BAO_0000218,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,N,1,,CHEMBL629750,,50597,11510,,,A,,,Intermediate,,,
14432,BAO_0000218,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,N,1,,CHEMBL629751,,50597,11510,,,A,,,Intermediate,,,
14433,BAO_0000218,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,N,1,,CHEMBL629752,,50597,11510,,,A,,,Intermediate,,,
14434,BAO_0000218,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,N,1,,CHEMBL629753,,50597,11510,,,A,,,Intermediate,,,
14435,BAO_0000218,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,N,1,,CHEMBL629754,,50597,11510,,,A,,,Intermediate,,,
14436,BAO_0000218,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,N,1,,CHEMBL629755,,50597,11510,,,A,,,Intermediate,,,
14437,BAO_0000218,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,N,1,,CHEMBL629756,,50597,11510,,,A,,,Intermediate,,,
14438,BAO_0000218,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,N,1,,CHEMBL629757,,50597,11510,,,A,,,Intermediate,,,
14439,BAO_0000218,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,N,1,,CHEMBL629758,,50597,11510,,,A,,,Intermediate,,,
14440,BAO_0000218,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,N,1,,CHEMBL629759,,50597,11510,,,A,,,Intermediate,,,
14441,BAO_0000218,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,N,1,,CHEMBL629760,,50597,11510,,,A,,,Intermediate,,,
14442,BAO_0000218,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,N,1,,CHEMBL876443,,50597,11510,,,A,,,Intermediate,,,
14443,BAO_0000218,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,N,1,,CHEMBL629761,,50588,8310,,,A,,,Intermediate,,,
14444,BAO_0000218,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,N,1,,CHEMBL629762,,50588,8310,,,A,,,Intermediate,,,
14445,BAO_0000218,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,1,,CHEMBL629763,,50594,8310,,,A,,,Intermediate,,,
14446,BAO_0000218,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,N,1,,CHEMBL629764,,50594,8310,,,A,,,Intermediate,,,
14447,BAO_0000218,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,N,1,,CHEMBL629765,,50594,8310,,,A,,,Intermediate,,,
14448,BAO_0000218,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,N,1,,CHEMBL629766,,50594,8310,,,A,,,Intermediate,,,
14449,BAO_0000218,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,1,,CHEMBL629767,,50594,8310,,,A,,,Intermediate,,,
14450,BAO_0000218,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,N,1,,CHEMBL629768,,50588,8310,,,A,,,Intermediate,,,
14451,BAO_0000218,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,N,1,,CHEMBL629769,,50594,8310,,,A,,,Intermediate,,,
14452,BAO_0000218,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,N,1,,CHEMBL629770,,50588,8310,,,A,,,Intermediate,,,
14453,BAO_0000218,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,N,1,,CHEMBL629771,,50588,8310,,,A,,,Intermediate,,,
14454,BAO_0000218,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,1,,CHEMBL629772,,50594,8310,,,A,,,Intermediate,,,
14455,BAO_0000218,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,1,,CHEMBL629773,,50594,8310,,,A,,,Intermediate,,,
14456,BAO_0000218,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,N,1,,CHEMBL625455,,50594,8310,,,A,,,Intermediate,,,
14457,BAO_0000218,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,N,1,,CHEMBL625456,,50594,8310,,,A,,,Intermediate,,,
14458,BAO_0000218,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,N,1,,CHEMBL625457,,50594,8310,,,A,,,Intermediate,,,
14459,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,N,1,,CHEMBL625458,,50597,12582,,Urine,A,,,Intermediate,,,
14460,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,N,1,,CHEMBL625459,,50597,12582,,Urine,A,,,Intermediate,,,
14461,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,N,1,,CHEMBL875483,,50597,12582,,Urine,A,,,Intermediate,,,
14462,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,N,1,,CHEMBL634779,,50597,12582,,Urine,A,,,Intermediate,,,
14463,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,N,1,,CHEMBL625460,,50597,12582,,Urine,A,,,Intermediate,,,
14464,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,N,1,,CHEMBL626117,,50597,12582,,Urine,A,,,Intermediate,,,
14465,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,N,1,,CHEMBL626118,,50597,12582,,Urine,A,,,Intermediate,,,
14466,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,N,1,,CHEMBL628342,,50597,12582,,Urine,A,,,Intermediate,,,
14467,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,N,1,,CHEMBL628343,,50597,12582,,Urine,A,,,Intermediate,,,
14468,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1088.0,N,1,,CHEMBL628344,,50597,12582,,Urine,A,,,Intermediate,,,
14469,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,N,1,,CHEMBL628345,,50597,12582,,Urine,A,,,Intermediate,,,
14470,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,N,1,,CHEMBL628346,,50597,12582,,Urine,A,,,Intermediate,,,
14471,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,N,1,,CHEMBL628347,,50597,12582,,Urine,A,,,Intermediate,,,
14472,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,N,1,,CHEMBL628348,,50597,12582,,Urine,A,,,Intermediate,,,
14473,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,N,1,,CHEMBL628349,,50597,12582,,Urine,A,,,Intermediate,,,
14474,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1088.0,N,1,,CHEMBL875611,,50597,12582,,Urine,A,,,Intermediate,,,
14475,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,N,1,,CHEMBL628350,,50597,12582,,Urine,A,,,Intermediate,,,
14476,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,N,1,,CHEMBL628351,,50597,12582,,Urine,A,,,Intermediate,,,
14477,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,N,1,,CHEMBL628352,,50597,12582,,Urine,A,,,Intermediate,,,
14478,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,N,1,,CHEMBL628353,,50597,12582,,Urine,A,,,Intermediate,,,
14479,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,N,1,,CHEMBL628354,,50597,12582,,Urine,A,,,Intermediate,,,
14480,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,N,1,,CHEMBL626667,,50597,12582,,Urine,A,,,Intermediate,,,
14481,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL626668,,50597,12582,,Urine,A,,,Intermediate,,,
14482,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,N,1,,CHEMBL626669,,50597,12582,,Urine,A,,,Intermediate,,,
14483,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,N,1,,CHEMBL626670,,50597,12582,,Urine,A,,,Intermediate,,,
14484,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,N,1,,CHEMBL626671,,50597,12582,,Urine,A,,,Intermediate,,,
14485,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,N,1,,CHEMBL626672,,50597,12582,,Urine,A,,,Intermediate,,,
14486,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1088.0,N,1,,CHEMBL626673,,50597,12582,,Urine,A,,,Intermediate,,,
14487,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,N,1,,CHEMBL626674,,50597,12582,,Urine,A,,,Intermediate,,,
14488,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,N,1,,CHEMBL626675,,50597,12582,,Urine,A,,,Intermediate,,,
14489,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1088.0,N,1,,CHEMBL626676,,50597,12582,,Urine,A,,,Intermediate,,,
14490,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1088.0,N,1,,CHEMBL626677,,50597,12582,,Urine,A,,,Intermediate,,,
14491,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,N,1,,CHEMBL626678,,50597,12582,,Urine,A,,,Intermediate,,,
14492,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,N,1,,CHEMBL626679,,50597,12582,,Urine,A,,,Intermediate,,,
14493,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,N,1,,CHEMBL875612,,50597,12582,,Urine,A,,,Intermediate,,,
14494,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,N,1,,CHEMBL626680,,50597,12582,,Urine,A,,,Intermediate,,,
14495,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,N,1,,CHEMBL626681,,50597,12582,,Urine,A,,,Intermediate,,,
14496,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,N,1,,CHEMBL626682,,50597,12582,,Urine,A,,,Intermediate,,,
14497,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,N,1,,CHEMBL626683,,50597,12582,,Urine,A,,,Intermediate,,,
14498,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,N,1,,CHEMBL626684,,50597,12582,,Urine,A,,,Intermediate,,,
14499,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,N,1,,CHEMBL626685,,50597,12582,,Urine,A,,,Intermediate,,,
14500,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,N,1,,CHEMBL626686,,50597,12582,,Urine,A,,,Intermediate,,,
14501,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,N,1,,CHEMBL626687,,50597,12582,,Urine,A,,,Intermediate,,,
14502,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,N,1,,CHEMBL624978,,50597,12582,,Urine,A,,,Intermediate,,,
14503,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,N,1,,CHEMBL624979,,50597,12582,,Urine,A,,,Intermediate,,,
14504,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,N,1,,CHEMBL624980,,50597,12582,,Urine,A,,,Intermediate,,,
14505,BAO_0000218,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,N,1,,CHEMBL624981,,50597,12582,,Urine,A,,,Intermediate,,,
14506,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,N,1,,CHEMBL624982,,50588,12582,,Urine,A,,,Intermediate,,,
14507,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),2367.0,U,1,,CHEMBL627564,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14508,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),2367.0,U,1,,CHEMBL627565,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14509,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,U,1,,CHEMBL627566,In vivo,22224,13257,,,A,,,Autocuration,,,
14510,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,2385.0,U,1,,CHEMBL627567,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14511,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,2106.0,U,1,,CHEMBL627568,In vivo,22224,13257,,Spleen,A,,,Autocuration,,,
14512,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,2113.0,U,1,,CHEMBL627569,In vivo,22224,13257,,Kidney,A,,,Autocuration,,,
14513,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,1255.0,U,1,,CHEMBL627570,In vivo,22224,13257,,Urinary bladder,A,,,Autocuration,,,
14514,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,178.0,U,1,,CHEMBL627571,In vivo,22224,13257,,Blood,A,,,Autocuration,,,
14515,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,1474.0,U,1,,CHEMBL627572,In vivo,22224,13257,,Bone element,A,,,Autocuration,,,
14516,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,U,1,,CHEMBL627573,In vivo,22224,13257,,,A,,,Autocuration,,,
14517,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,2113.0,U,1,,CHEMBL627574,In vivo,22224,13257,,Kidney,A,,,Autocuration,,,
14518,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,2107.0,U,1,,CHEMBL627575,In vivo,22224,13257,,Liver,A,,,Autocuration,,,
14519,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,2048.0,U,1,,CHEMBL627576,In vivo,22224,13257,,Lung,A,,,Autocuration,,,
14520,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,2385.0,U,1,,CHEMBL627577,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14521,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),2367.0,U,1,,CHEMBL627578,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14522,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,2367.0,U,1,,CHEMBL627579,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14523,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,2385.0,U,1,,CHEMBL627580,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14524,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),2367.0,U,1,,CHEMBL627581,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14525,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,U,1,,CHEMBL627582,In vivo,22224,13257,,,A,,,Autocuration,,,
14526,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,2385.0,U,1,,CHEMBL627583,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14527,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,2106.0,U,1,,CHEMBL627584,In vivo,22224,13257,,Spleen,A,,,Autocuration,,,
14528,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,2367.0,U,1,,CHEMBL627585,In vivo,22224,13257,,Prostate gland,A,,,Autocuration,,,
14529,BAO_0000218,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,2385.0,U,1,,CHEMBL627586,In vivo,22224,13257,,Muscle tissue,A,,,Autocuration,,,
14530,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,N,1,,CHEMBL627587,In vivo,50597,15413,,,A,,,Intermediate,,,
14531,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,N,1,,CHEMBL627588,In vivo,50597,15413,,,A,,,Intermediate,,,
14532,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,N,1,,CHEMBL628250,In vivo,50597,15413,,,A,,,Intermediate,,,
14533,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,N,1,,CHEMBL628251,In vivo,50597,15413,,,A,,,Intermediate,,,
14534,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,10000000.0,N,1,,CHEMBL628252,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14535,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,N,1,,CHEMBL628253,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14536,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1898.0,N,1,,CHEMBL628254,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14537,BAO_0000218,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1898.0,N,1,,CHEMBL877493,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14538,BAO_0000218,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,N,1,,CHEMBL628255,In vivo,50597,15413,,,A,,,Intermediate,,,
14539,BAO_0000218,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,N,1,,CHEMBL628256,In vivo,50597,15413,,,A,,,Intermediate,,,
14540,BAO_0000218,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,N,1,,CHEMBL628257,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14541,BAO_0000218,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1898.0,N,1,,CHEMBL628258,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14542,BAO_0000218,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,N,1,,CHEMBL628259,In vivo,50597,15413,,,A,,,Intermediate,,,
14543,BAO_0000218,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,N,1,,CHEMBL628429,In vivo,50597,15413,,,A,,,Intermediate,,,
14544,BAO_0000218,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,N,1,,CHEMBL626862,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14545,BAO_0000218,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1898.0,N,1,,CHEMBL626863,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14546,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,2037.0,N,1,,CHEMBL625886,In vivo,50597,15413,,Cerebellum,A,,,Intermediate,,,
14547,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,2037.0,N,1,,CHEMBL625887,In vivo,50597,15413,,Cerebellum,A,,,Intermediate,,,
14548,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,N,1,,CHEMBL625888,In vivo,50597,15413,,,A,,,Intermediate,,,
14549,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,N,1,,CHEMBL625889,In vivo,50597,15413,,,A,,,Intermediate,,,
14550,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,10000000.0,N,1,,CHEMBL625890,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14551,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,10000000.0,N,1,,CHEMBL625891,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14552,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1898.0,N,1,,CHEMBL625892,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14553,BAO_0000218,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1898.0,N,1,,CHEMBL625893,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14554,BAO_0000218,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,2037.0,N,1,,CHEMBL625894,In vivo,50597,15413,,Cerebellum,A,,,Intermediate,,,
14555,BAO_0000218,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,N,1,,CHEMBL625895,In vivo,50597,15413,,,A,,,Intermediate,,,
14556,BAO_0000019,Reaction rate parameter value for phosphate with transfer with respect to ATP,,U,1,,CHEMBL625896,,22224,12404,,,A,,,Autocuration,,,
14557,BAO_0000019,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,U,1,,CHEMBL625897,,22224,568,,,A,,,Autocuration,,,
14558,BAO_0000019,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,U,1,,CHEMBL625898,,22224,568,,,A,,,Autocuration,,,
14559,BAO_0000019,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,U,1,,CHEMBL625899,,22224,568,,,A,,,Autocuration,,,
14560,BAO_0000019,Reaction rate parameter value for phosphate with transfer with respect to ATP,,U,1,,CHEMBL626124,,22224,12404,,,A,,,Autocuration,,,
14561,BAO_0000218,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,N,1,,CHEMBL628500,,50212,7624,,,A,,,Intermediate,,,
14562,BAO_0000218,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,N,1,,CHEMBL857856,,50597,7624,,,A,,,Intermediate,,,
14563,BAO_0000218,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,N,1,,CHEMBL628501,,50597,7624,,,A,,,Intermediate,,,
14564,BAO_0000019,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,U,1,,CHEMBL628502,,22224,4643,,,A,,,Autocuration,,,
14565,BAO_0000019,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,U,1,,CHEMBL628503,,22224,11532,,,A,,,Autocuration,,,
14566,BAO_0000019,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,U,1,,CHEMBL628504,,22224,11018,,,A,,,Autocuration,,,
14567,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,U,1,,CHEMBL628505,,22224,2276,,,A,,,Autocuration,,,
14568,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,U,1,,CHEMBL874452,,22224,2276,,,A,,,Autocuration,,,
14569,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,U,1,,CHEMBL628506,,22224,2276,,,A,,,Autocuration,,,
14570,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,U,1,,CHEMBL628507,,22224,2276,,,A,,,Autocuration,,,
14571,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,U,1,,CHEMBL628508,,22224,2276,,,A,,,Autocuration,,,
14572,BAO_0000019,Michaelis constant (KM) was evaluated,,U,1,,CHEMBL628509,,22224,8949,,,A,,,Autocuration,,,
14573,BAO_0000019,Reaction rate parameter value for phosphate with transfer with respect to ATP,,U,1,,CHEMBL628510,,22224,12404,,,A,,,Autocuration,,,
14574,BAO_0000019,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,U,1,,CHEMBL628511,,22224,7625,,,B,,,Autocuration,,,
14575,BAO_0000019,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,U,1,,CHEMBL628512,,22224,7625,,,B,,,Autocuration,,,
14576,BAO_0000019,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,U,1,,CHEMBL628513,,22224,7625,,,B,,,Autocuration,,,
14577,BAO_0000019,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,U,1,,CHEMBL628514,,22224,7625,,,B,,,Autocuration,,,
14578,BAO_0000019,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,U,1,,CHEMBL628515,,22224,12908,,,A,,,Autocuration,,,
14579,BAO_0000019,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,U,1,,CHEMBL628516,,22224,10368,,,A,,,Autocuration,,,
14580,BAO_0000019,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,U,1,,CHEMBL628517,,22224,13108,,,A,,,Autocuration,,,
14581,BAO_0000019,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,U,1,,CHEMBL628518,,22224,13108,,,A,,,Autocuration,,,
14582,BAO_0000019,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,U,1,,CHEMBL628519,,22224,15217,,,A,,,Autocuration,,,
14583,BAO_0000019,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,U,1,,CHEMBL628520,,22224,15217,,,A,,,Autocuration,,,
14584,BAO_0000019,Binding constant was determined,,U,1,,CHEMBL628521,,22224,10933,,,A,,,Autocuration,,,
14585,BAO_0000019,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,U,1,,CHEMBL630443,,22224,2363,,,A,,,Autocuration,,,
14586,BAO_0000019,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,U,1,,CHEMBL630444,,22224,2363,,,A,,,Autocuration,,,
14587,BAO_0000019,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,U,1,,CHEMBL857732,,22224,2276,,,A,,,Autocuration,,,
14588,BAO_0000100,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,U,1,,CHEMBL630445,,22224,14915,,,P,,,Autocuration,,,
14589,BAO_0000019,Catalytic rate constant of the compound,,U,1,,CHEMBL630446,,22224,8847,,,A,,,Autocuration,,,
14590,BAO_0000019,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,U,1,,CHEMBL630447,,22224,15357,,,B,,,Autocuration,,,
14591,BAO_0000019,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,U,1,,CHEMBL630448,,22224,2869,,,A,,,Autocuration,,,
14592,BAO_0000019,Catalytic rate constant against phospholipase A2 was determined,,U,1,,CHEMBL630449,,22224,3484,,,A,,,Autocuration,,,
14593,BAO_0000019,"Compound was evaluated for catalytic constant, Kcat",,U,1,,CHEMBL630450,,22224,1373,,,A,,,Autocuration,,,
14594,BAO_0000019,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,U,1,,CHEMBL630451,,22224,8142,,,A,,,Autocuration,,,
14595,BAO_0000019,Kcat calculated from 0.693/T1/2,,U,1,,CHEMBL630452,,22224,14131,,,A,,,Autocuration,,,
14596,BAO_0000019,Kcat was determined,,U,1,,CHEMBL630453,,22224,17269,,,A,,,Autocuration,,,
14597,BAO_0000019,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,U,1,,CHEMBL630454,,22224,3485,,,A,,,Autocuration,,,
14598,BAO_0000019,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,U,1,,CHEMBL630455,,22224,3485,,,A,,,Autocuration,,,
14599,BAO_0000019,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,U,1,,CHEMBL631487,,22224,3485,,,A,,,Autocuration,,,
14600,BAO_0000019,Kcat value was determined,,U,1,,CHEMBL631488,,22224,5962,,,A,,,Autocuration,,,
14601,BAO_0000019,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,U,1,,CHEMBL876440,,22224,3133,,,A,,,Autocuration,,,
14602,BAO_0000019,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,U,1,,CHEMBL631489,,22224,3133,,,A,,,Autocuration,,,
14603,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,U,1,,CHEMBL857742,,22224,2276,,,A,,,Autocuration,,,
14604,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,U,1,,CHEMBL631490,,22224,2276,,,A,,,Autocuration,,,
14605,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,U,1,,CHEMBL631491,,22224,2276,,,A,,,Autocuration,,,
14606,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,U,1,,CHEMBL631492,,22224,2276,,,A,,,Autocuration,,,
14607,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,U,1,,CHEMBL631493,,22224,2276,,,A,,,Autocuration,,,
14608,BAO_0000019,Kinetic parameter for rate of conversion to PABA was determined,,U,1,,CHEMBL631494,,22224,4892,,,A,,,Autocuration,,,
14609,BAO_0000019,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,U,1,,CHEMBL631495,,22224,3133,,,A,,,Autocuration,,,
14610,BAO_0000218,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1988.0,N,1,,CHEMBL631496,,50597,11488,,Feces,A,,,Intermediate,,,
14611,BAO_0000218,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1088.0,N,1,,CHEMBL631497,,50597,11488,,Urine,A,,,Intermediate,,,
14612,BAO_0000218,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1088.0,N,1,,CHEMBL631498,,50597,11488,,Urine,A,,,Intermediate,,,
14613,BAO_0000218,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1088.0,N,1,,CHEMBL629776,,50597,11488,,Urine,A,,,Intermediate,,,
14614,BAO_0000218,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1088.0,N,1,,CHEMBL629777,,50597,11488,,Urine,A,,,Intermediate,,,
14615,BAO_0000218,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1088.0,N,1,,CHEMBL629778,,50597,11488,,Urine,A,,,Intermediate,,,
14616,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,N,1,,CHEMBL630456,,50597,11488,,,A,,,Intermediate,,,
14617,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,N,1,,CHEMBL630457,,50597,11488,,,A,,,Intermediate,,,
14618,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,N,1,,CHEMBL630458,,50597,11488,,,A,,,Intermediate,,,
14619,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,N,1,,CHEMBL630459,,50597,11488,,,A,,,Intermediate,,,
14620,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,N,1,,CHEMBL630460,,50597,11488,,,A,,,Intermediate,,,
14621,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,N,1,,CHEMBL876550,,50597,11488,,,A,,,Intermediate,,,
14622,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,N,1,,CHEMBL630461,,50597,11488,,,A,,,Intermediate,,,
14623,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,N,1,,CHEMBL630462,,50597,11488,,,A,,,Intermediate,,,
14624,BAO_0000218,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,N,1,,CHEMBL630463,,50597,11488,,,A,,,Intermediate,,,
14625,BAO_0000218,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,N,1,,CHEMBL630464,,50597,11488,,,A,,,Intermediate,,,
14626,BAO_0000218,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,N,1,,CHEMBL630465,,50597,11488,,,A,,,Intermediate,,,
14627,BAO_0000218,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,N,1,,CHEMBL630466,,50597,11488,,,A,,,Intermediate,,,
14628,BAO_0000218,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,N,1,,CHEMBL630467,,50597,11488,,,A,,,Intermediate,,,
14629,BAO_0000218,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,N,1,,CHEMBL630633,,50597,11488,,,A,,,Intermediate,,,
14630,BAO_0000218,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,N,1,,CHEMBL630634,,50597,11488,,,A,,,Intermediate,,,
14631,BAO_0000218,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,N,1,,CHEMBL630635,,50597,11488,,,A,,,Intermediate,,,
14632,BAO_0000218,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,N,1,,CHEMBL630636,,50597,11488,,,A,,,Intermediate,,,
14633,BAO_0000218,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,N,1,,CHEMBL630637,,50597,11488,,,A,,,Intermediate,,,
14634,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1988.0,N,1,,CHEMBL630638,,50592,7132,,Feces,A,,,Intermediate,,,
14635,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1988.0,N,1,,CHEMBL630639,,50592,7132,,Feces,A,,,Intermediate,,,
14636,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1988.0,N,1,,CHEMBL630640,,50592,7132,,Feces,A,,,Intermediate,,,
14637,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1988.0,N,1,,CHEMBL876551,,50592,7132,,Feces,A,,,Intermediate,,,
14638,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1088.0,N,1,,CHEMBL630641,,50592,7132,,Urine,A,,,Intermediate,,,
14639,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1088.0,N,1,,CHEMBL630642,,50592,7132,,Urine,A,,,Intermediate,,,
14640,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1088.0,N,1,,CHEMBL630643,,50592,7132,,Urine,A,,,Intermediate,,,
14641,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1088.0,N,1,,CHEMBL630644,,50592,7132,,Urine,A,,,Intermediate,,,
14642,BAO_0000218,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1088.0,N,1,,CHEMBL630645,,50592,7132,,Urine,A,,,Intermediate,,,
14643,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1988.0,N,1,,CHEMBL625599,,50592,7132,,Feces,A,,,Intermediate,,,
14644,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1988.0,N,1,,CHEMBL625600,,50592,7132,,Feces,A,,,Intermediate,,,
14645,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1988.0,N,1,,CHEMBL625601,,50592,7132,,Feces,A,,,Intermediate,,,
14646,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1988.0,N,1,,CHEMBL625602,,50592,7132,,Feces,A,,,Intermediate,,,
14647,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1088.0,N,1,,CHEMBL627470,,50592,7132,,Urine,A,,,Intermediate,,,
14648,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1088.0,N,1,,CHEMBL627471,,50592,7132,,Urine,A,,,Intermediate,,,
14649,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1088.0,N,1,,CHEMBL627472,,50592,7132,,Urine,A,,,Intermediate,,,
14650,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1088.0,N,1,,CHEMBL627473,,50592,7132,,Urine,A,,,Intermediate,,,
14651,BAO_0000218,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1088.0,N,1,,CHEMBL627474,,50592,7132,,Urine,A,,,Intermediate,,,
14652,BAO_0000218,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,178.0,N,1,,CHEMBL627475,In vivo,50597,13925,,Blood,A,,,Intermediate,,,
14653,BAO_0000218,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,178.0,N,1,,CHEMBL627476,In vivo,50597,13925,,Blood,A,,,Intermediate,,,
14654,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,N,1,,CHEMBL627477,,50588,12582,,Urine,A,,,Intermediate,,,
14655,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,N,1,,CHEMBL627478,,50588,12582,,Urine,A,,,Intermediate,,,
14656,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,N,1,,CHEMBL627479,,50588,12582,,Urine,A,,,Intermediate,,,
14657,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,N,1,,CHEMBL627480,,50588,12582,,Urine,A,,,Intermediate,,,
14658,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,N,1,,CHEMBL627481,,50588,12582,,Urine,A,,,Intermediate,,,
14659,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL627482,,50588,12582,,Urine,A,,,Intermediate,,,
14660,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,N,1,,CHEMBL627483,,50588,12582,,Urine,A,,,Intermediate,,,
14661,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,N,1,,CHEMBL875636,,50588,12582,,Urine,A,,,Intermediate,,,
14662,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,N,1,,CHEMBL625764,,50588,12582,,Urine,A,,,Intermediate,,,
14663,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,N,1,,CHEMBL625765,,50588,12582,,Urine,A,,,Intermediate,,,
14664,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1088.0,N,1,,CHEMBL625766,,50588,12582,,Urine,A,,,Intermediate,,,
14665,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,N,1,,CHEMBL625767,,50588,12582,,Urine,A,,,Intermediate,,,
14666,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,N,1,,CHEMBL625768,,50588,12582,,Urine,A,,,Intermediate,,,
14667,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL625769,,50588,12582,,Urine,A,,,Intermediate,,,
14668,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1088.0,N,1,,CHEMBL625770,,50588,12582,,Urine,A,,,Intermediate,,,
14669,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1088.0,N,1,,CHEMBL625771,,50588,12582,,Urine,A,,,Intermediate,,,
14670,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1088.0,N,1,,CHEMBL625772,,50588,12582,,Urine,A,,,Intermediate,,,
14671,BAO_0000218,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,N,1,,CHEMBL625773,,50588,12582,,Urine,A,,,Intermediate,,,
14672,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1088.0,N,1,,CHEMBL625774,,50597,12582,,Urine,A,,,Intermediate,,,
14673,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,N,1,,CHEMBL625775,,50597,12582,,Urine,A,,,Intermediate,,,
14674,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,N,1,,CHEMBL625776,,50597,12582,,Urine,A,,,Intermediate,,,
14675,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,N,1,,CHEMBL625777,,50597,12582,,Urine,A,,,Intermediate,,,
14676,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,N,1,,CHEMBL625778,,50597,12582,,Urine,A,,,Intermediate,,,
14677,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,N,1,,CHEMBL625779,,50597,12582,,Urine,A,,,Intermediate,,,
14678,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,N,1,,CHEMBL625780,,50597,12582,,Urine,A,,,Intermediate,,,
14679,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,N,1,,CHEMBL625781,,50597,12582,,Urine,A,,,Intermediate,,,
14680,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,N,1,,CHEMBL875637,,50597,12582,,Urine,A,,,Intermediate,,,
14681,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,N,1,,CHEMBL626473,,50597,12582,,Urine,A,,,Intermediate,,,
14682,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,N,1,,CHEMBL626474,,50597,12582,,Urine,A,,,Intermediate,,,
14683,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,N,1,,CHEMBL626475,,50597,12582,,Urine,A,,,Intermediate,,,
14684,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,N,1,,CHEMBL626476,,50597,12582,,Urine,A,,,Intermediate,,,
14685,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,N,1,,CHEMBL634397,,50597,12582,,Urine,A,,,Intermediate,,,
14686,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,N,1,,CHEMBL626477,,50597,12582,,Urine,A,,,Intermediate,,,
14687,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,N,1,,CHEMBL631069,,50597,12582,,Urine,A,,,Intermediate,,,
14688,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,N,1,,CHEMBL631070,,50597,12582,,Urine,A,,,Intermediate,,,
14689,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,N,1,,CHEMBL631071,,50597,12582,,Urine,A,,,Intermediate,,,
14690,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,N,1,,CHEMBL631072,,50597,12582,,Urine,A,,,Intermediate,,,
14691,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,N,1,,CHEMBL631073,,50597,12582,,Urine,A,,,Intermediate,,,
14692,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,N,1,,CHEMBL631074,,50597,12582,,Urine,A,,,Intermediate,,,
14693,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,N,1,,CHEMBL631075,,50597,12582,,Urine,A,,,Intermediate,,,
14694,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,N,1,,CHEMBL631725,,50597,12582,,Urine,A,,,Intermediate,,,
14695,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,N,1,,CHEMBL631726,,50597,12582,,Urine,A,,,Intermediate,,,
14696,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,N,1,,CHEMBL631727,,50597,12582,,Urine,A,,,Intermediate,,,
14697,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,N,1,,CHEMBL631728,,50597,12582,,Urine,A,,,Intermediate,,,
14698,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,N,1,,CHEMBL631729,,50597,12582,,Urine,A,,,Intermediate,,,
14699,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,N,1,,CHEMBL631730,,50597,12582,,Urine,A,,,Intermediate,,,
14700,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,N,1,,CHEMBL631731,,50597,12582,,Urine,A,,,Intermediate,,,
14701,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,N,1,,CHEMBL631910,,50597,12582,,Urine,A,,,Intermediate,,,
14702,BAO_0000218,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,10000000.0,N,1,,CHEMBL631911,In vivo,50597,15413,,Hippocampus,A,,,Intermediate,,,
14703,BAO_0000218,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1898.0,N,1,,CHEMBL631912,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14704,BAO_0000218,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1898.0,N,1,,CHEMBL631913,In vivo,50597,15413,,Hypothalamus,A,,,Intermediate,,,
14705,BAO_0000218,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631914,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14706,BAO_0000218,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631915,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14707,BAO_0000218,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,N,1,,CHEMBL875778,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14708,BAO_0000218,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631916,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14709,BAO_0000218,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631917,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14710,BAO_0000218,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631918,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14711,BAO_0000218,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631919,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14712,BAO_0000218,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,N,1,,CHEMBL631920,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14713,BAO_0000218,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631921,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14714,BAO_0000218,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,N,1,,CHEMBL631922,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14715,BAO_0000218,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,N,1,,CHEMBL631923,In vivo,50597,12017,,Blood,A,,,Intermediate,,,
14716,BAO_0000218,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL631924,In vivo,50597,12017,,,A,,,Intermediate,,,
14717,BAO_0000218,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630234,In vivo,50597,12017,,,A,,,Intermediate,,,
14718,BAO_0000218,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,1,,CHEMBL630235,In vivo,50597,12017,,,A,,,Intermediate,,,
14719,BAO_0000218,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630236,In vivo,50597,12017,,,A,,,Intermediate,,,
14720,BAO_0000218,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630237,In vivo,50597,12017,,,A,,,Intermediate,,,
14721,BAO_0000218,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630238,In vivo,50597,12017,,,A,,,Intermediate,,,
14722,BAO_0000218,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630239,In vivo,50597,12017,,,A,,,Intermediate,,,
14723,BAO_0000218,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,1,,CHEMBL630303,In vivo,50597,12017,,,A,,,Intermediate,,,
14724,BAO_0000218,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630304,In vivo,50597,12017,,,A,,,Intermediate,,,
14725,BAO_0000218,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,1,,CHEMBL630305,In vivo,50597,12017,,,A,,,Intermediate,,,
14726,BAO_0000218,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL630306,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14727,BAO_0000218,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL630307,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14728,BAO_0000218,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,N,1,,CHEMBL630308,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14729,BAO_0000218,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL630309,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14730,BAO_0000218,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL629309,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14731,BAO_0000218,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL629993,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14732,BAO_0000218,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL629994,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14733,BAO_0000218,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,N,1,,CHEMBL629995,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14734,BAO_0000218,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL631993,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14735,BAO_0000218,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL631994,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14736,BAO_0000218,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,N,1,,CHEMBL631995,In vivo,50597,12017,,Kidney,A,,,Intermediate,,,
14737,BAO_0000218,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,N,1,,CHEMBL631996,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14738,BAO_0000218,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL631997,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14739,BAO_0000218,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL631998,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14740,BAO_0000218,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL631999,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14741,BAO_0000218,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,N,1,,CHEMBL632000,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14742,BAO_0000218,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL632001,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14743,BAO_0000218,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL874424,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14744,BAO_0000218,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL632002,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14745,BAO_0000218,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL632003,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14746,BAO_0000019,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,U,1,,CHEMBL632004,,22224,3133,,,A,,,Autocuration,,,
14747,BAO_0000019,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,U,1,,CHEMBL632005,,22224,2742,,,A,,,Autocuration,,,
14748,BAO_0000019,Compound was tested for amidase rate in the presence of N62C screen enzyme,,U,1,,CHEMBL632006,,22224,2742,,,A,,,Autocuration,,,
14749,BAO_0000019,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,U,1,,CHEMBL632007,,22224,2742,,,A,,,Autocuration,,,
14750,BAO_0000019,Compound was tested for amidase rate in the presence of S166C screen enzyme,,U,1,,CHEMBL632008,,22224,2742,,,A,,,Autocuration,,,
14751,BAO_0000019,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,U,1,,CHEMBL632009,,22224,2742,,,A,,,Autocuration,,,
14752,BAO_0000019,Compound was tested for esterase rate in the presence of N62C screen enzyme,,U,1,,CHEMBL632010,,22224,2742,,,A,,,Autocuration,,,
14753,BAO_0000019,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,U,1,,CHEMBL857750,,22224,2742,,,A,,,Autocuration,,,
14754,BAO_0000019,Compound was tested for esterase rate in the presence of S166C screen enzyme,,U,1,,CHEMBL632011,,22224,2742,,,A,,,Autocuration,,,
14755,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,1,,CHEMBL632012,,22224,2276,,,A,,,Autocuration,,,
14756,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,1,,CHEMBL632013,,22224,2276,,,A,,,Autocuration,,,
14757,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,U,1,,CHEMBL632014,,22224,2276,,,A,,,Autocuration,,,
14758,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,1,,CHEMBL629622,,22224,2276,,,A,,,Autocuration,,,
14759,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,1,,CHEMBL629623,,22224,2276,,,A,,,Autocuration,,,
14760,BAO_0000019,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,U,1,,CHEMBL629624,,22224,2276,,,A,,,Autocuration,,,
14761,BAO_0000019,Ratio of Kcat to that of Km was determined,,U,1,,CHEMBL629625,,22224,17269,,,A,,,Autocuration,,,
14762,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,U,1,,CHEMBL629626,,22224,2276,,,A,,,Autocuration,,,
14763,BAO_0000019,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,U,1,,CHEMBL629627,,22224,2276,,,A,,,Autocuration,,,
14764,BAO_0000019,"Compound was evaluated for constant, Kd",,U,1,,CHEMBL629628,,22224,15917,,,A,,,Autocuration,,,
14765,BAO_0000019,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,U,1,,CHEMBL629629,,22224,10933,,,A,,,Autocuration,,,
14766,BAO_0000019,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,U,1,,CHEMBL629630,,22224,10933,,,A,,,Autocuration,,,
14767,BAO_0000019,Dissociation Constant of compound determined,,U,1,,CHEMBL856030,,22224,14293,,,A,,,Autocuration,,,
14768,BAO_0000019,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,U,1,,CHEMBL629631,,22224,6698,,,B,,,Autocuration,,,
14769,BAO_0000019,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,U,1,,CHEMBL629632,,22224,6698,,,B,,,Autocuration,,,
14770,BAO_0000100,Dissociation constant of compound with Fructose was determined,,U,1,,CHEMBL629633,,22224,4318,,,P,,,Autocuration,,,
14771,BAO_0000100,Dissociation constant of compound with Fructose was determined; Not determined,,U,1,,CHEMBL629634,,22224,4318,,,P,,,Autocuration,,,
14772,BAO_0000100,Dissociation constant of compound with Lactulose was determined,,U,1,,CHEMBL629635,,22224,4318,,,P,,,Autocuration,,,
14773,BAO_0000100,Dissociation constant of compound with Lactulose was determined; Not determined,,U,1,,CHEMBL629636,,22224,4318,,,P,,,Autocuration,,,
14774,BAO_0000100,Dissociation constant of the Compound,,U,1,,CHEMBL629637,,22224,14959,,,P,,,Autocuration,,,
14775,BAO_0000100,Dissociation constant by non-linear regression analysis,,U,1,,CHEMBL629638,,22224,5913,,,P,,,Autocuration,,,
14776,BAO_0000100,Dissociation constant was determined,,U,1,,CHEMBL629639,,22224,14218,,,P,,,Autocuration,,,
14777,BAO_0000100,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,U,1,,CHEMBL629640,,22224,10689,,,P,,,Autocuration,,,
14778,BAO_0000100,Dissociation constant was determined,,U,1,,CHEMBL629641,,22224,13925,,,P,,,Autocuration,,,
14779,BAO_0000100,Dissociation constant was determined,,U,1,,CHEMBL631344,,22224,16359,,,P,,,Autocuration,,,
14780,BAO_0000218,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,2385.0,N,1,,CHEMBL631345,,50597,10944,,Muscle tissue,A,,,Intermediate,,,
14781,BAO_0000019,The dissociation constant determined by fluorescence displacement assay,,U,1,,CHEMBL631346,,22224,11080,,,A,,,Autocuration,,,
14782,BAO_0000019,kd value surface plasmon resonance (SPR) method,,U,1,,CHEMBL631524,,22224,17805,,,A,,,Autocuration,,,
14783,BAO_0000218,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,2385.0,N,1,,CHEMBL631525,,50597,10944,,Muscle tissue,A,,,Intermediate,,,
14784,BAO_0000019,First dissociation constant of the binding of compound to V30M TTR,,U,1,,CHEMBL631526,,22224,16645,,,F,,,Autocuration,,,
14785,BAO_0000019,Second dissociation constant of the binding of compound to V30M TTR,,U,1,,CHEMBL631527,,22224,16645,,,F,,,Autocuration,,,
14786,BAO_0000019,"Compound was evaluated for equilibrium constant, Ke",,U,1,,CHEMBL631528,,22224,7793,,,A,,,Autocuration,,,
14787,BAO_0000019,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,1898.0,U,1,,CHEMBL631529,,22224,12199,,Hypothalamus,A,,,Autocuration,,,
14788,BAO_0000019,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,1898.0,U,1,,CHEMBL631530,,22224,12199,,Hypothalamus,A,,,Autocuration,,,
14789,BAO_0000019,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,U,1,,CHEMBL631531,,22224,9680,,,A,,,Autocuration,,,
14790,BAO_0000019,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,U,1,,CHEMBL631532,,22224,9680,,,A,,,Autocuration,,,
14791,BAO_0000019,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,U,1,,CHEMBL631533,,22224,9680,,,A,,,Autocuration,,,
14792,BAO_0000218,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,1,,CHEMBL876552,,50594,13758,,,A,,,Intermediate,,,
14793,BAO_0000218,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,N,1,,CHEMBL631534,,50594,13758,,,A,,,Intermediate,,,
14794,BAO_0000218,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,1,,CHEMBL631535,,50594,13758,,,A,,,Intermediate,,,
14795,BAO_0000218,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,1,,CHEMBL631536,,50594,13758,,,A,,,Intermediate,,,
14796,BAO_0000218,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,N,1,,CHEMBL631537,,50594,13758,,,A,,,Intermediate,,,
14797,BAO_0000218,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,N,1,,CHEMBL631538,,50594,13758,,,A,,,Intermediate,,,
14798,BAO_0000218,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,N,1,,CHEMBL631539,,50594,13758,,,A,,,Intermediate,,,
14799,BAO_0000218,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,1,,CHEMBL631540,,50594,13758,,,A,,,Intermediate,,,
14800,BAO_0000218,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,1,,CHEMBL625637,,50597,14393,,,A,,,Intermediate,,,
14801,BAO_0000218,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,1,,CHEMBL625638,,50597,14393,,,A,,,Intermediate,,,
14802,BAO_0000218,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,N,1,,CHEMBL625639,,50597,15078,,,A,,,Intermediate,,,
14803,BAO_0000218,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,955.0,N,1,,CHEMBL625640,In vivo,50597,13925,,Brain,A,,,Intermediate,,,
14804,BAO_0000218,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,955.0,N,1,,CHEMBL625641,In vivo,50597,13925,,Brain,A,,,Intermediate,,,
14805,BAO_0000218,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,948.0,N,1,,CHEMBL625642,In vivo,50597,13925,,Heart,A,,,Intermediate,,,
14806,BAO_0000218,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,948.0,N,1,,CHEMBL625643,In vivo,50597,13925,,Heart,A,,,Intermediate,,,
14807,BAO_0000218,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2113.0,N,1,,CHEMBL625644,In vivo,50597,13925,,Kidney,A,,,Intermediate,,,
14808,BAO_0000218,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2113.0,N,1,,CHEMBL625645,In vivo,50597,13925,,Kidney,A,,,Intermediate,,,
14809,BAO_0000218,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2107.0,N,1,,CHEMBL625646,In vivo,50597,13925,,Liver,A,,,Intermediate,,,
14810,BAO_0000218,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2107.0,N,1,,CHEMBL625647,In vivo,50597,13925,,Liver,A,,,Intermediate,,,
14811,BAO_0000218,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2048.0,N,1,,CHEMBL625648,In vivo,50597,13925,,Lung,A,,,Intermediate,,,
14812,BAO_0000218,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,2048.0,N,1,,CHEMBL625649,In vivo,50597,13925,,Lung,A,,,Intermediate,,,
14813,BAO_0000218,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2385.0,N,1,,CHEMBL625650,In vivo,50597,13925,,Muscle tissue,A,,,Intermediate,,,
14814,BAO_0000218,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2385.0,N,1,,CHEMBL625651,In vivo,50597,13925,,Muscle tissue,A,,,Intermediate,,,
14815,BAO_0000218,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,14.0,N,1,,CHEMBL625652,In vivo,50597,13925,,Zone of skin,A,,,Intermediate,,,
14816,BAO_0000218,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,14.0,N,1,,CHEMBL625653,In vivo,50597,13925,,Zone of skin,A,,,Intermediate,,,
14817,BAO_0000218,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2106.0,N,1,,CHEMBL625654,In vivo,50597,13925,,Spleen,A,,,Intermediate,,,
14818,BAO_0000218,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2106.0,N,1,,CHEMBL625655,In vivo,50597,13925,,Spleen,A,,,Intermediate,,,
14819,BAO_0000218,Biodistribution of Compound in rat blood after 15 minutes of administration,178.0,N,1,,CHEMBL625656,In vivo,50597,9712,,Blood,A,,,Intermediate,,,
14820,BAO_0000218,Biodistribution of Compound in rat blood after 2 minutes of administration,178.0,N,1,,CHEMBL625657,In vivo,50597,9712,,Blood,A,,,Intermediate,,,
14821,BAO_0000218,Biodistribution of Compound in rat brain after 15 minutes of administration,955.0,N,1,,CHEMBL625658,In vivo,50597,9712,,Brain,A,,,Intermediate,,,
14822,BAO_0000218,Biodistribution of Compound in rat brain after 2 minutes of administration,955.0,N,1,,CHEMBL625659,In vivo,50597,9712,,Brain,A,,,Intermediate,,,
14823,BAO_0000218,Biodistribution of Compound in rat heart after 15 minutes of administration,948.0,N,1,,CHEMBL625660,In vivo,50597,9712,,Heart,A,,,Intermediate,,,
14824,BAO_0000218,Biodistribution of Compound in rat heart after 2 minutes of administration,948.0,N,1,,CHEMBL625661,In vivo,50597,9712,,Heart,A,,,Intermediate,,,
14825,BAO_0000218,Biodistribution of Compound in rat liver after 15 minutes of administration,2107.0,N,1,,CHEMBL625662,In vivo,50597,9712,,Liver,A,,,Intermediate,,,
14826,BAO_0000218,Biodistribution of Compound in rat liver after 2 minutes of administration,2107.0,N,1,,CHEMBL625663,In vivo,50597,9712,,Liver,A,,,Intermediate,,,
14827,BAO_0000218,Biodistribution of Compound in rat lung after 15 minutes of administration,2048.0,N,1,,CHEMBL875621,In vivo,50597,9712,,Lung,A,,,Intermediate,,,
14828,BAO_0000218,Biodistribution of Compound in rat lung after 2 minutes of administration,2048.0,N,1,,CHEMBL628382,In vivo,50597,9712,,Lung,A,,,Intermediate,,,
14829,BAO_0000218,Biodistribution of Compound in rat muscle after 15 minutes of administration,2385.0,N,1,,CHEMBL628383,In vivo,50597,9712,,Muscle tissue,A,,,Intermediate,,,
14830,BAO_0000218,Biodistribution of Compound in rat muscle after 2 minutes of administration,2385.0,N,1,,CHEMBL628384,In vivo,50597,9712,,Muscle tissue,A,,,Intermediate,,,
14831,BAO_0000218,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,N,1,,CHEMBL628385,,50597,13925,,,A,,,Intermediate,,,
14832,BAO_0000218,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,N,1,,CHEMBL875753,,50597,13925,,,A,,,Intermediate,,,
14833,BAO_0000218,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,N,1,,CHEMBL628386,,50597,13925,,,A,,,Intermediate,,,
14834,BAO_0000218,Organ distribution in rat blood 2 minutes after intravenous injection,,N,1,,CHEMBL628387,,50597,6941,,,A,,,Intermediate,,,
14835,BAO_0000218,Organ distribution in rat blood 2 hr after intravenous injection,,N,1,,CHEMBL628388,,50597,6941,,,A,,,Intermediate,,,
14836,BAO_0000218,Organ distribution in rat blood 30 minutes after intravenous injection,,N,1,,CHEMBL628389,,50597,6941,,,A,,,Intermediate,,,
14837,BAO_0000218,Organ distribution in rat blood 30 min after intravenous injection,,N,1,,CHEMBL632756,,50597,6941,,,A,,,Intermediate,,,
14838,BAO_0000218,Organ distribution in rat brain 2 minutes after intravenous injection,,N,1,,CHEMBL628390,,50597,6941,,,A,,,Intermediate,,,
14839,BAO_0000218,Organ distribution in rat brain 2 hr after intravenous injection,,N,1,,CHEMBL631811,,50597,6941,,,A,,,Intermediate,,,
14840,BAO_0000218,Organ distribution in rat brain 30 minutes after intravenous injection,,N,1,,CHEMBL631812,,50597,6941,,,A,,,Intermediate,,,
14841,BAO_0000218,Organ distribution in rat heart 2 minutes after intravenous injection,,N,1,,CHEMBL631813,,50597,6941,,,A,,,Intermediate,,,
14842,BAO_0000218,Organ distribution in rat heart 2 hr after intravenous injection,,N,1,,CHEMBL631814,,50597,6941,,,A,,,Intermediate,,,
14843,BAO_0000218,Organ distribution in rat heart 30 minutes after intravenous injection,,N,1,,CHEMBL631815,,50597,6941,,,A,,,Intermediate,,,
14844,BAO_0000218,Organ distribution in rat kidney 2 minutes after intravenous injection,,N,1,,CHEMBL631816,,50597,6941,,,A,,,Intermediate,,,
14845,BAO_0000218,Organ distribution in rat kidney 2 hr after intravenous injection,,N,1,,CHEMBL875758,,50597,6941,,,A,,,Intermediate,,,
14846,BAO_0000218,Organ distribution in rat kidney 30 minutes after intravenous injection,,N,1,,CHEMBL631817,,50597,6941,,,A,,,Intermediate,,,
14847,BAO_0000218,Organ distribution in rat liver 2 minutes after intravenous injection,2107.0,N,1,,CHEMBL631818,,50597,6941,,Liver,A,,,Intermediate,,,
14848,BAO_0000218,Organ distribution in rat liver 2 hr after intravenous injection,2107.0,N,1,,CHEMBL631819,,50597,6941,,Liver,A,,,Intermediate,,,
14849,BAO_0000218,Organ distribution in rat liver 30 minutes after intravenous injection,2107.0,N,1,,CHEMBL631820,,50597,6941,,Liver,A,,,Intermediate,,,
14850,BAO_0000218,Organ distribution in rat lung 2 minutes after intravenous injection,,N,1,,CHEMBL631821,,50597,6941,,,A,,,Intermediate,,,
14851,BAO_0000218,Organ distribution in rat lung 2 hr after intravenous injection,,N,1,,CHEMBL631822,,50597,6941,,,A,,,Intermediate,,,
14852,BAO_0000218,Organ distribution in rat lung 30 minutes after intravenous injection,,N,1,,CHEMBL631823,,50597,6941,,,A,,,Intermediate,,,
14853,BAO_0000218,Organ distribution in rat muscle 2 minutes after intravenous injection,2385.0,N,1,,CHEMBL631824,,50597,6941,,Muscle tissue,A,,,Intermediate,,,
14854,BAO_0000218,Organ distribution in rat muscle 2 hr after intravenous injection,2385.0,N,1,,CHEMBL631825,,50597,6941,,Muscle tissue,A,,,Intermediate,,,
14855,BAO_0000218,Organ distribution in rat muscle 30 minutes after intravenous injection,2385.0,N,1,,CHEMBL631826,,50597,6941,,Muscle tissue,A,,,Intermediate,,,
14856,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,N,1,,CHEMBL631827,In vivo,50594,14439,,,A,,,Intermediate,,,
14857,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,N,1,,CHEMBL631828,In vivo,50594,14439,,,A,,,Intermediate,,,
14858,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,N,1,,CHEMBL631829,In vivo,50594,14439,,,A,,,Intermediate,,,
14859,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,N,1,,CHEMBL875759,,50597,12582,,Urine,A,,,Intermediate,,,
14860,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1088.0,N,1,,CHEMBL631830,,50597,12582,,Urine,A,,,Intermediate,,,
14861,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,N,1,,CHEMBL631831,,50597,12582,,Urine,A,,,Intermediate,,,
14862,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,N,1,,CHEMBL631832,,50597,12582,,Urine,A,,,Intermediate,,,
14863,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,N,1,,CHEMBL631833,,50597,12582,,Urine,A,,,Intermediate,,,
14864,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,N,1,,CHEMBL631834,,50597,12582,,Urine,A,,,Intermediate,,,
14865,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,N,1,,CHEMBL631835,,50597,12582,,Urine,A,,,Intermediate,,,
14866,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,N,1,,CHEMBL631836,,50597,12582,,Urine,A,,,Intermediate,,,
14867,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,N,1,,CHEMBL631837,,50597,12582,,Urine,A,,,Intermediate,,,
14868,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,N,1,,CHEMBL631838,,50597,12582,,Urine,A,,,Intermediate,,,
14869,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,N,1,,CHEMBL631839,,50597,12582,,Urine,A,,,Intermediate,,,
14870,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,N,1,,CHEMBL631840,,50597,12582,,Urine,A,,,Intermediate,,,
14871,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,N,1,,CHEMBL631841,,50597,12582,,Urine,A,,,Intermediate,,,
14872,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,N,1,,CHEMBL631842,,50597,12582,,Urine,A,,,Intermediate,,,
14873,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,N,1,,CHEMBL631843,,50597,12582,,Urine,A,,,Intermediate,,,
14874,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,N,1,,CHEMBL631844,,50597,12582,,Urine,A,,,Intermediate,,,
14875,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,N,1,,CHEMBL631845,,50597,12582,,Urine,A,,,Intermediate,,,
14876,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,N,1,,CHEMBL631846,,50597,12582,,Urine,A,,,Intermediate,,,
14877,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,N,1,,CHEMBL875760,,50597,12582,,Urine,A,,,Intermediate,,,
14878,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,N,1,,CHEMBL632199,,50597,12582,,Urine,A,,,Intermediate,,,
14879,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,N,1,,CHEMBL631847,,50597,12582,,Urine,A,,,Intermediate,,,
14880,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,N,1,,CHEMBL631848,,50597,12582,,Urine,A,,,Intermediate,,,
14881,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,N,1,,CHEMBL628707,,50597,12582,,Urine,A,,,Intermediate,,,
14882,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,N,1,,CHEMBL628708,,50597,12582,,Urine,A,,,Intermediate,,,
14883,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,N,1,,CHEMBL628709,,50597,12582,,Urine,A,,,Intermediate,,,
14884,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,N,1,,CHEMBL628710,,50597,12582,,Urine,A,,,Intermediate,,,
14885,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,N,1,,CHEMBL628711,,50597,12582,,Urine,A,,,Intermediate,,,
14886,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,N,1,,CHEMBL628712,,50597,12582,,Urine,A,,,Intermediate,,,
14887,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,N,1,,CHEMBL628713,,50597,12582,,Urine,A,,,Intermediate,,,
14888,BAO_0000218,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,N,1,,CHEMBL628714,,50597,12582,,Urine,A,,,Intermediate,,,
14889,BAO_0000218,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,N,1,,CHEMBL628715,,50597,7415,,,A,,,Intermediate,,,
14890,BAO_0000019,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,U,1,,CHEMBL629179,,22224,7313,,,A,,,Autocuration,,,
14891,BAO_0000019,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,U,1,,CHEMBL629180,,22224,7313,,,A,,,Autocuration,,,
14892,BAO_0000019,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,U,1,,CHEMBL875108,,22224,7313,,,A,,,Autocuration,,,
14893,BAO_0000019,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1235.0,U,1,,CHEMBL629181,,22224,7570,,Adrenal cortex,A,,,Autocuration,,,
14894,BAO_0000019,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1235.0,U,1,,CHEMBL629182,,22224,7570,,Adrenal cortex,A,,,Autocuration,,,
14895,BAO_0000019,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,U,1,,CHEMBL629183,,22224,7570,,,A,,,Autocuration,,,
14896,BAO_0000019,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,U,1,,CHEMBL629184,,22224,7570,,,A,,,Autocuration,,,
14897,BAO_0000019,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1235.0,U,1,,CHEMBL629185,,22224,7570,,Adrenal cortex,A,,,Autocuration,,,
14898,BAO_0000019,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,1235.0,U,1,,CHEMBL629186,,22224,7570,,Adrenal cortex,A,,,Autocuration,,,
14899,BAO_0000019,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,U,1,,CHEMBL629187,,22224,7570,,,A,,,Autocuration,,,
14900,BAO_0000019,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,U,1,,CHEMBL629887,,22224,7570,,,A,,,Autocuration,,,
14901,BAO_0000019,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,U,1,,CHEMBL629888,,22224,7570,,,A,,,Autocuration,,,
14902,BAO_0000019,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,U,1,,CHEMBL629889,,22224,7570,,,A,,,Autocuration,,,
14903,BAO_0000019,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,1235.0,U,1,,CHEMBL629890,,22224,7570,,Adrenal cortex,A,,,Autocuration,,,
14904,BAO_0000019,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,U,1,,CHEMBL629891,,22224,7570,,,A,,,Autocuration,,,
14905,BAO_0000019,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,U,1,,CHEMBL629892,,22224,7570,,,A,,,Autocuration,,,
14906,BAO_0000019,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1235.0,U,1,,CHEMBL629893,,22224,7570,,Adrenal cortex,A,,,Autocuration,,,
14907,BAO_0000019,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,U,1,,CHEMBL629894,,22224,7570,,,A,,,Autocuration,,,
14908,BAO_0000019,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,U,1,,CHEMBL629895,,22224,7570,,,A,,,Autocuration,,,
14909,BAO_0000218,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,U,1,,CHEMBL875109,In vivo,22224,14122,,,A,,,Autocuration,,,
14910,BAO_0000218,Absolute bioavailability in male cynomolgus monkeys,,U,1,,CHEMBL629896,In vivo,22224,16449,,,A,,,Autocuration,,,
14911,BAO_0000218,Absolute bioavailability in maleSprague-Dawley rats,,U,1,,CHEMBL629897,In vivo,22224,16449,,,A,,,Autocuration,,,
14912,BAO_0000218,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,N,1,,CHEMBL629898,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14913,BAO_0000218,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL630057,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14914,BAO_0000218,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,N,1,,CHEMBL630058,In vivo,50597,12017,,Liver,A,,,Intermediate,,,
14915,BAO_0000218,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630059,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14916,BAO_0000218,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630060,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14917,BAO_0000218,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,N,1,,CHEMBL630061,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14918,BAO_0000218,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630062,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14919,BAO_0000218,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630063,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14920,BAO_0000218,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630064,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14921,BAO_0000218,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630065,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14922,BAO_0000218,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,N,1,,CHEMBL630066,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14923,BAO_0000218,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630067,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14924,BAO_0000218,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,N,1,,CHEMBL630068,In vivo,50597,12017,,Lung,A,,,Intermediate,,,
14925,BAO_0000218,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL631113,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14926,BAO_0000218,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL631114,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14927,BAO_0000218,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,N,1,,CHEMBL631115,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14928,BAO_0000218,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL631116,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14929,BAO_0000218,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL630528,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14930,BAO_0000218,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL630529,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14931,BAO_0000218,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL630530,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14932,BAO_0000218,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,N,1,,CHEMBL630531,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14933,BAO_0000218,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL630532,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14934,BAO_0000218,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,N,1,,CHEMBL630533,In vivo,50597,12017,,Muscle tissue,A,,,Intermediate,,,
14935,BAO_0000218,Biodistribution in normal mice blood after 120 hr,178.0,N,1,,CHEMBL630534,In vivo,50594,15045,,Blood,A,,,Intermediate,,,
14936,BAO_0000218,Biodistribution in normal mice blood after 24 hr,178.0,N,1,,CHEMBL630535,In vivo,50594,15045,,Blood,A,,,Intermediate,,,
14937,BAO_0000218,Biodistribution in normal mice blood after 4 hr,178.0,N,1,,CHEMBL630536,In vivo,50594,15045,,Blood,A,,,Intermediate,,,
14938,BAO_0000218,Biodistribution in normal mice bone after 120 hr,10000001.0,N,1,,CHEMBL630537,In vivo,50594,15045,,Bone,A,,,Intermediate,,,
14939,BAO_0000218,Biodistribution in normal mice bone after 24 hr,10000001.0,N,1,,CHEMBL630538,In vivo,50594,15045,,Bone,A,,,Intermediate,,,
14940,BAO_0000218,Biodistribution in normal mice bone after 4 hr,10000001.0,N,1,,CHEMBL630539,In vivo,50594,15045,,Bone,A,,,Intermediate,,,
14941,BAO_0000218,Biodistribution in normal mice heart after 120 hr,948.0,N,1,,CHEMBL630540,In vivo,50594,15045,,Heart,A,,,Intermediate,,,
14942,BAO_0000218,Biodistribution in normal mice heart after 24 hr,948.0,N,1,,CHEMBL630541,In vivo,50594,15045,,Heart,A,,,Intermediate,,,
14943,BAO_0000218,Biodistribution in normal mice heart after 4 hr,948.0,N,1,,CHEMBL630542,In vivo,50594,15045,,Heart,A,,,Intermediate,,,
14944,BAO_0000218,Biodistribution in normal mice kidney after 120 hr,2113.0,N,1,,CHEMBL630543,In vivo,50594,15045,,Kidney,A,,,Intermediate,,,
14945,BAO_0000218,Biodistribution in normal mice kidney after 24 hr,2113.0,N,1,,CHEMBL630544,In vivo,50594,15045,,Kidney,A,,,Intermediate,,,
14946,BAO_0000218,Biodistribution in normal mice kidney after 4 hr,2113.0,N,1,,CHEMBL630545,In vivo,50594,15045,,Kidney,A,,,Intermediate,,,
14947,BAO_0000218,Biodistribution in normal mice liver after 120 hr,2107.0,N,1,,CHEMBL630546,In vivo,50594,15045,,Liver,A,,,Intermediate,,,
14948,BAO_0000218,Biodistribution in normal mice liver after 24 hr,2107.0,N,1,,CHEMBL630547,In vivo,50594,15045,,Liver,A,,,Intermediate,,,
14949,BAO_0000218,Biodistribution in normal mice liver after 4 hr,2107.0,N,1,,CHEMBL630548,In vivo,50594,15045,,Liver,A,,,Intermediate,,,
14950,BAO_0000218,Biodistribution in normal mice spleen after 120 hr,2106.0,N,1,,CHEMBL630549,In vivo,50594,15045,,Spleen,A,,,Intermediate,,,
14951,BAO_0000218,Biodistribution in normal mice spleen after 24 hr,2106.0,N,1,,CHEMBL630550,In vivo,50594,15045,,Spleen,A,,,Intermediate,,,
14952,BAO_0000218,Biodistribution in normal mice spleen after 4 hr,2106.0,N,1,,CHEMBL876426,In vivo,50594,15045,,Spleen,A,,,Intermediate,,,
14953,BAO_0000218,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630551,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14954,BAO_0000218,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630552,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14955,BAO_0000218,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,N,1,,CHEMBL630553,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14956,BAO_0000218,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630554,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14957,BAO_0000218,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630555,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14958,BAO_0000218,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630556,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14959,BAO_0000218,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630557,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14960,BAO_0000218,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,N,1,,CHEMBL630558,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14961,BAO_0000218,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630559,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14962,BAO_0000218,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,N,1,,CHEMBL630560,In vivo,50597,12017,,Spleen,A,,,Intermediate,,,
14963,BAO_0000218,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,N,1,,CHEMBL876427,In vivo,50597,12017,,Thyroid gland,A,,,Intermediate,,,
14964,BAO_0000218,The Kel values in female wistar rats.,,N,1,,CHEMBL630561,,50597,14941,,,A,,,Intermediate,,,
14965,BAO_0000019,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,U,1,,CHEMBL630562,,22224,4646,,,A,,,Autocuration,,,
14966,BAO_0000019,Hydrolysis rate constant of the compound,,U,1,,CHEMBL630563,,22224,8847,,,A,,,Autocuration,,,
14967,BAO_0000100,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,U,1,,CHEMBL629673,,22229,11778,,,P,,,Autocuration,,,
14968,BAO_0000019,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,U,1,,CHEMBL629674,,22224,2363,,,A,,,Autocuration,,,
14969,BAO_0000019,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,U,1,,CHEMBL629675,,22224,2363,,,A,,,Autocuration,,,
14970,BAO_0000019,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,U,1,,CHEMBL629676,,22224,2363,,,A,,,Autocuration,,,
14971,BAO_0000019,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,U,1,,CHEMBL629677,,22224,2363,,,A,,,Autocuration,,,
14972,BAO_0000019,Apparent inactivation rate constant was evaluated,,U,1,,CHEMBL629678,,22224,8371,,,A,,,Autocuration,,,
14973,BAO_0000019,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,U,1,,CHEMBL629679,,22224,14883,,,A,,,Autocuration,,,
14974,BAO_0000019,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,U,1,,CHEMBL629680,,22224,14883,,,A,,,Autocuration,,,
14975,BAO_0000019,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,U,1,,CHEMBL629681,,22224,4643,,,A,,,Autocuration,,,
14976,BAO_0000019,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,U,1,,CHEMBL629682,,22224,3519,,,A,,,Autocuration,,,
14977,BAO_0000019,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,U,1,,CHEMBL629683,,22224,10600,,,A,,,Autocuration,,,
14978,BAO_0000019,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,U,1,,CHEMBL629684,,22224,8501,,,F,,,Autocuration,,,
14979,BAO_0000100,Dissociation constant was determined,,U,1,,CHEMBL629685,,22224,8505,,,P,,,Autocuration,,,
14980,BAO_0000100,Dissociation constant was determined,,U,1,,CHEMBL629686,,22224,9778,,,P,,,Autocuration,,,
14981,BAO_0000100,Dissociation constant at pH 7.4,,U,1,,CHEMBL872932,,22224,9778,,,P,,,Autocuration,,,
14982,BAO_0000100,Dissociation constant in presence of 1 mM dithiothreitol,,U,1,,CHEMBL629687,,22224,9778,,,P,,,Autocuration,,,
14983,BAO_0000019,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,U,1,,CHEMBL872931,,22224,13007,,,A,,,Autocuration,,,
14984,BAO_0000019,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,U,1,,CHEMBL628151,,22224,13007,,,A,,,Autocuration,,,
14985,BAO_0000019,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,U,1,,CHEMBL628152,,22224,13007,,,A,,,Autocuration,,,
14986,BAO_0000019,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,U,1,,CHEMBL628153,,22224,13007,,,A,,,Autocuration,,,
14987,BAO_0000019,Kinetic constant for aromatization of androstenedione,,U,1,,CHEMBL628154,,22224,11482,,,A,,,Autocuration,,,
14988,BAO_0000019,Kinetic constant for aromatization of testosterone,,U,1,,CHEMBL628155,,22224,11482,,,A,,,Autocuration,,,
14989,BAO_0000019,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,U,1,,CHEMBL628156,,22224,2303,,,A,,,Autocuration,,,
14990,BAO_0000019,Local inhibition constant was determined,,U,1,,CHEMBL628157,,22224,11964,,,A,,,Autocuration,,,
14991,BAO_0000218,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,N,1,,CHEMBL857533,,50347,3140,,,A,,,Intermediate,,,
14992,BAO_0000100,Dissociation constant value of the compound,,U,1,,CHEMBL628158,,22224,10650,,,P,,,Autocuration,,,
14993,BAO_0000019,In vitro permeability through cornea without epithelium,964.0,U,1,,CHEMBL628159,,22224,4667,,Cornea,A,,,Autocuration,,,
14994,BAO_0000019,In vitro permeability through intact cornea,964.0,U,1,,CHEMBL875616,,22224,4667,,Cornea,A,,,Autocuration,,,
14995,BAO_0000218,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,964.0,N,1,,CHEMBL628160,,50592,9199,,Cornea,A,,,Intermediate,,,
14996,BAO_0000019,Rate of enzyme inactivation for the compound was determined,,U,1,,CHEMBL628161,,22224,11966,,,A,,,Autocuration,,,
14997,BAO_0000019,In vitro permeability through cornea without epithelium,964.0,U,1,,CHEMBL628162,,22224,4667,,Cornea,A,,,Autocuration,,,
14998,BAO_0000019,In vitro permeability through intact cornea,964.0,U,1,,CHEMBL628163,,22224,4667,,Cornea,A,,,Autocuration,,,
14999,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628164,,22224,8354,,,A,,,Autocuration,,,
15000,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628165,,22224,8354,,,A,,,Autocuration,,,
15001,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628166,,22224,8354,,,A,,,Autocuration,,,
15002,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628167,,22224,8354,,,A,,,Autocuration,,,
15003,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628168,,22224,8354,,,A,,,Autocuration,,,
15004,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628169,,22224,8354,,,A,,,Autocuration,,,
15005,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628170,,22224,8354,,,A,,,Autocuration,,,
15006,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628171,,22224,8354,,,A,,,Autocuration,,,
15007,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL627434,,22224,8354,,,A,,,Autocuration,,,
15008,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL627435,,22224,8354,,,A,,,Autocuration,,,
15009,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628110,,22224,8354,,,A,,,Autocuration,,,
15010,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628111,,22224,8354,,,A,,,Autocuration,,,
15011,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628112,,22224,8354,,,A,,,Autocuration,,,
15012,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628260,,22224,8354,,,A,,,Autocuration,,,
15013,BAO_0000019,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,1,,CHEMBL628261,,22224,8354,,,A,,,Autocuration,,,
15014,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,N,1,,CHEMBL628262,In vivo,50594,14439,,,A,,,Intermediate,,,
15015,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,N,1,,CHEMBL628263,In vivo,50587,14439,,,A,,,Intermediate,,,
15016,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,N,1,,CHEMBL628264,In vivo,50594,14439,,,A,,,Intermediate,,,
15017,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,N,1,,CHEMBL628265,In vivo,50594,14439,,,A,,,Intermediate,,,
15018,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,N,1,,CHEMBL628266,In vivo,50594,14439,,,A,,,Intermediate,,,
15019,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,N,1,,CHEMBL628267,In vivo,50594,14439,,,A,,,Intermediate,,,
15020,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,N,1,,CHEMBL628268,In vivo,50594,14439,,,A,,,Intermediate,,,
15021,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,N,1,,CHEMBL628269,In vivo,50594,14439,,,A,,,Intermediate,,,
15022,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,N,1,,CHEMBL628270,In vivo,50594,14439,,,A,,,Intermediate,,,
15023,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,N,1,,CHEMBL628271,In vivo,50594,14439,,,A,,,Intermediate,,,
15024,BAO_0000218,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,N,1,,CHEMBL628272,In vivo,50594,14439,,,A,,,Intermediate,,,
